{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\mese4\\Anaconda3\\lib\\site-packages\\IPython\\core\\interactiveshell.py:3063: DtypeWarning: Columns (5,6,13,14,16) have mixed types.Specify dtype option on import or set low_memory=False.\n",
      "  interactivity=interactivity, compiler=compiler, result=result)\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "%matplotlib inline\n",
    "import matplotlib.pyplot as plt\n",
    "import os\n",
    "from matplotlib.dates import (YEARLY, DateFormatter,\n",
    "                              rrulewrapper, RRuleLocator, drange)\n",
    "import datetime\n",
    "import seaborn as sns\n",
    "from nltk.stem.porter import PorterStemmer\n",
    "from nltk.stem.wordnet import WordNetLemmatizer\n",
    "import re\n",
    "import nltk\n",
    "#nltk.download('stopwords')\n",
    "from nltk.corpus import stopwords\n",
    "from nltk.tokenize import RegexpTokenizer#nltk.download('wordnet') \n",
    "\n",
    "\n",
    "os.chdir(r\"C:\\Users\\mese4\\Documents\\The Data incubator\\project\\cord-19_2020-07-01\\2020-07-01\")\n",
    "df=pd.read_csv('metadata.csv', encoding='ISO-8859-1')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>DrugBank ID</th>\n",
       "      <th>Accession Numbers</th>\n",
       "      <th>Common_name</th>\n",
       "      <th>CAS</th>\n",
       "      <th>UNII</th>\n",
       "      <th>Synonyms</th>\n",
       "      <th>Standard InChI Key</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>BIOD00024 | BTD00024</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>138068-37-8</td>\n",
       "      <td>Y43GF64R34</td>\n",
       "      <td>Hirudin variant-1 | Lepirudin recombinant</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>DB00002</td>\n",
       "      <td>BIOD00071 | BTD00071</td>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>205923-56-4</td>\n",
       "      <td>PQX0D8J21J</td>\n",
       "      <td>Cetuximab | CÃ©tuximab | Cetuximabum</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>DB00003</td>\n",
       "      <td>BIOD00001 | BTD00001</td>\n",
       "      <td>Dornase alfa</td>\n",
       "      <td>143831-71-4</td>\n",
       "      <td>953A26OA1Y</td>\n",
       "      <td>Deoxyribonuclease (human clone 18-1 protein mo...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>DB00004</td>\n",
       "      <td>BIOD00084 | BTD00084</td>\n",
       "      <td>Denileukin diftitox</td>\n",
       "      <td>173146-27-5</td>\n",
       "      <td>25E79B5CTM</td>\n",
       "      <td>Denileukin | Interleukin-2/diptheria toxin fus...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>DB00005</td>\n",
       "      <td>BIOD00052 | BTD00052</td>\n",
       "      <td>Etanercept</td>\n",
       "      <td>185243-69-0</td>\n",
       "      <td>OP401G7OJC</td>\n",
       "      <td>Etanercept | etanercept-szzs | etanercept-ykro...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13575</th>\n",
       "      <td>DB15689</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Azoximer bromide</td>\n",
       "      <td>892497-01-7</td>\n",
       "      <td>90G53638ZD</td>\n",
       "      <td>Poly((1-(carboxymethyl)piperazin-1-ium-1,4-diy...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13576</th>\n",
       "      <td>DB15690</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Fluoroestradiol F-18</td>\n",
       "      <td>94153-53-4</td>\n",
       "      <td>T32277KB09</td>\n",
       "      <td>(18F)FES | 16-alpha-(18-Fluoro)-17betaestradio...</td>\n",
       "      <td>KDLLNMRYZGUVMA-ZYMZXAKXSA-N</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13577</th>\n",
       "      <td>DB15691</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Anti-SARS-CoV-2 REGN-COV2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>REGN10933+REGN10987 combination therapy</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13578</th>\n",
       "      <td>DB15692</td>\n",
       "      <td>NaN</td>\n",
       "      <td>COVID-19 convalescent plasma</td>\n",
       "      <td>NaN</td>\n",
       "      <td>YM6LN8TU2V</td>\n",
       "      <td>Convalescent plasma (COVID-19)</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13579</th>\n",
       "      <td>DB15693</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INO-4800</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INO-4800 DNA Coronavirus Vaccine</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>13580 rows × 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      DrugBank ID     Accession Numbers                   Common_name  \\\n",
       "0         DB00001  BIOD00024 | BTD00024                     Lepirudin   \n",
       "1         DB00002  BIOD00071 | BTD00071                     Cetuximab   \n",
       "2         DB00003  BIOD00001 | BTD00001                  Dornase alfa   \n",
       "3         DB00004  BIOD00084 | BTD00084           Denileukin diftitox   \n",
       "4         DB00005  BIOD00052 | BTD00052                    Etanercept   \n",
       "...           ...                   ...                           ...   \n",
       "13575     DB15689                   NaN              Azoximer bromide   \n",
       "13576     DB15690                   NaN          Fluoroestradiol F-18   \n",
       "13577     DB15691                   NaN     Anti-SARS-CoV-2 REGN-COV2   \n",
       "13578     DB15692                   NaN  COVID-19 convalescent plasma   \n",
       "13579     DB15693                   NaN                      INO-4800   \n",
       "\n",
       "               CAS        UNII  \\\n",
       "0      138068-37-8  Y43GF64R34   \n",
       "1      205923-56-4  PQX0D8J21J   \n",
       "2      143831-71-4  953A26OA1Y   \n",
       "3      173146-27-5  25E79B5CTM   \n",
       "4      185243-69-0  OP401G7OJC   \n",
       "...            ...         ...   \n",
       "13575  892497-01-7  90G53638ZD   \n",
       "13576   94153-53-4  T32277KB09   \n",
       "13577          NaN         NaN   \n",
       "13578          NaN  YM6LN8TU2V   \n",
       "13579          NaN         NaN   \n",
       "\n",
       "                                                Synonyms  \\\n",
       "0              Hirudin variant-1 | Lepirudin recombinant   \n",
       "1                   Cetuximab | CÃ©tuximab | Cetuximabum   \n",
       "2      Deoxyribonuclease (human clone 18-1 protein mo...   \n",
       "3      Denileukin | Interleukin-2/diptheria toxin fus...   \n",
       "4      Etanercept | etanercept-szzs | etanercept-ykro...   \n",
       "...                                                  ...   \n",
       "13575  Poly((1-(carboxymethyl)piperazin-1-ium-1,4-diy...   \n",
       "13576  (18F)FES | 16-alpha-(18-Fluoro)-17betaestradio...   \n",
       "13577            REGN10933+REGN10987 combination therapy   \n",
       "13578                     Convalescent plasma (COVID-19)   \n",
       "13579                   INO-4800 DNA Coronavirus Vaccine   \n",
       "\n",
       "                Standard InChI Key  \n",
       "0                              NaN  \n",
       "1                              NaN  \n",
       "2                              NaN  \n",
       "3                              NaN  \n",
       "4                              NaN  \n",
       "...                            ...  \n",
       "13575                          NaN  \n",
       "13576  KDLLNMRYZGUVMA-ZYMZXAKXSA-N  \n",
       "13577                          NaN  \n",
       "13578                          NaN  \n",
       "13579                          NaN  \n",
       "\n",
       "[13580 rows x 7 columns]"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Get drug names database\n",
    "\n",
    "df_drugs=pd.read_csv(r\"C:\\Users\\mese4\\Documents\\The Data incubator\\project\\Drugmap\\drugbank vocabulary.csv\", encoding='ISO-8859-1')\n",
    "df_drugs.head()\n",
    "\n",
    "df_drugs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['hirudin variant-1 ',\n",
       " ' lepirudin recombinant',\n",
       " 'cetuximab ',\n",
       " ' cã©tuximab ',\n",
       " ' cetuximabum',\n",
       " 'deoxyribonuclease (human clone 18-1 protein moiety) ',\n",
       " ' dornasa alfa ',\n",
       " ' dornase alfa, recombinant ',\n",
       " ' dornase alpha ',\n",
       " ' recombinant deoxyribonuclease (dnase)',\n",
       " 'denileukin ',\n",
       " ' interleukin-2/diptheria toxin fusion protein',\n",
       " 'etanercept ',\n",
       " ' etanercept-szzs ',\n",
       " ' etanercept-ykro ',\n",
       " ' recombinant human tnf ',\n",
       " ' rhu tnfr:fc ',\n",
       " ' rhu-tnfr:fc ',\n",
       " ' tnfr-immunoadhesin',\n",
       " 'bivalirudin ',\n",
       " ' bivalirudina ',\n",
       " ' bivalirudinum',\n",
       " 'leuprorelin ',\n",
       " ' leuprorelina ',\n",
       " ' leuproreline ',\n",
       " ' leuprorelinum',\n",
       " 'peg-ifn alfa-2a ',\n",
       " ' peg-interferon alfa-2a ',\n",
       " ' peginterferon alfa-2a ',\n",
       " ' pegylated interfeaon alfa-2a ',\n",
       " ' pegylated interferon alfa-2a ',\n",
       " ' pegylated interferon alpha-2a ',\n",
       " ' pegylated-interferon alfa 2a',\n",
       " 'alteplasa ',\n",
       " ' alteplase (genetical recombination) ',\n",
       " ' alteplase, recombinant ',\n",
       " ' alteplase,recombinant ',\n",
       " ' plasminogen activator (human tissue-type protein moiety) ',\n",
       " ' rt-pa ',\n",
       " ' t-pa ',\n",
       " ' t-plasminogen activator ',\n",
       " ' tissue plasminogen activator ',\n",
       " ' tissue plasminogen activator alteplase ',\n",
       " ' tissue plasminogen activator, recombinant ',\n",
       " ' tpa',\n",
       " 'interferon alpha-n1 (ins)',\n",
       " 'darbepoetin ',\n",
       " ' darbepoetin alfa,recombinant ',\n",
       " ' darbepoetina alfa',\n",
       " 'kinase (enzyme-activating), uro-urokinase ',\n",
       " ' tcuk ',\n",
       " ' tissue culture urokinase ',\n",
       " ' two-chain urokinase ',\n",
       " ' urochinasi ',\n",
       " ' urokinase ',\n",
       " ' urokinasum ',\n",
       " ' uroquinasa',\n",
       " 'goserelin ',\n",
       " ' goserelina',\n",
       " 'human t-pa (residues 1-3 and 176-527) ',\n",
       " ' reteplasa ',\n",
       " ' reteplase, recombinant ',\n",
       " ' reteplase,recombinant',\n",
       " 'e.p.o. ',\n",
       " ' epoetin alfa ',\n",
       " ' epoetin alfa rdna ',\n",
       " ' epoetin alfa-epbx ',\n",
       " ' epoetin alfa, recombinant ',\n",
       " ' epoetin beta ',\n",
       " ' epoetin beta rdna ',\n",
       " ' epoetin epsilon ',\n",
       " ' epoetin gamma ',\n",
       " ' epoetin gamma rdna ',\n",
       " ' epoetin kappa ',\n",
       " ' epoetin omega ',\n",
       " ' epoetin theta ',\n",
       " ' epoetin zeta ',\n",
       " ' epoetina alfa ',\n",
       " ' epoetina beta ',\n",
       " ' epoetina dseta ',\n",
       " ' epoetina zeta ',\n",
       " ' epoã©tine zãªta ',\n",
       " ' epoetinum zeta ',\n",
       " ' erythropoiesis stimulating factor ',\n",
       " ' erythropoietin (human, recombinant) ',\n",
       " ' erythropoietin (recombinant human) ',\n",
       " ' esf ',\n",
       " ' sh-polypeptide-72',\n",
       " 'calcitonin (salmon synthetic) ',\n",
       " ' calcitonin salmon ',\n",
       " ' calcitonin salmon recombinant ',\n",
       " ' calcitonin-salmon ',\n",
       " ' calcitonin, salmon ',\n",
       " ' calcitonina salmã³n sintã©tica ',\n",
       " ' recombinant salmon calcitonin ',\n",
       " ' salmon calcitonin',\n",
       " 'granulocyte colony-stimulating factor pegfilgrastim ',\n",
       " ' peg-filgrastim ',\n",
       " ' pegfilgrastim-apgf ',\n",
       " ' pegfilgrastim-bmez ',\n",
       " ' pegfilgrastim-cbqv ',\n",
       " ' pegfilgrastim-jmdb',\n",
       " 'recombinant human granulocyte-macrophage colony stimulating factor ',\n",
       " ' rgm-csf ',\n",
       " ' rhu gm-csf ',\n",
       " ' sargramostim',\n",
       " 'asparaginase ',\n",
       " ' asparaginase (e. coli) ',\n",
       " ' colaspase ',\n",
       " ' escherichia coli l-asparaginase ',\n",
       " ' l-asparaginase ',\n",
       " ' l-asparagine amidohydrolase',\n",
       " 'recombinant human thyroid stimulating hormone ',\n",
       " ' recombinant thyrotropin alfa ',\n",
       " ' rhtsh ',\n",
       " ' rtsh ',\n",
       " ' thyrotropin alpha',\n",
       " 'antihemophilic factor (recombinant) ',\n",
       " ' antihemophilic factor recombinant ',\n",
       " ' antihemophilic factor, human recombinant ',\n",
       " ' antihemophilic factor, recombinant ',\n",
       " ' factor viii (rdna) ',\n",
       " ' factor viii (recombinant) ',\n",
       " ' factor viii recombin ',\n",
       " ' factor viii, recombinant ',\n",
       " ' human factor viii (recombinant) ',\n",
       " ' human factor viii recombinant ',\n",
       " ' octocog alfa ',\n",
       " ' rahf ',\n",
       " ' recombinant antihemophilic factor viii',\n",
       " 'anakinra ',\n",
       " ' il-1ra ',\n",
       " ' interleukin-1 receptor antagonist anakinra',\n",
       " 'bacillus brevis gramicidin d ',\n",
       " ' gramicidin ',\n",
       " ' gramicidin a ',\n",
       " ' gramicidin b ',\n",
       " ' gramicidin c ',\n",
       " ' gramicidina ',\n",
       " ' gramicidine',\n",
       " 'human igg ',\n",
       " ' human immunoglobulin g ',\n",
       " ' human normal immunoglobulin ',\n",
       " ' immune globulin (human) ',\n",
       " ' immune globulin human ',\n",
       " ' immunoglobulin (human) ',\n",
       " ' immunoglobulin g (human) ',\n",
       " ' immunoglobulin g, human ',\n",
       " ' ivig',\n",
       " 'anisoylated plasminogen streptokinase activator complex ',\n",
       " ' apsac',\n",
       " 'high molecular weight insulin human ',\n",
       " ' human insulin ',\n",
       " ' human insulin (rdna) ',\n",
       " ' insulin (human) ',\n",
       " ' insulin human ',\n",
       " ' insulin human [rdna origin] ',\n",
       " ' insulin human regular ',\n",
       " ' insulin human regular (rdna) ',\n",
       " ' insulin human, rdna origin ',\n",
       " ' insulin recombinant human ',\n",
       " ' insulin recombinant purified human ',\n",
       " ' insulin regular ',\n",
       " ' insulin, human ',\n",
       " ' insulina regular ',\n",
       " ' regular insulin, human',\n",
       " 'tenecteplasa ',\n",
       " ' tnk-tpa',\n",
       " 'human menopausal gonadotrophin ',\n",
       " ' menotrophin ',\n",
       " ' menotropin ',\n",
       " ' menotropina ',\n",
       " ' menotropins (fsh;lh)',\n",
       " 'ifn-gamma 1b ',\n",
       " ' ifn-gamma-1b ',\n",
       " ' interferon gamma 1-b ',\n",
       " ' interferon gamma-1b ',\n",
       " ' interferon gamma-1b, recombinant ',\n",
       " ' interferon gamma-2a',\n",
       " 'interferon alfa-2a ',\n",
       " ' interferon alfa-2a (recombinant) ',\n",
       " ' interferon alfa-2a, recombinant ',\n",
       " ' interferon alfa-2a,recombinant ',\n",
       " ' interferon alpha-2a ',\n",
       " ' interferon-alfa-2a ',\n",
       " ' recombinant human interferon alfa-2a ',\n",
       " ' recombinant human interferon-alfa-2a ',\n",
       " ' rifn-alpha-2a ',\n",
       " ' sh-polypeptide-46',\n",
       " '1-(3-mercaptopropionic acid)-8-d-arginine-vasopressin ',\n",
       " ' 1-deamino-8-d-arginine vasopressin ',\n",
       " ' 1-desamino-8-d-arginine vasopressin ',\n",
       " ' ddavp ',\n",
       " ' desmopresina ',\n",
       " ' desmopressin ',\n",
       " ' desmopressine ',\n",
       " ' desmopressinum',\n",
       " 'coagulation factor viia ',\n",
       " ' coagulation factor viia (recombinant) ',\n",
       " ' coagulation factor viia (recombinant)-jncw ',\n",
       " ' eptacog alfa ',\n",
       " ' eptacog alfa (activated) ',\n",
       " ' rfviia',\n",
       " 'il-11 ',\n",
       " ' interleukin 11 ',\n",
       " ' interleukin-11 ',\n",
       " ' oprelvekin ',\n",
       " ' recombinant interleukin-11',\n",
       " '24-163 fibroblast growth factor 7 (human) ',\n",
       " ' palifermina',\n",
       " 'glucagon ',\n",
       " ' glucagon (recombinant dna origin) ',\n",
       " ' glucagon recombinant ',\n",
       " ' glucagon, human ',\n",
       " ' glucagon, porcine ',\n",
       " ' glucagone ',\n",
       " ' glucagonum',\n",
       " '125-l-serine-2-133-interleukin 2 (human reduced) ',\n",
       " ' aldesleukina ',\n",
       " ' interleukin-2 aldesleukin ',\n",
       " ' interleukin-2(2-133),125-ser ',\n",
       " ' recombinant interleukin-2 human',\n",
       " 'botulin b ',\n",
       " ' botulinum b toxin ',\n",
       " ' botulinum neurotoxin type b precursor ',\n",
       " ' btx-b ',\n",
       " ' rimabotulinumtoxinb ',\n",
       " ' toxina botulã\\xadnica b',\n",
       " 'lutropin alfa ',\n",
       " ' lutropin alpha ',\n",
       " ' lutropina alfa',\n",
       " 'lipoprotein ospa antigen recombinant ',\n",
       " ' lipoprotein outer surface a borrelia burgdorferi antigen ',\n",
       " ' ospa lipoprotein',\n",
       " 'insulin lispro (genetical recombination) ',\n",
       " ' insulin lispro (rdna origin) ',\n",
       " ' insulin lispro protamine ',\n",
       " ' insulin lispro protamine recombinant ',\n",
       " ' insulin lispro recombinant ',\n",
       " ' insulin lispro-aabc ',\n",
       " ' insulin,lispro,human/rdna ',\n",
       " ' insulin,lispro,protamine/rdna ',\n",
       " ' insulina lispro',\n",
       " 'insulin glargine ',\n",
       " ' insulin glargine (rdna origin) ',\n",
       " ' insulin glargine recombinant ',\n",
       " ' insulina glargina',\n",
       " 'clostridium histolyticum enzymes ',\n",
       " ' collagenase ',\n",
       " ' collagenase clostridium histolyticum',\n",
       " 'rasburicasa ',\n",
       " ' rasburicase ',\n",
       " ' urate oxidase',\n",
       " 'cetrorelix ',\n",
       " ' cetrorelixum',\n",
       " 'adalimumab (genetical recombination) ',\n",
       " ' adalimumab-adaz ',\n",
       " ' adalimumab-adbm ',\n",
       " ' adalimumab-afzb ',\n",
       " ' adalimumab-atto ',\n",
       " ' adalimumab-bwwd',\n",
       " 'growth hormone ',\n",
       " ' growth hormone (human) ',\n",
       " ' hgh ',\n",
       " ' human growth hormone ',\n",
       " ' recombinant human growth hormone ',\n",
       " ' rhgh ',\n",
       " ' somatotropin (human) ',\n",
       " ' somatotropin human ',\n",
       " ' somatotropin human growth hormone ',\n",
       " ' somatropin ',\n",
       " ' somatropin (rdna origin) ',\n",
       " ' somatropin (recombinant dna origin) ',\n",
       " ' somatropin [rdna origin] ',\n",
       " ' somatropin recombinant ',\n",
       " ' somatropin(recombinant dna origin) ',\n",
       " ' somatropina',\n",
       " 'imiglucerasa',\n",
       " 'abciximab ',\n",
       " ' abciximab (genetical recombination) ',\n",
       " ' c7e3',\n",
       " 'activated protein c ',\n",
       " ' blood coagulation factor xiv (human) ',\n",
       " ' drotrecogin alfa (activated) ',\n",
       " ' drotrecogin alfa (activated), lyophilized ',\n",
       " ' drotrecogin alfa activated ',\n",
       " ' drotrecogin alfa, activated ',\n",
       " ' drotrecogin-alfa ',\n",
       " ' recombinant human activated protein c (rh-apc)',\n",
       " 'indium (111in) satumomab pendetide ',\n",
       " ' indium in 111 satumomab pendetide ',\n",
       " ' indium-111 satumomab pendetide',\n",
       " 'alfa 1-proteinase inhibitor (human) ',\n",
       " ' alfa-1-antitripsina ',\n",
       " ' alfa1 antitrypsin ',\n",
       " ' alpha 1-antitrypsin ',\n",
       " ' alpha 1-proteinase inhibitor ',\n",
       " ' alpha 1-proteinase inhibitor (human) ',\n",
       " ' alpha 1-proteinase inhibitor, human ',\n",
       " ' alpha-1 protease inhibitor ',\n",
       " ' alpha-1 proteinase inhibitor (human) ',\n",
       " ' alpha-1-antiproteinase ',\n",
       " ' alpha-1-antitrypsin ',\n",
       " ' alpha-1-proteinase inhibitor (human) ',\n",
       " ' alpha-1-proteinase inhibitor human ',\n",
       " ' alpha-1-proteinase inhibitor, human ',\n",
       " ' alpha-1-proteinase inhibitor,human ',\n",
       " ' alpha1-proteinase inhibitor ',\n",
       " ' alpha1-proteinase inhibitor (human) ',\n",
       " ' alpha1-proteinase inhibitor human ',\n",
       " ' api',\n",
       " 'peg-asparaginase ',\n",
       " ' peg/l-asparaginase ',\n",
       " ' pegaspargasa',\n",
       " 'interferon beta 1-a ',\n",
       " ' interferon beta 1a ',\n",
       " ' interferon beta-1a (recombinant human) ',\n",
       " ' interferon beta-1a,recombinant ',\n",
       " ' interferon-beta-1a',\n",
       " '(monomethoxypolyethylene glycol succinimidyl) 11-17-adenosine deaminase ',\n",
       " ' peg-adenosine deaminase ',\n",
       " ' pegada ',\n",
       " ' pegademase ',\n",
       " ' pegademase bovine',\n",
       " 'albumin (human) ',\n",
       " ' albumin human ',\n",
       " ' albumin, blood ',\n",
       " ' albumin, human ',\n",
       " ' albumin, human-kjda ',\n",
       " ' human albumin ',\n",
       " ' human serum albumin ',\n",
       " ' serum albumin',\n",
       " 'eptifibatida ',\n",
       " ' eptifibatide ',\n",
       " ' integrelin ',\n",
       " ' intrifiban',\n",
       " 'infliximab (genetical recombination) ',\n",
       " ' infliximab-abda ',\n",
       " ' infliximab-axxq ',\n",
       " ' infliximab-dyyb ',\n",
       " ' infliximab-qbtx',\n",
       " 'folitropina alfa ',\n",
       " ' folitropina beta ',\n",
       " ' folitropina delta ',\n",
       " ' follicle stimulating hormone ',\n",
       " ' follitrophin alfa ',\n",
       " ' follitrophin alpha ',\n",
       " ' follitrophin beta ',\n",
       " ' follitropin alfa ',\n",
       " ' follitropin alfa/beta ',\n",
       " ' follitropin alpha ',\n",
       " ' follitropin beta ',\n",
       " ' follitropin delta ',\n",
       " ' follitropin gamma ',\n",
       " ' follotropin recombinant ',\n",
       " ' fsh ',\n",
       " ' fsh alpha ',\n",
       " ' fsh-a ',\n",
       " ' fsh-b ',\n",
       " ' fsh-beta ',\n",
       " ' recombinant human follicle stimulating hormone beta ',\n",
       " ' recombinant human follicle-stimulating hormone (r-hfsh) ',\n",
       " ' rfsh-alpha',\n",
       " 'vasopressin, unspecified ',\n",
       " ' vasopressina',\n",
       " 'interferon beta 1b (recombinant) ',\n",
       " ' interferon beta-1b,recombinant ',\n",
       " ' interferon-beta-1b ',\n",
       " ' recombinant interferon beta-1b',\n",
       " 'ifn alfacon-1 ',\n",
       " ' ifn-con1 ',\n",
       " ' interferon alfacon-1',\n",
       " 'hyaluronidase (glycoprotein, sheep testis isoenzyme) ',\n",
       " ' hyaluronidase (ovine) ',\n",
       " ' hyaluronidase (sheep testis isoenzyme) ',\n",
       " ' hyaluronidase, ovine ',\n",
       " ' ovine hyaluronidase',\n",
       " 'insulin (pork) ',\n",
       " ' insulin porcine ',\n",
       " ' insulin purified porcine ',\n",
       " ' insulin purified pork ',\n",
       " ' insulin, porcine ',\n",
       " ' insulin, regular, pork ',\n",
       " ' porcine insulin',\n",
       " 'rhumab her2 ',\n",
       " ' trastuzumab-anns ',\n",
       " ' trastuzumab-dkst ',\n",
       " ' trastuzumab-dttb ',\n",
       " ' trastuzumab-pkrb ',\n",
       " ' trastuzumab-qyyp',\n",
       " 'rituximab-abbs ',\n",
       " ' rituximab-pvvr',\n",
       " 'basiliximab',\n",
       " 'anti-cd3 ',\n",
       " ' muromonab-cd3',\n",
       " 'digitalis antitoxin ',\n",
       " ' digoxin immune fab, ovine ',\n",
       " ' digoxin-specific antibody fragments ',\n",
       " ' ovine digoxin immune fab',\n",
       " 'ibritumomab ',\n",
       " ' mab murine (igg1) anti p19437 (cd20_mouse)',\n",
       " 'daptomicina ',\n",
       " ' daptomycin ',\n",
       " ' daptomycine ',\n",
       " ' daptomycinum',\n",
       " 'abobotulinumtoxina ',\n",
       " ' botulinum a neurotoxin ',\n",
       " ' botulinum toxin a ',\n",
       " ' botulinum toxin type a ',\n",
       " ' btx-a ',\n",
       " ' evabotulinumtoxina ',\n",
       " ' incobotulinumtoxina ',\n",
       " ' onabotulinumtoxina ',\n",
       " ' prabotulinumtoxin a ',\n",
       " ' toxina botulã\\xadnica a ',\n",
       " ' toxine botulinique a',\n",
       " 'pancrealipase ',\n",
       " ' pancreatic extract pancrelipase ',\n",
       " ' pancreatic protease ',\n",
       " ' pancreatin ',\n",
       " ' pancreatinum ',\n",
       " ' pancrelipase (amylase;lipase;protease)',\n",
       " 'estreptoquinasa ',\n",
       " ' streptochinasi ',\n",
       " ' streptococcal fibrinolysin ',\n",
       " ' streptokinase ',\n",
       " ' streptokinasum',\n",
       " '(111in)-capromab pendetide ',\n",
       " ' indium (111in) capromab pendetide ',\n",
       " ' indium 111 capromab pendetide ',\n",
       " ' indium in 111 capromab pendetide',\n",
       " 'alpha-l-idosiduronase ',\n",
       " ' human recombinant alpha-l-iduronidase ',\n",
       " ' laronidasa ',\n",
       " ' laronidase ',\n",
       " ' laronidase (genetical recombination)',\n",
       " 'ciclosporin ',\n",
       " ' ciclosporina ',\n",
       " ' ciclosporine ',\n",
       " ' ciclosporinum ',\n",
       " ' csa ',\n",
       " ' cya ',\n",
       " ' cyclosporin ',\n",
       " ' cyclosporin a ',\n",
       " ' cyclosporine',\n",
       " '2-(l-phenylalanine)-8-l-lysinevasopressin ',\n",
       " ' felipresina ',\n",
       " ' felypressin ',\n",
       " ' felypressine ',\n",
       " ' felypressinum ',\n",
       " ' plv-2',\n",
       " 'follitropin human ',\n",
       " ' urofollitrophin',\n",
       " 'anti-cd11a ',\n",
       " ' anticd11 alpha ',\n",
       " ' efalizumab',\n",
       " 'choriogonadotropin alpha ',\n",
       " ' chorionic gonadotropin (recombinant)',\n",
       " 'anti-human thymocyte immunoglobulin, rabbit ',\n",
       " ' anti-t-lymphocyte immune globulin, rabbit ',\n",
       " ' anti-thymocyte globulin (rabbit) ',\n",
       " ' anti-thymocyte globulin rabbit ',\n",
       " ' antithymocyte immunoglobulin ',\n",
       " ' lapine t-lymphocyte immune globulin ',\n",
       " ' rabbit anti-human thymocyte globulin ',\n",
       " ' rabbit anti-human thymocyte globulin (ratg) ',\n",
       " ' rabbit anti-human thymocyte immunoglobulin ',\n",
       " ' rabbit anti-thymocyte immunoglobulin ',\n",
       " ' rabbit antithymocyte globulin ',\n",
       " ' rabbit atg ',\n",
       " ' ratg ',\n",
       " ' thymoglobulin ',\n",
       " ' thymoglobuline',\n",
       " 'filgrastim-aafi ',\n",
       " ' filgrastim-sndz ',\n",
       " ' g-csf  ',\n",
       " ' granulocyte colony stimulating factor  ',\n",
       " ' tbo-filgrastim',\n",
       " 'coagulation factor ix (recombinant) ',\n",
       " ' coagulation factor ix recombinant human ',\n",
       " ' factor ix (recombinant) ',\n",
       " ' nonacog alfa ',\n",
       " ' nonacog gamma ',\n",
       " ' recombinant factor ix',\n",
       " 'becaplermin ',\n",
       " ' pdgf-2 ',\n",
       " ' pdgf-bb ',\n",
       " ' pdgfb ',\n",
       " ' platelet-derived growth factor bb, recombinant ',\n",
       " ' platelet-derived growth factor beta polypeptide ',\n",
       " ' recombinant platelet-derived growth factor bb ',\n",
       " ' rhpdgf-bb ',\n",
       " ' rpdgf-bb ',\n",
       " ' sh-polypeptide-59',\n",
       " 'agalsidasa alfa ',\n",
       " ' agalsidasa beta ',\n",
       " ' agalsidase alfa ',\n",
       " ' alpha-galactosidase a',\n",
       " 'octreotida ',\n",
       " ' octreotide ',\n",
       " ' octreotidum ',\n",
       " ' octrotide',\n",
       " 'interferon alfa-2b ',\n",
       " ' interferon alfa-2b, recombinant ',\n",
       " ' interferon alpha-2b ',\n",
       " ' interferon î±-2b ',\n",
       " ' intron (interferon î±2b) ',\n",
       " ' intron a ',\n",
       " ' intron a (interferon î±2b) ',\n",
       " ' r-inf-alpha ',\n",
       " ' rifn-alpha-2b',\n",
       " 'abarelix',\n",
       " 'oxitocina ',\n",
       " ' oxytocin',\n",
       " 'anti-alpha4 integrin ',\n",
       " ' anti-vla4',\n",
       " 'enfuvirtida',\n",
       " 'palivizumab',\n",
       " 'dacliximab ',\n",
       " ' daclizumab beta',\n",
       " 'anti-vegf humanized monoclonal antibody ',\n",
       " ' anti-vegf monoclonal antibody ',\n",
       " ' bevacizumab ',\n",
       " ' bevacizumab-awwb ',\n",
       " ' rhumab-vegf',\n",
       " 'arcitumomab technetium-99m ',\n",
       " ' technetium (99mtc) arcitumomab ',\n",
       " ' technetium tc 99m arcitumomab ',\n",
       " ' technetium-99m arcitumomab',\n",
       " '3-hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinecarboxaldehyde ',\n",
       " ' 3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate ',\n",
       " ' codecarboxylase ',\n",
       " ' plp ',\n",
       " ' pyridoxal 5-monophosphoric acid ester ',\n",
       " ' pyridoxal 5-phosphate ',\n",
       " \" pyridoxal 5'-phosphate \",\n",
       " ' pyridoxal p ',\n",
       " ' pyridoxal phosphate anhydrous ',\n",
       " ' pyridoxal-5p ',\n",
       " ' pyridoxal-p',\n",
       " 'cianocobalamina ',\n",
       " ' cyanocob(iii)alamin ',\n",
       " ' cyanocobalamin ',\n",
       " ' cyanocobalamine ',\n",
       " ' cyanocobalaminum ',\n",
       " ' vitamin b12 ',\n",
       " ' vitamin b12 complex ',\n",
       " ' vitamin b12 nos',\n",
       " '5,6,7,8-tetrahydrofolate ',\n",
       " ' 5,6,7,8-tetrahydrofolic acid ',\n",
       " ' tetrahydrofolate',\n",
       " '(s)-4-(2-amino-2-carboxyethyl)imidazole ',\n",
       " ' (s)-a-amino-1h-imidazole-4-propanoic acid ',\n",
       " ' (s)-alpha-amino-1h-imidazole-4-propanoic acid ',\n",
       " ' (s)-alpha-amino-1h-imidazole-4-propionic acid ',\n",
       " ' (s)-î±-amino-1h-imidazole-4-propanoic acid ',\n",
       " ' his ',\n",
       " ' histidina ',\n",
       " ' histidine ',\n",
       " ' l-(â\\x88\\x92)-histidine ',\n",
       " ' l-histidin ',\n",
       " ' l-histidine',\n",
       " 'ademetionine ',\n",
       " ' adomet ',\n",
       " ' l-s-adenosylmethionine ',\n",
       " ' s-adenosylmethionine ',\n",
       " ' sam ',\n",
       " ' sam-e ',\n",
       " ' same',\n",
       " '2-ketopropionic acid ',\n",
       " ' 2-oxopropanoic acid ',\n",
       " ' 2-oxopropansã¤ure ',\n",
       " ' 2-oxopropionsã¤ure ',\n",
       " ' a-ketopropionic acid ',\n",
       " ' acetylformic acid ',\n",
       " ' acide pyruvique ',\n",
       " ' alpha-ketopropionic acid ',\n",
       " ' brenztraubensã¤ure ',\n",
       " ' bts ',\n",
       " ' pyroracemic acid ',\n",
       " ' î±-ketopropionic acid ',\n",
       " ' î±-oxopropionsã¤ure',\n",
       " '(s)-2-amino-3-phenylpropionic acid ',\n",
       " ' (s)-alpha-amino-beta-phenylpropionic acid ',\n",
       " ' 3-phenyl-l-alanine ',\n",
       " ' beta-phenyl-l-alanine ',\n",
       " ' f ',\n",
       " ' fenilalanina ',\n",
       " ' l-phenylalanine ',\n",
       " ' phe ',\n",
       " ' phenylalanine ',\n",
       " ' phenylalaninum ',\n",
       " ' î²-phenyl-l-alanine',\n",
       " '(+)-cis-hexahydro-2-oxo-1h-thieno[3,4]imidazole-4-valeric acid ',\n",
       " ' (3as,4s,6ar)-hexahydro-2-oxo-1h-thieno[3,4-d]imidazole-4-valeric acid ',\n",
       " ' 5-(2-oxohexahydro-1h-thieno[3,4-d]imidazol-4-yl)pentanoic acid ',\n",
       " ' biotin ',\n",
       " ' biotina ',\n",
       " ' biotine ',\n",
       " ' biotinum ',\n",
       " ' cis-(+)-tetrahydro-2-oxothieno[3,4]imidazoline-4-valeric acid ',\n",
       " ' cis-hexahydro-2-oxo-1h-thieno(3,4)imidazole-4-valeric acid ',\n",
       " ' cis-tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid ',\n",
       " ' coenzyme r ',\n",
       " ' d-(+)-biotin ',\n",
       " ' d-biotin ',\n",
       " ' vitamin b7 ',\n",
       " ' vitamin h',\n",
       " 'bilineurine ',\n",
       " ' choline ion ',\n",
       " ' n-trimethylethanolamine ',\n",
       " ' n,n,n-trimethylethanol-ammonium ',\n",
       " ' trimethylethanolamine ',\n",
       " ' vitamin j',\n",
       " '(s)-2,6-diaminohexanoic acid ',\n",
       " ' (s)-lysine ',\n",
       " ' (s)-î±,îµ-diaminocaproic acid ',\n",
       " ' 6-ammonio-l-norleucine ',\n",
       " ' l-2,6-diaminocaproic acid ',\n",
       " ' l-lys ',\n",
       " ' l-lysin ',\n",
       " ' lys ',\n",
       " ' lysina ',\n",
       " ' lysine ',\n",
       " ' lysine acid ',\n",
       " ' lysinum',\n",
       " '(2s)-2-amino-5-(carbamimidamido)pentanoic acid ',\n",
       " ' (2s)-2-amino-5-guanidinopentanoic acid ',\n",
       " ' (s)-2-amino-5-guanidinopentanoic acid ',\n",
       " ' (s)-2-amino-5-guanidinovaleric acid ',\n",
       " ' arg ',\n",
       " ' arginina ',\n",
       " ' arginine ',\n",
       " ' l-(+)-arginine ',\n",
       " ' l-arg ',\n",
       " ' l-arginin ',\n",
       " ' l-arginine ',\n",
       " ' r',\n",
       " 'acide ascorbique ',\n",
       " ' ã¡cido ascã³rbico ',\n",
       " ' acidum ascorbicum ',\n",
       " ' acidum ascorbinicum ',\n",
       " ' ascorbate ',\n",
       " ' ascorbic acid ',\n",
       " ' ascorbinsã¤ure ',\n",
       " ' l-(+)-ascorbic acid ',\n",
       " ' l-ascorbate ',\n",
       " ' l-ascorbic acid ',\n",
       " ' vitamin c ',\n",
       " ' vitamina c',\n",
       " '4,9-diaza-1,12-dodecanediamine ',\n",
       " ' 4,9-diazadodecane-1,12-diamine ',\n",
       " ' musculamine ',\n",
       " \" n,n'-bis(3-aminopropyl)-1,4-butanediamine \",\n",
       " ' spermina ',\n",
       " ' spermine',\n",
       " '(s)-2-aminobutanedioic acid ',\n",
       " ' (s)-2-aminosuccinic acid ',\n",
       " ' 2-aminosuccinic acid ',\n",
       " ' ã¡cido aspã¡rtico ',\n",
       " ' acidum asparticum ',\n",
       " ' asp ',\n",
       " ' aspartic acid ',\n",
       " ' d ',\n",
       " ' l-asp ',\n",
       " ' l-asparaginsã¤ure ',\n",
       " ' l-aspartate ',\n",
       " ' l-aspartic acid',\n",
       " '(s)-2,5-diaminopentanoate ',\n",
       " ' (s)-2,5-diaminopentanoic acid ',\n",
       " ' (s)-2,5-diaminovaleric acid ',\n",
       " ' (s)-ornithine ',\n",
       " ' (s)-î±,î´-diaminovaleric acid ',\n",
       " ' l-ornithine ',\n",
       " ' levo-ornithine ',\n",
       " ' ornithine ',\n",
       " ' ornithinum ',\n",
       " ' ornitina',\n",
       " '(2s)-2-amino-4-carbamoylbutanoic acid ',\n",
       " ' (2s)-2,5-diamino-5-oxopentanoic acid ',\n",
       " ' (s)-2,5-diamino-5-oxopentanoic acid ',\n",
       " ' glutamic acid 5-amide ',\n",
       " ' glutamic acid amide ',\n",
       " ' glutamina ',\n",
       " ' glutamine ',\n",
       " ' l-(+)-glutamine ',\n",
       " ' l-2-aminoglutaramic acid ',\n",
       " ' l-glutamic acid î³-amide ',\n",
       " ' l-glutamin ',\n",
       " ' l-glutaminsã¤ure-5-amid ',\n",
       " ' levoglutamide ',\n",
       " ' q',\n",
       " \"5'-adenosine monophosphate \",\n",
       " \" 5'-adenylic acid \",\n",
       " \" 5'-amp \",\n",
       " \" 5'-o-phosphonoadenosine \",\n",
       " \" adenosine 5'-(dihydrogen phosphate) \",\n",
       " \" adenosine 5'-monophosphate \",\n",
       " \" adenosine 5'-phosphate \",\n",
       " ' adenosine monophosphate ',\n",
       " ' adenosine phosphate ',\n",
       " \" adenosine-5'-monophosphate \",\n",
       " \" adenosine-5'-monophosphoric acid \",\n",
       " \" adenosine-5'p \",\n",
       " ' adenosini phosphas ',\n",
       " ' adenylate ',\n",
       " ' adenylic acid ',\n",
       " \" ado5'p \",\n",
       " ' amp ',\n",
       " ' fosfato de adenosina ',\n",
       " ' pado ',\n",
       " \" phosphate d'adã©nosine\",\n",
       " '(9,12,15)-linolenic acid ',\n",
       " ' (9z,12z,15z)-octadecatrienoic acid ',\n",
       " ' (z,z,z)-9,12,15-octadecatrienoic acid ',\n",
       " ' 9-cis,12-cis,15-cis-octadecatrienoic acid ',\n",
       " ' 9,12,15-octadecatrienoic acid ',\n",
       " ' ala ',\n",
       " ' all-cis-9,12,15-octadecatrienoic acid ',\n",
       " ' alpha-linolenic acid ',\n",
       " ' cis-delta(9,12,15)-octadecatrienoic acid ',\n",
       " ' cis,cis,cis-9,12,15-octadecatrienoic acid ',\n",
       " ' linolenic acid ',\n",
       " ' î±-linolenic acid',\n",
       " '(s)-2-amino-3-hydroxypropanoic acid ',\n",
       " ' (s)-serine ',\n",
       " ' alpha-amino-beta-hydroxypropionic acid ',\n",
       " ' beta-hydroxyalanine ',\n",
       " ' l-serine ',\n",
       " ' ser ',\n",
       " ' serina ',\n",
       " ' serine ',\n",
       " ' serinum',\n",
       " '(2s)-2-amino-4-(methylsulfanyl)butanoic acid ',\n",
       " ' (s)-2-amino-4-(methylthio)butanoic acid ',\n",
       " ' (s)-2-amino-4-(methylthio)butyric acid ',\n",
       " ' (s)-methionine ',\n",
       " ' l-(â\\x88\\x92)-methionine ',\n",
       " ' l-a-amino-g-methylthiobutyric acid ',\n",
       " ' l-methionin ',\n",
       " ' l-methionine ',\n",
       " ' l-î±-amino-î³-methylmercaptobutyric acid ',\n",
       " ' m ',\n",
       " ' met ',\n",
       " ' methionine',\n",
       " '(â\\x88\\x92)-î±-amino-p-hydroxyhydrocinnamic acid ',\n",
       " ' (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid ',\n",
       " ' (s)-(-)-tyrosine ',\n",
       " ' (s)-2-amino-3-(p-hydroxyphenyl)propionic acid ',\n",
       " ' (s)-3-(p-hydroxyphenyl)alanine ',\n",
       " ' (s)-alpha-amino-4-hydroxybenzenepropanoic acid ',\n",
       " ' (s)-tyrosine ',\n",
       " ' (s)-î±-amino-4-hydroxybenzenepropanoic acid ',\n",
       " ' 4-hydroxy-l-phenylalanine ',\n",
       " ' l-tyrosin ',\n",
       " ' l-tyrosine ',\n",
       " ' tirosina ',\n",
       " ' tyr ',\n",
       " ' tyrosine ',\n",
       " ' tyrosinum ',\n",
       " ' y',\n",
       " '(1s,3r,5z,7e)-9,10-secocholesta-5,7,10-triene-1,3,25-triol ',\n",
       " ' (1î±,3î²,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol ',\n",
       " ' (5z,7e)-(1s,3r)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol ',\n",
       " ' 1-alpha-25-dihydroxyvitamin d3 ',\n",
       " ' 1,25-dhcc ',\n",
       " ' 1,25-dihydroxycholecalciferol ',\n",
       " ' 1î±,25-dihydroxycholecalciferol ',\n",
       " ' 1î±,25-dihydroxyvitamin d3 ',\n",
       " ' 1î±,25(oh)2d3 ',\n",
       " ' calcitriol ',\n",
       " ' calcitriolum',\n",
       " 'xanthophyll ',\n",
       " ' xantofyl',\n",
       " \"(r,r)-3,3'-dithiobis(2-aminopropanoic acid) \",\n",
       " ' cistina ',\n",
       " ' l-alpha-diamino-beta-dithiolactic acid ',\n",
       " ' l-cystine ',\n",
       " ' l-dicysteine ',\n",
       " \" î²,î²'-dithiodialanine\",\n",
       " '1,2-ethanedicarboxylic acid ',\n",
       " ' acide butanedioã¯que ',\n",
       " ' acide succinique ',\n",
       " ' acidum succinicum ',\n",
       " ' amber acid ',\n",
       " ' asuccin ',\n",
       " ' bernsteinsã¤ure ',\n",
       " ' butandisã¤ure ',\n",
       " ' butanedioic acid ',\n",
       " ' butanedionic acid ',\n",
       " ' dihydrofumaric acid ',\n",
       " ' ethylenesuccinic acid ',\n",
       " ' spirit of amber ',\n",
       " ' succinic acid',\n",
       " '1-deoxy-1-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2h)-yl)pentitol ',\n",
       " ' 6,7-dimethyl-9-d-ribitylisoalloxazine ',\n",
       " ' 7,8-dimethyl-10-(d-ribo-2,3,4,5-tetrahydroxypentyl)isoalloxazine ',\n",
       " ' 7,8-dimethyl-10-ribitylisoalloxazine ',\n",
       " ' lactoflavin ',\n",
       " ' lactoflavine ',\n",
       " ' riboflavin ',\n",
       " ' riboflavina ',\n",
       " ' riboflavine ',\n",
       " ' riboflavinum ',\n",
       " ' vitamin b2 ',\n",
       " ' vitamin bi ',\n",
       " ' vitamin g',\n",
       " '2-acetamido-2-deoxy-d-glucose ',\n",
       " ' aldehydo-n-acetyl-d-glucosamine ',\n",
       " ' d-glcnac ',\n",
       " ' n-acetyl-d-glucosamine ',\n",
       " ' n-acetylchitosamine',\n",
       " '(2s)-2-aminopentanedioic acid ',\n",
       " ' (s)-2-aminopentanedioic acid ',\n",
       " ' (s)-glutamic acid ',\n",
       " ' ã¡cido glutã¡mico ',\n",
       " ' glu ',\n",
       " ' glutamic acid ',\n",
       " ' l-glutamate ',\n",
       " ' l-glutamic acid ',\n",
       " ' l-glutaminic acid',\n",
       " '5-l-glutamyl-l-cysteinylglycine ',\n",
       " ' gamma-l-glutamyl-l-cysteinyl-glycine ',\n",
       " ' glutathione ',\n",
       " ' glutathione-sh ',\n",
       " ' gsh ',\n",
       " ' n-(n-gamma-l-glutamyl-l-cysteinyl)glycine ',\n",
       " ' reduced glutathione',\n",
       " 'phosphatidyl-l-serine ',\n",
       " ' phosphatidylserine ',\n",
       " ' ps ',\n",
       " ' ptd-l-ser',\n",
       " 'aminoacetic acid ',\n",
       " ' aminoessigsã¤ure ',\n",
       " ' aminoethanoic acid ',\n",
       " ' glicina ',\n",
       " ' gly ',\n",
       " ' glycin ',\n",
       " ' glycine ',\n",
       " ' glycocoll ',\n",
       " ' glykokoll ',\n",
       " ' glyzin ',\n",
       " ' leimzucker',\n",
       " '(3s,5z,7e)-9,10-secocholesta-5,7,10-triene-3,25-diol ',\n",
       " ' (3î²,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol ',\n",
       " ' (5z,7e)-(3s)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol ',\n",
       " ' 25-hydroxycholecalciferol ',\n",
       " ' 25-hydroxyvitamin d3 ',\n",
       " ' calcidiol ',\n",
       " ' calcifã©diol ',\n",
       " ' calcifediol ',\n",
       " ' calcifediol anhydrous ',\n",
       " ' calcifediolum',\n",
       " '2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine ',\n",
       " ' 3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinecarboxaldehyde ',\n",
       " ' 3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde ',\n",
       " ' 3-hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carboxaldehyde ',\n",
       " ' piridoxal ',\n",
       " ' pyridoxaldehyde',\n",
       " '((amino(imino)methyl)(methyl)amino)acetic acid ',\n",
       " ' (alpha-methylguanido)acetic acid ',\n",
       " ' (n-methylcarbamimidamido)acetic acid ',\n",
       " ' (î±-methylguanido)acetic acid ',\n",
       " ' alpha-methylguanidino acetic acid ',\n",
       " ' creatin ',\n",
       " ' creatine ',\n",
       " ' kreatin ',\n",
       " ' methylglycocyamine ',\n",
       " ' n-(aminoiminomethyl)-n-methylglycine ',\n",
       " ' n-amidinosarcosine ',\n",
       " ' n-carbamimidoyl-n-methylglycine ',\n",
       " ' n-methyl-n-guanylglycine',\n",
       " '(2s)-2-amino-4-methylpentanoic acid ',\n",
       " ' (2s)-alpha-2-amino-4-methylvaleric acid ',\n",
       " ' (2s)-alpha-leucine ',\n",
       " ' (s)-(+)-leucine ',\n",
       " ' (s)-leucine ',\n",
       " ' 2-amino-4-methylvaleric acid ',\n",
       " ' l ',\n",
       " ' l-leucin ',\n",
       " ' l-leucine ',\n",
       " ' l-leuzin ',\n",
       " ' leu ',\n",
       " ' leucine',\n",
       " '(2s)-2-amino-3-(1h-indol-3-yl)propanoic acid ',\n",
       " ' (s)-alpha-amino-beta-(3-indolyl)-propionic acid ',\n",
       " ' (s)-tryptophan ',\n",
       " ' (s)-î±-amino-1h-indole-3-propanoic acid ',\n",
       " ' l-(-)-tryptophan ',\n",
       " ' l-(â\\x88\\x92)-tryptophan ',\n",
       " ' l-tryptophan ',\n",
       " ' l-î²-3-indolylalanine ',\n",
       " ' triptofano ',\n",
       " ' trp ',\n",
       " ' tryptophan ',\n",
       " ' tryptophane ',\n",
       " ' tryptophanum ',\n",
       " ' w',\n",
       " '(2r)-2-amino-3-mercaptopropanoic acid ',\n",
       " ' (2r)-2-amino-3-sulfanylpropanoic acid ',\n",
       " ' (r)-2-amino-3-mercaptopropanoic acid ',\n",
       " ' cisteina ',\n",
       " ' cisteinum ',\n",
       " ' cys ',\n",
       " ' cysteine ',\n",
       " ' cysteinum ',\n",
       " ' free cysteine ',\n",
       " ' l-2-amino-3-mercaptopropionic acid ',\n",
       " ' l-cys ',\n",
       " ' l-cystein ',\n",
       " ' l-zystein',\n",
       " 'aneurin ',\n",
       " ' antiberiberi factor ',\n",
       " ' thiamin ',\n",
       " ' thiamine ',\n",
       " ' thiamine(1+) ',\n",
       " ' thiamine(1+) ion ',\n",
       " ' thiaminium ',\n",
       " ' thiaminum ',\n",
       " ' tiamina ',\n",
       " ' vitamin b1',\n",
       " '(3î²,5z,7e,22e)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol ',\n",
       " ' (5z,7e,22e)-(3s)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol ',\n",
       " ' (5z,7e,22e)-(3s)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol ',\n",
       " ' activated ergosterol ',\n",
       " ' ercalciol ',\n",
       " ' ergocalcifã©rol ',\n",
       " ' ergocalciferol ',\n",
       " ' ergocalciferolum ',\n",
       " ' oleovitamin d2 ',\n",
       " ' viosterol ',\n",
       " ' vitamin d2 ',\n",
       " ' vitamina d2',\n",
       " '(8z,11z,14z)-icosatrienoic acid ',\n",
       " ' (z,z,z)-8,11,14-eicosatrienoic acid ',\n",
       " ' (z,z,z)-8,11,14-icosatrienoate ',\n",
       " ' (z,z,z)-8,11,14-icosatrienoic acid ',\n",
       " ' 20:3, n-6,9,12 all-cis ',\n",
       " ' 8,11,14-eicosatrienoic acid ',\n",
       " ' 8c,11c,14c-eicosatrienoic acid ',\n",
       " ' 8c,11c,14c-eicosatriensã¤ure ',\n",
       " ' all-cis-8,11,14-eicosatrienoic acid ',\n",
       " ' all-cis-8,11,14-icosatrienoic acid ',\n",
       " ' all-cis-eicosa-8,11,14-trienoic acid ',\n",
       " ' all-cis-eicosa-8,11,14-triensã¤ure ',\n",
       " ' all-cis-icosa-8,11,14-trienoic acid ',\n",
       " ' c20:3, n-6,9,12 all-cis ',\n",
       " ' cis,cis,cis-8,11,14-eicosatrienoic acid ',\n",
       " ' dgla ',\n",
       " ' dihomo-î³-linolenic acid ',\n",
       " ' eicosa-8z,11z,14z-trienoic acid ',\n",
       " ' gamma-homolinolenic acid ',\n",
       " ' homo-gamma-linolenic acid ',\n",
       " ' homo-gamma-linolensã¤ure ',\n",
       " ' homo-î³-linolensã¤ure',\n",
       " '(s)-2-amino-5-ureidopentanoic acid ',\n",
       " ' 2-amino-5-ureidovaleric acid ',\n",
       " ' alpha-amino-delta-ureidovaleric acid ',\n",
       " ' cit ',\n",
       " ' citrulina ',\n",
       " ' citrulline ',\n",
       " ' delta-ureidonorvaline ',\n",
       " ' l-2-amino-5-ureidovaleric acid ',\n",
       " ' l-citrulline ',\n",
       " ' n(5)-(aminocarbonyl)-l-ornithine ',\n",
       " ' n(delta)-carbamylornithine ',\n",
       " ' n5-(aminocarbonyl)ornithine ',\n",
       " ' n5-carbamoyl-l-ornithine ',\n",
       " ' n5-carbamoylornithine ',\n",
       " ' î±-amino-î´-ureidovaleric acid ',\n",
       " ' î´-ureidonorvaline',\n",
       " '(2s,3r)-(-)-threonine ',\n",
       " ' (2s)-threonine ',\n",
       " ' 2-amino-3-hydroxybutyric acid ',\n",
       " ' l-(-)-threonine ',\n",
       " ' l-2-amino-3-hydroxybutyric acid ',\n",
       " ' l-alpha-amino-beta-hydroxybutyric acid ',\n",
       " ' l-threonin ',\n",
       " ' l-threonine ',\n",
       " ' l-î±-amino-î²-hydroxybutyric acid ',\n",
       " ' thr ',\n",
       " ' threonine ',\n",
       " ' threoninum ',\n",
       " ' treonina',\n",
       " '1,4-dihydronicotinamide adenine dinucleotide ',\n",
       " ' dpnh ',\n",
       " ' nad reduced form ',\n",
       " ' nicotinamide adenine dinucleotide (reduced) ',\n",
       " ' nicotinamide-adenine dinucleotide, reduced ',\n",
       " ' reduced nicotinamide adenine diphosphate ',\n",
       " ' reduced nicotinamide-adenine dinucleotide',\n",
       " 'acide folique ',\n",
       " ' ã¡cido fã³lico ',\n",
       " ' acidum folicum ',\n",
       " ' folacin ',\n",
       " ' folate ',\n",
       " ' folic acid ',\n",
       " ' folsã¤ure ',\n",
       " ' n-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-l-glutamic acid ',\n",
       " ' n-pteroyl-l-glutamic acid ',\n",
       " ...]"
      ]
     },
     "execution_count": 43,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "alias=df_drugs['Synonyms']\n",
    "\n",
    "alias=alias['Synonyms']\n",
    "\n",
    "alias=alias.tolist()\n",
    "\n",
    "\n",
    "def aliases_lst(df_alias_lst):\n",
    "    \n",
    "    alias_lst=[]\n",
    "    for x in alias:\n",
    "        gn=x.split('|')\n",
    "        alias_lst.append(gn)\n",
    "    \n",
    "    flat_list = []\n",
    "    for sublist in alias_lst:\n",
    "        for item in sublist:\n",
    "            item=item.lower()\n",
    "            flat_list.append(item)\n",
    "    return flat_list\n",
    "\n",
    "lst_alias_drugs=aliases_lst(alias) \n",
    "\n",
    "symbol=df_drugs['Common name']\n",
    "symbol=symbol.tolist()\n",
    "drug_check=symbol+lst_alias_drugs\n",
    "drug_check\n",
    "drug_check_lower=aliases_lst(drug_check)\n",
    "drug_check_lower"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Cetuximab']"
      ]
     },
     "execution_count": 88,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#pd.Series(df_drugs.Synonyms,index=df_drugs.Common_name).to_dict()\n",
    "\n",
    "synonyms = []\n",
    "drug_names = df_drugs['Common_name'].tolist()\n",
    "\n",
    "for row in df_drugs['Synonyms']:\n",
    "    row=str(row)\n",
    "    words = row.split(' | ')\n",
    "    synonyms.append(words)\n",
    "\n",
    "#print(synonyms)\n",
    "for x, y in zip(synonyms, drug_names):\n",
    "    x.append(y)\n",
    "drug_lists= list(zip(drug_names, synonyms))\n",
    "drug_dic = dict(drug_lists)\n",
    "\n",
    "drug_dic\n",
    "\n",
    "keys = [key for key, value in drug_dic.items() if 'Cetuximab' in value]\n",
    "keys"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Lepirudin': ['Hirudin variant-1', 'Lepirudin recombinant', 'Lepirudin'],\n",
       " 'Cetuximab': ['Cetuximab', 'CÃ©tuximab', 'Cetuximabum', 'Cetuximab'],\n",
       " 'Dornase alfa': ['Deoxyribonuclease (human clone 18-1 protein moiety)',\n",
       "  'Dornasa alfa',\n",
       "  'Dornase alfa, recombinant',\n",
       "  'Dornase alpha',\n",
       "  'Recombinant deoxyribonuclease (DNAse)',\n",
       "  'Dornase alfa'],\n",
       " 'Denileukin diftitox': ['Denileukin',\n",
       "  'Interleukin-2/diptheria toxin fusion protein',\n",
       "  'Denileukin diftitox'],\n",
       " 'Etanercept': ['Etanercept',\n",
       "  'etanercept-szzs',\n",
       "  'etanercept-ykro',\n",
       "  'Recombinant human TNF',\n",
       "  'rhu TNFR:Fc',\n",
       "  'rhu-TNFR:Fc',\n",
       "  'TNFR-Immunoadhesin',\n",
       "  'Etanercept'],\n",
       " 'Bivalirudin': ['Bivalirudin',\n",
       "  'Bivalirudina',\n",
       "  'Bivalirudinum',\n",
       "  'Bivalirudin'],\n",
       " 'Leuprolide': ['Leuprorelin',\n",
       "  'Leuprorelina',\n",
       "  'Leuproreline',\n",
       "  'Leuprorelinum',\n",
       "  'Leuprolide'],\n",
       " 'Peginterferon alfa-2a': ['PEG-IFN alfa-2A',\n",
       "  'PEG-Interferon alfa-2A',\n",
       "  'Peginterferon alfa-2a',\n",
       "  'Pegylated Interfeaon alfa-2A',\n",
       "  'Pegylated interferon alfa-2a',\n",
       "  'Pegylated interferon alpha-2a',\n",
       "  'Pegylated-interferon alfa 2a',\n",
       "  'Peginterferon alfa-2a'],\n",
       " 'Alteplase': ['Alteplasa',\n",
       "  'Alteplase (genetical recombination)',\n",
       "  'Alteplase, recombinant',\n",
       "  'Alteplase,recombinant',\n",
       "  'Plasminogen activator (human tissue-type protein moiety)',\n",
       "  'rt-PA',\n",
       "  't-PA',\n",
       "  't-plasminogen activator',\n",
       "  'Tissue plasminogen activator',\n",
       "  'Tissue plasminogen activator alteplase',\n",
       "  'Tissue plasminogen activator, recombinant',\n",
       "  'tPA',\n",
       "  'Alteplase'],\n",
       " 'Sermorelin': ['Sermorelin'],\n",
       " 'Interferon alfa-n1': ['Interferon alpha-n1 (INS)', 'Interferon alfa-n1'],\n",
       " 'Darbepoetin alfa': ['Darbepoetin',\n",
       "  'Darbepoetin alfa,recombinant',\n",
       "  'Darbepoetina alfa',\n",
       "  'Darbepoetin alfa'],\n",
       " 'Urokinase': ['Kinase (enzyme-activating), uro-urokinase',\n",
       "  'TCUK',\n",
       "  'Tissue culture urokinase',\n",
       "  'Two-chain urokinase',\n",
       "  'Urochinasi',\n",
       "  'Urokinase',\n",
       "  'Urokinasum',\n",
       "  'Uroquinasa',\n",
       "  'Urokinase'],\n",
       " 'Goserelin': ['Goserelin', 'Goserelina', 'Goserelin'],\n",
       " 'Reteplase': ['Human t-PA (residues 1-3 and 176-527)',\n",
       "  'Reteplasa',\n",
       "  'Reteplase, recombinant',\n",
       "  'Reteplase,recombinant',\n",
       "  'Reteplase'],\n",
       " 'Erythropoietin': ['E.P.O.',\n",
       "  'Epoetin alfa',\n",
       "  'Epoetin alfa rDNA',\n",
       "  'Epoetin alfa-epbx',\n",
       "  'Epoetin alfa, recombinant',\n",
       "  'Epoetin beta',\n",
       "  'Epoetin beta rDNA',\n",
       "  'Epoetin epsilon',\n",
       "  'Epoetin gamma',\n",
       "  'Epoetin gamma rDNA',\n",
       "  'Epoetin kappa',\n",
       "  'Epoetin omega',\n",
       "  'Epoetin theta',\n",
       "  'Epoetin zeta',\n",
       "  'Epoetina alfa',\n",
       "  'Epoetina beta',\n",
       "  'Epoetina dseta',\n",
       "  'Epoetina zeta',\n",
       "  'EpoÃ©tine zÃªta',\n",
       "  'Epoetinum zeta',\n",
       "  'Erythropoiesis stimulating factor',\n",
       "  'Erythropoietin (human, recombinant)',\n",
       "  'Erythropoietin (recombinant human)',\n",
       "  'ESF',\n",
       "  'SH-polypeptide-72',\n",
       "  'Erythropoietin'],\n",
       " 'Salmon calcitonin': ['Calcitonin (Salmon Synthetic)',\n",
       "  'Calcitonin salmon',\n",
       "  'Calcitonin salmon recombinant',\n",
       "  'Calcitonin-salmon',\n",
       "  'Calcitonin, salmon',\n",
       "  'Calcitonina salmÃ³n sintÃ©tica',\n",
       "  'Recombinant salmon calcitonin',\n",
       "  'Salmon calcitonin',\n",
       "  'Salmon calcitonin'],\n",
       " 'Interferon alfa-n3': ['Interferon alfa-n3'],\n",
       " 'Pegfilgrastim': ['Granulocyte colony-stimulating factor pegfilgrastim',\n",
       "  'peg-filgrastim',\n",
       "  'pegfilgrastim-apgf',\n",
       "  'pegfilgrastim-bmez',\n",
       "  'pegfilgrastim-cbqv',\n",
       "  'pegfilgrastim-jmdb',\n",
       "  'Pegfilgrastim'],\n",
       " 'Sargramostim': ['Recombinant human granulocyte-macrophage colony stimulating factor',\n",
       "  'rGM-CSF',\n",
       "  'rHu GM-CSF',\n",
       "  'Sargramostim',\n",
       "  'Sargramostim'],\n",
       " 'Peginterferon alfa-2b': ['Peginterferon alfa-2b'],\n",
       " 'Asparaginase Escherichia coli': ['Asparaginase',\n",
       "  'Asparaginase (E. coli)',\n",
       "  'Colaspase',\n",
       "  'Escherichia coli L-asparaginase',\n",
       "  'L-asparaginase',\n",
       "  'L-asparagine amidohydrolase',\n",
       "  'Asparaginase Escherichia coli'],\n",
       " 'Thyrotropin alfa': ['Recombinant Human Thyroid Stimulating Hormone',\n",
       "  'Recombinant thyrotropin alfa',\n",
       "  'rhTSH',\n",
       "  'rTSH',\n",
       "  'Thyrotropin alpha',\n",
       "  'Thyrotropin alfa'],\n",
       " 'Antihemophilic factor, human recombinant': ['Antihemophilic factor (recombinant)',\n",
       "  'Antihemophilic factor recombinant',\n",
       "  'Antihemophilic factor, human recombinant',\n",
       "  'Antihemophilic factor, recombinant',\n",
       "  'Factor VIII (rDNA)',\n",
       "  'Factor VIII (Recombinant)',\n",
       "  'Factor VIII recombin',\n",
       "  'Factor VIII, recombinant',\n",
       "  'Human Factor VIII (Recombinant)',\n",
       "  'Human factor VIII recombinant',\n",
       "  'Octocog alfa',\n",
       "  'rAHF',\n",
       "  'Recombinant antihemophilic factor VIII',\n",
       "  'Antihemophilic factor, human recombinant'],\n",
       " 'Anakinra': ['Anakinra',\n",
       "  'IL-1RA',\n",
       "  'Interleukin-1 receptor antagonist anakinra',\n",
       "  'Anakinra'],\n",
       " 'Gramicidin D': ['Bacillus brevis gramicidin D',\n",
       "  'Gramicidin',\n",
       "  'Gramicidin A',\n",
       "  'Gramicidin B',\n",
       "  'Gramicidin C',\n",
       "  'Gramicidina',\n",
       "  'Gramicidine',\n",
       "  'Gramicidin D'],\n",
       " 'Human immunoglobulin G': ['Human IGG',\n",
       "  'Human immunoglobulin G',\n",
       "  'Human normal immunoglobulin',\n",
       "  'Immune globulin (human)',\n",
       "  'Immune globulin human',\n",
       "  'Immunoglobulin (human)',\n",
       "  'Immunoglobulin G (human)',\n",
       "  'Immunoglobulin G, human',\n",
       "  'IVIg',\n",
       "  'Human immunoglobulin G'],\n",
       " 'Anistreplase': ['Anisoylated plasminogen streptokinase activator complex',\n",
       "  'APSAC',\n",
       "  'Anistreplase'],\n",
       " 'Insulin human': ['High molecular weight insulin human',\n",
       "  'Human insulin',\n",
       "  'human insulin (rDNA)',\n",
       "  'Insulin (human)',\n",
       "  'Insulin human',\n",
       "  'Insulin human [rDNA origin]',\n",
       "  'Insulin Human Regular',\n",
       "  'Insulin human regular (rDNA)',\n",
       "  'Insulin human, rDNA origin',\n",
       "  'Insulin recombinant human',\n",
       "  'Insulin recombinant purified human',\n",
       "  'Insulin regular',\n",
       "  'Insulin, human',\n",
       "  'Insulina regular',\n",
       "  'Regular Insulin, human',\n",
       "  'Insulin human'],\n",
       " 'Tenecteplase': ['Tenecteplasa', 'TNK-tPA', 'Tenecteplase'],\n",
       " 'Menotropins': ['Human menopausal gonadotrophin',\n",
       "  'Menotrophin',\n",
       "  'Menotropin',\n",
       "  'Menotropina',\n",
       "  'Menotropins (FSH;LH)',\n",
       "  'Menotropins'],\n",
       " 'Interferon gamma-1b': ['IFN-gamma 1b',\n",
       "  'IFN-gamma-1b',\n",
       "  'Interferon gamma 1-b',\n",
       "  'Interferon gamma-1b',\n",
       "  'Interferon gamma-1b, recombinant',\n",
       "  'Interferon gamma-2a',\n",
       "  'Interferon gamma-1b'],\n",
       " 'Interferon alfa-2a, Recombinant': ['Interferon alfa-2a',\n",
       "  'Interferon alfa-2a (recombinant)',\n",
       "  'Interferon alfa-2a, recombinant',\n",
       "  'Interferon alfa-2a,recombinant',\n",
       "  'Interferon alpha-2a',\n",
       "  'Interferon-alfa-2a',\n",
       "  'Recombinant human interferon alfa-2a',\n",
       "  'Recombinant human interferon-alfa-2a',\n",
       "  'rIFN-alpha-2a',\n",
       "  'SH-polypeptide-46',\n",
       "  'Interferon alfa-2a, Recombinant'],\n",
       " 'Desmopressin': ['1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin',\n",
       "  '1-deamino-8-D-arginine vasopressin',\n",
       "  '1-desamino-8-D-arginine vasopressin',\n",
       "  'dDAVP',\n",
       "  'Desmopresina',\n",
       "  'Desmopressin',\n",
       "  'Desmopressine',\n",
       "  'Desmopressinum',\n",
       "  'Desmopressin'],\n",
       " 'Coagulation factor VIIa Recombinant Human': ['Coagulation factor VIIa',\n",
       "  'Coagulation factor VIIa (recombinant)',\n",
       "  'Coagulation factor VIIa (recombinant)-jncw',\n",
       "  'Eptacog alfa',\n",
       "  'Eptacog alfa (activated)',\n",
       "  'rFVIIa',\n",
       "  'Coagulation factor VIIa Recombinant Human'],\n",
       " 'Oprelvekin': ['IL-11',\n",
       "  'Interleukin 11',\n",
       "  'Interleukin-11',\n",
       "  'Oprelvekin',\n",
       "  'Recombinant interleukin-11',\n",
       "  'Oprelvekin'],\n",
       " 'Palifermin': ['24-163 fibroblast growth factor 7 (human)',\n",
       "  'Palifermina',\n",
       "  'Palifermin'],\n",
       " 'Glucagon': ['Glucagon',\n",
       "  'Glucagon (recombinant dna origin)',\n",
       "  'Glucagon recombinant',\n",
       "  'Glucagon, human',\n",
       "  'Glucagon, porcine',\n",
       "  'Glucagone',\n",
       "  'Glucagonum',\n",
       "  'Glucagon'],\n",
       " 'Aldesleukin': ['125-L-serine-2-133-interleukin 2 (human reduced)',\n",
       "  'Aldesleukina',\n",
       "  'Interleukin-2 aldesleukin',\n",
       "  'Interleukin-2(2-133),125-ser',\n",
       "  'Recombinant interleukin-2 human',\n",
       "  'Aldesleukin'],\n",
       " 'Botulinum Toxin Type B': ['Botulin B',\n",
       "  'Botulinum B toxin',\n",
       "  'Botulinum neurotoxin type B precursor',\n",
       "  'BTX-B',\n",
       "  'RimabotulinumtoxinB',\n",
       "  'Toxina botulÃ\\xadnica B',\n",
       "  'Botulinum Toxin Type B'],\n",
       " 'Omalizumab': ['Omalizumab'],\n",
       " 'Lutropin alfa': ['Lutropin alfa',\n",
       "  'Lutropin alpha',\n",
       "  'Lutropina alfa',\n",
       "  'Lutropin alfa'],\n",
       " 'Lyme disease vaccine (recombinant OspA)': ['Lipoprotein OspA antigen recombinant',\n",
       "  'Lipoprotein outer surface a borrelia burgdorferi antigen',\n",
       "  'OspA lipoprotein',\n",
       "  'Lyme disease vaccine (recombinant OspA)'],\n",
       " 'Insulin lispro': ['Insulin lispro (genetical recombination)',\n",
       "  'Insulin lispro (rDNA origin)',\n",
       "  'Insulin lispro protamine',\n",
       "  'Insulin lispro protamine recombinant',\n",
       "  'Insulin lispro recombinant',\n",
       "  'insulin lispro-aabc',\n",
       "  'Insulin,lispro,human/rDNA',\n",
       "  'Insulin,lispro,protamine/rDNA',\n",
       "  'Insulina lispro',\n",
       "  'Insulin lispro'],\n",
       " 'Insulin glargine': ['Insulin glargine',\n",
       "  'Insulin Glargine (rDNA origin)',\n",
       "  'Insulin glargine recombinant',\n",
       "  'Insulina glargina',\n",
       "  'Insulin glargine'],\n",
       " 'Collagenase clostridium histolyticum': ['Clostridium histolyticum enzymes',\n",
       "  'Collagenase',\n",
       "  'Collagenase clostridium histolyticum',\n",
       "  'Collagenase clostridium histolyticum'],\n",
       " 'Rasburicase': ['Rasburicasa', 'Rasburicase', 'Urate oxidase', 'Rasburicase'],\n",
       " 'Cetrorelix': ['Cetrorelix', 'Cetrorelixum', 'Cetrorelix'],\n",
       " 'Adalimumab': ['Adalimumab (genetical recombination)',\n",
       "  'adalimumab-adaz',\n",
       "  'adalimumab-adbm',\n",
       "  'adalimumab-afzb',\n",
       "  'adalimumab-atto',\n",
       "  'adalimumab-bwwd',\n",
       "  'Adalimumab'],\n",
       " 'Somatotropin': ['Growth hormone',\n",
       "  'Growth hormone (human)',\n",
       "  'hGH',\n",
       "  'Human growth hormone',\n",
       "  'Recombinant human growth hormone',\n",
       "  'rhGH',\n",
       "  'Somatotropin (human)',\n",
       "  'Somatotropin human',\n",
       "  'Somatotropin human growth hormone',\n",
       "  'Somatropin',\n",
       "  'Somatropin (rDNA origin)',\n",
       "  'Somatropin (recombinant DNA origin)',\n",
       "  'Somatropin [rDNA origin]',\n",
       "  'Somatropin recombinant',\n",
       "  'Somatropin(recombinant DNA origin)',\n",
       "  'Somatropina',\n",
       "  'Somatotropin'],\n",
       " 'Imiglucerase': ['Imiglucerasa', 'Imiglucerase'],\n",
       " 'Abciximab': ['Abciximab',\n",
       "  'Abciximab (genetical recombination)',\n",
       "  'c7E3',\n",
       "  'Abciximab'],\n",
       " 'Drotrecogin alfa': ['Activated protein C',\n",
       "  'Blood coagulation factor XIV (human)',\n",
       "  'Drotrecogin alfa (activated)',\n",
       "  'Drotrecogin alfa (activated), lyophilized',\n",
       "  'Drotrecogin alfa activated',\n",
       "  'Drotrecogin alfa, activated',\n",
       "  'Drotrecogin-alfa',\n",
       "  'Recombinant human activated protein C (rH-APC)',\n",
       "  'Drotrecogin alfa'],\n",
       " 'Gemtuzumab ozogamicin': ['Gemtuzumab ozogamicin'],\n",
       " 'Indium In-111 satumomab pendetide': ['Indium (111In) satumomab pendetide',\n",
       "  'Indium In 111 satumomab pendetide',\n",
       "  'Indium-111 satumomab pendetide',\n",
       "  'Indium In-111 satumomab pendetide'],\n",
       " 'Alpha-1-proteinase inhibitor': ['Alfa 1-proteinase inhibitor (human)',\n",
       "  'Alfa-1-antitripsina',\n",
       "  'Alfa1 antitrypsin',\n",
       "  'Alpha 1-antitrypsin',\n",
       "  'Alpha 1-Proteinase Inhibitor',\n",
       "  'Alpha 1-proteinase inhibitor (human)',\n",
       "  'Alpha 1-proteinase inhibitor, human',\n",
       "  'Alpha-1 protease inhibitor',\n",
       "  'Alpha-1 proteinase inhibitor (human)',\n",
       "  'Alpha-1-antiproteinase',\n",
       "  'Alpha-1-antitrypsin',\n",
       "  'Alpha-1-proteinase Inhibitor (human)',\n",
       "  'Alpha-1-proteinase inhibitor human',\n",
       "  'Alpha-1-proteinase Inhibitor, Human',\n",
       "  'Alpha-1-proteinase inhibitor,human',\n",
       "  'Alpha1-proteinase Inhibitor',\n",
       "  'Alpha1-proteinase inhibitor (human)',\n",
       "  'alpha1-proteinase inhibitor human',\n",
       "  'API',\n",
       "  'Alpha-1-proteinase inhibitor'],\n",
       " 'Pegaspargase': ['Peg-asparaginase',\n",
       "  'Peg/L-asparaginase',\n",
       "  'Pegaspargasa',\n",
       "  'Pegaspargase'],\n",
       " 'Interferon beta-1a': ['Interferon beta 1-a',\n",
       "  'Interferon beta 1a',\n",
       "  'Interferon beta-1a (recombinant human)',\n",
       "  'Interferon beta-1a,recombinant',\n",
       "  'Interferon-beta-1a',\n",
       "  'Interferon beta-1a'],\n",
       " 'Pegademase': ['(monomethoxypolyethylene glycol succinimidyl) 11-17-adenosine deaminase',\n",
       "  'PEG-adenosine deaminase',\n",
       "  'pegADA',\n",
       "  'Pegademase',\n",
       "  'Pegademase bovine',\n",
       "  'Pegademase'],\n",
       " 'Albumin human': ['Albumin (human)',\n",
       "  'Albumin human',\n",
       "  'Albumin, blood',\n",
       "  'Albumin, human',\n",
       "  'Albumin, human-kjda',\n",
       "  'Human albumin',\n",
       "  'Human serum albumin',\n",
       "  'Serum albumin',\n",
       "  'Albumin human'],\n",
       " 'Eptifibatide': ['Eptifibatida',\n",
       "  'Eptifibatide',\n",
       "  'Integrelin',\n",
       "  'Intrifiban',\n",
       "  'Eptifibatide'],\n",
       " 'Infliximab': ['Infliximab (genetical recombination)',\n",
       "  'Infliximab-abda',\n",
       "  'Infliximab-axxq',\n",
       "  'Infliximab-dyyb',\n",
       "  'Infliximab-qbtx',\n",
       "  'Infliximab'],\n",
       " 'Follitropin': ['Folitropina alfa',\n",
       "  'Folitropina beta',\n",
       "  'Folitropina delta',\n",
       "  'Follicle stimulating hormone',\n",
       "  'Follitrophin alfa',\n",
       "  'Follitrophin alpha',\n",
       "  'Follitrophin beta',\n",
       "  'Follitropin alfa',\n",
       "  'Follitropin alfa/beta',\n",
       "  'Follitropin alpha',\n",
       "  'Follitropin beta',\n",
       "  'Follitropin delta',\n",
       "  'Follitropin gamma',\n",
       "  'Follotropin recombinant',\n",
       "  'FSH',\n",
       "  'FSH alpha',\n",
       "  'FSH-a',\n",
       "  'FSH-b',\n",
       "  'FSH-beta',\n",
       "  'Recombinant human follicle stimulating hormone beta',\n",
       "  'Recombinant human follicle-stimulating hormone (r-HFSH)',\n",
       "  'rFSH-alpha',\n",
       "  'Follitropin'],\n",
       " 'Vasopressin': ['Vasopressin, unspecified', 'Vasopressina', 'Vasopressin'],\n",
       " 'Interferon beta-1b': ['Interferon beta 1b (recombinant)',\n",
       "  'Interferon beta-1b,recombinant',\n",
       "  'Interferon-beta-1b',\n",
       "  'Recombinant interferon beta-1b',\n",
       "  'Interferon beta-1b'],\n",
       " 'Interferon alfacon-1': ['IFN Alfacon-1',\n",
       "  'IFN-Con1',\n",
       "  'Interferon alfacon-1',\n",
       "  'Interferon alfacon-1'],\n",
       " 'Hyaluronidase (ovine)': ['Hyaluronidase (glycoprotein, sheep testis isoenzyme)',\n",
       "  'Hyaluronidase (ovine)',\n",
       "  'Hyaluronidase (sheep testis isoenzyme)',\n",
       "  'Hyaluronidase, ovine',\n",
       "  'Ovine hyaluronidase',\n",
       "  'Hyaluronidase (ovine)'],\n",
       " 'Insulin pork': ['Insulin (pork)',\n",
       "  'Insulin porcine',\n",
       "  'Insulin purified porcine',\n",
       "  'Insulin purified pork',\n",
       "  'Insulin, porcine',\n",
       "  'Insulin, regular, pork',\n",
       "  'Porcine insulin',\n",
       "  'Insulin pork'],\n",
       " 'Trastuzumab': ['RHUMAB HER2',\n",
       "  'trastuzumab-anns',\n",
       "  'trastuzumab-dkst',\n",
       "  'trastuzumab-dttb',\n",
       "  'trastuzumab-pkrb',\n",
       "  'trastuzumab-qyyp',\n",
       "  'Trastuzumab'],\n",
       " 'Rituximab': ['rituximab-abbs', 'rituximab-pvvr', 'Rituximab'],\n",
       " 'Basiliximab': ['Basiliximab', 'Basiliximab'],\n",
       " 'Muromonab': ['Anti-CD3', 'Muromonab-CD3', 'Muromonab'],\n",
       " 'Digoxin Immune Fab (Ovine)': ['Digitalis antitoxin',\n",
       "  'Digoxin Immune Fab, Ovine',\n",
       "  'Digoxin-specific Antibody Fragments',\n",
       "  'Ovine digoxin immune fab',\n",
       "  'Digoxin Immune Fab (Ovine)'],\n",
       " 'Ibritumomab tiuxetan': ['Ibritumomab',\n",
       "  'mAb Murine (IGG1) Anti P19437 (CD20_MOUSE)',\n",
       "  'Ibritumomab tiuxetan'],\n",
       " 'Daptomycin': ['Daptomicina',\n",
       "  'Daptomycin',\n",
       "  'Daptomycine',\n",
       "  'Daptomycinum',\n",
       "  'Daptomycin'],\n",
       " 'Tositumomab': ['Tositumomab'],\n",
       " 'Pegvisomant': ['Pegvisomant'],\n",
       " 'Botulinum toxin type A': ['AbobotulinumtoxinA',\n",
       "  'Botulinum A neurotoxin',\n",
       "  'Botulinum toxin A',\n",
       "  'Botulinum toxin type A',\n",
       "  'BTX-A',\n",
       "  'Evabotulinumtoxina',\n",
       "  'IncobotulinumtoxinA',\n",
       "  'OnabotulinumtoxinA',\n",
       "  'Prabotulinumtoxin A',\n",
       "  'Toxina botulÃ\\xadnica A',\n",
       "  'Toxine botulinique A',\n",
       "  'Botulinum toxin type A'],\n",
       " 'Pancrelipase': ['Pancrealipase',\n",
       "  'Pancreatic extract pancrelipase',\n",
       "  'Pancreatic protease',\n",
       "  'Pancreatin',\n",
       "  'Pancreatinum',\n",
       "  'Pancrelipase (amylase;lipase;protease)',\n",
       "  'Pancrelipase'],\n",
       " 'Streptokinase': ['Estreptoquinasa',\n",
       "  'Streptochinasi',\n",
       "  'Streptococcal fibrinolysin',\n",
       "  'Streptokinase',\n",
       "  'Streptokinasum',\n",
       "  'Streptokinase'],\n",
       " 'Alemtuzumab': ['Alemtuzumab'],\n",
       " 'Alglucerase': ['Alglucerase'],\n",
       " 'Capromab pendetide': ['(111In)-Capromab pendetide',\n",
       "  'Indium (111In) capromab pendetide',\n",
       "  'Indium 111 Capromab Pendetide',\n",
       "  'Indium In 111 capromab pendetide',\n",
       "  'Capromab pendetide'],\n",
       " 'Laronidase': ['alpha-L-Idosiduronase',\n",
       "  'Human Recombinant alpha-L-iduronidase',\n",
       "  'Laronidasa',\n",
       "  'Laronidase',\n",
       "  'Laronidase (genetical recombination)',\n",
       "  'Laronidase'],\n",
       " 'Cyclosporine': ['Ciclosporin',\n",
       "  'Ciclosporina',\n",
       "  'Ciclosporine',\n",
       "  'Ciclosporinum',\n",
       "  'CsA',\n",
       "  'CyA',\n",
       "  'Cyclosporin',\n",
       "  'Cyclosporin A',\n",
       "  'Cyclosporine',\n",
       "  'Cyclosporine'],\n",
       " 'Alefacept': ['Alefacept'],\n",
       " 'Felypressin': ['2-(L-phenylalanine)-8-L-lysinevasopressin',\n",
       "  'Felipresina',\n",
       "  'Felypressin',\n",
       "  'Felypressine',\n",
       "  'Felypressinum',\n",
       "  'PLV-2',\n",
       "  'Felypressin'],\n",
       " 'Urofollitropin': ['Follitropin human', 'Urofollitrophin', 'Urofollitropin'],\n",
       " 'Efalizumab': ['anti-CD11a', 'antiCD11 alpha', 'Efalizumab', 'Efalizumab'],\n",
       " 'Choriogonadotropin alfa': ['Choriogonadotropin alpha',\n",
       "  'Chorionic gonadotropin (recombinant)',\n",
       "  'Choriogonadotropin alfa'],\n",
       " 'Antithymocyte immunoglobulin (rabbit)': ['Anti-human thymocyte immunoglobulin, rabbit',\n",
       "  'Anti-T-lymphocyte immune globulin, rabbit',\n",
       "  'Anti-thymocyte globulin (rabbit)',\n",
       "  'Anti-thymocyte globulin rabbit',\n",
       "  'Antithymocyte immunoglobulin',\n",
       "  'Lapine T-lymphocyte immune globulin',\n",
       "  'Rabbit anti-human thymocyte globulin',\n",
       "  'Rabbit anti-human thymocyte globulin (rATG)',\n",
       "  'Rabbit anti-human thymocyte immunoglobulin',\n",
       "  'Rabbit anti-thymocyte immunoglobulin',\n",
       "  'Rabbit antithymocyte globulin',\n",
       "  'Rabbit ATG',\n",
       "  'rATG',\n",
       "  'Thymoglobulin',\n",
       "  'Thymoglobuline',\n",
       "  'Antithymocyte immunoglobulin (rabbit)'],\n",
       " 'Filgrastim': ['Filgrastim-aafi',\n",
       "  'Filgrastim-sndz',\n",
       "  'G-CSF ',\n",
       "  'Granulocyte Colony Stimulating Factor ',\n",
       "  'Tbo-filgrastim',\n",
       "  'Filgrastim'],\n",
       " 'Coagulation Factor IX (Recombinant)': ['Coagulation factor IX (recombinant)',\n",
       "  'Coagulation factor IX recombinant human',\n",
       "  'Factor IX (Recombinant)',\n",
       "  'nonacog alfa',\n",
       "  'nonacog gamma',\n",
       "  'Recombinant factor IX',\n",
       "  'Coagulation Factor IX (Recombinant)'],\n",
       " 'Becaplermin': ['Becaplermin',\n",
       "  'PDGF-2',\n",
       "  'PDGF-BB',\n",
       "  'PDGFB',\n",
       "  'Platelet-derived growth factor BB, recombinant',\n",
       "  'Platelet-derived growth factor beta polypeptide',\n",
       "  'Recombinant platelet-derived growth factor BB',\n",
       "  'rhPDGF-BB',\n",
       "  'rPDGF-BB',\n",
       "  'SH-POLYPEPTIDE-59',\n",
       "  'Becaplermin'],\n",
       " 'Agalsidase beta': ['Agalsidasa alfa',\n",
       "  'Agalsidasa beta',\n",
       "  'Agalsidase alfa',\n",
       "  'Alpha-galactosidase A',\n",
       "  'Agalsidase beta'],\n",
       " 'Octreotide': ['Octreotida',\n",
       "  'Octreotide',\n",
       "  'Octreotidum',\n",
       "  'Octrotide',\n",
       "  'Octreotide'],\n",
       " 'Interferon alfa-2b': ['Interferon alfa-2b',\n",
       "  'Interferon alfa-2b, recombinant',\n",
       "  'Interferon alpha-2B',\n",
       "  'Interferon Î±-2b',\n",
       "  'Intron (Interferon Î±2b)',\n",
       "  'Intron A',\n",
       "  'Intron A (Interferon Î±2b)',\n",
       "  'r-INF-alpha',\n",
       "  'rIFN-alpha-2b',\n",
       "  'Interferon alfa-2b'],\n",
       " 'Abarelix': ['Abarelix', 'Abarelix'],\n",
       " 'Oxytocin': ['Oxitocina', 'Oxytocin', 'Oxytocin'],\n",
       " 'Natalizumab': ['Anti-alpha4 integrin', 'Anti-VLA4', 'Natalizumab'],\n",
       " 'Enfuvirtide': ['Enfuvirtida', 'Enfuvirtide'],\n",
       " 'Palivizumab': ['Palivizumab', 'Palivizumab'],\n",
       " 'Daclizumab': ['Dacliximab', 'Daclizumab beta', 'Daclizumab'],\n",
       " 'Bevacizumab': ['Anti-VEGF Humanized Monoclonal Antibody',\n",
       "  'Anti-VEGF monoclonal antibody',\n",
       "  'Bevacizumab',\n",
       "  'bevacizumab-awwb',\n",
       "  'rhuMAb-VEGF',\n",
       "  'Bevacizumab'],\n",
       " 'Technetium Tc-99m arcitumomab': ['Arcitumomab technetium-99m',\n",
       "  'Technetium (99mTc) arcitumomab',\n",
       "  'Technetium Tc 99m arcitumomab',\n",
       "  'Technetium-99m arcitumomab',\n",
       "  'Technetium Tc-99m arcitumomab'],\n",
       " 'Pyridoxal phosphate': ['3-hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinecarboxaldehyde',\n",
       "  '3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate',\n",
       "  'Codecarboxylase',\n",
       "  'PLP',\n",
       "  'Pyridoxal 5-monophosphoric acid ester',\n",
       "  'Pyridoxal 5-phosphate',\n",
       "  \"Pyridoxal 5'-phosphate\",\n",
       "  'Pyridoxal P',\n",
       "  'Pyridoxal phosphate anhydrous',\n",
       "  'Pyridoxal-5P',\n",
       "  'Pyridoxal-P',\n",
       "  'Pyridoxal phosphate'],\n",
       " 'Cyanocobalamin': ['Cianocobalamina',\n",
       "  'Cyanocob(III)alamin',\n",
       "  'Cyanocobalamin',\n",
       "  'Cyanocobalamine',\n",
       "  'Cyanocobalaminum',\n",
       "  'Vitamin B12',\n",
       "  'Vitamin B12 complex',\n",
       "  'Vitamin B12 NOS',\n",
       "  'Cyanocobalamin'],\n",
       " 'Tetrahydrofolic acid': ['5,6,7,8-tetrahydrofolate',\n",
       "  '5,6,7,8-tetrahydrofolic acid',\n",
       "  'Tetrahydrofolate',\n",
       "  'Tetrahydrofolic acid'],\n",
       " 'Histidine': ['(S)-4-(2-Amino-2-carboxyethyl)imidazole',\n",
       "  '(S)-a-Amino-1H-imidazole-4-propanoic acid',\n",
       "  '(S)-alpha-amino-1H-Imidazole-4-propanoic acid',\n",
       "  '(S)-alpha-Amino-1H-imidazole-4-propionic acid',\n",
       "  '(S)-Î±-amino-1H-Imidazole-4-propanoic acid',\n",
       "  'HIS',\n",
       "  'Histidina',\n",
       "  'Histidine',\n",
       "  'L-(â\\x88\\x92)-histidine',\n",
       "  'L-Histidin',\n",
       "  'L-Histidine',\n",
       "  'Histidine'],\n",
       " 'Ademetionine': ['Ademetionine',\n",
       "  'AdoMet',\n",
       "  'L-S-Adenosylmethionine',\n",
       "  'S-Adenosylmethionine',\n",
       "  'SAM',\n",
       "  'SAM-e',\n",
       "  'SAMe',\n",
       "  'Ademetionine'],\n",
       " 'Pyruvic acid': ['2-ketopropionic acid',\n",
       "  '2-oxopropanoic acid',\n",
       "  '2-OxopropansÃ¤ure',\n",
       "  '2-OxopropionsÃ¤ure',\n",
       "  'a-Ketopropionic acid',\n",
       "  'Acetylformic acid',\n",
       "  'acide pyruvique',\n",
       "  'alpha-ketopropionic acid',\n",
       "  'BrenztraubensÃ¤ure',\n",
       "  'BTS',\n",
       "  'Pyroracemic acid',\n",
       "  'Î±-ketopropionic acid',\n",
       "  'Î±-OxopropionsÃ¤ure',\n",
       "  'Pyruvic acid'],\n",
       " 'Phenylalanine': ['(S)-2-Amino-3-phenylpropionic acid',\n",
       "  '(S)-alpha-Amino-beta-phenylpropionic acid',\n",
       "  '3-phenyl-L-alanine',\n",
       "  'beta-Phenyl-L-alanine',\n",
       "  'F',\n",
       "  'Fenilalanina',\n",
       "  'L-Phenylalanine',\n",
       "  'Phe',\n",
       "  'Phenylalanine',\n",
       "  'Phenylalaninum',\n",
       "  'Î²-phenyl-L-alanine',\n",
       "  'Phenylalanine'],\n",
       " 'Biotin': ['(+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid',\n",
       "  '(3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acid',\n",
       "  '5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid',\n",
       "  'Biotin',\n",
       "  'Biotina',\n",
       "  'Biotine',\n",
       "  'Biotinum',\n",
       "  'cis-(+)-Tetrahydro-2-oxothieno[3,4]imidazoline-4-valeric acid',\n",
       "  'cis-Hexahydro-2-oxo-1H-thieno(3,4)imidazole-4-valeric acid',\n",
       "  'cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid',\n",
       "  'Coenzyme R',\n",
       "  'D-(+)-biotin',\n",
       "  'D-Biotin',\n",
       "  'Vitamin B7',\n",
       "  'Vitamin H',\n",
       "  'Biotin'],\n",
       " 'Choline': ['Bilineurine',\n",
       "  'Choline ion',\n",
       "  'N-trimethylethanolamine',\n",
       "  'N,N,N-trimethylethanol-ammonium',\n",
       "  'trimethylethanolamine',\n",
       "  'Vitamin J',\n",
       "  'Choline'],\n",
       " 'L-Lysine': ['(S)-2,6-diaminohexanoic acid',\n",
       "  '(S)-lysine',\n",
       "  '(S)-Î±,Îµ-diaminocaproic acid',\n",
       "  '6-ammonio-L-norleucine',\n",
       "  'L-2,6-Diaminocaproic acid',\n",
       "  'L-lys',\n",
       "  'L-Lysin',\n",
       "  'LYS',\n",
       "  'Lysina',\n",
       "  'Lysine',\n",
       "  'Lysine acid',\n",
       "  'Lysinum',\n",
       "  'L-Lysine'],\n",
       " 'Arginine': ['(2S)-2-amino-5-(carbamimidamido)pentanoic acid',\n",
       "  '(2S)-2-amino-5-guanidinopentanoic acid',\n",
       "  '(S)-2-amino-5-guanidinopentanoic acid',\n",
       "  '(S)-2-Amino-5-guanidinovaleric acid',\n",
       "  'Arg',\n",
       "  'Arginina',\n",
       "  'Arginine',\n",
       "  'L-(+)-Arginine',\n",
       "  'L-Arg',\n",
       "  'L-Arginin',\n",
       "  'L-arginine',\n",
       "  'R',\n",
       "  'Arginine'],\n",
       " 'Ascorbic acid': ['acide ascorbique',\n",
       "  'Ã¡cido ascÃ³rbico',\n",
       "  'Acidum ascorbicum',\n",
       "  'acidum ascorbinicum',\n",
       "  'Ascorbate',\n",
       "  'Ascorbic acid',\n",
       "  'AscorbinsÃ¤ure',\n",
       "  'L-(+)-ascorbic acid',\n",
       "  'L-Ascorbate',\n",
       "  'L-Ascorbic Acid',\n",
       "  'Vitamin C',\n",
       "  'Vitamina C',\n",
       "  'Ascorbic acid'],\n",
       " 'Spermine': ['4,9-diaza-1,12-dodecanediamine',\n",
       "  '4,9-diazadodecane-1,12-diamine',\n",
       "  'Musculamine',\n",
       "  \"N,N'-Bis(3-aminopropyl)-1,4-butanediamine\",\n",
       "  'Spermina',\n",
       "  'Spermine',\n",
       "  'Spermine'],\n",
       " 'Aspartic acid': ['(S)-2-aminobutanedioic acid',\n",
       "  '(S)-2-aminosuccinic acid',\n",
       "  '2-Aminosuccinic acid',\n",
       "  'Ã¡cido aspÃ¡rtico',\n",
       "  'Acidum asparticum',\n",
       "  'Asp',\n",
       "  'Aspartic acid',\n",
       "  'D',\n",
       "  'L-Asp',\n",
       "  'L-AsparaginsÃ¤ure',\n",
       "  'L-Aspartate',\n",
       "  'L-Aspartic acid',\n",
       "  'Aspartic acid'],\n",
       " 'Ornithine': ['(S)-2,5-Diaminopentanoate',\n",
       "  '(S)-2,5-Diaminopentanoic acid',\n",
       "  '(S)-2,5-diaminovaleric acid',\n",
       "  '(S)-ornithine',\n",
       "  '(S)-Î±,Î´-diaminovaleric acid',\n",
       "  'L-Ornithine',\n",
       "  'levo-ornithine',\n",
       "  'Ornithine',\n",
       "  'Ornithinum',\n",
       "  'Ornitina',\n",
       "  'Ornithine'],\n",
       " 'L-Glutamine': ['(2S)-2-amino-4-carbamoylbutanoic acid',\n",
       "  '(2S)-2,5-diamino-5-oxopentanoic acid',\n",
       "  '(S)-2,5-diamino-5-oxopentanoic acid',\n",
       "  'Glutamic acid 5-amide',\n",
       "  'Glutamic acid amide',\n",
       "  'Glutamina',\n",
       "  'Glutamine',\n",
       "  'L-(+)-glutamine',\n",
       "  'L-2-aminoglutaramic acid',\n",
       "  'L-glutamic acid Î³-amide',\n",
       "  'L-Glutamin',\n",
       "  'L-GlutaminsÃ¤ure-5-amid',\n",
       "  'Levoglutamide',\n",
       "  'Q',\n",
       "  'L-Glutamine'],\n",
       " 'Adenosine phosphate': [\"5'-Adenosine monophosphate\",\n",
       "  \"5'-Adenylic acid\",\n",
       "  \"5'-AMP\",\n",
       "  \"5'-O-Phosphonoadenosine\",\n",
       "  \"Adenosine 5'-(dihydrogen phosphate)\",\n",
       "  \"Adenosine 5'-monophosphate\",\n",
       "  \"Adenosine 5'-phosphate\",\n",
       "  'Adenosine monophosphate',\n",
       "  'Adenosine phosphate',\n",
       "  \"Adenosine-5'-Monophosphate\",\n",
       "  \"Adenosine-5'-monophosphoric acid\",\n",
       "  \"Adenosine-5'P\",\n",
       "  'Adenosini phosphas',\n",
       "  'Adenylate',\n",
       "  'Adenylic acid',\n",
       "  \"Ado5'P\",\n",
       "  'AMP',\n",
       "  'Fosfato de adenosina',\n",
       "  'PAdo',\n",
       "  \"Phosphate d'adÃ©nosine\",\n",
       "  'Adenosine phosphate'],\n",
       " 'alpha-Linolenic acid': ['(9,12,15)-linolenic acid',\n",
       "  '(9Z,12Z,15Z)-Octadecatrienoic acid',\n",
       "  '(Z,Z,Z)-9,12,15-octadecatrienoic acid',\n",
       "  '9-cis,12-cis,15-cis-octadecatrienoic acid',\n",
       "  '9,12,15-Octadecatrienoic acid',\n",
       "  'ALA',\n",
       "  'all-cis-9,12,15-Octadecatrienoic acid',\n",
       "  'alpha-Linolenic acid',\n",
       "  'cis-delta(9,12,15)-Octadecatrienoic acid',\n",
       "  'cis,cis,cis-9,12,15-Octadecatrienoic acid',\n",
       "  'Linolenic acid',\n",
       "  'Î±-linolenic acid',\n",
       "  'alpha-Linolenic acid'],\n",
       " 'Serine': ['(S)-2-Amino-3-hydroxypropanoic acid',\n",
       "  '(S)-Serine',\n",
       "  'alpha-Amino-beta-hydroxypropionic acid',\n",
       "  'beta-Hydroxyalanine',\n",
       "  'L-Serine',\n",
       "  'Ser',\n",
       "  'Serina',\n",
       "  'Serine',\n",
       "  'Serinum',\n",
       "  'Serine'],\n",
       " 'Methionine': ['(2S)-2-amino-4-(methylsulfanyl)butanoic acid',\n",
       "  '(S)-2-amino-4-(methylthio)butanoic acid',\n",
       "  '(S)-2-amino-4-(methylthio)butyric acid',\n",
       "  '(S)-methionine',\n",
       "  'L-(â\\x88\\x92)-methionine',\n",
       "  'L-a-Amino-g-methylthiobutyric acid',\n",
       "  'L-Methionin',\n",
       "  'L-Methionine',\n",
       "  'L-Î±-amino-Î³-methylmercaptobutyric acid',\n",
       "  'M',\n",
       "  'Met',\n",
       "  'Methionine',\n",
       "  'Methionine'],\n",
       " 'Tyrosine': ['(â\\x88\\x92)-Î±-amino-p-hydroxyhydrocinnamic acid',\n",
       "  '(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid',\n",
       "  '(S)-(-)-Tyrosine',\n",
       "  '(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid',\n",
       "  '(S)-3-(p-Hydroxyphenyl)alanine',\n",
       "  '(S)-alpha-amino-4-Hydroxybenzenepropanoic acid',\n",
       "  '(S)-Tyrosine',\n",
       "  '(S)-Î±-amino-4-hydroxybenzenepropanoic acid',\n",
       "  '4-hydroxy-L-phenylalanine',\n",
       "  'L-Tyrosin',\n",
       "  'L-tyrosine',\n",
       "  'Tirosina',\n",
       "  'Tyr',\n",
       "  'Tyrosine',\n",
       "  'Tyrosinum',\n",
       "  'Y',\n",
       "  'Tyrosine'],\n",
       " 'Calcitriol': ['(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol',\n",
       "  '(1Î±,3Î²,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol',\n",
       "  '(5Z,7E)-(1S,3R)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol',\n",
       "  '1-alpha-25-Dihydroxyvitamin D3',\n",
       "  '1,25-DHCC',\n",
       "  '1,25-dihydroxycholecalciferol',\n",
       "  '1Î±,25-dihydroxycholecalciferol',\n",
       "  '1Î±,25-dihydroxyvitamin D3',\n",
       "  '1Î±,25(OH)2D3',\n",
       "  'Calcitriol',\n",
       "  'Calcitriolum',\n",
       "  'Calcitriol'],\n",
       " 'Lutein': ['Xanthophyll', 'Xantofyl', 'Lutein'],\n",
       " 'Cystine': [\"(R,R)-3,3'-dithiobis(2-aminopropanoic acid)\",\n",
       "  'Cistina',\n",
       "  'L-alpha-Diamino-beta-dithiolactic acid',\n",
       "  'L-Cystine',\n",
       "  'L-Dicysteine',\n",
       "  \"Î²,Î²'-dithiodialanine\",\n",
       "  'Cystine'],\n",
       " 'Succinic acid': ['1,2-ethanedicarboxylic acid',\n",
       "  'Acide butanedioÃ¯que',\n",
       "  'Acide succinique',\n",
       "  'Acidum succinicum',\n",
       "  'Amber acid',\n",
       "  'Asuccin',\n",
       "  'BernsteinsÃ¤ure',\n",
       "  'ButandisÃ¤ure',\n",
       "  'Butanedioic acid',\n",
       "  'Butanedionic acid',\n",
       "  'Dihydrofumaric acid',\n",
       "  'Ethylenesuccinic acid',\n",
       "  'Spirit of amber',\n",
       "  'Succinic acid',\n",
       "  'Succinic acid'],\n",
       " 'Riboflavin': ['1-Deoxy-1-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl)pentitol',\n",
       "  '6,7-Dimethyl-9-D-ribitylisoalloxazine',\n",
       "  '7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)isoalloxazine',\n",
       "  '7,8-Dimethyl-10-ribitylisoalloxazine',\n",
       "  'Lactoflavin',\n",
       "  'Lactoflavine',\n",
       "  'Riboflavin',\n",
       "  'Riboflavina',\n",
       "  'Riboflavine',\n",
       "  'Riboflavinum',\n",
       "  'Vitamin B2',\n",
       "  'Vitamin Bi',\n",
       "  'Vitamin G',\n",
       "  'Riboflavin'],\n",
       " 'N-Acetylglucosamine': ['2-Acetamido-2-deoxy-D-glucose',\n",
       "  'aldehydo-N-acetyl-D-glucosamine',\n",
       "  'D-GlcNAc',\n",
       "  'N-Acetyl-D-glucosamine',\n",
       "  'N-Acetylchitosamine',\n",
       "  'N-Acetylglucosamine'],\n",
       " 'Glutamic acid': ['(2S)-2-Aminopentanedioic acid',\n",
       "  '(S)-2-Aminopentanedioic acid',\n",
       "  '(S)-Glutamic acid',\n",
       "  'Ã¡cido glutÃ¡mico',\n",
       "  'Glu',\n",
       "  'Glutamic acid',\n",
       "  'L-Glutamate',\n",
       "  'L-Glutamic acid',\n",
       "  'L-Glutaminic acid',\n",
       "  'Glutamic acid'],\n",
       " 'Glutathione': ['5-L-Glutamyl-L-cysteinylglycine',\n",
       "  'gamma-L-Glutamyl-L-cysteinyl-glycine',\n",
       "  'Glutathione',\n",
       "  'Glutathione-SH',\n",
       "  'GSH',\n",
       "  'N-(N-gamma-L-Glutamyl-L-cysteinyl)glycine',\n",
       "  'Reduced glutathione',\n",
       "  'Glutathione'],\n",
       " 'Phosphatidyl serine': ['Phosphatidyl-L-serine',\n",
       "  'Phosphatidylserine',\n",
       "  'PS',\n",
       "  'Ptd-L-Ser',\n",
       "  'Phosphatidyl serine'],\n",
       " 'Glycine': ['Aminoacetic acid',\n",
       "  'AminoessigsÃ¤ure',\n",
       "  'Aminoethanoic acid',\n",
       "  'Glicina',\n",
       "  'Gly',\n",
       "  'Glycin',\n",
       "  'Glycine',\n",
       "  'Glycocoll',\n",
       "  'Glykokoll',\n",
       "  'Glyzin',\n",
       "  'Leimzucker',\n",
       "  'Glycine'],\n",
       " 'Calcifediol': ['(3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol',\n",
       "  '(3Î²,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol',\n",
       "  '(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol',\n",
       "  '25-hydroxycholecalciferol',\n",
       "  '25-Hydroxyvitamin D3',\n",
       "  'Calcidiol',\n",
       "  'CalcifÃ©diol',\n",
       "  'Calcifediol',\n",
       "  'Calcifediol anhydrous',\n",
       "  'Calcifediolum',\n",
       "  'Calcifediol'],\n",
       " 'Pyridoxal': ['2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine',\n",
       "  '3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinecarboxaldehyde',\n",
       "  '3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde',\n",
       "  '3-hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carboxaldehyde',\n",
       "  'Piridoxal',\n",
       "  'Pyridoxaldehyde',\n",
       "  'Pyridoxal'],\n",
       " 'Creatine': ['((amino(Imino)methyl)(methyl)amino)acetic acid',\n",
       "  '(alpha-Methylguanido)acetic acid',\n",
       "  '(N-methylcarbamimidamido)acetic acid',\n",
       "  '(Î±-methylguanido)acetic acid',\n",
       "  'alpha-Methylguanidino acetic acid',\n",
       "  'Creatin',\n",
       "  'Creatine',\n",
       "  'Kreatin',\n",
       "  'Methylglycocyamine',\n",
       "  'N-(aminoiminomethyl)-N-methylglycine',\n",
       "  'N-amidinosarcosine',\n",
       "  'N-carbamimidoyl-N-methylglycine',\n",
       "  'N-methyl-N-guanylglycine',\n",
       "  'Creatine'],\n",
       " 'Leucine': ['(2S)-2-Amino-4-methylpentanoic acid',\n",
       "  '(2S)-alpha-2-Amino-4-methylvaleric acid',\n",
       "  '(2S)-alpha-Leucine',\n",
       "  '(S)-(+)-Leucine',\n",
       "  '(S)-Leucine',\n",
       "  '2-Amino-4-methylvaleric acid',\n",
       "  'L',\n",
       "  'L-Leucin',\n",
       "  'L-Leucine',\n",
       "  'L-Leuzin',\n",
       "  'Leu',\n",
       "  'Leucine',\n",
       "  'Leucine'],\n",
       " 'Tryptophan': ['(2S)-2-amino-3-(1H-indol-3-yl)propanoic acid',\n",
       "  '(S)-alpha-Amino-beta-(3-indolyl)-propionic acid',\n",
       "  '(S)-Tryptophan',\n",
       "  '(S)-Î±-amino-1H-indole-3-propanoic acid',\n",
       "  'L-(-)-Tryptophan',\n",
       "  'L-(â\\x88\\x92)-tryptophan',\n",
       "  'L-Tryptophan',\n",
       "  'L-Î²-3-indolylalanine',\n",
       "  'Triptofano',\n",
       "  'Trp',\n",
       "  'Tryptophan',\n",
       "  'Tryptophane',\n",
       "  'Tryptophanum',\n",
       "  'W',\n",
       "  'Tryptophan'],\n",
       " 'Cysteine': ['(2R)-2-amino-3-mercaptopropanoic acid',\n",
       "  '(2R)-2-amino-3-sulfanylpropanoic acid',\n",
       "  '(R)-2-Amino-3-mercaptopropanoic acid',\n",
       "  'Cisteina',\n",
       "  'Cisteinum',\n",
       "  'Cys',\n",
       "  'Cysteine',\n",
       "  'Cysteinum',\n",
       "  'Free Cysteine',\n",
       "  'L-2-Amino-3-mercaptopropionic acid',\n",
       "  'L-Cys',\n",
       "  'L-Cystein',\n",
       "  'L-Zystein',\n",
       "  'Cysteine'],\n",
       " 'Thiamine': ['Aneurin',\n",
       "  'Antiberiberi factor',\n",
       "  'Thiamin',\n",
       "  'Thiamine',\n",
       "  'thiamine(1+)',\n",
       "  'thiamine(1+) ion',\n",
       "  'thiaminium',\n",
       "  'Thiaminum',\n",
       "  'Tiamina',\n",
       "  'Vitamin B1',\n",
       "  'Thiamine'],\n",
       " 'Ergocalciferol': ['(3Î²,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol',\n",
       "  '(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol',\n",
       "  '(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol',\n",
       "  'Activated ergosterol',\n",
       "  'Ercalciol',\n",
       "  'ErgocalcifÃ©rol',\n",
       "  'Ergocalciferol',\n",
       "  'Ergocalciferolum',\n",
       "  'Oleovitamin D2',\n",
       "  'Viosterol',\n",
       "  'Vitamin D2',\n",
       "  'Vitamina D2',\n",
       "  'Ergocalciferol'],\n",
       " 'Dihomo-gamma-linolenic acid': ['(8Z,11Z,14Z)-Icosatrienoic acid',\n",
       "  '(Z,Z,Z)-8,11,14-Eicosatrienoic acid',\n",
       "  '(Z,Z,Z)-8,11,14-Icosatrienoate',\n",
       "  '(Z,Z,Z)-8,11,14-Icosatrienoic acid',\n",
       "  '20:3, n-6,9,12 all-cis',\n",
       "  '8,11,14-Eicosatrienoic Acid',\n",
       "  '8c,11c,14c-eicosatrienoic acid',\n",
       "  '8c,11c,14c-EicosatriensÃ¤ure',\n",
       "  'all-cis-8,11,14-eicosatrienoic acid',\n",
       "  'all-cis-8,11,14-icosatrienoic acid',\n",
       "  'all-cis-eicosa-8,11,14-trienoic acid',\n",
       "  'all-cis-Eicosa-8,11,14-triensÃ¤ure',\n",
       "  'all-cis-icosa-8,11,14-trienoic acid',\n",
       "  'C20:3, n-6,9,12 all-cis',\n",
       "  'cis,cis,cis-8,11,14-eicosatrienoic acid',\n",
       "  'DGLA',\n",
       "  'dihomo-Î³-linolenic acid',\n",
       "  'eicosa-8Z,11Z,14Z-trienoic acid',\n",
       "  'gamma-Homolinolenic acid',\n",
       "  'Homo-gamma-linolenic acid',\n",
       "  'Homo-gamma-linolensÃ¤ure',\n",
       "  'Homo-Î³-linolensÃ¤ure',\n",
       "  'Dihomo-gamma-linolenic acid'],\n",
       " 'Citrulline': ['(S)-2-Amino-5-ureidopentanoic acid',\n",
       "  '2-Amino-5-ureidovaleric acid',\n",
       "  'alpha-amino-delta-Ureidovaleric acid',\n",
       "  'Cit',\n",
       "  'Citrulina',\n",
       "  'Citrulline',\n",
       "  'delta-Ureidonorvaline',\n",
       "  'L-2-Amino-5-ureidovaleric acid',\n",
       "  'L-Citrulline',\n",
       "  'N(5)-(Aminocarbonyl)-L-ornithine',\n",
       "  'N(delta)-Carbamylornithine',\n",
       "  'N5-(Aminocarbonyl)ornithine',\n",
       "  'N5-Carbamoyl-L-ornithine',\n",
       "  'N5-carbamoylornithine',\n",
       "  'Î±-amino-Î´-ureidovaleric acid',\n",
       "  'Î´-ureidonorvaline',\n",
       "  'Citrulline'],\n",
       " 'Threonine': ['(2S,3R)-(-)-Threonine',\n",
       "  '(2S)-threonine',\n",
       "  '2-Amino-3-hydroxybutyric acid',\n",
       "  'L-(-)-Threonine',\n",
       "  'L-2-Amino-3-hydroxybutyric acid',\n",
       "  'L-alpha-amino-beta-hydroxybutyric acid',\n",
       "  'L-Threonin',\n",
       "  'L-Threonine',\n",
       "  'L-Î±-amino-Î²-hydroxybutyric acid',\n",
       "  'Thr',\n",
       "  'Threonine',\n",
       "  'Threoninum',\n",
       "  'Treonina',\n",
       "  'Threonine'],\n",
       " 'NADH': ['1,4-dihydronicotinamide adenine dinucleotide',\n",
       "  'DPNH',\n",
       "  'NAD reduced form',\n",
       "  'Nicotinamide adenine dinucleotide (reduced)',\n",
       "  'Nicotinamide-adenine dinucleotide, reduced',\n",
       "  'Reduced nicotinamide adenine diphosphate',\n",
       "  'Reduced nicotinamide-adenine dinucleotide',\n",
       "  'NADH'],\n",
       " 'Folic acid': ['Acide folique',\n",
       "  'Ã¡cido fÃ³lico',\n",
       "  'Acidum folicum',\n",
       "  'Folacin',\n",
       "  'Folate',\n",
       "  'Folic acid',\n",
       "  'FolsÃ¤ure',\n",
       "  'N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid',\n",
       "  'N-pteroyl-L-glutamic acid',\n",
       "  'PGA',\n",
       "  'PteGlu',\n",
       "  'Pteroyl-L-glutamate',\n",
       "  'Pteroyl-L-glutamic acid',\n",
       "  'Pteroyl-L-monoglutamic acid',\n",
       "  'Pteroylglutamic acid',\n",
       "  'Vitamin B9',\n",
       "  'Vitamin Bc',\n",
       "  'Vitamin M',\n",
       "  'Folic acid'],\n",
       " 'Icosapent': ['(5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid',\n",
       "  '(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate',\n",
       "  '(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid',\n",
       "  '(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid',\n",
       "  '(all-Z)-5,8,11,14,17-eicosapentaenoic acid',\n",
       "  '5,8,11,14,17-eicosapentaenoic acid',\n",
       "  '5,8,11,14,17-Icosapentaenoic acid',\n",
       "  'all-cis-5,8,11,14,17-eicosapentaenoic acid',\n",
       "  'all-cis-5,8,11,14,17-icosapentaenoic acid',\n",
       "  'all-cis-icosa-5,8,11,14,17-pentaenoic acid',\n",
       "  'cis-5,8,11,14,17-eicosapentaenoic acid',\n",
       "  'cis-5,8,11,14,17-EPA',\n",
       "  'cis-delta(5,8,11,14,17)-Eicosapentaenoic acid',\n",
       "  'Eicosapentaenoic acid',\n",
       "  'EPA',\n",
       "  'Icosapent',\n",
       "  'Icosapentaenoic acid',\n",
       "  'Icosapento',\n",
       "  'Icosapentum',\n",
       "  'Timnodonic acid',\n",
       "  'Icosapent'],\n",
       " 'Alanine': ['(2S)-2-aminopropanoic acid',\n",
       "  '(S)-2-aminopropanoic acid',\n",
       "  '(S)-alanine',\n",
       "  'Alanina',\n",
       "  'Alanine',\n",
       "  'Alaninum',\n",
       "  'L-2-Aminopropionic acid',\n",
       "  'L-Alanin',\n",
       "  'L-alanine',\n",
       "  'L-alpha-Alanine',\n",
       "  'L-Î±-alanine',\n",
       "  'Alanine'],\n",
       " 'Valine': ['(2S)-2-Amino-3-methylbutanoic acid',\n",
       "  '(S)-Valine',\n",
       "  '2-Amino-3-methylbutyric acid',\n",
       "  'L-(+)-alpha-Aminoisovaleric acid',\n",
       "  'L-alpha-Amino-beta-methylbutyric acid',\n",
       "  'L-valin',\n",
       "  'L-valine',\n",
       "  'Val',\n",
       "  'Valine',\n",
       "  'Valine'],\n",
       " 'Vitamin A': ['(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol',\n",
       "  'all-trans-retinol',\n",
       "  'all-trans-retinyl alcohol',\n",
       "  'all-trans-vitamin A alcohol',\n",
       "  'Retinol',\n",
       "  'Retinolum',\n",
       "  'Vitamin A1',\n",
       "  'Vitamin A'],\n",
       " 'Vitamin E': ['(+)-Î±-tocopherol',\n",
       "  \"(2R,4'R,8'R)-Î±-tocopherol\",\n",
       "  '(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL',\n",
       "  '(R,R,R)-Î±-tocopherol',\n",
       "  '5,7,8-trimethyltocol',\n",
       "  'alpha-tocopherol',\n",
       "  'd-Î±-tocopherol',\n",
       "  'Vitamin E'],\n",
       " 'Pyridoxine': ['2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine',\n",
       "  '3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine',\n",
       "  '3-hydroxy-4,5-dimethylol-Î±-picoline',\n",
       "  '5-hydroxy-6-methyl-3,4-pyridinedimethanol',\n",
       "  'Piridoxina',\n",
       "  'Pyridoxine',\n",
       "  'Pyridoxinum',\n",
       "  'Pyridoxol',\n",
       "  'Vitamin B6',\n",
       "  'Pyridoxine'],\n",
       " 'Lipoic acid': ['(+)-alpha-Lipoic acid',\n",
       "  '(R)-(+)-Lipoate',\n",
       "  '(R)-(+)-lipoic acid',\n",
       "  '(R)-1,2-Dithiolane-3-pentanoic acid',\n",
       "  '(R)-1,2-dithiolane-3-valeric acid',\n",
       "  '(R)-6,8-thioctic acid',\n",
       "  '(R)-lipoic acid',\n",
       "  'Alpha lipoic acid',\n",
       "  'alpha-Lipoic acid',\n",
       "  'alpha-LiponsÃ¤ure',\n",
       "  'D-thioctic acid',\n",
       "  'Lipoic acid',\n",
       "  'R-(+)-thioctic acid',\n",
       "  'R-alpha-lipoic acid',\n",
       "  'Thioctic acid',\n",
       "  'Thioctic acid D-form',\n",
       "  'Î±-lipoic acid',\n",
       "  'Lipoic acid'],\n",
       " 'Isoleucine': ['(2S,3S)-2-Amino-3-methylpentanoic acid',\n",
       "  '2-Amino-3-methylvaleric acid',\n",
       "  'alpha-amino-beta-methylvaleric acid',\n",
       "  'Ile',\n",
       "  'Isoleucina',\n",
       "  'Isoleucine',\n",
       "  'Isoleucinum',\n",
       "  'L-Isoleucine',\n",
       "  'Î±-amino-Î²-methylvaleric acid',\n",
       "  'Isoleucine'],\n",
       " 'Aspartame': ['1-Methyl N-L-alpha-aspartyl-L-phenylalanate',\n",
       "  '1-methyl N-L-Î±-aspartyl-L-phenylalanate',\n",
       "  '3-Amino-N-(alpha-carboxyphenethyl)succinamic acid N-methyl ester',\n",
       "  '3-Amino-N-(alpha-methoxycarbonylphenethyl) succinamic acid',\n",
       "  '3-Amino-N-(Î±-carboxyphenethyl)succinamic acid N-methyl ester',\n",
       "  '3-Amino-N-(Î±-methoxycarbonylphenethyl) succinamic acid',\n",
       "  'Asp-phe-ome',\n",
       "  'Aspartam',\n",
       "  'Aspartame',\n",
       "  'Aspartamo',\n",
       "  'Aspartamum',\n",
       "  'Aspartylphenylalanine methyl ester',\n",
       "  'L-Aspartyl-L-phenylalanine methyl ester',\n",
       "  'Aspartame'],\n",
       " 'Cholecalciferol': ['(+)-vitamin D3',\n",
       "  '(3Î²,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol',\n",
       "  '(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol',\n",
       "  'Activated 7-dehydrocholesterol',\n",
       "  'Calciol',\n",
       "  'CC',\n",
       "  'Cholecalciferol',\n",
       "  'Cholecalciferolum',\n",
       "  'Colecalciferol',\n",
       "  'Colecalciferolum',\n",
       "  'Oleovitamin D3',\n",
       "  'Vitamin D-3',\n",
       "  'Vitamin D3',\n",
       "  'Cholecalciferol'],\n",
       " 'Menadione': ['2-Methyl-1,4-Naphthalenedione',\n",
       "  '2-Methyl-1,4-naphthochinon',\n",
       "  '2-Methyl-1,4-naphthoquinone',\n",
       "  'Vitamin K 3',\n",
       "  'Vitamin K3',\n",
       "  'Menadione'],\n",
       " 'ATP': [\"Adenosine 5'-triphosphate\",\n",
       "  'Adenosine triphosphate',\n",
       "  \"Adenosine-5'-triphosphate\",\n",
       "  'ATP',\n",
       "  'ATP'],\n",
       " 'Proline': ['(-)-2-Pyrrolidinecarboxylic acid',\n",
       "  '(â\\x88\\x92)-(S)-proline',\n",
       "  '(â\\x88\\x92)-2-pyrrolidinecarboxylic acid',\n",
       "  '(â\\x88\\x92)-proline',\n",
       "  '(2S)-pyrrolidine-2-carboxylic acid',\n",
       "  '(S)-2-Carboxypyrrolidine',\n",
       "  '(S)-2-Pyrrolidinecarboxylic acid',\n",
       "  '(S)-pyrrolidine-2-carboxylic acid',\n",
       "  '2-Pyrrolidinecarboxylic acid',\n",
       "  'L-(â\\x88\\x92)-proline',\n",
       "  'L-alpha-pyrrolidinecarboxylic acid',\n",
       "  'L-Prolin',\n",
       "  'L-Proline',\n",
       "  'L-pyrrolidine-2-carboxylic acid',\n",
       "  'L-Î±-pyrrolidinecarboxylic acid',\n",
       "  'P',\n",
       "  'Prolina',\n",
       "  'Proline',\n",
       "  'Prolinum',\n",
       "  'Proline'],\n",
       " 'Adenine': ['6-Aminopurine', 'Adenin', 'Vitamin B4', 'Adenine'],\n",
       " 'Asparagine': ['(2S)-2-amino-3-carbamoylpropanoic acid',\n",
       "  '(2S)-2,4-diamino-4-oxobutanoic acid',\n",
       "  '(S)-2-amino-3-carbamoylpropanoic acid',\n",
       "  '(S)-Asparagine',\n",
       "  '2-Aminosuccinamic acid',\n",
       "  'alpha-aminosuccinamic acid',\n",
       "  'Asn',\n",
       "  'Asparagine',\n",
       "  'Aspartamic acid',\n",
       "  'L-2-aminosuccinamic acid',\n",
       "  'L-Asparagine',\n",
       "  'L-aspartic acid beta-amide',\n",
       "  'L-aspartic acid Î²-amide',\n",
       "  'Î±-aminosuccinamic acid',\n",
       "  'Asparagine'],\n",
       " 'Pravastatin': ['(+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid',\n",
       "  'Pravastatin',\n",
       "  'Pravastatin acid',\n",
       "  'Pravastatina',\n",
       "  'Pravastatine',\n",
       "  'Pravastatinum',\n",
       "  'Pravastatin'],\n",
       " 'Fluvoxamine': ['Fluvoxamina', 'Fluvoxamine', 'Fluvoxaminum', 'Fluvoxamine'],\n",
       " 'Valsartan': [\"(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine\",\n",
       "  'N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine',\n",
       "  \"N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine\",\n",
       "  'Valsartan',\n",
       "  'Valsartan'],\n",
       " 'Ramipril': ['(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid',\n",
       "  'Ramipril',\n",
       "  'Ramiprilum',\n",
       "  'Ramipril'],\n",
       " 'Masoprocol': ['erythro-nordihydroguaiaretic acid',\n",
       "  'masoprocol',\n",
       "  'Masoprocolum',\n",
       "  'meso-1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane',\n",
       "  'meso-2,3-bis(3,4-dihydroxyphenylmethyl)butane',\n",
       "  'meso-4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol',\n",
       "  \"meso-4,4'-(2,3-dimethyl-1,4-butanediyl)bis(pyrocatechol)\",\n",
       "  \"meso-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol\",\n",
       "  'meso-NDGA',\n",
       "  'meso-nordihydroguaiaretic acid',\n",
       "  'meso-Î²,Î³-dimethyl-Î±,Î´-bis(3,4-dihydroxyphenyl)butan',\n",
       "  'Nordihydroguaiaretic acid',\n",
       "  'Masoprocol'],\n",
       " 'Flunisolide': ['Flunisolida',\n",
       "  'Flunisolide',\n",
       "  'Flunisolide anhydrous',\n",
       "  'Flunisolidum',\n",
       "  'Flunisolide'],\n",
       " 'Baclofen': ['(+-)-Baclofen',\n",
       "  '4-Amino-3-(4-chlorophenyl)butyric acid',\n",
       "  'Baclofen',\n",
       "  'BaclofÃ¨ne',\n",
       "  'Baclofeno',\n",
       "  'Baclofenum',\n",
       "  'beta-(4-Chlorophenyl)gaba',\n",
       "  'beta-(Aminomethyl)-4-chlorobenzenepropanoic acid',\n",
       "  'beta-(Aminomethyl)-p-chlorohydrocinnamic acid',\n",
       "  'beta-(p-Chlorophenyl)-gamma-aminobutyric acid',\n",
       "  'DL-4-Amino-3-p-chlorophenylbutanoic acid',\n",
       "  'DL-Baclofen',\n",
       "  'gamma-Amino-beta-(p-chlorophenyl)butyric acid',\n",
       "  'Baclofen'],\n",
       " 'Amphetamine': ['(+-)-alpha-Methylphenylethylamine',\n",
       "  '1-phenyl-2-aminopropane',\n",
       "  'alpha-Methylbenzeneethaneamine',\n",
       "  'Amfetamina',\n",
       "  'Amfetamine',\n",
       "  'Amfetaminum',\n",
       "  'Amphetamine',\n",
       "  'beta-Aminopropylbenzene',\n",
       "  'beta-Phenylisopropylamin',\n",
       "  'Desoxynorephedrine',\n",
       "  'rac-(2R)-1-phenylpropan-2-amine',\n",
       "  'rac-amphetamine',\n",
       "  'Î±-methylbenzeneethaneamine',\n",
       "  'Î±-methylphenethylamine',\n",
       "  'Î²-aminopropylbenzene',\n",
       "  'Î²-phenylisopropylamine',\n",
       "  'Amphetamine'],\n",
       " 'Pentagastrin': ['Pentagastrin', 'Pentagastrin'],\n",
       " 'Nicotine': ['(â\\x88\\x92)-nicotine',\n",
       "  '(S)-(â\\x88\\x92)-nicotine',\n",
       "  '(S)-3-(1-methylpyrrolidin-2-yl)pyridine',\n",
       "  '(S)-3-(N-methylpyrrolidin-2-yl)pyridine',\n",
       "  '(S)-Nicotine',\n",
       "  '3-(2-(N-methylpyrrolidinyl))pyridine',\n",
       "  '3-(N-methylpyrollidino)pyridine',\n",
       "  'L(â\\x88\\x92)-nicotine',\n",
       "  'Nicotina',\n",
       "  'Nicotine betadex',\n",
       "  'Nicotine polacrilex',\n",
       "  'Nikotin',\n",
       "  'Nikotyna',\n",
       "  'Nicotine'],\n",
       " 'Cevimeline': ['2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine',\n",
       "  'Cevimelina',\n",
       "  'CÃ©vimÃ¨line',\n",
       "  'Cevimeline',\n",
       "  'Cevimelinum',\n",
       "  'Cevimeline'],\n",
       " 'Lorazepam': ['Loracepam',\n",
       "  'Lorazepam',\n",
       "  'o-Chlorooxazepam',\n",
       "  'o-Chloroxazepam',\n",
       "  'Lorazepam'],\n",
       " 'Esmolol': ['(Â±)-esmolol',\n",
       "  '(Â±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate',\n",
       "  '3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester',\n",
       "  'Esmolol',\n",
       "  'Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate',\n",
       "  'methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate',\n",
       "  'Esmolol'],\n",
       " 'Bortezomib': ['[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid',\n",
       "  'Bortezomib',\n",
       "  'N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide',\n",
       "  'Bortezomib'],\n",
       " 'Ethchlorvynol': ['1-chloro-3-ethyl-1-penten-4-yn-3-ol',\n",
       "  '1-Chloro-3-ethyl-pent-1-en-4-yn-3-ol',\n",
       "  '3-(beta-chlorovinyl)-1-pentyn-3-ol',\n",
       "  '3-(Î²-chlorovinyl)-1-pentyn-3-ol',\n",
       "  'etclorvinol',\n",
       "  'Ethchlorvynol',\n",
       "  'ethyl Î²-chlorovinyl ethynyl carbinol',\n",
       "  'Î²-chlorovinyl ethyl ethynyl carbinol',\n",
       "  'Ethchlorvynol'],\n",
       " 'Carbidopa': ['(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate',\n",
       "  '(S)-(â\\x88\\x92)-carbidopa',\n",
       "  '(S)-carbidopa',\n",
       "  '(Î±S)-Î±-hydrazino-3,4-dihydroxy-Î±-methylbenzenepropanoic acid',\n",
       "  'Carbidopa',\n",
       "  'Carbidopa (anhydrous)',\n",
       "  'Carbidopa anhydrous',\n",
       "  'Carbidopum',\n",
       "  'L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid',\n",
       "  'L-Î±-methyldopahydrazine',\n",
       "  'Carbidopa'],\n",
       " 'Phentermine': ['alpha,alpha-Dimethylphenethylamine',\n",
       "  'Fentermina',\n",
       "  'Phentermine',\n",
       "  'Phentermine resin',\n",
       "  'Phenterminum',\n",
       "  'Phentermine'],\n",
       " 'Indecainide': ['Indecainida', 'Indecainide', 'Indecainidum', 'Indecainide'],\n",
       " 'Tramadol': ['Tramadol', 'Tramadolum', 'Tramadol'],\n",
       " 'Vidarabine': ['9-beta-D-arabinofuranosyl-9H-purin-6-amine',\n",
       "  '9-beta-D-arabinofuranosyl-adenine',\n",
       "  '9-beta-D-Arabinofuranosyladenine',\n",
       "  '9-Î²-D-arabinofuranosyl-9H-purin-6-amine',\n",
       "  '9-Î²-D-arabinofuranosyladenine',\n",
       "  'Spongoadenosine',\n",
       "  'Vidarabine',\n",
       "  'Vidarabinum',\n",
       "  'Vidarabine'],\n",
       " 'Betaxolol': ['1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol',\n",
       "  '1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol',\n",
       "  'Betaxolol',\n",
       "  'BÃ©taxolol',\n",
       "  'Betaxololum',\n",
       "  'Betaxolol'],\n",
       " 'Fluconazole': ['Diflucan',\n",
       "  'Difluconazole',\n",
       "  'Fluconazol',\n",
       "  'Fluconazole',\n",
       "  'Fluconazolum',\n",
       "  'Triflucan',\n",
       "  'Fluconazole'],\n",
       " 'Troglitazone': ['Troglitazona', 'Troglitazone', 'Troglitazone'],\n",
       " 'Oseltamivir': ['(â\\x88\\x92)-oseltamivir',\n",
       "  '1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3alpha,4beta,5alpha))-',\n",
       "  'Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate',\n",
       "  'Oseltamivir',\n",
       "  'OsÃ©ltamivir',\n",
       "  'Oseltamivirum',\n",
       "  'Oseltamivir'],\n",
       " 'Erythromycin': [\"3''-O-demethylerythromycin\",\n",
       "  'Abomacetin',\n",
       "  'Eritromicina',\n",
       "  'Erythromycin',\n",
       "  'Erythromycin A',\n",
       "  'Erythromycin C',\n",
       "  'Ã©rythromycine',\n",
       "  'Erythromycinum',\n",
       "  'Erythromycin'],\n",
       " 'Hydroxocobalamin': ['Hydroxocobalamin',\n",
       "  'Hydroxocobalamin anhydrous',\n",
       "  'Hydroxocobalamine',\n",
       "  'Hydroxocobalaminum anhydrous',\n",
       "  'Hydroxycobalamin',\n",
       "  'OH-Cbl',\n",
       "  'Vitamin B-12b',\n",
       "  'Hydroxocobalamin'],\n",
       " 'Caffeine': ['1-methyltheobromine',\n",
       "  '1,3,7-trimethyl-2,6-dioxopurine',\n",
       "  '1,3,7-trimethylpurine-2,6-dione',\n",
       "  '1,3,7-trimethylxanthine',\n",
       "  '3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion',\n",
       "  '7-methyltheophylline',\n",
       "  'Anhydrous caffeine',\n",
       "  'CafeÃ\\xadna',\n",
       "  'CafÃ©ine',\n",
       "  'Caffeinum',\n",
       "  'Coffein',\n",
       "  'Coffeinum',\n",
       "  'Guaranine',\n",
       "  'Koffein',\n",
       "  'MateÃ\\xadna',\n",
       "  'Methyltheobromine',\n",
       "  'TeÃ\\xadna',\n",
       "  'Thein',\n",
       "  'Theine',\n",
       "  'Caffeine'],\n",
       " 'Succinylcholine': [\"2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)\",\n",
       "  'Dicholine succinate',\n",
       "  'Succinocholine',\n",
       "  'Succinoylcholine',\n",
       "  'Succinylbischoline',\n",
       "  'Succinyldicholine',\n",
       "  'Suxamethonium',\n",
       "  'Succinylcholine'],\n",
       " 'Sildenafil': ['1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine',\n",
       "  'Sildenafil',\n",
       "  'Sildenafilo',\n",
       "  'Sildenafil'],\n",
       " 'Dofetilide': ['beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide',\n",
       "  'Dofetilida',\n",
       "  'Dofetilide',\n",
       "  'Dofetilidum',\n",
       "  'Dofetilide'],\n",
       " 'Pyrimethamine': ['2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine',\n",
       "  '2,4-Diamino-5-(P-chlorophenyl)-6-ethylpyrimidine',\n",
       "  '2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine',\n",
       "  '5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine',\n",
       "  '5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidinediamine',\n",
       "  \"5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine\",\n",
       "  'CD',\n",
       "  'Chloridine',\n",
       "  'Chloridyn',\n",
       "  'Diaminopyritamin',\n",
       "  'Ethylpyrimidine',\n",
       "  'Pirimetamina',\n",
       "  'Primethamine',\n",
       "  'Pyrimethamine',\n",
       "  'PyrimÃ©thamine',\n",
       "  'Pyrimethaminum',\n",
       "  'Pyrimethamine'],\n",
       " 'Reserpine': ['(â\\x88\\x92)-reserpine',\n",
       "  '(3beta,16beta,17alpha,18beta,20alpha)-11,17-Dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester',\n",
       "  '3,4,5-trimethoxybenzoyl methyl reserpate',\n",
       "  'Reserpin',\n",
       "  'Reserpine',\n",
       "  'Reserpine'],\n",
       " 'Azithromycin': ['Azithromycin',\n",
       "  'Azithromycine',\n",
       "  'Azithromycinum',\n",
       "  'Azitromicina',\n",
       "  'Azithromycin'],\n",
       " 'Ticlopidine': ['Ticlopidina', 'Ticlopidine', 'Ticlopidinum', 'Ticlopidine'],\n",
       " 'Trospium': ['Trospium'],\n",
       " 'Adapalene': ['6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid',\n",
       "  'Adapalene',\n",
       "  'AdapalÃ¨ne',\n",
       "  'Adapaleno',\n",
       "  'Adapalenum',\n",
       "  'Adapalene'],\n",
       " 'Midodrine': ['(Â±)-2-amino-N-(Î²-hydroxy-2,5-dimethoxyphenethyl)acetamide',\n",
       "  \"1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol\",\n",
       "  '2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide',\n",
       "  'DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid',\n",
       "  'Midodrin',\n",
       "  'Midodrina',\n",
       "  'Midodrine',\n",
       "  'Midodrinum',\n",
       "  'Midodrine'],\n",
       " 'Remikiren': ['Remikiren', 'Remikiren'],\n",
       " 'Pantoprazole': ['Pantoprazol',\n",
       "  'Pantoprazole',\n",
       "  'Pantoprazolum',\n",
       "  'Pantoprazole'],\n",
       " 'Torasemide': ['1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea',\n",
       "  'N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide',\n",
       "  'Torasemida',\n",
       "  'Torasemide',\n",
       "  'TorasÃ©mide',\n",
       "  'Torasemidum',\n",
       "  'Torsemide',\n",
       "  'Torasemide'],\n",
       " 'Citalopram': ['Citalopram', 'Citalopramum', 'Nitalapram ', 'Citalopram'],\n",
       " 'Eletriptan': ['Eletriptan',\n",
       "  'Ã©lÃ©triptan',\n",
       "  'EletriptÃ¡n',\n",
       "  'Eletriptanum',\n",
       "  'Eletriptan'],\n",
       " 'Bethanidine': ['Betanidina',\n",
       "  'Betanidine',\n",
       "  'BÃ©tanidine',\n",
       "  'Betanidinum',\n",
       "  'Bethanidine',\n",
       "  \"N,N'-dimethyl-N''-(phenylmethyl)-guanidine\",\n",
       "  'Bethanidine'],\n",
       " 'Moxifloxacin': ['1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid',\n",
       "  'Moxifloxacin',\n",
       "  'Moxifloxacino',\n",
       "  'Moxifloxacin'],\n",
       " 'Oxyphenonium': ['Oxyphenonium cation', 'Oxyphenonium ion', 'Oxyphenonium'],\n",
       " 'Nelfinavir': ['Nelfinavir', 'Nelfinavir'],\n",
       " 'Isoetharine': ['Isoetarina', 'Isoetarinum', 'Isoetharine', 'Isoetharine'],\n",
       " 'Glimepiride': ['Glimepirida',\n",
       "  'Glimepiride',\n",
       "  'GlimÃ©piride',\n",
       "  'Glimepiridum',\n",
       "  'Glimepiride'],\n",
       " 'Diflorasone': ['(6Î±,11Î²,16Î²)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione',\n",
       "  'Diflorasona',\n",
       "  'Diflorasone',\n",
       "  'Diflorasonum',\n",
       "  'Diflorasone'],\n",
       " 'Indinavir': ['(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide',\n",
       "  'Indinavir',\n",
       "  'Indinavir anhydrous',\n",
       "  'Indinavir'],\n",
       " 'Gadodiamide': ['Gadodiamida',\n",
       "  'Gadodiamide',\n",
       "  'Gadodiamide anhydrous',\n",
       "  'Gadodiamide'],\n",
       " 'Guanadrel': ['Guanadrel', 'Guanadrelum', 'Guanadrel'],\n",
       " 'Lovastatin': ['(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate',\n",
       "  '2Î²,6Î±-dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone',\n",
       "  '6-alpha-methylcompactin',\n",
       "  '6alpha-methylcompactin',\n",
       "  '6Î±-methylcompactin',\n",
       "  'Lovastatin',\n",
       "  'Lovastatina',\n",
       "  'Lovastatine',\n",
       "  'Lovastatinum',\n",
       "  'Mevinolin',\n",
       "  'Lovastatin'],\n",
       " 'Enflurane': ['2-chloro-1,1,2-trifluoroethyl difluoromethyl ether',\n",
       "  'Alyrane',\n",
       "  'Efrane',\n",
       "  'Enflurane',\n",
       "  'Enflurano',\n",
       "  'Enfluranum',\n",
       "  'Methylflurether',\n",
       "  'Enflurane'],\n",
       " 'Cefotiam': ['(6R,7R)-7-[2-(2-Amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1H-tetrazol-5-ylsulfanylmethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  'Cefotiam',\n",
       "  'Cefotiamum',\n",
       "  'CTM',\n",
       "  'Cefotiam'],\n",
       " 'Pregabalin': ['(S)-3-Isobutyl GABA',\n",
       "  '3-Isobutyl GABA',\n",
       "  'Pregabalin',\n",
       "  'Pregabalina',\n",
       "  'Pregabalin'],\n",
       " 'Temazepam': ['Temazepam', 'Temazepam'],\n",
       " 'Methyclothiazide': ['Methyclothiazide', 'Methyclothiazide'],\n",
       " 'Aminosalicylic acid': ['4-amino-2-hydroxybenzoic acid',\n",
       "  '4-aminosalicylate',\n",
       "  '4-aminosalicylic acid',\n",
       "  'Aminosalicylic acid',\n",
       "  'p-aminosalicylic acid',\n",
       "  'para-amino salicylic acid',\n",
       "  'para-aminosalicylic acid',\n",
       "  'PAS',\n",
       "  'Aminosalicylic acid'],\n",
       " 'Reboxetine': ['Reboxetina', 'Reboxetine'],\n",
       " 'Milrinone': [\"1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile\",\n",
       "  'Milrinona',\n",
       "  'Milrinone',\n",
       "  'Milrinonum',\n",
       "  'Milrinone'],\n",
       " 'Pipobroman': ['1,4-bis(3-bromopropionyl)piperazine',\n",
       "  'N,N-bis-(3-bromopropionyl)-piperazine',\n",
       "  'Pipobroman',\n",
       "  'Pipobromanum',\n",
       "  'Pipobroman'],\n",
       " 'Butabarbital': ['5-ethyl-5-(1-methylpropyl)-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-ethyl-5-(1-methylpropyl)barbituric acid',\n",
       "  '5-sec-butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-sec-butyl-5-ethylbarbituric acid',\n",
       "  '5-sec-butyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione',\n",
       "  'Butabarbital',\n",
       "  'Secbutabarbital',\n",
       "  'Secbutabarbitale',\n",
       "  'Secbutabarbitalum',\n",
       "  'Butabarbital'],\n",
       " 'Nevirapine': [\"11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one\",\n",
       "  'NEV',\n",
       "  'Nevirapina',\n",
       "  'Nevirapine',\n",
       "  'Nevirapine anhydrous',\n",
       "  'Nevirapine, anhydrous',\n",
       "  'NVP',\n",
       "  'Nevirapine'],\n",
       " 'Oxiconazole': [\"2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-[O-(2,4-dichlorobenzyl)oxime]\",\n",
       "  'Oxiconazol',\n",
       "  'Oxiconazole',\n",
       "  'Oxiconazolum',\n",
       "  'Oxiconazole'],\n",
       " 'Alclometasone': ['(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione',\n",
       "  '7Î±-Chloro-16Î±-methylprednisolone',\n",
       "  'Alclometasone',\n",
       "  'Alclometasone'],\n",
       " 'Butalbital': ['5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione',\n",
       "  '5-allyl-5-(2-methylpropyl)barbituric acid',\n",
       "  \"5-allyl-5-(2'-methyl-n-propyl) barbituric acid\",\n",
       "  '5-allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione',\n",
       "  '5-allyl-5-isobutylbarbituric acid',\n",
       "  '5-isobutyl-5-allylbarbituric acid',\n",
       "  'Allylbarbital',\n",
       "  'Allylbarbitone',\n",
       "  'Allylbarbituric acid',\n",
       "  'Butalbarbital',\n",
       "  'Butalbital',\n",
       "  'Butalbitalum',\n",
       "  'iso-butylallylbarbituric acid',\n",
       "  'Itobarbital',\n",
       "  'Tetrallobarbital',\n",
       "  'Butalbital'],\n",
       " 'Cladribine': ['(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol',\n",
       "  '2-CdA',\n",
       "  \"2-Chloro-2'-deoxy-beta-adenosine\",\n",
       "  \"2-Chloro-2'-deoxyadenosine\",\n",
       "  '2-chloro-6-amino-9-(2-deoxy-Î²-D-erythro-pentofuranosyl)purine',\n",
       "  '2-chloro-deoxyadenosine',\n",
       "  '2-Chlorodeoxyadenosine',\n",
       "  '2ClAdo',\n",
       "  'Cladribina',\n",
       "  'Cladribine',\n",
       "  'Cladribinum',\n",
       "  'CldAdo',\n",
       "  'Cladribine'],\n",
       " 'Ranolazine': ['Ranolazina', 'Ranolazine', 'Ranolazine'],\n",
       " 'Mesalazine': ['3-carboxy-4-hydroxyaniline',\n",
       "  '5-aminosalicylic acid',\n",
       "  '5-ASA',\n",
       "  'm-Aminosalicylic acid',\n",
       "  'Mesalamine',\n",
       "  'Mesalazina',\n",
       "  'MÃ©salazine',\n",
       "  'Mesalazine',\n",
       "  'Mesalazinum',\n",
       "  'p-Aminosalicylsaeure',\n",
       "  'Mesalazine'],\n",
       " 'Benzatropine': ['3-alpha-(diphenylmethoxy)tropane',\n",
       "  '3endo-benzhydryloxytropane',\n",
       "  '3Î±-(diphenylmethoxy)-1Î±H,5Î±H-tropane',\n",
       "  '3Î±-(diphenylmethoxy)tropane',\n",
       "  '3Î±-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane',\n",
       "  'Benzatropina',\n",
       "  'Benzatropine',\n",
       "  'Benzatropinum',\n",
       "  'benzhydryl 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ether',\n",
       "  'Benztropine',\n",
       "  'Tropine benzohydryl ether',\n",
       "  'Benzatropine'],\n",
       " 'Ziprasidone': ['Ziprasidona', 'Ziprasidone', 'Ziprasidonum', 'Ziprasidone'],\n",
       " 'Methysergide': ['(+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8Î²-carboxamide',\n",
       "  '(+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide',\n",
       "  '1-Methyl-D-lysergic acid butanolamide',\n",
       "  '1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide',\n",
       "  '1-Methyllysergic acid butanolamide',\n",
       "  '1-Methylmethylergonovine',\n",
       "  '9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide',\n",
       "  'MÃ©thysergide',\n",
       "  'Methysergide',\n",
       "  'Methysergidum',\n",
       "  'Metisergida',\n",
       "  'Metisergido',\n",
       "  'N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide',\n",
       "  'Methysergide'],\n",
       " 'Cabergoline': ['(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide',\n",
       "  '(8Î²)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide',\n",
       "  '1-((6-allylergolin-8Î²-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea',\n",
       "  '1-[(6-allylergoline-8Î²-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea',\n",
       "  \"1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'Î²-carbonyl)urea\",\n",
       "  'Cabergolina',\n",
       "  'Cabergoline',\n",
       "  'Cabergolinum',\n",
       "  'Cabergoline'],\n",
       " 'Idoxuridine': [\"(+)-5-Iodo-2'-deoxyuridine\",\n",
       "  '1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil',\n",
       "  \"1-beta-D-2'-Deoxyribofuranosyl-5-iodouracil\",\n",
       "  \"1beta-D-2'-Deoxyribofuranosyl-5-iodouracil\",\n",
       "  \"2'-Deoxy-5-iodouridine\",\n",
       "  \"5-iodo-2'-deoxyuridine\",\n",
       "  '5-Iododeoxyuridine',\n",
       "  '5-Iodouracil deoxyriboside',\n",
       "  'Idoxuridin',\n",
       "  'Idoxuridina',\n",
       "  'Idoxuridine',\n",
       "  'Idoxuridinum',\n",
       "  'IdU',\n",
       "  'Iododeoxyridine',\n",
       "  'Iodoxuridine',\n",
       "  'Joddeoxiuridin',\n",
       "  'Idoxuridine'],\n",
       " 'Dapsone': [\"1,1'-sulfonylbis(4-aminobenzene)\",\n",
       "  \"1,1'-Sulfonylbis[4-aminobenzene]\",\n",
       "  '4-(4-amino-benzenesulfonyl)-phenylamine',\n",
       "  '4-(4-aminophenylsulfonyl)aniline',\n",
       "  '4-(4-aminophenylsulfonyl)benzenamine',\n",
       "  '4-aminophenyl sulfone',\n",
       "  \"4,4'-dapsone\",\n",
       "  \"4,4'-diaminodiphenyl sulfone\",\n",
       "  \"4,4'-Diaminodiphenyl sulphone\",\n",
       "  \"4,4'-Diaminodiphenylsulfone\",\n",
       "  \"4,4'-sulfonylbisaniline\",\n",
       "  \"4,4'-Sulfonylbisbenzenamine\",\n",
       "  \"4,4'-Sulfonylbisbenzeneamine\",\n",
       "  \"4,4'-Sulfonyldianilin\",\n",
       "  \"4,4'-sulfonyldianiline\",\n",
       "  'bis(4-aminophenyl)sulfone',\n",
       "  'Bis(p-aminophenyl) sulfone',\n",
       "  'DADPS',\n",
       "  'Dapsona',\n",
       "  'Dapsone',\n",
       "  'Dapsonum',\n",
       "  'DDS',\n",
       "  'Diaphenylsulfone',\n",
       "  'p-aminophenyl sulfone',\n",
       "  'p,p-sulphonylbisbenzamine',\n",
       "  'p,p-sulphonylbisbenzenamine',\n",
       "  \"p,p'-diaminodiphenyl sulfone\",\n",
       "  'Dapsone'],\n",
       " 'Terconazole': ['Terconazole', 'Terconazole'],\n",
       " 'Phenytoin': ['5,5-Diphenyl-imidazolidine-2,4-dione',\n",
       "  '5,5-diphenylimidazolidine-2,4-dione',\n",
       "  '5,5-diphenyltetrahydro-1H-2,4-imidazoledione\\t',\n",
       "  '5,5-Diphenyltetrahydro-1H-2,4-imidazoledione',\n",
       "  'Diphenylhydantoin',\n",
       "  'Fenitoina',\n",
       "  'Phentytoin',\n",
       "  'Phenytoin',\n",
       "  'Phenytoine',\n",
       "  'Phenytoinum',\n",
       "  'Phenytoin'],\n",
       " 'Medrysone': ['11beta-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione',\n",
       "  'Medrisona',\n",
       "  'Medrysone',\n",
       "  'Medrysonum',\n",
       "  'Medrysone'],\n",
       " 'Doxycycline': ['5-hydroxy-Î±-6-deoxytetracycline',\n",
       "  '6-alpha-deoxy-5-oxytetracycline',\n",
       "  '6alpha-deoxy-5-oxytetracycline',\n",
       "  '6Î±-deoxy-5-oxytetracycline',\n",
       "  'Anhydrous doxycycline',\n",
       "  'Doxiciclina',\n",
       "  'Doxycyclin',\n",
       "  'Doxycycline',\n",
       "  'Doxycycline (anhydrous)',\n",
       "  'Doxycycline anhydrous',\n",
       "  'Doxycyclinum',\n",
       "  'Doxycycline'],\n",
       " 'Diethylstilbestrol': ['(E)-3,4-bis(4-hydroxyphenyl)-3-hexene',\n",
       "  \"(E)-4,4'-(1,2-diethyl-1,2-ethenediyl)bisphenol\",\n",
       "  \"4,4'-dihydroxy-Î±,Î²-diethylstilbene\",\n",
       "  'DES',\n",
       "  'Diethylstilbestrol',\n",
       "  'DiÃ©thylstilbestrol',\n",
       "  'Diethylstilbestrolum',\n",
       "  'Dietilestilbestrol',\n",
       "  'Stilboestrol',\n",
       "  \"trans-4,4'-(1,2-diethyl-1,2-ethenediyl)bisphenol\",\n",
       "  'trans-Diethylstilbesterol',\n",
       "  'trans-Diethylstilbestrol',\n",
       "  'trans-Diethylstilboesterol',\n",
       "  \"Î±,Î±'-diethyl-(E)-4,4'-stilbenediol\",\n",
       "  'Diethylstilbestrol'],\n",
       " 'Lymecycline': ['(+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide',\n",
       "  'Limeciclina',\n",
       "  'Lymecycline',\n",
       "  'Lymecyclinum',\n",
       "  'N-Lysinomethyltetracycline',\n",
       "  'N2-(((+)-5-Amino-5-carboxypentylamino)methyl)tetracycline',\n",
       "  'N6-((4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamido)methyl)lysine',\n",
       "  'Tetracycline-L-methylene lysine',\n",
       "  'Tetracycline-L-methylenelysine',\n",
       "  'Lymecycline'],\n",
       " 'Clotrimazole': ['1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole',\n",
       "  '1-(o-Chloro-Î±,Î±-diphenylbenzyl)imidazole',\n",
       "  '1-(o-Chlorotrityl)imidazole',\n",
       "  '1-(Î±-(2-Chlorophenyl)benzhydryl)imidazole',\n",
       "  'Clotrimazol',\n",
       "  'Clotrimazole',\n",
       "  'Clotrimazolum',\n",
       "  'Clotrimazole'],\n",
       " 'Calcium acetate': ['Acetate of lime',\n",
       "  'Brown acetate of lime',\n",
       "  'Calcio acetato',\n",
       "  'Calcium acetate',\n",
       "  'calcium ethanoate',\n",
       "  'calcium(II) acetate',\n",
       "  'Gray acetate of lime',\n",
       "  'Lime acetate',\n",
       "  'Lime pyrolignite',\n",
       "  'Calcium acetate'],\n",
       " 'Sulfanilamide': ['4-aminobenzene sulfonic acid amide',\n",
       "  '4-azanylbenzenesulfonamide',\n",
       "  'p-aminobenzenesulfamide',\n",
       "  'p-aminobenzenesulfonamide',\n",
       "  'para-aminobenzenesulfonamide',\n",
       "  'Prontosil album',\n",
       "  'SA',\n",
       "  'Streptocide',\n",
       "  'Sulfamine',\n",
       "  'Sulfanilamida',\n",
       "  'Sulfanilamide',\n",
       "  'Sulfanilamidum',\n",
       "  'Sulphanilamide',\n",
       "  'Sulfanilamide'],\n",
       " 'Cycloserine': ['(+)-4-amino-3-isoxazolidinone',\n",
       "  '(+)-cycloserine',\n",
       "  'alpha-Cycloserine',\n",
       "  'Cicloserina',\n",
       "  'cyclo-D-Serine',\n",
       "  'CyclosÃ©rine',\n",
       "  'Cycloserine',\n",
       "  'Cycloserinum',\n",
       "  'D-(+)-cycloserine',\n",
       "  'D-4-amino-3-isoxazolidinone',\n",
       "  'D-4-amino-3-isoxazolidone',\n",
       "  'D-Cycloserine',\n",
       "  'DCS',\n",
       "  'Orientomycin',\n",
       "  'Î±-Cycloserine',\n",
       "  'Cycloserine'],\n",
       " 'Anagrelide': ['Anagrelida', 'Anagrelide', 'Anagrelidum', 'Anagrelide'],\n",
       " 'Carmustine': ['BCNU',\n",
       "  'bis-chloroethylnitrosourea',\n",
       "  'Bischloroethyl nitrosourea',\n",
       "  'Carmustina',\n",
       "  'Carmustine',\n",
       "  'Carmustinum',\n",
       "  \"N,N'-Bis(2-chloroethyl)-N-nitrosourea\",\n",
       "  'Carmustine'],\n",
       " 'Sulfisoxazole': ['3,4-Dimethyl-5-sulfanilamidoisoxazole',\n",
       "  '3,4-Dimethyl-5-sulfonamidoisoxazole',\n",
       "  '3,4-Dimethyl-5-sulphanilamidoisoxazole',\n",
       "  '3,4-Dimethyl-5-sulphonamidoisoxazole',\n",
       "  '3,4-Dimethylisoxazole-5-sulfanilamide',\n",
       "  '3,4-Dimethylisoxazole-5-sulphanilamide',\n",
       "  '4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide',\n",
       "  '4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulphonamide',\n",
       "  '5-(4-Aminophenylsulfonamido)-3,4-dimethylisoxazole',\n",
       "  '5-(p-Aminobenzenesulfonamido)-3,4-dimethylisoxazole',\n",
       "  '5-(p-Aminobenzenesulphonamido)-3,4-dimethylisoxazole',\n",
       "  '5-Sulfanilamido-3,4-dimethylisoxazole',\n",
       "  '5-Sulphanilamido-3,4-dimethyl-isoxazole',\n",
       "  \"N'-(3,4)Dimethylisoxazol-5-yl-sulphanilamide\",\n",
       "  'N1-(3,4-dimethyl-5-isoxazolyl)sulfanilamide',\n",
       "  'N1-(3,4-dimethyl-5-isoxazolyl)sulphanilamide',\n",
       "  'Sulfadimethylisoxazole',\n",
       "  'Sulfafurazol',\n",
       "  'Sulfafurazole',\n",
       "  'Sulfafurazolum',\n",
       "  'Sulfaisoxazole',\n",
       "  'Sulfasoxazole',\n",
       "  'Sulfisonazole',\n",
       "  'Sulfisoxasole',\n",
       "  'Sulfisoxazol',\n",
       "  'Sulfisoxazole',\n",
       "  'Sulfofurazole',\n",
       "  'Sulphadimethylisoxazole',\n",
       "  'Sulphafurazol',\n",
       "  'Sulphafurazole',\n",
       "  'Sulphaisoxazole',\n",
       "  'Sulphisoxazol',\n",
       "  'Sulphofurazole',\n",
       "  'Sulfisoxazole'],\n",
       " 'Metoprolol': ['(RS)-Metoprolol',\n",
       "  '1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol',\n",
       "  'DL-metoprolol',\n",
       "  'Metoprolol',\n",
       "  'Metoprolol'],\n",
       " 'Crotamiton': ['Crotamiton', 'Crotamiton'],\n",
       " 'Dicoumarol': [\"3,3'-methylen-bis(4-hydroxy-cumarin)\",\n",
       "  \"3,3'-methylene-bis(4-hydroxycoumarine)\",\n",
       "  \"3,3'-methylenebis(4-hydroxy-1,2-benzopyrone)\",\n",
       "  \"3,3'-methylenebis(4-hydroxy-2H-1-benzopyran-2-one)\",\n",
       "  \"3,3'-methylenebis(4-hydroxycoumarin)\",\n",
       "  \"bis-3,3'-(4-hydroxycoumarinyl)methane\",\n",
       "  'bis-hydroxycoumarin',\n",
       "  'bis(4-hydroxycoumarin-3-yl)methane',\n",
       "  'di-(4-hydroxy-3-coumarinyl)methane',\n",
       "  'Dicoumarol',\n",
       "  'Dicoumarolum',\n",
       "  'Dicumarol',\n",
       "  'Dicoumarol'],\n",
       " 'Cefmenoxime': ['(6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-((1-methyl-1H-5-tetraazolylthio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure',\n",
       "  '(6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  'Cefmenoxima',\n",
       "  'Cefmenoxime',\n",
       "  'Cefmenoximum',\n",
       "  'CMX',\n",
       "  'Cefmenoxime'],\n",
       " 'Ropinirole': ['Ropinirol', 'Ropinirole', 'Ropinirolum', 'Ropinirole'],\n",
       " 'Chlorotrianisene': ['Chloortrianisestrol',\n",
       "  'Chlorestrolo',\n",
       "  'Chlorotrianisene',\n",
       "  'Chlorotrianisenum',\n",
       "  'Chlorotrianisine',\n",
       "  'Chlorotrianizen',\n",
       "  'Chlortrianisen',\n",
       "  'Chlortrianisestrol',\n",
       "  'Chlortrianisoestrolum',\n",
       "  'Chlortrianizen',\n",
       "  'Clorotrianiseno',\n",
       "  'Chlorotrianisene'],\n",
       " 'Isradipine': ['Isradipine', 'Isradipino', 'Isradipinum', 'Isradipine'],\n",
       " 'Diatrizoate': ['2,4,6-Triiodo-3,5-diacetamidobenzoic acid',\n",
       "  '3,5-Bis(acetylamino)-2,4,6-triiodobenzoic acid',\n",
       "  '3,5-diacetamido-2,4,6-triiodobenzoic acid',\n",
       "  'Acide amidotrizoique',\n",
       "  'Acidum amidotrizoicum',\n",
       "  'Acidum diacetylaminotrijodbenzoicum',\n",
       "  'Amidotrizoate',\n",
       "  'Amidotrizoic Acid',\n",
       "  'Amidotrizoic acid (anhydrous)',\n",
       "  'Diatrizoesaure',\n",
       "  'Diatrizoic acid',\n",
       "  'Diatrizoic acid (anhydrous)',\n",
       "  'Methalamic acid',\n",
       "  'Triombrin',\n",
       "  'Urografin acid',\n",
       "  'Urogranoic acid',\n",
       "  'Diatrizoate'],\n",
       " 'Betazole': ['1H-pyrazole-3-ethanamine',\n",
       "  '2-(1H-pyrazol-5-yl)ethanamine',\n",
       "  '2-(3-pyrazolyl)ethylamine',\n",
       "  '3-(2-aminoethyl)pyrazole',\n",
       "  '3-(beta-aminoethyl)pyrazole',\n",
       "  '3-(Î²-aminoethyl)pyrazole',\n",
       "  'Ametazole',\n",
       "  'Betazol',\n",
       "  'Betazole',\n",
       "  'Betazolum',\n",
       "  'Betazole'],\n",
       " 'Topiramate': ['2,3:4,5-bis-O-(1-methylethylidene)-Î²-D-fructopyranose sulfamate',\n",
       "  '2,3:4,5-di-O-isopropylidene-Î²-D-fructopyranose sulfamate',\n",
       "  'Tipiramate',\n",
       "  'Tipiramato',\n",
       "  'Topiramate',\n",
       "  'Topiramato',\n",
       "  'Topiramatum',\n",
       "  'TPM',\n",
       "  'Topiramate'],\n",
       " 'Cefmetazole': ['(6R,7S)-7-({[(cyanomethyl)sulfanyl]acetyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  'Cefmetazole',\n",
       "  'Cefmetazolo',\n",
       "  'Cefmetazolum',\n",
       "  'Cefmetazole'],\n",
       " 'Olmesartan': [\"4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid\",\n",
       "  \"4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid\",\n",
       "  'Olmesartan',\n",
       "  'Olmesartan'],\n",
       " 'Amsacrine': [\"4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide\",\n",
       "  \"4'-(9-Acridinylamino)methanesulfon-m-anisidide\",\n",
       "  \"4'-(9-Acridinylamino)methanesulfon-meta-anisidide\",\n",
       "  \"4'-(9-Acridinylamino)methanesulphon-m-anisidide\",\n",
       "  'Acridinyl anisidide',\n",
       "  'Amsacrina',\n",
       "  'Amsacrine',\n",
       "  'Amsacrinum',\n",
       "  'm-AMSA',\n",
       "  'mAMSA',\n",
       "  'Amsacrine'],\n",
       " 'Theophylline': ['1,3-dimethyl-7H-purine-2,6-dione',\n",
       "  '1,3-dimethylxanthine',\n",
       "  'Teofilina',\n",
       "  'Theophyllin',\n",
       "  'Theophylline anhydrous',\n",
       "  'Theophylline, anhydrous',\n",
       "  'Theophylline'],\n",
       " 'Argatroban': ['Argatroban', 'Argatroban anhydrous', 'Argatroban'],\n",
       " 'Liothyronine': [\"3,3',5-triiodo-L-thyronine\",\n",
       "  \"3,5,3'-Triiodo-L-thyronine\",\n",
       "  \"3,5,3'-Triiodothyronine\",\n",
       "  '4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine',\n",
       "  \"L-3,5,3'-Triiodothyronine\",\n",
       "  'L-T3',\n",
       "  'Liothyronine',\n",
       "  'Liothyroninum',\n",
       "  'Liotironina',\n",
       "  'O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine',\n",
       "  'T3',\n",
       "  'Triiodothyronine',\n",
       "  'Liothyronine'],\n",
       " 'Disopyramide': ['Disopiramida',\n",
       "  'Disopyramide',\n",
       "  'Disopyramidum',\n",
       "  'Disopyramide'],\n",
       " 'Lidocaine': [\"2-(Diethylamino)-2',6'-acetoxylidide\",\n",
       "  '2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide',\n",
       "  'alpha-diethylamino-2,6-dimethylacetanilide',\n",
       "  'LidocaÃ\\xadna',\n",
       "  'Lidocaina',\n",
       "  'Lidocaine',\n",
       "  'Lidocainum',\n",
       "  'Lignocaine',\n",
       "  'Î±-diethylamino-2,6-dimethylacetanilide',\n",
       "  'Lidocaine'],\n",
       " 'Pamidronic acid': ['Acide pamidronique',\n",
       "  'Acido pamidronico',\n",
       "  'Acidum pamidronicum',\n",
       "  'Pamidronate',\n",
       "  'Pamidronic acid',\n",
       "  'Pamidronic acid'],\n",
       " 'Clemastine': ['(+)-(2R)-2-(2-(((R)-p-chloro-Î±-methyl-Î±-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine',\n",
       "  '(+)-(2R)-2-[2-[[(R)-p-chloro-Î±-methyl-Î±-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine',\n",
       "  'Clemastina',\n",
       "  'Clemastine',\n",
       "  'Clemastinum',\n",
       "  'Clemastine'],\n",
       " 'Acarbose': ['Acarbosa', 'Acarbose', 'Acarbosum', 'Acarbose'],\n",
       " 'Venlafaxine': ['Venlafaxina', 'Venlafaxine', 'Venlafaxinum', 'Venlafaxine'],\n",
       " 'Conjugated estrogens': ['Conjugated equine estrogens',\n",
       "  'Conjugated estrogens',\n",
       "  'Estrogens, Conjugated',\n",
       "  'Estrogens,conjugated',\n",
       "  'Conjugated estrogens'],\n",
       " 'Travoprost': ['isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(Î±,Î±,Î±-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate',\n",
       "  'Travoprost',\n",
       "  'Travoprostum',\n",
       "  'Travoprost'],\n",
       " 'Amcinonide': ['AmcinÃ³nida',\n",
       "  'Amcinonide',\n",
       "  'Amcinonidum',\n",
       "  'Triamcinolonacetatcyclopentanonid',\n",
       "  'Amcinonide'],\n",
       " 'Atomoxetine': ['(-)-Tomoxetine',\n",
       "  'Atomoxetina',\n",
       "  'Atomoxetine',\n",
       "  'Tomoxetina',\n",
       "  'Tomoxetine',\n",
       "  'Tomoxetinum',\n",
       "  'Atomoxetine'],\n",
       " 'Bleomycin': ['Bleocin',\n",
       "  'Bleomicin',\n",
       "  'Bleomicina',\n",
       "  'Bleomycin',\n",
       "  'Bleomycine',\n",
       "  'Bleomycinum',\n",
       "  'Bleomycin'],\n",
       " 'Chlorambucil': ['4-(p-bis(beta-chloroethyl)aminophenyl)butyric acid',\n",
       "  '4-(p-bis(Î²-chloroethyl)aminophenyl)butyric acid',\n",
       "  '4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid',\n",
       "  'Ambochlorin',\n",
       "  'Chlorambucil',\n",
       "  'Chloraminophen',\n",
       "  'Clorambucilo',\n",
       "  'gamma-[p-di(2-chloroethyl)aminophenyl]butyric acid',\n",
       "  'N,N-di-2-chloroethyl-gamma-p-aminophenylbutyric acid',\n",
       "  'N,N-di-2-chloroethyl-Î³-p-aminophenylbutyric acid',\n",
       "  'Phenylbutyric acid nitrogen mustard',\n",
       "  'Î³-[p-di(2-chloroethyl)aminophenyl]butyric acid',\n",
       "  'Chlorambucil'],\n",
       " 'Etomidate': ['(+)-ethyl 1-(Î±-methylbenzyl)imidazole-5-carboxylate',\n",
       "  '(+)-etomidate',\n",
       "  '(R)-(+)-1-(Î±-methylbenzyl)imidazole-5-carboxylic acid ethyl ester',\n",
       "  '(R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester',\n",
       "  '3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester',\n",
       "  'Etomidate',\n",
       "  'Etomidato',\n",
       "  'Etomidatum',\n",
       "  'R-(+)-ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate',\n",
       "  'Etomidate'],\n",
       " 'Raltitrexed': ['Raltitrexed', 'Raltitrexed'],\n",
       " 'Etonogestrel': ['3-Ketodesogestrel',\n",
       "  '3-Oxodesogestrel',\n",
       "  'Etonogestrel',\n",
       "  'Ã©tonogestrel',\n",
       "  'Etonogestrelum',\n",
       "  'Etonogestrel'],\n",
       " 'Morphine': ['(â\\x88\\x92)-morphine',\n",
       "  '(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol',\n",
       "  '(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol',\n",
       "  '(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol',\n",
       "  '(5Î±,6Î±)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol',\n",
       "  '(5Î±,6Î±)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol',\n",
       "  '(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol',\n",
       "  'Anhydrous morphine',\n",
       "  'Morfina',\n",
       "  'Morphia',\n",
       "  'Morphin',\n",
       "  'Morphine',\n",
       "  'Morphinum',\n",
       "  'Morphium',\n",
       "  'Morphine'],\n",
       " 'Ropivacaine': [\"(S)-(â\\x88\\x92)-1-propyl-2',6'-pipecoloxylidide\",\n",
       "  '(S)-ropivacaine',\n",
       "  'L-N-n-propylpipecolic acid-2,6-xylidide',\n",
       "  'Ropivacaina',\n",
       "  'Ropivacaine',\n",
       "  'Ropivacainum',\n",
       "  'Ropivacaine'],\n",
       " 'Bupivacaine': ['(Â±)-bupivacaine',\n",
       "  '(RS)-bupivacaine',\n",
       "  \"1-Butyl-2',6'-pipecoloxylidide\",\n",
       "  '1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide',\n",
       "  'Bupivacaina',\n",
       "  'Bupivacaine',\n",
       "  'Bupivacainum',\n",
       "  \"dl-1-Butyl-2',6'-pipecoloxylidide\",\n",
       "  'DL-Bupivacaine',\n",
       "  'Racemic bupivacaine',\n",
       "  'Bupivacaine'],\n",
       " 'Dapiprazole': ['5,6,7,8-Tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine',\n",
       "  'Dapiprazol',\n",
       "  'Dapiprazole',\n",
       "  'Dapiprazolum',\n",
       "  'Dapiprazole'],\n",
       " 'Penciclovir': ['9-(4-hydroxy-3-(hydroxymethyl)butyl)guanine',\n",
       "  '9-(4-hydroxy-3-hydroxymethylbut-1-yl)-guanine',\n",
       "  '9-[2-hydroxy-1-(hydroxymethyl)-ethoxymethyl]guanine',\n",
       "  '9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine',\n",
       "  'PCV',\n",
       "  'PE2',\n",
       "  'Penciclovir',\n",
       "  'Penciclovirum',\n",
       "  'Penciclovir'],\n",
       " 'Tenofovir disoproxil': ['Bis(POC)PMPA',\n",
       "  'Tenofovir bis(isopropyloxycarbonyloxymethyl) ester',\n",
       "  'Tenofovir disoproxil'],\n",
       " 'Flucloxacillin': ['(2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  '3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin',\n",
       "  'Floxacillin',\n",
       "  'Flucloxacilina',\n",
       "  'Flucloxacillin',\n",
       "  'Flucloxacilline',\n",
       "  'Flucloxacillinum',\n",
       "  'Flucloxacillin'],\n",
       " 'Tranexamic acid': ['Acide tranÃ©xamique',\n",
       "  'Ã¡cido tranexÃ¡mico',\n",
       "  'Acidum tranexamicum',\n",
       "  'Tranexamic acid',\n",
       "  'Tranexamsaeure',\n",
       "  'Tranexmic acid',\n",
       "  'Tranhexamic acid',\n",
       "  'Trans AMCHA',\n",
       "  'trans-4-(Aminomethyl)cyclohexanecarboxylic acid',\n",
       "  'trans-4-aminomethylcyclohexane-1-carboxylic acid',\n",
       "  'trans-Amcha',\n",
       "  'trans-Tranexamic acid',\n",
       "  'Tranexamic acid'],\n",
       " 'Ertapenem': [\"(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid\",\n",
       "  '(4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid',\n",
       "  'Ertapenem',\n",
       "  'Ertapenem'],\n",
       " 'Desogestrel': ['13-Ethyl-11-methylene-18,19-dinor-17Î±-pregn-4-en-20-yn-17-ol',\n",
       "  'Desogestrel',\n",
       "  'DÃ©sogestrel',\n",
       "  'Desogestrelum',\n",
       "  'Desogestrel'],\n",
       " 'Mitomycin': ['7-Amino-9alpha-methoxymitosane',\n",
       "  'Ametycine',\n",
       "  'Mitamycin',\n",
       "  'Mitocin-C',\n",
       "  'Mitomycin',\n",
       "  'Mitomycin C',\n",
       "  'MMC',\n",
       "  'Mitomycin'],\n",
       " 'Talbutal': ['(RS)-5-allyl-5-sec-butylpyrimidine-2,4,6(1H,3H,5H)-trione',\n",
       "  '5-allyl-5-sec-butylbarbituric acid',\n",
       "  'sec-Butyl allyl barbituric acid',\n",
       "  'Talbutal',\n",
       "  'Talbutale',\n",
       "  'Talbutalum',\n",
       "  'Talbutal'],\n",
       " 'Bexarotene': ['4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid',\n",
       "  '4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid',\n",
       "  'Bexaroten',\n",
       "  'BexarotÃ¨ne',\n",
       "  'Bexarotene',\n",
       "  'Bexaroteno',\n",
       "  'Bexarotenum',\n",
       "  'p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid',\n",
       "  'Bexarotene'],\n",
       " 'Ibutilide': ['Ibutilid',\n",
       "  'Ibutilida',\n",
       "  'Ibutilide',\n",
       "  'Ibutilidum',\n",
       "  'N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide',\n",
       "  'Ibutilide'],\n",
       " 'Vindesine': ['3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine',\n",
       "  '3-carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine',\n",
       "  'Desacetylvinblastine amide',\n",
       "  'Vindesina',\n",
       "  'Vindesine',\n",
       "  'Vindesinum',\n",
       "  'Vindesine'],\n",
       " 'Chlorthalidone': [\"1-keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline\",\n",
       "  '1-oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline',\n",
       "  '2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide',\n",
       "  '2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide',\n",
       "  \"3-(4'-chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine\",\n",
       "  '3-hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine',\n",
       "  'Chlorphthalidolone',\n",
       "  'Chlortalidone',\n",
       "  'Chlortalidonum',\n",
       "  'Chlorthalidone',\n",
       "  'Clortalidona',\n",
       "  'Phthalamodine',\n",
       "  'Phthalamudine',\n",
       "  'Chlorthalidone'],\n",
       " 'Ethoxzolamide': ['6-Ethoxy-1,3-benzothiazole-2-sulfonamide',\n",
       "  'Ethoxazolamide',\n",
       "  'Ethoxyzolamide',\n",
       "  'Ethoxzolamide'],\n",
       " 'Pentobarbital': ['5-Ethyl-5-(1-methyl-butyl)-pyrimidine-2,4,6-trione',\n",
       "  '5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-ethyl-5-(1-methylbutyl)barbituric acid',\n",
       "  '5-ethyl-5-(sec-pentyl)barbituric acid',\n",
       "  'Pentobarbital',\n",
       "  'Pentobarbitone',\n",
       "  'Pentobarbital'],\n",
       " 'Valproic acid': ['2-n-propyl-n-valeric acid',\n",
       "  '2-propyl-pentanoic acid',\n",
       "  '2-Propylpentanoic Acid',\n",
       "  '2-Propylvaleric Acid',\n",
       "  '4-heptanecarboxylic acid',\n",
       "  'acide valproÃ¯que',\n",
       "  'Ã¡cido valproico',\n",
       "  'acidum valproicum',\n",
       "  'di-n-propylacetic acid',\n",
       "  'Di-n-propylessigsÃ¤ure',\n",
       "  'Dipropylacetic acid',\n",
       "  'DPA',\n",
       "  'n-DPA',\n",
       "  'Valproate',\n",
       "  'Valproic acid',\n",
       "  'ValproinsÃ¤ure',\n",
       "  'VPA',\n",
       "  'Valproic acid'],\n",
       " 'Capreomycin': ['Capreomicina', 'Capreomycin', 'Capreomycin'],\n",
       " 'Zolmitriptan': ['(S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one',\n",
       "  '4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one',\n",
       "  'Zolmitriptan',\n",
       "  'ZolmitriptÃ¡n',\n",
       "  'Zolmitriptanum',\n",
       "  'Zolmitriptan'],\n",
       " 'Acetaminophen': ['4-(Acetylamino)phenol',\n",
       "  '4-acetamidophenol',\n",
       "  \"4'-hydroxyacetanilide\",\n",
       "  'Acenol',\n",
       "  'AcetaminofÃ©n',\n",
       "  'AcÃ©taminophÃ¨ne',\n",
       "  'APAP',\n",
       "  'N-acetyl-p-aminophenol',\n",
       "  'p-acetamidophenol',\n",
       "  'p-acetaminophenol',\n",
       "  'p-Acetylaminophenol',\n",
       "  'p-hydroxy-acetanilid',\n",
       "  'p-hydroxyacetanilide',\n",
       "  'p-hydroxyphenolacetamide',\n",
       "  'ParacÃ©tamol',\n",
       "  'Paracetamol',\n",
       "  'Paracetamolum',\n",
       "  'Acetaminophen'],\n",
       " 'Gefitinib': [\"4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline\",\n",
       "  'Gefitinib',\n",
       "  'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine',\n",
       "  'Gefitinib'],\n",
       " 'Codeine': ['(â\\x88\\x92)-Codeine',\n",
       "  '(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol',\n",
       "  '7,8-didehydro-4,5Î±-epoxy-3-methoxy-17-methylmorphinan-6Î±-ol',\n",
       "  'Codein',\n",
       "  'CodeÃ\\xadna',\n",
       "  'CodÃ©ine',\n",
       "  'Codeine anhydrous',\n",
       "  'Codeine polistirex',\n",
       "  'Codeinum',\n",
       "  'L-Codeine',\n",
       "  'Methylmorphine',\n",
       "  'morphine 3-methyl ether',\n",
       "  'Morphine monomethyl ether',\n",
       "  'morphine-3-methyl ether',\n",
       "  'O3-Methylmorphine',\n",
       "  'Codeine'],\n",
       " 'Piperacillin': ['(2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  'Piperacilina',\n",
       "  'Piperacillin',\n",
       "  'Piperacillin anhydrous',\n",
       "  'Piperacillina',\n",
       "  'PipÃ©racilline',\n",
       "  'Piperacillinum',\n",
       "  'Piperacillin'],\n",
       " 'Dihydroergotamine': ['(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide',\n",
       "  \"5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman\",\n",
       "  \"9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione\",\n",
       "  '9,10-dihydroergotamine',\n",
       "  'Dihidroergotamina',\n",
       "  'Dihydroergotamin',\n",
       "  'Dihydroergotamine',\n",
       "  'Dihydroergotaminum',\n",
       "  'Diidroergotamina',\n",
       "  'Dihydroergotamine'],\n",
       " 'Amitriptyline': ['10,11-dihydro-5-(Î³-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene',\n",
       "  '10,11-dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-Î\\x945,Î³-propylamine',\n",
       "  '3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine',\n",
       "  '3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine',\n",
       "  '5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene',\n",
       "  '5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene',\n",
       "  '5-(Î³-dimethylaminopropylidene)-5H-dibenzo[a,d][1,4]cycloheptadiene',\n",
       "  'Amitriptilina',\n",
       "  'Amitriptylin',\n",
       "  'Amitriptyline',\n",
       "  'Amitriptylinum',\n",
       "  'Amitriptyline'],\n",
       " 'Floxuridine': ['1-(2-Deoxy-beta-D-ribofuranosyl)-5-fluorouracil',\n",
       "  \"1-beta-D-2'-Deoxyribofuranosyl-5-flurouracil\",\n",
       "  \"1beta-D-2'-Deoxyribofuranosyl-5-flurouracil\",\n",
       "  \"2'-Deoxy-5-fluorouridine\",\n",
       "  '5-Fluoro-2-desoxyuridine',\n",
       "  \"5-fluoro-2'-deoxyuridine\",\n",
       "  '5-Fluorodeoxyuridine',\n",
       "  \"5-Fluorouracil 2'-deoxyriboside\",\n",
       "  '5-Fluorouracil deoxyriboside',\n",
       "  '5FDU',\n",
       "  \"beta-5-Fluoro-2'-deoxyuridine\",\n",
       "  'Deoxyfluorouridine',\n",
       "  'FdU',\n",
       "  'Floxiridina',\n",
       "  'Floxuridin',\n",
       "  'Floxuridine',\n",
       "  'Floxuridinum',\n",
       "  'Fluorodeoxyuridine',\n",
       "  'Fluoruridine deoxyribose',\n",
       "  'Floxuridine'],\n",
       " 'Tolcapone': ['(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone',\n",
       "  \"3,4-dihydroxy-4'-methyl-5-nitrobenzophenone\",\n",
       "  \"3,4-dihydroxy-5-nitro-4'-methylbenzophenone\",\n",
       "  \"4'-methyl-3,4-dihydroxy-5-nitrobenzophenone\",\n",
       "  'Tolcapon',\n",
       "  'Tolcapona',\n",
       "  'Tolcapone',\n",
       "  'Tolcaponum',\n",
       "  'Tolcapone'],\n",
       " 'Fluorometholone': ['(1R,2S,8S,10S,11S,14R,15S,17S)-14-acetyl-1-fluoro-14,17-dihydroxy-2,8,15-trimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-3,6-dien-5-one',\n",
       "  '9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione',\n",
       "  'Fluorometholon',\n",
       "  'FluoromÃ©tholone',\n",
       "  'Fluorometholone',\n",
       "  'Fluorometholonum',\n",
       "  'Fluorometolona',\n",
       "  'Fluorometholone'],\n",
       " 'Nitroprusside': ['Nitroferricyanide', 'Nitroprusside'],\n",
       " 'Calcium glucoheptonate': ['Calcii glucoheptonas',\n",
       "  'calcium (2Î¾)-D-gluco-heptonate',\n",
       "  'calcium bis[(2Î¾)-D-glycero-D-gulo-heptonate]',\n",
       "  'calcium bis[(2Î¾)-D-glycero-D-ido-heptonate]',\n",
       "  'calcium bis[(3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanoate]',\n",
       "  'Calcium gluceptate',\n",
       "  'Calcium glucoheptonat',\n",
       "  'Calcium glucoheptonate',\n",
       "  'Calcium glucoheptonate (1:2)',\n",
       "  'Glucoheptonate de calcium',\n",
       "  'Glucoheptonato calcico',\n",
       "  'Calcium glucoheptonate'],\n",
       " 'Hydromorphone': ['(-)-(5R)-4,5-Epoxy-3-hydroxy-9Î±-methylmorphinan-6-one',\n",
       "  '4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one',\n",
       "  '4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone',\n",
       "  '6-Deoxy-7,8-dihydro-6-oxomorphine',\n",
       "  '7,8-Dihydromorphinone',\n",
       "  'Dihydromorfinon',\n",
       "  'Dihydromorphinone',\n",
       "  'Dimorphone',\n",
       "  'Hidromorfona',\n",
       "  'Hydromorfona',\n",
       "  'Hydromorphone',\n",
       "  'Hydromorphonum',\n",
       "  'Idromorfone',\n",
       "  'Hydromorphone'],\n",
       " 'Indomethacin': ['{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid',\n",
       "  '1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid',\n",
       "  'Indometacin',\n",
       "  'Indometacina',\n",
       "  'Indometacine',\n",
       "  'Indometacinum',\n",
       "  'Indomethacin',\n",
       "  'Indomethacin'],\n",
       " 'Ethambutol': [\"(+)-2,2'-(ethylenediimino)di-1-butanol\",\n",
       "  '(+)-ethambutol',\n",
       "  \"(+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamine\",\n",
       "  '(+)-S,S-ethambutol',\n",
       "  '(2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol',\n",
       "  '(S,S)-ethambutol',\n",
       "  'EMB',\n",
       "  'Etambutol',\n",
       "  'Etambutolo',\n",
       "  'Ethambutol',\n",
       "  'Ethambutolum',\n",
       "  'S,S-Ethambutol',\n",
       "  'Ethambutol'],\n",
       " 'Metformin': ['1,1-Dimethylbiguanide',\n",
       "  'Dimethylbiguanid',\n",
       "  'Metformin',\n",
       "  'Metformina',\n",
       "  'Metformine',\n",
       "  'Metforminum',\n",
       "  'Metformin'],\n",
       " 'Ipratropium': ['bromuro de ipratropio',\n",
       "  'Ipratropium cation',\n",
       "  'Ipratropium ion',\n",
       "  'Ipratropium'],\n",
       " 'Methadone': ['(+-)-Methadone',\n",
       "  '(+/-)-Methadone',\n",
       "  '(Â±)-methadone',\n",
       "  '6-Dimethylamino-4,4-diphenyl-3-heptanone',\n",
       "  'dl-Methadone',\n",
       "  'Metadona',\n",
       "  'Methadone',\n",
       "  'Methadonum',\n",
       "  'Methadone'],\n",
       " 'Olanzapine': ['2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine',\n",
       "  'Olanzapin',\n",
       "  'Olanzapina',\n",
       "  'Olanzapine',\n",
       "  'Olanzapinum',\n",
       "  'Olanzapine'],\n",
       " 'Atenolol': ['1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol',\n",
       "  '2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide',\n",
       "  '4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide',\n",
       "  'Atenolol',\n",
       "  'Atenololum',\n",
       "  'Atenolol'],\n",
       " 'Nitrofural': ['5-Nitro-2-furaldehyde semicarbazone',\n",
       "  'Furacilin',\n",
       "  'Nitrofural',\n",
       "  'Nitrofural'],\n",
       " 'Pimecrolimus': ['33-Epi-chloro-33-desoxyascomycin',\n",
       "  'Pimecrolimus',\n",
       "  'Pimecrolimusum',\n",
       "  'Pimecrolimus'],\n",
       " 'Omeprazole': ['OMEP',\n",
       "  'Omeprazol',\n",
       "  'Omeprazole',\n",
       "  'Omeprazolum',\n",
       "  'Omeprazole'],\n",
       " 'Pyrazinamide': ['2-carbamylpyrazine',\n",
       "  '2-pyrazinecarboxamide',\n",
       "  'Aldinamide',\n",
       "  'Pirazinamida',\n",
       "  'Pirazinamide',\n",
       "  'Pyrazinamid',\n",
       "  'Pyrazinamida',\n",
       "  'Pyrazinamide',\n",
       "  'Pyrazinamidum',\n",
       "  'Pyrazine carboxamide',\n",
       "  'pyrazine-2-carboxamide',\n",
       "  'Pyrazineamide',\n",
       "  'Pyrazinecarboxamide',\n",
       "  'Pyrazinoic acid amide',\n",
       "  'Pyrizinamide',\n",
       "  'Pyrazinamide'],\n",
       " 'Metixene': ['Methixen',\n",
       "  'Methixene',\n",
       "  'Metisene',\n",
       "  'Metixene',\n",
       "  'MÃ©tixÃ¨ne',\n",
       "  'Metixeno',\n",
       "  'Metixenum',\n",
       "  'Metixene'],\n",
       " 'Cetirizine': ['Cetirizin',\n",
       "  'Cetirizina',\n",
       "  'Cetirizine',\n",
       "  'Cetirizinum',\n",
       "  'Cetirizine'],\n",
       " 'Terfenadine': ['(RS)-1-(4-tert-butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}-butan-1-ol',\n",
       "  'Terfenadin',\n",
       "  'Terfenadina',\n",
       "  'TerfÃ©nadine',\n",
       "  'Terfenadine',\n",
       "  'Terfenadinum',\n",
       "  'Terfenadine'],\n",
       " 'Diltiazem': ['(+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester',\n",
       "  '(2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one',\n",
       "  '(2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate',\n",
       "  'Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester',\n",
       "  'd-cis-diltiazem',\n",
       "  'Diltiazem',\n",
       "  'Diltiazemum',\n",
       "  'Diltiazem'],\n",
       " 'Protriptyline': ['3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine',\n",
       "  '3-(5H-dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine',\n",
       "  '5-(3-methylaminopropyl)-5H-dibenzo[a,d]cycloheptene',\n",
       "  '7-(3-methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene',\n",
       "  'Amimetilina',\n",
       "  'N-methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine',\n",
       "  'N-methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine',\n",
       "  'Protriptilina',\n",
       "  'Protriptylin',\n",
       "  'Protriptyline',\n",
       "  'Protriptylinum',\n",
       "  'Protriptyline'],\n",
       " 'Aminohippuric acid': ['4-aminohippuric acid',\n",
       "  'Aminohippurate',\n",
       "  'N-(p-Aminobenzoyl)aminoacetic acid',\n",
       "  'N-(p-Aminobenzoyl)glycine',\n",
       "  'N-(para-aminobenzoyl)glycine',\n",
       "  'p-aminohippurate',\n",
       "  'p-aminohippuric acid',\n",
       "  'PAH',\n",
       "  'PAHA',\n",
       "  'para-aminohippurate',\n",
       "  'para-aminohippuric acid ',\n",
       "  'paraaminohippuric acid',\n",
       "  'Aminohippuric acid'],\n",
       " 'Alfuzosin': ['(Â±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide',\n",
       "  'Alfuzosin',\n",
       "  'Alfuzosina',\n",
       "  'Alfuzosine',\n",
       "  'Alfuzosinum',\n",
       "  'N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide',\n",
       "  'Alfuzosin'],\n",
       " 'Trimethadione': ['Trimetadiona',\n",
       "  'Trimethadion',\n",
       "  'Trimethadione',\n",
       "  'TrimÃ©thadione',\n",
       "  'Trimethadionum',\n",
       "  'Trimethinum',\n",
       "  'Troxidone',\n",
       "  'Trimethadione'],\n",
       " 'Nitisinone': ['2-(alpha,alpha,alpha-Trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione',\n",
       "  'Nitisinona',\n",
       "  'Nitisinone',\n",
       "  'Nitisinonum',\n",
       "  'Nitisinone'],\n",
       " 'Clobazam': ['1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine',\n",
       "  '7-Chloro-1-methyl-5-phenyl-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione',\n",
       "  'Clobazam',\n",
       "  'Clobazamum',\n",
       "  'Clobazam'],\n",
       " 'Minoxidil': ['2,4-Diamino-6-piperidinopyrimidine 3-oxide',\n",
       "  '6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide',\n",
       "  'Minossidile',\n",
       "  'Minoxidil',\n",
       "  'Minoxidilum',\n",
       "  'Minoxidil'],\n",
       " 'Megestrol acetate': ['17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione',\n",
       "  '17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate',\n",
       "  '17alpha-Acetoxy-6-dehydro-6-methylprogesterone',\n",
       "  '17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate',\n",
       "  '17Î±-Acetoxy-6-dehydro-6-methylprogesterone',\n",
       "  '17Î±-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate',\n",
       "  '6-Dehydro-6-methyl-17alpha-acetoxyprogesterone',\n",
       "  '6-Dehydro-6-methyl-17Î±-acetoxyprogesterone',\n",
       "  '6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione',\n",
       "  '6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate',\n",
       "  '6-Methyl-17Î±-acetoxypregna-4,6-diene-3,20-dione',\n",
       "  '6-Methyl-17Î±-hydroxy-delta(sup 6)-progesterone acetate',\n",
       "  '6-Methyl-6-dehydro-17alpha-acetoxyprogesterone',\n",
       "  '6-Methyl-6-dehydro-17Î±-acetoxyprogesterone',\n",
       "  '6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate',\n",
       "  '6-Methyl-delta(sup 4,6)-pregnadien-17Î±-ol-3,20-dione acetate',\n",
       "  '6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone',\n",
       "  '6-Methyl-delta(sup 6)-dehydro-17Î±-acetoxyprogesterone',\n",
       "  'Megestrol acetate',\n",
       "  'MGA',\n",
       "  'Megestrol acetate'],\n",
       " 'Tioguanine': ['2-Amino 6MP',\n",
       "  '2-Amino-1,7-dihydro-6H-purine-6-thione',\n",
       "  '2-amino-1,9-dihydropurine-6-thione',\n",
       "  '2-Amino-6-mercaptopurine',\n",
       "  '2-Amino-6-merkaptopurin',\n",
       "  '2-Amino-6-purinethiol',\n",
       "  '2-Aminopurin-6-thiol',\n",
       "  '2-Aminopurine-6-thiol',\n",
       "  '2-Aminopurine-6(1H)-thione',\n",
       "  '6-Mercapto-2-aminopurine',\n",
       "  '6-Mercaptoguanine',\n",
       "  '6-TG',\n",
       "  '6-Thioguanine',\n",
       "  'TG',\n",
       "  'ThG',\n",
       "  'Thioguanine',\n",
       "  'Thioguanine anhydrous',\n",
       "  'Thioguanine, anhydrous',\n",
       "  'Tioguanin',\n",
       "  'Tioguanina',\n",
       "  'Tioguanine',\n",
       "  'Tioguaninum',\n",
       "  'Tioguanine'],\n",
       " 'Methylergometrine': ['9,10-Didehydro-N-[1-(hydroxymethyl)-propyl]-D-lysergamide',\n",
       "  'D-lysergic acid 1-butanolamide',\n",
       "  'Ergotyl',\n",
       "  'Methylergobasin',\n",
       "  'Methylergometrin',\n",
       "  'MÃ©thylergomÃ©trine',\n",
       "  'Methylergometrine',\n",
       "  'Methylergometrinum',\n",
       "  'Methylergonovine',\n",
       "  'Metilergometrina',\n",
       "  'Metilergometrinio',\n",
       "  'Methylergometrine'],\n",
       " 'Buclizine': ['1-(p-tert-Butylbenzyl)-4-(4-chloro-alpha-phenylbenzyl)piperazine',\n",
       "  'Buclizina',\n",
       "  'Buclizine',\n",
       "  'Buclizinum',\n",
       "  'Buclizine'],\n",
       " 'Aztreonam': ['(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid',\n",
       "  '2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl) -2- {[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino} -2- oxoethylidene]amino}oxy)-2-methylpropanoic acid',\n",
       "  'Aztreonam',\n",
       "  'AztrÃ©onam',\n",
       "  'Aztreonamum',\n",
       "  'Aztreonam'],\n",
       " 'Chlorzoxazone': ['2-hydroxy-5-chlorobenzoxazole',\n",
       "  '5-chloro-2-benzoxazolinone',\n",
       "  '5-chloro-2-benzoxazolol',\n",
       "  '5-chloro-2-benzoxazolone',\n",
       "  '5-chloro-2-hydroxybenzoxazole',\n",
       "  '5-chloro-2(3H)-benzoxazolone',\n",
       "  '5-chloro-3H-benzooxazol-2-one',\n",
       "  '5-chlorobenzoxazolidone',\n",
       "  '5-chlorobenzoxazolin-2-one',\n",
       "  'Chlorzoxane',\n",
       "  'Chlorzoxazon',\n",
       "  'Chlorzoxazona',\n",
       "  'Chlorzoxazone',\n",
       "  'Chlorzoxazonum',\n",
       "  'Clorzoxazona',\n",
       "  'Clorzoxazone',\n",
       "  'Chlorzoxazone'],\n",
       " 'Aminoglutethimide': ['2-(p-Aminophenyl)-2-ethylglutarimide',\n",
       "  '3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine',\n",
       "  'Aminoglutethimid',\n",
       "  'AminoglutÃ©thimide',\n",
       "  'Aminoglutethimide',\n",
       "  'Aminoglutethimidum',\n",
       "  'Aminoglutetimida',\n",
       "  'Aminoglutetimide',\n",
       "  'DL-Aminoglutethimide',\n",
       "  'p-Aminoglutethimide',\n",
       "  'Î±-(p-Aminophenyl)-Î±-ethylglutarimide',\n",
       "  'Aminoglutethimide'],\n",
       " 'Mefloquine': ['[(R*,S*)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol',\n",
       "  'alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol',\n",
       "  'Mefloquin',\n",
       "  'Mefloquina',\n",
       "  'MÃ©floquine',\n",
       "  'Mefloquine',\n",
       "  'Mefloquinum',\n",
       "  'Mefloquine'],\n",
       " 'Sulfadiazine': ['2-sulfanilamidopyrimidine',\n",
       "  '2-sulfanilylaminopyrimidine',\n",
       "  '4-amino-N-2-pyrimidinylbenzenesulfonamide',\n",
       "  'N(1)-2-Pyrimidinylsulfanilamide',\n",
       "  'N(1)-2-Pyrimidylsulfanilamide',\n",
       "  'Sulfadiazin',\n",
       "  'Sulfadiazina',\n",
       "  'Sulfadiazine',\n",
       "  'Sulfadiazinum',\n",
       "  'Sulfapyrimidine',\n",
       "  'Sulphadiazine',\n",
       "  'Sulfadiazine'],\n",
       " 'Sapropterin': ['(â\\x88\\x92)-(6R)-2-amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinone',\n",
       "  '(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin',\n",
       "  '(6R)-L-erythro-tetrahydrobiopterin',\n",
       "  '2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydoro-4(1H)-pteridinone',\n",
       "  '5,6,7,8-Tetrahydrobiopterin',\n",
       "  '6R-5,6,7,8-tetrahydrobiopterin',\n",
       "  '6R-BH4',\n",
       "  '6R-L-5,6,7,8-tetrahydrobiopterin',\n",
       "  'R-THBP',\n",
       "  'Sapropterin',\n",
       "  'Sapropterina',\n",
       "  'sapropterinum',\n",
       "  'Tetrahydrobiopterin',\n",
       "  'Sapropterin'],\n",
       " 'Vinorelbine': [\"5'-Noranhydrovinblastine\",\n",
       "  'Vinorelbin',\n",
       "  'Vinorelbina',\n",
       "  'Vinorelbine',\n",
       "  'Vinorelbinum',\n",
       "  'Vinorelbine'],\n",
       " 'Anidulafungin': ['Anidulafungin',\n",
       "  'Anidulafungina',\n",
       "  'Anidulafungine',\n",
       "  'Anidulafunginum',\n",
       "  'Anidulafungin'],\n",
       " 'Clozapine': ['Clozapin',\n",
       "  'Clozapina',\n",
       "  'Clozapine',\n",
       "  'Clozapinum',\n",
       "  'Clozapine'],\n",
       " 'Sucralfate': ['Hexadeca-Î¼-hydroxytetracosahydroxy[Î¼8-[1,3,4,6-tetra-O-sulfo-Î²-Dfructofuranosyl-Î±-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum',\n",
       "  'Sucralfat',\n",
       "  'Sucralfate',\n",
       "  'Sucralfato',\n",
       "  'Sucralfatum',\n",
       "  'Sucralfate'],\n",
       " 'Grepafloxacin': ['Grepafloxacin'],\n",
       " 'Doxylamine': ['2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine',\n",
       "  '2-Dimethylaminoethoxyphenylmethyl-2-picoline',\n",
       "  'Dossilamina',\n",
       "  'Doxilamina',\n",
       "  'Doxilminio',\n",
       "  'Doxylamine',\n",
       "  'Doxylaminum',\n",
       "  'N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine',\n",
       "  'Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether',\n",
       "  'Doxylamine'],\n",
       " 'Levonorgestrel': ['(-)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one',\n",
       "  '(8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- tetradecahydrocyclopenta[a] phenanthren-3-one',\n",
       "  '13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one',\n",
       "  '13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one',\n",
       "  '13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one',\n",
       "  '17-alpha-Ethinyl-13-beta-ethyl-17-beta-hydroxy-4-estren-3-one',\n",
       "  '17-alpha-Ethynyl-13-ethyl-19-nortestosterone',\n",
       "  '17-Ethynyl-18-methyl-19-nortestosterone',\n",
       "  '17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol',\n",
       "  '17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one',\n",
       "  '17alpha-Ethynyl-18-homo-19-nortestosterone',\n",
       "  '18-Methyl-17-alpha-ethynyl-19-nortestosterone',\n",
       "  '18-Methylnorethisterone',\n",
       "  'd(-)-Norgestrel',\n",
       "  'LÃ¨vonorgestrel',\n",
       "  'Levonorgestrel',\n",
       "  'Levonorgestrelum',\n",
       "  'Levonorgestrel'],\n",
       " 'Norepinephrine': ['(â\\x88\\x92)-arterenol',\n",
       "  '(â\\x88\\x92)-noradrenaline',\n",
       "  '(â\\x88\\x92)-norepinephrine',\n",
       "  '(R)-(â\\x88\\x92)-norepinephrine',\n",
       "  '(R)-4-(2-amino-1-hydroxyethyl)-1,2-benzenediol',\n",
       "  '(R)-noradrenaline',\n",
       "  '(R)-norepinephrine',\n",
       "  '4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol',\n",
       "  'Arterenol',\n",
       "  'L-noradrenaline',\n",
       "  'L-Norepinephrine',\n",
       "  'Nor-adrenaline',\n",
       "  'Noradrenaline',\n",
       "  'Norepinefrina',\n",
       "  'NorÃ©pinÃ©phrine',\n",
       "  'Norepinephrine',\n",
       "  'Norepinephrinum',\n",
       "  'Norepinephrine'],\n",
       " 'Cidofovir': ['({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid',\n",
       "  '(S)-(3-(4-amino-2-Oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid',\n",
       "  '(S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine',\n",
       "  '(S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine',\n",
       "  '(S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine',\n",
       "  '(S)-HPMPC',\n",
       "  '[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid',\n",
       "  '[[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid',\n",
       "  '1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine',\n",
       "  '1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine',\n",
       "  'CDV',\n",
       "  'Cidofovir',\n",
       "  'Cidofovir anhydrous',\n",
       "  'Cidofovirum',\n",
       "  'Cidofovir'],\n",
       " 'Mirtazapine': ['1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine',\n",
       "  '6-Azamianserin',\n",
       "  'Mepirzapine',\n",
       "  'Mirtazapin',\n",
       "  'Mirtazapina',\n",
       "  'Mirtazapine',\n",
       "  'Mirtazapinum',\n",
       "  'Mirtazapine'],\n",
       " 'Meprobamate': ['Meprobamat',\n",
       "  'Meprobamate',\n",
       "  'Meprobamato',\n",
       "  'Meprobamatum',\n",
       "  'Meprobamic acid',\n",
       "  'Meprobamate'],\n",
       " 'Thiethylperazine': ['2-(ethylthio)-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine',\n",
       "  'Norzine',\n",
       "  'Thiethylperazin',\n",
       "  'ThiÃ©thylpÃ©razine',\n",
       "  'Thiethylperazine',\n",
       "  'Thiethylperazinum',\n",
       "  'Tietilperazina',\n",
       "  'Thiethylperazine'],\n",
       " 'Timolol': ['(S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol',\n",
       "  'Timolol',\n",
       "  'Timolol anhydrous',\n",
       "  'Timololo',\n",
       "  'Timololum',\n",
       "  'Timolol'],\n",
       " 'Treprostinil': ['TrÃ©prostinil',\n",
       "  'Treprostinil',\n",
       "  'Treprostinilo',\n",
       "  'Treprostinilum',\n",
       "  'Treprostinil'],\n",
       " 'Colestipol': ['Colestipol',\n",
       "  'Colestipolum',\n",
       "  'Copolymer of bis(2-aminoethyl)amine and 2-(chloromethyl)oxirane',\n",
       "  'Epichlorohydrin-tetraethylenepentamine polymer',\n",
       "  'Colestipol'],\n",
       " 'Trihexyphenidyl': ['Trihexifenidilo',\n",
       "  'Trihexyphenidyl',\n",
       "  'TrihexyphÃ©nidyle',\n",
       "  'Trihexyphenidylum',\n",
       "  'Trihexyphenidyl'],\n",
       " 'Palonosetron': ['(3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one',\n",
       "  '2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one',\n",
       "  'Palonosetron',\n",
       "  'PalonosÃ©tron',\n",
       "  'PalonosetrÃ³n',\n",
       "  'Palonosetronum',\n",
       "  'Palonosetron'],\n",
       " 'Dydrogesterone': ['(9Î²,10Î±)-pregna-4,6-diene-3,20-dione',\n",
       "  '10Î±-Isopregnenone',\n",
       "  '6-Dehydro-retro-progesterone',\n",
       "  '9Î²,10Î±-pregna-4,6-diene-3,20-dione',\n",
       "  'delta(6)-Retroprogesterone',\n",
       "  'delta(sup 6)-Retroprogesterone',\n",
       "  'Didrogesterona',\n",
       "  'Didrogesterone',\n",
       "  'Dydrogesterona',\n",
       "  'DydrogestÃ©rone',\n",
       "  'Dydrogesterone',\n",
       "  'Dydrogesteronum',\n",
       "  'Gestatron',\n",
       "  'Hydrogesterone',\n",
       "  'Hydrogestrone',\n",
       "  'Isopregnenone',\n",
       "  'Retro-6-dehydroprogesterone',\n",
       "  'Dydrogesterone'],\n",
       " 'Mexiletine': ['(Â±)-1-(2,6-dimethylphenoxy)propan-2-amine',\n",
       "  '(2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane',\n",
       "  '1-(2,6-dimethylphenoxy)-2-propanamine',\n",
       "  \"1-(2',6'-dimethylphenoxy)-2-aminopropane\",\n",
       "  '1-methyl-2-(2,6-xylyloxy)ethanamine',\n",
       "  'Mexiletina',\n",
       "  'Mexiletine',\n",
       "  'MexilÃ©tine',\n",
       "  'Mexiletinum',\n",
       "  'Mexiletine'],\n",
       " 'Dexrazoxane': [\"(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione\",\n",
       "  '(+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane',\n",
       "  '4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione',\n",
       "  'Dexrazoxan',\n",
       "  'Dexrazoxane',\n",
       "  'Dexrazoxano',\n",
       "  'Dexrazoxanum',\n",
       "  'Dextrorazoxane',\n",
       "  'Dexrazoxane'],\n",
       " 'Amlodipine': ['(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate',\n",
       "  '3-Ethyl 5-methylester, (Â±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate',\n",
       "  'Amlodipine',\n",
       "  'Amlodipine free base',\n",
       "  'Amlodipino',\n",
       "  'Amlodipinum',\n",
       "  'Amlodipine'],\n",
       " 'Tacrine': ['1,2,3,4-tetrahydro-9-acridinamine',\n",
       "  '1,2,3,4-tetrahydro-9-aminoacridine',\n",
       "  '1,2,3,4-tetrahydroacridin-9-amine',\n",
       "  '5-amino-6,7,8,9-tetrahydroacridine',\n",
       "  '9-amino-1,2,3,4-tetrahydroacridine',\n",
       "  'Tacrin',\n",
       "  'Tacrine',\n",
       "  'Tacrinum',\n",
       "  'Tetrahydroaminacrine',\n",
       "  'Tetrahydroaminoacridine',\n",
       "  'THA',\n",
       "  'Tacrine'],\n",
       " 'Oxyphencyclimine': ['Oxifencicliminum',\n",
       "  'Oxyphencyclimine',\n",
       "  'Oxyphencycliminum',\n",
       "  'Oxyphencyclimine'],\n",
       " 'Triamterene': ['6-phenylpteridine-2,4,7-triamine',\n",
       "  'Teridin',\n",
       "  'Triamteren',\n",
       "  'Triamterena',\n",
       "  'TriamtÃ©rÃ¨ne',\n",
       "  'Triamterene',\n",
       "  'Triamtereno',\n",
       "  'Triamterenum',\n",
       "  'Triamterene'],\n",
       " 'Valrubicin': ['(8S, 10S)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-Î±-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione 8Â²-valerate',\n",
       "  '2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-({2,3,6-trideoxy-3-[(trifluoroacetyl)amino]hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate',\n",
       "  'Valrubicin',\n",
       "  'Valrubicina',\n",
       "  'Valrubicine',\n",
       "  'Valrubicinum',\n",
       "  'Valrubicin'],\n",
       " 'Procyclidine': ['1-cyclohexyl-1-phenyl-3-pyrrolidin-1-yl-propan-1-ol hydrochloride',\n",
       "  '1-Cyclohexyl-1-phenyl-3-pyrrolidino-1-propanol',\n",
       "  'Prociclidina',\n",
       "  'Procyclidin',\n",
       "  'Procyclidine',\n",
       "  'Procyclidinum',\n",
       "  'Tricyclamol',\n",
       "  'Procyclidine'],\n",
       " 'Phenylephrine': ['(â\\x88\\x92)-m-hydroxy-Î±-(methylaminomethyl)benzyl alcohol',\n",
       "  'Fenilefrina',\n",
       "  'l-(3-Hydroxyphenyl)-N-methylethanolamine',\n",
       "  'Phenylephrine',\n",
       "  'Phenylephrinum',\n",
       "  'R(-)-Phenylephrine',\n",
       "  'Phenylephrine'],\n",
       " 'Carbimazole': ['Athyromazole',\n",
       "  'Carbethoxymethimazole',\n",
       "  'Carbimazol',\n",
       "  'Carbimazolo',\n",
       "  'Carbimazolum',\n",
       "  'Carbinazole',\n",
       "  'Ethyl 3-methyl-2-thioimidazoline-1-carboxylate',\n",
       "  'Carbimazole'],\n",
       " 'Digoxin': ['12Î²-hydroxydigitoxin',\n",
       "  'Digossina',\n",
       "  'Digoxin',\n",
       "  'Digoxina',\n",
       "  'Digoxine',\n",
       "  'Digoxinum',\n",
       "  'Digoxin'],\n",
       " 'Sulpiride': ['(Â±)-sulpiride',\n",
       "  '5-(Aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide',\n",
       "  'N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamide',\n",
       "  'N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide',\n",
       "  'Sulpirid',\n",
       "  'Sulpirida',\n",
       "  'Sulpiride',\n",
       "  'Sulpiridum',\n",
       "  'Sulpyrid',\n",
       "  'Sulpiride'],\n",
       " 'Profenamine': ['10-(2-diethylaminopropyl)phenothiazine',\n",
       "  '10-[2-(diethylamino)-1-propyl]phenothiazine',\n",
       "  '10-[2-(diethylamino)-2-methylethyl]phenothiazine',\n",
       "  '10-[2-(diethylamino)propyl]phenothiazine',\n",
       "  '2-diethylamino-1-propyl-N-dibenzoparathiazine',\n",
       "  'Ethopropazine',\n",
       "  'N,N-diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine',\n",
       "  'N,N-diethyl-Î±-methyl-10H-phenothiazine-10-ethanamine',\n",
       "  'Profenamina',\n",
       "  'ProfÃ©namine',\n",
       "  'Profenamine',\n",
       "  'Profenaminum',\n",
       "  'Profenamine'],\n",
       " 'Nimodipine': [\"2,6-dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-Î²-methoxyethyl ester 5-isopropyl ester\",\n",
       "  'isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate',\n",
       "  'isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate',\n",
       "  'Nimodipine',\n",
       "  'Nimodipino',\n",
       "  'Nimodipinum',\n",
       "  'Nimodipine'],\n",
       " 'Beclomethasone dipropionate': ['(11Î²,16Î²)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione',\n",
       "  '9-chloro-11Î²-hydroxy-16Î²-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate',\n",
       "  '9-chloro-16Î²-methyl-11Î²,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate',\n",
       "  'beclometasone 17,21-dipropionate',\n",
       "  'Beclometasone dipropionate',\n",
       "  'Beclometasone dipropionato',\n",
       "  'Beclomethasone dipropionate',\n",
       "  'Beclomethasone dipropionate'],\n",
       " 'Carisoprodol': ['(Â±)-2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate',\n",
       "  '(1-methylethyl)carbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester',\n",
       "  '(RS)-2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate',\n",
       "  '2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate',\n",
       "  '2-methyl-2-propyltrimethylene carbamate isopropylcarbamate',\n",
       "  'carbamic acid 2-isopropylcarbamoyloxymethyl-2-methyl-pentyl ester',\n",
       "  'Carisoprodol',\n",
       "  'Carisoprodolo',\n",
       "  'Carisoprodolum',\n",
       "  'Isobamate',\n",
       "  'Isomeprobamate',\n",
       "  'Isopropyl meprobamate',\n",
       "  'Isopropylmeprobamate',\n",
       "  'N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate',\n",
       "  'Carisoprodol'],\n",
       " 'Progesterone': ['(S)-4-Pregnene-3,20-dione',\n",
       "  '(S)-Pregn-4-en-3,20-dione',\n",
       "  '(S)-Progesterone',\n",
       "  '17alpha-Progesterone',\n",
       "  '17Î±-progesterone',\n",
       "  '4-Pregnene-3,20-dione',\n",
       "  'Agolutin',\n",
       "  'Akrolutin',\n",
       "  'Corpus Luteum Hormone',\n",
       "  'delta(4)-Pregnene-3,20-dione',\n",
       "  'GelbkÃ¶rperhormon',\n",
       "  'Luteohormone',\n",
       "  'Lutogynon',\n",
       "  'Pregn-4-ene-3,20-dione',\n",
       "  'Progesteron',\n",
       "  'Progesterona',\n",
       "  'ProgestÃ©rone',\n",
       "  'Progesterone',\n",
       "  'Progesteronum',\n",
       "  'Progesterone'],\n",
       " 'Phenylpropanolamine': ['(+-)-Norephedrine',\n",
       "  '(+-)-Phenylpropanolamine',\n",
       "  'Fenilpropanolamina',\n",
       "  'Norephedrine',\n",
       "  'Phenylpropanolamin',\n",
       "  'Phenylpropanolamina',\n",
       "  'Phenylpropanolamine',\n",
       "  'PhÃ©nylpropanolamine',\n",
       "  'Phenylpropanolaminum',\n",
       "  'PPA',\n",
       "  'Phenylpropanolamine'],\n",
       " 'Sorafenib': ['4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide',\n",
       "  \"N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea\",\n",
       "  'SorafÃ©nib',\n",
       "  'Sorafenib',\n",
       "  'Sorafenibum',\n",
       "  'Sorafenib'],\n",
       " 'Zoledronic acid': ['(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid',\n",
       "  '(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid',\n",
       "  'Ã¡cido zoledrÃ³nico',\n",
       "  'Anhydrous Zoledronic Acid',\n",
       "  'Zol',\n",
       "  'Zoledronate',\n",
       "  'Zoledronic acid',\n",
       "  'Zoledronic Acid Anhydrous',\n",
       "  'Zoledronic Acid, Anhydrous',\n",
       "  'Zoledronic acid'],\n",
       " 'Griseofulvin': ['(+)-griseofulvin',\n",
       "  'Amudane',\n",
       "  'Griseofulvin',\n",
       "  'Griseofulvin, microcrystalline',\n",
       "  'Griseofulvin, ultramicrosize',\n",
       "  'Griseofulvina',\n",
       "  'GrisÃ©ofulvine',\n",
       "  'Griseofulvinum',\n",
       "  'Griseofulvin'],\n",
       " 'Nisoldipine': ['isobutyl methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate',\n",
       "  'Nisoldipin',\n",
       "  'Nisoldipina',\n",
       "  'Nisoldipine',\n",
       "  'Nisoldipino',\n",
       "  'Nisoldipinum',\n",
       "  'Nisoldipine'],\n",
       " 'Eszopiclone': ['(+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate',\n",
       "  '(+)-(5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl-4-methylpiperazine-1-carboxylate',\n",
       "  '(+)-Zopiclone',\n",
       "  '(S)-6-(5-Chloro-2-pyridinyl)- 7-oxo- 6,7-dihydro- 5H-pyrrolo[3,4-b]pyrazin-5-yl- 4-methyl- 1-piperazinecarboxylate',\n",
       "  '(S)-Zopiclone',\n",
       "  '1-Piperazinecarobxylic acid,4-methyl-,(5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester',\n",
       "  'Esopiclone',\n",
       "  'Eszopiclone',\n",
       "  'Eszopiclone'],\n",
       " 'Ceruletide': ['Caerulein',\n",
       "  'Cerulein',\n",
       "  'Ceruletida',\n",
       "  'Ceruletide',\n",
       "  'Ceruletidum',\n",
       "  'Ceruletide'],\n",
       " 'Alprazolam': ['8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine',\n",
       "  'Alprazolam',\n",
       "  'Alprazolam'],\n",
       " 'Dexbrompheniramine': ['(+)-brompheniraminum',\n",
       "  '(R)-3-(4-Bromophenyl)-3-(2-pyridyl)propyldimethylamine',\n",
       "  '(S)-(+)-brompheniramine',\n",
       "  '(S)-brompheniramine',\n",
       "  '3-(4-bromophenyl)- N,N-dimethyl- 3-pyridin-2-yl-propan-1-amine',\n",
       "  'd-brompheniramine',\n",
       "  'Desbrofeniramina',\n",
       "  'Dexbromfeniramina',\n",
       "  'Dexbrompheniramin',\n",
       "  'DexbromphÃ©niramine',\n",
       "  'Dexbrompheniramine',\n",
       "  'Dexbrompheniraminum',\n",
       "  'Dexbrompheniramine'],\n",
       " 'Gentian violet cation': ['Crystal Violet',\n",
       "  'Crystal violet carbocation',\n",
       "  'Crystal violet ion(1)',\n",
       "  'Crystal violet(1+)',\n",
       "  'Gentian violet carbocation',\n",
       "  'Gentian violet cation',\n",
       "  'Gentian violet(1+)',\n",
       "  'Methylrosaniline',\n",
       "  'Methylrosanilinium',\n",
       "  'Gentian violet cation'],\n",
       " 'Ardeparin': ['Ardeparin'],\n",
       " 'Loxapine': ['2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine',\n",
       "  'Loxapina',\n",
       "  'Loxapine',\n",
       "  'Loxapinum',\n",
       "  'Oxilapine',\n",
       "  'Loxapine'],\n",
       " 'Remoxipride': ['Remoxiprida', 'Remoxipride', 'Remoxipridum', 'Remoxipride'],\n",
       " 'Mupirocin': ['9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3- [(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid',\n",
       "  'Mupirocin',\n",
       "  'Mupirocina',\n",
       "  'Mupirocine',\n",
       "  'Mupirocinum',\n",
       "  'Pseudomonic acid',\n",
       "  'Pseudomonic acid A',\n",
       "  'Mupirocin'],\n",
       " 'Carbamoylcholine': ['Carbacholine',\n",
       "  'carbacol',\n",
       "  'Carbamylcholine',\n",
       "  'Choline carbamate',\n",
       "  'Carbamoylcholine'],\n",
       " 'Rosiglitazone': ['(Â±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione',\n",
       "  '(RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion',\n",
       "  'Rosiglitazon',\n",
       "  'Rosiglitazona',\n",
       "  'Rosiglitazone',\n",
       "  'Rosiglitazonum',\n",
       "  'Rosiglitazone'],\n",
       " 'Pramipexole': ['(-)-Pramipexole',\n",
       "  '(S)-Nâ\\x80\\x8aâ\\x80\\x8a6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine',\n",
       "  'Pramipexol',\n",
       "  'Pramipexole',\n",
       "  'Pramipexolum',\n",
       "  'Pramipexole'],\n",
       " 'Acetohexamide': ['1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea',\n",
       "  '1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamide',\n",
       "  'Acetohexamid',\n",
       "  'Acetohexamida',\n",
       "  'AcÃ©tohexamide',\n",
       "  'Acetohexamide',\n",
       "  'Acetohexamidum',\n",
       "  \"N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea\",\n",
       "  'Acetohexamide'],\n",
       " 'Ampicillin': ['ABPC',\n",
       "  'Aminobenzylpenicillin',\n",
       "  'Ampicilina',\n",
       "  'Ampicillin',\n",
       "  'Ampicillin (anhydrous)',\n",
       "  'Ampicillin acid',\n",
       "  'Ampicillin anhydrous',\n",
       "  'Ampicillin, anhydrous',\n",
       "  'Ampicilline',\n",
       "  'Ampicillinum',\n",
       "  'Anhydrous ampicillin',\n",
       "  'AP',\n",
       "  'D-(â\\x88\\x92)-6-(Î±-aminophenylacetamido)penicillanic acid',\n",
       "  'D-(â\\x88\\x92)-ampicillin',\n",
       "  'Ampicillin'],\n",
       " 'Metocurine iodide': ['Dimethyl tubocurarine iodide',\n",
       "  'Dimethylchondrocurarine iodide',\n",
       "  'Dimethyltubocurarinium iodide',\n",
       "  'Metocurine iodide',\n",
       "  'Metocurini iodidum',\n",
       "  'Metubine iodide',\n",
       "  'Metocurine iodide'],\n",
       " 'Phenoxymethylpenicillin': ['(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID',\n",
       "  '(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  '6-phenoxyacetamidopenicillanic acid',\n",
       "  'Fenoximetilpenicilina',\n",
       "  'Oracillin',\n",
       "  'Penicillin Phenoxymethyl',\n",
       "  'Penicillin V',\n",
       "  'Phenoxomethylpenicillin',\n",
       "  'Phenoxymethyl Penicillin',\n",
       "  'Phenoxymethylenepenicillinic acid',\n",
       "  'Phenoxymethylpenicillin',\n",
       "  'PhÃ©noxymÃ©thylpÃ©nicilline',\n",
       "  'Phenoxymethylpenicillinum',\n",
       "  'PV',\n",
       "  'Phenoxymethylpenicillin'],\n",
       " 'Secobarbital': ['(Â±)-secobarbital',\n",
       "  '5-(1-methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-allyl-5-(1-methylbutyl)barbituric acid',\n",
       "  '5-allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione',\n",
       "  'Quinalbarbitone',\n",
       "  'Secobarbital',\n",
       "  'Secobarbitalum',\n",
       "  'Secobarbitone',\n",
       "  'Secobarbital'],\n",
       " 'Miglustat': ['BuDNJ',\n",
       "  'Butyldeoxynojirimycin',\n",
       "  'Miglustat',\n",
       "  'Miglustatum',\n",
       "  'N-(n-Butyl)deoxynojirimycin',\n",
       "  'n-Butyl deoxynojirimycin',\n",
       "  'N-butyl-1-deoxynojirimycin',\n",
       "  'N-Butylmoranoline',\n",
       "  'NB-DNJ',\n",
       "  'Miglustat'],\n",
       " 'Promazine': ['10-(3-(Dimethylamino)propyl)phenothiazine',\n",
       "  'N-(3-Dimethylaminopropyl)phenothiazine',\n",
       "  'N-Dimethylamino-1-methylethyl thiodiphenylamine',\n",
       "  'N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine',\n",
       "  'Promazin',\n",
       "  'Promazina',\n",
       "  'Promazine',\n",
       "  'Promazinum',\n",
       "  'Promazine'],\n",
       " 'Spironolactone': ['Espironolactona',\n",
       "  'Spironolactone',\n",
       "  'Spironolactonum',\n",
       "  'Spironolattone',\n",
       "  'Spironolactone'],\n",
       " 'Methylphenidate': ['Methyl phenidylacetate',\n",
       "  'methyl phenyl(piperidin-2-yl)acetate',\n",
       "  'methyl Î±-phenyl-Î±-(2-piperidyl)acetate',\n",
       "  'methyl Î±-phenyl-Î±-2-piperidinylacetate',\n",
       "  'Methylphenidan',\n",
       "  'Methylphenidate',\n",
       "  'Methylphenidatum',\n",
       "  'Metilfenidato',\n",
       "  'MPH',\n",
       "  'Î±-phenyl-2-piperidineacetic acid methyl ester',\n",
       "  'Methylphenidate'],\n",
       " 'Methocarbamol': ['(RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate',\n",
       "  'Methocarbamol',\n",
       "  'MÃ©thocarbamol',\n",
       "  'Methocarbamolum',\n",
       "  'Metocarbamol',\n",
       "  'Metocarbamolo',\n",
       "  'Methocarbamol'],\n",
       " 'Hyoscyamine': ['(â\\x88\\x92)-atropine',\n",
       "  '(â\\x88\\x92)-hyoscyamine',\n",
       "  '(S)-(â\\x88\\x92)-hyoscyamine',\n",
       "  '(S)-atropine',\n",
       "  '[3(S)-endo]-Î±-(hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester',\n",
       "  'Daturin',\n",
       "  'Daturine',\n",
       "  'Duboisine',\n",
       "  'Hyoscyamin',\n",
       "  'Hyoscyamine',\n",
       "  'Hyoscyaminum',\n",
       "  'L-Hyoscyamine',\n",
       "  'L-Tropine tropate',\n",
       "  'Tropine-L-tropate',\n",
       "  'Hyoscyamine'],\n",
       " 'Zolpidem': ['N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide',\n",
       "  'Zolpidem',\n",
       "  'Zolpidemum',\n",
       "  'Zolpidem'],\n",
       " 'Famciclovir': ['2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate',\n",
       "  '9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine',\n",
       "  'acetic acid 2-acetoxymethyl-4-(2-amino-purin-9-yl)-butyl ester',\n",
       "  'Famciclovir',\n",
       "  'Famciclovirum',\n",
       "  'FCV',\n",
       "  'Famciclovir'],\n",
       " 'Triprolidine': ['(E)-2-[3-(1-pyrrolidinyl)-1-p-toluenepropenyl]pyridine',\n",
       "  'trans-1-(2-pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene',\n",
       "  'trans-1-(4-methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene',\n",
       "  'Tripolidina',\n",
       "  'Triprolidin',\n",
       "  'Triprolidina',\n",
       "  'Triprolidine',\n",
       "  'Triprolidinum',\n",
       "  'Triprolidine'],\n",
       " 'Streptozocin': ['2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose',\n",
       "  '2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose',\n",
       "  'Estreptozocina',\n",
       "  \"N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff\",\n",
       "  \"N-D-Glucosyl-(2)-N'-nitrosomethylurea\",\n",
       "  'Streptozocin',\n",
       "  'Streptozocine',\n",
       "  'Streptozocinium',\n",
       "  'Streptozocinum',\n",
       "  'Streptozotocin',\n",
       "  'Streptozocin'],\n",
       " 'Carboprost tromethamine': ['(15S)-15-methyl-PGF2Î± tromethamine salt',\n",
       "  '(15S)-15-methylprostaglandin F2Î± tromethamine',\n",
       "  '1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium (5Z,9Î±,11Î²,13E,15S)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oate',\n",
       "  '15(S)-15-methyl-PGF2Î± tromethamine salt',\n",
       "  '15(S)-15-methylprostaglandin F2Î± tromethamine',\n",
       "  'Carboprost trometamol',\n",
       "  'Carboprost tromethamine',\n",
       "  'Carboprost tromethamine'],\n",
       " 'Cefpiramide': ['Cefpiramide', 'Cefpiramido', 'Cefpiramidum', 'Cefpiramide'],\n",
       " 'Lindane': ['(1r,2c,3t,4c,5c,6t)-1,2,3,4,5,6-hexachlorocyclohexane',\n",
       "  '(1Î±,2Î±,3Î²,4Î±,5Î±,6Î²)-1,2,3,4,5,6-hexachlorocyclohexane',\n",
       "  '1,2,3,4,5,6-hexachlorocyclohexane',\n",
       "  'Benzene hexachloride',\n",
       "  'gamma-1,2,3,4,5,6-hexachlorocyclohexane',\n",
       "  'gamma-benzene hexachloride',\n",
       "  'gamma-BHC',\n",
       "  'gamma-HCH',\n",
       "  'gamma-Hexachlorocyclohexane',\n",
       "  'gamma-Lindane',\n",
       "  'Gammallin',\n",
       "  'Gammaxene',\n",
       "  'Lindan',\n",
       "  'Lindane',\n",
       "  'Lindano',\n",
       "  'Lindanum',\n",
       "  'Î³-hexachlorocyclohexane',\n",
       "  'Î³-Hexachlorzyklohexan',\n",
       "  'Î³-lindane',\n",
       "  'Lindane'],\n",
       " 'Trifluridine': ['5-(Trifluoromethyl)deoxyuridine',\n",
       "  '5-Trifluoromethyl-2-deoxyuridine',\n",
       "  'Fâ\\x82\\x83T',\n",
       "  'TFT',\n",
       "  'Trifluoromethyldeoxyuridine',\n",
       "  'Trifluorothymidine',\n",
       "  'Trifluorothymine deoxyriboside',\n",
       "  'Trifluridin',\n",
       "  'Trifluridina',\n",
       "  'Trifluridine',\n",
       "  'Trifluridinum',\n",
       "  'Trifluridine'],\n",
       " 'Prochlorperazine': ['2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine',\n",
       "  '2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine',\n",
       "  '3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine',\n",
       "  '3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine',\n",
       "  'Capazine',\n",
       "  'Chlormeprazine',\n",
       "  'Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine',\n",
       "  'Chloropernazine',\n",
       "  \"N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine\",\n",
       "  'Prochlorperazin',\n",
       "  'ProchlorpÃ©razine',\n",
       "  'Prochlorperazine',\n",
       "  'Prochlorperazinum',\n",
       "  'Prochlorpermazine',\n",
       "  'Prochlorpromazine',\n",
       "  'Procloperazine',\n",
       "  'Proclorperazina',\n",
       "  'Prochlorperazine'],\n",
       " 'Cyproheptadine': ['1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine',\n",
       "  '1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine',\n",
       "  '4-(5-dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine',\n",
       "  '4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine',\n",
       "  '4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine',\n",
       "  '5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene',\n",
       "  'Ciproheptadina',\n",
       "  'Cyproheptadin',\n",
       "  'Cyproheptadine',\n",
       "  'Cyproheptadinum',\n",
       "  'Cyproheptadine'],\n",
       " 'Nitric Oxide': ['EDRF',\n",
       "  'endothelium-derived relaxing factor',\n",
       "  'Mononitrogen monoxide',\n",
       "  'MonÃ³xido de nitrÃ³geno',\n",
       "  \"Monoxyde d'azote\",\n",
       "  'Nitric oxide',\n",
       "  'Nitrogen monooxide',\n",
       "  'Nitrogen monoxide',\n",
       "  'Nitrosyl',\n",
       "  'Ã³xido de nitrÃ³geno(II)',\n",
       "  'Ã³xido nÃ\\xadtrico',\n",
       "  'Oxyde azotique',\n",
       "  'Oxyde nitrique',\n",
       "  'Stickstoff(II)-oxid',\n",
       "  'Stickstoffmonoxid',\n",
       "  'Nitric Oxide'],\n",
       " 'Bendroflumethiazide': ['Â±-3-benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide',\n",
       "  '6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide',\n",
       "  'Bendrofluazide',\n",
       "  'Bendroflumethiazid',\n",
       "  'BendroflumÃ©thiazide',\n",
       "  'Bendroflumethiazide',\n",
       "  'Bendroflumethiazidum',\n",
       "  'Bendroflumetiazida',\n",
       "  'Benzhydroflumethiazide',\n",
       "  'Bendroflumethiazide'],\n",
       " 'Allopurinol': ['1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one',\n",
       "  '1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one',\n",
       "  '1H-Pyrazolo(3,4-d)pyrimidin-4-ol',\n",
       "  '4-HPP',\n",
       "  '4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine',\n",
       "  '4-Hydroxy-3,4-pyrazolopyrimidine',\n",
       "  '4-Hydroxypyrazolo(3,4-d)pyrimidine',\n",
       "  '4-Hydroxypyrazolopyrimidine',\n",
       "  '4-Hydroxypyrazolyl(3,4-d)pyrimidine',\n",
       "  \"4'-Hydroxypyrazolol(3,4-d)pyrimidine\",\n",
       "  '4H-Pyrazolo(3,4-d)pyrimidin-4-one',\n",
       "  'Allopurinol',\n",
       "  'Allopurinolum',\n",
       "  'Alopurinol',\n",
       "  'Allopurinol'],\n",
       " 'Ceftazidime': ['CAZ',\n",
       "  'Ceftazidim',\n",
       "  'Ceftazidima',\n",
       "  'Ceftazidime',\n",
       "  'Ceftazidime anhydrous',\n",
       "  'Ceftazidimum',\n",
       "  'Ceftazidime'],\n",
       " 'Cerivastatin': ['Cerivastatin', 'Cerivastatin'],\n",
       " 'Trimethoprim': ['2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine',\n",
       "  '5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine',\n",
       "  'Trimethoprim',\n",
       "  'TrimÃ©thoprime',\n",
       "  'Trimethoprimum',\n",
       "  'Trimetoprima',\n",
       "  'Trimethoprim'],\n",
       " 'Gemcitabine': [\"2'-Deoxy-2',2'-difluorocytidine\",\n",
       "  \"2',2'-Difluorodeoxycytidine\",\n",
       "  '4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one',\n",
       "  'Gemcitabin',\n",
       "  'Gemcitabina',\n",
       "  'Gemcitabine',\n",
       "  'Gemcitabinum',\n",
       "  'Gemcitabine'],\n",
       " 'Entecavir': ['Anhydrous entecavir',\n",
       "  'Entecavir',\n",
       "  'Entecavir (anhydrous)',\n",
       "  'Entecavir anhydrous',\n",
       "  'Entecavirum',\n",
       "  'Entecavir'],\n",
       " 'Betamethasone': ['16Î²-Methyl-1,4-pregnadiene-9Î±-fluoro-11Î²,17Î±,21-triol-3,20-dione',\n",
       "  '9-Fluoro-16Î²-methylprednisolone',\n",
       "  '9Î±-Fluoro-16Î²-methylprednisolone',\n",
       "  'beta-Methasone alcohol',\n",
       "  'Betadexamethasone',\n",
       "  'Betametasona',\n",
       "  'Betamethasone',\n",
       "  'BÃ©tamÃ©thasone',\n",
       "  'Betamethasonum',\n",
       "  'Betamethasone'],\n",
       " 'Teniposide': [\"4'-demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside)\",\n",
       "  'Epidophyllotoxin',\n",
       "  'Teniposid',\n",
       "  'Teniposide',\n",
       "  'TÃ©niposide',\n",
       "  'Teniposido',\n",
       "  'Teniposidum',\n",
       "  'Teniposide'],\n",
       " 'Epirubicin': [\"4'-Epiadriamycin\",\n",
       "  'Epiadriamycin',\n",
       "  'Epirubicin',\n",
       "  'Epirubicina',\n",
       "  'Epirubicine',\n",
       "  'Epirubicinum',\n",
       "  'Pidorubicina',\n",
       "  'Pidorubicine',\n",
       "  'Pidorubicinum',\n",
       "  'Epirubicin'],\n",
       " 'Chloramphenicol': ['ChloramphÃ©nicol',\n",
       "  'Chloramphenicol',\n",
       "  'Chloramphenicolum',\n",
       "  'Chlornitromycin',\n",
       "  'Cloramfenicol',\n",
       "  'Cloranfenicol',\n",
       "  'D-(â\\x88\\x92)-2,2-dichloro-N-(Î²-hydroxy-Î±-(hydroxymethyl)-p-nitrophenylethyl)acetamide',\n",
       "  'D-(â\\x88\\x92)-threo-1-p-nitrophenyl-2-dichloroacetylamino-1,3-propanediol',\n",
       "  'Laevomycetinum',\n",
       "  'Levomicetina',\n",
       "  'Levomycetin',\n",
       "  'Chloramphenicol'],\n",
       " 'Loracarbef': ['Anhydrous loracarbef',\n",
       "  'Loracarbef',\n",
       "  'Loracarbef anhydrous',\n",
       "  'Loracarbef, anhydrous',\n",
       "  'Loracarbefum',\n",
       "  'Loracarbef'],\n",
       " 'Lansoprazole': ['Lansoprazol',\n",
       "  'Lansoprazole',\n",
       "  'Lansoprazolum',\n",
       "  'Lansoprazole'],\n",
       " 'Dipivefrin': ['(Â±)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate',\n",
       "  \"1-(3',4'-dipivaloyloxyphenyl)-2-methylamino-1-ethanol\",\n",
       "  '4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate',\n",
       "  'Dipivalyl epinephrine',\n",
       "  'Dipivefrin',\n",
       "  'Dipivefrina',\n",
       "  'Dipivefrine',\n",
       "  'DipivÃ©frine',\n",
       "  'Dipivefrinum',\n",
       "  'Dipivefrin'],\n",
       " 'Droperidol': ['1-(1-(3-(p-fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone',\n",
       "  '1-(1-(4-(p-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone',\n",
       "  '1-{1-[4-(4-Fluoro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-one',\n",
       "  '1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl}-2,3-dihydro-1H-benzo[d]imidazol-2-one',\n",
       "  'Droperidol',\n",
       "  'DropÃ©ridol',\n",
       "  'Droperidolo',\n",
       "  'Droperidolum',\n",
       "  'Droperidol'],\n",
       " 'Levothyroxine': [\"3,3',5,5'-Tetraiodo-L-thyronine\",\n",
       "  \"3,5,3',5'-Tetraiodo-L-thyronine\",\n",
       "  '4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodo-L-phenylalanine',\n",
       "  'L-T4',\n",
       "  'L-Thyroxine',\n",
       "  'Levothyroxin',\n",
       "  'LT4',\n",
       "  'O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-tyrosine',\n",
       "  'O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine',\n",
       "  'T4',\n",
       "  'Thyroxine',\n",
       "  'Levothyroxine'],\n",
       " 'Framycetin': ['Fradiomycin B',\n",
       "  'Framicetina',\n",
       "  'Framycetin',\n",
       "  'FramycÃ©tine',\n",
       "  'Framycetinum',\n",
       "  'Neomycin B',\n",
       "  'Framycetin'],\n",
       " 'Clomocycline': ['Chlormethylenecycline',\n",
       "  'Clomociclina',\n",
       "  'Clomocyclina',\n",
       "  'Clomocycline',\n",
       "  'Clomocyclinum',\n",
       "  'Clomocycline'],\n",
       " 'Meperidine': ['IsonipecaÃ¯ne',\n",
       "  'Meperidina',\n",
       "  'Pethidin',\n",
       "  'Pethidine',\n",
       "  'PÃ©thidine',\n",
       "  'Pethidinum',\n",
       "  'Petidina',\n",
       "  'Petydyna',\n",
       "  'Meperidine'],\n",
       " 'Loratadine': ['Loratadina', 'Loratadine', 'Loratadinum', 'Loratadine'],\n",
       " 'Cefalotin': ['3-Acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid',\n",
       "  '7-(2-Thienylacetamido)cephalosporanic acid',\n",
       "  \"7-(2'-thienylacetamido)cephalosporanic acid\",\n",
       "  '7-(Thiophene-2-acetamido)cephalosporin',\n",
       "  'Cefalothin',\n",
       "  'Cefalotin',\n",
       "  'Cefalotina',\n",
       "  'CÃ©falotine',\n",
       "  'Cefalotinum',\n",
       "  'Cephalothin',\n",
       "  'Cephalotin',\n",
       "  'CET',\n",
       "  'Cefalotin'],\n",
       " 'Prazosin': ['1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine',\n",
       "  '2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline',\n",
       "  'Prazosin',\n",
       "  'Prazosina',\n",
       "  'Prazosine',\n",
       "  'Prazosinum',\n",
       "  'Prazosin'],\n",
       " 'Imipramine': ['10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine',\n",
       "  '5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine',\n",
       "  'Imipramin',\n",
       "  'Imipramina',\n",
       "  'Imipramine',\n",
       "  'Imipraminum',\n",
       "  'Imizine',\n",
       "  'N-(gamma-Dimethylaminopropyl)iminodibenzyl',\n",
       "  'N-(Î³-dimethylaminopropyl)iminodibenzyl',\n",
       "  'Imipramine'],\n",
       " 'Acitretin': ['(all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid',\n",
       "  'Acitretin',\n",
       "  'Acitretina',\n",
       "  'Acitretine',\n",
       "  'Acitretinum',\n",
       "  'all-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid',\n",
       "  'Etretin',\n",
       "  'Acitretin'],\n",
       " 'Verteporfin': ['Verteporfin',\n",
       "  'Verteporfina',\n",
       "  'VertÃ©porfine',\n",
       "  'Verteporfinum',\n",
       "  'Verteporfin'],\n",
       " 'Nabumetone': ['4-(6-Methoxy-2-naphthalenyl)-2-butanone',\n",
       "  '4-(6-Methoxy-2-naphthyl)-2-butanone',\n",
       "  'Nabumeton',\n",
       "  'Nabumetona',\n",
       "  'NabumÃ©tone',\n",
       "  'Nabumetone',\n",
       "  'Nabumetonum',\n",
       "  'Nabumetone'],\n",
       " 'Methscopolamine bromide': ['(â\\x88\\x92)-scopolamine methobromide',\n",
       "  '(â\\x88\\x92)-scopolamine methyl bromide',\n",
       "  'Hyoscine methobromide',\n",
       "  'Hyoscine methyl bromide',\n",
       "  'Methscopolamine bromide',\n",
       "  'Methylscopolamine bromide',\n",
       "  'N-methylhyoscine bromide',\n",
       "  'N-methylscopolammonium bromide',\n",
       "  'Scopolamine methobromide',\n",
       "  'Scopolamine methyl bromide',\n",
       "  'Methscopolamine bromide'],\n",
       " 'Metharbital': ['Metarbital', 'Metharbital', 'Metharbitalum', 'Metharbital'],\n",
       " 'Sodium tetradecyl sulfate': ['7-Ethyl-2-methyl-4-undecanol sulfate sodium salt',\n",
       "  '7-ethyl-2-methyl-4-undecanolsulfate, sodium salt',\n",
       "  'Natrii tetradecylis sulfa',\n",
       "  'Sodium 2-methyl-7-ethylundecanol-4-sulfate',\n",
       "  'Sodium 7-ethyl-2-methyl-4-undecanol sulfate',\n",
       "  'Sodium tetradecyl sulfate',\n",
       "  'Sodium tetradecyl sulphate',\n",
       "  'Sodium tetradecylsulfate',\n",
       "  'STS',\n",
       "  'Tetradecilsulfato sodico',\n",
       "  'Tetradecyl sodium sulfate',\n",
       "  'Tetradecyl sulfate de sodium',\n",
       "  'Sodium tetradecyl sulfate'],\n",
       " 'Ketorolac': ['Ketorolac',\n",
       "  'KÃ©torolac',\n",
       "  'Ketorolaco',\n",
       "  'Ketorolacum',\n",
       "  'rac-Ketorolac',\n",
       "  'Ketorolac'],\n",
       " 'Picrotoxin': ['cocculin', 'Picrotoxin'],\n",
       " 'Enoxacin': ['1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid',\n",
       "  '1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid',\n",
       "  'Enoxacin',\n",
       "  'Enoxacina',\n",
       "  'Ã\\x89noxacine',\n",
       "  'Enoxacino',\n",
       "  'Enoxacinum',\n",
       "  'Enoxacin'],\n",
       " 'Quinine': ['(-)-Quinine',\n",
       "  '(â\\x88\\x92)-quinine',\n",
       "  '(8S,9R)-quinine',\n",
       "  '(R)-(â\\x88\\x92)-quinine',\n",
       "  '(R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol',\n",
       "  \"6'-Methoxycinchonidine\",\n",
       "  'Chinin',\n",
       "  'Chinine',\n",
       "  'Chininum',\n",
       "  'Quinina',\n",
       "  'Quinine',\n",
       "  'Quinine'],\n",
       " 'Tenoxicam': ['Tenoxicam', 'TÃ©noxicam', 'Tenoxicamum', 'Tenoxicam'],\n",
       " 'Dronabinol': ['(-)-delta9-trans-Tetrahydrocannabinol',\n",
       "  '1-trans-delta-9-Tetrahydrocannabinol',\n",
       "  '3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-ol',\n",
       "  '6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol',\n",
       "  'delta-9-tetrahydrocannabinol',\n",
       "  'delta-9-THC',\n",
       "  'delta(1)-tetrahydrocannabinol',\n",
       "  'delta(9)-THC',\n",
       "  'delta9-tetrahydrocannabinol',\n",
       "  'Dronabinol',\n",
       "  'Dronabinolum',\n",
       "  'Tetrahydrocannabinol',\n",
       "  'THC',\n",
       "  'Î\\x949-tetrahydrocannabinol',\n",
       "  'Dronabinol'],\n",
       " 'Montelukast': ['(R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid',\n",
       "  '1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid',\n",
       "  'Montelukast',\n",
       "  'MontÃ©lukast',\n",
       "  'Montelukastum',\n",
       "  'Montelukast'],\n",
       " 'Fluoxetine': ['(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine',\n",
       "  '(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine',\n",
       "  'Fluoxetin',\n",
       "  'Fluoxetina',\n",
       "  'Fluoxetine',\n",
       "  'FluoxÃ©tine',\n",
       "  'Fluoxetinum',\n",
       "  'Fluoxetine'],\n",
       " 'Hexylcaine': ['Hexilcaina', 'Hexylcaine', 'Hexylcainum', 'Hexylcaine'],\n",
       " 'Methohexital': ['(Â±)-5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid',\n",
       "  '5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione',\n",
       "  '5-Allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid',\n",
       "  'Methohexital',\n",
       "  'Methohexitalum',\n",
       "  'Methohexitone',\n",
       "  'Metohexital',\n",
       "  \"Î±-DL-1-methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid\",\n",
       "  'Methohexital'],\n",
       " 'Chlordiazepoxide': ['7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxide',\n",
       "  'CDP',\n",
       "  'Chloradiazepoxide',\n",
       "  'Chlordiazepoxide',\n",
       "  'Chlordiazepoxidum',\n",
       "  'Clopoxide',\n",
       "  'ClordiazepÃ³xido',\n",
       "  'Methaminodiazepoxide',\n",
       "  'Chlordiazepoxide'],\n",
       " 'Duloxetine': ['(3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine',\n",
       "  '(S)-duloxetine',\n",
       "  'Duloxetina',\n",
       "  'Duloxetine',\n",
       "  'Duloxetine'],\n",
       " 'Chlorpromazine': ['3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine',\n",
       "  '3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine',\n",
       "  'Chlorpromazine',\n",
       "  'Chlorpromazinum',\n",
       "  'Clorpromazina',\n",
       "  'CPZ',\n",
       "  'N-(3-dimethylaminopropyl)-3-chlorophenothiazine',\n",
       "  'Chlorpromazine'],\n",
       " 'Rimantadine': ['alpha-Methyl-1-adamantanemethylamine',\n",
       "  'alpha-Methyladamantanemethylamine',\n",
       "  'Rimantadina',\n",
       "  'Rimantadine',\n",
       "  'Rimantadinum',\n",
       "  'Rimantadine'],\n",
       " 'Amikacin': ['1-N-(L(â\\x88\\x92)-Î³-amino-Î±-hydroxybutyryl)kanamycin A',\n",
       "  'Amikacin',\n",
       "  'Amikacina',\n",
       "  'Amikacine',\n",
       "  'Amikacinum',\n",
       "  'Amikacin'],\n",
       " 'Lenalidomide': ['1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline',\n",
       "  '3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione',\n",
       "  'Lenalidomida',\n",
       "  'Lenalidomide',\n",
       "  'Lenalidomide'],\n",
       " 'Raloxifene': ['(2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone',\n",
       "  'RaloxifÃ¨ne',\n",
       "  'Raloxifene',\n",
       "  'Raloxifeno',\n",
       "  'Raloxifenum',\n",
       "  'Raloxifene'],\n",
       " 'Celecoxib': ['Celecoxib',\n",
       "  'CÃ©lÃ©coxib',\n",
       "  'Celecoxibum',\n",
       "  'p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide',\n",
       "  'Celecoxib'],\n",
       " 'Gallamine triethiodide': ['Gallamin triethiodid',\n",
       "  'Gallamine triethiodide',\n",
       "  'Gallamini Triethiodidum',\n",
       "  'TriÃ©thiodure de Gallamine',\n",
       "  'Trietioduro de galamina',\n",
       "  'Gallamine triethiodide'],\n",
       " 'Brimonidine': ['5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline',\n",
       "  'Brimonidina',\n",
       "  'Brimonidine',\n",
       "  'Brimonidinum',\n",
       "  'Bromoxidine',\n",
       "  'Brimonidine'],\n",
       " 'Dicloxacillin': ['(2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  'Dicloxacilina',\n",
       "  'Dicloxacillin',\n",
       "  'Dicloxacillina',\n",
       "  'Dicloxacilline',\n",
       "  'Dicloxacillinum',\n",
       "  'Dicloxacillin'],\n",
       " 'Nabilone': ['Nabilon', 'Nabilona', 'Nabilone', 'Nabilonum', 'Nabilone'],\n",
       " 'Pefloxacin': ['Pefloxacin',\n",
       "  'Pefloxacine',\n",
       "  'Pefloxacino',\n",
       "  'Pefloxacinum',\n",
       "  'PFLX',\n",
       "  'Pefloxacin'],\n",
       " 'Altretamine': ['2,4,6-tris(dimethylamino)-1,3,5-triazine',\n",
       "  '2,4,6-tris(dimethylamino)-s-triazine',\n",
       "  'Altretamin',\n",
       "  'Altretamina',\n",
       "  'Altretamine',\n",
       "  'AltrÃ©tamine',\n",
       "  'Altretaminum',\n",
       "  'Hexamethylmelamine',\n",
       "  'HMM',\n",
       "  'Altretamine'],\n",
       " 'Sotalol': [\"4'-(1-hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide\",\n",
       "  'Sotalol',\n",
       "  'Sotalolo',\n",
       "  'Sotalolum',\n",
       "  'Î²-cardone',\n",
       "  'Sotalol'],\n",
       " 'Buspirone': ['8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione',\n",
       "  'Buspiron',\n",
       "  'Buspirona',\n",
       "  'Buspirone',\n",
       "  'Buspironum',\n",
       "  'Buspirone'],\n",
       " 'Miglitol': ['Miglitol', 'Miglitolum', 'Miglitol'],\n",
       " 'Fosinopril': ['Fosenopril', 'Fosinopril', 'Fosinopril'],\n",
       " 'Cefotaxime': ['(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  '(6R,7R)-3-(acetoxymethyl)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  '(6R,7R)-3-Acetoxymethyl-7-{2-(2-amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  'Cefotaxim',\n",
       "  'Cefotaxima',\n",
       "  'Cefotaxime',\n",
       "  'CÃ©fotaxime',\n",
       "  'Cefotaximum',\n",
       "  'Cephotaxime',\n",
       "  'Cefotaxime'],\n",
       " 'Entacapone': ['(E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide',\n",
       "  'Entacapona',\n",
       "  'Entacapone',\n",
       "  'Entacaponum',\n",
       "  'N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide',\n",
       "  'Entacapone'],\n",
       " 'Zidovudine': ['Azidothymidine',\n",
       "  'AZT',\n",
       "  'ZDV',\n",
       "  'Zidovudina',\n",
       "  'Zidovudine',\n",
       "  'Zidovudinum',\n",
       "  'Zidovudine'],\n",
       " 'Darifenacin': ['(S)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-Î±,Î±-diphenyl-3-pyrrolidineacetamide',\n",
       "  'Darifenacin',\n",
       "  'Darifenacina',\n",
       "  'DarifÃ©nacine',\n",
       "  'Darifenacinum',\n",
       "  'Darifenacin'],\n",
       " 'Oxycodone': ['(-)-14-Hydroxydihydrocodeinone',\n",
       "  '4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one',\n",
       "  '4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one',\n",
       "  '4,5Î±-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one',\n",
       "  'Dihydro-14-hydroxycodeinone',\n",
       "  'Dihydrohydroxycodeinone',\n",
       "  'Dihydroxycodeinone',\n",
       "  'Oxicodona',\n",
       "  'Oxycodone',\n",
       "  'Oxycodonum',\n",
       "  'Oxycodone'],\n",
       " 'Phenindione': ['2-phenyl-1,3-diketohydrindene',\n",
       "  '2-Phenyl-1,3-indandione',\n",
       "  '2-phenyl-1,3(2H)-Indenedione',\n",
       "  'Fenindiona',\n",
       "  'Fenindione',\n",
       "  'Phenindion',\n",
       "  'PhÃ©nindione',\n",
       "  'Phenindione',\n",
       "  'Phenindionum',\n",
       "  'PID',\n",
       "  'Phenindione'],\n",
       " 'Flutamide': [\"4'-nitro-3'-trifluoromethylisobutyranilide\",\n",
       "  'Flutamid',\n",
       "  'Flutamida',\n",
       "  'Flutamide',\n",
       "  'Flutamidum',\n",
       "  'FTA',\n",
       "  'NFBA',\n",
       "  'Niftolid',\n",
       "  'Niftolide',\n",
       "  \"Î±,Î±,Î±-trifluoro-2-methyl-4'-nitro-m-propionotoluidide\",\n",
       "  'Flutamide'],\n",
       " 'Tolmetin': ['1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid',\n",
       "  '1-Methyl-5-p-toluoylpyrrole-2-acetic acid',\n",
       "  '5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid',\n",
       "  'Tolmetin',\n",
       "  'Tolmetina',\n",
       "  'TolmÃ©tine',\n",
       "  'Tolmetino',\n",
       "  'Tolmetinum',\n",
       "  'Tolmetin'],\n",
       " 'Cimetidine': ['1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine',\n",
       "  '2-cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine',\n",
       "  'Cimetidin',\n",
       "  'Cimetidina',\n",
       "  'CimÃ©tidine',\n",
       "  'Cimetidine',\n",
       "  'Cimetidinum',\n",
       "  \"N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine\",\n",
       "  \"N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine\",\n",
       "  'Cimetidine'],\n",
       " 'Haloperidol': ['1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine',\n",
       "  \"4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone\",\n",
       "  '4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one',\n",
       "  \"4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone\",\n",
       "  \"4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone\",\n",
       "  'Haloperidol',\n",
       "  'Haloperidolum',\n",
       "  'Î³-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone',\n",
       "  'Haloperidol'],\n",
       " 'Ritonavir': ['Ritonavir', 'Ritonavirum', 'Ritonavir'],\n",
       " 'Levallorphan': ['Levallofano',\n",
       "  'Levallorphan',\n",
       "  'LÃ©vallorphane',\n",
       "  'Levallorphanum',\n",
       "  'Levalorfano',\n",
       "  'Levallorphan'],\n",
       " 'Tridihexethyl': ['Tridihexethyl'],\n",
       " 'Nitazoxanide': ['Nitaxozanid',\n",
       "  'Nitaxozanide',\n",
       "  'Nitazoxanida',\n",
       "  'Nitazoxanide',\n",
       "  'Nitazoxanidum',\n",
       "  'Nitazoxanide'],\n",
       " 'Triflupromazine': ['10-(3-(Dimethylamino)propyl)-2-(trifluoromethyl)phenothiazine',\n",
       "  '2-(Trifluoromethyl)promazine',\n",
       "  '2-Trifluoromethyl-10-(gamma-dimethylaminopropyl)phenothiazine',\n",
       "  'Fluopromazine',\n",
       "  'Triflupromazin',\n",
       "  'Triflupromazina',\n",
       "  'Triflupromazine',\n",
       "  'Triflupromazinum',\n",
       "  'Triflupromazine'],\n",
       " 'Dextrothyroxine': ['D-thyroxine',\n",
       "  'Dextrothyroxine',\n",
       "  'Dextrothyroxinum',\n",
       "  'O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-D-tyrosine',\n",
       "  'Dextrothyroxine'],\n",
       " 'Acetyldigitoxin': ['Acetildigitoxina',\n",
       "  'Acetyl-digitoxin-alpha',\n",
       "  'Acetyldiginatin',\n",
       "  'Acetyldigitoxin',\n",
       "  'Acetyldigitoxinum',\n",
       "  'Acetylgitoxin',\n",
       "  'alpha-Acetyldigitoxin',\n",
       "  'alpha-Acetylgitaloxin',\n",
       "  'alpha-Monoacetyldigitoxin',\n",
       "  'Desglucolanatoside A',\n",
       "  \"Digitoxin 3'''-acetate\",\n",
       "  'Acetyldigitoxin'],\n",
       " 'Vancomycin': ['Vancomicina',\n",
       "  'Vancomycin',\n",
       "  'Vancomycine',\n",
       "  'Vancomycinum',\n",
       "  'Vancomycin'],\n",
       " 'Aminocaproic acid': ['6-Aminocaproic acid',\n",
       "  '6-aminohexanoic acid',\n",
       "  'Acide aminocaproÃ¯que',\n",
       "  'Ã\\x81cido aminocaprÃ³ico',\n",
       "  'acidum aminocaproicum',\n",
       "  'Aminocaproic acid',\n",
       "  'AminocapronsÃ¤ure',\n",
       "  'EACA',\n",
       "  'EACS',\n",
       "  'Epsilcapramine',\n",
       "  'Epsilon Aminocaproic Acid',\n",
       "  'Epsilon-Aminocaproic acid',\n",
       "  'epsilon-Aminohexanoic acid',\n",
       "  'omega-Aminocaproic acid',\n",
       "  'omega-Aminohexanoic acid',\n",
       "  'Aminocaproic acid'],\n",
       " 'Dextromethorphan': ['(+)-dextromethorphan',\n",
       "  'D-methorphan',\n",
       "  'delta-Methorphan',\n",
       "  'Dex',\n",
       "  'Dextromethorfan',\n",
       "  'Dextromethorphan',\n",
       "  'DextromÃ©thorphane',\n",
       "  'Dextromethorphanum',\n",
       "  'Dextrometorfano',\n",
       "  'DM',\n",
       "  'Dextromethorphan'],\n",
       " 'Cisplatin': ['CDDP',\n",
       "  'Cis-DDP',\n",
       "  'cis-diamminedichloroplatinum(II)',\n",
       "  'Cisplatin',\n",
       "  'cisplatino',\n",
       "  'Cisplatin'],\n",
       " 'Bentoquatam': ['Bentoquatam'],\n",
       " 'Anisotropine methylbromide': ['8-Methyl-3-(2-propylpentanoyloxy)tropinium bromide',\n",
       "  '8-Methyltropinium bromide 2-propylpentanoate',\n",
       "  '8-Methyltropinium bromide 2-propylvalerate',\n",
       "  'Anisotropine methobromide',\n",
       "  'Anisotropine methylbromide',\n",
       "  'endo-8,8-Dimethyl-3-((1-oxo-2-propylpentyl)oxy)-8-azoniabicyclo(3.2.1)octane bromide',\n",
       "  \"MÃ©thylbromure d'octatropine\",\n",
       "  'Methyloctatropine bromide',\n",
       "  'Metilbromuro de octatropina',\n",
       "  'Octatropine methylbromide',\n",
       "  'Octatropini methylbromidum',\n",
       "  'Anisotropine methylbromide'],\n",
       " 'Albendazole': ['(5-(propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester',\n",
       "  '5-(propylthio)-2-carbomethoxyaminobenzimidazole',\n",
       "  'Albendazol',\n",
       "  'Albendazole',\n",
       "  'Albendazolum',\n",
       "  'Eskazole',\n",
       "  'O-methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate',\n",
       "  'Proftril',\n",
       "  'Albendazole'],\n",
       " 'Trandolapril': ['Trandolapril', 'Trandolaprilum', 'Trandolapril'],\n",
       " 'Caspofungin': ['(4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide',\n",
       "  'Caspofungin',\n",
       "  'Caspofungina',\n",
       "  'Caspofungin'],\n",
       " 'Carteolol': ['Carteolol', 'CartÃ©olol', 'Carteololum', 'Carteolol'],\n",
       " 'Bentiromide': ['Bentiromide',\n",
       "  'Bentiromido',\n",
       "  'Bentiromidum',\n",
       "  'BTPABA',\n",
       "  'PFT',\n",
       "  'Bentiromide'],\n",
       " 'Alitretinoin': ['(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid',\n",
       "  '(7E,9Z,11E,13E)-retinoic acid',\n",
       "  '9-cis-retinoic acid',\n",
       "  '9-cis-Tretinoin',\n",
       "  '9(Z)-Retinoic acid',\n",
       "  'Alitretinoin',\n",
       "  'AlitretinoÃ\\xadna',\n",
       "  'AlitrÃ©tinoÃ¯ne',\n",
       "  'Alitretinoinum',\n",
       "  'Alitretinoin'],\n",
       " 'Metolazone': ['2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone',\n",
       "  '7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide',\n",
       "  '7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide',\n",
       "  'Metolazon',\n",
       "  'Metolazona',\n",
       "  'MÃ©tolazone',\n",
       "  'Metolazone',\n",
       "  'Metolazonum',\n",
       "  'Metolazone'],\n",
       " 'Tolnaftate': ['2-Naphthyl N-methyl-N-(3-tolyl)thionocarbamate',\n",
       "  'm,N-Dimethylthiocarbanilic acid O-2-naphthyl ester',\n",
       "  'Methyl (3-methylphenyl)carbamothioic acid O-2-naphthalenyl ester',\n",
       "  'N-methyl-N-(3-methylphenyl)-1-(naphthalen-2-yloxy)methanethioamide',\n",
       "  'O-2-Naphthyl m,N-dimethylthiocarbanilate',\n",
       "  'Tolnaftate',\n",
       "  'Tolnaftato',\n",
       "  'Tolnaftatum',\n",
       "  'Tolnaphthate',\n",
       "  'Tolnaftate'],\n",
       " 'Oxaliplatin': ['Diaminocyclohexane Oxalatoplatinum',\n",
       "  'L-OHP',\n",
       "  'Oxalatoplatin',\n",
       "  'Oxalatoplatinum',\n",
       "  'Oxaliplatin',\n",
       "  'oxaliplatine',\n",
       "  'oxaliplatino',\n",
       "  'oxaliplatinum',\n",
       "  'Oxaliplatin'],\n",
       " 'Cinchocaine': ['2-butoxy-N-(2-(diethylamino)ethyl)cinchoninamide',\n",
       "  '2-butoxy-N-(Î±-diethylaminoethyl)cinchoninamide',\n",
       "  '2-butoxy-N-(Î²-diethylaminoethyl)cinchoninamide',\n",
       "  '2-butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide',\n",
       "  '2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide',\n",
       "  '2-butoxyquinoline-4-carboxylic acid diethylaminoethylamide',\n",
       "  '2-N-butoxy-N-(2-diethylaminoethyl)cinchoninamide',\n",
       "  'Cinchocaine',\n",
       "  'Cinchocainum',\n",
       "  'Cincocainio',\n",
       "  'Dibucaine',\n",
       "  'N-(2-(diethylamino)ethyl)-2-butoxycinchoninamide',\n",
       "  'Î±-butyloxycinchonic acid-Î³-diethylethylenediamine',\n",
       "  'Î±-butyloxycinchoninic acid diethylethylenediamide',\n",
       "  'Cinchocaine'],\n",
       " 'Lercanidipine': ['Lercanidipine', 'Lercanidipino', 'Lercanidipine'],\n",
       " 'Foscarnet': ['Carboxyphosphonic acid',\n",
       "  'Foscarmet',\n",
       "  'Phosphonoformate',\n",
       "  'Phosphonoformic acid',\n",
       "  'Phosphonomethanoic acid',\n",
       "  'Foscarnet'],\n",
       " 'Erlotinib': ['[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine',\n",
       "  'Erlotinib',\n",
       "  'Erlotinib'],\n",
       " 'Cyclophosphamide': ['(+-)-Cyclophosphamide',\n",
       "  '(RS)-Cyclophosphamide',\n",
       "  '2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide',\n",
       "  'Anhydrous cyclophosphamide',\n",
       "  'Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester',\n",
       "  'Ciclofosfamida',\n",
       "  'Ciclofosfamide',\n",
       "  'Cyclophosphamid',\n",
       "  'Cyclophosphamide',\n",
       "  'Cyclophosphamide anhydrous',\n",
       "  'Cyclophosphamidum',\n",
       "  'Cytophosphane',\n",
       "  'N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide',\n",
       "  'Cyclophosphamide'],\n",
       " 'Mephenytoin': ['mefenitoÃ\\xadna', 'Mephenytoin', 'Mephenytoin'],\n",
       " 'Rofecoxib': ['3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone',\n",
       "  '4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone',\n",
       "  'RofÃ©coxib',\n",
       "  'Rofecoxib',\n",
       "  'Rofecoxibum',\n",
       "  'Rofecoxib'],\n",
       " 'Chlormerodrin': ['{3-[(aminocarbonyl)amino]-2-methoxypropyl}chloromercury',\n",
       "  '1-[3-(chloromercuri)-2-methoxypropyl]urea',\n",
       "  'Chlormerodrin',\n",
       "  'Chlormerodrina',\n",
       "  'Chlormerodrine',\n",
       "  'Chlormerodrinum',\n",
       "  'Chlormerodrin'],\n",
       " 'Cefdinir': ['(6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  '(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  'Cefdinir',\n",
       "  'Cefdinirum',\n",
       "  'CFDN',\n",
       "  'Cefdinir'],\n",
       " 'Guanidine': ['Aminomethanamidine',\n",
       "  'Gu',\n",
       "  'Guanidin',\n",
       "  'Guanidine',\n",
       "  'Imidourea',\n",
       "  'Iminourea',\n",
       "  'Guanidine'],\n",
       " 'Ciprofloxacin': ['1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid',\n",
       "  '1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid',\n",
       "  '1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid',\n",
       "  '1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid',\n",
       "  '1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid',\n",
       "  '1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid',\n",
       "  'Ciprofloxacin',\n",
       "  'Ciprofloxacine',\n",
       "  'Ciprofloxacino',\n",
       "  'Ciprofloxacinum',\n",
       "  'Ciprofloxacin'],\n",
       " 'Gadoversetamide': ['Gadoversetamid',\n",
       "  'Gadoversetamida',\n",
       "  'Gadoversetamide',\n",
       "  'Gadoversetamidum',\n",
       "  'Gadoversetamide'],\n",
       " 'Toremifene': ['Toremifene', 'Toremifeno', 'Toremifenum', 'Toremifene'],\n",
       " 'Nortriptyline': ['10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Î\\x945,Î³-propylamine',\n",
       "  '3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine',\n",
       "  'Demethylamitriptyline',\n",
       "  'Desmethylamitriptyline',\n",
       "  'Nortriptylina',\n",
       "  'Nortriptyline',\n",
       "  'Nortriptylinum',\n",
       "  'Nortriptyline'],\n",
       " 'Vincristine': ['22-Oxovincaleukoblastin',\n",
       "  '22-Oxovincaleukoblastine',\n",
       "  'Leurocristine',\n",
       "  'Vincristin',\n",
       "  'Vincristina',\n",
       "  'Vincristine',\n",
       "  'Vincristinum',\n",
       "  'Vincristine'],\n",
       " 'Benazepril': ['BÃ©nazÃ©pril', 'Benazepril', 'Benazeprilum', 'Benazepril'],\n",
       " 'Amoxapine': ['2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine',\n",
       "  'Amoxapin',\n",
       "  'Amoxapina',\n",
       "  'Amoxapine',\n",
       "  'Amoxapinum',\n",
       "  'Amoxepine',\n",
       "  'Desmethylloxapin',\n",
       "  'Amoxapine'],\n",
       " 'Fluorouracil': ['5-Fluoracil',\n",
       "  '5-Fluoropyrimidine-2,4-dione',\n",
       "  '5-Fluorouracil',\n",
       "  '5-Fluracil',\n",
       "  '5-FU',\n",
       "  'Fluoro Uracil',\n",
       "  'Fluorouracil',\n",
       "  'Fluorouracilo',\n",
       "  'Fluorouracilum',\n",
       "  'Fluouracil',\n",
       "  'Fluorouracil'],\n",
       " 'Pyridostigmine': ['Piridostigmina',\n",
       "  'Pyridostigmine cation',\n",
       "  'Pyridostigmine'],\n",
       " 'Adinazolam': ['8-Chloro-1-((dimethylamino)methyl)-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine',\n",
       "  'Adinazolam',\n",
       "  'Adinazolamum',\n",
       "  'Adinazolam'],\n",
       " 'Desoximetasone': ['(11Î²,16Î±)-9-fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione',\n",
       "  '9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone',\n",
       "  'Desoximetason',\n",
       "  'Desoximetasona',\n",
       "  'DÃ©soximÃ©tasone',\n",
       "  'Desoximetasone',\n",
       "  'Desoximetasonum',\n",
       "  'Desoxymethasone',\n",
       "  'Desoximetasone'],\n",
       " 'Azelaic acid': ['1,7-dicarboxyheptane',\n",
       "  '1,7-Heptanedicarboxylic acid',\n",
       "  '1,9-nonanedioic acid',\n",
       "  'Acide azÃ©laÃ¯que',\n",
       "  'Ã\\x81cido azelaico',\n",
       "  'Acidum acelaicum',\n",
       "  'Acidum azelaicum',\n",
       "  'Anchoic acid',\n",
       "  'Azelaic acid',\n",
       "  'AzelainsÃ¤ure',\n",
       "  'Lepargylic acid',\n",
       "  'n-nonanedioic acid',\n",
       "  'NonandisÃ¤ure',\n",
       "  'Nonanedioic acid',\n",
       "  'Azelaic acid'],\n",
       " 'Zafirlukast': ['4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide',\n",
       "  'cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate',\n",
       "  'Zafirlukast',\n",
       "  'Zafirlukast'],\n",
       " 'Propylthiouracil': ['2-Mercapto-6-propyl-4-pyrimidone',\n",
       "  '2-Mercapto-6-propylpyrimid-4-one',\n",
       "  '2-Thio-4-oxo-6-propyl-1,3-pyrimidine',\n",
       "  '2-Thio-6-propyl-1,3-pyrimidin-4-one',\n",
       "  '4-propyl-2-thiouracil',\n",
       "  '6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione',\n",
       "  '6-propyl-2-thiouracil',\n",
       "  '6-propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one',\n",
       "  '6-Propylthiouracil',\n",
       "  '6-Thio-4-propyluracil',\n",
       "  'Propiltiouracilo',\n",
       "  'Propylthiouracil',\n",
       "  'Propylthiouracile',\n",
       "  'Propylthiouracilum',\n",
       "  'Propylthiouracil'],\n",
       " 'Acetohydroxamic acid': ['Acethydroxamsaeure',\n",
       "  'Acetic acid, oxime',\n",
       "  'Acetohydroxamate',\n",
       "  'Acetohydroxamic acid',\n",
       "  'Acetohydroximic acid',\n",
       "  'Acetyl hydroxyamino',\n",
       "  'Acetylhydroxamic acid',\n",
       "  'Acide acetohydroxamique',\n",
       "  'Acido acetohidroxamico',\n",
       "  'Acidum acetohydroxamicum',\n",
       "  'AHA',\n",
       "  'Cetohyroxamic acid',\n",
       "  'Methylhydroxamic acid',\n",
       "  'N-Acetyl hydroxyacetamide',\n",
       "  'N-Acetylhydroxylamine',\n",
       "  'N-Hydroxyacetamide',\n",
       "  'Acetohydroxamic acid'],\n",
       " 'Pentostatin': ['Co-vidarabine',\n",
       "  'Pentostatin',\n",
       "  'Pentostatina',\n",
       "  'Pentostatine',\n",
       "  'Pentostatinum',\n",
       "  'Pentostatin'],\n",
       " 'Methoxsalen': ['6-hydroxy-7-methoxy-5-benzofuranacrylic acid Î´-lactone',\n",
       "  \"8-methoxy-[furano-3'.2':6.7-coumarin]\",\n",
       "  \"8-methoxy-2',3',6,7-furocoumarin\",\n",
       "  \"8-methoxy-4',5':6,7-furocoumarin\",\n",
       "  '8-Methoxyfuranocoumarin',\n",
       "  '8-methoxypsoralen',\n",
       "  '8-MOP',\n",
       "  '8-MP',\n",
       "  '9-methoxy-7H-furo[3,2-g][1]benzopyran-7-one',\n",
       "  'Ammoidin',\n",
       "  'Methoxsalen',\n",
       "  'MÃ©thoxsalÃ¨ne',\n",
       "  'Metoxaleno',\n",
       "  'O-methylxanthotoxol',\n",
       "  'Xanthotoxin',\n",
       "  'Xanthotoxine',\n",
       "  'Methoxsalen'],\n",
       " 'Piroxicam': ['4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid',\n",
       "  'Piroxicam',\n",
       "  'Piroxicam betadex',\n",
       "  'Piroxicamum',\n",
       "  'Pyroxycam',\n",
       "  'Piroxicam'],\n",
       " 'Lamotrigine': ['3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine',\n",
       "  'Lamotrigina',\n",
       "  'Lamotrigine',\n",
       "  'Lamotriginum',\n",
       "  'Lamotrigine'],\n",
       " 'Perflutren': ['1,1,1,2,2,3,3,3-octafluoropropane',\n",
       "  'Freon 218',\n",
       "  'Octafluoropropane',\n",
       "  'Octafluorpropan',\n",
       "  'Oktafluorpropan',\n",
       "  'Perfluoropropane',\n",
       "  'Perflutren',\n",
       "  'Perflutreno',\n",
       "  'Perflutren'],\n",
       " 'Hydroxyzine': ['Hidroxizina',\n",
       "  'Hychotine',\n",
       "  'Hydroksyzyny',\n",
       "  'Hydroxine',\n",
       "  'Hydroxizine',\n",
       "  'Hydroxizinum',\n",
       "  'Hydroxycine',\n",
       "  'Hydroxyzin',\n",
       "  'Hydroxyzine',\n",
       "  'Hydroxyzinum',\n",
       "  'Idrossizina',\n",
       "  'Hydroxyzine'],\n",
       " 'Zanamivir': ['(2R,3R,4S)-3-(acetylamino)-4-carbamimidamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid',\n",
       "  '4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid',\n",
       "  '4-guanidino-Neu5Ac2en',\n",
       "  '5-(acetylamino)-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid',\n",
       "  '5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid',\n",
       "  'GANA',\n",
       "  'Zanamivir',\n",
       "  'Zanamivir'],\n",
       " 'Bosentan': [\"4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide\",\n",
       "  'bosentÃ¡n',\n",
       "  'Bosentan',\n",
       "  'bosentan anhydrous',\n",
       "  'bosentanum',\n",
       "  'p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide',\n",
       "  'Bosentan'],\n",
       " 'Tigecycline': ['(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide',\n",
       "  'Tigeciclina',\n",
       "  'Tigecycline',\n",
       "  'Tigecyclinum',\n",
       "  'Tigecycline'],\n",
       " 'Doxapram': ['(Â±)-doxapram',\n",
       "  '1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone',\n",
       "  'Doxapram',\n",
       "  'Doxapramum',\n",
       "  'Doxapram'],\n",
       " 'Benzthiazide': ['3-((benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine 1,1-dioxide',\n",
       "  '3-benzylthiomethyl-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide',\n",
       "  '3-benzylthiomethyl-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide',\n",
       "  '6-chloro-1,1-dioxo-3-(phenylmethylsulfanylmethyl)-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide',\n",
       "  '6-chloro-7-sulfamoyl-3-benzylthiomethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide',\n",
       "  'Benzothiazide',\n",
       "  'Benzotiazida',\n",
       "  'Benzthiazid',\n",
       "  'Benzthiazide',\n",
       "  'Benzthiazidum',\n",
       "  'Benztiazide',\n",
       "  'Benzthiazide'],\n",
       " 'Methotrexate': ['4-amino-10-methylfolic acid',\n",
       "  '4-amino-N(10)-methylpteroylglutamic acid',\n",
       "  'Amethopterin',\n",
       "  'Methotrexat',\n",
       "  'MÃ©thotrexate',\n",
       "  'Methotrexate',\n",
       "  'Methotrexatum',\n",
       "  'Metotrexato',\n",
       "  'MTX',\n",
       "  'N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid',\n",
       "  'Methotrexate'],\n",
       " 'Carbamazepine': ['5-Carbamoyl-5H-dibenz(b,f)azepine',\n",
       "  '5-carbamoyl-5H-dibenz[b,f]azepine',\n",
       "  '5-Carbamoyl-5H-dibenzo(b,f)azepine',\n",
       "  '5-Carbamyl-5H-dibenzo(b,f)azepine',\n",
       "  '5H-Dibenz(b,f)azepine-5-carboxamide',\n",
       "  'Carbamazepen',\n",
       "  'Carbamazepin',\n",
       "  'Carbamazepina',\n",
       "  'CarbamazÃ©pine',\n",
       "  'Carbamazepine',\n",
       "  'Carbamazepinum',\n",
       "  'CBZ',\n",
       "  'Carbamazepine'],\n",
       " 'Cisatracurium': ['Cisatracurium cation', 'Cisatracurium'],\n",
       " 'Succimer': ['DIM-SA',\n",
       "  'DMS',\n",
       "  'DMS-A',\n",
       "  'DMSA',\n",
       "  'meso-2,3-DimercaptobernsteinsÃ¤ure',\n",
       "  'meso-2,3-dimercaptosuccinic acid',\n",
       "  'meso-dimercaptosuccinic acid',\n",
       "  'Succimer',\n",
       "  'succimero',\n",
       "  'Succimer'],\n",
       " 'Cephalexin': ['(6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  '7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acid',\n",
       "  '7-beta-(D-alpha-Amino-alpha-phenylacetylamino)-3-methyl-3-cephem-4-carboxylic acid',\n",
       "  'Anhydrous cefalexin',\n",
       "  'Anhydrous cephalexin',\n",
       "  'Cefalexin',\n",
       "  'Cefalexin anhydrous',\n",
       "  'Cefalexina',\n",
       "  'CÃ©falexine',\n",
       "  'Cefalexinum',\n",
       "  'Cephalexin anhydrous',\n",
       "  'Cephalexin'],\n",
       " 'Cinnarizine': ['1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine',\n",
       "  '1-Benzhydryl-4-cinnamylpiperazin',\n",
       "  '1-Cinnamyl-4-(diphenylmethyl)piperazine',\n",
       "  'Cinarizina',\n",
       "  'Cinnarizine',\n",
       "  'Cinnarizinum',\n",
       "  'Cinnarizine'],\n",
       " 'Fondaparinux': ['Natural heparin pentasaccharide', 'Fondaparinux'],\n",
       " 'Vinblastine': ['Vinblastin',\n",
       "  'Vinblastina',\n",
       "  'Vinblastine',\n",
       "  'Vinblastinum',\n",
       "  'Vincaleukoblastine',\n",
       "  'Vinblastine'],\n",
       " 'Propranolol': ['1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol',\n",
       "  '1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol',\n",
       "  'beta-Propranolol',\n",
       "  'Propanalol',\n",
       "  'Propanolol',\n",
       "  'Propranolol',\n",
       "  'Propranololo',\n",
       "  'Propranololum',\n",
       "  'Î²-Propranolol',\n",
       "  'Propranolol'],\n",
       " 'Atropine': ['(Â±)-atropine',\n",
       "  '(Â±)-hyoscyamine',\n",
       "  'Atropin',\n",
       "  'Atropina',\n",
       "  'Atropine',\n",
       "  'Atropinum',\n",
       "  'dl-Hyoscyamine',\n",
       "  'dl-tropyltropate',\n",
       "  'Tropine tropate',\n",
       "  'Atropine'],\n",
       " 'Fenoprofen': ['(+/-)-fenoprofen',\n",
       "  '(+/-)-m-phenoxyhydratropic acid',\n",
       "  '(Â±)-2-(3-phenoxyphenyl)propionic acid',\n",
       "  '2-(3-phenoxyphenyl)propionic acid',\n",
       "  '2-(m-phenoxyphenyl)propionic acid',\n",
       "  '3-phenoxyhydratropic acid',\n",
       "  'DL-2-(3-phenoxyphenyl)propionic acid',\n",
       "  'Fenoprofen',\n",
       "  'FÃ©noprofÃ¨ne',\n",
       "  'Fenoprofeno',\n",
       "  'Fenoprofenum',\n",
       "  'Î±-(m-phenoxyphenyl)propionic acid',\n",
       "  'Î±-methyl-3-phenoxybenzeneacetic acid',\n",
       "  'Fenoprofen'],\n",
       " 'Fenfluramine': ['(Â±)-fenfluramine',\n",
       "  '1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane',\n",
       "  'DL-Fenfluramine',\n",
       "  'Fenfluramina',\n",
       "  'Fenfluramine',\n",
       "  'Fenfluraminum',\n",
       "  'Fenfluramine'],\n",
       " 'Clonidine': ['2-((2,6-Dichlorophenyl)imino)imidazolidine',\n",
       "  '2,6-Dichloro-N-2-imidazolidinylidenebenzenamine',\n",
       "  'Chlofazoline',\n",
       "  'Clonidin',\n",
       "  'Clonidina',\n",
       "  'Clonidine',\n",
       "  'Clonidinum',\n",
       "  'Clonidine'],\n",
       " 'Sulfamethizole': ['Sulfamethizol',\n",
       "  'SulfamÃ©thizol',\n",
       "  'Sulfamethizole',\n",
       "  'Sulfamethizolum',\n",
       "  'Sulfamethylthiadiazole',\n",
       "  'Sulfametizol',\n",
       "  'Sulfamethizole'],\n",
       " 'Valaciclovir': ['L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine',\n",
       "  'L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester',\n",
       "  'Valaciclovir',\n",
       "  'Valaciclovirum',\n",
       "  'Valacyclovir',\n",
       "  'Valaciclovir'],\n",
       " 'Carbenicillin': ['(2S,5R,6R)-6-{[carboxy(phenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  'Carbenicilina',\n",
       "  'Carbenicillin',\n",
       "  'Carbenicilline',\n",
       "  'Carbenicillinum',\n",
       "  'Carboxybenzylpenicillin',\n",
       "  'CBPC',\n",
       "  'N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid',\n",
       "  'Î±-carboxybenzylpencillin',\n",
       "  'Î±-phenyl(carboxymethylpenicillin)',\n",
       "  'Carbenicillin'],\n",
       " 'Mazindol': ['Mazindol', 'Mazindolo', 'Mazindolum', 'Mazindol'],\n",
       " 'Valdecoxib': ['Valdecoxib', 'Valdecoxib'],\n",
       " 'Lactulose': ['4-O-beta-D-Galactopyranosyl-D-fructofuranose',\n",
       "  '4-O-beta-D-Galactopyranosyl-D-fructose',\n",
       "  'Lactulosa',\n",
       "  'Lactulose',\n",
       "  'Lactulosum',\n",
       "  'Lactulose'],\n",
       " 'Voriconazole': ['(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol',\n",
       "  '(Î±R,Î²S)-Î±-(2,4-difluorophenyl)-5-fluoro-Î²-methyl-Î±(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol',\n",
       "  'VCZ',\n",
       "  'Voriconazol',\n",
       "  'Voriconazole',\n",
       "  'Voriconazolum',\n",
       "  'Voriconazole'],\n",
       " 'Levocarnitine': ['(-)-Carnitine',\n",
       "  '(-)-L-Carnitine',\n",
       "  '(R)-Carnitine',\n",
       "  '3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt',\n",
       "  'Carnitina',\n",
       "  'Carnitine',\n",
       "  'L-Carnitine',\n",
       "  'Levocarnitin',\n",
       "  'Levocarnitina',\n",
       "  'LÃ©vocarnitine',\n",
       "  'Levocarnitine',\n",
       "  'Levocarnitinum',\n",
       "  'Vitamin BT',\n",
       "  'Levocarnitine'],\n",
       " 'Enalapril': ['(S)-1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline',\n",
       "  '(S)-1-{(S)-2-[1-((S)-Ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid',\n",
       "  \"1-(N-((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester\",\n",
       "  'Ã¡nalapril',\n",
       "  'Enalapril',\n",
       "  'Enalaprila',\n",
       "  'Enalaprilum',\n",
       "  'Enalapril'],\n",
       " 'Nizatidine': ['N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamine',\n",
       "  'Nizatidina',\n",
       "  'Nizatidine',\n",
       "  'Nizatidinum',\n",
       "  'Nizatidine'],\n",
       " 'Diclofenac': ['[2-(2,6-dichloroanilino)phenyl]acetic acid',\n",
       "  '2-((2,6-dichlorophenyl)amino)benzeneacetic acid',\n",
       "  'Diclofenac',\n",
       "  'Diclofenac acid',\n",
       "  'Diclofenaco',\n",
       "  'Diclofenacum',\n",
       "  'Diclofenac'],\n",
       " 'Cinalukast': [\"3'-((E)-2-(4-cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acid\",\n",
       "  'Cinalukast',\n",
       "  'Cinalukast'],\n",
       " 'Fluticasone propionate': ['Fluticasone propionate',\n",
       "  'Fluticasone propionate'],\n",
       " 'Lisuride': ['Lisurid',\n",
       "  'Lisurida',\n",
       "  'Lisuride',\n",
       "  'Lisuridum',\n",
       "  \"N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea\",\n",
       "  'Lisuride'],\n",
       " 'Doxazosin': ['1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin',\n",
       "  '1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin',\n",
       "  'Doxazosin',\n",
       "  'Doxazosina',\n",
       "  'Doxazosine',\n",
       "  'Doxazosinum',\n",
       "  'Doxazosin'],\n",
       " 'Fluocinolone acetonide': ['6alpha-fluorotriamcinolone acetonide',\n",
       "  '6alpha,9alpha-difluoro-16alpha-hydroxyprednisolone 16,17-acetonide',\n",
       "  '6Î±-fluorotriamcinolone acetonide',\n",
       "  '6Î±,9Î±-difluoro-16Î±-hydroxyprednisolone 16,17-acetonide',\n",
       "  'acÃ©tonide de fluocinolone',\n",
       "  'acetÃ³nido de fluocinolona',\n",
       "  'fluocinolon acetonid',\n",
       "  'fluocinolone 16,17-acetonide',\n",
       "  'Fluocinolone acetonide',\n",
       "  'fluocinoloni acetonidum',\n",
       "  'Fluocinolone acetonide'],\n",
       " 'Piperazine': ['Diethylenediamine',\n",
       "  'Piperazidine',\n",
       "  'Piperazin',\n",
       "  'Piperazina',\n",
       "  'Piperazine'],\n",
       " 'Ethosuximide': ['(Â±)-2-ethyl-2-methylsuccinimide',\n",
       "  '2-ethyl-2-methylsuccinimide',\n",
       "  '2-methyl-2-ethylsuccinimide',\n",
       "  '3-ethyl-3-methyl-2,5-pyrrolidinedione',\n",
       "  '3-ethyl-3-methylsuccinimide',\n",
       "  '3-methyl-3-ethylpyrrolidine-2,5-dione',\n",
       "  '3-methyl-3-ethylsuccinimide',\n",
       "  'Aethosuximide',\n",
       "  'Atysmal',\n",
       "  'Ethosuximid',\n",
       "  'Ã©thosuximide',\n",
       "  'Ethosuximide',\n",
       "  'Ethosuximidum',\n",
       "  'Etosuximida',\n",
       "  'Thilopemal',\n",
       "  'Î±-ethyl-Î±-methylsuccinimide',\n",
       "  'Î±-methyl-Î±-ethylsuccinimide',\n",
       "  'Î³-ethyl-Î³-methyl-succinimide',\n",
       "  'Î³-methyl-Î³-ethyl-succinimide',\n",
       "  'Ethosuximide'],\n",
       " 'Amiloride': ['3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide',\n",
       "  'Amilorid',\n",
       "  'Amilorida',\n",
       "  'Amiloride',\n",
       "  'Amiloridum',\n",
       "  'Amipramidin',\n",
       "  'Amipramidine',\n",
       "  'Amyloride',\n",
       "  'N-amidino-3,5-diamino-6-chloropyrazinecarboxamide',\n",
       "  'Amiloride'],\n",
       " 'Oxytetracycline': ['5-Hydroxytetracycline',\n",
       "  'Embryostat',\n",
       "  'Hydroxytetracyclinum',\n",
       "  'Mepatar',\n",
       "  'Ossitetraciclina',\n",
       "  'Oxitetraciclina',\n",
       "  'Oxyterracin',\n",
       "  'Oxyterracine',\n",
       "  'Oxytetracyclin',\n",
       "  'OxytÃ©tracycline',\n",
       "  'Oxytetracycline',\n",
       "  'Oxytetracycline (anhydrous)',\n",
       "  'Oxytetracycline amphoteric',\n",
       "  'Oxytetracyclinum',\n",
       "  'Oxytetracycline'],\n",
       " 'Ulobetasol': ['21-chloro diflorasone',\n",
       "  'Halobetasol',\n",
       "  'Ulobetasol',\n",
       "  'UlobÃ©tasol',\n",
       "  'Ulobetasolum',\n",
       "  'Ulobetasol'],\n",
       " 'Gadoteridol': [\"gadolinium 2,2',2''-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate\",\n",
       "  'gadolinium-HP-DO3A',\n",
       "  'Gadoteridol',\n",
       "  'Gadoteridolum',\n",
       "  'GD-HP-DO 3A',\n",
       "  'Gd-HPDO3A',\n",
       "  'Gadoteridol'],\n",
       " 'Labetalol': ['3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol',\n",
       "  '5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide',\n",
       "  'LabÃ©talol',\n",
       "  'Labetalol',\n",
       "  'Labetalolum',\n",
       "  'Labetolol',\n",
       "  'Labetalol'],\n",
       " 'Thiopental': ['(Â±)-thiopental',\n",
       "  '2-Thio-5-ethyl-5-sec-pentylbarbituric acid',\n",
       "  '5-Ethyl-5-(1-methyl-butyl)-2-thioxo-dihydro-pyrimidine-4,6-dione',\n",
       "  'Penthiobarbital',\n",
       "  'Pentothiobarbital',\n",
       "  'Thiopental',\n",
       "  'Thiopentobarbital',\n",
       "  'Thiopentobarbitone',\n",
       "  'Thiopentobarbituric acid',\n",
       "  'Thiopentone',\n",
       "  'Tiopentale',\n",
       "  'Thiopental'],\n",
       " 'Monobenzone': ['4-(Benzyloxy)phenol',\n",
       "  '4-(Benzyloxyl)phenol',\n",
       "  '4-(Phenylmethoxy)phenol',\n",
       "  '4-Benzyloxy-phenol',\n",
       "  '4-Benzyloxyphenol',\n",
       "  'Benzyl p-hydroxyphenyl ether',\n",
       "  'Hydrochinon monobenzylether',\n",
       "  'Hydroquinone benzyl ether',\n",
       "  'Hydroquinone monobenzyl ether',\n",
       "  'Monobenzona',\n",
       "  'Monobenzone',\n",
       "  'Monobenzonum',\n",
       "  'Monobenzyl hydroquinone',\n",
       "  'p-(Benzyloxy)phenol',\n",
       "  'p-Hydroxyphenyl benzyl ether',\n",
       "  'Monobenzone'],\n",
       " 'Linezolid': ['Linezolid',\n",
       "  'Linezolide',\n",
       "  'Linezolidum',\n",
       "  'N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide',\n",
       "  'Linezolid'],\n",
       " 'Ivermectin': ['Ivermectin',\n",
       "  'Ivermectina',\n",
       "  'Ivermectine',\n",
       "  'Ivermectinum',\n",
       "  'Ivermectin'],\n",
       " 'Medroxyprogesterone acetate': ['(6Î±)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione',\n",
       "  '17-Acetoxy-6Î±-methylprogesterone',\n",
       "  '17Î±-hydroxy-6Î±-methylprogesterone acetate',\n",
       "  '6-alpha-Methyl-17-alpha-acetoxyprogesterone',\n",
       "  '6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate',\n",
       "  '6Î±-Methyl-17-acetoxy progesterone',\n",
       "  '6Î±-Methyl-17Î±-hydroxyprogesterone acetate',\n",
       "  '6Î±-Methyl-4-pregnene-3,20-dion-17Î±-ol acetate',\n",
       "  'Medroxyacetate progesterone',\n",
       "  'Medroxyprogesterone 17-acetate',\n",
       "  'Methylacetoxyprogesterone',\n",
       "  'Metigestrona',\n",
       "  'MPA',\n",
       "  'Medroxyprogesterone acetate'],\n",
       " 'Cisapride': ['Cisaprid',\n",
       "  'Cisaprida',\n",
       "  'Cisapride',\n",
       "  'Cisapridum',\n",
       "  'Cisapride'],\n",
       " 'Sulindac': ['(Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid',\n",
       "  'cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid',\n",
       "  'cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid',\n",
       "  'Sulindac',\n",
       "  'Sulindaco',\n",
       "  'Sulindacum',\n",
       "  'Sulindac'],\n",
       " 'Cyclothiazide': ['6-chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide',\n",
       "  '6-chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide',\n",
       "  '6-chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide',\n",
       "  '6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide',\n",
       "  'Ciclotiazida',\n",
       "  'Ciclotiazide',\n",
       "  'Cyclothiazide',\n",
       "  'Cyclothiazidum',\n",
       "  'Cyclothiazide'],\n",
       " 'Nafcillin': ['(2-ethoxy-1-naphthalenyl)penicillin',\n",
       "  '(2-ethoxy-1-naphthyl)penicillin',\n",
       "  '(2S,5R,6R)-6-[(2-ethoxy-1-naphthoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  '6-(2-ethoxy-1-naphthamido)penicillanic acid',\n",
       "  'Nafcilina',\n",
       "  'Nafcillin',\n",
       "  'Nafcilline',\n",
       "  'Nafcillinum',\n",
       "  'Naphcillin',\n",
       "  'Nafcillin'],\n",
       " 'Chloroquine': ['Chloraquine',\n",
       "  'Chlorochin',\n",
       "  'Chloroquina',\n",
       "  'Chloroquine',\n",
       "  'Chloroquinium',\n",
       "  'Chloroquinum',\n",
       "  'Cloroquina',\n",
       "  'N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine',\n",
       "  'Chloroquine'],\n",
       " 'Ethionamide': ['2-ethyl-4-thiopyridylamide',\n",
       "  '2-ethylthioisonicotinamide',\n",
       "  'ETH',\n",
       "  'Ethinamide',\n",
       "  'Ethionamide',\n",
       "  'Ethionamidum',\n",
       "  'Ethioniamide',\n",
       "  'Ethylisothiamide',\n",
       "  'Ethyonomide',\n",
       "  'Etionamid',\n",
       "  'Etionamida',\n",
       "  'Etionamide',\n",
       "  'Etioniamid',\n",
       "  'ETP',\n",
       "  'Ethionamide'],\n",
       " 'Metaraminol': ['(-)-Erythro-metaraminol',\n",
       "  '1-(m-Hydroxyphenyl)-2-amino-1-propanol',\n",
       "  '1-Metaraminol',\n",
       "  '2-Amino-1-(m-hydroxyphenyl)-1-propanol',\n",
       "  '3-Hydroxyphenylisopropanolamine',\n",
       "  'alpha-(1-Aminoethyl)-3-hydroxybenzenemethanol',\n",
       "  'alpha-(m-Hydroxyphenyl)-beta-aminopropanol',\n",
       "  'Hydroxynorephedrine',\n",
       "  'L-Metaraminol',\n",
       "  'm-Hydroxy norephedrine',\n",
       "  'm-Hydroxyphenylpropanolamine',\n",
       "  'm-Hydroxypropadrine',\n",
       "  'Metaraminol',\n",
       "  'MÃ©taraminol',\n",
       "  'Metaraminolum',\n",
       "  'Metaraminol'],\n",
       " 'Butorphanol': ['(â\\x88\\x92)-17-(cyclobutylmethyl)morphinan-3,14-diol',\n",
       "  '(â\\x88\\x92)-butorphanol',\n",
       "  '(â\\x88\\x92)-N-cyclobutylmethyl-3,14-dihydroxymorphinan',\n",
       "  'Butorfanol',\n",
       "  'Butorphanol',\n",
       "  'Butorphanolum',\n",
       "  'Butorphanol'],\n",
       " 'Bisoprolol': ['(+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol',\n",
       "  '(RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol',\n",
       "  'Bisoprolol',\n",
       "  'Bisoprololum',\n",
       "  'Bisoprolol'],\n",
       " 'Amodiaquine': ['Amodiaquina', 'Amodiaquine', 'Amodiaquinum', 'Amodiaquine'],\n",
       " 'Furazolidone': [\"3-(5'-Nitrofurfuralamino)-2-oxazolidone\",\n",
       "  '3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone',\n",
       "  '3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone',\n",
       "  '3-[(5-Nitrofurylidene)amino]-2-oxazolidone',\n",
       "  '3-{[(5-nitro-2-furanyl)methylene]amino}-2-oxazolidinone',\n",
       "  '5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine',\n",
       "  'Furazolidona',\n",
       "  'Furazolidonum',\n",
       "  'FZL',\n",
       "  'N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone',\n",
       "  'N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one',\n",
       "  'Nitrofurazolidone',\n",
       "  'Nitrofurazolidonum',\n",
       "  'Furazolidone'],\n",
       " 'Rifabutin': [\"1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV\",\n",
       "  '4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S',\n",
       "  '4-N-isobutylspiropiperidylrifamycin S',\n",
       "  'Ansamicin',\n",
       "  'Ansamycin',\n",
       "  'Rifabutin',\n",
       "  'Rifabutina',\n",
       "  'Rifabutine',\n",
       "  'Rifabutinum',\n",
       "  'Rifabutin'],\n",
       " 'Candoxatril': ['[4(S)-cis]-4-[[[1-[3-[(2,3-dihydro-1H-Indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid',\n",
       "  '4-({1-[(S)-2-(indan-5-yloxycarbonyl)-3-(2-methoxy-ethoxy)-propyl]-cyclopentanecarbonyl}-amino)-cyclohexanecarboxylic acid',\n",
       "  'Candoxatril',\n",
       "  'Candoxatril'],\n",
       " 'Paramethadione': ['Parametadiona',\n",
       "  'Parametadione',\n",
       "  'Paramethadione',\n",
       "  'Paramethadionum',\n",
       "  'Paramethadione'],\n",
       " 'Demeclocycline': ['[4S-(4Î±,4aÎ±,5aÎ±,6Î²,12aÎ±)]-7-chloro-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide',\n",
       "  '6-demethyl-7-chlorotetracycline',\n",
       "  '7-chloro-6-demethyltetracycline',\n",
       "  'Demeclociclina',\n",
       "  'Demeclocycline',\n",
       "  'Demeclocyclinum',\n",
       "  'Demethylchlortetracyclin',\n",
       "  'Demethylchlortetracycline',\n",
       "  'DMCT',\n",
       "  'DMCTC',\n",
       "  'Demeclocycline'],\n",
       " 'Imatinib': ['Imatinib',\n",
       "  'Imatinibum',\n",
       "  \"Î±-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide\",\n",
       "  'Imatinib'],\n",
       " 'Triamcinolone': ['11Î²,16Î±,17Î±,21-tetrahydroxy-9Î±-fluoro-1,4-pregnadiene-3,20-dione',\n",
       "  '9-fluoro-11Î²,16Î±,17,21-tetrahydroxypregna-1,4-diene-3,20-dione',\n",
       "  '9Î±-fluoro-11Î²,16Î±,17,21-tetrahydroxypregna-1,4-diene-3,20-dione',\n",
       "  '9Î±-fluoro-11Î²,16Î±,17Î±,21-tetrahydroxypregna-1,4-diene-3,20-dione',\n",
       "  '9Î±-fluoro-16Î±-hydroxyprednisolone',\n",
       "  'Fluoxyprednisolone',\n",
       "  'Tiamcinolonum',\n",
       "  'Triamcinolona',\n",
       "  'Triamcinolone',\n",
       "  'Triamcinolonum',\n",
       "  'Triamcinolone'],\n",
       " 'Oxandrolone': ['Ossandrolone',\n",
       "  'Oxandrolon',\n",
       "  'Oxandrolona',\n",
       "  'Oxandrolone',\n",
       "  'Oxandrolonum',\n",
       "  'Oxandrolone'],\n",
       " 'Nicardipine': ['Nicardipine', 'Nicardipino', 'Nicardipinum', 'Nicardipine'],\n",
       " 'Fluphenazine': ['1-(2-hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine',\n",
       "  '10-(3-(2-hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine',\n",
       "  \"10-(3'-(4''-(Î²-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine\",\n",
       "  '2-(4-(3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol',\n",
       "  '2-(trifluoromethyl)-10-(3-(1-(Î²-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine',\n",
       "  '4-(3-(-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol',\n",
       "  '4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol',\n",
       "  '4-(3-(2-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol',\n",
       "  'Flufenazina',\n",
       "  'Fluorfenazine',\n",
       "  'Fluorophenazine',\n",
       "  'Fluorphenazine',\n",
       "  'Fluphenazin',\n",
       "  'FluphÃ©nazine',\n",
       "  'Fluphenazine',\n",
       "  'Fluphenazinum',\n",
       "  'Triflumethazine',\n",
       "  'Fluphenazine'],\n",
       " 'Testosterone': ['17beta-hydroxy-4-androsten-3-one',\n",
       "  '4-androsten-17Î²-ol-3-one',\n",
       "  'Testosteron',\n",
       "  'Testosterona',\n",
       "  'Testosterone',\n",
       "  'TestostÃ©rone',\n",
       "  'Testosteronum',\n",
       "  'Virosterone',\n",
       "  'Testosterone'],\n",
       " 'Efavirenz': ['(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one',\n",
       "  '(S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one',\n",
       "  '6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one',\n",
       "  'Efavirenz',\n",
       "  'Ã\\x89favirenz',\n",
       "  'Efavirenzum',\n",
       "  'Efavirenz'],\n",
       " 'Bacitracin': ['Bacitracin', 'Bacitracin A', 'Bacitracina', 'Bacitracin'],\n",
       " 'Niacin': ['3-carboxypyridine',\n",
       "  '3-Pyridinecarboxylic acid',\n",
       "  '3-Pyridylcarboxylic acid',\n",
       "  'Acide nicotinique',\n",
       "  'Ã¡cido nicotÃ\\xadnico',\n",
       "  'Acidum Nicotinicum',\n",
       "  'anti-pellagra vitamin',\n",
       "  'm-pyridinecarboxylic acid',\n",
       "  'Niacin',\n",
       "  'Niacina',\n",
       "  'Nicotinic acid',\n",
       "  'NikotinsÃ¤ure',\n",
       "  'pyridine-Î²-carboxylic acid',\n",
       "  'Î²-pyridinecarboxylic acid',\n",
       "  'Niacin'],\n",
       " 'Clorazepic acid': ['7-chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid',\n",
       "  'Chlorazepate',\n",
       "  'Clorazepate',\n",
       "  'Clorazepic acid',\n",
       "  'Clorazepic acid'],\n",
       " 'Guanabenz': ['Guanabenz', 'Guanabenzo', 'Guanabenzum', 'Guanabenz'],\n",
       " 'Alendronic acid': ['(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)',\n",
       "  '(4-amino-1-hydroxybutylidene)bisphosphonic acid',\n",
       "  '4-amino-1-hydroxybutane-1,1-diphosphonic acid',\n",
       "  'ABDP',\n",
       "  'Acide Alendronique',\n",
       "  'Acido Alendronico',\n",
       "  'Acidum Alendronicum',\n",
       "  'Alendronate',\n",
       "  'Alendronic acid',\n",
       "  'Alendronic acid'],\n",
       " 'Clofarabine': ['(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol',\n",
       "  '2-chloro-9-(2-deoxy-2-fluoro-Î²-D-arabinofuranosyl)adenine',\n",
       "  \"2-chloro-9-(2'-deoxy-2'-fluoro-Î²-D-arabinofuranosyl)adenine\",\n",
       "  'CAFdA',\n",
       "  'Cl-F-Ara-A',\n",
       "  'Clofarabin',\n",
       "  'Clofarabina',\n",
       "  'Clofarabine',\n",
       "  'Clofarabinum',\n",
       "  'Clofarabine'],\n",
       " 'Docosanol': ['1-Docosanol',\n",
       "  'Behenic alcohol',\n",
       "  'Behenyl alcohol',\n",
       "  'Docosan-1-ol',\n",
       "  'Docosanol',\n",
       "  'Docosyl alcohol',\n",
       "  'N-Docosanol',\n",
       "  'Docosanol'],\n",
       " 'Dexmedetomidine': ['(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole',\n",
       "  '(+)-4-((S)-Î±,2,3-trimethylbenzyl)imidazole',\n",
       "  'Dexmedetomidin',\n",
       "  'Dexmedetomidina',\n",
       "  'DexmÃ©dÃ©tomidine',\n",
       "  'Dexmedetomidine',\n",
       "  'Dexmedetomidinum',\n",
       "  'Dexmedetomidine'],\n",
       " 'Sulfacetamide': ['Acetosulfamine',\n",
       "  'N-((p-Aminophenyl)sulfonyl)acetamide',\n",
       "  'N-(p-Aminobenzenesulfonyl)acetamide',\n",
       "  'N-[(p-Aminophenyl)sulfonyl]acetamide',\n",
       "  'N-Acetyl-4-aminobenzenesulfonamide',\n",
       "  'N-Acetylsulfanilamide',\n",
       "  'N-Sulfanilylacetamide',\n",
       "  'N-Sulphanilylacetamide',\n",
       "  \"N'-acetylsulfanilamide\",\n",
       "  'N(1)-Acetyl-4-aminophenylsulfonamide',\n",
       "  'N(1)-Acetylsulfanilamide',\n",
       "  'p-Aminobenzenesulfonacetamide',\n",
       "  'p-Aminobenzenesulfonoacetamide',\n",
       "  'Sulfacetamid',\n",
       "  'Sulfacetamida',\n",
       "  'SulfacÃ©tamide',\n",
       "  'Sulfacetamide',\n",
       "  'Sulfacetamidum',\n",
       "  'Sulfanilazetamid',\n",
       "  'Sulphacetamide',\n",
       "  'Sulphacetamidum',\n",
       "  'Sulfacetamide'],\n",
       " 'Prednisone': ['1,2-Dehydrocortisone',\n",
       "  '1,4-Pregnadiene-17Î±,21-diol-3,11,20-trione',\n",
       "  '17,21-Dihydroxypregna-1,4-diene-3,11,20-trione',\n",
       "  'Dehydrocortisone',\n",
       "  'Prednisona',\n",
       "  'Prednisone',\n",
       "  'Prednisonum',\n",
       "  'Prednisone'],\n",
       " 'Clofibrate': ['2-(4-Chlorophenoxy)-2-methylpropanoic acid ethyl ester',\n",
       "  '2-(p-Chlorophenoxy)-2-methylpropionic acid ethyl ester',\n",
       "  'alpha-(p-Chlorophenoxy)isobutyric acid, ethyl ester',\n",
       "  'alpha-p-Chlorophenoxyisobutyryl ethyl ester',\n",
       "  'Clofibrate',\n",
       "  'Clofibrato',\n",
       "  'Clofibratum',\n",
       "  'EPIB',\n",
       "  'Ethyl 2-(p-chlorophenoxy)isobutyrate',\n",
       "  'Ethyl chlorophenoxyisobutyrate',\n",
       "  'Ethyl clofibrate',\n",
       "  'Liprin',\n",
       "  'Clofibrate'],\n",
       " 'Astemizole': ['1-(p-Fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole',\n",
       "  '1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole',\n",
       "  'Astemizol',\n",
       "  'AstÃ©mizole',\n",
       "  'Astemizole',\n",
       "  'Astemizolum',\n",
       "  'Astemizole'],\n",
       " 'Inulin': ['Inulin'],\n",
       " 'Butoconazole': ['1-[4-(4-Chloro-phenyl)-2-(2,6-dichloro-phenylsulfanyl)-butyl]-1H-imidazole',\n",
       "  'Butoconazol',\n",
       "  'Butoconazole',\n",
       "  'Butoconazolum',\n",
       "  'Butoconazole'],\n",
       " 'Adenosine': ['(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol',\n",
       "  '6-Amino-9-beta-D-ribofuranosyl-9H-purine',\n",
       "  '9-beta-D-Ribofuranosidoadenine',\n",
       "  '9-beta-D-Ribofuranosyl-9H-purin-6-amine',\n",
       "  '9-Î²-D-ribofuranosyl-9H-purin-6-amine',\n",
       "  'Ade-Rib',\n",
       "  'Adenin riboside',\n",
       "  'Adenine Deoxyribonucleoside',\n",
       "  'Adenogesic',\n",
       "  'Adenosin',\n",
       "  'Adenosina',\n",
       "  'AdÃ©nosine',\n",
       "  'Adenosine',\n",
       "  'Adenosinum',\n",
       "  'Ado',\n",
       "  'beta-D-Adenosine',\n",
       "  'Adenosine'],\n",
       " 'Simvastatin': ['2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one',\n",
       "  'Simvastatin',\n",
       "  'Simvastatina',\n",
       "  'Simvastatine',\n",
       "  'Simvastatinum',\n",
       "  'Simvastatin'],\n",
       " 'Pemetrexed': ['Pemetrexed', 'Pemetrexed'],\n",
       " 'Mebendazole': ['(5-benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester',\n",
       "  'MBDZ',\n",
       "  'Mebendazol',\n",
       "  'MÃ©bendazole',\n",
       "  'Mebendazole',\n",
       "  'Mebendazolum',\n",
       "  'Mebendazole'],\n",
       " 'Gonadorelin': ['GnRH',\n",
       "  'Gonadorelin',\n",
       "  'Gonadorelina',\n",
       "  'GonadorÃ©line',\n",
       "  'Gonadorelinum',\n",
       "  'Gonadotropin-releasing hormone',\n",
       "  'Gonadorelin'],\n",
       " 'Dyclonine': ['1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone',\n",
       "  '2-(1-piperidyl)ethyl p-butoxyphenyl ketone',\n",
       "  \"3-piperidino-4'-butoxypropiophenone\",\n",
       "  '4-butoxy-Î²-piperidinopropiophenone',\n",
       "  '4-n-butoxy-Î²-(1-piperidyl)propiophenone',\n",
       "  \"4'-butoxy-3-piperidinopropiophenone\",\n",
       "  'Diclonina',\n",
       "  'Dyclocaine',\n",
       "  'Dyclonin',\n",
       "  'Dyclonine',\n",
       "  'Dycloninum',\n",
       "  'Dyclonine'],\n",
       " 'Nystatin': ['Nistatina',\n",
       "  'NYS',\n",
       "  'Nystatin',\n",
       "  'Nystatine',\n",
       "  'Nystatinum',\n",
       "  'Nystatin'],\n",
       " 'Dextropropoxyphene': ['d-Propoxyphene',\n",
       "  'Destropropossifene',\n",
       "  'Dextropropoxifeno',\n",
       "  'Dextropropoxyphen',\n",
       "  'DextropropoxyphÃ¨ne',\n",
       "  'Dextropropoxyphene',\n",
       "  'Dextropropoxyphenum',\n",
       "  'Dextroproxifeno',\n",
       "  'Propoxyphene',\n",
       "  'Dextropropoxyphene'],\n",
       " 'Mitotane': ['Mitotan', 'Mitotane', 'Mitotano', 'Mitotanum', 'Mitotane'],\n",
       " 'Stavudine': ['1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine',\n",
       "  \"2',3'-Didehydro-3'-deoxythimidine\",\n",
       "  \"3'-Deoxy-2'-thymidinene\",\n",
       "  'Estavudina',\n",
       "  'Sanilvudine',\n",
       "  'Stavudin',\n",
       "  'Stavudine',\n",
       "  'Stavudinum',\n",
       "  'STV',\n",
       "  'Stavudine'],\n",
       " 'Leucovorin': ['(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate',\n",
       "  '10-Formyl-7,8-dihydrofolic acid',\n",
       "  '5-Formyl-5,6,7,8-tetrahydrofolic acid',\n",
       "  '5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid',\n",
       "  '5-Formyltetrahydrofolate',\n",
       "  '5-formyltetrahydrofolic acid',\n",
       "  'Acide folinique',\n",
       "  'Acido folinico',\n",
       "  'Folinate',\n",
       "  'Folinic acid',\n",
       "  'L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid',\n",
       "  'Leucovorinum',\n",
       "  'N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid',\n",
       "  'N5-Formyl-5,6,7,8-tetrahydrofolic acid',\n",
       "  'N5-Formyltetrahydrofolic acid',\n",
       "  'Leucovorin'],\n",
       " 'Dyphylline': ['(Â±)-7-(2,3-dihydroxypropyl)theophylline',\n",
       "  '(Â±)-diprophylline',\n",
       "  '(Â±)-dyphylline',\n",
       "  '(1,2-dihydroxy-3-propyl)thiophyllin',\n",
       "  '1,3-dimethyl-7-(2,3-dihydroxypropyl)xanthine',\n",
       "  '7-(2,3-dihydroxypropyl)-1,3-dimethylxanthine',\n",
       "  '7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione',\n",
       "  '7-(2,3-dihydroxypropyl)theophylline',\n",
       "  '7-(Î²,Î³-dihydroxypropyl)theophylline',\n",
       "  'Dihydroxypropyl theopylin',\n",
       "  'Diprofilina',\n",
       "  'Diprophylline',\n",
       "  'Diprophyllinum',\n",
       "  'Dyphylline',\n",
       "  'Dyphylline'],\n",
       " 'Pentazocine': ['Pentazocin',\n",
       "  'Pentazocina',\n",
       "  'Pentazocine',\n",
       "  'Pentazocinum',\n",
       "  'Pentazocine'],\n",
       " 'Magnesium sulfate': ['Magnesium sulfate (1:1)',\n",
       "  'Magnesium sulfate anhydrous',\n",
       "  'Magnesium sulphate',\n",
       "  'magnesium(II) sulfate',\n",
       "  'Magnesiumsulfat',\n",
       "  'MgSO4',\n",
       "  'Magnesium sulfate'],\n",
       " 'Latanoprost': ['isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate',\n",
       "  'Latanoprost',\n",
       "  'Latanoprostum',\n",
       "  'propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate',\n",
       "  'Latanoprost'],\n",
       " 'Estrone': ['3-Hydroxy-1,3,5(10)-estratrien-17-one',\n",
       "  'Estrona',\n",
       "  'Estrone',\n",
       "  'Estronum',\n",
       "  'Follicular hormone',\n",
       "  'Folliculin',\n",
       "  'Oestrone',\n",
       "  'Estrone'],\n",
       " 'Trazodone': ['2-(3-[4-(3-chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one',\n",
       "  'Trazodona',\n",
       "  'Trazodone',\n",
       "  'Trazodonum',\n",
       "  'Trazodone'],\n",
       " 'Mecamylamine': ['Mecamylamine', 'Mecamylamine'],\n",
       " 'Sevelamer': ['Sevelamer',\n",
       "  'SÃ©vÃ©lamer',\n",
       "  'Sevelamero',\n",
       "  'Sevelamerum',\n",
       "  'Sevelamer'],\n",
       " 'Acamprosate': ['3-Acetamido-1-propanesulfonic acid',\n",
       "  'Acamprosate',\n",
       "  'Acamprosato',\n",
       "  'Acamprosatum',\n",
       "  'N-acetyl homotaurine',\n",
       "  'N-Acetylhomotaurine',\n",
       "  'Acamprosate'],\n",
       " 'Metaxalone': ['Metassalone',\n",
       "  'Metaxalon',\n",
       "  'Metaxalona',\n",
       "  'Metaxalone',\n",
       "  'Metaxalonum',\n",
       "  'Metaxalone'],\n",
       " 'Verapamil': ['Iproveratril',\n",
       "  'VÃ©rapamil',\n",
       "  'Verapamil',\n",
       "  'Verapamilo',\n",
       "  'Verapamilum',\n",
       "  'Verapamil'],\n",
       " 'Trimethobenzamide': ['N-[[4-(2-dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide',\n",
       "  'Trimethobenzamide',\n",
       "  'Trimethobenzamidum',\n",
       "  'Trimetobenzamida',\n",
       "  'Trimethobenzamide'],\n",
       " 'Flumethasone': ['6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione',\n",
       "  'Flumetasona',\n",
       "  'FlumÃ©tasone',\n",
       "  'Flumetasone',\n",
       "  'Flumetasonum',\n",
       "  'Flumethasone',\n",
       "  'Flumethasone'],\n",
       " 'Sulfametopyrazine': ['Solfametopirazina',\n",
       "  'Sulfalene',\n",
       "  'Sulfaleno',\n",
       "  'Sulfalenum',\n",
       "  'Sulfamethopyrazine',\n",
       "  'Sulfametopyrazine'],\n",
       " 'Nilutamide': ['5,5-Dimethyl-3-(Î±,Î±,Î±-trifluoro-4-nitro-m-tolyl)hydantoin',\n",
       "  'Nilutamida',\n",
       "  'Nilutamide',\n",
       "  'Nilutamidum',\n",
       "  'Nilutamide'],\n",
       " 'Nafarelin': ['Nafarelin',\n",
       "  'Nafarelina',\n",
       "  'NafarÃ©line',\n",
       "  'Nafarelinum',\n",
       "  'Nafarelin'],\n",
       " 'Epinephrine': ['(â\\x88\\x92)-(R)-epinephrine',\n",
       "  '(â\\x88\\x92)-3,4-dihydroxy-Î±-((methylamino)methyl)benzyl alcohol',\n",
       "  '(â\\x88\\x92)-adrenaline',\n",
       "  '(R)-(-)-Adnephrine',\n",
       "  '(R)-(-)-Adrenaline',\n",
       "  '(R)-(-)-Epinephrine',\n",
       "  '(R)-(-)-Epirenamine',\n",
       "  '(R)-(â\\x88\\x92)-adrenaline',\n",
       "  '4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol',\n",
       "  'AdrÃ©naline',\n",
       "  'Adrenaline',\n",
       "  'Epinefrin',\n",
       "  'Epinefrina',\n",
       "  'Epinephrin',\n",
       "  'Epinephrine',\n",
       "  'Epinephrinum',\n",
       "  'L-Adrenaline',\n",
       "  'Levoepinephrine',\n",
       "  'Epinephrine'],\n",
       " 'Sumatriptan': ['(3-[2-(dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide',\n",
       "  '1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide',\n",
       "  '3-(2-(dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide',\n",
       "  '3-[2-(dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide',\n",
       "  'Sumatriptan',\n",
       "  'SumatriptÃ¡n',\n",
       "  'Sumatriptanum',\n",
       "  'Sumatriptan'],\n",
       " 'Pirenzepine': ['11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one',\n",
       "  'Pirenzepin',\n",
       "  'Pirenzepina',\n",
       "  'PirenzÃ©pine',\n",
       "  'Pirenzepine',\n",
       "  'Pirenzepinum',\n",
       "  'Pirenzepine'],\n",
       " 'Cefixime': ['(â\\x88\\x92)-cefixim',\n",
       "  'Cefixim',\n",
       "  'Cefixima',\n",
       "  'CÃ©fixime',\n",
       "  'Cefixime',\n",
       "  'Cefixime anhydrous',\n",
       "  'Cefiximum',\n",
       "  'Cefixime'],\n",
       " 'Chlorpropamide': ['1-(p-chlorobenzenesulfonyl)-3-propylurea',\n",
       "  '1-(p-chlorophenylsulfonyl)-3-propylurea',\n",
       "  '1-propyl-3-(p-chlorobenzenesulfonyl)urea',\n",
       "  '4-chloro-N-((propylamino)carbonyl)benzenesulfonamide',\n",
       "  '4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide',\n",
       "  'Chlorpropamid',\n",
       "  'Chlorpropamide',\n",
       "  'Chlorpropamidum',\n",
       "  'Clorpropamida',\n",
       "  \"N-(4-chlorophenylsulfonyl)-N'-propylurea\",\n",
       "  \"N-(p-chlorobenzenesulfonyl)-N'-propylurea\",\n",
       "  \"n-propyl-N'-(p-chlorobenzenesulfonyl)urea\",\n",
       "  \"n-propyl-N'-p-chlorophenylsulfonylcarbamide\",\n",
       "  'Chlorpropamide'],\n",
       " 'Aprepitant': ['Aprepitant', 'AprÃ©pitant', 'Aprepitantum', 'Aprepitant'],\n",
       " 'Galantamine': ['(-)-Galanthamine',\n",
       "  'Galantamina',\n",
       "  'Galantamine',\n",
       "  'Galanthamine',\n",
       "  'Galantamine'],\n",
       " 'Tamoxifen': ['(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine',\n",
       "  '(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine',\n",
       "  '1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene',\n",
       "  '1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene',\n",
       "  'Tamoxifen',\n",
       "  'TamoxifÃ¨ne',\n",
       "  'Tamoxifene',\n",
       "  'Tamoxifeno',\n",
       "  'Tamoxifenum',\n",
       "  'trans-Tamoxifen',\n",
       "  'Tamoxifen'],\n",
       " 'Benzyl benzoate': ['Acarobenzyl',\n",
       "  'Benylate',\n",
       "  'Benzevan',\n",
       "  'Benzoate de benzyle',\n",
       "  'BenzoesÃ¤urebenzylester',\n",
       "  'Benzoic acid phenylmethylester',\n",
       "  'Benzoic acid, benzyl ester',\n",
       "  'Benzoic acid, phenylmethyl ester',\n",
       "  'Benzyl benzoat',\n",
       "  'Benzylis benzoas',\n",
       "  'Phenylmethyl benzoate',\n",
       "  'Benzyl benzoate'],\n",
       " 'Isoflurophate': ['DFP',\n",
       "  'Diisopropoxyphosphoryl fluoride',\n",
       "  'Diisopropyl fluorophosphate',\n",
       "  'Diisopropyl fluorophosphonate',\n",
       "  'Diisopropyl phosphofluoridate',\n",
       "  'Diisopropyl phosphorofluoridate',\n",
       "  'Diisopropylfluorophosphate',\n",
       "  'Diisopropylfluorophosphoric acid ester',\n",
       "  'Diisopropylphosphofluoridate',\n",
       "  'Diisopropylphosphorofluoridate',\n",
       "  'Fluorodiisopropyl phosphate',\n",
       "  'Fluorostigmine',\n",
       "  'Isofluorphate',\n",
       "  'Isoflurophate',\n",
       "  'Isoflurophosphate',\n",
       "  'Isopropyl fluophosphate',\n",
       "  'Isopropyl phosphorofluoridate',\n",
       "  \"O,O'-diisopropyl phosphoryl fluoride\",\n",
       "  'Isoflurophate'],\n",
       " 'Losartan': [\"(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol\",\n",
       "  \"2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole\",\n",
       "  'Losartan',\n",
       "  'Losartan'],\n",
       " 'Thioridazine': ['10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine',\n",
       "  '2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine',\n",
       "  \"3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine\",\n",
       "  'Thioridazin',\n",
       "  'Thioridazine',\n",
       "  'Thioridazinum',\n",
       "  'Tioridazina',\n",
       "  'Thioridazine'],\n",
       " 'Moricizine': ['[10-(3-Morpholin-4-yl-propionyl)-10H-phenothiazin-2-yl]-carbamic acid ethyl ester',\n",
       "  'Ethmozin',\n",
       "  'ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate',\n",
       "  'ethyl 10-(Î²-N-morpholinylpropionyl)phenothiazine-2-carbamate',\n",
       "  'Etmozin',\n",
       "  'Moracizin',\n",
       "  'Moracizina',\n",
       "  'Moracizine',\n",
       "  'Moracizinum',\n",
       "  'Moricizine',\n",
       "  'Moricizine'],\n",
       " 'Amphotericin B': ['Amfotericina B',\n",
       "  'AMPH-b',\n",
       "  'Amphotericin B',\n",
       "  'AmphotÃ©ricine B',\n",
       "  'Amphotericinum B',\n",
       "  'Liposomal amphotericin B',\n",
       "  'Amphotericin B'],\n",
       " 'Warfarin': ['4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin',\n",
       "  'Coumafene',\n",
       "  'Warfarin',\n",
       "  'Warfarina',\n",
       "  'Zoocoumarin',\n",
       "  'Warfarin'],\n",
       " 'Midazolam': ['Midazolam', 'Midazolamum', 'Midazolam'],\n",
       " 'Tobramycin': [\"3'-Deoxykanamycin B\",\n",
       "  'Nebramycin 6',\n",
       "  'O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine',\n",
       "  'Tobramicina',\n",
       "  'Tobramycin',\n",
       "  'Tobramycine',\n",
       "  'Tobramycinum',\n",
       "  'Tobramycin'],\n",
       " 'Trovafloxacin': ['Trovafloxacin', 'trovafloxacino', 'Trovafloxacin'],\n",
       " 'Pentosan polysulfate': ['Pentosan polysulfate',\n",
       "  'Pentosan sulfuric polyester',\n",
       "  'Pentosane polysulfate',\n",
       "  'Pentosani polysulfas',\n",
       "  'Pentosano polisulfato',\n",
       "  'Pentosanpolysulfat',\n",
       "  'Pentosan polysulfate'],\n",
       " 'Fludrocortisone': ['9alpha-Fluorocortisol',\n",
       "  'Fludrocortison',\n",
       "  'Fludrocortisona',\n",
       "  'Fludrocortisone',\n",
       "  'Fludrocortisonum',\n",
       "  'Fluohydrocortisone',\n",
       "  'Fludrocortisone'],\n",
       " 'Mycophenolate mofetil': ['2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate',\n",
       "  'Mycophenolate mofetil',\n",
       "  'Mycophenolic acid morpholinoethyl ester',\n",
       "  'Mycophenolate mofetil'],\n",
       " 'Cephaloglycin': ['7-(2-D-alpha-Aminophenylacetamido)cephalosporanic acid',\n",
       "  '7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup3)-cephem-4-carboxylic acid',\n",
       "  '7-(D-alpha-Aminophenyl-acetamido)cephalosporanic acid',\n",
       "  'Cefaloglicina',\n",
       "  'Cefaloglycin',\n",
       "  'Cefaloglycine',\n",
       "  'Cefaloglycinum',\n",
       "  'CEG',\n",
       "  'Cephaloglycin anhydrous',\n",
       "  'Cephaloglycine',\n",
       "  'Cephaoglycin acid',\n",
       "  'D-(-)-Cephaloglycin',\n",
       "  'D-Cephaloglycine',\n",
       "  'Cephaloglycin'],\n",
       " 'Flurazepam': ['Flurazepam', 'FlurazÃ©pam', 'Flurazepamum', 'Flurazepam'],\n",
       " 'Moexipril': ['Moexipril', 'Moexiprilum', 'Moexipril'],\n",
       " 'Phentolamine': ['2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline',\n",
       "  'Fentolamina',\n",
       "  'Phentolamin',\n",
       "  'Phentolamine',\n",
       "  'Phentolaminum',\n",
       "  'Phentolamine'],\n",
       " 'Fluorescein': ['3,6-fluorandiol',\n",
       "  \"3',6'-dihydroxyfluoran\",\n",
       "  '9-(o-carboxyphenyl)-6-hydroxy-3-isoxanthenone',\n",
       "  '9-(o-carboxyphenyl)-6-hydroxy-3H-xanthen-3-one',\n",
       "  'C.I. Solvent Yellow 94',\n",
       "  'D and C Yellow No. 7',\n",
       "  'D&C Yellow No. 7',\n",
       "  'Fluoresceina',\n",
       "  'FluoresceÃ\\xadna',\n",
       "  'Fluoresceine',\n",
       "  'Fluoreszein',\n",
       "  'Japan Yellow 201',\n",
       "  'Resorcinolphthalein',\n",
       "  'Solvent Yellow 94',\n",
       "  'Yellow fluorescein',\n",
       "  'Fluorescein'],\n",
       " 'Daunorubicin': ['(+)-Daunomycin',\n",
       "  '(8S-cis)-8-acetyl-10-((3-amino-2,3,6-trideoxy-Î±-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione',\n",
       "  'Acetyladriamycin',\n",
       "  'Daunomycin',\n",
       "  'Daunorubicin',\n",
       "  'Daunorubicina',\n",
       "  'Daunorubicine',\n",
       "  'Daunorubicinum',\n",
       "  'Leukaemomycin C',\n",
       "  'Rubidomycin',\n",
       "  'Daunorubicin'],\n",
       " 'Furosemide': ['2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid',\n",
       "  '4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid',\n",
       "  '4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid',\n",
       "  '4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid',\n",
       "  'Frusemide',\n",
       "  'Furosemid',\n",
       "  'Furosemida',\n",
       "  'Furosemide',\n",
       "  'Furosemidu',\n",
       "  'Furosemidum',\n",
       "  'Furosemide'],\n",
       " 'Ergotamine': [\"(5'Î±)-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione\",\n",
       "  \"12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione\",\n",
       "  \"12'-hydroxy-2'-methyl-5'Î±-(phenylmethyl)ergotaman-3',6',18-trione\",\n",
       "  'Ergotamin',\n",
       "  'Ergotamina',\n",
       "  'Ergotamine',\n",
       "  'Ergotaminum',\n",
       "  'Ergotamine'],\n",
       " 'Tizanidine': ['5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole',\n",
       "  'Tizanidin',\n",
       "  'Tizanidina',\n",
       "  'Tizanidine',\n",
       "  'Tizanidinum',\n",
       "  'Tizanidine'],\n",
       " 'Nitrofurantoin': ['1-((5-nitro-2-furanyl)methylene)amino-2,4-imidazolidenedione',\n",
       "  '1-((5-nitrofurfurylidene)amino)hydantoin',\n",
       "  '5-Nitrofurantoin',\n",
       "  'N-(5-Nitrofurfurylidene)-1-aminohydantoin',\n",
       "  'Nitrofurantoin',\n",
       "  'Nitrofurantoin anhydrous',\n",
       "  'Nitrofurantoin macrocrystal',\n",
       "  'Nitrofurantoin macrocrystalline',\n",
       "  'Nitrofurantoin, macrocrystalline',\n",
       "  'Nitrofurantoin, macrocrystals',\n",
       "  'nitrofurantoina',\n",
       "  'nitrofurantoine',\n",
       "  'nitrofurantoinum',\n",
       "  'Nitrofurantoinum anhydrous',\n",
       "  'Nitrofurantoin'],\n",
       " 'Nicergoline': ['(8Î²)-10-methoxy-1,6-dimethylergoline-8-methanol 5-bromo-3-pyridinecarboxylate (ester)',\n",
       "  '10-methoxy-1,6-dimethylergoline-8Î²-methanol 5-bromonicotinate',\n",
       "  'Nicergolin',\n",
       "  'Nicergolina',\n",
       "  'Nicergoline',\n",
       "  'Nicergolinum',\n",
       "  'Nicergoline'],\n",
       " 'Eplerenone': ['Eplerenona', 'Eplerenone', 'Epoxymexrenone', 'Eplerenone'],\n",
       " 'Amprenavir': ['(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate',\n",
       "  'Amprenavir',\n",
       "  'AmprÃ©navir',\n",
       "  'Amprenavirum',\n",
       "  'Amprenavir'],\n",
       " 'Icodextrin': ['Icodextrin',\n",
       "  'Icodextrina',\n",
       "  'Icodextrine',\n",
       "  'Icodextrinum',\n",
       "  'Icodextrin'],\n",
       " 'Methazolamide': ['Metazolamida',\n",
       "  'Methazolamid',\n",
       "  'Methazolamide',\n",
       "  'MÃ©thazolamide',\n",
       "  'Methazolamidum',\n",
       "  'Methenamide',\n",
       "  'Neptazaneat',\n",
       "  'Methazolamide'],\n",
       " 'Naltrexone': ['17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one',\n",
       "  '17-(Cyclopropylmethyl)-4,5Î±-epoxy-3,14-dihydroxymorphinan-6-one',\n",
       "  'N-Cyclopropylmethyl-14-hydroxydihydromorphinone',\n",
       "  'N-Cyclopropylmethylnoroxymorphone',\n",
       "  'Naltrexon',\n",
       "  'Naltrexona',\n",
       "  'Naltrexone',\n",
       "  'Naltrexonum',\n",
       "  'Naltrexone'],\n",
       " 'Delavirdine': ['(N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide)',\n",
       "  '1-(3-((1-methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine',\n",
       "  '2-(4-(5-methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine',\n",
       "  'Delavirdin',\n",
       "  'Delavirdina',\n",
       "  'Delavirdine',\n",
       "  'Delavirdinum',\n",
       "  'N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide',\n",
       "  'N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide',\n",
       "  'Delavirdine'],\n",
       " 'Tamsulosin': ['(â\\x88\\x92)-tamsulosin',\n",
       "  '(R)-(â\\x88\\x92)-tamsulosin',\n",
       "  '(R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide',\n",
       "  'Tamsulosin',\n",
       "  'Tamsulosina',\n",
       "  'Tamsulosine',\n",
       "  'Tamsulosinum',\n",
       "  'Tamsulosin'],\n",
       " 'Porfimer sodium': ['Porfimer natrium',\n",
       "  'Porfimer sodico',\n",
       "  'Porfimer sodium',\n",
       "  'PorfimÃ¨re sodique',\n",
       "  'Porfimerum natricum',\n",
       "  'Porfimer sodium'],\n",
       " 'Sufentanil': ['N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide',\n",
       "  'N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide',\n",
       "  'Sufentanil',\n",
       "  'Sufentanilo',\n",
       "  'Sufentanilum',\n",
       "  'Sufentanyl',\n",
       "  'Sufentanil'],\n",
       " 'Lamivudine': ['(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine',\n",
       "  \"(-)-2'-Deoxy-3'-thiacytidine\",\n",
       "  \"2',3'-Dideoxy-3'-thiacytidine\",\n",
       "  \"3'-Thia-2',3'-dideoxycytidine\",\n",
       "  '3TC',\n",
       "  \"beta-L-2',3'-Dideoxy-3'-thiacytidine\",\n",
       "  \"beta-L-3'-Thia-2',3'-dideoxycytidine\",\n",
       "  'Lamivudin',\n",
       "  'Lamivudina',\n",
       "  'Lamivudine',\n",
       "  'Lamivudinum',\n",
       "  'Lamivudine'],\n",
       " 'Ibandronate': ['Ã¡cido ibandrÃ³nico', 'Ibandronic acid', 'Ibandronate'],\n",
       " 'Diethylcarbamazine': ['Diethylcarbamazin',\n",
       "  'DiÃ©thylcarbamazine',\n",
       "  'Diethylcarbamazine',\n",
       "  'Diethylcarbamazinum',\n",
       "  'Dietilcarbamazina',\n",
       "  'Diethylcarbamazine'],\n",
       " 'Flurbiprofen': ['(Â±)-2-fluoro-Î±-methyl-4-biphenylacetic acid',\n",
       "  '2-(2-fluorobiphenyl-4-yl)propanoic acid',\n",
       "  \"2-fluoro-Î±-methyl-(1,1'-biphenyl)-4-acetic acid\",\n",
       "  '3-fluoro-4-phenylhydratropic acid',\n",
       "  'Flurbiprofen',\n",
       "  'Flurbiprofene',\n",
       "  'Flurbiprofeno',\n",
       "  'Flurbiprofenum',\n",
       "  'Flurbiprofen'],\n",
       " 'Oxacillin': ['(2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  '(5-methyl-3-phenyl-4-isoxazolyl)penicillin',\n",
       "  '5-methyl-3-phenyl-4-isoxazolyl-penicillin',\n",
       "  '6Î²-(5-methyl-3-phenylisoxazol-4-yl)penicillanic acid',\n",
       "  'Ossacillina',\n",
       "  'Oxacilina',\n",
       "  'Oxacillin',\n",
       "  'Oxacilline',\n",
       "  'Oxacillinum',\n",
       "  'Oxazocillin',\n",
       "  'Oxazocilline',\n",
       "  'Oxacillin'],\n",
       " 'Apomorphine': ['(â\\x88\\x92)-10,11-dihydroxyaporphine',\n",
       "  '(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol',\n",
       "  '(R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol',\n",
       "  'Apomorfina',\n",
       "  'Apomorphin',\n",
       "  'Apomorphine',\n",
       "  'R-(â\\x88\\x92)-apomorphine',\n",
       "  'Apomorphine'],\n",
       " 'Paroxetine': ['(â\\x88\\x92)-(3S,4R)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine',\n",
       "  '(3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine',\n",
       "  'Paroxetina',\n",
       "  'Paroxetine',\n",
       "  'Paroxetinum',\n",
       "  'Paroxetine'],\n",
       " 'Nedocromil': ['9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)chinolin-2,8-dicarbonsÃ¤ure',\n",
       "  '9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid',\n",
       "  'NÃ©docromil',\n",
       "  'Nedocromil',\n",
       "  'Nedocromilo',\n",
       "  'Nedocromilum',\n",
       "  'Nedocromil'],\n",
       " 'Norethisterone': ['(17alpha)-17-ethynyl-17-hydroxyestra-4,8(14),9-trien-3-one',\n",
       "  '17-hydroxy-19-nor-17-Î±-pregn-4-en-20-yn-3-one',\n",
       "  '17-hydroxy-19-nor-17Î±-pregn-4-en-20-yn-3-one',\n",
       "  '17-Î±-ethynyl-17-hydroxy-4-estren-3-one',\n",
       "  '17-Î±-ethynyl-19-norandrost-4-en-17-Î²-ol-3-one',\n",
       "  '17-Î±-ethynyl-19-nortestosterone',\n",
       "  '17-Î±-ethynyl-4-estren-17-ol-3-one',\n",
       "  '17-Î²-hydroxy-19-norpregn-4-en-20-yn-3-one',\n",
       "  '17Î±-ethinyl-19-nortestosterone',\n",
       "  '17Î±-ethinylestra-4-en-17Î²-ol-3-one',\n",
       "  '17Î±-ethynyl-17-hydroxy-4-estren-3-one',\n",
       "  '17Î±-ethynyl-17Î²-hydroxy-19-norandrost-4-en-3-one',\n",
       "  '17Î±-ethynyl-19-nor-4-androsten-17Î²-ol-3-one',\n",
       "  '17Î±-ethynyl-19-norandrost-4-en-17Î²-ol-3-one',\n",
       "  '17Î±-ethynyl-19-nortestosterone',\n",
       "  '17Î±-ethynyl-4-estren-17-ol-3-one',\n",
       "  '17Î²-hydroxy-19-norpregn-4-en-20-yn-3-one',\n",
       "  '19-nor-17-Î±-ethynyl-17-Î²-hydroxy-4-androsten-3-one',\n",
       "  '19-nor-17-Î±-ethynylandrosten-17-Î²-ol-3-one',\n",
       "  '19-nor-17-Î±-ethynyltestosterone',\n",
       "  '19-Nor-17alpha-ethynyl-17beta-hydroxy-4-androsten-3-one',\n",
       "  '19-nor-17Î±-ethynyl-17Î²-hydroxy-4-androsten-3-one',\n",
       "  '19-nor-17Î±-ethynylandrosten-17Î²-ol-3-one',\n",
       "  '19-nor-17Î±-ethynyltestosterone',\n",
       "  '19-nor-ethindrone',\n",
       "  '19-norethisterone',\n",
       "  '4-estren-17Î±-ethynyl-17Î²-ol-3-one',\n",
       "  'Norethindrone',\n",
       "  'Norethisteron',\n",
       "  'NorÃ©thistÃ©rone',\n",
       "  'Norethisterone',\n",
       "  'Norethisteronum',\n",
       "  'Noretisterona',\n",
       "  'Norethisterone'],\n",
       " 'Adefovir dipivoxil': ['Adefovir di(pivaloyloxymethyl) ester',\n",
       "  'Adefovir dipivoxil',\n",
       "  'Adefovir pivoxil',\n",
       "  'bis-POM PMEA',\n",
       "  'Adefovir dipivoxil'],\n",
       " 'Azatadine': ['11-(1-Methyl-4-piperidinylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine',\n",
       "  '6,11-Dihydro-11-(1-methyl-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine',\n",
       "  'Azatadin',\n",
       "  'Azatadina',\n",
       "  'Azatadine',\n",
       "  'Azatadinum',\n",
       "  'Azatadine'],\n",
       " 'Clodronic acid': ['(Dichloro-phosphono-methyl)-phosphonic acid',\n",
       "  '(dichloromethylene)bisphosphonic acid',\n",
       "  '(dichloromethylene)diphosphonic acid',\n",
       "  'Acide clodronique',\n",
       "  'Acido clodronico',\n",
       "  'Acidum clodronicum',\n",
       "  'Clodronate',\n",
       "  'Clodronic acid',\n",
       "  'Clodronsaeure',\n",
       "  'ClodronsÃ¤ure',\n",
       "  'dichloromethylene-1,1-bisphosphonic acid',\n",
       "  'dichloromethylene-1,1-diphosphonic acid',\n",
       "  'Dichloromethylidene diphosphonate',\n",
       "  'Clodronic acid'],\n",
       " 'Procaine': ['2-Diethylaminoethyl p-aminobenzoate',\n",
       "  '4-aminobenzoic acid 2-diethylaminoethyl ester',\n",
       "  'Novocaine',\n",
       "  'p-Aminobenzoic acid 2-diethylaminoethyl ester',\n",
       "  'Procaina',\n",
       "  'Procaine',\n",
       "  'Procainum',\n",
       "  'Vitamin H3',\n",
       "  'Î²-(diethylamino)ethyl 4-aminobenzoate',\n",
       "  'Î²-(diethylamino)ethyl p-aminobenzoate',\n",
       "  'Procaine'],\n",
       " 'Lisinopril': ['(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline',\n",
       "  '[N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline',\n",
       "  'Lisinopril',\n",
       "  'Lisinopril anhydrous',\n",
       "  'Lisinoprilum',\n",
       "  'Lisinopril'],\n",
       " 'Methoxamine': ['MÃ©thoxamÃ©drine',\n",
       "  'Methoxamin',\n",
       "  'MÃ©thoxamine',\n",
       "  'Methoxaminum',\n",
       "  'Metossamina',\n",
       "  'Metoxamina',\n",
       "  'Pseudomethoxamine',\n",
       "  'Methoxamine'],\n",
       " 'Imiquimod': ['1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine',\n",
       "  '4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline',\n",
       "  'Imiquimod',\n",
       "  'Imiquimodum',\n",
       "  'Imiquimod'],\n",
       " 'Homatropine methylbromide': ['3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide mandelate',\n",
       "  '8-Methylhomatropinium bromide',\n",
       "  'Homatropine methylbromide',\n",
       "  'Homatropini methylbromidum',\n",
       "  \"MÃ©thylbromure d'homatropine\",\n",
       "  'Methylhomatropine',\n",
       "  'Methylhomatropine bromide',\n",
       "  'Methylhomatropinum bromatum',\n",
       "  'Metilbromuro de homatropina',\n",
       "  'Omatropina metilbromuro',\n",
       "  'Tropinium methobromide mandelate',\n",
       "  'Homatropine methylbromide'],\n",
       " 'Trimipramine': ['10,11-dihydro-N,N,Î²-trimethyl-5H-dibenz[b,f]azepine-5-propanamine',\n",
       "  '5-(Î³-dimethylamino-Î²-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine',\n",
       "  '5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine',\n",
       "  'beta-Methylimipramine',\n",
       "  'Trimeprimina',\n",
       "  'Trimeprimine',\n",
       "  'Trimeproprimine',\n",
       "  'Trimipramina',\n",
       "  'Trimipramine',\n",
       "  'Trimipraminum',\n",
       "  'Î²-methylimipramine',\n",
       "  'Trimipramine'],\n",
       " 'Nitroglycerin': ['1,2,3-propanetrioltrinitrate',\n",
       "  '1,2,3-propanetriyl nitrate',\n",
       "  'Glycerin trinitrate',\n",
       "  'Glycerol trinitrate',\n",
       "  'Glycerol, nitric acid triester',\n",
       "  'Glyceroli trinitratis',\n",
       "  'Glyceroltrinitrat',\n",
       "  'Glyceryl trinitrate',\n",
       "  'NG',\n",
       "  'Nitroglicerina',\n",
       "  'Nitroglycerin',\n",
       "  'Nitroglycerine',\n",
       "  'Nitroglycerol',\n",
       "  'Nitromed',\n",
       "  'Propane-1,2,3-triyl trinitrate',\n",
       "  'Trinitrine',\n",
       "  'Trinitroglycerin',\n",
       "  'Trinitroglycerol',\n",
       "  'Nitroglycerin'],\n",
       " 'Rocuronium': ['Rocuronio', 'Rocuronium', 'Rocuronium'],\n",
       " 'Thiabendazole': ['2-(1,3-thiazole-4-yl)-1H-benzimidazole',\n",
       "  '2-(4-thiazolyl)-1H-benzimidazole',\n",
       "  '2-(thiazol-4-yl)benzimidazole',\n",
       "  '4-(2-benzimidazolyl)thiazole',\n",
       "  'TBDZ',\n",
       "  'Thiabendazole',\n",
       "  'Tiabendazol',\n",
       "  'Tiabendazole',\n",
       "  'Tiabendazolum',\n",
       "  'Thiabendazole'],\n",
       " 'Nateglinide': ['Nateglinida',\n",
       "  'NatÃ©glinide',\n",
       "  'Nateglinide',\n",
       "  'Nateglinidum',\n",
       "  'Nateglinide'],\n",
       " 'Atracurium besylate': ['Atracurium besilate',\n",
       "  'Atracurium besylate',\n",
       "  'Atracurium dibesylate',\n",
       "  \"Besilate d'atracurium\",\n",
       "  'Besilato de atracurio',\n",
       "  'Atracurium besylate'],\n",
       " 'Pralidoxime': ['2-PAM',\n",
       "  'Pralidoxim',\n",
       "  'Pralidoxima',\n",
       "  'Pralidoxime',\n",
       "  'Pralidoximum',\n",
       "  'Pralidoxime'],\n",
       " 'Risperidone': ['Risperidona',\n",
       "  'Risperidone',\n",
       "  'RispÃ©ridone',\n",
       "  'Risperidonum',\n",
       "  'Risperidone'],\n",
       " 'Naftifine': ['Naftifin',\n",
       "  'Naftifina',\n",
       "  'Naftifine',\n",
       "  'Naftifinum',\n",
       "  'Naftifine'],\n",
       " 'Esomeprazole': ['(â\\x88\\x92)-omeprazole',\n",
       "  '(S)-(â\\x88\\x92)-omeprazole',\n",
       "  '(S)-omeprazole',\n",
       "  'Esomeprazol',\n",
       "  'Ã\\x89somÃ©prazole',\n",
       "  'Esomeprazole',\n",
       "  'Esomeprazolum',\n",
       "  'Omeprazole S-form',\n",
       "  'Perprazole',\n",
       "  'Esomeprazole'],\n",
       " 'Meclizine': ['Meclizine', 'Meclozina', 'Meclozine', 'Meclizine'],\n",
       " 'Pentamidine': ['1,5-bis(4-amidinophenoxy)pentane',\n",
       "  \"4,4'-(1,5-pentanediylbis(oxy))bis-benzenecarboximidamide\",\n",
       "  \"4,4'-(pentamethylenedioxy)dibenzamidine\",\n",
       "  \"4,4'-Diamidinodiphenoxypentane\",\n",
       "  \"p,p'-(pentamethylenedioxy)dibenzamidine\",\n",
       "  'Pentamidin',\n",
       "  'Pentamidina',\n",
       "  'Pentamidine',\n",
       "  'Pentamidinum',\n",
       "  'Pentamidine'],\n",
       " 'Hetacillin': ['(2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  '6Î²-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]penicillanic acid',\n",
       "  'Hetacilina',\n",
       "  'Hetacillin',\n",
       "  'HÃ©tacilline',\n",
       "  'Hetacillinum',\n",
       "  'Hetacillin'],\n",
       " 'Riluzole': ['Riluzol', 'Riluzole', 'Riluzolum', 'Riluzole'],\n",
       " 'Hydrocortisone': ['(11Î²)-11,17,21-trihydroxypregn-4-ene-3,20-dione',\n",
       "  '11beta-hydrocortisone',\n",
       "  '11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione',\n",
       "  '11Î²-hydrocortisone',\n",
       "  '17-Hydroxycorticosterone',\n",
       "  '4-pregnen-11Î²,17Î±,21-triol-3,20-dione',\n",
       "  'Cortisol',\n",
       "  'Hidrocortisona',\n",
       "  'Hydrocortisone',\n",
       "  'Hydrocortisonum',\n",
       "  \"Kendall's compound F\",\n",
       "  \"Reichstein's substance M\",\n",
       "  'Hydrocortisone'],\n",
       " 'Mannitol': ['(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexaol',\n",
       "  '(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol',\n",
       "  'D-(-)-Mannitol',\n",
       "  'D-Mannitol',\n",
       "  'Manitol',\n",
       "  'Manna Sugar',\n",
       "  'Mannit',\n",
       "  'Mannite',\n",
       "  'Mannitol',\n",
       "  'Mannitolum',\n",
       "  'Mannitol'],\n",
       " 'Gadobenic acid': ['Acide gadobenique',\n",
       "  'Acido gadobenico',\n",
       "  'Acidum gadobenicum',\n",
       "  'Gadobenate',\n",
       "  'Gadobenic acid',\n",
       "  'GadobensÃ¤ure',\n",
       "  'Gadobenic acid'],\n",
       " 'Zileuton': ['(Â±)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea',\n",
       "  'Leutrol',\n",
       "  'N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea',\n",
       "  'N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea',\n",
       "  'Zileuton',\n",
       "  'ZileutÃ³n',\n",
       "  'Zileutonum',\n",
       "  'Zileuton'],\n",
       " 'Modafinil': ['2-((diphenylmethyl)sulfinyl)acetamide',\n",
       "  'Modafinil',\n",
       "  'Modafinilo',\n",
       "  'Modafinilum',\n",
       "  'Modafinil'],\n",
       " 'Deferoxamine': ['Deferoxamin',\n",
       "  'Deferoxamina',\n",
       "  'DÃ©feroxamine',\n",
       "  'Deferoxamine',\n",
       "  'Deferoxaminum',\n",
       "  'Deferrioxamine',\n",
       "  'Deferrioxamine B',\n",
       "  'Desferrioxamine',\n",
       "  'DFO',\n",
       "  'DFOA',\n",
       "  'DFOM',\n",
       "  'Deferoxamine'],\n",
       " 'Scopolamine': ['(-)-hyoscine',\n",
       "  '(-)-scopolamine',\n",
       "  '(1S,3S,5R,6R,7S)-6,7-Epoxytropan-3-yl (2S)-3-hydroxy-2-phenylpropanoate',\n",
       "  '6-beta,7-beta-Epoxy-3-alpha-tropanyl S-(-)-tropate',\n",
       "  '6,7-Epoxytropine tropate',\n",
       "  'alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester',\n",
       "  'Hyoscine',\n",
       "  'scopine (-)-tropate',\n",
       "  'scopine (â\\x88\\x92)-tropate',\n",
       "  'Scopolamine hydrobromide',\n",
       "  'Scopolamine'],\n",
       " 'Carbinoxamine': ['(Â±)-carbinoxamine',\n",
       "  '{2-[(4-Chloro-phenyl)-pyridin-2-yl-methoxy]-ethyl}-dimethyl-amine',\n",
       "  '2-(p-chloro-Î±-(2-(dimethylamino)ethoxy)benzyl)pyridine',\n",
       "  'Carbinoxamin',\n",
       "  'Carbinoxamina',\n",
       "  'Carbinoxamine',\n",
       "  'Carbinoxamine base',\n",
       "  'Carbinoxaminum',\n",
       "  'Paracarbinoxamine',\n",
       "  'Carbinoxamine'],\n",
       " 'Etodolac': ['(Â±)-1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid',\n",
       "  '(1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid',\n",
       "  '1,3,4,9-tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid',\n",
       "  '1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid',\n",
       "  '1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid',\n",
       "  'Ã\\x89todolac',\n",
       "  'Etodolac',\n",
       "  'Etodolaco',\n",
       "  'Etodolacum',\n",
       "  'Etodolic acid',\n",
       "  'EtodolsÃ¤ure',\n",
       "  'Etodolac'],\n",
       " 'Prilocaine': ['2-(Propylamino)-o-propionotoluidide',\n",
       "  '2-Methyl-alpha-propylaminopropionanilide',\n",
       "  'alpha-n-Propylamino-2-methylpropionanilide',\n",
       "  'N-(2-Methylphenyl)-2-(propylamino)propanamide',\n",
       "  'o-Methyl-2-propylaminopropionanilide',\n",
       "  'o-Methyl-alpha-propylaminopropionanilide',\n",
       "  'Prilocain',\n",
       "  'Prilocaina',\n",
       "  'PrilocaÃ¯ne',\n",
       "  'Prilocaine',\n",
       "  'Prilocaine base',\n",
       "  'Prilocainum',\n",
       "  'Propitocaine',\n",
       "  'Prilocaine'],\n",
       " 'Epinastine': ['(Â±)-epinastine',\n",
       "  '3-amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine',\n",
       "  'Epinastin',\n",
       "  'Epinastina',\n",
       "  'Epinastine',\n",
       "  'Ã©pinastine',\n",
       "  'Epinastinum',\n",
       "  'Epinastine'],\n",
       " 'Tranylcypromine': ['(Â±)-trans-2-phenylcyclopropylamine',\n",
       "  '(1R*,2S*)-2-phenylcyclopropan-1-amine',\n",
       "  'dl-tranylcypromine',\n",
       "  'Racemic Tranylcypromine',\n",
       "  'Tranilcipromina',\n",
       "  'trans-2-phenylcyclopropylamine',\n",
       "  'trans-DL-2-Phenylcyclopropylamine',\n",
       "  'Transamine',\n",
       "  'Tranylcypromin',\n",
       "  'Tranylcypromine',\n",
       "  'Tranylcyprominum',\n",
       "  'Tranylcypromine'],\n",
       " 'Isoflurane': ['1-chloro-2,2,2-trifluoroethyl difluoromethyl ether',\n",
       "  'Isoflurane',\n",
       "  'Isoflurano',\n",
       "  'Isofluranum',\n",
       "  'Isoflurane'],\n",
       " 'Ethotoin': ['(Â±)-3-ethyl-5-phenylhydantoin',\n",
       "  '1-ethyl-2,5-dioxo-4-phenylimidazolidine',\n",
       "  '3-ethyl-5-phenyl-2,4-imidazolidinedione',\n",
       "  '3-Ethyl-5-phenyl-imidazolidine-2,4-dione',\n",
       "  '3-ethyl-5-phenylhydantoin',\n",
       "  '3-ethyl-5-phenylimidazolidin-2,4-dione',\n",
       "  'Ethotoin',\n",
       "  'EthotoÃ¯ne',\n",
       "  'Ethotoinum',\n",
       "  'Etotoina',\n",
       "  'Ethotoin'],\n",
       " 'Tretinoin': ['(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid',\n",
       "  '3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL)',\n",
       "  'Acide retinoique',\n",
       "  'all trans Retinoic acid',\n",
       "  'all trans-Retinoic acid',\n",
       "  'all-(E)-Retinoic acid',\n",
       "  'all-trans-beta-Retinoic acid',\n",
       "  'all-trans-Retinoic acid',\n",
       "  'all-trans-Tretinoin',\n",
       "  'all-trans-Vitamin A acid',\n",
       "  'all-trans-Vitamin A1 acid',\n",
       "  'ATRA',\n",
       "  'beta-Retinoic acid',\n",
       "  'Retinoic acid',\n",
       "  'Retionic acid',\n",
       "  'trans-Retinoic acid',\n",
       "  'Tretin M',\n",
       "  'Tretinoin',\n",
       "  'Tretinoina',\n",
       "  'TrÃ©tinoÃ¯ne',\n",
       "  'Tretinoinum',\n",
       "  'Vitamin A acid',\n",
       "  'Tretinoin'],\n",
       " 'Hexachlorophene': [\"2,2'-dihydroxy-3,3',5,5',6,6'-hexachlorodiphenylmethane\",\n",
       "  \"2,2'-dihydroxy-3,5,6,3',5',6'-hexachlorodiphenylmethane\",\n",
       "  \"2,2'-methanediylbis(3,4,6-trichlorophenol)\",\n",
       "  \"2,2'-methylenebis(3,4,6-trichlorophenol)\",\n",
       "  \"2,2',3,3',5,5'-hexachloro-6,6'-dihydroxydiphenylmethane\",\n",
       "  'bis(2-hydroxy-3,5,6-trichlorophenyl)methane',\n",
       "  'bis(3,5,6-trichloro-2-hydroxyphenyl)methane',\n",
       "  'hexachlorophÃ¨ne',\n",
       "  'Hexachlorophene',\n",
       "  'Hexachlorophenum',\n",
       "  'Hexaclorofeno',\n",
       "  'Hexachlorophene'],\n",
       " 'Dolasetron': ['Dolasetron', 'DolasÃ©tron', 'Dolasetronum', 'Dolasetron'],\n",
       " 'Clopidogrel': ['(+)-Clopidogrel',\n",
       "  'Clopidogrel',\n",
       "  'Clopidogrelum',\n",
       "  'Clopidogrel'],\n",
       " 'Tetracycline': ['(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide',\n",
       "  'Abramycin',\n",
       "  'Anhydrotetracycline',\n",
       "  'Deschlorobiomycin',\n",
       "  'Tetracyclin',\n",
       "  'TÃ©tracycline',\n",
       "  'Tetracycline',\n",
       "  'Tetracyclinum',\n",
       "  'Tetrazyklin',\n",
       "  'Tsiklomitsin',\n",
       "  'Tetracycline'],\n",
       " 'Meropenem': ['(4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid',\n",
       "  'Meropenem',\n",
       "  'Meropenem anhydrous',\n",
       "  'Meropenemum',\n",
       "  'Meropenem'],\n",
       " 'Potassium chloride': ['Chlorid draselny',\n",
       "  'Chloride of potash',\n",
       "  'Kaliumchlorid',\n",
       "  'KCl',\n",
       "  'Monopotassium chloride',\n",
       "  'Muriate of potash',\n",
       "  'Sylvite',\n",
       "  'Potassium chloride'],\n",
       " 'Irinotecan': ['(+)-Irinotecan',\n",
       "  'Irinotecan',\n",
       "  'Irinotecan lactone',\n",
       "  'Irinotecanum',\n",
       "  'Irinotecan'],\n",
       " 'Methimazole': ['1-Methylimidazole-2(3H)-thione',\n",
       "  'Methimazole',\n",
       "  'Thiamazol',\n",
       "  'Thiamazole',\n",
       "  'Thiamazolum',\n",
       "  'Tiamazol',\n",
       "  'Methimazole'],\n",
       " 'Mometasone': ['(+)-Mometasone',\n",
       "  'Mometason',\n",
       "  'Mometasona',\n",
       "  'MomÃ©tasone',\n",
       "  'Mometasone',\n",
       "  'Mometasonum',\n",
       "  'Mometasone'],\n",
       " 'Metyrosine': ['(-)-alpha-Methyl-L-tyrosine',\n",
       "  '(â\\x80\\x93)-Î±-methyl-L-tyrosine',\n",
       "  '(S)-alpha-Methyltyrosine',\n",
       "  'Methyltyrosine',\n",
       "  'Metirosin',\n",
       "  'Metirosina',\n",
       "  'MÃ©tirosine',\n",
       "  'Metirosine',\n",
       "  'Metirosinum',\n",
       "  'Metyrosine',\n",
       "  'Î±-methyl-L-p-tyrosine',\n",
       "  'Î±-methyl-p-tyrosine',\n",
       "  'Î±-methyl-para-tyrosine',\n",
       "  'Î±-MPT',\n",
       "  'Metyrosine'],\n",
       " 'Clavulanic acid': ['(Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid',\n",
       "  'Acide clavulanique',\n",
       "  'Ã¡cido clavulÃ¡nico',\n",
       "  'Acidum clavulanicum',\n",
       "  'Clavulanate',\n",
       "  'Clavulanic acid',\n",
       "  'ClavulansÃ¤ure',\n",
       "  'Clavulanic acid'],\n",
       " 'Benzquinamide': ['benzquinamida', 'BZQ', 'Benzquinamide'],\n",
       " 'Olopatadine': ['Olopatadin',\n",
       "  'Olopatadina',\n",
       "  'Olopatadine',\n",
       "  'Olopatadinum',\n",
       "  'Olopatadine'],\n",
       " 'Hydrocortamate': ['17-Hydroxycorticosterone, 21-(diethylamino)acetate',\n",
       "  'Hidrocortamato',\n",
       "  'Hydrocortamate',\n",
       "  'Hydrocortamatum',\n",
       "  'Hydrocortamate'],\n",
       " 'Alprostadil': ['(11Î±,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid',\n",
       "  '(13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate',\n",
       "  '11Î±,15Î±-dihydroxy-9-oxo-13-trans-prostenoic acid',\n",
       "  'Alprostadil',\n",
       "  'Alprostadilum',\n",
       "  'PGE-1',\n",
       "  'PGE1',\n",
       "  'Prostaglandin E1',\n",
       "  'Alprostadil'],\n",
       " 'Clidinium': ['3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[2.2.2]octane',\n",
       "  '3-hydroxy-1-methylquinuclidinium benzilate ester',\n",
       "  'Bromure de Clidinium',\n",
       "  'Bromuro de clidinio',\n",
       "  'Clidinii Bromidum',\n",
       "  'Clidinium bromid',\n",
       "  'N-methyl quinuclidinyl benzilate',\n",
       "  'Clidinium'],\n",
       " 'Malathion': ['[(dimethoxyphosphinothioyl)thio]butanedioic acid diethyl ester',\n",
       "  'Carbophos',\n",
       "  'diethyl (dimethoxyphosphinothioylthio)succinate',\n",
       "  'Karbofos',\n",
       "  'Maldison',\n",
       "  'Mercaptothion',\n",
       "  'O,O-dimethyl S-(1,2-bis(ethoxycarbonyl)ethyl)',\n",
       "  'O,O-dimethyl S-(1,2-dicarbethoxyethyl) dithiophosphate',\n",
       "  'O,O-dimethyl S-(1,2-dicarbethoxyethyl)phosphorodithioate',\n",
       "  'O,O-dimethyl S-1,2-di(ethoxycarbamyl)ethyl',\n",
       "  'O,O-dimethyldithiophosphate diethylmercaptosuccinate',\n",
       "  'Malathion'],\n",
       " 'Etoposide': ['(â\\x88\\x92)-etoposide',\n",
       "  '4-demethylepipodophyllotoxin Î²-D-ethylideneglucoside',\n",
       "  \"4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)\",\n",
       "  \"9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one\",\n",
       "  'Etoposide',\n",
       "  'Etoposido',\n",
       "  'Etoposidum',\n",
       "  'trans-Etoposide',\n",
       "  'Etoposide'],\n",
       " 'Hydroflumethiazide': ['Dihydroflumethazide',\n",
       "  'Hidroflumetiazid',\n",
       "  'Hidroflumetiazida',\n",
       "  'HydroflumÃ©thiazide',\n",
       "  'Hydroflumethiazide',\n",
       "  'Hydroflumethiazidum',\n",
       "  'Idroflumetiazide',\n",
       "  'Metforylthiadiazin',\n",
       "  'Hydroflumethiazide'],\n",
       " 'Tirofiban': ['(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid',\n",
       "  'N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine',\n",
       "  'Tirofiban',\n",
       "  'TirofibÃ¡n',\n",
       "  'Tirofibanum',\n",
       "  'Tirofiban'],\n",
       " 'Oxcarbazepine': ['10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide',\n",
       "  'OCBZ',\n",
       "  'Oxcarbamazepine',\n",
       "  'Oxcarbazepina',\n",
       "  'Oxcarbazepine',\n",
       "  'Oxcarbazepinum',\n",
       "  'Oxcarbazepine'],\n",
       " 'Propiomazine': ['10-(2-Dimethylaminopropyl)-2-propionylphenothiazine',\n",
       "  '2-Propionyl-10-(2-(dimethylamino)propyl)phenothiazine',\n",
       "  '3-Propionyl-10-dimethylaminoisopropylphenothiazine',\n",
       "  'Propiomazin',\n",
       "  'Propiomazina',\n",
       "  'Propiomazine',\n",
       "  'Propiomazinum',\n",
       "  'Propiomazine'],\n",
       " 'Roxithromycin': ['(9E)-erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime)',\n",
       "  'Roxithromycin',\n",
       "  'Roxithromycine',\n",
       "  'Roxithromycinum',\n",
       "  'Roxitromicina',\n",
       "  'Roxithromycin'],\n",
       " 'Nalidixic acid': ['1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure',\n",
       "  '1-ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid',\n",
       "  '1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid',\n",
       "  '1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid',\n",
       "  '1,4-dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid',\n",
       "  '3-carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one',\n",
       "  'Acide nalidixique',\n",
       "  'Acido nalidixico',\n",
       "  'Acidum nalidixicum',\n",
       "  'Nalidixic acid',\n",
       "  'NalidixinsÃ¤ure',\n",
       "  'Nalidixic acid'],\n",
       " 'Phenelzine': ['Fenelzina',\n",
       "  'Phenelzin',\n",
       "  'Phenelzine',\n",
       "  'PhÃ©nelzine',\n",
       "  'Phenelzinum',\n",
       "  'Phenelzine'],\n",
       " 'Propantheline': ['Propantheline', 'Propantheline'],\n",
       " 'Estradiol': ['(17Î²)-estra-1,3,5(10)-triene-3,17-diol',\n",
       "  '17beta oestradiol',\n",
       "  '17Î²-estra-1,3,5(10)-triene-3,17-diol',\n",
       "  '17Î²-estradiol',\n",
       "  '17Î²-oestradiol',\n",
       "  'beta-Estradiol',\n",
       "  'cis-Estradiol',\n",
       "  'Estradiol',\n",
       "  'Estradiol-17beta',\n",
       "  'Estradiolum',\n",
       "  'Estradiol'],\n",
       " 'Mefenamic acid': ['Acide mÃ©fÃ©namique',\n",
       "  'Ã¡cido mefenÃ¡mico',\n",
       "  'Acidum mefenamicum',\n",
       "  'Mefenamic acid',\n",
       "  'MefenaminsÃ¤ure',\n",
       "  'N-(2,3-xylyl)-2-aminobenzoic acid',\n",
       "  'N-2,3-xylylanthranilic acid',\n",
       "  'Mefenamic acid'],\n",
       " 'Cryptenamine': ['Cryptenamine'],\n",
       " 'Marimastat': ['Marimastat', 'Marimastat'],\n",
       " 'Acyclovir': ['Aciclovir',\n",
       "  'Aciclovirum',\n",
       "  'Acycloguanosine',\n",
       "  'Acyclovir',\n",
       "  'Acyclovir'],\n",
       " 'Naproxen': ['(+)-(S)-6-Methoxy-Î±-methyl-2-naphthaleneacetic acid',\n",
       "  '(+)-(S)-Naproxen',\n",
       "  '(+)-2-(6-Methoxy-2-naphthyl)propionic acid',\n",
       "  '(+)-2-(Methoxy-2-naphthyl)-propionic acid',\n",
       "  '(+)-2-(Methoxy-2-naphthyl)-propionsÃ¤ure',\n",
       "  '(+)-Naproxen',\n",
       "  '(S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid',\n",
       "  '(S)-(+)-Naproxen',\n",
       "  '(S)-2-(6-Methoxy-2-naphthyl)propanoic acid',\n",
       "  '(S)-2-(6-Methoxy-2-naphthyl)propionic acid',\n",
       "  '(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid',\n",
       "  '(S)-Naproxen',\n",
       "  'Naprolag',\n",
       "  'Naproxen',\n",
       "  'NaproxÃ¨ne',\n",
       "  'Naproxeno',\n",
       "  'Naproxenum',\n",
       "  'Naproxen'],\n",
       " 'Gadopentetic acid': ['Acide gadopentetique',\n",
       "  'Ã¡cido gadopentÃ©tico',\n",
       "  'Acidum gadopenteticum',\n",
       "  'Gadolinium diethylenetriamine pentaacetic acid',\n",
       "  'Gadolinium DTPA',\n",
       "  'Gadopentetate',\n",
       "  'Gadopentetic acid',\n",
       "  'Gadopentetic acid'],\n",
       " 'Perindopril': ['(2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid',\n",
       "  'Perindopril',\n",
       "  'Perindoprilum',\n",
       "  'Perindopril'],\n",
       " 'Uracil mustard': ['5-(di-2-chloroethyl)aminouracil',\n",
       "  '5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione',\n",
       "  '5-[bis(2-chloroethyl)amino]uracil',\n",
       "  '5-[di(Î²-chloroethyl)amino]uracil',\n",
       "  '5-aminouracil mustard',\n",
       "  '5-N,N-bis(2-chloroethyl)aminouracil',\n",
       "  'Aminouracil mustard',\n",
       "  'Uracil mustard',\n",
       "  'Uracil nitrogen mustard',\n",
       "  'Uramustina',\n",
       "  'Uramustine',\n",
       "  'Uramustinum',\n",
       "  'Uracil mustard'],\n",
       " 'Tripelennamine': ['Tripelennamin',\n",
       "  'Tripelennamina',\n",
       "  'Tripelennamine',\n",
       "  'TripÃ©lennamine',\n",
       "  'Tripelennaminum',\n",
       "  'Tripelennamine'],\n",
       " 'Haloprogin': ['Haloprogin',\n",
       "  'Haloprogina',\n",
       "  'Haloprogine',\n",
       "  'Haloproginum',\n",
       "  'Haloprogin'],\n",
       " 'Primidone': ['2-deoxyphenobarbital',\n",
       "  '5-Phenyl-5-ethyl-Hexahydropyrimidine-4,6-dione',\n",
       "  'Primidon',\n",
       "  'Primidona',\n",
       "  'Primidone',\n",
       "  'Primidonum',\n",
       "  'Primidone'],\n",
       " 'Sulfasalazine': ['2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid',\n",
       "  '2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid',\n",
       "  \"4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene\",\n",
       "  '5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid',\n",
       "  '5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid',\n",
       "  '5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid',\n",
       "  'Azopyrin',\n",
       "  'Salazosulfapiridina',\n",
       "  'Salazosulfapyridine',\n",
       "  'Salazosulfapyridinum',\n",
       "  'Salicylazosulfapyridine',\n",
       "  'Sulfasalazin',\n",
       "  'Sulfasalazina',\n",
       "  'Sulfasalazine',\n",
       "  'Sulfasalazinum',\n",
       "  'Sulfasalazine'],\n",
       " 'Candesartan cilexetil': ['Candesartan cilexetil', 'Candesartan cilexetil'],\n",
       " 'Tolazoline': ['2-Benzyl-2-imidazoline',\n",
       "  '2-Benzyl-4,5-imidazoline',\n",
       "  '2-Benzylimidazoline',\n",
       "  '4,5-Dihydro-2-(phenylmethyl)-1H-imidazole',\n",
       "  'Benzazoline',\n",
       "  'Tolazolin',\n",
       "  'Tolazolina',\n",
       "  'Tolazoline',\n",
       "  'Tolazolinum',\n",
       "  'Tolazoline'],\n",
       " 'Gentamicin': ['Gentamicin', 'Gentamicina', 'Gentamicin'],\n",
       " 'Tazarotene': ['Tazarotene',\n",
       "  'TazarotÃ¨ne',\n",
       "  'Tazaroteno',\n",
       "  'Tazarotenum',\n",
       "  'Tazarotene'],\n",
       " 'Fenoldopam': ['FÃ©noldopam', 'Fenoldopam', 'Fenoldopamum', 'Fenoldopam'],\n",
       " 'Halazepam': ['HalazÃ©pam', 'Halazepam', 'Halazepamum', 'Halazepam'],\n",
       " 'Alfentanil': ['Alfentanil',\n",
       "  'Alfentanilo',\n",
       "  'Alfentanilum',\n",
       "  'Alfentanyl',\n",
       "  'N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide',\n",
       "  'Alfentanil'],\n",
       " 'Colistin': ['Colistin',\n",
       "  'Colistina',\n",
       "  'Colistine',\n",
       "  'Colistinum',\n",
       "  'Polymyxin E',\n",
       "  'Colistin'],\n",
       " 'Dicyclomine': ['2-(diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate',\n",
       "  'Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl ester',\n",
       "  'Dicicloverina',\n",
       "  'Dicyclomine',\n",
       "  'Dicycloverin',\n",
       "  'Dicycloverine',\n",
       "  'Dicycloverinum',\n",
       "  'Dicyclomine'],\n",
       " 'Minaprine': ['4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine',\n",
       "  '4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin',\n",
       "  'Minaprina',\n",
       "  'Minaprinum',\n",
       "  'N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine',\n",
       "  'Minaprine'],\n",
       " 'Pentoxifylline': ['Oxpentifylline',\n",
       "  'Pentoxifilina',\n",
       "  'Pentoxifyllin',\n",
       "  'Pentoxifylline',\n",
       "  'Pentoxifyllinum',\n",
       "  'Pentoxifylline'],\n",
       " 'Proparacaine': ['Proximetacaina',\n",
       "  'Proxymetacaine',\n",
       "  'Proxymetacainum',\n",
       "  'Proparacaine'],\n",
       " 'Indapamide': ['Indapamid',\n",
       "  'Indapamida',\n",
       "  'Indapamide',\n",
       "  'Indapamidum',\n",
       "  'Metindamide',\n",
       "  'Indapamide'],\n",
       " 'Tropicamide': ['Tropicamid',\n",
       "  'Tropicamida',\n",
       "  'Tropicamide',\n",
       "  'Tropicamidum',\n",
       "  'Tropicamide'],\n",
       " 'Biperiden': ['1-Bicyclo[2.2.1]hept-5-en-2-yl-1-phenyl-3-piperidin-1-yl-propan-1-ol',\n",
       "  'alpha-5-norbornen-2-yl-alpha-phenyl-1-piperidinepropanol',\n",
       "  'alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol',\n",
       "  'Biperiden',\n",
       "  'Biperidene',\n",
       "  'Biperideno',\n",
       "  'Biperidenum',\n",
       "  'Biperiden'],\n",
       " 'Ribavirin': ['1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide',\n",
       "  '1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide',\n",
       "  'RBV',\n",
       "  'Ribavirin',\n",
       "  'Ribavirina',\n",
       "  'Ribavirine',\n",
       "  'Ribavirinum',\n",
       "  'Tribavirin',\n",
       "  'Ribavirin'],\n",
       " 'Phenylbutazone': ['3,5-Dioxo-1,2-diphenyl-4-n-butylpyrazolidine',\n",
       "  '4-butyl-1,2-diphenyl-pyrazolidine-3,5-dione',\n",
       "  '4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione',\n",
       "  'Fenilbutazona',\n",
       "  'Phenbutazone',\n",
       "  'Phenylbutazon',\n",
       "  'PhÃ©nylbutazone',\n",
       "  'Phenylbutazone',\n",
       "  'Phenylbutazonum',\n",
       "  'Phenylbutazone'],\n",
       " 'Fentanyl': ['1-Phenethyl-4-(N-phenylpropionamido)piperidine',\n",
       "  '1-phenethyl-4-N-propionylanilinopiperidine',\n",
       "  'Fentanil',\n",
       "  'Fentanila',\n",
       "  'Fentanilo',\n",
       "  'Fentanyl',\n",
       "  'Fentanyl CII',\n",
       "  'Fentanylum',\n",
       "  'N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide',\n",
       "  'N-(1-phenethyl-4-piperidyl)propionanilide',\n",
       "  'N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide',\n",
       "  'N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide',\n",
       "  'N-phenethyl-4-(N-propionylanilino)piperidine',\n",
       "  'N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide',\n",
       "  'Phentanyl',\n",
       "  'Fentanyl'],\n",
       " 'Meloxicam': ['MÃ©loxicam', 'Meloxicam', 'Meloxicamum', 'Meloxicam'],\n",
       " 'Sodium lauryl sulfate': ['Laurylsiran sodny',\n",
       "  'NaDS',\n",
       "  'Natrium laurylsulfuricum',\n",
       "  'SDS',\n",
       "  'SLS',\n",
       "  'Sodium dodecyl sulfate',\n",
       "  'Sodium dodecyl sulphate',\n",
       "  'Sodium dodecylsulfate',\n",
       "  'Sodium laurilsulfate',\n",
       "  'Sodium lauryl sulfate',\n",
       "  'Sodium lauryl sulphate',\n",
       "  'Sodium lauryl sulfate'],\n",
       " 'Orciprenaline': ['Metaproterenol',\n",
       "  'Orciprenalina',\n",
       "  'Orciprenaline',\n",
       "  'Orciprenalinum',\n",
       "  'Orciprenaline'],\n",
       " 'Rosoxacin': ['1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid',\n",
       "  'Acrosoxacin',\n",
       "  'Rosoxacin',\n",
       "  'Rosoxacina',\n",
       "  'Rosoxacine',\n",
       "  'Rosoxacino',\n",
       "  'Rosoxacinum',\n",
       "  'Rosoxacin'],\n",
       " 'Propofol': ['2,6-bis(1-methylethyl)phenol',\n",
       "  '2,6-Diisopropylphenol',\n",
       "  'Propofol',\n",
       "  'Propofolum',\n",
       "  'Propofol'],\n",
       " 'Acetazolamide': ['2-acetylamino-1,3,4-thiadiazole-5-sulfonamide',\n",
       "  '5-acetamido-1,3,4-thiadiazole-2-sulfonamide',\n",
       "  '5-acetylamino-1,3,4-thiadiazole-2-sulfonamide',\n",
       "  'Acetazolamid',\n",
       "  'Acetazolamida',\n",
       "  'AcÃ©tazolamide',\n",
       "  'Acetazolamide',\n",
       "  'Acetazolamidum',\n",
       "  'N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide',\n",
       "  'N-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide',\n",
       "  'Acetazolamide'],\n",
       " 'Tadalafil': [\"(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione\",\n",
       "  \"(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione\",\n",
       "  'Tadalafil',\n",
       "  'Tadalafilo',\n",
       "  'Tadalafil'],\n",
       " 'Carprofen': ['(+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid',\n",
       "  '(Â±)-6-chloro-Î±-methylcarbazole-2-acetic acid',\n",
       "  '2-(6-Chloro-9H-carbazol-2-yl)-propionic acid',\n",
       "  '6-chloro-Î±-methyl-9H-carbazole-2-acetic acid',\n",
       "  'Carprofen',\n",
       "  'CarprofÃ¨ne',\n",
       "  'Carprofeno',\n",
       "  'Carprofenum',\n",
       "  'Carprofen'],\n",
       " 'Disulfiram': [\"1,1'-dithiobis(N,N-diethylthioformamide)\",\n",
       "  'bis(diethylthiocarbamoyl) disulfide',\n",
       "  'Disulfiram',\n",
       "  \"N,N,N',N'-tetraethylthiuram disulfide\",\n",
       "  'Tetraethylthioperoxydicarbonic diamide',\n",
       "  'Tetraethylthiuram disulfide',\n",
       "  'Tetraethylthiuram disulphide',\n",
       "  'Disulfiram'],\n",
       " 'Ethynodiol diacetate': ['17Î±-Ethynyl-19-norandrost-4-ene-3Î²,17-beta-diol diacetate',\n",
       "  '17Î±-Ethynyl-3,17-dihydroxy-4-estrene diacetate',\n",
       "  '17Î±-Ethynyl-4-estrene-3Î²,17Î²-diol diacetate',\n",
       "  '17Î±-Ethynylestr-4-ene-3Î²,17Î²-diol acetate',\n",
       "  '19-Nor-17Î±-pregn-4-en-20-yne-3Î²,17-diol diacetate',\n",
       "  '3Î², 17Î²-Diacetoxy-17Î±-ethynyl-4-oestrene',\n",
       "  '3Î²,17Î²-Diacetoxy-19-nor-17Î±-pregn-4-en-20-yne',\n",
       "  'Ethynodiol diacetate',\n",
       "  'Etynodiol acetate',\n",
       "  'Etynodiol diacetate',\n",
       "  'Ethynodiol diacetate'],\n",
       " 'Enprofylline': ['3-n-propylxanthine',\n",
       "  '3-Propyl-3,7-dihydro-purine-2,6-dione',\n",
       "  '3-propylxanthine',\n",
       "  '3,7-dihydro-3-propyl-1H-purine-2,6-dione',\n",
       "  'Enprofilina',\n",
       "  'Enprofylline',\n",
       "  'Enprofyllinum',\n",
       "  'Enprofylline'],\n",
       " 'Levomenthol': ['(-)-Menthol',\n",
       "  '(â\\x88\\x92)-(1R,3R,4S)-menthol',\n",
       "  '(â\\x88\\x92)-menthol',\n",
       "  '(1alpha,2beta,5alpha)-5-methyl-2(1-methylethyl)cyclohexanol',\n",
       "  '(1R-(1-Î±,2-Î²,5-Î±))-5-methyl-2-(1-methylethyl)cyclohexanol',\n",
       "  '(1R,3R,4S)-(â\\x88\\x92)-menthol',\n",
       "  'L-menthol',\n",
       "  'Levomenthol',\n",
       "  'LÃ©vomenthol',\n",
       "  'Levomentholum',\n",
       "  'Levomentol',\n",
       "  'Mentol',\n",
       "  'Levomenthol'],\n",
       " 'Natamycin': ['Natamicina',\n",
       "  'Natamycin',\n",
       "  'Natamycine',\n",
       "  'Natamycinum',\n",
       "  'Pimaracin',\n",
       "  'Pimaricin',\n",
       "  'Natamycin'],\n",
       " 'Cinoxacin': ['1-ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid',\n",
       "  '5-Ethyl-8-oxo-5,8-dihydro-1,3-dioxa-5,6-diaza-cyclopenta[b]naphthalene-7-carboxylic acid',\n",
       "  'Cinoxacin',\n",
       "  'Cinoxacine',\n",
       "  'Cinoxacino',\n",
       "  'Cinoxacinum',\n",
       "  'Cinoxacin'],\n",
       " 'Fosfomycin': ['(-)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid',\n",
       "  '(1R,2S)-epoxypropylphosphonic acid',\n",
       "  '(2R-cis)-(3-Methyloxiranyl)phosphonic acid',\n",
       "  '1R-cis-(1,2-epoxypropyl)phosphonic acid',\n",
       "  'cis-(1R,2S)-epoxypropylphosphonic acid',\n",
       "  'FCM',\n",
       "  'Fosfocina',\n",
       "  'Fosfomicina',\n",
       "  'Fosfomycin',\n",
       "  'Fosfomycine',\n",
       "  'Fosfomycinum',\n",
       "  'L-cis-1,2-epoxypropylphosphonic acid',\n",
       "  'Phosphomycin',\n",
       "  'Phosphonemycin',\n",
       "  'Phosphonomycin',\n",
       "  'Fosfomycin'],\n",
       " 'Diazepam': ['7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one',\n",
       "  'Diazepam',\n",
       "  'Methyl diazepinone',\n",
       "  'Diazepam'],\n",
       " 'Phenmetrazine': ['2-phenyl-3-methylmorpholine',\n",
       "  'Fenmetrazin',\n",
       "  'Fenmetrazina',\n",
       "  'Phenmetrazin',\n",
       "  'Phenmetrazinum',\n",
       "  'Phenmetrazine'],\n",
       " 'Trifluoperazine': ['10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine',\n",
       "  'Trifluoperazina',\n",
       "  'TrifluopÃ©razine',\n",
       "  'Trifluoperazine',\n",
       "  'Trifluoperazinum',\n",
       "  \"trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine\",\n",
       "  'Trifluoroperazine',\n",
       "  'Trifluperazine',\n",
       "  'Trifluoperazine'],\n",
       " 'Phensuximide': ['Fensuccimide',\n",
       "  'Fensuximida',\n",
       "  'Phensuximide',\n",
       "  'Phensuximidum',\n",
       "  'Phensuximide'],\n",
       " 'Cefaclor': ['3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid',\n",
       "  'CCL',\n",
       "  'CÃ©faclor',\n",
       "  'Cefaclor',\n",
       "  'Cefaclor anhydrous',\n",
       "  'Cefaclorum',\n",
       "  'CÃ©feaclor',\n",
       "  'Cephaclor',\n",
       "  'Cefaclor'],\n",
       " 'Mifepristone': ['Mifepriston',\n",
       "  'Mifepristona',\n",
       "  'MifÃ©pristone',\n",
       "  'Mifepristone',\n",
       "  'Mifepristonum',\n",
       "  'Mifepristone'],\n",
       " 'Brompheniramine': ['[3-(4-Bromo-phenyl)-3-pyridin-2-yl-propyl]-dimethyl-amine',\n",
       "  '1-(p-bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane',\n",
       "  '2-(p-bromo-Î±-(2-dimethylaminoethyl)benzyl)pyridine',\n",
       "  '3-(4-bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine',\n",
       "  '3-(p-bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine',\n",
       "  'BPN',\n",
       "  'Bromfeniramina',\n",
       "  'Brompheniramin',\n",
       "  'BromphÃ©niramine',\n",
       "  'Brompheniramine',\n",
       "  'Brompheniraminum',\n",
       "  'Brompheniramine'],\n",
       " 'Loperamide': ['Loperamid',\n",
       "  'Loperamida',\n",
       "  'LopÃ©ramide',\n",
       "  'Loperamide',\n",
       "  'Loperamidum',\n",
       "  'Loperamide'],\n",
       " 'Progabide': ['Halogabide',\n",
       "  'Progabida',\n",
       "  'Progabide',\n",
       "  'Progabidum',\n",
       "  'Progabide'],\n",
       " 'Clocortolone': ['9-chloro-6alpha-Fluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadien-3,20-dione',\n",
       "  '9-chloro-6alpha-Fluoro-16alpha-methyl-1,4-pregnadiene-11beta,21-diol-3,20-dione',\n",
       "  'Clocortolon',\n",
       "  'Clocortolona',\n",
       "  'Clocortolone',\n",
       "  'Clocortolonum',\n",
       "  'Clocortolone'],\n",
       " 'Tolazamide': ['1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea',\n",
       "  '1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea',\n",
       "  '4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide',\n",
       "  \"N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea\",\n",
       "  'Tolazamid',\n",
       "  'Tolazamida',\n",
       "  'Tolazamide',\n",
       "  'Tolazamidum',\n",
       "  'Tolazamide'],\n",
       " 'Hydroxypropyl cellulose': ['Cellulose hydroxypropyl ether',\n",
       "  'Cellulose, 2-hydroxypropyl ether',\n",
       "  'Hiprolosa',\n",
       "  'Hydroxypropyl cellulose',\n",
       "  'Hydroxypropyl cellulose (type H)',\n",
       "  'Hydroxypropylcellulose',\n",
       "  'Hyprolose',\n",
       "  'Hyprolosum',\n",
       "  'Modified cellulose',\n",
       "  'Hydroxypropyl cellulose'],\n",
       " 'Dobutamine': ['(Â±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol',\n",
       "  '3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-Î²-phenylethylamine',\n",
       "  '4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol',\n",
       "  'DL-dobutamine',\n",
       "  'Dobutamin',\n",
       "  'Dobutamina',\n",
       "  'Dobutamine',\n",
       "  'Dobutaminum',\n",
       "  'rac-dobutamine',\n",
       "  'racemic-dobutamine',\n",
       "  'Dobutamine'],\n",
       " 'Oxazepam': ['(+-)-Oxazepam', '(RS)-Oxazepam', 'Oxazepam', 'Oxazepam'],\n",
       " 'Donepezil': ['Domepezil',\n",
       "  'Donepezil',\n",
       "  'Donepezilo',\n",
       "  'Donepezilum',\n",
       "  'Donepezil'],\n",
       " 'Nalbuphine': ['N-cyclobutylmethyl-4,5Î±-epoxy-3,6Î±,14-morphinantriol',\n",
       "  'Nalbufina',\n",
       "  'Nalbuphin',\n",
       "  'Nalbuphine',\n",
       "  'Nalbuphinum',\n",
       "  'Nalbuphine'],\n",
       " 'Clofazimine': ['Clofazimin',\n",
       "  'Clofazimina',\n",
       "  'Clofazimine',\n",
       "  'Clofaziminum',\n",
       "  'Riminophenazine',\n",
       "  'Clofazimine'],\n",
       " 'Flurandrenolide': ['Fludroxicortida',\n",
       "  'Fludroxicortide',\n",
       "  'Fludroxycortid',\n",
       "  'Fludroxycortide',\n",
       "  'Fludroxycortidum',\n",
       "  'Flurandrenolide',\n",
       "  'Flurandrenolone',\n",
       "  'Flurandrenolide'],\n",
       " 'Cysteamine': ['2-amino-1-ethanethiol',\n",
       "  '2-amino-ethanethiol',\n",
       "  '2-aminoethanethiol',\n",
       "  'beta-aminoethanethiol',\n",
       "  'beta-Mercaptoethylamine',\n",
       "  'Cysteamine',\n",
       "  'MEA',\n",
       "  'Mercaptamina',\n",
       "  'Mercaptamine',\n",
       "  'Mercaptaminum',\n",
       "  'Thioethanolamine',\n",
       "  'Î²-aminoethylthiol',\n",
       "  'Î²-MEA',\n",
       "  'Cysteamine'],\n",
       " 'Levamisole': ['Levamisol', 'Levamisole', 'Levamisolum', 'Levamisole'],\n",
       " 'Methylphenobarbital': ['1-Methylphenobarbital',\n",
       "  '5-ethyl-1-methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-Ethyl-1-methyl-5-phenyl-pyrimidine-2,4,6-trione',\n",
       "  '5-ethyl-1-methyl-5-phenylbarbituric acid',\n",
       "  'Enphenemal',\n",
       "  'Mephobarbital',\n",
       "  'Mephobarbitone',\n",
       "  'MÃ©thylphÃ©nobarbital',\n",
       "  'Methylphenobarbital',\n",
       "  'Methylphenobarbitalum',\n",
       "  'Methylphenobarbitone',\n",
       "  'Metilfenobarbital',\n",
       "  'Metilfenobarbitale',\n",
       "  'N-Methylphenobarbital',\n",
       "  'Methylphenobarbital'],\n",
       " 'Perphenazine': ['2-(4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol',\n",
       "  '2-chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine',\n",
       "  '4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol',\n",
       "  '4-[3-(2-chlorophenothiazin-10-yl)propyl]-1-piperazineethanol',\n",
       "  'Chlorpiprazine',\n",
       "  'Etaperazin',\n",
       "  'Etaperazine',\n",
       "  'Ethaperazine',\n",
       "  'Perfenazina',\n",
       "  'Perfenazine',\n",
       "  'Perphenazin',\n",
       "  'PerphÃ©nazine',\n",
       "  'Perphenazine',\n",
       "  'Perphenazinum',\n",
       "  'Î³-(4-(Î²-hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine',\n",
       "  'Perphenazine'],\n",
       " 'Dacarbazine': ['4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide',\n",
       "  '4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide',\n",
       "  '4-(dimethyltriazeno)imidazole-5-carboxamide',\n",
       "  '5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide',\n",
       "  '5-(3,3-dimethyltriazeno)imidazole-4-carboxamide',\n",
       "  '5-(dimethyltriazeno)imidazole-4-carboxamide',\n",
       "  'Biocarbazine',\n",
       "  'Dacarbazin',\n",
       "  'Dacarbazina',\n",
       "  'Dacarbazine',\n",
       "  'Dacarbazinum',\n",
       "  'DIC',\n",
       "  'DTIC',\n",
       "  'ICDMT',\n",
       "  'Dacarbazine'],\n",
       " 'Pseudoephedrine': ['(+) threo-2-(methylamino)-1-phenyl-1-propanol',\n",
       "  '(+)-(1S,2S)-Pseudoephedrine',\n",
       "  '(+)-Pseudoephedrine',\n",
       "  '(+)-psi-Ephedrine',\n",
       "  '(+)-threo-Ephedrine',\n",
       "  'd-Isoephedrine',\n",
       "  'd-Pseudoephedrine',\n",
       "  'd-psi-2-Methylamino-1-phenyl-1-propanol',\n",
       "  'd-psi-Ephedrine',\n",
       "  'Isoephedrine',\n",
       "  'L-(+)-Pseudoephedrine',\n",
       "  'L(+)-psi-Ephedrine',\n",
       "  'Pseudoefedrina',\n",
       "  'Pseudoephedrine',\n",
       "  'pseudoÃ©phÃ©drine',\n",
       "  'Pseudoephedrine D-form',\n",
       "  'Pseudoephedrinum',\n",
       "  'Psi-ephedrin',\n",
       "  'Psi-ephedrine',\n",
       "  'trans-Ephedrine',\n",
       "  'Ï\\x88-ephedrine',\n",
       "  'Pseudoephedrine'],\n",
       " 'Temozolomide': ['3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide',\n",
       "  '3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide',\n",
       "  '3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide',\n",
       "  '8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one',\n",
       "  'Methazolastone',\n",
       "  'Temozolodida',\n",
       "  'Temozolomid',\n",
       "  'Temozolomida',\n",
       "  'Temozolomide',\n",
       "  'TÃ©mozolomide',\n",
       "  'Temozolomidum',\n",
       "  'Temozolomide'],\n",
       " 'Levorphanol': ['Levorfanol',\n",
       "  'Levorfanolo',\n",
       "  'LÃ©vorphanol',\n",
       "  'Levorphanol',\n",
       "  'Levorphanolum',\n",
       "  'Levorphanol'],\n",
       " 'Aminolevulinic acid': ['5-ALA',\n",
       "  '5-Aminolevulinic acid',\n",
       "  'Ã¡cido 5-aminolevulÃ\\xadnico',\n",
       "  'Aminolevulinic acid',\n",
       "  'dALA',\n",
       "  'Î´-ALA',\n",
       "  'Î´-aminolevulinic acid',\n",
       "  'Aminolevulinic acid'],\n",
       " 'Chlorphenesin': ['3-(4-chlorophenoxy)-1,2-propanediol',\n",
       "  '3-(p-chlorophenoxy)-1,2-propanediol',\n",
       "  '3-(p-chlorophenoxy)propane-1,2-diol',\n",
       "  'Chlorphenesin',\n",
       "  'ChlorphÃ©nÃ©sine',\n",
       "  'Chlorphenesinum',\n",
       "  'Clorfenesina',\n",
       "  'glycerol Î±-p-chlorophenyl ether',\n",
       "  'p-chlorophenyl-Î±-glyceryl ether',\n",
       "  'Chlorphenesin'],\n",
       " 'Terbinafine': ['(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine',\n",
       "  '(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine',\n",
       "  'Terbinafina',\n",
       "  'Terbinafine',\n",
       "  'Terbinafinum',\n",
       "  'Terbinafine'],\n",
       " 'Drostanolone': ['17beta-Hydroxy-2alpha-methyl-5alpha-androstan-3-one',\n",
       "  '2Î±-Methyldihydrotestosterone',\n",
       "  'Dihydro-2Î±-methyltestosterone',\n",
       "  'Dromostanolone',\n",
       "  'Drostanolona',\n",
       "  'Drostanolone',\n",
       "  'Drostanolonum',\n",
       "  'Medrosteron',\n",
       "  'Medrotestron',\n",
       "  'Metholone',\n",
       "  'Drostanolone'],\n",
       " 'Penicillamine': ['(â\\x88\\x92)-penicillamine',\n",
       "  '(S)-2-amino-3-mercapto-3-methylbutanoic acid',\n",
       "  '(S)-3,3-dimethylcysteine',\n",
       "  '3-mercapto-D-valine',\n",
       "  'D-(â\\x88\\x92)-penicillamine',\n",
       "  'D-penicillamine',\n",
       "  'D-Î²,Î²-dimethylcysteine',\n",
       "  'penicilamina',\n",
       "  'Penicillamine',\n",
       "  'Penicillamine'],\n",
       " 'Prednisolone': ['(11Î²)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione',\n",
       "  '1,4-pregnadiene-11Î²,17Î±,21-triol-3,20-dione',\n",
       "  '1,4-pregnadiene-3,20-dione-11Î²,17Î±,21-triol',\n",
       "  '3,20-dioxo-11Î²,17Î±,21-trihydroxy-1,4-pregnadiene',\n",
       "  'delta-dehydrocortisol',\n",
       "  'delta-dehydrohydrocortisone',\n",
       "  'delta-hydrocortisone',\n",
       "  'delta(1)-Dehydrocortisol',\n",
       "  'delta(1)-Dehydrohydrocortisone',\n",
       "  'delta(1)-Hydrocortisone',\n",
       "  'Hydroretrocortine',\n",
       "  'Metacortandralone',\n",
       "  'PRDL',\n",
       "  'Prednisolona',\n",
       "  'Prednisolone',\n",
       "  'Prednisolonum',\n",
       "  'Prednisolone'],\n",
       " 'Diflunisal': ['2-(hydroxy)-5-(2,4-difluorophenyl)benzoic acid',\n",
       "  \"2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid\",\n",
       "  '5-(2,4-difluorophenyl)salicylic acid',\n",
       "  'Diflunisal',\n",
       "  'Diflunisalum',\n",
       "  'Diflunisal'],\n",
       " 'Vardenafil': ['VardÃ©nafil',\n",
       "  'Vardenafil',\n",
       "  'Vardenafilo',\n",
       "  'Vardenafilum',\n",
       "  'Vardenafil'],\n",
       " 'Ranitidine': ['Ranitidina', 'Ranitidine', 'Ranitidinum', 'Ranitidine'],\n",
       " 'Tacrolimus': ['Anhydrous tacrolimus',\n",
       "  'Tacrolimus',\n",
       "  'Tacrolimus anhydrous',\n",
       "  'Tacrolimus, anhydrous',\n",
       "  'Tacrolimus'],\n",
       " 'Benzphetamine': ['(+)-benzphetamine',\n",
       "  '(+)-N-benzyl-N,Î±-dimethylphenethylamine',\n",
       "  '(+)-N,Î±-dimethyl-N-(phenylmethyl)-benzeneethanamine',\n",
       "  '(S)-(+)-benzphetamine',\n",
       "  '(S)-(+)-N-benzyl-N,Î±-dimethylphenethylamine',\n",
       "  '(S)-benzphetamine',\n",
       "  '(Î±S)-N,Î±-dimethylphenethylamine',\n",
       "  'Benzaphetamine',\n",
       "  'Benzfetamina',\n",
       "  'Benzfetamine',\n",
       "  'Benzfetaminum',\n",
       "  'Benzphetamine',\n",
       "  'Benzylamphetamine',\n",
       "  'd-N-methyl-N-benzyl-Î²-phenylisopropylamine',\n",
       "  'N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine',\n",
       "  'Benzphetamine'],\n",
       " 'Alprenolol': ['(RS)-1-(2-allylphenoxy)-3-(isopropylamino)propan-2-ol',\n",
       "  '1-(2-Allylphenoxy)-3-isopropylamino-2-propanol',\n",
       "  '1-(o-Allylphenoxy)-3-(isopropylamino)-2-propanol',\n",
       "  'Alfeprol',\n",
       "  'Alprenolol',\n",
       "  'AlprÃ©nolol',\n",
       "  'Alprenololum',\n",
       "  'Aprenololo',\n",
       "  'Alprenolol'],\n",
       " 'Ritodrine': ['p-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol',\n",
       "  'Ritodrina',\n",
       "  'Ritodrine',\n",
       "  'Ritodrinium',\n",
       "  'Ritodrine'],\n",
       " 'Benzonatate': ['2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoate',\n",
       "  '2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl p-(butylamino)benzoate',\n",
       "  '3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl 4-butylaminobenzoate',\n",
       "  '4-(butylamino)benzoic acid 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester',\n",
       "  'Benzonatat',\n",
       "  'Benzonatate',\n",
       "  'Benzonatato',\n",
       "  'Benzonatatum',\n",
       "  'Benzononatine',\n",
       "  'nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate',\n",
       "  'p-butylaminobenzoic acid Ï\\x89-O-methylnonaethyleneglycol ester',\n",
       "  'Benzonatate'],\n",
       " 'Dorzolamide': ['(4S,6S)-4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide',\n",
       "  '(4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide',\n",
       "  '4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide',\n",
       "  '4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide',\n",
       "  '4S,6S-dorzolamide',\n",
       "  'Dorzolamid',\n",
       "  'Dorzolamida',\n",
       "  'Dorzolamide',\n",
       "  'Dorzolamidum',\n",
       "  'Dorzolamide'],\n",
       " 'Suprofen': ['(Â±)-2-(p-(2-thenoyl)phenyl)propionic acid',\n",
       "  '2-(4-(2-Thenoyl)phenyl)propionsÃ¤ure',\n",
       "  '2-[4-(Thiophene-2-carbonyl)-phenyl]-propionic acid',\n",
       "  '4-(2-Thenoyl)hydratropsÃ¤ure',\n",
       "  'p-2-thenoylhydratropic acid',\n",
       "  'Suprofen',\n",
       "  'Suprofene',\n",
       "  'Suprofeno',\n",
       "  'Suprofenum',\n",
       "  'Sutoprofen',\n",
       "  'Î±-methyl-4-(2-thienylcarbonyl)benzeneacetic acid',\n",
       "  'Suprofen'],\n",
       " 'Terbutaline': ['Terbutalin',\n",
       "  'Terbutalina',\n",
       "  'Terbutaline',\n",
       "  'Terbutalinum',\n",
       "  'Terbutaline'],\n",
       " 'Conivaptan': [\"4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide\",\n",
       "  'Conivaptan',\n",
       "  'Conivaptan'],\n",
       " 'Loteprednol etabonate': ['Loteprednol etabonate', 'Loteprednol etabonate'],\n",
       " 'Guaifenesin': ['Glyceryl guaiacolate',\n",
       "  'Guaifenesin',\n",
       "  'Guaifenesina',\n",
       "  'guaiphenesin',\n",
       "  'Guaifenesin'],\n",
       " 'Flupentixol': ['Flupenthixol',\n",
       "  'Flupenthixole',\n",
       "  'Flupentixol',\n",
       "  'Flupentixolo',\n",
       "  'Flupentixolum',\n",
       "  'Flupentixol'],\n",
       " 'Eprosartan': ['(E)-2-butyl-1-(p-carboxybenzyl)-Î±-2-thenylimidazole-5-acrylic acid',\n",
       "  '(E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid',\n",
       "  '(E)-Î±{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid',\n",
       "  'Ã\\x89prosartan',\n",
       "  'Eprosartan',\n",
       "  'Eprosartanum',\n",
       "  'Eprosartan'],\n",
       " 'Sirolimus': ['(-)-Rapamycin',\n",
       "  'Rapamycin',\n",
       "  'SirolimÃºs',\n",
       "  'Sirolimus',\n",
       "  'Sirolimusum',\n",
       "  'Sirolimus'],\n",
       " 'Chlorhexidine': [\"1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide)\",\n",
       "  'Chlorhexidin',\n",
       "  'Chlorhexidine',\n",
       "  'Chlorhexidinum',\n",
       "  'Cloresidina',\n",
       "  'Clorhexidina',\n",
       "  \"N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide\",\n",
       "  'Chlorhexidine'],\n",
       " 'Emtricitabine': ['(â\\x88\\x92)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine',\n",
       "  \"(â\\x88\\x92)-2'-deoxy-5-fluoro-3'-thiacytidine\",\n",
       "  '(â\\x88\\x92)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one',\n",
       "  '(â\\x88\\x92)-FTC',\n",
       "  \"(â\\x88\\x92)-Î²-2',3'-dideoxy-5-fluoro-3'-thiacytidine\",\n",
       "  '(2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone',\n",
       "  '4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one',\n",
       "  '4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one',\n",
       "  '5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine',\n",
       "  'Emtricitabin',\n",
       "  'Emtricitabina',\n",
       "  'Emtricitabine',\n",
       "  'Emtricitabinum',\n",
       "  'Emtricitabine'],\n",
       " 'Chlorothiazide': ['6-Chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide',\n",
       "  '6-chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide',\n",
       "  'Chlorothiazid',\n",
       "  'Chlorothiazide',\n",
       "  'Chlorothiazidum',\n",
       "  'Chlorthiazide',\n",
       "  'Clorotiazida',\n",
       "  'Chlorothiazide'],\n",
       " 'Quinapril': ['Quinapril', 'Quinaprilum', 'Quinapril'],\n",
       " 'Clomifene': ['2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine',\n",
       "  '2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)triethylamine',\n",
       "  '2-(p-(Î²-chloro-Î±-phenylstyryl)phenoxy)triethylamine',\n",
       "  'Clomifene',\n",
       "  'Clomifeno',\n",
       "  'Clomifenum',\n",
       "  'Clomiphene',\n",
       "  'Clomifene'],\n",
       " 'Isosorbide dinitrate': ['1,4:3,6-Dianhydrosorbitol 2,5-dinitrate',\n",
       "  'D-Isosorbide dinitrate',\n",
       "  'Dianhydrosorbitol 2,5-dinitrate',\n",
       "  \"Dinitrate d'isosorbide\",\n",
       "  'Dinitrato de isosorbida',\n",
       "  'Dinitroisosorbide',\n",
       "  'Dinitrosorbide',\n",
       "  'ISDN',\n",
       "  'Isosorbide 2,5-dinitrate',\n",
       "  'Isosorbide dinitrate',\n",
       "  'Isosorbidi dinitras',\n",
       "  'Sorbide nitrate',\n",
       "  'Sorbidnitrate',\n",
       "  'Isosorbide dinitrate'],\n",
       " 'Risedronic acid': ['Acide risÃ©droniqe',\n",
       "  'Acido risedronico',\n",
       "  'Acidum risedronicum',\n",
       "  'Risedronate',\n",
       "  'Risedronic acid',\n",
       "  'RisedronsÃ¤ure',\n",
       "  'Risedronic acid'],\n",
       " 'Pemirolast': ['Pemirolast', 'Pemirolastum', 'Pemirolast'],\n",
       " 'Omapatrilat': ['Omapatrilate', 'Omapatrilat'],\n",
       " 'Bumetanide': ['3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid',\n",
       "  '3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid',\n",
       "  '3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid',\n",
       "  '3-butylamino-4-phenoxy-5-sulfamoylbenzoic acid',\n",
       "  'Bumetanida',\n",
       "  'Bumetanide',\n",
       "  'Bumetanidum',\n",
       "  'Bumetanide'],\n",
       " 'Mechlorethamine': [\"2,2'-dichloro-N-methyldiethylamine\",\n",
       "  'bis(2-chloroethyl)methylamine',\n",
       "  'bis(Î²-chloroethyl)methylamine',\n",
       "  'Chlormethine',\n",
       "  'Chlormethinum',\n",
       "  'Clormetina',\n",
       "  'Mechlorethamine',\n",
       "  'methylbis(2-chloroethyl)amine',\n",
       "  'methylbis(Î²-chloroethyl)amine',\n",
       "  'Mustine',\n",
       "  'N-methyl-bis(2-chloroethyl)amine',\n",
       "  'N-methyl-bis(Î²-chloroethyl)amine',\n",
       "  'Nitrogen mustard',\n",
       "  \"Î²,Î²'-dichlorodiethyl-N-methylamine\",\n",
       "  'Mechlorethamine'],\n",
       " 'Granisetron': ['GranisÃ©tron',\n",
       "  'GranisetrÃ³n',\n",
       "  'Granisetron',\n",
       "  'Granisetronum',\n",
       "  'Granisetron'],\n",
       " 'Dienestrol': [\"4,4'-Hydroxy-Î³,Î´-diphenyl-Î²,Î´-hexadiene\",\n",
       "  'alpha-dienestrol diacetate',\n",
       "  'Cycladiene',\n",
       "  'Dehydrostilbestrol',\n",
       "  'Dienestrol',\n",
       "  'DiÃ¨nestrol',\n",
       "  'Dienestrolum',\n",
       "  \"p,p'-(Diethylideneethylene)diphenol\",\n",
       "  'Dienestrol'],\n",
       " 'Sulfapyridine': ['2-(p-Aminobenzenesulphonamido)pyridine',\n",
       "  '2-Sulfanilamidopyridin',\n",
       "  '2-Sulfanilamidopyridine',\n",
       "  '2-Sulfanilylaminopyridine',\n",
       "  '2-Sulfapyridine',\n",
       "  '4-(2-Pyridinylsulfonyl)aniline',\n",
       "  '4-[(2-Pyridylamino)sulfonyl]aniline',\n",
       "  '4-Amino-N-pyridin-2-yl-benzenesulfonamide',\n",
       "  '4-Amino-N,2-pyridinylbenzenesulfonamide',\n",
       "  'N-2-Pyridylsulfanilamide',\n",
       "  'N(1)-2-Pyridylsulfanilamide',\n",
       "  'N(1)-Pyridylsulfanilamide',\n",
       "  'Solfapiridina',\n",
       "  'Sulfapiridina',\n",
       "  'Sulfapyridin',\n",
       "  'Sulfapyridine',\n",
       "  'Sulfapyridinum',\n",
       "  'Sulphapyridine',\n",
       "  'Sulfapyridine'],\n",
       " 'Oxybuprocaine': ['4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid',\n",
       "  '4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester',\n",
       "  '4-Amino-3-n-butoxy-benzoesÃ¤ure-diÃ¤thylaminoÃ¤thylester',\n",
       "  'Benoxinate',\n",
       "  'BNX',\n",
       "  'Butoxyaminobenzoyldiethylaminoethanol',\n",
       "  'Oxibuprocaina',\n",
       "  'Oxybucaine',\n",
       "  'Oxybuprocaine',\n",
       "  'Oxybuprocainum',\n",
       "  'Oxyriprocaine',\n",
       "  'Oxybuprocaine'],\n",
       " 'Iron Dextran': ['Dextran iron', 'Iron dextran complex', 'Iron Dextran'],\n",
       " 'Testolactone': ['(4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione',\n",
       "  '1-dehydrotestololactone',\n",
       "  '1,2-didehydrotestololactone',\n",
       "  '13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid Î´-lactone',\n",
       "  'D-homo-17a-oxaandrosta-1,4-diene-3,17-dione',\n",
       "  'delta(1)-testololactone',\n",
       "  'Testolactona',\n",
       "  'Testolactonum',\n",
       "  'Testolattone',\n",
       "  'Î\\x941-testololactone',\n",
       "  'Testolactone'],\n",
       " 'Benzylpenicilloyl polylysine': ['Benzyl penicilloyl-polylysine',\n",
       "  'Benzylpenicilloyl G polylysine',\n",
       "  'Benzylpenicilloyl-polylysine',\n",
       "  'Benzylpenicilloyl polylysine'],\n",
       " 'Rimexolone': ['Rimexolon', 'Rimexolona', 'Rimexolone', 'Rimexolone'],\n",
       " 'Triazolam': ['Triazolam', 'Triazolamum', 'Triazolam'],\n",
       " 'Ethanol': ['1-Hydroxyethane',\n",
       "  'Alcohol',\n",
       "  'Alcohol (ethyl)',\n",
       "  'Alcohol anhydrous',\n",
       "  'Alcohol denatured',\n",
       "  'Alcohol etÃ\\xadlico',\n",
       "  'Alcohol, denatured',\n",
       "  'Alcool Ã©thylique',\n",
       "  'Alkohol',\n",
       "  'Ã\\x84thanol',\n",
       "  'Ã\\x84thylalkohol',\n",
       "  'Dehydrated ethanol',\n",
       "  'etanol',\n",
       "  'Ã©thanol',\n",
       "  'Ethyl Alcohol',\n",
       "  'Grain alcohol',\n",
       "  'Hydroxyethane',\n",
       "  'Methylcarbinol',\n",
       "  'Spiritus vini',\n",
       "  'Ethanol'],\n",
       " 'Remifentanil': ['Remifentanil',\n",
       "  'Remifentanilo',\n",
       "  'Remifentanyl',\n",
       "  'Remifentanil'],\n",
       " 'Didanosine': ['2,3-Dideoxyinosine',\n",
       "  '9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one',\n",
       "  '9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one',\n",
       "  '9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol',\n",
       "  '9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one',\n",
       "  'ddI',\n",
       "  'ddIno',\n",
       "  'Didanosina',\n",
       "  'Didanosine',\n",
       "  'Didanosinum',\n",
       "  'Dideoxyinosine',\n",
       "  'Didanosine'],\n",
       " 'Bitolterol': ['4-(2-(tert-butylamino)-1-hydroxyethyl)-o-phenylene di-p-toluate',\n",
       "  '4-[2-(tert-butylamino)-1-hydroxyethyl]-o-phenylene di-p-toluate',\n",
       "  'bis(4-methylbenzoic acid) 4-[2-(tert-butylamino)-1-hydroxyethyl]-1,2-phenylene ester',\n",
       "  'Bitolterol',\n",
       "  'BitoltÃ©rol',\n",
       "  'Bitolterolum',\n",
       "  'Bitolterol'],\n",
       " 'Methdilazine': ['Methdilazinum', 'Metodilazina', 'Methdilazine'],\n",
       " 'Etacrynic acid': ['(2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid',\n",
       "  'Acide Ã©tacrynique',\n",
       "  'Ã¡cido etacrÃ\\xadnico',\n",
       "  'Acidum etacrynicum',\n",
       "  'Etacrinic acid',\n",
       "  'Etacrynic acid',\n",
       "  'Ethacrynate',\n",
       "  'Ethacrynic acid',\n",
       "  'Methylenebutyrylphenoxyacetic acid',\n",
       "  'Etacrynic acid'],\n",
       " 'Ondansetron': ['Ondansetron', 'Ondansetron'],\n",
       " 'Bimatoprost': ['(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide',\n",
       "  'Bimatoprost',\n",
       "  'Bimatoprostum',\n",
       "  'Bimatoprost'],\n",
       " 'Tiagabine': ['Tiagabina', 'Tiagabine', 'Tiagabinum', 'Tiagabine'],\n",
       " 'Cocaine': ['(-)-Cocaine',\n",
       "  '(â\\x88\\x92)-cocaine',\n",
       "  '[1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid, methyl ester',\n",
       "  '2-methyl-3Î²-hydroxy-1Î±H,5Î±H-tropane-2Î²-carboxylate benzoate (ester)',\n",
       "  'Benzoylmethylecgonine',\n",
       "  'beta-Cocain',\n",
       "  'Cocain',\n",
       "  'Cocaina',\n",
       "  'Cocainum',\n",
       "  'Kokain',\n",
       "  'L-Cocain',\n",
       "  'L-Cocaine',\n",
       "  'methyl [1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate',\n",
       "  'Methyl benzoylecgonine',\n",
       "  'Neurocaine',\n",
       "  'Cocaine'],\n",
       " 'Quinidine': ['(+)-quinidine',\n",
       "  '(8R,9S)-Quinidine',\n",
       "  '(R)-(6-Methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol',\n",
       "  '(S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol',\n",
       "  '(S)-(6-Methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanol',\n",
       "  '6-methoxy-Î±-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol',\n",
       "  'beta-Quinine',\n",
       "  'Chinidin',\n",
       "  'Chinidinum',\n",
       "  'CIN-QUIN',\n",
       "  'Conchinin',\n",
       "  'Conquinine',\n",
       "  'Pitayine',\n",
       "  'Quinidina',\n",
       "  'Î±-(6-methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol',\n",
       "  'Î²-quinine',\n",
       "  'Quinidine'],\n",
       " 'Zonisamide': ['1,2-Benzisoxazole-3-methanesulfonamide',\n",
       "  '3-(Sulfamoylmethyl)-1,2-benzisoxazole',\n",
       "  'Benzo[d]isoxazol-3-yl-methanesulfonamide',\n",
       "  'Zonisamida',\n",
       "  'Zonisamide',\n",
       "  'Zonisamidum',\n",
       "  'Zonisamide'],\n",
       " 'Paricalcitol': ['19-Nor-1alpha,25-dihydroxyvitamin D2',\n",
       "  'Paricalcitol',\n",
       "  'Paricalcitol'],\n",
       " 'Tinidazole': ['1-(2-(Ethylsulfonyl)ethyl)-2-methyl-5-nitroimidazole',\n",
       "  'Timidazole',\n",
       "  'Tinidazol',\n",
       "  'Tinidazole',\n",
       "  'Tinidazolum',\n",
       "  'Tinidazole'],\n",
       " 'Repaglinide': ['Repaglinida', 'Repaglinide', 'Repaglinidum', 'Repaglinide'],\n",
       " 'Anileridine': ['1-[2-(4-aminophenyl)ethyl]-4-phenyl-4-piperidinecarboxlic acid ethyl ester',\n",
       "  'Anileridina',\n",
       "  'Anileridine',\n",
       "  'Anileridinum',\n",
       "  'ethyl 1-(2-(4-aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylate',\n",
       "  'ethyl 1-(4-aminophenethyl)-4-phenylisonipecotate',\n",
       "  'ethyl 1-(p-aminophenethyl)-4-phenylisonipecotate',\n",
       "  'N-(Î²-(p-aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine',\n",
       "  'N-Î²-(p-aminophenyl)ethylnormeperidine',\n",
       "  'Anileridine'],\n",
       " 'Phenformin': ['Fenformin',\n",
       "  'Fenformina',\n",
       "  'Phenformin',\n",
       "  'Phenformine',\n",
       "  'Phenforminum',\n",
       "  'Î²-Phenethybiguanide',\n",
       "  'Phenformin'],\n",
       " 'Amantadine': ['1-adamantanamine',\n",
       "  '1-adamantylamine',\n",
       "  '1-aminoadamantane',\n",
       "  'Amantadina',\n",
       "  'Amantadine',\n",
       "  'Amantadinum',\n",
       "  'Amantidine',\n",
       "  'Aminoadamantane',\n",
       "  'Amantadine'],\n",
       " 'Metronidazole': ['1-(2-hydroxy-1-ethyl)-2-methyl-5-nitroimidazole',\n",
       "  '1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole',\n",
       "  '1-(Î²-ethylol)-2-methyl-5-nitro-3-azapyrrole',\n",
       "  '1-(Î²-hydroxyethyl)-2-methyl-5-nitroimidazole',\n",
       "  '1-(Î²-oxyethyl)-2-methyl-5-nitroimidazole',\n",
       "  '2-methyl-1-(2-hydroxyethyl)-5-nitroimidazole',\n",
       "  '2-methyl-3-(2-hydroxyethyl)-4-nitroimidazole',\n",
       "  '2-methyl-5-nitroimidazole-1-ethanol',\n",
       "  'Metronidazol',\n",
       "  'MÃ©tronidazole',\n",
       "  'Metronidazole',\n",
       "  'Metronidazolum',\n",
       "  'Metronidazole'],\n",
       " 'Dinoprostone': ['(15S)-prostaglandin E2',\n",
       "  '(5Z,11Î±,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid',\n",
       "  '(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate',\n",
       "  '(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoate',\n",
       "  '(E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid',\n",
       "  '(Z)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid',\n",
       "  'Dinoproston',\n",
       "  'Dinoprostona',\n",
       "  'Dinoprostone',\n",
       "  'Dinoprostone Prostaglandin E2',\n",
       "  'Dinoprostonum',\n",
       "  'PGE2',\n",
       "  'Prostaglandin E2',\n",
       "  'Dinoprostone'],\n",
       " 'Almotriptan': ['1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine',\n",
       "  'Almotriptan',\n",
       "  'Almotriptan'],\n",
       " 'Spectinomycin': ['Actinospectacina',\n",
       "  'Espectinomicina',\n",
       "  'SCM',\n",
       "  'Spectinomicina',\n",
       "  'Spectinomycin',\n",
       "  'Spectinomycine',\n",
       "  'Spectinomycinum',\n",
       "  'Spectinomycin'],\n",
       " 'Ketotifen': ['Ketotifen',\n",
       "  'Ketotifene',\n",
       "  'Ketotifeno',\n",
       "  'Ketotifenum',\n",
       "  'Ketotifen'],\n",
       " 'Buprenorphine': ['(â\\x88\\x92)-buprenorphine',\n",
       "  '17-cyclopropylmethyl-4,5Î±-epoxy-7Î±-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol',\n",
       "  '2-(N-cyclopropylmethyl-4,5Î±-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6Î±-yl)-3,3-dimethyl-2-butanol',\n",
       "  '2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol',\n",
       "  '21-cyclopropyl-7Î±-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine',\n",
       "  'Buprenophine',\n",
       "  'Buprenorfina',\n",
       "  'Buprenorphine',\n",
       "  'Buprenorphinum',\n",
       "  'Buprenorphine'],\n",
       " 'Levosimendan': ['LÃ©vosimendan',\n",
       "  'Levosimendan',\n",
       "  'LevosimendÃ¡n',\n",
       "  'Levosimendanum',\n",
       "  'Levosimendan'],\n",
       " 'Ceforanide': ['(6R,7R)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  '7-[O-(aminomethyl)phenylacetamido]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acid',\n",
       "  '7Î²-[2-(aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylic acid',\n",
       "  'Ceforanide',\n",
       "  'Ceforanido',\n",
       "  'Ceforanidum',\n",
       "  'Ceforanide'],\n",
       " 'Cyclobenzaprine': ['(3-Dibenzo[a,d]cyclohepten-5-ylidene-propyl)-dimethyl-amine',\n",
       "  'Ciclobenzaprina',\n",
       "  'Cyclobenzaprine',\n",
       "  'Cyclobenzaprinum',\n",
       "  'N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Î\\x945,Î³-propylamine',\n",
       "  'Cyclobenzaprine'],\n",
       " 'Phenoxybenzamine': ['Fenossibenzamina',\n",
       "  'Fenoxibenzamina',\n",
       "  'Phenoxybenzamine',\n",
       "  'Phenoxybenzaminum',\n",
       "  'POB',\n",
       "  'Phenoxybenzamine'],\n",
       " 'Etretinate': ['Etretinate', 'etretinato', 'Etretinate'],\n",
       " 'Famotidine': ['(1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide',\n",
       "  '3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide',\n",
       "  '3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine',\n",
       "  'Famotidina',\n",
       "  'Famotidine',\n",
       "  'Famotidinum',\n",
       "  'N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide',\n",
       "  'Famotidine'],\n",
       " 'Azacitidine': ['4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one',\n",
       "  '5-azacytidine',\n",
       "  'Azacitidina',\n",
       "  'Azacitidine',\n",
       "  'Azacitidinum',\n",
       "  'Azacytidine',\n",
       "  'Azacitidine'],\n",
       " 'Misoprostol': ['Misoprostol', 'Misoprostolum', 'Misoprostol'],\n",
       " 'Colesevelam': ['Colesevelam', 'Colesevelam'],\n",
       " 'Metacycline': ['6-Demethyl-6-deoxy-5-hydroxy-6-methylenetetracycline',\n",
       "  '6-Deoxy-6-demethyl-6-methylene-5-oxytetracycline',\n",
       "  '6-Methylene-5-hydroxytetracycline',\n",
       "  '6-Methylene-5-oxytetracycline',\n",
       "  '6-Methyleneoxytetracycline',\n",
       "  'Metaciclina',\n",
       "  'Metacycline',\n",
       "  'Methacycline',\n",
       "  'Methacyclinum',\n",
       "  'Methylenecycline',\n",
       "  'Tri-methacycline',\n",
       "  'Metacycline'],\n",
       " 'Tipranavir': ['Tipranavir', 'Tipranavir'],\n",
       " 'Mesoridazine': ['10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine',\n",
       "  '10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine',\n",
       "  '2-Methanesulfinyl-10-[2-(1-methyl-piperidin-2-yl)-ethyl]-10H-phenothiazine',\n",
       "  'Mesoridazina',\n",
       "  'Mesoridazine',\n",
       "  'Mesoridazinum',\n",
       "  'Thioridazine 2-sulfoxide',\n",
       "  'Thioridazine thiomethyl sulfoxide',\n",
       "  'Thioridazine-2-sulfoxide',\n",
       "  'Mesoridazine'],\n",
       " 'Maprotiline': ['Maprotilina',\n",
       "  'Maprotiline',\n",
       "  'Maprotilinum',\n",
       "  'Maprotylina',\n",
       "  'Maprotiline'],\n",
       " 'Oxymetazoline': ['2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline',\n",
       "  '3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol',\n",
       "  '6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol',\n",
       "  '6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol',\n",
       "  'Oximetazolinum',\n",
       "  'Oxymetazolina',\n",
       "  'Oxymetazoline',\n",
       "  'OxymÃ©tazoline',\n",
       "  'Oxymetazolinum',\n",
       "  'Oxymethazoline',\n",
       "  'Oxymetozoline',\n",
       "  'Oxymetazoline'],\n",
       " 'Salicylic acid': ['2-Carboxyphenol',\n",
       "  '2-Hydroxybenzoic acid',\n",
       "  'Ã¡cido salicÃ\\xadlico',\n",
       "  'Acidum salicylicum',\n",
       "  'O-carboxyphenol',\n",
       "  'O-hydroxybenzoic acid',\n",
       "  'Salicylic acid'],\n",
       " 'Diethylpropion': ['(Â±)-diethylpropion',\n",
       "  '1-phenyl-2-diethylamino-1-propanone',\n",
       "  '2-(diethylamino)-1-phenyl-1-propanone',\n",
       "  '2-(diethylamino)propiophenone',\n",
       "  'alpha-Benzoyltriethylamine',\n",
       "  'alpha-Diethylaminopropiophenone',\n",
       "  'Amfepramone',\n",
       "  'AmfÃ©pramone',\n",
       "  'Amfepramonum',\n",
       "  'Anfepramona',\n",
       "  'Diethylcathinone',\n",
       "  'Diethylpropion'],\n",
       " 'Salmeterol': ['Salmaterol', 'Salmeterol', 'Salmeterolum', 'Salmeterol'],\n",
       " 'Meclofenamic acid': ['Acide mÃ©clofÃ©namique',\n",
       "  'Ã¡cido meclofenÃ¡mico',\n",
       "  'Acidum meclofenamicum',\n",
       "  'Meclofenamate',\n",
       "  'Meclofenamic acid',\n",
       "  'N-(2,6-dichloro-3-methylphenyl)anthranilic acid',\n",
       "  'N-(2,6-dichloro-m-tolyl)anthranilic acid',\n",
       "  'N-(3-methyl-2,6-dichlorophenyl)anthranilic acid',\n",
       "  'Meclofenamic acid'],\n",
       " 'Methantheline': ['Methantheline',\n",
       "  'Methantheline cation',\n",
       "  'Methantheline ion',\n",
       "  'Methanthelinium',\n",
       "  'Methanthelinum',\n",
       "  'Methantheline'],\n",
       " 'Hexafluronium': ['Hexafluorenium',\n",
       "  'Hexafluorenium cation',\n",
       "  'Hexafluorenium ion',\n",
       "  'Hexamethylenebis(fluoren-9-yldimethylammonium)',\n",
       "  'Hexafluronium'],\n",
       " 'Cycrimine': ['(Â±)-cycrimine',\n",
       "  'alpha-cyclopentyl-alpha-phenyl-1-piperidinepropanol',\n",
       "  'Cicrimina',\n",
       "  'Cycrimine',\n",
       "  'Cycriminum',\n",
       "  'Cycrimine'],\n",
       " 'Zalcitabine': [\"2',3'-Dideoxycytidine\",\n",
       "  '4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one',\n",
       "  'DDC',\n",
       "  'DDCYD',\n",
       "  'Dideoxycytidine',\n",
       "  'Zalcitabine',\n",
       "  'Zalcitabine'],\n",
       " 'Demecarium': ['Demecarium',\n",
       "  'Demecarium cation',\n",
       "  'Demecarium ion',\n",
       "  'Demecarium'],\n",
       " 'Acetylsalicylic acid': ['2-Acetoxybenzenecarboxylic acid',\n",
       "  '2-Acetoxybenzoic acid',\n",
       "  'Acetylsalicylate',\n",
       "  'AcetylsalicylsÃ¤ure',\n",
       "  'acide 2-(acÃ©tyloxy)benzoÃ¯que',\n",
       "  'Acide acÃ©tylsalicylique',\n",
       "  'Ã¡cido acetilsalicÃ\\xadlico',\n",
       "  'Acidum acetylsalicylicum',\n",
       "  'ASA',\n",
       "  'Aspirin',\n",
       "  'Aspirina',\n",
       "  'AzetylsalizylsÃ¤ure',\n",
       "  'o-acetoxybenzoic acid',\n",
       "  'O-acetylsalicylic acid',\n",
       "  'o-carboxyphenyl acetate',\n",
       "  'Polopiryna',\n",
       "  'Salicylic acid acetate',\n",
       "  'Acetylsalicylic acid'],\n",
       " 'Phenprocoumon': ['3-(1-Phenylpropyl)-4-hydroxycoumarin',\n",
       "  \"3-(1'-Phenyl-propyl)-4-oxycoumarin\",\n",
       "  '3-(alpha-Ethylbenzyl)-4-hydroxycoumarin',\n",
       "  '3-(alpha-Phenylpropyl)-4-hydroxycoumarin',\n",
       "  '4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one',\n",
       "  '4-hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one',\n",
       "  'Fenprocumon',\n",
       "  'Fenprocumone',\n",
       "  'Phenprocoumarol',\n",
       "  'Phenprocoumarole',\n",
       "  'Phenprocoumon',\n",
       "  'Phenprocoumone',\n",
       "  'Phenprocoumonum',\n",
       "  'Phenprocumone',\n",
       "  'Phenprocoumon'],\n",
       " 'Fulvestrant': ['(7Î±,17Î²)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diol',\n",
       "  'Fulvestrant',\n",
       "  'Fulvestrant'],\n",
       " 'Mezlocillin': ['(2S,5R,6R)-3,3-dimethyl-6-{[(2R)-2-({[3-(methylsulfonyl)-2-oxoimidazolidin-1-yl]carbonyl}amino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  '6Î²-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}penicillanic acid',\n",
       "  'Mezlocilina',\n",
       "  'Mezlocillin',\n",
       "  'Mezlocilline',\n",
       "  'Mezlocillinum',\n",
       "  'Mezlocillin'],\n",
       " 'Felbamate': ['2-phenyl-1,3-propanediol dicarbamate',\n",
       "  'carbamic acid 2-phenyltrimethylene ester',\n",
       "  'Carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester',\n",
       "  'Felbamate',\n",
       "  'Felbamato',\n",
       "  'Felbamatum',\n",
       "  'Felbamate'],\n",
       " 'Fexofenadine': ['4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid',\n",
       "  'Carboxyterfenadine',\n",
       "  'Fexofenadina',\n",
       "  'Fexofenadine',\n",
       "  'Terfenadine acid metabolite',\n",
       "  'Terfenadine carboxylate',\n",
       "  'Terfenadine-COOH',\n",
       "  'Fexofenadine'],\n",
       " 'Isoniazid': ['4-pyridinecarbohydrazide',\n",
       "  'INH',\n",
       "  'Isoniazid',\n",
       "  'Isoniazida',\n",
       "  'Isonicotinic acid hydrazide',\n",
       "  'Isonicotinic hydrazide',\n",
       "  'Isonicotinohydrazide',\n",
       "  'Isonicotinoylhydrazide',\n",
       "  'IsonicotinsÃ¤urehydrazid',\n",
       "  'Isonicotinylhydrazine',\n",
       "  'Pyridine-4-carboxylic acid hydrazide',\n",
       "  'Isoniazid'],\n",
       " 'Naratriptan': ['N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide',\n",
       "  'N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide',\n",
       "  'NaratriptÃ¡n',\n",
       "  'Naratriptan',\n",
       "  'Naratriptanum',\n",
       "  'Naratriptan'],\n",
       " 'Rizatriptan': ['N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine',\n",
       "  'N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine',\n",
       "  'Risatriptan',\n",
       "  'RizatriptÃ¡n',\n",
       "  'Rizatriptan',\n",
       "  'Rizatriptanum',\n",
       "  'Rizatriptan'],\n",
       " 'Dirithromycin': ['(9S)-9-deoxo-11-deoxy-9,11-(imino((1R)-2-(2-methoxyethoxy)ethylidene)oxy)erythromycin',\n",
       "  'Dirithromycin',\n",
       "  'Dirithromycine',\n",
       "  'Dirithromycinum',\n",
       "  'Diritromicina',\n",
       "  'Dirithromycin'],\n",
       " 'Netilmicin': ['1-N-Ethylsisomicin', 'Netilmycin', 'Netilmicin'],\n",
       " 'Hydrocodone': ['(-)-Dihydrocodeinone',\n",
       "  '4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one',\n",
       "  'Dihydrocodeinone',\n",
       "  'Hidrocodona',\n",
       "  'Hydrocodon',\n",
       "  'Hydrocodone',\n",
       "  'Hydrocodonum',\n",
       "  'Hydrocone',\n",
       "  'Hydroconum',\n",
       "  'Idrocodone',\n",
       "  'Hydrocodone'],\n",
       " 'Norgestimate': ['(+)-13-Ethyl-17-hydroxy-18,19-dinor-17Î±-pregn-4-en-20-yn-3-one oxime acetate (ester)',\n",
       "  '(17Î±)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime',\n",
       "  'd-13Î²-Ethyl-17Î±-ethynyl-17Î²-acetoxygon-4-en-3-one oxime',\n",
       "  'Dexnorgestrel Acetime',\n",
       "  'Norgestimate',\n",
       "  'Norgestimato',\n",
       "  'Norgestimatum',\n",
       "  'Norgestimate'],\n",
       " 'Carboplatin': ['Carboplatin',\n",
       "  'Carboplatine',\n",
       "  'Carboplatino',\n",
       "  'CBDCA',\n",
       "  'cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)',\n",
       "  'cis-diammine(1,1-cyclobutanedicarboxylato)platinum',\n",
       "  'cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)',\n",
       "  'Carboplatin'],\n",
       " 'Methylprednisolone': ['(6Î±,11Î²)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione',\n",
       "  '1-dehydro-6Î±-methylhydrocortisone',\n",
       "  '6Î±-methyl-11Î²,17Î±,21-triol-1,4-pregnadiene-3,20-dione',\n",
       "  'delta(1)-6alpha-Methylhydrocortisone',\n",
       "  'Methylprednisolon',\n",
       "  'Methylprednisolone',\n",
       "  'Methylprednisolonum',\n",
       "  'Metilprednisolona',\n",
       "  'Methylprednisolone'],\n",
       " 'Pindolol': ['1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol',\n",
       "  '1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol',\n",
       "  '1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol',\n",
       "  '4-(2-hydroxy-3-isopropylaminopropoxy)-indole',\n",
       "  'Pindolol',\n",
       "  'Pindololum',\n",
       "  'Pindolol'],\n",
       " 'Mepivacaine': [\"(+-)-1-Methyl-2',6'-pipecoloxylidide\",\n",
       "  \"1-methyl-2',6'-pipecoloxylidide\",\n",
       "  'DL-Mepivacaine',\n",
       "  'Mepivacaina',\n",
       "  'Mepivacaine',\n",
       "  'Mepivacainum',\n",
       "  'N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide',\n",
       "  'N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide',\n",
       "  'Mepivacaine'],\n",
       " 'Zaleplon': [\"3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide\",\n",
       "  'Zaleplon',\n",
       "  'Zaleplon'],\n",
       " 'Bromfenac': ['[2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid',\n",
       "  '2-amino-3-(4-bromobenzoyl)benzeneacetic acid',\n",
       "  'Bromfenac',\n",
       "  'Bromfenaco',\n",
       "  'Bromfenacum',\n",
       "  'Bromfenac'],\n",
       " 'Apraclonidine': ['4-Aminoclonidine',\n",
       "  'Apraclonidina',\n",
       "  'Apraclonidine',\n",
       "  'Apraclonidinum',\n",
       "  'Apraclonidine'],\n",
       " 'Ethiodized oil': ['Ethiodized oil'],\n",
       " 'Telmisartan': [\"4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid\",\n",
       "  \"4'-((4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid\",\n",
       "  \"4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid\",\n",
       "  \"4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid\",\n",
       "  'Telmisartan',\n",
       "  'Telmisartan'],\n",
       " 'Desloratadine': ['8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine',\n",
       "  '8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine',\n",
       "  'Descarboethoxyloratadine',\n",
       "  'Desloratadina',\n",
       "  'Desloratadine',\n",
       "  'Desloratadine'],\n",
       " 'Methyldopa': ['(S)-(-)-alpha-Methyldopa',\n",
       "  '3-Hydroxy-alpha-methyl-L-tyrosine',\n",
       "  'Alpha medopa',\n",
       "  'alpha-Methyl dopa',\n",
       "  'alpha-methyl-L-dopa',\n",
       "  'Alphamethyldopa',\n",
       "  'AMD',\n",
       "  'Anhydrous methyldopa',\n",
       "  'L-alpha-Methyldopa',\n",
       "  'L-Methyl Dopa',\n",
       "  'Methyl dopa',\n",
       "  'Methyldopa',\n",
       "  'Methyldopa anhydrous',\n",
       "  'metildopa',\n",
       "  'Î±-Methyl dopa',\n",
       "  'Î±-methyl-L-dopa',\n",
       "  'Methyldopa'],\n",
       " 'Alosetron': ['2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one',\n",
       "  'Alosetron',\n",
       "  'Alosetron'],\n",
       " 'Dactinomycin': [\"2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide\",\n",
       "  'ActD',\n",
       "  'Actinomycin C1',\n",
       "  'Actinomycin D',\n",
       "  'Actinomycin IV',\n",
       "  'Dactinomicina',\n",
       "  'Dactinomycin',\n",
       "  'Dactinomycine',\n",
       "  'Dactinomycinum',\n",
       "  'Meractinomycin',\n",
       "  'Dactinomycin'],\n",
       " 'Selenium Sulfide': ['Selenii disulfidum',\n",
       "  'Selenium disulfide',\n",
       "  'Selenium disulphide',\n",
       "  'Selenium sulfide, micronized',\n",
       "  'Selenium sulphide',\n",
       "  'Selenium sulphide, micronized',\n",
       "  'Selenium(IV) disulfide',\n",
       "  'Selenium(IV) disulphide',\n",
       "  'Selenium(IV) sulfide',\n",
       "  'Selenium(IV) sulphide',\n",
       "  'Selenium Sulfide'],\n",
       " 'Azelastine': ['4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone',\n",
       "  'Azelastina',\n",
       "  'Azelastine',\n",
       "  'AzÃ©lastine',\n",
       "  'Azelastinum',\n",
       "  'Azelastine'],\n",
       " 'Ezetimibe': ['Ezetimiba',\n",
       "  'Ã©zÃ©timibe',\n",
       "  'Ezetimibe',\n",
       "  'Ezetimibum',\n",
       "  'Ezetimibe'],\n",
       " 'Edetic acid': ['(ethylenedinitrilo)tetraacetic acid, ion(4â\\x88\\x92)',\n",
       "  '{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid',\n",
       "  \"2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate\",\n",
       "  'Acide edetique',\n",
       "  'Acide ethylenediaminetetracetique',\n",
       "  'Acido edetico',\n",
       "  'Acidum edeticum',\n",
       "  'Edetic acid',\n",
       "  'EDTA',\n",
       "  'EDTA, ion(4-)',\n",
       "  'Ethylenediaminetetraacetate',\n",
       "  'Ethylenediaminetetraacetic acid',\n",
       "  \"N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine)\",\n",
       "  'Edetic acid'],\n",
       " 'Dipyridamole': ['Dipiridamol',\n",
       "  'Dipyridamine',\n",
       "  'Dipyridamole',\n",
       "  'Dipyridamolum',\n",
       "  'Dipyudamine',\n",
       "  'Dypyridamol',\n",
       "  'Dipyridamole'],\n",
       " 'Telithromycin': ['Telithromycin', 'telitromicina', 'Telithromycin'],\n",
       " 'Ethinylestradiol': ['17-ethinyl-3,17-estradiol',\n",
       "  '17-ethinyl-3,17-oestradiol',\n",
       "  '17-ethinylestradiol',\n",
       "  '17alpha-Ethinyl estradiol',\n",
       "  '17Î±-ethynylestradiol',\n",
       "  'Ethinyl estradiol',\n",
       "  'Ethinylestradiol',\n",
       "  'Ethinylestradiolum',\n",
       "  'Ethinyloestradiol',\n",
       "  'Ethynyl estradiol',\n",
       "  'Etinilestradiol',\n",
       "  'Ethinylestradiol'],\n",
       " 'Lomefloxacin': ['(Â±)-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid',\n",
       "  '1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid',\n",
       "  'LFLX',\n",
       "  'Lomefloxacin',\n",
       "  'Lomefloxacine',\n",
       "  'Lomefloxacino',\n",
       "  'Lomefloxacinum',\n",
       "  'Lomefloxacin'],\n",
       " 'Cyclopentolate': ['(Â±)-cyclopentolate',\n",
       "  '1-hydroxy-Î±-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester',\n",
       "  '2-(dimethylamino)ethyl 1-hydroxy-Î±-phenylcyclopentaneacetate',\n",
       "  '2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate',\n",
       "  '2-phenyl-2-(1-hydroxycyclopentyl)ethanoic acid Î²-(dimethylamino)ethyl ester',\n",
       "  'Ciclopentolato',\n",
       "  'Cyclopentolate',\n",
       "  'Cyclopentolatum',\n",
       "  'Î±-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester',\n",
       "  'Î²-(dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate',\n",
       "  'Î²-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate',\n",
       "  'Cyclopentolate'],\n",
       " 'Ramelteon': ['Ramelteon', 'Ramelteon'],\n",
       " 'Physostigmine': ['Eserine', 'Physostigmine', 'Physostol', 'Physostigmine'],\n",
       " 'Isotretinoin': ['(7E,9E,11E,13Z)-retinoic acid',\n",
       "  '13-cis-retinoic acid',\n",
       "  '13-cis-Vitamin A acid',\n",
       "  '13-RA',\n",
       "  'cis-RA',\n",
       "  'Isotretinoin',\n",
       "  'IsotretinoÃ\\xadna',\n",
       "  'IsotrÃ©tinoine',\n",
       "  'Isotretinoino',\n",
       "  'Isotretinoinum',\n",
       "  'Neovitamin A acid',\n",
       "  'Isotretinoin'],\n",
       " 'Formoterol': [\"2'-hydroxy-5'-(1-hydroxy-2-((p-methoxy-Î±-methylphenethyl)amino)ethyl)formanilide\",\n",
       "  \"2'-hydroxy-5'-{1-hydroxy-2-[(p-methoxy-Î±-methylphenethyl)amino]ethyl}formanilide\",\n",
       "  'Formoterol',\n",
       "  'Formoterolum',\n",
       "  'N-[2-hydroxy-5-(1-hydroxy-2-{[2-(4-methoxyphenyl)-1-methylethyl]amino}ethyl)phenyl]formamide',\n",
       "  'Formoterol'],\n",
       " 'Nandrolone phenpropionate': ['19NTPP',\n",
       "  'Nadrolone phenylpropionate',\n",
       "  'Nandrolon phenylpropionate',\n",
       "  'Nandrolone phenylpionate',\n",
       "  'Nandrolone phenylpropionate',\n",
       "  'Norandrolone phenyl propionate',\n",
       "  'Norandrostenolone phenylpropionate',\n",
       "  'Nortestosterone phenylpropionate',\n",
       "  'NPP',\n",
       "  'NTPP',\n",
       "  'Nandrolone phenpropionate'],\n",
       " 'Dimenhydrinate': ['(O-benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate',\n",
       "  '8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)',\n",
       "  'Benzhydryl-Î²-dimethylaminoethylether 8-chlorotheophylline',\n",
       "  'Dimenhidrinato',\n",
       "  'Dimenhydrinate',\n",
       "  'Dimenhydrinatum',\n",
       "  'diphenhydramine 8-chlorotheophyllinate',\n",
       "  'diphenhydramine 8-chlorotheophylline',\n",
       "  'Diphenhydramine theoclate',\n",
       "  'N,N-dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate',\n",
       "  'O-benzhydryldimethylaminoethanol 8-chlorotheophyllinate',\n",
       "  'Î²-dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine',\n",
       "  'Dimenhydrinate'],\n",
       " 'Glycopyrronium': ['Glicopirronio',\n",
       "  'Glycopyrrolate cation',\n",
       "  'Glycopyrrolate ion',\n",
       "  'Glycopyrronium',\n",
       "  'Glycopyrronium cation',\n",
       "  'Glycopyrronium ion',\n",
       "  'Glycopyrronium'],\n",
       " 'Cytarabine': ['1-beta-D-Arabinofuranosylcytosine',\n",
       "  '4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone',\n",
       "  'Citarabina',\n",
       "  'Cytarabine',\n",
       "  'Cytarabinum',\n",
       "  'Cytosine arabinoside',\n",
       "  'Cytosine-1-beta-D-arabinofuranoside',\n",
       "  'cytosine-Î²-D-arabinofuranoside',\n",
       "  'Cytarabine'],\n",
       " 'Dopamine': ['2-(3,4-dihydroxyphenyl)ethylamine',\n",
       "  '3-Hydroxytyramine',\n",
       "  '3,4-Dihydroxyphenethylamine',\n",
       "  '4-(2-aminoethyl)-1,2-benzenediol',\n",
       "  '4-(2-Aminoethyl)benzene-1,2-diol',\n",
       "  '4-(2-aminoethyl)catechol',\n",
       "  '4-(2-aminoethyl)pyrocatechol',\n",
       "  'Dopamina',\n",
       "  'Dopamine',\n",
       "  'Dopaminum',\n",
       "  'Oxytyramine',\n",
       "  'Dopamine'],\n",
       " 'Rivastigmine': ['(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate',\n",
       "  'm-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate',\n",
       "  'Rivastigmina',\n",
       "  'Rivastigmine',\n",
       "  'Rivastigmine'],\n",
       " 'Exemestane': ['6-methyleneandrosta-1,4-diene-3,17-dione',\n",
       "  'Exemestane',\n",
       "  'Exemestano',\n",
       "  'Exemestanum',\n",
       "  'Exemestane'],\n",
       " 'Oxaprozin': ['Oxaprozin',\n",
       "  'Oxaprozina',\n",
       "  'Oxaprozine',\n",
       "  'Oxaprozinum',\n",
       "  'Oxaprozin'],\n",
       " 'Methyl aminolevulinate': ['5-aminolevulinic acid methyl ester',\n",
       "  'Aminolevulinato de metilo',\n",
       "  'Aminolevulinic acid methyl ester',\n",
       "  'methyl 5-aminolevulinate',\n",
       "  'Methyl aminolevulinate',\n",
       "  'Methyl delta-aminolevulinate',\n",
       "  'methyl Î´-aminolevulinate',\n",
       "  'Methyl aminolevulinate'],\n",
       " 'Azathioprine': ['6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine',\n",
       "  \"6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine\",\n",
       "  'Azamun',\n",
       "  'Azathioprine',\n",
       "  'Azathioprinum',\n",
       "  'Azatioprina',\n",
       "  'Azathioprine'],\n",
       " 'Neomycin': ['Fradiomycin',\n",
       "  'Kaomycine',\n",
       "  'Neomicina',\n",
       "  'Neomycin',\n",
       "  'Vonamycin',\n",
       "  'Neomycin'],\n",
       " 'Auranofin': ['(1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate',\n",
       "  '2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold',\n",
       "  'Auranofin',\n",
       "  'Auranofina',\n",
       "  'Auranofine',\n",
       "  'Auranofinum',\n",
       "  'Triethylphosphine gold',\n",
       "  'Auranofin'],\n",
       " 'Gabapentin': ['1-(Aminomethyl)cyclohexaneacetic acid',\n",
       "  'Gabapentin',\n",
       "  'Gabapentina',\n",
       "  'Gabapentine',\n",
       "  'Gabapentino',\n",
       "  'Gabapentinum',\n",
       "  'Gabapentin'],\n",
       " 'Doxorubicin': ['(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-Î±-L-lyxo-hexopyranoside',\n",
       "  '(8S-cis)-10-((3-amino-2,3,6-trideoxy-Î±-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione',\n",
       "  '14-hydroxydaunomycin',\n",
       "  '14-hydroxydaunorubicine',\n",
       "  'Doxorubicin',\n",
       "  'Doxorubicina',\n",
       "  'Doxorubicine',\n",
       "  'Doxorubicinum',\n",
       "  'Hydroxydaunorubicin',\n",
       "  'Doxorubicin'],\n",
       " 'Frovatriptan': ['Frovatriptan', 'Frovatriptan'],\n",
       " 'Hydrochlorothiazide': ['HCTZ',\n",
       "  'Hidroclorotiazida',\n",
       "  'Hydrochlorothiazide',\n",
       "  'Hydrochlorothiazidum',\n",
       "  'Hydrochlorothiazide'],\n",
       " 'Cyclacillin': ['(1-aminocyclohexyl)penicillin',\n",
       "  '(2S,5R,6R)-6-{[(1-aminocyclohexyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  '6-(1-aminocyclohexanecarboxamido)penicillanic acid',\n",
       "  '6-(1-aminocyclohexylcarboxamido)penicillanic acid',\n",
       "  'Ciclacilina',\n",
       "  'Ciclacillin',\n",
       "  'Ciclacilline',\n",
       "  'Ciclacillinum',\n",
       "  'Cyclacillin',\n",
       "  'Cyclacillin'],\n",
       " 'Salbutamol': ['Albuterol', 'Salbutamol', 'Salbutamolum', 'Salbutamol'],\n",
       " 'Levobupivacaine': ['(-)-bupivacaine',\n",
       "  \"(S)-1-butyl-2',6'-pipecoloxylidide\",\n",
       "  '(S)-bupivacaine',\n",
       "  \"L-(-)-1-Butyl-2',6'-pipecoloxylidide\",\n",
       "  'L-(â\\x88\\x92)-bupivacaine',\n",
       "  'LevobupivacaÃ\\xadna',\n",
       "  'Levobupivacaine',\n",
       "  'Levobupivacaine'],\n",
       " 'Cromoglicic acid': ['5-[3-(2-carboxy-4-oxo-4H-5-chromenyloxy)-2-hydroxypropoxy]-4-oxo-4H-2-chromenecarboxylic acid',\n",
       "  'Acide Cromoglicique',\n",
       "  'Acido Cromoglicico',\n",
       "  'Acidum Cromoglicicum',\n",
       "  'Cromoglicate',\n",
       "  'Cromoglicic acid',\n",
       "  'Cromoglycate',\n",
       "  'Cromoglycic acid',\n",
       "  'Cromolyn',\n",
       "  'Cromoglicic acid'],\n",
       " 'Ganciclovir': ['2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol',\n",
       "  '2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one',\n",
       "  '2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one',\n",
       "  '2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol',\n",
       "  '2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one',\n",
       "  '2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone',\n",
       "  '9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine',\n",
       "  '9-[(1,3-dihydroxy-2-propoxy)methyl]guanine',\n",
       "  'GA2',\n",
       "  'Ganciclovir',\n",
       "  'Ganciclovirum',\n",
       "  'Gancyclovir',\n",
       "  'Ganciclovir'],\n",
       " 'Hydroxyurea': ['Carbamohydroxamic acid',\n",
       "  'Carbamohydroximic acid',\n",
       "  'Carbamoyl oxime',\n",
       "  'Carbamyl hydroxamate',\n",
       "  'Hidroxicarbamida',\n",
       "  'Hydrea',\n",
       "  'Hydroxycarbamid',\n",
       "  'Hydroxycarbamide',\n",
       "  'Hydroxycarbamidum',\n",
       "  'Hydroxyharnstoff',\n",
       "  'Hydroxyurea',\n",
       "  'N-Carbamoylhydroxylamine',\n",
       "  'N-Hydroxyurea',\n",
       "  'Oxyurea',\n",
       "  'Hydroxyurea'],\n",
       " 'Letrozole': ['Letrozol', 'Letrozole', 'Letrozole'],\n",
       " 'Tioconazole': ['Tioconazol', 'Tioconazole', 'Tioconazolum', 'Tioconazole'],\n",
       " 'Busulfan': ['1,4-Bis(methanesulfonoxy)butane',\n",
       "  '1,4-Butanediol dimethanesulfonate',\n",
       "  '1,4-Dimesyloxybutane',\n",
       "  '1,4-Dimethanesulfonoxybutane',\n",
       "  'Busulfan',\n",
       "  'Busulfano',\n",
       "  'Busulfanum',\n",
       "  'Busulphan',\n",
       "  'Tetramethylene bis(methanesulfonate)',\n",
       "  'Busulfan'],\n",
       " 'Ketoprofen': ['2-(3-Benzoylphenyl)propionic acid',\n",
       "  '3-Benzoyl-alpha-methylbenzeneacetic acid',\n",
       "  '3-Benzoyl-Î±-methylbenzeneacetic acid',\n",
       "  '3-Benzoylhydratropic acid',\n",
       "  'Ketoprofen',\n",
       "  'Ketoprofeno',\n",
       "  \"L'acide (benzoyl-3-phenyl)-2-propionique\",\n",
       "  'm-Benzoylhydratropic acid',\n",
       "  'Ketoprofen'],\n",
       " 'Edrophonium': ['(3-hydroxyphenyl)dimethylethylammonium',\n",
       "  '3-hydroxy-N,N-dimethyl-N-ethylanilinium',\n",
       "  'Edrophonium cation',\n",
       "  'Edrophonium ion',\n",
       "  'Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium',\n",
       "  'N-ethyl-3-hydroxy-N,N-dimethylanilinium',\n",
       "  'N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium',\n",
       "  'Edrophonium'],\n",
       " 'Metyrapone': ['Metirapona',\n",
       "  'MÃ©tyrapone',\n",
       "  'Metyrapone',\n",
       "  'Metyraponum',\n",
       "  'Metyrapone'],\n",
       " 'Cinacalcet': ['(R)-Î±-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine',\n",
       "  'Cinacalcet',\n",
       "  'CNC',\n",
       "  'N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine',\n",
       "  'Cinacalcet'],\n",
       " 'Clobetasol propionate': ['21-chloro-9-fluoro-11Î²,17-dihydroxy-16Î²-methylpregna-1,4-diene-3,20-dione 17-propionate',\n",
       "  'clobetasol 17-propanoate',\n",
       "  'clobetasol 17-propionate',\n",
       "  'Clobetasol propionate',\n",
       "  'Clobetasol propionate E',\n",
       "  'Clobetasol propionate'],\n",
       " 'Balsalazide': ['(E)-5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid',\n",
       "  '(E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid',\n",
       "  '3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid',\n",
       "  '5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid',\n",
       "  'Balsalazida',\n",
       "  'Balsalazide',\n",
       "  'Balsalazidum',\n",
       "  'Balsalazide'],\n",
       " 'Sulfamethoxazole': ['3-(p-Aminophenylsulfonamido)-5-methylisoxazole',\n",
       "  '3-Sulfanilamido-5-methylisoxazole',\n",
       "  '4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide',\n",
       "  'SMX',\n",
       "  'Sulfamethoxazole',\n",
       "  'Sulfametoxazol',\n",
       "  'Sulphamethoxazole',\n",
       "  'Sulfamethoxazole'],\n",
       " 'Glyburide': ['1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea',\n",
       "  '1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea',\n",
       "  '5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide',\n",
       "  'Glibenclamida',\n",
       "  'Glibenclamide',\n",
       "  'Glibenclamidum',\n",
       "  'Glyburide',\n",
       "  'Glyburide'],\n",
       " 'Minocycline': ['(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide',\n",
       "  '7-Dimethylamino-6-demethyl-6-deoxytetracycline',\n",
       "  'Minociclina',\n",
       "  'Minociclinum',\n",
       "  'Minocyclin',\n",
       "  'Minocycline',\n",
       "  'Minocyclinum',\n",
       "  'Minomycin',\n",
       "  'Minocycline'],\n",
       " ...}"
      ]
     },
     "execution_count": 107,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drug_dic = {k:[elem for elem in v if elem != 'nan' ] for k,v in drug_dic.items()}\n",
    "drug_dic\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "metadata": {},
   "outputs": [],
   "source": [
    "from joblib import dump, load\n",
    "\n",
    "dump(drug_dic, 'drug_dic.joblib') \n",
    "drug_dic = load('drug_dic.joblib') "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 109,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Lepirudin': ['Hirudin variant-1', 'Lepirudin recombinant', 'Lepirudin'],\n",
       " 'Cetuximab': ['Cetuximab', 'CÃ©tuximab', 'Cetuximabum', 'Cetuximab'],\n",
       " 'Dornase alfa': ['Deoxyribonuclease (human clone 18-1 protein moiety)',\n",
       "  'Dornasa alfa',\n",
       "  'Dornase alfa, recombinant',\n",
       "  'Dornase alpha',\n",
       "  'Recombinant deoxyribonuclease (DNAse)',\n",
       "  'Dornase alfa'],\n",
       " 'Denileukin diftitox': ['Denileukin',\n",
       "  'Interleukin-2/diptheria toxin fusion protein',\n",
       "  'Denileukin diftitox'],\n",
       " 'Etanercept': ['Etanercept',\n",
       "  'etanercept-szzs',\n",
       "  'etanercept-ykro',\n",
       "  'Recombinant human TNF',\n",
       "  'rhu TNFR:Fc',\n",
       "  'rhu-TNFR:Fc',\n",
       "  'TNFR-Immunoadhesin',\n",
       "  'Etanercept'],\n",
       " 'Bivalirudin': ['Bivalirudin',\n",
       "  'Bivalirudina',\n",
       "  'Bivalirudinum',\n",
       "  'Bivalirudin'],\n",
       " 'Leuprolide': ['Leuprorelin',\n",
       "  'Leuprorelina',\n",
       "  'Leuproreline',\n",
       "  'Leuprorelinum',\n",
       "  'Leuprolide'],\n",
       " 'Peginterferon alfa-2a': ['PEG-IFN alfa-2A',\n",
       "  'PEG-Interferon alfa-2A',\n",
       "  'Peginterferon alfa-2a',\n",
       "  'Pegylated Interfeaon alfa-2A',\n",
       "  'Pegylated interferon alfa-2a',\n",
       "  'Pegylated interferon alpha-2a',\n",
       "  'Pegylated-interferon alfa 2a',\n",
       "  'Peginterferon alfa-2a'],\n",
       " 'Alteplase': ['Alteplasa',\n",
       "  'Alteplase (genetical recombination)',\n",
       "  'Alteplase, recombinant',\n",
       "  'Alteplase,recombinant',\n",
       "  'Plasminogen activator (human tissue-type protein moiety)',\n",
       "  'rt-PA',\n",
       "  't-PA',\n",
       "  't-plasminogen activator',\n",
       "  'Tissue plasminogen activator',\n",
       "  'Tissue plasminogen activator alteplase',\n",
       "  'Tissue plasminogen activator, recombinant',\n",
       "  'tPA',\n",
       "  'Alteplase'],\n",
       " 'Sermorelin': ['Sermorelin'],\n",
       " 'Interferon alfa-n1': ['Interferon alpha-n1 (INS)', 'Interferon alfa-n1'],\n",
       " 'Darbepoetin alfa': ['Darbepoetin',\n",
       "  'Darbepoetin alfa,recombinant',\n",
       "  'Darbepoetina alfa',\n",
       "  'Darbepoetin alfa'],\n",
       " 'Urokinase': ['Kinase (enzyme-activating), uro-urokinase',\n",
       "  'TCUK',\n",
       "  'Tissue culture urokinase',\n",
       "  'Two-chain urokinase',\n",
       "  'Urochinasi',\n",
       "  'Urokinase',\n",
       "  'Urokinasum',\n",
       "  'Uroquinasa',\n",
       "  'Urokinase'],\n",
       " 'Goserelin': ['Goserelin', 'Goserelina', 'Goserelin'],\n",
       " 'Reteplase': ['Human t-PA (residues 1-3 and 176-527)',\n",
       "  'Reteplasa',\n",
       "  'Reteplase, recombinant',\n",
       "  'Reteplase,recombinant',\n",
       "  'Reteplase'],\n",
       " 'Erythropoietin': ['E.P.O.',\n",
       "  'Epoetin alfa',\n",
       "  'Epoetin alfa rDNA',\n",
       "  'Epoetin alfa-epbx',\n",
       "  'Epoetin alfa, recombinant',\n",
       "  'Epoetin beta',\n",
       "  'Epoetin beta rDNA',\n",
       "  'Epoetin epsilon',\n",
       "  'Epoetin gamma',\n",
       "  'Epoetin gamma rDNA',\n",
       "  'Epoetin kappa',\n",
       "  'Epoetin omega',\n",
       "  'Epoetin theta',\n",
       "  'Epoetin zeta',\n",
       "  'Epoetina alfa',\n",
       "  'Epoetina beta',\n",
       "  'Epoetina dseta',\n",
       "  'Epoetina zeta',\n",
       "  'EpoÃ©tine zÃªta',\n",
       "  'Epoetinum zeta',\n",
       "  'Erythropoiesis stimulating factor',\n",
       "  'Erythropoietin (human, recombinant)',\n",
       "  'Erythropoietin (recombinant human)',\n",
       "  'ESF',\n",
       "  'SH-polypeptide-72',\n",
       "  'Erythropoietin'],\n",
       " 'Salmon calcitonin': ['Calcitonin (Salmon Synthetic)',\n",
       "  'Calcitonin salmon',\n",
       "  'Calcitonin salmon recombinant',\n",
       "  'Calcitonin-salmon',\n",
       "  'Calcitonin, salmon',\n",
       "  'Calcitonina salmÃ³n sintÃ©tica',\n",
       "  'Recombinant salmon calcitonin',\n",
       "  'Salmon calcitonin',\n",
       "  'Salmon calcitonin'],\n",
       " 'Interferon alfa-n3': ['Interferon alfa-n3'],\n",
       " 'Pegfilgrastim': ['Granulocyte colony-stimulating factor pegfilgrastim',\n",
       "  'peg-filgrastim',\n",
       "  'pegfilgrastim-apgf',\n",
       "  'pegfilgrastim-bmez',\n",
       "  'pegfilgrastim-cbqv',\n",
       "  'pegfilgrastim-jmdb',\n",
       "  'Pegfilgrastim'],\n",
       " 'Sargramostim': ['Recombinant human granulocyte-macrophage colony stimulating factor',\n",
       "  'rGM-CSF',\n",
       "  'rHu GM-CSF',\n",
       "  'Sargramostim',\n",
       "  'Sargramostim'],\n",
       " 'Peginterferon alfa-2b': ['Peginterferon alfa-2b'],\n",
       " 'Asparaginase Escherichia coli': ['Asparaginase',\n",
       "  'Asparaginase (E. coli)',\n",
       "  'Colaspase',\n",
       "  'Escherichia coli L-asparaginase',\n",
       "  'L-asparaginase',\n",
       "  'L-asparagine amidohydrolase',\n",
       "  'Asparaginase Escherichia coli'],\n",
       " 'Thyrotropin alfa': ['Recombinant Human Thyroid Stimulating Hormone',\n",
       "  'Recombinant thyrotropin alfa',\n",
       "  'rhTSH',\n",
       "  'rTSH',\n",
       "  'Thyrotropin alpha',\n",
       "  'Thyrotropin alfa'],\n",
       " 'Antihemophilic factor, human recombinant': ['Antihemophilic factor (recombinant)',\n",
       "  'Antihemophilic factor recombinant',\n",
       "  'Antihemophilic factor, human recombinant',\n",
       "  'Antihemophilic factor, recombinant',\n",
       "  'Factor VIII (rDNA)',\n",
       "  'Factor VIII (Recombinant)',\n",
       "  'Factor VIII recombin',\n",
       "  'Factor VIII, recombinant',\n",
       "  'Human Factor VIII (Recombinant)',\n",
       "  'Human factor VIII recombinant',\n",
       "  'Octocog alfa',\n",
       "  'rAHF',\n",
       "  'Recombinant antihemophilic factor VIII',\n",
       "  'Antihemophilic factor, human recombinant'],\n",
       " 'Anakinra': ['Anakinra',\n",
       "  'IL-1RA',\n",
       "  'Interleukin-1 receptor antagonist anakinra',\n",
       "  'Anakinra'],\n",
       " 'Gramicidin D': ['Bacillus brevis gramicidin D',\n",
       "  'Gramicidin',\n",
       "  'Gramicidin A',\n",
       "  'Gramicidin B',\n",
       "  'Gramicidin C',\n",
       "  'Gramicidina',\n",
       "  'Gramicidine',\n",
       "  'Gramicidin D'],\n",
       " 'Human immunoglobulin G': ['Human IGG',\n",
       "  'Human immunoglobulin G',\n",
       "  'Human normal immunoglobulin',\n",
       "  'Immune globulin (human)',\n",
       "  'Immune globulin human',\n",
       "  'Immunoglobulin (human)',\n",
       "  'Immunoglobulin G (human)',\n",
       "  'Immunoglobulin G, human',\n",
       "  'IVIg',\n",
       "  'Human immunoglobulin G'],\n",
       " 'Anistreplase': ['Anisoylated plasminogen streptokinase activator complex',\n",
       "  'APSAC',\n",
       "  'Anistreplase'],\n",
       " 'Insulin human': ['High molecular weight insulin human',\n",
       "  'Human insulin',\n",
       "  'human insulin (rDNA)',\n",
       "  'Insulin (human)',\n",
       "  'Insulin human',\n",
       "  'Insulin human [rDNA origin]',\n",
       "  'Insulin Human Regular',\n",
       "  'Insulin human regular (rDNA)',\n",
       "  'Insulin human, rDNA origin',\n",
       "  'Insulin recombinant human',\n",
       "  'Insulin recombinant purified human',\n",
       "  'Insulin regular',\n",
       "  'Insulin, human',\n",
       "  'Insulina regular',\n",
       "  'Regular Insulin, human',\n",
       "  'Insulin human'],\n",
       " 'Tenecteplase': ['Tenecteplasa', 'TNK-tPA', 'Tenecteplase'],\n",
       " 'Menotropins': ['Human menopausal gonadotrophin',\n",
       "  'Menotrophin',\n",
       "  'Menotropin',\n",
       "  'Menotropina',\n",
       "  'Menotropins (FSH;LH)',\n",
       "  'Menotropins'],\n",
       " 'Interferon gamma-1b': ['IFN-gamma 1b',\n",
       "  'IFN-gamma-1b',\n",
       "  'Interferon gamma 1-b',\n",
       "  'Interferon gamma-1b',\n",
       "  'Interferon gamma-1b, recombinant',\n",
       "  'Interferon gamma-2a',\n",
       "  'Interferon gamma-1b'],\n",
       " 'Interferon alfa-2a, Recombinant': ['Interferon alfa-2a',\n",
       "  'Interferon alfa-2a (recombinant)',\n",
       "  'Interferon alfa-2a, recombinant',\n",
       "  'Interferon alfa-2a,recombinant',\n",
       "  'Interferon alpha-2a',\n",
       "  'Interferon-alfa-2a',\n",
       "  'Recombinant human interferon alfa-2a',\n",
       "  'Recombinant human interferon-alfa-2a',\n",
       "  'rIFN-alpha-2a',\n",
       "  'SH-polypeptide-46',\n",
       "  'Interferon alfa-2a, Recombinant'],\n",
       " 'Desmopressin': ['1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin',\n",
       "  '1-deamino-8-D-arginine vasopressin',\n",
       "  '1-desamino-8-D-arginine vasopressin',\n",
       "  'dDAVP',\n",
       "  'Desmopresina',\n",
       "  'Desmopressin',\n",
       "  'Desmopressine',\n",
       "  'Desmopressinum',\n",
       "  'Desmopressin'],\n",
       " 'Coagulation factor VIIa Recombinant Human': ['Coagulation factor VIIa',\n",
       "  'Coagulation factor VIIa (recombinant)',\n",
       "  'Coagulation factor VIIa (recombinant)-jncw',\n",
       "  'Eptacog alfa',\n",
       "  'Eptacog alfa (activated)',\n",
       "  'rFVIIa',\n",
       "  'Coagulation factor VIIa Recombinant Human'],\n",
       " 'Oprelvekin': ['IL-11',\n",
       "  'Interleukin 11',\n",
       "  'Interleukin-11',\n",
       "  'Oprelvekin',\n",
       "  'Recombinant interleukin-11',\n",
       "  'Oprelvekin'],\n",
       " 'Palifermin': ['24-163 fibroblast growth factor 7 (human)',\n",
       "  'Palifermina',\n",
       "  'Palifermin'],\n",
       " 'Glucagon': ['Glucagon',\n",
       "  'Glucagon (recombinant dna origin)',\n",
       "  'Glucagon recombinant',\n",
       "  'Glucagon, human',\n",
       "  'Glucagon, porcine',\n",
       "  'Glucagone',\n",
       "  'Glucagonum',\n",
       "  'Glucagon'],\n",
       " 'Aldesleukin': ['125-L-serine-2-133-interleukin 2 (human reduced)',\n",
       "  'Aldesleukina',\n",
       "  'Interleukin-2 aldesleukin',\n",
       "  'Interleukin-2(2-133),125-ser',\n",
       "  'Recombinant interleukin-2 human',\n",
       "  'Aldesleukin'],\n",
       " 'Botulinum Toxin Type B': ['Botulin B',\n",
       "  'Botulinum B toxin',\n",
       "  'Botulinum neurotoxin type B precursor',\n",
       "  'BTX-B',\n",
       "  'RimabotulinumtoxinB',\n",
       "  'Toxina botulÃ\\xadnica B',\n",
       "  'Botulinum Toxin Type B'],\n",
       " 'Omalizumab': ['Omalizumab'],\n",
       " 'Lutropin alfa': ['Lutropin alfa',\n",
       "  'Lutropin alpha',\n",
       "  'Lutropina alfa',\n",
       "  'Lutropin alfa'],\n",
       " 'Lyme disease vaccine (recombinant OspA)': ['Lipoprotein OspA antigen recombinant',\n",
       "  'Lipoprotein outer surface a borrelia burgdorferi antigen',\n",
       "  'OspA lipoprotein',\n",
       "  'Lyme disease vaccine (recombinant OspA)'],\n",
       " 'Insulin lispro': ['Insulin lispro (genetical recombination)',\n",
       "  'Insulin lispro (rDNA origin)',\n",
       "  'Insulin lispro protamine',\n",
       "  'Insulin lispro protamine recombinant',\n",
       "  'Insulin lispro recombinant',\n",
       "  'insulin lispro-aabc',\n",
       "  'Insulin,lispro,human/rDNA',\n",
       "  'Insulin,lispro,protamine/rDNA',\n",
       "  'Insulina lispro',\n",
       "  'Insulin lispro'],\n",
       " 'Insulin glargine': ['Insulin glargine',\n",
       "  'Insulin Glargine (rDNA origin)',\n",
       "  'Insulin glargine recombinant',\n",
       "  'Insulina glargina',\n",
       "  'Insulin glargine'],\n",
       " 'Collagenase clostridium histolyticum': ['Clostridium histolyticum enzymes',\n",
       "  'Collagenase',\n",
       "  'Collagenase clostridium histolyticum',\n",
       "  'Collagenase clostridium histolyticum'],\n",
       " 'Rasburicase': ['Rasburicasa', 'Rasburicase', 'Urate oxidase', 'Rasburicase'],\n",
       " 'Cetrorelix': ['Cetrorelix', 'Cetrorelixum', 'Cetrorelix'],\n",
       " 'Adalimumab': ['Adalimumab (genetical recombination)',\n",
       "  'adalimumab-adaz',\n",
       "  'adalimumab-adbm',\n",
       "  'adalimumab-afzb',\n",
       "  'adalimumab-atto',\n",
       "  'adalimumab-bwwd',\n",
       "  'Adalimumab'],\n",
       " 'Somatotropin': ['Growth hormone',\n",
       "  'Growth hormone (human)',\n",
       "  'hGH',\n",
       "  'Human growth hormone',\n",
       "  'Recombinant human growth hormone',\n",
       "  'rhGH',\n",
       "  'Somatotropin (human)',\n",
       "  'Somatotropin human',\n",
       "  'Somatotropin human growth hormone',\n",
       "  'Somatropin',\n",
       "  'Somatropin (rDNA origin)',\n",
       "  'Somatropin (recombinant DNA origin)',\n",
       "  'Somatropin [rDNA origin]',\n",
       "  'Somatropin recombinant',\n",
       "  'Somatropin(recombinant DNA origin)',\n",
       "  'Somatropina',\n",
       "  'Somatotropin'],\n",
       " 'Imiglucerase': ['Imiglucerasa', 'Imiglucerase'],\n",
       " 'Abciximab': ['Abciximab',\n",
       "  'Abciximab (genetical recombination)',\n",
       "  'c7E3',\n",
       "  'Abciximab'],\n",
       " 'Drotrecogin alfa': ['Activated protein C',\n",
       "  'Blood coagulation factor XIV (human)',\n",
       "  'Drotrecogin alfa (activated)',\n",
       "  'Drotrecogin alfa (activated), lyophilized',\n",
       "  'Drotrecogin alfa activated',\n",
       "  'Drotrecogin alfa, activated',\n",
       "  'Drotrecogin-alfa',\n",
       "  'Recombinant human activated protein C (rH-APC)',\n",
       "  'Drotrecogin alfa'],\n",
       " 'Gemtuzumab ozogamicin': ['Gemtuzumab ozogamicin'],\n",
       " 'Indium In-111 satumomab pendetide': ['Indium (111In) satumomab pendetide',\n",
       "  'Indium In 111 satumomab pendetide',\n",
       "  'Indium-111 satumomab pendetide',\n",
       "  'Indium In-111 satumomab pendetide'],\n",
       " 'Alpha-1-proteinase inhibitor': ['Alfa 1-proteinase inhibitor (human)',\n",
       "  'Alfa-1-antitripsina',\n",
       "  'Alfa1 antitrypsin',\n",
       "  'Alpha 1-antitrypsin',\n",
       "  'Alpha 1-Proteinase Inhibitor',\n",
       "  'Alpha 1-proteinase inhibitor (human)',\n",
       "  'Alpha 1-proteinase inhibitor, human',\n",
       "  'Alpha-1 protease inhibitor',\n",
       "  'Alpha-1 proteinase inhibitor (human)',\n",
       "  'Alpha-1-antiproteinase',\n",
       "  'Alpha-1-antitrypsin',\n",
       "  'Alpha-1-proteinase Inhibitor (human)',\n",
       "  'Alpha-1-proteinase inhibitor human',\n",
       "  'Alpha-1-proteinase Inhibitor, Human',\n",
       "  'Alpha-1-proteinase inhibitor,human',\n",
       "  'Alpha1-proteinase Inhibitor',\n",
       "  'Alpha1-proteinase inhibitor (human)',\n",
       "  'alpha1-proteinase inhibitor human',\n",
       "  'API',\n",
       "  'Alpha-1-proteinase inhibitor'],\n",
       " 'Pegaspargase': ['Peg-asparaginase',\n",
       "  'Peg/L-asparaginase',\n",
       "  'Pegaspargasa',\n",
       "  'Pegaspargase'],\n",
       " 'Interferon beta-1a': ['Interferon beta 1-a',\n",
       "  'Interferon beta 1a',\n",
       "  'Interferon beta-1a (recombinant human)',\n",
       "  'Interferon beta-1a,recombinant',\n",
       "  'Interferon-beta-1a',\n",
       "  'Interferon beta-1a'],\n",
       " 'Pegademase': ['(monomethoxypolyethylene glycol succinimidyl) 11-17-adenosine deaminase',\n",
       "  'PEG-adenosine deaminase',\n",
       "  'pegADA',\n",
       "  'Pegademase',\n",
       "  'Pegademase bovine',\n",
       "  'Pegademase'],\n",
       " 'Albumin human': ['Albumin (human)',\n",
       "  'Albumin human',\n",
       "  'Albumin, blood',\n",
       "  'Albumin, human',\n",
       "  'Albumin, human-kjda',\n",
       "  'Human albumin',\n",
       "  'Human serum albumin',\n",
       "  'Serum albumin',\n",
       "  'Albumin human'],\n",
       " 'Eptifibatide': ['Eptifibatida',\n",
       "  'Eptifibatide',\n",
       "  'Integrelin',\n",
       "  'Intrifiban',\n",
       "  'Eptifibatide'],\n",
       " 'Infliximab': ['Infliximab (genetical recombination)',\n",
       "  'Infliximab-abda',\n",
       "  'Infliximab-axxq',\n",
       "  'Infliximab-dyyb',\n",
       "  'Infliximab-qbtx',\n",
       "  'Infliximab'],\n",
       " 'Follitropin': ['Folitropina alfa',\n",
       "  'Folitropina beta',\n",
       "  'Folitropina delta',\n",
       "  'Follicle stimulating hormone',\n",
       "  'Follitrophin alfa',\n",
       "  'Follitrophin alpha',\n",
       "  'Follitrophin beta',\n",
       "  'Follitropin alfa',\n",
       "  'Follitropin alfa/beta',\n",
       "  'Follitropin alpha',\n",
       "  'Follitropin beta',\n",
       "  'Follitropin delta',\n",
       "  'Follitropin gamma',\n",
       "  'Follotropin recombinant',\n",
       "  'FSH',\n",
       "  'FSH alpha',\n",
       "  'FSH-a',\n",
       "  'FSH-b',\n",
       "  'FSH-beta',\n",
       "  'Recombinant human follicle stimulating hormone beta',\n",
       "  'Recombinant human follicle-stimulating hormone (r-HFSH)',\n",
       "  'rFSH-alpha',\n",
       "  'Follitropin'],\n",
       " 'Vasopressin': ['Vasopressin, unspecified', 'Vasopressina', 'Vasopressin'],\n",
       " 'Interferon beta-1b': ['Interferon beta 1b (recombinant)',\n",
       "  'Interferon beta-1b,recombinant',\n",
       "  'Interferon-beta-1b',\n",
       "  'Recombinant interferon beta-1b',\n",
       "  'Interferon beta-1b'],\n",
       " 'Interferon alfacon-1': ['IFN Alfacon-1',\n",
       "  'IFN-Con1',\n",
       "  'Interferon alfacon-1',\n",
       "  'Interferon alfacon-1'],\n",
       " 'Hyaluronidase (ovine)': ['Hyaluronidase (glycoprotein, sheep testis isoenzyme)',\n",
       "  'Hyaluronidase (ovine)',\n",
       "  'Hyaluronidase (sheep testis isoenzyme)',\n",
       "  'Hyaluronidase, ovine',\n",
       "  'Ovine hyaluronidase',\n",
       "  'Hyaluronidase (ovine)'],\n",
       " 'Insulin pork': ['Insulin (pork)',\n",
       "  'Insulin porcine',\n",
       "  'Insulin purified porcine',\n",
       "  'Insulin purified pork',\n",
       "  'Insulin, porcine',\n",
       "  'Insulin, regular, pork',\n",
       "  'Porcine insulin',\n",
       "  'Insulin pork'],\n",
       " 'Trastuzumab': ['RHUMAB HER2',\n",
       "  'trastuzumab-anns',\n",
       "  'trastuzumab-dkst',\n",
       "  'trastuzumab-dttb',\n",
       "  'trastuzumab-pkrb',\n",
       "  'trastuzumab-qyyp',\n",
       "  'Trastuzumab'],\n",
       " 'Rituximab': ['rituximab-abbs', 'rituximab-pvvr', 'Rituximab'],\n",
       " 'Basiliximab': ['Basiliximab', 'Basiliximab'],\n",
       " 'Muromonab': ['Anti-CD3', 'Muromonab-CD3', 'Muromonab'],\n",
       " 'Digoxin Immune Fab (Ovine)': ['Digitalis antitoxin',\n",
       "  'Digoxin Immune Fab, Ovine',\n",
       "  'Digoxin-specific Antibody Fragments',\n",
       "  'Ovine digoxin immune fab',\n",
       "  'Digoxin Immune Fab (Ovine)'],\n",
       " 'Ibritumomab tiuxetan': ['Ibritumomab',\n",
       "  'mAb Murine (IGG1) Anti P19437 (CD20_MOUSE)',\n",
       "  'Ibritumomab tiuxetan'],\n",
       " 'Daptomycin': ['Daptomicina',\n",
       "  'Daptomycin',\n",
       "  'Daptomycine',\n",
       "  'Daptomycinum',\n",
       "  'Daptomycin'],\n",
       " 'Tositumomab': ['Tositumomab'],\n",
       " 'Pegvisomant': ['Pegvisomant'],\n",
       " 'Botulinum toxin type A': ['AbobotulinumtoxinA',\n",
       "  'Botulinum A neurotoxin',\n",
       "  'Botulinum toxin A',\n",
       "  'Botulinum toxin type A',\n",
       "  'BTX-A',\n",
       "  'Evabotulinumtoxina',\n",
       "  'IncobotulinumtoxinA',\n",
       "  'OnabotulinumtoxinA',\n",
       "  'Prabotulinumtoxin A',\n",
       "  'Toxina botulÃ\\xadnica A',\n",
       "  'Toxine botulinique A',\n",
       "  'Botulinum toxin type A'],\n",
       " 'Pancrelipase': ['Pancrealipase',\n",
       "  'Pancreatic extract pancrelipase',\n",
       "  'Pancreatic protease',\n",
       "  'Pancreatin',\n",
       "  'Pancreatinum',\n",
       "  'Pancrelipase (amylase;lipase;protease)',\n",
       "  'Pancrelipase'],\n",
       " 'Streptokinase': ['Estreptoquinasa',\n",
       "  'Streptochinasi',\n",
       "  'Streptococcal fibrinolysin',\n",
       "  'Streptokinase',\n",
       "  'Streptokinasum',\n",
       "  'Streptokinase'],\n",
       " 'Alemtuzumab': ['Alemtuzumab'],\n",
       " 'Alglucerase': ['Alglucerase'],\n",
       " 'Capromab pendetide': ['(111In)-Capromab pendetide',\n",
       "  'Indium (111In) capromab pendetide',\n",
       "  'Indium 111 Capromab Pendetide',\n",
       "  'Indium In 111 capromab pendetide',\n",
       "  'Capromab pendetide'],\n",
       " 'Laronidase': ['alpha-L-Idosiduronase',\n",
       "  'Human Recombinant alpha-L-iduronidase',\n",
       "  'Laronidasa',\n",
       "  'Laronidase',\n",
       "  'Laronidase (genetical recombination)',\n",
       "  'Laronidase'],\n",
       " 'Cyclosporine': ['Ciclosporin',\n",
       "  'Ciclosporina',\n",
       "  'Ciclosporine',\n",
       "  'Ciclosporinum',\n",
       "  'CsA',\n",
       "  'CyA',\n",
       "  'Cyclosporin',\n",
       "  'Cyclosporin A',\n",
       "  'Cyclosporine',\n",
       "  'Cyclosporine'],\n",
       " 'Alefacept': ['Alefacept'],\n",
       " 'Felypressin': ['2-(L-phenylalanine)-8-L-lysinevasopressin',\n",
       "  'Felipresina',\n",
       "  'Felypressin',\n",
       "  'Felypressine',\n",
       "  'Felypressinum',\n",
       "  'PLV-2',\n",
       "  'Felypressin'],\n",
       " 'Urofollitropin': ['Follitropin human', 'Urofollitrophin', 'Urofollitropin'],\n",
       " 'Efalizumab': ['anti-CD11a', 'antiCD11 alpha', 'Efalizumab', 'Efalizumab'],\n",
       " 'Choriogonadotropin alfa': ['Choriogonadotropin alpha',\n",
       "  'Chorionic gonadotropin (recombinant)',\n",
       "  'Choriogonadotropin alfa'],\n",
       " 'Antithymocyte immunoglobulin (rabbit)': ['Anti-human thymocyte immunoglobulin, rabbit',\n",
       "  'Anti-T-lymphocyte immune globulin, rabbit',\n",
       "  'Anti-thymocyte globulin (rabbit)',\n",
       "  'Anti-thymocyte globulin rabbit',\n",
       "  'Antithymocyte immunoglobulin',\n",
       "  'Lapine T-lymphocyte immune globulin',\n",
       "  'Rabbit anti-human thymocyte globulin',\n",
       "  'Rabbit anti-human thymocyte globulin (rATG)',\n",
       "  'Rabbit anti-human thymocyte immunoglobulin',\n",
       "  'Rabbit anti-thymocyte immunoglobulin',\n",
       "  'Rabbit antithymocyte globulin',\n",
       "  'Rabbit ATG',\n",
       "  'rATG',\n",
       "  'Thymoglobulin',\n",
       "  'Thymoglobuline',\n",
       "  'Antithymocyte immunoglobulin (rabbit)'],\n",
       " 'Filgrastim': ['Filgrastim-aafi',\n",
       "  'Filgrastim-sndz',\n",
       "  'G-CSF ',\n",
       "  'Granulocyte Colony Stimulating Factor ',\n",
       "  'Tbo-filgrastim',\n",
       "  'Filgrastim'],\n",
       " 'Coagulation Factor IX (Recombinant)': ['Coagulation factor IX (recombinant)',\n",
       "  'Coagulation factor IX recombinant human',\n",
       "  'Factor IX (Recombinant)',\n",
       "  'nonacog alfa',\n",
       "  'nonacog gamma',\n",
       "  'Recombinant factor IX',\n",
       "  'Coagulation Factor IX (Recombinant)'],\n",
       " 'Becaplermin': ['Becaplermin',\n",
       "  'PDGF-2',\n",
       "  'PDGF-BB',\n",
       "  'PDGFB',\n",
       "  'Platelet-derived growth factor BB, recombinant',\n",
       "  'Platelet-derived growth factor beta polypeptide',\n",
       "  'Recombinant platelet-derived growth factor BB',\n",
       "  'rhPDGF-BB',\n",
       "  'rPDGF-BB',\n",
       "  'SH-POLYPEPTIDE-59',\n",
       "  'Becaplermin'],\n",
       " 'Agalsidase beta': ['Agalsidasa alfa',\n",
       "  'Agalsidasa beta',\n",
       "  'Agalsidase alfa',\n",
       "  'Alpha-galactosidase A',\n",
       "  'Agalsidase beta'],\n",
       " 'Octreotide': ['Octreotida',\n",
       "  'Octreotide',\n",
       "  'Octreotidum',\n",
       "  'Octrotide',\n",
       "  'Octreotide'],\n",
       " 'Interferon alfa-2b': ['Interferon alfa-2b',\n",
       "  'Interferon alfa-2b, recombinant',\n",
       "  'Interferon alpha-2B',\n",
       "  'Interferon Î±-2b',\n",
       "  'Intron (Interferon Î±2b)',\n",
       "  'Intron A',\n",
       "  'Intron A (Interferon Î±2b)',\n",
       "  'r-INF-alpha',\n",
       "  'rIFN-alpha-2b',\n",
       "  'Interferon alfa-2b'],\n",
       " 'Abarelix': ['Abarelix', 'Abarelix'],\n",
       " 'Oxytocin': ['Oxitocina', 'Oxytocin', 'Oxytocin'],\n",
       " 'Natalizumab': ['Anti-alpha4 integrin', 'Anti-VLA4', 'Natalizumab'],\n",
       " 'Enfuvirtide': ['Enfuvirtida', 'Enfuvirtide'],\n",
       " 'Palivizumab': ['Palivizumab', 'Palivizumab'],\n",
       " 'Daclizumab': ['Dacliximab', 'Daclizumab beta', 'Daclizumab'],\n",
       " 'Bevacizumab': ['Anti-VEGF Humanized Monoclonal Antibody',\n",
       "  'Anti-VEGF monoclonal antibody',\n",
       "  'Bevacizumab',\n",
       "  'bevacizumab-awwb',\n",
       "  'rhuMAb-VEGF',\n",
       "  'Bevacizumab'],\n",
       " 'Technetium Tc-99m arcitumomab': ['Arcitumomab technetium-99m',\n",
       "  'Technetium (99mTc) arcitumomab',\n",
       "  'Technetium Tc 99m arcitumomab',\n",
       "  'Technetium-99m arcitumomab',\n",
       "  'Technetium Tc-99m arcitumomab'],\n",
       " 'Pyridoxal phosphate': ['3-hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinecarboxaldehyde',\n",
       "  '3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde 5-phosphate',\n",
       "  'Codecarboxylase',\n",
       "  'PLP',\n",
       "  'Pyridoxal 5-monophosphoric acid ester',\n",
       "  'Pyridoxal 5-phosphate',\n",
       "  \"Pyridoxal 5'-phosphate\",\n",
       "  'Pyridoxal P',\n",
       "  'Pyridoxal phosphate anhydrous',\n",
       "  'Pyridoxal-5P',\n",
       "  'Pyridoxal-P',\n",
       "  'Pyridoxal phosphate'],\n",
       " 'Cyanocobalamin': ['Cianocobalamina',\n",
       "  'Cyanocob(III)alamin',\n",
       "  'Cyanocobalamin',\n",
       "  'Cyanocobalamine',\n",
       "  'Cyanocobalaminum',\n",
       "  'Vitamin B12',\n",
       "  'Vitamin B12 complex',\n",
       "  'Vitamin B12 NOS',\n",
       "  'Cyanocobalamin'],\n",
       " 'Tetrahydrofolic acid': ['5,6,7,8-tetrahydrofolate',\n",
       "  '5,6,7,8-tetrahydrofolic acid',\n",
       "  'Tetrahydrofolate',\n",
       "  'Tetrahydrofolic acid'],\n",
       " 'Histidine': ['(S)-4-(2-Amino-2-carboxyethyl)imidazole',\n",
       "  '(S)-a-Amino-1H-imidazole-4-propanoic acid',\n",
       "  '(S)-alpha-amino-1H-Imidazole-4-propanoic acid',\n",
       "  '(S)-alpha-Amino-1H-imidazole-4-propionic acid',\n",
       "  '(S)-Î±-amino-1H-Imidazole-4-propanoic acid',\n",
       "  'HIS',\n",
       "  'Histidina',\n",
       "  'Histidine',\n",
       "  'L-(â\\x88\\x92)-histidine',\n",
       "  'L-Histidin',\n",
       "  'L-Histidine',\n",
       "  'Histidine'],\n",
       " 'Ademetionine': ['Ademetionine',\n",
       "  'AdoMet',\n",
       "  'L-S-Adenosylmethionine',\n",
       "  'S-Adenosylmethionine',\n",
       "  'SAM',\n",
       "  'SAM-e',\n",
       "  'SAMe',\n",
       "  'Ademetionine'],\n",
       " 'Pyruvic acid': ['2-ketopropionic acid',\n",
       "  '2-oxopropanoic acid',\n",
       "  '2-OxopropansÃ¤ure',\n",
       "  '2-OxopropionsÃ¤ure',\n",
       "  'a-Ketopropionic acid',\n",
       "  'Acetylformic acid',\n",
       "  'acide pyruvique',\n",
       "  'alpha-ketopropionic acid',\n",
       "  'BrenztraubensÃ¤ure',\n",
       "  'BTS',\n",
       "  'Pyroracemic acid',\n",
       "  'Î±-ketopropionic acid',\n",
       "  'Î±-OxopropionsÃ¤ure',\n",
       "  'Pyruvic acid'],\n",
       " 'Phenylalanine': ['(S)-2-Amino-3-phenylpropionic acid',\n",
       "  '(S)-alpha-Amino-beta-phenylpropionic acid',\n",
       "  '3-phenyl-L-alanine',\n",
       "  'beta-Phenyl-L-alanine',\n",
       "  'F',\n",
       "  'Fenilalanina',\n",
       "  'L-Phenylalanine',\n",
       "  'Phe',\n",
       "  'Phenylalanine',\n",
       "  'Phenylalaninum',\n",
       "  'Î²-phenyl-L-alanine',\n",
       "  'Phenylalanine'],\n",
       " 'Biotin': ['(+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid',\n",
       "  '(3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acid',\n",
       "  '5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid',\n",
       "  'Biotin',\n",
       "  'Biotina',\n",
       "  'Biotine',\n",
       "  'Biotinum',\n",
       "  'cis-(+)-Tetrahydro-2-oxothieno[3,4]imidazoline-4-valeric acid',\n",
       "  'cis-Hexahydro-2-oxo-1H-thieno(3,4)imidazole-4-valeric acid',\n",
       "  'cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid',\n",
       "  'Coenzyme R',\n",
       "  'D-(+)-biotin',\n",
       "  'D-Biotin',\n",
       "  'Vitamin B7',\n",
       "  'Vitamin H',\n",
       "  'Biotin'],\n",
       " 'Choline': ['Bilineurine',\n",
       "  'Choline ion',\n",
       "  'N-trimethylethanolamine',\n",
       "  'N,N,N-trimethylethanol-ammonium',\n",
       "  'trimethylethanolamine',\n",
       "  'Vitamin J',\n",
       "  'Choline'],\n",
       " 'L-Lysine': ['(S)-2,6-diaminohexanoic acid',\n",
       "  '(S)-lysine',\n",
       "  '(S)-Î±,Îµ-diaminocaproic acid',\n",
       "  '6-ammonio-L-norleucine',\n",
       "  'L-2,6-Diaminocaproic acid',\n",
       "  'L-lys',\n",
       "  'L-Lysin',\n",
       "  'LYS',\n",
       "  'Lysina',\n",
       "  'Lysine',\n",
       "  'Lysine acid',\n",
       "  'Lysinum',\n",
       "  'L-Lysine'],\n",
       " 'Arginine': ['(2S)-2-amino-5-(carbamimidamido)pentanoic acid',\n",
       "  '(2S)-2-amino-5-guanidinopentanoic acid',\n",
       "  '(S)-2-amino-5-guanidinopentanoic acid',\n",
       "  '(S)-2-Amino-5-guanidinovaleric acid',\n",
       "  'Arg',\n",
       "  'Arginina',\n",
       "  'Arginine',\n",
       "  'L-(+)-Arginine',\n",
       "  'L-Arg',\n",
       "  'L-Arginin',\n",
       "  'L-arginine',\n",
       "  'R',\n",
       "  'Arginine'],\n",
       " 'Ascorbic acid': ['acide ascorbique',\n",
       "  'Ã¡cido ascÃ³rbico',\n",
       "  'Acidum ascorbicum',\n",
       "  'acidum ascorbinicum',\n",
       "  'Ascorbate',\n",
       "  'Ascorbic acid',\n",
       "  'AscorbinsÃ¤ure',\n",
       "  'L-(+)-ascorbic acid',\n",
       "  'L-Ascorbate',\n",
       "  'L-Ascorbic Acid',\n",
       "  'Vitamin C',\n",
       "  'Vitamina C',\n",
       "  'Ascorbic acid'],\n",
       " 'Spermine': ['4,9-diaza-1,12-dodecanediamine',\n",
       "  '4,9-diazadodecane-1,12-diamine',\n",
       "  'Musculamine',\n",
       "  \"N,N'-Bis(3-aminopropyl)-1,4-butanediamine\",\n",
       "  'Spermina',\n",
       "  'Spermine',\n",
       "  'Spermine'],\n",
       " 'Aspartic acid': ['(S)-2-aminobutanedioic acid',\n",
       "  '(S)-2-aminosuccinic acid',\n",
       "  '2-Aminosuccinic acid',\n",
       "  'Ã¡cido aspÃ¡rtico',\n",
       "  'Acidum asparticum',\n",
       "  'Asp',\n",
       "  'Aspartic acid',\n",
       "  'D',\n",
       "  'L-Asp',\n",
       "  'L-AsparaginsÃ¤ure',\n",
       "  'L-Aspartate',\n",
       "  'L-Aspartic acid',\n",
       "  'Aspartic acid'],\n",
       " 'Ornithine': ['(S)-2,5-Diaminopentanoate',\n",
       "  '(S)-2,5-Diaminopentanoic acid',\n",
       "  '(S)-2,5-diaminovaleric acid',\n",
       "  '(S)-ornithine',\n",
       "  '(S)-Î±,Î´-diaminovaleric acid',\n",
       "  'L-Ornithine',\n",
       "  'levo-ornithine',\n",
       "  'Ornithine',\n",
       "  'Ornithinum',\n",
       "  'Ornitina',\n",
       "  'Ornithine'],\n",
       " 'L-Glutamine': ['(2S)-2-amino-4-carbamoylbutanoic acid',\n",
       "  '(2S)-2,5-diamino-5-oxopentanoic acid',\n",
       "  '(S)-2,5-diamino-5-oxopentanoic acid',\n",
       "  'Glutamic acid 5-amide',\n",
       "  'Glutamic acid amide',\n",
       "  'Glutamina',\n",
       "  'Glutamine',\n",
       "  'L-(+)-glutamine',\n",
       "  'L-2-aminoglutaramic acid',\n",
       "  'L-glutamic acid Î³-amide',\n",
       "  'L-Glutamin',\n",
       "  'L-GlutaminsÃ¤ure-5-amid',\n",
       "  'Levoglutamide',\n",
       "  'Q',\n",
       "  'L-Glutamine'],\n",
       " 'Adenosine phosphate': [\"5'-Adenosine monophosphate\",\n",
       "  \"5'-Adenylic acid\",\n",
       "  \"5'-AMP\",\n",
       "  \"5'-O-Phosphonoadenosine\",\n",
       "  \"Adenosine 5'-(dihydrogen phosphate)\",\n",
       "  \"Adenosine 5'-monophosphate\",\n",
       "  \"Adenosine 5'-phosphate\",\n",
       "  'Adenosine monophosphate',\n",
       "  'Adenosine phosphate',\n",
       "  \"Adenosine-5'-Monophosphate\",\n",
       "  \"Adenosine-5'-monophosphoric acid\",\n",
       "  \"Adenosine-5'P\",\n",
       "  'Adenosini phosphas',\n",
       "  'Adenylate',\n",
       "  'Adenylic acid',\n",
       "  \"Ado5'P\",\n",
       "  'AMP',\n",
       "  'Fosfato de adenosina',\n",
       "  'PAdo',\n",
       "  \"Phosphate d'adÃ©nosine\",\n",
       "  'Adenosine phosphate'],\n",
       " 'alpha-Linolenic acid': ['(9,12,15)-linolenic acid',\n",
       "  '(9Z,12Z,15Z)-Octadecatrienoic acid',\n",
       "  '(Z,Z,Z)-9,12,15-octadecatrienoic acid',\n",
       "  '9-cis,12-cis,15-cis-octadecatrienoic acid',\n",
       "  '9,12,15-Octadecatrienoic acid',\n",
       "  'ALA',\n",
       "  'all-cis-9,12,15-Octadecatrienoic acid',\n",
       "  'alpha-Linolenic acid',\n",
       "  'cis-delta(9,12,15)-Octadecatrienoic acid',\n",
       "  'cis,cis,cis-9,12,15-Octadecatrienoic acid',\n",
       "  'Linolenic acid',\n",
       "  'Î±-linolenic acid',\n",
       "  'alpha-Linolenic acid'],\n",
       " 'Serine': ['(S)-2-Amino-3-hydroxypropanoic acid',\n",
       "  '(S)-Serine',\n",
       "  'alpha-Amino-beta-hydroxypropionic acid',\n",
       "  'beta-Hydroxyalanine',\n",
       "  'L-Serine',\n",
       "  'Ser',\n",
       "  'Serina',\n",
       "  'Serine',\n",
       "  'Serinum',\n",
       "  'Serine'],\n",
       " 'Methionine': ['(2S)-2-amino-4-(methylsulfanyl)butanoic acid',\n",
       "  '(S)-2-amino-4-(methylthio)butanoic acid',\n",
       "  '(S)-2-amino-4-(methylthio)butyric acid',\n",
       "  '(S)-methionine',\n",
       "  'L-(â\\x88\\x92)-methionine',\n",
       "  'L-a-Amino-g-methylthiobutyric acid',\n",
       "  'L-Methionin',\n",
       "  'L-Methionine',\n",
       "  'L-Î±-amino-Î³-methylmercaptobutyric acid',\n",
       "  'M',\n",
       "  'Met',\n",
       "  'Methionine',\n",
       "  'Methionine'],\n",
       " 'Tyrosine': ['(â\\x88\\x92)-Î±-amino-p-hydroxyhydrocinnamic acid',\n",
       "  '(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid',\n",
       "  '(S)-(-)-Tyrosine',\n",
       "  '(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid',\n",
       "  '(S)-3-(p-Hydroxyphenyl)alanine',\n",
       "  '(S)-alpha-amino-4-Hydroxybenzenepropanoic acid',\n",
       "  '(S)-Tyrosine',\n",
       "  '(S)-Î±-amino-4-hydroxybenzenepropanoic acid',\n",
       "  '4-hydroxy-L-phenylalanine',\n",
       "  'L-Tyrosin',\n",
       "  'L-tyrosine',\n",
       "  'Tirosina',\n",
       "  'Tyr',\n",
       "  'Tyrosine',\n",
       "  'Tyrosinum',\n",
       "  'Y',\n",
       "  'Tyrosine'],\n",
       " 'Calcitriol': ['(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol',\n",
       "  '(1Î±,3Î²,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol',\n",
       "  '(5Z,7E)-(1S,3R)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol',\n",
       "  '1-alpha-25-Dihydroxyvitamin D3',\n",
       "  '1,25-DHCC',\n",
       "  '1,25-dihydroxycholecalciferol',\n",
       "  '1Î±,25-dihydroxycholecalciferol',\n",
       "  '1Î±,25-dihydroxyvitamin D3',\n",
       "  '1Î±,25(OH)2D3',\n",
       "  'Calcitriol',\n",
       "  'Calcitriolum',\n",
       "  'Calcitriol'],\n",
       " 'Lutein': ['Xanthophyll', 'Xantofyl', 'Lutein'],\n",
       " 'Cystine': [\"(R,R)-3,3'-dithiobis(2-aminopropanoic acid)\",\n",
       "  'Cistina',\n",
       "  'L-alpha-Diamino-beta-dithiolactic acid',\n",
       "  'L-Cystine',\n",
       "  'L-Dicysteine',\n",
       "  \"Î²,Î²'-dithiodialanine\",\n",
       "  'Cystine'],\n",
       " 'Succinic acid': ['1,2-ethanedicarboxylic acid',\n",
       "  'Acide butanedioÃ¯que',\n",
       "  'Acide succinique',\n",
       "  'Acidum succinicum',\n",
       "  'Amber acid',\n",
       "  'Asuccin',\n",
       "  'BernsteinsÃ¤ure',\n",
       "  'ButandisÃ¤ure',\n",
       "  'Butanedioic acid',\n",
       "  'Butanedionic acid',\n",
       "  'Dihydrofumaric acid',\n",
       "  'Ethylenesuccinic acid',\n",
       "  'Spirit of amber',\n",
       "  'Succinic acid',\n",
       "  'Succinic acid'],\n",
       " 'Riboflavin': ['1-Deoxy-1-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl)pentitol',\n",
       "  '6,7-Dimethyl-9-D-ribitylisoalloxazine',\n",
       "  '7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)isoalloxazine',\n",
       "  '7,8-Dimethyl-10-ribitylisoalloxazine',\n",
       "  'Lactoflavin',\n",
       "  'Lactoflavine',\n",
       "  'Riboflavin',\n",
       "  'Riboflavina',\n",
       "  'Riboflavine',\n",
       "  'Riboflavinum',\n",
       "  'Vitamin B2',\n",
       "  'Vitamin Bi',\n",
       "  'Vitamin G',\n",
       "  'Riboflavin'],\n",
       " 'N-Acetylglucosamine': ['2-Acetamido-2-deoxy-D-glucose',\n",
       "  'aldehydo-N-acetyl-D-glucosamine',\n",
       "  'D-GlcNAc',\n",
       "  'N-Acetyl-D-glucosamine',\n",
       "  'N-Acetylchitosamine',\n",
       "  'N-Acetylglucosamine'],\n",
       " 'Glutamic acid': ['(2S)-2-Aminopentanedioic acid',\n",
       "  '(S)-2-Aminopentanedioic acid',\n",
       "  '(S)-Glutamic acid',\n",
       "  'Ã¡cido glutÃ¡mico',\n",
       "  'Glu',\n",
       "  'Glutamic acid',\n",
       "  'L-Glutamate',\n",
       "  'L-Glutamic acid',\n",
       "  'L-Glutaminic acid',\n",
       "  'Glutamic acid'],\n",
       " 'Glutathione': ['5-L-Glutamyl-L-cysteinylglycine',\n",
       "  'gamma-L-Glutamyl-L-cysteinyl-glycine',\n",
       "  'Glutathione',\n",
       "  'Glutathione-SH',\n",
       "  'GSH',\n",
       "  'N-(N-gamma-L-Glutamyl-L-cysteinyl)glycine',\n",
       "  'Reduced glutathione',\n",
       "  'Glutathione'],\n",
       " 'Phosphatidyl serine': ['Phosphatidyl-L-serine',\n",
       "  'Phosphatidylserine',\n",
       "  'PS',\n",
       "  'Ptd-L-Ser',\n",
       "  'Phosphatidyl serine'],\n",
       " 'Glycine': ['Aminoacetic acid',\n",
       "  'AminoessigsÃ¤ure',\n",
       "  'Aminoethanoic acid',\n",
       "  'Glicina',\n",
       "  'Gly',\n",
       "  'Glycin',\n",
       "  'Glycine',\n",
       "  'Glycocoll',\n",
       "  'Glykokoll',\n",
       "  'Glyzin',\n",
       "  'Leimzucker',\n",
       "  'Glycine'],\n",
       " 'Calcifediol': ['(3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol',\n",
       "  '(3Î²,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol',\n",
       "  '(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol',\n",
       "  '25-hydroxycholecalciferol',\n",
       "  '25-Hydroxyvitamin D3',\n",
       "  'Calcidiol',\n",
       "  'CalcifÃ©diol',\n",
       "  'Calcifediol',\n",
       "  'Calcifediol anhydrous',\n",
       "  'Calcifediolum',\n",
       "  'Calcifediol'],\n",
       " 'Pyridoxal': ['2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine',\n",
       "  '3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinecarboxaldehyde',\n",
       "  '3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde',\n",
       "  '3-hydroxy-5-(hydroxymethyl)-2-methylpyridine-4-carboxaldehyde',\n",
       "  'Piridoxal',\n",
       "  'Pyridoxaldehyde',\n",
       "  'Pyridoxal'],\n",
       " 'Creatine': ['((amino(Imino)methyl)(methyl)amino)acetic acid',\n",
       "  '(alpha-Methylguanido)acetic acid',\n",
       "  '(N-methylcarbamimidamido)acetic acid',\n",
       "  '(Î±-methylguanido)acetic acid',\n",
       "  'alpha-Methylguanidino acetic acid',\n",
       "  'Creatin',\n",
       "  'Creatine',\n",
       "  'Kreatin',\n",
       "  'Methylglycocyamine',\n",
       "  'N-(aminoiminomethyl)-N-methylglycine',\n",
       "  'N-amidinosarcosine',\n",
       "  'N-carbamimidoyl-N-methylglycine',\n",
       "  'N-methyl-N-guanylglycine',\n",
       "  'Creatine'],\n",
       " 'Leucine': ['(2S)-2-Amino-4-methylpentanoic acid',\n",
       "  '(2S)-alpha-2-Amino-4-methylvaleric acid',\n",
       "  '(2S)-alpha-Leucine',\n",
       "  '(S)-(+)-Leucine',\n",
       "  '(S)-Leucine',\n",
       "  '2-Amino-4-methylvaleric acid',\n",
       "  'L',\n",
       "  'L-Leucin',\n",
       "  'L-Leucine',\n",
       "  'L-Leuzin',\n",
       "  'Leu',\n",
       "  'Leucine',\n",
       "  'Leucine'],\n",
       " 'Tryptophan': ['(2S)-2-amino-3-(1H-indol-3-yl)propanoic acid',\n",
       "  '(S)-alpha-Amino-beta-(3-indolyl)-propionic acid',\n",
       "  '(S)-Tryptophan',\n",
       "  '(S)-Î±-amino-1H-indole-3-propanoic acid',\n",
       "  'L-(-)-Tryptophan',\n",
       "  'L-(â\\x88\\x92)-tryptophan',\n",
       "  'L-Tryptophan',\n",
       "  'L-Î²-3-indolylalanine',\n",
       "  'Triptofano',\n",
       "  'Trp',\n",
       "  'Tryptophan',\n",
       "  'Tryptophane',\n",
       "  'Tryptophanum',\n",
       "  'W',\n",
       "  'Tryptophan'],\n",
       " 'Cysteine': ['(2R)-2-amino-3-mercaptopropanoic acid',\n",
       "  '(2R)-2-amino-3-sulfanylpropanoic acid',\n",
       "  '(R)-2-Amino-3-mercaptopropanoic acid',\n",
       "  'Cisteina',\n",
       "  'Cisteinum',\n",
       "  'Cys',\n",
       "  'Cysteine',\n",
       "  'Cysteinum',\n",
       "  'Free Cysteine',\n",
       "  'L-2-Amino-3-mercaptopropionic acid',\n",
       "  'L-Cys',\n",
       "  'L-Cystein',\n",
       "  'L-Zystein',\n",
       "  'Cysteine'],\n",
       " 'Thiamine': ['Aneurin',\n",
       "  'Antiberiberi factor',\n",
       "  'Thiamin',\n",
       "  'Thiamine',\n",
       "  'thiamine(1+)',\n",
       "  'thiamine(1+) ion',\n",
       "  'thiaminium',\n",
       "  'Thiaminum',\n",
       "  'Tiamina',\n",
       "  'Vitamin B1',\n",
       "  'Thiamine'],\n",
       " 'Ergocalciferol': ['(3Î²,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol',\n",
       "  '(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol',\n",
       "  '(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol',\n",
       "  'Activated ergosterol',\n",
       "  'Ercalciol',\n",
       "  'ErgocalcifÃ©rol',\n",
       "  'Ergocalciferol',\n",
       "  'Ergocalciferolum',\n",
       "  'Oleovitamin D2',\n",
       "  'Viosterol',\n",
       "  'Vitamin D2',\n",
       "  'Vitamina D2',\n",
       "  'Ergocalciferol'],\n",
       " 'Dihomo-gamma-linolenic acid': ['(8Z,11Z,14Z)-Icosatrienoic acid',\n",
       "  '(Z,Z,Z)-8,11,14-Eicosatrienoic acid',\n",
       "  '(Z,Z,Z)-8,11,14-Icosatrienoate',\n",
       "  '(Z,Z,Z)-8,11,14-Icosatrienoic acid',\n",
       "  '20:3, n-6,9,12 all-cis',\n",
       "  '8,11,14-Eicosatrienoic Acid',\n",
       "  '8c,11c,14c-eicosatrienoic acid',\n",
       "  '8c,11c,14c-EicosatriensÃ¤ure',\n",
       "  'all-cis-8,11,14-eicosatrienoic acid',\n",
       "  'all-cis-8,11,14-icosatrienoic acid',\n",
       "  'all-cis-eicosa-8,11,14-trienoic acid',\n",
       "  'all-cis-Eicosa-8,11,14-triensÃ¤ure',\n",
       "  'all-cis-icosa-8,11,14-trienoic acid',\n",
       "  'C20:3, n-6,9,12 all-cis',\n",
       "  'cis,cis,cis-8,11,14-eicosatrienoic acid',\n",
       "  'DGLA',\n",
       "  'dihomo-Î³-linolenic acid',\n",
       "  'eicosa-8Z,11Z,14Z-trienoic acid',\n",
       "  'gamma-Homolinolenic acid',\n",
       "  'Homo-gamma-linolenic acid',\n",
       "  'Homo-gamma-linolensÃ¤ure',\n",
       "  'Homo-Î³-linolensÃ¤ure',\n",
       "  'Dihomo-gamma-linolenic acid'],\n",
       " 'Citrulline': ['(S)-2-Amino-5-ureidopentanoic acid',\n",
       "  '2-Amino-5-ureidovaleric acid',\n",
       "  'alpha-amino-delta-Ureidovaleric acid',\n",
       "  'Cit',\n",
       "  'Citrulina',\n",
       "  'Citrulline',\n",
       "  'delta-Ureidonorvaline',\n",
       "  'L-2-Amino-5-ureidovaleric acid',\n",
       "  'L-Citrulline',\n",
       "  'N(5)-(Aminocarbonyl)-L-ornithine',\n",
       "  'N(delta)-Carbamylornithine',\n",
       "  'N5-(Aminocarbonyl)ornithine',\n",
       "  'N5-Carbamoyl-L-ornithine',\n",
       "  'N5-carbamoylornithine',\n",
       "  'Î±-amino-Î´-ureidovaleric acid',\n",
       "  'Î´-ureidonorvaline',\n",
       "  'Citrulline'],\n",
       " 'Threonine': ['(2S,3R)-(-)-Threonine',\n",
       "  '(2S)-threonine',\n",
       "  '2-Amino-3-hydroxybutyric acid',\n",
       "  'L-(-)-Threonine',\n",
       "  'L-2-Amino-3-hydroxybutyric acid',\n",
       "  'L-alpha-amino-beta-hydroxybutyric acid',\n",
       "  'L-Threonin',\n",
       "  'L-Threonine',\n",
       "  'L-Î±-amino-Î²-hydroxybutyric acid',\n",
       "  'Thr',\n",
       "  'Threonine',\n",
       "  'Threoninum',\n",
       "  'Treonina',\n",
       "  'Threonine'],\n",
       " 'NADH': ['1,4-dihydronicotinamide adenine dinucleotide',\n",
       "  'DPNH',\n",
       "  'NAD reduced form',\n",
       "  'Nicotinamide adenine dinucleotide (reduced)',\n",
       "  'Nicotinamide-adenine dinucleotide, reduced',\n",
       "  'Reduced nicotinamide adenine diphosphate',\n",
       "  'Reduced nicotinamide-adenine dinucleotide',\n",
       "  'NADH'],\n",
       " 'Folic acid': ['Acide folique',\n",
       "  'Ã¡cido fÃ³lico',\n",
       "  'Acidum folicum',\n",
       "  'Folacin',\n",
       "  'Folate',\n",
       "  'Folic acid',\n",
       "  'FolsÃ¤ure',\n",
       "  'N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid',\n",
       "  'N-pteroyl-L-glutamic acid',\n",
       "  'PGA',\n",
       "  'PteGlu',\n",
       "  'Pteroyl-L-glutamate',\n",
       "  'Pteroyl-L-glutamic acid',\n",
       "  'Pteroyl-L-monoglutamic acid',\n",
       "  'Pteroylglutamic acid',\n",
       "  'Vitamin B9',\n",
       "  'Vitamin Bc',\n",
       "  'Vitamin M',\n",
       "  'Folic acid'],\n",
       " 'Icosapent': ['(5Z,8Z,11Z,14Z,17Z)-5,8,11,14,17-eicosapentaenoic acid',\n",
       "  '(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoate',\n",
       "  '(5Z,8Z,11Z,14Z,17Z)-Eicosapentaenoic acid',\n",
       "  '(5Z,8Z,11Z,14Z,17Z)-Icosapentaenoic acid',\n",
       "  '(all-Z)-5,8,11,14,17-eicosapentaenoic acid',\n",
       "  '5,8,11,14,17-eicosapentaenoic acid',\n",
       "  '5,8,11,14,17-Icosapentaenoic acid',\n",
       "  'all-cis-5,8,11,14,17-eicosapentaenoic acid',\n",
       "  'all-cis-5,8,11,14,17-icosapentaenoic acid',\n",
       "  'all-cis-icosa-5,8,11,14,17-pentaenoic acid',\n",
       "  'cis-5,8,11,14,17-eicosapentaenoic acid',\n",
       "  'cis-5,8,11,14,17-EPA',\n",
       "  'cis-delta(5,8,11,14,17)-Eicosapentaenoic acid',\n",
       "  'Eicosapentaenoic acid',\n",
       "  'EPA',\n",
       "  'Icosapent',\n",
       "  'Icosapentaenoic acid',\n",
       "  'Icosapento',\n",
       "  'Icosapentum',\n",
       "  'Timnodonic acid',\n",
       "  'Icosapent'],\n",
       " 'Alanine': ['(2S)-2-aminopropanoic acid',\n",
       "  '(S)-2-aminopropanoic acid',\n",
       "  '(S)-alanine',\n",
       "  'Alanina',\n",
       "  'Alanine',\n",
       "  'Alaninum',\n",
       "  'L-2-Aminopropionic acid',\n",
       "  'L-Alanin',\n",
       "  'L-alanine',\n",
       "  'L-alpha-Alanine',\n",
       "  'L-Î±-alanine',\n",
       "  'Alanine'],\n",
       " 'Valine': ['(2S)-2-Amino-3-methylbutanoic acid',\n",
       "  '(S)-Valine',\n",
       "  '2-Amino-3-methylbutyric acid',\n",
       "  'L-(+)-alpha-Aminoisovaleric acid',\n",
       "  'L-alpha-Amino-beta-methylbutyric acid',\n",
       "  'L-valin',\n",
       "  'L-valine',\n",
       "  'Val',\n",
       "  'Valine',\n",
       "  'Valine'],\n",
       " 'Vitamin A': ['(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol',\n",
       "  'all-trans-retinol',\n",
       "  'all-trans-retinyl alcohol',\n",
       "  'all-trans-vitamin A alcohol',\n",
       "  'Retinol',\n",
       "  'Retinolum',\n",
       "  'Vitamin A1',\n",
       "  'Vitamin A'],\n",
       " 'Vitamin E': ['(+)-Î±-tocopherol',\n",
       "  \"(2R,4'R,8'R)-Î±-tocopherol\",\n",
       "  '(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL',\n",
       "  '(R,R,R)-Î±-tocopherol',\n",
       "  '5,7,8-trimethyltocol',\n",
       "  'alpha-tocopherol',\n",
       "  'd-Î±-tocopherol',\n",
       "  'Vitamin E'],\n",
       " 'Pyridoxine': ['2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine',\n",
       "  '3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine',\n",
       "  '3-hydroxy-4,5-dimethylol-Î±-picoline',\n",
       "  '5-hydroxy-6-methyl-3,4-pyridinedimethanol',\n",
       "  'Piridoxina',\n",
       "  'Pyridoxine',\n",
       "  'Pyridoxinum',\n",
       "  'Pyridoxol',\n",
       "  'Vitamin B6',\n",
       "  'Pyridoxine'],\n",
       " 'Lipoic acid': ['(+)-alpha-Lipoic acid',\n",
       "  '(R)-(+)-Lipoate',\n",
       "  '(R)-(+)-lipoic acid',\n",
       "  '(R)-1,2-Dithiolane-3-pentanoic acid',\n",
       "  '(R)-1,2-dithiolane-3-valeric acid',\n",
       "  '(R)-6,8-thioctic acid',\n",
       "  '(R)-lipoic acid',\n",
       "  'Alpha lipoic acid',\n",
       "  'alpha-Lipoic acid',\n",
       "  'alpha-LiponsÃ¤ure',\n",
       "  'D-thioctic acid',\n",
       "  'Lipoic acid',\n",
       "  'R-(+)-thioctic acid',\n",
       "  'R-alpha-lipoic acid',\n",
       "  'Thioctic acid',\n",
       "  'Thioctic acid D-form',\n",
       "  'Î±-lipoic acid',\n",
       "  'Lipoic acid'],\n",
       " 'Isoleucine': ['(2S,3S)-2-Amino-3-methylpentanoic acid',\n",
       "  '2-Amino-3-methylvaleric acid',\n",
       "  'alpha-amino-beta-methylvaleric acid',\n",
       "  'Ile',\n",
       "  'Isoleucina',\n",
       "  'Isoleucine',\n",
       "  'Isoleucinum',\n",
       "  'L-Isoleucine',\n",
       "  'Î±-amino-Î²-methylvaleric acid',\n",
       "  'Isoleucine'],\n",
       " 'Aspartame': ['1-Methyl N-L-alpha-aspartyl-L-phenylalanate',\n",
       "  '1-methyl N-L-Î±-aspartyl-L-phenylalanate',\n",
       "  '3-Amino-N-(alpha-carboxyphenethyl)succinamic acid N-methyl ester',\n",
       "  '3-Amino-N-(alpha-methoxycarbonylphenethyl) succinamic acid',\n",
       "  '3-Amino-N-(Î±-carboxyphenethyl)succinamic acid N-methyl ester',\n",
       "  '3-Amino-N-(Î±-methoxycarbonylphenethyl) succinamic acid',\n",
       "  'Asp-phe-ome',\n",
       "  'Aspartam',\n",
       "  'Aspartame',\n",
       "  'Aspartamo',\n",
       "  'Aspartamum',\n",
       "  'Aspartylphenylalanine methyl ester',\n",
       "  'L-Aspartyl-L-phenylalanine methyl ester',\n",
       "  'Aspartame'],\n",
       " 'Cholecalciferol': ['(+)-vitamin D3',\n",
       "  '(3Î²,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol',\n",
       "  '(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol',\n",
       "  'Activated 7-dehydrocholesterol',\n",
       "  'Calciol',\n",
       "  'CC',\n",
       "  'Cholecalciferol',\n",
       "  'Cholecalciferolum',\n",
       "  'Colecalciferol',\n",
       "  'Colecalciferolum',\n",
       "  'Oleovitamin D3',\n",
       "  'Vitamin D-3',\n",
       "  'Vitamin D3',\n",
       "  'Cholecalciferol'],\n",
       " 'Menadione': ['2-Methyl-1,4-Naphthalenedione',\n",
       "  '2-Methyl-1,4-naphthochinon',\n",
       "  '2-Methyl-1,4-naphthoquinone',\n",
       "  'Vitamin K 3',\n",
       "  'Vitamin K3',\n",
       "  'Menadione'],\n",
       " 'ATP': [\"Adenosine 5'-triphosphate\",\n",
       "  'Adenosine triphosphate',\n",
       "  \"Adenosine-5'-triphosphate\",\n",
       "  'ATP',\n",
       "  'ATP'],\n",
       " 'Proline': ['(-)-2-Pyrrolidinecarboxylic acid',\n",
       "  '(â\\x88\\x92)-(S)-proline',\n",
       "  '(â\\x88\\x92)-2-pyrrolidinecarboxylic acid',\n",
       "  '(â\\x88\\x92)-proline',\n",
       "  '(2S)-pyrrolidine-2-carboxylic acid',\n",
       "  '(S)-2-Carboxypyrrolidine',\n",
       "  '(S)-2-Pyrrolidinecarboxylic acid',\n",
       "  '(S)-pyrrolidine-2-carboxylic acid',\n",
       "  '2-Pyrrolidinecarboxylic acid',\n",
       "  'L-(â\\x88\\x92)-proline',\n",
       "  'L-alpha-pyrrolidinecarboxylic acid',\n",
       "  'L-Prolin',\n",
       "  'L-Proline',\n",
       "  'L-pyrrolidine-2-carboxylic acid',\n",
       "  'L-Î±-pyrrolidinecarboxylic acid',\n",
       "  'P',\n",
       "  'Prolina',\n",
       "  'Proline',\n",
       "  'Prolinum',\n",
       "  'Proline'],\n",
       " 'Adenine': ['6-Aminopurine', 'Adenin', 'Vitamin B4', 'Adenine'],\n",
       " 'Asparagine': ['(2S)-2-amino-3-carbamoylpropanoic acid',\n",
       "  '(2S)-2,4-diamino-4-oxobutanoic acid',\n",
       "  '(S)-2-amino-3-carbamoylpropanoic acid',\n",
       "  '(S)-Asparagine',\n",
       "  '2-Aminosuccinamic acid',\n",
       "  'alpha-aminosuccinamic acid',\n",
       "  'Asn',\n",
       "  'Asparagine',\n",
       "  'Aspartamic acid',\n",
       "  'L-2-aminosuccinamic acid',\n",
       "  'L-Asparagine',\n",
       "  'L-aspartic acid beta-amide',\n",
       "  'L-aspartic acid Î²-amide',\n",
       "  'Î±-aminosuccinamic acid',\n",
       "  'Asparagine'],\n",
       " 'Pravastatin': ['(+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid',\n",
       "  'Pravastatin',\n",
       "  'Pravastatin acid',\n",
       "  'Pravastatina',\n",
       "  'Pravastatine',\n",
       "  'Pravastatinum',\n",
       "  'Pravastatin'],\n",
       " 'Fluvoxamine': ['Fluvoxamina', 'Fluvoxamine', 'Fluvoxaminum', 'Fluvoxamine'],\n",
       " 'Valsartan': [\"(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine\",\n",
       "  'N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine',\n",
       "  \"N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine\",\n",
       "  'Valsartan',\n",
       "  'Valsartan'],\n",
       " 'Ramipril': ['(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid',\n",
       "  'Ramipril',\n",
       "  'Ramiprilum',\n",
       "  'Ramipril'],\n",
       " 'Masoprocol': ['erythro-nordihydroguaiaretic acid',\n",
       "  'masoprocol',\n",
       "  'Masoprocolum',\n",
       "  'meso-1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane',\n",
       "  'meso-2,3-bis(3,4-dihydroxyphenylmethyl)butane',\n",
       "  'meso-4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol',\n",
       "  \"meso-4,4'-(2,3-dimethyl-1,4-butanediyl)bis(pyrocatechol)\",\n",
       "  \"meso-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol\",\n",
       "  'meso-NDGA',\n",
       "  'meso-nordihydroguaiaretic acid',\n",
       "  'meso-Î²,Î³-dimethyl-Î±,Î´-bis(3,4-dihydroxyphenyl)butan',\n",
       "  'Nordihydroguaiaretic acid',\n",
       "  'Masoprocol'],\n",
       " 'Flunisolide': ['Flunisolida',\n",
       "  'Flunisolide',\n",
       "  'Flunisolide anhydrous',\n",
       "  'Flunisolidum',\n",
       "  'Flunisolide'],\n",
       " 'Baclofen': ['(+-)-Baclofen',\n",
       "  '4-Amino-3-(4-chlorophenyl)butyric acid',\n",
       "  'Baclofen',\n",
       "  'BaclofÃ¨ne',\n",
       "  'Baclofeno',\n",
       "  'Baclofenum',\n",
       "  'beta-(4-Chlorophenyl)gaba',\n",
       "  'beta-(Aminomethyl)-4-chlorobenzenepropanoic acid',\n",
       "  'beta-(Aminomethyl)-p-chlorohydrocinnamic acid',\n",
       "  'beta-(p-Chlorophenyl)-gamma-aminobutyric acid',\n",
       "  'DL-4-Amino-3-p-chlorophenylbutanoic acid',\n",
       "  'DL-Baclofen',\n",
       "  'gamma-Amino-beta-(p-chlorophenyl)butyric acid',\n",
       "  'Baclofen'],\n",
       " 'Amphetamine': ['(+-)-alpha-Methylphenylethylamine',\n",
       "  '1-phenyl-2-aminopropane',\n",
       "  'alpha-Methylbenzeneethaneamine',\n",
       "  'Amfetamina',\n",
       "  'Amfetamine',\n",
       "  'Amfetaminum',\n",
       "  'Amphetamine',\n",
       "  'beta-Aminopropylbenzene',\n",
       "  'beta-Phenylisopropylamin',\n",
       "  'Desoxynorephedrine',\n",
       "  'rac-(2R)-1-phenylpropan-2-amine',\n",
       "  'rac-amphetamine',\n",
       "  'Î±-methylbenzeneethaneamine',\n",
       "  'Î±-methylphenethylamine',\n",
       "  'Î²-aminopropylbenzene',\n",
       "  'Î²-phenylisopropylamine',\n",
       "  'Amphetamine'],\n",
       " 'Pentagastrin': ['Pentagastrin', 'Pentagastrin'],\n",
       " 'Nicotine': ['(â\\x88\\x92)-nicotine',\n",
       "  '(S)-(â\\x88\\x92)-nicotine',\n",
       "  '(S)-3-(1-methylpyrrolidin-2-yl)pyridine',\n",
       "  '(S)-3-(N-methylpyrrolidin-2-yl)pyridine',\n",
       "  '(S)-Nicotine',\n",
       "  '3-(2-(N-methylpyrrolidinyl))pyridine',\n",
       "  '3-(N-methylpyrollidino)pyridine',\n",
       "  'L(â\\x88\\x92)-nicotine',\n",
       "  'Nicotina',\n",
       "  'Nicotine betadex',\n",
       "  'Nicotine polacrilex',\n",
       "  'Nikotin',\n",
       "  'Nikotyna',\n",
       "  'Nicotine'],\n",
       " 'Cevimeline': ['2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine',\n",
       "  'Cevimelina',\n",
       "  'CÃ©vimÃ¨line',\n",
       "  'Cevimeline',\n",
       "  'Cevimelinum',\n",
       "  'Cevimeline'],\n",
       " 'Lorazepam': ['Loracepam',\n",
       "  'Lorazepam',\n",
       "  'o-Chlorooxazepam',\n",
       "  'o-Chloroxazepam',\n",
       "  'Lorazepam'],\n",
       " 'Esmolol': ['(Â±)-esmolol',\n",
       "  '(Â±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate',\n",
       "  '3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester',\n",
       "  'Esmolol',\n",
       "  'Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate',\n",
       "  'methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate',\n",
       "  'Esmolol'],\n",
       " 'Bortezomib': ['[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid',\n",
       "  'Bortezomib',\n",
       "  'N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide',\n",
       "  'Bortezomib'],\n",
       " 'Ethchlorvynol': ['1-chloro-3-ethyl-1-penten-4-yn-3-ol',\n",
       "  '1-Chloro-3-ethyl-pent-1-en-4-yn-3-ol',\n",
       "  '3-(beta-chlorovinyl)-1-pentyn-3-ol',\n",
       "  '3-(Î²-chlorovinyl)-1-pentyn-3-ol',\n",
       "  'etclorvinol',\n",
       "  'Ethchlorvynol',\n",
       "  'ethyl Î²-chlorovinyl ethynyl carbinol',\n",
       "  'Î²-chlorovinyl ethyl ethynyl carbinol',\n",
       "  'Ethchlorvynol'],\n",
       " 'Carbidopa': ['(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate',\n",
       "  '(S)-(â\\x88\\x92)-carbidopa',\n",
       "  '(S)-carbidopa',\n",
       "  '(Î±S)-Î±-hydrazino-3,4-dihydroxy-Î±-methylbenzenepropanoic acid',\n",
       "  'Carbidopa',\n",
       "  'Carbidopa (anhydrous)',\n",
       "  'Carbidopa anhydrous',\n",
       "  'Carbidopum',\n",
       "  'L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid',\n",
       "  'L-Î±-methyldopahydrazine',\n",
       "  'Carbidopa'],\n",
       " 'Phentermine': ['alpha,alpha-Dimethylphenethylamine',\n",
       "  'Fentermina',\n",
       "  'Phentermine',\n",
       "  'Phentermine resin',\n",
       "  'Phenterminum',\n",
       "  'Phentermine'],\n",
       " 'Indecainide': ['Indecainida', 'Indecainide', 'Indecainidum', 'Indecainide'],\n",
       " 'Tramadol': ['Tramadol', 'Tramadolum', 'Tramadol'],\n",
       " 'Vidarabine': ['9-beta-D-arabinofuranosyl-9H-purin-6-amine',\n",
       "  '9-beta-D-arabinofuranosyl-adenine',\n",
       "  '9-beta-D-Arabinofuranosyladenine',\n",
       "  '9-Î²-D-arabinofuranosyl-9H-purin-6-amine',\n",
       "  '9-Î²-D-arabinofuranosyladenine',\n",
       "  'Spongoadenosine',\n",
       "  'Vidarabine',\n",
       "  'Vidarabinum',\n",
       "  'Vidarabine'],\n",
       " 'Betaxolol': ['1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol',\n",
       "  '1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol',\n",
       "  'Betaxolol',\n",
       "  'BÃ©taxolol',\n",
       "  'Betaxololum',\n",
       "  'Betaxolol'],\n",
       " 'Fluconazole': ['Diflucan',\n",
       "  'Difluconazole',\n",
       "  'Fluconazol',\n",
       "  'Fluconazole',\n",
       "  'Fluconazolum',\n",
       "  'Triflucan',\n",
       "  'Fluconazole'],\n",
       " 'Troglitazone': ['Troglitazona', 'Troglitazone', 'Troglitazone'],\n",
       " 'Oseltamivir': ['(â\\x88\\x92)-oseltamivir',\n",
       "  '1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3alpha,4beta,5alpha))-',\n",
       "  'Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate',\n",
       "  'Oseltamivir',\n",
       "  'OsÃ©ltamivir',\n",
       "  'Oseltamivirum',\n",
       "  'Oseltamivir'],\n",
       " 'Erythromycin': [\"3''-O-demethylerythromycin\",\n",
       "  'Abomacetin',\n",
       "  'Eritromicina',\n",
       "  'Erythromycin',\n",
       "  'Erythromycin A',\n",
       "  'Erythromycin C',\n",
       "  'Ã©rythromycine',\n",
       "  'Erythromycinum',\n",
       "  'Erythromycin'],\n",
       " 'Hydroxocobalamin': ['Hydroxocobalamin',\n",
       "  'Hydroxocobalamin anhydrous',\n",
       "  'Hydroxocobalamine',\n",
       "  'Hydroxocobalaminum anhydrous',\n",
       "  'Hydroxycobalamin',\n",
       "  'OH-Cbl',\n",
       "  'Vitamin B-12b',\n",
       "  'Hydroxocobalamin'],\n",
       " 'Caffeine': ['1-methyltheobromine',\n",
       "  '1,3,7-trimethyl-2,6-dioxopurine',\n",
       "  '1,3,7-trimethylpurine-2,6-dione',\n",
       "  '1,3,7-trimethylxanthine',\n",
       "  '3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion',\n",
       "  '7-methyltheophylline',\n",
       "  'Anhydrous caffeine',\n",
       "  'CafeÃ\\xadna',\n",
       "  'CafÃ©ine',\n",
       "  'Caffeinum',\n",
       "  'Coffein',\n",
       "  'Coffeinum',\n",
       "  'Guaranine',\n",
       "  'Koffein',\n",
       "  'MateÃ\\xadna',\n",
       "  'Methyltheobromine',\n",
       "  'TeÃ\\xadna',\n",
       "  'Thein',\n",
       "  'Theine',\n",
       "  'Caffeine'],\n",
       " 'Succinylcholine': [\"2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)\",\n",
       "  'Dicholine succinate',\n",
       "  'Succinocholine',\n",
       "  'Succinoylcholine',\n",
       "  'Succinylbischoline',\n",
       "  'Succinyldicholine',\n",
       "  'Suxamethonium',\n",
       "  'Succinylcholine'],\n",
       " 'Sildenafil': ['1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine',\n",
       "  'Sildenafil',\n",
       "  'Sildenafilo',\n",
       "  'Sildenafil'],\n",
       " 'Dofetilide': ['beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide',\n",
       "  'Dofetilida',\n",
       "  'Dofetilide',\n",
       "  'Dofetilidum',\n",
       "  'Dofetilide'],\n",
       " 'Pyrimethamine': ['2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine',\n",
       "  '2,4-Diamino-5-(P-chlorophenyl)-6-ethylpyrimidine',\n",
       "  '2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine',\n",
       "  '5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine',\n",
       "  '5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidinediamine',\n",
       "  \"5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine\",\n",
       "  'CD',\n",
       "  'Chloridine',\n",
       "  'Chloridyn',\n",
       "  'Diaminopyritamin',\n",
       "  'Ethylpyrimidine',\n",
       "  'Pirimetamina',\n",
       "  'Primethamine',\n",
       "  'Pyrimethamine',\n",
       "  'PyrimÃ©thamine',\n",
       "  'Pyrimethaminum',\n",
       "  'Pyrimethamine'],\n",
       " 'Reserpine': ['(â\\x88\\x92)-reserpine',\n",
       "  '(3beta,16beta,17alpha,18beta,20alpha)-11,17-Dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester',\n",
       "  '3,4,5-trimethoxybenzoyl methyl reserpate',\n",
       "  'Reserpin',\n",
       "  'Reserpine',\n",
       "  'Reserpine'],\n",
       " 'Azithromycin': ['Azithromycin',\n",
       "  'Azithromycine',\n",
       "  'Azithromycinum',\n",
       "  'Azitromicina',\n",
       "  'Azithromycin'],\n",
       " 'Ticlopidine': ['Ticlopidina', 'Ticlopidine', 'Ticlopidinum', 'Ticlopidine'],\n",
       " 'Trospium': ['Trospium'],\n",
       " 'Adapalene': ['6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid',\n",
       "  'Adapalene',\n",
       "  'AdapalÃ¨ne',\n",
       "  'Adapaleno',\n",
       "  'Adapalenum',\n",
       "  'Adapalene'],\n",
       " 'Midodrine': ['(Â±)-2-amino-N-(Î²-hydroxy-2,5-dimethoxyphenethyl)acetamide',\n",
       "  \"1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol\",\n",
       "  '2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide',\n",
       "  'DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid',\n",
       "  'Midodrin',\n",
       "  'Midodrina',\n",
       "  'Midodrine',\n",
       "  'Midodrinum',\n",
       "  'Midodrine'],\n",
       " 'Remikiren': ['Remikiren', 'Remikiren'],\n",
       " 'Pantoprazole': ['Pantoprazol',\n",
       "  'Pantoprazole',\n",
       "  'Pantoprazolum',\n",
       "  'Pantoprazole'],\n",
       " 'Torasemide': ['1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea',\n",
       "  'N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide',\n",
       "  'Torasemida',\n",
       "  'Torasemide',\n",
       "  'TorasÃ©mide',\n",
       "  'Torasemidum',\n",
       "  'Torsemide',\n",
       "  'Torasemide'],\n",
       " 'Citalopram': ['Citalopram', 'Citalopramum', 'Nitalapram ', 'Citalopram'],\n",
       " 'Eletriptan': ['Eletriptan',\n",
       "  'Ã©lÃ©triptan',\n",
       "  'EletriptÃ¡n',\n",
       "  'Eletriptanum',\n",
       "  'Eletriptan'],\n",
       " 'Bethanidine': ['Betanidina',\n",
       "  'Betanidine',\n",
       "  'BÃ©tanidine',\n",
       "  'Betanidinum',\n",
       "  'Bethanidine',\n",
       "  \"N,N'-dimethyl-N''-(phenylmethyl)-guanidine\",\n",
       "  'Bethanidine'],\n",
       " 'Moxifloxacin': ['1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid',\n",
       "  'Moxifloxacin',\n",
       "  'Moxifloxacino',\n",
       "  'Moxifloxacin'],\n",
       " 'Oxyphenonium': ['Oxyphenonium cation', 'Oxyphenonium ion', 'Oxyphenonium'],\n",
       " 'Nelfinavir': ['Nelfinavir', 'Nelfinavir'],\n",
       " 'Isoetharine': ['Isoetarina', 'Isoetarinum', 'Isoetharine', 'Isoetharine'],\n",
       " 'Glimepiride': ['Glimepirida',\n",
       "  'Glimepiride',\n",
       "  'GlimÃ©piride',\n",
       "  'Glimepiridum',\n",
       "  'Glimepiride'],\n",
       " 'Diflorasone': ['(6Î±,11Î²,16Î²)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione',\n",
       "  'Diflorasona',\n",
       "  'Diflorasone',\n",
       "  'Diflorasonum',\n",
       "  'Diflorasone'],\n",
       " 'Indinavir': ['(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide',\n",
       "  'Indinavir',\n",
       "  'Indinavir anhydrous',\n",
       "  'Indinavir'],\n",
       " 'Gadodiamide': ['Gadodiamida',\n",
       "  'Gadodiamide',\n",
       "  'Gadodiamide anhydrous',\n",
       "  'Gadodiamide'],\n",
       " 'Guanadrel': ['Guanadrel', 'Guanadrelum', 'Guanadrel'],\n",
       " 'Lovastatin': ['(1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate',\n",
       "  '2Î²,6Î±-dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone',\n",
       "  '6-alpha-methylcompactin',\n",
       "  '6alpha-methylcompactin',\n",
       "  '6Î±-methylcompactin',\n",
       "  'Lovastatin',\n",
       "  'Lovastatina',\n",
       "  'Lovastatine',\n",
       "  'Lovastatinum',\n",
       "  'Mevinolin',\n",
       "  'Lovastatin'],\n",
       " 'Enflurane': ['2-chloro-1,1,2-trifluoroethyl difluoromethyl ether',\n",
       "  'Alyrane',\n",
       "  'Efrane',\n",
       "  'Enflurane',\n",
       "  'Enflurano',\n",
       "  'Enfluranum',\n",
       "  'Methylflurether',\n",
       "  'Enflurane'],\n",
       " 'Cefotiam': ['(6R,7R)-7-[2-(2-Amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1H-tetrazol-5-ylsulfanylmethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  'Cefotiam',\n",
       "  'Cefotiamum',\n",
       "  'CTM',\n",
       "  'Cefotiam'],\n",
       " 'Pregabalin': ['(S)-3-Isobutyl GABA',\n",
       "  '3-Isobutyl GABA',\n",
       "  'Pregabalin',\n",
       "  'Pregabalina',\n",
       "  'Pregabalin'],\n",
       " 'Temazepam': ['Temazepam', 'Temazepam'],\n",
       " 'Methyclothiazide': ['Methyclothiazide', 'Methyclothiazide'],\n",
       " 'Aminosalicylic acid': ['4-amino-2-hydroxybenzoic acid',\n",
       "  '4-aminosalicylate',\n",
       "  '4-aminosalicylic acid',\n",
       "  'Aminosalicylic acid',\n",
       "  'p-aminosalicylic acid',\n",
       "  'para-amino salicylic acid',\n",
       "  'para-aminosalicylic acid',\n",
       "  'PAS',\n",
       "  'Aminosalicylic acid'],\n",
       " 'Reboxetine': ['Reboxetina', 'Reboxetine'],\n",
       " 'Milrinone': [\"1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile\",\n",
       "  'Milrinona',\n",
       "  'Milrinone',\n",
       "  'Milrinonum',\n",
       "  'Milrinone'],\n",
       " 'Pipobroman': ['1,4-bis(3-bromopropionyl)piperazine',\n",
       "  'N,N-bis-(3-bromopropionyl)-piperazine',\n",
       "  'Pipobroman',\n",
       "  'Pipobromanum',\n",
       "  'Pipobroman'],\n",
       " 'Butabarbital': ['5-ethyl-5-(1-methylpropyl)-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-ethyl-5-(1-methylpropyl)barbituric acid',\n",
       "  '5-sec-butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-sec-butyl-5-ethylbarbituric acid',\n",
       "  '5-sec-butyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione',\n",
       "  'Butabarbital',\n",
       "  'Secbutabarbital',\n",
       "  'Secbutabarbitale',\n",
       "  'Secbutabarbitalum',\n",
       "  'Butabarbital'],\n",
       " 'Nevirapine': [\"11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one\",\n",
       "  'NEV',\n",
       "  'Nevirapina',\n",
       "  'Nevirapine',\n",
       "  'Nevirapine anhydrous',\n",
       "  'Nevirapine, anhydrous',\n",
       "  'NVP',\n",
       "  'Nevirapine'],\n",
       " 'Oxiconazole': [\"2',4'-Dichloro-2-imidazol-1-ylacetophenone (Z)-[O-(2,4-dichlorobenzyl)oxime]\",\n",
       "  'Oxiconazol',\n",
       "  'Oxiconazole',\n",
       "  'Oxiconazolum',\n",
       "  'Oxiconazole'],\n",
       " 'Alclometasone': ['(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione',\n",
       "  '7Î±-Chloro-16Î±-methylprednisolone',\n",
       "  'Alclometasone',\n",
       "  'Alclometasone'],\n",
       " 'Butalbital': ['5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione',\n",
       "  '5-allyl-5-(2-methylpropyl)barbituric acid',\n",
       "  \"5-allyl-5-(2'-methyl-n-propyl) barbituric acid\",\n",
       "  '5-allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione',\n",
       "  '5-allyl-5-isobutylbarbituric acid',\n",
       "  '5-isobutyl-5-allylbarbituric acid',\n",
       "  'Allylbarbital',\n",
       "  'Allylbarbitone',\n",
       "  'Allylbarbituric acid',\n",
       "  'Butalbarbital',\n",
       "  'Butalbital',\n",
       "  'Butalbitalum',\n",
       "  'iso-butylallylbarbituric acid',\n",
       "  'Itobarbital',\n",
       "  'Tetrallobarbital',\n",
       "  'Butalbital'],\n",
       " 'Cladribine': ['(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol',\n",
       "  '2-CdA',\n",
       "  \"2-Chloro-2'-deoxy-beta-adenosine\",\n",
       "  \"2-Chloro-2'-deoxyadenosine\",\n",
       "  '2-chloro-6-amino-9-(2-deoxy-Î²-D-erythro-pentofuranosyl)purine',\n",
       "  '2-chloro-deoxyadenosine',\n",
       "  '2-Chlorodeoxyadenosine',\n",
       "  '2ClAdo',\n",
       "  'Cladribina',\n",
       "  'Cladribine',\n",
       "  'Cladribinum',\n",
       "  'CldAdo',\n",
       "  'Cladribine'],\n",
       " 'Ranolazine': ['Ranolazina', 'Ranolazine', 'Ranolazine'],\n",
       " 'Mesalazine': ['3-carboxy-4-hydroxyaniline',\n",
       "  '5-aminosalicylic acid',\n",
       "  '5-ASA',\n",
       "  'm-Aminosalicylic acid',\n",
       "  'Mesalamine',\n",
       "  'Mesalazina',\n",
       "  'MÃ©salazine',\n",
       "  'Mesalazine',\n",
       "  'Mesalazinum',\n",
       "  'p-Aminosalicylsaeure',\n",
       "  'Mesalazine'],\n",
       " 'Benzatropine': ['3-alpha-(diphenylmethoxy)tropane',\n",
       "  '3endo-benzhydryloxytropane',\n",
       "  '3Î±-(diphenylmethoxy)-1Î±H,5Î±H-tropane',\n",
       "  '3Î±-(diphenylmethoxy)tropane',\n",
       "  '3Î±-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane',\n",
       "  'Benzatropina',\n",
       "  'Benzatropine',\n",
       "  'Benzatropinum',\n",
       "  'benzhydryl 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ether',\n",
       "  'Benztropine',\n",
       "  'Tropine benzohydryl ether',\n",
       "  'Benzatropine'],\n",
       " 'Ziprasidone': ['Ziprasidona', 'Ziprasidone', 'Ziprasidonum', 'Ziprasidone'],\n",
       " 'Methysergide': ['(+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8Î²-carboxamide',\n",
       "  '(+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide',\n",
       "  '1-Methyl-D-lysergic acid butanolamide',\n",
       "  '1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide',\n",
       "  '1-Methyllysergic acid butanolamide',\n",
       "  '1-Methylmethylergonovine',\n",
       "  '9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide',\n",
       "  'MÃ©thysergide',\n",
       "  'Methysergide',\n",
       "  'Methysergidum',\n",
       "  'Metisergida',\n",
       "  'Metisergido',\n",
       "  'N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide',\n",
       "  'Methysergide'],\n",
       " 'Cabergoline': ['(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide',\n",
       "  '(8Î²)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide',\n",
       "  '1-((6-allylergolin-8Î²-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea',\n",
       "  '1-[(6-allylergoline-8Î²-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea',\n",
       "  \"1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'Î²-carbonyl)urea\",\n",
       "  'Cabergolina',\n",
       "  'Cabergoline',\n",
       "  'Cabergolinum',\n",
       "  'Cabergoline'],\n",
       " 'Idoxuridine': [\"(+)-5-Iodo-2'-deoxyuridine\",\n",
       "  '1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil',\n",
       "  \"1-beta-D-2'-Deoxyribofuranosyl-5-iodouracil\",\n",
       "  \"1beta-D-2'-Deoxyribofuranosyl-5-iodouracil\",\n",
       "  \"2'-Deoxy-5-iodouridine\",\n",
       "  \"5-iodo-2'-deoxyuridine\",\n",
       "  '5-Iododeoxyuridine',\n",
       "  '5-Iodouracil deoxyriboside',\n",
       "  'Idoxuridin',\n",
       "  'Idoxuridina',\n",
       "  'Idoxuridine',\n",
       "  'Idoxuridinum',\n",
       "  'IdU',\n",
       "  'Iododeoxyridine',\n",
       "  'Iodoxuridine',\n",
       "  'Joddeoxiuridin',\n",
       "  'Idoxuridine'],\n",
       " 'Dapsone': [\"1,1'-sulfonylbis(4-aminobenzene)\",\n",
       "  \"1,1'-Sulfonylbis[4-aminobenzene]\",\n",
       "  '4-(4-amino-benzenesulfonyl)-phenylamine',\n",
       "  '4-(4-aminophenylsulfonyl)aniline',\n",
       "  '4-(4-aminophenylsulfonyl)benzenamine',\n",
       "  '4-aminophenyl sulfone',\n",
       "  \"4,4'-dapsone\",\n",
       "  \"4,4'-diaminodiphenyl sulfone\",\n",
       "  \"4,4'-Diaminodiphenyl sulphone\",\n",
       "  \"4,4'-Diaminodiphenylsulfone\",\n",
       "  \"4,4'-sulfonylbisaniline\",\n",
       "  \"4,4'-Sulfonylbisbenzenamine\",\n",
       "  \"4,4'-Sulfonylbisbenzeneamine\",\n",
       "  \"4,4'-Sulfonyldianilin\",\n",
       "  \"4,4'-sulfonyldianiline\",\n",
       "  'bis(4-aminophenyl)sulfone',\n",
       "  'Bis(p-aminophenyl) sulfone',\n",
       "  'DADPS',\n",
       "  'Dapsona',\n",
       "  'Dapsone',\n",
       "  'Dapsonum',\n",
       "  'DDS',\n",
       "  'Diaphenylsulfone',\n",
       "  'p-aminophenyl sulfone',\n",
       "  'p,p-sulphonylbisbenzamine',\n",
       "  'p,p-sulphonylbisbenzenamine',\n",
       "  \"p,p'-diaminodiphenyl sulfone\",\n",
       "  'Dapsone'],\n",
       " 'Terconazole': ['Terconazole', 'Terconazole'],\n",
       " 'Phenytoin': ['5,5-Diphenyl-imidazolidine-2,4-dione',\n",
       "  '5,5-diphenylimidazolidine-2,4-dione',\n",
       "  '5,5-diphenyltetrahydro-1H-2,4-imidazoledione\\t',\n",
       "  '5,5-Diphenyltetrahydro-1H-2,4-imidazoledione',\n",
       "  'Diphenylhydantoin',\n",
       "  'Fenitoina',\n",
       "  'Phentytoin',\n",
       "  'Phenytoin',\n",
       "  'Phenytoine',\n",
       "  'Phenytoinum',\n",
       "  'Phenytoin'],\n",
       " 'Medrysone': ['11beta-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione',\n",
       "  'Medrisona',\n",
       "  'Medrysone',\n",
       "  'Medrysonum',\n",
       "  'Medrysone'],\n",
       " 'Doxycycline': ['5-hydroxy-Î±-6-deoxytetracycline',\n",
       "  '6-alpha-deoxy-5-oxytetracycline',\n",
       "  '6alpha-deoxy-5-oxytetracycline',\n",
       "  '6Î±-deoxy-5-oxytetracycline',\n",
       "  'Anhydrous doxycycline',\n",
       "  'Doxiciclina',\n",
       "  'Doxycyclin',\n",
       "  'Doxycycline',\n",
       "  'Doxycycline (anhydrous)',\n",
       "  'Doxycycline anhydrous',\n",
       "  'Doxycyclinum',\n",
       "  'Doxycycline'],\n",
       " 'Diethylstilbestrol': ['(E)-3,4-bis(4-hydroxyphenyl)-3-hexene',\n",
       "  \"(E)-4,4'-(1,2-diethyl-1,2-ethenediyl)bisphenol\",\n",
       "  \"4,4'-dihydroxy-Î±,Î²-diethylstilbene\",\n",
       "  'DES',\n",
       "  'Diethylstilbestrol',\n",
       "  'DiÃ©thylstilbestrol',\n",
       "  'Diethylstilbestrolum',\n",
       "  'Dietilestilbestrol',\n",
       "  'Stilboestrol',\n",
       "  \"trans-4,4'-(1,2-diethyl-1,2-ethenediyl)bisphenol\",\n",
       "  'trans-Diethylstilbesterol',\n",
       "  'trans-Diethylstilbestrol',\n",
       "  'trans-Diethylstilboesterol',\n",
       "  \"Î±,Î±'-diethyl-(E)-4,4'-stilbenediol\",\n",
       "  'Diethylstilbestrol'],\n",
       " 'Lymecycline': ['(+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide',\n",
       "  'Limeciclina',\n",
       "  'Lymecycline',\n",
       "  'Lymecyclinum',\n",
       "  'N-Lysinomethyltetracycline',\n",
       "  'N2-(((+)-5-Amino-5-carboxypentylamino)methyl)tetracycline',\n",
       "  'N6-((4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamido)methyl)lysine',\n",
       "  'Tetracycline-L-methylene lysine',\n",
       "  'Tetracycline-L-methylenelysine',\n",
       "  'Lymecycline'],\n",
       " 'Clotrimazole': ['1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole',\n",
       "  '1-(o-Chloro-Î±,Î±-diphenylbenzyl)imidazole',\n",
       "  '1-(o-Chlorotrityl)imidazole',\n",
       "  '1-(Î±-(2-Chlorophenyl)benzhydryl)imidazole',\n",
       "  'Clotrimazol',\n",
       "  'Clotrimazole',\n",
       "  'Clotrimazolum',\n",
       "  'Clotrimazole'],\n",
       " 'Calcium acetate': ['Acetate of lime',\n",
       "  'Brown acetate of lime',\n",
       "  'Calcio acetato',\n",
       "  'Calcium acetate',\n",
       "  'calcium ethanoate',\n",
       "  'calcium(II) acetate',\n",
       "  'Gray acetate of lime',\n",
       "  'Lime acetate',\n",
       "  'Lime pyrolignite',\n",
       "  'Calcium acetate'],\n",
       " 'Sulfanilamide': ['4-aminobenzene sulfonic acid amide',\n",
       "  '4-azanylbenzenesulfonamide',\n",
       "  'p-aminobenzenesulfamide',\n",
       "  'p-aminobenzenesulfonamide',\n",
       "  'para-aminobenzenesulfonamide',\n",
       "  'Prontosil album',\n",
       "  'SA',\n",
       "  'Streptocide',\n",
       "  'Sulfamine',\n",
       "  'Sulfanilamida',\n",
       "  'Sulfanilamide',\n",
       "  'Sulfanilamidum',\n",
       "  'Sulphanilamide',\n",
       "  'Sulfanilamide'],\n",
       " 'Cycloserine': ['(+)-4-amino-3-isoxazolidinone',\n",
       "  '(+)-cycloserine',\n",
       "  'alpha-Cycloserine',\n",
       "  'Cicloserina',\n",
       "  'cyclo-D-Serine',\n",
       "  'CyclosÃ©rine',\n",
       "  'Cycloserine',\n",
       "  'Cycloserinum',\n",
       "  'D-(+)-cycloserine',\n",
       "  'D-4-amino-3-isoxazolidinone',\n",
       "  'D-4-amino-3-isoxazolidone',\n",
       "  'D-Cycloserine',\n",
       "  'DCS',\n",
       "  'Orientomycin',\n",
       "  'Î±-Cycloserine',\n",
       "  'Cycloserine'],\n",
       " 'Anagrelide': ['Anagrelida', 'Anagrelide', 'Anagrelidum', 'Anagrelide'],\n",
       " 'Carmustine': ['BCNU',\n",
       "  'bis-chloroethylnitrosourea',\n",
       "  'Bischloroethyl nitrosourea',\n",
       "  'Carmustina',\n",
       "  'Carmustine',\n",
       "  'Carmustinum',\n",
       "  \"N,N'-Bis(2-chloroethyl)-N-nitrosourea\",\n",
       "  'Carmustine'],\n",
       " 'Sulfisoxazole': ['3,4-Dimethyl-5-sulfanilamidoisoxazole',\n",
       "  '3,4-Dimethyl-5-sulfonamidoisoxazole',\n",
       "  '3,4-Dimethyl-5-sulphanilamidoisoxazole',\n",
       "  '3,4-Dimethyl-5-sulphonamidoisoxazole',\n",
       "  '3,4-Dimethylisoxazole-5-sulfanilamide',\n",
       "  '3,4-Dimethylisoxazole-5-sulphanilamide',\n",
       "  '4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide',\n",
       "  '4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulphonamide',\n",
       "  '5-(4-Aminophenylsulfonamido)-3,4-dimethylisoxazole',\n",
       "  '5-(p-Aminobenzenesulfonamido)-3,4-dimethylisoxazole',\n",
       "  '5-(p-Aminobenzenesulphonamido)-3,4-dimethylisoxazole',\n",
       "  '5-Sulfanilamido-3,4-dimethylisoxazole',\n",
       "  '5-Sulphanilamido-3,4-dimethyl-isoxazole',\n",
       "  \"N'-(3,4)Dimethylisoxazol-5-yl-sulphanilamide\",\n",
       "  'N1-(3,4-dimethyl-5-isoxazolyl)sulfanilamide',\n",
       "  'N1-(3,4-dimethyl-5-isoxazolyl)sulphanilamide',\n",
       "  'Sulfadimethylisoxazole',\n",
       "  'Sulfafurazol',\n",
       "  'Sulfafurazole',\n",
       "  'Sulfafurazolum',\n",
       "  'Sulfaisoxazole',\n",
       "  'Sulfasoxazole',\n",
       "  'Sulfisonazole',\n",
       "  'Sulfisoxasole',\n",
       "  'Sulfisoxazol',\n",
       "  'Sulfisoxazole',\n",
       "  'Sulfofurazole',\n",
       "  'Sulphadimethylisoxazole',\n",
       "  'Sulphafurazol',\n",
       "  'Sulphafurazole',\n",
       "  'Sulphaisoxazole',\n",
       "  'Sulphisoxazol',\n",
       "  'Sulphofurazole',\n",
       "  'Sulfisoxazole'],\n",
       " 'Metoprolol': ['(RS)-Metoprolol',\n",
       "  '1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol',\n",
       "  'DL-metoprolol',\n",
       "  'Metoprolol',\n",
       "  'Metoprolol'],\n",
       " 'Crotamiton': ['Crotamiton', 'Crotamiton'],\n",
       " 'Dicoumarol': [\"3,3'-methylen-bis(4-hydroxy-cumarin)\",\n",
       "  \"3,3'-methylene-bis(4-hydroxycoumarine)\",\n",
       "  \"3,3'-methylenebis(4-hydroxy-1,2-benzopyrone)\",\n",
       "  \"3,3'-methylenebis(4-hydroxy-2H-1-benzopyran-2-one)\",\n",
       "  \"3,3'-methylenebis(4-hydroxycoumarin)\",\n",
       "  \"bis-3,3'-(4-hydroxycoumarinyl)methane\",\n",
       "  'bis-hydroxycoumarin',\n",
       "  'bis(4-hydroxycoumarin-3-yl)methane',\n",
       "  'di-(4-hydroxy-3-coumarinyl)methane',\n",
       "  'Dicoumarol',\n",
       "  'Dicoumarolum',\n",
       "  'Dicumarol',\n",
       "  'Dicoumarol'],\n",
       " 'Cefmenoxime': ['(6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-((1-methyl-1H-5-tetraazolylthio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure',\n",
       "  '(6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  'Cefmenoxima',\n",
       "  'Cefmenoxime',\n",
       "  'Cefmenoximum',\n",
       "  'CMX',\n",
       "  'Cefmenoxime'],\n",
       " 'Ropinirole': ['Ropinirol', 'Ropinirole', 'Ropinirolum', 'Ropinirole'],\n",
       " 'Chlorotrianisene': ['Chloortrianisestrol',\n",
       "  'Chlorestrolo',\n",
       "  'Chlorotrianisene',\n",
       "  'Chlorotrianisenum',\n",
       "  'Chlorotrianisine',\n",
       "  'Chlorotrianizen',\n",
       "  'Chlortrianisen',\n",
       "  'Chlortrianisestrol',\n",
       "  'Chlortrianisoestrolum',\n",
       "  'Chlortrianizen',\n",
       "  'Clorotrianiseno',\n",
       "  'Chlorotrianisene'],\n",
       " 'Isradipine': ['Isradipine', 'Isradipino', 'Isradipinum', 'Isradipine'],\n",
       " 'Diatrizoate': ['2,4,6-Triiodo-3,5-diacetamidobenzoic acid',\n",
       "  '3,5-Bis(acetylamino)-2,4,6-triiodobenzoic acid',\n",
       "  '3,5-diacetamido-2,4,6-triiodobenzoic acid',\n",
       "  'Acide amidotrizoique',\n",
       "  'Acidum amidotrizoicum',\n",
       "  'Acidum diacetylaminotrijodbenzoicum',\n",
       "  'Amidotrizoate',\n",
       "  'Amidotrizoic Acid',\n",
       "  'Amidotrizoic acid (anhydrous)',\n",
       "  'Diatrizoesaure',\n",
       "  'Diatrizoic acid',\n",
       "  'Diatrizoic acid (anhydrous)',\n",
       "  'Methalamic acid',\n",
       "  'Triombrin',\n",
       "  'Urografin acid',\n",
       "  'Urogranoic acid',\n",
       "  'Diatrizoate'],\n",
       " 'Betazole': ['1H-pyrazole-3-ethanamine',\n",
       "  '2-(1H-pyrazol-5-yl)ethanamine',\n",
       "  '2-(3-pyrazolyl)ethylamine',\n",
       "  '3-(2-aminoethyl)pyrazole',\n",
       "  '3-(beta-aminoethyl)pyrazole',\n",
       "  '3-(Î²-aminoethyl)pyrazole',\n",
       "  'Ametazole',\n",
       "  'Betazol',\n",
       "  'Betazole',\n",
       "  'Betazolum',\n",
       "  'Betazole'],\n",
       " 'Topiramate': ['2,3:4,5-bis-O-(1-methylethylidene)-Î²-D-fructopyranose sulfamate',\n",
       "  '2,3:4,5-di-O-isopropylidene-Î²-D-fructopyranose sulfamate',\n",
       "  'Tipiramate',\n",
       "  'Tipiramato',\n",
       "  'Topiramate',\n",
       "  'Topiramato',\n",
       "  'Topiramatum',\n",
       "  'TPM',\n",
       "  'Topiramate'],\n",
       " 'Cefmetazole': ['(6R,7S)-7-({[(cyanomethyl)sulfanyl]acetyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  'Cefmetazole',\n",
       "  'Cefmetazolo',\n",
       "  'Cefmetazolum',\n",
       "  'Cefmetazole'],\n",
       " 'Olmesartan': [\"4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid\",\n",
       "  \"4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid\",\n",
       "  'Olmesartan',\n",
       "  'Olmesartan'],\n",
       " 'Amsacrine': [\"4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide\",\n",
       "  \"4'-(9-Acridinylamino)methanesulfon-m-anisidide\",\n",
       "  \"4'-(9-Acridinylamino)methanesulfon-meta-anisidide\",\n",
       "  \"4'-(9-Acridinylamino)methanesulphon-m-anisidide\",\n",
       "  'Acridinyl anisidide',\n",
       "  'Amsacrina',\n",
       "  'Amsacrine',\n",
       "  'Amsacrinum',\n",
       "  'm-AMSA',\n",
       "  'mAMSA',\n",
       "  'Amsacrine'],\n",
       " 'Theophylline': ['1,3-dimethyl-7H-purine-2,6-dione',\n",
       "  '1,3-dimethylxanthine',\n",
       "  'Teofilina',\n",
       "  'Theophyllin',\n",
       "  'Theophylline anhydrous',\n",
       "  'Theophylline, anhydrous',\n",
       "  'Theophylline'],\n",
       " 'Argatroban': ['Argatroban', 'Argatroban anhydrous', 'Argatroban'],\n",
       " 'Liothyronine': [\"3,3',5-triiodo-L-thyronine\",\n",
       "  \"3,5,3'-Triiodo-L-thyronine\",\n",
       "  \"3,5,3'-Triiodothyronine\",\n",
       "  '4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine',\n",
       "  \"L-3,5,3'-Triiodothyronine\",\n",
       "  'L-T3',\n",
       "  'Liothyronine',\n",
       "  'Liothyroninum',\n",
       "  'Liotironina',\n",
       "  'O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine',\n",
       "  'T3',\n",
       "  'Triiodothyronine',\n",
       "  'Liothyronine'],\n",
       " 'Disopyramide': ['Disopiramida',\n",
       "  'Disopyramide',\n",
       "  'Disopyramidum',\n",
       "  'Disopyramide'],\n",
       " 'Lidocaine': [\"2-(Diethylamino)-2',6'-acetoxylidide\",\n",
       "  '2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide',\n",
       "  'alpha-diethylamino-2,6-dimethylacetanilide',\n",
       "  'LidocaÃ\\xadna',\n",
       "  'Lidocaina',\n",
       "  'Lidocaine',\n",
       "  'Lidocainum',\n",
       "  'Lignocaine',\n",
       "  'Î±-diethylamino-2,6-dimethylacetanilide',\n",
       "  'Lidocaine'],\n",
       " 'Pamidronic acid': ['Acide pamidronique',\n",
       "  'Acido pamidronico',\n",
       "  'Acidum pamidronicum',\n",
       "  'Pamidronate',\n",
       "  'Pamidronic acid',\n",
       "  'Pamidronic acid'],\n",
       " 'Clemastine': ['(+)-(2R)-2-(2-(((R)-p-chloro-Î±-methyl-Î±-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine',\n",
       "  '(+)-(2R)-2-[2-[[(R)-p-chloro-Î±-methyl-Î±-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine',\n",
       "  'Clemastina',\n",
       "  'Clemastine',\n",
       "  'Clemastinum',\n",
       "  'Clemastine'],\n",
       " 'Acarbose': ['Acarbosa', 'Acarbose', 'Acarbosum', 'Acarbose'],\n",
       " 'Venlafaxine': ['Venlafaxina', 'Venlafaxine', 'Venlafaxinum', 'Venlafaxine'],\n",
       " 'Conjugated estrogens': ['Conjugated equine estrogens',\n",
       "  'Conjugated estrogens',\n",
       "  'Estrogens, Conjugated',\n",
       "  'Estrogens,conjugated',\n",
       "  'Conjugated estrogens'],\n",
       " 'Travoprost': ['isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(Î±,Î±,Î±-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate',\n",
       "  'Travoprost',\n",
       "  'Travoprostum',\n",
       "  'Travoprost'],\n",
       " 'Amcinonide': ['AmcinÃ³nida',\n",
       "  'Amcinonide',\n",
       "  'Amcinonidum',\n",
       "  'Triamcinolonacetatcyclopentanonid',\n",
       "  'Amcinonide'],\n",
       " 'Atomoxetine': ['(-)-Tomoxetine',\n",
       "  'Atomoxetina',\n",
       "  'Atomoxetine',\n",
       "  'Tomoxetina',\n",
       "  'Tomoxetine',\n",
       "  'Tomoxetinum',\n",
       "  'Atomoxetine'],\n",
       " 'Bleomycin': ['Bleocin',\n",
       "  'Bleomicin',\n",
       "  'Bleomicina',\n",
       "  'Bleomycin',\n",
       "  'Bleomycine',\n",
       "  'Bleomycinum',\n",
       "  'Bleomycin'],\n",
       " 'Chlorambucil': ['4-(p-bis(beta-chloroethyl)aminophenyl)butyric acid',\n",
       "  '4-(p-bis(Î²-chloroethyl)aminophenyl)butyric acid',\n",
       "  '4-[p-[bis(2-chloroethyl)amino]phenyl]butyric acid',\n",
       "  'Ambochlorin',\n",
       "  'Chlorambucil',\n",
       "  'Chloraminophen',\n",
       "  'Clorambucilo',\n",
       "  'gamma-[p-di(2-chloroethyl)aminophenyl]butyric acid',\n",
       "  'N,N-di-2-chloroethyl-gamma-p-aminophenylbutyric acid',\n",
       "  'N,N-di-2-chloroethyl-Î³-p-aminophenylbutyric acid',\n",
       "  'Phenylbutyric acid nitrogen mustard',\n",
       "  'Î³-[p-di(2-chloroethyl)aminophenyl]butyric acid',\n",
       "  'Chlorambucil'],\n",
       " 'Etomidate': ['(+)-ethyl 1-(Î±-methylbenzyl)imidazole-5-carboxylate',\n",
       "  '(+)-etomidate',\n",
       "  '(R)-(+)-1-(Î±-methylbenzyl)imidazole-5-carboxylic acid ethyl ester',\n",
       "  '(R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester',\n",
       "  '3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester',\n",
       "  'Etomidate',\n",
       "  'Etomidato',\n",
       "  'Etomidatum',\n",
       "  'R-(+)-ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate',\n",
       "  'Etomidate'],\n",
       " 'Raltitrexed': ['Raltitrexed', 'Raltitrexed'],\n",
       " 'Etonogestrel': ['3-Ketodesogestrel',\n",
       "  '3-Oxodesogestrel',\n",
       "  'Etonogestrel',\n",
       "  'Ã©tonogestrel',\n",
       "  'Etonogestrelum',\n",
       "  'Etonogestrel'],\n",
       " 'Morphine': ['(â\\x88\\x92)-morphine',\n",
       "  '(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol',\n",
       "  '(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol',\n",
       "  '(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol',\n",
       "  '(5Î±,6Î±)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol',\n",
       "  '(5Î±,6Î±)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol',\n",
       "  '(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol',\n",
       "  'Anhydrous morphine',\n",
       "  'Morfina',\n",
       "  'Morphia',\n",
       "  'Morphin',\n",
       "  'Morphine',\n",
       "  'Morphinum',\n",
       "  'Morphium',\n",
       "  'Morphine'],\n",
       " 'Ropivacaine': [\"(S)-(â\\x88\\x92)-1-propyl-2',6'-pipecoloxylidide\",\n",
       "  '(S)-ropivacaine',\n",
       "  'L-N-n-propylpipecolic acid-2,6-xylidide',\n",
       "  'Ropivacaina',\n",
       "  'Ropivacaine',\n",
       "  'Ropivacainum',\n",
       "  'Ropivacaine'],\n",
       " 'Bupivacaine': ['(Â±)-bupivacaine',\n",
       "  '(RS)-bupivacaine',\n",
       "  \"1-Butyl-2',6'-pipecoloxylidide\",\n",
       "  '1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide',\n",
       "  'Bupivacaina',\n",
       "  'Bupivacaine',\n",
       "  'Bupivacainum',\n",
       "  \"dl-1-Butyl-2',6'-pipecoloxylidide\",\n",
       "  'DL-Bupivacaine',\n",
       "  'Racemic bupivacaine',\n",
       "  'Bupivacaine'],\n",
       " 'Dapiprazole': ['5,6,7,8-Tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine',\n",
       "  'Dapiprazol',\n",
       "  'Dapiprazole',\n",
       "  'Dapiprazolum',\n",
       "  'Dapiprazole'],\n",
       " 'Penciclovir': ['9-(4-hydroxy-3-(hydroxymethyl)butyl)guanine',\n",
       "  '9-(4-hydroxy-3-hydroxymethylbut-1-yl)-guanine',\n",
       "  '9-[2-hydroxy-1-(hydroxymethyl)-ethoxymethyl]guanine',\n",
       "  '9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine',\n",
       "  'PCV',\n",
       "  'PE2',\n",
       "  'Penciclovir',\n",
       "  'Penciclovirum',\n",
       "  'Penciclovir'],\n",
       " 'Tenofovir disoproxil': ['Bis(POC)PMPA',\n",
       "  'Tenofovir bis(isopropyloxycarbonyloxymethyl) ester',\n",
       "  'Tenofovir disoproxil'],\n",
       " 'Flucloxacillin': ['(2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  '3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin',\n",
       "  'Floxacillin',\n",
       "  'Flucloxacilina',\n",
       "  'Flucloxacillin',\n",
       "  'Flucloxacilline',\n",
       "  'Flucloxacillinum',\n",
       "  'Flucloxacillin'],\n",
       " 'Tranexamic acid': ['Acide tranÃ©xamique',\n",
       "  'Ã¡cido tranexÃ¡mico',\n",
       "  'Acidum tranexamicum',\n",
       "  'Tranexamic acid',\n",
       "  'Tranexamsaeure',\n",
       "  'Tranexmic acid',\n",
       "  'Tranhexamic acid',\n",
       "  'Trans AMCHA',\n",
       "  'trans-4-(Aminomethyl)cyclohexanecarboxylic acid',\n",
       "  'trans-4-aminomethylcyclohexane-1-carboxylic acid',\n",
       "  'trans-Amcha',\n",
       "  'trans-Tranexamic acid',\n",
       "  'Tranexamic acid'],\n",
       " 'Ertapenem': [\"(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid\",\n",
       "  '(4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid',\n",
       "  'Ertapenem',\n",
       "  'Ertapenem'],\n",
       " 'Desogestrel': ['13-Ethyl-11-methylene-18,19-dinor-17Î±-pregn-4-en-20-yn-17-ol',\n",
       "  'Desogestrel',\n",
       "  'DÃ©sogestrel',\n",
       "  'Desogestrelum',\n",
       "  'Desogestrel'],\n",
       " 'Mitomycin': ['7-Amino-9alpha-methoxymitosane',\n",
       "  'Ametycine',\n",
       "  'Mitamycin',\n",
       "  'Mitocin-C',\n",
       "  'Mitomycin',\n",
       "  'Mitomycin C',\n",
       "  'MMC',\n",
       "  'Mitomycin'],\n",
       " 'Talbutal': ['(RS)-5-allyl-5-sec-butylpyrimidine-2,4,6(1H,3H,5H)-trione',\n",
       "  '5-allyl-5-sec-butylbarbituric acid',\n",
       "  'sec-Butyl allyl barbituric acid',\n",
       "  'Talbutal',\n",
       "  'Talbutale',\n",
       "  'Talbutalum',\n",
       "  'Talbutal'],\n",
       " 'Bexarotene': ['4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid',\n",
       "  '4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid',\n",
       "  'Bexaroten',\n",
       "  'BexarotÃ¨ne',\n",
       "  'Bexarotene',\n",
       "  'Bexaroteno',\n",
       "  'Bexarotenum',\n",
       "  'p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid',\n",
       "  'Bexarotene'],\n",
       " 'Ibutilide': ['Ibutilid',\n",
       "  'Ibutilida',\n",
       "  'Ibutilide',\n",
       "  'Ibutilidum',\n",
       "  'N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide',\n",
       "  'Ibutilide'],\n",
       " 'Vindesine': ['3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine',\n",
       "  '3-carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine',\n",
       "  'Desacetylvinblastine amide',\n",
       "  'Vindesina',\n",
       "  'Vindesine',\n",
       "  'Vindesinum',\n",
       "  'Vindesine'],\n",
       " 'Chlorthalidone': [\"1-keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline\",\n",
       "  '1-oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline',\n",
       "  '2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide',\n",
       "  '2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide',\n",
       "  \"3-(4'-chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine\",\n",
       "  '3-hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine',\n",
       "  'Chlorphthalidolone',\n",
       "  'Chlortalidone',\n",
       "  'Chlortalidonum',\n",
       "  'Chlorthalidone',\n",
       "  'Clortalidona',\n",
       "  'Phthalamodine',\n",
       "  'Phthalamudine',\n",
       "  'Chlorthalidone'],\n",
       " 'Ethoxzolamide': ['6-Ethoxy-1,3-benzothiazole-2-sulfonamide',\n",
       "  'Ethoxazolamide',\n",
       "  'Ethoxyzolamide',\n",
       "  'Ethoxzolamide'],\n",
       " 'Pentobarbital': ['5-Ethyl-5-(1-methyl-butyl)-pyrimidine-2,4,6-trione',\n",
       "  '5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-ethyl-5-(1-methylbutyl)barbituric acid',\n",
       "  '5-ethyl-5-(sec-pentyl)barbituric acid',\n",
       "  'Pentobarbital',\n",
       "  'Pentobarbitone',\n",
       "  'Pentobarbital'],\n",
       " 'Valproic acid': ['2-n-propyl-n-valeric acid',\n",
       "  '2-propyl-pentanoic acid',\n",
       "  '2-Propylpentanoic Acid',\n",
       "  '2-Propylvaleric Acid',\n",
       "  '4-heptanecarboxylic acid',\n",
       "  'acide valproÃ¯que',\n",
       "  'Ã¡cido valproico',\n",
       "  'acidum valproicum',\n",
       "  'di-n-propylacetic acid',\n",
       "  'Di-n-propylessigsÃ¤ure',\n",
       "  'Dipropylacetic acid',\n",
       "  'DPA',\n",
       "  'n-DPA',\n",
       "  'Valproate',\n",
       "  'Valproic acid',\n",
       "  'ValproinsÃ¤ure',\n",
       "  'VPA',\n",
       "  'Valproic acid'],\n",
       " 'Capreomycin': ['Capreomicina', 'Capreomycin', 'Capreomycin'],\n",
       " 'Zolmitriptan': ['(S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one',\n",
       "  '4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one',\n",
       "  'Zolmitriptan',\n",
       "  'ZolmitriptÃ¡n',\n",
       "  'Zolmitriptanum',\n",
       "  'Zolmitriptan'],\n",
       " 'Acetaminophen': ['4-(Acetylamino)phenol',\n",
       "  '4-acetamidophenol',\n",
       "  \"4'-hydroxyacetanilide\",\n",
       "  'Acenol',\n",
       "  'AcetaminofÃ©n',\n",
       "  'AcÃ©taminophÃ¨ne',\n",
       "  'APAP',\n",
       "  'N-acetyl-p-aminophenol',\n",
       "  'p-acetamidophenol',\n",
       "  'p-acetaminophenol',\n",
       "  'p-Acetylaminophenol',\n",
       "  'p-hydroxy-acetanilid',\n",
       "  'p-hydroxyacetanilide',\n",
       "  'p-hydroxyphenolacetamide',\n",
       "  'ParacÃ©tamol',\n",
       "  'Paracetamol',\n",
       "  'Paracetamolum',\n",
       "  'Acetaminophen'],\n",
       " 'Gefitinib': [\"4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline\",\n",
       "  'Gefitinib',\n",
       "  'N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine',\n",
       "  'Gefitinib'],\n",
       " 'Codeine': ['(â\\x88\\x92)-Codeine',\n",
       "  '(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol',\n",
       "  '7,8-didehydro-4,5Î±-epoxy-3-methoxy-17-methylmorphinan-6Î±-ol',\n",
       "  'Codein',\n",
       "  'CodeÃ\\xadna',\n",
       "  'CodÃ©ine',\n",
       "  'Codeine anhydrous',\n",
       "  'Codeine polistirex',\n",
       "  'Codeinum',\n",
       "  'L-Codeine',\n",
       "  'Methylmorphine',\n",
       "  'morphine 3-methyl ether',\n",
       "  'Morphine monomethyl ether',\n",
       "  'morphine-3-methyl ether',\n",
       "  'O3-Methylmorphine',\n",
       "  'Codeine'],\n",
       " 'Piperacillin': ['(2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  'Piperacilina',\n",
       "  'Piperacillin',\n",
       "  'Piperacillin anhydrous',\n",
       "  'Piperacillina',\n",
       "  'PipÃ©racilline',\n",
       "  'Piperacillinum',\n",
       "  'Piperacillin'],\n",
       " 'Dihydroergotamine': ['(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide',\n",
       "  \"5'-benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman\",\n",
       "  \"9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione\",\n",
       "  '9,10-dihydroergotamine',\n",
       "  'Dihidroergotamina',\n",
       "  'Dihydroergotamin',\n",
       "  'Dihydroergotamine',\n",
       "  'Dihydroergotaminum',\n",
       "  'Diidroergotamina',\n",
       "  'Dihydroergotamine'],\n",
       " 'Amitriptyline': ['10,11-dihydro-5-(Î³-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene',\n",
       "  '10,11-dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-Î\\x945,Î³-propylamine',\n",
       "  '3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine',\n",
       "  '3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine',\n",
       "  '5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene',\n",
       "  '5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene',\n",
       "  '5-(Î³-dimethylaminopropylidene)-5H-dibenzo[a,d][1,4]cycloheptadiene',\n",
       "  'Amitriptilina',\n",
       "  'Amitriptylin',\n",
       "  'Amitriptyline',\n",
       "  'Amitriptylinum',\n",
       "  'Amitriptyline'],\n",
       " 'Floxuridine': ['1-(2-Deoxy-beta-D-ribofuranosyl)-5-fluorouracil',\n",
       "  \"1-beta-D-2'-Deoxyribofuranosyl-5-flurouracil\",\n",
       "  \"1beta-D-2'-Deoxyribofuranosyl-5-flurouracil\",\n",
       "  \"2'-Deoxy-5-fluorouridine\",\n",
       "  '5-Fluoro-2-desoxyuridine',\n",
       "  \"5-fluoro-2'-deoxyuridine\",\n",
       "  '5-Fluorodeoxyuridine',\n",
       "  \"5-Fluorouracil 2'-deoxyriboside\",\n",
       "  '5-Fluorouracil deoxyriboside',\n",
       "  '5FDU',\n",
       "  \"beta-5-Fluoro-2'-deoxyuridine\",\n",
       "  'Deoxyfluorouridine',\n",
       "  'FdU',\n",
       "  'Floxiridina',\n",
       "  'Floxuridin',\n",
       "  'Floxuridine',\n",
       "  'Floxuridinum',\n",
       "  'Fluorodeoxyuridine',\n",
       "  'Fluoruridine deoxyribose',\n",
       "  'Floxuridine'],\n",
       " 'Tolcapone': ['(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone',\n",
       "  \"3,4-dihydroxy-4'-methyl-5-nitrobenzophenone\",\n",
       "  \"3,4-dihydroxy-5-nitro-4'-methylbenzophenone\",\n",
       "  \"4'-methyl-3,4-dihydroxy-5-nitrobenzophenone\",\n",
       "  'Tolcapon',\n",
       "  'Tolcapona',\n",
       "  'Tolcapone',\n",
       "  'Tolcaponum',\n",
       "  'Tolcapone'],\n",
       " 'Fluorometholone': ['(1R,2S,8S,10S,11S,14R,15S,17S)-14-acetyl-1-fluoro-14,17-dihydroxy-2,8,15-trimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-3,6-dien-5-one',\n",
       "  '9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione',\n",
       "  'Fluorometholon',\n",
       "  'FluoromÃ©tholone',\n",
       "  'Fluorometholone',\n",
       "  'Fluorometholonum',\n",
       "  'Fluorometolona',\n",
       "  'Fluorometholone'],\n",
       " 'Nitroprusside': ['Nitroferricyanide', 'Nitroprusside'],\n",
       " 'Calcium glucoheptonate': ['Calcii glucoheptonas',\n",
       "  'calcium (2Î¾)-D-gluco-heptonate',\n",
       "  'calcium bis[(2Î¾)-D-glycero-D-gulo-heptonate]',\n",
       "  'calcium bis[(2Î¾)-D-glycero-D-ido-heptonate]',\n",
       "  'calcium bis[(3R,4S,5R,6R)-2,3,4,5,6,7-hexahydroxyheptanoate]',\n",
       "  'Calcium gluceptate',\n",
       "  'Calcium glucoheptonat',\n",
       "  'Calcium glucoheptonate',\n",
       "  'Calcium glucoheptonate (1:2)',\n",
       "  'Glucoheptonate de calcium',\n",
       "  'Glucoheptonato calcico',\n",
       "  'Calcium glucoheptonate'],\n",
       " 'Hydromorphone': ['(-)-(5R)-4,5-Epoxy-3-hydroxy-9Î±-methylmorphinan-6-one',\n",
       "  '4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one',\n",
       "  '4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone',\n",
       "  '6-Deoxy-7,8-dihydro-6-oxomorphine',\n",
       "  '7,8-Dihydromorphinone',\n",
       "  'Dihydromorfinon',\n",
       "  'Dihydromorphinone',\n",
       "  'Dimorphone',\n",
       "  'Hidromorfona',\n",
       "  'Hydromorfona',\n",
       "  'Hydromorphone',\n",
       "  'Hydromorphonum',\n",
       "  'Idromorfone',\n",
       "  'Hydromorphone'],\n",
       " 'Indomethacin': ['{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid',\n",
       "  '1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid',\n",
       "  'Indometacin',\n",
       "  'Indometacina',\n",
       "  'Indometacine',\n",
       "  'Indometacinum',\n",
       "  'Indomethacin',\n",
       "  'Indomethacin'],\n",
       " 'Ethambutol': [\"(+)-2,2'-(ethylenediimino)di-1-butanol\",\n",
       "  '(+)-ethambutol',\n",
       "  \"(+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamine\",\n",
       "  '(+)-S,S-ethambutol',\n",
       "  '(2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol',\n",
       "  '(S,S)-ethambutol',\n",
       "  'EMB',\n",
       "  'Etambutol',\n",
       "  'Etambutolo',\n",
       "  'Ethambutol',\n",
       "  'Ethambutolum',\n",
       "  'S,S-Ethambutol',\n",
       "  'Ethambutol'],\n",
       " 'Metformin': ['1,1-Dimethylbiguanide',\n",
       "  'Dimethylbiguanid',\n",
       "  'Metformin',\n",
       "  'Metformina',\n",
       "  'Metformine',\n",
       "  'Metforminum',\n",
       "  'Metformin'],\n",
       " 'Ipratropium': ['bromuro de ipratropio',\n",
       "  'Ipratropium cation',\n",
       "  'Ipratropium ion',\n",
       "  'Ipratropium'],\n",
       " 'Methadone': ['(+-)-Methadone',\n",
       "  '(+/-)-Methadone',\n",
       "  '(Â±)-methadone',\n",
       "  '6-Dimethylamino-4,4-diphenyl-3-heptanone',\n",
       "  'dl-Methadone',\n",
       "  'Metadona',\n",
       "  'Methadone',\n",
       "  'Methadonum',\n",
       "  'Methadone'],\n",
       " 'Olanzapine': ['2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine',\n",
       "  'Olanzapin',\n",
       "  'Olanzapina',\n",
       "  'Olanzapine',\n",
       "  'Olanzapinum',\n",
       "  'Olanzapine'],\n",
       " 'Atenolol': ['1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol',\n",
       "  '2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide',\n",
       "  '4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide',\n",
       "  'Atenolol',\n",
       "  'Atenololum',\n",
       "  'Atenolol'],\n",
       " 'Nitrofural': ['5-Nitro-2-furaldehyde semicarbazone',\n",
       "  'Furacilin',\n",
       "  'Nitrofural',\n",
       "  'Nitrofural'],\n",
       " 'Pimecrolimus': ['33-Epi-chloro-33-desoxyascomycin',\n",
       "  'Pimecrolimus',\n",
       "  'Pimecrolimusum',\n",
       "  'Pimecrolimus'],\n",
       " 'Omeprazole': ['OMEP',\n",
       "  'Omeprazol',\n",
       "  'Omeprazole',\n",
       "  'Omeprazolum',\n",
       "  'Omeprazole'],\n",
       " 'Pyrazinamide': ['2-carbamylpyrazine',\n",
       "  '2-pyrazinecarboxamide',\n",
       "  'Aldinamide',\n",
       "  'Pirazinamida',\n",
       "  'Pirazinamide',\n",
       "  'Pyrazinamid',\n",
       "  'Pyrazinamida',\n",
       "  'Pyrazinamide',\n",
       "  'Pyrazinamidum',\n",
       "  'Pyrazine carboxamide',\n",
       "  'pyrazine-2-carboxamide',\n",
       "  'Pyrazineamide',\n",
       "  'Pyrazinecarboxamide',\n",
       "  'Pyrazinoic acid amide',\n",
       "  'Pyrizinamide',\n",
       "  'Pyrazinamide'],\n",
       " 'Metixene': ['Methixen',\n",
       "  'Methixene',\n",
       "  'Metisene',\n",
       "  'Metixene',\n",
       "  'MÃ©tixÃ¨ne',\n",
       "  'Metixeno',\n",
       "  'Metixenum',\n",
       "  'Metixene'],\n",
       " 'Cetirizine': ['Cetirizin',\n",
       "  'Cetirizina',\n",
       "  'Cetirizine',\n",
       "  'Cetirizinum',\n",
       "  'Cetirizine'],\n",
       " 'Terfenadine': ['(RS)-1-(4-tert-butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}-butan-1-ol',\n",
       "  'Terfenadin',\n",
       "  'Terfenadina',\n",
       "  'TerfÃ©nadine',\n",
       "  'Terfenadine',\n",
       "  'Terfenadinum',\n",
       "  'Terfenadine'],\n",
       " 'Diltiazem': ['(+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester',\n",
       "  '(2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one',\n",
       "  '(2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate',\n",
       "  'Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester',\n",
       "  'd-cis-diltiazem',\n",
       "  'Diltiazem',\n",
       "  'Diltiazemum',\n",
       "  'Diltiazem'],\n",
       " 'Protriptyline': ['3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine',\n",
       "  '3-(5H-dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine',\n",
       "  '5-(3-methylaminopropyl)-5H-dibenzo[a,d]cycloheptene',\n",
       "  '7-(3-methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene',\n",
       "  'Amimetilina',\n",
       "  'N-methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine',\n",
       "  'N-methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine',\n",
       "  'Protriptilina',\n",
       "  'Protriptylin',\n",
       "  'Protriptyline',\n",
       "  'Protriptylinum',\n",
       "  'Protriptyline'],\n",
       " 'Aminohippuric acid': ['4-aminohippuric acid',\n",
       "  'Aminohippurate',\n",
       "  'N-(p-Aminobenzoyl)aminoacetic acid',\n",
       "  'N-(p-Aminobenzoyl)glycine',\n",
       "  'N-(para-aminobenzoyl)glycine',\n",
       "  'p-aminohippurate',\n",
       "  'p-aminohippuric acid',\n",
       "  'PAH',\n",
       "  'PAHA',\n",
       "  'para-aminohippurate',\n",
       "  'para-aminohippuric acid ',\n",
       "  'paraaminohippuric acid',\n",
       "  'Aminohippuric acid'],\n",
       " 'Alfuzosin': ['(Â±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide',\n",
       "  'Alfuzosin',\n",
       "  'Alfuzosina',\n",
       "  'Alfuzosine',\n",
       "  'Alfuzosinum',\n",
       "  'N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide',\n",
       "  'Alfuzosin'],\n",
       " 'Trimethadione': ['Trimetadiona',\n",
       "  'Trimethadion',\n",
       "  'Trimethadione',\n",
       "  'TrimÃ©thadione',\n",
       "  'Trimethadionum',\n",
       "  'Trimethinum',\n",
       "  'Troxidone',\n",
       "  'Trimethadione'],\n",
       " 'Nitisinone': ['2-(alpha,alpha,alpha-Trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione',\n",
       "  'Nitisinona',\n",
       "  'Nitisinone',\n",
       "  'Nitisinonum',\n",
       "  'Nitisinone'],\n",
       " 'Clobazam': ['1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine',\n",
       "  '7-Chloro-1-methyl-5-phenyl-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione',\n",
       "  'Clobazam',\n",
       "  'Clobazamum',\n",
       "  'Clobazam'],\n",
       " 'Minoxidil': ['2,4-Diamino-6-piperidinopyrimidine 3-oxide',\n",
       "  '6-Piperidin-1-ylpyrimidine-2,4-diamine 3-oxide',\n",
       "  'Minossidile',\n",
       "  'Minoxidil',\n",
       "  'Minoxidilum',\n",
       "  'Minoxidil'],\n",
       " 'Megestrol acetate': ['17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione',\n",
       "  '17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate',\n",
       "  '17alpha-Acetoxy-6-dehydro-6-methylprogesterone',\n",
       "  '17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate',\n",
       "  '17Î±-Acetoxy-6-dehydro-6-methylprogesterone',\n",
       "  '17Î±-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate',\n",
       "  '6-Dehydro-6-methyl-17alpha-acetoxyprogesterone',\n",
       "  '6-Dehydro-6-methyl-17Î±-acetoxyprogesterone',\n",
       "  '6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione',\n",
       "  '6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate',\n",
       "  '6-Methyl-17Î±-acetoxypregna-4,6-diene-3,20-dione',\n",
       "  '6-Methyl-17Î±-hydroxy-delta(sup 6)-progesterone acetate',\n",
       "  '6-Methyl-6-dehydro-17alpha-acetoxyprogesterone',\n",
       "  '6-Methyl-6-dehydro-17Î±-acetoxyprogesterone',\n",
       "  '6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate',\n",
       "  '6-Methyl-delta(sup 4,6)-pregnadien-17Î±-ol-3,20-dione acetate',\n",
       "  '6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone',\n",
       "  '6-Methyl-delta(sup 6)-dehydro-17Î±-acetoxyprogesterone',\n",
       "  'Megestrol acetate',\n",
       "  'MGA',\n",
       "  'Megestrol acetate'],\n",
       " 'Tioguanine': ['2-Amino 6MP',\n",
       "  '2-Amino-1,7-dihydro-6H-purine-6-thione',\n",
       "  '2-amino-1,9-dihydropurine-6-thione',\n",
       "  '2-Amino-6-mercaptopurine',\n",
       "  '2-Amino-6-merkaptopurin',\n",
       "  '2-Amino-6-purinethiol',\n",
       "  '2-Aminopurin-6-thiol',\n",
       "  '2-Aminopurine-6-thiol',\n",
       "  '2-Aminopurine-6(1H)-thione',\n",
       "  '6-Mercapto-2-aminopurine',\n",
       "  '6-Mercaptoguanine',\n",
       "  '6-TG',\n",
       "  '6-Thioguanine',\n",
       "  'TG',\n",
       "  'ThG',\n",
       "  'Thioguanine',\n",
       "  'Thioguanine anhydrous',\n",
       "  'Thioguanine, anhydrous',\n",
       "  'Tioguanin',\n",
       "  'Tioguanina',\n",
       "  'Tioguanine',\n",
       "  'Tioguaninum',\n",
       "  'Tioguanine'],\n",
       " 'Methylergometrine': ['9,10-Didehydro-N-[1-(hydroxymethyl)-propyl]-D-lysergamide',\n",
       "  'D-lysergic acid 1-butanolamide',\n",
       "  'Ergotyl',\n",
       "  'Methylergobasin',\n",
       "  'Methylergometrin',\n",
       "  'MÃ©thylergomÃ©trine',\n",
       "  'Methylergometrine',\n",
       "  'Methylergometrinum',\n",
       "  'Methylergonovine',\n",
       "  'Metilergometrina',\n",
       "  'Metilergometrinio',\n",
       "  'Methylergometrine'],\n",
       " 'Buclizine': ['1-(p-tert-Butylbenzyl)-4-(4-chloro-alpha-phenylbenzyl)piperazine',\n",
       "  'Buclizina',\n",
       "  'Buclizine',\n",
       "  'Buclizinum',\n",
       "  'Buclizine'],\n",
       " 'Aztreonam': ['(Z,)-2-((((2-Amino-4-thiazolyl)(((2S,3S,)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid',\n",
       "  '2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl) -2- {[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino} -2- oxoethylidene]amino}oxy)-2-methylpropanoic acid',\n",
       "  'Aztreonam',\n",
       "  'AztrÃ©onam',\n",
       "  'Aztreonamum',\n",
       "  'Aztreonam'],\n",
       " 'Chlorzoxazone': ['2-hydroxy-5-chlorobenzoxazole',\n",
       "  '5-chloro-2-benzoxazolinone',\n",
       "  '5-chloro-2-benzoxazolol',\n",
       "  '5-chloro-2-benzoxazolone',\n",
       "  '5-chloro-2-hydroxybenzoxazole',\n",
       "  '5-chloro-2(3H)-benzoxazolone',\n",
       "  '5-chloro-3H-benzooxazol-2-one',\n",
       "  '5-chlorobenzoxazolidone',\n",
       "  '5-chlorobenzoxazolin-2-one',\n",
       "  'Chlorzoxane',\n",
       "  'Chlorzoxazon',\n",
       "  'Chlorzoxazona',\n",
       "  'Chlorzoxazone',\n",
       "  'Chlorzoxazonum',\n",
       "  'Clorzoxazona',\n",
       "  'Clorzoxazone',\n",
       "  'Chlorzoxazone'],\n",
       " 'Aminoglutethimide': ['2-(p-Aminophenyl)-2-ethylglutarimide',\n",
       "  '3-Ethyl-3-(p-aminophenyl)-2,6-dioxopiperidine',\n",
       "  'Aminoglutethimid',\n",
       "  'AminoglutÃ©thimide',\n",
       "  'Aminoglutethimide',\n",
       "  'Aminoglutethimidum',\n",
       "  'Aminoglutetimida',\n",
       "  'Aminoglutetimide',\n",
       "  'DL-Aminoglutethimide',\n",
       "  'p-Aminoglutethimide',\n",
       "  'Î±-(p-Aminophenyl)-Î±-ethylglutarimide',\n",
       "  'Aminoglutethimide'],\n",
       " 'Mefloquine': ['[(R*,S*)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol',\n",
       "  'alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol',\n",
       "  'Mefloquin',\n",
       "  'Mefloquina',\n",
       "  'MÃ©floquine',\n",
       "  'Mefloquine',\n",
       "  'Mefloquinum',\n",
       "  'Mefloquine'],\n",
       " 'Sulfadiazine': ['2-sulfanilamidopyrimidine',\n",
       "  '2-sulfanilylaminopyrimidine',\n",
       "  '4-amino-N-2-pyrimidinylbenzenesulfonamide',\n",
       "  'N(1)-2-Pyrimidinylsulfanilamide',\n",
       "  'N(1)-2-Pyrimidylsulfanilamide',\n",
       "  'Sulfadiazin',\n",
       "  'Sulfadiazina',\n",
       "  'Sulfadiazine',\n",
       "  'Sulfadiazinum',\n",
       "  'Sulfapyrimidine',\n",
       "  'Sulphadiazine',\n",
       "  'Sulfadiazine'],\n",
       " 'Sapropterin': ['(â\\x88\\x92)-(6R)-2-amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinone',\n",
       "  '(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin',\n",
       "  '(6R)-L-erythro-tetrahydrobiopterin',\n",
       "  '2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydoro-4(1H)-pteridinone',\n",
       "  '5,6,7,8-Tetrahydrobiopterin',\n",
       "  '6R-5,6,7,8-tetrahydrobiopterin',\n",
       "  '6R-BH4',\n",
       "  '6R-L-5,6,7,8-tetrahydrobiopterin',\n",
       "  'R-THBP',\n",
       "  'Sapropterin',\n",
       "  'Sapropterina',\n",
       "  'sapropterinum',\n",
       "  'Tetrahydrobiopterin',\n",
       "  'Sapropterin'],\n",
       " 'Vinorelbine': [\"5'-Noranhydrovinblastine\",\n",
       "  'Vinorelbin',\n",
       "  'Vinorelbina',\n",
       "  'Vinorelbine',\n",
       "  'Vinorelbinum',\n",
       "  'Vinorelbine'],\n",
       " 'Anidulafungin': ['Anidulafungin',\n",
       "  'Anidulafungina',\n",
       "  'Anidulafungine',\n",
       "  'Anidulafunginum',\n",
       "  'Anidulafungin'],\n",
       " 'Clozapine': ['Clozapin',\n",
       "  'Clozapina',\n",
       "  'Clozapine',\n",
       "  'Clozapinum',\n",
       "  'Clozapine'],\n",
       " 'Sucralfate': ['Hexadeca-Î¼-hydroxytetracosahydroxy[Î¼8-[1,3,4,6-tetra-O-sulfo-Î²-Dfructofuranosyl-Î±-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum',\n",
       "  'Sucralfat',\n",
       "  'Sucralfate',\n",
       "  'Sucralfato',\n",
       "  'Sucralfatum',\n",
       "  'Sucralfate'],\n",
       " 'Grepafloxacin': ['Grepafloxacin'],\n",
       " 'Doxylamine': ['2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine',\n",
       "  '2-Dimethylaminoethoxyphenylmethyl-2-picoline',\n",
       "  'Dossilamina',\n",
       "  'Doxilamina',\n",
       "  'Doxilminio',\n",
       "  'Doxylamine',\n",
       "  'Doxylaminum',\n",
       "  'N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine',\n",
       "  'Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether',\n",
       "  'Doxylamine'],\n",
       " 'Levonorgestrel': ['(-)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one',\n",
       "  '(8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- tetradecahydrocyclopenta[a] phenanthren-3-one',\n",
       "  '13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one',\n",
       "  '13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one',\n",
       "  '13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one',\n",
       "  '17-alpha-Ethinyl-13-beta-ethyl-17-beta-hydroxy-4-estren-3-one',\n",
       "  '17-alpha-Ethynyl-13-ethyl-19-nortestosterone',\n",
       "  '17-Ethynyl-18-methyl-19-nortestosterone',\n",
       "  '17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol',\n",
       "  '17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one',\n",
       "  '17alpha-Ethynyl-18-homo-19-nortestosterone',\n",
       "  '18-Methyl-17-alpha-ethynyl-19-nortestosterone',\n",
       "  '18-Methylnorethisterone',\n",
       "  'd(-)-Norgestrel',\n",
       "  'LÃ¨vonorgestrel',\n",
       "  'Levonorgestrel',\n",
       "  'Levonorgestrelum',\n",
       "  'Levonorgestrel'],\n",
       " 'Norepinephrine': ['(â\\x88\\x92)-arterenol',\n",
       "  '(â\\x88\\x92)-noradrenaline',\n",
       "  '(â\\x88\\x92)-norepinephrine',\n",
       "  '(R)-(â\\x88\\x92)-norepinephrine',\n",
       "  '(R)-4-(2-amino-1-hydroxyethyl)-1,2-benzenediol',\n",
       "  '(R)-noradrenaline',\n",
       "  '(R)-norepinephrine',\n",
       "  '4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol',\n",
       "  'Arterenol',\n",
       "  'L-noradrenaline',\n",
       "  'L-Norepinephrine',\n",
       "  'Nor-adrenaline',\n",
       "  'Noradrenaline',\n",
       "  'Norepinefrina',\n",
       "  'NorÃ©pinÃ©phrine',\n",
       "  'Norepinephrine',\n",
       "  'Norepinephrinum',\n",
       "  'Norepinephrine'],\n",
       " 'Cidofovir': ['({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid',\n",
       "  '(S)-(3-(4-amino-2-Oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid',\n",
       "  '(S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine',\n",
       "  '(S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine',\n",
       "  '(S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine',\n",
       "  '(S)-HPMPC',\n",
       "  '[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid',\n",
       "  '[[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid',\n",
       "  '1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine',\n",
       "  '1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine',\n",
       "  'CDV',\n",
       "  'Cidofovir',\n",
       "  'Cidofovir anhydrous',\n",
       "  'Cidofovirum',\n",
       "  'Cidofovir'],\n",
       " 'Mirtazapine': ['1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine',\n",
       "  '6-Azamianserin',\n",
       "  'Mepirzapine',\n",
       "  'Mirtazapin',\n",
       "  'Mirtazapina',\n",
       "  'Mirtazapine',\n",
       "  'Mirtazapinum',\n",
       "  'Mirtazapine'],\n",
       " 'Meprobamate': ['Meprobamat',\n",
       "  'Meprobamate',\n",
       "  'Meprobamato',\n",
       "  'Meprobamatum',\n",
       "  'Meprobamic acid',\n",
       "  'Meprobamate'],\n",
       " 'Thiethylperazine': ['2-(ethylthio)-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine',\n",
       "  'Norzine',\n",
       "  'Thiethylperazin',\n",
       "  'ThiÃ©thylpÃ©razine',\n",
       "  'Thiethylperazine',\n",
       "  'Thiethylperazinum',\n",
       "  'Tietilperazina',\n",
       "  'Thiethylperazine'],\n",
       " 'Timolol': ['(S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol',\n",
       "  'Timolol',\n",
       "  'Timolol anhydrous',\n",
       "  'Timololo',\n",
       "  'Timololum',\n",
       "  'Timolol'],\n",
       " 'Treprostinil': ['TrÃ©prostinil',\n",
       "  'Treprostinil',\n",
       "  'Treprostinilo',\n",
       "  'Treprostinilum',\n",
       "  'Treprostinil'],\n",
       " 'Colestipol': ['Colestipol',\n",
       "  'Colestipolum',\n",
       "  'Copolymer of bis(2-aminoethyl)amine and 2-(chloromethyl)oxirane',\n",
       "  'Epichlorohydrin-tetraethylenepentamine polymer',\n",
       "  'Colestipol'],\n",
       " 'Trihexyphenidyl': ['Trihexifenidilo',\n",
       "  'Trihexyphenidyl',\n",
       "  'TrihexyphÃ©nidyle',\n",
       "  'Trihexyphenidylum',\n",
       "  'Trihexyphenidyl'],\n",
       " 'Palonosetron': ['(3aS)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one',\n",
       "  '2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one',\n",
       "  'Palonosetron',\n",
       "  'PalonosÃ©tron',\n",
       "  'PalonosetrÃ³n',\n",
       "  'Palonosetronum',\n",
       "  'Palonosetron'],\n",
       " 'Dydrogesterone': ['(9Î²,10Î±)-pregna-4,6-diene-3,20-dione',\n",
       "  '10Î±-Isopregnenone',\n",
       "  '6-Dehydro-retro-progesterone',\n",
       "  '9Î²,10Î±-pregna-4,6-diene-3,20-dione',\n",
       "  'delta(6)-Retroprogesterone',\n",
       "  'delta(sup 6)-Retroprogesterone',\n",
       "  'Didrogesterona',\n",
       "  'Didrogesterone',\n",
       "  'Dydrogesterona',\n",
       "  'DydrogestÃ©rone',\n",
       "  'Dydrogesterone',\n",
       "  'Dydrogesteronum',\n",
       "  'Gestatron',\n",
       "  'Hydrogesterone',\n",
       "  'Hydrogestrone',\n",
       "  'Isopregnenone',\n",
       "  'Retro-6-dehydroprogesterone',\n",
       "  'Dydrogesterone'],\n",
       " 'Mexiletine': ['(Â±)-1-(2,6-dimethylphenoxy)propan-2-amine',\n",
       "  '(2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane',\n",
       "  '1-(2,6-dimethylphenoxy)-2-propanamine',\n",
       "  \"1-(2',6'-dimethylphenoxy)-2-aminopropane\",\n",
       "  '1-methyl-2-(2,6-xylyloxy)ethanamine',\n",
       "  'Mexiletina',\n",
       "  'Mexiletine',\n",
       "  'MexilÃ©tine',\n",
       "  'Mexiletinum',\n",
       "  'Mexiletine'],\n",
       " 'Dexrazoxane': [\"(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione\",\n",
       "  '(+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane',\n",
       "  '4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione',\n",
       "  'Dexrazoxan',\n",
       "  'Dexrazoxane',\n",
       "  'Dexrazoxano',\n",
       "  'Dexrazoxanum',\n",
       "  'Dextrorazoxane',\n",
       "  'Dexrazoxane'],\n",
       " 'Amlodipine': ['(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate',\n",
       "  '3-Ethyl 5-methylester, (Â±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate',\n",
       "  'Amlodipine',\n",
       "  'Amlodipine free base',\n",
       "  'Amlodipino',\n",
       "  'Amlodipinum',\n",
       "  'Amlodipine'],\n",
       " 'Tacrine': ['1,2,3,4-tetrahydro-9-acridinamine',\n",
       "  '1,2,3,4-tetrahydro-9-aminoacridine',\n",
       "  '1,2,3,4-tetrahydroacridin-9-amine',\n",
       "  '5-amino-6,7,8,9-tetrahydroacridine',\n",
       "  '9-amino-1,2,3,4-tetrahydroacridine',\n",
       "  'Tacrin',\n",
       "  'Tacrine',\n",
       "  'Tacrinum',\n",
       "  'Tetrahydroaminacrine',\n",
       "  'Tetrahydroaminoacridine',\n",
       "  'THA',\n",
       "  'Tacrine'],\n",
       " 'Oxyphencyclimine': ['Oxifencicliminum',\n",
       "  'Oxyphencyclimine',\n",
       "  'Oxyphencycliminum',\n",
       "  'Oxyphencyclimine'],\n",
       " 'Triamterene': ['6-phenylpteridine-2,4,7-triamine',\n",
       "  'Teridin',\n",
       "  'Triamteren',\n",
       "  'Triamterena',\n",
       "  'TriamtÃ©rÃ¨ne',\n",
       "  'Triamterene',\n",
       "  'Triamtereno',\n",
       "  'Triamterenum',\n",
       "  'Triamterene'],\n",
       " 'Valrubicin': ['(8S, 10S)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-Î±-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione 8Â²-valerate',\n",
       "  '2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-({2,3,6-trideoxy-3-[(trifluoroacetyl)amino]hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate',\n",
       "  'Valrubicin',\n",
       "  'Valrubicina',\n",
       "  'Valrubicine',\n",
       "  'Valrubicinum',\n",
       "  'Valrubicin'],\n",
       " 'Procyclidine': ['1-cyclohexyl-1-phenyl-3-pyrrolidin-1-yl-propan-1-ol hydrochloride',\n",
       "  '1-Cyclohexyl-1-phenyl-3-pyrrolidino-1-propanol',\n",
       "  'Prociclidina',\n",
       "  'Procyclidin',\n",
       "  'Procyclidine',\n",
       "  'Procyclidinum',\n",
       "  'Tricyclamol',\n",
       "  'Procyclidine'],\n",
       " 'Phenylephrine': ['(â\\x88\\x92)-m-hydroxy-Î±-(methylaminomethyl)benzyl alcohol',\n",
       "  'Fenilefrina',\n",
       "  'l-(3-Hydroxyphenyl)-N-methylethanolamine',\n",
       "  'Phenylephrine',\n",
       "  'Phenylephrinum',\n",
       "  'R(-)-Phenylephrine',\n",
       "  'Phenylephrine'],\n",
       " 'Carbimazole': ['Athyromazole',\n",
       "  'Carbethoxymethimazole',\n",
       "  'Carbimazol',\n",
       "  'Carbimazolo',\n",
       "  'Carbimazolum',\n",
       "  'Carbinazole',\n",
       "  'Ethyl 3-methyl-2-thioimidazoline-1-carboxylate',\n",
       "  'Carbimazole'],\n",
       " 'Digoxin': ['12Î²-hydroxydigitoxin',\n",
       "  'Digossina',\n",
       "  'Digoxin',\n",
       "  'Digoxina',\n",
       "  'Digoxine',\n",
       "  'Digoxinum',\n",
       "  'Digoxin'],\n",
       " 'Sulpiride': ['(Â±)-sulpiride',\n",
       "  '5-(Aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide',\n",
       "  'N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamide',\n",
       "  'N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide',\n",
       "  'Sulpirid',\n",
       "  'Sulpirida',\n",
       "  'Sulpiride',\n",
       "  'Sulpiridum',\n",
       "  'Sulpyrid',\n",
       "  'Sulpiride'],\n",
       " 'Profenamine': ['10-(2-diethylaminopropyl)phenothiazine',\n",
       "  '10-[2-(diethylamino)-1-propyl]phenothiazine',\n",
       "  '10-[2-(diethylamino)-2-methylethyl]phenothiazine',\n",
       "  '10-[2-(diethylamino)propyl]phenothiazine',\n",
       "  '2-diethylamino-1-propyl-N-dibenzoparathiazine',\n",
       "  'Ethopropazine',\n",
       "  'N,N-diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine',\n",
       "  'N,N-diethyl-Î±-methyl-10H-phenothiazine-10-ethanamine',\n",
       "  'Profenamina',\n",
       "  'ProfÃ©namine',\n",
       "  'Profenamine',\n",
       "  'Profenaminum',\n",
       "  'Profenamine'],\n",
       " 'Nimodipine': [\"2,6-dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-Î²-methoxyethyl ester 5-isopropyl ester\",\n",
       "  'isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate',\n",
       "  'isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate',\n",
       "  'Nimodipine',\n",
       "  'Nimodipino',\n",
       "  'Nimodipinum',\n",
       "  'Nimodipine'],\n",
       " 'Beclomethasone dipropionate': ['(11Î²,16Î²)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione',\n",
       "  '9-chloro-11Î²-hydroxy-16Î²-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate',\n",
       "  '9-chloro-16Î²-methyl-11Î²,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate',\n",
       "  'beclometasone 17,21-dipropionate',\n",
       "  'Beclometasone dipropionate',\n",
       "  'Beclometasone dipropionato',\n",
       "  'Beclomethasone dipropionate',\n",
       "  'Beclomethasone dipropionate'],\n",
       " 'Carisoprodol': ['(Â±)-2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate',\n",
       "  '(1-methylethyl)carbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester',\n",
       "  '(RS)-2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate',\n",
       "  '2-methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate',\n",
       "  '2-methyl-2-propyltrimethylene carbamate isopropylcarbamate',\n",
       "  'carbamic acid 2-isopropylcarbamoyloxymethyl-2-methyl-pentyl ester',\n",
       "  'Carisoprodol',\n",
       "  'Carisoprodolo',\n",
       "  'Carisoprodolum',\n",
       "  'Isobamate',\n",
       "  'Isomeprobamate',\n",
       "  'Isopropyl meprobamate',\n",
       "  'Isopropylmeprobamate',\n",
       "  'N-isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate',\n",
       "  'Carisoprodol'],\n",
       " 'Progesterone': ['(S)-4-Pregnene-3,20-dione',\n",
       "  '(S)-Pregn-4-en-3,20-dione',\n",
       "  '(S)-Progesterone',\n",
       "  '17alpha-Progesterone',\n",
       "  '17Î±-progesterone',\n",
       "  '4-Pregnene-3,20-dione',\n",
       "  'Agolutin',\n",
       "  'Akrolutin',\n",
       "  'Corpus Luteum Hormone',\n",
       "  'delta(4)-Pregnene-3,20-dione',\n",
       "  'GelbkÃ¶rperhormon',\n",
       "  'Luteohormone',\n",
       "  'Lutogynon',\n",
       "  'Pregn-4-ene-3,20-dione',\n",
       "  'Progesteron',\n",
       "  'Progesterona',\n",
       "  'ProgestÃ©rone',\n",
       "  'Progesterone',\n",
       "  'Progesteronum',\n",
       "  'Progesterone'],\n",
       " 'Phenylpropanolamine': ['(+-)-Norephedrine',\n",
       "  '(+-)-Phenylpropanolamine',\n",
       "  'Fenilpropanolamina',\n",
       "  'Norephedrine',\n",
       "  'Phenylpropanolamin',\n",
       "  'Phenylpropanolamina',\n",
       "  'Phenylpropanolamine',\n",
       "  'PhÃ©nylpropanolamine',\n",
       "  'Phenylpropanolaminum',\n",
       "  'PPA',\n",
       "  'Phenylpropanolamine'],\n",
       " 'Sorafenib': ['4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide',\n",
       "  \"N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea\",\n",
       "  'SorafÃ©nib',\n",
       "  'Sorafenib',\n",
       "  'Sorafenibum',\n",
       "  'Sorafenib'],\n",
       " 'Zoledronic acid': ['(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid',\n",
       "  '(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid',\n",
       "  'Ã¡cido zoledrÃ³nico',\n",
       "  'Anhydrous Zoledronic Acid',\n",
       "  'Zol',\n",
       "  'Zoledronate',\n",
       "  'Zoledronic acid',\n",
       "  'Zoledronic Acid Anhydrous',\n",
       "  'Zoledronic Acid, Anhydrous',\n",
       "  'Zoledronic acid'],\n",
       " 'Griseofulvin': ['(+)-griseofulvin',\n",
       "  'Amudane',\n",
       "  'Griseofulvin',\n",
       "  'Griseofulvin, microcrystalline',\n",
       "  'Griseofulvin, ultramicrosize',\n",
       "  'Griseofulvina',\n",
       "  'GrisÃ©ofulvine',\n",
       "  'Griseofulvinum',\n",
       "  'Griseofulvin'],\n",
       " 'Nisoldipine': ['isobutyl methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate',\n",
       "  'Nisoldipin',\n",
       "  'Nisoldipina',\n",
       "  'Nisoldipine',\n",
       "  'Nisoldipino',\n",
       "  'Nisoldipinum',\n",
       "  'Nisoldipine'],\n",
       " 'Eszopiclone': ['(+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate',\n",
       "  '(+)-(5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl-4-methylpiperazine-1-carboxylate',\n",
       "  '(+)-Zopiclone',\n",
       "  '(S)-6-(5-Chloro-2-pyridinyl)- 7-oxo- 6,7-dihydro- 5H-pyrrolo[3,4-b]pyrazin-5-yl- 4-methyl- 1-piperazinecarboxylate',\n",
       "  '(S)-Zopiclone',\n",
       "  '1-Piperazinecarobxylic acid,4-methyl-,(5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester',\n",
       "  'Esopiclone',\n",
       "  'Eszopiclone',\n",
       "  'Eszopiclone'],\n",
       " 'Ceruletide': ['Caerulein',\n",
       "  'Cerulein',\n",
       "  'Ceruletida',\n",
       "  'Ceruletide',\n",
       "  'Ceruletidum',\n",
       "  'Ceruletide'],\n",
       " 'Alprazolam': ['8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine',\n",
       "  'Alprazolam',\n",
       "  'Alprazolam'],\n",
       " 'Dexbrompheniramine': ['(+)-brompheniraminum',\n",
       "  '(R)-3-(4-Bromophenyl)-3-(2-pyridyl)propyldimethylamine',\n",
       "  '(S)-(+)-brompheniramine',\n",
       "  '(S)-brompheniramine',\n",
       "  '3-(4-bromophenyl)- N,N-dimethyl- 3-pyridin-2-yl-propan-1-amine',\n",
       "  'd-brompheniramine',\n",
       "  'Desbrofeniramina',\n",
       "  'Dexbromfeniramina',\n",
       "  'Dexbrompheniramin',\n",
       "  'DexbromphÃ©niramine',\n",
       "  'Dexbrompheniramine',\n",
       "  'Dexbrompheniraminum',\n",
       "  'Dexbrompheniramine'],\n",
       " 'Gentian violet cation': ['Crystal Violet',\n",
       "  'Crystal violet carbocation',\n",
       "  'Crystal violet ion(1)',\n",
       "  'Crystal violet(1+)',\n",
       "  'Gentian violet carbocation',\n",
       "  'Gentian violet cation',\n",
       "  'Gentian violet(1+)',\n",
       "  'Methylrosaniline',\n",
       "  'Methylrosanilinium',\n",
       "  'Gentian violet cation'],\n",
       " 'Ardeparin': ['Ardeparin'],\n",
       " 'Loxapine': ['2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine',\n",
       "  'Loxapina',\n",
       "  'Loxapine',\n",
       "  'Loxapinum',\n",
       "  'Oxilapine',\n",
       "  'Loxapine'],\n",
       " 'Remoxipride': ['Remoxiprida', 'Remoxipride', 'Remoxipridum', 'Remoxipride'],\n",
       " 'Mupirocin': ['9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3- [(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid',\n",
       "  'Mupirocin',\n",
       "  'Mupirocina',\n",
       "  'Mupirocine',\n",
       "  'Mupirocinum',\n",
       "  'Pseudomonic acid',\n",
       "  'Pseudomonic acid A',\n",
       "  'Mupirocin'],\n",
       " 'Carbamoylcholine': ['Carbacholine',\n",
       "  'carbacol',\n",
       "  'Carbamylcholine',\n",
       "  'Choline carbamate',\n",
       "  'Carbamoylcholine'],\n",
       " 'Rosiglitazone': ['(Â±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione',\n",
       "  '(RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion',\n",
       "  'Rosiglitazon',\n",
       "  'Rosiglitazona',\n",
       "  'Rosiglitazone',\n",
       "  'Rosiglitazonum',\n",
       "  'Rosiglitazone'],\n",
       " 'Pramipexole': ['(-)-Pramipexole',\n",
       "  '(S)-Nâ\\x80\\x8aâ\\x80\\x8a6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine',\n",
       "  'Pramipexol',\n",
       "  'Pramipexole',\n",
       "  'Pramipexolum',\n",
       "  'Pramipexole'],\n",
       " 'Acetohexamide': ['1-((p-Acetylphenyl)sulfonyl)-3-cyclohexylurea',\n",
       "  '1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamide',\n",
       "  'Acetohexamid',\n",
       "  'Acetohexamida',\n",
       "  'AcÃ©tohexamide',\n",
       "  'Acetohexamide',\n",
       "  'Acetohexamidum',\n",
       "  \"N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea\",\n",
       "  'Acetohexamide'],\n",
       " 'Ampicillin': ['ABPC',\n",
       "  'Aminobenzylpenicillin',\n",
       "  'Ampicilina',\n",
       "  'Ampicillin',\n",
       "  'Ampicillin (anhydrous)',\n",
       "  'Ampicillin acid',\n",
       "  'Ampicillin anhydrous',\n",
       "  'Ampicillin, anhydrous',\n",
       "  'Ampicilline',\n",
       "  'Ampicillinum',\n",
       "  'Anhydrous ampicillin',\n",
       "  'AP',\n",
       "  'D-(â\\x88\\x92)-6-(Î±-aminophenylacetamido)penicillanic acid',\n",
       "  'D-(â\\x88\\x92)-ampicillin',\n",
       "  'Ampicillin'],\n",
       " 'Metocurine iodide': ['Dimethyl tubocurarine iodide',\n",
       "  'Dimethylchondrocurarine iodide',\n",
       "  'Dimethyltubocurarinium iodide',\n",
       "  'Metocurine iodide',\n",
       "  'Metocurini iodidum',\n",
       "  'Metubine iodide',\n",
       "  'Metocurine iodide'],\n",
       " 'Phenoxymethylpenicillin': ['(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID',\n",
       "  '(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  '6-phenoxyacetamidopenicillanic acid',\n",
       "  'Fenoximetilpenicilina',\n",
       "  'Oracillin',\n",
       "  'Penicillin Phenoxymethyl',\n",
       "  'Penicillin V',\n",
       "  'Phenoxomethylpenicillin',\n",
       "  'Phenoxymethyl Penicillin',\n",
       "  'Phenoxymethylenepenicillinic acid',\n",
       "  'Phenoxymethylpenicillin',\n",
       "  'PhÃ©noxymÃ©thylpÃ©nicilline',\n",
       "  'Phenoxymethylpenicillinum',\n",
       "  'PV',\n",
       "  'Phenoxymethylpenicillin'],\n",
       " 'Secobarbital': ['(Â±)-secobarbital',\n",
       "  '5-(1-methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-allyl-5-(1-methylbutyl)barbituric acid',\n",
       "  '5-allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione',\n",
       "  'Quinalbarbitone',\n",
       "  'Secobarbital',\n",
       "  'Secobarbitalum',\n",
       "  'Secobarbitone',\n",
       "  'Secobarbital'],\n",
       " 'Miglustat': ['BuDNJ',\n",
       "  'Butyldeoxynojirimycin',\n",
       "  'Miglustat',\n",
       "  'Miglustatum',\n",
       "  'N-(n-Butyl)deoxynojirimycin',\n",
       "  'n-Butyl deoxynojirimycin',\n",
       "  'N-butyl-1-deoxynojirimycin',\n",
       "  'N-Butylmoranoline',\n",
       "  'NB-DNJ',\n",
       "  'Miglustat'],\n",
       " 'Promazine': ['10-(3-(Dimethylamino)propyl)phenothiazine',\n",
       "  'N-(3-Dimethylaminopropyl)phenothiazine',\n",
       "  'N-Dimethylamino-1-methylethyl thiodiphenylamine',\n",
       "  'N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine',\n",
       "  'Promazin',\n",
       "  'Promazina',\n",
       "  'Promazine',\n",
       "  'Promazinum',\n",
       "  'Promazine'],\n",
       " 'Spironolactone': ['Espironolactona',\n",
       "  'Spironolactone',\n",
       "  'Spironolactonum',\n",
       "  'Spironolattone',\n",
       "  'Spironolactone'],\n",
       " 'Methylphenidate': ['Methyl phenidylacetate',\n",
       "  'methyl phenyl(piperidin-2-yl)acetate',\n",
       "  'methyl Î±-phenyl-Î±-(2-piperidyl)acetate',\n",
       "  'methyl Î±-phenyl-Î±-2-piperidinylacetate',\n",
       "  'Methylphenidan',\n",
       "  'Methylphenidate',\n",
       "  'Methylphenidatum',\n",
       "  'Metilfenidato',\n",
       "  'MPH',\n",
       "  'Î±-phenyl-2-piperidineacetic acid methyl ester',\n",
       "  'Methylphenidate'],\n",
       " 'Methocarbamol': ['(RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate',\n",
       "  'Methocarbamol',\n",
       "  'MÃ©thocarbamol',\n",
       "  'Methocarbamolum',\n",
       "  'Metocarbamol',\n",
       "  'Metocarbamolo',\n",
       "  'Methocarbamol'],\n",
       " 'Hyoscyamine': ['(â\\x88\\x92)-atropine',\n",
       "  '(â\\x88\\x92)-hyoscyamine',\n",
       "  '(S)-(â\\x88\\x92)-hyoscyamine',\n",
       "  '(S)-atropine',\n",
       "  '[3(S)-endo]-Î±-(hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester',\n",
       "  'Daturin',\n",
       "  'Daturine',\n",
       "  'Duboisine',\n",
       "  'Hyoscyamin',\n",
       "  'Hyoscyamine',\n",
       "  'Hyoscyaminum',\n",
       "  'L-Hyoscyamine',\n",
       "  'L-Tropine tropate',\n",
       "  'Tropine-L-tropate',\n",
       "  'Hyoscyamine'],\n",
       " 'Zolpidem': ['N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide',\n",
       "  'Zolpidem',\n",
       "  'Zolpidemum',\n",
       "  'Zolpidem'],\n",
       " 'Famciclovir': ['2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate',\n",
       "  '9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine',\n",
       "  'acetic acid 2-acetoxymethyl-4-(2-amino-purin-9-yl)-butyl ester',\n",
       "  'Famciclovir',\n",
       "  'Famciclovirum',\n",
       "  'FCV',\n",
       "  'Famciclovir'],\n",
       " 'Triprolidine': ['(E)-2-[3-(1-pyrrolidinyl)-1-p-toluenepropenyl]pyridine',\n",
       "  'trans-1-(2-pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene',\n",
       "  'trans-1-(4-methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene',\n",
       "  'Tripolidina',\n",
       "  'Triprolidin',\n",
       "  'Triprolidina',\n",
       "  'Triprolidine',\n",
       "  'Triprolidinum',\n",
       "  'Triprolidine'],\n",
       " 'Streptozocin': ['2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose',\n",
       "  '2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose',\n",
       "  'Estreptozocina',\n",
       "  \"N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff\",\n",
       "  \"N-D-Glucosyl-(2)-N'-nitrosomethylurea\",\n",
       "  'Streptozocin',\n",
       "  'Streptozocine',\n",
       "  'Streptozocinium',\n",
       "  'Streptozocinum',\n",
       "  'Streptozotocin',\n",
       "  'Streptozocin'],\n",
       " 'Carboprost tromethamine': ['(15S)-15-methyl-PGF2Î± tromethamine salt',\n",
       "  '(15S)-15-methylprostaglandin F2Î± tromethamine',\n",
       "  '1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium (5Z,9Î±,11Î²,13E,15S)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oate',\n",
       "  '15(S)-15-methyl-PGF2Î± tromethamine salt',\n",
       "  '15(S)-15-methylprostaglandin F2Î± tromethamine',\n",
       "  'Carboprost trometamol',\n",
       "  'Carboprost tromethamine',\n",
       "  'Carboprost tromethamine'],\n",
       " 'Cefpiramide': ['Cefpiramide', 'Cefpiramido', 'Cefpiramidum', 'Cefpiramide'],\n",
       " 'Lindane': ['(1r,2c,3t,4c,5c,6t)-1,2,3,4,5,6-hexachlorocyclohexane',\n",
       "  '(1Î±,2Î±,3Î²,4Î±,5Î±,6Î²)-1,2,3,4,5,6-hexachlorocyclohexane',\n",
       "  '1,2,3,4,5,6-hexachlorocyclohexane',\n",
       "  'Benzene hexachloride',\n",
       "  'gamma-1,2,3,4,5,6-hexachlorocyclohexane',\n",
       "  'gamma-benzene hexachloride',\n",
       "  'gamma-BHC',\n",
       "  'gamma-HCH',\n",
       "  'gamma-Hexachlorocyclohexane',\n",
       "  'gamma-Lindane',\n",
       "  'Gammallin',\n",
       "  'Gammaxene',\n",
       "  'Lindan',\n",
       "  'Lindane',\n",
       "  'Lindano',\n",
       "  'Lindanum',\n",
       "  'Î³-hexachlorocyclohexane',\n",
       "  'Î³-Hexachlorzyklohexan',\n",
       "  'Î³-lindane',\n",
       "  'Lindane'],\n",
       " 'Trifluridine': ['5-(Trifluoromethyl)deoxyuridine',\n",
       "  '5-Trifluoromethyl-2-deoxyuridine',\n",
       "  'Fâ\\x82\\x83T',\n",
       "  'TFT',\n",
       "  'Trifluoromethyldeoxyuridine',\n",
       "  'Trifluorothymidine',\n",
       "  'Trifluorothymine deoxyriboside',\n",
       "  'Trifluridin',\n",
       "  'Trifluridina',\n",
       "  'Trifluridine',\n",
       "  'Trifluridinum',\n",
       "  'Trifluridine'],\n",
       " 'Prochlorperazine': ['2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine',\n",
       "  '2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine',\n",
       "  '3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine',\n",
       "  '3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine',\n",
       "  'Capazine',\n",
       "  'Chlormeprazine',\n",
       "  'Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine',\n",
       "  'Chloropernazine',\n",
       "  \"N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine\",\n",
       "  'Prochlorperazin',\n",
       "  'ProchlorpÃ©razine',\n",
       "  'Prochlorperazine',\n",
       "  'Prochlorperazinum',\n",
       "  'Prochlorpermazine',\n",
       "  'Prochlorpromazine',\n",
       "  'Procloperazine',\n",
       "  'Proclorperazina',\n",
       "  'Prochlorperazine'],\n",
       " 'Cyproheptadine': ['1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine',\n",
       "  '1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine',\n",
       "  '4-(5-dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine',\n",
       "  '4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine',\n",
       "  '4-Dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine',\n",
       "  '5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene',\n",
       "  'Ciproheptadina',\n",
       "  'Cyproheptadin',\n",
       "  'Cyproheptadine',\n",
       "  'Cyproheptadinum',\n",
       "  'Cyproheptadine'],\n",
       " 'Nitric Oxide': ['EDRF',\n",
       "  'endothelium-derived relaxing factor',\n",
       "  'Mononitrogen monoxide',\n",
       "  'MonÃ³xido de nitrÃ³geno',\n",
       "  \"Monoxyde d'azote\",\n",
       "  'Nitric oxide',\n",
       "  'Nitrogen monooxide',\n",
       "  'Nitrogen monoxide',\n",
       "  'Nitrosyl',\n",
       "  'Ã³xido de nitrÃ³geno(II)',\n",
       "  'Ã³xido nÃ\\xadtrico',\n",
       "  'Oxyde azotique',\n",
       "  'Oxyde nitrique',\n",
       "  'Stickstoff(II)-oxid',\n",
       "  'Stickstoffmonoxid',\n",
       "  'Nitric Oxide'],\n",
       " 'Bendroflumethiazide': ['Â±-3-benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide',\n",
       "  '6-trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide',\n",
       "  'Bendrofluazide',\n",
       "  'Bendroflumethiazid',\n",
       "  'BendroflumÃ©thiazide',\n",
       "  'Bendroflumethiazide',\n",
       "  'Bendroflumethiazidum',\n",
       "  'Bendroflumetiazida',\n",
       "  'Benzhydroflumethiazide',\n",
       "  'Bendroflumethiazide'],\n",
       " 'Allopurinol': ['1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one',\n",
       "  '1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one',\n",
       "  '1H-Pyrazolo(3,4-d)pyrimidin-4-ol',\n",
       "  '4-HPP',\n",
       "  '4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine',\n",
       "  '4-Hydroxy-3,4-pyrazolopyrimidine',\n",
       "  '4-Hydroxypyrazolo(3,4-d)pyrimidine',\n",
       "  '4-Hydroxypyrazolopyrimidine',\n",
       "  '4-Hydroxypyrazolyl(3,4-d)pyrimidine',\n",
       "  \"4'-Hydroxypyrazolol(3,4-d)pyrimidine\",\n",
       "  '4H-Pyrazolo(3,4-d)pyrimidin-4-one',\n",
       "  'Allopurinol',\n",
       "  'Allopurinolum',\n",
       "  'Alopurinol',\n",
       "  'Allopurinol'],\n",
       " 'Ceftazidime': ['CAZ',\n",
       "  'Ceftazidim',\n",
       "  'Ceftazidima',\n",
       "  'Ceftazidime',\n",
       "  'Ceftazidime anhydrous',\n",
       "  'Ceftazidimum',\n",
       "  'Ceftazidime'],\n",
       " 'Cerivastatin': ['Cerivastatin', 'Cerivastatin'],\n",
       " 'Trimethoprim': ['2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine',\n",
       "  '5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine',\n",
       "  'Trimethoprim',\n",
       "  'TrimÃ©thoprime',\n",
       "  'Trimethoprimum',\n",
       "  'Trimetoprima',\n",
       "  'Trimethoprim'],\n",
       " 'Gemcitabine': [\"2'-Deoxy-2',2'-difluorocytidine\",\n",
       "  \"2',2'-Difluorodeoxycytidine\",\n",
       "  '4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one',\n",
       "  'Gemcitabin',\n",
       "  'Gemcitabina',\n",
       "  'Gemcitabine',\n",
       "  'Gemcitabinum',\n",
       "  'Gemcitabine'],\n",
       " 'Entecavir': ['Anhydrous entecavir',\n",
       "  'Entecavir',\n",
       "  'Entecavir (anhydrous)',\n",
       "  'Entecavir anhydrous',\n",
       "  'Entecavirum',\n",
       "  'Entecavir'],\n",
       " 'Betamethasone': ['16Î²-Methyl-1,4-pregnadiene-9Î±-fluoro-11Î²,17Î±,21-triol-3,20-dione',\n",
       "  '9-Fluoro-16Î²-methylprednisolone',\n",
       "  '9Î±-Fluoro-16Î²-methylprednisolone',\n",
       "  'beta-Methasone alcohol',\n",
       "  'Betadexamethasone',\n",
       "  'Betametasona',\n",
       "  'Betamethasone',\n",
       "  'BÃ©tamÃ©thasone',\n",
       "  'Betamethasonum',\n",
       "  'Betamethasone'],\n",
       " 'Teniposide': [\"4'-demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside)\",\n",
       "  'Epidophyllotoxin',\n",
       "  'Teniposid',\n",
       "  'Teniposide',\n",
       "  'TÃ©niposide',\n",
       "  'Teniposido',\n",
       "  'Teniposidum',\n",
       "  'Teniposide'],\n",
       " 'Epirubicin': [\"4'-Epiadriamycin\",\n",
       "  'Epiadriamycin',\n",
       "  'Epirubicin',\n",
       "  'Epirubicina',\n",
       "  'Epirubicine',\n",
       "  'Epirubicinum',\n",
       "  'Pidorubicina',\n",
       "  'Pidorubicine',\n",
       "  'Pidorubicinum',\n",
       "  'Epirubicin'],\n",
       " 'Chloramphenicol': ['ChloramphÃ©nicol',\n",
       "  'Chloramphenicol',\n",
       "  'Chloramphenicolum',\n",
       "  'Chlornitromycin',\n",
       "  'Cloramfenicol',\n",
       "  'Cloranfenicol',\n",
       "  'D-(â\\x88\\x92)-2,2-dichloro-N-(Î²-hydroxy-Î±-(hydroxymethyl)-p-nitrophenylethyl)acetamide',\n",
       "  'D-(â\\x88\\x92)-threo-1-p-nitrophenyl-2-dichloroacetylamino-1,3-propanediol',\n",
       "  'Laevomycetinum',\n",
       "  'Levomicetina',\n",
       "  'Levomycetin',\n",
       "  'Chloramphenicol'],\n",
       " 'Loracarbef': ['Anhydrous loracarbef',\n",
       "  'Loracarbef',\n",
       "  'Loracarbef anhydrous',\n",
       "  'Loracarbef, anhydrous',\n",
       "  'Loracarbefum',\n",
       "  'Loracarbef'],\n",
       " 'Lansoprazole': ['Lansoprazol',\n",
       "  'Lansoprazole',\n",
       "  'Lansoprazolum',\n",
       "  'Lansoprazole'],\n",
       " 'Dipivefrin': ['(Â±)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate',\n",
       "  \"1-(3',4'-dipivaloyloxyphenyl)-2-methylamino-1-ethanol\",\n",
       "  '4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate',\n",
       "  'Dipivalyl epinephrine',\n",
       "  'Dipivefrin',\n",
       "  'Dipivefrina',\n",
       "  'Dipivefrine',\n",
       "  'DipivÃ©frine',\n",
       "  'Dipivefrinum',\n",
       "  'Dipivefrin'],\n",
       " 'Droperidol': ['1-(1-(3-(p-fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone',\n",
       "  '1-(1-(4-(p-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone',\n",
       "  '1-{1-[4-(4-Fluoro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-one',\n",
       "  '1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl}-2,3-dihydro-1H-benzo[d]imidazol-2-one',\n",
       "  'Droperidol',\n",
       "  'DropÃ©ridol',\n",
       "  'Droperidolo',\n",
       "  'Droperidolum',\n",
       "  'Droperidol'],\n",
       " 'Levothyroxine': [\"3,3',5,5'-Tetraiodo-L-thyronine\",\n",
       "  \"3,5,3',5'-Tetraiodo-L-thyronine\",\n",
       "  '4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-diiodo-L-phenylalanine',\n",
       "  'L-T4',\n",
       "  'L-Thyroxine',\n",
       "  'Levothyroxin',\n",
       "  'LT4',\n",
       "  'O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-tyrosine',\n",
       "  'O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine',\n",
       "  'T4',\n",
       "  'Thyroxine',\n",
       "  'Levothyroxine'],\n",
       " 'Framycetin': ['Fradiomycin B',\n",
       "  'Framicetina',\n",
       "  'Framycetin',\n",
       "  'FramycÃ©tine',\n",
       "  'Framycetinum',\n",
       "  'Neomycin B',\n",
       "  'Framycetin'],\n",
       " 'Clomocycline': ['Chlormethylenecycline',\n",
       "  'Clomociclina',\n",
       "  'Clomocyclina',\n",
       "  'Clomocycline',\n",
       "  'Clomocyclinum',\n",
       "  'Clomocycline'],\n",
       " 'Meperidine': ['IsonipecaÃ¯ne',\n",
       "  'Meperidina',\n",
       "  'Pethidin',\n",
       "  'Pethidine',\n",
       "  'PÃ©thidine',\n",
       "  'Pethidinum',\n",
       "  'Petidina',\n",
       "  'Petydyna',\n",
       "  'Meperidine'],\n",
       " 'Loratadine': ['Loratadina', 'Loratadine', 'Loratadinum', 'Loratadine'],\n",
       " 'Cefalotin': ['3-Acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid',\n",
       "  '7-(2-Thienylacetamido)cephalosporanic acid',\n",
       "  \"7-(2'-thienylacetamido)cephalosporanic acid\",\n",
       "  '7-(Thiophene-2-acetamido)cephalosporin',\n",
       "  'Cefalothin',\n",
       "  'Cefalotin',\n",
       "  'Cefalotina',\n",
       "  'CÃ©falotine',\n",
       "  'Cefalotinum',\n",
       "  'Cephalothin',\n",
       "  'Cephalotin',\n",
       "  'CET',\n",
       "  'Cefalotin'],\n",
       " 'Prazosin': ['1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine',\n",
       "  '2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline',\n",
       "  'Prazosin',\n",
       "  'Prazosina',\n",
       "  'Prazosine',\n",
       "  'Prazosinum',\n",
       "  'Prazosin'],\n",
       " 'Imipramine': ['10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine',\n",
       "  '5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine',\n",
       "  'Imipramin',\n",
       "  'Imipramina',\n",
       "  'Imipramine',\n",
       "  'Imipraminum',\n",
       "  'Imizine',\n",
       "  'N-(gamma-Dimethylaminopropyl)iminodibenzyl',\n",
       "  'N-(Î³-dimethylaminopropyl)iminodibenzyl',\n",
       "  'Imipramine'],\n",
       " 'Acitretin': ['(all-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid',\n",
       "  'Acitretin',\n",
       "  'Acitretina',\n",
       "  'Acitretine',\n",
       "  'Acitretinum',\n",
       "  'all-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid',\n",
       "  'Etretin',\n",
       "  'Acitretin'],\n",
       " 'Verteporfin': ['Verteporfin',\n",
       "  'Verteporfina',\n",
       "  'VertÃ©porfine',\n",
       "  'Verteporfinum',\n",
       "  'Verteporfin'],\n",
       " 'Nabumetone': ['4-(6-Methoxy-2-naphthalenyl)-2-butanone',\n",
       "  '4-(6-Methoxy-2-naphthyl)-2-butanone',\n",
       "  'Nabumeton',\n",
       "  'Nabumetona',\n",
       "  'NabumÃ©tone',\n",
       "  'Nabumetone',\n",
       "  'Nabumetonum',\n",
       "  'Nabumetone'],\n",
       " 'Methscopolamine bromide': ['(â\\x88\\x92)-scopolamine methobromide',\n",
       "  '(â\\x88\\x92)-scopolamine methyl bromide',\n",
       "  'Hyoscine methobromide',\n",
       "  'Hyoscine methyl bromide',\n",
       "  'Methscopolamine bromide',\n",
       "  'Methylscopolamine bromide',\n",
       "  'N-methylhyoscine bromide',\n",
       "  'N-methylscopolammonium bromide',\n",
       "  'Scopolamine methobromide',\n",
       "  'Scopolamine methyl bromide',\n",
       "  'Methscopolamine bromide'],\n",
       " 'Metharbital': ['Metarbital', 'Metharbital', 'Metharbitalum', 'Metharbital'],\n",
       " 'Sodium tetradecyl sulfate': ['7-Ethyl-2-methyl-4-undecanol sulfate sodium salt',\n",
       "  '7-ethyl-2-methyl-4-undecanolsulfate, sodium salt',\n",
       "  'Natrii tetradecylis sulfa',\n",
       "  'Sodium 2-methyl-7-ethylundecanol-4-sulfate',\n",
       "  'Sodium 7-ethyl-2-methyl-4-undecanol sulfate',\n",
       "  'Sodium tetradecyl sulfate',\n",
       "  'Sodium tetradecyl sulphate',\n",
       "  'Sodium tetradecylsulfate',\n",
       "  'STS',\n",
       "  'Tetradecilsulfato sodico',\n",
       "  'Tetradecyl sodium sulfate',\n",
       "  'Tetradecyl sulfate de sodium',\n",
       "  'Sodium tetradecyl sulfate'],\n",
       " 'Ketorolac': ['Ketorolac',\n",
       "  'KÃ©torolac',\n",
       "  'Ketorolaco',\n",
       "  'Ketorolacum',\n",
       "  'rac-Ketorolac',\n",
       "  'Ketorolac'],\n",
       " 'Picrotoxin': ['cocculin', 'Picrotoxin'],\n",
       " 'Enoxacin': ['1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid',\n",
       "  '1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid',\n",
       "  'Enoxacin',\n",
       "  'Enoxacina',\n",
       "  'Ã\\x89noxacine',\n",
       "  'Enoxacino',\n",
       "  'Enoxacinum',\n",
       "  'Enoxacin'],\n",
       " 'Quinine': ['(-)-Quinine',\n",
       "  '(â\\x88\\x92)-quinine',\n",
       "  '(8S,9R)-quinine',\n",
       "  '(R)-(â\\x88\\x92)-quinine',\n",
       "  '(R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol',\n",
       "  \"6'-Methoxycinchonidine\",\n",
       "  'Chinin',\n",
       "  'Chinine',\n",
       "  'Chininum',\n",
       "  'Quinina',\n",
       "  'Quinine',\n",
       "  'Quinine'],\n",
       " 'Tenoxicam': ['Tenoxicam', 'TÃ©noxicam', 'Tenoxicamum', 'Tenoxicam'],\n",
       " 'Dronabinol': ['(-)-delta9-trans-Tetrahydrocannabinol',\n",
       "  '1-trans-delta-9-Tetrahydrocannabinol',\n",
       "  '3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-ol',\n",
       "  '6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol',\n",
       "  'delta-9-tetrahydrocannabinol',\n",
       "  'delta-9-THC',\n",
       "  'delta(1)-tetrahydrocannabinol',\n",
       "  'delta(9)-THC',\n",
       "  'delta9-tetrahydrocannabinol',\n",
       "  'Dronabinol',\n",
       "  'Dronabinolum',\n",
       "  'Tetrahydrocannabinol',\n",
       "  'THC',\n",
       "  'Î\\x949-tetrahydrocannabinol',\n",
       "  'Dronabinol'],\n",
       " 'Montelukast': ['(R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid',\n",
       "  '1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid',\n",
       "  'Montelukast',\n",
       "  'MontÃ©lukast',\n",
       "  'Montelukastum',\n",
       "  'Montelukast'],\n",
       " 'Fluoxetine': ['(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine',\n",
       "  '(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine',\n",
       "  'Fluoxetin',\n",
       "  'Fluoxetina',\n",
       "  'Fluoxetine',\n",
       "  'FluoxÃ©tine',\n",
       "  'Fluoxetinum',\n",
       "  'Fluoxetine'],\n",
       " 'Hexylcaine': ['Hexilcaina', 'Hexylcaine', 'Hexylcainum', 'Hexylcaine'],\n",
       " 'Methohexital': ['(Â±)-5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid',\n",
       "  '5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione',\n",
       "  '5-Allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid',\n",
       "  'Methohexital',\n",
       "  'Methohexitalum',\n",
       "  'Methohexitone',\n",
       "  'Metohexital',\n",
       "  \"Î±-DL-1-methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid\",\n",
       "  'Methohexital'],\n",
       " 'Chlordiazepoxide': ['7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxide',\n",
       "  'CDP',\n",
       "  'Chloradiazepoxide',\n",
       "  'Chlordiazepoxide',\n",
       "  'Chlordiazepoxidum',\n",
       "  'Clopoxide',\n",
       "  'ClordiazepÃ³xido',\n",
       "  'Methaminodiazepoxide',\n",
       "  'Chlordiazepoxide'],\n",
       " 'Duloxetine': ['(3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine',\n",
       "  '(S)-duloxetine',\n",
       "  'Duloxetina',\n",
       "  'Duloxetine',\n",
       "  'Duloxetine'],\n",
       " 'Chlorpromazine': ['3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine',\n",
       "  '3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine',\n",
       "  'Chlorpromazine',\n",
       "  'Chlorpromazinum',\n",
       "  'Clorpromazina',\n",
       "  'CPZ',\n",
       "  'N-(3-dimethylaminopropyl)-3-chlorophenothiazine',\n",
       "  'Chlorpromazine'],\n",
       " 'Rimantadine': ['alpha-Methyl-1-adamantanemethylamine',\n",
       "  'alpha-Methyladamantanemethylamine',\n",
       "  'Rimantadina',\n",
       "  'Rimantadine',\n",
       "  'Rimantadinum',\n",
       "  'Rimantadine'],\n",
       " 'Amikacin': ['1-N-(L(â\\x88\\x92)-Î³-amino-Î±-hydroxybutyryl)kanamycin A',\n",
       "  'Amikacin',\n",
       "  'Amikacina',\n",
       "  'Amikacine',\n",
       "  'Amikacinum',\n",
       "  'Amikacin'],\n",
       " 'Lenalidomide': ['1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline',\n",
       "  '3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione',\n",
       "  'Lenalidomida',\n",
       "  'Lenalidomide',\n",
       "  'Lenalidomide'],\n",
       " 'Raloxifene': ['(2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone',\n",
       "  'RaloxifÃ¨ne',\n",
       "  'Raloxifene',\n",
       "  'Raloxifeno',\n",
       "  'Raloxifenum',\n",
       "  'Raloxifene'],\n",
       " 'Celecoxib': ['Celecoxib',\n",
       "  'CÃ©lÃ©coxib',\n",
       "  'Celecoxibum',\n",
       "  'p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide',\n",
       "  'Celecoxib'],\n",
       " 'Gallamine triethiodide': ['Gallamin triethiodid',\n",
       "  'Gallamine triethiodide',\n",
       "  'Gallamini Triethiodidum',\n",
       "  'TriÃ©thiodure de Gallamine',\n",
       "  'Trietioduro de galamina',\n",
       "  'Gallamine triethiodide'],\n",
       " 'Brimonidine': ['5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline',\n",
       "  'Brimonidina',\n",
       "  'Brimonidine',\n",
       "  'Brimonidinum',\n",
       "  'Bromoxidine',\n",
       "  'Brimonidine'],\n",
       " 'Dicloxacillin': ['(2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  'Dicloxacilina',\n",
       "  'Dicloxacillin',\n",
       "  'Dicloxacillina',\n",
       "  'Dicloxacilline',\n",
       "  'Dicloxacillinum',\n",
       "  'Dicloxacillin'],\n",
       " 'Nabilone': ['Nabilon', 'Nabilona', 'Nabilone', 'Nabilonum', 'Nabilone'],\n",
       " 'Pefloxacin': ['Pefloxacin',\n",
       "  'Pefloxacine',\n",
       "  'Pefloxacino',\n",
       "  'Pefloxacinum',\n",
       "  'PFLX',\n",
       "  'Pefloxacin'],\n",
       " 'Altretamine': ['2,4,6-tris(dimethylamino)-1,3,5-triazine',\n",
       "  '2,4,6-tris(dimethylamino)-s-triazine',\n",
       "  'Altretamin',\n",
       "  'Altretamina',\n",
       "  'Altretamine',\n",
       "  'AltrÃ©tamine',\n",
       "  'Altretaminum',\n",
       "  'Hexamethylmelamine',\n",
       "  'HMM',\n",
       "  'Altretamine'],\n",
       " 'Sotalol': [\"4'-(1-hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide\",\n",
       "  'Sotalol',\n",
       "  'Sotalolo',\n",
       "  'Sotalolum',\n",
       "  'Î²-cardone',\n",
       "  'Sotalol'],\n",
       " 'Buspirone': ['8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione',\n",
       "  'Buspiron',\n",
       "  'Buspirona',\n",
       "  'Buspirone',\n",
       "  'Buspironum',\n",
       "  'Buspirone'],\n",
       " 'Miglitol': ['Miglitol', 'Miglitolum', 'Miglitol'],\n",
       " 'Fosinopril': ['Fosenopril', 'Fosinopril', 'Fosinopril'],\n",
       " 'Cefotaxime': ['(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  '(6R,7R)-3-(acetoxymethyl)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  '(6R,7R)-3-Acetoxymethyl-7-{2-(2-amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  'Cefotaxim',\n",
       "  'Cefotaxima',\n",
       "  'Cefotaxime',\n",
       "  'CÃ©fotaxime',\n",
       "  'Cefotaximum',\n",
       "  'Cephotaxime',\n",
       "  'Cefotaxime'],\n",
       " 'Entacapone': ['(E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide',\n",
       "  'Entacapona',\n",
       "  'Entacapone',\n",
       "  'Entacaponum',\n",
       "  'N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide',\n",
       "  'Entacapone'],\n",
       " 'Zidovudine': ['Azidothymidine',\n",
       "  'AZT',\n",
       "  'ZDV',\n",
       "  'Zidovudina',\n",
       "  'Zidovudine',\n",
       "  'Zidovudinum',\n",
       "  'Zidovudine'],\n",
       " 'Darifenacin': ['(S)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-Î±,Î±-diphenyl-3-pyrrolidineacetamide',\n",
       "  'Darifenacin',\n",
       "  'Darifenacina',\n",
       "  'DarifÃ©nacine',\n",
       "  'Darifenacinum',\n",
       "  'Darifenacin'],\n",
       " 'Oxycodone': ['(-)-14-Hydroxydihydrocodeinone',\n",
       "  '4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one',\n",
       "  '4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one',\n",
       "  '4,5Î±-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one',\n",
       "  'Dihydro-14-hydroxycodeinone',\n",
       "  'Dihydrohydroxycodeinone',\n",
       "  'Dihydroxycodeinone',\n",
       "  'Oxicodona',\n",
       "  'Oxycodone',\n",
       "  'Oxycodonum',\n",
       "  'Oxycodone'],\n",
       " 'Phenindione': ['2-phenyl-1,3-diketohydrindene',\n",
       "  '2-Phenyl-1,3-indandione',\n",
       "  '2-phenyl-1,3(2H)-Indenedione',\n",
       "  'Fenindiona',\n",
       "  'Fenindione',\n",
       "  'Phenindion',\n",
       "  'PhÃ©nindione',\n",
       "  'Phenindione',\n",
       "  'Phenindionum',\n",
       "  'PID',\n",
       "  'Phenindione'],\n",
       " 'Flutamide': [\"4'-nitro-3'-trifluoromethylisobutyranilide\",\n",
       "  'Flutamid',\n",
       "  'Flutamida',\n",
       "  'Flutamide',\n",
       "  'Flutamidum',\n",
       "  'FTA',\n",
       "  'NFBA',\n",
       "  'Niftolid',\n",
       "  'Niftolide',\n",
       "  \"Î±,Î±,Î±-trifluoro-2-methyl-4'-nitro-m-propionotoluidide\",\n",
       "  'Flutamide'],\n",
       " 'Tolmetin': ['1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid',\n",
       "  '1-Methyl-5-p-toluoylpyrrole-2-acetic acid',\n",
       "  '5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid',\n",
       "  'Tolmetin',\n",
       "  'Tolmetina',\n",
       "  'TolmÃ©tine',\n",
       "  'Tolmetino',\n",
       "  'Tolmetinum',\n",
       "  'Tolmetin'],\n",
       " 'Cimetidine': ['1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine',\n",
       "  '2-cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine',\n",
       "  'Cimetidin',\n",
       "  'Cimetidina',\n",
       "  'CimÃ©tidine',\n",
       "  'Cimetidine',\n",
       "  'Cimetidinum',\n",
       "  \"N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine\",\n",
       "  \"N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine\",\n",
       "  'Cimetidine'],\n",
       " 'Haloperidol': ['1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine',\n",
       "  \"4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone\",\n",
       "  '4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one',\n",
       "  \"4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone\",\n",
       "  \"4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone\",\n",
       "  'Haloperidol',\n",
       "  'Haloperidolum',\n",
       "  'Î³-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone',\n",
       "  'Haloperidol'],\n",
       " 'Ritonavir': ['Ritonavir', 'Ritonavirum', 'Ritonavir'],\n",
       " 'Levallorphan': ['Levallofano',\n",
       "  'Levallorphan',\n",
       "  'LÃ©vallorphane',\n",
       "  'Levallorphanum',\n",
       "  'Levalorfano',\n",
       "  'Levallorphan'],\n",
       " 'Tridihexethyl': ['Tridihexethyl'],\n",
       " 'Nitazoxanide': ['Nitaxozanid',\n",
       "  'Nitaxozanide',\n",
       "  'Nitazoxanida',\n",
       "  'Nitazoxanide',\n",
       "  'Nitazoxanidum',\n",
       "  'Nitazoxanide'],\n",
       " 'Triflupromazine': ['10-(3-(Dimethylamino)propyl)-2-(trifluoromethyl)phenothiazine',\n",
       "  '2-(Trifluoromethyl)promazine',\n",
       "  '2-Trifluoromethyl-10-(gamma-dimethylaminopropyl)phenothiazine',\n",
       "  'Fluopromazine',\n",
       "  'Triflupromazin',\n",
       "  'Triflupromazina',\n",
       "  'Triflupromazine',\n",
       "  'Triflupromazinum',\n",
       "  'Triflupromazine'],\n",
       " 'Dextrothyroxine': ['D-thyroxine',\n",
       "  'Dextrothyroxine',\n",
       "  'Dextrothyroxinum',\n",
       "  'O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-D-tyrosine',\n",
       "  'Dextrothyroxine'],\n",
       " 'Acetyldigitoxin': ['Acetildigitoxina',\n",
       "  'Acetyl-digitoxin-alpha',\n",
       "  'Acetyldiginatin',\n",
       "  'Acetyldigitoxin',\n",
       "  'Acetyldigitoxinum',\n",
       "  'Acetylgitoxin',\n",
       "  'alpha-Acetyldigitoxin',\n",
       "  'alpha-Acetylgitaloxin',\n",
       "  'alpha-Monoacetyldigitoxin',\n",
       "  'Desglucolanatoside A',\n",
       "  \"Digitoxin 3'''-acetate\",\n",
       "  'Acetyldigitoxin'],\n",
       " 'Vancomycin': ['Vancomicina',\n",
       "  'Vancomycin',\n",
       "  'Vancomycine',\n",
       "  'Vancomycinum',\n",
       "  'Vancomycin'],\n",
       " 'Aminocaproic acid': ['6-Aminocaproic acid',\n",
       "  '6-aminohexanoic acid',\n",
       "  'Acide aminocaproÃ¯que',\n",
       "  'Ã\\x81cido aminocaprÃ³ico',\n",
       "  'acidum aminocaproicum',\n",
       "  'Aminocaproic acid',\n",
       "  'AminocapronsÃ¤ure',\n",
       "  'EACA',\n",
       "  'EACS',\n",
       "  'Epsilcapramine',\n",
       "  'Epsilon Aminocaproic Acid',\n",
       "  'Epsilon-Aminocaproic acid',\n",
       "  'epsilon-Aminohexanoic acid',\n",
       "  'omega-Aminocaproic acid',\n",
       "  'omega-Aminohexanoic acid',\n",
       "  'Aminocaproic acid'],\n",
       " 'Dextromethorphan': ['(+)-dextromethorphan',\n",
       "  'D-methorphan',\n",
       "  'delta-Methorphan',\n",
       "  'Dex',\n",
       "  'Dextromethorfan',\n",
       "  'Dextromethorphan',\n",
       "  'DextromÃ©thorphane',\n",
       "  'Dextromethorphanum',\n",
       "  'Dextrometorfano',\n",
       "  'DM',\n",
       "  'Dextromethorphan'],\n",
       " 'Cisplatin': ['CDDP',\n",
       "  'Cis-DDP',\n",
       "  'cis-diamminedichloroplatinum(II)',\n",
       "  'Cisplatin',\n",
       "  'cisplatino',\n",
       "  'Cisplatin'],\n",
       " 'Bentoquatam': ['Bentoquatam'],\n",
       " 'Anisotropine methylbromide': ['8-Methyl-3-(2-propylpentanoyloxy)tropinium bromide',\n",
       "  '8-Methyltropinium bromide 2-propylpentanoate',\n",
       "  '8-Methyltropinium bromide 2-propylvalerate',\n",
       "  'Anisotropine methobromide',\n",
       "  'Anisotropine methylbromide',\n",
       "  'endo-8,8-Dimethyl-3-((1-oxo-2-propylpentyl)oxy)-8-azoniabicyclo(3.2.1)octane bromide',\n",
       "  \"MÃ©thylbromure d'octatropine\",\n",
       "  'Methyloctatropine bromide',\n",
       "  'Metilbromuro de octatropina',\n",
       "  'Octatropine methylbromide',\n",
       "  'Octatropini methylbromidum',\n",
       "  'Anisotropine methylbromide'],\n",
       " 'Albendazole': ['(5-(propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester',\n",
       "  '5-(propylthio)-2-carbomethoxyaminobenzimidazole',\n",
       "  'Albendazol',\n",
       "  'Albendazole',\n",
       "  'Albendazolum',\n",
       "  'Eskazole',\n",
       "  'O-methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate',\n",
       "  'Proftril',\n",
       "  'Albendazole'],\n",
       " 'Trandolapril': ['Trandolapril', 'Trandolaprilum', 'Trandolapril'],\n",
       " 'Caspofungin': ['(4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide',\n",
       "  'Caspofungin',\n",
       "  'Caspofungina',\n",
       "  'Caspofungin'],\n",
       " 'Carteolol': ['Carteolol', 'CartÃ©olol', 'Carteololum', 'Carteolol'],\n",
       " 'Bentiromide': ['Bentiromide',\n",
       "  'Bentiromido',\n",
       "  'Bentiromidum',\n",
       "  'BTPABA',\n",
       "  'PFT',\n",
       "  'Bentiromide'],\n",
       " 'Alitretinoin': ['(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid',\n",
       "  '(7E,9Z,11E,13E)-retinoic acid',\n",
       "  '9-cis-retinoic acid',\n",
       "  '9-cis-Tretinoin',\n",
       "  '9(Z)-Retinoic acid',\n",
       "  'Alitretinoin',\n",
       "  'AlitretinoÃ\\xadna',\n",
       "  'AlitrÃ©tinoÃ¯ne',\n",
       "  'Alitretinoinum',\n",
       "  'Alitretinoin'],\n",
       " 'Metolazone': ['2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone',\n",
       "  '7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide',\n",
       "  '7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide',\n",
       "  'Metolazon',\n",
       "  'Metolazona',\n",
       "  'MÃ©tolazone',\n",
       "  'Metolazone',\n",
       "  'Metolazonum',\n",
       "  'Metolazone'],\n",
       " 'Tolnaftate': ['2-Naphthyl N-methyl-N-(3-tolyl)thionocarbamate',\n",
       "  'm,N-Dimethylthiocarbanilic acid O-2-naphthyl ester',\n",
       "  'Methyl (3-methylphenyl)carbamothioic acid O-2-naphthalenyl ester',\n",
       "  'N-methyl-N-(3-methylphenyl)-1-(naphthalen-2-yloxy)methanethioamide',\n",
       "  'O-2-Naphthyl m,N-dimethylthiocarbanilate',\n",
       "  'Tolnaftate',\n",
       "  'Tolnaftato',\n",
       "  'Tolnaftatum',\n",
       "  'Tolnaphthate',\n",
       "  'Tolnaftate'],\n",
       " 'Oxaliplatin': ['Diaminocyclohexane Oxalatoplatinum',\n",
       "  'L-OHP',\n",
       "  'Oxalatoplatin',\n",
       "  'Oxalatoplatinum',\n",
       "  'Oxaliplatin',\n",
       "  'oxaliplatine',\n",
       "  'oxaliplatino',\n",
       "  'oxaliplatinum',\n",
       "  'Oxaliplatin'],\n",
       " 'Cinchocaine': ['2-butoxy-N-(2-(diethylamino)ethyl)cinchoninamide',\n",
       "  '2-butoxy-N-(Î±-diethylaminoethyl)cinchoninamide',\n",
       "  '2-butoxy-N-(Î²-diethylaminoethyl)cinchoninamide',\n",
       "  '2-butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide',\n",
       "  '2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide',\n",
       "  '2-butoxyquinoline-4-carboxylic acid diethylaminoethylamide',\n",
       "  '2-N-butoxy-N-(2-diethylaminoethyl)cinchoninamide',\n",
       "  'Cinchocaine',\n",
       "  'Cinchocainum',\n",
       "  'Cincocainio',\n",
       "  'Dibucaine',\n",
       "  'N-(2-(diethylamino)ethyl)-2-butoxycinchoninamide',\n",
       "  'Î±-butyloxycinchonic acid-Î³-diethylethylenediamine',\n",
       "  'Î±-butyloxycinchoninic acid diethylethylenediamide',\n",
       "  'Cinchocaine'],\n",
       " 'Lercanidipine': ['Lercanidipine', 'Lercanidipino', 'Lercanidipine'],\n",
       " 'Foscarnet': ['Carboxyphosphonic acid',\n",
       "  'Foscarmet',\n",
       "  'Phosphonoformate',\n",
       "  'Phosphonoformic acid',\n",
       "  'Phosphonomethanoic acid',\n",
       "  'Foscarnet'],\n",
       " 'Erlotinib': ['[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine',\n",
       "  'Erlotinib',\n",
       "  'Erlotinib'],\n",
       " 'Cyclophosphamide': ['(+-)-Cyclophosphamide',\n",
       "  '(RS)-Cyclophosphamide',\n",
       "  '2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide',\n",
       "  'Anhydrous cyclophosphamide',\n",
       "  'Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester',\n",
       "  'Ciclofosfamida',\n",
       "  'Ciclofosfamide',\n",
       "  'Cyclophosphamid',\n",
       "  'Cyclophosphamide',\n",
       "  'Cyclophosphamide anhydrous',\n",
       "  'Cyclophosphamidum',\n",
       "  'Cytophosphane',\n",
       "  'N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide',\n",
       "  'Cyclophosphamide'],\n",
       " 'Mephenytoin': ['mefenitoÃ\\xadna', 'Mephenytoin', 'Mephenytoin'],\n",
       " 'Rofecoxib': ['3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone',\n",
       "  '4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone',\n",
       "  'RofÃ©coxib',\n",
       "  'Rofecoxib',\n",
       "  'Rofecoxibum',\n",
       "  'Rofecoxib'],\n",
       " 'Chlormerodrin': ['{3-[(aminocarbonyl)amino]-2-methoxypropyl}chloromercury',\n",
       "  '1-[3-(chloromercuri)-2-methoxypropyl]urea',\n",
       "  'Chlormerodrin',\n",
       "  'Chlormerodrina',\n",
       "  'Chlormerodrine',\n",
       "  'Chlormerodrinum',\n",
       "  'Chlormerodrin'],\n",
       " 'Cefdinir': ['(6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  '(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  'Cefdinir',\n",
       "  'Cefdinirum',\n",
       "  'CFDN',\n",
       "  'Cefdinir'],\n",
       " 'Guanidine': ['Aminomethanamidine',\n",
       "  'Gu',\n",
       "  'Guanidin',\n",
       "  'Guanidine',\n",
       "  'Imidourea',\n",
       "  'Iminourea',\n",
       "  'Guanidine'],\n",
       " 'Ciprofloxacin': ['1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid',\n",
       "  '1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid',\n",
       "  '1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid',\n",
       "  '1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid',\n",
       "  '1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid',\n",
       "  '1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid',\n",
       "  'Ciprofloxacin',\n",
       "  'Ciprofloxacine',\n",
       "  'Ciprofloxacino',\n",
       "  'Ciprofloxacinum',\n",
       "  'Ciprofloxacin'],\n",
       " 'Gadoversetamide': ['Gadoversetamid',\n",
       "  'Gadoversetamida',\n",
       "  'Gadoversetamide',\n",
       "  'Gadoversetamidum',\n",
       "  'Gadoversetamide'],\n",
       " 'Toremifene': ['Toremifene', 'Toremifeno', 'Toremifenum', 'Toremifene'],\n",
       " 'Nortriptyline': ['10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Î\\x945,Î³-propylamine',\n",
       "  '3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine',\n",
       "  'Demethylamitriptyline',\n",
       "  'Desmethylamitriptyline',\n",
       "  'Nortriptylina',\n",
       "  'Nortriptyline',\n",
       "  'Nortriptylinum',\n",
       "  'Nortriptyline'],\n",
       " 'Vincristine': ['22-Oxovincaleukoblastin',\n",
       "  '22-Oxovincaleukoblastine',\n",
       "  'Leurocristine',\n",
       "  'Vincristin',\n",
       "  'Vincristina',\n",
       "  'Vincristine',\n",
       "  'Vincristinum',\n",
       "  'Vincristine'],\n",
       " 'Benazepril': ['BÃ©nazÃ©pril', 'Benazepril', 'Benazeprilum', 'Benazepril'],\n",
       " 'Amoxapine': ['2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine',\n",
       "  'Amoxapin',\n",
       "  'Amoxapina',\n",
       "  'Amoxapine',\n",
       "  'Amoxapinum',\n",
       "  'Amoxepine',\n",
       "  'Desmethylloxapin',\n",
       "  'Amoxapine'],\n",
       " 'Fluorouracil': ['5-Fluoracil',\n",
       "  '5-Fluoropyrimidine-2,4-dione',\n",
       "  '5-Fluorouracil',\n",
       "  '5-Fluracil',\n",
       "  '5-FU',\n",
       "  'Fluoro Uracil',\n",
       "  'Fluorouracil',\n",
       "  'Fluorouracilo',\n",
       "  'Fluorouracilum',\n",
       "  'Fluouracil',\n",
       "  'Fluorouracil'],\n",
       " 'Pyridostigmine': ['Piridostigmina',\n",
       "  'Pyridostigmine cation',\n",
       "  'Pyridostigmine'],\n",
       " 'Adinazolam': ['8-Chloro-1-((dimethylamino)methyl)-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine',\n",
       "  'Adinazolam',\n",
       "  'Adinazolamum',\n",
       "  'Adinazolam'],\n",
       " 'Desoximetasone': ['(11Î²,16Î±)-9-fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione',\n",
       "  '9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone',\n",
       "  'Desoximetason',\n",
       "  'Desoximetasona',\n",
       "  'DÃ©soximÃ©tasone',\n",
       "  'Desoximetasone',\n",
       "  'Desoximetasonum',\n",
       "  'Desoxymethasone',\n",
       "  'Desoximetasone'],\n",
       " 'Azelaic acid': ['1,7-dicarboxyheptane',\n",
       "  '1,7-Heptanedicarboxylic acid',\n",
       "  '1,9-nonanedioic acid',\n",
       "  'Acide azÃ©laÃ¯que',\n",
       "  'Ã\\x81cido azelaico',\n",
       "  'Acidum acelaicum',\n",
       "  'Acidum azelaicum',\n",
       "  'Anchoic acid',\n",
       "  'Azelaic acid',\n",
       "  'AzelainsÃ¤ure',\n",
       "  'Lepargylic acid',\n",
       "  'n-nonanedioic acid',\n",
       "  'NonandisÃ¤ure',\n",
       "  'Nonanedioic acid',\n",
       "  'Azelaic acid'],\n",
       " 'Zafirlukast': ['4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide',\n",
       "  'cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate',\n",
       "  'Zafirlukast',\n",
       "  'Zafirlukast'],\n",
       " 'Propylthiouracil': ['2-Mercapto-6-propyl-4-pyrimidone',\n",
       "  '2-Mercapto-6-propylpyrimid-4-one',\n",
       "  '2-Thio-4-oxo-6-propyl-1,3-pyrimidine',\n",
       "  '2-Thio-6-propyl-1,3-pyrimidin-4-one',\n",
       "  '4-propyl-2-thiouracil',\n",
       "  '6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione',\n",
       "  '6-propyl-2-thiouracil',\n",
       "  '6-propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one',\n",
       "  '6-Propylthiouracil',\n",
       "  '6-Thio-4-propyluracil',\n",
       "  'Propiltiouracilo',\n",
       "  'Propylthiouracil',\n",
       "  'Propylthiouracile',\n",
       "  'Propylthiouracilum',\n",
       "  'Propylthiouracil'],\n",
       " 'Acetohydroxamic acid': ['Acethydroxamsaeure',\n",
       "  'Acetic acid, oxime',\n",
       "  'Acetohydroxamate',\n",
       "  'Acetohydroxamic acid',\n",
       "  'Acetohydroximic acid',\n",
       "  'Acetyl hydroxyamino',\n",
       "  'Acetylhydroxamic acid',\n",
       "  'Acide acetohydroxamique',\n",
       "  'Acido acetohidroxamico',\n",
       "  'Acidum acetohydroxamicum',\n",
       "  'AHA',\n",
       "  'Cetohyroxamic acid',\n",
       "  'Methylhydroxamic acid',\n",
       "  'N-Acetyl hydroxyacetamide',\n",
       "  'N-Acetylhydroxylamine',\n",
       "  'N-Hydroxyacetamide',\n",
       "  'Acetohydroxamic acid'],\n",
       " 'Pentostatin': ['Co-vidarabine',\n",
       "  'Pentostatin',\n",
       "  'Pentostatina',\n",
       "  'Pentostatine',\n",
       "  'Pentostatinum',\n",
       "  'Pentostatin'],\n",
       " 'Methoxsalen': ['6-hydroxy-7-methoxy-5-benzofuranacrylic acid Î´-lactone',\n",
       "  \"8-methoxy-[furano-3'.2':6.7-coumarin]\",\n",
       "  \"8-methoxy-2',3',6,7-furocoumarin\",\n",
       "  \"8-methoxy-4',5':6,7-furocoumarin\",\n",
       "  '8-Methoxyfuranocoumarin',\n",
       "  '8-methoxypsoralen',\n",
       "  '8-MOP',\n",
       "  '8-MP',\n",
       "  '9-methoxy-7H-furo[3,2-g][1]benzopyran-7-one',\n",
       "  'Ammoidin',\n",
       "  'Methoxsalen',\n",
       "  'MÃ©thoxsalÃ¨ne',\n",
       "  'Metoxaleno',\n",
       "  'O-methylxanthotoxol',\n",
       "  'Xanthotoxin',\n",
       "  'Xanthotoxine',\n",
       "  'Methoxsalen'],\n",
       " 'Piroxicam': ['4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid',\n",
       "  'Piroxicam',\n",
       "  'Piroxicam betadex',\n",
       "  'Piroxicamum',\n",
       "  'Pyroxycam',\n",
       "  'Piroxicam'],\n",
       " 'Lamotrigine': ['3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine',\n",
       "  'Lamotrigina',\n",
       "  'Lamotrigine',\n",
       "  'Lamotriginum',\n",
       "  'Lamotrigine'],\n",
       " 'Perflutren': ['1,1,1,2,2,3,3,3-octafluoropropane',\n",
       "  'Freon 218',\n",
       "  'Octafluoropropane',\n",
       "  'Octafluorpropan',\n",
       "  'Oktafluorpropan',\n",
       "  'Perfluoropropane',\n",
       "  'Perflutren',\n",
       "  'Perflutreno',\n",
       "  'Perflutren'],\n",
       " 'Hydroxyzine': ['Hidroxizina',\n",
       "  'Hychotine',\n",
       "  'Hydroksyzyny',\n",
       "  'Hydroxine',\n",
       "  'Hydroxizine',\n",
       "  'Hydroxizinum',\n",
       "  'Hydroxycine',\n",
       "  'Hydroxyzin',\n",
       "  'Hydroxyzine',\n",
       "  'Hydroxyzinum',\n",
       "  'Idrossizina',\n",
       "  'Hydroxyzine'],\n",
       " 'Zanamivir': ['(2R,3R,4S)-3-(acetylamino)-4-carbamimidamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid',\n",
       "  '4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid',\n",
       "  '4-guanidino-Neu5Ac2en',\n",
       "  '5-(acetylamino)-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid',\n",
       "  '5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid',\n",
       "  'GANA',\n",
       "  'Zanamivir',\n",
       "  'Zanamivir'],\n",
       " 'Bosentan': [\"4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide\",\n",
       "  'bosentÃ¡n',\n",
       "  'Bosentan',\n",
       "  'bosentan anhydrous',\n",
       "  'bosentanum',\n",
       "  'p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide',\n",
       "  'Bosentan'],\n",
       " 'Tigecycline': ['(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide',\n",
       "  'Tigeciclina',\n",
       "  'Tigecycline',\n",
       "  'Tigecyclinum',\n",
       "  'Tigecycline'],\n",
       " 'Doxapram': ['(Â±)-doxapram',\n",
       "  '1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone',\n",
       "  'Doxapram',\n",
       "  'Doxapramum',\n",
       "  'Doxapram'],\n",
       " 'Benzthiazide': ['3-((benzylthio)methyl)-6-chloro-7-sulfamoyl-2H-benzo-1,2,4-thiadiazine 1,1-dioxide',\n",
       "  '3-benzylthiomethyl-6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide',\n",
       "  '3-benzylthiomethyl-6-chloro-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide',\n",
       "  '6-chloro-1,1-dioxo-3-(phenylmethylsulfanylmethyl)-4H-benzo[e][1,2,4]thiadiazine-7-sulfonamide',\n",
       "  '6-chloro-7-sulfamoyl-3-benzylthiomethyl-2H-1,2,4-benzothiadiazine 1,1-dioxide',\n",
       "  'Benzothiazide',\n",
       "  'Benzotiazida',\n",
       "  'Benzthiazid',\n",
       "  'Benzthiazide',\n",
       "  'Benzthiazidum',\n",
       "  'Benztiazide',\n",
       "  'Benzthiazide'],\n",
       " 'Methotrexate': ['4-amino-10-methylfolic acid',\n",
       "  '4-amino-N(10)-methylpteroylglutamic acid',\n",
       "  'Amethopterin',\n",
       "  'Methotrexat',\n",
       "  'MÃ©thotrexate',\n",
       "  'Methotrexate',\n",
       "  'Methotrexatum',\n",
       "  'Metotrexato',\n",
       "  'MTX',\n",
       "  'N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid',\n",
       "  'Methotrexate'],\n",
       " 'Carbamazepine': ['5-Carbamoyl-5H-dibenz(b,f)azepine',\n",
       "  '5-carbamoyl-5H-dibenz[b,f]azepine',\n",
       "  '5-Carbamoyl-5H-dibenzo(b,f)azepine',\n",
       "  '5-Carbamyl-5H-dibenzo(b,f)azepine',\n",
       "  '5H-Dibenz(b,f)azepine-5-carboxamide',\n",
       "  'Carbamazepen',\n",
       "  'Carbamazepin',\n",
       "  'Carbamazepina',\n",
       "  'CarbamazÃ©pine',\n",
       "  'Carbamazepine',\n",
       "  'Carbamazepinum',\n",
       "  'CBZ',\n",
       "  'Carbamazepine'],\n",
       " 'Cisatracurium': ['Cisatracurium cation', 'Cisatracurium'],\n",
       " 'Succimer': ['DIM-SA',\n",
       "  'DMS',\n",
       "  'DMS-A',\n",
       "  'DMSA',\n",
       "  'meso-2,3-DimercaptobernsteinsÃ¤ure',\n",
       "  'meso-2,3-dimercaptosuccinic acid',\n",
       "  'meso-dimercaptosuccinic acid',\n",
       "  'Succimer',\n",
       "  'succimero',\n",
       "  'Succimer'],\n",
       " 'Cephalexin': ['(6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  '7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acid',\n",
       "  '7-beta-(D-alpha-Amino-alpha-phenylacetylamino)-3-methyl-3-cephem-4-carboxylic acid',\n",
       "  'Anhydrous cefalexin',\n",
       "  'Anhydrous cephalexin',\n",
       "  'Cefalexin',\n",
       "  'Cefalexin anhydrous',\n",
       "  'Cefalexina',\n",
       "  'CÃ©falexine',\n",
       "  'Cefalexinum',\n",
       "  'Cephalexin anhydrous',\n",
       "  'Cephalexin'],\n",
       " 'Cinnarizine': ['1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine',\n",
       "  '1-Benzhydryl-4-cinnamylpiperazin',\n",
       "  '1-Cinnamyl-4-(diphenylmethyl)piperazine',\n",
       "  'Cinarizina',\n",
       "  'Cinnarizine',\n",
       "  'Cinnarizinum',\n",
       "  'Cinnarizine'],\n",
       " 'Fondaparinux': ['Natural heparin pentasaccharide', 'Fondaparinux'],\n",
       " 'Vinblastine': ['Vinblastin',\n",
       "  'Vinblastina',\n",
       "  'Vinblastine',\n",
       "  'Vinblastinum',\n",
       "  'Vincaleukoblastine',\n",
       "  'Vinblastine'],\n",
       " 'Propranolol': ['1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol',\n",
       "  '1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol',\n",
       "  'beta-Propranolol',\n",
       "  'Propanalol',\n",
       "  'Propanolol',\n",
       "  'Propranolol',\n",
       "  'Propranololo',\n",
       "  'Propranololum',\n",
       "  'Î²-Propranolol',\n",
       "  'Propranolol'],\n",
       " 'Atropine': ['(Â±)-atropine',\n",
       "  '(Â±)-hyoscyamine',\n",
       "  'Atropin',\n",
       "  'Atropina',\n",
       "  'Atropine',\n",
       "  'Atropinum',\n",
       "  'dl-Hyoscyamine',\n",
       "  'dl-tropyltropate',\n",
       "  'Tropine tropate',\n",
       "  'Atropine'],\n",
       " 'Fenoprofen': ['(+/-)-fenoprofen',\n",
       "  '(+/-)-m-phenoxyhydratropic acid',\n",
       "  '(Â±)-2-(3-phenoxyphenyl)propionic acid',\n",
       "  '2-(3-phenoxyphenyl)propionic acid',\n",
       "  '2-(m-phenoxyphenyl)propionic acid',\n",
       "  '3-phenoxyhydratropic acid',\n",
       "  'DL-2-(3-phenoxyphenyl)propionic acid',\n",
       "  'Fenoprofen',\n",
       "  'FÃ©noprofÃ¨ne',\n",
       "  'Fenoprofeno',\n",
       "  'Fenoprofenum',\n",
       "  'Î±-(m-phenoxyphenyl)propionic acid',\n",
       "  'Î±-methyl-3-phenoxybenzeneacetic acid',\n",
       "  'Fenoprofen'],\n",
       " 'Fenfluramine': ['(Â±)-fenfluramine',\n",
       "  '1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane',\n",
       "  'DL-Fenfluramine',\n",
       "  'Fenfluramina',\n",
       "  'Fenfluramine',\n",
       "  'Fenfluraminum',\n",
       "  'Fenfluramine'],\n",
       " 'Clonidine': ['2-((2,6-Dichlorophenyl)imino)imidazolidine',\n",
       "  '2,6-Dichloro-N-2-imidazolidinylidenebenzenamine',\n",
       "  'Chlofazoline',\n",
       "  'Clonidin',\n",
       "  'Clonidina',\n",
       "  'Clonidine',\n",
       "  'Clonidinum',\n",
       "  'Clonidine'],\n",
       " 'Sulfamethizole': ['Sulfamethizol',\n",
       "  'SulfamÃ©thizol',\n",
       "  'Sulfamethizole',\n",
       "  'Sulfamethizolum',\n",
       "  'Sulfamethylthiadiazole',\n",
       "  'Sulfametizol',\n",
       "  'Sulfamethizole'],\n",
       " 'Valaciclovir': ['L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanine',\n",
       "  'L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester',\n",
       "  'Valaciclovir',\n",
       "  'Valaciclovirum',\n",
       "  'Valacyclovir',\n",
       "  'Valaciclovir'],\n",
       " 'Carbenicillin': ['(2S,5R,6R)-6-{[carboxy(phenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  'Carbenicilina',\n",
       "  'Carbenicillin',\n",
       "  'Carbenicilline',\n",
       "  'Carbenicillinum',\n",
       "  'Carboxybenzylpenicillin',\n",
       "  'CBPC',\n",
       "  'N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-6-yl)-2-phenylmalonamic acid',\n",
       "  'Î±-carboxybenzylpencillin',\n",
       "  'Î±-phenyl(carboxymethylpenicillin)',\n",
       "  'Carbenicillin'],\n",
       " 'Mazindol': ['Mazindol', 'Mazindolo', 'Mazindolum', 'Mazindol'],\n",
       " 'Valdecoxib': ['Valdecoxib', 'Valdecoxib'],\n",
       " 'Lactulose': ['4-O-beta-D-Galactopyranosyl-D-fructofuranose',\n",
       "  '4-O-beta-D-Galactopyranosyl-D-fructose',\n",
       "  'Lactulosa',\n",
       "  'Lactulose',\n",
       "  'Lactulosum',\n",
       "  'Lactulose'],\n",
       " 'Voriconazole': ['(R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol',\n",
       "  '(Î±R,Î²S)-Î±-(2,4-difluorophenyl)-5-fluoro-Î²-methyl-Î±(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol',\n",
       "  'VCZ',\n",
       "  'Voriconazol',\n",
       "  'Voriconazole',\n",
       "  'Voriconazolum',\n",
       "  'Voriconazole'],\n",
       " 'Levocarnitine': ['(-)-Carnitine',\n",
       "  '(-)-L-Carnitine',\n",
       "  '(R)-Carnitine',\n",
       "  '3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt',\n",
       "  'Carnitina',\n",
       "  'Carnitine',\n",
       "  'L-Carnitine',\n",
       "  'Levocarnitin',\n",
       "  'Levocarnitina',\n",
       "  'LÃ©vocarnitine',\n",
       "  'Levocarnitine',\n",
       "  'Levocarnitinum',\n",
       "  'Vitamin BT',\n",
       "  'Levocarnitine'],\n",
       " 'Enalapril': ['(S)-1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline',\n",
       "  '(S)-1-{(S)-2-[1-((S)-Ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid',\n",
       "  \"1-(N-((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester\",\n",
       "  'Ã¡nalapril',\n",
       "  'Enalapril',\n",
       "  'Enalaprila',\n",
       "  'Enalaprilum',\n",
       "  'Enalapril'],\n",
       " 'Nizatidine': ['N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamine',\n",
       "  'Nizatidina',\n",
       "  'Nizatidine',\n",
       "  'Nizatidinum',\n",
       "  'Nizatidine'],\n",
       " 'Diclofenac': ['[2-(2,6-dichloroanilino)phenyl]acetic acid',\n",
       "  '2-((2,6-dichlorophenyl)amino)benzeneacetic acid',\n",
       "  'Diclofenac',\n",
       "  'Diclofenac acid',\n",
       "  'Diclofenaco',\n",
       "  'Diclofenacum',\n",
       "  'Diclofenac'],\n",
       " 'Cinalukast': [\"3'-((E)-2-(4-cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acid\",\n",
       "  'Cinalukast',\n",
       "  'Cinalukast'],\n",
       " 'Fluticasone propionate': ['Fluticasone propionate',\n",
       "  'Fluticasone propionate'],\n",
       " 'Lisuride': ['Lisurid',\n",
       "  'Lisurida',\n",
       "  'Lisuride',\n",
       "  'Lisuridum',\n",
       "  \"N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea\",\n",
       "  'Lisuride'],\n",
       " 'Doxazosin': ['1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin',\n",
       "  '1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin',\n",
       "  'Doxazosin',\n",
       "  'Doxazosina',\n",
       "  'Doxazosine',\n",
       "  'Doxazosinum',\n",
       "  'Doxazosin'],\n",
       " 'Fluocinolone acetonide': ['6alpha-fluorotriamcinolone acetonide',\n",
       "  '6alpha,9alpha-difluoro-16alpha-hydroxyprednisolone 16,17-acetonide',\n",
       "  '6Î±-fluorotriamcinolone acetonide',\n",
       "  '6Î±,9Î±-difluoro-16Î±-hydroxyprednisolone 16,17-acetonide',\n",
       "  'acÃ©tonide de fluocinolone',\n",
       "  'acetÃ³nido de fluocinolona',\n",
       "  'fluocinolon acetonid',\n",
       "  'fluocinolone 16,17-acetonide',\n",
       "  'Fluocinolone acetonide',\n",
       "  'fluocinoloni acetonidum',\n",
       "  'Fluocinolone acetonide'],\n",
       " 'Piperazine': ['Diethylenediamine',\n",
       "  'Piperazidine',\n",
       "  'Piperazin',\n",
       "  'Piperazina',\n",
       "  'Piperazine'],\n",
       " 'Ethosuximide': ['(Â±)-2-ethyl-2-methylsuccinimide',\n",
       "  '2-ethyl-2-methylsuccinimide',\n",
       "  '2-methyl-2-ethylsuccinimide',\n",
       "  '3-ethyl-3-methyl-2,5-pyrrolidinedione',\n",
       "  '3-ethyl-3-methylsuccinimide',\n",
       "  '3-methyl-3-ethylpyrrolidine-2,5-dione',\n",
       "  '3-methyl-3-ethylsuccinimide',\n",
       "  'Aethosuximide',\n",
       "  'Atysmal',\n",
       "  'Ethosuximid',\n",
       "  'Ã©thosuximide',\n",
       "  'Ethosuximide',\n",
       "  'Ethosuximidum',\n",
       "  'Etosuximida',\n",
       "  'Thilopemal',\n",
       "  'Î±-ethyl-Î±-methylsuccinimide',\n",
       "  'Î±-methyl-Î±-ethylsuccinimide',\n",
       "  'Î³-ethyl-Î³-methyl-succinimide',\n",
       "  'Î³-methyl-Î³-ethyl-succinimide',\n",
       "  'Ethosuximide'],\n",
       " 'Amiloride': ['3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide',\n",
       "  'Amilorid',\n",
       "  'Amilorida',\n",
       "  'Amiloride',\n",
       "  'Amiloridum',\n",
       "  'Amipramidin',\n",
       "  'Amipramidine',\n",
       "  'Amyloride',\n",
       "  'N-amidino-3,5-diamino-6-chloropyrazinecarboxamide',\n",
       "  'Amiloride'],\n",
       " 'Oxytetracycline': ['5-Hydroxytetracycline',\n",
       "  'Embryostat',\n",
       "  'Hydroxytetracyclinum',\n",
       "  'Mepatar',\n",
       "  'Ossitetraciclina',\n",
       "  'Oxitetraciclina',\n",
       "  'Oxyterracin',\n",
       "  'Oxyterracine',\n",
       "  'Oxytetracyclin',\n",
       "  'OxytÃ©tracycline',\n",
       "  'Oxytetracycline',\n",
       "  'Oxytetracycline (anhydrous)',\n",
       "  'Oxytetracycline amphoteric',\n",
       "  'Oxytetracyclinum',\n",
       "  'Oxytetracycline'],\n",
       " 'Ulobetasol': ['21-chloro diflorasone',\n",
       "  'Halobetasol',\n",
       "  'Ulobetasol',\n",
       "  'UlobÃ©tasol',\n",
       "  'Ulobetasolum',\n",
       "  'Ulobetasol'],\n",
       " 'Gadoteridol': [\"gadolinium 2,2',2''-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate\",\n",
       "  'gadolinium-HP-DO3A',\n",
       "  'Gadoteridol',\n",
       "  'Gadoteridolum',\n",
       "  'GD-HP-DO 3A',\n",
       "  'Gd-HPDO3A',\n",
       "  'Gadoteridol'],\n",
       " 'Labetalol': ['3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol',\n",
       "  '5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide',\n",
       "  'LabÃ©talol',\n",
       "  'Labetalol',\n",
       "  'Labetalolum',\n",
       "  'Labetolol',\n",
       "  'Labetalol'],\n",
       " 'Thiopental': ['(Â±)-thiopental',\n",
       "  '2-Thio-5-ethyl-5-sec-pentylbarbituric acid',\n",
       "  '5-Ethyl-5-(1-methyl-butyl)-2-thioxo-dihydro-pyrimidine-4,6-dione',\n",
       "  'Penthiobarbital',\n",
       "  'Pentothiobarbital',\n",
       "  'Thiopental',\n",
       "  'Thiopentobarbital',\n",
       "  'Thiopentobarbitone',\n",
       "  'Thiopentobarbituric acid',\n",
       "  'Thiopentone',\n",
       "  'Tiopentale',\n",
       "  'Thiopental'],\n",
       " 'Monobenzone': ['4-(Benzyloxy)phenol',\n",
       "  '4-(Benzyloxyl)phenol',\n",
       "  '4-(Phenylmethoxy)phenol',\n",
       "  '4-Benzyloxy-phenol',\n",
       "  '4-Benzyloxyphenol',\n",
       "  'Benzyl p-hydroxyphenyl ether',\n",
       "  'Hydrochinon monobenzylether',\n",
       "  'Hydroquinone benzyl ether',\n",
       "  'Hydroquinone monobenzyl ether',\n",
       "  'Monobenzona',\n",
       "  'Monobenzone',\n",
       "  'Monobenzonum',\n",
       "  'Monobenzyl hydroquinone',\n",
       "  'p-(Benzyloxy)phenol',\n",
       "  'p-Hydroxyphenyl benzyl ether',\n",
       "  'Monobenzone'],\n",
       " 'Linezolid': ['Linezolid',\n",
       "  'Linezolide',\n",
       "  'Linezolidum',\n",
       "  'N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide',\n",
       "  'Linezolid'],\n",
       " 'Ivermectin': ['Ivermectin',\n",
       "  'Ivermectina',\n",
       "  'Ivermectine',\n",
       "  'Ivermectinum',\n",
       "  'Ivermectin'],\n",
       " 'Medroxyprogesterone acetate': ['(6Î±)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione',\n",
       "  '17-Acetoxy-6Î±-methylprogesterone',\n",
       "  '17Î±-hydroxy-6Î±-methylprogesterone acetate',\n",
       "  '6-alpha-Methyl-17-alpha-acetoxyprogesterone',\n",
       "  '6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate',\n",
       "  '6Î±-Methyl-17-acetoxy progesterone',\n",
       "  '6Î±-Methyl-17Î±-hydroxyprogesterone acetate',\n",
       "  '6Î±-Methyl-4-pregnene-3,20-dion-17Î±-ol acetate',\n",
       "  'Medroxyacetate progesterone',\n",
       "  'Medroxyprogesterone 17-acetate',\n",
       "  'Methylacetoxyprogesterone',\n",
       "  'Metigestrona',\n",
       "  'MPA',\n",
       "  'Medroxyprogesterone acetate'],\n",
       " 'Cisapride': ['Cisaprid',\n",
       "  'Cisaprida',\n",
       "  'Cisapride',\n",
       "  'Cisapridum',\n",
       "  'Cisapride'],\n",
       " 'Sulindac': ['(Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid',\n",
       "  'cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid',\n",
       "  'cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid',\n",
       "  'Sulindac',\n",
       "  'Sulindaco',\n",
       "  'Sulindacum',\n",
       "  'Sulindac'],\n",
       " 'Cyclothiazide': ['6-chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide',\n",
       "  '6-chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide',\n",
       "  '6-chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide',\n",
       "  '6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide',\n",
       "  'Ciclotiazida',\n",
       "  'Ciclotiazide',\n",
       "  'Cyclothiazide',\n",
       "  'Cyclothiazidum',\n",
       "  'Cyclothiazide'],\n",
       " 'Nafcillin': ['(2-ethoxy-1-naphthalenyl)penicillin',\n",
       "  '(2-ethoxy-1-naphthyl)penicillin',\n",
       "  '(2S,5R,6R)-6-[(2-ethoxy-1-naphthoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  '6-(2-ethoxy-1-naphthamido)penicillanic acid',\n",
       "  'Nafcilina',\n",
       "  'Nafcillin',\n",
       "  'Nafcilline',\n",
       "  'Nafcillinum',\n",
       "  'Naphcillin',\n",
       "  'Nafcillin'],\n",
       " 'Chloroquine': ['Chloraquine',\n",
       "  'Chlorochin',\n",
       "  'Chloroquina',\n",
       "  'Chloroquine',\n",
       "  'Chloroquinium',\n",
       "  'Chloroquinum',\n",
       "  'Cloroquina',\n",
       "  'N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine',\n",
       "  'Chloroquine'],\n",
       " 'Ethionamide': ['2-ethyl-4-thiopyridylamide',\n",
       "  '2-ethylthioisonicotinamide',\n",
       "  'ETH',\n",
       "  'Ethinamide',\n",
       "  'Ethionamide',\n",
       "  'Ethionamidum',\n",
       "  'Ethioniamide',\n",
       "  'Ethylisothiamide',\n",
       "  'Ethyonomide',\n",
       "  'Etionamid',\n",
       "  'Etionamida',\n",
       "  'Etionamide',\n",
       "  'Etioniamid',\n",
       "  'ETP',\n",
       "  'Ethionamide'],\n",
       " 'Metaraminol': ['(-)-Erythro-metaraminol',\n",
       "  '1-(m-Hydroxyphenyl)-2-amino-1-propanol',\n",
       "  '1-Metaraminol',\n",
       "  '2-Amino-1-(m-hydroxyphenyl)-1-propanol',\n",
       "  '3-Hydroxyphenylisopropanolamine',\n",
       "  'alpha-(1-Aminoethyl)-3-hydroxybenzenemethanol',\n",
       "  'alpha-(m-Hydroxyphenyl)-beta-aminopropanol',\n",
       "  'Hydroxynorephedrine',\n",
       "  'L-Metaraminol',\n",
       "  'm-Hydroxy norephedrine',\n",
       "  'm-Hydroxyphenylpropanolamine',\n",
       "  'm-Hydroxypropadrine',\n",
       "  'Metaraminol',\n",
       "  'MÃ©taraminol',\n",
       "  'Metaraminolum',\n",
       "  'Metaraminol'],\n",
       " 'Butorphanol': ['(â\\x88\\x92)-17-(cyclobutylmethyl)morphinan-3,14-diol',\n",
       "  '(â\\x88\\x92)-butorphanol',\n",
       "  '(â\\x88\\x92)-N-cyclobutylmethyl-3,14-dihydroxymorphinan',\n",
       "  'Butorfanol',\n",
       "  'Butorphanol',\n",
       "  'Butorphanolum',\n",
       "  'Butorphanol'],\n",
       " 'Bisoprolol': ['(+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol',\n",
       "  '(RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol',\n",
       "  'Bisoprolol',\n",
       "  'Bisoprololum',\n",
       "  'Bisoprolol'],\n",
       " 'Amodiaquine': ['Amodiaquina', 'Amodiaquine', 'Amodiaquinum', 'Amodiaquine'],\n",
       " 'Furazolidone': [\"3-(5'-Nitrofurfuralamino)-2-oxazolidone\",\n",
       "  '3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone',\n",
       "  '3-[(5-Nitrofurfurylidene)amino]-2-oxazolidone',\n",
       "  '3-[(5-Nitrofurylidene)amino]-2-oxazolidone',\n",
       "  '3-{[(5-nitro-2-furanyl)methylene]amino}-2-oxazolidinone',\n",
       "  '5-Nitro-N-(2-oxo-3-oxazolidinyl)-2-furanmethanimine',\n",
       "  'Furazolidona',\n",
       "  'Furazolidonum',\n",
       "  'FZL',\n",
       "  'N-(5-Nitro-2-furfurylidene)-3-amino-2-oxazolidone',\n",
       "  'N-(5-Nitro-2-furfurylidene)-3-aminooxazolidine-2-one',\n",
       "  'Nitrofurazolidone',\n",
       "  'Nitrofurazolidonum',\n",
       "  'Furazolidone'],\n",
       " 'Rifabutin': [\"1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV\",\n",
       "  '4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S',\n",
       "  '4-N-isobutylspiropiperidylrifamycin S',\n",
       "  'Ansamicin',\n",
       "  'Ansamycin',\n",
       "  'Rifabutin',\n",
       "  'Rifabutina',\n",
       "  'Rifabutine',\n",
       "  'Rifabutinum',\n",
       "  'Rifabutin'],\n",
       " 'Candoxatril': ['[4(S)-cis]-4-[[[1-[3-[(2,3-dihydro-1H-Indeb5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]cyclohexanecarboxylic acid',\n",
       "  '4-({1-[(S)-2-(indan-5-yloxycarbonyl)-3-(2-methoxy-ethoxy)-propyl]-cyclopentanecarbonyl}-amino)-cyclohexanecarboxylic acid',\n",
       "  'Candoxatril',\n",
       "  'Candoxatril'],\n",
       " 'Paramethadione': ['Parametadiona',\n",
       "  'Parametadione',\n",
       "  'Paramethadione',\n",
       "  'Paramethadionum',\n",
       "  'Paramethadione'],\n",
       " 'Demeclocycline': ['[4S-(4Î±,4aÎ±,5aÎ±,6Î²,12aÎ±)]-7-chloro-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide',\n",
       "  '6-demethyl-7-chlorotetracycline',\n",
       "  '7-chloro-6-demethyltetracycline',\n",
       "  'Demeclociclina',\n",
       "  'Demeclocycline',\n",
       "  'Demeclocyclinum',\n",
       "  'Demethylchlortetracyclin',\n",
       "  'Demethylchlortetracycline',\n",
       "  'DMCT',\n",
       "  'DMCTC',\n",
       "  'Demeclocycline'],\n",
       " 'Imatinib': ['Imatinib',\n",
       "  'Imatinibum',\n",
       "  \"Î±-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide\",\n",
       "  'Imatinib'],\n",
       " 'Triamcinolone': ['11Î²,16Î±,17Î±,21-tetrahydroxy-9Î±-fluoro-1,4-pregnadiene-3,20-dione',\n",
       "  '9-fluoro-11Î²,16Î±,17,21-tetrahydroxypregna-1,4-diene-3,20-dione',\n",
       "  '9Î±-fluoro-11Î²,16Î±,17,21-tetrahydroxypregna-1,4-diene-3,20-dione',\n",
       "  '9Î±-fluoro-11Î²,16Î±,17Î±,21-tetrahydroxypregna-1,4-diene-3,20-dione',\n",
       "  '9Î±-fluoro-16Î±-hydroxyprednisolone',\n",
       "  'Fluoxyprednisolone',\n",
       "  'Tiamcinolonum',\n",
       "  'Triamcinolona',\n",
       "  'Triamcinolone',\n",
       "  'Triamcinolonum',\n",
       "  'Triamcinolone'],\n",
       " 'Oxandrolone': ['Ossandrolone',\n",
       "  'Oxandrolon',\n",
       "  'Oxandrolona',\n",
       "  'Oxandrolone',\n",
       "  'Oxandrolonum',\n",
       "  'Oxandrolone'],\n",
       " 'Nicardipine': ['Nicardipine', 'Nicardipino', 'Nicardipinum', 'Nicardipine'],\n",
       " 'Fluphenazine': ['1-(2-hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine',\n",
       "  '10-(3-(2-hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine',\n",
       "  \"10-(3'-(4''-(Î²-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine\",\n",
       "  '2-(4-(3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol',\n",
       "  '2-(trifluoromethyl)-10-(3-(1-(Î²-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine',\n",
       "  '4-(3-(-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol',\n",
       "  '4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol',\n",
       "  '4-(3-(2-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol',\n",
       "  'Flufenazina',\n",
       "  'Fluorfenazine',\n",
       "  'Fluorophenazine',\n",
       "  'Fluorphenazine',\n",
       "  'Fluphenazin',\n",
       "  'FluphÃ©nazine',\n",
       "  'Fluphenazine',\n",
       "  'Fluphenazinum',\n",
       "  'Triflumethazine',\n",
       "  'Fluphenazine'],\n",
       " 'Testosterone': ['17beta-hydroxy-4-androsten-3-one',\n",
       "  '4-androsten-17Î²-ol-3-one',\n",
       "  'Testosteron',\n",
       "  'Testosterona',\n",
       "  'Testosterone',\n",
       "  'TestostÃ©rone',\n",
       "  'Testosteronum',\n",
       "  'Virosterone',\n",
       "  'Testosterone'],\n",
       " 'Efavirenz': ['(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one',\n",
       "  '(S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one',\n",
       "  '6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one',\n",
       "  'Efavirenz',\n",
       "  'Ã\\x89favirenz',\n",
       "  'Efavirenzum',\n",
       "  'Efavirenz'],\n",
       " 'Bacitracin': ['Bacitracin', 'Bacitracin A', 'Bacitracina', 'Bacitracin'],\n",
       " 'Niacin': ['3-carboxypyridine',\n",
       "  '3-Pyridinecarboxylic acid',\n",
       "  '3-Pyridylcarboxylic acid',\n",
       "  'Acide nicotinique',\n",
       "  'Ã¡cido nicotÃ\\xadnico',\n",
       "  'Acidum Nicotinicum',\n",
       "  'anti-pellagra vitamin',\n",
       "  'm-pyridinecarboxylic acid',\n",
       "  'Niacin',\n",
       "  'Niacina',\n",
       "  'Nicotinic acid',\n",
       "  'NikotinsÃ¤ure',\n",
       "  'pyridine-Î²-carboxylic acid',\n",
       "  'Î²-pyridinecarboxylic acid',\n",
       "  'Niacin'],\n",
       " 'Clorazepic acid': ['7-chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid',\n",
       "  'Chlorazepate',\n",
       "  'Clorazepate',\n",
       "  'Clorazepic acid',\n",
       "  'Clorazepic acid'],\n",
       " 'Guanabenz': ['Guanabenz', 'Guanabenzo', 'Guanabenzum', 'Guanabenz'],\n",
       " 'Alendronic acid': ['(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)',\n",
       "  '(4-amino-1-hydroxybutylidene)bisphosphonic acid',\n",
       "  '4-amino-1-hydroxybutane-1,1-diphosphonic acid',\n",
       "  'ABDP',\n",
       "  'Acide Alendronique',\n",
       "  'Acido Alendronico',\n",
       "  'Acidum Alendronicum',\n",
       "  'Alendronate',\n",
       "  'Alendronic acid',\n",
       "  'Alendronic acid'],\n",
       " 'Clofarabine': ['(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol',\n",
       "  '2-chloro-9-(2-deoxy-2-fluoro-Î²-D-arabinofuranosyl)adenine',\n",
       "  \"2-chloro-9-(2'-deoxy-2'-fluoro-Î²-D-arabinofuranosyl)adenine\",\n",
       "  'CAFdA',\n",
       "  'Cl-F-Ara-A',\n",
       "  'Clofarabin',\n",
       "  'Clofarabina',\n",
       "  'Clofarabine',\n",
       "  'Clofarabinum',\n",
       "  'Clofarabine'],\n",
       " 'Docosanol': ['1-Docosanol',\n",
       "  'Behenic alcohol',\n",
       "  'Behenyl alcohol',\n",
       "  'Docosan-1-ol',\n",
       "  'Docosanol',\n",
       "  'Docosyl alcohol',\n",
       "  'N-Docosanol',\n",
       "  'Docosanol'],\n",
       " 'Dexmedetomidine': ['(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole',\n",
       "  '(+)-4-((S)-Î±,2,3-trimethylbenzyl)imidazole',\n",
       "  'Dexmedetomidin',\n",
       "  'Dexmedetomidina',\n",
       "  'DexmÃ©dÃ©tomidine',\n",
       "  'Dexmedetomidine',\n",
       "  'Dexmedetomidinum',\n",
       "  'Dexmedetomidine'],\n",
       " 'Sulfacetamide': ['Acetosulfamine',\n",
       "  'N-((p-Aminophenyl)sulfonyl)acetamide',\n",
       "  'N-(p-Aminobenzenesulfonyl)acetamide',\n",
       "  'N-[(p-Aminophenyl)sulfonyl]acetamide',\n",
       "  'N-Acetyl-4-aminobenzenesulfonamide',\n",
       "  'N-Acetylsulfanilamide',\n",
       "  'N-Sulfanilylacetamide',\n",
       "  'N-Sulphanilylacetamide',\n",
       "  \"N'-acetylsulfanilamide\",\n",
       "  'N(1)-Acetyl-4-aminophenylsulfonamide',\n",
       "  'N(1)-Acetylsulfanilamide',\n",
       "  'p-Aminobenzenesulfonacetamide',\n",
       "  'p-Aminobenzenesulfonoacetamide',\n",
       "  'Sulfacetamid',\n",
       "  'Sulfacetamida',\n",
       "  'SulfacÃ©tamide',\n",
       "  'Sulfacetamide',\n",
       "  'Sulfacetamidum',\n",
       "  'Sulfanilazetamid',\n",
       "  'Sulphacetamide',\n",
       "  'Sulphacetamidum',\n",
       "  'Sulfacetamide'],\n",
       " 'Prednisone': ['1,2-Dehydrocortisone',\n",
       "  '1,4-Pregnadiene-17Î±,21-diol-3,11,20-trione',\n",
       "  '17,21-Dihydroxypregna-1,4-diene-3,11,20-trione',\n",
       "  'Dehydrocortisone',\n",
       "  'Prednisona',\n",
       "  'Prednisone',\n",
       "  'Prednisonum',\n",
       "  'Prednisone'],\n",
       " 'Clofibrate': ['2-(4-Chlorophenoxy)-2-methylpropanoic acid ethyl ester',\n",
       "  '2-(p-Chlorophenoxy)-2-methylpropionic acid ethyl ester',\n",
       "  'alpha-(p-Chlorophenoxy)isobutyric acid, ethyl ester',\n",
       "  'alpha-p-Chlorophenoxyisobutyryl ethyl ester',\n",
       "  'Clofibrate',\n",
       "  'Clofibrato',\n",
       "  'Clofibratum',\n",
       "  'EPIB',\n",
       "  'Ethyl 2-(p-chlorophenoxy)isobutyrate',\n",
       "  'Ethyl chlorophenoxyisobutyrate',\n",
       "  'Ethyl clofibrate',\n",
       "  'Liprin',\n",
       "  'Clofibrate'],\n",
       " 'Astemizole': ['1-(p-Fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole',\n",
       "  '1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole',\n",
       "  'Astemizol',\n",
       "  'AstÃ©mizole',\n",
       "  'Astemizole',\n",
       "  'Astemizolum',\n",
       "  'Astemizole'],\n",
       " 'Inulin': ['Inulin'],\n",
       " 'Butoconazole': ['1-[4-(4-Chloro-phenyl)-2-(2,6-dichloro-phenylsulfanyl)-butyl]-1H-imidazole',\n",
       "  'Butoconazol',\n",
       "  'Butoconazole',\n",
       "  'Butoconazolum',\n",
       "  'Butoconazole'],\n",
       " 'Adenosine': ['(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol',\n",
       "  '6-Amino-9-beta-D-ribofuranosyl-9H-purine',\n",
       "  '9-beta-D-Ribofuranosidoadenine',\n",
       "  '9-beta-D-Ribofuranosyl-9H-purin-6-amine',\n",
       "  '9-Î²-D-ribofuranosyl-9H-purin-6-amine',\n",
       "  'Ade-Rib',\n",
       "  'Adenin riboside',\n",
       "  'Adenine Deoxyribonucleoside',\n",
       "  'Adenogesic',\n",
       "  'Adenosin',\n",
       "  'Adenosina',\n",
       "  'AdÃ©nosine',\n",
       "  'Adenosine',\n",
       "  'Adenosinum',\n",
       "  'Ado',\n",
       "  'beta-D-Adenosine',\n",
       "  'Adenosine'],\n",
       " 'Simvastatin': ['2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one',\n",
       "  'Simvastatin',\n",
       "  'Simvastatina',\n",
       "  'Simvastatine',\n",
       "  'Simvastatinum',\n",
       "  'Simvastatin'],\n",
       " 'Pemetrexed': ['Pemetrexed', 'Pemetrexed'],\n",
       " 'Mebendazole': ['(5-benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester',\n",
       "  'MBDZ',\n",
       "  'Mebendazol',\n",
       "  'MÃ©bendazole',\n",
       "  'Mebendazole',\n",
       "  'Mebendazolum',\n",
       "  'Mebendazole'],\n",
       " 'Gonadorelin': ['GnRH',\n",
       "  'Gonadorelin',\n",
       "  'Gonadorelina',\n",
       "  'GonadorÃ©line',\n",
       "  'Gonadorelinum',\n",
       "  'Gonadotropin-releasing hormone',\n",
       "  'Gonadorelin'],\n",
       " 'Dyclonine': ['1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone',\n",
       "  '2-(1-piperidyl)ethyl p-butoxyphenyl ketone',\n",
       "  \"3-piperidino-4'-butoxypropiophenone\",\n",
       "  '4-butoxy-Î²-piperidinopropiophenone',\n",
       "  '4-n-butoxy-Î²-(1-piperidyl)propiophenone',\n",
       "  \"4'-butoxy-3-piperidinopropiophenone\",\n",
       "  'Diclonina',\n",
       "  'Dyclocaine',\n",
       "  'Dyclonin',\n",
       "  'Dyclonine',\n",
       "  'Dycloninum',\n",
       "  'Dyclonine'],\n",
       " 'Nystatin': ['Nistatina',\n",
       "  'NYS',\n",
       "  'Nystatin',\n",
       "  'Nystatine',\n",
       "  'Nystatinum',\n",
       "  'Nystatin'],\n",
       " 'Dextropropoxyphene': ['d-Propoxyphene',\n",
       "  'Destropropossifene',\n",
       "  'Dextropropoxifeno',\n",
       "  'Dextropropoxyphen',\n",
       "  'DextropropoxyphÃ¨ne',\n",
       "  'Dextropropoxyphene',\n",
       "  'Dextropropoxyphenum',\n",
       "  'Dextroproxifeno',\n",
       "  'Propoxyphene',\n",
       "  'Dextropropoxyphene'],\n",
       " 'Mitotane': ['Mitotan', 'Mitotane', 'Mitotano', 'Mitotanum', 'Mitotane'],\n",
       " 'Stavudine': ['1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine',\n",
       "  \"2',3'-Didehydro-3'-deoxythimidine\",\n",
       "  \"3'-Deoxy-2'-thymidinene\",\n",
       "  'Estavudina',\n",
       "  'Sanilvudine',\n",
       "  'Stavudin',\n",
       "  'Stavudine',\n",
       "  'Stavudinum',\n",
       "  'STV',\n",
       "  'Stavudine'],\n",
       " 'Leucovorin': ['(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate',\n",
       "  '10-Formyl-7,8-dihydrofolic acid',\n",
       "  '5-Formyl-5,6,7,8-tetrahydrofolic acid',\n",
       "  '5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid',\n",
       "  '5-Formyltetrahydrofolate',\n",
       "  '5-formyltetrahydrofolic acid',\n",
       "  'Acide folinique',\n",
       "  'Acido folinico',\n",
       "  'Folinate',\n",
       "  'Folinic acid',\n",
       "  'L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid',\n",
       "  'Leucovorinum',\n",
       "  'N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid',\n",
       "  'N5-Formyl-5,6,7,8-tetrahydrofolic acid',\n",
       "  'N5-Formyltetrahydrofolic acid',\n",
       "  'Leucovorin'],\n",
       " 'Dyphylline': ['(Â±)-7-(2,3-dihydroxypropyl)theophylline',\n",
       "  '(Â±)-diprophylline',\n",
       "  '(Â±)-dyphylline',\n",
       "  '(1,2-dihydroxy-3-propyl)thiophyllin',\n",
       "  '1,3-dimethyl-7-(2,3-dihydroxypropyl)xanthine',\n",
       "  '7-(2,3-dihydroxypropyl)-1,3-dimethylxanthine',\n",
       "  '7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione',\n",
       "  '7-(2,3-dihydroxypropyl)theophylline',\n",
       "  '7-(Î²,Î³-dihydroxypropyl)theophylline',\n",
       "  'Dihydroxypropyl theopylin',\n",
       "  'Diprofilina',\n",
       "  'Diprophylline',\n",
       "  'Diprophyllinum',\n",
       "  'Dyphylline',\n",
       "  'Dyphylline'],\n",
       " 'Pentazocine': ['Pentazocin',\n",
       "  'Pentazocina',\n",
       "  'Pentazocine',\n",
       "  'Pentazocinum',\n",
       "  'Pentazocine'],\n",
       " 'Magnesium sulfate': ['Magnesium sulfate (1:1)',\n",
       "  'Magnesium sulfate anhydrous',\n",
       "  'Magnesium sulphate',\n",
       "  'magnesium(II) sulfate',\n",
       "  'Magnesiumsulfat',\n",
       "  'MgSO4',\n",
       "  'Magnesium sulfate'],\n",
       " 'Latanoprost': ['isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate',\n",
       "  'Latanoprost',\n",
       "  'Latanoprostum',\n",
       "  'propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate',\n",
       "  'Latanoprost'],\n",
       " 'Estrone': ['3-Hydroxy-1,3,5(10)-estratrien-17-one',\n",
       "  'Estrona',\n",
       "  'Estrone',\n",
       "  'Estronum',\n",
       "  'Follicular hormone',\n",
       "  'Folliculin',\n",
       "  'Oestrone',\n",
       "  'Estrone'],\n",
       " 'Trazodone': ['2-(3-[4-(3-chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one',\n",
       "  'Trazodona',\n",
       "  'Trazodone',\n",
       "  'Trazodonum',\n",
       "  'Trazodone'],\n",
       " 'Mecamylamine': ['Mecamylamine', 'Mecamylamine'],\n",
       " 'Sevelamer': ['Sevelamer',\n",
       "  'SÃ©vÃ©lamer',\n",
       "  'Sevelamero',\n",
       "  'Sevelamerum',\n",
       "  'Sevelamer'],\n",
       " 'Acamprosate': ['3-Acetamido-1-propanesulfonic acid',\n",
       "  'Acamprosate',\n",
       "  'Acamprosato',\n",
       "  'Acamprosatum',\n",
       "  'N-acetyl homotaurine',\n",
       "  'N-Acetylhomotaurine',\n",
       "  'Acamprosate'],\n",
       " 'Metaxalone': ['Metassalone',\n",
       "  'Metaxalon',\n",
       "  'Metaxalona',\n",
       "  'Metaxalone',\n",
       "  'Metaxalonum',\n",
       "  'Metaxalone'],\n",
       " 'Verapamil': ['Iproveratril',\n",
       "  'VÃ©rapamil',\n",
       "  'Verapamil',\n",
       "  'Verapamilo',\n",
       "  'Verapamilum',\n",
       "  'Verapamil'],\n",
       " 'Trimethobenzamide': ['N-[[4-(2-dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide',\n",
       "  'Trimethobenzamide',\n",
       "  'Trimethobenzamidum',\n",
       "  'Trimetobenzamida',\n",
       "  'Trimethobenzamide'],\n",
       " 'Flumethasone': ['6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione',\n",
       "  'Flumetasona',\n",
       "  'FlumÃ©tasone',\n",
       "  'Flumetasone',\n",
       "  'Flumetasonum',\n",
       "  'Flumethasone',\n",
       "  'Flumethasone'],\n",
       " 'Sulfametopyrazine': ['Solfametopirazina',\n",
       "  'Sulfalene',\n",
       "  'Sulfaleno',\n",
       "  'Sulfalenum',\n",
       "  'Sulfamethopyrazine',\n",
       "  'Sulfametopyrazine'],\n",
       " 'Nilutamide': ['5,5-Dimethyl-3-(Î±,Î±,Î±-trifluoro-4-nitro-m-tolyl)hydantoin',\n",
       "  'Nilutamida',\n",
       "  'Nilutamide',\n",
       "  'Nilutamidum',\n",
       "  'Nilutamide'],\n",
       " 'Nafarelin': ['Nafarelin',\n",
       "  'Nafarelina',\n",
       "  'NafarÃ©line',\n",
       "  'Nafarelinum',\n",
       "  'Nafarelin'],\n",
       " 'Epinephrine': ['(â\\x88\\x92)-(R)-epinephrine',\n",
       "  '(â\\x88\\x92)-3,4-dihydroxy-Î±-((methylamino)methyl)benzyl alcohol',\n",
       "  '(â\\x88\\x92)-adrenaline',\n",
       "  '(R)-(-)-Adnephrine',\n",
       "  '(R)-(-)-Adrenaline',\n",
       "  '(R)-(-)-Epinephrine',\n",
       "  '(R)-(-)-Epirenamine',\n",
       "  '(R)-(â\\x88\\x92)-adrenaline',\n",
       "  '4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol',\n",
       "  'AdrÃ©naline',\n",
       "  'Adrenaline',\n",
       "  'Epinefrin',\n",
       "  'Epinefrina',\n",
       "  'Epinephrin',\n",
       "  'Epinephrine',\n",
       "  'Epinephrinum',\n",
       "  'L-Adrenaline',\n",
       "  'Levoepinephrine',\n",
       "  'Epinephrine'],\n",
       " 'Sumatriptan': ['(3-[2-(dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide',\n",
       "  '1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide',\n",
       "  '3-(2-(dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide',\n",
       "  '3-[2-(dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide',\n",
       "  'Sumatriptan',\n",
       "  'SumatriptÃ¡n',\n",
       "  'Sumatriptanum',\n",
       "  'Sumatriptan'],\n",
       " 'Pirenzepine': ['11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one',\n",
       "  'Pirenzepin',\n",
       "  'Pirenzepina',\n",
       "  'PirenzÃ©pine',\n",
       "  'Pirenzepine',\n",
       "  'Pirenzepinum',\n",
       "  'Pirenzepine'],\n",
       " 'Cefixime': ['(â\\x88\\x92)-cefixim',\n",
       "  'Cefixim',\n",
       "  'Cefixima',\n",
       "  'CÃ©fixime',\n",
       "  'Cefixime',\n",
       "  'Cefixime anhydrous',\n",
       "  'Cefiximum',\n",
       "  'Cefixime'],\n",
       " 'Chlorpropamide': ['1-(p-chlorobenzenesulfonyl)-3-propylurea',\n",
       "  '1-(p-chlorophenylsulfonyl)-3-propylurea',\n",
       "  '1-propyl-3-(p-chlorobenzenesulfonyl)urea',\n",
       "  '4-chloro-N-((propylamino)carbonyl)benzenesulfonamide',\n",
       "  '4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide',\n",
       "  'Chlorpropamid',\n",
       "  'Chlorpropamide',\n",
       "  'Chlorpropamidum',\n",
       "  'Clorpropamida',\n",
       "  \"N-(4-chlorophenylsulfonyl)-N'-propylurea\",\n",
       "  \"N-(p-chlorobenzenesulfonyl)-N'-propylurea\",\n",
       "  \"n-propyl-N'-(p-chlorobenzenesulfonyl)urea\",\n",
       "  \"n-propyl-N'-p-chlorophenylsulfonylcarbamide\",\n",
       "  'Chlorpropamide'],\n",
       " 'Aprepitant': ['Aprepitant', 'AprÃ©pitant', 'Aprepitantum', 'Aprepitant'],\n",
       " 'Galantamine': ['(-)-Galanthamine',\n",
       "  'Galantamina',\n",
       "  'Galantamine',\n",
       "  'Galanthamine',\n",
       "  'Galantamine'],\n",
       " 'Tamoxifen': ['(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine',\n",
       "  '(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine',\n",
       "  '1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene',\n",
       "  '1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene',\n",
       "  'Tamoxifen',\n",
       "  'TamoxifÃ¨ne',\n",
       "  'Tamoxifene',\n",
       "  'Tamoxifeno',\n",
       "  'Tamoxifenum',\n",
       "  'trans-Tamoxifen',\n",
       "  'Tamoxifen'],\n",
       " 'Benzyl benzoate': ['Acarobenzyl',\n",
       "  'Benylate',\n",
       "  'Benzevan',\n",
       "  'Benzoate de benzyle',\n",
       "  'BenzoesÃ¤urebenzylester',\n",
       "  'Benzoic acid phenylmethylester',\n",
       "  'Benzoic acid, benzyl ester',\n",
       "  'Benzoic acid, phenylmethyl ester',\n",
       "  'Benzyl benzoat',\n",
       "  'Benzylis benzoas',\n",
       "  'Phenylmethyl benzoate',\n",
       "  'Benzyl benzoate'],\n",
       " 'Isoflurophate': ['DFP',\n",
       "  'Diisopropoxyphosphoryl fluoride',\n",
       "  'Diisopropyl fluorophosphate',\n",
       "  'Diisopropyl fluorophosphonate',\n",
       "  'Diisopropyl phosphofluoridate',\n",
       "  'Diisopropyl phosphorofluoridate',\n",
       "  'Diisopropylfluorophosphate',\n",
       "  'Diisopropylfluorophosphoric acid ester',\n",
       "  'Diisopropylphosphofluoridate',\n",
       "  'Diisopropylphosphorofluoridate',\n",
       "  'Fluorodiisopropyl phosphate',\n",
       "  'Fluorostigmine',\n",
       "  'Isofluorphate',\n",
       "  'Isoflurophate',\n",
       "  'Isoflurophosphate',\n",
       "  'Isopropyl fluophosphate',\n",
       "  'Isopropyl phosphorofluoridate',\n",
       "  \"O,O'-diisopropyl phosphoryl fluoride\",\n",
       "  'Isoflurophate'],\n",
       " 'Losartan': [\"(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol\",\n",
       "  \"2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole\",\n",
       "  'Losartan',\n",
       "  'Losartan'],\n",
       " 'Thioridazine': ['10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine',\n",
       "  '2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine',\n",
       "  \"3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine\",\n",
       "  'Thioridazin',\n",
       "  'Thioridazine',\n",
       "  'Thioridazinum',\n",
       "  'Tioridazina',\n",
       "  'Thioridazine'],\n",
       " 'Moricizine': ['[10-(3-Morpholin-4-yl-propionyl)-10H-phenothiazin-2-yl]-carbamic acid ethyl ester',\n",
       "  'Ethmozin',\n",
       "  'ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate',\n",
       "  'ethyl 10-(Î²-N-morpholinylpropionyl)phenothiazine-2-carbamate',\n",
       "  'Etmozin',\n",
       "  'Moracizin',\n",
       "  'Moracizina',\n",
       "  'Moracizine',\n",
       "  'Moracizinum',\n",
       "  'Moricizine',\n",
       "  'Moricizine'],\n",
       " 'Amphotericin B': ['Amfotericina B',\n",
       "  'AMPH-b',\n",
       "  'Amphotericin B',\n",
       "  'AmphotÃ©ricine B',\n",
       "  'Amphotericinum B',\n",
       "  'Liposomal amphotericin B',\n",
       "  'Amphotericin B'],\n",
       " 'Warfarin': ['4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin',\n",
       "  'Coumafene',\n",
       "  'Warfarin',\n",
       "  'Warfarina',\n",
       "  'Zoocoumarin',\n",
       "  'Warfarin'],\n",
       " 'Midazolam': ['Midazolam', 'Midazolamum', 'Midazolam'],\n",
       " 'Tobramycin': [\"3'-Deoxykanamycin B\",\n",
       "  'Nebramycin 6',\n",
       "  'O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine',\n",
       "  'Tobramicina',\n",
       "  'Tobramycin',\n",
       "  'Tobramycine',\n",
       "  'Tobramycinum',\n",
       "  'Tobramycin'],\n",
       " 'Trovafloxacin': ['Trovafloxacin', 'trovafloxacino', 'Trovafloxacin'],\n",
       " 'Pentosan polysulfate': ['Pentosan polysulfate',\n",
       "  'Pentosan sulfuric polyester',\n",
       "  'Pentosane polysulfate',\n",
       "  'Pentosani polysulfas',\n",
       "  'Pentosano polisulfato',\n",
       "  'Pentosanpolysulfat',\n",
       "  'Pentosan polysulfate'],\n",
       " 'Fludrocortisone': ['9alpha-Fluorocortisol',\n",
       "  'Fludrocortison',\n",
       "  'Fludrocortisona',\n",
       "  'Fludrocortisone',\n",
       "  'Fludrocortisonum',\n",
       "  'Fluohydrocortisone',\n",
       "  'Fludrocortisone'],\n",
       " 'Mycophenolate mofetil': ['2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate',\n",
       "  'Mycophenolate mofetil',\n",
       "  'Mycophenolic acid morpholinoethyl ester',\n",
       "  'Mycophenolate mofetil'],\n",
       " 'Cephaloglycin': ['7-(2-D-alpha-Aminophenylacetamido)cephalosporanic acid',\n",
       "  '7-(D-2-Amino-2-phenylacetamido)-3-acetoxymethyl-delta(sup3)-cephem-4-carboxylic acid',\n",
       "  '7-(D-alpha-Aminophenyl-acetamido)cephalosporanic acid',\n",
       "  'Cefaloglicina',\n",
       "  'Cefaloglycin',\n",
       "  'Cefaloglycine',\n",
       "  'Cefaloglycinum',\n",
       "  'CEG',\n",
       "  'Cephaloglycin anhydrous',\n",
       "  'Cephaloglycine',\n",
       "  'Cephaoglycin acid',\n",
       "  'D-(-)-Cephaloglycin',\n",
       "  'D-Cephaloglycine',\n",
       "  'Cephaloglycin'],\n",
       " 'Flurazepam': ['Flurazepam', 'FlurazÃ©pam', 'Flurazepamum', 'Flurazepam'],\n",
       " 'Moexipril': ['Moexipril', 'Moexiprilum', 'Moexipril'],\n",
       " 'Phentolamine': ['2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline',\n",
       "  'Fentolamina',\n",
       "  'Phentolamin',\n",
       "  'Phentolamine',\n",
       "  'Phentolaminum',\n",
       "  'Phentolamine'],\n",
       " 'Fluorescein': ['3,6-fluorandiol',\n",
       "  \"3',6'-dihydroxyfluoran\",\n",
       "  '9-(o-carboxyphenyl)-6-hydroxy-3-isoxanthenone',\n",
       "  '9-(o-carboxyphenyl)-6-hydroxy-3H-xanthen-3-one',\n",
       "  'C.I. Solvent Yellow 94',\n",
       "  'D and C Yellow No. 7',\n",
       "  'D&C Yellow No. 7',\n",
       "  'Fluoresceina',\n",
       "  'FluoresceÃ\\xadna',\n",
       "  'Fluoresceine',\n",
       "  'Fluoreszein',\n",
       "  'Japan Yellow 201',\n",
       "  'Resorcinolphthalein',\n",
       "  'Solvent Yellow 94',\n",
       "  'Yellow fluorescein',\n",
       "  'Fluorescein'],\n",
       " 'Daunorubicin': ['(+)-Daunomycin',\n",
       "  '(8S-cis)-8-acetyl-10-((3-amino-2,3,6-trideoxy-Î±-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione',\n",
       "  'Acetyladriamycin',\n",
       "  'Daunomycin',\n",
       "  'Daunorubicin',\n",
       "  'Daunorubicina',\n",
       "  'Daunorubicine',\n",
       "  'Daunorubicinum',\n",
       "  'Leukaemomycin C',\n",
       "  'Rubidomycin',\n",
       "  'Daunorubicin'],\n",
       " 'Furosemide': ['2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid',\n",
       "  '4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid',\n",
       "  '4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid',\n",
       "  '4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid',\n",
       "  'Frusemide',\n",
       "  'Furosemid',\n",
       "  'Furosemida',\n",
       "  'Furosemide',\n",
       "  'Furosemidu',\n",
       "  'Furosemidum',\n",
       "  'Furosemide'],\n",
       " 'Ergotamine': [\"(5'Î±)-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione\",\n",
       "  \"12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione\",\n",
       "  \"12'-hydroxy-2'-methyl-5'Î±-(phenylmethyl)ergotaman-3',6',18-trione\",\n",
       "  'Ergotamin',\n",
       "  'Ergotamina',\n",
       "  'Ergotamine',\n",
       "  'Ergotaminum',\n",
       "  'Ergotamine'],\n",
       " 'Tizanidine': ['5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole',\n",
       "  'Tizanidin',\n",
       "  'Tizanidina',\n",
       "  'Tizanidine',\n",
       "  'Tizanidinum',\n",
       "  'Tizanidine'],\n",
       " 'Nitrofurantoin': ['1-((5-nitro-2-furanyl)methylene)amino-2,4-imidazolidenedione',\n",
       "  '1-((5-nitrofurfurylidene)amino)hydantoin',\n",
       "  '5-Nitrofurantoin',\n",
       "  'N-(5-Nitrofurfurylidene)-1-aminohydantoin',\n",
       "  'Nitrofurantoin',\n",
       "  'Nitrofurantoin anhydrous',\n",
       "  'Nitrofurantoin macrocrystal',\n",
       "  'Nitrofurantoin macrocrystalline',\n",
       "  'Nitrofurantoin, macrocrystalline',\n",
       "  'Nitrofurantoin, macrocrystals',\n",
       "  'nitrofurantoina',\n",
       "  'nitrofurantoine',\n",
       "  'nitrofurantoinum',\n",
       "  'Nitrofurantoinum anhydrous',\n",
       "  'Nitrofurantoin'],\n",
       " 'Nicergoline': ['(8Î²)-10-methoxy-1,6-dimethylergoline-8-methanol 5-bromo-3-pyridinecarboxylate (ester)',\n",
       "  '10-methoxy-1,6-dimethylergoline-8Î²-methanol 5-bromonicotinate',\n",
       "  'Nicergolin',\n",
       "  'Nicergolina',\n",
       "  'Nicergoline',\n",
       "  'Nicergolinum',\n",
       "  'Nicergoline'],\n",
       " 'Eplerenone': ['Eplerenona', 'Eplerenone', 'Epoxymexrenone', 'Eplerenone'],\n",
       " 'Amprenavir': ['(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate',\n",
       "  'Amprenavir',\n",
       "  'AmprÃ©navir',\n",
       "  'Amprenavirum',\n",
       "  'Amprenavir'],\n",
       " 'Icodextrin': ['Icodextrin',\n",
       "  'Icodextrina',\n",
       "  'Icodextrine',\n",
       "  'Icodextrinum',\n",
       "  'Icodextrin'],\n",
       " 'Methazolamide': ['Metazolamida',\n",
       "  'Methazolamid',\n",
       "  'Methazolamide',\n",
       "  'MÃ©thazolamide',\n",
       "  'Methazolamidum',\n",
       "  'Methenamide',\n",
       "  'Neptazaneat',\n",
       "  'Methazolamide'],\n",
       " 'Naltrexone': ['17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one',\n",
       "  '17-(Cyclopropylmethyl)-4,5Î±-epoxy-3,14-dihydroxymorphinan-6-one',\n",
       "  'N-Cyclopropylmethyl-14-hydroxydihydromorphinone',\n",
       "  'N-Cyclopropylmethylnoroxymorphone',\n",
       "  'Naltrexon',\n",
       "  'Naltrexona',\n",
       "  'Naltrexone',\n",
       "  'Naltrexonum',\n",
       "  'Naltrexone'],\n",
       " 'Delavirdine': ['(N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide)',\n",
       "  '1-(3-((1-methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine',\n",
       "  '2-(4-(5-methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine',\n",
       "  'Delavirdin',\n",
       "  'Delavirdina',\n",
       "  'Delavirdine',\n",
       "  'Delavirdinum',\n",
       "  'N-(2-(1-(3-(isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide',\n",
       "  'N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide',\n",
       "  'Delavirdine'],\n",
       " 'Tamsulosin': ['(â\\x88\\x92)-tamsulosin',\n",
       "  '(R)-(â\\x88\\x92)-tamsulosin',\n",
       "  '(R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide',\n",
       "  'Tamsulosin',\n",
       "  'Tamsulosina',\n",
       "  'Tamsulosine',\n",
       "  'Tamsulosinum',\n",
       "  'Tamsulosin'],\n",
       " 'Porfimer sodium': ['Porfimer natrium',\n",
       "  'Porfimer sodico',\n",
       "  'Porfimer sodium',\n",
       "  'PorfimÃ¨re sodique',\n",
       "  'Porfimerum natricum',\n",
       "  'Porfimer sodium'],\n",
       " 'Sufentanil': ['N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide',\n",
       "  'N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide',\n",
       "  'Sufentanil',\n",
       "  'Sufentanilo',\n",
       "  'Sufentanilum',\n",
       "  'Sufentanyl',\n",
       "  'Sufentanil'],\n",
       " 'Lamivudine': ['(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine',\n",
       "  \"(-)-2'-Deoxy-3'-thiacytidine\",\n",
       "  \"2',3'-Dideoxy-3'-thiacytidine\",\n",
       "  \"3'-Thia-2',3'-dideoxycytidine\",\n",
       "  '3TC',\n",
       "  \"beta-L-2',3'-Dideoxy-3'-thiacytidine\",\n",
       "  \"beta-L-3'-Thia-2',3'-dideoxycytidine\",\n",
       "  'Lamivudin',\n",
       "  'Lamivudina',\n",
       "  'Lamivudine',\n",
       "  'Lamivudinum',\n",
       "  'Lamivudine'],\n",
       " 'Ibandronate': ['Ã¡cido ibandrÃ³nico', 'Ibandronic acid', 'Ibandronate'],\n",
       " 'Diethylcarbamazine': ['Diethylcarbamazin',\n",
       "  'DiÃ©thylcarbamazine',\n",
       "  'Diethylcarbamazine',\n",
       "  'Diethylcarbamazinum',\n",
       "  'Dietilcarbamazina',\n",
       "  'Diethylcarbamazine'],\n",
       " 'Flurbiprofen': ['(Â±)-2-fluoro-Î±-methyl-4-biphenylacetic acid',\n",
       "  '2-(2-fluorobiphenyl-4-yl)propanoic acid',\n",
       "  \"2-fluoro-Î±-methyl-(1,1'-biphenyl)-4-acetic acid\",\n",
       "  '3-fluoro-4-phenylhydratropic acid',\n",
       "  'Flurbiprofen',\n",
       "  'Flurbiprofene',\n",
       "  'Flurbiprofeno',\n",
       "  'Flurbiprofenum',\n",
       "  'Flurbiprofen'],\n",
       " 'Oxacillin': ['(2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  '(5-methyl-3-phenyl-4-isoxazolyl)penicillin',\n",
       "  '5-methyl-3-phenyl-4-isoxazolyl-penicillin',\n",
       "  '6Î²-(5-methyl-3-phenylisoxazol-4-yl)penicillanic acid',\n",
       "  'Ossacillina',\n",
       "  'Oxacilina',\n",
       "  'Oxacillin',\n",
       "  'Oxacilline',\n",
       "  'Oxacillinum',\n",
       "  'Oxazocillin',\n",
       "  'Oxazocilline',\n",
       "  'Oxacillin'],\n",
       " 'Apomorphine': ['(â\\x88\\x92)-10,11-dihydroxyaporphine',\n",
       "  '(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol',\n",
       "  '(R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol',\n",
       "  'Apomorfina',\n",
       "  'Apomorphin',\n",
       "  'Apomorphine',\n",
       "  'R-(â\\x88\\x92)-apomorphine',\n",
       "  'Apomorphine'],\n",
       " 'Paroxetine': ['(â\\x88\\x92)-(3S,4R)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine',\n",
       "  '(3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine',\n",
       "  'Paroxetina',\n",
       "  'Paroxetine',\n",
       "  'Paroxetinum',\n",
       "  'Paroxetine'],\n",
       " 'Nedocromil': ['9-Ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)chinolin-2,8-dicarbonsÃ¤ure',\n",
       "  '9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid',\n",
       "  'NÃ©docromil',\n",
       "  'Nedocromil',\n",
       "  'Nedocromilo',\n",
       "  'Nedocromilum',\n",
       "  'Nedocromil'],\n",
       " 'Norethisterone': ['(17alpha)-17-ethynyl-17-hydroxyestra-4,8(14),9-trien-3-one',\n",
       "  '17-hydroxy-19-nor-17-Î±-pregn-4-en-20-yn-3-one',\n",
       "  '17-hydroxy-19-nor-17Î±-pregn-4-en-20-yn-3-one',\n",
       "  '17-Î±-ethynyl-17-hydroxy-4-estren-3-one',\n",
       "  '17-Î±-ethynyl-19-norandrost-4-en-17-Î²-ol-3-one',\n",
       "  '17-Î±-ethynyl-19-nortestosterone',\n",
       "  '17-Î±-ethynyl-4-estren-17-ol-3-one',\n",
       "  '17-Î²-hydroxy-19-norpregn-4-en-20-yn-3-one',\n",
       "  '17Î±-ethinyl-19-nortestosterone',\n",
       "  '17Î±-ethinylestra-4-en-17Î²-ol-3-one',\n",
       "  '17Î±-ethynyl-17-hydroxy-4-estren-3-one',\n",
       "  '17Î±-ethynyl-17Î²-hydroxy-19-norandrost-4-en-3-one',\n",
       "  '17Î±-ethynyl-19-nor-4-androsten-17Î²-ol-3-one',\n",
       "  '17Î±-ethynyl-19-norandrost-4-en-17Î²-ol-3-one',\n",
       "  '17Î±-ethynyl-19-nortestosterone',\n",
       "  '17Î±-ethynyl-4-estren-17-ol-3-one',\n",
       "  '17Î²-hydroxy-19-norpregn-4-en-20-yn-3-one',\n",
       "  '19-nor-17-Î±-ethynyl-17-Î²-hydroxy-4-androsten-3-one',\n",
       "  '19-nor-17-Î±-ethynylandrosten-17-Î²-ol-3-one',\n",
       "  '19-nor-17-Î±-ethynyltestosterone',\n",
       "  '19-Nor-17alpha-ethynyl-17beta-hydroxy-4-androsten-3-one',\n",
       "  '19-nor-17Î±-ethynyl-17Î²-hydroxy-4-androsten-3-one',\n",
       "  '19-nor-17Î±-ethynylandrosten-17Î²-ol-3-one',\n",
       "  '19-nor-17Î±-ethynyltestosterone',\n",
       "  '19-nor-ethindrone',\n",
       "  '19-norethisterone',\n",
       "  '4-estren-17Î±-ethynyl-17Î²-ol-3-one',\n",
       "  'Norethindrone',\n",
       "  'Norethisteron',\n",
       "  'NorÃ©thistÃ©rone',\n",
       "  'Norethisterone',\n",
       "  'Norethisteronum',\n",
       "  'Noretisterona',\n",
       "  'Norethisterone'],\n",
       " 'Adefovir dipivoxil': ['Adefovir di(pivaloyloxymethyl) ester',\n",
       "  'Adefovir dipivoxil',\n",
       "  'Adefovir pivoxil',\n",
       "  'bis-POM PMEA',\n",
       "  'Adefovir dipivoxil'],\n",
       " 'Azatadine': ['11-(1-Methyl-4-piperidinylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine',\n",
       "  '6,11-Dihydro-11-(1-methyl-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine',\n",
       "  'Azatadin',\n",
       "  'Azatadina',\n",
       "  'Azatadine',\n",
       "  'Azatadinum',\n",
       "  'Azatadine'],\n",
       " 'Clodronic acid': ['(Dichloro-phosphono-methyl)-phosphonic acid',\n",
       "  '(dichloromethylene)bisphosphonic acid',\n",
       "  '(dichloromethylene)diphosphonic acid',\n",
       "  'Acide clodronique',\n",
       "  'Acido clodronico',\n",
       "  'Acidum clodronicum',\n",
       "  'Clodronate',\n",
       "  'Clodronic acid',\n",
       "  'Clodronsaeure',\n",
       "  'ClodronsÃ¤ure',\n",
       "  'dichloromethylene-1,1-bisphosphonic acid',\n",
       "  'dichloromethylene-1,1-diphosphonic acid',\n",
       "  'Dichloromethylidene diphosphonate',\n",
       "  'Clodronic acid'],\n",
       " 'Procaine': ['2-Diethylaminoethyl p-aminobenzoate',\n",
       "  '4-aminobenzoic acid 2-diethylaminoethyl ester',\n",
       "  'Novocaine',\n",
       "  'p-Aminobenzoic acid 2-diethylaminoethyl ester',\n",
       "  'Procaina',\n",
       "  'Procaine',\n",
       "  'Procainum',\n",
       "  'Vitamin H3',\n",
       "  'Î²-(diethylamino)ethyl 4-aminobenzoate',\n",
       "  'Î²-(diethylamino)ethyl p-aminobenzoate',\n",
       "  'Procaine'],\n",
       " 'Lisinopril': ['(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline',\n",
       "  '[N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline',\n",
       "  'Lisinopril',\n",
       "  'Lisinopril anhydrous',\n",
       "  'Lisinoprilum',\n",
       "  'Lisinopril'],\n",
       " 'Methoxamine': ['MÃ©thoxamÃ©drine',\n",
       "  'Methoxamin',\n",
       "  'MÃ©thoxamine',\n",
       "  'Methoxaminum',\n",
       "  'Metossamina',\n",
       "  'Metoxamina',\n",
       "  'Pseudomethoxamine',\n",
       "  'Methoxamine'],\n",
       " 'Imiquimod': ['1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine',\n",
       "  '4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline',\n",
       "  'Imiquimod',\n",
       "  'Imiquimodum',\n",
       "  'Imiquimod'],\n",
       " 'Homatropine methylbromide': ['3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide mandelate',\n",
       "  '8-Methylhomatropinium bromide',\n",
       "  'Homatropine methylbromide',\n",
       "  'Homatropini methylbromidum',\n",
       "  \"MÃ©thylbromure d'homatropine\",\n",
       "  'Methylhomatropine',\n",
       "  'Methylhomatropine bromide',\n",
       "  'Methylhomatropinum bromatum',\n",
       "  'Metilbromuro de homatropina',\n",
       "  'Omatropina metilbromuro',\n",
       "  'Tropinium methobromide mandelate',\n",
       "  'Homatropine methylbromide'],\n",
       " 'Trimipramine': ['10,11-dihydro-N,N,Î²-trimethyl-5H-dibenz[b,f]azepine-5-propanamine',\n",
       "  '5-(Î³-dimethylamino-Î²-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine',\n",
       "  '5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine',\n",
       "  'beta-Methylimipramine',\n",
       "  'Trimeprimina',\n",
       "  'Trimeprimine',\n",
       "  'Trimeproprimine',\n",
       "  'Trimipramina',\n",
       "  'Trimipramine',\n",
       "  'Trimipraminum',\n",
       "  'Î²-methylimipramine',\n",
       "  'Trimipramine'],\n",
       " 'Nitroglycerin': ['1,2,3-propanetrioltrinitrate',\n",
       "  '1,2,3-propanetriyl nitrate',\n",
       "  'Glycerin trinitrate',\n",
       "  'Glycerol trinitrate',\n",
       "  'Glycerol, nitric acid triester',\n",
       "  'Glyceroli trinitratis',\n",
       "  'Glyceroltrinitrat',\n",
       "  'Glyceryl trinitrate',\n",
       "  'NG',\n",
       "  'Nitroglicerina',\n",
       "  'Nitroglycerin',\n",
       "  'Nitroglycerine',\n",
       "  'Nitroglycerol',\n",
       "  'Nitromed',\n",
       "  'Propane-1,2,3-triyl trinitrate',\n",
       "  'Trinitrine',\n",
       "  'Trinitroglycerin',\n",
       "  'Trinitroglycerol',\n",
       "  'Nitroglycerin'],\n",
       " 'Rocuronium': ['Rocuronio', 'Rocuronium', 'Rocuronium'],\n",
       " 'Thiabendazole': ['2-(1,3-thiazole-4-yl)-1H-benzimidazole',\n",
       "  '2-(4-thiazolyl)-1H-benzimidazole',\n",
       "  '2-(thiazol-4-yl)benzimidazole',\n",
       "  '4-(2-benzimidazolyl)thiazole',\n",
       "  'TBDZ',\n",
       "  'Thiabendazole',\n",
       "  'Tiabendazol',\n",
       "  'Tiabendazole',\n",
       "  'Tiabendazolum',\n",
       "  'Thiabendazole'],\n",
       " 'Nateglinide': ['Nateglinida',\n",
       "  'NatÃ©glinide',\n",
       "  'Nateglinide',\n",
       "  'Nateglinidum',\n",
       "  'Nateglinide'],\n",
       " 'Atracurium besylate': ['Atracurium besilate',\n",
       "  'Atracurium besylate',\n",
       "  'Atracurium dibesylate',\n",
       "  \"Besilate d'atracurium\",\n",
       "  'Besilato de atracurio',\n",
       "  'Atracurium besylate'],\n",
       " 'Pralidoxime': ['2-PAM',\n",
       "  'Pralidoxim',\n",
       "  'Pralidoxima',\n",
       "  'Pralidoxime',\n",
       "  'Pralidoximum',\n",
       "  'Pralidoxime'],\n",
       " 'Risperidone': ['Risperidona',\n",
       "  'Risperidone',\n",
       "  'RispÃ©ridone',\n",
       "  'Risperidonum',\n",
       "  'Risperidone'],\n",
       " 'Naftifine': ['Naftifin',\n",
       "  'Naftifina',\n",
       "  'Naftifine',\n",
       "  'Naftifinum',\n",
       "  'Naftifine'],\n",
       " 'Esomeprazole': ['(â\\x88\\x92)-omeprazole',\n",
       "  '(S)-(â\\x88\\x92)-omeprazole',\n",
       "  '(S)-omeprazole',\n",
       "  'Esomeprazol',\n",
       "  'Ã\\x89somÃ©prazole',\n",
       "  'Esomeprazole',\n",
       "  'Esomeprazolum',\n",
       "  'Omeprazole S-form',\n",
       "  'Perprazole',\n",
       "  'Esomeprazole'],\n",
       " 'Meclizine': ['Meclizine', 'Meclozina', 'Meclozine', 'Meclizine'],\n",
       " 'Pentamidine': ['1,5-bis(4-amidinophenoxy)pentane',\n",
       "  \"4,4'-(1,5-pentanediylbis(oxy))bis-benzenecarboximidamide\",\n",
       "  \"4,4'-(pentamethylenedioxy)dibenzamidine\",\n",
       "  \"4,4'-Diamidinodiphenoxypentane\",\n",
       "  \"p,p'-(pentamethylenedioxy)dibenzamidine\",\n",
       "  'Pentamidin',\n",
       "  'Pentamidina',\n",
       "  'Pentamidine',\n",
       "  'Pentamidinum',\n",
       "  'Pentamidine'],\n",
       " 'Hetacillin': ['(2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  '6Î²-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]penicillanic acid',\n",
       "  'Hetacilina',\n",
       "  'Hetacillin',\n",
       "  'HÃ©tacilline',\n",
       "  'Hetacillinum',\n",
       "  'Hetacillin'],\n",
       " 'Riluzole': ['Riluzol', 'Riluzole', 'Riluzolum', 'Riluzole'],\n",
       " 'Hydrocortisone': ['(11Î²)-11,17,21-trihydroxypregn-4-ene-3,20-dione',\n",
       "  '11beta-hydrocortisone',\n",
       "  '11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione',\n",
       "  '11Î²-hydrocortisone',\n",
       "  '17-Hydroxycorticosterone',\n",
       "  '4-pregnen-11Î²,17Î±,21-triol-3,20-dione',\n",
       "  'Cortisol',\n",
       "  'Hidrocortisona',\n",
       "  'Hydrocortisone',\n",
       "  'Hydrocortisonum',\n",
       "  \"Kendall's compound F\",\n",
       "  \"Reichstein's substance M\",\n",
       "  'Hydrocortisone'],\n",
       " 'Mannitol': ['(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexaol',\n",
       "  '(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol',\n",
       "  'D-(-)-Mannitol',\n",
       "  'D-Mannitol',\n",
       "  'Manitol',\n",
       "  'Manna Sugar',\n",
       "  'Mannit',\n",
       "  'Mannite',\n",
       "  'Mannitol',\n",
       "  'Mannitolum',\n",
       "  'Mannitol'],\n",
       " 'Gadobenic acid': ['Acide gadobenique',\n",
       "  'Acido gadobenico',\n",
       "  'Acidum gadobenicum',\n",
       "  'Gadobenate',\n",
       "  'Gadobenic acid',\n",
       "  'GadobensÃ¤ure',\n",
       "  'Gadobenic acid'],\n",
       " 'Zileuton': ['(Â±)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea',\n",
       "  'Leutrol',\n",
       "  'N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea',\n",
       "  'N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea',\n",
       "  'Zileuton',\n",
       "  'ZileutÃ³n',\n",
       "  'Zileutonum',\n",
       "  'Zileuton'],\n",
       " 'Modafinil': ['2-((diphenylmethyl)sulfinyl)acetamide',\n",
       "  'Modafinil',\n",
       "  'Modafinilo',\n",
       "  'Modafinilum',\n",
       "  'Modafinil'],\n",
       " 'Deferoxamine': ['Deferoxamin',\n",
       "  'Deferoxamina',\n",
       "  'DÃ©feroxamine',\n",
       "  'Deferoxamine',\n",
       "  'Deferoxaminum',\n",
       "  'Deferrioxamine',\n",
       "  'Deferrioxamine B',\n",
       "  'Desferrioxamine',\n",
       "  'DFO',\n",
       "  'DFOA',\n",
       "  'DFOM',\n",
       "  'Deferoxamine'],\n",
       " 'Scopolamine': ['(-)-hyoscine',\n",
       "  '(-)-scopolamine',\n",
       "  '(1S,3S,5R,6R,7S)-6,7-Epoxytropan-3-yl (2S)-3-hydroxy-2-phenylpropanoate',\n",
       "  '6-beta,7-beta-Epoxy-3-alpha-tropanyl S-(-)-tropate',\n",
       "  '6,7-Epoxytropine tropate',\n",
       "  'alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester',\n",
       "  'Hyoscine',\n",
       "  'scopine (-)-tropate',\n",
       "  'scopine (â\\x88\\x92)-tropate',\n",
       "  'Scopolamine hydrobromide',\n",
       "  'Scopolamine'],\n",
       " 'Carbinoxamine': ['(Â±)-carbinoxamine',\n",
       "  '{2-[(4-Chloro-phenyl)-pyridin-2-yl-methoxy]-ethyl}-dimethyl-amine',\n",
       "  '2-(p-chloro-Î±-(2-(dimethylamino)ethoxy)benzyl)pyridine',\n",
       "  'Carbinoxamin',\n",
       "  'Carbinoxamina',\n",
       "  'Carbinoxamine',\n",
       "  'Carbinoxamine base',\n",
       "  'Carbinoxaminum',\n",
       "  'Paracarbinoxamine',\n",
       "  'Carbinoxamine'],\n",
       " 'Etodolac': ['(Â±)-1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid',\n",
       "  '(1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid',\n",
       "  '1,3,4,9-tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid',\n",
       "  '1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid',\n",
       "  '1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid',\n",
       "  'Ã\\x89todolac',\n",
       "  'Etodolac',\n",
       "  'Etodolaco',\n",
       "  'Etodolacum',\n",
       "  'Etodolic acid',\n",
       "  'EtodolsÃ¤ure',\n",
       "  'Etodolac'],\n",
       " 'Prilocaine': ['2-(Propylamino)-o-propionotoluidide',\n",
       "  '2-Methyl-alpha-propylaminopropionanilide',\n",
       "  'alpha-n-Propylamino-2-methylpropionanilide',\n",
       "  'N-(2-Methylphenyl)-2-(propylamino)propanamide',\n",
       "  'o-Methyl-2-propylaminopropionanilide',\n",
       "  'o-Methyl-alpha-propylaminopropionanilide',\n",
       "  'Prilocain',\n",
       "  'Prilocaina',\n",
       "  'PrilocaÃ¯ne',\n",
       "  'Prilocaine',\n",
       "  'Prilocaine base',\n",
       "  'Prilocainum',\n",
       "  'Propitocaine',\n",
       "  'Prilocaine'],\n",
       " 'Epinastine': ['(Â±)-epinastine',\n",
       "  '3-amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine',\n",
       "  'Epinastin',\n",
       "  'Epinastina',\n",
       "  'Epinastine',\n",
       "  'Ã©pinastine',\n",
       "  'Epinastinum',\n",
       "  'Epinastine'],\n",
       " 'Tranylcypromine': ['(Â±)-trans-2-phenylcyclopropylamine',\n",
       "  '(1R*,2S*)-2-phenylcyclopropan-1-amine',\n",
       "  'dl-tranylcypromine',\n",
       "  'Racemic Tranylcypromine',\n",
       "  'Tranilcipromina',\n",
       "  'trans-2-phenylcyclopropylamine',\n",
       "  'trans-DL-2-Phenylcyclopropylamine',\n",
       "  'Transamine',\n",
       "  'Tranylcypromin',\n",
       "  'Tranylcypromine',\n",
       "  'Tranylcyprominum',\n",
       "  'Tranylcypromine'],\n",
       " 'Isoflurane': ['1-chloro-2,2,2-trifluoroethyl difluoromethyl ether',\n",
       "  'Isoflurane',\n",
       "  'Isoflurano',\n",
       "  'Isofluranum',\n",
       "  'Isoflurane'],\n",
       " 'Ethotoin': ['(Â±)-3-ethyl-5-phenylhydantoin',\n",
       "  '1-ethyl-2,5-dioxo-4-phenylimidazolidine',\n",
       "  '3-ethyl-5-phenyl-2,4-imidazolidinedione',\n",
       "  '3-Ethyl-5-phenyl-imidazolidine-2,4-dione',\n",
       "  '3-ethyl-5-phenylhydantoin',\n",
       "  '3-ethyl-5-phenylimidazolidin-2,4-dione',\n",
       "  'Ethotoin',\n",
       "  'EthotoÃ¯ne',\n",
       "  'Ethotoinum',\n",
       "  'Etotoina',\n",
       "  'Ethotoin'],\n",
       " 'Tretinoin': ['(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid',\n",
       "  '3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ECL)',\n",
       "  'Acide retinoique',\n",
       "  'all trans Retinoic acid',\n",
       "  'all trans-Retinoic acid',\n",
       "  'all-(E)-Retinoic acid',\n",
       "  'all-trans-beta-Retinoic acid',\n",
       "  'all-trans-Retinoic acid',\n",
       "  'all-trans-Tretinoin',\n",
       "  'all-trans-Vitamin A acid',\n",
       "  'all-trans-Vitamin A1 acid',\n",
       "  'ATRA',\n",
       "  'beta-Retinoic acid',\n",
       "  'Retinoic acid',\n",
       "  'Retionic acid',\n",
       "  'trans-Retinoic acid',\n",
       "  'Tretin M',\n",
       "  'Tretinoin',\n",
       "  'Tretinoina',\n",
       "  'TrÃ©tinoÃ¯ne',\n",
       "  'Tretinoinum',\n",
       "  'Vitamin A acid',\n",
       "  'Tretinoin'],\n",
       " 'Hexachlorophene': [\"2,2'-dihydroxy-3,3',5,5',6,6'-hexachlorodiphenylmethane\",\n",
       "  \"2,2'-dihydroxy-3,5,6,3',5',6'-hexachlorodiphenylmethane\",\n",
       "  \"2,2'-methanediylbis(3,4,6-trichlorophenol)\",\n",
       "  \"2,2'-methylenebis(3,4,6-trichlorophenol)\",\n",
       "  \"2,2',3,3',5,5'-hexachloro-6,6'-dihydroxydiphenylmethane\",\n",
       "  'bis(2-hydroxy-3,5,6-trichlorophenyl)methane',\n",
       "  'bis(3,5,6-trichloro-2-hydroxyphenyl)methane',\n",
       "  'hexachlorophÃ¨ne',\n",
       "  'Hexachlorophene',\n",
       "  'Hexachlorophenum',\n",
       "  'Hexaclorofeno',\n",
       "  'Hexachlorophene'],\n",
       " 'Dolasetron': ['Dolasetron', 'DolasÃ©tron', 'Dolasetronum', 'Dolasetron'],\n",
       " 'Clopidogrel': ['(+)-Clopidogrel',\n",
       "  'Clopidogrel',\n",
       "  'Clopidogrelum',\n",
       "  'Clopidogrel'],\n",
       " 'Tetracycline': ['(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide',\n",
       "  'Abramycin',\n",
       "  'Anhydrotetracycline',\n",
       "  'Deschlorobiomycin',\n",
       "  'Tetracyclin',\n",
       "  'TÃ©tracycline',\n",
       "  'Tetracycline',\n",
       "  'Tetracyclinum',\n",
       "  'Tetrazyklin',\n",
       "  'Tsiklomitsin',\n",
       "  'Tetracycline'],\n",
       " 'Meropenem': ['(4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid',\n",
       "  'Meropenem',\n",
       "  'Meropenem anhydrous',\n",
       "  'Meropenemum',\n",
       "  'Meropenem'],\n",
       " 'Potassium chloride': ['Chlorid draselny',\n",
       "  'Chloride of potash',\n",
       "  'Kaliumchlorid',\n",
       "  'KCl',\n",
       "  'Monopotassium chloride',\n",
       "  'Muriate of potash',\n",
       "  'Sylvite',\n",
       "  'Potassium chloride'],\n",
       " 'Irinotecan': ['(+)-Irinotecan',\n",
       "  'Irinotecan',\n",
       "  'Irinotecan lactone',\n",
       "  'Irinotecanum',\n",
       "  'Irinotecan'],\n",
       " 'Methimazole': ['1-Methylimidazole-2(3H)-thione',\n",
       "  'Methimazole',\n",
       "  'Thiamazol',\n",
       "  'Thiamazole',\n",
       "  'Thiamazolum',\n",
       "  'Tiamazol',\n",
       "  'Methimazole'],\n",
       " 'Mometasone': ['(+)-Mometasone',\n",
       "  'Mometason',\n",
       "  'Mometasona',\n",
       "  'MomÃ©tasone',\n",
       "  'Mometasone',\n",
       "  'Mometasonum',\n",
       "  'Mometasone'],\n",
       " 'Metyrosine': ['(-)-alpha-Methyl-L-tyrosine',\n",
       "  '(â\\x80\\x93)-Î±-methyl-L-tyrosine',\n",
       "  '(S)-alpha-Methyltyrosine',\n",
       "  'Methyltyrosine',\n",
       "  'Metirosin',\n",
       "  'Metirosina',\n",
       "  'MÃ©tirosine',\n",
       "  'Metirosine',\n",
       "  'Metirosinum',\n",
       "  'Metyrosine',\n",
       "  'Î±-methyl-L-p-tyrosine',\n",
       "  'Î±-methyl-p-tyrosine',\n",
       "  'Î±-methyl-para-tyrosine',\n",
       "  'Î±-MPT',\n",
       "  'Metyrosine'],\n",
       " 'Clavulanic acid': ['(Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid',\n",
       "  'Acide clavulanique',\n",
       "  'Ã¡cido clavulÃ¡nico',\n",
       "  'Acidum clavulanicum',\n",
       "  'Clavulanate',\n",
       "  'Clavulanic acid',\n",
       "  'ClavulansÃ¤ure',\n",
       "  'Clavulanic acid'],\n",
       " 'Benzquinamide': ['benzquinamida', 'BZQ', 'Benzquinamide'],\n",
       " 'Olopatadine': ['Olopatadin',\n",
       "  'Olopatadina',\n",
       "  'Olopatadine',\n",
       "  'Olopatadinum',\n",
       "  'Olopatadine'],\n",
       " 'Hydrocortamate': ['17-Hydroxycorticosterone, 21-(diethylamino)acetate',\n",
       "  'Hidrocortamato',\n",
       "  'Hydrocortamate',\n",
       "  'Hydrocortamatum',\n",
       "  'Hydrocortamate'],\n",
       " 'Alprostadil': ['(11Î±,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid',\n",
       "  '(13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate',\n",
       "  '11Î±,15Î±-dihydroxy-9-oxo-13-trans-prostenoic acid',\n",
       "  'Alprostadil',\n",
       "  'Alprostadilum',\n",
       "  'PGE-1',\n",
       "  'PGE1',\n",
       "  'Prostaglandin E1',\n",
       "  'Alprostadil'],\n",
       " 'Clidinium': ['3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[2.2.2]octane',\n",
       "  '3-hydroxy-1-methylquinuclidinium benzilate ester',\n",
       "  'Bromure de Clidinium',\n",
       "  'Bromuro de clidinio',\n",
       "  'Clidinii Bromidum',\n",
       "  'Clidinium bromid',\n",
       "  'N-methyl quinuclidinyl benzilate',\n",
       "  'Clidinium'],\n",
       " 'Malathion': ['[(dimethoxyphosphinothioyl)thio]butanedioic acid diethyl ester',\n",
       "  'Carbophos',\n",
       "  'diethyl (dimethoxyphosphinothioylthio)succinate',\n",
       "  'Karbofos',\n",
       "  'Maldison',\n",
       "  'Mercaptothion',\n",
       "  'O,O-dimethyl S-(1,2-bis(ethoxycarbonyl)ethyl)',\n",
       "  'O,O-dimethyl S-(1,2-dicarbethoxyethyl) dithiophosphate',\n",
       "  'O,O-dimethyl S-(1,2-dicarbethoxyethyl)phosphorodithioate',\n",
       "  'O,O-dimethyl S-1,2-di(ethoxycarbamyl)ethyl',\n",
       "  'O,O-dimethyldithiophosphate diethylmercaptosuccinate',\n",
       "  'Malathion'],\n",
       " 'Etoposide': ['(â\\x88\\x92)-etoposide',\n",
       "  '4-demethylepipodophyllotoxin Î²-D-ethylideneglucoside',\n",
       "  \"4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)\",\n",
       "  \"9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one\",\n",
       "  'Etoposide',\n",
       "  'Etoposido',\n",
       "  'Etoposidum',\n",
       "  'trans-Etoposide',\n",
       "  'Etoposide'],\n",
       " 'Hydroflumethiazide': ['Dihydroflumethazide',\n",
       "  'Hidroflumetiazid',\n",
       "  'Hidroflumetiazida',\n",
       "  'HydroflumÃ©thiazide',\n",
       "  'Hydroflumethiazide',\n",
       "  'Hydroflumethiazidum',\n",
       "  'Idroflumetiazide',\n",
       "  'Metforylthiadiazin',\n",
       "  'Hydroflumethiazide'],\n",
       " 'Tirofiban': ['(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid',\n",
       "  'N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine',\n",
       "  'Tirofiban',\n",
       "  'TirofibÃ¡n',\n",
       "  'Tirofibanum',\n",
       "  'Tirofiban'],\n",
       " 'Oxcarbazepine': ['10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide',\n",
       "  'OCBZ',\n",
       "  'Oxcarbamazepine',\n",
       "  'Oxcarbazepina',\n",
       "  'Oxcarbazepine',\n",
       "  'Oxcarbazepinum',\n",
       "  'Oxcarbazepine'],\n",
       " 'Propiomazine': ['10-(2-Dimethylaminopropyl)-2-propionylphenothiazine',\n",
       "  '2-Propionyl-10-(2-(dimethylamino)propyl)phenothiazine',\n",
       "  '3-Propionyl-10-dimethylaminoisopropylphenothiazine',\n",
       "  'Propiomazin',\n",
       "  'Propiomazina',\n",
       "  'Propiomazine',\n",
       "  'Propiomazinum',\n",
       "  'Propiomazine'],\n",
       " 'Roxithromycin': ['(9E)-erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime)',\n",
       "  'Roxithromycin',\n",
       "  'Roxithromycine',\n",
       "  'Roxithromycinum',\n",
       "  'Roxitromicina',\n",
       "  'Roxithromycin'],\n",
       " 'Nalidixic acid': ['1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure',\n",
       "  '1-ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid',\n",
       "  '1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid',\n",
       "  '1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid',\n",
       "  '1,4-dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid',\n",
       "  '3-carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one',\n",
       "  'Acide nalidixique',\n",
       "  'Acido nalidixico',\n",
       "  'Acidum nalidixicum',\n",
       "  'Nalidixic acid',\n",
       "  'NalidixinsÃ¤ure',\n",
       "  'Nalidixic acid'],\n",
       " 'Phenelzine': ['Fenelzina',\n",
       "  'Phenelzin',\n",
       "  'Phenelzine',\n",
       "  'PhÃ©nelzine',\n",
       "  'Phenelzinum',\n",
       "  'Phenelzine'],\n",
       " 'Propantheline': ['Propantheline', 'Propantheline'],\n",
       " 'Estradiol': ['(17Î²)-estra-1,3,5(10)-triene-3,17-diol',\n",
       "  '17beta oestradiol',\n",
       "  '17Î²-estra-1,3,5(10)-triene-3,17-diol',\n",
       "  '17Î²-estradiol',\n",
       "  '17Î²-oestradiol',\n",
       "  'beta-Estradiol',\n",
       "  'cis-Estradiol',\n",
       "  'Estradiol',\n",
       "  'Estradiol-17beta',\n",
       "  'Estradiolum',\n",
       "  'Estradiol'],\n",
       " 'Mefenamic acid': ['Acide mÃ©fÃ©namique',\n",
       "  'Ã¡cido mefenÃ¡mico',\n",
       "  'Acidum mefenamicum',\n",
       "  'Mefenamic acid',\n",
       "  'MefenaminsÃ¤ure',\n",
       "  'N-(2,3-xylyl)-2-aminobenzoic acid',\n",
       "  'N-2,3-xylylanthranilic acid',\n",
       "  'Mefenamic acid'],\n",
       " 'Cryptenamine': ['Cryptenamine'],\n",
       " 'Marimastat': ['Marimastat', 'Marimastat'],\n",
       " 'Acyclovir': ['Aciclovir',\n",
       "  'Aciclovirum',\n",
       "  'Acycloguanosine',\n",
       "  'Acyclovir',\n",
       "  'Acyclovir'],\n",
       " 'Naproxen': ['(+)-(S)-6-Methoxy-Î±-methyl-2-naphthaleneacetic acid',\n",
       "  '(+)-(S)-Naproxen',\n",
       "  '(+)-2-(6-Methoxy-2-naphthyl)propionic acid',\n",
       "  '(+)-2-(Methoxy-2-naphthyl)-propionic acid',\n",
       "  '(+)-2-(Methoxy-2-naphthyl)-propionsÃ¤ure',\n",
       "  '(+)-Naproxen',\n",
       "  '(S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid',\n",
       "  '(S)-(+)-Naproxen',\n",
       "  '(S)-2-(6-Methoxy-2-naphthyl)propanoic acid',\n",
       "  '(S)-2-(6-Methoxy-2-naphthyl)propionic acid',\n",
       "  '(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid',\n",
       "  '(S)-Naproxen',\n",
       "  'Naprolag',\n",
       "  'Naproxen',\n",
       "  'NaproxÃ¨ne',\n",
       "  'Naproxeno',\n",
       "  'Naproxenum',\n",
       "  'Naproxen'],\n",
       " 'Gadopentetic acid': ['Acide gadopentetique',\n",
       "  'Ã¡cido gadopentÃ©tico',\n",
       "  'Acidum gadopenteticum',\n",
       "  'Gadolinium diethylenetriamine pentaacetic acid',\n",
       "  'Gadolinium DTPA',\n",
       "  'Gadopentetate',\n",
       "  'Gadopentetic acid',\n",
       "  'Gadopentetic acid'],\n",
       " 'Perindopril': ['(2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid',\n",
       "  'Perindopril',\n",
       "  'Perindoprilum',\n",
       "  'Perindopril'],\n",
       " 'Uracil mustard': ['5-(di-2-chloroethyl)aminouracil',\n",
       "  '5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione',\n",
       "  '5-[bis(2-chloroethyl)amino]uracil',\n",
       "  '5-[di(Î²-chloroethyl)amino]uracil',\n",
       "  '5-aminouracil mustard',\n",
       "  '5-N,N-bis(2-chloroethyl)aminouracil',\n",
       "  'Aminouracil mustard',\n",
       "  'Uracil mustard',\n",
       "  'Uracil nitrogen mustard',\n",
       "  'Uramustina',\n",
       "  'Uramustine',\n",
       "  'Uramustinum',\n",
       "  'Uracil mustard'],\n",
       " 'Tripelennamine': ['Tripelennamin',\n",
       "  'Tripelennamina',\n",
       "  'Tripelennamine',\n",
       "  'TripÃ©lennamine',\n",
       "  'Tripelennaminum',\n",
       "  'Tripelennamine'],\n",
       " 'Haloprogin': ['Haloprogin',\n",
       "  'Haloprogina',\n",
       "  'Haloprogine',\n",
       "  'Haloproginum',\n",
       "  'Haloprogin'],\n",
       " 'Primidone': ['2-deoxyphenobarbital',\n",
       "  '5-Phenyl-5-ethyl-Hexahydropyrimidine-4,6-dione',\n",
       "  'Primidon',\n",
       "  'Primidona',\n",
       "  'Primidone',\n",
       "  'Primidonum',\n",
       "  'Primidone'],\n",
       " 'Sulfasalazine': ['2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid',\n",
       "  '2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid',\n",
       "  \"4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene\",\n",
       "  '5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid',\n",
       "  '5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid',\n",
       "  '5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid',\n",
       "  'Azopyrin',\n",
       "  'Salazosulfapiridina',\n",
       "  'Salazosulfapyridine',\n",
       "  'Salazosulfapyridinum',\n",
       "  'Salicylazosulfapyridine',\n",
       "  'Sulfasalazin',\n",
       "  'Sulfasalazina',\n",
       "  'Sulfasalazine',\n",
       "  'Sulfasalazinum',\n",
       "  'Sulfasalazine'],\n",
       " 'Candesartan cilexetil': ['Candesartan cilexetil', 'Candesartan cilexetil'],\n",
       " 'Tolazoline': ['2-Benzyl-2-imidazoline',\n",
       "  '2-Benzyl-4,5-imidazoline',\n",
       "  '2-Benzylimidazoline',\n",
       "  '4,5-Dihydro-2-(phenylmethyl)-1H-imidazole',\n",
       "  'Benzazoline',\n",
       "  'Tolazolin',\n",
       "  'Tolazolina',\n",
       "  'Tolazoline',\n",
       "  'Tolazolinum',\n",
       "  'Tolazoline'],\n",
       " 'Gentamicin': ['Gentamicin', 'Gentamicina', 'Gentamicin'],\n",
       " 'Tazarotene': ['Tazarotene',\n",
       "  'TazarotÃ¨ne',\n",
       "  'Tazaroteno',\n",
       "  'Tazarotenum',\n",
       "  'Tazarotene'],\n",
       " 'Fenoldopam': ['FÃ©noldopam', 'Fenoldopam', 'Fenoldopamum', 'Fenoldopam'],\n",
       " 'Halazepam': ['HalazÃ©pam', 'Halazepam', 'Halazepamum', 'Halazepam'],\n",
       " 'Alfentanil': ['Alfentanil',\n",
       "  'Alfentanilo',\n",
       "  'Alfentanilum',\n",
       "  'Alfentanyl',\n",
       "  'N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide',\n",
       "  'Alfentanil'],\n",
       " 'Colistin': ['Colistin',\n",
       "  'Colistina',\n",
       "  'Colistine',\n",
       "  'Colistinum',\n",
       "  'Polymyxin E',\n",
       "  'Colistin'],\n",
       " 'Dicyclomine': ['2-(diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate',\n",
       "  'Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl ester',\n",
       "  'Dicicloverina',\n",
       "  'Dicyclomine',\n",
       "  'Dicycloverin',\n",
       "  'Dicycloverine',\n",
       "  'Dicycloverinum',\n",
       "  'Dicyclomine'],\n",
       " 'Minaprine': ['4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine',\n",
       "  '4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin',\n",
       "  'Minaprina',\n",
       "  'Minaprinum',\n",
       "  'N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine',\n",
       "  'Minaprine'],\n",
       " 'Pentoxifylline': ['Oxpentifylline',\n",
       "  'Pentoxifilina',\n",
       "  'Pentoxifyllin',\n",
       "  'Pentoxifylline',\n",
       "  'Pentoxifyllinum',\n",
       "  'Pentoxifylline'],\n",
       " 'Proparacaine': ['Proximetacaina',\n",
       "  'Proxymetacaine',\n",
       "  'Proxymetacainum',\n",
       "  'Proparacaine'],\n",
       " 'Indapamide': ['Indapamid',\n",
       "  'Indapamida',\n",
       "  'Indapamide',\n",
       "  'Indapamidum',\n",
       "  'Metindamide',\n",
       "  'Indapamide'],\n",
       " 'Tropicamide': ['Tropicamid',\n",
       "  'Tropicamida',\n",
       "  'Tropicamide',\n",
       "  'Tropicamidum',\n",
       "  'Tropicamide'],\n",
       " 'Biperiden': ['1-Bicyclo[2.2.1]hept-5-en-2-yl-1-phenyl-3-piperidin-1-yl-propan-1-ol',\n",
       "  'alpha-5-norbornen-2-yl-alpha-phenyl-1-piperidinepropanol',\n",
       "  'alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol',\n",
       "  'Biperiden',\n",
       "  'Biperidene',\n",
       "  'Biperideno',\n",
       "  'Biperidenum',\n",
       "  'Biperiden'],\n",
       " 'Ribavirin': ['1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide',\n",
       "  '1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide',\n",
       "  'RBV',\n",
       "  'Ribavirin',\n",
       "  'Ribavirina',\n",
       "  'Ribavirine',\n",
       "  'Ribavirinum',\n",
       "  'Tribavirin',\n",
       "  'Ribavirin'],\n",
       " 'Phenylbutazone': ['3,5-Dioxo-1,2-diphenyl-4-n-butylpyrazolidine',\n",
       "  '4-butyl-1,2-diphenyl-pyrazolidine-3,5-dione',\n",
       "  '4-n-Butyl-1,2-diphenyl-3,5-pyrazolidinedione',\n",
       "  'Fenilbutazona',\n",
       "  'Phenbutazone',\n",
       "  'Phenylbutazon',\n",
       "  'PhÃ©nylbutazone',\n",
       "  'Phenylbutazone',\n",
       "  'Phenylbutazonum',\n",
       "  'Phenylbutazone'],\n",
       " 'Fentanyl': ['1-Phenethyl-4-(N-phenylpropionamido)piperidine',\n",
       "  '1-phenethyl-4-N-propionylanilinopiperidine',\n",
       "  'Fentanil',\n",
       "  'Fentanila',\n",
       "  'Fentanilo',\n",
       "  'Fentanyl',\n",
       "  'Fentanyl CII',\n",
       "  'Fentanylum',\n",
       "  'N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide',\n",
       "  'N-(1-phenethyl-4-piperidyl)propionanilide',\n",
       "  'N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide',\n",
       "  'N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide',\n",
       "  'N-phenethyl-4-(N-propionylanilino)piperidine',\n",
       "  'N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide',\n",
       "  'Phentanyl',\n",
       "  'Fentanyl'],\n",
       " 'Meloxicam': ['MÃ©loxicam', 'Meloxicam', 'Meloxicamum', 'Meloxicam'],\n",
       " 'Sodium lauryl sulfate': ['Laurylsiran sodny',\n",
       "  'NaDS',\n",
       "  'Natrium laurylsulfuricum',\n",
       "  'SDS',\n",
       "  'SLS',\n",
       "  'Sodium dodecyl sulfate',\n",
       "  'Sodium dodecyl sulphate',\n",
       "  'Sodium dodecylsulfate',\n",
       "  'Sodium laurilsulfate',\n",
       "  'Sodium lauryl sulfate',\n",
       "  'Sodium lauryl sulphate',\n",
       "  'Sodium lauryl sulfate'],\n",
       " 'Orciprenaline': ['Metaproterenol',\n",
       "  'Orciprenalina',\n",
       "  'Orciprenaline',\n",
       "  'Orciprenalinum',\n",
       "  'Orciprenaline'],\n",
       " 'Rosoxacin': ['1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid',\n",
       "  'Acrosoxacin',\n",
       "  'Rosoxacin',\n",
       "  'Rosoxacina',\n",
       "  'Rosoxacine',\n",
       "  'Rosoxacino',\n",
       "  'Rosoxacinum',\n",
       "  'Rosoxacin'],\n",
       " 'Propofol': ['2,6-bis(1-methylethyl)phenol',\n",
       "  '2,6-Diisopropylphenol',\n",
       "  'Propofol',\n",
       "  'Propofolum',\n",
       "  'Propofol'],\n",
       " 'Acetazolamide': ['2-acetylamino-1,3,4-thiadiazole-5-sulfonamide',\n",
       "  '5-acetamido-1,3,4-thiadiazole-2-sulfonamide',\n",
       "  '5-acetylamino-1,3,4-thiadiazole-2-sulfonamide',\n",
       "  'Acetazolamid',\n",
       "  'Acetazolamida',\n",
       "  'AcÃ©tazolamide',\n",
       "  'Acetazolamide',\n",
       "  'Acetazolamidum',\n",
       "  'N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide',\n",
       "  'N-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide',\n",
       "  'Acetazolamide'],\n",
       " 'Tadalafil': [\"(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione\",\n",
       "  \"(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione\",\n",
       "  'Tadalafil',\n",
       "  'Tadalafilo',\n",
       "  'Tadalafil'],\n",
       " 'Carprofen': ['(+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid',\n",
       "  '(Â±)-6-chloro-Î±-methylcarbazole-2-acetic acid',\n",
       "  '2-(6-Chloro-9H-carbazol-2-yl)-propionic acid',\n",
       "  '6-chloro-Î±-methyl-9H-carbazole-2-acetic acid',\n",
       "  'Carprofen',\n",
       "  'CarprofÃ¨ne',\n",
       "  'Carprofeno',\n",
       "  'Carprofenum',\n",
       "  'Carprofen'],\n",
       " 'Disulfiram': [\"1,1'-dithiobis(N,N-diethylthioformamide)\",\n",
       "  'bis(diethylthiocarbamoyl) disulfide',\n",
       "  'Disulfiram',\n",
       "  \"N,N,N',N'-tetraethylthiuram disulfide\",\n",
       "  'Tetraethylthioperoxydicarbonic diamide',\n",
       "  'Tetraethylthiuram disulfide',\n",
       "  'Tetraethylthiuram disulphide',\n",
       "  'Disulfiram'],\n",
       " 'Ethynodiol diacetate': ['17Î±-Ethynyl-19-norandrost-4-ene-3Î²,17-beta-diol diacetate',\n",
       "  '17Î±-Ethynyl-3,17-dihydroxy-4-estrene diacetate',\n",
       "  '17Î±-Ethynyl-4-estrene-3Î²,17Î²-diol diacetate',\n",
       "  '17Î±-Ethynylestr-4-ene-3Î²,17Î²-diol acetate',\n",
       "  '19-Nor-17Î±-pregn-4-en-20-yne-3Î²,17-diol diacetate',\n",
       "  '3Î², 17Î²-Diacetoxy-17Î±-ethynyl-4-oestrene',\n",
       "  '3Î²,17Î²-Diacetoxy-19-nor-17Î±-pregn-4-en-20-yne',\n",
       "  'Ethynodiol diacetate',\n",
       "  'Etynodiol acetate',\n",
       "  'Etynodiol diacetate',\n",
       "  'Ethynodiol diacetate'],\n",
       " 'Enprofylline': ['3-n-propylxanthine',\n",
       "  '3-Propyl-3,7-dihydro-purine-2,6-dione',\n",
       "  '3-propylxanthine',\n",
       "  '3,7-dihydro-3-propyl-1H-purine-2,6-dione',\n",
       "  'Enprofilina',\n",
       "  'Enprofylline',\n",
       "  'Enprofyllinum',\n",
       "  'Enprofylline'],\n",
       " 'Levomenthol': ['(-)-Menthol',\n",
       "  '(â\\x88\\x92)-(1R,3R,4S)-menthol',\n",
       "  '(â\\x88\\x92)-menthol',\n",
       "  '(1alpha,2beta,5alpha)-5-methyl-2(1-methylethyl)cyclohexanol',\n",
       "  '(1R-(1-Î±,2-Î²,5-Î±))-5-methyl-2-(1-methylethyl)cyclohexanol',\n",
       "  '(1R,3R,4S)-(â\\x88\\x92)-menthol',\n",
       "  'L-menthol',\n",
       "  'Levomenthol',\n",
       "  'LÃ©vomenthol',\n",
       "  'Levomentholum',\n",
       "  'Levomentol',\n",
       "  'Mentol',\n",
       "  'Levomenthol'],\n",
       " 'Natamycin': ['Natamicina',\n",
       "  'Natamycin',\n",
       "  'Natamycine',\n",
       "  'Natamycinum',\n",
       "  'Pimaracin',\n",
       "  'Pimaricin',\n",
       "  'Natamycin'],\n",
       " 'Cinoxacin': ['1-ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid',\n",
       "  '5-Ethyl-8-oxo-5,8-dihydro-1,3-dioxa-5,6-diaza-cyclopenta[b]naphthalene-7-carboxylic acid',\n",
       "  'Cinoxacin',\n",
       "  'Cinoxacine',\n",
       "  'Cinoxacino',\n",
       "  'Cinoxacinum',\n",
       "  'Cinoxacin'],\n",
       " 'Fosfomycin': ['(-)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid',\n",
       "  '(1R,2S)-epoxypropylphosphonic acid',\n",
       "  '(2R-cis)-(3-Methyloxiranyl)phosphonic acid',\n",
       "  '1R-cis-(1,2-epoxypropyl)phosphonic acid',\n",
       "  'cis-(1R,2S)-epoxypropylphosphonic acid',\n",
       "  'FCM',\n",
       "  'Fosfocina',\n",
       "  'Fosfomicina',\n",
       "  'Fosfomycin',\n",
       "  'Fosfomycine',\n",
       "  'Fosfomycinum',\n",
       "  'L-cis-1,2-epoxypropylphosphonic acid',\n",
       "  'Phosphomycin',\n",
       "  'Phosphonemycin',\n",
       "  'Phosphonomycin',\n",
       "  'Fosfomycin'],\n",
       " 'Diazepam': ['7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one',\n",
       "  'Diazepam',\n",
       "  'Methyl diazepinone',\n",
       "  'Diazepam'],\n",
       " 'Phenmetrazine': ['2-phenyl-3-methylmorpholine',\n",
       "  'Fenmetrazin',\n",
       "  'Fenmetrazina',\n",
       "  'Phenmetrazin',\n",
       "  'Phenmetrazinum',\n",
       "  'Phenmetrazine'],\n",
       " 'Trifluoperazine': ['10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine',\n",
       "  'Trifluoperazina',\n",
       "  'TrifluopÃ©razine',\n",
       "  'Trifluoperazine',\n",
       "  'Trifluoperazinum',\n",
       "  \"trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine\",\n",
       "  'Trifluoroperazine',\n",
       "  'Trifluperazine',\n",
       "  'Trifluoperazine'],\n",
       " 'Phensuximide': ['Fensuccimide',\n",
       "  'Fensuximida',\n",
       "  'Phensuximide',\n",
       "  'Phensuximidum',\n",
       "  'Phensuximide'],\n",
       " 'Cefaclor': ['3-Chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxylic acid',\n",
       "  'CCL',\n",
       "  'CÃ©faclor',\n",
       "  'Cefaclor',\n",
       "  'Cefaclor anhydrous',\n",
       "  'Cefaclorum',\n",
       "  'CÃ©feaclor',\n",
       "  'Cephaclor',\n",
       "  'Cefaclor'],\n",
       " 'Mifepristone': ['Mifepriston',\n",
       "  'Mifepristona',\n",
       "  'MifÃ©pristone',\n",
       "  'Mifepristone',\n",
       "  'Mifepristonum',\n",
       "  'Mifepristone'],\n",
       " 'Brompheniramine': ['[3-(4-Bromo-phenyl)-3-pyridin-2-yl-propyl]-dimethyl-amine',\n",
       "  '1-(p-bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane',\n",
       "  '2-(p-bromo-Î±-(2-dimethylaminoethyl)benzyl)pyridine',\n",
       "  '3-(4-bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine',\n",
       "  '3-(p-bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine',\n",
       "  'BPN',\n",
       "  'Bromfeniramina',\n",
       "  'Brompheniramin',\n",
       "  'BromphÃ©niramine',\n",
       "  'Brompheniramine',\n",
       "  'Brompheniraminum',\n",
       "  'Brompheniramine'],\n",
       " 'Loperamide': ['Loperamid',\n",
       "  'Loperamida',\n",
       "  'LopÃ©ramide',\n",
       "  'Loperamide',\n",
       "  'Loperamidum',\n",
       "  'Loperamide'],\n",
       " 'Progabide': ['Halogabide',\n",
       "  'Progabida',\n",
       "  'Progabide',\n",
       "  'Progabidum',\n",
       "  'Progabide'],\n",
       " 'Clocortolone': ['9-chloro-6alpha-Fluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadien-3,20-dione',\n",
       "  '9-chloro-6alpha-Fluoro-16alpha-methyl-1,4-pregnadiene-11beta,21-diol-3,20-dione',\n",
       "  'Clocortolon',\n",
       "  'Clocortolona',\n",
       "  'Clocortolone',\n",
       "  'Clocortolonum',\n",
       "  'Clocortolone'],\n",
       " 'Tolazamide': ['1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea',\n",
       "  '1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea',\n",
       "  '4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide',\n",
       "  \"N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea\",\n",
       "  'Tolazamid',\n",
       "  'Tolazamida',\n",
       "  'Tolazamide',\n",
       "  'Tolazamidum',\n",
       "  'Tolazamide'],\n",
       " 'Hydroxypropyl cellulose': ['Cellulose hydroxypropyl ether',\n",
       "  'Cellulose, 2-hydroxypropyl ether',\n",
       "  'Hiprolosa',\n",
       "  'Hydroxypropyl cellulose',\n",
       "  'Hydroxypropyl cellulose (type H)',\n",
       "  'Hydroxypropylcellulose',\n",
       "  'Hyprolose',\n",
       "  'Hyprolosum',\n",
       "  'Modified cellulose',\n",
       "  'Hydroxypropyl cellulose'],\n",
       " 'Dobutamine': ['(Â±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol',\n",
       "  '3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-Î²-phenylethylamine',\n",
       "  '4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol',\n",
       "  'DL-dobutamine',\n",
       "  'Dobutamin',\n",
       "  'Dobutamina',\n",
       "  'Dobutamine',\n",
       "  'Dobutaminum',\n",
       "  'rac-dobutamine',\n",
       "  'racemic-dobutamine',\n",
       "  'Dobutamine'],\n",
       " 'Oxazepam': ['(+-)-Oxazepam', '(RS)-Oxazepam', 'Oxazepam', 'Oxazepam'],\n",
       " 'Donepezil': ['Domepezil',\n",
       "  'Donepezil',\n",
       "  'Donepezilo',\n",
       "  'Donepezilum',\n",
       "  'Donepezil'],\n",
       " 'Nalbuphine': ['N-cyclobutylmethyl-4,5Î±-epoxy-3,6Î±,14-morphinantriol',\n",
       "  'Nalbufina',\n",
       "  'Nalbuphin',\n",
       "  'Nalbuphine',\n",
       "  'Nalbuphinum',\n",
       "  'Nalbuphine'],\n",
       " 'Clofazimine': ['Clofazimin',\n",
       "  'Clofazimina',\n",
       "  'Clofazimine',\n",
       "  'Clofaziminum',\n",
       "  'Riminophenazine',\n",
       "  'Clofazimine'],\n",
       " 'Flurandrenolide': ['Fludroxicortida',\n",
       "  'Fludroxicortide',\n",
       "  'Fludroxycortid',\n",
       "  'Fludroxycortide',\n",
       "  'Fludroxycortidum',\n",
       "  'Flurandrenolide',\n",
       "  'Flurandrenolone',\n",
       "  'Flurandrenolide'],\n",
       " 'Cysteamine': ['2-amino-1-ethanethiol',\n",
       "  '2-amino-ethanethiol',\n",
       "  '2-aminoethanethiol',\n",
       "  'beta-aminoethanethiol',\n",
       "  'beta-Mercaptoethylamine',\n",
       "  'Cysteamine',\n",
       "  'MEA',\n",
       "  'Mercaptamina',\n",
       "  'Mercaptamine',\n",
       "  'Mercaptaminum',\n",
       "  'Thioethanolamine',\n",
       "  'Î²-aminoethylthiol',\n",
       "  'Î²-MEA',\n",
       "  'Cysteamine'],\n",
       " 'Levamisole': ['Levamisol', 'Levamisole', 'Levamisolum', 'Levamisole'],\n",
       " 'Methylphenobarbital': ['1-Methylphenobarbital',\n",
       "  '5-ethyl-1-methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione',\n",
       "  '5-Ethyl-1-methyl-5-phenyl-pyrimidine-2,4,6-trione',\n",
       "  '5-ethyl-1-methyl-5-phenylbarbituric acid',\n",
       "  'Enphenemal',\n",
       "  'Mephobarbital',\n",
       "  'Mephobarbitone',\n",
       "  'MÃ©thylphÃ©nobarbital',\n",
       "  'Methylphenobarbital',\n",
       "  'Methylphenobarbitalum',\n",
       "  'Methylphenobarbitone',\n",
       "  'Metilfenobarbital',\n",
       "  'Metilfenobarbitale',\n",
       "  'N-Methylphenobarbital',\n",
       "  'Methylphenobarbital'],\n",
       " 'Perphenazine': ['2-(4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol',\n",
       "  '2-chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine',\n",
       "  '4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol',\n",
       "  '4-[3-(2-chlorophenothiazin-10-yl)propyl]-1-piperazineethanol',\n",
       "  'Chlorpiprazine',\n",
       "  'Etaperazin',\n",
       "  'Etaperazine',\n",
       "  'Ethaperazine',\n",
       "  'Perfenazina',\n",
       "  'Perfenazine',\n",
       "  'Perphenazin',\n",
       "  'PerphÃ©nazine',\n",
       "  'Perphenazine',\n",
       "  'Perphenazinum',\n",
       "  'Î³-(4-(Î²-hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine',\n",
       "  'Perphenazine'],\n",
       " 'Dacarbazine': ['4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide',\n",
       "  '4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide',\n",
       "  '4-(dimethyltriazeno)imidazole-5-carboxamide',\n",
       "  '5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide',\n",
       "  '5-(3,3-dimethyltriazeno)imidazole-4-carboxamide',\n",
       "  '5-(dimethyltriazeno)imidazole-4-carboxamide',\n",
       "  'Biocarbazine',\n",
       "  'Dacarbazin',\n",
       "  'Dacarbazina',\n",
       "  'Dacarbazine',\n",
       "  'Dacarbazinum',\n",
       "  'DIC',\n",
       "  'DTIC',\n",
       "  'ICDMT',\n",
       "  'Dacarbazine'],\n",
       " 'Pseudoephedrine': ['(+) threo-2-(methylamino)-1-phenyl-1-propanol',\n",
       "  '(+)-(1S,2S)-Pseudoephedrine',\n",
       "  '(+)-Pseudoephedrine',\n",
       "  '(+)-psi-Ephedrine',\n",
       "  '(+)-threo-Ephedrine',\n",
       "  'd-Isoephedrine',\n",
       "  'd-Pseudoephedrine',\n",
       "  'd-psi-2-Methylamino-1-phenyl-1-propanol',\n",
       "  'd-psi-Ephedrine',\n",
       "  'Isoephedrine',\n",
       "  'L-(+)-Pseudoephedrine',\n",
       "  'L(+)-psi-Ephedrine',\n",
       "  'Pseudoefedrina',\n",
       "  'Pseudoephedrine',\n",
       "  'pseudoÃ©phÃ©drine',\n",
       "  'Pseudoephedrine D-form',\n",
       "  'Pseudoephedrinum',\n",
       "  'Psi-ephedrin',\n",
       "  'Psi-ephedrine',\n",
       "  'trans-Ephedrine',\n",
       "  'Ï\\x88-ephedrine',\n",
       "  'Pseudoephedrine'],\n",
       " 'Temozolomide': ['3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide',\n",
       "  '3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide',\n",
       "  '3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide',\n",
       "  '8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one',\n",
       "  'Methazolastone',\n",
       "  'Temozolodida',\n",
       "  'Temozolomid',\n",
       "  'Temozolomida',\n",
       "  'Temozolomide',\n",
       "  'TÃ©mozolomide',\n",
       "  'Temozolomidum',\n",
       "  'Temozolomide'],\n",
       " 'Levorphanol': ['Levorfanol',\n",
       "  'Levorfanolo',\n",
       "  'LÃ©vorphanol',\n",
       "  'Levorphanol',\n",
       "  'Levorphanolum',\n",
       "  'Levorphanol'],\n",
       " 'Aminolevulinic acid': ['5-ALA',\n",
       "  '5-Aminolevulinic acid',\n",
       "  'Ã¡cido 5-aminolevulÃ\\xadnico',\n",
       "  'Aminolevulinic acid',\n",
       "  'dALA',\n",
       "  'Î´-ALA',\n",
       "  'Î´-aminolevulinic acid',\n",
       "  'Aminolevulinic acid'],\n",
       " 'Chlorphenesin': ['3-(4-chlorophenoxy)-1,2-propanediol',\n",
       "  '3-(p-chlorophenoxy)-1,2-propanediol',\n",
       "  '3-(p-chlorophenoxy)propane-1,2-diol',\n",
       "  'Chlorphenesin',\n",
       "  'ChlorphÃ©nÃ©sine',\n",
       "  'Chlorphenesinum',\n",
       "  'Clorfenesina',\n",
       "  'glycerol Î±-p-chlorophenyl ether',\n",
       "  'p-chlorophenyl-Î±-glyceryl ether',\n",
       "  'Chlorphenesin'],\n",
       " 'Terbinafine': ['(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine',\n",
       "  '(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine',\n",
       "  'Terbinafina',\n",
       "  'Terbinafine',\n",
       "  'Terbinafinum',\n",
       "  'Terbinafine'],\n",
       " 'Drostanolone': ['17beta-Hydroxy-2alpha-methyl-5alpha-androstan-3-one',\n",
       "  '2Î±-Methyldihydrotestosterone',\n",
       "  'Dihydro-2Î±-methyltestosterone',\n",
       "  'Dromostanolone',\n",
       "  'Drostanolona',\n",
       "  'Drostanolone',\n",
       "  'Drostanolonum',\n",
       "  'Medrosteron',\n",
       "  'Medrotestron',\n",
       "  'Metholone',\n",
       "  'Drostanolone'],\n",
       " 'Penicillamine': ['(â\\x88\\x92)-penicillamine',\n",
       "  '(S)-2-amino-3-mercapto-3-methylbutanoic acid',\n",
       "  '(S)-3,3-dimethylcysteine',\n",
       "  '3-mercapto-D-valine',\n",
       "  'D-(â\\x88\\x92)-penicillamine',\n",
       "  'D-penicillamine',\n",
       "  'D-Î²,Î²-dimethylcysteine',\n",
       "  'penicilamina',\n",
       "  'Penicillamine',\n",
       "  'Penicillamine'],\n",
       " 'Prednisolone': ['(11Î²)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione',\n",
       "  '1,4-pregnadiene-11Î²,17Î±,21-triol-3,20-dione',\n",
       "  '1,4-pregnadiene-3,20-dione-11Î²,17Î±,21-triol',\n",
       "  '3,20-dioxo-11Î²,17Î±,21-trihydroxy-1,4-pregnadiene',\n",
       "  'delta-dehydrocortisol',\n",
       "  'delta-dehydrohydrocortisone',\n",
       "  'delta-hydrocortisone',\n",
       "  'delta(1)-Dehydrocortisol',\n",
       "  'delta(1)-Dehydrohydrocortisone',\n",
       "  'delta(1)-Hydrocortisone',\n",
       "  'Hydroretrocortine',\n",
       "  'Metacortandralone',\n",
       "  'PRDL',\n",
       "  'Prednisolona',\n",
       "  'Prednisolone',\n",
       "  'Prednisolonum',\n",
       "  'Prednisolone'],\n",
       " 'Diflunisal': ['2-(hydroxy)-5-(2,4-difluorophenyl)benzoic acid',\n",
       "  \"2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid\",\n",
       "  '5-(2,4-difluorophenyl)salicylic acid',\n",
       "  'Diflunisal',\n",
       "  'Diflunisalum',\n",
       "  'Diflunisal'],\n",
       " 'Vardenafil': ['VardÃ©nafil',\n",
       "  'Vardenafil',\n",
       "  'Vardenafilo',\n",
       "  'Vardenafilum',\n",
       "  'Vardenafil'],\n",
       " 'Ranitidine': ['Ranitidina', 'Ranitidine', 'Ranitidinum', 'Ranitidine'],\n",
       " 'Tacrolimus': ['Anhydrous tacrolimus',\n",
       "  'Tacrolimus',\n",
       "  'Tacrolimus anhydrous',\n",
       "  'Tacrolimus, anhydrous',\n",
       "  'Tacrolimus'],\n",
       " 'Benzphetamine': ['(+)-benzphetamine',\n",
       "  '(+)-N-benzyl-N,Î±-dimethylphenethylamine',\n",
       "  '(+)-N,Î±-dimethyl-N-(phenylmethyl)-benzeneethanamine',\n",
       "  '(S)-(+)-benzphetamine',\n",
       "  '(S)-(+)-N-benzyl-N,Î±-dimethylphenethylamine',\n",
       "  '(S)-benzphetamine',\n",
       "  '(Î±S)-N,Î±-dimethylphenethylamine',\n",
       "  'Benzaphetamine',\n",
       "  'Benzfetamina',\n",
       "  'Benzfetamine',\n",
       "  'Benzfetaminum',\n",
       "  'Benzphetamine',\n",
       "  'Benzylamphetamine',\n",
       "  'd-N-methyl-N-benzyl-Î²-phenylisopropylamine',\n",
       "  'N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine',\n",
       "  'Benzphetamine'],\n",
       " 'Alprenolol': ['(RS)-1-(2-allylphenoxy)-3-(isopropylamino)propan-2-ol',\n",
       "  '1-(2-Allylphenoxy)-3-isopropylamino-2-propanol',\n",
       "  '1-(o-Allylphenoxy)-3-(isopropylamino)-2-propanol',\n",
       "  'Alfeprol',\n",
       "  'Alprenolol',\n",
       "  'AlprÃ©nolol',\n",
       "  'Alprenololum',\n",
       "  'Aprenololo',\n",
       "  'Alprenolol'],\n",
       " 'Ritodrine': ['p-Hydroxy-alpha-(1-((p-hydroxyphenethyl)amino)ethyl)benzyl alcohol',\n",
       "  'Ritodrina',\n",
       "  'Ritodrine',\n",
       "  'Ritodrinium',\n",
       "  'Ritodrine'],\n",
       " 'Benzonatate': ['2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoate',\n",
       "  '2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl p-(butylamino)benzoate',\n",
       "  '3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl 4-butylaminobenzoate',\n",
       "  '4-(butylamino)benzoic acid 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester',\n",
       "  'Benzonatat',\n",
       "  'Benzonatate',\n",
       "  'Benzonatato',\n",
       "  'Benzonatatum',\n",
       "  'Benzononatine',\n",
       "  'nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate',\n",
       "  'p-butylaminobenzoic acid Ï\\x89-O-methylnonaethyleneglycol ester',\n",
       "  'Benzonatate'],\n",
       " 'Dorzolamide': ['(4S,6S)-4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide',\n",
       "  '(4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide',\n",
       "  '4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide',\n",
       "  '4-ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide',\n",
       "  '4S,6S-dorzolamide',\n",
       "  'Dorzolamid',\n",
       "  'Dorzolamida',\n",
       "  'Dorzolamide',\n",
       "  'Dorzolamidum',\n",
       "  'Dorzolamide'],\n",
       " 'Suprofen': ['(Â±)-2-(p-(2-thenoyl)phenyl)propionic acid',\n",
       "  '2-(4-(2-Thenoyl)phenyl)propionsÃ¤ure',\n",
       "  '2-[4-(Thiophene-2-carbonyl)-phenyl]-propionic acid',\n",
       "  '4-(2-Thenoyl)hydratropsÃ¤ure',\n",
       "  'p-2-thenoylhydratropic acid',\n",
       "  'Suprofen',\n",
       "  'Suprofene',\n",
       "  'Suprofeno',\n",
       "  'Suprofenum',\n",
       "  'Sutoprofen',\n",
       "  'Î±-methyl-4-(2-thienylcarbonyl)benzeneacetic acid',\n",
       "  'Suprofen'],\n",
       " 'Terbutaline': ['Terbutalin',\n",
       "  'Terbutalina',\n",
       "  'Terbutaline',\n",
       "  'Terbutalinum',\n",
       "  'Terbutaline'],\n",
       " 'Conivaptan': [\"4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide\",\n",
       "  'Conivaptan',\n",
       "  'Conivaptan'],\n",
       " 'Loteprednol etabonate': ['Loteprednol etabonate', 'Loteprednol etabonate'],\n",
       " 'Guaifenesin': ['Glyceryl guaiacolate',\n",
       "  'Guaifenesin',\n",
       "  'Guaifenesina',\n",
       "  'guaiphenesin',\n",
       "  'Guaifenesin'],\n",
       " 'Flupentixol': ['Flupenthixol',\n",
       "  'Flupenthixole',\n",
       "  'Flupentixol',\n",
       "  'Flupentixolo',\n",
       "  'Flupentixolum',\n",
       "  'Flupentixol'],\n",
       " 'Eprosartan': ['(E)-2-butyl-1-(p-carboxybenzyl)-Î±-2-thenylimidazole-5-acrylic acid',\n",
       "  '(E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid',\n",
       "  '(E)-Î±{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid',\n",
       "  'Ã\\x89prosartan',\n",
       "  'Eprosartan',\n",
       "  'Eprosartanum',\n",
       "  'Eprosartan'],\n",
       " 'Sirolimus': ['(-)-Rapamycin',\n",
       "  'Rapamycin',\n",
       "  'SirolimÃºs',\n",
       "  'Sirolimus',\n",
       "  'Sirolimusum',\n",
       "  'Sirolimus'],\n",
       " 'Chlorhexidine': [\"1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide)\",\n",
       "  'Chlorhexidin',\n",
       "  'Chlorhexidine',\n",
       "  'Chlorhexidinum',\n",
       "  'Cloresidina',\n",
       "  'Clorhexidina',\n",
       "  \"N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide\",\n",
       "  'Chlorhexidine'],\n",
       " 'Emtricitabine': ['(â\\x88\\x92)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine',\n",
       "  \"(â\\x88\\x92)-2'-deoxy-5-fluoro-3'-thiacytidine\",\n",
       "  '(â\\x88\\x92)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one',\n",
       "  '(â\\x88\\x92)-FTC',\n",
       "  \"(â\\x88\\x92)-Î²-2',3'-dideoxy-5-fluoro-3'-thiacytidine\",\n",
       "  '(2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone',\n",
       "  '4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one',\n",
       "  '4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one',\n",
       "  '5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine',\n",
       "  'Emtricitabin',\n",
       "  'Emtricitabina',\n",
       "  'Emtricitabine',\n",
       "  'Emtricitabinum',\n",
       "  'Emtricitabine'],\n",
       " 'Chlorothiazide': ['6-Chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide',\n",
       "  '6-chloro-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide',\n",
       "  'Chlorothiazid',\n",
       "  'Chlorothiazide',\n",
       "  'Chlorothiazidum',\n",
       "  'Chlorthiazide',\n",
       "  'Clorotiazida',\n",
       "  'Chlorothiazide'],\n",
       " 'Quinapril': ['Quinapril', 'Quinaprilum', 'Quinapril'],\n",
       " 'Clomifene': ['2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine',\n",
       "  '2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)triethylamine',\n",
       "  '2-(p-(Î²-chloro-Î±-phenylstyryl)phenoxy)triethylamine',\n",
       "  'Clomifene',\n",
       "  'Clomifeno',\n",
       "  'Clomifenum',\n",
       "  'Clomiphene',\n",
       "  'Clomifene'],\n",
       " 'Isosorbide dinitrate': ['1,4:3,6-Dianhydrosorbitol 2,5-dinitrate',\n",
       "  'D-Isosorbide dinitrate',\n",
       "  'Dianhydrosorbitol 2,5-dinitrate',\n",
       "  \"Dinitrate d'isosorbide\",\n",
       "  'Dinitrato de isosorbida',\n",
       "  'Dinitroisosorbide',\n",
       "  'Dinitrosorbide',\n",
       "  'ISDN',\n",
       "  'Isosorbide 2,5-dinitrate',\n",
       "  'Isosorbide dinitrate',\n",
       "  'Isosorbidi dinitras',\n",
       "  'Sorbide nitrate',\n",
       "  'Sorbidnitrate',\n",
       "  'Isosorbide dinitrate'],\n",
       " 'Risedronic acid': ['Acide risÃ©droniqe',\n",
       "  'Acido risedronico',\n",
       "  'Acidum risedronicum',\n",
       "  'Risedronate',\n",
       "  'Risedronic acid',\n",
       "  'RisedronsÃ¤ure',\n",
       "  'Risedronic acid'],\n",
       " 'Pemirolast': ['Pemirolast', 'Pemirolastum', 'Pemirolast'],\n",
       " 'Omapatrilat': ['Omapatrilate', 'Omapatrilat'],\n",
       " 'Bumetanide': ['3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid',\n",
       "  '3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid',\n",
       "  '3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid',\n",
       "  '3-butylamino-4-phenoxy-5-sulfamoylbenzoic acid',\n",
       "  'Bumetanida',\n",
       "  'Bumetanide',\n",
       "  'Bumetanidum',\n",
       "  'Bumetanide'],\n",
       " 'Mechlorethamine': [\"2,2'-dichloro-N-methyldiethylamine\",\n",
       "  'bis(2-chloroethyl)methylamine',\n",
       "  'bis(Î²-chloroethyl)methylamine',\n",
       "  'Chlormethine',\n",
       "  'Chlormethinum',\n",
       "  'Clormetina',\n",
       "  'Mechlorethamine',\n",
       "  'methylbis(2-chloroethyl)amine',\n",
       "  'methylbis(Î²-chloroethyl)amine',\n",
       "  'Mustine',\n",
       "  'N-methyl-bis(2-chloroethyl)amine',\n",
       "  'N-methyl-bis(Î²-chloroethyl)amine',\n",
       "  'Nitrogen mustard',\n",
       "  \"Î²,Î²'-dichlorodiethyl-N-methylamine\",\n",
       "  'Mechlorethamine'],\n",
       " 'Granisetron': ['GranisÃ©tron',\n",
       "  'GranisetrÃ³n',\n",
       "  'Granisetron',\n",
       "  'Granisetronum',\n",
       "  'Granisetron'],\n",
       " 'Dienestrol': [\"4,4'-Hydroxy-Î³,Î´-diphenyl-Î²,Î´-hexadiene\",\n",
       "  'alpha-dienestrol diacetate',\n",
       "  'Cycladiene',\n",
       "  'Dehydrostilbestrol',\n",
       "  'Dienestrol',\n",
       "  'DiÃ¨nestrol',\n",
       "  'Dienestrolum',\n",
       "  \"p,p'-(Diethylideneethylene)diphenol\",\n",
       "  'Dienestrol'],\n",
       " 'Sulfapyridine': ['2-(p-Aminobenzenesulphonamido)pyridine',\n",
       "  '2-Sulfanilamidopyridin',\n",
       "  '2-Sulfanilamidopyridine',\n",
       "  '2-Sulfanilylaminopyridine',\n",
       "  '2-Sulfapyridine',\n",
       "  '4-(2-Pyridinylsulfonyl)aniline',\n",
       "  '4-[(2-Pyridylamino)sulfonyl]aniline',\n",
       "  '4-Amino-N-pyridin-2-yl-benzenesulfonamide',\n",
       "  '4-Amino-N,2-pyridinylbenzenesulfonamide',\n",
       "  'N-2-Pyridylsulfanilamide',\n",
       "  'N(1)-2-Pyridylsulfanilamide',\n",
       "  'N(1)-Pyridylsulfanilamide',\n",
       "  'Solfapiridina',\n",
       "  'Sulfapiridina',\n",
       "  'Sulfapyridin',\n",
       "  'Sulfapyridine',\n",
       "  'Sulfapyridinum',\n",
       "  'Sulphapyridine',\n",
       "  'Sulfapyridine'],\n",
       " 'Oxybuprocaine': ['4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid',\n",
       "  '4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester',\n",
       "  '4-Amino-3-n-butoxy-benzoesÃ¤ure-diÃ¤thylaminoÃ¤thylester',\n",
       "  'Benoxinate',\n",
       "  'BNX',\n",
       "  'Butoxyaminobenzoyldiethylaminoethanol',\n",
       "  'Oxibuprocaina',\n",
       "  'Oxybucaine',\n",
       "  'Oxybuprocaine',\n",
       "  'Oxybuprocainum',\n",
       "  'Oxyriprocaine',\n",
       "  'Oxybuprocaine'],\n",
       " 'Iron Dextran': ['Dextran iron', 'Iron dextran complex', 'Iron Dextran'],\n",
       " 'Testolactone': ['(4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione',\n",
       "  '1-dehydrotestololactone',\n",
       "  '1,2-didehydrotestololactone',\n",
       "  '13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid Î´-lactone',\n",
       "  'D-homo-17a-oxaandrosta-1,4-diene-3,17-dione',\n",
       "  'delta(1)-testololactone',\n",
       "  'Testolactona',\n",
       "  'Testolactonum',\n",
       "  'Testolattone',\n",
       "  'Î\\x941-testololactone',\n",
       "  'Testolactone'],\n",
       " 'Benzylpenicilloyl polylysine': ['Benzyl penicilloyl-polylysine',\n",
       "  'Benzylpenicilloyl G polylysine',\n",
       "  'Benzylpenicilloyl-polylysine',\n",
       "  'Benzylpenicilloyl polylysine'],\n",
       " 'Rimexolone': ['Rimexolon', 'Rimexolona', 'Rimexolone', 'Rimexolone'],\n",
       " 'Triazolam': ['Triazolam', 'Triazolamum', 'Triazolam'],\n",
       " 'Ethanol': ['1-Hydroxyethane',\n",
       "  'Alcohol',\n",
       "  'Alcohol (ethyl)',\n",
       "  'Alcohol anhydrous',\n",
       "  'Alcohol denatured',\n",
       "  'Alcohol etÃ\\xadlico',\n",
       "  'Alcohol, denatured',\n",
       "  'Alcool Ã©thylique',\n",
       "  'Alkohol',\n",
       "  'Ã\\x84thanol',\n",
       "  'Ã\\x84thylalkohol',\n",
       "  'Dehydrated ethanol',\n",
       "  'etanol',\n",
       "  'Ã©thanol',\n",
       "  'Ethyl Alcohol',\n",
       "  'Grain alcohol',\n",
       "  'Hydroxyethane',\n",
       "  'Methylcarbinol',\n",
       "  'Spiritus vini',\n",
       "  'Ethanol'],\n",
       " 'Remifentanil': ['Remifentanil',\n",
       "  'Remifentanilo',\n",
       "  'Remifentanyl',\n",
       "  'Remifentanil'],\n",
       " 'Didanosine': ['2,3-Dideoxyinosine',\n",
       "  '9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one',\n",
       "  '9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one',\n",
       "  '9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol',\n",
       "  '9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one',\n",
       "  'ddI',\n",
       "  'ddIno',\n",
       "  'Didanosina',\n",
       "  'Didanosine',\n",
       "  'Didanosinum',\n",
       "  'Dideoxyinosine',\n",
       "  'Didanosine'],\n",
       " 'Bitolterol': ['4-(2-(tert-butylamino)-1-hydroxyethyl)-o-phenylene di-p-toluate',\n",
       "  '4-[2-(tert-butylamino)-1-hydroxyethyl]-o-phenylene di-p-toluate',\n",
       "  'bis(4-methylbenzoic acid) 4-[2-(tert-butylamino)-1-hydroxyethyl]-1,2-phenylene ester',\n",
       "  'Bitolterol',\n",
       "  'BitoltÃ©rol',\n",
       "  'Bitolterolum',\n",
       "  'Bitolterol'],\n",
       " 'Methdilazine': ['Methdilazinum', 'Metodilazina', 'Methdilazine'],\n",
       " 'Etacrynic acid': ['(2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid',\n",
       "  'Acide Ã©tacrynique',\n",
       "  'Ã¡cido etacrÃ\\xadnico',\n",
       "  'Acidum etacrynicum',\n",
       "  'Etacrinic acid',\n",
       "  'Etacrynic acid',\n",
       "  'Ethacrynate',\n",
       "  'Ethacrynic acid',\n",
       "  'Methylenebutyrylphenoxyacetic acid',\n",
       "  'Etacrynic acid'],\n",
       " 'Ondansetron': ['Ondansetron', 'Ondansetron'],\n",
       " 'Bimatoprost': ['(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide',\n",
       "  'Bimatoprost',\n",
       "  'Bimatoprostum',\n",
       "  'Bimatoprost'],\n",
       " 'Tiagabine': ['Tiagabina', 'Tiagabine', 'Tiagabinum', 'Tiagabine'],\n",
       " 'Cocaine': ['(-)-Cocaine',\n",
       "  '(â\\x88\\x92)-cocaine',\n",
       "  '[1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid, methyl ester',\n",
       "  '2-methyl-3Î²-hydroxy-1Î±H,5Î±H-tropane-2Î²-carboxylate benzoate (ester)',\n",
       "  'Benzoylmethylecgonine',\n",
       "  'beta-Cocain',\n",
       "  'Cocain',\n",
       "  'Cocaina',\n",
       "  'Cocainum',\n",
       "  'Kokain',\n",
       "  'L-Cocain',\n",
       "  'L-Cocaine',\n",
       "  'methyl [1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate',\n",
       "  'Methyl benzoylecgonine',\n",
       "  'Neurocaine',\n",
       "  'Cocaine'],\n",
       " 'Quinidine': ['(+)-quinidine',\n",
       "  '(8R,9S)-Quinidine',\n",
       "  '(R)-(6-Methoxyquinolin-4-yl)((3S,4R,7S)-3-vinylquinuclidin-7-yl)methanol',\n",
       "  '(S)-(6-Methoxy-quinolin-4-yl)-((2R,5R)-5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol',\n",
       "  '(S)-(6-Methoxyquinolin-4-yl)((2R,5R)-5-vinylquinuclidin-2-yl)methanol',\n",
       "  '6-methoxy-Î±-(5-vinyl-2-quinuclidinyl)-4-quinolinemethanol',\n",
       "  'beta-Quinine',\n",
       "  'Chinidin',\n",
       "  'Chinidinum',\n",
       "  'CIN-QUIN',\n",
       "  'Conchinin',\n",
       "  'Conquinine',\n",
       "  'Pitayine',\n",
       "  'Quinidina',\n",
       "  'Î±-(6-methoxy-4-quinolyl)-5-vinyl-2-quinuclidinemethanol',\n",
       "  'Î²-quinine',\n",
       "  'Quinidine'],\n",
       " 'Zonisamide': ['1,2-Benzisoxazole-3-methanesulfonamide',\n",
       "  '3-(Sulfamoylmethyl)-1,2-benzisoxazole',\n",
       "  'Benzo[d]isoxazol-3-yl-methanesulfonamide',\n",
       "  'Zonisamida',\n",
       "  'Zonisamide',\n",
       "  'Zonisamidum',\n",
       "  'Zonisamide'],\n",
       " 'Paricalcitol': ['19-Nor-1alpha,25-dihydroxyvitamin D2',\n",
       "  'Paricalcitol',\n",
       "  'Paricalcitol'],\n",
       " 'Tinidazole': ['1-(2-(Ethylsulfonyl)ethyl)-2-methyl-5-nitroimidazole',\n",
       "  'Timidazole',\n",
       "  'Tinidazol',\n",
       "  'Tinidazole',\n",
       "  'Tinidazolum',\n",
       "  'Tinidazole'],\n",
       " 'Repaglinide': ['Repaglinida', 'Repaglinide', 'Repaglinidum', 'Repaglinide'],\n",
       " 'Anileridine': ['1-[2-(4-aminophenyl)ethyl]-4-phenyl-4-piperidinecarboxlic acid ethyl ester',\n",
       "  'Anileridina',\n",
       "  'Anileridine',\n",
       "  'Anileridinum',\n",
       "  'ethyl 1-(2-(4-aminophenyl)ethyl)-4-phenyl-4-piperidinecarboxylate',\n",
       "  'ethyl 1-(4-aminophenethyl)-4-phenylisonipecotate',\n",
       "  'ethyl 1-(p-aminophenethyl)-4-phenylisonipecotate',\n",
       "  'N-(Î²-(p-aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine',\n",
       "  'N-Î²-(p-aminophenyl)ethylnormeperidine',\n",
       "  'Anileridine'],\n",
       " 'Phenformin': ['Fenformin',\n",
       "  'Fenformina',\n",
       "  'Phenformin',\n",
       "  'Phenformine',\n",
       "  'Phenforminum',\n",
       "  'Î²-Phenethybiguanide',\n",
       "  'Phenformin'],\n",
       " 'Amantadine': ['1-adamantanamine',\n",
       "  '1-adamantylamine',\n",
       "  '1-aminoadamantane',\n",
       "  'Amantadina',\n",
       "  'Amantadine',\n",
       "  'Amantadinum',\n",
       "  'Amantidine',\n",
       "  'Aminoadamantane',\n",
       "  'Amantadine'],\n",
       " 'Metronidazole': ['1-(2-hydroxy-1-ethyl)-2-methyl-5-nitroimidazole',\n",
       "  '1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole',\n",
       "  '1-(Î²-ethylol)-2-methyl-5-nitro-3-azapyrrole',\n",
       "  '1-(Î²-hydroxyethyl)-2-methyl-5-nitroimidazole',\n",
       "  '1-(Î²-oxyethyl)-2-methyl-5-nitroimidazole',\n",
       "  '2-methyl-1-(2-hydroxyethyl)-5-nitroimidazole',\n",
       "  '2-methyl-3-(2-hydroxyethyl)-4-nitroimidazole',\n",
       "  '2-methyl-5-nitroimidazole-1-ethanol',\n",
       "  'Metronidazol',\n",
       "  'MÃ©tronidazole',\n",
       "  'Metronidazole',\n",
       "  'Metronidazolum',\n",
       "  'Metronidazole'],\n",
       " 'Dinoprostone': ['(15S)-prostaglandin E2',\n",
       "  '(5Z,11Î±,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid',\n",
       "  '(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate',\n",
       "  '(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprosta-5,13-dienoate',\n",
       "  '(E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid',\n",
       "  '(Z)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid',\n",
       "  'Dinoproston',\n",
       "  'Dinoprostona',\n",
       "  'Dinoprostone',\n",
       "  'Dinoprostone Prostaglandin E2',\n",
       "  'Dinoprostonum',\n",
       "  'PGE2',\n",
       "  'Prostaglandin E2',\n",
       "  'Dinoprostone'],\n",
       " 'Almotriptan': ['1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine',\n",
       "  'Almotriptan',\n",
       "  'Almotriptan'],\n",
       " 'Spectinomycin': ['Actinospectacina',\n",
       "  'Espectinomicina',\n",
       "  'SCM',\n",
       "  'Spectinomicina',\n",
       "  'Spectinomycin',\n",
       "  'Spectinomycine',\n",
       "  'Spectinomycinum',\n",
       "  'Spectinomycin'],\n",
       " 'Ketotifen': ['Ketotifen',\n",
       "  'Ketotifene',\n",
       "  'Ketotifeno',\n",
       "  'Ketotifenum',\n",
       "  'Ketotifen'],\n",
       " 'Buprenorphine': ['(â\\x88\\x92)-buprenorphine',\n",
       "  '17-cyclopropylmethyl-4,5Î±-epoxy-7Î±-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol',\n",
       "  '2-(N-cyclopropylmethyl-4,5Î±-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6Î±-yl)-3,3-dimethyl-2-butanol',\n",
       "  '2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol',\n",
       "  '21-cyclopropyl-7Î±-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine',\n",
       "  'Buprenophine',\n",
       "  'Buprenorfina',\n",
       "  'Buprenorphine',\n",
       "  'Buprenorphinum',\n",
       "  'Buprenorphine'],\n",
       " 'Levosimendan': ['LÃ©vosimendan',\n",
       "  'Levosimendan',\n",
       "  'LevosimendÃ¡n',\n",
       "  'Levosimendanum',\n",
       "  'Levosimendan'],\n",
       " 'Ceforanide': ['(6R,7R)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid',\n",
       "  '7-[O-(aminomethyl)phenylacetamido]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acid',\n",
       "  '7Î²-[2-(aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylic acid',\n",
       "  'Ceforanide',\n",
       "  'Ceforanido',\n",
       "  'Ceforanidum',\n",
       "  'Ceforanide'],\n",
       " 'Cyclobenzaprine': ['(3-Dibenzo[a,d]cyclohepten-5-ylidene-propyl)-dimethyl-amine',\n",
       "  'Ciclobenzaprina',\n",
       "  'Cyclobenzaprine',\n",
       "  'Cyclobenzaprinum',\n",
       "  'N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Î\\x945,Î³-propylamine',\n",
       "  'Cyclobenzaprine'],\n",
       " 'Phenoxybenzamine': ['Fenossibenzamina',\n",
       "  'Fenoxibenzamina',\n",
       "  'Phenoxybenzamine',\n",
       "  'Phenoxybenzaminum',\n",
       "  'POB',\n",
       "  'Phenoxybenzamine'],\n",
       " 'Etretinate': ['Etretinate', 'etretinato', 'Etretinate'],\n",
       " 'Famotidine': ['(1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide',\n",
       "  '3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide',\n",
       "  '3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine',\n",
       "  'Famotidina',\n",
       "  'Famotidine',\n",
       "  'Famotidinum',\n",
       "  'N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide',\n",
       "  'Famotidine'],\n",
       " 'Azacitidine': ['4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one',\n",
       "  '5-azacytidine',\n",
       "  'Azacitidina',\n",
       "  'Azacitidine',\n",
       "  'Azacitidinum',\n",
       "  'Azacytidine',\n",
       "  'Azacitidine'],\n",
       " 'Misoprostol': ['Misoprostol', 'Misoprostolum', 'Misoprostol'],\n",
       " 'Colesevelam': ['Colesevelam', 'Colesevelam'],\n",
       " 'Metacycline': ['6-Demethyl-6-deoxy-5-hydroxy-6-methylenetetracycline',\n",
       "  '6-Deoxy-6-demethyl-6-methylene-5-oxytetracycline',\n",
       "  '6-Methylene-5-hydroxytetracycline',\n",
       "  '6-Methylene-5-oxytetracycline',\n",
       "  '6-Methyleneoxytetracycline',\n",
       "  'Metaciclina',\n",
       "  'Metacycline',\n",
       "  'Methacycline',\n",
       "  'Methacyclinum',\n",
       "  'Methylenecycline',\n",
       "  'Tri-methacycline',\n",
       "  'Metacycline'],\n",
       " 'Tipranavir': ['Tipranavir', 'Tipranavir'],\n",
       " 'Mesoridazine': ['10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine',\n",
       "  '10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine',\n",
       "  '2-Methanesulfinyl-10-[2-(1-methyl-piperidin-2-yl)-ethyl]-10H-phenothiazine',\n",
       "  'Mesoridazina',\n",
       "  'Mesoridazine',\n",
       "  'Mesoridazinum',\n",
       "  'Thioridazine 2-sulfoxide',\n",
       "  'Thioridazine thiomethyl sulfoxide',\n",
       "  'Thioridazine-2-sulfoxide',\n",
       "  'Mesoridazine'],\n",
       " 'Maprotiline': ['Maprotilina',\n",
       "  'Maprotiline',\n",
       "  'Maprotilinum',\n",
       "  'Maprotylina',\n",
       "  'Maprotiline'],\n",
       " 'Oxymetazoline': ['2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline',\n",
       "  '3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol',\n",
       "  '6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol',\n",
       "  '6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol',\n",
       "  'Oximetazolinum',\n",
       "  'Oxymetazolina',\n",
       "  'Oxymetazoline',\n",
       "  'OxymÃ©tazoline',\n",
       "  'Oxymetazolinum',\n",
       "  'Oxymethazoline',\n",
       "  'Oxymetozoline',\n",
       "  'Oxymetazoline'],\n",
       " 'Salicylic acid': ['2-Carboxyphenol',\n",
       "  '2-Hydroxybenzoic acid',\n",
       "  'Ã¡cido salicÃ\\xadlico',\n",
       "  'Acidum salicylicum',\n",
       "  'O-carboxyphenol',\n",
       "  'O-hydroxybenzoic acid',\n",
       "  'Salicylic acid'],\n",
       " 'Diethylpropion': ['(Â±)-diethylpropion',\n",
       "  '1-phenyl-2-diethylamino-1-propanone',\n",
       "  '2-(diethylamino)-1-phenyl-1-propanone',\n",
       "  '2-(diethylamino)propiophenone',\n",
       "  'alpha-Benzoyltriethylamine',\n",
       "  'alpha-Diethylaminopropiophenone',\n",
       "  'Amfepramone',\n",
       "  'AmfÃ©pramone',\n",
       "  'Amfepramonum',\n",
       "  'Anfepramona',\n",
       "  'Diethylcathinone',\n",
       "  'Diethylpropion'],\n",
       " 'Salmeterol': ['Salmaterol', 'Salmeterol', 'Salmeterolum', 'Salmeterol'],\n",
       " 'Meclofenamic acid': ['Acide mÃ©clofÃ©namique',\n",
       "  'Ã¡cido meclofenÃ¡mico',\n",
       "  'Acidum meclofenamicum',\n",
       "  'Meclofenamate',\n",
       "  'Meclofenamic acid',\n",
       "  'N-(2,6-dichloro-3-methylphenyl)anthranilic acid',\n",
       "  'N-(2,6-dichloro-m-tolyl)anthranilic acid',\n",
       "  'N-(3-methyl-2,6-dichlorophenyl)anthranilic acid',\n",
       "  'Meclofenamic acid'],\n",
       " 'Methantheline': ['Methantheline',\n",
       "  'Methantheline cation',\n",
       "  'Methantheline ion',\n",
       "  'Methanthelinium',\n",
       "  'Methanthelinum',\n",
       "  'Methantheline'],\n",
       " 'Hexafluronium': ['Hexafluorenium',\n",
       "  'Hexafluorenium cation',\n",
       "  'Hexafluorenium ion',\n",
       "  'Hexamethylenebis(fluoren-9-yldimethylammonium)',\n",
       "  'Hexafluronium'],\n",
       " 'Cycrimine': ['(Â±)-cycrimine',\n",
       "  'alpha-cyclopentyl-alpha-phenyl-1-piperidinepropanol',\n",
       "  'Cicrimina',\n",
       "  'Cycrimine',\n",
       "  'Cycriminum',\n",
       "  'Cycrimine'],\n",
       " 'Zalcitabine': [\"2',3'-Dideoxycytidine\",\n",
       "  '4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one',\n",
       "  'DDC',\n",
       "  'DDCYD',\n",
       "  'Dideoxycytidine',\n",
       "  'Zalcitabine',\n",
       "  'Zalcitabine'],\n",
       " 'Demecarium': ['Demecarium',\n",
       "  'Demecarium cation',\n",
       "  'Demecarium ion',\n",
       "  'Demecarium'],\n",
       " 'Acetylsalicylic acid': ['2-Acetoxybenzenecarboxylic acid',\n",
       "  '2-Acetoxybenzoic acid',\n",
       "  'Acetylsalicylate',\n",
       "  'AcetylsalicylsÃ¤ure',\n",
       "  'acide 2-(acÃ©tyloxy)benzoÃ¯que',\n",
       "  'Acide acÃ©tylsalicylique',\n",
       "  'Ã¡cido acetilsalicÃ\\xadlico',\n",
       "  'Acidum acetylsalicylicum',\n",
       "  'ASA',\n",
       "  'Aspirin',\n",
       "  'Aspirina',\n",
       "  'AzetylsalizylsÃ¤ure',\n",
       "  'o-acetoxybenzoic acid',\n",
       "  'O-acetylsalicylic acid',\n",
       "  'o-carboxyphenyl acetate',\n",
       "  'Polopiryna',\n",
       "  'Salicylic acid acetate',\n",
       "  'Acetylsalicylic acid'],\n",
       " 'Phenprocoumon': ['3-(1-Phenylpropyl)-4-hydroxycoumarin',\n",
       "  \"3-(1'-Phenyl-propyl)-4-oxycoumarin\",\n",
       "  '3-(alpha-Ethylbenzyl)-4-hydroxycoumarin',\n",
       "  '3-(alpha-Phenylpropyl)-4-hydroxycoumarin',\n",
       "  '4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one',\n",
       "  '4-hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one',\n",
       "  'Fenprocumon',\n",
       "  'Fenprocumone',\n",
       "  'Phenprocoumarol',\n",
       "  'Phenprocoumarole',\n",
       "  'Phenprocoumon',\n",
       "  'Phenprocoumone',\n",
       "  'Phenprocoumonum',\n",
       "  'Phenprocumone',\n",
       "  'Phenprocoumon'],\n",
       " 'Fulvestrant': ['(7Î±,17Î²)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diol',\n",
       "  'Fulvestrant',\n",
       "  'Fulvestrant'],\n",
       " 'Mezlocillin': ['(2S,5R,6R)-3,3-dimethyl-6-{[(2R)-2-({[3-(methylsulfonyl)-2-oxoimidazolidin-1-yl]carbonyl}amino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  '6Î²-{(2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido}penicillanic acid',\n",
       "  'Mezlocilina',\n",
       "  'Mezlocillin',\n",
       "  'Mezlocilline',\n",
       "  'Mezlocillinum',\n",
       "  'Mezlocillin'],\n",
       " 'Felbamate': ['2-phenyl-1,3-propanediol dicarbamate',\n",
       "  'carbamic acid 2-phenyltrimethylene ester',\n",
       "  'Carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester',\n",
       "  'Felbamate',\n",
       "  'Felbamato',\n",
       "  'Felbamatum',\n",
       "  'Felbamate'],\n",
       " 'Fexofenadine': ['4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid',\n",
       "  'Carboxyterfenadine',\n",
       "  'Fexofenadina',\n",
       "  'Fexofenadine',\n",
       "  'Terfenadine acid metabolite',\n",
       "  'Terfenadine carboxylate',\n",
       "  'Terfenadine-COOH',\n",
       "  'Fexofenadine'],\n",
       " 'Isoniazid': ['4-pyridinecarbohydrazide',\n",
       "  'INH',\n",
       "  'Isoniazid',\n",
       "  'Isoniazida',\n",
       "  'Isonicotinic acid hydrazide',\n",
       "  'Isonicotinic hydrazide',\n",
       "  'Isonicotinohydrazide',\n",
       "  'Isonicotinoylhydrazide',\n",
       "  'IsonicotinsÃ¤urehydrazid',\n",
       "  'Isonicotinylhydrazine',\n",
       "  'Pyridine-4-carboxylic acid hydrazide',\n",
       "  'Isoniazid'],\n",
       " 'Naratriptan': ['N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide',\n",
       "  'N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide',\n",
       "  'NaratriptÃ¡n',\n",
       "  'Naratriptan',\n",
       "  'Naratriptanum',\n",
       "  'Naratriptan'],\n",
       " 'Rizatriptan': ['N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine',\n",
       "  'N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine',\n",
       "  'Risatriptan',\n",
       "  'RizatriptÃ¡n',\n",
       "  'Rizatriptan',\n",
       "  'Rizatriptanum',\n",
       "  'Rizatriptan'],\n",
       " 'Dirithromycin': ['(9S)-9-deoxo-11-deoxy-9,11-(imino((1R)-2-(2-methoxyethoxy)ethylidene)oxy)erythromycin',\n",
       "  'Dirithromycin',\n",
       "  'Dirithromycine',\n",
       "  'Dirithromycinum',\n",
       "  'Diritromicina',\n",
       "  'Dirithromycin'],\n",
       " 'Netilmicin': ['1-N-Ethylsisomicin', 'Netilmycin', 'Netilmicin'],\n",
       " 'Hydrocodone': ['(-)-Dihydrocodeinone',\n",
       "  '4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one',\n",
       "  'Dihydrocodeinone',\n",
       "  'Hidrocodona',\n",
       "  'Hydrocodon',\n",
       "  'Hydrocodone',\n",
       "  'Hydrocodonum',\n",
       "  'Hydrocone',\n",
       "  'Hydroconum',\n",
       "  'Idrocodone',\n",
       "  'Hydrocodone'],\n",
       " 'Norgestimate': ['(+)-13-Ethyl-17-hydroxy-18,19-dinor-17Î±-pregn-4-en-20-yn-3-one oxime acetate (ester)',\n",
       "  '(17Î±)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime',\n",
       "  'd-13Î²-Ethyl-17Î±-ethynyl-17Î²-acetoxygon-4-en-3-one oxime',\n",
       "  'Dexnorgestrel Acetime',\n",
       "  'Norgestimate',\n",
       "  'Norgestimato',\n",
       "  'Norgestimatum',\n",
       "  'Norgestimate'],\n",
       " 'Carboplatin': ['Carboplatin',\n",
       "  'Carboplatine',\n",
       "  'Carboplatino',\n",
       "  'CBDCA',\n",
       "  'cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)',\n",
       "  'cis-diammine(1,1-cyclobutanedicarboxylato)platinum',\n",
       "  'cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)',\n",
       "  'Carboplatin'],\n",
       " 'Methylprednisolone': ['(6Î±,11Î²)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione',\n",
       "  '1-dehydro-6Î±-methylhydrocortisone',\n",
       "  '6Î±-methyl-11Î²,17Î±,21-triol-1,4-pregnadiene-3,20-dione',\n",
       "  'delta(1)-6alpha-Methylhydrocortisone',\n",
       "  'Methylprednisolon',\n",
       "  'Methylprednisolone',\n",
       "  'Methylprednisolonum',\n",
       "  'Metilprednisolona',\n",
       "  'Methylprednisolone'],\n",
       " 'Pindolol': ['1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol',\n",
       "  '1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol',\n",
       "  '1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol',\n",
       "  '4-(2-hydroxy-3-isopropylaminopropoxy)-indole',\n",
       "  'Pindolol',\n",
       "  'Pindololum',\n",
       "  'Pindolol'],\n",
       " 'Mepivacaine': [\"(+-)-1-Methyl-2',6'-pipecoloxylidide\",\n",
       "  \"1-methyl-2',6'-pipecoloxylidide\",\n",
       "  'DL-Mepivacaine',\n",
       "  'Mepivacaina',\n",
       "  'Mepivacaine',\n",
       "  'Mepivacainum',\n",
       "  'N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide',\n",
       "  'N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide',\n",
       "  'Mepivacaine'],\n",
       " 'Zaleplon': [\"3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide\",\n",
       "  'Zaleplon',\n",
       "  'Zaleplon'],\n",
       " 'Bromfenac': ['[2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid',\n",
       "  '2-amino-3-(4-bromobenzoyl)benzeneacetic acid',\n",
       "  'Bromfenac',\n",
       "  'Bromfenaco',\n",
       "  'Bromfenacum',\n",
       "  'Bromfenac'],\n",
       " 'Apraclonidine': ['4-Aminoclonidine',\n",
       "  'Apraclonidina',\n",
       "  'Apraclonidine',\n",
       "  'Apraclonidinum',\n",
       "  'Apraclonidine'],\n",
       " 'Ethiodized oil': ['Ethiodized oil'],\n",
       " 'Telmisartan': [\"4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid\",\n",
       "  \"4'-((4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid\",\n",
       "  \"4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid\",\n",
       "  \"4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid\",\n",
       "  'Telmisartan',\n",
       "  'Telmisartan'],\n",
       " 'Desloratadine': ['8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine',\n",
       "  '8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine',\n",
       "  'Descarboethoxyloratadine',\n",
       "  'Desloratadina',\n",
       "  'Desloratadine',\n",
       "  'Desloratadine'],\n",
       " 'Methyldopa': ['(S)-(-)-alpha-Methyldopa',\n",
       "  '3-Hydroxy-alpha-methyl-L-tyrosine',\n",
       "  'Alpha medopa',\n",
       "  'alpha-Methyl dopa',\n",
       "  'alpha-methyl-L-dopa',\n",
       "  'Alphamethyldopa',\n",
       "  'AMD',\n",
       "  'Anhydrous methyldopa',\n",
       "  'L-alpha-Methyldopa',\n",
       "  'L-Methyl Dopa',\n",
       "  'Methyl dopa',\n",
       "  'Methyldopa',\n",
       "  'Methyldopa anhydrous',\n",
       "  'metildopa',\n",
       "  'Î±-Methyl dopa',\n",
       "  'Î±-methyl-L-dopa',\n",
       "  'Methyldopa'],\n",
       " 'Alosetron': ['2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one',\n",
       "  'Alosetron',\n",
       "  'Alosetron'],\n",
       " 'Dactinomycin': [\"2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide\",\n",
       "  'ActD',\n",
       "  'Actinomycin C1',\n",
       "  'Actinomycin D',\n",
       "  'Actinomycin IV',\n",
       "  'Dactinomicina',\n",
       "  'Dactinomycin',\n",
       "  'Dactinomycine',\n",
       "  'Dactinomycinum',\n",
       "  'Meractinomycin',\n",
       "  'Dactinomycin'],\n",
       " 'Selenium Sulfide': ['Selenii disulfidum',\n",
       "  'Selenium disulfide',\n",
       "  'Selenium disulphide',\n",
       "  'Selenium sulfide, micronized',\n",
       "  'Selenium sulphide',\n",
       "  'Selenium sulphide, micronized',\n",
       "  'Selenium(IV) disulfide',\n",
       "  'Selenium(IV) disulphide',\n",
       "  'Selenium(IV) sulfide',\n",
       "  'Selenium(IV) sulphide',\n",
       "  'Selenium Sulfide'],\n",
       " 'Azelastine': ['4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone',\n",
       "  'Azelastina',\n",
       "  'Azelastine',\n",
       "  'AzÃ©lastine',\n",
       "  'Azelastinum',\n",
       "  'Azelastine'],\n",
       " 'Ezetimibe': ['Ezetimiba',\n",
       "  'Ã©zÃ©timibe',\n",
       "  'Ezetimibe',\n",
       "  'Ezetimibum',\n",
       "  'Ezetimibe'],\n",
       " 'Edetic acid': ['(ethylenedinitrilo)tetraacetic acid, ion(4â\\x88\\x92)',\n",
       "  '{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid',\n",
       "  \"2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate\",\n",
       "  'Acide edetique',\n",
       "  'Acide ethylenediaminetetracetique',\n",
       "  'Acido edetico',\n",
       "  'Acidum edeticum',\n",
       "  'Edetic acid',\n",
       "  'EDTA',\n",
       "  'EDTA, ion(4-)',\n",
       "  'Ethylenediaminetetraacetate',\n",
       "  'Ethylenediaminetetraacetic acid',\n",
       "  \"N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine)\",\n",
       "  'Edetic acid'],\n",
       " 'Dipyridamole': ['Dipiridamol',\n",
       "  'Dipyridamine',\n",
       "  'Dipyridamole',\n",
       "  'Dipyridamolum',\n",
       "  'Dipyudamine',\n",
       "  'Dypyridamol',\n",
       "  'Dipyridamole'],\n",
       " 'Telithromycin': ['Telithromycin', 'telitromicina', 'Telithromycin'],\n",
       " 'Ethinylestradiol': ['17-ethinyl-3,17-estradiol',\n",
       "  '17-ethinyl-3,17-oestradiol',\n",
       "  '17-ethinylestradiol',\n",
       "  '17alpha-Ethinyl estradiol',\n",
       "  '17Î±-ethynylestradiol',\n",
       "  'Ethinyl estradiol',\n",
       "  'Ethinylestradiol',\n",
       "  'Ethinylestradiolum',\n",
       "  'Ethinyloestradiol',\n",
       "  'Ethynyl estradiol',\n",
       "  'Etinilestradiol',\n",
       "  'Ethinylestradiol'],\n",
       " 'Lomefloxacin': ['(Â±)-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid',\n",
       "  '1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid',\n",
       "  'LFLX',\n",
       "  'Lomefloxacin',\n",
       "  'Lomefloxacine',\n",
       "  'Lomefloxacino',\n",
       "  'Lomefloxacinum',\n",
       "  'Lomefloxacin'],\n",
       " 'Cyclopentolate': ['(Â±)-cyclopentolate',\n",
       "  '1-hydroxy-Î±-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester',\n",
       "  '2-(dimethylamino)ethyl 1-hydroxy-Î±-phenylcyclopentaneacetate',\n",
       "  '2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate',\n",
       "  '2-phenyl-2-(1-hydroxycyclopentyl)ethanoic acid Î²-(dimethylamino)ethyl ester',\n",
       "  'Ciclopentolato',\n",
       "  'Cyclopentolate',\n",
       "  'Cyclopentolatum',\n",
       "  'Î±-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester',\n",
       "  'Î²-(dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate',\n",
       "  'Î²-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate',\n",
       "  'Cyclopentolate'],\n",
       " 'Ramelteon': ['Ramelteon', 'Ramelteon'],\n",
       " 'Physostigmine': ['Eserine', 'Physostigmine', 'Physostol', 'Physostigmine'],\n",
       " 'Isotretinoin': ['(7E,9E,11E,13Z)-retinoic acid',\n",
       "  '13-cis-retinoic acid',\n",
       "  '13-cis-Vitamin A acid',\n",
       "  '13-RA',\n",
       "  'cis-RA',\n",
       "  'Isotretinoin',\n",
       "  'IsotretinoÃ\\xadna',\n",
       "  'IsotrÃ©tinoine',\n",
       "  'Isotretinoino',\n",
       "  'Isotretinoinum',\n",
       "  'Neovitamin A acid',\n",
       "  'Isotretinoin'],\n",
       " 'Formoterol': [\"2'-hydroxy-5'-(1-hydroxy-2-((p-methoxy-Î±-methylphenethyl)amino)ethyl)formanilide\",\n",
       "  \"2'-hydroxy-5'-{1-hydroxy-2-[(p-methoxy-Î±-methylphenethyl)amino]ethyl}formanilide\",\n",
       "  'Formoterol',\n",
       "  'Formoterolum',\n",
       "  'N-[2-hydroxy-5-(1-hydroxy-2-{[2-(4-methoxyphenyl)-1-methylethyl]amino}ethyl)phenyl]formamide',\n",
       "  'Formoterol'],\n",
       " 'Nandrolone phenpropionate': ['19NTPP',\n",
       "  'Nadrolone phenylpropionate',\n",
       "  'Nandrolon phenylpropionate',\n",
       "  'Nandrolone phenylpionate',\n",
       "  'Nandrolone phenylpropionate',\n",
       "  'Norandrolone phenyl propionate',\n",
       "  'Norandrostenolone phenylpropionate',\n",
       "  'Nortestosterone phenylpropionate',\n",
       "  'NPP',\n",
       "  'NTPP',\n",
       "  'Nandrolone phenpropionate'],\n",
       " 'Dimenhydrinate': ['(O-benzhydryl(dimethylamino)ethanol) 8-chlorotheophyllinate',\n",
       "  '8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)',\n",
       "  'Benzhydryl-Î²-dimethylaminoethylether 8-chlorotheophylline',\n",
       "  'Dimenhidrinato',\n",
       "  'Dimenhydrinate',\n",
       "  'Dimenhydrinatum',\n",
       "  'diphenhydramine 8-chlorotheophyllinate',\n",
       "  'diphenhydramine 8-chlorotheophylline',\n",
       "  'Diphenhydramine theoclate',\n",
       "  'N,N-dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate',\n",
       "  'O-benzhydryldimethylaminoethanol 8-chlorotheophyllinate',\n",
       "  'Î²-dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine',\n",
       "  'Dimenhydrinate'],\n",
       " 'Glycopyrronium': ['Glicopirronio',\n",
       "  'Glycopyrrolate cation',\n",
       "  'Glycopyrrolate ion',\n",
       "  'Glycopyrronium',\n",
       "  'Glycopyrronium cation',\n",
       "  'Glycopyrronium ion',\n",
       "  'Glycopyrronium'],\n",
       " 'Cytarabine': ['1-beta-D-Arabinofuranosylcytosine',\n",
       "  '4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone',\n",
       "  'Citarabina',\n",
       "  'Cytarabine',\n",
       "  'Cytarabinum',\n",
       "  'Cytosine arabinoside',\n",
       "  'Cytosine-1-beta-D-arabinofuranoside',\n",
       "  'cytosine-Î²-D-arabinofuranoside',\n",
       "  'Cytarabine'],\n",
       " 'Dopamine': ['2-(3,4-dihydroxyphenyl)ethylamine',\n",
       "  '3-Hydroxytyramine',\n",
       "  '3,4-Dihydroxyphenethylamine',\n",
       "  '4-(2-aminoethyl)-1,2-benzenediol',\n",
       "  '4-(2-Aminoethyl)benzene-1,2-diol',\n",
       "  '4-(2-aminoethyl)catechol',\n",
       "  '4-(2-aminoethyl)pyrocatechol',\n",
       "  'Dopamina',\n",
       "  'Dopamine',\n",
       "  'Dopaminum',\n",
       "  'Oxytyramine',\n",
       "  'Dopamine'],\n",
       " 'Rivastigmine': ['(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate',\n",
       "  'm-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate',\n",
       "  'Rivastigmina',\n",
       "  'Rivastigmine',\n",
       "  'Rivastigmine'],\n",
       " 'Exemestane': ['6-methyleneandrosta-1,4-diene-3,17-dione',\n",
       "  'Exemestane',\n",
       "  'Exemestano',\n",
       "  'Exemestanum',\n",
       "  'Exemestane'],\n",
       " 'Oxaprozin': ['Oxaprozin',\n",
       "  'Oxaprozina',\n",
       "  'Oxaprozine',\n",
       "  'Oxaprozinum',\n",
       "  'Oxaprozin'],\n",
       " 'Methyl aminolevulinate': ['5-aminolevulinic acid methyl ester',\n",
       "  'Aminolevulinato de metilo',\n",
       "  'Aminolevulinic acid methyl ester',\n",
       "  'methyl 5-aminolevulinate',\n",
       "  'Methyl aminolevulinate',\n",
       "  'Methyl delta-aminolevulinate',\n",
       "  'methyl Î´-aminolevulinate',\n",
       "  'Methyl aminolevulinate'],\n",
       " 'Azathioprine': ['6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine',\n",
       "  \"6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine\",\n",
       "  'Azamun',\n",
       "  'Azathioprine',\n",
       "  'Azathioprinum',\n",
       "  'Azatioprina',\n",
       "  'Azathioprine'],\n",
       " 'Neomycin': ['Fradiomycin',\n",
       "  'Kaomycine',\n",
       "  'Neomicina',\n",
       "  'Neomycin',\n",
       "  'Vonamycin',\n",
       "  'Neomycin'],\n",
       " 'Auranofin': ['(1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate',\n",
       "  '2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold',\n",
       "  'Auranofin',\n",
       "  'Auranofina',\n",
       "  'Auranofine',\n",
       "  'Auranofinum',\n",
       "  'Triethylphosphine gold',\n",
       "  'Auranofin'],\n",
       " 'Gabapentin': ['1-(Aminomethyl)cyclohexaneacetic acid',\n",
       "  'Gabapentin',\n",
       "  'Gabapentina',\n",
       "  'Gabapentine',\n",
       "  'Gabapentino',\n",
       "  'Gabapentinum',\n",
       "  'Gabapentin'],\n",
       " 'Doxorubicin': ['(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-Î±-L-lyxo-hexopyranoside',\n",
       "  '(8S-cis)-10-((3-amino-2,3,6-trideoxy-Î±-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione',\n",
       "  '14-hydroxydaunomycin',\n",
       "  '14-hydroxydaunorubicine',\n",
       "  'Doxorubicin',\n",
       "  'Doxorubicina',\n",
       "  'Doxorubicine',\n",
       "  'Doxorubicinum',\n",
       "  'Hydroxydaunorubicin',\n",
       "  'Doxorubicin'],\n",
       " 'Frovatriptan': ['Frovatriptan', 'Frovatriptan'],\n",
       " 'Hydrochlorothiazide': ['HCTZ',\n",
       "  'Hidroclorotiazida',\n",
       "  'Hydrochlorothiazide',\n",
       "  'Hydrochlorothiazidum',\n",
       "  'Hydrochlorothiazide'],\n",
       " 'Cyclacillin': ['(1-aminocyclohexyl)penicillin',\n",
       "  '(2S,5R,6R)-6-{[(1-aminocyclohexyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid',\n",
       "  '6-(1-aminocyclohexanecarboxamido)penicillanic acid',\n",
       "  '6-(1-aminocyclohexylcarboxamido)penicillanic acid',\n",
       "  'Ciclacilina',\n",
       "  'Ciclacillin',\n",
       "  'Ciclacilline',\n",
       "  'Ciclacillinum',\n",
       "  'Cyclacillin',\n",
       "  'Cyclacillin'],\n",
       " 'Salbutamol': ['Albuterol', 'Salbutamol', 'Salbutamolum', 'Salbutamol'],\n",
       " 'Levobupivacaine': ['(-)-bupivacaine',\n",
       "  \"(S)-1-butyl-2',6'-pipecoloxylidide\",\n",
       "  '(S)-bupivacaine',\n",
       "  \"L-(-)-1-Butyl-2',6'-pipecoloxylidide\",\n",
       "  'L-(â\\x88\\x92)-bupivacaine',\n",
       "  'LevobupivacaÃ\\xadna',\n",
       "  'Levobupivacaine',\n",
       "  'Levobupivacaine'],\n",
       " 'Cromoglicic acid': ['5-[3-(2-carboxy-4-oxo-4H-5-chromenyloxy)-2-hydroxypropoxy]-4-oxo-4H-2-chromenecarboxylic acid',\n",
       "  'Acide Cromoglicique',\n",
       "  'Acido Cromoglicico',\n",
       "  'Acidum Cromoglicicum',\n",
       "  'Cromoglicate',\n",
       "  'Cromoglicic acid',\n",
       "  'Cromoglycate',\n",
       "  'Cromoglycic acid',\n",
       "  'Cromolyn',\n",
       "  'Cromoglicic acid'],\n",
       " 'Ganciclovir': ['2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol',\n",
       "  '2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one',\n",
       "  '2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one',\n",
       "  '2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol',\n",
       "  '2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one',\n",
       "  '2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone',\n",
       "  '9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine',\n",
       "  '9-[(1,3-dihydroxy-2-propoxy)methyl]guanine',\n",
       "  'GA2',\n",
       "  'Ganciclovir',\n",
       "  'Ganciclovirum',\n",
       "  'Gancyclovir',\n",
       "  'Ganciclovir'],\n",
       " 'Hydroxyurea': ['Carbamohydroxamic acid',\n",
       "  'Carbamohydroximic acid',\n",
       "  'Carbamoyl oxime',\n",
       "  'Carbamyl hydroxamate',\n",
       "  'Hidroxicarbamida',\n",
       "  'Hydrea',\n",
       "  'Hydroxycarbamid',\n",
       "  'Hydroxycarbamide',\n",
       "  'Hydroxycarbamidum',\n",
       "  'Hydroxyharnstoff',\n",
       "  'Hydroxyurea',\n",
       "  'N-Carbamoylhydroxylamine',\n",
       "  'N-Hydroxyurea',\n",
       "  'Oxyurea',\n",
       "  'Hydroxyurea'],\n",
       " 'Letrozole': ['Letrozol', 'Letrozole', 'Letrozole'],\n",
       " 'Tioconazole': ['Tioconazol', 'Tioconazole', 'Tioconazolum', 'Tioconazole'],\n",
       " 'Busulfan': ['1,4-Bis(methanesulfonoxy)butane',\n",
       "  '1,4-Butanediol dimethanesulfonate',\n",
       "  '1,4-Dimesyloxybutane',\n",
       "  '1,4-Dimethanesulfonoxybutane',\n",
       "  'Busulfan',\n",
       "  'Busulfano',\n",
       "  'Busulfanum',\n",
       "  'Busulphan',\n",
       "  'Tetramethylene bis(methanesulfonate)',\n",
       "  'Busulfan'],\n",
       " 'Ketoprofen': ['2-(3-Benzoylphenyl)propionic acid',\n",
       "  '3-Benzoyl-alpha-methylbenzeneacetic acid',\n",
       "  '3-Benzoyl-Î±-methylbenzeneacetic acid',\n",
       "  '3-Benzoylhydratropic acid',\n",
       "  'Ketoprofen',\n",
       "  'Ketoprofeno',\n",
       "  \"L'acide (benzoyl-3-phenyl)-2-propionique\",\n",
       "  'm-Benzoylhydratropic acid',\n",
       "  'Ketoprofen'],\n",
       " 'Edrophonium': ['(3-hydroxyphenyl)dimethylethylammonium',\n",
       "  '3-hydroxy-N,N-dimethyl-N-ethylanilinium',\n",
       "  'Edrophonium cation',\n",
       "  'Edrophonium ion',\n",
       "  'Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium',\n",
       "  'N-ethyl-3-hydroxy-N,N-dimethylanilinium',\n",
       "  'N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium',\n",
       "  'Edrophonium'],\n",
       " 'Metyrapone': ['Metirapona',\n",
       "  'MÃ©tyrapone',\n",
       "  'Metyrapone',\n",
       "  'Metyraponum',\n",
       "  'Metyrapone'],\n",
       " 'Cinacalcet': ['(R)-Î±-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine',\n",
       "  'Cinacalcet',\n",
       "  'CNC',\n",
       "  'N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine',\n",
       "  'Cinacalcet'],\n",
       " 'Clobetasol propionate': ['21-chloro-9-fluoro-11Î²,17-dihydroxy-16Î²-methylpregna-1,4-diene-3,20-dione 17-propionate',\n",
       "  'clobetasol 17-propanoate',\n",
       "  'clobetasol 17-propionate',\n",
       "  'Clobetasol propionate',\n",
       "  'Clobetasol propionate E',\n",
       "  'Clobetasol propionate'],\n",
       " 'Balsalazide': ['(E)-5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid',\n",
       "  '(E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid',\n",
       "  '3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid',\n",
       "  '5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid',\n",
       "  'Balsalazida',\n",
       "  'Balsalazide',\n",
       "  'Balsalazidum',\n",
       "  'Balsalazide'],\n",
       " 'Sulfamethoxazole': ['3-(p-Aminophenylsulfonamido)-5-methylisoxazole',\n",
       "  '3-Sulfanilamido-5-methylisoxazole',\n",
       "  '4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide',\n",
       "  'SMX',\n",
       "  'Sulfamethoxazole',\n",
       "  'Sulfametoxazol',\n",
       "  'Sulphamethoxazole',\n",
       "  'Sulfamethoxazole'],\n",
       " 'Glyburide': ['1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea',\n",
       "  '1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea',\n",
       "  '5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide',\n",
       "  'Glibenclamida',\n",
       "  'Glibenclamide',\n",
       "  'Glibenclamidum',\n",
       "  'Glyburide',\n",
       "  'Glyburide'],\n",
       " 'Minocycline': ['(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide',\n",
       "  '7-Dimethylamino-6-demethyl-6-deoxytetracycline',\n",
       "  'Minociclina',\n",
       "  'Minociclinum',\n",
       "  'Minocyclin',\n",
       "  'Minocycline',\n",
       "  'Minocyclinum',\n",
       "  'Minomycin',\n",
       "  'Minocycline'],\n",
       " ...}"
      ]
     },
     "execution_count": 109,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\mese4\\Anaconda3\\lib\\site-packages\\IPython\\core\\interactiveshell.py:3063: DtypeWarning: Columns (32,34,38) have mixed types.Specify dtype option on import or set low_memory=False.\n",
      "  interactivity=interactivity, compiler=compiler, result=result)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th># ensembl_gene_id</th>\n",
       "      <th>hgnc_id</th>\n",
       "      <th>symbol</th>\n",
       "      <th>name</th>\n",
       "      <th>locus_group</th>\n",
       "      <th>locus_type</th>\n",
       "      <th>status</th>\n",
       "      <th>location</th>\n",
       "      <th>location_sortable</th>\n",
       "      <th>alias_symbol</th>\n",
       "      <th>...</th>\n",
       "      <th>horde_id</th>\n",
       "      <th>merops</th>\n",
       "      <th>imgt</th>\n",
       "      <th>iuphar</th>\n",
       "      <th>kznf_gene_catalog</th>\n",
       "      <th>mamit-trnadb</th>\n",
       "      <th>cd</th>\n",
       "      <th>lncrnadb</th>\n",
       "      <th>enzyme_id</th>\n",
       "      <th>intermediate_filament_db</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ENSG00000121410</td>\n",
       "      <td>HGNC:5</td>\n",
       "      <td>A1BG</td>\n",
       "      <td>alpha-1-B glycoprotein</td>\n",
       "      <td>protein-coding gene</td>\n",
       "      <td>gene with protein product</td>\n",
       "      <td>Approved</td>\n",
       "      <td>19q13.43</td>\n",
       "      <td>19q13.43</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>I43.950</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ENSG00000268895</td>\n",
       "      <td>HGNC:37133</td>\n",
       "      <td>A1BG-AS1</td>\n",
       "      <td>A1BG antisense RNA 1</td>\n",
       "      <td>non-coding RNA</td>\n",
       "      <td>RNA, long non-coding</td>\n",
       "      <td>Approved</td>\n",
       "      <td>19q13.43</td>\n",
       "      <td>19q13.43</td>\n",
       "      <td>FLJ23569</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ENSG00000148584</td>\n",
       "      <td>HGNC:24086</td>\n",
       "      <td>A1CF</td>\n",
       "      <td>APOBEC1 complementation factor</td>\n",
       "      <td>protein-coding gene</td>\n",
       "      <td>gene with protein product</td>\n",
       "      <td>Approved</td>\n",
       "      <td>10q21.1</td>\n",
       "      <td>10q21.1</td>\n",
       "      <td>ACF|ASP|ACF64|ACF65|APOBEC1CF</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ENSG00000175899</td>\n",
       "      <td>HGNC:7</td>\n",
       "      <td>A2M</td>\n",
       "      <td>alpha-2-macroglobulin</td>\n",
       "      <td>protein-coding gene</td>\n",
       "      <td>gene with protein product</td>\n",
       "      <td>Approved</td>\n",
       "      <td>12p13.31</td>\n",
       "      <td>12p13.31</td>\n",
       "      <td>FWP007|S863-7|CPAMD5</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>I39.001</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>ENSG00000245105</td>\n",
       "      <td>HGNC:27057</td>\n",
       "      <td>A2M-AS1</td>\n",
       "      <td>A2M antisense RNA 1 (head to head)</td>\n",
       "      <td>non-coding RNA</td>\n",
       "      <td>RNA, long non-coding</td>\n",
       "      <td>Approved</td>\n",
       "      <td>12p13.31</td>\n",
       "      <td>12p13.31</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>ENSG00000166535</td>\n",
       "      <td>HGNC:23336</td>\n",
       "      <td>A2ML1</td>\n",
       "      <td>alpha-2-macroglobulin like 1</td>\n",
       "      <td>protein-coding gene</td>\n",
       "      <td>gene with protein product</td>\n",
       "      <td>Approved</td>\n",
       "      <td>12p13</td>\n",
       "      <td>12p13</td>\n",
       "      <td>FLJ25179</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>I39.007</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>ENSG00000256661</td>\n",
       "      <td>HGNC:41022</td>\n",
       "      <td>A2ML1-AS1</td>\n",
       "      <td>A2ML1 antisense RNA 1</td>\n",
       "      <td>non-coding RNA</td>\n",
       "      <td>RNA, long non-coding</td>\n",
       "      <td>Approved</td>\n",
       "      <td>12p13.31</td>\n",
       "      <td>12p13.31</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>ENSG00000256904</td>\n",
       "      <td>HGNC:41523</td>\n",
       "      <td>A2ML1-AS2</td>\n",
       "      <td>A2ML1 antisense RNA 2</td>\n",
       "      <td>non-coding RNA</td>\n",
       "      <td>RNA, long non-coding</td>\n",
       "      <td>Approved</td>\n",
       "      <td>12p13.31</td>\n",
       "      <td>12p13.31</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>ENSG00000256069</td>\n",
       "      <td>HGNC:8</td>\n",
       "      <td>A2MP1</td>\n",
       "      <td>alpha-2-macroglobulin pseudogene 1</td>\n",
       "      <td>pseudogene</td>\n",
       "      <td>pseudogene</td>\n",
       "      <td>Approved</td>\n",
       "      <td>12p13.31</td>\n",
       "      <td>12p13.31</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>ENSG00000184389</td>\n",
       "      <td>HGNC:30005</td>\n",
       "      <td>A3GALT2</td>\n",
       "      <td>alpha 1,3-galactosyltransferase 2</td>\n",
       "      <td>protein-coding gene</td>\n",
       "      <td>gene with protein product</td>\n",
       "      <td>Approved</td>\n",
       "      <td>1p35.1</td>\n",
       "      <td>01p35.1</td>\n",
       "      <td>IGBS3S|IGB3S</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10 rows × 48 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "  # ensembl_gene_id     hgnc_id     symbol  \\\n",
       "0   ENSG00000121410      HGNC:5       A1BG   \n",
       "1   ENSG00000268895  HGNC:37133   A1BG-AS1   \n",
       "2   ENSG00000148584  HGNC:24086       A1CF   \n",
       "3   ENSG00000175899      HGNC:7        A2M   \n",
       "4   ENSG00000245105  HGNC:27057    A2M-AS1   \n",
       "5   ENSG00000166535  HGNC:23336      A2ML1   \n",
       "6   ENSG00000256661  HGNC:41022  A2ML1-AS1   \n",
       "7   ENSG00000256904  HGNC:41523  A2ML1-AS2   \n",
       "8   ENSG00000256069      HGNC:8      A2MP1   \n",
       "9   ENSG00000184389  HGNC:30005    A3GALT2   \n",
       "\n",
       "                                 name          locus_group  \\\n",
       "0              alpha-1-B glycoprotein  protein-coding gene   \n",
       "1                A1BG antisense RNA 1       non-coding RNA   \n",
       "2      APOBEC1 complementation factor  protein-coding gene   \n",
       "3               alpha-2-macroglobulin  protein-coding gene   \n",
       "4  A2M antisense RNA 1 (head to head)       non-coding RNA   \n",
       "5        alpha-2-macroglobulin like 1  protein-coding gene   \n",
       "6               A2ML1 antisense RNA 1       non-coding RNA   \n",
       "7               A2ML1 antisense RNA 2       non-coding RNA   \n",
       "8  alpha-2-macroglobulin pseudogene 1           pseudogene   \n",
       "9   alpha 1,3-galactosyltransferase 2  protein-coding gene   \n",
       "\n",
       "                  locus_type    status  location location_sortable  \\\n",
       "0  gene with protein product  Approved  19q13.43          19q13.43   \n",
       "1       RNA, long non-coding  Approved  19q13.43          19q13.43   \n",
       "2  gene with protein product  Approved   10q21.1           10q21.1   \n",
       "3  gene with protein product  Approved  12p13.31          12p13.31   \n",
       "4       RNA, long non-coding  Approved  12p13.31          12p13.31   \n",
       "5  gene with protein product  Approved     12p13             12p13   \n",
       "6       RNA, long non-coding  Approved  12p13.31          12p13.31   \n",
       "7       RNA, long non-coding  Approved  12p13.31          12p13.31   \n",
       "8                 pseudogene  Approved  12p13.31          12p13.31   \n",
       "9  gene with protein product  Approved    1p35.1           01p35.1   \n",
       "\n",
       "                    alias_symbol  ... horde_id   merops imgt iuphar  \\\n",
       "0                            NaN  ...      NaN  I43.950  NaN    NaN   \n",
       "1                       FLJ23569  ...      NaN      NaN  NaN    NaN   \n",
       "2  ACF|ASP|ACF64|ACF65|APOBEC1CF  ...      NaN      NaN  NaN    NaN   \n",
       "3           FWP007|S863-7|CPAMD5  ...      NaN  I39.001  NaN    NaN   \n",
       "4                            NaN  ...      NaN      NaN  NaN    NaN   \n",
       "5                       FLJ25179  ...      NaN  I39.007  NaN    NaN   \n",
       "6                            NaN  ...      NaN      NaN  NaN    NaN   \n",
       "7                            NaN  ...      NaN      NaN  NaN    NaN   \n",
       "8                            NaN  ...      NaN      NaN  NaN    NaN   \n",
       "9                   IGBS3S|IGB3S  ...      NaN      NaN  NaN    NaN   \n",
       "\n",
       "  kznf_gene_catalog mamit-trnadb   cd lncrnadb enzyme_id  \\\n",
       "0               NaN          NaN  NaN      NaN       NaN   \n",
       "1               NaN          NaN  NaN      NaN       NaN   \n",
       "2               NaN          NaN  NaN      NaN       NaN   \n",
       "3               NaN          NaN  NaN      NaN       NaN   \n",
       "4               NaN          NaN  NaN      NaN       NaN   \n",
       "5               NaN          NaN  NaN      NaN       NaN   \n",
       "6               NaN          NaN  NaN      NaN       NaN   \n",
       "7               NaN          NaN  NaN      NaN       NaN   \n",
       "8               NaN          NaN  NaN      NaN       NaN   \n",
       "9               NaN          NaN  NaN      NaN       NaN   \n",
       "\n",
       "   intermediate_filament_db  \n",
       "0                       NaN  \n",
       "1                       NaN  \n",
       "2                       NaN  \n",
       "3                       NaN  \n",
       "4                       NaN  \n",
       "5                       NaN  \n",
       "6                       NaN  \n",
       "7                       NaN  \n",
       "8                       NaN  \n",
       "9                       NaN  \n",
       "\n",
       "[10 rows x 48 columns]"
      ]
     },
     "execution_count": 90,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_genes=pd.read_csv(r\"C:\\Users\\mese4\\Documents\\The Data incubator\\project\\genes_dataset\\G-SynMiner_miner-geneHUGO.tsv\",sep='\\t')\n",
    "#df_genes=df_genes.set_index('symbol')\n",
    "df_genes.head(10)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'A1BG': ['nan', 'A1BG', 'alpha-1-B glycoprotein'],\n",
       " 'A1BG-AS1': ['FLJ23569', 'A1BG-AS1', 'A1BG antisense RNA 1'],\n",
       " 'A1CF': ['ACF',\n",
       "  'ASP',\n",
       "  'ACF64',\n",
       "  'ACF65',\n",
       "  'APOBEC1CF',\n",
       "  'A1CF',\n",
       "  'APOBEC1 complementation factor'],\n",
       " 'A2M': ['FWP007', 'S863-7', 'CPAMD5', 'A2M', 'alpha-2-macroglobulin'],\n",
       " 'A2M-AS1': ['nan', 'A2M-AS1', 'A2M antisense RNA 1 (head to head)'],\n",
       " 'A2ML1': ['FLJ25179', 'A2ML1', 'alpha-2-macroglobulin like 1'],\n",
       " 'A2ML1-AS1': ['nan', 'A2ML1-AS1', 'A2ML1 antisense RNA 1'],\n",
       " 'A2ML1-AS2': ['nan', 'A2ML1-AS2', 'A2ML1 antisense RNA 2'],\n",
       " 'A2MP1': ['nan', 'A2MP1', 'alpha-2-macroglobulin pseudogene 1'],\n",
       " 'A3GALT2': ['IGBS3S',\n",
       "  'IGB3S',\n",
       "  'A3GALT2',\n",
       "  'alpha 1,3-galactosyltransferase 2'],\n",
       " 'A4GALT': ['A14GALT',\n",
       "  'Gb3S',\n",
       "  'P(k)',\n",
       "  'A4GALT',\n",
       "  'alpha 1,4-galactosyltransferase'],\n",
       " 'A4GNT': ['alpha4GnT', 'A4GNT', 'alpha-1,4-N-acetylglucosaminyltransferase'],\n",
       " 'AAAS': ['nan', 'AAAS', 'aladin WD repeat nucleoporin'],\n",
       " 'AACS': ['FLJ12389', 'SUR-5', 'ACSF1', 'AACS', 'acetoacetyl-CoA synthetase'],\n",
       " 'AACSP1': ['nan', 'AACSP1', 'acetoacetyl-CoA synthetase pseudogene 1'],\n",
       " 'AADAC': ['DAC', 'CES5A1', 'AADAC', 'arylacetamide deacetylase'],\n",
       " 'AADACL2': ['MGC72001', 'AADACL2', 'arylacetamide deacetylase-like 2'],\n",
       " 'AADACL2-AS1': ['nan', 'AADACL2-AS1', 'AADACL2 antisense RNA 1'],\n",
       " 'AADACL3': ['OTTHUMG00000001887',\n",
       "  'AADACL3',\n",
       "  'arylacetamide deacetylase-like 3'],\n",
       " 'AADACL4': ['OTTHUMG00000001889',\n",
       "  'AADACL4',\n",
       "  'arylacetamide deacetylase-like 4'],\n",
       " 'AADACP1': ['nan', 'AADACP1', 'arylacetamide deacetylase pseudogene 1'],\n",
       " 'AADAT': ['KATII', 'KAT2', 'AADAT', 'aminoadipate aminotransferase'],\n",
       " 'AAED1': ['nan', 'AAED1', 'AhpC/TSA antioxidant enzyme domain containing 1'],\n",
       " 'AAGAB': ['FLJ11506',\n",
       "  'p34',\n",
       "  'AAGAB',\n",
       "  'alpha- and gamma-adaptin binding protein'],\n",
       " 'AAK1': ['KIAA1048', 'DKFZp686K16132', 'AAK1', 'AP2 associated kinase 1'],\n",
       " 'AAMDC': ['PTD015',\n",
       "  'FLJ21035',\n",
       "  'CK067',\n",
       "  'AAMDC',\n",
       "  'adipogenesis associated, Mth938 domain containing'],\n",
       " 'AAMP': ['nan', 'AAMP', 'angio associated migratory cell protein'],\n",
       " 'AANAT': ['SNAT', 'AANAT', 'aralkylamine N-acetyltransferase'],\n",
       " 'AAR2': ['bA234K24.2', 'AAR2', 'AAR2 splicing factor homolog'],\n",
       " 'AARD': ['LOC441376',\n",
       "  'AARD',\n",
       "  'alanine and arginine rich domain containing protein'],\n",
       " 'AARS': ['CMT2N', 'AARS', 'alanyl-tRNA synthetase'],\n",
       " 'AARS2': ['KIAA1270',\n",
       "  'bA444E17.1',\n",
       "  'AARS2',\n",
       "  'alanyl-tRNA synthetase 2, mitochondrial'],\n",
       " 'AARSD1': ['MGC2744', 'AARSD1', 'alanyl-tRNA synthetase domain containing 1'],\n",
       " 'AARSP1': ['nan', 'AARSP1', 'alanyl-tRNA synthetase pseudogene 1'],\n",
       " 'AASDH': ['NRPS998',\n",
       "  'LYS2',\n",
       "  'ACSF4',\n",
       "  'AASDH',\n",
       "  'aminoadipate-semialdehyde dehydrogenase'],\n",
       " 'AASDHPPT': ['LYS5',\n",
       "  'CGI-80',\n",
       "  'AASD-PPT',\n",
       "  'ACPS',\n",
       "  'AASDHPPT',\n",
       "  'aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase'],\n",
       " 'AASS': ['LORSDH', 'LKRSDH', 'AASS', 'aminoadipate-semialdehyde synthase'],\n",
       " 'AATBC': ['nan',\n",
       "  'AATBC',\n",
       "  'apoptosis associated transcript in bladder cancer'],\n",
       " 'AATF': ['DED',\n",
       "  'CHE-1',\n",
       "  'CHE1',\n",
       "  'BFR2',\n",
       "  'AATF',\n",
       "  'apoptosis antagonizing transcription factor'],\n",
       " 'AATK': ['AATYK',\n",
       "  'KIAA0641',\n",
       "  'LMTK1',\n",
       "  'LMR1',\n",
       "  'AATYK1',\n",
       "  'PPP1R77',\n",
       "  'AATK',\n",
       "  'apoptosis-associated tyrosine kinase'],\n",
       " 'AATK-AS1': ['nan', 'AATK-AS1', 'AATK antisense RNA 1'],\n",
       " 'ABALON': ['INXS',\n",
       "  'ABALON',\n",
       "  'apoptotic BCL2L1-antisense long non-coding RNA'],\n",
       " 'ABAT': ['GABAT', 'ABAT', '4-aminobutyrate aminotransferase'],\n",
       " 'ABCA1': ['TGD', 'ABCA1', 'ATP binding cassette subfamily A member 1'],\n",
       " 'ABCA2': ['nan', 'ABCA2', 'ATP binding cassette subfamily A member 2'],\n",
       " 'ABCA3': ['ABC-C',\n",
       "  'EST111653',\n",
       "  'LBM180',\n",
       "  'ABCA3',\n",
       "  'ATP binding cassette subfamily A member 3'],\n",
       " 'ABCA4': ['FFM',\n",
       "  'ARMD2',\n",
       "  'CORD3',\n",
       "  'ABCA4',\n",
       "  'ATP binding cassette subfamily A member 4'],\n",
       " 'ABCA5': ['EST90625', 'ABCA5', 'ATP binding cassette subfamily A member 5'],\n",
       " 'ABCA6': ['EST155051', 'ABCA6', 'ATP binding cassette subfamily A member 6'],\n",
       " 'ABCA7': ['ABCX', 'ABCA7', 'ATP binding cassette subfamily A member 7'],\n",
       " 'ABCA8': ['KIAA0822', 'ABCA8', 'ATP binding cassette subfamily A member 8'],\n",
       " 'ABCA9': ['EST640918', 'ABCA9', 'ATP binding cassette subfamily A member 9'],\n",
       " 'ABCA9-AS1': ['nan', 'ABCA9-AS1', 'ABCA9 antisense RNA 1'],\n",
       " 'ABCA10': ['EST698739',\n",
       "  'ABCA10',\n",
       "  'ATP binding cassette subfamily A member 10'],\n",
       " 'ABCA11P': ['EST1133530',\n",
       "  'FLJ14297',\n",
       "  'ABCA11P',\n",
       "  'ATP binding cassette subfamily A member 11, pseudogene'],\n",
       " 'ABCA12': ['DKFZP434G232',\n",
       "  'LI2',\n",
       "  'ABCA12',\n",
       "  'ATP binding cassette subfamily A member 12'],\n",
       " 'ABCA13': ['FLJ33876',\n",
       "  'FLJ33951',\n",
       "  'ABCA13',\n",
       "  'ATP binding cassette subfamily A member 13'],\n",
       " 'ABCA17P': ['nan',\n",
       "  'ABCA17P',\n",
       "  'ATP binding cassette subfamily A member 17, pseudogene'],\n",
       " 'ABCB1': ['P-gp',\n",
       "  'CD243',\n",
       "  'GP170',\n",
       "  'ABC20',\n",
       "  'ABCB1',\n",
       "  'ATP binding cassette subfamily B member 1'],\n",
       " 'ABCB4': ['MDR2',\n",
       "  'PFIC-3',\n",
       "  'GBD1',\n",
       "  'ABCB4',\n",
       "  'ATP binding cassette subfamily B member 4'],\n",
       " 'ABCB5': ['EST422562',\n",
       "  'ABCB5beta',\n",
       "  'ABCB5alpha',\n",
       "  'ABCB5',\n",
       "  'ATP binding cassette subfamily B member 5'],\n",
       " 'ABCB6': ['EST45597',\n",
       "  'umat',\n",
       "  'MTABC3',\n",
       "  'ABCB6',\n",
       "  'ATP binding cassette subfamily B member 6 (Langereis blood group)'],\n",
       " 'ABCB7': ['EST140535',\n",
       "  'Atm1p',\n",
       "  'ASAT',\n",
       "  'ABCB7',\n",
       "  'ATP binding cassette subfamily B member 7'],\n",
       " 'ABCB8': ['EST328128',\n",
       "  'M-ABC1',\n",
       "  'MABC1',\n",
       "  'ABCB8',\n",
       "  'ATP binding cassette subfamily B member 8'],\n",
       " 'ABCB9': ['EST122234', 'ABCB9', 'ATP binding cassette subfamily B member 9'],\n",
       " 'ABCB10': ['EST20237',\n",
       "  'M-ABC2',\n",
       "  'MTABC2',\n",
       "  'ABCB10',\n",
       "  'ATP binding cassette subfamily B member 10'],\n",
       " 'ABCB10P1': ['M-ABC2',\n",
       "  'MABC2',\n",
       "  'ABCB10P1',\n",
       "  'ATP binding cassette subfamily B member 10 pseudogene 1'],\n",
       " 'ABCB10P3': ['nan',\n",
       "  'ABCB10P3',\n",
       "  'ATP binding cassette subfamily B member 10 pseudogene 3'],\n",
       " 'ABCB10P4': ['nan',\n",
       "  'ABCB10P4',\n",
       "  'ATP binding cassette subfamily B member 10 pseudogene 4'],\n",
       " 'ABCB11': ['ABC16',\n",
       "  'SPGP',\n",
       "  'PFIC-2',\n",
       "  'PGY4',\n",
       "  'ABCB11',\n",
       "  'ATP binding cassette subfamily B member 11'],\n",
       " 'ABCC1': ['GS-X', 'ABCC1', 'ATP binding cassette subfamily C member 1'],\n",
       " 'ABCC2': ['DJS',\n",
       "  'MRP2',\n",
       "  'cMRP',\n",
       "  'ABCC2',\n",
       "  'ATP binding cassette subfamily C member 2'],\n",
       " 'ABCC3': ['MRP3',\n",
       "  'cMOAT2',\n",
       "  'EST90757',\n",
       "  'MLP2',\n",
       "  'MOAT-D',\n",
       "  'ABCC3',\n",
       "  'ATP binding cassette subfamily C member 3'],\n",
       " 'ABCC4': ['MRP4',\n",
       "  'EST170205',\n",
       "  'MOAT-B',\n",
       "  'MOATB',\n",
       "  'ABCC4',\n",
       "  'ATP binding cassette subfamily C member 4'],\n",
       " 'ABCC5': ['MRP5',\n",
       "  'SMRP',\n",
       "  'EST277145',\n",
       "  'MOAT-C',\n",
       "  'ABCC5',\n",
       "  'ATP binding cassette subfamily C member 5'],\n",
       " 'ABCC5-AS1': ['nan', 'ABCC5-AS1', 'ABCC5 antisense RNA 1'],\n",
       " 'ABCC6': ['MRP6',\n",
       "  'EST349056',\n",
       "  'MLP1',\n",
       "  'URG7',\n",
       "  'ABCC6',\n",
       "  'ATP binding cassette subfamily C member 6'],\n",
       " 'ABCC6P1': ['nan',\n",
       "  'ABCC6P1',\n",
       "  'ATP binding cassette subfamily C member 6 pseudogene 1'],\n",
       " 'ABCC6P2': ['nan',\n",
       "  'ABCC6P2',\n",
       "  'ATP binding cassette subfamily C member 6 pseudogene 2'],\n",
       " 'ABCC8': ['HI',\n",
       "  'PHHI',\n",
       "  'SUR1',\n",
       "  'MRP8',\n",
       "  'ABC36',\n",
       "  'HHF1',\n",
       "  'TNDM2',\n",
       "  'ABCC8',\n",
       "  'ATP binding cassette subfamily C member 8'],\n",
       " 'ABCC9': ['SUR2',\n",
       "  'CMD1O',\n",
       "  'ABCC9',\n",
       "  'ATP binding cassette subfamily C member 9'],\n",
       " 'ABCC10': ['EST182763',\n",
       "  'MRP7',\n",
       "  'SIMRP7',\n",
       "  'ABCC10',\n",
       "  'ATP binding cassette subfamily C member 10'],\n",
       " 'ABCC11': ['MRP8', 'ABCC11', 'ATP binding cassette subfamily C member 11'],\n",
       " 'ABCC12': ['MRP9', 'ABCC12', 'ATP binding cassette subfamily C member 12'],\n",
       " 'ABCC13': ['PRED6',\n",
       "  'C21orf73',\n",
       "  'ABCC13P',\n",
       "  'ABCC13',\n",
       "  'ATP binding cassette subfamily C member 13 (pseudogene)'],\n",
       " 'ABCD1': ['AMN',\n",
       "  'ALDP',\n",
       "  'adrenoleukodystrophy',\n",
       "  'ABCD1',\n",
       "  'ATP binding cassette subfamily D member 1'],\n",
       " 'ABCD1P2': ['bA453N3.6',\n",
       "  'ABCD1P2',\n",
       "  'ATP binding cassette subfamily D member 1 pseudogene 2'],\n",
       " 'ABCD1P3': ['nan',\n",
       "  'ABCD1P3',\n",
       "  'ATP binding cassette subfamily D member 1 pseudogene 3'],\n",
       " 'ABCD1P4': ['nan',\n",
       "  'ABCD1P4',\n",
       "  'ATP binding cassette subfamily D member 1 pseudogene 4'],\n",
       " 'ABCD1P5': ['nan',\n",
       "  'ABCD1P5',\n",
       "  'ATP binding cassette subfamily D member 1 pseudogene 5'],\n",
       " 'ABCD2': ['ALDR',\n",
       "  'ALDRP',\n",
       "  'ABCD2',\n",
       "  'ATP binding cassette subfamily D member 2'],\n",
       " 'ABCD3': ['PMP70',\n",
       "  'ZWS2',\n",
       "  'ABCD3',\n",
       "  'ATP binding cassette subfamily D member 3'],\n",
       " 'ABCD4': ['PMP69',\n",
       "  'P70R',\n",
       "  'EST352188',\n",
       "  'ABCD4',\n",
       "  'ATP binding cassette subfamily D member 4'],\n",
       " 'ABCE1': ['RLI',\n",
       "  'OABP',\n",
       "  'ABCE1',\n",
       "  'ATP binding cassette subfamily E member 1'],\n",
       " 'ABCF1': ['EST123147', 'ABCF1', 'ATP binding cassette subfamily F member 1'],\n",
       " 'ABCF2': ['EST133090',\n",
       "  'ABC28',\n",
       "  'M-ABC1',\n",
       "  'HUSSY-18',\n",
       "  'ABCF2',\n",
       "  'ATP binding cassette subfamily F member 2'],\n",
       " 'ABCF2P1': ['nan',\n",
       "  'ABCF2P1',\n",
       "  'ATP binding cassette subfamily F member 2 pseudogene 1'],\n",
       " 'ABCF2P2': ['nan',\n",
       "  'ABCF2P2',\n",
       "  'ATP binding cassette subfamily F member 2 pseudogene 2'],\n",
       " 'ABCF3': ['EST201864', 'ABCF3', 'ATP binding cassette subfamily F member 3'],\n",
       " 'ABCG1': ['ABC8', 'ABCG1', 'ATP binding cassette subfamily G member 1'],\n",
       " 'ABCG2': ['EST157481',\n",
       "  'MXR',\n",
       "  'BCRP',\n",
       "  'ABCP',\n",
       "  'CD338',\n",
       "  'ABCG2',\n",
       "  'ATP binding cassette subfamily G member 2 (Junior blood group)'],\n",
       " 'ABCG4': ['WHITE2', 'ABCG4', 'ATP binding cassette subfamily G member 4'],\n",
       " 'ABCG5': ['STSL', 'ABCG5', 'ATP binding cassette subfamily G member 5'],\n",
       " 'ABCG8': ['GBD4', 'ABCG8', 'ATP binding cassette subfamily G member 8'],\n",
       " 'ABHD1': ['LABH1', 'FLJ36128', 'ABHD1', 'abhydrolase domain containing 1'],\n",
       " 'ABHD2': ['LABH2', 'ABHD2', 'abhydrolase domain containing 2'],\n",
       " 'ABHD3': ['LABH3', 'ABHD3', 'abhydrolase domain containing 3'],\n",
       " 'ABHD4': ['FLJ12816', 'ABHD4', 'abhydrolase domain containing 4'],\n",
       " 'ABHD5': ['CGI-58', 'NCIE2', 'ABHD5', 'abhydrolase domain containing 5'],\n",
       " 'ABHD6': ['nan', 'ABHD6', 'abhydrolase domain containing 6'],\n",
       " 'ABHD8': ['FLJ11743',\n",
       "  'MGC14280',\n",
       "  'MGC2512',\n",
       "  'ABHD8',\n",
       "  'abhydrolase domain containing 8'],\n",
       " 'ABHD10': ['FLJ11342', 'ABHD10', 'abhydrolase domain containing 10'],\n",
       " 'ABHD11': ['PP1226', 'ABHD11', 'abhydrolase domain containing 11'],\n",
       " 'ABHD11-AS1': ['NCRNA00035',\n",
       "  'ABHD11-AS1',\n",
       "  'ABHD11 antisense RNA 1 (tail to tail)'],\n",
       " 'ABHD12': ['DKFZP434P106',\n",
       "  'dJ965G21.2',\n",
       "  'BEM46L2',\n",
       "  'ABHD12A',\n",
       "  'ABHD12',\n",
       "  'abhydrolase domain containing 12'],\n",
       " 'ABHD12B': ['BEM46L3', 'ABHD12B', 'abhydrolase domain containing 12B'],\n",
       " 'ABHD13': ['bA153I24.2',\n",
       "  'FLJ14906',\n",
       "  'BEM46L1',\n",
       "  'ABHD13',\n",
       "  'abhydrolase domain containing 13'],\n",
       " 'ABHD14A': ['DKFZP564O243',\n",
       "  'DORZ1',\n",
       "  'ABHD14A',\n",
       "  'abhydrolase domain containing 14A'],\n",
       " 'ABHD14A-ACY1': ['nan', 'ABHD14A-ACY1', 'ABHD14A-ACY1 readthrough'],\n",
       " 'ABHD14B': ['MGC15429',\n",
       "  'CIB',\n",
       "  'ABHD14B',\n",
       "  'abhydrolase domain containing 14B'],\n",
       " 'ABHD15': ['nan', 'ABHD15', 'abhydrolase domain containing 15'],\n",
       " 'ABHD15-AS1': ['linc-TP53I13',\n",
       "  'lnc-TP53I13',\n",
       "  'ABHD15-AS1',\n",
       "  'ABHD15 antisense RNA 1'],\n",
       " 'ABHD16A': ['NG26', 'D6S82E', 'ABHD16A', 'abhydrolase domain containing 16A'],\n",
       " 'ABHD16B': ['dJ591C20.1', 'ABHD16B', 'abhydrolase domain containing 16B'],\n",
       " 'ABHD17A': ['MGC5244', 'ABHD17A', 'abhydrolase domain containing 17A'],\n",
       " 'ABHD17AP1': ['C1orf47',\n",
       "  'ABHD17AP1',\n",
       "  'abhydrolase domain containing 17A pseudogene 1'],\n",
       " 'ABHD17AP3': ['nan',\n",
       "  'ABHD17AP3',\n",
       "  'abhydrolase domain containing 17A pseudogene 3'],\n",
       " 'ABHD17AP4': ['nan',\n",
       "  'ABHD17AP4',\n",
       "  'abhydrolase domain containing 17A pseudogene P4'],\n",
       " 'ABHD17AP5': ['nan',\n",
       "  'ABHD17AP5',\n",
       "  'abhydrolase domain containing 17A pseudogene 5'],\n",
       " 'ABHD17AP6': ['nan',\n",
       "  'ABHD17AP6',\n",
       "  'abhydrolase domain containing 17A pseudogene 6'],\n",
       " 'ABHD17AP7': ['nan',\n",
       "  'ABHD17AP7',\n",
       "  'abhydrolase domain containing 17A pseudogene 7'],\n",
       " 'ABHD17AP8': ['nan',\n",
       "  'ABHD17AP8',\n",
       "  'abhydrolase domain containing 17A pseudogene 8'],\n",
       " 'ABHD17AP9': ['nan',\n",
       "  'ABHD17AP9',\n",
       "  'abhydrolase domain containing 17A pseudogene 9'],\n",
       " 'ABHD17B': ['CGI-67', 'ABHD17B', 'abhydrolase domain containing 17B'],\n",
       " 'ABHD17C': ['nan', 'ABHD17C', 'abhydrolase domain containing 17C'],\n",
       " 'ABHD18': ['FLJ21106', 'ABHD18', 'abhydrolase domain containing 18'],\n",
       " 'ABI1': ['E3B1', 'ABI-1', 'ABI1', 'abl interactor 1'],\n",
       " 'ABI2': ['ABI-2',\n",
       "  'AIP-1',\n",
       "  'ABI2B',\n",
       "  'AblBP3',\n",
       "  'argBPIA',\n",
       "  'SSH3BP2',\n",
       "  'ABI2',\n",
       "  'abl-interactor 2'],\n",
       " 'ABI3': ['NESH', 'SSH3BP3', 'ABI3', 'ABI family member 3'],\n",
       " 'ABI3BP': ['NESHBP',\n",
       "  'DKFZP586L2024',\n",
       "  'TARSH',\n",
       "  'ABI3BP',\n",
       "  'ABI family member 3 binding protein'],\n",
       " 'ABL1': ['JTK7',\n",
       "  'c-ABL',\n",
       "  'p150',\n",
       "  'ABL1',\n",
       "  'ABL proto-oncogene 1, non-receptor tyrosine kinase'],\n",
       " 'ABL2': ['ARG', 'ABL2', 'ABL proto-oncogene 2, non-receptor tyrosine kinase'],\n",
       " 'ABLIM1': ['abLIM', 'limatin', 'ABLIM1', 'actin binding LIM protein 1'],\n",
       " 'ABLIM2': ['KIAA1808', 'ABLIM2', 'actin binding LIM protein family member 2'],\n",
       " 'ABLIM3': ['KIAA0843', 'ABLIM3', 'actin binding LIM protein family member 3'],\n",
       " 'ABO': ['A3GALNT',\n",
       "  'A3GALT1',\n",
       "  'ABO',\n",
       "  'ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase)'],\n",
       " 'ABR': ['MDB', 'ABR', 'active BCR-related'],\n",
       " 'ABRA': ['STARS', 'ABRA', 'actin binding Rho activating protein'],\n",
       " 'ABRACL': ['PRO2013', 'HSPC280', 'Costars', 'ABRACL', 'ABRA C-terminal like'],\n",
       " 'ABT1': ['nan', 'ABT1', 'activator of basal transcription 1'],\n",
       " 'ABT1P1': ['nan',\n",
       "  'ABT1P1',\n",
       "  'activator of basal transcription 1 pseudogene 1'],\n",
       " 'ABTB1': ['BPOZ',\n",
       "  'EF1ABP',\n",
       "  'Btb3',\n",
       "  'BTBD21',\n",
       "  'ABTB1',\n",
       "  'ankyrin repeat and BTB domain containing 1'],\n",
       " 'ABTB2': ['DKFZP586C1619',\n",
       "  'BTBD22',\n",
       "  'ABTB2A',\n",
       "  'ABTB2',\n",
       "  'ankyrin repeat and BTB domain containing 2'],\n",
       " 'ACAA1': ['nan', 'ACAA1', 'acetyl-CoA acyltransferase 1'],\n",
       " 'ACAA2': ['DSAEC', 'ACAA2', 'acetyl-CoA acyltransferase 2'],\n",
       " 'ACACA': ['ACC1', 'ACACA', 'acetyl-CoA carboxylase alpha'],\n",
       " 'ACACB': ['HACC275', 'ACC2', 'ACCB', 'ACACB', 'acetyl-CoA carboxylase beta'],\n",
       " 'ACAD8': ['nan', 'ACAD8', 'acyl-CoA dehydrogenase family member 8'],\n",
       " 'ACAD9': ['NPD002',\n",
       "  'MGC14452',\n",
       "  'ACAD9',\n",
       "  'acyl-CoA dehydrogenase family member 9'],\n",
       " 'ACAD10': ['MGC5601', 'ACAD10', 'acyl-CoA dehydrogenase family member 10'],\n",
       " 'ACAD11': ['FLJ12592', 'ACAD11', 'acyl-CoA dehydrogenase family member 11'],\n",
       " 'ACADL': ['LCAD', 'ACAD4', 'ACADL', 'acyl-CoA dehydrogenase, long chain'],\n",
       " 'ACADM': ['MCAD',\n",
       "  'MCADH',\n",
       "  'ACAD1',\n",
       "  'ACADM',\n",
       "  'acyl-CoA dehydrogenase, C-4 to C-12 straight chain'],\n",
       " 'ACADS': ['SCAD',\n",
       "  'ACAD3',\n",
       "  'ACADS',\n",
       "  'acyl-CoA dehydrogenase, C-2 to C-3 short chain'],\n",
       " 'ACADSB': ['SBCAD',\n",
       "  'ACAD7',\n",
       "  'ACADSB',\n",
       "  'acyl-CoA dehydrogenase, short/branched chain'],\n",
       " 'ACADVL': ['VLCAD',\n",
       "  'LCACD',\n",
       "  'ACAD6',\n",
       "  'ACADVL',\n",
       "  'acyl-CoA dehydrogenase, very long chain'],\n",
       " 'ACAN': ['CSPGCP', 'ACAN', 'aggrecan'],\n",
       " 'ACAP1': ['KIAA0050',\n",
       "  'ACAP1',\n",
       "  'ArfGAP with coiled-coil, ankyrin repeat and PH domains 1'],\n",
       " 'ACAP2': ['KIAA0041',\n",
       "  'CNT-B2',\n",
       "  'ACAP2',\n",
       "  'ArfGAP with coiled-coil, ankyrin repeat and PH domains 2'],\n",
       " 'ACAP2-IT1': ['nan', 'ACAP2-IT1', 'ACAP2 intronic transcript 1'],\n",
       " 'ACAP3': ['KIAA1716',\n",
       "  'ACAP3',\n",
       "  'ArfGAP with coiled-coil, ankyrin repeat and PH domains 3'],\n",
       " 'ACAT1': ['THIL', 'ACAT1', 'acetyl-CoA acetyltransferase 1'],\n",
       " 'ACAT2': ['nan', 'ACAT2', 'acetyl-CoA acetyltransferase 2'],\n",
       " 'ACBD3': ['GCP60', 'PAP7', 'ACBD3', 'acyl-CoA binding domain containing 3'],\n",
       " 'ACBD4': ['FLJ13322', 'ACBD4', 'acyl-CoA binding domain containing 4'],\n",
       " 'ACBD5': ['DKFZp434A2417',\n",
       "  'KIAA1996',\n",
       "  'ACBD5',\n",
       "  'acyl-CoA binding domain containing 5'],\n",
       " 'ACBD6': ['MGC2404', 'ACBD6', 'acyl-CoA binding domain containing 6'],\n",
       " 'ACBD7': ['FLJ38219',\n",
       "  'bA455B2.2',\n",
       "  'ACBD7',\n",
       "  'acyl-CoA binding domain containing 7'],\n",
       " 'ACCS': ['PHACS',\n",
       "  'ACS',\n",
       "  'ACCS',\n",
       "  '1-aminocyclopropane-1-carboxylate synthase homolog (inactive)'],\n",
       " 'ACCSL': ['nan',\n",
       "  'ACCSL',\n",
       "  '1-aminocyclopropane-1-carboxylate synthase (inactive)-like'],\n",
       " 'ACD': ['Ptop',\n",
       "  'Pip1',\n",
       "  'Tpp1',\n",
       "  'Tint1',\n",
       "  'ACD',\n",
       "  'adrenocortical dysplasia homolog'],\n",
       " 'ACE': ['ACE1', 'CD143', 'ACE', 'angiotensin I converting enzyme'],\n",
       " 'ACE2': ['nan', 'ACE2', 'angiotensin I converting enzyme 2'],\n",
       " 'ACE3P': ['nan',\n",
       "  'ACE3P',\n",
       "  'angiotensin I converting enzyme (peptidyl-dipeptidase A) 3, pseudogene'],\n",
       " 'ACER1': ['nan', 'ACER1', 'alkaline ceramidase 1'],\n",
       " 'ACER2': ['FLJ41587', 'ACER2', 'alkaline ceramidase 2'],\n",
       " 'ACER3': ['FLJ11238', 'APHC', 'ACER3', 'alkaline ceramidase 3'],\n",
       " 'ACHE': ['nan', 'ACHE', 'acetylcholinesterase (Cartwright blood group)'],\n",
       " 'ACIN1': ['KIAA0670',\n",
       "  'fSAP152',\n",
       "  'ACIN1',\n",
       "  'apoptotic chromatin condensation inducer 1'],\n",
       " 'ACKR1': ['CCBP1',\n",
       "  'GPD',\n",
       "  'Dfy',\n",
       "  'CD234',\n",
       "  'ACKR1',\n",
       "  'atypical chemokine receptor 1 (Duffy blood group)'],\n",
       " 'ACKR2': ['CCR10', 'D6', 'CCR9', 'ACKR2', 'atypical chemokine receptor 2'],\n",
       " 'ACKR3': ['RDC1', 'GPR159', 'ACKR3', 'atypical chemokine receptor 3'],\n",
       " 'ACKR4': ['CCR11',\n",
       "  'CCBP2',\n",
       "  'VSHK1',\n",
       "  'CCX-CKR',\n",
       "  'PPR1',\n",
       "  'ACKR4',\n",
       "  'atypical chemokine receptor 4'],\n",
       " 'ACLY': ['ATPCL', 'CLATP', 'ACL', 'ACLY', 'ATP citrate lyase'],\n",
       " 'ACMSD': ['nan', 'ACMSD', 'aminocarboxymuconate semialdehyde decarboxylase'],\n",
       " 'ACO1': ['IRP1', 'IREBP', 'ACO1', 'aconitase 1'],\n",
       " 'ACO2': ['ACONM', 'ACO2', 'aconitase 2'],\n",
       " 'ACOD1': ['CAD', 'ACOD1', 'aconitate decarboxylase 1'],\n",
       " 'ACOT1': ['ACH2', 'CTE-1', 'LACH2', 'ACOT1', 'acyl-CoA thioesterase 1'],\n",
       " 'ACOT2': ['Mte1', 'ZAP128', 'ACOT2', 'acyl-CoA thioesterase 2'],\n",
       " 'ACOT4': ['FLJ31235', 'PTE-Ib', 'PTE2B', 'ACOT4', 'acyl-CoA thioesterase 4'],\n",
       " 'ACOT6': ['nan', 'ACOT6', 'acyl-CoA thioesterase 6'],\n",
       " 'ACOT7': ['BACH',\n",
       "  'ACH1',\n",
       "  'ACT',\n",
       "  'CTE-II',\n",
       "  'LACH1',\n",
       "  'MGC1126',\n",
       "  'hBACH',\n",
       "  'ACOT7',\n",
       "  'acyl-CoA thioesterase 7'],\n",
       " 'ACOT8': ['hACTE-III',\n",
       "  'hTE',\n",
       "  'PTE-2',\n",
       "  'NAP1',\n",
       "  'ACOT8',\n",
       "  'acyl-CoA thioesterase 8'],\n",
       " 'ACOT9': ['CGI-16', 'MT-ACT48', 'ACATE2', 'ACOT9', 'acyl-CoA thioesterase 9'],\n",
       " 'ACOT11': ['STARD14',\n",
       "  'BFIT',\n",
       "  'KIAA0707',\n",
       "  'BFIT1',\n",
       "  'THEM1',\n",
       "  'ACOT11',\n",
       "  'acyl-CoA thioesterase 11'],\n",
       " 'ACOT12': ['Cach', 'THEAL', 'STARD15', 'ACOT12', 'acyl-CoA thioesterase 12'],\n",
       " 'ACOT13': ['HT012', 'ACOT13', 'acyl-CoA thioesterase 13'],\n",
       " 'ACOX1': ['PALMCOX', 'ACOX1', 'acyl-CoA oxidase 1, palmitoyl'],\n",
       " 'ACOX2': ['BRCACOX',\n",
       "  'BRCOX',\n",
       "  'THCCox',\n",
       "  'ACOX2',\n",
       "  'acyl-CoA oxidase 2, branched chain'],\n",
       " 'ACOX3': ['nan', 'ACOX3', 'acyl-CoA oxidase 3, pristanoyl'],\n",
       " 'ACOXL': ['FLJ11042', 'ACOXL', 'acyl-CoA oxidase-like'],\n",
       " 'ACP1': ['HAAP', 'LMW-PTP', 'ACP1', 'acid phosphatase 1, soluble'],\n",
       " 'ACP2': ['LAP', 'ACP2', 'acid phosphatase 2, lysosomal'],\n",
       " 'ACP5': ['TRAP', 'HPAP', 'ACP5', 'acid phosphatase 5, tartrate resistant'],\n",
       " 'ACP6': ['LPAP', 'ACPL1', 'ACP6', 'acid phosphatase 6, lysophosphatidic'],\n",
       " 'ACP7': ['FLJ16165',\n",
       "  'PAPL1',\n",
       "  'ACP7',\n",
       "  'acid phosphatase 7, tartrate resistant (putative)'],\n",
       " 'ACPP': ['ACP3', 'ACP-3', 'PAP', 'ACPP', 'acid phosphatase, prostate'],\n",
       " 'ACPT': ['nan', 'ACPT', 'acid phosphatase, testicular'],\n",
       " 'ACR': ['nan', 'ACR', 'acrosin'],\n",
       " 'ACRBP': ['SP32', 'OY-TES-1', 'CT23', 'ACRBP', 'acrosin binding protein'],\n",
       " 'ACRC': ['nan', 'ACRC', 'acidic repeat containing'],\n",
       " 'ACRV1': ['SPACA2',\n",
       "  'SP-10',\n",
       "  'D11S4365',\n",
       "  'ACRV1',\n",
       "  'acrosomal vesicle protein 1'],\n",
       " 'ACSBG1': ['BGM',\n",
       "  'FLJ30320',\n",
       "  'MGC14352',\n",
       "  'BG1',\n",
       "  'KIAA0631',\n",
       "  'hBG1',\n",
       "  'hsBG',\n",
       "  'ACSBG1',\n",
       "  'acyl-CoA synthetase bubblegum family member 1'],\n",
       " 'ACSBG2': ['BGR',\n",
       "  'PRTD-NY3',\n",
       "  'DKFZp434K1635',\n",
       "  'ACSBG2',\n",
       "  'acyl-CoA synthetase bubblegum family member 2'],\n",
       " 'ACSF2': ['FLJ20920',\n",
       "  'ACSMW',\n",
       "  'ACSF2',\n",
       "  'acyl-CoA synthetase family member 2'],\n",
       " 'ACSF3': ['nan', 'ACSF3', 'acyl-CoA synthetase family member 3'],\n",
       " 'ACSL1': ['LACS2',\n",
       "  'LACS',\n",
       "  'ACS1',\n",
       "  'LACS1',\n",
       "  'FACL1',\n",
       "  'ACSL1',\n",
       "  'acyl-CoA synthetase long-chain family member 1'],\n",
       " 'ACSL3': ['ACS3',\n",
       "  'PRO2194',\n",
       "  'ACSL3',\n",
       "  'acyl-CoA synthetase long-chain family member 3'],\n",
       " 'ACSL4': ['ACS4',\n",
       "  'LACS4',\n",
       "  'ACSL4',\n",
       "  'acyl-CoA synthetase long-chain family member 4'],\n",
       " 'ACSL5': ['ACS5',\n",
       "  'ACS2',\n",
       "  'ACSL5',\n",
       "  'acyl-CoA synthetase long-chain family member 5'],\n",
       " 'ACSL6': ['KIAA0837',\n",
       "  'ACS2',\n",
       "  'LACS5',\n",
       "  'LACS2',\n",
       "  'ACSL6',\n",
       "  'acyl-CoA synthetase long-chain family member 6'],\n",
       " 'ACSM1': ['MACS1',\n",
       "  'ACSM1',\n",
       "  'acyl-CoA synthetase medium-chain family member 1'],\n",
       " 'ACSM2A': ['A-923A4.1',\n",
       "  'MGC150530',\n",
       "  'ACSM2A',\n",
       "  'acyl-CoA synthetase medium-chain family member 2A'],\n",
       " 'ACSM2B': ['HXMA',\n",
       "  'HYST1046',\n",
       "  'ACSM2B',\n",
       "  'acyl-CoA synthetase medium-chain family member 2B'],\n",
       " 'ACSM3': ['SA', 'ACSM3', 'acyl-CoA synthetase medium-chain family member 3'],\n",
       " 'ACSM4': ['nan', 'ACSM4', 'acyl-CoA synthetase medium-chain family member 4'],\n",
       " 'ACSM5': ['FLJ20581',\n",
       "  'ACSM5',\n",
       "  'acyl-CoA synthetase medium-chain family member 5'],\n",
       " 'ACSM5P1': ['nan',\n",
       "  'ACSM5P1',\n",
       "  'acyl-CoA synthetase medium-chain family member 5 pseudogene 1'],\n",
       " 'ACSM6': ['bA310E22.3',\n",
       "  'ACSM6',\n",
       "  'acyl-CoA synthetase medium-chain family member 6'],\n",
       " 'ACSS1': ['dJ568C11.3',\n",
       "  'AceCS2L',\n",
       "  'MGC33843',\n",
       "  'ACSS1',\n",
       "  'acyl-CoA synthetase short-chain family member 1'],\n",
       " 'ACSS2': ['ACS',\n",
       "  'ACSA',\n",
       "  'AceCS',\n",
       "  'dJ1161H23.1',\n",
       "  'ACSS2',\n",
       "  'acyl-CoA synthetase short-chain family member 2'],\n",
       " 'ACSS3': ['FLJ21963',\n",
       "  'ACSS3',\n",
       "  'acyl-CoA synthetase short-chain family member 3'],\n",
       " 'ACTA1': ['NEM3', 'ACTA1', 'actin, alpha 1, skeletal muscle'],\n",
       " 'ACTA2': ['ACTSA', 'ACTA2', 'actin, alpha 2, smooth muscle, aorta'],\n",
       " 'ACTA2-AS1': ['uc001kfo.1', 'ZXF1', 'ACTA2-AS1', 'ACTA2 antisense RNA 1'],\n",
       " 'ACTB': ['nan', 'ACTB', 'actin, beta'],\n",
       " 'ACTBL2': ['DKFZp686D0972', 'ACTBL2', 'actin, beta-like 2'],\n",
       " 'ACTBP1': ['nan', 'ACTBP1', 'actin, beta pseudogene 1'],\n",
       " 'ACTBP2': ['nan', 'ACTBP2', 'actin, beta pseudogene 2'],\n",
       " 'ACTBP6': ['nan', 'ACTBP6', 'actin, beta pseudogene 6'],\n",
       " 'ACTBP7': ['nan', 'ACTBP7', 'actin, beta pseudogene 7'],\n",
       " 'ACTBP8': ['ACTBP2', 'ACTBP8', 'actin, beta pseudogene 8'],\n",
       " 'ACTBP9': ['nan', 'ACTBP9', 'actin, beta pseudogene 9'],\n",
       " 'ACTBP11': ['nan', 'ACTBP11', 'actin, beta pseudogene 11'],\n",
       " 'ACTBP12': ['nan', 'ACTBP12', 'actin, beta pseudogene 12'],\n",
       " 'ACTBP13': ['nan', 'ACTBP13', 'actin, beta pseudogene 13'],\n",
       " 'ACTBP14': ['nan', 'ACTBP14', 'actin, beta pseudogene 14'],\n",
       " 'ACTC1': ['CMD1R', 'ACTC1', 'actin, alpha, cardiac muscle 1'],\n",
       " 'ACTG1': ['nan', 'ACTG1', 'actin gamma 1'],\n",
       " 'ACTG1P1': ['nan', 'ACTG1P1', 'actin gamma 1 pseudogene 1'],\n",
       " 'ACTG1P2': ['nan', 'ACTG1P2', 'actin gamma 1 pseudogene 2'],\n",
       " 'ACTG1P3': ['nan', 'ACTG1P3', 'actin gamma 1 pseudogene 3'],\n",
       " 'ACTG1P4': ['nan', 'ACTG1P4', 'actin gamma 1 pseudogene 4'],\n",
       " 'ACTG1P9': ['nan', 'ACTG1P9', 'actin gamma 1 pseudogene 9'],\n",
       " 'ACTG1P10': ['nan', 'ACTG1P10', 'actin gamma 1 pseudogene 10'],\n",
       " 'ACTG1P11': ['nan', 'ACTG1P11', 'actin gamma 1 pseudogene 11'],\n",
       " 'ACTG1P12': ['nan', 'ACTG1P12', 'actin gamma 1 pseudogene 12'],\n",
       " 'ACTG1P13': ['nan', 'ACTG1P13', 'actin gamma 1 pseudogene 13'],\n",
       " 'ACTG1P14': ['nan', 'ACTG1P14', 'actin gamma 1 pseudogene 14'],\n",
       " 'ACTG1P15': ['nan', 'ACTG1P15', 'actin gamma 1 pseudogene 15'],\n",
       " 'ACTG1P16': ['nan', 'ACTG1P16', 'actin gamma 1 pseudogene 16'],\n",
       " 'ACTG1P17': ['nan', 'ACTG1P17', 'actin gamma 1 pseudogene 17'],\n",
       " 'ACTG1P18': ['nan', 'ACTG1P18', 'actin gamma 1 pseudogene 18'],\n",
       " 'ACTG1P19': ['nan', 'ACTG1P19', 'actin gamma 1 pseudogene 19'],\n",
       " 'ACTG1P20': ['nan', 'ACTG1P20', 'actin gamma 1 pseudogene 20'],\n",
       " 'ACTG1P21': ['nan', 'ACTG1P21', 'actin gamma 1 pseudogene 21'],\n",
       " 'ACTG1P22': ['nan', 'ACTG1P22', 'actin gamma 1 pseudogene 22'],\n",
       " 'ACTG1P23': ['nan', 'ACTG1P23', 'actin gamma 1 pseudogene 23'],\n",
       " 'ACTG1P24': ['nan', 'ACTG1P24', 'actin gamma 1 pseudogene 24'],\n",
       " 'ACTG2': ['ACTSG', 'ACTG2', 'actin, gamma 2, smooth muscle, enteric'],\n",
       " 'ACTL6A': ['Actl6',\n",
       "  'BAF53A',\n",
       "  'Arp4',\n",
       "  'Baf53a',\n",
       "  'INO80K',\n",
       "  'ACTL6A',\n",
       "  'actin like 6A'],\n",
       " 'ACTL6B': ['BAF53B', 'ACTL6B', 'actin like 6B'],\n",
       " 'ACTL7A': ['nan', 'ACTL7A', 'actin like 7A'],\n",
       " 'ACTL7B': ['Tact1', 'ACTL7B', 'actin like 7B'],\n",
       " 'ACTL8': ['CT57', 'ACTL8', 'actin like 8'],\n",
       " 'ACTL9': ['MGC33407', 'ACTL9', 'actin like 9'],\n",
       " 'ACTL10': ['nan', 'ACTL10', 'actin like 10'],\n",
       " 'ACTN1': ['nan', 'ACTN1', 'actinin alpha 1'],\n",
       " 'ACTN1-AS1': ['nan', 'ACTN1-AS1', 'ACTN1 antisense RNA 1'],\n",
       " 'ACTN2': ['nan', 'ACTN2', 'actinin alpha 2'],\n",
       " 'ACTN3': ['nan', 'ACTN3', 'actinin alpha 3 (gene/pseudogene)'],\n",
       " 'ACTN4': ['nan', 'ACTN4', 'actinin alpha 4'],\n",
       " 'ACTN4P1': ['nan', 'ACTN4P1', 'actinin alpha 4 pseudogene 1'],\n",
       " 'ACTN4P2': ['nan', 'ACTN4P2', 'actinin alpha 4 pseudogene 2'],\n",
       " 'ACTP1': ['nan', 'ACTP1', 'actin family pseudogene 1'],\n",
       " 'ACTR1A': ['ARP1',\n",
       "  'Arp1A',\n",
       "  'ACTR1A',\n",
       "  'ARP1 actin-related protein 1 homolog A, centractin alpha'],\n",
       " 'ACTR1B': ['Arp1B',\n",
       "  'ACTR1B',\n",
       "  'ARP1 actin-related protein 1 homolog B, centractin beta'],\n",
       " 'ACTR2': ['ARP2', 'ACTR2', 'ARP2 actin-related protein 2 homolog (yeast)'],\n",
       " 'ACTR3': ['ARP3', 'ACTR3', 'ARP3 actin-related protein 3 homolog (yeast)'],\n",
       " 'ACTR3B': ['ARP11',\n",
       "  'ARP3beta',\n",
       "  'ACTR3B',\n",
       "  'ARP3 actin-related protein 3 homolog B (yeast)'],\n",
       " 'ACTR3BP1': ['nan', 'ACTR3BP1', 'ACTR3B pseudogene 1'],\n",
       " 'ACTR3BP2': ['FKSG73', 'ACTR3BP2', 'ACTR3B pseudogene 2'],\n",
       " 'ACTR3BP3': ['nan', 'ACTR3BP3', 'ACTR3B pseudogene 3'],\n",
       " 'ACTR3BP4': ['nan', 'ACTR3BP4', 'ACTR3B pseudogene 4'],\n",
       " 'ACTR3BP5': ['nan', 'ACTR3BP5', 'ACTR3B pseudogene 5'],\n",
       " 'ACTR3BP6': ['nan', 'ACTR3BP6', 'ACTR3B pseudogene 6'],\n",
       " 'ACTR3C': ['ARP11', 'ACTR3C', 'ARP3 actin-related protein 3 homolog C'],\n",
       " 'ACTR3P2': ['nan', 'ACTR3P2', 'ACTR3 pseudogene 2'],\n",
       " 'ACTR3P3': ['nan', 'ACTR3P3', 'ACTR3 pseudogene 3'],\n",
       " 'ACTR5': ['FLJ12785',\n",
       "  'Arp5',\n",
       "  'INO80M',\n",
       "  'ACTR5',\n",
       "  'ARP5 actin-related protein 5 homolog'],\n",
       " 'ACTR6': ['ARP6',\n",
       "  'FLJ13433',\n",
       "  'ACTR6',\n",
       "  'ARP6 actin-related protein 6 homolog'],\n",
       " 'ACTR6P1': ['nan', 'ACTR6P1', 'ACTR6 pseudogene 1'],\n",
       " 'ACTR8': ['INO80N', 'ACTR8', 'ARP8 actin-related protein 8 homolog'],\n",
       " 'ACTR10': ['HARP11',\n",
       "  'ACTR11',\n",
       "  'Arp11',\n",
       "  'Arp10',\n",
       "  'ACTR10',\n",
       "  'actin-related protein 10 homolog'],\n",
       " 'ACTRT1': ['AIP1',\n",
       "  'KIAA0705',\n",
       "  'ARIP1',\n",
       "  'Arp-T1',\n",
       "  'ACTRT1',\n",
       "  'actin related protein T1'],\n",
       " 'ACTRT2': ['Arp-T2',\n",
       "  'ARPM2',\n",
       "  'FLJ25424',\n",
       "  'ACTRT2',\n",
       "  'actin related protein T2'],\n",
       " 'ACTRT3': ['ARPM1', 'ACTRT3', 'actin related protein T3'],\n",
       " 'ACVR1': ['SKR1', 'ALK2', 'ACVR1A', 'ACVR1', 'activin A receptor type 1'],\n",
       " 'ACVR1B': ['ALK4', 'SKR2', 'ActRIB', 'ACVR1B', 'activin A receptor type 1B'],\n",
       " 'ACVR1C': ['ALK7', 'ACVRLK7', 'ACVR1C', 'activin A receptor type 1C'],\n",
       " 'ACVR2A': ['ACTRII', 'ACVR2A', 'activin A receptor type 2A'],\n",
       " 'ACVR2B': ['ActR-IIB', 'ACVR2B', 'activin A receptor type 2B'],\n",
       " 'ACVR2B-AS1': ['nan', 'ACVR2B-AS1', 'ACVR2B antisense RNA 1'],\n",
       " 'ACVRL1': ['HHT2', 'ALK1', 'HHT', 'ACVRL1', 'activin A receptor like type 1'],\n",
       " 'ACY1': ['nan', 'ACY1', 'aminoacylase 1'],\n",
       " 'ACY3': ['HCBP1', 'MGC9740', 'ACY-3', 'ACY3', 'aminoacylase 3'],\n",
       " 'ACYP1': ['nan', 'ACYP1', 'acylphosphatase 1'],\n",
       " 'ACYP2': ['nan', 'ACYP2', 'acylphosphatase 2'],\n",
       " 'ADA': ['nan', 'ADA', 'adenosine deaminase'],\n",
       " 'ADAD1': ['Tenr', 'ADAD1', 'adenosine deaminase domain containing 1'],\n",
       " 'ADAD1P2': ['nan',\n",
       "  'ADAD1P2',\n",
       "  'adenosine deaminase domain containing 1 pseudogene 2'],\n",
       " 'ADAD2': ['TENRL',\n",
       "  'FLJ00337',\n",
       "  'ADAD2',\n",
       "  'adenosine deaminase domain containing 2'],\n",
       " 'ADAL': ['nan', 'ADAL', 'adenosine deaminase-like'],\n",
       " 'ADAM1A': ['FTNAP',\n",
       "  'PH-30a',\n",
       "  'Ftna',\n",
       "  'ADAM1P',\n",
       "  'ADAM1A',\n",
       "  'ADAM metallopeptidase domain 1A (pseudogene)'],\n",
       " 'ADAM1B': ['nan', 'ADAM1B', 'ADAM metallopeptidase domain 1B (pseudogene)'],\n",
       " 'ADAM2': ['PH-30b',\n",
       "  'PH30',\n",
       "  'CT15',\n",
       "  'ADAM2',\n",
       "  'ADAM metallopeptidase domain 2'],\n",
       " 'ADAM3A': ['ADAM3',\n",
       "  'tMDCI',\n",
       "  'ADAM3A',\n",
       "  'ADAM metallopeptidase domain 3A (pseudogene)'],\n",
       " 'ADAM3B': ['nan', 'ADAM3B', 'ADAM metallopeptidase domain 3B (pseudogene)'],\n",
       " 'ADAM5': ['tMDCII', 'ADAM5', 'ADAM metallopeptidase domain 5 (pseudogene)'],\n",
       " 'ADAM6': ['tMDCIV', 'ADAM6', 'ADAM metallopeptidase domain 6 (pseudogene)'],\n",
       " 'ADAM7': ['GP-83', 'EAPI', 'ADAM7', 'ADAM metallopeptidase domain 7'],\n",
       " 'ADAM8': ['CD156',\n",
       "  'MS2',\n",
       "  'CD156a',\n",
       "  'ADAM8',\n",
       "  'ADAM metallopeptidase domain 8'],\n",
       " 'ADAM9': ['MDC9',\n",
       "  'KIAA0021',\n",
       "  'MCMP',\n",
       "  'Mltng',\n",
       "  'ADAM9',\n",
       "  'ADAM metallopeptidase domain 9'],\n",
       " 'ADAM10': ['kuz',\n",
       "  'MADM',\n",
       "  'HsT18717',\n",
       "  'CD156c',\n",
       "  'ADAM10',\n",
       "  'ADAM metallopeptidase domain 10'],\n",
       " 'ADAM11': ['nan', 'ADAM11', 'ADAM metallopeptidase domain 11'],\n",
       " 'ADAM12': ['MCMPMltna', 'MLTN', 'ADAM12', 'ADAM metallopeptidase domain 12'],\n",
       " 'ADAM15': ['MDC15', 'ADAM15', 'ADAM metallopeptidase domain 15'],\n",
       " 'ADAM17': ['cSVP', 'CD156B', 'ADAM17', 'ADAM metallopeptidase domain 17'],\n",
       " 'ADAM18': ['tMDCIII', 'ADAM27', 'ADAM18', 'ADAM metallopeptidase domain 18'],\n",
       " 'ADAM19': ['MLTNB', 'ADAM19', 'ADAM metallopeptidase domain 19'],\n",
       " 'ADAM20': ['nan', 'ADAM20', 'ADAM metallopeptidase domain 20'],\n",
       " 'ADAM20P1': ['nan',\n",
       "  'ADAM20P1',\n",
       "  'ADAM metallopeptidase domain 20 pseudogene 1'],\n",
       " 'ADAM20P2': ['nan',\n",
       "  'ADAM20P2',\n",
       "  'ADAM metallopeptidase domain 20 pseudogene 2'],\n",
       " 'ADAM20P3': ['nan',\n",
       "  'ADAM20P3',\n",
       "  'ADAM metallopeptidase domain 20 pseudogene 3'],\n",
       " 'ADAM21': ['ADAM31', 'ADAM21', 'ADAM metallopeptidase domain 21'],\n",
       " 'ADAM21P1': ['nan',\n",
       "  'ADAM21P1',\n",
       "  'ADAM metallopeptidase domain 21 pseudogene 1'],\n",
       " 'ADAM22': ['MDC2', 'ADAM22', 'ADAM metallopeptidase domain 22'],\n",
       " 'ADAM23': ['MDC3', 'ADAM23', 'ADAM metallopeptidase domain 23'],\n",
       " 'ADAM24P': ['nan', 'ADAM24P', 'ADAM metallopeptidase domain 24, pseudogene'],\n",
       " 'ADAM28': ['eMDCII',\n",
       "  'MDC-Lm',\n",
       "  'MDC-Ls',\n",
       "  'ADAM23',\n",
       "  'ADAM28',\n",
       "  'ADAM metallopeptidase domain 28'],\n",
       " 'ADAM29': ['svph1', 'CT73', 'ADAM29', 'ADAM metallopeptidase domain 29'],\n",
       " 'ADAM30': ['svph4', 'ADAM30', 'ADAM metallopeptidase domain 30'],\n",
       " 'ADAM32': ['nan', 'ADAM32', 'ADAM metallopeptidase domain 32'],\n",
       " 'ADAM33': ['DKFZp434K0521',\n",
       "  'dJ964F7.1',\n",
       "  'ADAM33',\n",
       "  'ADAM metallopeptidase domain 33'],\n",
       " 'ADAMDEC1': ['M12.219', 'ADAMDEC1', 'ADAM-like, decysin 1'],\n",
       " 'ADAMTS1': ['C3-C5',\n",
       "  'METH1',\n",
       "  'KIAA1346',\n",
       "  'ADAMTS1',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 1'],\n",
       " 'ADAMTS2': ['ADAMTS-3',\n",
       "  'hPCPNI',\n",
       "  'PCINP',\n",
       "  'ADAM-TS2',\n",
       "  'NPI',\n",
       "  'ADAMTS2',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 2'],\n",
       " 'ADAMTS3': ['KIAA0366',\n",
       "  'ADAMTS-4',\n",
       "  'ADAMTS3',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 3'],\n",
       " 'ADAMTS4': ['KIAA0688',\n",
       "  'ADAMTS-2',\n",
       "  'ADMP-1',\n",
       "  'ADAMTS4',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 4'],\n",
       " 'ADAMTS5': ['ADMP-2',\n",
       "  'ADAMTS11',\n",
       "  'ADAMTS5',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 5'],\n",
       " 'ADAMTS6': ['ADAM-TS6',\n",
       "  'ADAMTS6',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 6'],\n",
       " 'ADAMTS7': ['ADAM-TS7',\n",
       "  'DKFZp434H204',\n",
       "  'ADAMTS7',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 7'],\n",
       " 'ADAMTS7P1': ['nan', 'ADAMTS7P1', 'ADAMTS7 pseudogene 1'],\n",
       " 'ADAMTS7P3': ['nan', 'ADAMTS7P3', 'ADAMTS7 pseudogene 3'],\n",
       " 'ADAMTS7P4': ['nan', 'ADAMTS7P4', 'ADAMTS7 pseudogene 4'],\n",
       " 'ADAMTS8': ['METH2',\n",
       "  'FLJ41712',\n",
       "  'ADAM-TS8',\n",
       "  'ADAMTS8',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 8'],\n",
       " 'ADAMTS9': ['KIAA1312',\n",
       "  'ADAMTS9',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 9'],\n",
       " 'ADAMTS9-AS1': ['nan', 'ADAMTS9-AS1', 'ADAMTS9 antisense RNA 1'],\n",
       " 'ADAMTS9-AS2': ['nan', 'ADAMTS9-AS2', 'ADAMTS9 antisense RNA 2'],\n",
       " 'ADAMTS10': ['ADAM-TS10',\n",
       "  'ADAMTS10',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 10'],\n",
       " 'ADAMTS12': ['nan',\n",
       "  'ADAMTS12',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 12'],\n",
       " 'ADAMTS13': ['VWFCP',\n",
       "  'TTP',\n",
       "  'vWF-CP',\n",
       "  'FLJ42993',\n",
       "  'MGC118899',\n",
       "  'MGC118900',\n",
       "  'DKFZp434C2322',\n",
       "  'ADAMTS13',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 13'],\n",
       " 'ADAMTS14': ['nan',\n",
       "  'ADAMTS14',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 14'],\n",
       " 'ADAMTS15': ['nan',\n",
       "  'ADAMTS15',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 15'],\n",
       " 'ADAMTS16': ['ADAMTS16s',\n",
       "  'ADAMTS16',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 16'],\n",
       " 'ADAMTS17': ['FLJ32769',\n",
       "  'FLJ16363',\n",
       "  'ADAMTS17',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 17'],\n",
       " 'ADAMTS18': ['nan',\n",
       "  'ADAMTS18',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 18'],\n",
       " 'ADAMTS19': ['nan',\n",
       "  'ADAMTS19',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 19'],\n",
       " 'ADAMTS19-AS1': ['RP11-346A9.1', 'ADAMTS19-AS1', 'ADAMTS19 antisense RNA 1'],\n",
       " 'ADAMTS20': ['GON-1',\n",
       "  'ADAMTS20',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 20'],\n",
       " 'ADAMTSL1': ['ADAMTSR1', 'FLJ35283', 'ADAMTSL1', 'ADAMTS like 1'],\n",
       " 'ADAMTSL2': ['KIAA0605', 'ADAMTSL2', 'ADAMTS like 2'],\n",
       " 'ADAMTSL3': ['KIAA1233', 'punctin-2', 'ADAMTSL3', 'ADAMTS like 3'],\n",
       " 'ADAMTSL4': ['DKFZP434K1772', 'ADAMTSL4', 'ADAMTS like 4'],\n",
       " 'ADAMTSL4-AS1': ['FLJ45786', 'ADAMTSL4-AS1', 'ADAMTSL4 antisense RNA 1'],\n",
       " 'ADAMTSL5': ['nan', 'ADAMTSL5', 'ADAMTS like 5'],\n",
       " 'ADAP1': ['GCS1L', 'ADAP1', 'ArfGAP with dual PH domains 1'],\n",
       " 'ADAP2': ['nan', 'ADAP2', 'ArfGAP with dual PH domains 2'],\n",
       " 'ADAR': ['ADAR1', 'ADAR', 'adenosine deaminase, RNA-specific'],\n",
       " 'ADARB1': ['ADAR2',\n",
       "  'DRADA2',\n",
       "  'ADAR2g',\n",
       "  'DRABA2',\n",
       "  'RED1',\n",
       "  'hRED1',\n",
       "  'ADAR2a-L1',\n",
       "  'ADAR2a-L2',\n",
       "  'ADAR2a-L3',\n",
       "  'ADAR2a',\n",
       "  'ADAR2b',\n",
       "  'ADAR2c',\n",
       "  'ADAR2d',\n",
       "  'ADARB1',\n",
       "  'adenosine deaminase, RNA specific B1'],\n",
       " 'ADARB2': ['RED2',\n",
       "  'hRED2',\n",
       "  'ADAR3',\n",
       "  'ADARB2',\n",
       "  'adenosine deaminase, RNA specific B2 (inactive)'],\n",
       " 'ADARB2-AS1': ['bA466B20.1', 'ADARB2-AS1', 'ADARB2 antisense RNA 1'],\n",
       " 'ADAT1': ['nan', 'ADAT1', 'adenosine deaminase, tRNA specific 1'],\n",
       " 'ADAT2': ['dJ20N2.1',\n",
       "  'TAD2',\n",
       "  'ADAT2',\n",
       "  'adenosine deaminase, tRNA specific 2'],\n",
       " 'ADAT3': ['TAD3', 'ADAT3', 'adenosine deaminase, tRNA specific 3'],\n",
       " 'ADCK1': ['FLJ39600', 'ADCK1', 'aarF domain containing kinase 1'],\n",
       " 'ADCK2': ['MGC20727', 'ADCK2', 'aarF domain containing kinase 2'],\n",
       " 'ADCK3': ['COQ8', 'SCAR9', 'ADCK3', 'aarF domain containing kinase 3'],\n",
       " 'ADCK4': ['FLJ12229', 'COQ8', 'ADCK4', 'aarF domain containing kinase 4'],\n",
       " 'ADCK5': ['FLJ35454', 'ADCK5', 'aarF domain containing kinase 5'],\n",
       " 'ADCY1': ['AC1', 'ADCY1', 'adenylate cyclase 1 (brain)'],\n",
       " 'ADCY2': ['HBAC2', 'KIAA1060', 'AC2', 'ADCY2', 'adenylate cyclase 2 (brain)'],\n",
       " 'ADCY3': ['AC3', 'ADCY3', 'adenylate cyclase 3'],\n",
       " 'ADCY4': ['AC4', 'ADCY4', 'adenylate cyclase 4'],\n",
       " 'ADCY5': ['AC5', 'ADCY5', 'adenylate cyclase 5'],\n",
       " 'ADCY6': ['AC6', 'ADCY6', 'adenylate cyclase 6'],\n",
       " 'ADCY7': ['KIAA0037', 'AC7', 'ADCY7', 'adenylate cyclase 7'],\n",
       " 'ADCY8': ['HBAC1', 'AC8', 'ADCY8', 'adenylate cyclase 8 (brain)'],\n",
       " 'ADCY9': ['AC9', 'ADCY9', 'adenylate cyclase 9'],\n",
       " 'ADCY10': ['SAC',\n",
       "  'Sacy',\n",
       "  'SACI',\n",
       "  'HCA2',\n",
       "  'RP1-313L4.2',\n",
       "  'ADCY10',\n",
       "  'adenylate cyclase 10 (soluble)'],\n",
       " 'ADCY10P1': ['nan',\n",
       "  'ADCY10P1',\n",
       "  'adenylate cyclase 10 (soluble) pseudogene 1'],\n",
       " 'ADCYAP1': ['PACAP', 'ADCYAP1', 'adenylate cyclase activating polypeptide 1'],\n",
       " 'ADCYAP1R1': ['PAC1',\n",
       "  'PACAPR',\n",
       "  'PAC1R',\n",
       "  'ADCYAP1R1',\n",
       "  'ADCYAP receptor type I'],\n",
       " 'ADD1': ['nan', 'ADD1', 'adducin 1'],\n",
       " 'ADD2': ['ADDB', 'ADD2', 'adducin 2'],\n",
       " 'ADD3': ['nan', 'ADD3', 'adducin 3'],\n",
       " 'ADD3-AS1': ['nan', 'ADD3-AS1', 'ADD3 antisense RNA 1'],\n",
       " 'ADGB': ['FLJ23121', 'dJ408K24.1', 'CAPN16', 'ADGB', 'androglobin'],\n",
       " 'ADGRA1': ['KIAA1828', 'ADGRA1', 'adhesion G protein-coupled receptor A1'],\n",
       " 'ADGRA1-AS1': ['nan',\n",
       "  'ADGRA1-AS1',\n",
       "  'adhesion G protein-coupled receptor A1 antisense RNA 1'],\n",
       " 'ADGRA2': ['TEM5',\n",
       "  'DKFZp434C211',\n",
       "  'DKFZp434J0911',\n",
       "  'KIAA1531',\n",
       "  'FLJ14390',\n",
       "  'ADGRA2',\n",
       "  'adhesion G protein-coupled receptor A2'],\n",
       " 'ADGRA3': ['FLJ38547',\n",
       "  'PGR21',\n",
       "  'ADGRA3',\n",
       "  'adhesion G protein-coupled receptor A3'],\n",
       " 'ADGRB1': ['nan', 'ADGRB1', 'adhesion G protein-coupled receptor B1'],\n",
       " 'ADGRB2': ['nan', 'ADGRB2', 'adhesion G protein-coupled receptor B2'],\n",
       " 'ADGRB3': ['KIAA0550', 'ADGRB3', 'adhesion G protein-coupled receptor B3'],\n",
       " 'ADGRD1': ['DKFZp434B1272',\n",
       "  'PGR25',\n",
       "  'ADGRD1',\n",
       "  'adhesion G protein-coupled receptor D1'],\n",
       " 'ADGRD2': ['PGR24', 'ADGRD2', 'adhesion G protein-coupled receptor D2'],\n",
       " 'ADGRE1': ['nan', 'ADGRE1', 'adhesion G protein-coupled receptor E1'],\n",
       " 'ADGRE2': ['CD312', 'ADGRE2', 'adhesion G protein-coupled receptor E2'],\n",
       " 'ADGRE3': ['nan', 'ADGRE3', 'adhesion G protein-coupled receptor E3'],\n",
       " 'ADGRE4P': ['PGR16',\n",
       "  'ADGRE4P',\n",
       "  'adhesion G protein-coupled receptor E4, pseudogene'],\n",
       " 'ADGRE5': ['TM7LN1', 'ADGRE5', 'adhesion G protein-coupled receptor E5'],\n",
       " 'ADGRF1': ['hGPCR36',\n",
       "  'PGR19',\n",
       "  'ADGRF1',\n",
       "  'adhesion G protein-coupled receptor F1'],\n",
       " 'ADGRF2': ['hGPCR35',\n",
       "  'PGR20',\n",
       "  'ADGRF2',\n",
       "  'adhesion G protein-coupled receptor F2'],\n",
       " 'ADGRF3': ['hGPCR37',\n",
       "  'PGR23',\n",
       "  'ADGRF3',\n",
       "  'adhesion G protein-coupled receptor F3'],\n",
       " 'ADGRF4': ['FLJ38076',\n",
       "  'PGR18',\n",
       "  'ADGRF4',\n",
       "  'adhesion G protein-coupled receptor F4'],\n",
       " 'ADGRF5': ['DKFZp564O1923',\n",
       "  'KIAA0758',\n",
       "  'ADGRF5',\n",
       "  'adhesion G protein-coupled receptor F5'],\n",
       " 'ADGRF5P1': ['nan',\n",
       "  'ADGRF5P1',\n",
       "  'adhesion G protein-coupled receptor F5 pseudogene 1'],\n",
       " 'ADGRF5P2': ['nan',\n",
       "  'ADGRF5P2',\n",
       "  'adhesion G protein-coupled receptor F5 pseudogene 2'],\n",
       " 'ADGRG1': ['TM7LN4',\n",
       "  'TM7XN1',\n",
       "  'ADGRG1',\n",
       "  'adhesion G protein-coupled receptor G1'],\n",
       " 'ADGRG2': ['HE6',\n",
       "  'TM7LN2',\n",
       "  'EDDM6',\n",
       "  'ADGRG2',\n",
       "  'adhesion G protein-coupled receptor G2'],\n",
       " 'ADGRG3': ['Pb99',\n",
       "  'PGR26',\n",
       "  'ADGRG3',\n",
       "  'adhesion G protein-coupled receptor G3'],\n",
       " 'ADGRG4': ['RP1-299I16',\n",
       "  'PGR17',\n",
       "  'ADGRG4',\n",
       "  'adhesion G protein-coupled receptor G4'],\n",
       " 'ADGRG5': ['PGR27', 'ADGRG5', 'adhesion G protein-coupled receptor G5'],\n",
       " 'ADGRG6': ['FLJ14937', 'ADGRG6', 'adhesion G protein-coupled receptor G6'],\n",
       " 'ADGRG7': ['FLJ14454', 'ADGRG7', 'adhesion G protein-coupled receptor G7'],\n",
       " 'ADGRL1': ['KIAA0821',\n",
       "  'CIRL1',\n",
       "  'LEC2',\n",
       "  'ADGRL1',\n",
       "  'adhesion G protein-coupled receptor L1'],\n",
       " 'ADGRL2': ['KIAA0786',\n",
       "  'LEC1',\n",
       "  'ADGRL2',\n",
       "  'adhesion G protein-coupled receptor L2'],\n",
       " 'ADGRL3': ['KIAA0768',\n",
       "  'LEC3',\n",
       "  'ADGRL3',\n",
       "  'adhesion G protein-coupled receptor L3'],\n",
       " 'ADGRL3-AS1': ['nan',\n",
       "  'ADGRL3-AS1',\n",
       "  'adhesion G protein-coupled receptor L3 antisense RNA 1'],\n",
       " 'ADGRL4': ['ETL', 'ADGRL4', 'adhesion G protein-coupled receptor L4'],\n",
       " 'ADGRV1': ['DKFZp761P0710',\n",
       "  'KIAA0686',\n",
       "  'FEB4',\n",
       "  'VLGR1',\n",
       "  'ADGRV1',\n",
       "  'adhesion G protein-coupled receptor V1'],\n",
       " 'ADH1A': ['nan',\n",
       "  'ADH1A',\n",
       "  'alcohol dehydrogenase 1A (class I), alpha polypeptide'],\n",
       " 'ADH1B': ['nan',\n",
       "  'ADH1B',\n",
       "  'alcohol dehydrogenase 1B (class I), beta polypeptide'],\n",
       " 'ADH1C': ['nan',\n",
       "  'ADH1C',\n",
       "  'alcohol dehydrogenase 1C (class I), gamma polypeptide'],\n",
       " 'ADH4': ['ADH-2',\n",
       "  'ADH4',\n",
       "  'alcohol dehydrogenase 4 (class II), pi polypeptide'],\n",
       " 'ADH5': ['ADH-3',\n",
       "  'ADHX',\n",
       "  'ADH5',\n",
       "  'alcohol dehydrogenase 5 (class III), chi polypeptide'],\n",
       " 'ADH5P2': ['nan',\n",
       "  'ADH5P2',\n",
       "  'alcohol dehydrogenase 5 (class III), chi polypeptide, pseudogene 2'],\n",
       " 'ADH5P3': ['nan',\n",
       "  'ADH5P3',\n",
       "  'alcohol dehydrogenase 5 (class III), chi polypeptide, pseudogene 3'],\n",
       " 'ADH5P4': ['bA707M13.2',\n",
       "  'ADH5P4',\n",
       "  'alcohol dehydrogenase 5 (class III), chi polypeptide, pseudogene 4'],\n",
       " 'ADH6': ['ADH-5', 'ADH6', 'alcohol dehydrogenase 6 (class V)'],\n",
       " 'ADH7': ['ADH-4',\n",
       "  'ADH7',\n",
       "  'alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide'],\n",
       " 'ADHFE1': ['ADHFe1',\n",
       "  'FLJ32430',\n",
       "  'ADHFE1',\n",
       "  'alcohol dehydrogenase, iron containing 1'],\n",
       " 'ADI1': ['SIPL',\n",
       "  'MTCBP-1',\n",
       "  'ARD',\n",
       "  'APL1',\n",
       "  'FLJ10913',\n",
       "  'HMFT1638',\n",
       "  'mtnD',\n",
       "  'ADI1',\n",
       "  'acireductone dioxygenase 1'],\n",
       " 'ADIG': ['MGC39724', 'SMAF1', 'RP5-1100H13.2', 'ADIG', 'adipogenin'],\n",
       " 'ADIPOQ': ['ACRP30',\n",
       "  'AdipoQ',\n",
       "  'apM1',\n",
       "  'GBP28',\n",
       "  'adiponectin',\n",
       "  'ADIPOQ',\n",
       "  'adiponectin, C1Q and collagen domain containing'],\n",
       " 'ADIPOQ-AS1': ['nan', 'ADIPOQ-AS1', 'ADIPOQ antisense RNA 1'],\n",
       " 'ADIPOR1': ['PAQR1', 'ACDCR1', 'ADIPOR1', 'adiponectin receptor 1'],\n",
       " 'ADIPOR1P1': ['nan', 'ADIPOR1P1', 'adiponectin receptor 1 pseudogene 1'],\n",
       " 'ADIPOR1P2': ['nan', 'ADIPOR1P2', 'adiponectin receptor 1 pseudogene 2'],\n",
       " 'ADIPOR2': ['PAQR2', 'ACDCR2', 'ADIPOR2', 'adiponectin receptor 2'],\n",
       " 'ADIRF': ['APM2', 'AFRO', 'ADIRF', 'adipogenesis regulatory factor'],\n",
       " 'ADIRF-AS1': ['nan', 'ADIRF-AS1', 'ADIRF antisense RNA 1'],\n",
       " 'ADK': ['AK', 'ADK', 'adenosine kinase'],\n",
       " 'ADM': ['AM', 'ADM', 'adrenomedullin'],\n",
       " 'ADM2': ['AM2', 'FLJ21135', 'ADM2', 'adrenomedullin 2'],\n",
       " 'ADM5': ['AM5', 'ADM5', 'adrenomedullin 5 (putative)'],\n",
       " 'ADNP': ['KIAA0784',\n",
       "  'ADNP1',\n",
       "  'ADNP',\n",
       "  'activity-dependent neuroprotector homeobox'],\n",
       " 'ADNP-AS1': ['nan', 'ADNP-AS1', 'ADNP antisense RNA 1'],\n",
       " 'ADNP2': ['KIAA0863', 'ADNP2', 'ADNP homeobox 2'],\n",
       " 'ADO': ['FLJ14547', 'ADO', '2-aminoethanethiol (cysteamine) dioxygenase'],\n",
       " 'ADORA1': ['RDC7', 'ADORA1', 'adenosine A1 receptor'],\n",
       " 'ADORA2A': ['RDC8', 'ADORA2A', 'adenosine A2a receptor'],\n",
       " 'ADORA2A-AS1': ['FLJ34651', 'ADORA2A-AS1', 'ADORA2A antisense RNA 1'],\n",
       " 'ADORA2B': ['nan', 'ADORA2B', 'adenosine A2b receptor'],\n",
       " 'ADORA2BP1': ['nan', 'ADORA2BP1', 'adenosine A2b receptor pseudogene 1'],\n",
       " 'ADORA3': ['AD026', 'ADORA3', 'adenosine A3 receptor'],\n",
       " 'ADPGK': ['DKFZp434B195', 'ADP-GK', 'ADPGK', 'ADP-dependent glucokinase'],\n",
       " 'ADPGK-AS1': ['nan', 'ADPGK-AS1', 'ADPGK antisense RNA 1'],\n",
       " 'ADPRH': ['ARH1', 'ADPRH', 'ADP-ribosylarginine hydrolase'],\n",
       " 'ADPRHL1': ['ARH2', 'ADPRHL1', 'ADP-ribosylhydrolase like 1'],\n",
       " 'ADPRHL2': ['ARH3', 'FLJ20446', 'ADPRHL2', 'ADP-ribosylhydrolase like 2'],\n",
       " 'ADPRM': ['MDS006',\n",
       "  'ADPRM',\n",
       "  'ADP-ribose/CDP-alcohol diphosphatase, manganese dependent'],\n",
       " 'ADRA1A': ['ADRA1L1', 'ADRA1A', 'adrenoceptor alpha 1A'],\n",
       " 'ADRA1B': ['nan', 'ADRA1B', 'adrenoceptor alpha 1B'],\n",
       " 'ADRA1D': ['ADRA1R', 'ADRA1A', 'ADRA1', 'ADRA1D', 'adrenoceptor alpha 1D'],\n",
       " 'ADRA2A': ['ADRAR', 'ADRA2A', 'adrenoceptor alpha 2A'],\n",
       " 'ADRA2B': ['ADRARL1', 'ADRA2B', 'adrenoceptor alpha 2B'],\n",
       " 'ADRA2C': ['ADRARL2', 'ADRA2C', 'adrenoceptor alpha 2C'],\n",
       " 'ADRB1': ['nan', 'ADRB1', 'adrenoceptor beta 1'],\n",
       " 'ADRB2': ['ADRBR', 'BAR', 'B2AR', 'ADRB2', 'adrenoceptor beta 2'],\n",
       " 'ADRB3': ['nan', 'ADRB3', 'adrenoceptor beta 3'],\n",
       " 'ADRBK1': ['GRK2', 'BARK1', 'ADRBK1', 'adrenergic, beta, receptor kinase 1'],\n",
       " 'ADRBK2': ['GRK3', 'BARK2', 'ADRBK2', 'adrenergic, beta, receptor kinase 2'],\n",
       " 'ADRM1': ['GP110',\n",
       "  'Rpn13',\n",
       "  'ARM1',\n",
       "  'ADRM1',\n",
       "  'adhesion regulating molecule 1'],\n",
       " 'ADSL': ['nan', 'ADSL', 'adenylosuccinate lyase'],\n",
       " 'ADSS': ['nan', 'ADSS', 'adenylosuccinate synthase'],\n",
       " 'ADSSL1': ['FLJ38602', 'ADSSL1', 'adenylosuccinate synthase like 1'],\n",
       " 'ADTRP': ['dJ413H6.1',\n",
       "  'AIG1L',\n",
       "  'ADTRP',\n",
       "  'androgen dependent TFPI regulating protein'],\n",
       " 'AEBP1': ['ACLP', 'AEBP1', 'AE binding protein 1'],\n",
       " 'AEBP2': ['MGC17922', 'AEBP2', 'AE binding protein 2'],\n",
       " 'AEN': ['FLJ12484', 'FLJ12562', 'AEN', 'apoptosis enhancing nuclease'],\n",
       " 'AES': ['GRG5', 'TLE5', 'AES', 'amino-terminal enhancer of split'],\n",
       " 'AFAP1': ['AFAP-110', 'AFAP', 'AFAP1', 'actin filament associated protein 1'],\n",
       " 'AFAP1-AS1': ['MGC10981', 'AFAP1-AS1', 'AFAP1 antisense RNA 1'],\n",
       " 'AFAP1L1': ['FLJ36748',\n",
       "  'AFAP1L1',\n",
       "  'actin filament associated protein 1 like 1'],\n",
       " 'AFAP1L2': ['FLJ14564',\n",
       "  'Em:AC005383.4',\n",
       "  'XB130',\n",
       "  'AFAP1L2',\n",
       "  'actin filament associated protein 1 like 2'],\n",
       " 'AFF1': ['AF-4', 'AF4', 'AFF1', 'AF4/FMR2 family member 1'],\n",
       " 'AFF2': ['FRAXE', 'AFF2', 'AF4/FMR2 family member 2'],\n",
       " 'AFF2-IT1': ['nan', 'AFF2-IT1', 'AFF2 intronic transcript 1'],\n",
       " 'AFF3': ['MLLT2-like', 'AFF3', 'AF4/FMR2 family member 3'],\n",
       " 'AFF4': ['AF5Q31', 'MCEF', 'AFF4', 'AF4/FMR2 family member 4'],\n",
       " 'AFG3L1P': ['nan',\n",
       "  'AFG3L1P',\n",
       "  'AFG3 like matrix AAA peptidase subunit 1, pseudogene'],\n",
       " 'AFG3L2': ['SPAX5', 'AFG3L2', 'AFG3 like matrix AAA peptidase subunit 2'],\n",
       " 'AFG3L2P1': ['nan', 'AFG3L2P1', 'AFG3 like AAA ATPase 2 pseudogene 1'],\n",
       " 'AFM': ['ALB2', 'ALBA', 'AFM', 'afamin'],\n",
       " 'AFMID': ['DKFZp686F03259', 'KF', 'AFMID', 'arylformamidase'],\n",
       " 'AFP': ['FETA', 'AFP', 'alpha fetoprotein'],\n",
       " 'AFTPH': ['MGC33965',\n",
       "  'FLJ20080',\n",
       "  'FLJ23793',\n",
       "  'Nbla10388',\n",
       "  'AFTPH',\n",
       "  'aftiphilin'],\n",
       " 'AGA': ['ASRG', 'AGA', 'aspartylglucosaminidase'],\n",
       " 'AGAP1': ['KIAA1099',\n",
       "  'GGAP1',\n",
       "  'AGAP1',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 1'],\n",
       " 'AGAP1-IT1': ['nan', 'AGAP1-IT1', 'AGAP1 intronic transcript 1'],\n",
       " 'AGAP2': ['nan',\n",
       "  'AGAP2',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 2'],\n",
       " 'AGAP2-AS1': ['LOC100130776',\n",
       "  'PUNISHER',\n",
       "  'AGAP2-AS1',\n",
       "  'AGAP2 antisense RNA 1'],\n",
       " 'AGAP3': ['nan',\n",
       "  'AGAP3',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 3'],\n",
       " 'AGAP4': ['Em:AC012044.1',\n",
       "  'MRIP2',\n",
       "  'AGAP4',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 4'],\n",
       " 'AGAP5': ['Em:AC073389.1',\n",
       "  'AGAP5',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 5'],\n",
       " 'AGAP6': ['bA324H6.1',\n",
       "  'AGAP6',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 6'],\n",
       " 'AGAP7P': ['bA109G10.1',\n",
       "  'AGAP7P',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 7, pseudogene'],\n",
       " 'AGAP9': ['bA301J7.2',\n",
       "  'FLJ00312',\n",
       "  'AGAP9',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 9'],\n",
       " 'AGAP10P': ['bA358L16.1',\n",
       "  'bA144G6.2',\n",
       "  'AGAP10P',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 10 pseudogene'],\n",
       " 'AGAP11': ['KIAA1975',\n",
       "  'AGAP11',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 11'],\n",
       " 'AGAP12P': ['bA164N7.2',\n",
       "  'AGAP12P',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 12, pseudogene'],\n",
       " 'AGAP13P': ['bA548K23.1',\n",
       "  'AGAP13P',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 13, pseudogene'],\n",
       " 'AGAP14P': ['bA145E20.1',\n",
       "  'AGAP14P',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 14, pseudogene'],\n",
       " 'AGBL1': ['FLJ32310', 'CCP4', 'AGBL1', 'ATP/GTP binding protein-like 1'],\n",
       " 'AGBL1-AS1': ['nan', 'AGBL1-AS1', 'AGBL1 antisense RNA 1'],\n",
       " 'AGBL2': ['FLJ23598', 'CCP2', 'AGBL2', 'ATP/GTP binding protein-like 2'],\n",
       " 'AGBL3': ['MGC32955', 'CCP3', 'AGBL3', 'ATP/GTP binding protein-like 3'],\n",
       " 'AGBL4': ['FLJ14442', 'CCP6', 'AGBL4', 'ATP/GTP binding protein-like 4'],\n",
       " 'AGBL4-IT1': ['nan', 'AGBL4-IT1', 'AGBL4 intronic transcript 1'],\n",
       " 'AGBL5': ['FLJ21839', 'CCP5', 'AGBL5', 'ATP/GTP binding protein-like 5'],\n",
       " 'AGBL5-AS1': ['nan', 'AGBL5-AS1', 'AGBL5 antisense RNA 1'],\n",
       " 'AGBL5-IT1': ['nan', 'AGBL5-IT1', 'AGBL5 intronic transcript 1'],\n",
       " 'AGER': ['RAGE',\n",
       "  'AGER',\n",
       "  'advanced glycosylation end product-specific receptor'],\n",
       " 'AGFG1': ['RIP', 'RAB', 'AGFG1', 'ArfGAP with FG repeats 1'],\n",
       " 'AGFG2': ['RABR', 'AGFG2', 'ArfGAP with FG repeats 2'],\n",
       " 'AGGF1': ['VG5Q',\n",
       "  'HSU84971',\n",
       "  'FLJ10283',\n",
       "  'GPATC7',\n",
       "  'GPATCH7',\n",
       "  'AGGF1',\n",
       "  'angiogenic factor with G-patch and FHA domains 1'],\n",
       " 'AGGF1P1': ['nan',\n",
       "  'AGGF1P1',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 1'],\n",
       " 'AGGF1P2': ['nan',\n",
       "  'AGGF1P2',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 2'],\n",
       " 'AGGF1P3': ['nan',\n",
       "  'AGGF1P3',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 3'],\n",
       " 'AGGF1P4': ['nan',\n",
       "  'AGGF1P4',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 4'],\n",
       " 'AGGF1P5': ['nan',\n",
       "  'AGGF1P5',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 5'],\n",
       " 'AGGF1P6': ['nan',\n",
       "  'AGGF1P6',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 6'],\n",
       " 'AGGF1P7': ['nan',\n",
       "  'AGGF1P7',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 7'],\n",
       " 'AGGF1P8': ['nan',\n",
       "  'AGGF1P8',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 8'],\n",
       " 'AGGF1P9': ['nan',\n",
       "  'AGGF1P9',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 9'],\n",
       " 'AGGF1P10': ['nan',\n",
       "  'AGGF1P10',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 10'],\n",
       " 'AGK': ['FLJ10842', 'AGK', 'acylglycerol kinase'],\n",
       " 'AGKP1': ['AGKY1', 'AGKP1', 'acylglycerol kinase pseudogene 1'],\n",
       " 'AGL': ['nan',\n",
       "  'AGL',\n",
       "  'amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase'],\n",
       " 'AGMAT': ['FLJ23384', 'AGMAT', 'agmatinase'],\n",
       " 'AGMO': ['FLJ16237', 'AGMO', 'alkylglycerol monooxygenase'],\n",
       " 'AGO1': ['hAGO1', 'AGO1', 'argonaute 1, RISC catalytic component'],\n",
       " 'AGO2': ['hAGO2', 'Q10', 'AGO2', 'argonaute 2, RISC catalytic component'],\n",
       " 'AGO3': ['hAGO3',\n",
       "  'FLJ12765',\n",
       "  'AGO3',\n",
       "  'argonaute 3, RISC catalytic component'],\n",
       " 'AGO4': ['hAGO4',\n",
       "  'KIAA1567',\n",
       "  'FLJ20033',\n",
       "  'AGO4',\n",
       "  'argonaute 4, RISC catalytic component'],\n",
       " 'AGPAT1': ['LPAAT-alpha',\n",
       "  'AGPAT1',\n",
       "  '1-acylglycerol-3-phosphate O-acyltransferase 1'],\n",
       " 'AGPAT2': ['LPAAT-beta',\n",
       "  'AGPAT2',\n",
       "  '1-acylglycerol-3-phosphate O-acyltransferase 2'],\n",
       " 'AGPAT3': ['LPAAT-gamma',\n",
       "  'AGPAT3',\n",
       "  '1-acylglycerol-3-phosphate O-acyltransferase 3'],\n",
       " 'AGPAT4': ['LPAAT-delta',\n",
       "  'dJ473J16.2',\n",
       "  'AGPAT4',\n",
       "  '1-acylglycerol-3-phosphate O-acyltransferase 4'],\n",
       " 'AGPAT4-IT1': ['FLJ23112', 'AGPAT4-IT1', 'AGPAT4 intronic transcript 1'],\n",
       " 'AGPAT5': ['FLJ11210',\n",
       "  'LPAAT-e',\n",
       "  'LPAAT-epsilon',\n",
       "  'AGPAT5',\n",
       "  '1-acylglycerol-3-phosphate O-acyltransferase 5'],\n",
       " 'AGPAT5P1': ['nan',\n",
       "  'AGPAT5P1',\n",
       "  '1-acylglycerol-3-phosphate O-acyltransferase 5 pseudogene 1'],\n",
       " 'AGPS': ['ADHAPS',\n",
       "  'ADAS',\n",
       "  'ALDHPSY',\n",
       "  'ADPS',\n",
       "  'ADAP-S',\n",
       "  'AGPS',\n",
       "  'alkylglycerone phosphate synthase'],\n",
       " 'AGR2': ['XAG-2',\n",
       "  'HAG-2',\n",
       "  'AG2',\n",
       "  'PDIA17',\n",
       "  'AGR2',\n",
       "  'anterior gradient 2, protein disulphide isomerase family member'],\n",
       " 'AGR3': ['HAG3',\n",
       "  'hAG-3',\n",
       "  'BCMP11',\n",
       "  'PDIA18',\n",
       "  'AGR3',\n",
       "  'anterior gradient 3, protein disulphide isomerase family member'],\n",
       " 'AGRN': ['AGRIN', 'AGRN', 'agrin'],\n",
       " 'AGRP': ['Agrt', 'ART', 'ASIP2', 'AGRP', 'agouti related neuropeptide'],\n",
       " 'AGT': ['nan', 'AGT', 'angiotensinogen'],\n",
       " 'AGTPBP1': ['KIAA1035',\n",
       "  'Nna1',\n",
       "  'CCP1',\n",
       "  'AGTPBP1',\n",
       "  'ATP/GTP binding protein 1'],\n",
       " 'AGTR1': ['AT1',\n",
       "  'AT2R1',\n",
       "  'AGTR1A',\n",
       "  'AT2R1A',\n",
       "  'HAT1R',\n",
       "  'AG2S',\n",
       "  'AT2R1B',\n",
       "  'AT1B',\n",
       "  'AGTR1',\n",
       "  'angiotensin II receptor type 1'],\n",
       " 'AGTR2': ['AT2', 'MRX88', 'AGTR2', 'angiotensin II receptor type 2'],\n",
       " 'AGTRAP': ['ATRAP', 'AGTRAP', 'angiotensin II receptor associated protein'],\n",
       " 'AGXT': ['AGXT1',\n",
       "  'PH1',\n",
       "  'AGT',\n",
       "  'SPT',\n",
       "  'AGT1',\n",
       "  'AGXT',\n",
       "  'alanine-glyoxylate aminotransferase'],\n",
       " 'AGXT2': ['AGT2', 'AGXT2', 'alanine--glyoxylate aminotransferase 2'],\n",
       " 'AHCTF1': ['ELYS', 'AHCTF1', 'AT-hook containing transcription factor 1'],\n",
       " 'AHCY': ['SAHH', 'AHCY', 'adenosylhomocysteinase'],\n",
       " 'AHCYL1': ['XPVKONA',\n",
       "  'IRBIT',\n",
       "  'PPP1R78',\n",
       "  'AHCYL1',\n",
       "  'adenosylhomocysteinase like 1'],\n",
       " 'AHCYL2': ['KIAA0828', 'AHCYL2', 'adenosylhomocysteinase like 2'],\n",
       " 'AHCYP2': ['nan', 'AHCYP2', 'adenosylhomocysteinase pseudogene 2'],\n",
       " 'AHCYP3': ['nan', 'AHCYP3', 'adenosylhomocysteinase pseudogene 3'],\n",
       " 'AHCYP4': ['nan', 'AHCYP4', 'adenosylhomocysteinase pseudogene 4'],\n",
       " 'AHCYP5': ['nan', 'AHCYP5', 'adenosylhomocysteinase pseudogene 5'],\n",
       " 'AHCYP7': ['nan', 'AHCYP7', 'adenosylhomocysteinase pseudogene 7'],\n",
       " 'AHCYP8': ['nan', 'AHCYP8', 'adenosylhomocysteinase pseudogene 8'],\n",
       " 'AHDC1': ['DJ159A19.3',\n",
       "  'RP1-159A19.1',\n",
       "  'AHDC1',\n",
       "  'AT-hook DNA binding motif containing 1'],\n",
       " 'AHI1': ['FLJ20069',\n",
       "  'ORF1',\n",
       "  'JBTS3',\n",
       "  'AHI1',\n",
       "  'Abelson helper integration site 1'],\n",
       " 'AHNAK': ['MGC5395', 'AHNAK', 'AHNAK nucleoprotein'],\n",
       " 'AHNAK2': ['nan', 'AHNAK2', 'AHNAK nucleoprotein 2'],\n",
       " 'AHR': ['bHLHe76', 'AHR', 'aryl hydrocarbon receptor'],\n",
       " 'AHRR': ['KIAA1234',\n",
       "  'bHLHe77',\n",
       "  'AHRR',\n",
       "  'aryl-hydrocarbon receptor repressor'],\n",
       " 'AHSA1': ['p38',\n",
       "  'Aha1',\n",
       "  'hAha1',\n",
       "  'AHSA1',\n",
       "  'AHA1, activator of heat shock 90kDa protein ATPase homolog 1 (yeast)'],\n",
       " 'AHSA2': ['DKFZp564C236',\n",
       "  'Hch1',\n",
       "  'AHSA2',\n",
       "  'AHA1, activator of heat shock 90kDa protein ATPase homolog 2 (yeast)'],\n",
       " 'AHSG': ['FETUA', 'A2HS', 'HSGA', 'AHSG', 'alpha-2-HS-glycoprotein'],\n",
       " 'AHSP': ['EDRF', 'AHSP', 'alpha hemoglobin stabilizing protein'],\n",
       " 'AICDA': ['HIGM2',\n",
       "  'CDA2',\n",
       "  'ARP2',\n",
       "  'AID',\n",
       "  'AICDA',\n",
       "  'activation-induced cytidine deaminase'],\n",
       " 'AIDA': ['FLJ12806', 'AIDA', 'axin interactor, dorsalization associated'],\n",
       " 'AIF1': ['IRT-1',\n",
       "  'AIF-1',\n",
       "  'Em:AF129756.17',\n",
       "  'IBA1',\n",
       "  'AIF1',\n",
       "  'allograft inflammatory factor 1'],\n",
       " 'AIF1L': ['IBA2',\n",
       "  'FLJ12783',\n",
       "  'AIF1L',\n",
       "  'allograft inflammatory factor 1 like'],\n",
       " 'AIFM1': ['AIF',\n",
       "  'CMTX4',\n",
       "  'AIFM1',\n",
       "  'apoptosis inducing factor, mitochondria associated 1'],\n",
       " 'AIFM1P1': ['nan',\n",
       "  'AIFM1P1',\n",
       "  'apoptosis inducing factor, mitochondria associated 1 pseudogene 1'],\n",
       " 'AIFM2': ['FLJ14497',\n",
       "  'PRG3',\n",
       "  'AIFM2',\n",
       "  'apoptosis inducing factor, mitochondria associated 2'],\n",
       " 'AIFM3': ['AIFL',\n",
       "  'FLJ30473',\n",
       "  'AIFM3',\n",
       "  'apoptosis inducing factor, mitochondria associated 3'],\n",
       " 'AIG1': ['dJ95L4.1', 'AIG-1', 'FLJ10485', 'AIG1', 'androgen-induced 1'],\n",
       " 'AIG1P1': ['nan', 'AIG1P1', 'androgen-induced 1 pseudogene 1'],\n",
       " 'AIM1': ['CRYBG1', 'AIM1', 'absent in melanoma 1'],\n",
       " 'AIM1L': ['CRYBG2', 'FLJ38020', 'AIM1L', 'absent in melanoma 1-like'],\n",
       " 'AIM2': ['PYHIN4', 'AIM2', 'absent in melanoma 2'],\n",
       " 'AIMP1': ['EMAPII',\n",
       "  'EMAP-2',\n",
       "  'p43',\n",
       "  'AIMP1',\n",
       "  'aminoacyl tRNA synthetase complex-interacting multifunctional protein 1'],\n",
       " 'AIMP1P1': ['bA400P21.1',\n",
       "  'AIMP1P1',\n",
       "  'aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 pseudogene 1'],\n",
       " 'AIMP1P2': ['nan',\n",
       "  'AIMP1P2',\n",
       "  'aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 pseudogene 2'],\n",
       " 'AIMP2': ['p38',\n",
       "  'PRO0992',\n",
       "  'JTV-1',\n",
       "  'JTV1',\n",
       "  'AIMP2',\n",
       "  'aminoacyl tRNA synthetase complex-interacting multifunctional protein 2'],\n",
       " 'AIP': ['XAP2',\n",
       "  'ARA9',\n",
       "  'FKBP16',\n",
       "  'AIP',\n",
       "  'aryl hydrocarbon receptor interacting protein'],\n",
       " 'AIPL1': ['nan',\n",
       "  'AIPL1',\n",
       "  'aryl hydrocarbon receptor interacting protein like 1'],\n",
       " 'AIRE': ['PGA1', 'APS1', 'AIRE', 'autoimmune regulator'],\n",
       " 'AIRN': ['AIR',\n",
       "  'NCRNA00088',\n",
       "  'IGF2RAS',\n",
       "  'IGF2R-AS1',\n",
       "  'AIRN',\n",
       "  'antisense of IGF2R non-protein coding RNA'],\n",
       " 'AJAP1': ['SHREW1',\n",
       "  'SHREW-1',\n",
       "  'MOT8',\n",
       "  'AJAP1',\n",
       "  'adherens junctions associated protein 1'],\n",
       " 'AJUBA': ['MGC15563', 'AJUBA', 'ajuba LIM protein'],\n",
       " 'AK1': ['nan', 'AK1', 'adenylate kinase 1'],\n",
       " 'AK2': ['nan', 'AK2', 'adenylate kinase 2'],\n",
       " 'AK2P2': ['nan', 'AK2P2', 'adenylate kinase 2 pseudogene 2'],\n",
       " 'AK3': ['AKL3L1', 'AK3', 'adenylate kinase 3'],\n",
       " 'AK3P2': ['HsT26053', 'AK3P2', 'adenylate kinase 3 pseudogene 2'],\n",
       " 'AK3P3': ['nan', 'AK3P3', 'adenylate kinase 3 pseudogene 3'],\n",
       " 'AK3P4': ['nan', 'AK3P4', 'adenylate kinase 3 pseudogene 4'],\n",
       " 'AK3P5': ['nan', 'AK3P5', 'adenylate kinase 3 pseudogene 5'],\n",
       " 'AK4': ['nan', 'AK4', 'adenylate kinase 4'],\n",
       " 'AK4P1': ['nan', 'AK4P1', 'adenylate kinase 4 pseudogene 1'],\n",
       " 'AK4P2': ['nan', 'AK4P2', 'adenylate kinase 4 pseudogene 2'],\n",
       " 'AK4P3': ['AK3L2P', 'AK4P3', 'adenylate kinase 4 pseudogene 3'],\n",
       " 'AK4P4': ['nan', 'AK4P4', 'adenylate kinase 4 pseudogene 4'],\n",
       " 'AK4P5': ['nan', 'AK4P5', 'adenylate kinase 4 pseudogene 5'],\n",
       " 'AK4P6': ['nan', 'AK4P6', 'adenylate kinase 4 pseudogene 6'],\n",
       " 'AK5': ['nan', 'AK5', 'adenylate kinase 5'],\n",
       " 'AK6': ['CINAP', 'AK6', 'adenylate kinase 6'],\n",
       " 'AK6P1': ['nan', 'AK6P1', 'adenylate kinase 6 pseudogene 1'],\n",
       " 'AK6P2': ['nan', 'AK6P2', 'adenylate kinase 6 pseudogene 2'],\n",
       " 'AK7': ['FLJ32864', 'AK7', 'adenylate kinase 7'],\n",
       " 'AK8': ['FLJ32704', 'AK8', 'adenylate kinase 8'],\n",
       " 'AK9': ['FLJ42177',\n",
       "  'FLJ25791',\n",
       "  'dJ70A9.1',\n",
       "  'MGC26954',\n",
       "  'AK9',\n",
       "  'adenylate kinase 9'],\n",
       " 'AKAIN1': ['nan', 'AKAIN1', 'A kinase (PRKA) anchor inhibitor 1'],\n",
       " 'AKAP1': ['AKAP121',\n",
       "  'AKAP149',\n",
       "  'SAKAP84',\n",
       "  'S-AKAP84',\n",
       "  'AKAP84',\n",
       "  'D-AKAP1',\n",
       "  'PPP1R43',\n",
       "  'TDRD17',\n",
       "  'AKAP1',\n",
       "  'A-kinase anchoring protein 1'],\n",
       " 'AKAP2': ['AKAP-KL',\n",
       "  'KIAA0920',\n",
       "  'DKFZp564L0716',\n",
       "  'AKAP2',\n",
       "  'A-kinase anchoring protein 2'],\n",
       " 'AKAP3': ['FSP95',\n",
       "  'SOB1',\n",
       "  'AKAP110',\n",
       "  'CT82',\n",
       "  'AKAP3',\n",
       "  'A-kinase anchoring protein 3'],\n",
       " 'AKAP4': ['p82',\n",
       "  'hAKAP82',\n",
       "  'AKAP82',\n",
       "  'Fsc1',\n",
       "  'HI',\n",
       "  'CT99',\n",
       "  'AKAP4',\n",
       "  'A-kinase anchoring protein 4'],\n",
       " 'AKAP5': ['AKAP75', 'AKAP79', 'AKAP5', 'A-kinase anchoring protein 5'],\n",
       " 'AKAP6': ['KIAA0311',\n",
       "  'mAKAP',\n",
       "  'AKAP100',\n",
       "  'PRKA6',\n",
       "  'ADAP6',\n",
       "  'AKAP6',\n",
       "  'A-kinase anchoring protein 6'],\n",
       " 'AKAP7': ['AKAP18', 'AKAP15', 'AKAP7', 'A-kinase anchoring protein 7'],\n",
       " 'AKAP8': ['AKAP95', 'DKFZp586B1222', 'AKAP8', 'A-kinase anchoring protein 8'],\n",
       " 'AKAP8L': ['NAKAP95', 'HAP95', 'AKAP8L', 'A-kinase anchoring protein 8 like'],\n",
       " 'AKAP8P1': ['nan', 'AKAP8P1', 'A-kinase anchoring protein 8 pseudogene 1'],\n",
       " 'AKAP9': ['KIAA0803',\n",
       "  'AKAP350',\n",
       "  'AKAP450',\n",
       "  'CG-NAP',\n",
       "  'YOTIAO',\n",
       "  'HYPERION',\n",
       "  'PRKA9',\n",
       "  'MU-RMS-40.16A',\n",
       "  'PPP1R45',\n",
       "  'LQT11',\n",
       "  'AKAP9',\n",
       "  'A-kinase anchoring protein 9'],\n",
       " 'AKAP10': ['D-AKAP2',\n",
       "  'PRKA10',\n",
       "  'MGC9414',\n",
       "  'AKAP10',\n",
       "  'A-kinase anchoring protein 10'],\n",
       " 'AKAP11': ['KIAA0629',\n",
       "  'AKAP220',\n",
       "  'PRKA11',\n",
       "  'FLJ11304',\n",
       "  'DKFZp781I12161',\n",
       "  'PPP1R44',\n",
       "  'AKAP11',\n",
       "  'A-kinase anchoring protein 11'],\n",
       " 'AKAP12': ['AKAP250', 'SSeCKS', 'AKAP12', 'A-kinase anchoring protein 12'],\n",
       " 'AKAP13': ['Ht31',\n",
       "  'BRX',\n",
       "  'AKAP-Lbc',\n",
       "  'c-lbc',\n",
       "  'PROTO-LB',\n",
       "  'HA-3',\n",
       "  'ARHGEF13',\n",
       "  'AKAP13',\n",
       "  'A-kinase anchoring protein 13'],\n",
       " 'AKAP14': ['AKAP28', 'AKAP14', 'A-kinase anchoring protein 14'],\n",
       " 'AKAP17A': ['XE7',\n",
       "  'XE7Y',\n",
       "  'DXYS155E',\n",
       "  'MGC39904',\n",
       "  '721P',\n",
       "  'CCDC133',\n",
       "  'AKAP17A',\n",
       "  'A-kinase anchoring protein 17A'],\n",
       " 'AKAP17BP': ['nan', 'AKAP17BP', 'A-kinase anchoring protein 17B, pseudogene'],\n",
       " 'AKIP1': ['BCA3', 'AKIP1', 'A-kinase interacting protein 1'],\n",
       " 'AKIRIN1': ['FLJ12666', 'AKIRIN1', 'akirin 1'],\n",
       " 'AKIRIN1P1': ['nan', 'AKIRIN1P1', 'akirin 1 pseudogene 1'],\n",
       " 'AKIRIN1P2': ['nan', 'AKIRIN1P2', 'akirin 1 pseudogene 2'],\n",
       " 'AKIRIN2': ['FLJ10342', 'dJ486L4.2', 'AKIRIN2', 'akirin 2'],\n",
       " 'AKIRIN2P1': ['nan', 'AKIRIN2P1', 'akirin 2 pseudogene 1'],\n",
       " 'AKNA': ['KIAA1968', 'AKNA', 'AT-hook transcription factor'],\n",
       " 'AKNAD1': ['MGC26989', 'AKNAD1', 'AKNA domain containing 1'],\n",
       " 'AKR1A1': ['ALR',\n",
       "  'DD3',\n",
       "  'AKR1A1',\n",
       "  'aldo-keto reductase family 1, member A1 (aldehyde reductase)'],\n",
       " 'AKR1B1': ['AR',\n",
       "  'AKR1B1',\n",
       "  'aldo-keto reductase family 1, member B1 (aldose reductase)'],\n",
       " 'AKR1B1P1': ['nan',\n",
       "  'AKR1B1P1',\n",
       "  'aldehyde reductase family 1, member B1 pseudogene 1'],\n",
       " 'AKR1B1P2': ['nan',\n",
       "  'AKR1B1P2',\n",
       "  'aldo-keto reductase family 1, member B1 pseudogene 2'],\n",
       " 'AKR1B1P4': ['nan',\n",
       "  'AKR1B1P4',\n",
       "  'aldo-keto reductase family 1, member B1 pseudogene 4'],\n",
       " 'AKR1B1P6': ['nan',\n",
       "  'AKR1B1P6',\n",
       "  'aldo-keto reductase family 1, member B1 pseudogene 6'],\n",
       " 'AKR1B1P7': ['nan',\n",
       "  'AKR1B1P7',\n",
       "  'aldo-keto reductase family 1, member B1 pseudogene 7'],\n",
       " 'AKR1B1P8': ['nan',\n",
       "  'AKR1B1P8',\n",
       "  'aldo-keto reductase family 1, member B1 pseudogene 8'],\n",
       " 'AKR1B10': ['AKR1B12',\n",
       "  'ARL-1',\n",
       "  'HIS',\n",
       "  'ARL1',\n",
       "  'HSI',\n",
       "  'ALDRLn',\n",
       "  'AKR1B10',\n",
       "  'aldo-keto reductase family 1, member B10 (aldose reductase)'],\n",
       " 'AKR1B10P1': ['nan',\n",
       "  'AKR1B10P1',\n",
       "  'aldo-keto reductase family 1, member B10 pseudogene 1'],\n",
       " 'AKR1B10P2': ['nan',\n",
       "  'AKR1B10P2',\n",
       "  'aldo-keto reductase family 1, member B10 pseudogene 2'],\n",
       " 'AKR1B15': ['nan', 'AKR1B15', 'aldo-keto reductase family 1, member B15'],\n",
       " 'AKR1C1': ['DDH',\n",
       "  'MBAB',\n",
       "  'DD1',\n",
       "  'HAKRC',\n",
       "  'AKR1C1',\n",
       "  'aldo-keto reductase family 1, member C1'],\n",
       " 'AKR1C2': ['DD',\n",
       "  'BABP',\n",
       "  'DD2',\n",
       "  'HAKRD',\n",
       "  'MCDR2',\n",
       "  'AKR1C2',\n",
       "  'aldo-keto reductase family 1, member C2'],\n",
       " 'AKR1C3': ['KIAA0119',\n",
       "  'DDX',\n",
       "  'HAKRB',\n",
       "  'PGFS',\n",
       "  'AKR1C3',\n",
       "  'aldo-keto reductase family 1, member C3'],\n",
       " 'AKR1C4': ['DD4',\n",
       "  'HAKRA',\n",
       "  'C11',\n",
       "  '3-alpha-HSD',\n",
       "  'CDR',\n",
       "  'MGC22581',\n",
       "  'AKR1C4',\n",
       "  'aldo-keto reductase family 1, member C4'],\n",
       " 'AKR1C5P': ['nan',\n",
       "  'AKR1C5P',\n",
       "  'aldo-keto reductase family 1, member C5, pseudogene'],\n",
       " 'AKR1C6P': ['TAKR',\n",
       "  'AKR1C6P',\n",
       "  'aldo-keto reductase family 1, member C6, pseudogene'],\n",
       " 'AKR1C7P': ['nan',\n",
       "  'AKR1C7P',\n",
       "  'aldo-keto reductase family 1, member C7, pseudogene'],\n",
       " 'AKR1C8P': ['nan',\n",
       "  'AKR1C8P',\n",
       "  'aldo-keto reductase family 1, member C8, pseudogene'],\n",
       " 'AKR1D1': ['nan', 'AKR1D1', 'aldo-keto reductase family 1, member D1'],\n",
       " 'AKR1D1P1': ['nan',\n",
       "  'AKR1D1P1',\n",
       "  'aldo-keto reductase family 1, member D1 pseudogene 1'],\n",
       " 'AKR1E2': ['MGC10612', 'AKR1E2', 'aldo-keto reductase family 1, member E2'],\n",
       " 'AKR7A2': ['AFAR', 'AKR7A2', 'aldo-keto reductase family 7, member A2'],\n",
       " 'AKR7A2P1': ['AFARP1',\n",
       "  'AKR7A2P1',\n",
       "  'aldo-keto reductase family 7, member A2 pseudogene 1'],\n",
       " 'AKR7A3': ['nan',\n",
       "  'AKR7A3',\n",
       "  'aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase)'],\n",
       " 'AKR7L': ['AFAR3',\n",
       "  'AKR7L',\n",
       "  'aldo-keto reductase family 7-like (gene/pseudogene)'],\n",
       " 'AKT1': ['RAC',\n",
       "  'PKB',\n",
       "  'PRKBA',\n",
       "  'AKT',\n",
       "  'AKT1',\n",
       "  'v-akt murine thymoma viral oncogene homolog 1'],\n",
       " 'AKT1S1': ['PRAS40',\n",
       "  'MGC2865',\n",
       "  'Lobe',\n",
       "  'AKT1S1',\n",
       "  'AKT1 substrate 1 (proline rich)'],\n",
       " 'AKT2': ['nan', 'AKT2', 'v-akt murine thymoma viral oncogene homolog 2'],\n",
       " 'AKT3': ['PKBG',\n",
       "  'RAC-gamma',\n",
       "  'PRKBG',\n",
       "  'AKT3',\n",
       "  'v-akt murine thymoma viral oncogene homolog 3'],\n",
       " 'AKT3-IT1': ['nan', 'AKT3-IT1', 'AKT3 intronic transcript 1'],\n",
       " 'AKTIP': ['FLJ13258', 'AKTIP', 'AKT interacting protein'],\n",
       " 'ALAD': ['ALADH', 'PBGS', 'ALAD', 'aminolevulinate dehydratase'],\n",
       " 'ALAS1': ['nan', 'ALAS1', \"5'-aminolevulinate synthase 1\"],\n",
       " 'ALAS2': ['nan', 'ALAS2', \"5'-aminolevulinate synthase 2\"],\n",
       " 'ALB': ['nan', 'ALB', 'albumin'],\n",
       " 'ALCAM': ['CD166',\n",
       "  'MEMD',\n",
       "  'ALCAM',\n",
       "  'activated leukocyte cell adhesion molecule'],\n",
       " 'ALDH1A1': ['RALDH1', 'ALDH1A1', 'aldehyde dehydrogenase 1 family member A1'],\n",
       " 'ALDH1A2': ['RALDH2', 'ALDH1A2', 'aldehyde dehydrogenase 1 family member A2'],\n",
       " 'ALDH1A3': ['RALDH3', 'ALDH1A3', 'aldehyde dehydrogenase 1 family member A3'],\n",
       " 'ALDH1B1': ['ALDHX', 'ALDH1B1', 'aldehyde dehydrogenase 1 family member B1'],\n",
       " 'ALDH1L1': ['10-fTHF',\n",
       "  'ALDH1L1',\n",
       "  'aldehyde dehydrogenase 1 family member L1'],\n",
       " 'ALDH1L1-AS1': ['nan', 'ALDH1L1-AS1', 'ALDH1L1 antisense RNA 1'],\n",
       " 'ALDH1L1-AS2': ['nan', 'ALDH1L1-AS2', 'ALDH1L1 antisense RNA 2'],\n",
       " 'ALDH1L2': ['FLJ38508',\n",
       "  'mtFDH',\n",
       "  'ALDH1L2',\n",
       "  'aldehyde dehydrogenase 1 family member L2'],\n",
       " 'ALDH2': ['nan', 'ALDH2', 'aldehyde dehydrogenase 2 family (mitochondrial)'],\n",
       " 'ALDH3A1': ['nan', 'ALDH3A1', 'aldehyde dehydrogenase 3 family member A1'],\n",
       " 'ALDH3A2': ['FALDH', 'ALDH3A2', 'aldehyde dehydrogenase 3 family member A2'],\n",
       " 'ALDH3B1': ['nan', 'ALDH3B1', 'aldehyde dehydrogenase 3 family member B1'],\n",
       " 'ALDH3B2': ['nan', 'ALDH3B2', 'aldehyde dehydrogenase 3 family member B2'],\n",
       " 'ALDH4A1': ['P5CDh', 'ALDH4A1', 'aldehyde dehydrogenase 4 family member A1'],\n",
       " 'ALDH5A1': ['SSADH',\n",
       "  'SSDH',\n",
       "  'ALDH5A1',\n",
       "  'aldehyde dehydrogenase 5 family member A1'],\n",
       " 'ALDH6A1': ['nan', 'ALDH6A1', 'aldehyde dehydrogenase 6 family member A1'],\n",
       " 'ALDH7A1': ['EPD',\n",
       "  'PDE',\n",
       "  'ALDH7A1',\n",
       "  'aldehyde dehydrogenase 7 family member A1'],\n",
       " 'ALDH7A1P1': ['nan',\n",
       "  'ALDH7A1P1',\n",
       "  'aldehyde dehydrogenase 7 family member A1 pseudogene 1'],\n",
       " 'ALDH7A1P2': ['nan',\n",
       "  'ALDH7A1P2',\n",
       "  'aldehyde dehydrogenase 7 family member A1 pseudogene 2'],\n",
       " 'ALDH7A1P3': ['nan',\n",
       "  'ALDH7A1P3',\n",
       "  'aldehyde dehydrogenase 7 family member A1 pseudogene 3'],\n",
       " 'ALDH7A1P4': ['nan',\n",
       "  'ALDH7A1P4',\n",
       "  'aldehyde dehydrogenase 7 family member A1 pseudogene 4'],\n",
       " 'ALDH8A1': ['ALDH12', 'ALDH8A1', 'aldehyde dehydrogenase 8 family member A1'],\n",
       " 'ALDH9A1': ['E3', 'ALDH9A1', 'aldehyde dehydrogenase 9 family member A1'],\n",
       " 'ALDH16A1': ['MGC10204',\n",
       "  'ALDH16A1',\n",
       "  'aldehyde dehydrogenase 16 family member A1'],\n",
       " 'ALDH18A1': ['P5CS',\n",
       "  'ALDH18A1',\n",
       "  'aldehyde dehydrogenase 18 family member A1'],\n",
       " 'ALDOA': ['nan', 'ALDOA', 'aldolase, fructose-bisphosphate A'],\n",
       " 'ALDOAP1': ['nan',\n",
       "  'ALDOAP1',\n",
       "  'aldolase, fructose-bisphosphate A pseudogene 1'],\n",
       " 'ALDOAP2': ['nan',\n",
       "  'ALDOAP2',\n",
       "  'aldolase, fructose-bisphosphate A pseudogene 2'],\n",
       " 'ALDOB': ['nan', 'ALDOB', 'aldolase, fructose-bisphosphate B'],\n",
       " 'ALDOC': ['nan', 'ALDOC', 'aldolase, fructose-bisphosphate C'],\n",
       " 'ALG1': ['HMT-1',\n",
       "  'HMAT1',\n",
       "  'ALG1',\n",
       "  'ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase'],\n",
       " 'ALG1L': ['ALG1L1',\n",
       "  'ALG1L',\n",
       "  'ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase-like'],\n",
       " 'ALG1L2': ['nan',\n",
       "  'ALG1L2',\n",
       "  'ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase-like 2'],\n",
       " 'ALG1L3P': ['nan',\n",
       "  'ALG1L3P',\n",
       "  'asparagine-linked glycosylation 1-like 3, pseudogene'],\n",
       " 'ALG1L5P': ['nan',\n",
       "  'ALG1L5P',\n",
       "  'asparagine-linked glycosylation 1-like 5, pseudogene'],\n",
       " 'ALG1L6P': ['nan',\n",
       "  'ALG1L6P',\n",
       "  'asparagine-linked glycosylation 1-like 6, pseudogene'],\n",
       " 'ALG1L7P': ['nan',\n",
       "  'ALG1L7P',\n",
       "  'asparagine-linked glycosylation 1-like 7, pseudogene'],\n",
       " 'ALG1L8P': ['nan',\n",
       "  'ALG1L8P',\n",
       "  'asparagine-linked glycosylation 1-like 8, pseudogene'],\n",
       " 'ALG1L9P': ['nan',\n",
       "  'ALG1L9P',\n",
       "  'asparagine-linked glycosylation 1-like 9, pseudogene'],\n",
       " 'ALG1L10P': ['nan',\n",
       "  'ALG1L10P',\n",
       "  'asparagine-linked glycosylation 1-like 10, pseudogene'],\n",
       " 'ALG1L11P': ['nan',\n",
       "  'ALG1L11P',\n",
       "  'asparagine-linked glycosylation 1-like 11, pseudogene'],\n",
       " 'ALG1L12P': ['nan',\n",
       "  'ALG1L12P',\n",
       "  'asparagine-linked glycosylation 1-like 12, pseudogene'],\n",
       " 'ALG1L13P': ['nan',\n",
       "  'ALG1L13P',\n",
       "  'asparagine-linked glycosylation 1-like 13, pseudogene'],\n",
       " 'ALG1L14P': ['nan',\n",
       "  'ALG1L14P',\n",
       "  'asparagine-linked glycosylation 1-like 14, pseudogene'],\n",
       " 'ALG1L15P': ['nan',\n",
       "  'ALG1L15P',\n",
       "  'asparagine-linked glycosylation 1-like 15, pseudogene'],\n",
       " 'ALG2': ['CDGIi',\n",
       "  'FLJ14511',\n",
       "  'hALPG2',\n",
       "  'NET38',\n",
       "  'ALG2',\n",
       "  'ALG2, alpha-1,3/1,6-mannosyltransferase'],\n",
       " 'ALG3': ['NOT56L',\n",
       "  'Not56',\n",
       "  'CDGS4',\n",
       "  'D16Ertd36e',\n",
       "  'ALG3',\n",
       "  'ALG3, alpha-1,3- mannosyltransferase'],\n",
       " 'ALG3P1': ['nan',\n",
       "  'ALG3P1',\n",
       "  'ALG3, alpha-1,3- mannosyltransferase pseudogene 1'],\n",
       " 'ALG5': ['bA421P11.2',\n",
       "  'ALG5',\n",
       "  'ALG5, dolichyl-phosphate beta-glucosyltransferase'],\n",
       " 'ALG6': ['nan', 'ALG6', 'ALG6, alpha-1,3-glucosyltransferase'],\n",
       " 'ALG8': ['MGC2840', 'ALG8', 'ALG8, alpha-1,3-glucosyltransferase'],\n",
       " 'ALG9': ['nan', 'ALG9', 'ALG9, alpha-1,2-mannosyltransferase'],\n",
       " 'ALG9-IT1': ['nan', 'ALG9-IT1', 'ALG9 intronic transcript 1'],\n",
       " 'ALG10': ['FLJ14751',\n",
       "  'DIE2',\n",
       "  'ALG10A',\n",
       "  'ALG10',\n",
       "  'ALG10, alpha-1,2-glucosyltransferase'],\n",
       " 'ALG10B': ['KCR1', 'ALG10B', 'ALG10B, alpha-1,2-glucosyltransferase'],\n",
       " 'ALG11': ['KIAA0266', 'ALG11', 'ALG11, alpha-1,2-mannosyltransferase'],\n",
       " 'ALG12': ['ECM39', 'ALG12', 'ALG12, alpha-1,6-mannosyltransferase'],\n",
       " 'ALG13': ['MDS031',\n",
       "  'YGL047W',\n",
       "  'FLJ23018',\n",
       "  'TDRD13',\n",
       "  'ALG13',\n",
       "  'ALG13, UDP-N-acetylglucosaminyltransferase subunit'],\n",
       " 'ALG13-AS1': ['nan', 'ALG13-AS1', 'ALG13 antisense RNA 1'],\n",
       " 'ALG14': ['MGC19780',\n",
       "  'ALG14',\n",
       "  'ALG14, UDP-N-acetylglucosaminyltransferase subunit'],\n",
       " 'ALK': ['CD246', 'ALK', 'anaplastic lymphoma receptor tyrosine kinase'],\n",
       " 'ALKBH1': ['hABH',\n",
       "  'alkB',\n",
       "  'ABH',\n",
       "  'ALKBH1',\n",
       "  'alkB homolog 1, histone H2A dioxygenase'],\n",
       " 'ALKBH2': ['MGC90512',\n",
       "  'ABH2',\n",
       "  'ALKBH2',\n",
       "  'alkB homolog 2, alpha-ketoglutarate-dependent dioxygenase'],\n",
       " 'ALKBH3': ['DEPC-1',\n",
       "  'ALKBH3',\n",
       "  'alkB homolog 3, alpha-ketoglutarate-dependent dioxygenase'],\n",
       " 'ALKBH3-AS1': ['nan', 'ALKBH3-AS1', 'ALKBH3 antisense RNA 1'],\n",
       " 'ALKBH4': ['FLJ20013', 'ALKBH4', 'alkB homolog 4, lysine demethylase'],\n",
       " 'ALKBH5': ['FLJ20308', 'ALKBH5', 'alkB homolog 5, RNA demethylase'],\n",
       " 'ALKBH6': ['MGC15677', 'ALKBH6', 'alkB homolog 6'],\n",
       " 'ALKBH7': ['MGC10974', 'ALKBH7', 'alkB homolog 7'],\n",
       " 'ALKBH8': ['MGC10235',\n",
       "  'TRM9',\n",
       "  'TRMT9',\n",
       "  'ALKBH8',\n",
       "  'alkB homolog 8, tRNA methyltransferase'],\n",
       " 'ALLC': ['ALC', 'ALLC', 'allantoicase'],\n",
       " 'ALMS1': ['KIAA0328',\n",
       "  'ALMS1',\n",
       "  'ALMS1, centrosome and basal body associated protein'],\n",
       " 'ALMS1-IT1': ['nan', 'ALMS1-IT1', 'ALMS1 intronic transcript 1'],\n",
       " 'ALMS1P1': ['nan',\n",
       "  'ALMS1P1',\n",
       "  'ALMS1, centrosome and basal body associated protein pseudogene 1'],\n",
       " 'ALOX5': ['5-LOX', 'ALOX5', 'arachidonate 5-lipoxygenase'],\n",
       " 'ALOX5AP': ['FLAP',\n",
       "  'ALOX5AP',\n",
       "  'arachidonate 5-lipoxygenase activating protein'],\n",
       " 'ALOX12': ['12S-LOX', 'ALOX12', 'arachidonate 12-lipoxygenase'],\n",
       " 'ALOX12-AS1': ['nan', 'ALOX12-AS1', 'ALOX12 antisense RNA 1'],\n",
       " 'ALOX12B': ['12R-LOX', 'ALOX12B', 'arachidonate 12-lipoxygenase, 12R type'],\n",
       " 'ALOX12P1': ['nan', 'ALOX12P1', 'arachidonate 12-lipoxygenase pseudogene 1'],\n",
       " 'ALOX12P2': ['nan', 'ALOX12P2', 'arachidonate 12-lipoxygenase pseudogene 2'],\n",
       " 'ALOX15': ['15-LOX-1', 'ALOX15', 'arachidonate 15-lipoxygenase'],\n",
       " 'ALOX15B': ['15-LOX-2', 'ALOX15B', 'arachidonate 15-lipoxygenase, type B'],\n",
       " 'ALOX15P2': ['nan', 'ALOX15P2', 'arachidonate 15-lipoxygenase pseudogene 2'],\n",
       " 'ALOXE3': ['eLOX3', 'E-LOX', 'ALOXE3', 'arachidonate lipoxygenase 3'],\n",
       " 'ALPI': ['nan', 'ALPI', 'alkaline phosphatase, intestinal'],\n",
       " 'ALPK1': ['Lak', 'FLJ22670', 'KIAA1527', 'ALPK1', 'alpha kinase 1'],\n",
       " 'ALPK2': ['HAK', 'ALPK2', 'alpha kinase 2'],\n",
       " 'ALPK3': ['MAK', 'KIAA1330', 'Midori', 'ALPK3', 'alpha kinase 3'],\n",
       " 'ALPL': ['TNSALP', 'ALPL', 'alkaline phosphatase, liver/bone/kidney'],\n",
       " 'ALPP': ['nan', 'ALPP', 'alkaline phosphatase, placental'],\n",
       " 'ALPPL2': ['nan', 'ALPPL2', 'alkaline phosphatase, placental like 2'],\n",
       " 'ALS2': ['nan', 'ALS2', 'ALS2, alsin Rho guanine nucleotide exchange factor'],\n",
       " 'ALS2CL': ['FLJ36525',\n",
       "  'RN49018',\n",
       "  'DKFZp686I0110',\n",
       "  'ALS2CL',\n",
       "  'ALS2 C-terminal like'],\n",
       " 'ALS2CR11': ['FLJ25351',\n",
       "  'ALS2CR11',\n",
       "  'amyotrophic lateral sclerosis 2 chromosome region candidate 11'],\n",
       " 'ALS2CR12': ['nan',\n",
       "  'ALS2CR12',\n",
       "  'amyotrophic lateral sclerosis 2 chromosome region candidate 12'],\n",
       " 'ALX1': ['nan', 'ALX1', 'ALX homeobox 1'],\n",
       " 'ALX3': ['nan', 'ALX3', 'ALX homeobox 3'],\n",
       " 'ALX4': ['FPP', 'PFM', 'KIAA1788', 'ALX4', 'ALX homeobox 4'],\n",
       " 'ALYREF': ['ALY', 'BEF', 'ALY/REF', 'REF', 'ALYREF', 'Aly/REF export factor'],\n",
       " 'AMACR': ['RACE', 'AMACR', 'alpha-methylacyl-CoA racemase'],\n",
       " 'AMBN': ['nan', 'AMBN', 'ameloblastin'],\n",
       " 'AMBP': ['UTI',\n",
       "  'HCP',\n",
       "  'EDC1',\n",
       "  'HI30',\n",
       "  'IATIL',\n",
       "  'ITILC',\n",
       "  'AMBP',\n",
       "  'alpha-1-microglobulin/bikunin precursor'],\n",
       " 'AMBRA1': ['FLJ20294',\n",
       "  'KIAA1736',\n",
       "  'WDR94',\n",
       "  'DCAF3',\n",
       "  'AMBRA1',\n",
       "  'autophagy/beclin-1 regulator 1'],\n",
       " 'AMD1': ['SAMDC', 'AMD1', 'adenosylmethionine decarboxylase 1'],\n",
       " 'AMD1P1': ['nan',\n",
       "  'AMD1P1',\n",
       "  'adenosylmethionine decarboxylase 1 pseudogene 1'],\n",
       " 'AMD1P2': ['AMDPX',\n",
       "  'AMDPY',\n",
       "  'AMD1P2',\n",
       "  'adenosylmethionine decarboxylase 1 pseudogene 2'],\n",
       " 'AMD1P3': ['nan',\n",
       "  'AMD1P3',\n",
       "  'adenosylmethionine decarboxylase 1 pseudogene 3'],\n",
       " 'AMD1P4': ['nan',\n",
       "  'AMD1P4',\n",
       "  'adenosylmethionine decarboxylase 1 pseudogene 4'],\n",
       " 'AMDHD1': ['MGC35366', 'AMDHD1', 'amidohydrolase domain containing 1'],\n",
       " 'AMDHD2': ['CGI-14', 'AMDHD2', 'amidohydrolase domain containing 2'],\n",
       " 'AMELX': ['nan', 'AMELX', 'amelogenin, X-linked'],\n",
       " 'AMELY': ['nan', 'AMELY', 'amelogenin, Y-linked'],\n",
       " 'AMER1': ['RP11-403E24.2',\n",
       "  'FLJ39827',\n",
       "  'WTX',\n",
       "  'AMER1',\n",
       "  'APC membrane recruitment protein 1'],\n",
       " 'AMER2': ['FLJ25477', 'AMER2', 'APC membrane recruitment protein 2'],\n",
       " 'AMER3': ['FLJ38377', 'AMER3', 'APC membrane recruitment protein 3'],\n",
       " 'AMFR': ['RNF45', 'gp78', 'AMFR', 'autocrine motility factor receptor'],\n",
       " 'AMH': ['MIS', 'AMH', 'anti-Mullerian hormone'],\n",
       " 'AMHR2': ['MISR2',\n",
       "  'MISRII',\n",
       "  'AMHR2',\n",
       "  'anti-Mullerian hormone receptor type II'],\n",
       " 'AMIGO1': ['AMIGO',\n",
       "  'KIAA1163',\n",
       "  'AMIGO1',\n",
       "  'adhesion molecule with Ig-like domain 1'],\n",
       " 'AMIGO2': ['ALI1',\n",
       "  'DEGA',\n",
       "  'AMIGO2',\n",
       "  'adhesion molecule with Ig-like domain 2'],\n",
       " 'AMIGO3': ['nan', 'AMIGO3', 'adhesion molecule with Ig-like domain 3'],\n",
       " 'AMMECR1': ['nan',\n",
       "  'AMMECR1',\n",
       "  'Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1'],\n",
       " 'AMMECR1-IT1': ['nan', 'AMMECR1-IT1', 'AMMECR1 intronic transcript 1'],\n",
       " 'AMMECR1L': ['MGC4268', 'AMMECR1L', 'AMMECR1 like'],\n",
       " 'AMMECR1LP1': ['nan', 'AMMECR1LP1', 'AMMECR1 like pseudogene 1'],\n",
       " 'AMN': ['amnionless', 'AMN', 'amnion associated transmembrane protein'],\n",
       " 'AMN1': ['nan', 'AMN1', 'antagonist of mitotic exit network 1 homolog'],\n",
       " 'AMOT': ['KIAA1071', 'AMOT', 'angiomotin'],\n",
       " 'AMOTL1': ['JEAP', 'AMOTL1', 'angiomotin like 1'],\n",
       " 'AMOTL2': ['LCCP', 'AMOTL2', 'angiomotin like 2'],\n",
       " 'AMPD1': ['MAD', 'MADA', 'AMPD1', 'adenosine monophosphate deaminase 1'],\n",
       " 'AMPD2': ['SPG63', 'AMPD2', 'adenosine monophosphate deaminase 2'],\n",
       " 'AMPD3': ['nan', 'AMPD3', 'adenosine monophosphate deaminase 3'],\n",
       " 'AMPH': ['nan', 'AMPH', 'amphiphysin'],\n",
       " 'AMT': ['GCST', 'NKH', 'AMT', 'aminomethyltransferase'],\n",
       " 'AMTN': ['UNQ689', 'RSTI689', 'AMTN', 'amelotin'],\n",
       " 'AMY1A': ['nan', 'AMY1A', 'amylase, alpha 1A (salivary)'],\n",
       " 'AMY1B': ['nan', 'AMY1B', 'amylase, alpha 1B (salivary)'],\n",
       " 'AMY1C': ['nan', 'AMY1C', 'amylase, alpha 1C (salivary)'],\n",
       " 'AMY2A': ['nan', 'AMY2A', 'amylase, alpha 2A (pancreatic)'],\n",
       " 'AMY2B': ['nan', 'AMY2B', 'amylase, alpha 2B (pancreatic)'],\n",
       " 'AMYP1': ['nan', 'AMYP1', 'amylase, alpha pseudogene 1'],\n",
       " 'AMZ1': ['KIAA1950', 'AMZ1', 'archaelysin family metallopeptidase 1'],\n",
       " 'AMZ2': ['nan', 'AMZ2', 'archaelysin family metallopeptidase 2'],\n",
       " 'AMZ2P1': ['FLJ32065',\n",
       "  'AMZ2P1',\n",
       "  'archaelysin family metallopeptidase 2 pseudogene 1'],\n",
       " 'AMZ2P2': ['nan',\n",
       "  'AMZ2P2',\n",
       "  'archaelysin family metallopeptidase 2 pseudogene 2'],\n",
       " 'ANAPC1': ['MCPR',\n",
       "  'TSG24',\n",
       "  'APC1',\n",
       "  'ANAPC1',\n",
       "  'anaphase promoting complex subunit 1'],\n",
       " 'ANAPC1P1': ['nan',\n",
       "  'ANAPC1P1',\n",
       "  'anaphase promoting complex subunit 1 pseudogene 1'],\n",
       " 'ANAPC2': ['APC2',\n",
       "  'KIAA1406',\n",
       "  'ANAPC2',\n",
       "  'anaphase promoting complex subunit 2'],\n",
       " 'ANAPC4': ['APC4', 'ANAPC4', 'anaphase promoting complex subunit 4'],\n",
       " 'ANAPC5': ['APC5', 'ANAPC5', 'anaphase promoting complex subunit 5'],\n",
       " 'ANAPC7': ['APC7', 'ANAPC7', 'anaphase promoting complex subunit 7'],\n",
       " 'ANAPC10': ['APC10',\n",
       "  'DOC1',\n",
       "  'DKFZP564L0562',\n",
       "  'ANAPC10',\n",
       "  'anaphase promoting complex subunit 10'],\n",
       " 'ANAPC10P1': ['nan',\n",
       "  'ANAPC10P1',\n",
       "  'anaphase promoting complex subunit 10 pseudogene 1'],\n",
       " 'ANAPC11': ['HSPC214',\n",
       "  'APC11',\n",
       "  'Apc11p',\n",
       "  'MGC882',\n",
       "  'ANAPC11',\n",
       "  'anaphase promoting complex subunit 11'],\n",
       " 'ANAPC13': ['SWM1',\n",
       "  'APC13',\n",
       "  'DKFZP566D193',\n",
       "  'ANAPC13',\n",
       "  'anaphase promoting complex subunit 13'],\n",
       " 'ANAPC15': ['HSPC020',\n",
       "  'DKFZP564M082',\n",
       "  'APC15',\n",
       "  'ANAPC15',\n",
       "  'anaphase promoting complex subunit 15'],\n",
       " 'ANAPC16': ['bA570G20.3',\n",
       "  'FLJ33728',\n",
       "  'APC16',\n",
       "  'CENP-27',\n",
       "  'ANAPC16',\n",
       "  'anaphase promoting complex subunit 16'],\n",
       " 'ANG': ['RNASE5',\n",
       "  'RAA1',\n",
       "  'ANG',\n",
       "  'angiogenin, ribonuclease, RNase A family, 5'],\n",
       " 'ANGEL1': ['Ccr4e', 'ANGEL1', 'angel homolog 1 (Drosophila)'],\n",
       " 'ANGEL2': ['KIAA0759L',\n",
       "  'FLJ12793',\n",
       "  'Ccr4d',\n",
       "  'ANGEL2',\n",
       "  'angel homolog 2 (Drosophila)'],\n",
       " 'ANGPT1': ['KIAA0003', 'Ang1', 'ANGPT1', 'angiopoietin 1'],\n",
       " 'ANGPT2': ['Ang2', 'ANGPT2', 'angiopoietin 2'],\n",
       " 'ANGPT4': ['nan', 'ANGPT4', 'angiopoietin 4'],\n",
       " 'ANGPTL1': ['ANG3', 'AngY', 'ARP1', 'ANGPTL1', 'angiopoietin like 1'],\n",
       " 'ANGPTL2': ['ARP2', 'HARP', 'ANGPTL2', 'angiopoietin like 2'],\n",
       " 'ANGPTL3': ['nan', 'ANGPTL3', 'angiopoietin like 3'],\n",
       " 'ANGPTL4': ['pp1158',\n",
       "  'PGAR',\n",
       "  'ARP4',\n",
       "  'HFARP',\n",
       "  'FIAF',\n",
       "  'NL2',\n",
       "  'ANGPTL4',\n",
       "  'angiopoietin like 4'],\n",
       " 'ANGPTL5': ['nan', 'ANGPTL5', 'angiopoietin like 5'],\n",
       " 'ANGPTL6': ['ARP5', 'AGF', 'ANGPTL6', 'angiopoietin like 6'],\n",
       " 'ANGPTL7': ['CDT6', 'AngX', 'ANGPTL7', 'angiopoietin like 7'],\n",
       " 'ANGPTL8': ['TD26', 'RIFL', 'ANGPTL8', 'angiopoietin like 8'],\n",
       " 'ANHX': ['nan', 'ANHX', 'anomalous homeobox'],\n",
       " 'ANK1': ['SPH1', 'ANK1', 'ankyrin 1'],\n",
       " 'ANK2': ['nan', 'ANK2', 'ankyrin 2, neuronal'],\n",
       " 'ANK3': ['nan', 'ANK3', 'ankyrin 3, node of Ranvier (ankyrin G)'],\n",
       " 'ANKAR': ['FLJ25415', 'ANKAR', 'ankyrin and armadillo repeat containing'],\n",
       " 'ANKDD1A': ['FLJ25870',\n",
       "  'ANKDD1A',\n",
       "  'ankyrin repeat and death domain containing 1A'],\n",
       " 'ANKDD1B': ['nan',\n",
       "  'ANKDD1B',\n",
       "  'ankyrin repeat and death domain containing 1B'],\n",
       " 'ANKEF1': ['FLJ21669',\n",
       "  'dJ839B4.6',\n",
       "  'ANKEF1',\n",
       "  'ankyrin repeat and EF-hand domain containing 1'],\n",
       " 'ANKFN1': ['FLJ38335',\n",
       "  'ANKFN1',\n",
       "  'ankyrin repeat and fibronectin type III domain containing 1'],\n",
       " 'ANKFY1': ['ANKHZN',\n",
       "  'KIAA1255',\n",
       "  'ZFYVE14',\n",
       "  'BTBD23',\n",
       "  'RANK-5',\n",
       "  'ANKFY1',\n",
       "  'ankyrin repeat and FYVE domain containing 1'],\n",
       " 'ANKH': ['HANK',\n",
       "  'ANK',\n",
       "  'CPPDD',\n",
       "  'ANKH',\n",
       "  'ANKH inorganic pyrophosphate transport regulator'],\n",
       " 'ANKHD1': ['MASK',\n",
       "  'FLJ20288',\n",
       "  'FLJ11979',\n",
       "  'FLJ10042',\n",
       "  'FLJ14127',\n",
       "  'KIAA1085',\n",
       "  'MASK1',\n",
       "  'ANKHD1',\n",
       "  'ankyrin repeat and KH domain containing 1'],\n",
       " 'ANKHD1-EIF4EBP3': ['MASK-BP3',\n",
       "  'ANKHD1-EIF4EBP3',\n",
       "  'ANKHD1-EIF4EBP3 readthrough'],\n",
       " 'ANKIB1': ['DKFZP434A0225',\n",
       "  'KIAA1386',\n",
       "  'ANKIB1',\n",
       "  'ankyrin repeat and IBR domain containing 1'],\n",
       " 'ANKK1': ['X-kinase',\n",
       "  'ANKK1',\n",
       "  'ankyrin repeat and kinase domain containing 1'],\n",
       " 'ANKLE1': ['FLJ39369',\n",
       "  'LEMD6',\n",
       "  'ANKLE1',\n",
       "  'ankyrin repeat and LEM domain containing 1'],\n",
       " 'ANKLE2': ['LEMD7',\n",
       "  'Lem4',\n",
       "  'ANKLE2',\n",
       "  'ankyrin repeat and LEM domain containing 2'],\n",
       " 'ANKMY1': ['FLJ20499',\n",
       "  'ZMYND13',\n",
       "  'ANKMY1',\n",
       "  'ankyrin repeat and MYND domain containing 1'],\n",
       " 'ANKMY2': ['DKFZP564O043',\n",
       "  'ZMYND20',\n",
       "  'ANKMY2',\n",
       "  'ankyrin repeat and MYND domain containing 2'],\n",
       " 'ANKRA2': ['nan', 'ANKRA2', 'ankyrin repeat family A member 2'],\n",
       " 'ANKRD1': ['C-193',\n",
       "  'ALRP',\n",
       "  'CARP',\n",
       "  'CVARP',\n",
       "  'MCARP',\n",
       "  'ANKRD1',\n",
       "  'ankyrin repeat domain 1'],\n",
       " 'ANKRD2': ['ARPP', 'ANKRD2', 'ankyrin repeat domain 2'],\n",
       " 'ANKRD6': ['KIAA0957', 'ANKRD6', 'ankyrin repeat domain 6'],\n",
       " 'ANKRD7': ['TSA806', 'ANKRD7', 'ankyrin repeat domain 7'],\n",
       " 'ANKRD9': ['nan', 'ANKRD9', 'ankyrin repeat domain 9'],\n",
       " 'ANKRD10': ['FLJ20093', 'ANKRD10', 'ankyrin repeat domain 10'],\n",
       " 'ANKRD10-IT1': ['nan', 'ANKRD10-IT1', 'ANKRD10 intronic transcript 1'],\n",
       " 'ANKRD11': ['LZ16', 'T13', 'ANKRD11', 'ankyrin repeat domain 11'],\n",
       " 'ANKRD12': ['KIAA0874',\n",
       "  'FLJ20053',\n",
       "  'GAC-1',\n",
       "  'ANKRD12',\n",
       "  'ankyrin repeat domain 12'],\n",
       " 'ANKRD13A': ['NY-REN-25', 'ANKRD13A', 'ankyrin repeat domain 13A'],\n",
       " 'ANKRD13B': ['FLJ25555', 'ANKRD13B', 'ankyrin repeat domain 13B'],\n",
       " 'ANKRD13C': ['DKFZP566D1346',\n",
       "  'dJ677H15.3',\n",
       "  'ANKRD13C',\n",
       "  'ankyrin repeat domain 13C'],\n",
       " 'ANKRD13D': ['nan', 'ANKRD13D', 'ankyrin repeat domain 13 family member D'],\n",
       " 'ANKRD16': ['DKFZP434N1511', 'ANKRD16', 'ankyrin repeat domain 16'],\n",
       " 'ANKRD17': ['GTAR',\n",
       "  'KIAA0697',\n",
       "  'FLJ22206',\n",
       "  'NY-BR-16',\n",
       "  'MASK2',\n",
       "  'ANKRD17',\n",
       "  'ankyrin repeat domain 17'],\n",
       " 'ANKRD18A': ['KIAA2015', 'FLJ35740', 'ANKRD18A', 'ankyrin repeat domain 18A'],\n",
       " 'ANKRD18B': ['bA255A11.3', 'ANKRD18B', 'ankyrin repeat domain 18B'],\n",
       " 'ANKRD18CP': ['nan', 'ANKRD18CP', 'ankyrin repeat domain 18C, pseudogene'],\n",
       " 'ANKRD18DP': ['nan', 'ANKRD18DP', 'ankyrin repeat domain 18D, pseudogene'],\n",
       " 'ANKRD18EP': ['nan', 'ANKRD18EP', 'ankyrin repeat domain 18E, pseudogene'],\n",
       " 'ANKRD19P': ['FLJ36178', 'ANKRD19P', 'ankyrin repeat domain 19, pseudogene'],\n",
       " 'ANKRD20A1': ['DKFZp434A171',\n",
       "  'ANKRD20A1',\n",
       "  'ankyrin repeat domain 20 family member A1'],\n",
       " 'ANKRD20A2': ['nan',\n",
       "  'ANKRD20A2',\n",
       "  'ankyrin repeat domain 20 family member A2'],\n",
       " 'ANKRD20A3': ['nan',\n",
       "  'ANKRD20A3',\n",
       "  'ankyrin repeat domain 20 family member A3'],\n",
       " 'ANKRD20A4': ['OTTHUMG00000066855',\n",
       "  'ANKRD20A4',\n",
       "  'ankyrin repeat domain 20 family member A4'],\n",
       " 'ANKRD20A5P': ['MGC26718',\n",
       "  'ANKRD20A5P',\n",
       "  'ankyrin repeat domain 20 family member A5, pseudogene'],\n",
       " 'ANKRD20A7P': ['nan',\n",
       "  'ANKRD20A7P',\n",
       "  'ankyrin repeat domain 20 family member A7, pseudogene'],\n",
       " 'ANKRD20A8P': ['nan',\n",
       "  'ANKRD20A8P',\n",
       "  'ankyrin repeat domain 20 family member A8, pseudogene'],\n",
       " 'ANKRD20A9P': ['nan',\n",
       "  'ANKRD20A9P',\n",
       "  'ankyrin repeat domain 20 family member A9, pseudogene'],\n",
       " 'ANKRD20A10P': ['nan',\n",
       "  'ANKRD20A10P',\n",
       "  'ankyrin repeat domain 20 family member A10, pseudogene'],\n",
       " 'ANKRD20A11P': ['nan',\n",
       "  'ANKRD20A11P',\n",
       "  'ankyrin repeat domain 20 family member A11, pseudogene'],\n",
       " 'ANKRD20A17P': ['nan',\n",
       "  'ANKRD20A17P',\n",
       "  'ankyrin repeat domain 20 family member A17, pseudogene'],\n",
       " 'ANKRD20A18P': ['nan',\n",
       "  'ANKRD20A18P',\n",
       "  'ankyrin repeat domain 20 family member A18, pseudogene'],\n",
       " 'ANKRD20A19P': ['nan',\n",
       "  'ANKRD20A19P',\n",
       "  'ankyrin repeat domain 20 family member A19, pseudogene'],\n",
       " 'ANKRD22': ['MGC22805', 'ANKRD22', 'ankyrin repeat domain 22'],\n",
       " 'ANKRD23': ['DARP',\n",
       "  'FLJ32449',\n",
       "  'MARP3',\n",
       "  'ANKRD23',\n",
       "  'ankyrin repeat domain 23'],\n",
       " 'ANKRD24': ['KIAA1981', 'ANKRD24', 'ankyrin repeat domain 24'],\n",
       " 'ANKRD26': ['KIAA1074', 'ANKRD26', 'ankyrin repeat domain 26'],\n",
       " 'ANKRD26P1': ['FLJ43980',\n",
       "  'ANKRD26P1',\n",
       "  'ankyrin repeat domain 26 pseudogene 1'],\n",
       " 'ANKRD26P2': ['nan', 'ANKRD26P2', 'ankyrin repeat domain 26 pseudogene 2'],\n",
       " 'ANKRD26P3': ['nan', 'ANKRD26P3', 'ankyrin repeat domain 26 pseudogene 3'],\n",
       " 'ANKRD26P4': ['nan', 'ANKRD26P4', 'ankyrin repeat domain 26 pseudogene 4'],\n",
       " 'ANKRD27': ['FLJ00040',\n",
       "  'DKFZp434L0718',\n",
       "  'VARP',\n",
       "  'ANKRD27',\n",
       "  'ankyrin repeat domain 27'],\n",
       " 'ANKRD28': ['KIAA0379',\n",
       "  'PITK',\n",
       "  'PP6-ARS-A',\n",
       "  'PPP1R65',\n",
       "  'ANKRD28',\n",
       "  'ankyrin repeat domain 28'],\n",
       " 'ANKRD29': ['FLJ25053', 'ANKRD29', 'ankyrin repeat domain 29'],\n",
       " 'ANKRD30A': ['NY-BR-1', 'ANKRD30A', 'ankyrin repeat domain 30A'],\n",
       " 'ANKRD30B': ['NY-BR-1.1', 'ANKRD30B', 'ankyrin repeat domain 30B'],\n",
       " 'ANKRD30BL': ['nan', 'ANKRD30BL', 'ankyrin repeat domain 30B-like'],\n",
       " 'ANKRD30BP1': ['PRED4',\n",
       "  'ANKRD30BP1',\n",
       "  'ankyrin repeat domain 30B pseudogene 1'],\n",
       " 'ANKRD30BP2': ['CT85',\n",
       "  'CTSP-1',\n",
       "  'ANKRD30BP2',\n",
       "  'ankyrin repeat domain 30B pseudogene 2'],\n",
       " 'ANKRD30BP3': ['nan', 'ANKRD30BP3', 'ankyrin repeat domain 30B pseudogene 3'],\n",
       " 'ANKRD31': ['FLJ40191', 'ANKRD31', 'ankyrin repeat domain 31'],\n",
       " 'ANKRD33': ['DKFZp686O1689', 'PANKY', 'ANKRD33', 'ankyrin repeat domain 33'],\n",
       " 'ANKRD33B': ['nan', 'ANKRD33B', 'ankyrin repeat domain 33B'],\n",
       " 'ANKRD33B-AS1': ['nan', 'ANKRD33B-AS1', 'ANKRD33B antisense RNA 1'],\n",
       " 'ANKRD34A': ['nan', 'ANKRD34A', 'ankyrin repeat domain 34A'],\n",
       " 'ANKRD34B': ['DP58', 'ANKRD34B', 'ankyrin repeat domain 34B'],\n",
       " 'ANKRD34C': ['nan', 'ANKRD34C', 'ankyrin repeat domain 34C'],\n",
       " 'ANKRD34C-AS1': ['nan', 'ANKRD34C-AS1', 'ANKRD34C antisense RNA 1'],\n",
       " 'ANKRD35': ['FLJ25124', 'ANKRD35', 'ankyrin repeat domain 35'],\n",
       " 'ANKRD36': ['UNQ2430', 'ANKRD36', 'ankyrin repeat domain 36'],\n",
       " 'ANKRD36B': ['FLJ21281', 'ANKRD36B', 'ankyrin repeat domain 36B'],\n",
       " 'ANKRD36BP1': ['MGC12538',\n",
       "  'ANKRD36BP1',\n",
       "  'ankyrin repeat domain 36B pseudogene 1'],\n",
       " 'ANKRD36BP2': ['nan', 'ANKRD36BP2', 'ankyrin repeat domain 36B pseudogene 2'],\n",
       " 'ANKRD36C': ['DKFZp667P0924', 'ANKRD36C', 'ankyrin repeat domain 36C'],\n",
       " 'ANKRD36P1': ['nan', 'ANKRD36P1', 'ankyrin repeat domain 36 pseudogene 1'],\n",
       " 'ANKRD37': ['Lrp2bp', 'ANKRD37', 'ankyrin repeat domain 37'],\n",
       " 'ANKRD39': ['MGC41816', 'ANKRD39', 'ankyrin repeat domain 39'],\n",
       " 'ANKRD40': ['MGC15396', 'ANKRD40', 'ankyrin repeat domain 40'],\n",
       " 'ANKRD42': ['FLJ37874',\n",
       "  'SARP',\n",
       "  'PPP1R79',\n",
       "  'ANKRD42',\n",
       "  'ankyrin repeat domain 42'],\n",
       " ...}"
      ]
     },
     "execution_count": 99,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "synonyms_gene = []\n",
    "gene_tag = df_genes['symbol'].tolist()\n",
    "gene_name = df_genes['name'].tolist()\n",
    "\n",
    "\n",
    "for row in df_genes['alias_symbol']:\n",
    "    row=str(row)\n",
    "    words = row.split('|')\n",
    "    synonyms_gene.append(words)\n",
    "\n",
    "#print(synonyms)\n",
    "for x, y in zip(synonyms_gene, gene_tag):\n",
    "    x.append(y)\n",
    "    \n",
    "for x, y in zip(synonyms_gene, gene_name):\n",
    "    x.append(y)\n",
    "gene_lists= list(zip(gene_tag, synonyms_gene))\n",
    "gene_dic = dict(gene_lists)\n",
    "gene_dic = {k:[elem for elem in v if elem != 'nan' ] for k,v in gene_dic.items()}\n",
    "\n",
    "\n",
    "\n",
    "keys = [key for key, value in gene_dic.items() if 'LORSDH' in value]\n",
    "\n",
    "\n",
    "gene_dic"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 106,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'A1BG': ['A1BG', 'alpha-1-B glycoprotein'],\n",
       " 'A1BG-AS1': ['FLJ23569', 'A1BG-AS1', 'A1BG antisense RNA 1'],\n",
       " 'A1CF': ['ACF',\n",
       "  'ASP',\n",
       "  'ACF64',\n",
       "  'ACF65',\n",
       "  'APOBEC1CF',\n",
       "  'A1CF',\n",
       "  'APOBEC1 complementation factor'],\n",
       " 'A2M': ['FWP007', 'S863-7', 'CPAMD5', 'A2M', 'alpha-2-macroglobulin'],\n",
       " 'A2M-AS1': ['A2M-AS1', 'A2M antisense RNA 1 (head to head)'],\n",
       " 'A2ML1': ['FLJ25179', 'A2ML1', 'alpha-2-macroglobulin like 1'],\n",
       " 'A2ML1-AS1': ['A2ML1-AS1', 'A2ML1 antisense RNA 1'],\n",
       " 'A2ML1-AS2': ['A2ML1-AS2', 'A2ML1 antisense RNA 2'],\n",
       " 'A2MP1': ['A2MP1', 'alpha-2-macroglobulin pseudogene 1'],\n",
       " 'A3GALT2': ['IGBS3S',\n",
       "  'IGB3S',\n",
       "  'A3GALT2',\n",
       "  'alpha 1,3-galactosyltransferase 2'],\n",
       " 'A4GALT': ['A14GALT',\n",
       "  'Gb3S',\n",
       "  'P(k)',\n",
       "  'A4GALT',\n",
       "  'alpha 1,4-galactosyltransferase'],\n",
       " 'A4GNT': ['alpha4GnT', 'A4GNT', 'alpha-1,4-N-acetylglucosaminyltransferase'],\n",
       " 'AAAS': ['AAAS', 'aladin WD repeat nucleoporin'],\n",
       " 'AACS': ['FLJ12389', 'SUR-5', 'ACSF1', 'AACS', 'acetoacetyl-CoA synthetase'],\n",
       " 'AACSP1': ['AACSP1', 'acetoacetyl-CoA synthetase pseudogene 1'],\n",
       " 'AADAC': ['DAC', 'CES5A1', 'AADAC', 'arylacetamide deacetylase'],\n",
       " 'AADACL2': ['MGC72001', 'AADACL2', 'arylacetamide deacetylase-like 2'],\n",
       " 'AADACL2-AS1': ['AADACL2-AS1', 'AADACL2 antisense RNA 1'],\n",
       " 'AADACL3': ['OTTHUMG00000001887',\n",
       "  'AADACL3',\n",
       "  'arylacetamide deacetylase-like 3'],\n",
       " 'AADACL4': ['OTTHUMG00000001889',\n",
       "  'AADACL4',\n",
       "  'arylacetamide deacetylase-like 4'],\n",
       " 'AADACP1': ['AADACP1', 'arylacetamide deacetylase pseudogene 1'],\n",
       " 'AADAT': ['KATII', 'KAT2', 'AADAT', 'aminoadipate aminotransferase'],\n",
       " 'AAED1': ['AAED1', 'AhpC/TSA antioxidant enzyme domain containing 1'],\n",
       " 'AAGAB': ['FLJ11506',\n",
       "  'p34',\n",
       "  'AAGAB',\n",
       "  'alpha- and gamma-adaptin binding protein'],\n",
       " 'AAK1': ['KIAA1048', 'DKFZp686K16132', 'AAK1', 'AP2 associated kinase 1'],\n",
       " 'AAMDC': ['PTD015',\n",
       "  'FLJ21035',\n",
       "  'CK067',\n",
       "  'AAMDC',\n",
       "  'adipogenesis associated, Mth938 domain containing'],\n",
       " 'AAMP': ['AAMP', 'angio associated migratory cell protein'],\n",
       " 'AANAT': ['SNAT', 'AANAT', 'aralkylamine N-acetyltransferase'],\n",
       " 'AAR2': ['bA234K24.2', 'AAR2', 'AAR2 splicing factor homolog'],\n",
       " 'AARD': ['LOC441376',\n",
       "  'AARD',\n",
       "  'alanine and arginine rich domain containing protein'],\n",
       " 'AARS': ['CMT2N', 'AARS', 'alanyl-tRNA synthetase'],\n",
       " 'AARS2': ['KIAA1270',\n",
       "  'bA444E17.1',\n",
       "  'AARS2',\n",
       "  'alanyl-tRNA synthetase 2, mitochondrial'],\n",
       " 'AARSD1': ['MGC2744', 'AARSD1', 'alanyl-tRNA synthetase domain containing 1'],\n",
       " 'AARSP1': ['AARSP1', 'alanyl-tRNA synthetase pseudogene 1'],\n",
       " 'AASDH': ['NRPS998',\n",
       "  'LYS2',\n",
       "  'ACSF4',\n",
       "  'AASDH',\n",
       "  'aminoadipate-semialdehyde dehydrogenase'],\n",
       " 'AASDHPPT': ['LYS5',\n",
       "  'CGI-80',\n",
       "  'AASD-PPT',\n",
       "  'ACPS',\n",
       "  'AASDHPPT',\n",
       "  'aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase'],\n",
       " 'AASS': ['LORSDH', 'LKRSDH', 'AASS', 'aminoadipate-semialdehyde synthase'],\n",
       " 'AATBC': ['AATBC', 'apoptosis associated transcript in bladder cancer'],\n",
       " 'AATF': ['DED',\n",
       "  'CHE-1',\n",
       "  'CHE1',\n",
       "  'BFR2',\n",
       "  'AATF',\n",
       "  'apoptosis antagonizing transcription factor'],\n",
       " 'AATK': ['AATYK',\n",
       "  'KIAA0641',\n",
       "  'LMTK1',\n",
       "  'LMR1',\n",
       "  'AATYK1',\n",
       "  'PPP1R77',\n",
       "  'AATK',\n",
       "  'apoptosis-associated tyrosine kinase'],\n",
       " 'AATK-AS1': ['AATK-AS1', 'AATK antisense RNA 1'],\n",
       " 'ABALON': ['INXS',\n",
       "  'ABALON',\n",
       "  'apoptotic BCL2L1-antisense long non-coding RNA'],\n",
       " 'ABAT': ['GABAT', 'ABAT', '4-aminobutyrate aminotransferase'],\n",
       " 'ABCA1': ['TGD', 'ABCA1', 'ATP binding cassette subfamily A member 1'],\n",
       " 'ABCA2': ['ABCA2', 'ATP binding cassette subfamily A member 2'],\n",
       " 'ABCA3': ['ABC-C',\n",
       "  'EST111653',\n",
       "  'LBM180',\n",
       "  'ABCA3',\n",
       "  'ATP binding cassette subfamily A member 3'],\n",
       " 'ABCA4': ['FFM',\n",
       "  'ARMD2',\n",
       "  'CORD3',\n",
       "  'ABCA4',\n",
       "  'ATP binding cassette subfamily A member 4'],\n",
       " 'ABCA5': ['EST90625', 'ABCA5', 'ATP binding cassette subfamily A member 5'],\n",
       " 'ABCA6': ['EST155051', 'ABCA6', 'ATP binding cassette subfamily A member 6'],\n",
       " 'ABCA7': ['ABCX', 'ABCA7', 'ATP binding cassette subfamily A member 7'],\n",
       " 'ABCA8': ['KIAA0822', 'ABCA8', 'ATP binding cassette subfamily A member 8'],\n",
       " 'ABCA9': ['EST640918', 'ABCA9', 'ATP binding cassette subfamily A member 9'],\n",
       " 'ABCA9-AS1': ['ABCA9-AS1', 'ABCA9 antisense RNA 1'],\n",
       " 'ABCA10': ['EST698739',\n",
       "  'ABCA10',\n",
       "  'ATP binding cassette subfamily A member 10'],\n",
       " 'ABCA11P': ['EST1133530',\n",
       "  'FLJ14297',\n",
       "  'ABCA11P',\n",
       "  'ATP binding cassette subfamily A member 11, pseudogene'],\n",
       " 'ABCA12': ['DKFZP434G232',\n",
       "  'LI2',\n",
       "  'ABCA12',\n",
       "  'ATP binding cassette subfamily A member 12'],\n",
       " 'ABCA13': ['FLJ33876',\n",
       "  'FLJ33951',\n",
       "  'ABCA13',\n",
       "  'ATP binding cassette subfamily A member 13'],\n",
       " 'ABCA17P': ['ABCA17P',\n",
       "  'ATP binding cassette subfamily A member 17, pseudogene'],\n",
       " 'ABCB1': ['P-gp',\n",
       "  'CD243',\n",
       "  'GP170',\n",
       "  'ABC20',\n",
       "  'ABCB1',\n",
       "  'ATP binding cassette subfamily B member 1'],\n",
       " 'ABCB4': ['MDR2',\n",
       "  'PFIC-3',\n",
       "  'GBD1',\n",
       "  'ABCB4',\n",
       "  'ATP binding cassette subfamily B member 4'],\n",
       " 'ABCB5': ['EST422562',\n",
       "  'ABCB5beta',\n",
       "  'ABCB5alpha',\n",
       "  'ABCB5',\n",
       "  'ATP binding cassette subfamily B member 5'],\n",
       " 'ABCB6': ['EST45597',\n",
       "  'umat',\n",
       "  'MTABC3',\n",
       "  'ABCB6',\n",
       "  'ATP binding cassette subfamily B member 6 (Langereis blood group)'],\n",
       " 'ABCB7': ['EST140535',\n",
       "  'Atm1p',\n",
       "  'ASAT',\n",
       "  'ABCB7',\n",
       "  'ATP binding cassette subfamily B member 7'],\n",
       " 'ABCB8': ['EST328128',\n",
       "  'M-ABC1',\n",
       "  'MABC1',\n",
       "  'ABCB8',\n",
       "  'ATP binding cassette subfamily B member 8'],\n",
       " 'ABCB9': ['EST122234', 'ABCB9', 'ATP binding cassette subfamily B member 9'],\n",
       " 'ABCB10': ['EST20237',\n",
       "  'M-ABC2',\n",
       "  'MTABC2',\n",
       "  'ABCB10',\n",
       "  'ATP binding cassette subfamily B member 10'],\n",
       " 'ABCB10P1': ['M-ABC2',\n",
       "  'MABC2',\n",
       "  'ABCB10P1',\n",
       "  'ATP binding cassette subfamily B member 10 pseudogene 1'],\n",
       " 'ABCB10P3': ['ABCB10P3',\n",
       "  'ATP binding cassette subfamily B member 10 pseudogene 3'],\n",
       " 'ABCB10P4': ['ABCB10P4',\n",
       "  'ATP binding cassette subfamily B member 10 pseudogene 4'],\n",
       " 'ABCB11': ['ABC16',\n",
       "  'SPGP',\n",
       "  'PFIC-2',\n",
       "  'PGY4',\n",
       "  'ABCB11',\n",
       "  'ATP binding cassette subfamily B member 11'],\n",
       " 'ABCC1': ['GS-X', 'ABCC1', 'ATP binding cassette subfamily C member 1'],\n",
       " 'ABCC2': ['DJS',\n",
       "  'MRP2',\n",
       "  'cMRP',\n",
       "  'ABCC2',\n",
       "  'ATP binding cassette subfamily C member 2'],\n",
       " 'ABCC3': ['MRP3',\n",
       "  'cMOAT2',\n",
       "  'EST90757',\n",
       "  'MLP2',\n",
       "  'MOAT-D',\n",
       "  'ABCC3',\n",
       "  'ATP binding cassette subfamily C member 3'],\n",
       " 'ABCC4': ['MRP4',\n",
       "  'EST170205',\n",
       "  'MOAT-B',\n",
       "  'MOATB',\n",
       "  'ABCC4',\n",
       "  'ATP binding cassette subfamily C member 4'],\n",
       " 'ABCC5': ['MRP5',\n",
       "  'SMRP',\n",
       "  'EST277145',\n",
       "  'MOAT-C',\n",
       "  'ABCC5',\n",
       "  'ATP binding cassette subfamily C member 5'],\n",
       " 'ABCC5-AS1': ['ABCC5-AS1', 'ABCC5 antisense RNA 1'],\n",
       " 'ABCC6': ['MRP6',\n",
       "  'EST349056',\n",
       "  'MLP1',\n",
       "  'URG7',\n",
       "  'ABCC6',\n",
       "  'ATP binding cassette subfamily C member 6'],\n",
       " 'ABCC6P1': ['ABCC6P1',\n",
       "  'ATP binding cassette subfamily C member 6 pseudogene 1'],\n",
       " 'ABCC6P2': ['ABCC6P2',\n",
       "  'ATP binding cassette subfamily C member 6 pseudogene 2'],\n",
       " 'ABCC8': ['HI',\n",
       "  'PHHI',\n",
       "  'SUR1',\n",
       "  'MRP8',\n",
       "  'ABC36',\n",
       "  'HHF1',\n",
       "  'TNDM2',\n",
       "  'ABCC8',\n",
       "  'ATP binding cassette subfamily C member 8'],\n",
       " 'ABCC9': ['SUR2',\n",
       "  'CMD1O',\n",
       "  'ABCC9',\n",
       "  'ATP binding cassette subfamily C member 9'],\n",
       " 'ABCC10': ['EST182763',\n",
       "  'MRP7',\n",
       "  'SIMRP7',\n",
       "  'ABCC10',\n",
       "  'ATP binding cassette subfamily C member 10'],\n",
       " 'ABCC11': ['MRP8', 'ABCC11', 'ATP binding cassette subfamily C member 11'],\n",
       " 'ABCC12': ['MRP9', 'ABCC12', 'ATP binding cassette subfamily C member 12'],\n",
       " 'ABCC13': ['PRED6',\n",
       "  'C21orf73',\n",
       "  'ABCC13P',\n",
       "  'ABCC13',\n",
       "  'ATP binding cassette subfamily C member 13 (pseudogene)'],\n",
       " 'ABCD1': ['AMN',\n",
       "  'ALDP',\n",
       "  'adrenoleukodystrophy',\n",
       "  'ABCD1',\n",
       "  'ATP binding cassette subfamily D member 1'],\n",
       " 'ABCD1P2': ['bA453N3.6',\n",
       "  'ABCD1P2',\n",
       "  'ATP binding cassette subfamily D member 1 pseudogene 2'],\n",
       " 'ABCD1P3': ['ABCD1P3',\n",
       "  'ATP binding cassette subfamily D member 1 pseudogene 3'],\n",
       " 'ABCD1P4': ['ABCD1P4',\n",
       "  'ATP binding cassette subfamily D member 1 pseudogene 4'],\n",
       " 'ABCD1P5': ['ABCD1P5',\n",
       "  'ATP binding cassette subfamily D member 1 pseudogene 5'],\n",
       " 'ABCD2': ['ALDR',\n",
       "  'ALDRP',\n",
       "  'ABCD2',\n",
       "  'ATP binding cassette subfamily D member 2'],\n",
       " 'ABCD3': ['PMP70',\n",
       "  'ZWS2',\n",
       "  'ABCD3',\n",
       "  'ATP binding cassette subfamily D member 3'],\n",
       " 'ABCD4': ['PMP69',\n",
       "  'P70R',\n",
       "  'EST352188',\n",
       "  'ABCD4',\n",
       "  'ATP binding cassette subfamily D member 4'],\n",
       " 'ABCE1': ['RLI',\n",
       "  'OABP',\n",
       "  'ABCE1',\n",
       "  'ATP binding cassette subfamily E member 1'],\n",
       " 'ABCF1': ['EST123147', 'ABCF1', 'ATP binding cassette subfamily F member 1'],\n",
       " 'ABCF2': ['EST133090',\n",
       "  'ABC28',\n",
       "  'M-ABC1',\n",
       "  'HUSSY-18',\n",
       "  'ABCF2',\n",
       "  'ATP binding cassette subfamily F member 2'],\n",
       " 'ABCF2P1': ['ABCF2P1',\n",
       "  'ATP binding cassette subfamily F member 2 pseudogene 1'],\n",
       " 'ABCF2P2': ['ABCF2P2',\n",
       "  'ATP binding cassette subfamily F member 2 pseudogene 2'],\n",
       " 'ABCF3': ['EST201864', 'ABCF3', 'ATP binding cassette subfamily F member 3'],\n",
       " 'ABCG1': ['ABC8', 'ABCG1', 'ATP binding cassette subfamily G member 1'],\n",
       " 'ABCG2': ['EST157481',\n",
       "  'MXR',\n",
       "  'BCRP',\n",
       "  'ABCP',\n",
       "  'CD338',\n",
       "  'ABCG2',\n",
       "  'ATP binding cassette subfamily G member 2 (Junior blood group)'],\n",
       " 'ABCG4': ['WHITE2', 'ABCG4', 'ATP binding cassette subfamily G member 4'],\n",
       " 'ABCG5': ['STSL', 'ABCG5', 'ATP binding cassette subfamily G member 5'],\n",
       " 'ABCG8': ['GBD4', 'ABCG8', 'ATP binding cassette subfamily G member 8'],\n",
       " 'ABHD1': ['LABH1', 'FLJ36128', 'ABHD1', 'abhydrolase domain containing 1'],\n",
       " 'ABHD2': ['LABH2', 'ABHD2', 'abhydrolase domain containing 2'],\n",
       " 'ABHD3': ['LABH3', 'ABHD3', 'abhydrolase domain containing 3'],\n",
       " 'ABHD4': ['FLJ12816', 'ABHD4', 'abhydrolase domain containing 4'],\n",
       " 'ABHD5': ['CGI-58', 'NCIE2', 'ABHD5', 'abhydrolase domain containing 5'],\n",
       " 'ABHD6': ['ABHD6', 'abhydrolase domain containing 6'],\n",
       " 'ABHD8': ['FLJ11743',\n",
       "  'MGC14280',\n",
       "  'MGC2512',\n",
       "  'ABHD8',\n",
       "  'abhydrolase domain containing 8'],\n",
       " 'ABHD10': ['FLJ11342', 'ABHD10', 'abhydrolase domain containing 10'],\n",
       " 'ABHD11': ['PP1226', 'ABHD11', 'abhydrolase domain containing 11'],\n",
       " 'ABHD11-AS1': ['NCRNA00035',\n",
       "  'ABHD11-AS1',\n",
       "  'ABHD11 antisense RNA 1 (tail to tail)'],\n",
       " 'ABHD12': ['DKFZP434P106',\n",
       "  'dJ965G21.2',\n",
       "  'BEM46L2',\n",
       "  'ABHD12A',\n",
       "  'ABHD12',\n",
       "  'abhydrolase domain containing 12'],\n",
       " 'ABHD12B': ['BEM46L3', 'ABHD12B', 'abhydrolase domain containing 12B'],\n",
       " 'ABHD13': ['bA153I24.2',\n",
       "  'FLJ14906',\n",
       "  'BEM46L1',\n",
       "  'ABHD13',\n",
       "  'abhydrolase domain containing 13'],\n",
       " 'ABHD14A': ['DKFZP564O243',\n",
       "  'DORZ1',\n",
       "  'ABHD14A',\n",
       "  'abhydrolase domain containing 14A'],\n",
       " 'ABHD14A-ACY1': ['ABHD14A-ACY1', 'ABHD14A-ACY1 readthrough'],\n",
       " 'ABHD14B': ['MGC15429',\n",
       "  'CIB',\n",
       "  'ABHD14B',\n",
       "  'abhydrolase domain containing 14B'],\n",
       " 'ABHD15': ['ABHD15', 'abhydrolase domain containing 15'],\n",
       " 'ABHD15-AS1': ['linc-TP53I13',\n",
       "  'lnc-TP53I13',\n",
       "  'ABHD15-AS1',\n",
       "  'ABHD15 antisense RNA 1'],\n",
       " 'ABHD16A': ['NG26', 'D6S82E', 'ABHD16A', 'abhydrolase domain containing 16A'],\n",
       " 'ABHD16B': ['dJ591C20.1', 'ABHD16B', 'abhydrolase domain containing 16B'],\n",
       " 'ABHD17A': ['MGC5244', 'ABHD17A', 'abhydrolase domain containing 17A'],\n",
       " 'ABHD17AP1': ['C1orf47',\n",
       "  'ABHD17AP1',\n",
       "  'abhydrolase domain containing 17A pseudogene 1'],\n",
       " 'ABHD17AP3': ['ABHD17AP3', 'abhydrolase domain containing 17A pseudogene 3'],\n",
       " 'ABHD17AP4': ['ABHD17AP4', 'abhydrolase domain containing 17A pseudogene P4'],\n",
       " 'ABHD17AP5': ['ABHD17AP5', 'abhydrolase domain containing 17A pseudogene 5'],\n",
       " 'ABHD17AP6': ['ABHD17AP6', 'abhydrolase domain containing 17A pseudogene 6'],\n",
       " 'ABHD17AP7': ['ABHD17AP7', 'abhydrolase domain containing 17A pseudogene 7'],\n",
       " 'ABHD17AP8': ['ABHD17AP8', 'abhydrolase domain containing 17A pseudogene 8'],\n",
       " 'ABHD17AP9': ['ABHD17AP9', 'abhydrolase domain containing 17A pseudogene 9'],\n",
       " 'ABHD17B': ['CGI-67', 'ABHD17B', 'abhydrolase domain containing 17B'],\n",
       " 'ABHD17C': ['ABHD17C', 'abhydrolase domain containing 17C'],\n",
       " 'ABHD18': ['FLJ21106', 'ABHD18', 'abhydrolase domain containing 18'],\n",
       " 'ABI1': ['E3B1', 'ABI-1', 'ABI1', 'abl interactor 1'],\n",
       " 'ABI2': ['ABI-2',\n",
       "  'AIP-1',\n",
       "  'ABI2B',\n",
       "  'AblBP3',\n",
       "  'argBPIA',\n",
       "  'SSH3BP2',\n",
       "  'ABI2',\n",
       "  'abl-interactor 2'],\n",
       " 'ABI3': ['NESH', 'SSH3BP3', 'ABI3', 'ABI family member 3'],\n",
       " 'ABI3BP': ['NESHBP',\n",
       "  'DKFZP586L2024',\n",
       "  'TARSH',\n",
       "  'ABI3BP',\n",
       "  'ABI family member 3 binding protein'],\n",
       " 'ABL1': ['JTK7',\n",
       "  'c-ABL',\n",
       "  'p150',\n",
       "  'ABL1',\n",
       "  'ABL proto-oncogene 1, non-receptor tyrosine kinase'],\n",
       " 'ABL2': ['ARG', 'ABL2', 'ABL proto-oncogene 2, non-receptor tyrosine kinase'],\n",
       " 'ABLIM1': ['abLIM', 'limatin', 'ABLIM1', 'actin binding LIM protein 1'],\n",
       " 'ABLIM2': ['KIAA1808', 'ABLIM2', 'actin binding LIM protein family member 2'],\n",
       " 'ABLIM3': ['KIAA0843', 'ABLIM3', 'actin binding LIM protein family member 3'],\n",
       " 'ABO': ['A3GALNT',\n",
       "  'A3GALT1',\n",
       "  'ABO',\n",
       "  'ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase)'],\n",
       " 'ABR': ['MDB', 'ABR', 'active BCR-related'],\n",
       " 'ABRA': ['STARS', 'ABRA', 'actin binding Rho activating protein'],\n",
       " 'ABRACL': ['PRO2013', 'HSPC280', 'Costars', 'ABRACL', 'ABRA C-terminal like'],\n",
       " 'ABT1': ['ABT1', 'activator of basal transcription 1'],\n",
       " 'ABT1P1': ['ABT1P1', 'activator of basal transcription 1 pseudogene 1'],\n",
       " 'ABTB1': ['BPOZ',\n",
       "  'EF1ABP',\n",
       "  'Btb3',\n",
       "  'BTBD21',\n",
       "  'ABTB1',\n",
       "  'ankyrin repeat and BTB domain containing 1'],\n",
       " 'ABTB2': ['DKFZP586C1619',\n",
       "  'BTBD22',\n",
       "  'ABTB2A',\n",
       "  'ABTB2',\n",
       "  'ankyrin repeat and BTB domain containing 2'],\n",
       " 'ACAA1': ['ACAA1', 'acetyl-CoA acyltransferase 1'],\n",
       " 'ACAA2': ['DSAEC', 'ACAA2', 'acetyl-CoA acyltransferase 2'],\n",
       " 'ACACA': ['ACC1', 'ACACA', 'acetyl-CoA carboxylase alpha'],\n",
       " 'ACACB': ['HACC275', 'ACC2', 'ACCB', 'ACACB', 'acetyl-CoA carboxylase beta'],\n",
       " 'ACAD8': ['ACAD8', 'acyl-CoA dehydrogenase family member 8'],\n",
       " 'ACAD9': ['NPD002',\n",
       "  'MGC14452',\n",
       "  'ACAD9',\n",
       "  'acyl-CoA dehydrogenase family member 9'],\n",
       " 'ACAD10': ['MGC5601', 'ACAD10', 'acyl-CoA dehydrogenase family member 10'],\n",
       " 'ACAD11': ['FLJ12592', 'ACAD11', 'acyl-CoA dehydrogenase family member 11'],\n",
       " 'ACADL': ['LCAD', 'ACAD4', 'ACADL', 'acyl-CoA dehydrogenase, long chain'],\n",
       " 'ACADM': ['MCAD',\n",
       "  'MCADH',\n",
       "  'ACAD1',\n",
       "  'ACADM',\n",
       "  'acyl-CoA dehydrogenase, C-4 to C-12 straight chain'],\n",
       " 'ACADS': ['SCAD',\n",
       "  'ACAD3',\n",
       "  'ACADS',\n",
       "  'acyl-CoA dehydrogenase, C-2 to C-3 short chain'],\n",
       " 'ACADSB': ['SBCAD',\n",
       "  'ACAD7',\n",
       "  'ACADSB',\n",
       "  'acyl-CoA dehydrogenase, short/branched chain'],\n",
       " 'ACADVL': ['VLCAD',\n",
       "  'LCACD',\n",
       "  'ACAD6',\n",
       "  'ACADVL',\n",
       "  'acyl-CoA dehydrogenase, very long chain'],\n",
       " 'ACAN': ['CSPGCP', 'ACAN', 'aggrecan'],\n",
       " 'ACAP1': ['KIAA0050',\n",
       "  'ACAP1',\n",
       "  'ArfGAP with coiled-coil, ankyrin repeat and PH domains 1'],\n",
       " 'ACAP2': ['KIAA0041',\n",
       "  'CNT-B2',\n",
       "  'ACAP2',\n",
       "  'ArfGAP with coiled-coil, ankyrin repeat and PH domains 2'],\n",
       " 'ACAP2-IT1': ['ACAP2-IT1', 'ACAP2 intronic transcript 1'],\n",
       " 'ACAP3': ['KIAA1716',\n",
       "  'ACAP3',\n",
       "  'ArfGAP with coiled-coil, ankyrin repeat and PH domains 3'],\n",
       " 'ACAT1': ['THIL', 'ACAT1', 'acetyl-CoA acetyltransferase 1'],\n",
       " 'ACAT2': ['ACAT2', 'acetyl-CoA acetyltransferase 2'],\n",
       " 'ACBD3': ['GCP60', 'PAP7', 'ACBD3', 'acyl-CoA binding domain containing 3'],\n",
       " 'ACBD4': ['FLJ13322', 'ACBD4', 'acyl-CoA binding domain containing 4'],\n",
       " 'ACBD5': ['DKFZp434A2417',\n",
       "  'KIAA1996',\n",
       "  'ACBD5',\n",
       "  'acyl-CoA binding domain containing 5'],\n",
       " 'ACBD6': ['MGC2404', 'ACBD6', 'acyl-CoA binding domain containing 6'],\n",
       " 'ACBD7': ['FLJ38219',\n",
       "  'bA455B2.2',\n",
       "  'ACBD7',\n",
       "  'acyl-CoA binding domain containing 7'],\n",
       " 'ACCS': ['PHACS',\n",
       "  'ACS',\n",
       "  'ACCS',\n",
       "  '1-aminocyclopropane-1-carboxylate synthase homolog (inactive)'],\n",
       " 'ACCSL': ['ACCSL',\n",
       "  '1-aminocyclopropane-1-carboxylate synthase (inactive)-like'],\n",
       " 'ACD': ['Ptop',\n",
       "  'Pip1',\n",
       "  'Tpp1',\n",
       "  'Tint1',\n",
       "  'ACD',\n",
       "  'adrenocortical dysplasia homolog'],\n",
       " 'ACE': ['ACE1', 'CD143', 'ACE', 'angiotensin I converting enzyme'],\n",
       " 'ACE2': ['ACE2', 'angiotensin I converting enzyme 2'],\n",
       " 'ACE3P': ['ACE3P',\n",
       "  'angiotensin I converting enzyme (peptidyl-dipeptidase A) 3, pseudogene'],\n",
       " 'ACER1': ['ACER1', 'alkaline ceramidase 1'],\n",
       " 'ACER2': ['FLJ41587', 'ACER2', 'alkaline ceramidase 2'],\n",
       " 'ACER3': ['FLJ11238', 'APHC', 'ACER3', 'alkaline ceramidase 3'],\n",
       " 'ACHE': ['ACHE', 'acetylcholinesterase (Cartwright blood group)'],\n",
       " 'ACIN1': ['KIAA0670',\n",
       "  'fSAP152',\n",
       "  'ACIN1',\n",
       "  'apoptotic chromatin condensation inducer 1'],\n",
       " 'ACKR1': ['CCBP1',\n",
       "  'GPD',\n",
       "  'Dfy',\n",
       "  'CD234',\n",
       "  'ACKR1',\n",
       "  'atypical chemokine receptor 1 (Duffy blood group)'],\n",
       " 'ACKR2': ['CCR10', 'D6', 'CCR9', 'ACKR2', 'atypical chemokine receptor 2'],\n",
       " 'ACKR3': ['RDC1', 'GPR159', 'ACKR3', 'atypical chemokine receptor 3'],\n",
       " 'ACKR4': ['CCR11',\n",
       "  'CCBP2',\n",
       "  'VSHK1',\n",
       "  'CCX-CKR',\n",
       "  'PPR1',\n",
       "  'ACKR4',\n",
       "  'atypical chemokine receptor 4'],\n",
       " 'ACLY': ['ATPCL', 'CLATP', 'ACL', 'ACLY', 'ATP citrate lyase'],\n",
       " 'ACMSD': ['ACMSD', 'aminocarboxymuconate semialdehyde decarboxylase'],\n",
       " 'ACO1': ['IRP1', 'IREBP', 'ACO1', 'aconitase 1'],\n",
       " 'ACO2': ['ACONM', 'ACO2', 'aconitase 2'],\n",
       " 'ACOD1': ['CAD', 'ACOD1', 'aconitate decarboxylase 1'],\n",
       " 'ACOT1': ['ACH2', 'CTE-1', 'LACH2', 'ACOT1', 'acyl-CoA thioesterase 1'],\n",
       " 'ACOT2': ['Mte1', 'ZAP128', 'ACOT2', 'acyl-CoA thioesterase 2'],\n",
       " 'ACOT4': ['FLJ31235', 'PTE-Ib', 'PTE2B', 'ACOT4', 'acyl-CoA thioesterase 4'],\n",
       " 'ACOT6': ['ACOT6', 'acyl-CoA thioesterase 6'],\n",
       " 'ACOT7': ['BACH',\n",
       "  'ACH1',\n",
       "  'ACT',\n",
       "  'CTE-II',\n",
       "  'LACH1',\n",
       "  'MGC1126',\n",
       "  'hBACH',\n",
       "  'ACOT7',\n",
       "  'acyl-CoA thioesterase 7'],\n",
       " 'ACOT8': ['hACTE-III',\n",
       "  'hTE',\n",
       "  'PTE-2',\n",
       "  'NAP1',\n",
       "  'ACOT8',\n",
       "  'acyl-CoA thioesterase 8'],\n",
       " 'ACOT9': ['CGI-16', 'MT-ACT48', 'ACATE2', 'ACOT9', 'acyl-CoA thioesterase 9'],\n",
       " 'ACOT11': ['STARD14',\n",
       "  'BFIT',\n",
       "  'KIAA0707',\n",
       "  'BFIT1',\n",
       "  'THEM1',\n",
       "  'ACOT11',\n",
       "  'acyl-CoA thioesterase 11'],\n",
       " 'ACOT12': ['Cach', 'THEAL', 'STARD15', 'ACOT12', 'acyl-CoA thioesterase 12'],\n",
       " 'ACOT13': ['HT012', 'ACOT13', 'acyl-CoA thioesterase 13'],\n",
       " 'ACOX1': ['PALMCOX', 'ACOX1', 'acyl-CoA oxidase 1, palmitoyl'],\n",
       " 'ACOX2': ['BRCACOX',\n",
       "  'BRCOX',\n",
       "  'THCCox',\n",
       "  'ACOX2',\n",
       "  'acyl-CoA oxidase 2, branched chain'],\n",
       " 'ACOX3': ['ACOX3', 'acyl-CoA oxidase 3, pristanoyl'],\n",
       " 'ACOXL': ['FLJ11042', 'ACOXL', 'acyl-CoA oxidase-like'],\n",
       " 'ACP1': ['HAAP', 'LMW-PTP', 'ACP1', 'acid phosphatase 1, soluble'],\n",
       " 'ACP2': ['LAP', 'ACP2', 'acid phosphatase 2, lysosomal'],\n",
       " 'ACP5': ['TRAP', 'HPAP', 'ACP5', 'acid phosphatase 5, tartrate resistant'],\n",
       " 'ACP6': ['LPAP', 'ACPL1', 'ACP6', 'acid phosphatase 6, lysophosphatidic'],\n",
       " 'ACP7': ['FLJ16165',\n",
       "  'PAPL1',\n",
       "  'ACP7',\n",
       "  'acid phosphatase 7, tartrate resistant (putative)'],\n",
       " 'ACPP': ['ACP3', 'ACP-3', 'PAP', 'ACPP', 'acid phosphatase, prostate'],\n",
       " 'ACPT': ['ACPT', 'acid phosphatase, testicular'],\n",
       " 'ACR': ['ACR', 'acrosin'],\n",
       " 'ACRBP': ['SP32', 'OY-TES-1', 'CT23', 'ACRBP', 'acrosin binding protein'],\n",
       " 'ACRC': ['ACRC', 'acidic repeat containing'],\n",
       " 'ACRV1': ['SPACA2',\n",
       "  'SP-10',\n",
       "  'D11S4365',\n",
       "  'ACRV1',\n",
       "  'acrosomal vesicle protein 1'],\n",
       " 'ACSBG1': ['BGM',\n",
       "  'FLJ30320',\n",
       "  'MGC14352',\n",
       "  'BG1',\n",
       "  'KIAA0631',\n",
       "  'hBG1',\n",
       "  'hsBG',\n",
       "  'ACSBG1',\n",
       "  'acyl-CoA synthetase bubblegum family member 1'],\n",
       " 'ACSBG2': ['BGR',\n",
       "  'PRTD-NY3',\n",
       "  'DKFZp434K1635',\n",
       "  'ACSBG2',\n",
       "  'acyl-CoA synthetase bubblegum family member 2'],\n",
       " 'ACSF2': ['FLJ20920',\n",
       "  'ACSMW',\n",
       "  'ACSF2',\n",
       "  'acyl-CoA synthetase family member 2'],\n",
       " 'ACSF3': ['ACSF3', 'acyl-CoA synthetase family member 3'],\n",
       " 'ACSL1': ['LACS2',\n",
       "  'LACS',\n",
       "  'ACS1',\n",
       "  'LACS1',\n",
       "  'FACL1',\n",
       "  'ACSL1',\n",
       "  'acyl-CoA synthetase long-chain family member 1'],\n",
       " 'ACSL3': ['ACS3',\n",
       "  'PRO2194',\n",
       "  'ACSL3',\n",
       "  'acyl-CoA synthetase long-chain family member 3'],\n",
       " 'ACSL4': ['ACS4',\n",
       "  'LACS4',\n",
       "  'ACSL4',\n",
       "  'acyl-CoA synthetase long-chain family member 4'],\n",
       " 'ACSL5': ['ACS5',\n",
       "  'ACS2',\n",
       "  'ACSL5',\n",
       "  'acyl-CoA synthetase long-chain family member 5'],\n",
       " 'ACSL6': ['KIAA0837',\n",
       "  'ACS2',\n",
       "  'LACS5',\n",
       "  'LACS2',\n",
       "  'ACSL6',\n",
       "  'acyl-CoA synthetase long-chain family member 6'],\n",
       " 'ACSM1': ['MACS1',\n",
       "  'ACSM1',\n",
       "  'acyl-CoA synthetase medium-chain family member 1'],\n",
       " 'ACSM2A': ['A-923A4.1',\n",
       "  'MGC150530',\n",
       "  'ACSM2A',\n",
       "  'acyl-CoA synthetase medium-chain family member 2A'],\n",
       " 'ACSM2B': ['HXMA',\n",
       "  'HYST1046',\n",
       "  'ACSM2B',\n",
       "  'acyl-CoA synthetase medium-chain family member 2B'],\n",
       " 'ACSM3': ['SA', 'ACSM3', 'acyl-CoA synthetase medium-chain family member 3'],\n",
       " 'ACSM4': ['ACSM4', 'acyl-CoA synthetase medium-chain family member 4'],\n",
       " 'ACSM5': ['FLJ20581',\n",
       "  'ACSM5',\n",
       "  'acyl-CoA synthetase medium-chain family member 5'],\n",
       " 'ACSM5P1': ['ACSM5P1',\n",
       "  'acyl-CoA synthetase medium-chain family member 5 pseudogene 1'],\n",
       " 'ACSM6': ['bA310E22.3',\n",
       "  'ACSM6',\n",
       "  'acyl-CoA synthetase medium-chain family member 6'],\n",
       " 'ACSS1': ['dJ568C11.3',\n",
       "  'AceCS2L',\n",
       "  'MGC33843',\n",
       "  'ACSS1',\n",
       "  'acyl-CoA synthetase short-chain family member 1'],\n",
       " 'ACSS2': ['ACS',\n",
       "  'ACSA',\n",
       "  'AceCS',\n",
       "  'dJ1161H23.1',\n",
       "  'ACSS2',\n",
       "  'acyl-CoA synthetase short-chain family member 2'],\n",
       " 'ACSS3': ['FLJ21963',\n",
       "  'ACSS3',\n",
       "  'acyl-CoA synthetase short-chain family member 3'],\n",
       " 'ACTA1': ['NEM3', 'ACTA1', 'actin, alpha 1, skeletal muscle'],\n",
       " 'ACTA2': ['ACTSA', 'ACTA2', 'actin, alpha 2, smooth muscle, aorta'],\n",
       " 'ACTA2-AS1': ['uc001kfo.1', 'ZXF1', 'ACTA2-AS1', 'ACTA2 antisense RNA 1'],\n",
       " 'ACTB': ['ACTB', 'actin, beta'],\n",
       " 'ACTBL2': ['DKFZp686D0972', 'ACTBL2', 'actin, beta-like 2'],\n",
       " 'ACTBP1': ['ACTBP1', 'actin, beta pseudogene 1'],\n",
       " 'ACTBP2': ['ACTBP2', 'actin, beta pseudogene 2'],\n",
       " 'ACTBP6': ['ACTBP6', 'actin, beta pseudogene 6'],\n",
       " 'ACTBP7': ['ACTBP7', 'actin, beta pseudogene 7'],\n",
       " 'ACTBP8': ['ACTBP2', 'ACTBP8', 'actin, beta pseudogene 8'],\n",
       " 'ACTBP9': ['ACTBP9', 'actin, beta pseudogene 9'],\n",
       " 'ACTBP11': ['ACTBP11', 'actin, beta pseudogene 11'],\n",
       " 'ACTBP12': ['ACTBP12', 'actin, beta pseudogene 12'],\n",
       " 'ACTBP13': ['ACTBP13', 'actin, beta pseudogene 13'],\n",
       " 'ACTBP14': ['ACTBP14', 'actin, beta pseudogene 14'],\n",
       " 'ACTC1': ['CMD1R', 'ACTC1', 'actin, alpha, cardiac muscle 1'],\n",
       " 'ACTG1': ['ACTG1', 'actin gamma 1'],\n",
       " 'ACTG1P1': ['ACTG1P1', 'actin gamma 1 pseudogene 1'],\n",
       " 'ACTG1P2': ['ACTG1P2', 'actin gamma 1 pseudogene 2'],\n",
       " 'ACTG1P3': ['ACTG1P3', 'actin gamma 1 pseudogene 3'],\n",
       " 'ACTG1P4': ['ACTG1P4', 'actin gamma 1 pseudogene 4'],\n",
       " 'ACTG1P9': ['ACTG1P9', 'actin gamma 1 pseudogene 9'],\n",
       " 'ACTG1P10': ['ACTG1P10', 'actin gamma 1 pseudogene 10'],\n",
       " 'ACTG1P11': ['ACTG1P11', 'actin gamma 1 pseudogene 11'],\n",
       " 'ACTG1P12': ['ACTG1P12', 'actin gamma 1 pseudogene 12'],\n",
       " 'ACTG1P13': ['ACTG1P13', 'actin gamma 1 pseudogene 13'],\n",
       " 'ACTG1P14': ['ACTG1P14', 'actin gamma 1 pseudogene 14'],\n",
       " 'ACTG1P15': ['ACTG1P15', 'actin gamma 1 pseudogene 15'],\n",
       " 'ACTG1P16': ['ACTG1P16', 'actin gamma 1 pseudogene 16'],\n",
       " 'ACTG1P17': ['ACTG1P17', 'actin gamma 1 pseudogene 17'],\n",
       " 'ACTG1P18': ['ACTG1P18', 'actin gamma 1 pseudogene 18'],\n",
       " 'ACTG1P19': ['ACTG1P19', 'actin gamma 1 pseudogene 19'],\n",
       " 'ACTG1P20': ['ACTG1P20', 'actin gamma 1 pseudogene 20'],\n",
       " 'ACTG1P21': ['ACTG1P21', 'actin gamma 1 pseudogene 21'],\n",
       " 'ACTG1P22': ['ACTG1P22', 'actin gamma 1 pseudogene 22'],\n",
       " 'ACTG1P23': ['ACTG1P23', 'actin gamma 1 pseudogene 23'],\n",
       " 'ACTG1P24': ['ACTG1P24', 'actin gamma 1 pseudogene 24'],\n",
       " 'ACTG2': ['ACTSG', 'ACTG2', 'actin, gamma 2, smooth muscle, enteric'],\n",
       " 'ACTL6A': ['Actl6',\n",
       "  'BAF53A',\n",
       "  'Arp4',\n",
       "  'Baf53a',\n",
       "  'INO80K',\n",
       "  'ACTL6A',\n",
       "  'actin like 6A'],\n",
       " 'ACTL6B': ['BAF53B', 'ACTL6B', 'actin like 6B'],\n",
       " 'ACTL7A': ['ACTL7A', 'actin like 7A'],\n",
       " 'ACTL7B': ['Tact1', 'ACTL7B', 'actin like 7B'],\n",
       " 'ACTL8': ['CT57', 'ACTL8', 'actin like 8'],\n",
       " 'ACTL9': ['MGC33407', 'ACTL9', 'actin like 9'],\n",
       " 'ACTL10': ['ACTL10', 'actin like 10'],\n",
       " 'ACTN1': ['ACTN1', 'actinin alpha 1'],\n",
       " 'ACTN1-AS1': ['ACTN1-AS1', 'ACTN1 antisense RNA 1'],\n",
       " 'ACTN2': ['ACTN2', 'actinin alpha 2'],\n",
       " 'ACTN3': ['ACTN3', 'actinin alpha 3 (gene/pseudogene)'],\n",
       " 'ACTN4': ['ACTN4', 'actinin alpha 4'],\n",
       " 'ACTN4P1': ['ACTN4P1', 'actinin alpha 4 pseudogene 1'],\n",
       " 'ACTN4P2': ['ACTN4P2', 'actinin alpha 4 pseudogene 2'],\n",
       " 'ACTP1': ['ACTP1', 'actin family pseudogene 1'],\n",
       " 'ACTR1A': ['ARP1',\n",
       "  'Arp1A',\n",
       "  'ACTR1A',\n",
       "  'ARP1 actin-related protein 1 homolog A, centractin alpha'],\n",
       " 'ACTR1B': ['Arp1B',\n",
       "  'ACTR1B',\n",
       "  'ARP1 actin-related protein 1 homolog B, centractin beta'],\n",
       " 'ACTR2': ['ARP2', 'ACTR2', 'ARP2 actin-related protein 2 homolog (yeast)'],\n",
       " 'ACTR3': ['ARP3', 'ACTR3', 'ARP3 actin-related protein 3 homolog (yeast)'],\n",
       " 'ACTR3B': ['ARP11',\n",
       "  'ARP3beta',\n",
       "  'ACTR3B',\n",
       "  'ARP3 actin-related protein 3 homolog B (yeast)'],\n",
       " 'ACTR3BP1': ['ACTR3BP1', 'ACTR3B pseudogene 1'],\n",
       " 'ACTR3BP2': ['FKSG73', 'ACTR3BP2', 'ACTR3B pseudogene 2'],\n",
       " 'ACTR3BP3': ['ACTR3BP3', 'ACTR3B pseudogene 3'],\n",
       " 'ACTR3BP4': ['ACTR3BP4', 'ACTR3B pseudogene 4'],\n",
       " 'ACTR3BP5': ['ACTR3BP5', 'ACTR3B pseudogene 5'],\n",
       " 'ACTR3BP6': ['ACTR3BP6', 'ACTR3B pseudogene 6'],\n",
       " 'ACTR3C': ['ARP11', 'ACTR3C', 'ARP3 actin-related protein 3 homolog C'],\n",
       " 'ACTR3P2': ['ACTR3P2', 'ACTR3 pseudogene 2'],\n",
       " 'ACTR3P3': ['ACTR3P3', 'ACTR3 pseudogene 3'],\n",
       " 'ACTR5': ['FLJ12785',\n",
       "  'Arp5',\n",
       "  'INO80M',\n",
       "  'ACTR5',\n",
       "  'ARP5 actin-related protein 5 homolog'],\n",
       " 'ACTR6': ['ARP6',\n",
       "  'FLJ13433',\n",
       "  'ACTR6',\n",
       "  'ARP6 actin-related protein 6 homolog'],\n",
       " 'ACTR6P1': ['ACTR6P1', 'ACTR6 pseudogene 1'],\n",
       " 'ACTR8': ['INO80N', 'ACTR8', 'ARP8 actin-related protein 8 homolog'],\n",
       " 'ACTR10': ['HARP11',\n",
       "  'ACTR11',\n",
       "  'Arp11',\n",
       "  'Arp10',\n",
       "  'ACTR10',\n",
       "  'actin-related protein 10 homolog'],\n",
       " 'ACTRT1': ['AIP1',\n",
       "  'KIAA0705',\n",
       "  'ARIP1',\n",
       "  'Arp-T1',\n",
       "  'ACTRT1',\n",
       "  'actin related protein T1'],\n",
       " 'ACTRT2': ['Arp-T2',\n",
       "  'ARPM2',\n",
       "  'FLJ25424',\n",
       "  'ACTRT2',\n",
       "  'actin related protein T2'],\n",
       " 'ACTRT3': ['ARPM1', 'ACTRT3', 'actin related protein T3'],\n",
       " 'ACVR1': ['SKR1', 'ALK2', 'ACVR1A', 'ACVR1', 'activin A receptor type 1'],\n",
       " 'ACVR1B': ['ALK4', 'SKR2', 'ActRIB', 'ACVR1B', 'activin A receptor type 1B'],\n",
       " 'ACVR1C': ['ALK7', 'ACVRLK7', 'ACVR1C', 'activin A receptor type 1C'],\n",
       " 'ACVR2A': ['ACTRII', 'ACVR2A', 'activin A receptor type 2A'],\n",
       " 'ACVR2B': ['ActR-IIB', 'ACVR2B', 'activin A receptor type 2B'],\n",
       " 'ACVR2B-AS1': ['ACVR2B-AS1', 'ACVR2B antisense RNA 1'],\n",
       " 'ACVRL1': ['HHT2', 'ALK1', 'HHT', 'ACVRL1', 'activin A receptor like type 1'],\n",
       " 'ACY1': ['ACY1', 'aminoacylase 1'],\n",
       " 'ACY3': ['HCBP1', 'MGC9740', 'ACY-3', 'ACY3', 'aminoacylase 3'],\n",
       " 'ACYP1': ['ACYP1', 'acylphosphatase 1'],\n",
       " 'ACYP2': ['ACYP2', 'acylphosphatase 2'],\n",
       " 'ADA': ['ADA', 'adenosine deaminase'],\n",
       " 'ADAD1': ['Tenr', 'ADAD1', 'adenosine deaminase domain containing 1'],\n",
       " 'ADAD1P2': ['ADAD1P2',\n",
       "  'adenosine deaminase domain containing 1 pseudogene 2'],\n",
       " 'ADAD2': ['TENRL',\n",
       "  'FLJ00337',\n",
       "  'ADAD2',\n",
       "  'adenosine deaminase domain containing 2'],\n",
       " 'ADAL': ['ADAL', 'adenosine deaminase-like'],\n",
       " 'ADAM1A': ['FTNAP',\n",
       "  'PH-30a',\n",
       "  'Ftna',\n",
       "  'ADAM1P',\n",
       "  'ADAM1A',\n",
       "  'ADAM metallopeptidase domain 1A (pseudogene)'],\n",
       " 'ADAM1B': ['ADAM1B', 'ADAM metallopeptidase domain 1B (pseudogene)'],\n",
       " 'ADAM2': ['PH-30b',\n",
       "  'PH30',\n",
       "  'CT15',\n",
       "  'ADAM2',\n",
       "  'ADAM metallopeptidase domain 2'],\n",
       " 'ADAM3A': ['ADAM3',\n",
       "  'tMDCI',\n",
       "  'ADAM3A',\n",
       "  'ADAM metallopeptidase domain 3A (pseudogene)'],\n",
       " 'ADAM3B': ['ADAM3B', 'ADAM metallopeptidase domain 3B (pseudogene)'],\n",
       " 'ADAM5': ['tMDCII', 'ADAM5', 'ADAM metallopeptidase domain 5 (pseudogene)'],\n",
       " 'ADAM6': ['tMDCIV', 'ADAM6', 'ADAM metallopeptidase domain 6 (pseudogene)'],\n",
       " 'ADAM7': ['GP-83', 'EAPI', 'ADAM7', 'ADAM metallopeptidase domain 7'],\n",
       " 'ADAM8': ['CD156',\n",
       "  'MS2',\n",
       "  'CD156a',\n",
       "  'ADAM8',\n",
       "  'ADAM metallopeptidase domain 8'],\n",
       " 'ADAM9': ['MDC9',\n",
       "  'KIAA0021',\n",
       "  'MCMP',\n",
       "  'Mltng',\n",
       "  'ADAM9',\n",
       "  'ADAM metallopeptidase domain 9'],\n",
       " 'ADAM10': ['kuz',\n",
       "  'MADM',\n",
       "  'HsT18717',\n",
       "  'CD156c',\n",
       "  'ADAM10',\n",
       "  'ADAM metallopeptidase domain 10'],\n",
       " 'ADAM11': ['ADAM11', 'ADAM metallopeptidase domain 11'],\n",
       " 'ADAM12': ['MCMPMltna', 'MLTN', 'ADAM12', 'ADAM metallopeptidase domain 12'],\n",
       " 'ADAM15': ['MDC15', 'ADAM15', 'ADAM metallopeptidase domain 15'],\n",
       " 'ADAM17': ['cSVP', 'CD156B', 'ADAM17', 'ADAM metallopeptidase domain 17'],\n",
       " 'ADAM18': ['tMDCIII', 'ADAM27', 'ADAM18', 'ADAM metallopeptidase domain 18'],\n",
       " 'ADAM19': ['MLTNB', 'ADAM19', 'ADAM metallopeptidase domain 19'],\n",
       " 'ADAM20': ['ADAM20', 'ADAM metallopeptidase domain 20'],\n",
       " 'ADAM20P1': ['ADAM20P1', 'ADAM metallopeptidase domain 20 pseudogene 1'],\n",
       " 'ADAM20P2': ['ADAM20P2', 'ADAM metallopeptidase domain 20 pseudogene 2'],\n",
       " 'ADAM20P3': ['ADAM20P3', 'ADAM metallopeptidase domain 20 pseudogene 3'],\n",
       " 'ADAM21': ['ADAM31', 'ADAM21', 'ADAM metallopeptidase domain 21'],\n",
       " 'ADAM21P1': ['ADAM21P1', 'ADAM metallopeptidase domain 21 pseudogene 1'],\n",
       " 'ADAM22': ['MDC2', 'ADAM22', 'ADAM metallopeptidase domain 22'],\n",
       " 'ADAM23': ['MDC3', 'ADAM23', 'ADAM metallopeptidase domain 23'],\n",
       " 'ADAM24P': ['ADAM24P', 'ADAM metallopeptidase domain 24, pseudogene'],\n",
       " 'ADAM28': ['eMDCII',\n",
       "  'MDC-Lm',\n",
       "  'MDC-Ls',\n",
       "  'ADAM23',\n",
       "  'ADAM28',\n",
       "  'ADAM metallopeptidase domain 28'],\n",
       " 'ADAM29': ['svph1', 'CT73', 'ADAM29', 'ADAM metallopeptidase domain 29'],\n",
       " 'ADAM30': ['svph4', 'ADAM30', 'ADAM metallopeptidase domain 30'],\n",
       " 'ADAM32': ['ADAM32', 'ADAM metallopeptidase domain 32'],\n",
       " 'ADAM33': ['DKFZp434K0521',\n",
       "  'dJ964F7.1',\n",
       "  'ADAM33',\n",
       "  'ADAM metallopeptidase domain 33'],\n",
       " 'ADAMDEC1': ['M12.219', 'ADAMDEC1', 'ADAM-like, decysin 1'],\n",
       " 'ADAMTS1': ['C3-C5',\n",
       "  'METH1',\n",
       "  'KIAA1346',\n",
       "  'ADAMTS1',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 1'],\n",
       " 'ADAMTS2': ['ADAMTS-3',\n",
       "  'hPCPNI',\n",
       "  'PCINP',\n",
       "  'ADAM-TS2',\n",
       "  'NPI',\n",
       "  'ADAMTS2',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 2'],\n",
       " 'ADAMTS3': ['KIAA0366',\n",
       "  'ADAMTS-4',\n",
       "  'ADAMTS3',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 3'],\n",
       " 'ADAMTS4': ['KIAA0688',\n",
       "  'ADAMTS-2',\n",
       "  'ADMP-1',\n",
       "  'ADAMTS4',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 4'],\n",
       " 'ADAMTS5': ['ADMP-2',\n",
       "  'ADAMTS11',\n",
       "  'ADAMTS5',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 5'],\n",
       " 'ADAMTS6': ['ADAM-TS6',\n",
       "  'ADAMTS6',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 6'],\n",
       " 'ADAMTS7': ['ADAM-TS7',\n",
       "  'DKFZp434H204',\n",
       "  'ADAMTS7',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 7'],\n",
       " 'ADAMTS7P1': ['ADAMTS7P1', 'ADAMTS7 pseudogene 1'],\n",
       " 'ADAMTS7P3': ['ADAMTS7P3', 'ADAMTS7 pseudogene 3'],\n",
       " 'ADAMTS7P4': ['ADAMTS7P4', 'ADAMTS7 pseudogene 4'],\n",
       " 'ADAMTS8': ['METH2',\n",
       "  'FLJ41712',\n",
       "  'ADAM-TS8',\n",
       "  'ADAMTS8',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 8'],\n",
       " 'ADAMTS9': ['KIAA1312',\n",
       "  'ADAMTS9',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 9'],\n",
       " 'ADAMTS9-AS1': ['ADAMTS9-AS1', 'ADAMTS9 antisense RNA 1'],\n",
       " 'ADAMTS9-AS2': ['ADAMTS9-AS2', 'ADAMTS9 antisense RNA 2'],\n",
       " 'ADAMTS10': ['ADAM-TS10',\n",
       "  'ADAMTS10',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 10'],\n",
       " 'ADAMTS12': ['ADAMTS12',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 12'],\n",
       " 'ADAMTS13': ['VWFCP',\n",
       "  'TTP',\n",
       "  'vWF-CP',\n",
       "  'FLJ42993',\n",
       "  'MGC118899',\n",
       "  'MGC118900',\n",
       "  'DKFZp434C2322',\n",
       "  'ADAMTS13',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 13'],\n",
       " 'ADAMTS14': ['ADAMTS14',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 14'],\n",
       " 'ADAMTS15': ['ADAMTS15',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 15'],\n",
       " 'ADAMTS16': ['ADAMTS16s',\n",
       "  'ADAMTS16',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 16'],\n",
       " 'ADAMTS17': ['FLJ32769',\n",
       "  'FLJ16363',\n",
       "  'ADAMTS17',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 17'],\n",
       " 'ADAMTS18': ['ADAMTS18',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 18'],\n",
       " 'ADAMTS19': ['ADAMTS19',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 19'],\n",
       " 'ADAMTS19-AS1': ['RP11-346A9.1', 'ADAMTS19-AS1', 'ADAMTS19 antisense RNA 1'],\n",
       " 'ADAMTS20': ['GON-1',\n",
       "  'ADAMTS20',\n",
       "  'ADAM metallopeptidase with thrombospondin type 1 motif 20'],\n",
       " 'ADAMTSL1': ['ADAMTSR1', 'FLJ35283', 'ADAMTSL1', 'ADAMTS like 1'],\n",
       " 'ADAMTSL2': ['KIAA0605', 'ADAMTSL2', 'ADAMTS like 2'],\n",
       " 'ADAMTSL3': ['KIAA1233', 'punctin-2', 'ADAMTSL3', 'ADAMTS like 3'],\n",
       " 'ADAMTSL4': ['DKFZP434K1772', 'ADAMTSL4', 'ADAMTS like 4'],\n",
       " 'ADAMTSL4-AS1': ['FLJ45786', 'ADAMTSL4-AS1', 'ADAMTSL4 antisense RNA 1'],\n",
       " 'ADAMTSL5': ['ADAMTSL5', 'ADAMTS like 5'],\n",
       " 'ADAP1': ['GCS1L', 'ADAP1', 'ArfGAP with dual PH domains 1'],\n",
       " 'ADAP2': ['ADAP2', 'ArfGAP with dual PH domains 2'],\n",
       " 'ADAR': ['ADAR1', 'ADAR', 'adenosine deaminase, RNA-specific'],\n",
       " 'ADARB1': ['ADAR2',\n",
       "  'DRADA2',\n",
       "  'ADAR2g',\n",
       "  'DRABA2',\n",
       "  'RED1',\n",
       "  'hRED1',\n",
       "  'ADAR2a-L1',\n",
       "  'ADAR2a-L2',\n",
       "  'ADAR2a-L3',\n",
       "  'ADAR2a',\n",
       "  'ADAR2b',\n",
       "  'ADAR2c',\n",
       "  'ADAR2d',\n",
       "  'ADARB1',\n",
       "  'adenosine deaminase, RNA specific B1'],\n",
       " 'ADARB2': ['RED2',\n",
       "  'hRED2',\n",
       "  'ADAR3',\n",
       "  'ADARB2',\n",
       "  'adenosine deaminase, RNA specific B2 (inactive)'],\n",
       " 'ADARB2-AS1': ['bA466B20.1', 'ADARB2-AS1', 'ADARB2 antisense RNA 1'],\n",
       " 'ADAT1': ['ADAT1', 'adenosine deaminase, tRNA specific 1'],\n",
       " 'ADAT2': ['dJ20N2.1',\n",
       "  'TAD2',\n",
       "  'ADAT2',\n",
       "  'adenosine deaminase, tRNA specific 2'],\n",
       " 'ADAT3': ['TAD3', 'ADAT3', 'adenosine deaminase, tRNA specific 3'],\n",
       " 'ADCK1': ['FLJ39600', 'ADCK1', 'aarF domain containing kinase 1'],\n",
       " 'ADCK2': ['MGC20727', 'ADCK2', 'aarF domain containing kinase 2'],\n",
       " 'ADCK3': ['COQ8', 'SCAR9', 'ADCK3', 'aarF domain containing kinase 3'],\n",
       " 'ADCK4': ['FLJ12229', 'COQ8', 'ADCK4', 'aarF domain containing kinase 4'],\n",
       " 'ADCK5': ['FLJ35454', 'ADCK5', 'aarF domain containing kinase 5'],\n",
       " 'ADCY1': ['AC1', 'ADCY1', 'adenylate cyclase 1 (brain)'],\n",
       " 'ADCY2': ['HBAC2', 'KIAA1060', 'AC2', 'ADCY2', 'adenylate cyclase 2 (brain)'],\n",
       " 'ADCY3': ['AC3', 'ADCY3', 'adenylate cyclase 3'],\n",
       " 'ADCY4': ['AC4', 'ADCY4', 'adenylate cyclase 4'],\n",
       " 'ADCY5': ['AC5', 'ADCY5', 'adenylate cyclase 5'],\n",
       " 'ADCY6': ['AC6', 'ADCY6', 'adenylate cyclase 6'],\n",
       " 'ADCY7': ['KIAA0037', 'AC7', 'ADCY7', 'adenylate cyclase 7'],\n",
       " 'ADCY8': ['HBAC1', 'AC8', 'ADCY8', 'adenylate cyclase 8 (brain)'],\n",
       " 'ADCY9': ['AC9', 'ADCY9', 'adenylate cyclase 9'],\n",
       " 'ADCY10': ['SAC',\n",
       "  'Sacy',\n",
       "  'SACI',\n",
       "  'HCA2',\n",
       "  'RP1-313L4.2',\n",
       "  'ADCY10',\n",
       "  'adenylate cyclase 10 (soluble)'],\n",
       " 'ADCY10P1': ['ADCY10P1', 'adenylate cyclase 10 (soluble) pseudogene 1'],\n",
       " 'ADCYAP1': ['PACAP', 'ADCYAP1', 'adenylate cyclase activating polypeptide 1'],\n",
       " 'ADCYAP1R1': ['PAC1',\n",
       "  'PACAPR',\n",
       "  'PAC1R',\n",
       "  'ADCYAP1R1',\n",
       "  'ADCYAP receptor type I'],\n",
       " 'ADD1': ['ADD1', 'adducin 1'],\n",
       " 'ADD2': ['ADDB', 'ADD2', 'adducin 2'],\n",
       " 'ADD3': ['ADD3', 'adducin 3'],\n",
       " 'ADD3-AS1': ['ADD3-AS1', 'ADD3 antisense RNA 1'],\n",
       " 'ADGB': ['FLJ23121', 'dJ408K24.1', 'CAPN16', 'ADGB', 'androglobin'],\n",
       " 'ADGRA1': ['KIAA1828', 'ADGRA1', 'adhesion G protein-coupled receptor A1'],\n",
       " 'ADGRA1-AS1': ['ADGRA1-AS1',\n",
       "  'adhesion G protein-coupled receptor A1 antisense RNA 1'],\n",
       " 'ADGRA2': ['TEM5',\n",
       "  'DKFZp434C211',\n",
       "  'DKFZp434J0911',\n",
       "  'KIAA1531',\n",
       "  'FLJ14390',\n",
       "  'ADGRA2',\n",
       "  'adhesion G protein-coupled receptor A2'],\n",
       " 'ADGRA3': ['FLJ38547',\n",
       "  'PGR21',\n",
       "  'ADGRA3',\n",
       "  'adhesion G protein-coupled receptor A3'],\n",
       " 'ADGRB1': ['ADGRB1', 'adhesion G protein-coupled receptor B1'],\n",
       " 'ADGRB2': ['ADGRB2', 'adhesion G protein-coupled receptor B2'],\n",
       " 'ADGRB3': ['KIAA0550', 'ADGRB3', 'adhesion G protein-coupled receptor B3'],\n",
       " 'ADGRD1': ['DKFZp434B1272',\n",
       "  'PGR25',\n",
       "  'ADGRD1',\n",
       "  'adhesion G protein-coupled receptor D1'],\n",
       " 'ADGRD2': ['PGR24', 'ADGRD2', 'adhesion G protein-coupled receptor D2'],\n",
       " 'ADGRE1': ['ADGRE1', 'adhesion G protein-coupled receptor E1'],\n",
       " 'ADGRE2': ['CD312', 'ADGRE2', 'adhesion G protein-coupled receptor E2'],\n",
       " 'ADGRE3': ['ADGRE3', 'adhesion G protein-coupled receptor E3'],\n",
       " 'ADGRE4P': ['PGR16',\n",
       "  'ADGRE4P',\n",
       "  'adhesion G protein-coupled receptor E4, pseudogene'],\n",
       " 'ADGRE5': ['TM7LN1', 'ADGRE5', 'adhesion G protein-coupled receptor E5'],\n",
       " 'ADGRF1': ['hGPCR36',\n",
       "  'PGR19',\n",
       "  'ADGRF1',\n",
       "  'adhesion G protein-coupled receptor F1'],\n",
       " 'ADGRF2': ['hGPCR35',\n",
       "  'PGR20',\n",
       "  'ADGRF2',\n",
       "  'adhesion G protein-coupled receptor F2'],\n",
       " 'ADGRF3': ['hGPCR37',\n",
       "  'PGR23',\n",
       "  'ADGRF3',\n",
       "  'adhesion G protein-coupled receptor F3'],\n",
       " 'ADGRF4': ['FLJ38076',\n",
       "  'PGR18',\n",
       "  'ADGRF4',\n",
       "  'adhesion G protein-coupled receptor F4'],\n",
       " 'ADGRF5': ['DKFZp564O1923',\n",
       "  'KIAA0758',\n",
       "  'ADGRF5',\n",
       "  'adhesion G protein-coupled receptor F5'],\n",
       " 'ADGRF5P1': ['ADGRF5P1',\n",
       "  'adhesion G protein-coupled receptor F5 pseudogene 1'],\n",
       " 'ADGRF5P2': ['ADGRF5P2',\n",
       "  'adhesion G protein-coupled receptor F5 pseudogene 2'],\n",
       " 'ADGRG1': ['TM7LN4',\n",
       "  'TM7XN1',\n",
       "  'ADGRG1',\n",
       "  'adhesion G protein-coupled receptor G1'],\n",
       " 'ADGRG2': ['HE6',\n",
       "  'TM7LN2',\n",
       "  'EDDM6',\n",
       "  'ADGRG2',\n",
       "  'adhesion G protein-coupled receptor G2'],\n",
       " 'ADGRG3': ['Pb99',\n",
       "  'PGR26',\n",
       "  'ADGRG3',\n",
       "  'adhesion G protein-coupled receptor G3'],\n",
       " 'ADGRG4': ['RP1-299I16',\n",
       "  'PGR17',\n",
       "  'ADGRG4',\n",
       "  'adhesion G protein-coupled receptor G4'],\n",
       " 'ADGRG5': ['PGR27', 'ADGRG5', 'adhesion G protein-coupled receptor G5'],\n",
       " 'ADGRG6': ['FLJ14937', 'ADGRG6', 'adhesion G protein-coupled receptor G6'],\n",
       " 'ADGRG7': ['FLJ14454', 'ADGRG7', 'adhesion G protein-coupled receptor G7'],\n",
       " 'ADGRL1': ['KIAA0821',\n",
       "  'CIRL1',\n",
       "  'LEC2',\n",
       "  'ADGRL1',\n",
       "  'adhesion G protein-coupled receptor L1'],\n",
       " 'ADGRL2': ['KIAA0786',\n",
       "  'LEC1',\n",
       "  'ADGRL2',\n",
       "  'adhesion G protein-coupled receptor L2'],\n",
       " 'ADGRL3': ['KIAA0768',\n",
       "  'LEC3',\n",
       "  'ADGRL3',\n",
       "  'adhesion G protein-coupled receptor L3'],\n",
       " 'ADGRL3-AS1': ['ADGRL3-AS1',\n",
       "  'adhesion G protein-coupled receptor L3 antisense RNA 1'],\n",
       " 'ADGRL4': ['ETL', 'ADGRL4', 'adhesion G protein-coupled receptor L4'],\n",
       " 'ADGRV1': ['DKFZp761P0710',\n",
       "  'KIAA0686',\n",
       "  'FEB4',\n",
       "  'VLGR1',\n",
       "  'ADGRV1',\n",
       "  'adhesion G protein-coupled receptor V1'],\n",
       " 'ADH1A': ['ADH1A', 'alcohol dehydrogenase 1A (class I), alpha polypeptide'],\n",
       " 'ADH1B': ['ADH1B', 'alcohol dehydrogenase 1B (class I), beta polypeptide'],\n",
       " 'ADH1C': ['ADH1C', 'alcohol dehydrogenase 1C (class I), gamma polypeptide'],\n",
       " 'ADH4': ['ADH-2',\n",
       "  'ADH4',\n",
       "  'alcohol dehydrogenase 4 (class II), pi polypeptide'],\n",
       " 'ADH5': ['ADH-3',\n",
       "  'ADHX',\n",
       "  'ADH5',\n",
       "  'alcohol dehydrogenase 5 (class III), chi polypeptide'],\n",
       " 'ADH5P2': ['ADH5P2',\n",
       "  'alcohol dehydrogenase 5 (class III), chi polypeptide, pseudogene 2'],\n",
       " 'ADH5P3': ['ADH5P3',\n",
       "  'alcohol dehydrogenase 5 (class III), chi polypeptide, pseudogene 3'],\n",
       " 'ADH5P4': ['bA707M13.2',\n",
       "  'ADH5P4',\n",
       "  'alcohol dehydrogenase 5 (class III), chi polypeptide, pseudogene 4'],\n",
       " 'ADH6': ['ADH-5', 'ADH6', 'alcohol dehydrogenase 6 (class V)'],\n",
       " 'ADH7': ['ADH-4',\n",
       "  'ADH7',\n",
       "  'alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide'],\n",
       " 'ADHFE1': ['ADHFe1',\n",
       "  'FLJ32430',\n",
       "  'ADHFE1',\n",
       "  'alcohol dehydrogenase, iron containing 1'],\n",
       " 'ADI1': ['SIPL',\n",
       "  'MTCBP-1',\n",
       "  'ARD',\n",
       "  'APL1',\n",
       "  'FLJ10913',\n",
       "  'HMFT1638',\n",
       "  'mtnD',\n",
       "  'ADI1',\n",
       "  'acireductone dioxygenase 1'],\n",
       " 'ADIG': ['MGC39724', 'SMAF1', 'RP5-1100H13.2', 'ADIG', 'adipogenin'],\n",
       " 'ADIPOQ': ['ACRP30',\n",
       "  'AdipoQ',\n",
       "  'apM1',\n",
       "  'GBP28',\n",
       "  'adiponectin',\n",
       "  'ADIPOQ',\n",
       "  'adiponectin, C1Q and collagen domain containing'],\n",
       " 'ADIPOQ-AS1': ['ADIPOQ-AS1', 'ADIPOQ antisense RNA 1'],\n",
       " 'ADIPOR1': ['PAQR1', 'ACDCR1', 'ADIPOR1', 'adiponectin receptor 1'],\n",
       " 'ADIPOR1P1': ['ADIPOR1P1', 'adiponectin receptor 1 pseudogene 1'],\n",
       " 'ADIPOR1P2': ['ADIPOR1P2', 'adiponectin receptor 1 pseudogene 2'],\n",
       " 'ADIPOR2': ['PAQR2', 'ACDCR2', 'ADIPOR2', 'adiponectin receptor 2'],\n",
       " 'ADIRF': ['APM2', 'AFRO', 'ADIRF', 'adipogenesis regulatory factor'],\n",
       " 'ADIRF-AS1': ['ADIRF-AS1', 'ADIRF antisense RNA 1'],\n",
       " 'ADK': ['AK', 'ADK', 'adenosine kinase'],\n",
       " 'ADM': ['AM', 'ADM', 'adrenomedullin'],\n",
       " 'ADM2': ['AM2', 'FLJ21135', 'ADM2', 'adrenomedullin 2'],\n",
       " 'ADM5': ['AM5', 'ADM5', 'adrenomedullin 5 (putative)'],\n",
       " 'ADNP': ['KIAA0784',\n",
       "  'ADNP1',\n",
       "  'ADNP',\n",
       "  'activity-dependent neuroprotector homeobox'],\n",
       " 'ADNP-AS1': ['ADNP-AS1', 'ADNP antisense RNA 1'],\n",
       " 'ADNP2': ['KIAA0863', 'ADNP2', 'ADNP homeobox 2'],\n",
       " 'ADO': ['FLJ14547', 'ADO', '2-aminoethanethiol (cysteamine) dioxygenase'],\n",
       " 'ADORA1': ['RDC7', 'ADORA1', 'adenosine A1 receptor'],\n",
       " 'ADORA2A': ['RDC8', 'ADORA2A', 'adenosine A2a receptor'],\n",
       " 'ADORA2A-AS1': ['FLJ34651', 'ADORA2A-AS1', 'ADORA2A antisense RNA 1'],\n",
       " 'ADORA2B': ['ADORA2B', 'adenosine A2b receptor'],\n",
       " 'ADORA2BP1': ['ADORA2BP1', 'adenosine A2b receptor pseudogene 1'],\n",
       " 'ADORA3': ['AD026', 'ADORA3', 'adenosine A3 receptor'],\n",
       " 'ADPGK': ['DKFZp434B195', 'ADP-GK', 'ADPGK', 'ADP-dependent glucokinase'],\n",
       " 'ADPGK-AS1': ['ADPGK-AS1', 'ADPGK antisense RNA 1'],\n",
       " 'ADPRH': ['ARH1', 'ADPRH', 'ADP-ribosylarginine hydrolase'],\n",
       " 'ADPRHL1': ['ARH2', 'ADPRHL1', 'ADP-ribosylhydrolase like 1'],\n",
       " 'ADPRHL2': ['ARH3', 'FLJ20446', 'ADPRHL2', 'ADP-ribosylhydrolase like 2'],\n",
       " 'ADPRM': ['MDS006',\n",
       "  'ADPRM',\n",
       "  'ADP-ribose/CDP-alcohol diphosphatase, manganese dependent'],\n",
       " 'ADRA1A': ['ADRA1L1', 'ADRA1A', 'adrenoceptor alpha 1A'],\n",
       " 'ADRA1B': ['ADRA1B', 'adrenoceptor alpha 1B'],\n",
       " 'ADRA1D': ['ADRA1R', 'ADRA1A', 'ADRA1', 'ADRA1D', 'adrenoceptor alpha 1D'],\n",
       " 'ADRA2A': ['ADRAR', 'ADRA2A', 'adrenoceptor alpha 2A'],\n",
       " 'ADRA2B': ['ADRARL1', 'ADRA2B', 'adrenoceptor alpha 2B'],\n",
       " 'ADRA2C': ['ADRARL2', 'ADRA2C', 'adrenoceptor alpha 2C'],\n",
       " 'ADRB1': ['ADRB1', 'adrenoceptor beta 1'],\n",
       " 'ADRB2': ['ADRBR', 'BAR', 'B2AR', 'ADRB2', 'adrenoceptor beta 2'],\n",
       " 'ADRB3': ['ADRB3', 'adrenoceptor beta 3'],\n",
       " 'ADRBK1': ['GRK2', 'BARK1', 'ADRBK1', 'adrenergic, beta, receptor kinase 1'],\n",
       " 'ADRBK2': ['GRK3', 'BARK2', 'ADRBK2', 'adrenergic, beta, receptor kinase 2'],\n",
       " 'ADRM1': ['GP110',\n",
       "  'Rpn13',\n",
       "  'ARM1',\n",
       "  'ADRM1',\n",
       "  'adhesion regulating molecule 1'],\n",
       " 'ADSL': ['ADSL', 'adenylosuccinate lyase'],\n",
       " 'ADSS': ['ADSS', 'adenylosuccinate synthase'],\n",
       " 'ADSSL1': ['FLJ38602', 'ADSSL1', 'adenylosuccinate synthase like 1'],\n",
       " 'ADTRP': ['dJ413H6.1',\n",
       "  'AIG1L',\n",
       "  'ADTRP',\n",
       "  'androgen dependent TFPI regulating protein'],\n",
       " 'AEBP1': ['ACLP', 'AEBP1', 'AE binding protein 1'],\n",
       " 'AEBP2': ['MGC17922', 'AEBP2', 'AE binding protein 2'],\n",
       " 'AEN': ['FLJ12484', 'FLJ12562', 'AEN', 'apoptosis enhancing nuclease'],\n",
       " 'AES': ['GRG5', 'TLE5', 'AES', 'amino-terminal enhancer of split'],\n",
       " 'AFAP1': ['AFAP-110', 'AFAP', 'AFAP1', 'actin filament associated protein 1'],\n",
       " 'AFAP1-AS1': ['MGC10981', 'AFAP1-AS1', 'AFAP1 antisense RNA 1'],\n",
       " 'AFAP1L1': ['FLJ36748',\n",
       "  'AFAP1L1',\n",
       "  'actin filament associated protein 1 like 1'],\n",
       " 'AFAP1L2': ['FLJ14564',\n",
       "  'Em:AC005383.4',\n",
       "  'XB130',\n",
       "  'AFAP1L2',\n",
       "  'actin filament associated protein 1 like 2'],\n",
       " 'AFF1': ['AF-4', 'AF4', 'AFF1', 'AF4/FMR2 family member 1'],\n",
       " 'AFF2': ['FRAXE', 'AFF2', 'AF4/FMR2 family member 2'],\n",
       " 'AFF2-IT1': ['AFF2-IT1', 'AFF2 intronic transcript 1'],\n",
       " 'AFF3': ['MLLT2-like', 'AFF3', 'AF4/FMR2 family member 3'],\n",
       " 'AFF4': ['AF5Q31', 'MCEF', 'AFF4', 'AF4/FMR2 family member 4'],\n",
       " 'AFG3L1P': ['AFG3L1P',\n",
       "  'AFG3 like matrix AAA peptidase subunit 1, pseudogene'],\n",
       " 'AFG3L2': ['SPAX5', 'AFG3L2', 'AFG3 like matrix AAA peptidase subunit 2'],\n",
       " 'AFG3L2P1': ['AFG3L2P1', 'AFG3 like AAA ATPase 2 pseudogene 1'],\n",
       " 'AFM': ['ALB2', 'ALBA', 'AFM', 'afamin'],\n",
       " 'AFMID': ['DKFZp686F03259', 'KF', 'AFMID', 'arylformamidase'],\n",
       " 'AFP': ['FETA', 'AFP', 'alpha fetoprotein'],\n",
       " 'AFTPH': ['MGC33965',\n",
       "  'FLJ20080',\n",
       "  'FLJ23793',\n",
       "  'Nbla10388',\n",
       "  'AFTPH',\n",
       "  'aftiphilin'],\n",
       " 'AGA': ['ASRG', 'AGA', 'aspartylglucosaminidase'],\n",
       " 'AGAP1': ['KIAA1099',\n",
       "  'GGAP1',\n",
       "  'AGAP1',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 1'],\n",
       " 'AGAP1-IT1': ['AGAP1-IT1', 'AGAP1 intronic transcript 1'],\n",
       " 'AGAP2': ['AGAP2',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 2'],\n",
       " 'AGAP2-AS1': ['LOC100130776',\n",
       "  'PUNISHER',\n",
       "  'AGAP2-AS1',\n",
       "  'AGAP2 antisense RNA 1'],\n",
       " 'AGAP3': ['AGAP3',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 3'],\n",
       " 'AGAP4': ['Em:AC012044.1',\n",
       "  'MRIP2',\n",
       "  'AGAP4',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 4'],\n",
       " 'AGAP5': ['Em:AC073389.1',\n",
       "  'AGAP5',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 5'],\n",
       " 'AGAP6': ['bA324H6.1',\n",
       "  'AGAP6',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 6'],\n",
       " 'AGAP7P': ['bA109G10.1',\n",
       "  'AGAP7P',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 7, pseudogene'],\n",
       " 'AGAP9': ['bA301J7.2',\n",
       "  'FLJ00312',\n",
       "  'AGAP9',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 9'],\n",
       " 'AGAP10P': ['bA358L16.1',\n",
       "  'bA144G6.2',\n",
       "  'AGAP10P',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 10 pseudogene'],\n",
       " 'AGAP11': ['KIAA1975',\n",
       "  'AGAP11',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 11'],\n",
       " 'AGAP12P': ['bA164N7.2',\n",
       "  'AGAP12P',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 12, pseudogene'],\n",
       " 'AGAP13P': ['bA548K23.1',\n",
       "  'AGAP13P',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 13, pseudogene'],\n",
       " 'AGAP14P': ['bA145E20.1',\n",
       "  'AGAP14P',\n",
       "  'ArfGAP with GTPase domain, ankyrin repeat and PH domain 14, pseudogene'],\n",
       " 'AGBL1': ['FLJ32310', 'CCP4', 'AGBL1', 'ATP/GTP binding protein-like 1'],\n",
       " 'AGBL1-AS1': ['AGBL1-AS1', 'AGBL1 antisense RNA 1'],\n",
       " 'AGBL2': ['FLJ23598', 'CCP2', 'AGBL2', 'ATP/GTP binding protein-like 2'],\n",
       " 'AGBL3': ['MGC32955', 'CCP3', 'AGBL3', 'ATP/GTP binding protein-like 3'],\n",
       " 'AGBL4': ['FLJ14442', 'CCP6', 'AGBL4', 'ATP/GTP binding protein-like 4'],\n",
       " 'AGBL4-IT1': ['AGBL4-IT1', 'AGBL4 intronic transcript 1'],\n",
       " 'AGBL5': ['FLJ21839', 'CCP5', 'AGBL5', 'ATP/GTP binding protein-like 5'],\n",
       " 'AGBL5-AS1': ['AGBL5-AS1', 'AGBL5 antisense RNA 1'],\n",
       " 'AGBL5-IT1': ['AGBL5-IT1', 'AGBL5 intronic transcript 1'],\n",
       " 'AGER': ['RAGE',\n",
       "  'AGER',\n",
       "  'advanced glycosylation end product-specific receptor'],\n",
       " 'AGFG1': ['RIP', 'RAB', 'AGFG1', 'ArfGAP with FG repeats 1'],\n",
       " 'AGFG2': ['RABR', 'AGFG2', 'ArfGAP with FG repeats 2'],\n",
       " 'AGGF1': ['VG5Q',\n",
       "  'HSU84971',\n",
       "  'FLJ10283',\n",
       "  'GPATC7',\n",
       "  'GPATCH7',\n",
       "  'AGGF1',\n",
       "  'angiogenic factor with G-patch and FHA domains 1'],\n",
       " 'AGGF1P1': ['AGGF1P1',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 1'],\n",
       " 'AGGF1P2': ['AGGF1P2',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 2'],\n",
       " 'AGGF1P3': ['AGGF1P3',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 3'],\n",
       " 'AGGF1P4': ['AGGF1P4',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 4'],\n",
       " 'AGGF1P5': ['AGGF1P5',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 5'],\n",
       " 'AGGF1P6': ['AGGF1P6',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 6'],\n",
       " 'AGGF1P7': ['AGGF1P7',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 7'],\n",
       " 'AGGF1P8': ['AGGF1P8',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 8'],\n",
       " 'AGGF1P9': ['AGGF1P9',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 9'],\n",
       " 'AGGF1P10': ['AGGF1P10',\n",
       "  'angiogenic factor with G-patch and FHA domains 1 pseudogene 10'],\n",
       " 'AGK': ['FLJ10842', 'AGK', 'acylglycerol kinase'],\n",
       " 'AGKP1': ['AGKY1', 'AGKP1', 'acylglycerol kinase pseudogene 1'],\n",
       " 'AGL': ['AGL', 'amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase'],\n",
       " 'AGMAT': ['FLJ23384', 'AGMAT', 'agmatinase'],\n",
       " 'AGMO': ['FLJ16237', 'AGMO', 'alkylglycerol monooxygenase'],\n",
       " 'AGO1': ['hAGO1', 'AGO1', 'argonaute 1, RISC catalytic component'],\n",
       " 'AGO2': ['hAGO2', 'Q10', 'AGO2', 'argonaute 2, RISC catalytic component'],\n",
       " 'AGO3': ['hAGO3',\n",
       "  'FLJ12765',\n",
       "  'AGO3',\n",
       "  'argonaute 3, RISC catalytic component'],\n",
       " 'AGO4': ['hAGO4',\n",
       "  'KIAA1567',\n",
       "  'FLJ20033',\n",
       "  'AGO4',\n",
       "  'argonaute 4, RISC catalytic component'],\n",
       " 'AGPAT1': ['LPAAT-alpha',\n",
       "  'AGPAT1',\n",
       "  '1-acylglycerol-3-phosphate O-acyltransferase 1'],\n",
       " 'AGPAT2': ['LPAAT-beta',\n",
       "  'AGPAT2',\n",
       "  '1-acylglycerol-3-phosphate O-acyltransferase 2'],\n",
       " 'AGPAT3': ['LPAAT-gamma',\n",
       "  'AGPAT3',\n",
       "  '1-acylglycerol-3-phosphate O-acyltransferase 3'],\n",
       " 'AGPAT4': ['LPAAT-delta',\n",
       "  'dJ473J16.2',\n",
       "  'AGPAT4',\n",
       "  '1-acylglycerol-3-phosphate O-acyltransferase 4'],\n",
       " 'AGPAT4-IT1': ['FLJ23112', 'AGPAT4-IT1', 'AGPAT4 intronic transcript 1'],\n",
       " 'AGPAT5': ['FLJ11210',\n",
       "  'LPAAT-e',\n",
       "  'LPAAT-epsilon',\n",
       "  'AGPAT5',\n",
       "  '1-acylglycerol-3-phosphate O-acyltransferase 5'],\n",
       " 'AGPAT5P1': ['AGPAT5P1',\n",
       "  '1-acylglycerol-3-phosphate O-acyltransferase 5 pseudogene 1'],\n",
       " 'AGPS': ['ADHAPS',\n",
       "  'ADAS',\n",
       "  'ALDHPSY',\n",
       "  'ADPS',\n",
       "  'ADAP-S',\n",
       "  'AGPS',\n",
       "  'alkylglycerone phosphate synthase'],\n",
       " 'AGR2': ['XAG-2',\n",
       "  'HAG-2',\n",
       "  'AG2',\n",
       "  'PDIA17',\n",
       "  'AGR2',\n",
       "  'anterior gradient 2, protein disulphide isomerase family member'],\n",
       " 'AGR3': ['HAG3',\n",
       "  'hAG-3',\n",
       "  'BCMP11',\n",
       "  'PDIA18',\n",
       "  'AGR3',\n",
       "  'anterior gradient 3, protein disulphide isomerase family member'],\n",
       " 'AGRN': ['AGRIN', 'AGRN', 'agrin'],\n",
       " 'AGRP': ['Agrt', 'ART', 'ASIP2', 'AGRP', 'agouti related neuropeptide'],\n",
       " 'AGT': ['AGT', 'angiotensinogen'],\n",
       " 'AGTPBP1': ['KIAA1035',\n",
       "  'Nna1',\n",
       "  'CCP1',\n",
       "  'AGTPBP1',\n",
       "  'ATP/GTP binding protein 1'],\n",
       " 'AGTR1': ['AT1',\n",
       "  'AT2R1',\n",
       "  'AGTR1A',\n",
       "  'AT2R1A',\n",
       "  'HAT1R',\n",
       "  'AG2S',\n",
       "  'AT2R1B',\n",
       "  'AT1B',\n",
       "  'AGTR1',\n",
       "  'angiotensin II receptor type 1'],\n",
       " 'AGTR2': ['AT2', 'MRX88', 'AGTR2', 'angiotensin II receptor type 2'],\n",
       " 'AGTRAP': ['ATRAP', 'AGTRAP', 'angiotensin II receptor associated protein'],\n",
       " 'AGXT': ['AGXT1',\n",
       "  'PH1',\n",
       "  'AGT',\n",
       "  'SPT',\n",
       "  'AGT1',\n",
       "  'AGXT',\n",
       "  'alanine-glyoxylate aminotransferase'],\n",
       " 'AGXT2': ['AGT2', 'AGXT2', 'alanine--glyoxylate aminotransferase 2'],\n",
       " 'AHCTF1': ['ELYS', 'AHCTF1', 'AT-hook containing transcription factor 1'],\n",
       " 'AHCY': ['SAHH', 'AHCY', 'adenosylhomocysteinase'],\n",
       " 'AHCYL1': ['XPVKONA',\n",
       "  'IRBIT',\n",
       "  'PPP1R78',\n",
       "  'AHCYL1',\n",
       "  'adenosylhomocysteinase like 1'],\n",
       " 'AHCYL2': ['KIAA0828', 'AHCYL2', 'adenosylhomocysteinase like 2'],\n",
       " 'AHCYP2': ['AHCYP2', 'adenosylhomocysteinase pseudogene 2'],\n",
       " 'AHCYP3': ['AHCYP3', 'adenosylhomocysteinase pseudogene 3'],\n",
       " 'AHCYP4': ['AHCYP4', 'adenosylhomocysteinase pseudogene 4'],\n",
       " 'AHCYP5': ['AHCYP5', 'adenosylhomocysteinase pseudogene 5'],\n",
       " 'AHCYP7': ['AHCYP7', 'adenosylhomocysteinase pseudogene 7'],\n",
       " 'AHCYP8': ['AHCYP8', 'adenosylhomocysteinase pseudogene 8'],\n",
       " 'AHDC1': ['DJ159A19.3',\n",
       "  'RP1-159A19.1',\n",
       "  'AHDC1',\n",
       "  'AT-hook DNA binding motif containing 1'],\n",
       " 'AHI1': ['FLJ20069',\n",
       "  'ORF1',\n",
       "  'JBTS3',\n",
       "  'AHI1',\n",
       "  'Abelson helper integration site 1'],\n",
       " 'AHNAK': ['MGC5395', 'AHNAK', 'AHNAK nucleoprotein'],\n",
       " 'AHNAK2': ['AHNAK2', 'AHNAK nucleoprotein 2'],\n",
       " 'AHR': ['bHLHe76', 'AHR', 'aryl hydrocarbon receptor'],\n",
       " 'AHRR': ['KIAA1234',\n",
       "  'bHLHe77',\n",
       "  'AHRR',\n",
       "  'aryl-hydrocarbon receptor repressor'],\n",
       " 'AHSA1': ['p38',\n",
       "  'Aha1',\n",
       "  'hAha1',\n",
       "  'AHSA1',\n",
       "  'AHA1, activator of heat shock 90kDa protein ATPase homolog 1 (yeast)'],\n",
       " 'AHSA2': ['DKFZp564C236',\n",
       "  'Hch1',\n",
       "  'AHSA2',\n",
       "  'AHA1, activator of heat shock 90kDa protein ATPase homolog 2 (yeast)'],\n",
       " 'AHSG': ['FETUA', 'A2HS', 'HSGA', 'AHSG', 'alpha-2-HS-glycoprotein'],\n",
       " 'AHSP': ['EDRF', 'AHSP', 'alpha hemoglobin stabilizing protein'],\n",
       " 'AICDA': ['HIGM2',\n",
       "  'CDA2',\n",
       "  'ARP2',\n",
       "  'AID',\n",
       "  'AICDA',\n",
       "  'activation-induced cytidine deaminase'],\n",
       " 'AIDA': ['FLJ12806', 'AIDA', 'axin interactor, dorsalization associated'],\n",
       " 'AIF1': ['IRT-1',\n",
       "  'AIF-1',\n",
       "  'Em:AF129756.17',\n",
       "  'IBA1',\n",
       "  'AIF1',\n",
       "  'allograft inflammatory factor 1'],\n",
       " 'AIF1L': ['IBA2',\n",
       "  'FLJ12783',\n",
       "  'AIF1L',\n",
       "  'allograft inflammatory factor 1 like'],\n",
       " 'AIFM1': ['AIF',\n",
       "  'CMTX4',\n",
       "  'AIFM1',\n",
       "  'apoptosis inducing factor, mitochondria associated 1'],\n",
       " 'AIFM1P1': ['AIFM1P1',\n",
       "  'apoptosis inducing factor, mitochondria associated 1 pseudogene 1'],\n",
       " 'AIFM2': ['FLJ14497',\n",
       "  'PRG3',\n",
       "  'AIFM2',\n",
       "  'apoptosis inducing factor, mitochondria associated 2'],\n",
       " 'AIFM3': ['AIFL',\n",
       "  'FLJ30473',\n",
       "  'AIFM3',\n",
       "  'apoptosis inducing factor, mitochondria associated 3'],\n",
       " 'AIG1': ['dJ95L4.1', 'AIG-1', 'FLJ10485', 'AIG1', 'androgen-induced 1'],\n",
       " 'AIG1P1': ['AIG1P1', 'androgen-induced 1 pseudogene 1'],\n",
       " 'AIM1': ['CRYBG1', 'AIM1', 'absent in melanoma 1'],\n",
       " 'AIM1L': ['CRYBG2', 'FLJ38020', 'AIM1L', 'absent in melanoma 1-like'],\n",
       " 'AIM2': ['PYHIN4', 'AIM2', 'absent in melanoma 2'],\n",
       " 'AIMP1': ['EMAPII',\n",
       "  'EMAP-2',\n",
       "  'p43',\n",
       "  'AIMP1',\n",
       "  'aminoacyl tRNA synthetase complex-interacting multifunctional protein 1'],\n",
       " 'AIMP1P1': ['bA400P21.1',\n",
       "  'AIMP1P1',\n",
       "  'aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 pseudogene 1'],\n",
       " 'AIMP1P2': ['AIMP1P2',\n",
       "  'aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 pseudogene 2'],\n",
       " 'AIMP2': ['p38',\n",
       "  'PRO0992',\n",
       "  'JTV-1',\n",
       "  'JTV1',\n",
       "  'AIMP2',\n",
       "  'aminoacyl tRNA synthetase complex-interacting multifunctional protein 2'],\n",
       " 'AIP': ['XAP2',\n",
       "  'ARA9',\n",
       "  'FKBP16',\n",
       "  'AIP',\n",
       "  'aryl hydrocarbon receptor interacting protein'],\n",
       " 'AIPL1': ['AIPL1', 'aryl hydrocarbon receptor interacting protein like 1'],\n",
       " 'AIRE': ['PGA1', 'APS1', 'AIRE', 'autoimmune regulator'],\n",
       " 'AIRN': ['AIR',\n",
       "  'NCRNA00088',\n",
       "  'IGF2RAS',\n",
       "  'IGF2R-AS1',\n",
       "  'AIRN',\n",
       "  'antisense of IGF2R non-protein coding RNA'],\n",
       " 'AJAP1': ['SHREW1',\n",
       "  'SHREW-1',\n",
       "  'MOT8',\n",
       "  'AJAP1',\n",
       "  'adherens junctions associated protein 1'],\n",
       " 'AJUBA': ['MGC15563', 'AJUBA', 'ajuba LIM protein'],\n",
       " 'AK1': ['AK1', 'adenylate kinase 1'],\n",
       " 'AK2': ['AK2', 'adenylate kinase 2'],\n",
       " 'AK2P2': ['AK2P2', 'adenylate kinase 2 pseudogene 2'],\n",
       " 'AK3': ['AKL3L1', 'AK3', 'adenylate kinase 3'],\n",
       " 'AK3P2': ['HsT26053', 'AK3P2', 'adenylate kinase 3 pseudogene 2'],\n",
       " 'AK3P3': ['AK3P3', 'adenylate kinase 3 pseudogene 3'],\n",
       " 'AK3P4': ['AK3P4', 'adenylate kinase 3 pseudogene 4'],\n",
       " 'AK3P5': ['AK3P5', 'adenylate kinase 3 pseudogene 5'],\n",
       " 'AK4': ['AK4', 'adenylate kinase 4'],\n",
       " 'AK4P1': ['AK4P1', 'adenylate kinase 4 pseudogene 1'],\n",
       " 'AK4P2': ['AK4P2', 'adenylate kinase 4 pseudogene 2'],\n",
       " 'AK4P3': ['AK3L2P', 'AK4P3', 'adenylate kinase 4 pseudogene 3'],\n",
       " 'AK4P4': ['AK4P4', 'adenylate kinase 4 pseudogene 4'],\n",
       " 'AK4P5': ['AK4P5', 'adenylate kinase 4 pseudogene 5'],\n",
       " 'AK4P6': ['AK4P6', 'adenylate kinase 4 pseudogene 6'],\n",
       " 'AK5': ['AK5', 'adenylate kinase 5'],\n",
       " 'AK6': ['CINAP', 'AK6', 'adenylate kinase 6'],\n",
       " 'AK6P1': ['AK6P1', 'adenylate kinase 6 pseudogene 1'],\n",
       " 'AK6P2': ['AK6P2', 'adenylate kinase 6 pseudogene 2'],\n",
       " 'AK7': ['FLJ32864', 'AK7', 'adenylate kinase 7'],\n",
       " 'AK8': ['FLJ32704', 'AK8', 'adenylate kinase 8'],\n",
       " 'AK9': ['FLJ42177',\n",
       "  'FLJ25791',\n",
       "  'dJ70A9.1',\n",
       "  'MGC26954',\n",
       "  'AK9',\n",
       "  'adenylate kinase 9'],\n",
       " 'AKAIN1': ['AKAIN1', 'A kinase (PRKA) anchor inhibitor 1'],\n",
       " 'AKAP1': ['AKAP121',\n",
       "  'AKAP149',\n",
       "  'SAKAP84',\n",
       "  'S-AKAP84',\n",
       "  'AKAP84',\n",
       "  'D-AKAP1',\n",
       "  'PPP1R43',\n",
       "  'TDRD17',\n",
       "  'AKAP1',\n",
       "  'A-kinase anchoring protein 1'],\n",
       " 'AKAP2': ['AKAP-KL',\n",
       "  'KIAA0920',\n",
       "  'DKFZp564L0716',\n",
       "  'AKAP2',\n",
       "  'A-kinase anchoring protein 2'],\n",
       " 'AKAP3': ['FSP95',\n",
       "  'SOB1',\n",
       "  'AKAP110',\n",
       "  'CT82',\n",
       "  'AKAP3',\n",
       "  'A-kinase anchoring protein 3'],\n",
       " 'AKAP4': ['p82',\n",
       "  'hAKAP82',\n",
       "  'AKAP82',\n",
       "  'Fsc1',\n",
       "  'HI',\n",
       "  'CT99',\n",
       "  'AKAP4',\n",
       "  'A-kinase anchoring protein 4'],\n",
       " 'AKAP5': ['AKAP75', 'AKAP79', 'AKAP5', 'A-kinase anchoring protein 5'],\n",
       " 'AKAP6': ['KIAA0311',\n",
       "  'mAKAP',\n",
       "  'AKAP100',\n",
       "  'PRKA6',\n",
       "  'ADAP6',\n",
       "  'AKAP6',\n",
       "  'A-kinase anchoring protein 6'],\n",
       " 'AKAP7': ['AKAP18', 'AKAP15', 'AKAP7', 'A-kinase anchoring protein 7'],\n",
       " 'AKAP8': ['AKAP95', 'DKFZp586B1222', 'AKAP8', 'A-kinase anchoring protein 8'],\n",
       " 'AKAP8L': ['NAKAP95', 'HAP95', 'AKAP8L', 'A-kinase anchoring protein 8 like'],\n",
       " 'AKAP8P1': ['AKAP8P1', 'A-kinase anchoring protein 8 pseudogene 1'],\n",
       " 'AKAP9': ['KIAA0803',\n",
       "  'AKAP350',\n",
       "  'AKAP450',\n",
       "  'CG-NAP',\n",
       "  'YOTIAO',\n",
       "  'HYPERION',\n",
       "  'PRKA9',\n",
       "  'MU-RMS-40.16A',\n",
       "  'PPP1R45',\n",
       "  'LQT11',\n",
       "  'AKAP9',\n",
       "  'A-kinase anchoring protein 9'],\n",
       " 'AKAP10': ['D-AKAP2',\n",
       "  'PRKA10',\n",
       "  'MGC9414',\n",
       "  'AKAP10',\n",
       "  'A-kinase anchoring protein 10'],\n",
       " 'AKAP11': ['KIAA0629',\n",
       "  'AKAP220',\n",
       "  'PRKA11',\n",
       "  'FLJ11304',\n",
       "  'DKFZp781I12161',\n",
       "  'PPP1R44',\n",
       "  'AKAP11',\n",
       "  'A-kinase anchoring protein 11'],\n",
       " 'AKAP12': ['AKAP250', 'SSeCKS', 'AKAP12', 'A-kinase anchoring protein 12'],\n",
       " 'AKAP13': ['Ht31',\n",
       "  'BRX',\n",
       "  'AKAP-Lbc',\n",
       "  'c-lbc',\n",
       "  'PROTO-LB',\n",
       "  'HA-3',\n",
       "  'ARHGEF13',\n",
       "  'AKAP13',\n",
       "  'A-kinase anchoring protein 13'],\n",
       " 'AKAP14': ['AKAP28', 'AKAP14', 'A-kinase anchoring protein 14'],\n",
       " 'AKAP17A': ['XE7',\n",
       "  'XE7Y',\n",
       "  'DXYS155E',\n",
       "  'MGC39904',\n",
       "  '721P',\n",
       "  'CCDC133',\n",
       "  'AKAP17A',\n",
       "  'A-kinase anchoring protein 17A'],\n",
       " 'AKAP17BP': ['AKAP17BP', 'A-kinase anchoring protein 17B, pseudogene'],\n",
       " 'AKIP1': ['BCA3', 'AKIP1', 'A-kinase interacting protein 1'],\n",
       " 'AKIRIN1': ['FLJ12666', 'AKIRIN1', 'akirin 1'],\n",
       " 'AKIRIN1P1': ['AKIRIN1P1', 'akirin 1 pseudogene 1'],\n",
       " 'AKIRIN1P2': ['AKIRIN1P2', 'akirin 1 pseudogene 2'],\n",
       " 'AKIRIN2': ['FLJ10342', 'dJ486L4.2', 'AKIRIN2', 'akirin 2'],\n",
       " 'AKIRIN2P1': ['AKIRIN2P1', 'akirin 2 pseudogene 1'],\n",
       " 'AKNA': ['KIAA1968', 'AKNA', 'AT-hook transcription factor'],\n",
       " 'AKNAD1': ['MGC26989', 'AKNAD1', 'AKNA domain containing 1'],\n",
       " 'AKR1A1': ['ALR',\n",
       "  'DD3',\n",
       "  'AKR1A1',\n",
       "  'aldo-keto reductase family 1, member A1 (aldehyde reductase)'],\n",
       " 'AKR1B1': ['AR',\n",
       "  'AKR1B1',\n",
       "  'aldo-keto reductase family 1, member B1 (aldose reductase)'],\n",
       " 'AKR1B1P1': ['AKR1B1P1',\n",
       "  'aldehyde reductase family 1, member B1 pseudogene 1'],\n",
       " 'AKR1B1P2': ['AKR1B1P2',\n",
       "  'aldo-keto reductase family 1, member B1 pseudogene 2'],\n",
       " 'AKR1B1P4': ['AKR1B1P4',\n",
       "  'aldo-keto reductase family 1, member B1 pseudogene 4'],\n",
       " 'AKR1B1P6': ['AKR1B1P6',\n",
       "  'aldo-keto reductase family 1, member B1 pseudogene 6'],\n",
       " 'AKR1B1P7': ['AKR1B1P7',\n",
       "  'aldo-keto reductase family 1, member B1 pseudogene 7'],\n",
       " 'AKR1B1P8': ['AKR1B1P8',\n",
       "  'aldo-keto reductase family 1, member B1 pseudogene 8'],\n",
       " 'AKR1B10': ['AKR1B12',\n",
       "  'ARL-1',\n",
       "  'HIS',\n",
       "  'ARL1',\n",
       "  'HSI',\n",
       "  'ALDRLn',\n",
       "  'AKR1B10',\n",
       "  'aldo-keto reductase family 1, member B10 (aldose reductase)'],\n",
       " 'AKR1B10P1': ['AKR1B10P1',\n",
       "  'aldo-keto reductase family 1, member B10 pseudogene 1'],\n",
       " 'AKR1B10P2': ['AKR1B10P2',\n",
       "  'aldo-keto reductase family 1, member B10 pseudogene 2'],\n",
       " 'AKR1B15': ['AKR1B15', 'aldo-keto reductase family 1, member B15'],\n",
       " 'AKR1C1': ['DDH',\n",
       "  'MBAB',\n",
       "  'DD1',\n",
       "  'HAKRC',\n",
       "  'AKR1C1',\n",
       "  'aldo-keto reductase family 1, member C1'],\n",
       " 'AKR1C2': ['DD',\n",
       "  'BABP',\n",
       "  'DD2',\n",
       "  'HAKRD',\n",
       "  'MCDR2',\n",
       "  'AKR1C2',\n",
       "  'aldo-keto reductase family 1, member C2'],\n",
       " 'AKR1C3': ['KIAA0119',\n",
       "  'DDX',\n",
       "  'HAKRB',\n",
       "  'PGFS',\n",
       "  'AKR1C3',\n",
       "  'aldo-keto reductase family 1, member C3'],\n",
       " 'AKR1C4': ['DD4',\n",
       "  'HAKRA',\n",
       "  'C11',\n",
       "  '3-alpha-HSD',\n",
       "  'CDR',\n",
       "  'MGC22581',\n",
       "  'AKR1C4',\n",
       "  'aldo-keto reductase family 1, member C4'],\n",
       " 'AKR1C5P': ['AKR1C5P', 'aldo-keto reductase family 1, member C5, pseudogene'],\n",
       " 'AKR1C6P': ['TAKR',\n",
       "  'AKR1C6P',\n",
       "  'aldo-keto reductase family 1, member C6, pseudogene'],\n",
       " 'AKR1C7P': ['AKR1C7P', 'aldo-keto reductase family 1, member C7, pseudogene'],\n",
       " 'AKR1C8P': ['AKR1C8P', 'aldo-keto reductase family 1, member C8, pseudogene'],\n",
       " 'AKR1D1': ['AKR1D1', 'aldo-keto reductase family 1, member D1'],\n",
       " 'AKR1D1P1': ['AKR1D1P1',\n",
       "  'aldo-keto reductase family 1, member D1 pseudogene 1'],\n",
       " 'AKR1E2': ['MGC10612', 'AKR1E2', 'aldo-keto reductase family 1, member E2'],\n",
       " 'AKR7A2': ['AFAR', 'AKR7A2', 'aldo-keto reductase family 7, member A2'],\n",
       " 'AKR7A2P1': ['AFARP1',\n",
       "  'AKR7A2P1',\n",
       "  'aldo-keto reductase family 7, member A2 pseudogene 1'],\n",
       " 'AKR7A3': ['AKR7A3',\n",
       "  'aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase)'],\n",
       " 'AKR7L': ['AFAR3',\n",
       "  'AKR7L',\n",
       "  'aldo-keto reductase family 7-like (gene/pseudogene)'],\n",
       " 'AKT1': ['RAC',\n",
       "  'PKB',\n",
       "  'PRKBA',\n",
       "  'AKT',\n",
       "  'AKT1',\n",
       "  'v-akt murine thymoma viral oncogene homolog 1'],\n",
       " 'AKT1S1': ['PRAS40',\n",
       "  'MGC2865',\n",
       "  'Lobe',\n",
       "  'AKT1S1',\n",
       "  'AKT1 substrate 1 (proline rich)'],\n",
       " 'AKT2': ['AKT2', 'v-akt murine thymoma viral oncogene homolog 2'],\n",
       " 'AKT3': ['PKBG',\n",
       "  'RAC-gamma',\n",
       "  'PRKBG',\n",
       "  'AKT3',\n",
       "  'v-akt murine thymoma viral oncogene homolog 3'],\n",
       " 'AKT3-IT1': ['AKT3-IT1', 'AKT3 intronic transcript 1'],\n",
       " 'AKTIP': ['FLJ13258', 'AKTIP', 'AKT interacting protein'],\n",
       " 'ALAD': ['ALADH', 'PBGS', 'ALAD', 'aminolevulinate dehydratase'],\n",
       " 'ALAS1': ['ALAS1', \"5'-aminolevulinate synthase 1\"],\n",
       " 'ALAS2': ['ALAS2', \"5'-aminolevulinate synthase 2\"],\n",
       " 'ALB': ['ALB', 'albumin'],\n",
       " 'ALCAM': ['CD166',\n",
       "  'MEMD',\n",
       "  'ALCAM',\n",
       "  'activated leukocyte cell adhesion molecule'],\n",
       " 'ALDH1A1': ['RALDH1', 'ALDH1A1', 'aldehyde dehydrogenase 1 family member A1'],\n",
       " 'ALDH1A2': ['RALDH2', 'ALDH1A2', 'aldehyde dehydrogenase 1 family member A2'],\n",
       " 'ALDH1A3': ['RALDH3', 'ALDH1A3', 'aldehyde dehydrogenase 1 family member A3'],\n",
       " 'ALDH1B1': ['ALDHX', 'ALDH1B1', 'aldehyde dehydrogenase 1 family member B1'],\n",
       " 'ALDH1L1': ['10-fTHF',\n",
       "  'ALDH1L1',\n",
       "  'aldehyde dehydrogenase 1 family member L1'],\n",
       " 'ALDH1L1-AS1': ['ALDH1L1-AS1', 'ALDH1L1 antisense RNA 1'],\n",
       " 'ALDH1L1-AS2': ['ALDH1L1-AS2', 'ALDH1L1 antisense RNA 2'],\n",
       " 'ALDH1L2': ['FLJ38508',\n",
       "  'mtFDH',\n",
       "  'ALDH1L2',\n",
       "  'aldehyde dehydrogenase 1 family member L2'],\n",
       " 'ALDH2': ['ALDH2', 'aldehyde dehydrogenase 2 family (mitochondrial)'],\n",
       " 'ALDH3A1': ['ALDH3A1', 'aldehyde dehydrogenase 3 family member A1'],\n",
       " 'ALDH3A2': ['FALDH', 'ALDH3A2', 'aldehyde dehydrogenase 3 family member A2'],\n",
       " 'ALDH3B1': ['ALDH3B1', 'aldehyde dehydrogenase 3 family member B1'],\n",
       " 'ALDH3B2': ['ALDH3B2', 'aldehyde dehydrogenase 3 family member B2'],\n",
       " 'ALDH4A1': ['P5CDh', 'ALDH4A1', 'aldehyde dehydrogenase 4 family member A1'],\n",
       " 'ALDH5A1': ['SSADH',\n",
       "  'SSDH',\n",
       "  'ALDH5A1',\n",
       "  'aldehyde dehydrogenase 5 family member A1'],\n",
       " 'ALDH6A1': ['ALDH6A1', 'aldehyde dehydrogenase 6 family member A1'],\n",
       " 'ALDH7A1': ['EPD',\n",
       "  'PDE',\n",
       "  'ALDH7A1',\n",
       "  'aldehyde dehydrogenase 7 family member A1'],\n",
       " 'ALDH7A1P1': ['ALDH7A1P1',\n",
       "  'aldehyde dehydrogenase 7 family member A1 pseudogene 1'],\n",
       " 'ALDH7A1P2': ['ALDH7A1P2',\n",
       "  'aldehyde dehydrogenase 7 family member A1 pseudogene 2'],\n",
       " 'ALDH7A1P3': ['ALDH7A1P3',\n",
       "  'aldehyde dehydrogenase 7 family member A1 pseudogene 3'],\n",
       " 'ALDH7A1P4': ['ALDH7A1P4',\n",
       "  'aldehyde dehydrogenase 7 family member A1 pseudogene 4'],\n",
       " 'ALDH8A1': ['ALDH12', 'ALDH8A1', 'aldehyde dehydrogenase 8 family member A1'],\n",
       " 'ALDH9A1': ['E3', 'ALDH9A1', 'aldehyde dehydrogenase 9 family member A1'],\n",
       " 'ALDH16A1': ['MGC10204',\n",
       "  'ALDH16A1',\n",
       "  'aldehyde dehydrogenase 16 family member A1'],\n",
       " 'ALDH18A1': ['P5CS',\n",
       "  'ALDH18A1',\n",
       "  'aldehyde dehydrogenase 18 family member A1'],\n",
       " 'ALDOA': ['ALDOA', 'aldolase, fructose-bisphosphate A'],\n",
       " 'ALDOAP1': ['ALDOAP1', 'aldolase, fructose-bisphosphate A pseudogene 1'],\n",
       " 'ALDOAP2': ['ALDOAP2', 'aldolase, fructose-bisphosphate A pseudogene 2'],\n",
       " 'ALDOB': ['ALDOB', 'aldolase, fructose-bisphosphate B'],\n",
       " 'ALDOC': ['ALDOC', 'aldolase, fructose-bisphosphate C'],\n",
       " 'ALG1': ['HMT-1',\n",
       "  'HMAT1',\n",
       "  'ALG1',\n",
       "  'ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase'],\n",
       " 'ALG1L': ['ALG1L1',\n",
       "  'ALG1L',\n",
       "  'ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase-like'],\n",
       " 'ALG1L2': ['ALG1L2',\n",
       "  'ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase-like 2'],\n",
       " 'ALG1L3P': ['ALG1L3P',\n",
       "  'asparagine-linked glycosylation 1-like 3, pseudogene'],\n",
       " 'ALG1L5P': ['ALG1L5P',\n",
       "  'asparagine-linked glycosylation 1-like 5, pseudogene'],\n",
       " 'ALG1L6P': ['ALG1L6P',\n",
       "  'asparagine-linked glycosylation 1-like 6, pseudogene'],\n",
       " 'ALG1L7P': ['ALG1L7P',\n",
       "  'asparagine-linked glycosylation 1-like 7, pseudogene'],\n",
       " 'ALG1L8P': ['ALG1L8P',\n",
       "  'asparagine-linked glycosylation 1-like 8, pseudogene'],\n",
       " 'ALG1L9P': ['ALG1L9P',\n",
       "  'asparagine-linked glycosylation 1-like 9, pseudogene'],\n",
       " 'ALG1L10P': ['ALG1L10P',\n",
       "  'asparagine-linked glycosylation 1-like 10, pseudogene'],\n",
       " 'ALG1L11P': ['ALG1L11P',\n",
       "  'asparagine-linked glycosylation 1-like 11, pseudogene'],\n",
       " 'ALG1L12P': ['ALG1L12P',\n",
       "  'asparagine-linked glycosylation 1-like 12, pseudogene'],\n",
       " 'ALG1L13P': ['ALG1L13P',\n",
       "  'asparagine-linked glycosylation 1-like 13, pseudogene'],\n",
       " 'ALG1L14P': ['ALG1L14P',\n",
       "  'asparagine-linked glycosylation 1-like 14, pseudogene'],\n",
       " 'ALG1L15P': ['ALG1L15P',\n",
       "  'asparagine-linked glycosylation 1-like 15, pseudogene'],\n",
       " 'ALG2': ['CDGIi',\n",
       "  'FLJ14511',\n",
       "  'hALPG2',\n",
       "  'NET38',\n",
       "  'ALG2',\n",
       "  'ALG2, alpha-1,3/1,6-mannosyltransferase'],\n",
       " 'ALG3': ['NOT56L',\n",
       "  'Not56',\n",
       "  'CDGS4',\n",
       "  'D16Ertd36e',\n",
       "  'ALG3',\n",
       "  'ALG3, alpha-1,3- mannosyltransferase'],\n",
       " 'ALG3P1': ['ALG3P1', 'ALG3, alpha-1,3- mannosyltransferase pseudogene 1'],\n",
       " 'ALG5': ['bA421P11.2',\n",
       "  'ALG5',\n",
       "  'ALG5, dolichyl-phosphate beta-glucosyltransferase'],\n",
       " 'ALG6': ['ALG6', 'ALG6, alpha-1,3-glucosyltransferase'],\n",
       " 'ALG8': ['MGC2840', 'ALG8', 'ALG8, alpha-1,3-glucosyltransferase'],\n",
       " 'ALG9': ['ALG9', 'ALG9, alpha-1,2-mannosyltransferase'],\n",
       " 'ALG9-IT1': ['ALG9-IT1', 'ALG9 intronic transcript 1'],\n",
       " 'ALG10': ['FLJ14751',\n",
       "  'DIE2',\n",
       "  'ALG10A',\n",
       "  'ALG10',\n",
       "  'ALG10, alpha-1,2-glucosyltransferase'],\n",
       " 'ALG10B': ['KCR1', 'ALG10B', 'ALG10B, alpha-1,2-glucosyltransferase'],\n",
       " 'ALG11': ['KIAA0266', 'ALG11', 'ALG11, alpha-1,2-mannosyltransferase'],\n",
       " 'ALG12': ['ECM39', 'ALG12', 'ALG12, alpha-1,6-mannosyltransferase'],\n",
       " 'ALG13': ['MDS031',\n",
       "  'YGL047W',\n",
       "  'FLJ23018',\n",
       "  'TDRD13',\n",
       "  'ALG13',\n",
       "  'ALG13, UDP-N-acetylglucosaminyltransferase subunit'],\n",
       " 'ALG13-AS1': ['ALG13-AS1', 'ALG13 antisense RNA 1'],\n",
       " 'ALG14': ['MGC19780',\n",
       "  'ALG14',\n",
       "  'ALG14, UDP-N-acetylglucosaminyltransferase subunit'],\n",
       " 'ALK': ['CD246', 'ALK', 'anaplastic lymphoma receptor tyrosine kinase'],\n",
       " 'ALKBH1': ['hABH',\n",
       "  'alkB',\n",
       "  'ABH',\n",
       "  'ALKBH1',\n",
       "  'alkB homolog 1, histone H2A dioxygenase'],\n",
       " 'ALKBH2': ['MGC90512',\n",
       "  'ABH2',\n",
       "  'ALKBH2',\n",
       "  'alkB homolog 2, alpha-ketoglutarate-dependent dioxygenase'],\n",
       " 'ALKBH3': ['DEPC-1',\n",
       "  'ALKBH3',\n",
       "  'alkB homolog 3, alpha-ketoglutarate-dependent dioxygenase'],\n",
       " 'ALKBH3-AS1': ['ALKBH3-AS1', 'ALKBH3 antisense RNA 1'],\n",
       " 'ALKBH4': ['FLJ20013', 'ALKBH4', 'alkB homolog 4, lysine demethylase'],\n",
       " 'ALKBH5': ['FLJ20308', 'ALKBH5', 'alkB homolog 5, RNA demethylase'],\n",
       " 'ALKBH6': ['MGC15677', 'ALKBH6', 'alkB homolog 6'],\n",
       " 'ALKBH7': ['MGC10974', 'ALKBH7', 'alkB homolog 7'],\n",
       " 'ALKBH8': ['MGC10235',\n",
       "  'TRM9',\n",
       "  'TRMT9',\n",
       "  'ALKBH8',\n",
       "  'alkB homolog 8, tRNA methyltransferase'],\n",
       " 'ALLC': ['ALC', 'ALLC', 'allantoicase'],\n",
       " 'ALMS1': ['KIAA0328',\n",
       "  'ALMS1',\n",
       "  'ALMS1, centrosome and basal body associated protein'],\n",
       " 'ALMS1-IT1': ['ALMS1-IT1', 'ALMS1 intronic transcript 1'],\n",
       " 'ALMS1P1': ['ALMS1P1',\n",
       "  'ALMS1, centrosome and basal body associated protein pseudogene 1'],\n",
       " 'ALOX5': ['5-LOX', 'ALOX5', 'arachidonate 5-lipoxygenase'],\n",
       " 'ALOX5AP': ['FLAP',\n",
       "  'ALOX5AP',\n",
       "  'arachidonate 5-lipoxygenase activating protein'],\n",
       " 'ALOX12': ['12S-LOX', 'ALOX12', 'arachidonate 12-lipoxygenase'],\n",
       " 'ALOX12-AS1': ['ALOX12-AS1', 'ALOX12 antisense RNA 1'],\n",
       " 'ALOX12B': ['12R-LOX', 'ALOX12B', 'arachidonate 12-lipoxygenase, 12R type'],\n",
       " 'ALOX12P1': ['ALOX12P1', 'arachidonate 12-lipoxygenase pseudogene 1'],\n",
       " 'ALOX12P2': ['ALOX12P2', 'arachidonate 12-lipoxygenase pseudogene 2'],\n",
       " 'ALOX15': ['15-LOX-1', 'ALOX15', 'arachidonate 15-lipoxygenase'],\n",
       " 'ALOX15B': ['15-LOX-2', 'ALOX15B', 'arachidonate 15-lipoxygenase, type B'],\n",
       " 'ALOX15P2': ['ALOX15P2', 'arachidonate 15-lipoxygenase pseudogene 2'],\n",
       " 'ALOXE3': ['eLOX3', 'E-LOX', 'ALOXE3', 'arachidonate lipoxygenase 3'],\n",
       " 'ALPI': ['ALPI', 'alkaline phosphatase, intestinal'],\n",
       " 'ALPK1': ['Lak', 'FLJ22670', 'KIAA1527', 'ALPK1', 'alpha kinase 1'],\n",
       " 'ALPK2': ['HAK', 'ALPK2', 'alpha kinase 2'],\n",
       " 'ALPK3': ['MAK', 'KIAA1330', 'Midori', 'ALPK3', 'alpha kinase 3'],\n",
       " 'ALPL': ['TNSALP', 'ALPL', 'alkaline phosphatase, liver/bone/kidney'],\n",
       " 'ALPP': ['ALPP', 'alkaline phosphatase, placental'],\n",
       " 'ALPPL2': ['ALPPL2', 'alkaline phosphatase, placental like 2'],\n",
       " 'ALS2': ['ALS2', 'ALS2, alsin Rho guanine nucleotide exchange factor'],\n",
       " 'ALS2CL': ['FLJ36525',\n",
       "  'RN49018',\n",
       "  'DKFZp686I0110',\n",
       "  'ALS2CL',\n",
       "  'ALS2 C-terminal like'],\n",
       " 'ALS2CR11': ['FLJ25351',\n",
       "  'ALS2CR11',\n",
       "  'amyotrophic lateral sclerosis 2 chromosome region candidate 11'],\n",
       " 'ALS2CR12': ['ALS2CR12',\n",
       "  'amyotrophic lateral sclerosis 2 chromosome region candidate 12'],\n",
       " 'ALX1': ['ALX1', 'ALX homeobox 1'],\n",
       " 'ALX3': ['ALX3', 'ALX homeobox 3'],\n",
       " 'ALX4': ['FPP', 'PFM', 'KIAA1788', 'ALX4', 'ALX homeobox 4'],\n",
       " 'ALYREF': ['ALY', 'BEF', 'ALY/REF', 'REF', 'ALYREF', 'Aly/REF export factor'],\n",
       " 'AMACR': ['RACE', 'AMACR', 'alpha-methylacyl-CoA racemase'],\n",
       " 'AMBN': ['AMBN', 'ameloblastin'],\n",
       " 'AMBP': ['UTI',\n",
       "  'HCP',\n",
       "  'EDC1',\n",
       "  'HI30',\n",
       "  'IATIL',\n",
       "  'ITILC',\n",
       "  'AMBP',\n",
       "  'alpha-1-microglobulin/bikunin precursor'],\n",
       " 'AMBRA1': ['FLJ20294',\n",
       "  'KIAA1736',\n",
       "  'WDR94',\n",
       "  'DCAF3',\n",
       "  'AMBRA1',\n",
       "  'autophagy/beclin-1 regulator 1'],\n",
       " 'AMD1': ['SAMDC', 'AMD1', 'adenosylmethionine decarboxylase 1'],\n",
       " 'AMD1P1': ['AMD1P1', 'adenosylmethionine decarboxylase 1 pseudogene 1'],\n",
       " 'AMD1P2': ['AMDPX',\n",
       "  'AMDPY',\n",
       "  'AMD1P2',\n",
       "  'adenosylmethionine decarboxylase 1 pseudogene 2'],\n",
       " 'AMD1P3': ['AMD1P3', 'adenosylmethionine decarboxylase 1 pseudogene 3'],\n",
       " 'AMD1P4': ['AMD1P4', 'adenosylmethionine decarboxylase 1 pseudogene 4'],\n",
       " 'AMDHD1': ['MGC35366', 'AMDHD1', 'amidohydrolase domain containing 1'],\n",
       " 'AMDHD2': ['CGI-14', 'AMDHD2', 'amidohydrolase domain containing 2'],\n",
       " 'AMELX': ['AMELX', 'amelogenin, X-linked'],\n",
       " 'AMELY': ['AMELY', 'amelogenin, Y-linked'],\n",
       " 'AMER1': ['RP11-403E24.2',\n",
       "  'FLJ39827',\n",
       "  'WTX',\n",
       "  'AMER1',\n",
       "  'APC membrane recruitment protein 1'],\n",
       " 'AMER2': ['FLJ25477', 'AMER2', 'APC membrane recruitment protein 2'],\n",
       " 'AMER3': ['FLJ38377', 'AMER3', 'APC membrane recruitment protein 3'],\n",
       " 'AMFR': ['RNF45', 'gp78', 'AMFR', 'autocrine motility factor receptor'],\n",
       " 'AMH': ['MIS', 'AMH', 'anti-Mullerian hormone'],\n",
       " 'AMHR2': ['MISR2',\n",
       "  'MISRII',\n",
       "  'AMHR2',\n",
       "  'anti-Mullerian hormone receptor type II'],\n",
       " 'AMIGO1': ['AMIGO',\n",
       "  'KIAA1163',\n",
       "  'AMIGO1',\n",
       "  'adhesion molecule with Ig-like domain 1'],\n",
       " 'AMIGO2': ['ALI1',\n",
       "  'DEGA',\n",
       "  'AMIGO2',\n",
       "  'adhesion molecule with Ig-like domain 2'],\n",
       " 'AMIGO3': ['AMIGO3', 'adhesion molecule with Ig-like domain 3'],\n",
       " 'AMMECR1': ['AMMECR1',\n",
       "  'Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1'],\n",
       " 'AMMECR1-IT1': ['AMMECR1-IT1', 'AMMECR1 intronic transcript 1'],\n",
       " 'AMMECR1L': ['MGC4268', 'AMMECR1L', 'AMMECR1 like'],\n",
       " 'AMMECR1LP1': ['AMMECR1LP1', 'AMMECR1 like pseudogene 1'],\n",
       " 'AMN': ['amnionless', 'AMN', 'amnion associated transmembrane protein'],\n",
       " 'AMN1': ['AMN1', 'antagonist of mitotic exit network 1 homolog'],\n",
       " 'AMOT': ['KIAA1071', 'AMOT', 'angiomotin'],\n",
       " 'AMOTL1': ['JEAP', 'AMOTL1', 'angiomotin like 1'],\n",
       " 'AMOTL2': ['LCCP', 'AMOTL2', 'angiomotin like 2'],\n",
       " 'AMPD1': ['MAD', 'MADA', 'AMPD1', 'adenosine monophosphate deaminase 1'],\n",
       " 'AMPD2': ['SPG63', 'AMPD2', 'adenosine monophosphate deaminase 2'],\n",
       " 'AMPD3': ['AMPD3', 'adenosine monophosphate deaminase 3'],\n",
       " 'AMPH': ['AMPH', 'amphiphysin'],\n",
       " 'AMT': ['GCST', 'NKH', 'AMT', 'aminomethyltransferase'],\n",
       " 'AMTN': ['UNQ689', 'RSTI689', 'AMTN', 'amelotin'],\n",
       " 'AMY1A': ['AMY1A', 'amylase, alpha 1A (salivary)'],\n",
       " 'AMY1B': ['AMY1B', 'amylase, alpha 1B (salivary)'],\n",
       " 'AMY1C': ['AMY1C', 'amylase, alpha 1C (salivary)'],\n",
       " 'AMY2A': ['AMY2A', 'amylase, alpha 2A (pancreatic)'],\n",
       " 'AMY2B': ['AMY2B', 'amylase, alpha 2B (pancreatic)'],\n",
       " 'AMYP1': ['AMYP1', 'amylase, alpha pseudogene 1'],\n",
       " 'AMZ1': ['KIAA1950', 'AMZ1', 'archaelysin family metallopeptidase 1'],\n",
       " 'AMZ2': ['AMZ2', 'archaelysin family metallopeptidase 2'],\n",
       " 'AMZ2P1': ['FLJ32065',\n",
       "  'AMZ2P1',\n",
       "  'archaelysin family metallopeptidase 2 pseudogene 1'],\n",
       " 'AMZ2P2': ['AMZ2P2', 'archaelysin family metallopeptidase 2 pseudogene 2'],\n",
       " 'ANAPC1': ['MCPR',\n",
       "  'TSG24',\n",
       "  'APC1',\n",
       "  'ANAPC1',\n",
       "  'anaphase promoting complex subunit 1'],\n",
       " 'ANAPC1P1': ['ANAPC1P1', 'anaphase promoting complex subunit 1 pseudogene 1'],\n",
       " 'ANAPC2': ['APC2',\n",
       "  'KIAA1406',\n",
       "  'ANAPC2',\n",
       "  'anaphase promoting complex subunit 2'],\n",
       " 'ANAPC4': ['APC4', 'ANAPC4', 'anaphase promoting complex subunit 4'],\n",
       " 'ANAPC5': ['APC5', 'ANAPC5', 'anaphase promoting complex subunit 5'],\n",
       " 'ANAPC7': ['APC7', 'ANAPC7', 'anaphase promoting complex subunit 7'],\n",
       " 'ANAPC10': ['APC10',\n",
       "  'DOC1',\n",
       "  'DKFZP564L0562',\n",
       "  'ANAPC10',\n",
       "  'anaphase promoting complex subunit 10'],\n",
       " 'ANAPC10P1': ['ANAPC10P1',\n",
       "  'anaphase promoting complex subunit 10 pseudogene 1'],\n",
       " 'ANAPC11': ['HSPC214',\n",
       "  'APC11',\n",
       "  'Apc11p',\n",
       "  'MGC882',\n",
       "  'ANAPC11',\n",
       "  'anaphase promoting complex subunit 11'],\n",
       " 'ANAPC13': ['SWM1',\n",
       "  'APC13',\n",
       "  'DKFZP566D193',\n",
       "  'ANAPC13',\n",
       "  'anaphase promoting complex subunit 13'],\n",
       " 'ANAPC15': ['HSPC020',\n",
       "  'DKFZP564M082',\n",
       "  'APC15',\n",
       "  'ANAPC15',\n",
       "  'anaphase promoting complex subunit 15'],\n",
       " 'ANAPC16': ['bA570G20.3',\n",
       "  'FLJ33728',\n",
       "  'APC16',\n",
       "  'CENP-27',\n",
       "  'ANAPC16',\n",
       "  'anaphase promoting complex subunit 16'],\n",
       " 'ANG': ['RNASE5',\n",
       "  'RAA1',\n",
       "  'ANG',\n",
       "  'angiogenin, ribonuclease, RNase A family, 5'],\n",
       " 'ANGEL1': ['Ccr4e', 'ANGEL1', 'angel homolog 1 (Drosophila)'],\n",
       " 'ANGEL2': ['KIAA0759L',\n",
       "  'FLJ12793',\n",
       "  'Ccr4d',\n",
       "  'ANGEL2',\n",
       "  'angel homolog 2 (Drosophila)'],\n",
       " 'ANGPT1': ['KIAA0003', 'Ang1', 'ANGPT1', 'angiopoietin 1'],\n",
       " 'ANGPT2': ['Ang2', 'ANGPT2', 'angiopoietin 2'],\n",
       " 'ANGPT4': ['ANGPT4', 'angiopoietin 4'],\n",
       " 'ANGPTL1': ['ANG3', 'AngY', 'ARP1', 'ANGPTL1', 'angiopoietin like 1'],\n",
       " 'ANGPTL2': ['ARP2', 'HARP', 'ANGPTL2', 'angiopoietin like 2'],\n",
       " 'ANGPTL3': ['ANGPTL3', 'angiopoietin like 3'],\n",
       " 'ANGPTL4': ['pp1158',\n",
       "  'PGAR',\n",
       "  'ARP4',\n",
       "  'HFARP',\n",
       "  'FIAF',\n",
       "  'NL2',\n",
       "  'ANGPTL4',\n",
       "  'angiopoietin like 4'],\n",
       " 'ANGPTL5': ['ANGPTL5', 'angiopoietin like 5'],\n",
       " 'ANGPTL6': ['ARP5', 'AGF', 'ANGPTL6', 'angiopoietin like 6'],\n",
       " 'ANGPTL7': ['CDT6', 'AngX', 'ANGPTL7', 'angiopoietin like 7'],\n",
       " 'ANGPTL8': ['TD26', 'RIFL', 'ANGPTL8', 'angiopoietin like 8'],\n",
       " 'ANHX': ['ANHX', 'anomalous homeobox'],\n",
       " 'ANK1': ['SPH1', 'ANK1', 'ankyrin 1'],\n",
       " 'ANK2': ['ANK2', 'ankyrin 2, neuronal'],\n",
       " 'ANK3': ['ANK3', 'ankyrin 3, node of Ranvier (ankyrin G)'],\n",
       " 'ANKAR': ['FLJ25415', 'ANKAR', 'ankyrin and armadillo repeat containing'],\n",
       " 'ANKDD1A': ['FLJ25870',\n",
       "  'ANKDD1A',\n",
       "  'ankyrin repeat and death domain containing 1A'],\n",
       " 'ANKDD1B': ['ANKDD1B', 'ankyrin repeat and death domain containing 1B'],\n",
       " 'ANKEF1': ['FLJ21669',\n",
       "  'dJ839B4.6',\n",
       "  'ANKEF1',\n",
       "  'ankyrin repeat and EF-hand domain containing 1'],\n",
       " 'ANKFN1': ['FLJ38335',\n",
       "  'ANKFN1',\n",
       "  'ankyrin repeat and fibronectin type III domain containing 1'],\n",
       " 'ANKFY1': ['ANKHZN',\n",
       "  'KIAA1255',\n",
       "  'ZFYVE14',\n",
       "  'BTBD23',\n",
       "  'RANK-5',\n",
       "  'ANKFY1',\n",
       "  'ankyrin repeat and FYVE domain containing 1'],\n",
       " 'ANKH': ['HANK',\n",
       "  'ANK',\n",
       "  'CPPDD',\n",
       "  'ANKH',\n",
       "  'ANKH inorganic pyrophosphate transport regulator'],\n",
       " 'ANKHD1': ['MASK',\n",
       "  'FLJ20288',\n",
       "  'FLJ11979',\n",
       "  'FLJ10042',\n",
       "  'FLJ14127',\n",
       "  'KIAA1085',\n",
       "  'MASK1',\n",
       "  'ANKHD1',\n",
       "  'ankyrin repeat and KH domain containing 1'],\n",
       " 'ANKHD1-EIF4EBP3': ['MASK-BP3',\n",
       "  'ANKHD1-EIF4EBP3',\n",
       "  'ANKHD1-EIF4EBP3 readthrough'],\n",
       " 'ANKIB1': ['DKFZP434A0225',\n",
       "  'KIAA1386',\n",
       "  'ANKIB1',\n",
       "  'ankyrin repeat and IBR domain containing 1'],\n",
       " 'ANKK1': ['X-kinase',\n",
       "  'ANKK1',\n",
       "  'ankyrin repeat and kinase domain containing 1'],\n",
       " 'ANKLE1': ['FLJ39369',\n",
       "  'LEMD6',\n",
       "  'ANKLE1',\n",
       "  'ankyrin repeat and LEM domain containing 1'],\n",
       " 'ANKLE2': ['LEMD7',\n",
       "  'Lem4',\n",
       "  'ANKLE2',\n",
       "  'ankyrin repeat and LEM domain containing 2'],\n",
       " 'ANKMY1': ['FLJ20499',\n",
       "  'ZMYND13',\n",
       "  'ANKMY1',\n",
       "  'ankyrin repeat and MYND domain containing 1'],\n",
       " 'ANKMY2': ['DKFZP564O043',\n",
       "  'ZMYND20',\n",
       "  'ANKMY2',\n",
       "  'ankyrin repeat and MYND domain containing 2'],\n",
       " 'ANKRA2': ['ANKRA2', 'ankyrin repeat family A member 2'],\n",
       " 'ANKRD1': ['C-193',\n",
       "  'ALRP',\n",
       "  'CARP',\n",
       "  'CVARP',\n",
       "  'MCARP',\n",
       "  'ANKRD1',\n",
       "  'ankyrin repeat domain 1'],\n",
       " 'ANKRD2': ['ARPP', 'ANKRD2', 'ankyrin repeat domain 2'],\n",
       " 'ANKRD6': ['KIAA0957', 'ANKRD6', 'ankyrin repeat domain 6'],\n",
       " 'ANKRD7': ['TSA806', 'ANKRD7', 'ankyrin repeat domain 7'],\n",
       " 'ANKRD9': ['ANKRD9', 'ankyrin repeat domain 9'],\n",
       " 'ANKRD10': ['FLJ20093', 'ANKRD10', 'ankyrin repeat domain 10'],\n",
       " 'ANKRD10-IT1': ['ANKRD10-IT1', 'ANKRD10 intronic transcript 1'],\n",
       " 'ANKRD11': ['LZ16', 'T13', 'ANKRD11', 'ankyrin repeat domain 11'],\n",
       " 'ANKRD12': ['KIAA0874',\n",
       "  'FLJ20053',\n",
       "  'GAC-1',\n",
       "  'ANKRD12',\n",
       "  'ankyrin repeat domain 12'],\n",
       " 'ANKRD13A': ['NY-REN-25', 'ANKRD13A', 'ankyrin repeat domain 13A'],\n",
       " 'ANKRD13B': ['FLJ25555', 'ANKRD13B', 'ankyrin repeat domain 13B'],\n",
       " 'ANKRD13C': ['DKFZP566D1346',\n",
       "  'dJ677H15.3',\n",
       "  'ANKRD13C',\n",
       "  'ankyrin repeat domain 13C'],\n",
       " 'ANKRD13D': ['ANKRD13D', 'ankyrin repeat domain 13 family member D'],\n",
       " 'ANKRD16': ['DKFZP434N1511', 'ANKRD16', 'ankyrin repeat domain 16'],\n",
       " 'ANKRD17': ['GTAR',\n",
       "  'KIAA0697',\n",
       "  'FLJ22206',\n",
       "  'NY-BR-16',\n",
       "  'MASK2',\n",
       "  'ANKRD17',\n",
       "  'ankyrin repeat domain 17'],\n",
       " 'ANKRD18A': ['KIAA2015', 'FLJ35740', 'ANKRD18A', 'ankyrin repeat domain 18A'],\n",
       " 'ANKRD18B': ['bA255A11.3', 'ANKRD18B', 'ankyrin repeat domain 18B'],\n",
       " 'ANKRD18CP': ['ANKRD18CP', 'ankyrin repeat domain 18C, pseudogene'],\n",
       " 'ANKRD18DP': ['ANKRD18DP', 'ankyrin repeat domain 18D, pseudogene'],\n",
       " 'ANKRD18EP': ['ANKRD18EP', 'ankyrin repeat domain 18E, pseudogene'],\n",
       " 'ANKRD19P': ['FLJ36178', 'ANKRD19P', 'ankyrin repeat domain 19, pseudogene'],\n",
       " 'ANKRD20A1': ['DKFZp434A171',\n",
       "  'ANKRD20A1',\n",
       "  'ankyrin repeat domain 20 family member A1'],\n",
       " 'ANKRD20A2': ['ANKRD20A2', 'ankyrin repeat domain 20 family member A2'],\n",
       " 'ANKRD20A3': ['ANKRD20A3', 'ankyrin repeat domain 20 family member A3'],\n",
       " 'ANKRD20A4': ['OTTHUMG00000066855',\n",
       "  'ANKRD20A4',\n",
       "  'ankyrin repeat domain 20 family member A4'],\n",
       " 'ANKRD20A5P': ['MGC26718',\n",
       "  'ANKRD20A5P',\n",
       "  'ankyrin repeat domain 20 family member A5, pseudogene'],\n",
       " 'ANKRD20A7P': ['ANKRD20A7P',\n",
       "  'ankyrin repeat domain 20 family member A7, pseudogene'],\n",
       " 'ANKRD20A8P': ['ANKRD20A8P',\n",
       "  'ankyrin repeat domain 20 family member A8, pseudogene'],\n",
       " 'ANKRD20A9P': ['ANKRD20A9P',\n",
       "  'ankyrin repeat domain 20 family member A9, pseudogene'],\n",
       " 'ANKRD20A10P': ['ANKRD20A10P',\n",
       "  'ankyrin repeat domain 20 family member A10, pseudogene'],\n",
       " 'ANKRD20A11P': ['ANKRD20A11P',\n",
       "  'ankyrin repeat domain 20 family member A11, pseudogene'],\n",
       " 'ANKRD20A17P': ['ANKRD20A17P',\n",
       "  'ankyrin repeat domain 20 family member A17, pseudogene'],\n",
       " 'ANKRD20A18P': ['ANKRD20A18P',\n",
       "  'ankyrin repeat domain 20 family member A18, pseudogene'],\n",
       " 'ANKRD20A19P': ['ANKRD20A19P',\n",
       "  'ankyrin repeat domain 20 family member A19, pseudogene'],\n",
       " 'ANKRD22': ['MGC22805', 'ANKRD22', 'ankyrin repeat domain 22'],\n",
       " 'ANKRD23': ['DARP',\n",
       "  'FLJ32449',\n",
       "  'MARP3',\n",
       "  'ANKRD23',\n",
       "  'ankyrin repeat domain 23'],\n",
       " 'ANKRD24': ['KIAA1981', 'ANKRD24', 'ankyrin repeat domain 24'],\n",
       " 'ANKRD26': ['KIAA1074', 'ANKRD26', 'ankyrin repeat domain 26'],\n",
       " 'ANKRD26P1': ['FLJ43980',\n",
       "  'ANKRD26P1',\n",
       "  'ankyrin repeat domain 26 pseudogene 1'],\n",
       " 'ANKRD26P2': ['ANKRD26P2', 'ankyrin repeat domain 26 pseudogene 2'],\n",
       " 'ANKRD26P3': ['ANKRD26P3', 'ankyrin repeat domain 26 pseudogene 3'],\n",
       " 'ANKRD26P4': ['ANKRD26P4', 'ankyrin repeat domain 26 pseudogene 4'],\n",
       " 'ANKRD27': ['FLJ00040',\n",
       "  'DKFZp434L0718',\n",
       "  'VARP',\n",
       "  'ANKRD27',\n",
       "  'ankyrin repeat domain 27'],\n",
       " 'ANKRD28': ['KIAA0379',\n",
       "  'PITK',\n",
       "  'PP6-ARS-A',\n",
       "  'PPP1R65',\n",
       "  'ANKRD28',\n",
       "  'ankyrin repeat domain 28'],\n",
       " 'ANKRD29': ['FLJ25053', 'ANKRD29', 'ankyrin repeat domain 29'],\n",
       " 'ANKRD30A': ['NY-BR-1', 'ANKRD30A', 'ankyrin repeat domain 30A'],\n",
       " 'ANKRD30B': ['NY-BR-1.1', 'ANKRD30B', 'ankyrin repeat domain 30B'],\n",
       " 'ANKRD30BL': ['ANKRD30BL', 'ankyrin repeat domain 30B-like'],\n",
       " 'ANKRD30BP1': ['PRED4',\n",
       "  'ANKRD30BP1',\n",
       "  'ankyrin repeat domain 30B pseudogene 1'],\n",
       " 'ANKRD30BP2': ['CT85',\n",
       "  'CTSP-1',\n",
       "  'ANKRD30BP2',\n",
       "  'ankyrin repeat domain 30B pseudogene 2'],\n",
       " 'ANKRD30BP3': ['ANKRD30BP3', 'ankyrin repeat domain 30B pseudogene 3'],\n",
       " 'ANKRD31': ['FLJ40191', 'ANKRD31', 'ankyrin repeat domain 31'],\n",
       " 'ANKRD33': ['DKFZp686O1689', 'PANKY', 'ANKRD33', 'ankyrin repeat domain 33'],\n",
       " 'ANKRD33B': ['ANKRD33B', 'ankyrin repeat domain 33B'],\n",
       " 'ANKRD33B-AS1': ['ANKRD33B-AS1', 'ANKRD33B antisense RNA 1'],\n",
       " 'ANKRD34A': ['ANKRD34A', 'ankyrin repeat domain 34A'],\n",
       " 'ANKRD34B': ['DP58', 'ANKRD34B', 'ankyrin repeat domain 34B'],\n",
       " 'ANKRD34C': ['ANKRD34C', 'ankyrin repeat domain 34C'],\n",
       " 'ANKRD34C-AS1': ['ANKRD34C-AS1', 'ANKRD34C antisense RNA 1'],\n",
       " 'ANKRD35': ['FLJ25124', 'ANKRD35', 'ankyrin repeat domain 35'],\n",
       " 'ANKRD36': ['UNQ2430', 'ANKRD36', 'ankyrin repeat domain 36'],\n",
       " 'ANKRD36B': ['FLJ21281', 'ANKRD36B', 'ankyrin repeat domain 36B'],\n",
       " 'ANKRD36BP1': ['MGC12538',\n",
       "  'ANKRD36BP1',\n",
       "  'ankyrin repeat domain 36B pseudogene 1'],\n",
       " 'ANKRD36BP2': ['ANKRD36BP2', 'ankyrin repeat domain 36B pseudogene 2'],\n",
       " 'ANKRD36C': ['DKFZp667P0924', 'ANKRD36C', 'ankyrin repeat domain 36C'],\n",
       " 'ANKRD36P1': ['ANKRD36P1', 'ankyrin repeat domain 36 pseudogene 1'],\n",
       " 'ANKRD37': ['Lrp2bp', 'ANKRD37', 'ankyrin repeat domain 37'],\n",
       " 'ANKRD39': ['MGC41816', 'ANKRD39', 'ankyrin repeat domain 39'],\n",
       " 'ANKRD40': ['MGC15396', 'ANKRD40', 'ankyrin repeat domain 40'],\n",
       " 'ANKRD42': ['FLJ37874',\n",
       "  'SARP',\n",
       "  'PPP1R79',\n",
       "  'ANKRD42',\n",
       "  'ankyrin repeat domain 42'],\n",
       " ...}"
      ]
     },
     "execution_count": 106,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "gene_dic = {k:[elem for elem in v if elem != 'nan' ] for k,v in gene_dic.items()}\n",
    "gene_dic\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "metadata": {},
   "outputs": [],
   "source": [
    "dump(gene_dic, 'gene_dic.joblib') \n",
    "gene_dic = load('gene_dic.joblib') "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [],
   "source": [
    "alias=df_genes[df_genes['alias_symbol'].notnull()]\n",
    "\n",
    "alias=alias['alias_symbol']\n",
    "\n",
    "alias=alias.tolist()\n",
    "\n",
    "\n",
    "def aliases_lst(df_alias_lst):\n",
    "    \n",
    "    alias_lst=[]\n",
    "    for x in alias:\n",
    "        gn=x.split('|')\n",
    "        alias_lst.append(gn)\n",
    "    \n",
    "    flat_list = []\n",
    "    for sublist in alias_lst:\n",
    "        for item in sublist:\n",
    "            item=item.lower()\n",
    "            flat_list.append(item)\n",
    "    return flat_list\n",
    "\n",
    "lst_alias_gns=aliases_lst(alias) \n",
    "\n",
    "symbol=df_genes['symbol']\n",
    "symbol=symbol.tolist()\n",
    "gene_check=symbol+lst_alias_gns\n",
    "gene_check\n",
    "gene_check_lower=aliases_lst(gene_check)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#gene_check_lower"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "rule = rrulewrapper(YEARLY, byeaster=1, interval=1)\n",
    "loc = RRuleLocator(rule)\n",
    "formatter = DateFormatter('%m/%d/%y')\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\mese4\\Anaconda3\\lib\\site-packages\\ipykernel_launcher.py:21: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "C:\\Users\\mese4\\Anaconda3\\lib\\site-packages\\ipykernel_launcher.py:22: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "C:\\Users\\mese4\\Anaconda3\\lib\\site-packages\\ipykernel_launcher.py:24: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>cord_uid</th>\n",
       "      <th>sha</th>\n",
       "      <th>source_x</th>\n",
       "      <th>title</th>\n",
       "      <th>doi</th>\n",
       "      <th>pmcid</th>\n",
       "      <th>pubmed_id</th>\n",
       "      <th>license</th>\n",
       "      <th>abstract</th>\n",
       "      <th>publish_time</th>\n",
       "      <th>...</th>\n",
       "      <th>who_covidence_id</th>\n",
       "      <th>arxiv_id</th>\n",
       "      <th>pdf_json_files</th>\n",
       "      <th>pmc_json_files</th>\n",
       "      <th>url</th>\n",
       "      <th>s2_id</th>\n",
       "      <th>preprint</th>\n",
       "      <th>year</th>\n",
       "      <th>month</th>\n",
       "      <th>year_month</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>4231</th>\n",
       "      <td>4tt0vnr4</td>\n",
       "      <td>aa3858e3cf21baa00c6f60272e4b59d3490129e0</td>\n",
       "      <td>PMC</td>\n",
       "      <td>CXCR6 regulates localization of tissue-residen...</td>\n",
       "      <td>10.1084/jem.20181308</td>\n",
       "      <td>PMC6888981</td>\n",
       "      <td>3.15586e+07</td>\n",
       "      <td>cc-by-nc-sa</td>\n",
       "      <td>Resident memory T cells (T(RM) cells) are an i...</td>\n",
       "      <td>2019-12-02</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>document_parses/pdf_json/aa3858e3cf21baa00c6f6...</td>\n",
       "      <td>document_parses/pmc_json/PMC6888981.xml.json</td>\n",
       "      <td>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2019.0</td>\n",
       "      <td>12.0</td>\n",
       "      <td>2019.0-12.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4234</th>\n",
       "      <td>9c0zrp7p</td>\n",
       "      <td>23d0641f1f78528bbf3fa7b0b749abc1299a9cb4</td>\n",
       "      <td>PMC</td>\n",
       "      <td>Local risk perception enhances epidemic control</td>\n",
       "      <td>10.1371/journal.pone.0225576</td>\n",
       "      <td>PMC6890219</td>\n",
       "      <td>3.17946e+07</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>As infectious disease outbreaks emerge, public...</td>\n",
       "      <td>2019-12-03</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>document_parses/pdf_json/23d0641f1f78528bbf3fa...</td>\n",
       "      <td>document_parses/pmc_json/PMC6890219.xml.json</td>\n",
       "      <td>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2019.0</td>\n",
       "      <td>12.0</td>\n",
       "      <td>2019.0-12.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4236</th>\n",
       "      <td>iaktm72a</td>\n",
       "      <td>9be8c80283a7fed59057d7788eb2850708f45450</td>\n",
       "      <td>PMC</td>\n",
       "      <td>Curcumin to Promote the Synthesis of Silver NP...</td>\n",
       "      <td>10.1038/s41598-019-54752-4</td>\n",
       "      <td>PMC6890765</td>\n",
       "      <td>3.17969e+07</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>This work presents a simple one-pot protocol t...</td>\n",
       "      <td>2019-12-03</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>document_parses/pdf_json/9be8c80283a7fed59057d...</td>\n",
       "      <td>document_parses/pmc_json/PMC6890765.xml.json</td>\n",
       "      <td>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2019.0</td>\n",
       "      <td>12.0</td>\n",
       "      <td>2019.0-12.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4237</th>\n",
       "      <td>gcmpatlb</td>\n",
       "      <td>d5d29d1d48e1a4fe8f39d38639766c86dc976e5e</td>\n",
       "      <td>PMC</td>\n",
       "      <td>Factors that enable effective One Health colla...</td>\n",
       "      <td>10.1371/journal.pone.0224660</td>\n",
       "      <td>PMC6892547</td>\n",
       "      <td>3.18006e+07</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>Advocates for a One Health approach recognize ...</td>\n",
       "      <td>2019-12-04</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>document_parses/pdf_json/d5d29d1d48e1a4fe8f39d...</td>\n",
       "      <td>document_parses/pmc_json/PMC6892547.xml.json</td>\n",
       "      <td>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2019.0</td>\n",
       "      <td>12.0</td>\n",
       "      <td>2019.0-12.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4246</th>\n",
       "      <td>k2monfg0</td>\n",
       "      <td>772046ceb62525b9f5c685e2d2b8dd33573107ba</td>\n",
       "      <td>PMC</td>\n",
       "      <td>Risk factors for the development of acute resp...</td>\n",
       "      <td>10.1186/s13054-019-2646-8</td>\n",
       "      <td>PMC6898929</td>\n",
       "      <td>3.18105e+07</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>BACKGROUND: Clinical and epidemiological diffe...</td>\n",
       "      <td>2019-12-06</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>document_parses/pdf_json/772046ceb62525b9f5c68...</td>\n",
       "      <td>document_parses/pmc_json/PMC6898929.xml.json</td>\n",
       "      <td>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2019.0</td>\n",
       "      <td>12.0</td>\n",
       "      <td>2019.0-12.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>169809</th>\n",
       "      <td>vbw0wbn1</td>\n",
       "      <td>07c638d72edcbd6f41a84d30023b0cfd864c3d68</td>\n",
       "      <td>PMC; WHO</td>\n",
       "      <td>Statistical analysis and visualization of the ...</td>\n",
       "      <td>10.1007/s13337-020-00610-1</td>\n",
       "      <td>PMC7283982</td>\n",
       "      <td>NaN</td>\n",
       "      <td>no-cc</td>\n",
       "      <td>A local outbreak of initially unknown cause pn...</td>\n",
       "      <td>2020-06-10</td>\n",
       "      <td>...</td>\n",
       "      <td>#592057</td>\n",
       "      <td>NaN</td>\n",
       "      <td>document_parses/pdf_json/07c638d72edcbd6f41a84...</td>\n",
       "      <td>document_parses/pmc_json/PMC7283982.xml.json</td>\n",
       "      <td>https://doi.org/10.1007/s13337-020-00610-1</td>\n",
       "      <td>219554233.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>2020.0-6.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>169811</th>\n",
       "      <td>7dqr5adm</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Medline; WHO</td>\n",
       "      <td>A cohort of patients with COVID-19 in a major ...</td>\n",
       "      <td>10.3390/jcm9061733</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.25127e+07</td>\n",
       "      <td>unk</td>\n",
       "      <td>Background: Since the confirmation of the firs...</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>...</td>\n",
       "      <td>#32512688</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://doi.org/10.3390/jcm9061733; https://ww...</td>\n",
       "      <td>219553115.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>2020.0-1.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>169813</th>\n",
       "      <td>ajqbljai</td>\n",
       "      <td>76ca0fe38a7e8bc1b730be50658fa9cb2eb7e4f2; e33a...</td>\n",
       "      <td>Medline; PMC</td>\n",
       "      <td>Epidemiology of Covid-19 in a Long-Term Care F...</td>\n",
       "      <td>10.1056/nejmoa2005412</td>\n",
       "      <td>PMC7121761</td>\n",
       "      <td>3.22202e+07</td>\n",
       "      <td>no-cc</td>\n",
       "      <td>BACKGROUND: Long-term care facilities are high...</td>\n",
       "      <td>2020-03-27</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>document_parses/pdf_json/76ca0fe38a7e8bc1b730b...</td>\n",
       "      <td>document_parses/pmc_json/PMC7121761.xml.json</td>\n",
       "      <td>https://www.ncbi.nlm.nih.gov/pubmed/32220208/;...</td>\n",
       "      <td>214683161.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>2020.0-3.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>169814</th>\n",
       "      <td>gsktliyd</td>\n",
       "      <td>24741265a77032e848afe0cd1745adda124818be</td>\n",
       "      <td>Elsevier; Medline; PMC</td>\n",
       "      <td>A SARS-CoV-2 familial cluster infection reveal...</td>\n",
       "      <td>10.1016/j.jiph.2020.05.018</td>\n",
       "      <td>PMC7250748</td>\n",
       "      <td>3.25055e+07</td>\n",
       "      <td>no-cc</td>\n",
       "      <td>Information on SARS-CoV-2 asymptomatic infecti...</td>\n",
       "      <td>2020-05-27</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>document_parses/pdf_json/24741265a77032e848afe...</td>\n",
       "      <td>document_parses/pmc_json/PMC7250748.xml.json</td>\n",
       "      <td>https://www.sciencedirect.com/science/article/...</td>\n",
       "      <td>218891131.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>5.0</td>\n",
       "      <td>2020.0-5.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>169817</th>\n",
       "      <td>9svgq9f1</td>\n",
       "      <td>75a2fe5ad9b6eb8caf30399b9440f7dd610a32d3; 4461...</td>\n",
       "      <td>Medline; PMC</td>\n",
       "      <td>Virusâvirus interactions impact the populati...</td>\n",
       "      <td>10.1073/pnas.1911083116</td>\n",
       "      <td>PMC6936719</td>\n",
       "      <td>3.18439e+07</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>The human respiratory tract hosts a diverse co...</td>\n",
       "      <td>2019-12-26</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>document_parses/pdf_json/75a2fe5ad9b6eb8caf303...</td>\n",
       "      <td>document_parses/pmc_json/PMC6936719.xml.json</td>\n",
       "      <td>https://doi.org/10.1073/pnas.1911083116; https...</td>\n",
       "      <td>209388856.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2019.0</td>\n",
       "      <td>12.0</td>\n",
       "      <td>2019.0-12.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>49511 rows × 23 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        cord_uid                                                sha  \\\n",
       "4231    4tt0vnr4           aa3858e3cf21baa00c6f60272e4b59d3490129e0   \n",
       "4234    9c0zrp7p           23d0641f1f78528bbf3fa7b0b749abc1299a9cb4   \n",
       "4236    iaktm72a           9be8c80283a7fed59057d7788eb2850708f45450   \n",
       "4237    gcmpatlb           d5d29d1d48e1a4fe8f39d38639766c86dc976e5e   \n",
       "4246    k2monfg0           772046ceb62525b9f5c685e2d2b8dd33573107ba   \n",
       "...          ...                                                ...   \n",
       "169809  vbw0wbn1           07c638d72edcbd6f41a84d30023b0cfd864c3d68   \n",
       "169811  7dqr5adm                                                NaN   \n",
       "169813  ajqbljai  76ca0fe38a7e8bc1b730be50658fa9cb2eb7e4f2; e33a...   \n",
       "169814  gsktliyd           24741265a77032e848afe0cd1745adda124818be   \n",
       "169817  9svgq9f1  75a2fe5ad9b6eb8caf30399b9440f7dd610a32d3; 4461...   \n",
       "\n",
       "                      source_x  \\\n",
       "4231                       PMC   \n",
       "4234                       PMC   \n",
       "4236                       PMC   \n",
       "4237                       PMC   \n",
       "4246                       PMC   \n",
       "...                        ...   \n",
       "169809                PMC; WHO   \n",
       "169811            Medline; WHO   \n",
       "169813            Medline; PMC   \n",
       "169814  Elsevier; Medline; PMC   \n",
       "169817            Medline; PMC   \n",
       "\n",
       "                                                    title  \\\n",
       "4231    CXCR6 regulates localization of tissue-residen...   \n",
       "4234      Local risk perception enhances epidemic control   \n",
       "4236    Curcumin to Promote the Synthesis of Silver NP...   \n",
       "4237    Factors that enable effective One Health colla...   \n",
       "4246    Risk factors for the development of acute resp...   \n",
       "...                                                   ...   \n",
       "169809  Statistical analysis and visualization of the ...   \n",
       "169811  A cohort of patients with COVID-19 in a major ...   \n",
       "169813  Epidemiology of Covid-19 in a Long-Term Care F...   \n",
       "169814  A SARS-CoV-2 familial cluster infection reveal...   \n",
       "169817  Virusâvirus interactions impact the populati...   \n",
       "\n",
       "                                 doi       pmcid    pubmed_id      license  \\\n",
       "4231            10.1084/jem.20181308  PMC6888981  3.15586e+07  cc-by-nc-sa   \n",
       "4234    10.1371/journal.pone.0225576  PMC6890219  3.17946e+07        cc-by   \n",
       "4236      10.1038/s41598-019-54752-4  PMC6890765  3.17969e+07        cc-by   \n",
       "4237    10.1371/journal.pone.0224660  PMC6892547  3.18006e+07        cc-by   \n",
       "4246       10.1186/s13054-019-2646-8  PMC6898929  3.18105e+07        cc-by   \n",
       "...                              ...         ...          ...          ...   \n",
       "169809    10.1007/s13337-020-00610-1  PMC7283982          NaN        no-cc   \n",
       "169811            10.3390/jcm9061733         NaN  3.25127e+07          unk   \n",
       "169813         10.1056/nejmoa2005412  PMC7121761  3.22202e+07        no-cc   \n",
       "169814    10.1016/j.jiph.2020.05.018  PMC7250748  3.25055e+07        no-cc   \n",
       "169817       10.1073/pnas.1911083116  PMC6936719  3.18439e+07        cc-by   \n",
       "\n",
       "                                                 abstract publish_time  ...  \\\n",
       "4231    Resident memory T cells (T(RM) cells) are an i...   2019-12-02  ...   \n",
       "4234    As infectious disease outbreaks emerge, public...   2019-12-03  ...   \n",
       "4236    This work presents a simple one-pot protocol t...   2019-12-03  ...   \n",
       "4237    Advocates for a One Health approach recognize ...   2019-12-04  ...   \n",
       "4246    BACKGROUND: Clinical and epidemiological diffe...   2019-12-06  ...   \n",
       "...                                                   ...          ...  ...   \n",
       "169809  A local outbreak of initially unknown cause pn...   2020-06-10  ...   \n",
       "169811  Background: Since the confirmation of the firs...   2020-01-01  ...   \n",
       "169813  BACKGROUND: Long-term care facilities are high...   2020-03-27  ...   \n",
       "169814  Information on SARS-CoV-2 asymptomatic infecti...   2020-05-27  ...   \n",
       "169817  The human respiratory tract hosts a diverse co...   2019-12-26  ...   \n",
       "\n",
       "       who_covidence_id arxiv_id  \\\n",
       "4231                NaN      NaN   \n",
       "4234                NaN      NaN   \n",
       "4236                NaN      NaN   \n",
       "4237                NaN      NaN   \n",
       "4246                NaN      NaN   \n",
       "...                 ...      ...   \n",
       "169809          #592057      NaN   \n",
       "169811        #32512688      NaN   \n",
       "169813              NaN      NaN   \n",
       "169814              NaN      NaN   \n",
       "169817              NaN      NaN   \n",
       "\n",
       "                                           pdf_json_files  \\\n",
       "4231    document_parses/pdf_json/aa3858e3cf21baa00c6f6...   \n",
       "4234    document_parses/pdf_json/23d0641f1f78528bbf3fa...   \n",
       "4236    document_parses/pdf_json/9be8c80283a7fed59057d...   \n",
       "4237    document_parses/pdf_json/d5d29d1d48e1a4fe8f39d...   \n",
       "4246    document_parses/pdf_json/772046ceb62525b9f5c68...   \n",
       "...                                                   ...   \n",
       "169809  document_parses/pdf_json/07c638d72edcbd6f41a84...   \n",
       "169811                                                NaN   \n",
       "169813  document_parses/pdf_json/76ca0fe38a7e8bc1b730b...   \n",
       "169814  document_parses/pdf_json/24741265a77032e848afe...   \n",
       "169817  document_parses/pdf_json/75a2fe5ad9b6eb8caf303...   \n",
       "\n",
       "                                      pmc_json_files  \\\n",
       "4231    document_parses/pmc_json/PMC6888981.xml.json   \n",
       "4234    document_parses/pmc_json/PMC6890219.xml.json   \n",
       "4236    document_parses/pmc_json/PMC6890765.xml.json   \n",
       "4237    document_parses/pmc_json/PMC6892547.xml.json   \n",
       "4246    document_parses/pmc_json/PMC6898929.xml.json   \n",
       "...                                              ...   \n",
       "169809  document_parses/pmc_json/PMC7283982.xml.json   \n",
       "169811                                           NaN   \n",
       "169813  document_parses/pmc_json/PMC7121761.xml.json   \n",
       "169814  document_parses/pmc_json/PMC7250748.xml.json   \n",
       "169817  document_parses/pmc_json/PMC6936719.xml.json   \n",
       "\n",
       "                                                      url        s2_id  \\\n",
       "4231    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6...          NaN   \n",
       "4234    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6...          NaN   \n",
       "4236    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6...          NaN   \n",
       "4237    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6...          NaN   \n",
       "4246    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6...          NaN   \n",
       "...                                                   ...          ...   \n",
       "169809         https://doi.org/10.1007/s13337-020-00610-1  219554233.0   \n",
       "169811  https://doi.org/10.3390/jcm9061733; https://ww...  219553115.0   \n",
       "169813  https://www.ncbi.nlm.nih.gov/pubmed/32220208/;...  214683161.0   \n",
       "169814  https://www.sciencedirect.com/science/article/...  218891131.0   \n",
       "169817  https://doi.org/10.1073/pnas.1911083116; https...  209388856.0   \n",
       "\n",
       "           preprint    year  month   year_month  \n",
       "4231    Peer-Review  2019.0   12.0  2019.0-12.0  \n",
       "4234    Peer-Review  2019.0   12.0  2019.0-12.0  \n",
       "4236    Peer-Review  2019.0   12.0  2019.0-12.0  \n",
       "4237    Peer-Review  2019.0   12.0  2019.0-12.0  \n",
       "4246    Peer-Review  2019.0   12.0  2019.0-12.0  \n",
       "...             ...     ...    ...          ...  \n",
       "169809  Peer-Review  2020.0    6.0   2020.0-6.0  \n",
       "169811  Peer-Review  2020.0    1.0   2020.0-1.0  \n",
       "169813  Peer-Review  2020.0    3.0   2020.0-3.0  \n",
       "169814  Peer-Review  2020.0    5.0   2020.0-5.0  \n",
       "169817  Peer-Review  2019.0   12.0  2019.0-12.0  \n",
       "\n",
       "[49511 rows x 23 columns]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "df1=df['source_x']\n",
    "def preprint(a):\n",
    "\n",
    "    if 'BioRxiv' in a :\n",
    "        return 'Preprint'\n",
    "    elif 'MedRxiv' in a:\n",
    "        return 'Preprint'\n",
    "    elif 'ArXiv' in a:\n",
    "        return 'Preprint'\n",
    "    else:\n",
    "        return 'Peer-Review'\n",
    "    \n",
    "a=[preprint(n) for n in df1]\n",
    "\n",
    "df_abs = pd.DataFrame(a,columns =['preprint'])  \n",
    "df_abs\n",
    "df['preprint']=df_abs\n",
    "df_19=df[(df['publish_time'] > '2019-12-01')]\n",
    "\n",
    "df['publish_time'] = pd.to_datetime(df['publish_time'], errors='coerce')\n",
    "df_19['year'] = df['publish_time'].dt.year\n",
    "df_19['month'] = df['publish_time'].dt.month\n",
    "\n",
    "df_19 ['year_month']= df_19['year'].map(str) + '-' + df_19['month'].map(str)\n",
    "df_19 = df_19.dropna(subset=['abstract'])\n",
    "df_19"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_19"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "sns.set_context(\"talk\")\n",
    "sns.set_style('darkgrid')\n",
    "\n",
    "g = sns.catplot(x=\"year_month\", hue=\"preprint\", \n",
    "\n",
    "                data=df_19, kind=\"count\",\n",
    "\n",
    "                height=5, aspect=5)\n",
    "\n",
    "g.savefig(\"publications_years.png\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "\n",
    "##Creating a list of stop words and adding custom stopwords\n",
    "stop_words = set(stopwords.words(\"english\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "\n",
    "#nltk.download('wordnet')\n",
    "\n",
    "stop_words = set(stopwords.words(\"english\"))\n",
    "new_words = [\"using\", \"show\", 'covid','patient','disease','patients','treatment','viral','data','including','coronavirus','health','study',\"result\",'unknown','2555','method','infection','day','case','however','moreover','conclusion','virus','patient', \"large\", \"also\", \"iv\", \"one\",'nan', \"new\", \"previously\", \"shown\",'recently','promising']\n",
    "stop_words = stop_words.union(new_words)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "len(df_19['abstract'])\n",
    "dataset=df_19"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "\n",
    "#text = dataset['abstract'].translate(string.maketrans(“”,””), string.punctuation)\n",
    "import string\n",
    "#dataset['abstract_']=dataset['abstract'].str.replace('[{}]'.format(string.punctuation), '')\n",
    "dataset['abstract_'] = dataset['abstract'].astype(str)\n",
    "corpus = []\n",
    "for i in range(0, len(dataset['abstract_'])):\n",
    "    #Remove punctuations\n",
    "    text = dataset['abstract_'].iloc[i]\n",
    "    \n",
    "    #Convert to lowercase\n",
    "    text = text.lower()\n",
    "    \n",
    "    #remove tags\n",
    "    #text=re.sub(\"&lt;/?.*?&gt;\",\" &lt;&gt; \",text)\n",
    "    \n",
    "    # remove special characters and digits\n",
    "   # text=re.sub(\"(\\\\d|\\\\W)+\",\" \",text)\n",
    "    \n",
    "    ##Convert to list from string\n",
    "    text = text.split() \n",
    "    \n",
    "    ##Stemming\n",
    "    ps=PorterStemmer()    #Lemmatisation\n",
    "    lem = WordNetLemmatizer()\n",
    "    text = [lem.lemmatize(word) for word in text if not word in  \n",
    "            stop_words] \n",
    "    text = \" \".join(text)\n",
    "    corpus.append(text)\n",
    "\n",
    "#len(corpus)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'sequential recommendation leverage temporal information usersâ\\x80\\x99 transaction transition dependency better inferring user preference, become increasingly popular academic research practical applications. short-term transition dependency contain information partial item orders, long-term transition dependency infer long-range user preference, two dependency mutually restrictive complementary. although work investigates unifying long-term short-term dependency better performance, still neglect fact short-term interaction multi-folds, either individual-level interaction union-level interactions. existing sequential recommendation mainly focus userâ\\x80\\x99s individual (i.e., individual-level) interaction ignore important collective influence union-level. since union-level interaction reflect human decision made based multiple item he/she already interacted, ignoring interaction disability capturing collective influence items. alleviate issue, proposed joint relational dependency learning (jrd-l) sequential recommendation exploit long-term short-term preference individual-level union-level. specifically, jrd-l combine long-term user preference short-term interest measuring short-term pair relation individual-level union-level. moreover, jrd-l alleviate sparsity problem union-level interaction adding descriptive detail item, carried individual-level relations. extensive numerical experiment demonstrate jrd-l outperforms state-of-the-art baseline sequential recommendation.'"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#dataset['corpus']\n",
    "\n",
    "corpus[2010]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>cord_uid</th>\n",
       "      <th>sha</th>\n",
       "      <th>source_x</th>\n",
       "      <th>title</th>\n",
       "      <th>doi</th>\n",
       "      <th>pmcid</th>\n",
       "      <th>pubmed_id</th>\n",
       "      <th>license</th>\n",
       "      <th>abstract</th>\n",
       "      <th>publish_time</th>\n",
       "      <th>...</th>\n",
       "      <th>pdf_json_files</th>\n",
       "      <th>pmc_json_files</th>\n",
       "      <th>url</th>\n",
       "      <th>s2_id</th>\n",
       "      <th>preprint</th>\n",
       "      <th>year</th>\n",
       "      <th>month</th>\n",
       "      <th>year_month</th>\n",
       "      <th>abstract_</th>\n",
       "      <th>corpus</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>169809</th>\n",
       "      <td>vbw0wbn1</td>\n",
       "      <td>07c638d72edcbd6f41a84d30023b0cfd864c3d68</td>\n",
       "      <td>PMC; WHO</td>\n",
       "      <td>Statistical analysis and visualization of the ...</td>\n",
       "      <td>10.1007/s13337-020-00610-1</td>\n",
       "      <td>PMC7283982</td>\n",
       "      <td>NaN</td>\n",
       "      <td>no-cc</td>\n",
       "      <td>A local outbreak of initially unknown cause pn...</td>\n",
       "      <td>2020-06-10</td>\n",
       "      <td>...</td>\n",
       "      <td>document_parses/pdf_json/07c638d72edcbd6f41a84...</td>\n",
       "      <td>document_parses/pmc_json/PMC7283982.xml.json</td>\n",
       "      <td>https://doi.org/10.1007/s13337-020-00610-1</td>\n",
       "      <td>219554233.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>2020.0-6.0</td>\n",
       "      <td>A local outbreak of initially unknown cause pn...</td>\n",
       "      <td>local outbreak initially cause pneumonia detec...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>169811</th>\n",
       "      <td>7dqr5adm</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Medline; WHO</td>\n",
       "      <td>A cohort of patients with COVID-19 in a major ...</td>\n",
       "      <td>10.3390/jcm9061733</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.25127e+07</td>\n",
       "      <td>unk</td>\n",
       "      <td>Background: Since the confirmation of the firs...</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://doi.org/10.3390/jcm9061733; https://ww...</td>\n",
       "      <td>219553115.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>2020.0-1.0</td>\n",
       "      <td>Background: Since the confirmation of the firs...</td>\n",
       "      <td>background: since confirmation first infected ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>169813</th>\n",
       "      <td>ajqbljai</td>\n",
       "      <td>76ca0fe38a7e8bc1b730be50658fa9cb2eb7e4f2; e33a...</td>\n",
       "      <td>Medline; PMC</td>\n",
       "      <td>Epidemiology of Covid-19 in a Long-Term Care F...</td>\n",
       "      <td>10.1056/nejmoa2005412</td>\n",
       "      <td>PMC7121761</td>\n",
       "      <td>3.22202e+07</td>\n",
       "      <td>no-cc</td>\n",
       "      <td>BACKGROUND: Long-term care facilities are high...</td>\n",
       "      <td>2020-03-27</td>\n",
       "      <td>...</td>\n",
       "      <td>document_parses/pdf_json/76ca0fe38a7e8bc1b730b...</td>\n",
       "      <td>document_parses/pmc_json/PMC7121761.xml.json</td>\n",
       "      <td>https://www.ncbi.nlm.nih.gov/pubmed/32220208/;...</td>\n",
       "      <td>214683161.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>2020.0-3.0</td>\n",
       "      <td>BACKGROUND: Long-term care facilities are high...</td>\n",
       "      <td>background: long-term care facility high-risk ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>169814</th>\n",
       "      <td>gsktliyd</td>\n",
       "      <td>24741265a77032e848afe0cd1745adda124818be</td>\n",
       "      <td>Elsevier; Medline; PMC</td>\n",
       "      <td>A SARS-CoV-2 familial cluster infection reveal...</td>\n",
       "      <td>10.1016/j.jiph.2020.05.018</td>\n",
       "      <td>PMC7250748</td>\n",
       "      <td>3.25055e+07</td>\n",
       "      <td>no-cc</td>\n",
       "      <td>Information on SARS-CoV-2 asymptomatic infecti...</td>\n",
       "      <td>2020-05-27</td>\n",
       "      <td>...</td>\n",
       "      <td>document_parses/pdf_json/24741265a77032e848afe...</td>\n",
       "      <td>document_parses/pmc_json/PMC7250748.xml.json</td>\n",
       "      <td>https://www.sciencedirect.com/science/article/...</td>\n",
       "      <td>218891131.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>5.0</td>\n",
       "      <td>2020.0-5.0</td>\n",
       "      <td>Information on SARS-CoV-2 asymptomatic infecti...</td>\n",
       "      <td>information sars-cov-2 asymptomatic infectivit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>169817</th>\n",
       "      <td>9svgq9f1</td>\n",
       "      <td>75a2fe5ad9b6eb8caf30399b9440f7dd610a32d3; 4461...</td>\n",
       "      <td>Medline; PMC</td>\n",
       "      <td>Virusâvirus interactions impact the populati...</td>\n",
       "      <td>10.1073/pnas.1911083116</td>\n",
       "      <td>PMC6936719</td>\n",
       "      <td>3.18439e+07</td>\n",
       "      <td>cc-by</td>\n",
       "      <td>The human respiratory tract hosts a diverse co...</td>\n",
       "      <td>2019-12-26</td>\n",
       "      <td>...</td>\n",
       "      <td>document_parses/pdf_json/75a2fe5ad9b6eb8caf303...</td>\n",
       "      <td>document_parses/pmc_json/PMC6936719.xml.json</td>\n",
       "      <td>https://doi.org/10.1073/pnas.1911083116; https...</td>\n",
       "      <td>209388856.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2019.0</td>\n",
       "      <td>12.0</td>\n",
       "      <td>2019.0-12.0</td>\n",
       "      <td>The human respiratory tract hosts a diverse co...</td>\n",
       "      <td>human respiratory tract host diverse community...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows × 25 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        cord_uid                                                sha  \\\n",
       "169809  vbw0wbn1           07c638d72edcbd6f41a84d30023b0cfd864c3d68   \n",
       "169811  7dqr5adm                                                NaN   \n",
       "169813  ajqbljai  76ca0fe38a7e8bc1b730be50658fa9cb2eb7e4f2; e33a...   \n",
       "169814  gsktliyd           24741265a77032e848afe0cd1745adda124818be   \n",
       "169817  9svgq9f1  75a2fe5ad9b6eb8caf30399b9440f7dd610a32d3; 4461...   \n",
       "\n",
       "                      source_x  \\\n",
       "169809                PMC; WHO   \n",
       "169811            Medline; WHO   \n",
       "169813            Medline; PMC   \n",
       "169814  Elsevier; Medline; PMC   \n",
       "169817            Medline; PMC   \n",
       "\n",
       "                                                    title  \\\n",
       "169809  Statistical analysis and visualization of the ...   \n",
       "169811  A cohort of patients with COVID-19 in a major ...   \n",
       "169813  Epidemiology of Covid-19 in a Long-Term Care F...   \n",
       "169814  A SARS-CoV-2 familial cluster infection reveal...   \n",
       "169817  Virusâvirus interactions impact the populati...   \n",
       "\n",
       "                               doi       pmcid    pubmed_id license  \\\n",
       "169809  10.1007/s13337-020-00610-1  PMC7283982          NaN   no-cc   \n",
       "169811          10.3390/jcm9061733         NaN  3.25127e+07     unk   \n",
       "169813       10.1056/nejmoa2005412  PMC7121761  3.22202e+07   no-cc   \n",
       "169814  10.1016/j.jiph.2020.05.018  PMC7250748  3.25055e+07   no-cc   \n",
       "169817     10.1073/pnas.1911083116  PMC6936719  3.18439e+07   cc-by   \n",
       "\n",
       "                                                 abstract publish_time  ...  \\\n",
       "169809  A local outbreak of initially unknown cause pn...   2020-06-10  ...   \n",
       "169811  Background: Since the confirmation of the firs...   2020-01-01  ...   \n",
       "169813  BACKGROUND: Long-term care facilities are high...   2020-03-27  ...   \n",
       "169814  Information on SARS-CoV-2 asymptomatic infecti...   2020-05-27  ...   \n",
       "169817  The human respiratory tract hosts a diverse co...   2019-12-26  ...   \n",
       "\n",
       "                                           pdf_json_files  \\\n",
       "169809  document_parses/pdf_json/07c638d72edcbd6f41a84...   \n",
       "169811                                                NaN   \n",
       "169813  document_parses/pdf_json/76ca0fe38a7e8bc1b730b...   \n",
       "169814  document_parses/pdf_json/24741265a77032e848afe...   \n",
       "169817  document_parses/pdf_json/75a2fe5ad9b6eb8caf303...   \n",
       "\n",
       "                                      pmc_json_files  \\\n",
       "169809  document_parses/pmc_json/PMC7283982.xml.json   \n",
       "169811                                           NaN   \n",
       "169813  document_parses/pmc_json/PMC7121761.xml.json   \n",
       "169814  document_parses/pmc_json/PMC7250748.xml.json   \n",
       "169817  document_parses/pmc_json/PMC6936719.xml.json   \n",
       "\n",
       "                                                      url        s2_id  \\\n",
       "169809         https://doi.org/10.1007/s13337-020-00610-1  219554233.0   \n",
       "169811  https://doi.org/10.3390/jcm9061733; https://ww...  219553115.0   \n",
       "169813  https://www.ncbi.nlm.nih.gov/pubmed/32220208/;...  214683161.0   \n",
       "169814  https://www.sciencedirect.com/science/article/...  218891131.0   \n",
       "169817  https://doi.org/10.1073/pnas.1911083116; https...  209388856.0   \n",
       "\n",
       "           preprint    year month   year_month  \\\n",
       "169809  Peer-Review  2020.0   6.0   2020.0-6.0   \n",
       "169811  Peer-Review  2020.0   1.0   2020.0-1.0   \n",
       "169813  Peer-Review  2020.0   3.0   2020.0-3.0   \n",
       "169814  Peer-Review  2020.0   5.0   2020.0-5.0   \n",
       "169817  Peer-Review  2019.0  12.0  2019.0-12.0   \n",
       "\n",
       "                                                abstract_  \\\n",
       "169809  A local outbreak of initially unknown cause pn...   \n",
       "169811  Background: Since the confirmation of the firs...   \n",
       "169813  BACKGROUND: Long-term care facilities are high...   \n",
       "169814  Information on SARS-CoV-2 asymptomatic infecti...   \n",
       "169817  The human respiratory tract hosts a diverse co...   \n",
       "\n",
       "                                                   corpus  \n",
       "169809  local outbreak initially cause pneumonia detec...  \n",
       "169811  background: since confirmation first infected ...  \n",
       "169813  background: long-term care facility high-risk ...  \n",
       "169814  information sars-cov-2 asymptomatic infectivit...  \n",
       "169817  human respiratory tract host diverse community...  \n",
       "\n",
       "[5 rows x 25 columns]"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "corpus[1050]\n",
    "dataset['corpus']=corpus\n",
    "\n",
    "dataset.tail()\n",
    "\n"
   ]
  },
  {
   "cell_type": "raw",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "count                                                 49511\n",
       "unique                                                42783\n",
       "top       An amendment to this paper has been published ...\n",
       "freq                                                     40\n",
       "Name: abstract, dtype: object"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dataset['abstract'].describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>cord_uid</th>\n",
       "      <th>sha</th>\n",
       "      <th>source_x</th>\n",
       "      <th>title</th>\n",
       "      <th>doi</th>\n",
       "      <th>pmcid</th>\n",
       "      <th>pubmed_id</th>\n",
       "      <th>license</th>\n",
       "      <th>abstract</th>\n",
       "      <th>publish_time</th>\n",
       "      <th>...</th>\n",
       "      <th>pdf_json_files</th>\n",
       "      <th>pmc_json_files</th>\n",
       "      <th>url</th>\n",
       "      <th>s2_id</th>\n",
       "      <th>preprint</th>\n",
       "      <th>year</th>\n",
       "      <th>month</th>\n",
       "      <th>year_month</th>\n",
       "      <th>abstract_</th>\n",
       "      <th>corpus</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>72754</th>\n",
       "      <td>hrmx9eav</td>\n",
       "      <td>23ec3684bc9bab1e88497d714cf3a67b8f99f50f</td>\n",
       "      <td>BioRxiv</td>\n",
       "      <td>Modeling the structure of the frameshift stimu...</td>\n",
       "      <td>10.1101/2020.06.08.141150</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>biorxiv</td>\n",
       "      <td>The coronavirus causing the COVID-19 pandemic,...</td>\n",
       "      <td>2020-06-11</td>\n",
       "      <td>...</td>\n",
       "      <td>document_parses/pdf_json/23ec3684bc9bab1e88497...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://doi.org/10.1101/2020.06.08.141150</td>\n",
       "      <td>219636821.0</td>\n",
       "      <td>Preprint</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>2020.0-6.0</td>\n",
       "      <td>The coronavirus causing the COVID-19 pandemic,...</td>\n",
       "      <td>causing covid-19 pandemic, sars-cov-2, us â1...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>135808</th>\n",
       "      <td>3jmy9dy3</td>\n",
       "      <td>1a9f79f247a64d013a2644ea05151d9b39524bc8</td>\n",
       "      <td>Elsevier; Medline; PMC</td>\n",
       "      <td>Running a Radiation Oncology Department at the...</td>\n",
       "      <td>10.1016/j.adro.2020.03.003</td>\n",
       "      <td>PMC7102610</td>\n",
       "      <td>32292837</td>\n",
       "      <td>els-covid</td>\n",
       "      <td>Abstract Starting from Wuhan, China, SARS-CoV-...</td>\n",
       "      <td>2020-03-20</td>\n",
       "      <td>...</td>\n",
       "      <td>document_parses/pdf_json/1a9f79f247a64d013a264...</td>\n",
       "      <td>document_parses/pmc_json/PMC7102610.xml.json</td>\n",
       "      <td>https://www.sciencedirect.com/science/article/...</td>\n",
       "      <td>214729950.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>2020.0-3.0</td>\n",
       "      <td>Abstract Starting from Wuhan, China, SARS-CoV-...</td>\n",
       "      <td>abstract starting wuhan, china, sars-cov-2 cat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>66911</th>\n",
       "      <td>6jfvs677</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WHO</td>\n",
       "      <td>Recommendation for the diagnosis and treatment...</td>\n",
       "      <td>10.7499/j.issn.1008-8830.2020.02.003</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>unk</td>\n",
       "      <td>Since December 2019, a cluster of patients hav...</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://doi.org/10.7499/j.issn.1008-8830.2020....</td>\n",
       "      <td>216406312.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>2020.0-1.0</td>\n",
       "      <td>Since December 2019, a cluster of patients hav...</td>\n",
       "      <td>since december 2019, cluster diagnosed infecte...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89495</th>\n",
       "      <td>djxw2n23</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WHO</td>\n",
       "      <td>The Perception of COVID-19 among Italian Denti...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>unk</td>\n",
       "      <td>COVID-19 has severely impacted dentists, who a...</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>219991389.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>2020.0-1.0</td>\n",
       "      <td>COVID-19 has severely impacted dentists, who a...</td>\n",
       "      <td>covid-19 severely impacted dentists, great ris...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>68899</th>\n",
       "      <td>eqo1lrjv</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WHO</td>\n",
       "      <td>Randomization amid a pandemic - a critical app...</td>\n",
       "      <td>10.1111/voxs.12564</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>unk</td>\n",
       "      <td>Abstract The novel coronavirus disease (COVID-...</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://doi.org/10.1111/voxs.12564</td>\n",
       "      <td>219429421.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>2020.0-1.0</td>\n",
       "      <td>Abstract The novel coronavirus disease (COVID-...</td>\n",
       "      <td>abstract novel (covid-19) spreading rapidly, p...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>142017</th>\n",
       "      <td>f3w2gu8c</td>\n",
       "      <td>86c58960f3733a069909fe40cb2c20301e5f794b</td>\n",
       "      <td>Elsevier; Medline; PMC</td>\n",
       "      <td>Anaesthesia and COVID-19: infection control</td>\n",
       "      <td>10.1016/j.bja.2020.03.025</td>\n",
       "      <td>PMC7142687</td>\n",
       "      <td>32307115</td>\n",
       "      <td>els-covid</td>\n",
       "      <td>Summary The world is currently facing an unpre...</td>\n",
       "      <td>2020-04-08</td>\n",
       "      <td>...</td>\n",
       "      <td>document_parses/pdf_json/86c58960f3733a069909f...</td>\n",
       "      <td>document_parses/pmc_json/PMC7142687.xml.json</td>\n",
       "      <td>https://api.elsevier.com/content/article/pii/S...</td>\n",
       "      <td>215516074.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>2020.0-4.0</td>\n",
       "      <td>Summary The world is currently facing an unpre...</td>\n",
       "      <td>summary world currently facing unprecedented h...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57337</th>\n",
       "      <td>v88f9e7m</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Medline</td>\n",
       "      <td>Prudent public health intervention strategies ...</td>\n",
       "      <td>10.4103/ijmr.ijmr_504_20</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.22023e+07</td>\n",
       "      <td>unk</td>\n",
       "      <td>Background &amp; objectives :Coronavirus disease 2...</td>\n",
       "      <td>2020-03-23</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://doi.org/10.4103/ijmr.ijmr_504_20; http...</td>\n",
       "      <td>214616960.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>2020.0-3.0</td>\n",
       "      <td>Background &amp; objectives :Coronavirus disease 2...</td>\n",
       "      <td>background &amp; objective :coronavirus 2019 (covi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>109771</th>\n",
       "      <td>ib87gmr8</td>\n",
       "      <td>NaN</td>\n",
       "      <td>WHO</td>\n",
       "      <td>The application of privacy protection and arti...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>unk</td>\n",
       "      <td>Objective The outbreak of novel coronavirus ra...</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>215909872.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>2020.0-1.0</td>\n",
       "      <td>Objective The outbreak of novel coronavirus ra...</td>\n",
       "      <td>objective outbreak novel raised many problem a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>100485</th>\n",
       "      <td>uzgp7u1n</td>\n",
       "      <td>73eeae7a6d4b86c87623113ccadf6c018a6231de</td>\n",
       "      <td>ArXiv</td>\n",
       "      <td>Endpoints for randomized controlled clinical t...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>arxiv</td>\n",
       "      <td>Introduction: Endpoint choice for randomized c...</td>\n",
       "      <td>2020-06-09</td>\n",
       "      <td>...</td>\n",
       "      <td>document_parses/pdf_json/73eeae7a6d4b86c876231...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://arxiv.org/pdf/2006.10533v1.pdf</td>\n",
       "      <td>219793031.0</td>\n",
       "      <td>Preprint</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>2020.0-6.0</td>\n",
       "      <td>Introduction: Endpoint choice for randomized c...</td>\n",
       "      <td>introduction: endpoint choice randomized contr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38321</th>\n",
       "      <td>r4qnxp1z</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Medline</td>\n",
       "      <td>Effects of Slaughter Knife Sharpness on Blood ...</td>\n",
       "      <td>10.3390/ani10040579</td>\n",
       "      <td>NaN</td>\n",
       "      <td>3.22355e+07</td>\n",
       "      <td>unk</td>\n",
       "      <td>The sharpness of the knife used for slaughter ...</td>\n",
       "      <td>2020-03-30</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://doi.org/10.3390/ani10040579; https://w...</td>\n",
       "      <td>214769524.0</td>\n",
       "      <td>Peer-Review</td>\n",
       "      <td>2020.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>2020.0-3.0</td>\n",
       "      <td>The sharpness of the knife used for slaughter ...</td>\n",
       "      <td>sharpness knife used slaughter utmost importan...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>100 rows × 25 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        cord_uid                                       sha  \\\n",
       "72754   hrmx9eav  23ec3684bc9bab1e88497d714cf3a67b8f99f50f   \n",
       "135808  3jmy9dy3  1a9f79f247a64d013a2644ea05151d9b39524bc8   \n",
       "66911   6jfvs677                                       NaN   \n",
       "89495   djxw2n23                                       NaN   \n",
       "68899   eqo1lrjv                                       NaN   \n",
       "...          ...                                       ...   \n",
       "142017  f3w2gu8c  86c58960f3733a069909fe40cb2c20301e5f794b   \n",
       "57337   v88f9e7m                                       NaN   \n",
       "109771  ib87gmr8                                       NaN   \n",
       "100485  uzgp7u1n  73eeae7a6d4b86c87623113ccadf6c018a6231de   \n",
       "38321   r4qnxp1z                                       NaN   \n",
       "\n",
       "                      source_x  \\\n",
       "72754                  BioRxiv   \n",
       "135808  Elsevier; Medline; PMC   \n",
       "66911                      WHO   \n",
       "89495                      WHO   \n",
       "68899                      WHO   \n",
       "...                        ...   \n",
       "142017  Elsevier; Medline; PMC   \n",
       "57337                  Medline   \n",
       "109771                     WHO   \n",
       "100485                   ArXiv   \n",
       "38321                  Medline   \n",
       "\n",
       "                                                    title  \\\n",
       "72754   Modeling the structure of the frameshift stimu...   \n",
       "135808  Running a Radiation Oncology Department at the...   \n",
       "66911   Recommendation for the diagnosis and treatment...   \n",
       "89495   The Perception of COVID-19 among Italian Denti...   \n",
       "68899   Randomization amid a pandemic - a critical app...   \n",
       "...                                                   ...   \n",
       "142017        Anaesthesia and COVID-19: infection control   \n",
       "57337   Prudent public health intervention strategies ...   \n",
       "109771  The application of privacy protection and arti...   \n",
       "100485  Endpoints for randomized controlled clinical t...   \n",
       "38321   Effects of Slaughter Knife Sharpness on Blood ...   \n",
       "\n",
       "                                         doi       pmcid    pubmed_id  \\\n",
       "72754              10.1101/2020.06.08.141150         NaN          NaN   \n",
       "135808            10.1016/j.adro.2020.03.003  PMC7102610     32292837   \n",
       "66911   10.7499/j.issn.1008-8830.2020.02.003         NaN          NaN   \n",
       "89495                                    NaN         NaN          NaN   \n",
       "68899                     10.1111/voxs.12564         NaN          NaN   \n",
       "...                                      ...         ...          ...   \n",
       "142017             10.1016/j.bja.2020.03.025  PMC7142687     32307115   \n",
       "57337               10.4103/ijmr.ijmr_504_20         NaN  3.22023e+07   \n",
       "109771                                   NaN         NaN          NaN   \n",
       "100485                                   NaN         NaN          NaN   \n",
       "38321                    10.3390/ani10040579         NaN  3.22355e+07   \n",
       "\n",
       "          license                                           abstract  \\\n",
       "72754     biorxiv  The coronavirus causing the COVID-19 pandemic,...   \n",
       "135808  els-covid  Abstract Starting from Wuhan, China, SARS-CoV-...   \n",
       "66911         unk  Since December 2019, a cluster of patients hav...   \n",
       "89495         unk  COVID-19 has severely impacted dentists, who a...   \n",
       "68899         unk  Abstract The novel coronavirus disease (COVID-...   \n",
       "...           ...                                                ...   \n",
       "142017  els-covid  Summary The world is currently facing an unpre...   \n",
       "57337         unk  Background & objectives :Coronavirus disease 2...   \n",
       "109771        unk  Objective The outbreak of novel coronavirus ra...   \n",
       "100485      arxiv  Introduction: Endpoint choice for randomized c...   \n",
       "38321         unk  The sharpness of the knife used for slaughter ...   \n",
       "\n",
       "       publish_time  ...                                     pdf_json_files  \\\n",
       "72754    2020-06-11  ...  document_parses/pdf_json/23ec3684bc9bab1e88497...   \n",
       "135808   2020-03-20  ...  document_parses/pdf_json/1a9f79f247a64d013a264...   \n",
       "66911    2020-01-01  ...                                                NaN   \n",
       "89495    2020-01-01  ...                                                NaN   \n",
       "68899    2020-01-01  ...                                                NaN   \n",
       "...             ...  ...                                                ...   \n",
       "142017   2020-04-08  ...  document_parses/pdf_json/86c58960f3733a069909f...   \n",
       "57337    2020-03-23  ...                                                NaN   \n",
       "109771   2020-01-01  ...                                                NaN   \n",
       "100485   2020-06-09  ...  document_parses/pdf_json/73eeae7a6d4b86c876231...   \n",
       "38321    2020-03-30  ...                                                NaN   \n",
       "\n",
       "                                      pmc_json_files  \\\n",
       "72754                                            NaN   \n",
       "135808  document_parses/pmc_json/PMC7102610.xml.json   \n",
       "66911                                            NaN   \n",
       "89495                                            NaN   \n",
       "68899                                            NaN   \n",
       "...                                              ...   \n",
       "142017  document_parses/pmc_json/PMC7142687.xml.json   \n",
       "57337                                            NaN   \n",
       "109771                                           NaN   \n",
       "100485                                           NaN   \n",
       "38321                                            NaN   \n",
       "\n",
       "                                                      url        s2_id  \\\n",
       "72754           https://doi.org/10.1101/2020.06.08.141150  219636821.0   \n",
       "135808  https://www.sciencedirect.com/science/article/...  214729950.0   \n",
       "66911   https://doi.org/10.7499/j.issn.1008-8830.2020....  216406312.0   \n",
       "89495                                                 NaN  219991389.0   \n",
       "68899                  https://doi.org/10.1111/voxs.12564  219429421.0   \n",
       "...                                                   ...          ...   \n",
       "142017  https://api.elsevier.com/content/article/pii/S...  215516074.0   \n",
       "57337   https://doi.org/10.4103/ijmr.ijmr_504_20; http...  214616960.0   \n",
       "109771                                                NaN  215909872.0   \n",
       "100485             https://arxiv.org/pdf/2006.10533v1.pdf  219793031.0   \n",
       "38321   https://doi.org/10.3390/ani10040579; https://w...  214769524.0   \n",
       "\n",
       "           preprint    year month  year_month  \\\n",
       "72754      Preprint  2020.0   6.0  2020.0-6.0   \n",
       "135808  Peer-Review  2020.0   3.0  2020.0-3.0   \n",
       "66911   Peer-Review  2020.0   1.0  2020.0-1.0   \n",
       "89495   Peer-Review  2020.0   1.0  2020.0-1.0   \n",
       "68899   Peer-Review  2020.0   1.0  2020.0-1.0   \n",
       "...             ...     ...   ...         ...   \n",
       "142017  Peer-Review  2020.0   4.0  2020.0-4.0   \n",
       "57337   Peer-Review  2020.0   3.0  2020.0-3.0   \n",
       "109771  Peer-Review  2020.0   1.0  2020.0-1.0   \n",
       "100485     Preprint  2020.0   6.0  2020.0-6.0   \n",
       "38321   Peer-Review  2020.0   3.0  2020.0-3.0   \n",
       "\n",
       "                                                abstract_  \\\n",
       "72754   The coronavirus causing the COVID-19 pandemic,...   \n",
       "135808  Abstract Starting from Wuhan, China, SARS-CoV-...   \n",
       "66911   Since December 2019, a cluster of patients hav...   \n",
       "89495   COVID-19 has severely impacted dentists, who a...   \n",
       "68899   Abstract The novel coronavirus disease (COVID-...   \n",
       "...                                                   ...   \n",
       "142017  Summary The world is currently facing an unpre...   \n",
       "57337   Background & objectives :Coronavirus disease 2...   \n",
       "109771  Objective The outbreak of novel coronavirus ra...   \n",
       "100485  Introduction: Endpoint choice for randomized c...   \n",
       "38321   The sharpness of the knife used for slaughter ...   \n",
       "\n",
       "                                                   corpus  \n",
       "72754   causing covid-19 pandemic, sars-cov-2, us â1...  \n",
       "135808  abstract starting wuhan, china, sars-cov-2 cat...  \n",
       "66911   since december 2019, cluster diagnosed infecte...  \n",
       "89495   covid-19 severely impacted dentists, great ris...  \n",
       "68899   abstract novel (covid-19) spreading rapidly, p...  \n",
       "...                                                   ...  \n",
       "142017  summary world currently facing unprecedented h...  \n",
       "57337   background & objective :coronavirus 2019 (covi...  \n",
       "109771  objective outbreak novel raised many problem a...  \n",
       "100485  introduction: endpoint choice randomized contr...  \n",
       "38321   sharpness knife used slaughter utmost importan...  \n",
       "\n",
       "[100 rows x 25 columns]"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_sub=dataset.sample(n = 100) \n",
    "df_sub"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "pandas.core.frame.DataFrame"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(df_sub)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_sub.to_csv('df_sub.csv',encoding='utf-8')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.feature_extraction.text import CountVectorizer\n",
    "\n",
    "import re\n",
    "\n",
    "cv=CountVectorizer(max_df=0.9,stop_words=stop_words, max_features=10000, ngram_range=(1,3))\n",
    "X=cv.fit_transform(genes_found)\n",
    "\n",
    "#list(cv.vocabulary_.keys())[:10]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Most frequently occuring words\n",
    "def get_top_n_words(corpus, n=None):\n",
    "    vec = CountVectorizer().fit(corpus)\n",
    "    bag_of_words = vec.transform(corpus)\n",
    "    sum_words = bag_of_words.sum(axis=0) \n",
    "    words_freq = [(word, sum_words[0, idx]) for word, idx in      \n",
    "                   vec.vocabulary_.items()]\n",
    "    words_freq =sorted(words_freq, key = lambda x: x[1], \n",
    "                       reverse=True)\n",
    "    return words_freq[:n]#Convert most freq words to dataframe for plotting bar plot\n",
    "top_words = get_top_n_words(genes_found, n=20)\n",
    "top_df = pd.DataFrame(top_words)\n",
    "top_df.columns=[\"Gene\", \"Freq\"]#Barplot of most freq words\n",
    "sns.set(rc={'figure.figsize':(13,8)})\n",
    "g = sns.barplot(x=\"Gene\", y=\"Freq\", data=top_df)\n",
    "g.set_xticklabels(g.get_xticklabels(), rotation=30)\n",
    "\n",
    "g.figure.savefig('most_frqu_gene.png')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.feature_extraction.text import TfidfTransformer\n",
    " \n",
    "tfidf_transformer=TfidfTransformer(smooth_idf=True,use_idf=True)\n",
    "tfidf_transformer.fit(X)# get feature names\n",
    "feature_names=cv.get_feature_names()\n",
    " \n",
    "# fetch document for which keywords needs to be extracted\n",
    "doc=corpus[1]\n",
    " \n",
    "#generate tf-idf for the given document\n",
    "tf_idf_vector=tfidf_transformer.transform(cv.transform([doc]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Function for sorting tf_idf in descending order\n",
    "from scipy.sparse import coo_matrix\n",
    "def sort_coo(coo_matrix):\n",
    "    tuples = zip(coo_matrix.col, coo_matrix.data)\n",
    "    return sorted(tuples, key=lambda x: (x[1], x[0]), reverse=True)\n",
    " \n",
    "def extract_topn_from_vector(feature_names, sorted_items, topn=10):\n",
    "    \"\"\"get the feature names and tf-idf score of top n items\"\"\"\n",
    "    \n",
    "    #use only topn items from vector\n",
    "    sorted_items = sorted_items[:topn]\n",
    " \n",
    "    score_vals = []\n",
    "    feature_vals = []\n",
    "    \n",
    "    # word index and corresponding tf-idf score\n",
    "    for idx, score in sorted_items:\n",
    "        \n",
    "        #keep track of feature name and its corresponding score\n",
    "        score_vals.append(round(score, 3))\n",
    "        feature_vals.append(feature_names[idx])\n",
    " \n",
    "    #create a tuples of feature,score\n",
    "    #results = zip(feature_vals,score_vals)\n",
    "    results= {}\n",
    "    for idx in range(len(feature_vals)):\n",
    "        results[feature_vals[idx]]=score_vals[idx]\n",
    "    \n",
    "    return results\n",
    "#sort the tf-idf vectors by descending order of scores\n",
    "sorted_items=sort_coo(tf_idf_vector.tocoo())#extract only the top n; n here is 10\n",
    "keywords=extract_topn_from_vector(feature_names,sorted_items,5)\n",
    " \n",
    "# now print the results\n",
    "print(\"\\nAbstract:\")\n",
    "print(doc)\n",
    "print(\"\\nKeywords:\")\n",
    "for k in keywords:\n",
    "    print(k,keywords[k])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.DataFrame(gene_names)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pyensembl\n",
    "ensembl = pyensembl.EnsemblRelease(99)\n",
    "ensembl\n",
    "#import sys\n",
    "#!{sys.executable} -m pip install pyensembl\n",
    "\n",
    "#!pyensembl install --release 75 99 --species human\n",
    "\n",
    "\n",
    "gene_names = ensembl.gene_names(contig=None, strand=None)#(contig=6, position=29945884)\n",
    "\n",
    "\n",
    "gene_names\n",
    "genes_low=[]\n",
    "\n",
    "for gene in gene_names:\n",
    "    l=gene.lower()\n",
    "    genes_low.append(l)\n",
    "    \n",
    "genes_low"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "gene_names\n",
    "genes_low=[]\n",
    "\n",
    "for gene in gene_names:\n",
    "    l=gene.lower()\n",
    "    print(l)\n",
    "    genes_low.append(l)\n",
    "    \n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Nanemd entity recognion for gene identification\n",
    "import PySysrev, spacy, random\n",
    "#TRAIN_DATA = PySysrev.processAnnotations(project_id=3144,label='GENE')\n",
    "\n",
    "#TRAIN_DATA[1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "nlp = spacy.blank('en')          # create a spacy model\n",
    "nlp.meta['name'] = 'gene'        # name the model 'gene'\n",
    "\n",
    "ner = nlp.create_pipe('ner')     # create an NER stage\n",
    "ner.add_label('GENE')            # add the label 'GENE' to the stage\n",
    "\n",
    "nlp.add_pipe(ner)                # put the pipe together\n",
    "optimizer = nlp.begin_training() # get an optimizer for training the model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "for itn in range(10):\n",
    "    random.shuffle(TRAIN_DATA)                     #shuffle examples \n",
    "    text = [item[0] for item in TRAIN_DATA]        #get training text items\n",
    "    annotations = [item[1] for item in TRAIN_DATA] #get training annotations\n",
    "    nlp.update(text, annotations, sgd=optimizer, drop=0.6)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "print('done')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#print('done')\n",
    "#nlp.to_disk(r\"C:\\Users\\mese4\\Documents\\The Data incubator\\project\\Spacy model\\gene_id_model\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "nlp=nlp.from_disk(r\"C:\\Users\\mese4\\Documents\\The Data incubator\\project\\Spacy model\\gene_id_model\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "doc = nlp(\"\"\"Epigenetic Silencing of the mutL homolog 1 (MLH1) Promoter in\n",
    "Relation to the Development of Gastric Cancer (GC) and its use as a\n",
    "Biomarker for Patients with Microsatellite, CD8 and HIF-1α, HIF1 for the Covid19 gene N, \n",
    "TRPM7 mmp8 MMP1 MMP2  and GAID2a, HNF4α, hnf4 ACE2  ORF1b  a nrf2 , Nucleoprotein1 , \n",
    "Nrf2 and brca2 Instability.\"\"\")\n",
    "\n",
    "\n",
    "from spacy import displacy\n",
    "displacy.render(doc,style=\"ent\",jupyter=True,options={'distance':140})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "4231      resident memory cell (t(rm) cells) important f...\n",
       "4234      infectious outbreak emerge, public agency ofte...\n",
       "4236      work present simple one-pot protocol achieve c...\n",
       "4237      advocate approach recognize global challenge r...\n",
       "4246      background: clinical epidemiological differenc...\n",
       "                                ...                        \n",
       "169811    background: since confirmation first infected ...\n",
       "169813    background: long-term care facility high-risk ...\n",
       "169814    information sars-cov-2 asymptomatic infectivit...\n",
       "169817    human respiratory tract host diverse community...\n",
       "169818                                                     \n",
       "Name: corpus, Length: 82306, dtype: object"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "text = dataset['corpus']\n",
    "#gene_listsof_ls=get_all_genes(text)\n",
    "\n",
    "#gene_listsof_ls[:20]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "import pickle\n",
    "DOC_genes = pickle.dumps(text)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['resident memory cell (t(rm) cells) important first-line defense respiratory pathogens, unique contribution lung t(rm) cell population protective immunity factor govern localization different compartment lung well understood. here, airway interstitial t(rm) cell distinct effector function cxcr6 control partitioning t(rm) cell within lung recruiting cd8 t(rm) cell airways. absence cxcr6 significantly decrease airway cd8 t(rm) cell due altered trafficking cxcr6(â\\x88\\x92/â\\x88\\x92) cell within lung, decreased survival airways. cxcl16, ligand cxcr6, localized primarily respiratory epithelium, mouse lacking cxcl16 decreased cd8 t(rm) cell airways. finally, blocking cxcl16 inhibited steady-state maintenance airway t(rm) cells. thus, cxcr6/cxcl16 signaling axis control localization t(rm) cell different compartment lung maintains airway t(rm) cells.',\n",
       " 'infectious outbreak emerge, public agency often enact vaccination social distancing measure slow transmission. success depends strategy resources, public adherence. individual willingness take precaution may influenced global factors, news media, local factors, infected family member friends. here, compare three mode epidemiological decision-making midst growing outbreak network-based mathematical model capture plausible heterogeneity human contact patterns. individual decide whether adopt recommended intervention based overall prevalence, proportion social contact infected, number social contact infected. strategy substantially mitigate transmission, vaccinating (or self isolating) based number infected acquaintance expected prevent infection requiring fewest intervention resources. unlike strategies, substantial herd effect, providing indirect protection fraction population.',\n",
       " 'work present simple one-pot protocol achieve core-doped shell nanohybrids comprising silver nanoparticles, curcumin thermoresponsive polymeric shell taking advantage reducing property phenolic curcumin substance ability decorate metallic surfaces. silver nanoparticles synthesized, via sodium citrate silver nitrate addition boiling aqueous solution curcumin, monomer surfactant. curcumin sodium citrate promoted silver nucleation, acting reducing stabilizing agents. curcumin-capped agnps enabled, adding radical polymerization initiator, assembling growing polymer chain around hydrophobic agnp surface. resultant core-doped shell nanohybrids exhibit plasmonic, luminescent volume thermoresponsive properties, improved possibility used successful therapeutic platforms. fact, possibility nanoconfine synergistic antioxidant, antiviral, antibacterial feature silver curcumin bioavailable hybrid pave way application biomedical field.',\n",
       " 'advocate approach recognize global challenge require multidisciplinary collaborative efforts. past publication looked interdisciplinary competency training collaboration, identified factor condition enable operational health. scoping review literature, multidisciplinary team researcher analyzed peer-reviewed publication describing multisectoral collaboration around infectious disease-related events. review identified 12 factor support successful collaboration coordinated response event across three levels: two individual factor (education & training prior experience & existing relationships), four organizational factor (organizational structures, culture, human resource and, communication), six network factor (network structures, relationships, leadership, management, available & accessible resources, political environment). researcher identified stage collaboration factor critical, organizing starting condition process-based factors. research found publication multisectoral collaboration event uniformly report success challenge collaboration rarely identify output outcome collaborative process. paper proposes common language framework enable uniform reporting, implementation, evaluation future collaborations.',\n",
       " 'background: clinical epidemiological difference acute respiratory distress syndrome (ards) present initiation mechanical ventilation [mv] (ards mv onset) develops course mv (ards mv onset) well understood. conducted observational five peruvian icu characterize difference ards mv onset mv onset identify risk factor development ards mv onset. methods: consecutively enrolled critically ill acute respiratory failure requiring least 24 h mechanical ventilation followed prospectively first 28 day compared baseline characteristic clinical outcome ards status. results: enrolled 1657 participant mv (mean age 60.0 years, 55% males) 334 (20.2%) ards mv onset 180 (10.9%) developed ards mv onset. average tidal volume initiation mv 8.7 ml/kg predicted body weight (pbw) participant ards mv onset, 8.6 ml/kg pbw developed ards mv onset, 8.5 ml/kg pbw never developed ards (p = 0.23). overall, 90-day mortality 56% 55% ards mv onset ards mv onset, respectively, compared 46% among never developed ards (p < 0.01). adult ards higher body mass index (bmi) without ards (27.3 v 26.5 kg/m(2), p < 0.01). higher peak pressure (adjusted interquartile = 1.51, 95% ci 1.21â\\x80\\x931.88), higher mean airway pressure (adjusted interquartile = 1.41, 95% ci 1.13â\\x80\\x931.76), higher positive end-expiratory pressure (adjusted interquartile = 1.29, 95% ci 1.10â\\x80\\x931.50) mv onset associated higher odds developing ards mv onset. conclusions: mechanically ventilated patients, 31% participant ards point icu stay. optimal lung-protective ventilation used majority patients. ards mv onset similar 90-day mortality ards mv onset. higher airway pressure mv onset, higher peep, higher bmi associated development ards mv onset.',\n",
       " 'background: increasing number aging individual chronic co-morbidities travel region falciparum malaria endemic. non-communicable disease leading risk factor death countries. thus, influence chronic disease outcome falciparum malaria issue major importance. aim present ass whether non-communicable disease increase risk severe imported falciparum malaria. methods: retrospective observational adult case imported falciparum malaria hospitalized 2001 2015 tertiary care charitã© university hospital, berlin, performed. results: total 536 adult (median age 37 years; 31.3% female) enrolled. these, 329 (61.4%) originated endemic countries, 207 (38.6%) non-endemic regions. criterion severe malaria fulfilled 68 (12.7%) cases. older age, lack previous malaria episodes, tourist, delayed presentation, well-characterized risk factor associated severe malaria univariate analysis. adjustment potential confounders hypertension (adjusted odds ratio aor, 3.06 95% confidence interval, ci 1.34â\\x80\\x937.02), cardiovascular disease (aor, 8.20 95% ci 2.30â\\x80\\x9329.22), dyslipidaemia (aor, 6.08 95% ci 1.13â\\x80\\x9332.88) individual disease associated severe multivariable logistic regression. hypertension proved independent risk factor among individual endemic (aor, 4.83, 95% ci 1.44â\\x80\\x9316.22) well non-endemic origin (aor, 3.60 95% ci 1.05â\\x80\\x9312.35). conclusions: imported falciparum malaria hypertension related disease risk factor severe disease.',\n",
       " 'background: marked paucity concerning aki sub-saharan africa, substantial burden trauma hiv. methods: prospective collected admitted multi-disciplinary icu south africa 2017. development aki (before icu admission) recorded renal recovery 90 day icu discharge determined. results: 849 admissions, mean age 42.5 year mean sap 3 score 48.1. comorbidities included hypertension (30.5%), hiv (32.6%), diabetes (13.3%), ckd (7.8%) active tuberculosis (6.2%). common reason admission trauma (26%). aki developed 497 (58.5%). male gender, illness severity, length stay, vasopressor drug sepsis independently associated aki. aki associated higher in-hospital mortality rate 31.8% v 7.23% without aki. age, active tuberculosis, higher sap 3 score, mechanical ventilation, vasopressor support sepsis associated increased adjusted odds ratio death. hiv independently associated aki hospital mortality. ckd developed 14 110 (12.7%) stage 3 aki; none dialysis-dependent. conclusions: prospective multidisciplinary icu cohort younger patients, aki common, often associated trauma addition traditional risk factor associated good functional renal recovery 90 day survivors. although hiv prevalence high associated higher mortality, related severity illness hiv status per se.',\n",
       " 'background: use extracorporeal membrane oxygenation (ecmo) awake, spontaneously breathing non-intubated (awake ecmo) may novel therapeutic strategy severe acute respiratory distress syndrome (ards) patients. purpose ass feasibility safety awake ecmo severe ards receiving prolonged ecmo (> 14 days). methods: describe experience 12 consecutive severe ards (age, 39.1 â± 16.4 years) supported awake ecmo wait native lung recovery prolonged ecmo july 2013 january 2018. outcome reported hospital mortality, ecmo-related complication physiological weaning invasive ventilation. results: received median 26.0 (15.5, 64.8) day total ecmo duration cohort. longest ecmo support duration 121 days. awake ecmo extubation implemented median 10.2(5.0, 42.9) day ecmo. awake ecmo associated increased morbidity. total invasive ventilation duration, length stay icu hospital cohort 14.0(12.0, 37.3) days, 33.0(22.3, 56.5) day 46.5(27.3, 84.8) days, respectively. hospital mortality rate 33.3% (4/12) cohort. survivor stable respiratory rate heart rate extubation compared non-survivors. conclusions: carefully selected patients, awake ecmo feasible safe strategy severe pulmonary ards receiving prolonged ecmo support wait native lung recovery.',\n",
       " 'objectives: feline immunodeficiency (fiv) feline leukaemia (felv) retrovirus affecting cat worldwide. objective estimate prevalence retrovirus domestic cat hungary characterise phylogenetic relationship fiv strains. methods: total 335 anticoagulated whole-blood sample obtained healthy ill cat population examined presence fiv felv two methods: elisa pcr. statistical analysis carried analyse obtained. sequencing phylogenetic analysis partial polymerase (pol) gene sequence performed describe circulating fiv subtypes. results: statistical analysis showed 11.8% 9.9% true prevalence felv fiv, respectively, elisa. apparent prevalence calculated pcr result 17.3% felv 13.1% fiv. phylogenetic analysis partial pol gene sequence obtained 22 fiv strain showed observed hungarian strain belonged fiv subtype b. strain grouped several monophyletic subgroup reflecting geographic location origin samples. overall mean genetic similarity analysed strain 98.2%. conclusion relevance: report first thorough overview prevalence felv fiv hungary, relatively high, give insight genetic diversity hungarian strain fiv.',\n",
       " 'background: ebolavirus (ebov) outbreaks, sporadic, cause tremendous morbidity mortality. therapeutic vaccine currently licensed; however, vaccine promise clinical trials. critical step towards development effective therapeutic better understanding factor govern host susceptibility pathogen. macrophage important cell population targeted replication, explore effect cytokine polarization macrophage infection. methods/main findings: utilized bsl2 ebov model virus, infectious, recombinant vesicular stomatitis encoding ebov glycoprotein (gp) (rvsv/ebov gp) place native glycoprotein. macrophage polarized towards m2-like anti-inflammatory state combined il-4 il-13 susceptible rvsv/ebov gp, wild-type vsv (rvsv/g), suggesting ebov gp-dependent entry event enhanced cytokines. examination rna expression known surface receptor bind internalize filovirus demonstrated il-4/il-13 stimulated expression c-type lectin receptor dc-sign human macrophage addition competitive inhibitor mannan abrogated il-4/il-13 enhanced infection. two murine dc-sign-like family members, signr3 signr5, upregulated il-4/il-13 murine macrophages, signr3 enhanced mannan-inhibited manner, suggesting murine signr3 play similar role human dc-sign. vivo il-4/il-13 administration significantly increased virus-mediated mortality mouse model transfer ex vivo il-4/il-13-treated murine peritoneal macrophage peritoneal cavity mouse enhanced pathogenesis. significance: study highlight ability macrophage polarization influence ebov gp-dependent replication vivo ex vivo, m2a polarization upregulating cell surface receptor expression thereby enhancing replication. finding provide increased understanding host factor macrophage governing susceptibility filovirus identify novel murine receptor mediating ebov entry.',\n",
       " 'child vulnerable risk air pollution, susceptibility acquiring chronic disease developing lungs. despite these, specific mask designed tested child available protect young common particulate air pollutant today. evaluated safety, fit comfort specially designed paediatric n95 mask optional micro ventilator (micro fan, mf) healthy child aged 7â\\x80\\x9314 years, randomized, two-period crossover design. subjectsâ\\x80\\x99 cardiorespiratory physiological measurement assessed different state physical activity different intervention (mask without mf). total 106 subject recruited july-august 2016. use mask without mf increased end-tidal co(2) (etco(2)) fractional concentration inspired co(2) (fico(2)) rest mild exertion, expected. use mask mf brought fico(2) level comparably closer baseline level without mask activities. mask, without mf, found well fitting, comfortable safe use child rest mild exertion. n95 mask tested offer start study paediatric population.',\n",
       " 'background: pristine carbon dot (cds) derived citric acid pyrolysis used variety biomedical research imaging drug delivery. however, potential cytotoxic effect pyrolysis temperature cell underexplored. address need, studied toxicity cd breast cancer cell mtt ldh assays. addition, investigated photo-induced cytotoxicity synthesized cd wide concentration range white light. results: result suggest little cytotoxicity cd 24 h exposure cells. high quantum yield cd caused significant toxicity cell highest concentration 2.0 1.5 mg/ml compared cd similar concentrations. synthesized cd entered cell without significant cytotoxicity. cd caused concentration- irradiation time-dependent photo-induced cytotoxicity. conclusion: optimization synthesis condition may help develop safe efficient cd imaging drug delivery.',\n",
       " 'background: thrombotic thrombocytopenic purpura autoimmune carry high mortality. report literature described relationship graf thrombotic thrombocytopenic purpura. present graf found biochemically clinically hyperthyroid concurrent thrombotic thrombocytopenic purpura. presentation: 30-year-old african american woman history hypertension family history graf diagnosed hyperthyroidism placed methimazole. presented hospital complaint progressive shortness breath dizziness. vital sign stable. evaluation, diagnosed thrombotic thrombocytopenic purpura, depending clinical laboratory results, found highly elevated free t4 suppressed thyroid-stimulating hormone. received multiple session plasmapheresis ultimately total thyroidectomy. patientâ\\x80\\x99s hospital course complicated pneumonia acute respiratory distress syndrome. platelet stabilized approximately 50,000/î¼l, adamts13 activity normalized despite multiple complications. ultimately cardiac arrest pulseless electrical activity died despite multiple attempt cardiopulmonary resuscitation. conclusion: graf uncommon trigger development thrombotic thrombocytopenic purpura, case reported thus far. therefore, clinician aware association appropriate clinical context comprehensively monitor hyperthyroid treatment.',\n",
       " 'recent years, outbreak infectious caused zika (zikv) posed major threat global public health, calling development therapeutic treat zikv disease. here, described different stage zikv life cycle summarized latest progress development small-molecule inhibitor zikv infection. discussed general strategy discovery small-molecule zikv inhibitors.',\n",
       " 'npl4 likely upstream factor recognizing lys48-linked polyubiquitylated substrate proteasomal degradation pathway yeast. along ufd1, npl4 form heterodimer (un), function cofactor cdc48 atpase. here, report crystal structure yeast npl4 complex lys48-linked diubiquitin npl4-binding motif ufd1. distal proximal ubiquitin moiety lys48-linked diubiquitin primarily interact c-terminal helix n-terminal loop npl4 c-terminal domain (ctd), respectively. mutational analysis suggests ctd contributes linkage selectivity initial binding ubiquitin chains. ufd1 occupies hydrophobic groove mpr1/pad1 n-terminal (mpn) domain npl4, corresponds catalytic groove mpn domain jab1/mpn/mov34 metalloenzyme (jamm)-family deubiquitylating enzyme. provides important structural insight polyubiquitin chain recognition cdc48â\\x80\\x93un complex assembly.',\n",
       " 'rotavirus (rv) replicates round-shaped cytoplasmic factories, although assemble remains unknown. rv infection, nsp5 undergoes hyperphosphorylation, primed phosphorylation single serine residue. role posttranslational modification formation viroplasms impact replication remain obscure. here, investigated role nsp5 rv taking advantage modified fully tractable reverse-genetics system. trans-complementing cell line stably producing nsp5 used generate characterize several recombinant rotavirus (rrvs) mutation nsp5. demonstrate rrv lacking nsp5 completely unable assemble viroplasms replicate, confirming pivotal role rotavirus replication. number mutant impaired nsp5 phosphorylation generated interrogate function posttranslational modification assembly replication-competent viroplasms. showed rrv mutant strain exhibited impaired replication ability assemble round-shaped viroplasms ma104 cells. furthermore, investigated mechanism nsp5 hyperphosphorylation rv nsp5 phosphorylation-negative rrv strains, well ma104-derived stable transfectant cell line expressing either wild-type nsp5 selected nsp5 deletion mutants. result indicate nsp5 hyperphosphorylation crucial step assembly round-shaped viroplasms, highlighting key role c-terminal tail nsp5 formation replication-competent factories. complex nsp5 phosphorylation cascade may serve paradigm assembly functional factory rna viruses. importance rotavirus (rv) double-stranded rna genome replicated packaged progeny cytoplasmic structure termed viroplasms. nonstructural protein nsp5, undergoes complex hyperphosphorylation process rv infection, required formation virus-induced organelles. however, role viroplasm formation rv replication never directly assessed due lack fully tractable reverse-genetics (rg) system rotaviruses. here, novel application developed rg system establishing stable trans-complementing nsp5-producing cell line required rescue rotavirus mutation nsp5. approach allowed u provide first direct evidence pivotal role protein rv replication. furthermore, recombinant rv mutants, shed light molecular mechanism nsp5 hyperphosphorylation involvement assembly maturation replication-competent viroplasms.',\n",
       " 'acute respiratory distress syndrome (ards) devastating hypoxemic respiratory failure, characterized disruption alveolar-capillary membrane barrier. current management ards remains supportive, lung-protective ventilation conservative fluid strategy. mesenchymal stem cell (mscs) emerged potentially attractive candidate management ards facilitating lung tissue regeneration repair releasing paracrine soluble factors. last decade, variety strategy emerged optimize msc-based therapy. among these, strategy genetically modified msc received increased attention due distinct advantage, conferring incremental migratory capacity and, enhancing anti-inflammatory, immunomodulatory, angiogenic, antifibrotic effect cell numerous preclinical ards models, may turn provide additional benefit management ards. here, provide overview recent study testing efficacy genetically modified msc preclinical model ards.',\n",
       " 'mortality rate hemorrhagic african swine fever (asf), target domestic pig wild boar caused african swine fever (asfv), reach 100%. since first confirmed asf outbreak china 3 august 2018, 156 asf outbreak detected 32 provinces. 1,170,000 pig culled order halt spread. effective vaccine present molecular diagnosis technology trade-off sensitivity, specificity, cost speed, none cater perfectly asf control. thus, technology overcomes need laboratory facilities, relatively low cost, rapidly sensitively detects asfv would highly valuable. here, describe raa-cas12a-based system combine recombinase aided amplification (raa) crispr/cas12a asfv detection. fluorescence intensity readout system detected asfv p72 gene level low 10 am. on-site asfv detection, lateral-flow strip readout introduced first time raa-cas12a based system (named cords, cas12a-based on-site rapid detection system). used cord detect target dna highly specifically lateral-flow strip readout assay displayed cross-reactivity 13 swine virus classical swine fever (csf). cord could identify asfv dna target femtomolar sensitivity hour 37â°c, requires incubator. ease use, reagent cord lyophilized three tube remained sensitivity stored 4â°c least 7 days. thus, cord provide rapid, sensitive easily operable asfv on-site detection. lyophilized cord withstand long-term transportation storage, ready field-based applications.',\n",
       " 'anaplasma phagocytophilum agent tick-borne fever, equine, canine human granulocytic anaplasmosis. common route a. phagocytophilum transmission tick bite, main vector europe ixodes ricinus. despite apparently ubiquitous presence pathogen a. phagocytophilum tick various wild domestic animal europe, date published clinical case human granulocytic anaplasmosis (hga) remain rare compared worldwide status. unclear reflects epidemiological dynamic human europe underdiagnosed underreported. epidemiologic study europe suggested increased occupational risk forestry workers, hunters, veterinarians, farmer tick-bite history living endemic areas. although overall genetic diversity a. phagocytophilum europe higher usa, strain responsible human infection related continents. however, genetic variability assessment difference pathogenicity infectivity strain various host insufficiently explored date. european hga case presented mild infection, common clinical sign pyrexia, headache, myalgia arthralgia. diagnosis hga usa recommended based clinical sign patientâ\\x80\\x99s history later confirmed specialized laboratory tests. however, europe since majority case presenting mild infection, laboratory test may performed order avoid antibiotic overuse. drug choice hga doxycycline potential serious complication instituted clinical suspicion alone.',\n",
       " 'tick-borne nairoviruses (order bunyavirales) encode ovarian tumor domain protease (otu) suppresses innate immune response reversing post-translational modification protein ubiquitin (ub) interferon-stimulated gene product 15 (isg15). ub highly conserved across eukaryotes, whereas isg15 present vertebrate show substantial sequence diversity. prior attempt address effect isg15 diversity protein-isg15 interaction focused single speciesâ\\x80\\x99 isg15 limited selection nairovirus otus. gain complete perspective otu-isg15 interactions, biochemically assessed relative activity 14 diverse nairovirus otus 12 speciesâ\\x80\\x99 isg15 found isg15 activity predominantly restricted particular nairovirus lineage reflecting, general, known virus-host associations. uncover underlying molecular factor driving otus affinity isg15, x-ray crystal structure kupe ganjam otus bound sheep isg15 solved compared complex crimean-congo hemorrhagic fever erve otus bound human mouse isg15, respectively. mutational structural analysis seven residue isg15 identified predominantly influence isg15 specie specificity among nairovirus otus. additionally, otu residue identified influence isg15 preference, suggesting potential otus adapt different host isg15s. finding provide foundation develop research method trace nairovirus-host relationship delineate full impact isg15 diversity nairovirus infection.',\n",
       " 'background: herpesviridae reactivation among non-immunocompromised critically ill associated impaired prognosis, especially acute respiratory distress syndrome (ards). however, little known herpes simplex (hsv) cytomegalovirus (cmv) reactivation occurring severe ards veno-venous extracorporeal membrane oxygenation (ecmo). tried determine frequency herpesviridae reactivation impact patientsâ\\x80\\x99 prognosis ecmo severe ards. results: 5-year period, 123 non-immunocompromised severe ards requiring veno-venous ecmo included. sixty-seven (54%) experienced hsv and/or cmv reactivation ecmo course (20 co-infection, 40 hsv alone, 7 cmv alone). hsv reactivation occurred earlier cmv beginning mv [(6â\\x80\\x9315) vs. 19 (13â\\x80\\x9329) days; p < 0.01] ecmo implementation [(2â\\x80\\x938) vs. 14 (10â\\x80\\x9320) days; p < 0.01]. univariate analysis, hsv/cmv reactivation associated longer duration mechanical ventilation [(22â\\x80\\x9352.5) vs. 17.5 (9â\\x80\\x9328) days; p < 0.01], longer duration ecmo [15 (10â\\x80\\x9322.5) vs. 9 (5â\\x80\\x9314) days; p < 0.01], prolonged icu [29 (19.5â\\x80\\x9347.5) vs. 16 (9â\\x80\\x9330) days; p < 0.01] hospital stay [44 (29â\\x80\\x9363.5) vs. 24 (11â\\x80\\x9343) days; p < 0.01] compared non-reactivated patients. however, multivariate analysis, reactivation remained associated prolonged mv only. considered separately, hsv cmv reactivation associated longer duration mv compared non-reactivation [29 (19.5â\\x80\\x9341) 28 (20.5â\\x80\\x9337), respectively, vs. 17.5 (9â\\x80\\x9328) days; p < 0.05]. co-reactivation longer duration mv [58.5 (38â\\x80\\x9372.3); p < 0.05] icu stay [51.5 (32.5â\\x80\\x9369) vs. 27.5 (17.75â\\x80\\x9335.5) 29 (20â\\x80\\x9330.5), respectively] compared hsv cmv reactivation alone. multivariate analysis, hsv reactivation remained independently associated longer duration mv hospital length stay. conclusions: herpesviridae reactivation frequent among severe ards veno-venous ecmo associated longer duration mechanical ventilation. direct causative link hsv cmv reactivation respiratory function worsening ecmo remains confirmed.',\n",
       " 'influenza major cause morbidity mortality worldwide, well china. knowledge spatial temporal characteristic influenza important evaluating developing control programs. aim describe accurate spatiotemporal pattern influenza prefecture level explore risk factor associated influenza incidence risk mainland china 2005 2018. incidence influenza obtained chinese notifiable infectious reporting system (cnidrs). besag york molliã© (bym) model extended include temporal space-time interaction terms. parameter extended bayesian spatiotemporal model estimated integrated nested laplace approximation (inla) package r-inla r. total 702,226 influenza case reported mainland china cnidrs 2005â\\x80\\x932018. yearly reported incidence rate influenza increased 15.6 time period, 3.51 2005 55.09 2008 per 100,000 populations. temporal term spatiotemporal model showed much increase occurred last 3 year period. risk factor analysis showed decreased number influenza vaccine sale, update influenza surveillance protocol, increase rate influenza (h1n1)pdm09 among processed specimen influenza-like illness (ili) patients, increase latitude longitude geographic location associated increase influenza incidence risk. adjusting fixed covariate effect time random effects, map spatial structured term show high-risk area clustered central part china lowest-risk area east west. space-time variation influenza found since 2009. conclusion, increasing trend influenza observed 2005 2018. insufficient flu vaccine supplements, newly emerging influenza (h1n1)pdm09 expansion influenza surveillance effort might major cause dramatic change outbreak spatio-temporal epidemic patterns. cluster prefecture high relative risk influenza identified central part china. future research risk factor national local level necessary explain changing spatiotemporal pattern influenza china.',\n",
       " 'porcine epidemic diarrhea (pedv) induce intestinal dysfunction, resulting severe diarrhea even death, mode action underlying effect remains unclear. determined effect pedv intestinal absorption expression gene nutrient transporter via biochemical test microarray analysis. sixteen 7-day-old healthy piglet fed milk replacer randomly allocated two groups. 5-day adaption, piglet (n = 8/group) orally administrated either sterile saline pedv (the strain yunnan province) 10(4.5) tcid(50) (50% tissue culture infectious dose) per pig. pig orally infused d-xylose (0.1 g/kg bw) 5 post pedv saline administration. hour later, jugular vein blood sample well intestinal sample collected analysis. comparison control group, pedv increased diarrhea incidence, blood diamine oxidase activity, ifabp level, reducing growth plasma d-xylose concentration piglets. moreover, pedv altered plasma jejunal amino acid profiles, decreased expression aquaporins amino acid transporter (l-type amino acid transporter 1, sodium-independent amino acid transporter, b(â°(,+))-type amino acid transport protein, sodium-dependent neutral amino acid transporter 1, sodium-dependent glutamate/aspartate transporter 3, peptide transporter (1), lipid transport metabolism-related gene (lipoprotein lipase, apolipoprotein a1, apolipoprotein a4, apolipoprotein c2, solute carrier family 27 member 2, solute carrier family 27 member 4, fatty acid synthase, long-chain acyl-coa synthetase (3), glucose transport gene (glucose transporter-2 insulin receptor) jejunum. however, pedv administration increased mrna level phosphoenolpyruvate carboxykinase 1, argininosuccinate synthase 1, sodium/glucose co-transporter-1, cystic fibrosis transmembrane conductance regulator jejunum. collectively, comprehensive result indicate pedv induces intestinal injury inhibits expression gene encoding nutrient transporters.',\n",
       " 'chronic kidney epidemiologically identified risk factor development severe dengue dengue-affected patients. however, available immune pathogenesis end stage renal (esrd) affected dengue insufficient. performed vitro evaluate sequential immunological reaction load dengue type 2-infected mononuclear cell esrd (n = 34) healthy control (n = 30). concentration interleukin (il)-1 receptor antagonist (ra), il-2, il-6, il-8, il-10, il-12p40, granulocyte-macrophage colony-stimulating factor (gm-csf), monocyte chemotactic protein-1 (mcp-1), macrophage inflammatory protein-1b (mip-1b), vascular endothelial growth factor (vegf), tumor necrosis factor (tnf)-î± load cycle threshold (ct) measured dengue type 2-infected mononuclear cell 6 h, 24 h, 48 h, 72 h post-infection. found esrd group significantly higher gm-csf il-2 level 6 h post-infection. however, il-8, il-10, il-12p40, tnf-î±, mcp-1, mip-1b level found significantly lower control group. 24 h, 48 h, 72 h post-infection, significantly lower level il-1ra, il-6, il-8, il-10, il-12p40, tnf-î±, mcp-1, mip-1b detected esrd group. concentration vegf 24 h 48 h, gm-csf 48 h 72 h found lower esrd group control group. compared controls, load ct value significantly lower esrd group 6 h 24 h post-infection significant difference load ct value two group found 48 h 72 h post-infection. discloses expression immune mediator dengue-infected mononuclear cell impaired esrd patients.',\n",
       " 'background: rna pseudoknot structure play important role biological processes. however, existing rna secondary structure prediction algorithm cannot predict pseudoknot structure efficiently. although random matching improve number base pairs, non-consecutive base pair cannot make contribution reduce free energy. result: order improve efficiency searching procedure, algorithm take consecutive base pair basic components. firstly, algorithm calculates archive consecutive base pair triplet structure, number consecutive base pair greater given minimum stem length. secondly, annealing schedule adapted select optimal solution minimum free energy. finally, proposed algorithm evaluated real instance pseudobase. conclusion: experimental result demonstrated provide competitive oftentimes better performance compared chosen state-of-the-art rna structure prediction algorithms.',\n",
       " 'background: telocytes (tcs) newly identified interstitial cell participate tissue protection repair. present investigated mechanism underlying protective effect tc mouse model respiratory distress. methods: mouse model acute respiratory distress syndrome (ards) established intratracheal instillation lipopolysaccharide (lps). instillation tc culture medium, lung injury assessed, angiogenesis markers, cd31 endothelial nitric oxide synthase (enos), detected immunofluorescence. bioinformatics analysis used screen significantly differentially expressed micrornas (mirnas) cultured tc stimulated lps, regulation downstream angiogenesis gene mirnas analysed verified. pi3k subunit pathway evaluated pi3k p110î± inhibitor involved mechanisms. results: ards mice, instillation tc culture medium ameliorated lps-induced inflammation lung injury increased protein level cd31 enos injured lungs. total 7 mirnas 1899 mrna differentially regulated tc stimulated lps. functional prediction analysis showed differentially expressed mrna enriched angiogenesis-related processes, highly correlated mir-21a-3p. culture medium tc mir-21a-3p inhibition failed promote angiogenesis mouse model lps-induced ards. cultured tcs, lp stimulation upregulated expression mir-21a-3p, targeted transcription factor e2f8 decreased notch2 protein expression. tc culture medium enhanced hemangioendothelioma endothelial cell (eoma cells) proliferation, blocked mir-21a-3p inhibitor. pi3k p110î± inhibitor decreased vascular endothelial growth factor level lps-stimulated tc reversed enhancing effect tc culture medium eoma cell proliferation. conclusions: tc exerted protective effect inflammatory condition promoting angiogenesis via mir-21a-3p. pi3k p110î± subunit transcriptional factor e2f8 could involved process.',\n",
       " 'monitored survival human pathogenic bacteria [escherichia coli (atcc), extended-spectrum î²-lactamase-producing e. coli (clinical isolate), delhi metallo-î²-lactamase-producing e. coli (clinical isolate), staphylococcus aureus (atcc)] dry material (vinyl chloride, aluminum, plastic, stainless steel) distinct temperature (room temperature 15â°câ\\x80\\x9337â°c). bacteria favored lower temperature prolonged survival dry fomites, regardless material type. interestingly, mixed s. aureus, e. coli survived longer time lower temperature. cardiolipin, promote survival s. aureus harsh environments, effect maintaining survival e. coli. although trend remained unchanged, adjusting humidity 40% 60% affected survival bacteria dry surfaces. scanning electron microscopic analysis revealed morphological difference bacteria immediately dry conditions. addition, atp assessment, used visualize high-touch surface hospitals, effective monitoring bacterial dynamics. specialized handrail device fitted heater, maintained normal human body core temperature, successfully prohibited prolonged survival bacteria [enterococcus faecalis (atcc), e. coli (atcc), pseudomonas aeruginosa (atcc), s. aureus (atcc), acinetobacter baumannii (clinical isolate), serratia marcescens (clinical isolate)], exception spore-forming bacillus subtilis (from laboratory collection) yeast-like fungus candida albicans (from laboratory collection)] dry surfaces. taken together, concluded tested bacteria favor lower temperature survival dry environments. therefore, thermal control dry fomite potential control bacterial survival high-touch surface hospitals.',\n",
       " 'ebola (evd) epidemic western africa (2013â\\x80\\x922016), antimalarial administered evd due high coexisting malaria burden accordance world organization guidelines. ebola center liberia, evd receiving combination antimalarial artesunate-amodiaquine lower risk death compared treated artemether-lumefantrine. artemether artesunate derivative artemisinin, beneficial anti-ebola (ebov) effect observed could possibly attributed change lumefantrine amodiaquine. amodiaquine widely used antimalarial country experience outbreak evd and, therefore, hold promise approved drug could repurposed treating ebov infections. investigated potential anti-ebov effect amodiaquine well-characterized nonhuman primate model evd. similar 3-day antimalarial dosing strategy human patients, plasma concentration amodiaquine healthy animal similar found humans. however, regimen survival benefit decrease sign ebov-infected animals. amodiaquine failed demonstrate efficacy, cannot exclude potential therapeutic value amodiaquine used combination artesunate another antiviral.',\n",
       " 'zika (zikv) currently major concern human public due association neurological disorders. intensive effort implemented zikv, currently approved vaccine antiviral available combat zikv infection. sense, identification virulence factor associated change zikv virulence could help develop safe effective countermeasure treat zikv prevent future outbreaks. here, compared virulence two related zikv strain recent outbreak brazil (2015), rio grande norte natal (rgn) paraiba. spite virus identified period time region, significant difference virulence replication observed validated mouse model zikv infection. zikv-rgn 50% mouse lethal dose (mld(50)) ~10(5) focus forming unit (ffus), zikv-paraiba resulted 100% lethality le 10 ffus. combining deep-sequencing analysis described infectious zikv-rgn cdna clone, identified natural polymorphism non-structural protein 2 (ns2a) increase virulence zikv. moreover, result demonstrate single amino acid alanine valine substitution position 117 (a117v) ns2a sufficient convert attenuated rzikv-rgn virulent paraiba-like (mld(50) < 10 ffu). mechanism action evaluated indicate substitution a117v zikv ns2a protein reduces host innate immune response viral-induced apoptosis vitro. therefore, amino acid substitution a117v zikv ns2a could used genetic risk-assessment marker future zikv outbreaks.',\n",
       " 'influenza major global public threat highly pathogenic variants, zoonotic reservoir, pandemic potential. metagenomic sequencing offer potential diagnostic test influenza provides insight transmission, evolution, drug resistance simultaneously detects viruses. therefore set apply oxford nanopore technology sequencing metagenomic sequencing respiratory samples. generated influenza read limit detection 10(2) 10(3) genome copies/ml pooled samples, observing strong relationship titer proportion influenza read (p = 4.7 ã\\x97 10(â\\x88\\x925)). applying method clinical throat swabs, generated influenza read 27/27 sample mid-to-high titer (cycle threshold [c(t)] values, <30) 6/13 sample low titer (c(t) values, 30 40). false-positive read generated 10 influenza virus-negative samples. thus, nanopore sequencing operated 83% sensitivity (95% confidence interval [ci], 67 93%) 100% specificity (95% ci, 69 100%) compared current diagnostic standard. coverage full-length dependent sample composition, negatively influenced increased host bacterial reads. however, high influenza titers, able reconstruct >99% complete sequence eight gene segments. detected human coinfection clinical sample. optimization required improve sensitivity, approach show promise nanopore platform used diagnosis genetic analysis influenza respiratory viruses.',\n",
       " 'background: telocytes (tcs) capacity cellâ\\x80\\x93cell communication adjacent cell within tissue, contributing tissue repair recovery injury. present aim investigating molecular mechanism tgfî²1-itgb1-pi3k signal pathway regulate tc cycle proliferation. methods: gene expression integrin (itg) family measured mouse primary tc compare cells. tc proliferation, movement, cell cycle, pi3k isoform protein gene assayed itgb1-negative positive mouse lung tc treated inhibition pi3kp110î±, pi3kî±/î´, pkcî², gsk3, followed tgfî²1 treatment. results: found character interaction itg pkc family member network primary mouse lung tcs, different cell lung tissue. deletion itgb1 changed tc sensitivity multifunctional cytokine signal pathway inhibitors. compensatory mechanism occur among tgfî²1-induced pi3kp110î±, pi3kî±/î´, pkcî², gsk3 itgb1 gene deleted, leading alteration tc cell cycle proliferation. pi3k isoform protein genes, mrna expression pik3cg altered itgb1-negative tc cycle proliferation. conclusion: tc strong capacity proliferation compensatory signaling mechanism contribute development drug resistance due alteration tc sensitivity.',\n",
       " 'pre-emptive vaccination regarded protective measure control influenza outbreak. mainly two type influenza virusesâ\\x80\\x94influenza b several subtypesâ\\x80\\x94that commonly found circulate among humans. traditional trivalent (tiv) flu vaccine target two strain influenza strain influenza b. quadrivalent (qiv) vaccine target extra b strain ensures better protection influenza; however, use qiv vaccine costly, hence impose extra financial burden society. scenario might create dilemma choosing vaccine type individual level. article endeavour explain dilemma framework vaccination game, individual opt three options: choose either qiv tiv vaccine none. approach presumes mean-field framework vaccination game infinite well-mixed population, entangling spreading process influenza coevolution two type vaccination decision-making process taking place epidemic season. conduct series numerical simulation attempt illustrate different scenarios. framework validated so-called multi-agent simulation (mas) approach.',\n",
       " 'dynamic spreadable largely governed four factors: proactive vaccination, retroactive treatment, individual decisions, prescribing behaviour physicians. imposed vaccination policy antiviral society, complex factor (costs expected effect vaccine treatments, fear infected) trigger emulous situation individual avoid pre-emptive ex post provision. aside established voluntary vaccination game, propose game model associated resistance evolution antiviral/antibiotic overuse. moreover, imperfectness vaccination inevitably led anti-vaccine behaviour, necessitating proactive policy. however, excessively heavy implementation treatment antiviral medicine, resistant strain emerge. model explicitly exhibit dual social dilemma situation, behaviour change local time scale, vaccination uptake later evolves global time scale. impact resistance evolution coexistence dual dilemma investigated control reproduction number social efficiency deficit, respectively. investigation might elucidate substantial impact vaccination framework epidemic dynamics, hence suggest appropriate use antiviral treatment.',\n",
       " 'background: influenza infection often remain undiagnosed admitted hospital due lack routine testing. tested for, diagnosis influenza often delayed due slow turnaround time centralised laboratory pcr testing. newer molecular systems, comparable accuracy laboratory pcr testing, generate 1 hour, making potentially deployable point-of-care test (pocts). high-quality evidence impact routine poct influenza clinical outcome is, however, currently lacking. pragmatic multicentre randomised controlled trial aim address evidence gap. method analysis: flupoc trial pragmatic, multicentre, randomised controlled trial evaluating adult admitted teaching hospital district general hospital acute respiratory illness, influenza season defined public england. 840 recruited three influenza seasons, randomised (1:1) receive either poct filmarray respiratory panel, routine clinical care. clinical control team informed result real time influenza detected clinical team encouraged offer neuraminidase inhibitor (nai) accordance national guidelines. allocated standard clinical care swab taken later analysis allow assessment missed diagnoses. outcome assessment retrospective note analysis. outcome measure include proportion influenza-positive detected appropriately treated nais, isolation facility use, antibiotic use, length hospital stay, complication mortality. ethic dissemination: prior commencing study, approval obtained south central hampshire ethic committee (reference 17/sc/0368, granted 7 september 2017). result generated protocol published peer-reviewed scientific journal presented national international conferences. trial registration number: isrctn17197293',\n",
       " 'background: dexmedetomidine reported improve organ dysfunction critically ill patients. recent randomized controlled trial (dexmedetomidine sepsis intensive care unit (icu) randomized evolution [desire]), demonstrated dexmedetomidine associated reduced mortality risk among severe sepsis. performed exploratory sub-analysis examine mechanism underlying improved survival sedated dexmedetomidine. methods: desire trial compared sedation strategy without dexmedetomidine among 201 mechanically ventilated adult sepsis across eight icu japan. present study, included 104 acute physiology chronic evaluation ii (apache ii) score â\\x89¥ 23 (54 dexmedetomidine [dex] group 50 non-dexmedetomidine [non-dex] group). initially, compared change sequential organ failure assessment (sofa) score baseline within 6 day randomization groups. subsequently, evaluated variable comprising organ component sofa score showed relevant improvement initial comparison. results: mean age 71.0 â± 14.1 years. difference median apache ii score two group (29 [interquartile range (iqr), 25â\\x80\\x9331] vs. 30 [iqr, 25â\\x80\\x9333]; p = 0.35). median sofa score baseline lower dex group (9 [iqr, 7â\\x80\\x9311] vs. 11 [iqr, 9â\\x80\\x9313]; p = 0.01). renal sofa subscore baseline similar groups, significantly decreased dex group 4 (p = 0.02). first 6 days, urinary output significantly different (p = 0.09), serum creatinine level significantly lower (p = 0.04) dex group. 28-day in-hospital mortality rate significantly lower dex group (22% vs. 42%; p = 0.03, 28% vs. 52%; p = 0.01, respectively). conclusion: sedation strategy dexmedetomidine associated improved renal function decrease mortality rate among severe sepsis. trial registration: trial registered clinicaltrials.gov (nct01760967) january 1, 2013.',\n",
       " 'background: global end-diastolic volume (gedv) measured transpulmonary thermodilution regarded indicator cardiac preload. bolus cold saline injected central vein travel heart lung, aorta detection femoral artery. well accepted injection inferior vena cava result higher values, impact aortic volume gedv unknown. study, hypothesized larger aortic volume directly translates numerically higher gedv measurement. methods: retrospectively analyzed 88 critically ill thermodilution monitoring require contrast-enhanced thoraco-abdominal computed tomography scan. aortic volume derived imaging compared gedv measurement temporal proximity. results: median aortic volume 194 ml (interquartile range 147 249 ml). per milliliter increase aortic volume, found gedv increase 3.0 ml (95% ci 2.0 4.1 ml, p < 0.001). femoral central venous line used saline bolus injection, gedv raised additionally 2.1 ml (95% ci 0.5 3.7 ml, p = 0.01) per ml volume vena cava inferior. aortic volume explained 59.3% variance thermodilution-derived gedv. aortic volume included multivariate regression, gedv variance unaffected sex, age, body height, weight. conclusions: result suggest aortic volume substantial confounding variable gedv measurement performed transpulmonary thermodilution. aorta anatomically located heart, gedv considered reflect cardiac preload. guiding volume management raw indexed reference range gedv may misleading.',\n",
       " 'background: human metapneumovirus (hmpv) important cause acute respiratory illness young children. whole genome sequencing enables better identification transmission event outbreaks, always possible sub-genomic sequences. results: report 2-reaction amplicon-based next generation sequencing determine complete genome sequence five hmpv strains, representing three subgroup (a2, b1 b2), directly clinical samples. addition reporting five novel hmpv genome africa examined genetic diversity sequence pattern publicly available hmpv genomes. found overall nucleotide sequence identity 71.3 80% hmpv group b, respectively, diversity hmpv group greater amino acid level sh g surface protein genes, multiple subgroup co-circulated various countries. comparison sequence hmpv group revealed variability g protein length (219 241 amino acids) due change stop codon position. genome-wide phylogenetic analysis showed congruence individual gene sequence set except f m2 genes. conclusion: first genomic characterization hmpv genome african patients.',\n",
       " 'background: antimicrobial resistance (amr) compromise serious infection intensive care unit (icus), intensive care physician increasingly facing bacterial infection limited adequate therapeutic options. survey conducted ass intensive care physiciansâ\\x80\\x99 perception amr situation european union/european economic area (eu/eea). methods: may july 2017, physician working european icu invited complete online questionnaire hosted european society intensive care medicine. survey included 20 question hospital icu characteristics, frequency infection multidrug-resistant (mdr) bacteria relevance amr respondentâ\\x80\\x99s icu, management antimicrobial well use last-line antibiotic six month preceding survey. analysis regional differences, eu/eea country grouped four sub-regions eastern, northern, southern western europe. results: overall, 1062 response four european sub-regions analysed. infection mdr bacteria icu rated major problem 257 (24.2%), moderate problem 360 (33.9%) minor problem 391 (36.8%) respondents. third-generation cephalosporin-resistant enterobacteriaceae frequently encountered mdr bacteria followed by, order decreasing frequency, meticillin-resistant staphylococcus aureus, carbapenem-resistant enterobacteriaceae, carbapenem-resistant pseudomonas aeruginosa vancomycin-resistant enterococci. perception relevance amr problem frequency specific mdr bacteria varied european sub-region. bacteria resistant almost available antibiotic encountered 132 (12.4%) respondents. many physician reported access specific last-line antibiotics. conclusions: percentage european icu physician perceiving amr substantial problem icu high variation sub-region line epidemiological studies. report bacteria resistant almost available antibiotic limited availability last-line antibiotic icu eu/eea concern.',\n",
       " 'glycoconjugate vaccine based bacterial capsular polysaccharide (cps) extremely successful preventing bacterial infections. glycan antigen preparation cps based glycoconjugate vaccine mainly obtained bacterial fermentation, quality length glycans always inconsistent. kind situation make cmc glycoconjugate vaccine difficult well control. thanks advantage synthetic method carbohydrate syntheses. well controlled glycan antigen easily obtain, conjugated carrier protein so-call homogeneous fully synthetic glycoconjugate vaccines. several fully glycoconjugate vaccine different phase clinical trial bacteria cancers. review introduce recent development fully synthetic glycoconjugate vaccine.',\n",
       " 'background: acute kidney injury (aki) common complication burn admitted intensive care unit (icu) associated increased morbidity mortality. primary aim review incidence, risk factors, outcome aki burn admitted icu. secondary aim review use renal replacement therapy (rrt) impact care costs. methods: conducted systematic search pubmed, uptodate, nice 3 december 2018. review cochrane database systematic review except protocol added pubmed search. searched study aki according risk, injury, failure, loss kidney function, end-stage kidney (rifle); acute kidney injury network (akin); and/or kidney disease: improving global outcome (kdigo) criterion burn admitted icu. collected aki incidence, risk factors, use rrt, renal recovery, length stay (los), mortality, care costs. results: included 33 observational study comprising 8200 patients. overall quality, scored according newcastle-ottawa scale, moderate. random effect model meta-analysis revealed incidence aki among burn icu 38 (30â\\x80\\x9346) %. aki almost evenly distributed mild, moderate, severe aki subgroups. rrt used 12 (8â\\x80\\x9316) % patients. risk factor aki high age, chronic hypertension, diabetes mellitus, high total body surface area percent burnt, high abbreviated burn severity index score, inhalation injury, rhabdomyolysis, surgery, high acute physiology chronic evaluation ii score, high sequential organ failure assessment score, sepsis, mechanical ventilation. aki 8.6 (4.0â\\x80\\x9313.2) day longer icu los higher mortality non-aki patients, 11.3 (7.3â\\x80\\x9317.4). study reported renal recovery, reported care costs. conclusions: aki occurred 38% burn admitted icu, 12% received rrt. presence aki associated increased los mortality. trial registration: prospero (crd42017060420)',\n",
       " 'mycobacterium tuberculosis (m.tb) responsible death globally pathogen. available vaccine, bacillus calmette-guã©rin (bcg), variable efficacy throughout world. effective vaccine urgently needed. immune response tuberculosis relies, least part, cd4(+) cells. protective vaccine require induction antigen-specific cd4(+) cell via mycobacterial peptide presented mhc class-ii infected macrophages. order identify mycobacterial antigen bound mhc, immunoprecipitated mhc class-i class-ii complex thp-1 macrophage infected bcg, purified mhc class-i mhc class-ii peptide analysed liquid chromatography tandem mass spectrometry. successfully identified 94 mycobacterial peptide presented mhc-ii 43 presented mhc-i, 76 41 antigens, respectively. antigen found highly expressed infected macrophages. gene ontology analysis suggests antigen associated membrane involved lipid biosynthesis transport. sequence selected peptide confirmed spectral match validation immunogenicity evaluated ifn-gamma elispot peripheral blood mononuclear cell volunteer vaccinated bcg, m.tb latently infected subject tuberculosis disease. three antigen expressed vectors, evaluated vaccine candidate alone combination murine aerosol m.tb challenge model. delivered combination, three candidate vaccine conferred significant protection lung spleen compared bcg alone, demonstrating proof-of-concept unbiased approach identifying candidate antigens.',\n",
       " 'wide range cancer immunotherapy approach developed non-specific immune-stimulants cytokines, cancer vaccines, immune checkpoint inhibitor (icis), adoptive cell therapy. among them, icis commonly used intensively studied. since 2011, drug received marketing authorisation melanoma, lung, bladder, renal, head neck cancers, remarkable long-lasting response patients. novel mechanism action icis, immune cell activation, lead unusual pattern response imaging, advent so-called pseudoprogression pronounced frequently observed compared anticancer therapies. pseudoprogression, described 2â\\x80\\x9310% treated icis, corresponds increase tumour burden and/or appearance lesion due infiltration activated cell responds therapy. overcome limitation response evaluation criterion solid tumor (recist) ass specific changes, imaging criteriaâ\\x80\\x94so-called immune-related response criterion immune-related recist (irrecist)â\\x80\\x94were proposed. major modification involved inclusion measurement target lesion assessment need 4-week re-assessment confirm confirm progression. recist working group introduced concept â\\x80\\x9cunconfirmed progressionâ\\x80\\x9d, irrecist. paper review current immunotherapeutic approach summarises radiologic criterion evaluate pattern response immunotherapy. furthermore, imaging feature immunotherapy-related adverse event available predictive biomarkers response presented.',\n",
       " 'background: efficient surface cleaning strategy would first target cleaning surface make contribution risk infections. methods: study, used literature methicillin-resistant staphylococcus aureus (mrsa) developed ordinary differential equation based mathematical model quantify impact contact heterogeneity mrsa transmission hypothetical 6-bed intensive care unit (icu). susceptible divided two types, cared nurse mrsa infected (type 1) (type 2). results: result showed mean mrsa concentration three kind susceptible nearby surface significantly linearly associated hand-touch frequency (p < 0.05). noncompliance daily cleaning nearby high-touch surface (htss) impact mrsa transmission. htss cleaned, mrsa exposure type 1 2 susceptible would increase 118.4% (standard deviation (sd): 33.0%) 115.4% (sd: 30.5%) respectively. communal surface (css) least impact, cs cleaned, mrsa exposure type 1 susceptible would increase 1.7% (sd: 1.3). impact clinical equipment (ce) differed largely two type susceptible patients. ce cleaned, exposure type 1 would increase 8.4% (sd: 3.0%), type 2 patients, increase 70.4% (sd: 25.4%). conclusions: provided framework pathogen concentration dynamic environmental surface quantitatively showed importance cleaning nearby htss controlling nosocomial transmission via contact route.',\n",
       " 'background: general self-efficacy considered influential parameter affecting quality clinical practice nursesâ\\x80\\x99 perceived professional benefit (nppb). perceived organizational support (pos) regarded central understanding job-related attitudes, important enhance po nurse maintain current employment. nppb reduce nursesâ\\x80\\x99 job burnout turn-over intention. many study explored relationship among general self-efficacy, pos, nursing practice environment (npe) nppb. however, moderating effect npe fully explored nurses, especially among paediatric nurses. methods: descriptive cross-sectional conducted july october 2018 300 paediatric nurse 3 class tertiary hospital jilin province. respondent completed general self-efficacy scale, perceived organizational support scale, practice environment scale nursesâ\\x80\\x99 perceived professional benefit scale. analyzed path analysis spss (version 23.0, ibm). results: general self-efficacy po significantly positively associated nppb, showed model good fit data. npe found play partial mediating role po nppb complete mediating role general self-efficacy nppb. conclusions: result suggest general self-efficacy indirectly influence nppb, po directly indirectly influence nppb npe. effective measure taken improve nursesâ\\x80\\x99 practice environment hospital raise nursesâ\\x80\\x99 enthusiasm confidence work.',\n",
       " 'background: aimed compare clinical characteristic community-acquired pneumonia (cap), healthcare-associated pneumonia (hcap), hospital-acquired pneumonia (hap) caused klebsiella pneumoniae analyze antimicrobial resistance proportion hypervirluent strain microbial isolates. methods: conducted retrospective pneumonia caused k. pneumoniae taipei veteran general hospital taiwan january 2014 december 2016. analyze clinical characteristic patients, extracted medical records. k. pneumoniae strain subjected antimicrobial susceptibility testing, capsular genotyping detection rmpa rmpa2 gene identify hypervirulent strains. results: identified 276 pneumonia caused k. pneumoniae, 68 (24.6%), 74 (26.8%), 134 (48.6%) presented cap, hcap, hap, respectively. 28-day mortality highest hap group (39.6%), followed hcap (29.7%) cap (27.9%) groups. hap group featured highest proportion multi-drug resistant strain (49.3%), followed hcap (36.5%) cap group (10.3%), cap group highest proportion hypervirulent strain (79.4%), followed hcap (55.4%) hap group (41.0%). conclusion: pneumonia caused k. pneumoniae associated high mortality. importantly, multi-drug resistant strain detected cap. hypervirulent strain prevalent 3 group pneumonia patients, even hap.',\n",
       " 'objective: describe epidemiology carbapenem-resistant enterobacteriaceae (cre) healthcare-associated infection (hai) egyptian hospital reporting national hai surveillance system. methods: design: descriptive analysis cre hais retrospective observational cohort national hai surveillance data. setting: egyptian hospital participating hai surveillance system. population included admitted intensive care unit (icu) participating hospitals. enterobacteriaceae hai case klebsiella, escherichia coli, enterobacter isolates blood, urine, wound respiratory specimen collected 3 icu admission. cre hai case resistant least carbapenem. cre hai case reported 2011â\\x80\\x932017, hospital-level patient-level analysis conducted first cre isolate pathogen specimen type patient. facility, microbiology, clinical characteristics, frequency mean calculated among cre hai case compared carbapenem-susceptible enterobacteriaceae hai case univariate multivariate logistic regression stata 13. results: 1598 enterobacteriaceae hai cases, 871 (54.1%) carbapenem resistant. multivariate regression analysis demonstrated carbapenem resistance associated specimen type, pathogen, location prior admission, length icu stay. 2011 2017, increase proportion enterobacteriaceae hai case due cre (p-value = 0.003) incidence cre hais (p-value = 0.09). conclusions: analysis demonstrated high increasing burden cre egyptian hospitals, highlighting importance enhancing prevention control (ipc) program antimicrobial stewardship activity guiding implementation targeted ipc measure contain cre egyptian icuâ\\x80\\x99s .',\n",
       " 'mammalian asparagine endopeptidase (aep) cysteine protease cleaves protein substrate c-terminal side asparagine residues. converging line evidence indicate aep may involved pathogenesis several neurological diseases, alzheimerâ\\x80\\x99s disease, parkinsonâ\\x80\\x99s disease, frontotemporal dementia. aep activated aging brain, cleaves amyloid precursor protein (app) promotes production amyloid-î² (aî²). renamed aep î´-secretase emphasize role app fragmentation aî² production. aep cleaves substrates, tau, î±-synuclein, set, tar dna-binding protein 43, generating neurotoxic fragment disturbing physiological functions. activity î´-secretase tightly regulated transcriptional posttranslational levels. here, review recent advance role î´-secretase neurodegenerative diseases, focus biochemical property transcriptional posttranslational regulation activity, discus clinical implication î´-secretase diagnostic biomarker therapeutic target neurodegenerative diseases.',\n",
       " 'background: influenza virus cause epidemics/severe pandemic pose great global threat. among eight rna segments, multiple function nucleoprotein (np) play important role replication transcription. methods: understand np contributes evolution, analyzed np gene h3n2 virus taiwan 14,220 np sequence collected influenza research database. identified genetic variation analyzed mini-genome assay, growth assay, rna protein expression well ferret model analyze impact replication properties. results: np genetic analysis taiwan global sequence showed similar evolution pattern np backbone changed time accompanied specific residue substitution 1999 2018. conserved residues, fifteen sporadic substitution observed 31r, 377g 450s showed higher frequency. found 31r 450s decreased polymerase activity dominant residue (31 k 450g) higher activity. 31 k 450g showed better translation replication vitro vivo. conclusions: finding indicated variation identified evolution role modulating replication vitro vivo. demonstrates interaction variation np evolution deserves future attention.',\n",
       " 'background: heart failure (hf) recognized global pandemic high rate hospitalization, morbidity, mortality. although numerous advance made, representative molecular signature remain largely unknown, especially role gene hf progression. aim present prospective follow-up reveal potential biomarkers associated progression heart failure. methods: generated multi-level transcriptomic cohort left ventricular heart tissue collected 21 hf 9 healthy donors. masson staining calculate fibrosis percentage sample, applied lasso regression model identify gene associated fibrosis well progression. gene validated immunohistochemistry (ihc) staining cohort qrt-pcr another independent cohort (20 hf 9 healthy donors). enzyme-linked immunosorbent assay (elisa) used measure plasma level validation cohort (139 hf patients) predicting hf progression. results: based multi-level transcriptomic data, examined differentially expressed gene [mrnas, micrornas, long non-coding rna (lncrnas)] cohort. follow-up functional annotation regulatory network analysis revealed potential role regulating extracellular matrix. identified several gene associated fibrosis. survival time transplantation, col1a1 identified potential biomarker hf progression upregulation confirmed ihc qrt-pcr. furthermore, col1a1 content â\\x89¥ 256.5 ng/ml plasma found associated poor survival within 1 year heart transplantation heart failure [hazard ratio (hr) 7.4, 95% confidence interval (ci) 3.5 15.8, log-rank p value < 1.0 ã\\x97 10(â\\x88\\x92 4)]. conclusions: result suggested col1a1 might plasma biomarker hf associated hf progression, especially predict 1-year survival hf onset transplantation.',\n",
       " 'modern society exposed myriad risk ranging natural hazard technological disruptions. exploring awareness risk spread trigger diffusion coping strategy prominent research agenda various domains. requires deep understanding individual perceive risk communicate effectiveness protective measures, highlighting learning social interaction core mechanism driving processes. methodological approach range purely physics-based diffusion model data-driven environmental method rely agent-based modeling accommodate context-dependent learning social interaction diffusion process. mixing agent-based modeling data-driven machine learning become popularity. however, little attention paid role intelligent learning risk appraisal protective decisions, whether used individual collective process. difference collective learning individual learning sufficiently explored diffusion modeling general agent-based model socio-environmental system particular. address research gap, explored implication intelligent learning gradient individual collective learning, agent-based model enhanced machine learning. simulation experiment showed individual intelligent judgement risk selection coping strategy group majority vote outperformed leader-based group even individual deciding alone. social interaction appeared essential individual learning group learning. choice represent social learning agent-based model could driven existing cultural social norm prevalent modeled society.',\n",
       " 'mortality acute respiratory distress syndrome (ards) remains unacceptably high approximately 39%. treatment supportive: mechanical ventilation. however, improperly set mechanical ventilation increase risk death ards. recent study suggest ventilation-induced lung injury (vili) caused exaggerated regional lung strain, particularly area alveolar instability subject tidal recruitment/derecruitment stress-multiplication. thus, reasonable expect ventilation strategy maintain stable lung inflation homogeneity, regional dynamic strain would reduced vili attenuated. time-controlled adaptive ventilation (tcav) developed minimize dynamic alveolar strain adjusting delivered breath according mechanical characteristic lung. goal review describe tcav impact pathophysiology protects lung with, high risk of, acute lung injury. present work group others identifies novel mechanism vili alveolar microenvironment demonstrates tcav reduce vili translational animal ards model mortality surgical/trauma patients. tcav utilizes airway pressure release ventilation (aprv) mode based opening collapsing time constants, reflect viscoelastic property terminal airspaces. time-controlled adaptive ventilation us inspiratory expiratory time (1) gradually â\\x80\\x9cnudgeâ\\x80\\x9d alveolus alveolar duct open extended inspiratory duration (2) prevent alveolar collapse brief (sub-second) expiratory duration allow time alveolar collapse. paradigm tcav configuring breath guided previous one, achieves real-time titration ventilator setting minimizes instability induced tissue damage. novel methodology change current approach mechanical ventilation, arbitrary personalized adaptive. outcome approach open stable lung reduced regional strain greater lung protection.',\n",
       " 'background: systematic study microbiological difference antibiotic treatment. aim evaluate effect prior receipt antibiotic microorganism distribution. methods: retrospective, observational cohort conducted 3200-bed tertiary, referral, teaching hospital eastern china. 2-year period, hospitalized treated antimicrobial agent enrolled study. among 48,692 evaluated, 27,792 (57.1%) sampled within 2 day administration first dose antimicrobial agent included. distribution clinical specimen microorganism compared antibiotic drug groups. results: compared specimen taken antibiotic exposure, specimen taken antibiotic exposure higher proportion blood urine specimen higher culture positive rate (all p < 0.001). higher percentage staphylococcus aureus (9.9% vs. 8.5%, p = 0.041), non-fermenting bacteria (27.7% vs. 19.9%, p < 0.001), fungi (8.4% vs. 4.0%, p < 0.001) isolated group antibiotic exposure, percentage streptococcus spp. (4.8% vs. 2.7%, p < 0.001), haemophilus influenzae (2.3% vs. 0.8%, p < 0.001), moraxella catarrhalis (0.7% vs. 0.1%, p < 0.001) higher group antibiotic exposure. analysis found significant difference microbe derived respiratory secretions, blood urine samples. found, antibiotic exposure, separation rate non-fermenting bacteria significantly increased (all p < 0.05), separation rate candida spp. higher, statistical significance airway secretion urine sample (both p < 0.05), separation rate staphylococcus aureus among three group affected antibiotics. addition, isolation rate streptococcus spp. blood urine sample decreased significantly (both p < 0.05) antibiotic exposure. interestingly, statistical difference found microbe isolated body fluid specimen two groups. conclusions: outcome revealed antibiotic-insensitive organism non-fermentative bacteria fungi frequently isolated antibiotic exposure. however, trend might specimen dependent obvious body fluid specimens.',\n",
       " 'background: pediatric cardiac anesthesiology, increased focus minimizing morbidity, ensuring optimal functional status, care resource sparingly. aspect care potential affect postoperative mechanical ventilation. historically, postoperative ventilation considered must maintaining stability. ironically, recognized mechanical ventilation may increase risk adverse outcome postoperative period. hence, many institution advocated immediate extubation early extubation many congenital heart surgery first reported decade ago. methods: 637 consecutive chart reviewed pediatric undergoing cardiac surgery cardiopulmonary bypass. placed three groups. extubated operating room (or) surgery (immediate extubation ie), extubated within six hour admission icu (early extubation ee) extubated sometime six hour (delayed extubation de). multiple variable recorded see factor correlated successful immediate early extubation. results: overall, 338 (53.1%) ie), 273 (42.8%) de 26 (4.1%) ee. median age 1174 day ie patients, 39 day de patients, whereas 194 day ee (p < 0.001). weight length significantly different least extubation group two (p < 0.001). median icu los 3 4 day ie ee respectively, whereas 9.5 day de (p < 0.001). de group significant longer median anesthesia time cardiopulmonary bypass time two extubation group (p > 63,826.88 < 0.001). regional low flow perfusion, deep hypothermia, deep hypothermic circulatory arrest, redo sternotomy, use sedatives, furosemide, epinephrine, vasopressin, open chest, cardiopulmonary support, pulmonary edema, syndrome, well difficult intubation significantly associated delayed extubation (ie, ee de). conclusions: immediate early extubation significantly associated several factors, age size, duration cpb, use certain anesthetic drugs, amount blood loss blood replacement. ie successfully accomplished majority pediatric undergoing surgery congenital heart disease, minority infants.',\n",
       " 'background: vaccine reliable alternative elicit sterile immunity malaria development hindered polymorphism strain-specificity studied antigens. vaccine candidate therefore urgently needed. highly conserved plasmodium falciparum reticulocyte-binding protein homologue-5 (pfrh5) identified potential candidate anti-disease vaccine development. pfrh5 essential erythrocyte invasion merozoite crucial parasite survival. however, paucity extent genetic variation pfrh5 field isolates plasmodium falciparum. described genetic polymorphism high affinity binding polypeptide (habps) 36718, 36727, 36728 pfrh5 nigerian isolates p. falciparum. tested hypothesis specific conserved b cell epitope pfrh5 habps crucial vaccine development. methods: hundred ninety-five microscopically confirmed p. falciparum sample collected prospective cross-sectional three different population lagos, nigeria. genetic diversity haplotype construct pfrh5 gene determined bi-directional sequencing approach. tajimaâ\\x80\\x99s ratio nonsynonymous v synonymous mutation utilized estimate extent balancing directional selection pfrh5 gene. results: sequence analysis revealed three haplotype pfrh5 negative tajimaâ\\x80\\x99s dn/ds value â\\x88\\x92 1.717 0.011 â± 0.020, respectively. single nucleotide polymorphism, snp (g â\\x86\\x92 a) position 608 observed, resulted change amino acid cysteine position 203 tyrosine. haplotype nucleotide diversity 0.318 â± 0.016 0.0046 â± 0.0001 inter-population genetic differentiation ranged 0.007 0.037. five polypeptide variant identified, frequent ktkyh frequency 51.3%. b-cell epitope, 151 major histocompatibility complex (mhc) class ii t-cell epitopes, four intrinsically unstructured region (iurs) six mhc class t-cell epitope observed study. phylogenetic analysis sequence showed clustering evidence evolutionary relationship 3d7, pas-2 fcb-2 rh5 sequences. conclusions: revealed low level genetic polymorphism pfrh5 antigen b- t-cell epitope intrinsically unstructured region along pfrh5 gene lagos, nigeria. broader investigation required part country support possible inclusion pfrh5 cross-protective multi-component vaccine.',\n",
       " 'brainstem conveys sensory motor input spinal cord brain, contains nucleus cranial nerves. control sleep-wake cycle vital function via ascending reticular activating system autonomic nuclei, respectively. brainstem dysfunction may lead sensory motor deficits, cranial nerve palsies, impairment consciousness, dysautonomia, respiratory failure. brainstem prone various primary secondary insults, resulting acute chronic dysfunction. particular importance characterizing brainstem dysfunction identifying underlying etiology detailed clinical examination, mri, neurophysiologic test brainstem auditory evoked potentials, analysis cerebrospinal fluid. detection brainstem dysfunction challenging utmost importance comatose deeply sedated guide therapy support outcome prediction. present review, summarize neuroanatomy, clinical syndromes, diagnostic technique critical illness-associated brainstem dysfunction critical care setting.',\n",
       " 'background: growth hormone inducible transmembrane protein (ghitm) highly conserved transmembrane protein. conducted investigate role ghitm gene apoptosis growth golden apple snail pomacea canaliculate. results: complete cdna gene cloned rapid amplification cdna end (race) subjected bioinformatics analysis. full-length cdna 2242 bp, open reading frame 1021 bp encoded protein 342 amino acid residues. mrna expression profile ghitm gene different tissue (liver, kidney, gonad foot) different growth phase (6-months old 2-years old) showed expressed various tissue different growth phases. silencing ghitm gene rnai (rna interference) experiment revealed ghitm gene possibly play role inhibiting apoptosis detecting caspase (cysteine-requiring aspartate protease)-3 activity. addition, aperture width body whorl length snail significantly affected rnai, suggesting gene play significant role promoting growth organism. conclusions: result demonstrated ghitm gene involved apoptosis growth golden apple snail.',\n",
       " 'objective: examine extent acute care hospital netherlands adopted recommended practice prevent catheter-associated urinary tract (cauti), central line-associated bloodstream (clabsi), ventilator-associated pneumonia (vap), clostridioides difficile (cdi). methods: 18 july 2017 31 october 2017, surveyed prevention team acute care hospital netherlands. survey instrument based â\\x80\\x98translating healthcare-associated prevention research practiceâ\\x80\\x99 (trip) questionnaire adapted dutch context. descriptive statistic used examine reported regular use cauti, clabsi, vap, cdi prevention practice well hospital characteristics. results: 72 eligible hospitals, 47 (65.3%) responded. surveillance system monitoring cauti, clabsi, vap, cdi present 17.8, 95.4, 26.2, 77.3% hospitals, respectively. antimicrobial stewardship program established 91.5% participating hospitals. cauti, majority hospital regularly used aseptic technique catheter insertion (95%) portable bladder ultrasound scanner (86.1%). intermittent catheterization catheter stop-orders regularly used 65.8 62.2% hospitals. clabsi, hospital regularly used maximum sterile barrier precaution chlorhexidine gluconate insertion site antisepsis. avoidance femoral site central line insertion regularly used 65.9% hospitals. urinary catheter central-lines impregnated antibiotic antiseptic rarely used (â\\x89¤ 5%). selective decontamination strategy preventing vap used 84% hospitals. exception disposable thermometer (31.8%), prevention practice prevent cdi regularly used 80% hospitals. conclusions: dutch hospital report regular use recommended practice preventing clabsi cdi. several specific practice prevent cauti vap le frequently used, however, providing opportunity improvement.',\n",
       " 'described poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (phbv) accumulation bacillus aryabhattai phb10 first time evaluated polymer induced cytotoxicity in-vitro phbv/poly(ethylene glycol) (peg) blends. b. aryabhattai strain produced 2.8 g/l phbv, equivalent 71.15% cell dry mass medium supplemented propionic acid, 48 h incubation. optimum temperature ph copolymer accumulation 31 â°c 7, respectively. gas chromatographyâ\\x80\\x93mass spectrometry nuclear magnetic resonance analysis confirmed polymer obtained phbv. differential scanning calorimetry analysis revealed melting point material 90 â°c thermal stability 220 â°c. average molecular weight (mn) polydispersity index sample estimated gel permeation chromatography analysis observed 128.508 kda 2.82, respectively. phbv showed tensile strength 10.3 mpa elongation break 13.3%. phbv blend peg tested cytotoxicity human keratinocytes (hacat cells) cell incubated phbv/peg2kda blend 99% viable, whereas phbv alone showed comparatively higher cytotoxicity. significant improvement cell viability phbv/peg2kda blend indicates potential candidate skin graft applications.',\n",
       " 'pcv3 capsid protein (cap) important antigen diagnosis vaccine development. achieve high-level expression recombinant pcv3 cap escherichia coli (e. coli), gene wild-type entire cap (wt-ecap) amplified clinical samples, three optimized entire cap (opti-ecap) optimized cap deleted nuclear location signal (nls) (opti-dcap) gene fragment encoding amino acid sequence wt-ecap synthesized based codon bias e. coli. gene fragment inserted pet30a expression vector. recombinant strain highest expressed soluble ecap four entire cap (one wt-ecap three opti-ecap) recombinant strain expressed opti-dcap selected purification. purified ecap dcap identified transmission electron microscopy (tem), number round hollow particle diameter 10 nm virus-like particle (vlps) observed ecap, whereas irregular aggregation protein observed dcap. formation vlps applied coating antigen establish indirect elisa (i-elisa) detection pcv3-specific antibody swine serum. 373 clinical swine serum sample china collected 2019 tested utilizing vlp-based i-elisa optimized conditions. best knowledge, first report self-assembly vlps pcv3 recombinant cap. result demonstrated vlp-based i-elisa valuable tool detecting presence pcv3 antibody serum sample facilitate screening number swine serum clinical purposes.',\n",
       " 'background: randomised controlled trial (rcts) provide reliable information inform clinical practice care. aimed map global clinical research publication activity rct-related article high-impact-factor medical journal past five decades. methods: conducted cross-sectional analysis article published highest ranked medical journal impact factor > 10 (according journal citation report published 2017). searched pubmed/medline (from inception december 31, 2017) rct-related article (e.g. primary rcts, secondary analysis methodology papers) published high-impact-factor medical journals. included article, raw metadata abstracted web science. process standardization conducted unify different term grammatical variant remove typographical, transcription and/or indexing errors. descriptive analysis conducted (including number articles, citations, prolific authors, countries, journals, funding source keywords). network analysis collaboration country co-words presented. results: included 39,305 article (for period 1965â\\x80\\x932017) published forty journals. lancet (n = 3593; 9.1%), journal clinical oncology (n = 3343; 8.5%) england journal medicine (n = 3275 articles; 8.3%) published largest number rcts. total 154 country involved production articles. global productivity ranking led united state (n = 18,393 articles), followed united kingdom (n = 8028 articles), canada (n = 4548 articles) germany (n = 4415 articles). seventeen author published 100 article identified; prolific author affiliated duke university (united states), harvard university (united states) mcmaster university (canada). main funding institution national institute (united states), hoffmann-la roche (switzerland), pfizer (united states), merck sharp & dohme (united states) novartis (switzerland). 100 cited rcts published nine journals, led england journal medicine (n = 78 articles), lancet (n = 9 articles) jama (n = 7 articles). landmark contribution focused novel methodological approach (e.g. â\\x80\\x9cbland-altman methodâ\\x80\\x9d) trial management chronic condition (e.g. diabetes control, hormone replacement therapy postmenopausal women, multiple therapy diverse cancers, cardiovascular therapy lipid-lowering statins, antihypertensive medications, antiplatelet antithrombotic therapy). conclusions: analysis identified authors, countries, funding institutions, landmark contribution high-impact-factor medical journal publishing rcts. last 50 years, publication production leading medical journal increased, western country leading research low- middle-income country showing limited representation.',\n",
       " 'background: professional caregiver working child youth welfare institution frequently faced complex mental issues, emotional need challenging coping strategy client cumulated traumatic experiences, leaving prone developing high level stress, burn-out compassion fatigue. trauma-informed care (tic) milieu-therapeutic approach aim promote self-efficacy self-care youth welfare staff guiding better understanding clientsâ\\x80\\x99 stress symptom countertransference. despite increasing effort implement tic practices, widespread recognition value youth welfare systems, lack study evaluating effectiveness approach. aim ass effect tic practice youth welfare institution physiological stress staff member clientsâ\\x80\\x99 physical aggression towards caregivers. . methods: obtained longitudinal investigating effectiveness tic 14 residential youth welfare institutions. sample consisted 47 youth welfare employee (66.0% female) aged 23 60 year (m = 37.4, sd = 10.4 years). hair cortisol concentration (hcc) occurrence client physical aggression assessed four annual measurement time point (t1 t4). results: participant five institution employing tic practice (intervention group) showed significantly lower hcc t4 staff member institution receive training tic (control group), indicating reduced physiological stress levels. t4, intervention group reported significantly le physical aggression control group. conclusions: tic might approach reducing emotional burden employee institution invest training staff tic practices. research necessary, investigate benefit efficacy tic, youth staff members, foster better understanding specific factor may contribute stress reduction.',\n",
       " 'background: catheter-related bloodstream infection (cr-bsi) cause high neonatal mortality related inadequate aseptic technique care maintenance catheter. incidence cr-bsi among neonate hung vuong hospital higher neonatal care centre vietnam. methods: 18-month pre- post-intervention conducted three 6-month period evaluate effectiveness intervention cr-bsi identify risk factor associated cr-bsi. intervention period, trained nurse department neonatology bsi preventive practices, provided auditing feedback aseptic technique catheter care maintenance, reorganised preparation total parenteral nutrition. neonate intravenous catheter insertion â\\x89¥48 h pre- post-intervention period enrolled. standardised questionnaire used collect data. blood sample collected cultures. used poisson regression calculate rate ratio (rr) 95% confidence interval (ci) cr-bsi incidence rate logistic regression identify risk factor associated cr-bsi. results: 2225 neonate enrolled, 1027 enrolled pre-intervention period, 53 cr-bsi case occurred 8399 catheter-days, 1198 enrolled post-intervention period, 32 cr-bsi case occurred 8324 catheter-days. incidence rate cr-bsi significantly decreased intervention (rr = 0.61, 95% ci 0.39â\\x80\\x930.94). day hospitalisation, episode non-catheterâ\\x80\\x93related hospital-acquired infections, proportion death significantly decreased intervention (p < 0.01). cr-bsi associated day intravenous catheter (odds ratio [or] = 1.05, 95% ci 1.03â\\x80\\x931.08), use endotracheal intubation (or = 2.27, 95% ci 1.27â\\x80\\x934.06), intravenous injection (or = 8.50, 95% ci 1.14â\\x80\\x9363.4). conclusions: intervention significantly decreased incidence rate cr-bsi. regular refresher training auditing feedback aseptic technique care maintenance catheter critical reducing cr-bsi.',\n",
       " 'background: pneumonia frequent complication undergoing heart transplantation (htx) increase morbidity mortality population. nevertheless, risk factor postoperative pneumonia (pop) still unknown. aim investigate predictive risk factor pop htx recipients. methods: retrospective study, undergoing htx january 2014 december 2015 included. case pop occurring hospital discharge investigated. aimed determine risk factor univariate multivariate cox regression models. expressed odds ratio [95% ci]. p < 0.05 necessary reject null hypothesis. results: total 175 included without lost follow-up, 89 instance pop diagnosed 59 (34%) patients. enterobacteriaceae pseudomonas aeruginosa common pathogens. multivariate analysis, risk factor preoperative mechanical ventilation (or 1.42 [1.12â\\x80\\x931.80], p < 0.01) perioperative blood transfusion (or 1.42 [95% ci: 1.20â\\x80\\x931.70], p < 0.01). pop significantly impacted mortality 30 day (or: 4 [1.3â\\x80\\x9312.4], p = 0.01) 1 year (or: 6.8 [2.5â\\x80\\x938.4], p < 0.01) associated longer duration mechanical ventilation, time weaning venoarterial extracorporeal membrane oxygenation stay intensive care unit. plasma exchange intravenous administration immunoglobulin increase risk pop. conclusion: htx, preoperative mechanical ventilation blood transfusion risk factor pop associated increased mortality. enterobacteriaceae pseudomonas aeruginosa common pathogen pop.',\n",
       " 'background: immunization attenuated malaria sporozoite protects human experimental malaria challenge mosquito bite. protection human strongly correlated production cell targeting heterogeneous population pre-erythrocyte antigen proteoforms, liver stage antigens. currently, cell epitope derived plasmodium falciparum, major aetiologic agent malaria human known. methods: vitro vivo malaria liver stage model used sequence host pathogen proteoforms. proteoforms diverse model subjected mild acid elution (of soluble forms), multi-dimensional fractionation, tandem mass spectrometry, top-down bioinformatics analysis identify proteoforms intact state. results: result identify group host malaria liver stage proteoforms meet 5% false discovery rate threshold. conclusions: work provides proof-of-concept validity mass spectrometry/bioinformatic approach future study seeking reveal malaria liver stage antigen towards vaccine development.',\n",
       " 'background: toxocariasis worldwide zoonotic parasitic caused specie toxocara toxascaris, common dog cats. herein, meta-analysis contrived ass prevalence toxocara/toxascaris carnivore human host different region iran april 1969 june 2019. methods: available online article english (pubmed, science direct, scopus, ovid) persian (sid, iran medex, magiran, iran doc) database article presented held parasitology congress iran involved. results: weighted prevalence toxocara/toxascaris dog (canis familiaris) cat (felis catus) 24.2% (95% ci: 18.0â\\x80\\x9331.0%) 32.6% (95% ci: 22.6â\\x80\\x9343.4%), respectively. also, pooled prevalence jackal (canis aureus) red fox (vulpes vulpes) 23.3% (95% ci: 7.7â\\x80\\x9343.2%) 69.4% (95% ci: 60.3â\\x80\\x9377.8%), correspondingly. weighted mean prevalence human case overall 28 record 9.3% (95% ci: 6.3â\\x80\\x9313.1%). weighted prevalence toxocara canis, toxocara cati, toxascaris leonina represented 13.8% (95% ci: 9.8â\\x80\\x9318.3%), 28.5% (95% ci: 20â\\x80\\x9337.7%) 14.3% (95% ci: 8.1â\\x80\\x9322.0%), respectively. conclusion: meta-analysis result illustrate considerable prevalence rate toxocara/toxascaris, particularly cat dog northern part iran. presence suitable animal hosts, optimum climate close contact human animal would reason higher seroprevalence rate human case region. given significance clinical outcome human toxocara/toxascaris, necessary measure taken.',\n",
       " \"despite availability highly effective direct-acting antiviral (daa) regimen hepatitis c (hcv) infections, sustained response (svr) rate remain suboptimal difficult-to-treat population hcv genotype 3, cirrhosis prior experience, warranting development potent hcv replication antivirals. at-527 hemi-sulfate salt at-511, novel phosphoramidate prodrug 2â\\x80\\x99-fluoro-2â\\x80\\x99-c-methylguanosine-5'-monophosphate potent vitro activity hcv. ec(50) at-511, determined hcv laboratory strain clinical isolates genotype 1â\\x80\\x935, ranged 5â\\x80\\x9328 nm. active 5'-triphosphate metabolite, at-9010, specifically inhibited hcv rna-dependent rna polymerase. at-511 inhibit replication selected rna dna virus vitro. at-511 approximately 10-fold active sofosbuvir (sof) panel laboratory strain clinical isolates hcv genotype 1â\\x80\\x935 remained fully active s282t resistance-associated variants, 58-fold potency sof. vitro, at-511 inhibit human dna polymerase elicit cytotoxicity mitochondrial toxicity concentration 100 î¼m. unlike potent guanosine analog psi-938 psi-661, mutagenic o(6)-alkylguanine base formed incubated cytochrome p450 (cyp) 3a4, at-511 ic(50) value â\\x89¥25 î¼m panel cyp enzymes. hepatocytes multiple species, active triphosphate predominant metabolite produced prodrug, half-life 10 h human hepatocytes. given orally rat monkeys, at-527 preferentially delivered high level at-9010 liver vivo. favorable preclinical attribute support ongoing clinical development at-527 suggest that, used combination hcv daa different class, at-527 may increase svr rates, especially difficult-to-treat populations, could potentially shorten duration patients.\",\n",
       " 'retrospective cohort investigated association in-hospital survival two-dimensional (2d) echocardiography within 24 hour return spontaneous circulation (rosc) underwent in-hospital cardiopulmonary resuscitation (icpr) in-hospital cardiopulmonary arrest (ihca). 2d-echo non-2d-echo group comprised eligible underwent transthoracic 2d echocardiography performed cardiology team within 24 hour rosc not, respectively. propensity score (ps) matching, 142 284 2d-echo non-2d-echo groups, respectively, included. logistic regression analysis showed likelihood in-hospital survival 2.35-fold higher 2d-echo group non-2d-echo group (p < 0.001). regarding ihca aetiology, in-hospital survival cardiac arrest cardiac cause 2.51-fold likely 2d-echo group non-2d-echo group (p < 0.001), significant inter-group difference survival cardiac arrest non-cardiac cause (p = 0.120). study, 2d echocardiography performed within 24 hour rosc associated better in-hospital survival outcome underwent icpr ihca cardiac aetiology. thus, 2d echocardiography may performed within 24 hour rosc experiencing ihca enable better treatment.',\n",
       " 'qx-type avian infectious bronchitis (ibv) still prevalent genotype southwestern china. analyze antigenicity pathogenicity characteristic dominant genotype strain (qx-type), s1 gene sequence analysis, cross-neutralization tests, pathogenicity test eight qx-type ibv isolates conducted. sequence analysis showed nucleotide homology eight strain high, distantly related h120 4/91 vaccine strains. cross-neutralization test showed eight strain isolated 2015 2017 belonged serotype, exhibited antigenic variation time. pathogenicity test five qx-type ibv isolates showed three strains, ck/ch/sc/dyw/16, ck/ch/sc/ms/17, ck/ch/sc/gh/15, high mortality rate strong respiratory renal pathogenicity, whereas ck/ch/sc/pz/17 ck/ch/sc/dyyj/17 caused mild clinical symptom tissue lesions. result indicate prevalent qx-type ibvs displayed antigenic variation pathogenicity difference. finding may provide reference research evolution ibv vaccine preparation infectious bronchitis (ib).',\n",
       " 'background: prostaglandin (pg) lipid mediator derived arachidonic acid metabolism. involved cellular process inflammation tissue homeostasis. pg production restricted multicellular organisms. trypanosomatids synthesize several metabolite arachidonic acid. nevertheless, biological role early-branching parasite role host-parasite interaction well elucidated. prostaglandin f(2î±) synthase (pgf2s) observed leishmania braziliensis secreted proteome l. donovani extracellular vesicles. furthermore, reported positive correlation l. braziliensis pgf2s (lbrpgf2s) expression pathogenicity mice. methods: lbrpgf2s gene expression pgf2î± synthesis promastigotes detected quantified western blotting eia assay kit, respectively. investigate lbrpgf2s localization amastigotes bone marrow-derived macrophage infection, parasite expressing mcherry-lbrpgf2s generated followed time-lapse imaging 48 h post-infection. pgf2s homolog sequence leishmania human analyzed silico clustalw geneious v6 emboss needle. results: leishmania braziliensis promastigotes synthesize prostaglandin f(2î±) presence arachidonic acid, peak production stationary growth phase heat stress. lbrpgf2s cytoplasmic protein enriched secretory site parasite cell body, flagellar pocket. enzyme constitutively expressed throughout promastigote development, overexpression lbrpgf2s lead increase infectivity vitro. suggest lbrpgf2s may released intracellular amastigotes cytoplasm bone marrow-derived macrophage 48-hour period, time-lapse microscopy mcherry-pgf2s (mchpgf2s)-expressing parasites. conclusions: lbrpgf2s, parasite-derived protein, targeted host cell cytoplasm. putative transfer enzyme, involved pro-inflammatory lipid mediator synthesis, host cell suggests potential role host-parasite interaction may partially explain increased pathogenicity associated overexpression lbrpgf2s l. braziliensis. provide valuable insight help understand importance parasite-derived lipid mediator pathogenesis. [image: see text]',\n",
       " 'background: plasmodium falciparum (pf) whole-organism sporozoite vaccine provide significant protection controlled human malaria (chmi) clinical trials. initial chmi study showed significantly higher durable protection homologous heterologous strains, suggesting presence strain-specific vaccine-induced protection. however, interpretation result understanding relevance vaccine efficacy hampered lack knowledge genetic difference vaccine chmi strains, strain related parasite malaria endemic regions. methods: whole genome sequencing long-read (pacific biosciences) short-read (illumina) sequencing platform conducted generate de novo genome assembly vaccine strain, nf54, strain used heterologous chmi (7g8 brazil, nf166.c8 guinea, nf135.c10 cambodia). assembly used characterize sequence strain relative reference 3d7 (a clone nf54) genome. strain compared collection clinical isolates (sequenced part public repositories) south america, sub-saharan africa, southeast asia. results: variant detected 3d7 nf54, identified ten thousand variant nf54 three heterologous strains. variant include snps, indels, small structural variant fall regulatory immunologically important regions, transcription factor (such pfap2-l pfap2-g) pre-erythrocytic antigen may key sporozoite vaccine-induced protection. additionally, variant directly contributed diversity immunologically important region genome detected silico cd8(+) cell epitope predictions. heterologous strains, nf135.c10 highest number unique predicted epitope sequence compared nf54. comparison global clinical isolates revealed four strain representative geographic origin despite long-term culture adaptation; note, nf135.c10 admixed population, part formed subpopulation resistant artemisinin-based therapy present greater mekong sub-region. conclusions: result assist interpretation vaccine efficacy whole-organism vaccine homologous heterologous chmi. electronic supplementary material: online version article (10.1186/s13073-019-0708-9) contains supplementary material, available authorized users.',\n",
       " 'background: knowledge parasitic infection crucial information animal health, particularly free-ranging specie might come contact livestock humans. methods: investigated seroprevalence three tissue-cyst-forming apicomplexan parasite (toxoplasma gondii, neospora caninum besnoitia besnoiti) 506 individual 12 wildlife specie namibia in-house enzyme linked immunosorbent assay (indirect elisa applying purified antigens) screening immunoblots confirmatory tests. included six specie suborder feliformia, four specie suborder caniformia two specie suborder ruminantia. two specie sample life-history information, i.e. cheetah (acinonyx jubatus, n = 250) leopard (panthera pardus, n = 58), investigated t. gondii seroprevalence relation age class, sex, sociality (solitary, mother-offspring group, independent sibling group, coalition group) site (natural habitat v farmland). results: carnivore specie (bat-eared fox otocyon megalotis, n = 4) seropositive t. gondii, seroprevalence ranging 52.4% (131/250) cheetah 93.2% (55/59) african lion (panthera leo). detected antibody t. gondii 10.0% (2/20) blue wildebeest (connochaetes taurinus). adult cheetah leopard likely seropositive t. gondii subadult conspecifics, whereas seroprevalence vary sex, sociality site. furthermore, measured antibody n. caninum 15.4% (2/13) brown hyena (hyaena brunnea) 2.6% (1/39) black-backed jackal (canis mesomelas). antibody b. besnoiti detected 3.4% (2/59) african lion 20.0% (4/20) blue wildebeest. conclusions: result demonstrate namibian wildlife specie exposed apicomplexan parasite different prevalences, depending parasite host species. addition serological work, molecular work needed better understand sylvatic cycle clear role wildlife epidemiology parasite southern africa.',\n",
       " 'plasmacytoid dendritic cell (pdcs) sensor cell diverse immune functions, type interferon (ifn-i) production antigen presentation, cell activation, tolerance. regulation function remains poorly understood could mediated functionally specialized pdc subpopulations. address pdc diversity high-dimensional single-cell approach: mass cytometry (cytof). analysis uncovers murine pdc-like population specializes antigen presentation limited capacity ifn-i production. multifaceted cross-species comparison, pdc-like population definitive murine equivalent described human axl(+) dcs, unify name transitional dc (tdcs) given continuum pdc cdc2 characteristics. tdcs share developmental trait pdcs, well recruitment dynamic infection. altogether, provide framework deciphering function pdcs tdcs diseases, potential open avenue therapeutic design.',\n",
       " 'freya shearer co-authors discus use decision analysis planning infectious pandemics.',\n",
       " 'hiv infection, cell-to-cell transmission result endosomal uptake target cd4+ cell potential exposure ssrna genome endosomal toll-like receptor (tlrs). tlrs instrumental activating inflammatory response innate immune cells, function adaptive immune cell le well understood. synthetic ligand tlr8 boosted cell receptor signaling, resulting increased cytokine production upregulation surface activation markers. adjuvant tlr8 stimulation, tlr7 tlr9, promoted helper cell differentiation towards th1 th17. addition, found endosomal hiv induced cytokine secretion cd4+ cell tlr8-specific manner. tlr8 engagement enhanced hiv-1 replication potentiated reversal latency patient-derived cells. adjuvant tlr8 activity cell contribute dissemination lymph node low-grade inflammation hiv patients. addition, potentially exploited therapeutic targeting vaccine development.',\n",
       " 'role laparoscopic surgery left-sided colon cancer supported result randomized controlled trials. however, benefit disadvantage real world setting assessed population-based studies.the hospitalization undergoing open laparoscopic surgery left-sided colon cancer sourced taiwan national insurance research database. hospital characteristic perioperative outcome length hospital stay, operation time, opioid use, blood transfusion, intensive care unit (icu) admission, use mechanical ventilation compared. overall survival assessed. undergoing laparoscopic surgery shorter hospital stay (p < 0.0001) le demand opioid analgesia (p = 0.0005). logistic regression revealed undergoing open surgery 1.70, 2.89, 3.00 time likely blood transfusion, admitted icu, use mechanical ventilation undergoing laparoscopic surgery. operation performed medical center associated le adverse events. overall survival comparable 2 groups.with adequate hospital quality volume, laparoscopic surgery left-sided colon cancer associated improved perioperative outcomes. long-term survival compromised.',\n",
       " 'background: spirochetal organism treponema genus responsible causing treponematoses. pathogenic treponemes gram-negative, motile, spirochete pathogen cause syphilis human. treponema pallidum subsp. endemicum (ten) cause endemic syphilis (bejel); t. pallidum subsp. pallidum (tpa) cause venereal syphilis; t. pallidum subsp. pertenue (tpe) cause yaws; t. pallidum subsp. ccarateum cause pinta. four high morbidity diseases, venereal syphilis mediated sexual contact; three disease transmitted close personal contact. global distribution syphilis alarming increasing need proper preventive measures. unfortunately, effective measure limited. results: here, genome sequence 53 t. pallidum strain isolated different part world diverse range host comparatively analysed pan-genomic strategy. phylogenomic, pan-genomic, core genomic singleton analysis disclosed close connection among strain pathogen t. pallidum, clonal behaviour showed increase size pan-genome. based genome plasticity analysis subset containing subspecies pallidum subsp. pallidum, t. pallidum subsp. endemicum t. pallidum subsp. pertenue, found difference presence/absence pathogenicity island (pais) genomic island (gis) subsp.-based study. conclusions: summary, identified four pathogenicity island (pais), eight genomic island (gis) subsp. pallidum, whereas subsp. endemicum three pais seven gi subsp. pertenue harbour three pais eight gis. concerning presence gene pais gis, found gene related lipid amino acid biosynthesis present subsp. t. pallidum, compared t. pallidum subsp. endemicum t. pallidum subsp. pertenue.',\n",
       " 'background: epidemiologic study cocaine- amphetamine-regulated transcript prepropeptide (cartpt) gene polymorphism modifies diet-obesity relationships. however, interaction cartpt gene polymorphism diet quality index investigated yet. current aimed evaluate interaction major dietary index diet quality index-international (dqi-i) healthy eating index (hei)-2015 cartpt gene rs2239670 variant among apparently healthy obese iranians. methods: cross-sectional carried employing 288 apparently healthy obese adult aged 20â\\x80\\x9350 year bmi 30â\\x80\\x9340 kg/m(2). diet quality evaluated diet quality index-international (dqi-i) healthy eating index-2015 (hei-2015) 132-items semi-quantitative validated food frequency questionnaire. cartpt gene rs2239670 polymorphism genotyped polymerase chain reaction-restriction fragment length polymorphism (pcrâ\\x80\\x93rflp) technique. blood concentration glycemic markers, lipid profile, î±-melanocyte stimulating hormone (msh) agouti-related peptide (agrp) measured. ancova multivariate interaction model used analyze gene-diet interactions. results: significant interaction identified cartpt gene polymorphism hei, affecting bmr (p(interaction) = 0.003), serum glucose (p(interaction) = 0.009) high density lipoprotein cholesterol hdl concentration (p(interaction) = 0.03) adjusting effect sex age. found gene-diet interaction cartpt genotype dqi-i term fat mass (fm; p(interaction) = 0.02), waist circumference (wc; p(interaction) < 0.001), body mass index (bmi; p(interaction) < 0.001), basal metabolic rate (bmr, p(interaction) < 0.001), serum fasting glucose (p(interaction) < 0.01) agrp (p(interaction) = 0.05) individual even adjusting potential confounders. conclusion: current showed effect interaction cartpt genotype adherence hei dqi-i score obesity-related anthropometric metabolic risk-factors.',\n",
       " 'avian influenza outbreak 1997 highlighted potential highly pathogenic h5n1 cause severe humans. therefore, effective vaccine h5n1 virus needed counter potential threat global pandemic. developed fast-acting efficacious vaccine ebola (ebov) vesicular stomatitis (vsv) platform. study, generated recombinant vsv-based h5n1 influenza vector demonstrate feasibility platform fast-acting pan-h5 influenza vaccine. chose multiple approach regarding antigen design genome location define optimized vaccine approach. vsv-based h5n1 influenza construct recovered characterized vitro, mouse vaccinated single dose prime/boost regimen followed challenge lethal dose homologous h5 clade 1 virus. found single dose vsv vector expressing full-length hemagglutinin (hafl) sufficient provide 100% protection. vaccine vector fast-acting demonstrated uniform protection administered 3 day prior lethal challenge. moreover, single vaccination induced cross-protective h5-specific antibody protected mouse lethal challenge various h5 clade 2 viruses, highlighting potential vsv-based hafl pan-h5 influenza emergency vaccine.',\n",
       " 'background: optimal anti-bacterial activity meropenem requires maintenance plasma concentration (cp) minimum inhibitory concentration (mic) pathogen least 40% dosing interval (ft > mic > 40). aimed determine whether 3-h extended infusion (ei) meropenem achieves ft > mic > 40 first third day therapy severe sepsis septic shock. simulated performance ei respect pharmacokinetic (pk) target ft > 4 ã\\x97 mic > 40, ft > mic = 100, ft > 4 ã\\x97 mic = 100. methods: arterial blood sample 25 adult severe sepsis septic shock receiving meropenem 1000 mg 3-h ei eight hourly (q8h) obtained various interval first seventh doses. plasma meropenem concentration determined reverse-phase high-performance liquid chromatography assay, followed modeling simulation pk data. european committee antimicrobial susceptibility testing (eucast) definition mic breakpoints sensitive resistant gram-negative bacteria used. results: 3-h ei meropenem 1000 mg q8h achieved ft > 2 âµg/ml > 40 first third days, providing activity sensitive strain enterobacteriaceae, pseudomonas aeruginosa acinetobacter baumannii. however, failed achieve ft > 4 âµg/ml > 40 provide activity strain susceptible increased exposure 33.3 39.1% first third days, respectively. modeling simulation showed bolus dose 500 mg followed 3-h ei meropenem 1500 mg q8h achieve target. bolus 500 mg followed infusion 2000 mg would required achieve ft > 8 âµg > 40. target ft > 4 âµg/ml = 100 ft > 8 âµg/ml = 100 may achievable two-thirds increasing frequency dosing six hourly (q6h). conclusions: severe sepsis septic shock, ei 1000 mg meropenem 3 h administered q8h inadequate provide activity (ft > 4 âµg/ml > 40) strain susceptible increased exposure, requires bolus 500 mg followed ei 1500 mg q8h. ft > 8 âµg/ml > 40 require escalation ei dose, ft > 4 âµg/ml = 100 ft > 8 âµg/ml = 100 require escalation ei dose frequency.',\n",
       " 'background: herpes simplex (hsv) replication detected respiratory secretion high proportion ventilated intensive care unit (icu) patients. however, clinical significance remains poorly defined. investigated whether ventilator-associated pneumonia responding antibiotic high level hsv could detected respiratory secretion benefit acyclovir treatment. methods: respiratory secretion (bronchoalveolar lavage fluid tracheal aspirates) tested hsv replication quantitative real-time pcr. icu survival times, clinical parameters, radiographic finding retrospectively compared untreated acyclovir treated high (> 10(5) hsv copies/ml) low (10(3)â\\x80\\x9310(5) hsv copies/ml) load. results: fifty-seven low 69 high load identified. fewer high load responded antibiotic (12% compared 40% low load patients, p = 0.001). acyclovir improved median icu survival (8 v 22 days, p = 0.014) associated significantly reduced hazard ratio icu death (hr = 0.31, 95% ci 0.11â\\x80\\x930.92, p = 0.035) high load only. moreover, circulatory pulmonary oxygenation function high load improved significantly course acyclovir treatment: mean norepinephrine dos decreased 0.05 0.02 î¼g/kg body weight/min day 0 6 (p = 0.049), median pao(2)/fio(2) ratio increased 187 241 3 7 (p = 0.02). chest radiographic finding improved significantly (p < 0.001). conclusions: ventilator-associated pneumonia, antibiotic failure, high level hsv replication, acyclovir associated significantly longer time death icu improved circulatory pulmonary function. suggests causative role hsv highly selected group patients.',\n",
       " 'background: predisposing condition risk modifier instead cause risk factor used alternative identify risk acute respiratory distress syndrome (ards). however, regarding risk modifier among non-pulmonary sepsis rare. methods: conducted secondary analysis multicenter, prospective, focused outcome research emergency care acute respiratory distress syndrome, sepsis trauma (forecast) cohort conducted 59 intensive care unit (icus) japan january 2016â\\x80\\x93march 2017. adult severe sepsis caused non-pulmonary included, primary outcome ards, defined meeting berlin definition first fourth screening. multivariate logistic regression modeling used identify risk modifier associated ards, odds ratio (ors) 95% confidence interval reported. following explanatory variable assessed: age, sex, admission source, body mass index, smoking status, congestive heart failure, chronic obstructive pulmonary disease, diabetes mellitus, steroid use, statin use, site, septic shock, acute physiology chronic evaluation (apache) ii score. results: applying inclusion exclusion criteria, 594 non-pulmonary sepsis enrolled, among 85 (14.3%) ards. septic shock diagnosed 80% ards 66% without ards (p = 0.01). apache ii score higher ards [26 (22â\\x80\\x9333)] without ards [21 (16â\\x80\\x9328), p < 0.01]. multivariate logistic regression model, following independently associated ards: icu admission source [or, 1.89 (1.06â\\x80\\x933.40) emergency department compared hospital wards], smoking status [or, 0.18 (0.06â\\x80\\x930.59) current smoking compared never smoked], site [or, 2.39 (1.04â\\x80\\x935.40) soft tissue compared abdominal infection], apache ii score [or, 1.08 (1.05â\\x80\\x931.12) higher compared lower score]. conclusions: soft tissue infection, icu admission emergency department, higher apache ii score appear risk modifier ards non-pulmonary sepsis.',\n",
       " 'background: vietnam shifting toward integrating hiv service public system social insurance (shi), hiv service delivery system becoming decentralized. aim investigate current shi coverage patientsâ\\x80\\x99 perspective transition. methods: survey 1348 hiv-positive antiretroviral therapy (aged â\\x89¥18 years) conducted hiv outpatient clinic central-level hospital hanoi, vietnam, october november 2018. insurance coverage, reason shi card, perceived concern receiving hiv service shi-registered local facilities, willingness continue regularly visiting current hospital self-reported. logistic regression analysis performed analyze factor associated shi card concern receiving hiv service shi-registered hospitals/clinics. results: shi coverage 78.0%. frequently reported reason shi card obtaining burdensome, followed lack information obtain card, financial problems. (86.6%) concern receiving hiv service shi-registered local facilities, disclosure hiv status neighbor low quality hiv service main concern reported. participant aged < 40 year old unmarried likely report lack shi cards, woman aged â\\x89¥40 year likely concerns. however, 91.4% showed willingness continue regular visit current hospital. conclusions: although shi coverage rapidly improving among hiv patients, participant concern current system transition vietnam. response voiced concerns, strengthening link higher-level lower-level facility may help ensure good quality hiv service level mitigating patientsâ\\x80\\x99 worry anxieties.',\n",
       " 'background: acute diarrhoea common cause illness death among child low- middle-income settings. world organization guideline clinical management acute watery diarrhoea child focus oral rehydration, supplemental zinc feeding advice. routine use antibiotic recommended except diarrhoea bloody cholera suspected. young child undernourished dehydrating diarrhoea susceptible death 90 day onset diarrhoea. given mortality risk associated diarrhoea child malnutrition dehydrating diarrhoea, expanding use antibiotic subset child could important intervention reduce diarrhoea-associated mortality morbidity. designed antibiotic childhood diarrhoea (abcd) trial test intervention. methods: abcd double-blind, randomised trial recruiting 11,500 child aged 2â\\x80\\x9323 month presenting acute non-bloody diarrhoea dehydrated and/or undernourished (i.e. high risk mortality). enrolled child bangladesh, india, kenya, malawi, mali, pakistan tanzania randomised (1:1) oral azithromycin 10 mg/kg placebo daily 3 day followed-up 180 days. primary efficacy endpoint all-cause mortality 180 day post-enrolment change linear growth 90 day post-enrolment. discussion: expanding acute watery diarrhoea high-risk child include antibiotic may offer opportunity reduce deaths. benefit may direct antimicrobial effect pathogen incompletely understood mechanism improved nutrition, alteration immune responsiveness improved enteric function. expansion indication antibiotic use raise concern emergence antimicrobial resistance within treated child community live. abcd monitor antimicrobial resistance. abcd trial important policy implications. trial show significant benefit azithromycin use, may provide evidence support reconsideration antibiotic indication present world organization diarrhoea management guidelines. conversely, evidence benefit, result support current avoidance antibiotic except dysentery cholera, thereby avoiding inappropriate use antibiotic reaffirming current guidelines. trial registration: clinicaltrials.gov, nct03130114. registered april 26 2017.',\n",
       " 'background: retrograde type aortic dissection (rtad) fatal aortic secondary descending aortic dissection, might misdiagnosed due atypical symptom lead catastrophic outcomes. presentation: herein reported 40-year old chinese non-comorbid man received conservative acute type b aortic dissection progressed rtad painless manner week. open surgical aortic repair stented elephant truck technique, survived without obvious complication cured satisfactory outcome half-year follow-up. conclusion: indicates rtad may present without typical symptoms, early diagnosis open surgical procedure imperative treating rtad.',\n",
       " 'paper introduce single serotype transmission model, age-dependent mosquito biting rate, find optimal vaccination age dengue brazil dengvaxia. optimal vaccination age minimal lifetime expected risk hospitalisation found adapting due hethcote (math biosci 89:29â\\x80\\x9352). number combination four dengue serotypes denv1â\\x80\\x934 considered. successful vaccination serotype corresponds silent infection. effect antibody-dependent enhancement (ade) permanent cross-immunity two heterologous infection studied. ade assumed imply risk-free primary infections, permanent cross-immunity implies risk-free tertiary quaternary infections. trial dengvaxia indicate vaccine efficacy age serostatus dependent vaccination seronegative individual induce increased risk hospitalisation. scenario therefore reconsidered taking finding account. optimal vaccination age compared achievable current age restriction vaccine. vaccination considered induce risk, optimal vaccination age low. assumption ade generally lead higher optimal vaccination age case. single serotype vaccination recommended ade. permanent cross-immunity result slightly lower optimal vaccination age. vaccination induces risk, optimal vaccination age much higher, particularly permanent cross-immunity. ade effect optimal vaccination age permanent cross-immunity considered; otherwise, lead slight increase optimal vaccination age. electronic supplementary material: online version article (10.1007/s11538-019-00690-1) contains supplementary material, available authorized users.',\n",
       " 'background: aim investigate concordance ventilator-associated event (vae) ventilator-associated lower respiratory tract infection (va-lrti), impact outcome. methods: retrospective performed five 10-bed icu teaching hospital, 2-year period. ventilator-associated lower respiratory tract infection (va-lrti), ventilator-associated tracheobronchitis (vat) ventilator-associated pneumonia (vap) prospectively diagnosed. agreement vae, vat vap assessed k statistics. results: total 1059 (15,029 ventilator-days) included. 268 vap (17.8 per 1000 ventilator-days), 127 vat (8.5 per 1000 ventilator-days) 262 vae (17.4 per 1000 ventilator-days) diagnosed. agreement vat vae, agreement poor vap vae (k = 0.12, 95% ci 0.03â\\x80\\x930.20). vae va-lrti associated significantly longer duration mechanical ventilation, icu hospital length stay. vap, vat vae significantly associated mortality multivariate analysis. conclusions: agreement poor vae vap. agreement found vae vat. vae episode significantly associated longer duration mechanical ventilation length stay, icu mortality.',\n",
       " 'sepsis typically triggered overwhelming systemic inflammatory response pathogens, may lead severe organ dysfunction and/or death. sepsis consequently high mortality rate high rate complication survivors, despite modern medical advances. therefore, drug identification validation sepsis utmost importance. selective phosphodiesterase-4 inhibitor, rolipram exhibit ability inhibiting multiple pro-inflammatory cytokine production macrophage toxin-induced inflammation mice. however, drug never studied sepsis method. found rolipram significantly improves survival mouse challenged gram-negative bacterium e. coli, clp, e. coli derived lipopolysaccharide. found rolipram inhibits organ damage, pro-inflammatory cytokine production, intracellular migration early-stage inflammatory elements. result rolipram increase anti-inflammatory cytokine production. protective effect rolipram septic mouse may inhibition map kinase nf-îºb signaling pathways. rolipram may therefore potential novel sepsis treatment, would bypass time-consuming costly drug-discovery process.',\n",
       " 'background: streptococcus agalctiae (group b streptococcus, gbs) perinatal pathogen leading cause neonatal infection worldwide. serotype, sequence type, clonality, antibiotic resistance gene surface protein profile gb scarce ethiopia, reason planned investigate. . methods: sixteen colonizing gb isolates obtained recto-vaginal swab pregnant woman body surface newborn analyzed. minimum inhibitory concentration (mic) test, whole genome sequence (wgs) method done antibiotic susceptibility test, molecular characterization isolates. results: gb isolates analyzed belonged four capsular serotypes: ii, 11/16(68.8%), v, 3/16(18.8%), ia vi 1/16(6.3%) five sequence type (st-2, st-10, st-14, st-569 st-933). sequence type-10 predominant st followed st-569. five sts grouped four clonal complex (cc - 1, cc-10, cc-19, cc-23). different surface protein pili family alp1, alpha, alp23, pi-1 / pi-2a1, pi-1 / pi-2b, srr1 detected wgs data. isolates found susceptible tested antibiotic except tetracycline mic wgs test method used. tetracycline resistant determinant gene tetm tetl / tetm combination identified. conclusion: study serotype molecular epidemiology provide comprehensive gb capsular serotype clone available ethiopia.',\n",
       " 'background: use extracorporeal membrane oxygenation (ecmo) bridge lung transplantation greatly increased. however, regarding clinical outcome approach lacking. objective multicenter prospective observational cohort evaluate lung transplantation outcome korean organ transplantation registry (kotry) ecmo used bridge transplantation. methods: march 2015 december 2017, total 112 received lung transplantation registered kotry, prospective, multicenter cohort registry. entire cohort divided two groups: control group (n = 85, 75.9%) bridge-ecmo group (n = 27, 24.1%). results: significant difference pre-transplant intraoperative characteristic except poorer oxygenation, ventilator use, longer operation time bridge-ecmo group. prevalence primary graft dysfunction 0, 24, 48, 72 h transplantation differ two groups. although postoperative hospital stay longer bridge-ecmo group control group, hospital mortality differ two group (25.9% vs. 13.3%, p = 0.212). majority (70.4% bridge-ecmo group 77.6% control group) discharged directly homes. finally, use ecmo bridge lung transplantation significantly affect overall survival graft function. conclusions: short- long-term post-transplant outcome bridge-ecmo comparable recipient receive ecmo.',\n",
       " 'background: new-onset atrial fibrillation (noaf) commonly encountered critically ill adults. evidence evaluating association noaf patient-important outcome population conflicting. furthermore, little known regarding association noaf resource use hospital costs. methods: retrospective analysis (2011â\\x80\\x932016) prospectively collected registry two canadian hospital consecutive icu aged â\\x89¥ 18 years. excluded known history af prior hospital admission. occurrence atrial fibrillation (af) prospectively recorded bedside nurses. primary outcome hospital mortality, used multivariable logistic regression adjust confounders. used generalized linear model evaluate contributor total cost. results: included 15,014 patients, 1541 (10.3%) noaf icu admission. noaf associated increased odds hospital death among entire cohort (adjusted odds ratio [aor] 1.02 [95% confidence interval [ci] 0.97â\\x80\\x931.08]), interaction noted noaf sepsis, presence associated higher odds hospital mortality (aor 1.28 [95% ci 1.09â\\x80\\x931.36]) either alone. noaf higher total cost (cost ratio [cr] 1.09 [95% ci 1.02â\\x80\\x931.20]). among noaf, rhythm-control strategy associated higher cost (cr 1.24 [95% ci 1.07â\\x80\\x931.40]). conclusions: noaf associated death requiring discharge long-term care among critically ill patients, associated increased length stay icu increased total costs.',\n",
       " 'background: present aim ass cost-effectiveness influenza vaccination program child netherlands. requires evaluation long-term impact program burden influenza across age groups, transmission model account seasonal variability vaccine effectiveness shorter duration protection following vaccination compared natural infection. methods: performed cost-effectiveness analysis based stochastic dynamic transmission model calibrated reported gp visit influenza-like illness netherlands 11 season (2003/2004 2014/2015). analyzed cost effect extending current program vaccination child aged 2â\\x80\\x9316 year 50% coverage 20 consecutive seasons. measured effect quality-adjusted life-years (qalys) adopted societal perspective. results: childhood vaccination program estimated average incremental cost-effectiveness ratio (icer) â\\x82¬3944 per qaly gained cost-effective general population (across 1000 simulations; conventional dutch threshold â\\x82¬20,000 per qaly gained). childhood vaccination program estimated cost-effective target-group average icer â\\x82¬57,054 per qaly gained. uncertainty analysis reveal icers hide wide range outcomes. even though introduction childhood vaccination program decrease number infections, tends lead larger epidemics: 23.3% 1000 simulations, childhood vaccination program result increase season symptomatic attack rate larger 5%, expected cause serious strain care system. 6.4% 1000 simulations, childhood vaccination program lead net loss qalys. finding robust across different targeted age group vaccination coverages. conclusions: modeling indicates childhood influenza vaccination cost-effective netherlands. however, childhood influenza vaccination cost-effective outcome child considered. approximately quarter simulations, introduction childhood vaccination program increase frequency season symptomatic attack rate larger 5%. possibility overall loss cannot excluded.',\n",
       " 'backgrounds: aim investigating benefit harm neuromuscular blocking agent (nmbas) acute respiratory distress syndrome (ards). methods: comprehensively searched pubmed, embase, cochrane library randomized controlled trial comparing nmbas comparator. pooled relative risk (rr) dichotomous outcome weighted mean difference (wmd) continuous outcomes, 95% confidence intervals. assessed quality included study cochrane tool level evidence grade method. results: finally, six rcts (n = 1557 patients) eligible analysis. result showed nmbas use associated reduced 28 day mortality (rr 0.78; 95% ci, 0.58 1.06; p = 0.11), 90 day mortality (rr, 0.92; 95% ci, 0.81 1.04; p = 0.16), intensive care unit (icu) mortality (rr, 0.90; 95% ci, 0.79 1.03; p = 0.13) ards. however, 21â\\x80\\x9328 day mortality slightly lower received nmbas (rr 0.73; 95% ci, 0.54 0.99; p = 0.04; i(2) = 53%). besides, nmbas use could improve pao(2)/fio(2) ratio 48 72 h, decrease plateau pressure peep 72 h. additionally, nmbas significant effect day free ventilation 28 (wmd, 0.55; 95% ci, â\\x88\\x92 0.46 1.57; p = 0.29), day icu 28 (wmd, 0.12; 95% ci, â\\x88\\x92 0.85 1.08; p = 0.82), icu-acquired weakness (rr, 1.23; 95% ci, 0.99 1.93; p = 0.06). finally, nmbas use associated lower risk barotrauma (rr, 0.55; 95% ci, 0.35 0.85; p = 0.007). conclusion: respiratory distress syndrome, nmbas may beneficial reverse refractory hypoxemia may associated reduced short-term mortality incidence barotrauma. however, significant effect nmbas mid-term long-term mortality, study required.',\n",
       " 'central role erythrocyte invasion play plasmodium falciparum survival reproduction make process attractive target therapeutic vaccine development. however, multiple invasion-related gene complementary overlapping function afford parasite plasticity vary ligand used invasion, leading phenotypic variation immune evasion. overcoming challenge posed redundant ligand requires deeper understanding condition select variant phenotype molecular mediators. host factor receptor heterogeneity acquired immune response may drive parasite phenotypic variation, host-independent change invasion phenotype achieved continuous culturing w2mef dd2 p. falciparum strain moving suspension opposed static conditions. here, used highly biologically replicated whole transcriptome sequencing approach identify molecular signature variation associated phenotype switch. increased expression particular invasion-related gene switched parasites, well number gene encoding protein either exported form part export machinery. gene markedly increased expression included member erythrocyte binding antigen (eba), reticulocyte binding homologues (rh), surface associated interspersed protein (surfin), exported protein family 1 (epf1) plasmodium helical interspersed sub-telomeric (phist) gene families. indicate change expression repertoire gene associated erythrocyte invasion phenotypes, suggesting possibility moving suspension culture may select traits.',\n",
       " 'investigate ctl epitope application swine, sla-1(*)1502-restricted peptide epitope matching porcine reproductive respiratory syndrome (prrsv) strain explored crystallography, biochemistry, specific pathogen-free (spf) swine experiments. first, nine predicted prrsv peptide tested assembly peptide-sla-1(*)1502 (psla-1(*)1502) complexes, crystal structure sla-1(*)1502 complex peptide (nsp9-tmp9) determined. nsp9-tmp9 peptide conformation presented psla-1(*)1502 different peptide presented known psla-1(*)0401 psla-3(*)hs0202 complexes. two consecutive pro residue make turn p3 p4 nsp9-tmp9 much sharper. pocket psla-1(*)1502 unique important peptide binding. next, potential sla-1(*)1502-restricted peptide epitope matching four typical genetic prrsv strain identified based peptide-binding motif sla-1(*)1502 determined structural analysis alanine scanning nsp9-tmp9 peptide. tetrameric complex sla-1(*)1502 nsp9-tmp9 constructed examined. finally, taking nsp9-tmp9 example, ctl immunogenicity identified prrsv peptide epitope evaluated. spf swine expressing sla-1(*)1502 allele divided three groups: modified live vaccine (mlv), mlv+nsp9-tmp9, blank control group. nsp9-tmp9 determined prrsv ctl epitope strong immunogenicity flow cytometry ifn-î³ expression. developed integrated approach identify sla-i-restricted ctl epitope various important virus helpful designing applying effective peptide-based vaccine swine.',\n",
       " 'background: substantial proportion breast cancer develop metastatic disease, 450,000 death globally per year. bone common first site metastatic accounting 40% first recurrence 70% advanced develop skeletal involvement. bone metastasis currently focus symptom relief prevention skeletal complications. however, remains need option bone metastases. combining systemic therapy bone-targeted agent, radium-223, may provide effective minimal additional side effects. methods/design: carbon uk-based, open-label, multi-centre comprises initial safety phase establish feasibility safety combining radium-223 given 6-weekly schedule combination orally administered capecitabine followed randomised extension phase characterise safety profile provide preliminary estimation efficacy. discussion: carbon important result first ass radium-223 chemotherapy advanced breast cancer. result find acceptable rate toxicity decrease bone turnover markers, work necessary phase ii/iii setting ass efficacy clinical benefit. trial registration: isrctn, isrctn92755158, registered 17 february 2016. electronic supplementary material: online version article (10.1186/s13063-019-3643-6) contains supplementary material, available authorized users.',\n",
       " 'introduction: annual influenza vaccination recommended older adults, evidence regarding impact repeated vaccination inconclusive. aim: investigated vaccine effectiveness (ve) laboratory-confirmed influenza impact repeated vaccination 10 previous season current season among older adults. methods: conducted observational test-negative community-dwelling adult aged > 65 year ontario, canada 2010/11 2015/16 season linking laboratory administrative data. estimated multivariable logistic regression. assessed impact repeated vaccination stratifying previous vaccination history. results: included 58,304 testing episode respiratory viruses, 11,496 (20%) testing positive influenza 31,004 (53%) vaccinated. adjusted laboratory-confirmed influenza six season combined 21% (95% confidence interval (ci): 18 24%). vaccinated current season, received vaccination previous 10 seasons, higher current season (34%; 95%ci: 9 52%) received 1â\\x80\\x933 (26%; 95%ci: 13 37%), 4â\\x80\\x936 (24%; 95%ci: 15 33%), 7â\\x80\\x938 (13%; 95%ci: 2 22%), 9â\\x80\\x9310 (7%; 95%ci: â\\x88\\x924 16%) vaccination (trend test p = 0.001). estimate higher correcting misclassification current season vaccination status. vaccinated current season, residual protection rose significantly increasing number vaccination received previously. conclusions: although appeared decrease increasing number previous vaccinations, current season vaccination likely provides protection influenza regardless number vaccination received previous 10 influenza seasons.',\n",
       " 'mechanical ventilation induces lung injury damaging alveolar epithelial cell (aecs), pathogenesis remains unknown. focal adhesion kinase (fak) cytoplasmic protein tyrosine kinase involved cell growth intracellular signal transduction pathways. explored potential role fak aec lung injury induced mechanical ventilation. high-volume mechanical ventilation (hmv) used create mouse lung injury model, validated analysis lung weight, bronchoalveolar lavage fluid histological investigation. expression fak akt aec evaluated. addition, recombinant fak administered mouse via tail vein, extent lung injury assessed. mouse aec cultured vitro, fak expression cell stretch investigated. effect fak cell proliferation, migration apoptosis investigated. result showed hmv decreased fak expression aec mice, fak supplementation attenuated lung injury, reduced protein levels/cell count bronchoalveolar lavage fluid decreased histological lung injury oedema. protective effect fak promoted aec proliferation migration prevented cell undergoing apoptosis, restored integrity alveolus akt pathway. therefore, decrease fak expression hmv essential injury epithelial cell disruption alveolar integrity. fak supplementation reduce aec injury associated hmv.',\n",
       " 'demonstrated recombinant listeria ivanovii (li) strain expressing esat-6 ag85c protein mycobacterium tuberculosis (mtb) tuberculosis (tb) vaccine candidate induced antigen-specific cellular immune response intravenous immunization mice. however, whether recombinant strain could induce desired immune response lung, tb occurs, clear. paper, c57bl/6 j mouse intranasally vaccinated attenuated liî\\x94actaplcb-rv3875 (î\\x94 refers gene deletion bacterial genome) liî\\x94actaplcb-rv0129c, two vaccine candidate utilize li antigen delivery vector. bacterial load target organs, histological change infected organs, percentage specific cytokine-secreting cell lung spleen, igg level serum secretory iga (siga) levles bronchoalveolar lavage (bal) fluid determined specific day post inoculation (dpi). result showed strain mainly confined lung eliminated 10 dpi. histological damage caused lung slight recovered 5. intranasal vaccination mouse twice interval 4 week notably elicited tb antigen-specific cd4(+) cd8(+) cell response lung siga secretion pulmonary mucosa, significantly enhanced percentage double-functional cd8(+) cell (ifn-î³(+) tnf-î±(+) cd8(+)). knowledge, first report regarding used li vector vaccine induce lung-localized cellular humoral immune response intranasal vaccination. suggest li could novel live vector construct intranasal vaccine respiratory diseases.',\n",
       " 'plasmodium falciparum gametocyte surface protein, pfs48/45, potential target malaria transmission-blocking vaccines. however, due size complexity, expression full-length protein difficult, leading focus c-terminal six cysteine domain (6c) use fusion protein facilitate expression folding. study, utilized baculovirus system evaluate expression three pfs48/45 protein full-length protein, 6c domain fragment 6c domain mutant prevent glycosylation. expression recombinant pfs48/45 protein conducted super sf9 cell combined use tunicamycin prevent n-glycosylation. protein evaluated immunogen mouse demonstrate induction functionally active polyclonal antibody response measured standard membrane feeding assay (smfa). 6c protein found exhibit significant transmission-reducing activity. characterization biologically active 6c protein demonstrated homogeneous term size, charge, conformation, absence glycosylation, containing proper disulfide bond pairings. present alternative expression system, without need fusion protein partner, pfs48/45 6c protein fragment evaluation potential transmission-blocking vaccine candidate.',\n",
       " 'initial exponential growth rate epidemic important measure severeness epidemic, closely related basic reproduction number. estimating growth rate epidemic curve challenge, decay time. fast epidemics, estimation subject over-fitting due limited number point available, limit choice model epidemic curve. discus estimation growth rate maximum likelihood simple models.',\n",
       " 'antimicrobial stewardship program (asp) important strategy managing infectious preventing antimicrobial resistance. successful implementation asp community system (chs) challenging. evaluated perception current asp, potential setback asp implementation, future demand asp service among physician pharmacist chs. qualitative research conducted in-depth individual interview focus group discussion 11 physician 11 pharmacists. addition, quantitative gap analysis conducted ass different awareness demand service asp preferred antimicrobial-related problem (arp). overall, perception asp varied profession. identified setback unorganized institutional leadership, undefined role healthcare professionals, lack reimbursement, hierarchical structure system, labor-intensive working environment pharmacy services. although demand asp improvement similar among professionals, different preference prioritizing service item asp/arp development profession responsible service. continuous administrative financial investments, understanding asp contents, asp-specific information technology, interdisciplinary collaboration good communication among healthcare profession needed continue progression asp.',\n",
       " 'background: acinetobacter baumannii gram-negative opportunistic pathogen notorious reputation resistant antimicrobial agents. capability a. baumannii persist disseminate healthcare setting raised major concern worldwide. methods: investigated antibiotic resistance feature molecular epidemiology 52 clinical isolates a. baumannii collected pakistan 2013 2015. antimicrobial susceptibility pattern determined agar disc diffusion method. comparative sequence analysis ampc bla(oxa-51-like) allele used assign isolates clusters. whole genome 25 representative isolates sequenced miseq desktop sequencer. free online application used determine phylogeny genomic sequences, retrieve multilocus sequence type (st), detect acquired antimicrobial resistance genes. results: overall, isolates grouped 7 cluster 3 sporadic isolates. largest cluster, ab-pak-cluster-1 (bla(oxa-66) isaba1-ampc-19) included 24 isolates, belonged st2 international clone (ic) ii, distributed two geographical far-off cities, lahore peshawar. ab-pak-clusters-2 (bla(oxa-66), isaba1-ampc-2), -3 (bla(oxa-66), isaba1-ampc-20) individual isolate ab-pak-lah-01 (isaba1-bla(oxa-66), isaba1-ampc-2) assigned st2 ic ii. hand, ab-pak-clusters-4 (bla(oxa-69), ampc-1), -5 (bla(oxa-69), isaba1-ampc-78), -6a (bla(oxa-371), isaba1-ampc-3) belonged st1, ab-pak-cluster-6b (bla(oxa-371), isaba1-ampc-8) belonged st1106, st1 st1106 member ic i. five isolates belonged ab-pak-cluster-7 (bla(oxa-65), ampc-43). cluster corresponded st158, showed well-delineated position genomic phylogenetic tree, equipped several antimicrobial resistance gene bla(oxa-23) bla(ges-11). conclusions: detected occurrence 7 cluster a. baumannii pakistan. altogether, 6/7 cluster 45/52 (86.5%) isolates belonged ic (n = 9) ii (n = 36), making pakistan exception global domination two clones. onset st158 pakistan marked geographical dispersal clone beyond middle east brought need detailed characterization.',\n",
       " 'background: endemic areas, pregnant woman highly susceptible plasmodium falciparum malaria characterized accumulation parasitized red blood cell (prbc) placenta. subsequent pregnancies, woman develop protective immunity pregnancy-associated malaria hypothesized due acquisition antibody parasite variant surface antigen var2csa. systematic review provide first synthesis association antibody pregnancy-specific p. falciparum antigen pregnancy birth outcomes. methods: conducted systematic review meta-analysis population-based study (published 07 june 2019) pregnant woman living p. falciparum endemic area examined antibody response pregnancy-specific p. falciparum antigen outcome placental malaria, low birthweight, preterm birth, peripheral parasitaemia, maternal anaemia, severe malaria. results: searched 6 database identified 33 study (30 africa) met predetermined inclusion quality criteria: 16 study contributed estimate format enabling inclusion meta-analysis 17 included narrative form only. estimate mostly cross-sectional (10 studies) heterogeneous term magnitude direction effect. included study varied term antigen tested, methodology used measure antibody responses, epidemiological setting. antibody response pregnancy-specific prbc var2csa antigens, measured delivery, associated placental malaria (9 studies) may therefore represent marker infection, rather correlate protection. antibody response pregnancy-specific prbc, recombinant var2csa antigens, associated trend towards protection low birthweight (5 studies). conclusions: whilst antibody response several antigen positively associated presence placental peripheral infections, review identify evidence specific antibody response associated protection pregnancy-associated malaria across multiple populations. prospective cohort study standardized laboratory method examine response broad range antigen different epidemiological setting throughout gestational period, necessary identify prioritize pregnancy-specific p. falciparum antigen advance development vaccine serosurveillance tool targeting pregnant women.',\n",
       " 'background: optimal duration bloodstream understudied. bacteremia antibiotic length actually needed clinical effectiveness (balance) pilot randomized clinical trial (rct) determined feasible enroll randomize intensive care unit (icu) bloodstream 7 versus 14 day treatment, served vanguard ongoing balance main rct. performed balance-ward pilot rct examine feasibility impact potentially extending balance main rct include hospitalized non-icu wards. methods: conducted open pilot rct among subset six site participating ongoing balance rct, randomizing positive non-staphylococcus aureus blood culture non-icu ward 7 versus 14 day antibiotic treatment. co-primary feasibility outcome recruitment rate adherence duration protocol. compared feasibility outcomes, patient/pathogen characteristics, overall outcome among enrolled balance-ward prior balance-icu pilot rcts. estimated sample size non-inferiority margin impact expanding balance main rct include non-icu patients. results: total 134 recruited 47 site-months (mean 2.9 patients/site-month, median 1.0, range 0.1â\\x80\\x934.4 patients/site-month). overall recruitment rate exceeded balance-icu pilot rct (mean 1.10 patients/site-month, p < 0.0001). overall protocol adherence exceeded adherence balance-icu pilot rct (125/134, 93% v 89/115, 77%, p = 0.0003). balance-ward older, lower sequential organ failure assessment scores, higher proportion infection caused escherichia coli genito-urinary source bloodstream infection. balance-ward pilot rct overall 90-day mortality rate 17/133 (12.8%), comparable 90-day mortality rate icu pilot rct (17/115, 14.8%) (p = 0.65). simulation model indicated would minimal sample size non-inferiority margin implication expanding enrolment increasing proportion non-icu versus icu patients. conclusion: feasible enroll non-icu trial 7 versus 14 day antibiotic bloodstream infection, expanding balance rct hospital-wide potential improve timeliness generalizability trial results. trial registration: clinicaltrials.gov, nct02917551. registered september 28, 2016.',\n",
       " 'standard inactivated influenza vaccine poorly immunogenic immunologically naive healthy young children, particularly vulnerable complication influenza. them, unmet need better influenza vaccines. oil-in-water emulsion-adjuvanted influenza vaccine candidates, clinical trial yielded inconsistent results. here, meta-analyze randomized controlled trial efficacy (3 trials, n = 15,310) immunogenicity (17 trials, n = 9062). compared non-adjuvanted counterparts, adjuvanted influenza vaccine provide significantly better protection (weighted estimate risk ratio rt-pcr-confirmed influenza: 0.26) significantly immunogenic (weighted estimate seroprotection rate ratio: 4.6 7.9) healthy immunologically naive young children. nevertheless, immunologically non-naive children, adjuvanted non-adjuvanted vaccine provide similar protection similarly immunogenic. result indicate oil-in-water emulsion adjuvant improves efficacy inactivated influenza vaccine healthy young child first-time seasonal influenza vaccination.',\n",
       " 'abnormal elevation pressure serious complication involving extracorporeal circulation circuit. clot formation might associated complication, precise mechanism abnormal elevation pressure identified. investigated sufficient condition in-circuit elevation pressure ex vivo re-circulation circuit porcine blood. specifically, investigated effect blood conditions, type anticoagulation, pro-inflammatory stimulation in-circuit pressure. examined cause abnormal elevation in-circuit pressure specifically degrading dna, rna, protein component obstructed filter immunofluorescent techniques. neither change temperature change ph blood increased in-circuit pressure. contrast, long-term storage blood, pro-inflammatory stimulation phorbol myristate acetate, heparin administration significantly increased in-circuit pressure. abnormal in-circuit elevation pressure associated deposition extracellular dna outlet surface filter. administration dnase resulted rapid decline in-circuit pressure. ex vivo re-circulation circuit system, extracellular dna deposition filter responsible abnormal in-circuit elevation pressure. senescent leukocytes, stimulated leukocytes, heparin exposure associated extracellular dna deposition.',\n",
       " 'investigate evolution lung function preterm infant without bronchopulmonary dysplasia (bpd) determine perinatal characteristic associated index lung function later infancy. longitudinal lung function assessment performed approximately 6, 12, 18, 24 month corrected age preterm infants. perinatal characteristic analyzed ascertain determinant lung function indexes. although preterm infant (n = 121; 61 without bpd 60 bpd) exhibited decreased lung function early infancy (6 month age), body length adjusted for, infant bpd exhibited poor performance. furthermore, lung function infant mild moderate bpd caught gradually, generally poor lung function performance infant severe bpd, especially forced expiratory flow, persisted later age (24 months). regarding perinatal characteristics, z-score body length time examination total number day positive-pressure ventilation major determinant lung function later infancy.',\n",
       " 'zika (zikv) mosquito-borne member flaviviridae family known circulate decade causing mild febrile illness. recent zikv outbreak america caribbean associated congenital malformation guillain-barrã© syndrome adult placed public official high alert highlight significant impact zikv human health. technology biology zikv develop effective prevention option highly desired. demonstrate direct delivery mouse infectious zikv cdna clone allows rescue recombinant (r)zikv vivo. bacterial artificial chromosome containing sequence zikv strain paraiba/2015 control cytomegalovirus promoter complexed commercial transfection reagent administrated different route type-i interferon receptor deficient a129 mice. clinical sign death associated zikv viremia observed mice. rzikv recovered mouse remained fully virulent second passage mice. interestingly, infectious rzikv recovered intraperitoneal inoculation rzikv cdna absence transfection reagent. expanding studies, demonstrate single intraperitoneal inoculation cdna clone encoding attenuated rzikv safe, highly immunogenic, provided full protection lethal zikv challenge. novel vivo reverse genetics potentially suitable delivery platform wild-type live-attenuated zikv devoid confounding factor typical associated vitro systems. moreover, result open possibility employing similar vivo reverse genetic approach generation virus and, therefore, change way use reverse genetics future.',\n",
       " 'fast endospore germinability assay (ega) validated traditional plate count enumerate single endospore germination event monitoring surface sterilization. assay based time-gated luminescence microscopy technique enabling visualization enumeration individual germinating endospores. germinating endospore release calcium dipicolinate form highly luminescent terbium dipicolinate complex surrounding germinating endospore. ega heterotrophic plate counting (hpc) used evaluate swab/rinse recovery efficiency endospore stainless steel surfaces. ega hpc result highly correlated endospore recovery stainless steel coupon inoculated range 1,000 endospore per coupon sterility. dosage-dependent decrease surface endospore germinability observed dry heat, uv irradiation, oxygen plasma vaporized hydrogen peroxide treatments, measured ega hpc. ega fast complementary traditional hpc quantitative sterility assurance testing surfaces. work introduces validates 15-minute faster assay germinable endospore complement conventional lengthy, culture-based surface sterility validation, critical hospitals, food pharmaceutical industry help minimize nosocomial infection, food spoilage, pharmaceutical contamination.',\n",
       " 'regulation ubiquitination status cell controlled ubiquitin ligases acting tandem deubiquitinating enzymes. ubiquitination control many key process cell division death making tight regulation key optimal cell function. activity based protein profiling emerged powerful technique important enzymes. around 100 deubiquitinating enzyme 600 ubiquitin ligases human genome targeting subclass enzyme even single enzyme compelling strategy unpick complex system. review discus different approach adopted, activity-based probe centered around ubiquitin-protein, ubiquitin-peptide mutated ubiquitin scaffolds. examine challenge faced opportunity presented increase specificity activity-based protein profiling ubiquitin conjugation/deconjugation machinery.',\n",
       " 'background: young woman sub-saharan africa remain epicentre hiv epidemic, surveillance indicating persistent high level hiv incidence. south africa, adolescent girl young woman (agyw) account quarter hiv infections. determined, resilient, empowered, aids-free, mentored safe (dreams) strategy introduced united state presidentâ\\x80\\x99s emergency plan aid relief (pepfar) aimed reducing hiv incidence among agyw 10 country sub-saharan africa 25% programmeâ\\x80\\x99s first year, 40% second year. ass change hiv incidence reduction risk associated behaviour attributed dream initiative south africa, population-based cross-sectional survey. methods: collected household-based representative sample agyw (between age 12â\\x80\\x9324 years) four high prevalence district (more 10% population hiv districts) south africa dream implemented. stratified cluster-based sampling approach used select eligible participant cross-sectional survey 18,500, conducted 2017/2018. questionnaire administered containing question sexual risk behaviour, selected academic developmental milestones, prevalence gender based violence, whilst examining exposure dream programmes. biological samples, two micro-containers blood self-collected vulvovaginal swab samples, collected survey test hiv infection, hiv incidence, sexually transmitted infection (stis) pregnancy. measure trend population level hiv incidence limiting antigen (lag) avidity enzyme immuno-assay (eia) monitor change hiv incidence. discussion: ending hiv/aids pandemic 2030 requires continual monitoring evaluation prevention programmes, aim optimising effort ensuring achievement epidemic control. determine impact dream intervention hiv incidence among agyw â\\x80\\x98real world, non-trial settingâ\\x80\\x99.',\n",
       " 'background: klebsiella pneumoniae leading cause bloodstream (bsi). strain producing extended-spectrum beta-lactamase (esbls) carbapenemases considered global priority pathogen prevention strategy urgently required, due severely limited therapeutic options. south southeast asia major hub antimicrobial-resistant (amr) k. pneumoniae characteristically antimicrobial-sensitive, community-acquired â\\x80\\x9chypervirulentâ\\x80\\x9d strains. emergence hypervirulent amr strain lack exopolysaccharide diversity pose challenge k. pneumoniae bsi control strategy worldwide. methods: conducted retrospective genomic epidemiology 365 bsi k. pneumoniae seven major healthcare facility across south southeast asia, extracting clinically relevant information (amr, virulence, k antigen loci) kleborate, k. pneumoniae-specific genomic typing tool. results: k. pneumoniae bsi isolates highly diverse, comprising 120 multi-locus sequence type (sts) 63 k-loci. esbl carbapenemase gene frequency 47% 17%, respectively. aerobactin synthesis locus (iuc), associated hypervirulence, detected 28% isolates. importantly, 7% isolates harboured iuc plus esbl and/or carbapenemase genes. latter represent genotypic amr-virulence convergence, generally considered rare phenomenon particularly common among south asian bsi (17%). greatest concern, identified seven novel plasmid carrying iuc amr genes, raising prospect co-transfer phenotype among k. pneumoniae. conclusions: k. pneumoniae bsi south southeast asia caused different sts predominating regions, higher frequency acquired virulence determinants. k. pneumoniae carrying iuc amr gene detected higher rate reported elsewhere. demonstrates genomics-based surveillanceâ\\x80\\x94reporting full molecular profile sts, amr, virulence serotype locus informationâ\\x80\\x94can help standardise comparison site identify regional difference pathogen populations. electronic supplementary material: online version article (10.1186/s13073-019-0706-y) contains supplementary material, available authorized users.',\n",
       " 'background: inadequate hospital cleaning may contribute cross-transmission pathogens. important implement effective cleaning safe hospital environment. conducted three-phase human factor engineering (hfe) approach enhance environmental cleanliness. methods: conducted prospective interventional trial, 28 (33.3%) 84 ward medical center sampled. three-phases included pre-intervention analysis (phase 1), implementing intervention hfe principle (phase 2), programmatic analysis (phase 3). evaluation terminal cleaning disinfection performed fluorescent marker, adenosine triphosphate bioluminescence assay, aerobic colony count simultaneously phases. effective terminal cleaning disinfection qualified aggregate outcome 10 high-touch surface per room. score high-touch surface recorded, 0 denoting fail 10 denoting pas benchmark evaluation method, total terminal cleaning disinfection score (tcd score) score 100. results: phase, 840 high-touch surface collected 84 room terminal cleaning disinfection. interventions, tcd score three evaluation method showed significant improved. carriage incidence multidrug-resistant organism (mdro) decreased significantly 4.1 per 1000 patient-days 3.6 per 1000 patient-days (p = .03). conclusion: hfe approach improve thoroughness effectiveness terminal cleaning disinfection, resulted reduction carriage mdro hospitals. larger study necessary establish whether effort cleanliness reduce incidence healthcare-associated infection.',\n",
       " 'diphtheria infectious caused corynebacterium diphtheriae. bacterium primarily infects throat upper airway produced diphtheria toxin (dt), bind elongation factor 2 block protein synthesis, spread bloodstream affect organs, heart kidneys. 125 years, therapy diphtheria based polyclonal horse serum directed dt (diphtheria antitoxin; dat). animal serum many disadvantage serum sickness, batch-to-batch variation quality use animal production. work, 400 human recombinant antibody generated dt two different phage display panning strategy human immune library. panning microtiter plate resulted 22 unique vitro neutralizing antibody panning solution combined functional neutralization screening resulted 268 vitro neutralizing antibodies. 61 unique antibody characterized scfv-fc 35 produced fully human igg1. best vitro neutralizing antibody showed estimated relative potency 454 iu/mg minimal effective dose 50% (med50%) 3.0 pm constant amount dt (4x minimal cytopathic dose) igg format. targeted domain 35 antibody analyzed immunoblot epitope mapping phage display. three dt domain (enzymatic domain, translocation domain receptor binding domain) target neutralizing antibodies. toxin neutralization assay performed higher toxin dose levels, neutralizing capacity individual antibody markedly reduced largely compensated two antibody combination, resulting potency 79.4 iu/mg vivo intradermal challenge assay. recombinant antibody combination candidate clinical regulatory development replace equine dat.',\n",
       " 'streptococcus agalactiae causative agent streptococcosis various fish species, nile tilapia (oreochromis niloticus linn.). vaccination effective prevention control method, limitation remain protecting catastrophic mortality fish infected different strain streptococci. immunoproteomics analysis s. agalactiae used identify antigenic protein construct chimeric multiepitope vaccine. epitope five antigenic protein shuffled five helix flavodoxin backbone, silico analysis predicted suitable rna protein structure protein expression. 45f2 42e2 identified best candidate chimeric multiepitope vaccine. recombinant plasmid constructed produce recombinant protein vaccine dna vaccine system. overexpressed protein determined 30 kda 25 kda e. coli tk1 systems, respectively. efficacy chimeric multiepitope construct recombinant protein vaccine dna vaccine evaluated nile tilapia, followed s. agalactiae challenge 1 ã\\x97 10(7) cfu/ml. relative percentage survival (rps) cumulative mortality recorded approximately 57â\\x80\\x9376% 17â\\x80\\x9330%, respectively. chimeric multiepitope vaccine applied streptococcosis control developed multivalent vaccine control multiple diseases.',\n",
       " 'atrial fibrillation (af) progressive arrhythmia underlying mechanism fully elucidated, partially due lack reliable affordable animal models. here, introduce system long-term assessment af susceptibility (substrate) ambulatory rat implanted miniature electrode atrium. rat subjected excessive aldosterone (aldo) solvent (sham). additional group exposed myocardial infarction (mi). af substrate tested two- four-weeks post implantation compared implanted rat early post-implantation (base). aldo mi increased af substrate atrial fibrosis. mi group only, af duration correlated level atrial fibrosis inversely correlated systolic function. unexpectedly, sham developed progressive af substrate relative base individuals. study indicated serum inflammatory marker (il-6, tnf-alpha) elevated shams. addition, excluded anxiety\\\\depression due social-isolation af promoting factor. finally, enhanced biocompatibility atrial electrode inhibit gradual development af substrate testing period 8 weeks. overall, successfully validated first system long-term af substrate testing ambulatory rats.',\n",
       " 'background: critically ill undergo extensive physiological alteration impact antibiotic pharmacokinetics. 60% intensive care unit (icu) meet pharmacodynamic target beta-lactam antibiotics, 30% fluoroquinolones. reaching target might increase chance therapeutic failure, resulting increased mortality morbidity, antibiotic resistance. dolphin trial designed demonstrate added value therapeutic drug monitoring (tdm) beta-lactam fluoroquinolones critically ill icu. methods: multi-centre, randomised controlled trial (rct) designed ass efficacy cost-effectiveness model-based tdm beta-lactam fluoroquinolones. four hundred fifty included within 24 month start inclusion. eligible randomly allocated either group: intervention group (active tdm) control group (non-tdm). intervention group dose adjustment antibiotic (cefotaxime, ceftazidime, ceftriaxone, cefuroxime, amoxicillin, amoxicillin clavulanic acid, flucloxacillin, piperacillin tazobactam, meropenem, ciprofloxacin) 1, 3, 5 performed based upon tdm bayesian model. primary outcome icu length stay. outcome amongst survival, severity, safety, quality life icu discharge, cost effectiveness included. discussion: trial investigated effect early tdm beta-lactam fluoroquinolones clinical outcome critically ill patients. finding dolphin trial possibly lead insight clinical management critically ill receiving antibiotics. short, tdm tdm? trial registration: eudract number: 2017â\\x80\\x93004677-14. sponsor protocol name: dolphin. registered 6 march 2018 . protocol version 6, protocol date: 27 november 2019.',\n",
       " 'background: use biomaterials expanded improve characteristic vaccines. identified peptide ph((1â\\x80\\x93110)) polyhedrin self-aggregates incorporates foreign protein form particles. proposed peptide used antigen carrying system vaccines. however, immune response generated antigen fused peptide fully characterized. addition, adjuvant effect thermostability particle evaluated. results: present demonstrate use system developed generate nano microparticles carrying fusion protein peptide protein interest used vaccines. particle purified easily centrifugation. immunization animal particle absence adjuvant robust long-lasting immune response. protein contained inside particle maintained 1 year ambient temperature, preserving immunological properties. conclusion: rapid efficient production particle addition robust immune response generate position system excellent rapid response emerging diseases. thermostability conferred particle system facilitates distribution vaccine developing country area electricity.',\n",
       " 'background: aim evaluate gap countriesâ\\x80\\x99 self-evaluation external evaluation regarding core capacity infectious control required international regulation influence factor gap. methods: collected countriesâ\\x80\\x99 self-evaluated score (international regulation monitoring tool, ihrmt) 2016 2017, external evaluation score (joint external evaluation, jee) website 4rd 27rd november, 2018. 127 163 country ihrmt score 2016 2017, 74 country jee score included analysis. gap countriesâ\\x80\\x99 self-evaluation external evaluation represented difference condensed ihr score jee. civil liberty (cl) score collected indicator transparency country. human development index (hdi) indicating density physician nurse (hwd) collected reflect countriesâ\\x80\\x99 development workforce statuses. then, chi-square test logistic regression performed determine correlation gap ihrmt jee, civil liberties, human development, workforce status. results: countriesâ\\x80\\x99 self-evaluation score significantly decreased 2016 2017. countriesâ\\x80\\x99 external evaluation score consistently 1 1.5 lower self-evaluation scores. significantly country high hdi status, high cl status high hwd status group bigger gap ihrmt jee. country higher hdi status presented higher risk bigger gap countriesâ\\x80\\x99 self external score (or = 3.181). conclusion: indicated countriesâ\\x80\\x99 transparency represented cl status play role gap ihr jee scores. hdi status key factor significantly associated gap. main reason gap current world different interpretation evaluation high hdi countries, though low cl country tended over-scored capacity.',\n",
       " 'background: left ventricular assist device (lvad) long expected survival, incidence noncardiac surgery population increasing. here, present anesthetic management continuous-flow lvad underwent video-assisted thoracic surgery (vats). presentation: 37-year-old man lvad scheduled undergo vat repeated spontaneous pneumothorax. generally, device marginal right heart function; therefore, important avoid factor worsen pulmonary vascular resistance (pvr). however, vat requires one-lung ventilation (olv) tends cause increase pvr, leading right heart failure. present case, set lateral decubitus position progressive hypoxia observed olv, transesophageal echocardiography demonstrated dilated right ventricle temporally flattened interventricular septum, central venous pressure increased approximately 20 mmhg. anticipated deterioration right heart function, dobutamine milrinone administered and/or respirator setting changed decrease pvr maintaining lvad performance. finally, resection bulla completed, discharged stable condition postoperative 37. conclusions: anesthetic management lvad vat challenging possible hemodynamic change induced hypoxia associated olv affect lvad performance right heart function. experience, vat requires olv well tolerated lvad preserved right heart function, multidisciplinary approach maintain right heart function needed.',\n",
       " 'optimal way treat severe thoracic scoliosis remains controversial. compared conventional procedures, uniportal video-assisted thoracoscopic surgery (univats) rise popularity thoracic surgery le pain faster recovery. retrospective aimed apply univats treat severe thoracic scoliosis. october 2013 march 2018, eight scoliotic extremely cobb angle profoundly limited flexibility underwent univats anterior release, followed posterior instrumentation fusion. mean age time surgery 14.8 â± 2.4 year mean follow-up 2.2 â± 1.3 years. average level anterior thoracic discectomy posterior fusion 3.6 â± 0.7 11.5 â± 1.2, respectively. mean coronal sagittal correction rate 70 â± 19% 71 â± 23%, respectively. univats contributed minor access trauma (3-cm incision) minimal blood loss, shorter operation time (75 â± 13 mins), le requirement stay intensive care unit (0.3 â± 0.5 day) chest tube placement (0.3 â± 0.7 day), speedier narcotic-free recovery, earlier ambulation within day. first ass safety efficacy univats severely stiff thoracic scoliosis, providing comparable surgical outcomes, le pain, faster recovery superior cosmetic result without significant complications.',\n",
       " '2020 installment annual â\\x80\\x98antibodies watchâ\\x80\\x99 series document antibody therapeutic approved 2019 regulatory review united state european union, well late-stage clinical studies, november 2019*. time, total 5 novel antibody therapeutic (romosozumab, risankizumab, polatuzumab vedotin, brolucizumab, crizanlizumab) granted first approval either u eu, marketing application 13 novel antibody therapeutic (eptinezumab, teprotumumab, enfortumab vedotin, isatuximab, [fam-]trastuzumab deruxtecan, inebilizumab, leronlimab, sacituzumab govitecan, satralizumab, narsoplimab, tafasitamab, regneb3 naxituximab) undergoing review regions, represent major market antibody therapeutics. november 2019, 79 novel antibody undergoing evaluation late-stage clinical studies. 79 antibodies, 39 undergoing evaluation late-stage study non-cancer indications, 2 (ublituximab, pamrevlumab) late-stage study cancer indications. company developing 7 (tanezumab, aducanumab, evinacumab, etrolizumab, sutimlimab, anifrolumab, teplizumab) 39 drug indicated may submit marketing application either u eu 2020. 79 antibody late-stage studies, 40 undergoing evaluation treatment cancer, potentially 9 (belantamab mafodotin, oportuzumab monatox, margetuximab, dostarlimab, spartalizumab, 131i-omburtamab, loncastuximab tesirine, balstilimab, zalifrelimab) may enter regulatory review late 2019 2020. overall, biopharmaceutical industryâ\\x80\\x99s clinical pipeline antibody therapeutic robust, provide continuous supply innovative product future. *note key update december 18, 2019: 1) u food drug administration granted accelerated approval enfortumab vedotin-ejfv (padcev) december 18, 2019, bringing total number novel antibody therapeutic granted first approval either u eu 2019 6; 2) european commission approved romosozumab december 9, 2019; 3) european medicine agency issued positive opinion brolucizumab; 4) sesen bio initiated rolling biologics license application (bla) december 6, 2019; 5) glaxosmithkline submitted bla belantamab mafodotin; 6) status phase 3 (nct04128696) gsk3359609, humanized igg4 anti-icos antibody, head neck squamous cell carcinoma updated recruiting yet recruiting.',\n",
       " '',\n",
       " 'background: aim analyze risk factor nosocomial cardiac surgery child congenital heart (chd). methods: performed retrospective cohort study, child chd underwent open-heart surgery shanghai childrenâ\\x80\\x99s medical center january 1, 2012 december 31, 2018 included. baseline characteristic different ages, neonate (0â\\x80\\x931 month old), infant (1â\\x80\\x9312 month old) child (1â\\x80\\x9310 year old), analyzed, association risk factor postoperative nosocomial assessed. results: total 11,651 subject included study. overall nosocomial rate 10.8%. nosocomial rate neonates, infants, child congenital heart 32.9, 15.4, 5.2%, respectively. multivariate logistic regression analysis found age (or 0798, 95%ci: 0.769â\\x80\\x930.829; p < 0.001), sts risk grade (or 1.267, 95%ci: 1.159â\\x80\\x931.385; p < 0.001), body mass index (bmi) <5th percentile (or 1.295, 95%ci: 1.023â\\x80\\x931.639; p = 0.032), bmi >95th percentile (or 0.792, 95%ci: 0.647â\\x80\\x930.969; p = 0.023), cardiopulmonary bypass (cpb) time (or 1.008, 95%ci: 1.003â\\x80\\x931.012; p < 0.001) aortic clamping time (or 1.009, 1.002â\\x80\\x931.015; p = 0.008) significantly associated nosocomial chd infants. adjusted confounding factors, found sts risk grade (or 1.38, 95%ci: 1.167â\\x80\\x931.633; p < 0.001), bmi < 5th percentile (or 1.934, 95%ci: 1.377â\\x80\\x932.715; p < 0.001), cpb time (or 1.018, 95%ci: 1.015â\\x80\\x931.022; p < 0.001), lymphocyte/wbc ratio<cut value (or 3.818, 95%ci: 1.529â\\x80\\x939.533; p = 0.004) ast>cut value (or 1.546, 95%ci: 1.119â\\x80\\x932.136; p = 0.008) significantly associated nosocomial chd children. conclusion: suggested sts risk grade, bmi, cpb duration, low lymphocyte/wbc high neutrophil/wbc ratio independently associated nosocomial chd infant child cardiac surgery.',\n",
       " 'background: timely infant testing hiv critical ensure optimal outcome among exposed infants. world organization recommends hiv exposed infant tested 4 6 week age, developing country like ethiopia, access timely infant testing still limited. intended ass timely infant testing, testing hiv 18th month, test result factor influencing hiv positivity among infant born hiv positive mother public hospital mekelle, ethiopia. methods: cross-sectional design employed 558 hiv exposed infants, consecutive sampling technique. checklist used extract 4 year (january 2014â\\x80\\x93december 2017) secondary data, collected januaryâ\\x80\\x93april 2018. analyzed spss version 20, binary logistic regression model used examine association independent variable outcome variables. results: timely infant testing hiv accounted 346(62.0%). mother attended antenatal care (aor: 2.77; 95% ci: 1.17, 6.55) counselled feeding option (aor: 2.01; 95% ci: 1.11, 3.65) strongly associated timely infant testing. poor maternal adherence status associated infantsâ\\x80\\x99 hiv positivity 18th month antibody test (aor: 15.93; 95% ci: 2.21, 94.66). rural resident (aor: 4.0; 95% ci: 1.23, 13.04), low birth weight (aor: 5.64; 95% ci: 2.00, 16.71) receiving arv prophylaxis (aor: 4.70; 95% ci: 1.15, 19.11) positively associated overall hiv positivity. conclusions: considerable proportion exposed infant undergo timely testing hiv. antenatal care follow-up counselling feeding option associated timely infant testing. motherâ\\x80\\x99s poor adherence status associated infantâ\\x80\\x99s hiv positivity 18th month antibody testing. rural resident, low birth weight, receiving arv prophylaxis factor enhance overall hiv positivity. timely infant testing, counselling feeding option adherence intensified, prevention mother-to-child transmission program rural setting need strengthened.',\n",
       " 'activation arginineâ\\x80\\x93vasopressin hormonal response face vasodilation-related hypotension. released post-pituitary gland, vasopressin induces vasoconstriction activation v1a receptor located vascular smooth muscle cells. due non-selective receptor affinity arginineâ\\x80\\x93vasopressin activates v2 (located renal tubular cell collecting ducts) v1b (located anterior pituitary pancreas) receptors, thereby potentially promoting undesired side effect anti-diuresis, procoagulant property due release von willebrandâ\\x80\\x99s factor platelet activation. finally, cross-activates oxytocin receptors. septic shock, vasopressin plasma level reported lower expected, hypersensitivity vasopressor effect reported situation. terlipressin selepressin synthetic vasopressin analogue higher affinity v1 receptor, and, hence, potentially le side effects. narrative review, present current knowledge rationale, benefit risk vasopressin use setting septic shock vasoplegic shock following cardiac surgery. clearly, vasopressin administration allows reducing norepinephrine requirements, far, improvement survival reported side effect frequent, particularly ischaemic events. finally, discus current indication vasopressin agonist setting septic shock, remaining unresolved questions.',\n",
       " 'hypoxemic respiratory failure usually accompanied certain extent consolidation alveolar derecruitment, may still present even achieved status readiness extubate. functional residual capacity (frc) indicator lung aeration. aimed evaluate whether pre-extubation frc associated risk extubation failure hypoxemic respiratory failure. prospectively included 92 intubated hypoxemic respiratory failure. used technique based nitrogen multiple breath washout measure frc planned extubation. median frc extubation 25 ml/kg (interquartile range, 20â\\x80\\x9332 ml/kg) per predicted body weight (pbw). extubation, 20 (21.7%) reintubated within 48 hours. median frc higher extubation success group extubation failure group (27 versus 21 ml/kg, p < 0.001). reduced frc associated higher risk extubation failure (odds ratio, 1.14 per decreased 1 ml/kg frc/pbw, 95% ci, 1.05â\\x80\\x931.23, p = 0.002). conclusion, pre-extubation frc associated risk extubation failure. reduced frc may incorporated traditional risk factor identify high risk extubation failure.',\n",
       " 'background: reproductive failure sow herd due influenza virus described literature, study focused pathogenesis clinical sign infection. report indicate association infection influenza virus reduced reproductive performance, although difficult experimentally reproduce clinical outcome poor reproductive performance. aim present longitudinal field compare reproductive performance parameter implementation vaccination influenza (h1n1)pdm09 sow herd infected pandemic influenza virus. therefore, farm-specific 137 sow herd germany, 60,153 sows, well clinical presentation surveyed via questionnaire. furthermore, average performance parameter (return oestrus rate, abortion rate, stillbirth rate, number piglet born alive per litter, preweaning mortality rate number piglet weaned per sow per year) recorded 6 month vaccination 6 month completion primary vaccination. results: 79.8% farms, clinical presentation characterised reduced reproductive performance. finding confirmed analysis performance parameters, revealed significant decline return oestrus rate (p < 0.001), abortion rate (p < 0.001) preweaning mortality rate (p = 0.023) significant increase number piglet born alive (p = 0.001) piglet weaned per sow per year (p < 0.001) immunisation. stillbirth rate change significantly. conclusion: present represents first attempt demonstrate association influenza infection, vaccination alteration reproductive performance parameters, investigating number cases. result vaccinating influenza (h1n1)pdm09 virus, improvement reproductive performance achieved sow herd infected pandemic influenza virus. additionally, number herd affected poor reproductive performance aforementioned confirms assumption association pandemic influenza reproductive losses.',\n",
       " '',\n",
       " 'background: hcc healthy subject equally responsive rnadjuvant(â®), novel tlr-7/8/rig-i agonist based noncoding rna developed curevac, ex vivo evaluation. however, immunological effect adjuvant immune cell cancer undergoing chemotherapy remains demonstrated. different adjuvant currently used cancer vaccine clinical trial evaluated present immune cell cancer chemotherapy ex vivo setting. methods: pbmcs obtained 4 healthy volunteer 23 affected either colon (oma) lung cancer (ot). effect cpg, poly i:c, imiquimod rna-based adjuvant (rnadjuvant(â®)) assessed multiparametric approach analyze network dynamic early immune responses. evaluation cd80, cd86 hla-dr expression well downstream effect cd4(+) cell phenotyping performed flow cytometry; cytokine chemokine production evaluated bio-plex protm. results: rnadjuvant(â®) induced strongest response cancer term activation innate adoptive immunity. indeed, cd80, cd86 hla-dr expression found upregulated circulating dendritic cells, promoted cd4(+) cell differentiation towards effector phenotype. rnadjuvant(â®) induce cytokines/chemokines tested pronounced th1 cytokine pattern. according different parameter evaluated study, clear cut difference immune response adjuvant observed healthy subject cancer patients. moreover, latter group, chemotherapy consistently correlate significant altered response different parameters. conclusions: present first analysis immunological effect induced adjuvant cancer undergo chemotherapy, enrolled currently ongoing cancer vaccine clinical trials. result rnadjuvant(â®) potent th1 driving adjuvant, compared tested present study. importantly, demonstrated chemotherapy significantly impair immune system, implying cancer likely respond cancer vaccine even chemotherapy treatment.',\n",
       " 'schistosomiasis cause significant level morbidity mortality many geographical region world. caused infection parasitic blood fluke known schistosomes. control schistosomiasis last several decade centered mass drug administration (mda) praziquantel (pzq), drug currently available treatment. despite concerted effort mda programs, prevalence transmission schistosomiasis remained largely unchecked due fact pzq ineffective juvenile schistosomes, prevent re-infection emergence pzq-resistant parasites. addition, measure water, sanitation hygiene program snail intermediate host control little impact. drawback indicate current control strategy severely inadequate interrupting transmission therefore, implementation control strategy required. ideally, efficient vaccine needed long term protection thereby eliminating current effort repeated mass drug administration. however, general consensus field integration viable vaccine mda control measure offer best chance achieving goal schistosomiasis elimination. review focus present status schistosomiasis vaccine candidate different phase human clinical trial provide insight future vaccine discovery design.',\n",
       " 'rift valley fever (rvf) emerging zoonotic arbovirus complex cycle transmission make difficult prediction expansion. recent outbreak outside africa led rediscover human remains poorly known. wide spectrum acute delayed manifestation potential unfavorable outcome much complicate management suspected case prediction morbidity mortality outbreak. reviewed literature bio-clinical characteristic treatment rvf human illness. identified gap field provided practical algorithm assist clinician case assessment, determination setting care prolonged follow-up.',\n",
       " 'background: postoperative hypoxemia acute type aortic dissection (aada) common complication associated negative outcomes. aimed analyze efficacy low-dose (5â\\x80\\x9310 ppm) inhaled nitric oxide (ino) management hypoxemia aada surgery. methods: retrospective observational study, medical record underwent aada surgery two institution january 2015 january 2018 collected. postoperative hypoxemia classified ino control groups. clinical characteristic outcome compared propensity score-matched (psm) analysis. results: among 436 underwent surgical repair, 187 (42.9%) hypoxemia 43 treated low-dose ino. psm, included ino (n = 40) psm control (n = 94) group 1:3 ratio. ino ameliorated hypoxemia 6, 24, 48, 72 h initiation, shortened duration ventilator support (39.0 h (31.3â\\x80\\x9347.8) vs. 69.0 h (47.8â\\x80\\x93110.3), p < 0.001) icu stay (122.0 h (80.8â\\x80\\x93155.0) v 179.5 h (114.0â\\x80\\x93258.0), p < 0.001). significant between-group difference mortality, complications, length hospital stay. conclusions: study, found low-dose ino improved oxygenation hypoxemia aada surgery shortened duration mechanical ventilation icu stay. significant side effect increase postoperative mortality morbidity observed ino treatment. finding warrant randomized multicenter controlled trial ass exact efficiency ino hypoxemia aada.',\n",
       " 'yersinia pestis, cause plague, could weaponized. unfortunately, development vaccine limited lack correlate protection. used pre- post-vaccination serum peripheral blood mononuclear cell flagellin adjuvanted f1/v vaccine trial evaluate protective markers. here, report first time human inverse caspase-3 levels, measure protective antibody, significantly increased 29% 75% day 14 28 post-second vaccination, respectively. addition, significant increase t-cell response 28 post-second vaccination. strongest positive negative correlation protective antibody level gene expression signature identified ifng ensg00000225107 genes, respectively. flagellin/f1/v subunit vaccine induced macrophage-protective antibody significant cd4(+) t-cell responses. several gene associated response identified could serve potential correlate protection.',\n",
       " 'invasive candidiasis (ic) common nosocomial leading cause mycoses-related deaths. high-systemic toxicity emergence antifungal-resistant specie warrant development newer preventive approach ic. here, adopted immunotherapeutic peptide vaccine-based approach, enhance bodyâ\\x80\\x99s immune response invasive candida infections. computational tools, screened entire candida proteome (6030 proteins) identified immunodominant hla class i, hla class ii b- cell epitopes. immunoinformatic analysis enhanced vaccine efficacy, selected 18- epitopes, joined together molecular linkers create multivalent recombinant protein candida albicans (mvpc). increase mvpcâ\\x80\\x99s immunogenicity, added synthetic adjuvant (rs09) mvpc design. selected mvpc epitope homologous currently available annotated reference sequence 22 c. albicans strains, thus offering higher coverage greater protective response. major advantage current vaccine approach mvpcâ\\x80\\x99s multivalent nature (recognizing multiple-epitopes), likely provide enhanced protection complex candida antigens. here, describe computational analysis leading mvpc design.',\n",
       " 'background: influenza reassortment, mechanism influenza virus exchange rna segment co-infecting single cell, implicated several major pandemic since 19th century. owing significant impact public social stability, great attention received identification influenza reassortment. methods: proposed novel computational named hopper (host-prediction-based probability estimation reassortment), sturdily estimate reassortment probability host tropism prediction 147 feature generated seven physicochemical property amino acids. conducted experiment range real synthetic datasets compared hopper several state-of-the-art methods. results: 280 318 candidate reassortants successfully identified. additionally, hopper applied complete genome effectiveness incomplete genome demonstrated. analysis evolutionary success avian, human swine virus generated reassortment across different year hopper revealed reassortment history influenza viruses. conclusions: present novel prediction influenza reassortment. hope could facilitate rapid reassortment detection provide novel insight evolutionary pattern influenza viruses.',\n",
       " '',\n",
       " '',\n",
       " 'bordetella bronchiseptica isolate km22 used experimental infection swine model clinical b. bronchiseptica host-to-host transmission. draft genome sequence km22 reported 2014. here, report complete genome sequence km22.',\n",
       " 'avian pathogenic escherichia coli (apec), pathotype extraintestinal pathogenic e. coli, cause serious infectious disease poultry share common virulence gene neonatal meningitis-associated e. coli. tonb-dependent receptor (tbdrs) ubiquitous outer membrane î²-barrel proteins; play important role recognition siderophores iron uptake. here, apec strain de205b, investigated role four putative tbdrsâ\\x80\\x94irea, 0007, 0008, 2235â\\x80\\x94in iron uptake. glutathione-s-transferase pulldown assay indicated protein encoded gene directly interact tonb. moreover, expression level four gene significantly upregulated iron-depleted condition compared iron-rich conditions. expression level several iron uptake-related gene significantly increased irea, 0007, 0008, 2235 deletion strains, upregulation prominent irea deletion mutant. furthermore, iron uptake irea deletion strain significantly increased compared wild-type strain. moreover, tonb mutant strain constructed effect tonb deletion tbdrs. found regardless presence tonb, expression level gene encoding four tbdrs regulated fur. conclusion, finding indicated irea, 0007, 0008, 2235 indeed encode tbdrs, irea important role iron uptake. result help future study explore mechanism underlying tonb-dependent iron uptake pathway.',\n",
       " 'measuring antimalarial antibody estimate transmission population. compare outputs, standardized laboratory testing required. describe in-country establishment quality control (qc) multiplex bead assay (mba) three sero-surveys haiti. total igg 21 antigen collected 32,758 participants. titration curve hyperimmune serum included assay plates, assay signal underwent 5-parameter regression, inspection median interquartile range (iqr) y-inflection point used determine assay precision. median iqrs similar survey 1 2 antigens, iqrs increased antigen survey 3. levey-jennings chart selected antigen provided pass/fail criterion assay plate and, 387 assay plates, 13 (3.4%) repeated. individual sample failed igg binding generic glutathione-s-transferase protein observed, 659 (2.0%) sample failing. additional 455 (1.4%) observation failed due low bead number (<20/analyte). final dataset included 609,438 anti-malaria igg point 32,099 participants; 96.6% potential point qc failure occurred. mba deployed high-throughput collection low inter-plate variability ensuring quality.',\n",
       " 'humanization animal model immune system genetic engineering great promise antibody discovery, tolerance study evaluation vaccines. assessment baseline antibody repertoire unimmunized model animal useful benchmark future immunization experiments. characterized heavy chain kappa light chain antibody repertoire model animal, omnirat, high throughput antibody sequencing made use two novel datasets comparison human repertoires. intra-animal inter-animal repertoire comparison reveal high level conservation antibody diversity lymph node spleen member species. multiple difference found heavy kappa chain repertoire omnirats human gene segment usage, cdr3 length distributions, class switch recombination, somatic hypermutation level feature v(d)j recombination. inference generation repertoire (igor) software tool used model recombination vh region allowed quantification differences. diversity estimate omnirat heavy chain repertoire almost reached humans, around two order magnitude less. despite variation specie repertoires, high frequency omnirat clonotypes found human repertoire. give insight development selection humanized animal antibody provide actionable information use vaccine studies.',\n",
       " 'obesity multifaceted pathophysiological condition associated lipid accumulation, adipocyte dysfunction, impaired mitochondrial biogenesis altered metabolic profile. redox imbalance excessive release inflammatory mediator intricately linked obesity-associated phenotypes. hence, understanding mechanism redox signaling pathway molecular target exacerbating oxidative stress crucial improving outcomes. activation na/k-atpase/src signaling, downstream pathways, reactive oxygen specie (ros) implicated obesity subsequent nonalcoholic steatohepatitis (nash), cause production ro creating oxidant amplification loop. apart that, numerous study characterized antioxidant property heme oxygenase 1 (ho-1), suppressed obese state. induction ho-1 restores cellular redox processes, contributes inhibition toxic milieu. novelty independent mechanism present unique opportunity unravel potential molecular target redox regulation obesity nash. attenuation oxidative stress, understanding underlying molecular mechanism associated mediators, targeted modality may provide improved therapeutic option combat clinical disorders.',\n",
       " 'late 2012 evidenced human genome transcribed small percentage transcript translated. observation supported importance non-coding rna confirmed several organisms. abundant non-translated transcript long non-coding rna (lncrnas). contrast protein-coding rnas, cell-specific expression. understand function lncrnas, fundamental investigate cell preferentially expressed detect subcellular localization. recent improvement technique localize single rna molecule tissue like single-cell rna sequencing fluorescence amplification method given considerable boost knowledge lncrna functions. recent years, single-cell transcription variability associated non-coding rna expression, revealing class rna important transcript cell lineage specification. purpose review collect updated information lncrna classification finding function derived single-cell analysis. retained useful researcher describe method available single-cell analysis database collecting single-cell lncrna data. table included schematize, describe, compare exposed concepts.',\n",
       " 'background: pneumonia single largest cause death under-five child worldwide. conducted systematic review identify knowledge gap around childhood pneumonia bhutan. methods: searched pubmed, sciencedirect google scholar conception 3rd december 2018, world organization, unicef, bhutanâ\\x80\\x99s ministry local database relevant reports. included report describing pneumonia bhutanese child regard burden disease, aetiology, related risk factors, clinical prognostic characteristics, surveillance system national preventive strategies. two review author identified records. summarized finding narratively. results: included 44 records. although notable decreasing trends, pneumonia still accountable high burden mortality rate bhutanese children. national surveillance system focus mainly influenza identification introduced aetiology monitor. found scarce regard bacterial aetiology, related risk factor clinico-radiological prognostic characteristics. conclusion: dearth regarding epidemiological, microbiological, clinical radiological characteristic pneumonia child bhutan, leading challenge implementing evidence-based management effective national preventive strategies.',\n",
       " 'near-fatal asthma requiring ecmo likely younger female likely positive fungal isolates bronchoalveolar lavage compared receiving conventional mechanical ventilation http://bit.ly/2s38sac',\n",
       " 'haloferax volcanii obligate halophilic archaeon origin dead sea. simple laboratory culture condition wide range genetic tool made model organism studying haloarchaeal cell biology. halophilic enzyme potential interest biotechnology opened application organism biocatalysis, bioremediation, nanobiotechnology, bioplastics biofuel industry. functionally active halophilic protein easily expressed halophilic environment, extensive genetic toolkit option regulated protein overexpression allowed purification biotechnologically important enzyme different halophile h. volcanii. however, corrosion mediated damage caused stainless-steel bioreactors high salt concentration tendency form biofilms cultured high volume challenge applying h. volcanii biotechnology. ability employ expressed active protein immobilized cell within porous biocompatible matrix offer avenue exploiting h. volcanii biotechnology. review critically evaluates various application potentials, challenge toolkits available extreme halophilic organism biotechnology.',\n",
       " 'propose automatic identify people potentially-infected droplet-transmitted diseases. high-risk group identified conducting large-scale visits/interviews, manually screening among ton recorded surveillance videos. time-intensive likely delay control communicable disease like influenza. paper, address challenge solving multi-tasking problem captured surveillance videos. multi-tasking framework aim model principle close proximity interaction thus infer risk individuals. complete workflow includes three essential sub-tasks: (1) person re-identification (reid), identify diagnosed infected individual across different cameras, (2) depth estimation, provide spatial knowledge captured environment, (3) pose estimation, evaluate distance diagnosed potentially-infected subjects. significantly reduces time labor costs. demonstrate advantage high accuracy efficiency method. expected effective accelerating process identifying potentially infected group ultimately contribute well-being public health.',\n",
       " 'pulmonary stem/progenitor cells, could differentiated downstream cell repair tissue damage caused influenza virus, target cell influenza infection. study, mouse pulmonary stem/progenitor cell (mpscs) capability differentiate type type ii alveolar cell used vitro cell model characterize replication pathogenic effect influenza virus pscs. first, mpscs immortalized cell line mpscs(oct4+) susceptible pr8, seasonal h1n1, 2009 pandemic h1n1, h7n9 influenza virus generate infectious particles, although lower titer, could attributed reduced vrna replication nucleoprotein (np) aggregation cytoplasm. nevertheless, significant increase interleukin (il)-6 interferon (ifn)-î³ 12 h ifn-î² 24 h post mpscs implicates mpscs might function sensor modulate immune response influenza infection. summary, result demonstrated mpscs, target cell influenza viruses, could modulate early proinflammatory response influenza infection.',\n",
       " 'n(4)-hydroxycytidine (nhc) antiviral ribonucleoside analog act competitive alternative substrate virally encoded rna-dependent rna polymerases. exhibit measurable level cytotoxicity, 50% cytotoxic concentration value ranging 7.5 î¼m cem cell >100 î¼m cell lines. mitochondrial dna-dependent rna polymerase (polrmt) incorporate nucleotide analog mitochondrial rnas, resulting substantial mitochondrial toxicity. nhc tested multiple assay intended determine potential cause mitochondrial toxicity. nhc showed similar cytotoxicity hepg2 cell incubated glucose-free glucose-containing media, suggesting nhc impair mitochondrial function cell line based crabtree effect. demonstrate 5â\\x80²-triphosphate nhc used polrmt incorporation nascent rna chain cause immediate chain termination. pc-3 cell treated nhc, 50% inhibitory concentration mitochondrial protein expression inhibition 2.7-fold lower nuclear-encoded protein expression, effect selective mitochondrial toxicity. 14-day incubation hepg2 cell nhc effect mitochondrial dna copy number extracellular lactate levels. cem cell treated nhc 10 î¼m, slight decrease (by â\\x88¼20%) mitochondrial dna copy number corresponding slight increase extracellular lactate level detected, effect enhanced increase nhc concentration. summary, result indicate mitochondrial impairment nhc main contributor compoundâ\\x80\\x99s observed cytotoxicity cell lines.',\n",
       " 'rationale: remains significant controversy regarding optimal approach fluid resuscitation shock. magnitude care variability shock resuscitation, confounding effect severity comorbidity, relative impact sepsis survival poorly understood. objective: evaluate usual care variability determine differential effect observed predicted fluid resuscitation volume risk-adjusted hospital mortality mechanically ventilated shock. methods: performed retrospective outcome analysis mechanically ventilated admitted intensive care unit 2013 premier hospital database (premier, inc.). observed predicted hospital mortality evaluated observed predicted 1 fluid administration, difference predicted observed outcome adjust severity groups. predictive model validated second administrative database (truven analytics inc.). secondary outcome included duration mechanical ventilation, hospital icu length stay, cost. results: among 33,831 patients, observed hospital mortality incrementally higher predicted additional liter 1 fluid beginning 7 l (40.9% vs. 37.2%, p = 0.008). compared received expected (â± 1.5 l predicted) 1 fluid volumes, greater-than-expected fluid resuscitation associated increased risk-adjusted hospital mortality (52.3% vs. 45.0%, p < 0.0001) among shock among subgroup shock comorbid condition predictive lower fluid volume administration (47.1% vs. 41.5%, p < 0.0001). however, shock without conditions, greater-than-expected (57.5% vs. 49.2%, p < 0.0001) less-than-expected (52.1% vs. 49.2%, p = 0.037) 1 fluid resuscitation associated increased risk-adjusted hospital mortality. conclusions: highly variable 1 fluid resuscitation associated non-uniform impact risk-adjusted hospital mortality among distinct subgroup mechanically ventilated shock. finding support closer evaluation fluid resuscitation strategy include broadly applied fluid volume target early phase shock resuscitation.',\n",
       " 'background: neuromuscular blocking agent (nmba) proposed medical guideline early severe acute respiratory distress syndrome (ards) survival benefits. however, study provided evidence contradicting results. method: search performed pubmed, scopus, clinicaltrials.gov, virtual library database randomized controlled trial (rct) evaluating 28-day mortality ards treated nmba within 48 h. english language restriction applied. relevant extracted pooled risk ratio (rr), mean difference (md), corresponding 95% confidence interval (ci) random-effect model. sensitivity meta-regression analysis performed. results: 2675 studies, included five rcts analysis, total 1461 mean pao(2)/fio(2) 104 â± 35 mmhg. cisatracurium group risk death 28 day (rr, 0.90; 95% ci, 0.78â\\x80\\x931.03; i(2) = 50%, p = 0.12) 90 day (rr, 0.81; 95% ci, 0.62â\\x80\\x931.06; i(2) = 56%, p = 0.06) control group (no cisatracurium). secondary outcome mechanical ventilation duration ventilator-free day different two groups. cisatracurium significantly lower risk barotrauma control group difference intensive care unit (icu)â\\x80\\x93induced weakness. pao(2)/fio(2) ratio higher cisatracurium group 48 h. meta-regression analysis baseline pao(2)/fio(2) ratio, positive end-expiratory pressure (peep) revealed heterogeneity. subgroup analysis excluding trial high peep light sedation strategy yielded improvement mortality outcomes. conclusion: nmba improves oxygenation 48 h moderate, severe ards lower barotrauma risk without affecting icu weakness. however, nmba reduce ventilator-free days, duration mechanical ventilation or, importantly, mortality risk regardless severity ards.',\n",
       " '',\n",
       " 'care-associated infection pseudomonas aeruginosa bacteremia pose major clinical risk hospitalized patients. however, systemic infection presumed â\\x80\\x9cdead-endâ\\x80\\x9d p. aeruginosa impact transmission. here, use mouse model p. aeruginosa spread bloodstream gallbladder, replicates extremely high numbers. bacteria gallbladder seed intestine feces, leading transmission uninfected cage-mate mice. work show gallbladder crucial spread p. aeruginosa bloodstream feces bacteremia, process promotes transmission experimental system. research needed test extent finding relevant infection patients.',\n",
       " '',\n",
       " 'peste de petits ruminant cause highly contagious disease, pose enormous economic loss domestic animal threatens conservation wild herbivores. diagnosis remains cornerstone peste de petits ruminant global control eradication strategy, initiative world organisation animal food agriculture organisation. present review present peste de petits ruminant diagnostic landscape, practicality commercially available diagnostic tools, prototype test opportunity technologies. common peste de petits ruminant diagnostic tool include; agar gel immunodiffusion, counter-immunoelectrophoresis, enzyme-linked immunosorbent assays, reverse transcription polymerase chain reaction either gel-based real-time, reverse transcription loop-mediated isothermal amplification, reverse transcription recombinase polymerase amplification assays, immunochromatographic lateral flow devices, luciferase immunoprecipitation system pseudotype-based assays. test vary technical demands, require laboratory exception immunochromatographic lateral flow possibly reverse transcription loop-mediated isothermal amplification reverse transcription recombinase polymerase amplification assays. thus, proposing efficient integration diagnostic test rapid correct identification peste de petits ruminant endemic zone rapidly confirm outbreaks. deployment pen-side test improve diagnostic capacity extremely remote setting susceptible wildlife ecosystems, transportation clinical sample optimum cold chain unreliable.',\n",
       " 'background: no-touch environmental disinfection ultraviolet device highlighted past several year control transmission multidrug-resistant organism (mdros). however, effectiveness non-us healthcare setting yet examined. aimed evaluate effectiveness disinfection portable pulsed xenon ultraviolet (px-uv) device controlling transmission mdros non-us healthcare setting. methods: admitted intensive care unit 629-bed tertiary referral hospital japan august 2016 february 2019 enrolled. period, px-uv disinfection added manual terminal cleaning every transfer/discharge. microbiological evaluation, surface selected sampling contact plate before/after manual cleaning px-uv. overnight incubation, colony plate counted. results: incidence newly acquired methicillin-resistant staphylococcus aureus (mrsa) declined significantly (13.8 9.9 per 10,000 days, incidence rate ratio 0.71, p = 0.002), well newly acquired drug-resistant acinetobacter (48.5 18.1, 0.37, p < 0.001). percent reduction microbiological burden manual cleaning 81%, 59% reduction achieved px-uv. conclusions: px-uv effective reducing microbial burden controlling mdros non-us healthcare setting.',\n",
       " 'background: addition outbreak nosocomial influenza, sporadic nosocomial influenza infection occur generally reported literature. aimed determine epidemiologic characteristic case nosocomial influenza compared remaining severe case severe influenza acute hospital catalonia (spain) identified surveillance. methods: observational case-case epidemiological carried aged â\\x89¥18 year catalan 12 hospital 2010 2016. laboratory-confirmed influenza (nosocomial not) collected demographic, virological clinical characteristics. defined nosocomial influenza admitted hospital reason acute respiratory ili symptom developed â\\x89¥48 h admission influenza confirmed rt-pcr. mixed-effects regression used estimate crude adjusted or. results: thousand seven hundred twenty-two hospitalized severe laboratory-confirmed influenza included: 96 (5.6%) classified nosocomial influenza frequently > 14 day hospital stay (42.7% vs. 27.7%, p < .001) higher mortality (18.8% vs. 12.6%, p < .02). variable associated nosocomial influenza case acute-care hospital setting chronic renal (aor 2.44 95% ci 1.44â\\x80\\x934.15) immunodeficiency (aor 1.79 95% ci 1.04â\\x80\\x933.06). conclusions: nosocomial infection recurring problem associated high rate chronic disease death. finding underline need adherence control guidelines.',\n",
       " '',\n",
       " 'network property govern rate extent various spreading processes, simple contagion complex cascades. recently, analysis spreading process extended static network temporal networks, node link appear disappear. focus effect accessibility, whether temporally consistent path node another, reachability, density corresponding accessibility graph representation temporal network. level reachability thus inherently limit possible extent spreading process temporal network. reachability term overall level temporal concurrency edge structural cohesion network agglomerating edges. use simulation result develop heterogeneous mean-field model prediction random network better quantify property underlying temporal network regulate reachability.',\n",
       " 'drug-resistant mycobacterium tuberculosis (m. tuberculosis) become increasingly serious public problem complicated tuberculosis (tb) treatment. levofloxacin (lof) ideal anti-tuberculosis drug clinical applications. however, detailed molecular mechanism lof-resistant m. tuberculosis tb revealed. performed transcriptome methylome sequencing investigate potential biological characteristic lof resistance m. tuberculosis h37rv. transcriptome analysis, 953 differentially expressed gene (degs) identified; 514 439 degs significantly downregulated upregulated lof-resistant group control group, respectively. kegg pathway analysis revealed 97 pathway enriched study. methylome analysis, 239 differentially methylated gene (dmgs) identified; 150 89 dmgs hypomethylated hypermethylated lof-resistant group control group, respectively. kegg pathway analysis revealed 74 pathway enriched study. overlap suggested 25 gene obtained. notable nine gene expressed downregulated mrna upregulated methylated levels, pgi, fade4, php, cyp132, pcka, rpmb1, pfkb, acg, ctpf, especially cyp132, pcka, pfkb, vital lof-resistant m. tuberculosis h37rv. overlapping gene transcriptome methylome could essential studying molecular mechanism lof-resistant m. tuberculosis h37rv. result may provide informative evidence tb lof. electronic supplementary material: online version article (10.1007/s00239-019-09926-z) contains supplementary material, available authorized users.',\n",
       " 'background: gastrointestinal (gi) cytomegaloviral (cmv) common among immunocompromised status; however, specific gi-cmv immunocompetent comparatively limited. methods: retrospective included diagnosed gi-cmv siriraj hospital (bangkok, thailand) 2008â\\x80\\x932017. baseline characteristics, presentations, comorbid conditions, endoscopic findings, treatments, outcome compared immunocompetent immunocompromised. results: hundred seventy-three (56 immunocompetent, 117 immunocompromised) included. immunocompetent significantly older immunocompromised (73 vs. 48.6 years, p < 0.0001). significantly immunocompetent icu time diagnosis (21.0% vs. 8.6%, p = 0.024). gi bleeding leading presentation immunocompetent, diarrhea abdominal pain common immunocompromised. blood cmv load negative significantly immunocompetent immunocompromised (40.7% vs. 12.9%, p = 0.002). ganciclovir main groups. significantly immunocompetent immunocompromised receive specific therapy (25.5% vs. 4.4%, p â\\x89¤ 0.01). six-month mortality significantly higher among immunocompetent (39.0% vs. 22.0%, p = 0.047). independent predictor death old age inpatient icu clinical setting. antiviral agent independent protective factor. conclusion: gi-cmv frequently observed among immunocompetent elderly comorbidities severe concomitant illnesses. gi bleeding common presentation. blood cmv load diagnostically helpful. significantly higher mortality observed immunocompetent immunocompromised patients, could due severe concomitant illness immunocompetent group.',\n",
       " 'intracellular vesicle fusion mediated soluble n-ethylmaleimide sensitive factor attachment protein receptor (snares) sec1/munc18 (sm) proteins. generally accepted membrane fusion occurs vesicle target membrane brought close proximity snare sm proteins. work, demonstrate that, fusion occur, membrane bilayers must destabilized conserved membrane-embedded motif located juxtamembrane region vesicle-anchored v-snare. comprised basic hydrophobic residues, juxtamembrane motif perturbs lipid bilayer structure promotes snare-sm-mediated membrane fusion. juxtamembrane motif functionally substituted unrelated membrane-disrupting peptide membrane fusion reaction. finding establish juxtamembrane motif v-snare membrane-destabilizing peptide. requirement membrane-destabilizing peptide likely common feature biological membrane fusion.',\n",
       " 'past two decade significant expansion number therapeutic monoclonal antibody (mabs) approved regulators. discovery medicine driven primarily approach inflammatory disease oncology, especially immuno-oncology. recent success included antibody use diseases, hiv. perception high cost associated mabs led assumption play role prophylaxis disease poverty. however, improvement antibody-expression yield manufacturing process indicate cost-effective option providing protection many type revisited. recent technology development indicate several month protection could achieved single dose. moreover, method b cell sorting enable systematic identification high-quality antibody humanized mice, patients. review discus potential passive immunization schistosomiasis, fungal infections, dengue, neglected diseases.',\n",
       " 'background: outbreak acute undifferentiated febrile illness (aufi) common nepal, exact etiology risk factor often go unrecognized. disease like influenza, enteric fever rickettsial fever account majority outbreaks. optimal diagnostic test inform decision available point-of-care. proper epidemiological clinical characterization outbreak important appropriate control efforts. methods: investigation initiated response increased presentation patan hospital chalnakhel locality dakchinkali municipality, kathmandu aufi june 10 july 1, 2016. focused group discussion local inhabitant epidemiological curve febrile local primary care centre confirmed outbreak. household-survey conducted area questionnaire administered characterize illness medical record reviewed. different set questionnaire administered control investigate association common risk factors. water sample collected analyzed microbiologically. results: eighty 137 household suffered febrile illness within 6 week window investigation. 67 sampled acute fever generalized illness without discernible focus infection. 38% received clinical diagnosis rest treated empirically without diagnosis. three blood culture confirmed enteric fever. forty-two (63%) administered antibiotics, commonly, ofloxacin, cefixime azithromycin mean fever clearance time 4 days. definite association several risk factor fever. fecal contamination noted tap water samples. conclusion: based pattern illness, outbreak likely mixture self-limiting infection enteric fever. show even absence confirmed diagnosis, detailed characterization illness presentation recovery course suggest diagnosis help formulating appropriate recommendation control.',\n",
       " 'background: influenza (iav) continues pose serious threat public health. current prophylaxis therapeutic intervention iav requires frequent change due continuous antigenic drift antigenic shift iav. emerging evidence indicates host micrornas (mirnas) play critical role intricate host-pathogen interaction networks. cellular mirnas may directly target inhibit developed potential anti-virus drugs. methods: study, established broad-spectrum anti-iav mirna screening miranda software. screened mirnas verified luciferase assay, protein expression assay replication assay. results: five cellular mirnas (mir-188-3p, mir-345-5p, mir-3183, mir-15-3p mir-769-3p), targeting 99.96, 95.31, 92.9, 94.58 97.24% human iav strain recorded ncbi, respectively, chosen experimental verification. finally, found mir-188-3p downregulated pb2 expression mrna protein level directly targeted predicted site pb2 effectively inhibited replication iav (h1n1, h5n6 h7n9) a549 cells. conclusions: first report screening cellular mirnas broad-spectrum inhibiting iav infection. finding suggested cellular mir-188-3p could used rnai-mediated anti-iav therapeutic strategies.',\n",
       " 'background: multi-drug resistant (mdr) acinetobacter baumannii pseudomonas aeruginosa major cause nosocomial infection globally. current world organization critical priority pathogen resistance, antimicrobial resistance (amr) surveillance discovery antibiotics. however, paucity nosocomial infection (nis) caused superbug ethiopia. therefore, determined magnitude profile nosocomial mdr a. baumannii p. aeruginosa infection among hospitalized felegehiwot referral hospital, northwest ethiopia. methods: cross-sectional conducted felegehiwot referral hospital april 1 july 31, 2018. total 238 blood stream, urinary tract surgical site ni enrolled conveniently. either blood, urine wound swab specimen collected processed standard bacteriological procedures. a. baumannii p. aeruginosa isolates identified standard bacteriological technique confirmed automated vitek2 compact. antimicrobial susceptibility testing isolates performed disk diffusion technique. result interpreted per standard zone size clinical laboratory standard institute.chi-square test done determine association among variables. p value < 0.05 considered statistical significant. results: median age participant 29 years. overall,20(8.4%) nosocomial mdr a. baumannii p. aeruginosa infections. proportion nosocomial mdr blood stream, urinary tract surgical site infection 13(8.9%), 5(8.3%) 2 (6.3%), respectively. ni lower mean age (24.9 years) (p = 0.035). isolates ni intravenous catheterization. frequency ni 9(3.8%) mdr a. baumannii 11(4.6%) mdr p.aeruginosa. a. baumannii p. aeruginosa isolates 100% mdr. isolates a. baumannii p. aeruginosa 100% resistant ampicillin piperacillin.a. baumannii isolates 33.3 44.5% resistance meropenem ciprofloxacin, respectively p.aeruginosa isolates revealed 36.4 45.5% resistance ciprofloxacin meropenem, respectively. conclusions: care associated infection mdr a.baumannii p. aeruginosa critical problem area. therefore, urgent focused intervention required contain spreading mdr nis. ni care guided antimicrobial susceptibility testing.',\n",
       " 'background: previous study suggest prone positioning (pp) increase pao(2)/fio(2) reduce mortality moderate severe acute respiratory distress syndrome (ards). aim determine whether early use pp combined non-invasive ventilation (niv) high-flow nasal cannula (hfnc) avoid need intubation moderate severe ards patients. methods: prospective observational cohort performed two teaching hospitals. non-intubated moderate severe ards included placed pp niv hfnc. efficacy improving oxygenation four support methodsâ\\x80\\x94hfnc, hfnc+pp, niv, niv+ppâ\\x80\\x94were evaluated blood gas analysis. primary outcome rate intubation. results: january 2018 april 2019, 20 ards enrolled. main cause ards pneumonia due influenza (9 cases, 45%) virus (2 cases, 10%). ten case moderate ards 10 case severe. eleven avoided intubation (success group), 9 intubated (failure group). 7 pao(2)/fio(2) < 100 mmhg niv required intubation. pao(2)/fio(2) hfnc+pp significantly higher success group failure group (125 â± 41 mmhg v 119 â± 19 mmhg, p = 0.043). pao(2)/fio(2) demonstrated upward trend four support strategies: hfnc < hfnc+pp â\\x89¤ niv < niv+pp. average duration pp 2 h twice daily. conclusions: early application pp hfnc, especially moderate ards baseline spo(2) > 95%, may help avoid intubation. pp well tolerated, efficacy pao(2)/fio(2) four support strategy hfnc < hfnc+pp â\\x89¤ niv < niv+pp. severe ards appropriate candidate hfnc/niv+pp. trial registration: chictr, chictr1900023564. registered 1 june 2019 (retrospectively registered)',\n",
       " '',\n",
       " 'significance integral membrane protein niemann-pick c1 (npc1) ebolavirus entry process determined various cell line derived humans, non-human primate fruit bats. fruit bat long purported potential reservoir host ebolaviruses, several study provide evidence mop condylurus, insectivorous microbat, ebolavirus reservoir. npc1 receptor expression context ebolavirus replication microbat cell remains unstudied. order ebola (ebov) cellular entry replication m. condylurus, derived primary immortalized cell culture 12 different organs. npc1 receptor expression characterized confocal microscopy flow cytometry comparing expression level m. condylurus primary immortalized cells, hela cells, human embryonic kidney cell cell european microbat species. ebov replication kinetics studied four representative cell culture qrt-pcr. aim elucidate suitability primary immortalized cell different tissue studying npc1 receptor expression level potential influence ebov replication. npc1 receptor expression level m. condylurus primary cell differed depending organ derived cell type significantly lower human cell lines. immortalized cell showed cell type higher expression level corresponding primary cells. concluding experiment ebov suggest potential correlation npc1 receptor expression level replication rate vitro.',\n",
       " 'plasmodium falciparum (pf) cysteine-rich protective antigen (pfcyrpa) emerged blood-stage candidate antigen inclusion broadly cross-reactive malaria vaccine. highly conserved protein among various geographical strain play key role red blood cell invasion process p. falciparum merozoites, antibody pfcyrpa efficiently prevent entry malaria parasite red blood cells. aim present develop human-compatible formulation pfcyrpa vaccine candidate confirming activity preclinical studies. recombinant pfcyrpa expressed hek 293 cell chemically coupled phosphoethanolamine incorporated membrane unadjuvanted influenza virosomes approved antigen delivery system humans. laboratory animal immunised virosome-based pfcyrpa vaccine determine immunogenic property particular, capacity elicit parasite binding growth-inhibitory antibodies. vaccine elicited mouse rabbit high titer pfcyrpa-specific antibody bound blood-stage parasites. concentration 10 mg/ml, purified total serum igg immunised rabbit inhibited parasite growth vitro 80%. furthermore, p. falciparum mouse model, passive transfer 10 mg purified total igg pfcyrpa vaccinated rabbit reduced vivo parasite load 77%. influenza virosomes thus represent suitable antigen delivery system induction protective antibody recombinant pfcyrpa, designating highly suitable component inclusion multivalent multi-stage virosomal malaria vaccine.',\n",
       " 'background: compared continuous vibrating mesh nebulizer (vmn), inspiration synchronized vmn increased inhaled dose noninvasive ventilation; however, use aerosol delivery via high-flow nasal cannula (hfnc) still unknown. methods: adult manikin connected dual-chamber model lung, driven critical care ventilator simulate spontaneous breathing. hfnc system utilized temperature 37 â° c gas flow 5, 10, 20, 40, 60 l/min. inspiration synchronized continuous aerosol generation compared different position (at inlet humidifier v close patient). milliliter albuterol (2.5 mg/ml) used run (n = 3). collection filter placed trachea removed run. drug eluted filter assayed uv spectrophotometry (276 nm). results: nebulizer placed close patient, inhaled dose higher inspiration synchronized continuous aerosol generation gas flow (p = 0.05) except 5 l/min. placed inlet humidifier, compared continuous, inspiration synchronized aerosol generated higher inhaled dose gas flow set 50% inspiratory flow [23.9 (20.6, 28.3)% v 18.1 (16.7, 19.6)%, p < 0.001], lower inhaled dose gas flow set 50% inspiratory flow [3.5 (2.2, 9.3)% v 9.9 (8.2, 16.4)%, p = 0.001]. regardless breathing pattern, continuous aerosol delivered greater inhaled dose nebulizer placed humidifier close gas flow except 5 l/min. conclusion: hfnc gas flow set higher 50% inspiratory flow, significant advantage found inspiration synchronized continuous aerosol. however, inspiration synchronized aerosol generated 30% inhaled dose continuous gas flow set 50% inspiratory flow, regardless nebulizer placement. continuous nebulizer need placed inlet humidifier.',\n",
       " 'background: high-frequency oscillatory ventilation (hfov) use associated greater mortality adult acute respiratory distress syndrome (ards). nevertheless, hfov still frequently used rescue therapy paediatric acute respiratory distress syndrome (pards). view limited evidence hfov pards evidence demonstrating harm adult ards, hypothesized hfov use compared mode mechanical ventilation associated increased mortality pards. methods: pards 10 paediatric intensive care unit across asia 2009 2015 identified. epidemiology clinical outcome collected. hfov compared mode ventilation. primary outcome 28-day mortality secondary outcome 28-day ventilator- (vfd) intensive care unit- (ifd) free days. genetic matching (gm) used analyse association hfov primary outcome. additionally, performed sensitivity analysis, propensity score (ps) matching, inverse probability weighting (iptw) marginal structural modelling (msm) estimate effect. results: total 328 included. first 7 day pards, 122/328 (37.2%) supported hfov. significant difference baseline oxygenation index (oi) hfov non-hfov group (18.8 [12.0, 30.2] vs. 7.7 [5.1, 13.1] respectively; p < 0.001). total 118 pair matched gm found significant association hfov 28-day mortality pards [odds ratio 2.3, 95% confidence interval (ci) 1.3, 4.4, p value 0.01]. vfd indifferent hfov non-hfov group [mean difference â\\x88\\x92 1.3 (95%ci â\\x88\\x92 3.4, 0.9); p = 0.29] ifd significantly lower hfov group [â\\x88\\x92 2.5 (95%ci â\\x88\\x92 4.9, â\\x88\\x92 0.5); p = 0.03]. sensitivity analysis, p matching, iptw msm showed consistent direction hfov effect pards. conclusion: use hfov associated increased 28-day mortality pards. suggests caution eliminate equivocality randomized controlled trial justified examine true association. electronic supplementary material: online version article (10.1186/s13054-020-2741-x) contains supplementary material, available authorized users.',\n",
       " 'ace2 monocarboxypeptidase generates angiotensin (1â\\x80\\x937) angiotensin ii (1â\\x80\\x938). attempt target kidney renin angiotensin system native ace2 treat kidney hampered molecular size, 100 kda, precludes glomerular filtration subsequent tubular uptake. here, urine kidney lysates capable digesting native ace2 shorter protein ~60â\\x80\\x9375 kda demonstrate enzymatically active. truncated native ace2 design c-terminus generate two short recombinant (r)ace2 variant (1-605 1-619aa). two truncates molecular size ~70 kda, expected amino acid sequence western blot. ace2 enzyme activity, measured specific substrate, higher native race2 (1-740 aa). infused mouse genetic ace2 deficiency, single i.v. injection 1-619 resulted detectable ace2 activity urine, whereas infusion native ace2 not. moreover, ace2 activity recovered harvested kidney ace2-deficient mouse infused 1-619, control (23.1 â± 4.3 rfu/âµg creatinine/h 1.96 â± 0.73 rfu/âµg protein/hr, respectively). addition, kidney ace2-null mouse infused 1-619 studied ex vivo formed ang (1â\\x80\\x937) exogenous ang ii infused vehicle (auc 8555 â± 1933 vs. 3439 â± 753 ng/ml, respectively, p < 0.05) demonstrating functional effect increasing kidney ace2 activity infusion short ace2 1-619 variant. conclude novel short recombinant ace2 variant undergo glomerular filtration, associated kidney uptake enzymatically active protein enhance formation ang (1â\\x80\\x937) ang ii. small ace2 variant may offer potentially useful approach target kidney ra overactivity combat kidney injury.',\n",
       " 'hepatitis e enteric highly prevalent developing countries. basis high mortality among pregnant hepatitis e remains unclear. importantly, proportion infected pregnant woman present subclinical well. order understand possible mechanism influencing clinical presentation hepatitis e pregnant women, explored system biology approach. this, pbmcs various category subjected rnaseq analysis. included non-pregnant (npr, acute convalescent phases) pregnant (pr, 2(nd) 3(rd) trimesters, acute phase subclinical hev infections) corresponding healthy controls. current deal immune response genes. contrast exclusive up-regulation nonspecific, early immune response transcript npr patients, pr exhibited broader heightened expression gene associated innate well adaptive b cell responses. identified first time (1) inverse relationship immunoglobulin (ig) gene overexpression (2) association differential expression s100 series gene presentation. suggests possible involvement tlr4 nod1 pregnant alpha defensins category suggesting role protection. induction ifnî³ gene detected acute phase irrespective pregnancy. association response vitamin d, transcript related nk/nkt regulatory cell subclinical noteworthy. obtained could correlated several study reported earlier hepatitis e suggesting utility pbmcs alternate specimen. extensive, informative provided first time form basis future study help understanding pathogenesis fulminant hepatitis e.',\n",
       " 'background: prone positioning (pp) veno-venous ecmo feasible, physiological effect never thoroughly evaluated. objective describe, electrical impedance tomography (eit), impact pp global regional ventilation, optimal peep level. methods: monocentric conducted ecmo-supported severe ards patients, ventilated pressure-controlled mode, 14-cmh(2)o driving pressure eit-based â\\x80\\x9coptimal peepâ\\x80\\x9d. before, 16-h pp session, eit-based distribution variation tidal impedance, vt(dorsal)/vt(global) ratio, end-expiratory lung impedance (eeli) static compliance collected. subgroup analysis performed increased static compliance â\\x89¥ 3 ml/cmh(2)o 16 h pp. results: (n = 21), tidal volume eeli redistributed ventral dorsal region pp. eit-based optimal peep significantly lower pp supine position. median (iqr) optimal peep decreased 14 (12â\\x80\\x9316) 10 (8â\\x80\\x9314) cmh(2)o. thirteen (62%) increased static compliance â\\x89¥ 3 ml/cmh(2)o pp ecmo. subgroup higher body mass index, frequent pneumonia, shorter ecmo duration, lower baseline vt(dorsal)/vt(global) ratio compliance â\\x89¤ 3 ml/cmh(2)o (p < 0.01). conclusion: although baseline tidal volume distribution eit may predict static compliance improvement pp ecmo, result support physiological benefit pp ecmo patients, modifying lung mechanic potentially reducing vili. studies, randomizedâ\\x80\\x93controlled trial, warranted confirm potential pp benefit ecmo.',\n",
       " 'background: overfeeding underfeeding intensive care unit (icu) associated worse outcomes. reliable estimation energy expenditure (ee) icu may help avoid phenomena. several factor influence ee studied previously. however, effect neuromuscular blocking agent ee, conceptually would lower ee, extensively investigated. methods: studied cohort adult critically ill requiring invasive mechanical ventilation continuous infusion cisatracurium least 12 h. aimed quantify effect cisatracurium infusion ee (primary endpoint). ee estimated based ventilator-derived vco(2) (ee kcal/day = vco(2) ã\\x97 8.19). subgroup analysis septic non-septic performed. furthermore, effect body temperature sepsis ee evaluated. secondary endpoint hypercaloric feeding (> 110% ee) cisatracurium infusion. results: total, 122 included. mean ee cisatracurium infusion 1974 kcal/day 1888 kcal/day cisatracurium infusion. multivariable analysis showed significantly lower ee cisatracurium infusion (md â\\x88\\x92 132.0 kcal (95% ci â\\x88\\x92 212.0 â\\x88\\x92 52.0; p = 0.001) patients. difference statistically significant sepsis non-sepsis (p = 0.036 p = 0.011). non-sepsis lower ee sepsis (md â\\x88\\x92 120.6 kcal; 95% ci â\\x88\\x92 200.5 â\\x88\\x92 40.8, p = 0.003). body temperature ee positively correlated (spearmanâ\\x80\\x99s rho = 0.486, p < 0.001). hypercaloric feeding observed 7 patients. conclusions: suggest continuous infusion cisatracurium mechanically ventilated icu associated significant reduction ee, although magnitude effect small. sepsis higher body temperature associated increased ee. cisatracurium infusion associated overfeeding minority therefore, patients, reduction caloric prescription necessary.',\n",
       " 'nutrition therapy critical illness focus recent research, rapid increase publication accompanied two updated international clinical guidelines. however, translation evidence practice challenging due continually evolving, often conflicting trial finding guideline recommendations. narrative review aim provide comprehensive synthesis interpretation adult critical care nutrition literature, particular focus continuing practice gap area data, assist clinician making practical, yet evidence-based decision regarding nutrition management different stage critical illness.',\n",
       " 'background: diagnostic interventional option becoming available use pediatric patients, technique procedural sedation analgesia (psa) administered considerably growing number well. aims: objective research effort conduct first countrywide survey status quo sedation analgesia delivered child adolescent germany. methods: dispatched letter pediatric hospital setting germany (n = 305), questionnaire developed existing guideline taken account. item designed elucidate current practice psa throughout pediatric center regarding (a) organizational structure (b) standard medication staffing. results: total 138 center returned questionnaire, hence response rate 45.2%. numerous center implemented adequate structure staffing standards. deficit nevertheless identified, notably term on-location equipment staff provided deliver sedations. essential item equipment provided 26.8% centers. adequate staffing provided 44.2% centers, depending diagnostic interventional procedure psa delivered. widely used sedative agent midazolam, ketamine/esketamine, propofol. conclusions: adequate care structure management procedural sedation analgesia implemented many pediatric center germany. downside, finding reveal deficit take effort eliminated.',\n",
       " 'background: epidemiological control malaria hampered appearance parasite resistance anti-malarial drug resistance mosquito vector control measures. associated weak transmission control, mostly due poor control asymptomatic associated host-vector transmission. highlight importance studying parasiteâ\\x80\\x99s sexual form (gametocytes) involved phase parasiteâ\\x80\\x99s life-cycle. african asian strain plasmodium falciparum fully characterized regarding sexual formsâ\\x80\\x99 production; however, latin-american strain characterized. aimed characterizing colombian fcb2 strain gametocyte producer able infect mosquitoes. methods: gametocyte production induced vitro cultured p. falciparum fcb2 3d7 strains. pfap2g pfs25 gene expression detected fcb2 strain gametocyte culture rt-pcr. comparative analysis gametocyte obtained strain made (counts morphological changes). vitro zygote formation fcb2 gametocyte induced incubating gametocyte culture sample 27 â°c 20 min. controlled anopheles albimanus made artificial feed system cultured fcb2 gametocyte (14â\\x80\\x9315 day old). mosquito midgut dissection carried analyzing oocysts. results: fcb2 strain expressed pfap2g, pfs16, pfg27/25 pfs25 sexual differentiation-related gene vitro sexual differentiation induction, producing gametocyte conserved expected morphological features. amount fcb2 gametocyte produced similar 3d7 strain. fcb2 gametocyte differentiated zygote ookinetes vitro low-temperature stimulus infected an. albimanus mosquitoes, developing oocyst stage. conclusions: even history long-term fcb2 strain vitro culture maintenance, retained sexual differentiation ability. gametocyte produced preserved parasite formsâ\\x80\\x99 usual characteristic an. albimanus capability, thus enabling use tool studying sexual form biology, an. albimanus comparative analysis anti-malarial drug vaccine development.',\n",
       " 'background: haemonchus contortus (h. contortus) important parasite cause huge economic loss small ruminant industry worldwide. effective prognosis depend upon early diagnosis h. contortus infection. date, widely-approved method identification prepatent h. contortus available identify prepatent h. contortus properly. aim evaluate diagnostic potential recombinant cold shock h. contortus protein (rhc-cs) early late infection h. contortus goat. results: purified rhc-cs exhibited clear band, molecular weight 38 kda. h. contortus egg detected fecal egg count technique feces collected 0 14 day post (d.p.i). however, egg detected 21, 28 35 d.p.i. hence, result immunoblotting assay showed specific anti rhc-cs antibody detection goat serum collected early stage (14 d.p.i) late stage (21â\\x80\\x93103 d.p.i) h. contortus infection. furthermore, cross reactivity observed trichinella spiralis, fasciola hepatica toxoplasma gondii uninfected goats. among several evaluated rhc-cs indirect-elisa format variables, favorable antigen coating concentration found 0.28 î¼g/well 37 â°c 1 h overnight 4 â°c. moreover, optimum dilution ratio serum rabbit anti-goat igg recorded 1:100 1:4000, respectively. best blocking buffer 5% bovine serum albumin (bsa) best time blocking, serum incubation tmb reaction recorded 60, 120 10 min, respectively. cut-off value positive negative interpretation determined 0.352 (od(450)). diagnostic specificity sensitivity rhc-cs, recorded 100%. conclusion: result validated rhc-cs potential immunodiagnostic antigen detect specific antibody early late h. contortus infection goat.',\n",
       " 'background: muscle weakness following critical illness consequence loss muscle mass alteration muscle quality. associated long-term disability. ultrasonography reliable tool quantify muscle mass, study evaluate muscle quality critically ill bedside lacking. shear wave ultrasound elastography (swe) provides spatial representation soft tissue stiffness measure muscle quality. reliability reproducibility swe critically ill never evaluated. methods: two operator tested healthy control critically ill intra- inter-operator reliability swe transversal longitudinal view diaphragm limb muscles. reliability calculated intra-class correlation coefficient bootstrap sampling assessed consistency. results: collected 560 images. longitudinal view diaphragm (icc 0.83 [0.50â\\x80\\x930.94]), biceps brachii (icc 0.88 [0.67â\\x80\\x930.96]) rectus femoris (icc 0.76 [0.34â\\x80\\x930.91]) reliable view training set healthy controls. intra-class correlation coefficient inter-operator reproducibility intra-operator reliability 0.9 muscle validation set healthy controls. critically ill patients, inter-operator reproducibility intra-operator 1 2 reliability icc respectively 0.92 [0.71â\\x80\\x930.98], 0.93 [0.82â\\x80\\x930.98] 0.92 [0.81â\\x80\\x930.98] diaphragm; 0.96 [0.86â\\x80\\x930.99], 0.98 [0.94â\\x80\\x930.99] 0.99 [0.96â\\x80\\x931] biceps brachii 0.91 [0.51â\\x80\\x930.98], 0.97 [0.93â\\x80\\x930.99] 0.99 [0.97â\\x80\\x931] rectus femoris. probability reach intra-class correlation coefficient greater 0.8 10,000 bootstrap sampling inter-operator reproducibility respectively 81%, 84% 78% diaphragm, biceps brachii rectus femoris respectively. conclusions: swe reliable technique evaluate limb muscle diaphragm healthy control critically ill patients. trial registration: registered (clinicaltrial nct03550222).',\n",
       " 'background: demonstrated global ebola crisis 2014â\\x80\\x932016, healthcare institution high resource setting need support concerning preparedness threat infectious outbreaks. aimed exploratively develop standardized preparedness system use unfolding threat severe infectious diseases. methods: qualitative three-step among infectious prevention control expert performed. first, interview (n = 5) conducted identify factor trigger preparedness activity unfolding threat. second, trigger informed design phased preparedness system tested focus group discussion (n = 5) conducted identify factor trigger preparedness activity unfolding threat. second, trigger informed design phased preparedness system tested focus group discussion (n = 5) conducted identify factor trigger preparedness activity unfolding threat. second, trigger informed design phased preparedness system tested focus group discussion ( results: four preparedness phase identified: preparedness phase green situation without presence infectious threat requires centralized care, anywhere world. phase yellow outbreak world likelihood imported cases. phase orange realistic chance unexpected within country, unrest developing among population staff; phase red case admitted hospital country, potentially causing shortage resources. specific preparedness activity included prevention, diagnostics, care, staff, communication. consensus reached need development preparedness system national coordination threats. conclusions: study, developed standardized system support institutional preparedness increasing threat. use system curative healthcare institution (municipal) public service, could help effectively communicate align preparedness activity future threat severe infectious diseases.',\n",
       " 'background: fast-paced aging increasing digitalization society, growing interest effect mobile device use cognitive function depression older adults. however, research examining issue among older adult residential care home (rchs) scant. therefore, aimed examine impact mobile device use cognitive function depressive symptom older adult living rchs. methods: cross-sectional survey conducted sociodemographic questionnaire, montreal cognitive assessment (moca) 15-item geriatric depression scale (gds-15). results: total 235 senior resident (aged 82.58 â± 5.54) four rchs surveyed. user mobile device significantly higher total moca score (25.02 â± 4.14) significantly lower gds-15 score (3.28 â± 2.74) non-users (moca: 19.34 â± 5.21, gds-15: 4.69 â± 2.90). multivariate linear regression indicate mobile device use significantly associated total moca score, six seven sub-scores (visuospatial ability execution functions, attention, language, abstraction, delayed recall, orientation)(p < 0.05). logistic regression showed mobile device use significantly associated level depressive symptom (or = 0.458, 95%ci = 0.249â\\x80\\x930.845). conclusions: use mobile device significant association cognitive function depressive symptom older adult living rchs, thus encouraged measure maintain improve cognition prevent depression.',\n",
       " 'worldwide strategy 2010 2017 aimed controlling malarial parasite (mainly plasmodium falciparum) led reduction 18% regarding incidence rates. many biologically-derived anti-malarial vaccine candidate developed date; involved many experimental animals, immense amount work investment million dollars. review provides overview current state main result clinical trial sporozoite-targeting vaccine (i.e. parasite stage infecting liver) carried research group area variable malaria transmission rates. however, none led result regarding effective control disease, thereby making necessary complement effort finding/introducing vaccine candidate adopting multi-epitope, multi-stage approach, based minimal subunit main sporozoite protein involved invasion liver.',\n",
       " 'protective ventilation cornerstone acute respiratory distress syndrome (ards); however, study yet established best ventilatory strategy adopt acute exacerbation interstitial lung (ae-ild) admitted intensive care unit. due severe impairment respiratory mechanics, fibrotic lung high risk developing ventilator-induced lung injury, regardless lung fibrosis etiology. purpose review analyze effect mechanical ventilation ae-ild increase knowledge characteristic fibrotic lung artificial ventilation, introducing concept â\\x80\\x9csquishy ball lungâ\\x80\\x9d. role positive end-expiratory pressure discussed, proposing â\\x80\\x9clung resting strategyâ\\x80\\x9d opposed â\\x80\\x9copen lung approachâ\\x80\\x9d. review discus practical management ae-ild discussing illustrative clinical cases.',\n",
       " 'despite research done first zika (zikv) epidemics, brazilian epidemic congenital zika syndrome described. made possible due number baby born microcephaly northeast region (ne) narrow time. hypothesize fivefold difference rate microcephalic neonate ne region partially effect population prior immunity dengue virus (denv), cross-react zikv. ecological study, analysed interaction dengue fever epidemic 2001 2014 2015/2016 microcephaly epidemic 400 microregions brazil random-effects model bayesian approach. estimated effect time lag recent dengue epidemic (>400/100,000 inhabitants) microcephaly epidemic ranged protection (up 6 year prior) increased risk (from 7 12 years). sustained window protection, larger described previous longitudinal studies, possibly effect herd immunity multiple exposure denv could boost immunity.',\n",
       " 'mrna technology potential transform area medicine, prophylaxis infectious diseases. advantage vaccine range acceleration immunogen discovery rapid response multiple target manufacturing. greater understanding quality attribute dictate translation efficiency, well comprehensive appreciation importance mrna delivery, influencing era investment development activities. application translational science growing early-phase clinical experience continue inform candidate vaccine selection. review state art prevention infectious disease mrna pertinent topic biotechnology pharmaceutical industries.',\n",
       " 'background: austria paediatric influenza-associated hospitalisation death never systematically monitored. examined influenza season 2017/18 term hospitalisation mortality austrian paediatric population put result perspective available last 15 years. methods: case influenza-associated hospitalisation death season 2017/18 child 18 year retrospectively collected 12 33 austrian hospitals, respectively. hospitalisation mortality rate whole austrian paediatric population estimated, adjusting population catchment area. two austrian database queried hospitalisation death associated influenza 2002â\\x80\\x932016. rough estimate vaccination coverage calculated survey 100 inpatients. results: influenza-related paediatric hospitalisation rate season 2017/18 estimated 128 (ci: 122â\\x80\\x93135) per 100,000 children, much higher national average 40 per 100,000 year 2002â\\x80\\x932016. nine reported influenza-associated death among children, resulting mortality rate 0.67 (ci: 0.32â\\x80\\x931.21) per 100,000 children. conclusions: reported influenza-associated hospitalisation fatality demonstrate high burden influenza austrian paediatric population corresponding low vaccination coverage.',\n",
       " 'background: various transcription factor involved process mutually exclusive expression clonal variation plasmodium multigene (var) family. recent study revealed p. falciparum swi/snf-related matrix-associated actin-dependent regulator chromatin (pfswib) might trigger stage-specific programmed cell death (pcd), crucial survival development parasite, profound effect parasite interacting proteins. however, remains unclear whether pfsiwb involved transcriptional regulation virulence gene functional properties. methods: conditional knockdown system â\\x80\\x9cpfswib-fkbp-lidâ\\x80\\x9d introduced parasite clone 3d7, integrated parasite line â\\x80\\x9cpfswib-ha-fkbp-lidâ\\x80\\x9d obtained drug cycling clone screening. growth curve analysis (gca) performed investigate growth development different parasite line 96 h vitro culturing, assessing parasitemia. finally, performed qpcr assay detect var gene expression profiling various comparison groups, well mutually exclusive expression pattern var gene within single 48 h life-cycle p. falciparum different parasite lines. addition, rna-seq applied analyze var gene expression different lines. results: gca revealed conditional knockdown pfswib could interfere growth development p. falciparum. parasitemia pfswibâ\\x88\\x86 showed significant decline 96 h vitro culture compared pfswib 3d7 line (p < 0.0001). qpcr rna-seq analysis confirmed depletion pfswib silence upsa, upsc partial upsb var genes, well remove silencing partial upsb var gene ring stage pfswibâ\\x88\\x86 line, lead aberrant expression upsa partial upsb/upsc var gene mature stage p. falciparum, single 48-h life-cycle. conclusions: demonstrated pfswib involved process clonal variation var gene expression, crucial survival development plasmodium parasite. finding could provide better understanding mechanism function pfswib contributing pathogenesis malaria parasites. [image: see text]',\n",
       " 'background: obesity global epidemic, widely known increased body mass index (bmi) associated alteration respiratory mechanics. bariatric surgery established effective condition. objective: ass safety effectiveness different ventilation strategy obese undergoing bariatric surgery. methods: systematic review randomized clinical trial aimed evaluating ventilation strategy obese carried out. primary outcomes: in-hospital mortality, adequacy gas exchange, respiration mechanic alterations. results: fourteen clinical trial 574 participant included. recruitment maneuver (rm) v positive end-expiratory pressure (peep) compared, rm resulted better oxygenation p = 0.03 (md 79.93), higher plateau pressure p < 0.00001 (md 7.30), higher mean airway pressure p < 0.00001 (md 6.61), higher compliance p < 0.00001 (md 21.00); comparing rm + zero end-expiratory pressure (zeep) v rm + peep 5 10 cmh2o, rm associated peep led better oxygenation p = 0.001 (md 167.00); comparing continuous positive airway pressure (cpap) 40 cmh2o + peep 10 cmh2o v cpap 40 cmh2o + peep 15 cmh2o, cpap 40 + peep 15 achieved better gas exchange p = 0.003 (md 36.00) compliance p = 0.0003 (md 3.00). conclusion: evidence alveolar recruitment maneuver associated peep lead better oxygenation higher compliance. evidence difference pressure control ventilation (pcv) volume control ventilation (vcv).',\n",
       " 'international symposium pneumococcus pneumococcal disease (isppd) premier global scientific symposium dedicated exchange, advancement dissemination latest research pneumococcus, worldâ\\x80\\x99s deadliest bacterial pathogens. since first isppd held 1998, substantial progress made control pneumococcal disease, instance, half surviving infant (78.6 million) 143 country access life-saving pneumococcal conjugate vaccine (pcv). 11th isppd (isppd-11) held melbourne, australia april 2018 proceeding symposium captured report. twenty year first isppd, remain many challenge unanswered question continued disparity incidence indigenous populations, slow roll-out pcv region asia, persisting burden adults, serotype replacement diagnosis pneumococcal pneumonia. isppd-11 put spotlight cutting-edge science metagenomic, transcriptomic, microscopy, medical imaging mathematical modelling approaches. isppd-11 highly diverse, bringing together 1184 delegate 86 countries, representing various field academia, primary healthcare, pharmaceuticals, biotechnology, policymakers public health.',\n",
       " 'hantaviruses (hvs) rodent-transmitted virus cause hantavirus cardiopulmonary syndrome (hcps) america hemorrhagic fever renal syndrome (hfrs) eurasia. together, virus annually caused approximately 200,000 human infection worldwide recent years, fatality rate 5â\\x80\\x9315% hfrs 40% hcps. currently effective available either hfrs hcps. whole inactivated vaccine htnv seov licensed use republic korea china, protective efficacy vaccine uncertain. extent, immune correlate protection hantavirus known. review, summarized epidemiology, virology, pathogenesis four hfrs-causing viruses, htnv, seov, puuv, dobv, two hcps-causing viruses, andv snv, discussed existing knowledge vaccine therapeutic diseases. think information shed light rational development vaccine treatments.',\n",
       " 'influenza contributes significantly childhood morbidity mortality. given magnitude school-aged child population, sizeable proportion influenza transmission event expected occur within school settings. however, influenza activity school well-understood, likely due limited ability accurately monitor respiratory virus without disrupting school environment. study, evaluated use bioaerosol sampling noninvasively detect quantify airborne influenza (iav) density public elementary school. air sample collected multiple location school, two day per week, throughout eight-week sampling period influenza season. real-time rt-pcr targeting iav gene revealed detectable iav five occasion density ranging 2.0 ã\\x97 10(â\\x88\\x921) 1.9 ã\\x97 10(4). significant difference iav density related student presence/absence. majority iav-associated particle â\\x89¤4 î¼m diameter, theoretical calculation indicate infectious threshold minute exposure. represents first identification quantification airborne influenza elementary school, result suggest airborne iav potential circulate school influenza season, enough dos known cause infection.',\n",
       " 'background: human mesenchymal stem/stromal cell (hmscs) represent therapeutic strategy ventilator-induced lung injury (vili) acute respiratory distress syndrome. translational challenge include restoring hmsc efficacy following cryopreservation, developing effective xenogeneic-free (xf) hmscs establishing true therapeutic potential clinically relevant time point administration. wished determine whether cytokine pre-activation cryopreserved, bone marrow-derived xf-hmscs would enhance capacity facilitate injury resolution following vili elucidate mechanism action. methods: initially, vitro study examined potential secretome cytokine pre-activated xf-hmscs attenuate pulmonary epithelial injury induced cyclic mechanical stretch. later, anaesthetised rat underwent vili and, 6 h following injury, randomized receive 1 ã\\x97 10(7) xf-hmsc/kg (i) naive fresh, (ii) naive cryopreserved, (iii) cytokine pre-activated fresh (iv) cytokine pre-activated cryopreserved, control animal received (v) vehicle. extent injury resolution measured 24 h injury. finally, role keratinocyte growth factor (kgf) mediating effect pre-activated xf-hmscs determined pulmonary epithelial wound repair model. results: pre-activation enhanced capacity xf-hmsc secretome decrease stretch-induced pulmonary epithelial inflammation injury. pre-activated fresh cryopreserved xf-hmscs enhanced resolution injury following vili, restoring oxygenation, improving lung compliance, reducing lung leak improving resolution lung structural injury. finally, secretome pre-activated xf-hmscs enhanced epithelial wound repair, part via kgf-dependent mechanism. conclusions: cytokine pre-activation enhanced capacity cryopreserved, xf-hmscs promote injury resolution following vili, potentially via kgf-dependent mechanism.',\n",
       " 'madin-darby canine kidney (mdck) cell line widely used epithelial cell model study ranging environmental pollutants, vaccine production. however, little known basal expression gene involved innate immunity, ability respond infectious non-infectious stressors. therefore, aim evaluate basal level expression pivotal gene innate immune response cell cycle regulation, well evaluate ability cell line respond infectious non-infectious stressors. surmised working hypothesis, demonstrated constitutive expression gene involved innate immune response cell defense alike, tlrs, interleukins, myd88, p65/nf-kb p53. moreover, described ability cell line respond lp cadmium (cd2+) term gene expression cytokine release. confirm possibility cell line model study host/pathogen interaction response non-infectious stressors.',\n",
       " '',\n",
       " 'background: human study (his) valuable vaccine development. deliberate infection, however, creates challenging questions, particularly low middle-income country (lmics) ethical challenge may heightened. consultation stakeholder needed support contextually appropriate acceptable design. examined stakeholder perception acceptability ethic malawi, inform decision planned pneumococcal challenge research wider understanding ethic lmics. methods: conducted 6 deliberative focus group 15 follow-up interview research staff, medical students, community representative rural urban blantyre. conducted 5 key informant interview clinicians, ethic committee members, district government officials. results: stakeholder perceived research potential population benefits, concerns, particularly related safety volunteer negative community reactions. acceptability depended range condition related procedure voluntary informed consent, inclusion criteria, medical care support, compensation, regulation, robust community engagement. condition largely mirror existing guideline biomedical research lmics. stakeholder perception pointed potential tensions, example, balancing equity, safety, relevance inclusion criteria. conclusions: finding suggest research could acceptable malawi, provided certain condition place. ongoing assessment participant experience stakeholder perception required strengthen research development roll-out.',\n",
       " '2014â\\x80\\x932015 highly pathogenic avian influenza (hpai) h5nx outbreak represents largest expensive hpai outbreak united state date. despite extensive traditional molecular epidemiological studies, factor associated spread hpai among midwestern poultry premise remain unclear. better understand dynamic outbreak, 182 full genome hpai h5n2 sequence isolated commercial layer chicken turkey production premise analyzed evolutionary model able accommodate epidemiological geographic information. epidemiological compartmental model embedded phylogenetic framework provided evidence poultry type acted barrier transmission among midwestern poultry farms. furthermore, initial introduction, propagation hpai case self-sustainable within commercial poultry industries. discrete trait diffusion model indicated within state transition occurred frequently inter-state transitions. distance sample size strongly supported associated transition county group (bayes factor > 30.0). together finding indicate different type midwestern poultry industry single homogenous population, rather, outbreak shaped poultry industry geographic factors.',\n",
       " 'purpose investigation identify prevalence hypoalbuminemia obesity orthopaedic trauma high-energy injury investigate impact incidence surgical site complications. 18 year age older undergoing intramedullary nail fixation femoral shaft fracture university-based level-1 trauma centre assessed. malnutrition measured serum marker (albumin <3.5 g/dl) well body mass index (bmi) marker obesity (bmi > 30 kg/m(2)). primary outcome measure surgical wound complications. total 249 included study. ninety-eight (39.4%) presented hypoalbuminaemia 80 (32.1%) obese. overall incidence wound complication population 9.65% (n = 25/259). logistic regression model showed non-obese (bmi < 30 kg/m(2)) significantly reduced risk perioperative wound complication (odds ratio 0.400 [95% confidence interval 0.168, 0.954], p = 0.039). demonstrated substantial prevalence hypoalbuminemia obesity among orthopaedic trauma high-energy injuries. obesity may increase risk surgical site complications. future study required define malnutrition correlation surgical site complication orthopaedic trauma patients.',\n",
       " 'washington, dc continues experience generalized hiv-1 epidemic. characterized local phylodynamics hiv-1 dc next-generation sequencing (ngs) data. sample 68 participant 2016 2017 sequenced paired epidemiological data. phylogenetic network inferences, drug resistant mutation (drms), subtypes hiv-1 diversity estimation completed. haplotype reconstructed infer transmission clusters. phylodynamic inference based hiv-1 polymerase (pol) envelope gene (env) compared. higher hiv-1 diversity (n.s.) seen men sex men, heterosexual, male participant dc. 54.0% participant contained least drm. 40â\\x80\\x9349 year-olds showed highest prevalence drms (22.9%). phylogenetic analysis pol env sequence grouped 31.9â\\x80\\x9333.8% participant clusters. hiv-trace grouped 2.9â\\x80\\x9312.8% participant consensus sequence 9.0â\\x80\\x9364.2% haplotypes. ng allowed u characterize local phylodynamics hiv-1 dc broadly accurately, given better representation diversity dynamics. reconstructed haplotype provided novel deeper phylodynamic insights, led network linking higher number participants. understanding hiv-1 epidemic expanded powerful coupling hiv-1 ng epidemiological data.',\n",
       " 'endoplasmic reticulum (er) major organelle cell protein folding play important role cellular functions. unfolded protein response (upr) activated response misfolded unfolded protein accumulation er. however, upr successfully alleviates er stress. upr fails restore er homeostasis, apoptosis induced. er stress play important role innate immune signaling response microorganisms. dysregulation upr signaling contributes pathogenesis variety infectious diseases. review, summarize contribution er stress innate immune response invading microorganism role pathogenesis infectious diseases.',\n",
       " 'since cancer stem cell (cscs) first identified leukemia 1994, considered therapeutic target cancer therapy. cell self-renewal capacity differentiation potential contribute multiple tumor malignancies, recurrence, metastasis, heterogeneity, multidrug resistance, radiation resistance. biological activity cscs regulated several pluripotent transcription factors, oct4, sox2, nanog, klf4, myc. addition, many intracellular signaling pathways, wnt, nf-îºb (nuclear factor-îºb), notch, hedgehog, jak-stat (janus kinase/signal transducer activator transcription), pi3k/akt/mtor (phosphoinositide 3-kinase/akt/mammalian target rapamycin), tgf (transforming growth factor)/smad, ppar (peroxisome proliferator-activated receptor), well extracellular factors, vascular niches, hypoxia, tumor-associated macrophages, cancer-associated fibroblasts, cancer-associated mesenchymal stem cells, extracellular matrix, exosomes, important regulator cscs. molecules, vaccines, antibodies, car-t (chimeric antigen receptor cell) cell developed specifically target cscs, factor already undergoing clinical trials. review summarizes characterization identification cscs, depicts major factor pathway regulate csc development, discus potential targeted therapy cscs.',\n",
       " '30% impaired cardiac function ventricular dyssynchrony seek cardiac resynchronization therapy (crt). study, demonstrate synchronized biventricular (biv) pacing leadless fashion implementing miniaturized wirelessly powered pacemakers. flexible form factors, two pacemaker implanted epicardially right left ventricle porcine model inductively powered 13.56 mhz 40.68 mhz industrial, scientific, medical (ism) bands, respectively. power consumption pacemaker reduced âµw-level novel integrated circuit design, considerably extends maximum operating distance. leadless biv pacing demonstrated first time open-chest closed-chest porcine settings. clinical outcome associated different interventricular delay verified electrophysiologic hemodynamic responses. closed-chest pacing requires external source power 0.3 w 0.8 w 13.56 mhz 40.68 mhz, respectively, lead specific absorption rate (sars) 2â\\x80\\x933 order magnitude lower safety regulation limit. work serf basis future wirelessly powered leadless pacemaker address various cardiac resynchronization challenges.',\n",
       " 'human influenza virus known transmitted via air person person. anatomical site respiratory tract influenza transmission occurs. here, pair genetically tagged untagged influenza a/h1n1, a/h3n2 a/h5n1 virus transmissible via air used co-infect donor ferret via intranasal intratracheal route cause upper lower respiratory tract infection, respectively. transmission cases, observe virus recipient ferret genotype virus inoculated intranasally, demonstrating expelled upper respiratory tract ferret rather trachea lower airways. moreover, influenza virus transmissible via air preferentially infect ferret human nasal respiratory epithelium. result indicate replication upper respiratory tract, nasal respiratory epithelium particular, donor driver transmission influenza virus via air.',\n",
       " 'bacterial infection continue threaten humankind rapid spread antibiotic resistant bacteria alarming. current antibiotic target essential bacterial process thereby apply strong selective pressure pathogenic non-pathogenic bacteria alike. alternative strategy block bacterial virulence system essential ability cause general bacterial viability. plant natural product (-)-hopeaphenol block type iii secretion system (t3ss) gram-negative pathogen yersinia pseudotuberculosis pseudomonas aeruginosa. (-)-hopeaphenol resveratrol tetramer present explore various resveratrol dimers, partial structure (-)-hopeaphenol, t3ss inhibitors. allow rapid efficient assessment t3ss inhibition p. aeruginosa, developed screening green fluorescent protein reporter control exos promoter. panel assay showed compound benzofuran core structure i.e. viniferifuran, dehydroampelopsin b, anigopreissin a, dehydro-î´-viniferin resveratrol-piceatannol hybrid displayed significant moderate activity towards t3ss y. pseudotuberculosis p. aeruginosa.',\n",
       " 'conserved hemagglutinin (ha) stem focus universal influenza vaccine efforts. influenza group 1 ha stem-nanoparticles demonstrated confer heterosubtypic protection animals; however, protection extend group 2 viruses, due part difference glycosylation group 1 2 stems. here, introducing group 2 glycan asn38(ha1) group 1 stem-nanoparticle (gn38 variant) based a/new caledonia/20/99 (h1n1) broadens antibody response cross-react group 2 has. immunoglobulin elicited gn38 variant provide complete protection group 2 h7n9 infection, variant loses protection group 1 h5n1 virus. n38(ha1) glycan thus pivotal directing antibody response controlling access group-determining stem epitopes. precise targeting stem-directed antibody response site vulnerability glycan repositioning may step towards achieving cross-group influenza protection.',\n",
       " 'background: ventilator-associated pneumonia (vap) significant cause mortality intensive care unit. early diagnosis vap important provide appropriate reduce mortality. developing noninvasive highly accurate diagnostic important. invention electronic sensor applied analyze volatile organic compound breath detect vap machine learning technique. however, process building algorithm usually unclear prevents physician applying artificial intelligence technique clinical practice. clear process model building assessing accuracy warranted. objective develop breath test vap standardized protocol machine learning technique. methods: conducted case-control study. enrolled subject intensive care unit hospital southern taiwan february 2017 june 2019. recruited vap group ventilated without pneumonia control group. collected exhaled breath analyzed electric resistance change 32 sensor array electronic nose. split set training algorithm set testing. applied eight machine learning algorithm build prediction models, improving model performance providing estimated diagnostic accuracy. results: total 33 case 26 control used final analysis. eight machine learning algorithms, mean accuracy testing set 0.81 â± 0.04, sensitivity 0.79 â± 0.08, specificity 0.83 â± 0.00, positive predictive value 0.85 â± 0.02, negative predictive value 0.77 â± 0.06, area receiver operator characteristic curve 0.85 â± 0.04. mean kappa value testing set 0.62 â± 0.08, suggested good agreement. conclusions: good accuracy detecting vap sensor array machine learning techniques. artificial intelligence potential assist physician making clinical diagnosis. clear protocol processing modeling procedure needed increase generalizability.',\n",
       " 'background: recent meta-analysis indicated vitamin c may shorten length icu stay duration mechanical ventilation. analyze modification vitamin c effect ventilation time, control group ventilation time (which used proxy severity trial). methods: searched medline, scopus, cochrane central register controlled trial reference list relevant publications. included controlled trial administration vitamin c difference groups. limit search randomized trial require placebo control. included dos duration vitamin c administration. author extracted characteristic outcome trial report entered spreadsheet. author checked entered original reports. used meta-regression examine whether vitamin c effect ventilation time depends duration ventilation control group. results: identified nine potentially eligible trials, eight included meta-analysis. pooled result eight trials, 685 total, found vitamin c shortened length mechanical ventilation average 14% (p = 0.00001). however, significant heterogeneity effect vitamin c trials. heterogeneity fully explained ventilation time untreated control group. vitamin c beneficial longest ventilation, corresponding severely ill patients. five trial 471 requiring ventilation 10 h, dosage 1â\\x80\\x936 g/day vitamin c shortened ventilation time average 25% (p < 0.0001). conclusions: found strong evidence vitamin c shortens duration mechanical ventilation, magnitude effect seems depend duration ventilation untreated control group. level baseline illness severity considered research. different dos compared directly future trials.',\n",
       " 'background: previous scoring model acute physiologic assessment chronic evaluation ii (apache ii) sequential organ failure assessment (sofa) scoring system adequately predict mortality undergoing continuous renal replacement therapy (crrt) severe acute kidney injury. accordingly, present applies machine learning algorithm improve prediction accuracy subset. methods: randomly divided total 1571 adult started crrt acute kidney injury training (70%, n = 1094) test (30%, n = 477) sets. primary output consisted probability mortality admission intensive care unit (icu) hospital. compared area receiver operating characteristic curve (aucs) several machine learning algorithm apache ii, sofa, abbreviated mortality scoring system acute kidney injury crrt (mosaic model) results. results: icu mortality, random forest model showed highest auc (0.784 [0.744â\\x80\\x930.825]), artificial neural network extreme gradient boost model demonstrated next best result (0.776 [0.735â\\x80\\x930.818]). auc random forest model higher 0.611 (0.583â\\x80\\x930.640), 0.677 (0.651â\\x80\\x930.703), 0.722 (0.677â\\x80\\x930.767), achieved apache ii, sofa, mosaic, respectively. machine learning model predicted in-hospital mortality better apache ii, sofa, mosaic. conclusion: machine learning algorithm increase accuracy mortality prediction undergoing crrt acute kidney injury compared previous scoring models.',\n",
       " '',\n",
       " 'background: high glycemic variability (gv) common critically ill patients; however, prevalence mortality association early gv sepsis remains unclear. methods: retrospective cohort conducted medical intensive care unit (icu) central taiwan. icu sepsis january 2014 december 2015 included analysis. received protocol-based management, blood sugar monitoring every 2 h first 24 h icu admission. mean amplitude glycemic excursion (mage) coefficient variation (cov) used ass gv. results: total 452 (mean age 71.4 â± 14.7 years; 76.7% men) enrolled analysis. divided high gv (43.4%, 196/452) low gv (56.6%, 256/512) group mage 65 mg/dl cut-off point. high gv tended higher hba1c (6.7 â± 1.8% vs. 5.9 â± 0.9%, p < 0.01) likely diabetes mellitus (dm) (50.0% vs. 23.4%, p < 0.01) compared low gv group. kaplanâ\\x80\\x93meier analysis showed high gv associated increased 30-day mortality (log-rank test, p = 0.018). association remained strong non-dm (log-rank test, p = 0.035), dm (log-rank test, p = 0.254) group. multivariate cox proportional hazard regression analysis identified high apache ii score (adjusted hazard ratio (ahr) 1.045, 95% confidence interval (ci) 1.013â\\x80\\x931.078), high serum lactate level 0 h (ahr 1.009, 95% ci 1.003â\\x80\\x931.014), chronic airway (ahr 0.478, 95% ci 0.302â\\x80\\x930.756), high mean 1 glucose (ahr 1.008, 95% ci 1.000â\\x80\\x931.016), high mage (ahr 1.607, 95% ci 1.008â\\x80\\x932.563) independently associated increased 30-day mortality. association 30-day mortality remained consistent cov ass gv. conclusions: found approximately 40% septic high early gv, defined mage > 65 mg/dl. higher gv within 24 h icu admission independently associated increased 30-day mortality. finding highlight need monitor gv septic early icu admission.',\n",
       " 'background: risk factor multi-drug resistant (mdri) pediatric intensive care unit (picu) remain unclear. itâ\\x80\\x99s necessary evaluate epidemiological characteristic risk factor mdri picu, provide insight prophylaxis mdri clinically. methods: clinical 79 picu child mdri identified, 80 child picu without mdri period selected control group. related childrenâ\\x80\\x99s characteristics, clinical care, microbiologic data, treatment provided, outcome reviewed collected. univariate multivariate logistic regression analysis performed identify potential risk mdri picu. results: diagnosed 79 case mdri, were28 case cr-ab, 24 case mrsa, 22 case pdr-pa,3 case vre 2 case cre respectively. univariate analysis indicated length picu stay, duration mechanical ventilation > 5 days, parenteral nutrition, coma, urinary catheter indwelling, invasive operation, 2 antibiotic use associated mdris (all p < 0.05); logistic multiple regression analysis indicated coma, parenteral nutrition, 2 antibiotic use duration mechanical ventilation > 5 day independent risk factor associated mdri (all p < 0.05). conclusions: present identified several potentially modifiable risk factor mdri picu, itâ\\x80\\x99s conducive take appropriate measure targeting risk factor mdri care provider reduce mdri.',\n",
       " 'ability preserve metabolically active liver ex vivo 1 week could allow repair poor-quality liver would otherwise declined transplantation. current approach normothermic perfusion preserve human liver 24 h. report liver perfusion machine integrates multiple core physiological functions, automated management glucose level oxygenation, waste-product removal hematocrit control. developed machine stepwise fashion pig livers. multiple ex vivo parameter early phase reperfusion vivo demonstrated viability pig liver perfused 1 week without need additional blood product perfusate exchange. tested approach ten injured human liver declined transplantation european centers. 7-d perfusion, six human liver showed preserved function indicated bile production, synthesis coagulation factors, maintained cellular energy (atp) intact liver structure.',\n",
       " 'study reporting chest image respiratory syncytial (rsv)-induced lower respiratory tract (lrti) outbreak setting relationship clinical manifestation limited. genetically confirmed rsv outbreak, eight underwent chest x-ray computed tomography (ct). among these, 5 case newly appearing abnormality ct, although chest x-ray able detect abnormality 2 case (40%). although bronchial wall thickening common, finding distribution variable, even outbreak setting. history anticancer chemotherapy hematological cancer lower respiratory symptoms, wheezing, sputum, hypoxemia, abnormality ct, suggesting two factor might important predicting existence lrti rsv-infected patients.',\n",
       " 'pharyngitis usually caused antibiotic often unnecessarily prescribed, adding burden antimicrobial resistance. identifying need antibiotic challenging; microbiological confirmation clinical score used limitations. cross-sectional nested within randomized controlled trial, estimated prevalence antibiotic susceptibility profile group streptococcus (gas) presenting primary care sore throat fever northern thailand. evaluated use c-reactive protein (crp) clinical score (centor feverpain) identify presence gas. hundred sixty-nine enrolled, 35 (20.7%) î²-hemolytic streptococci (bhs) isolated throat swab culture, 11 (6.5%) gas. gas isolates sensitive penicillin g. median crp without bh isolation 10 mg/l (interquartile range [iqr] â\\x89¤ 8â\\x80\\x9318), compared 18 mg/l (iqr 9â\\x80\\x9371, p = 0.0302) gas 14 mg/l (iqr â\\x89¤ 8â\\x80\\x9338, p = 0.0516) bh isolated. however, significant relationship crp > 8 mg/l (p = 0.112), centor â\\x89¥ 3 (p = 0.212), feverpain â\\x89¥ 4 (p = 1.000), diagnosis gas compared bh isolation. identifying requires antibiotic pharyngitis remains challenging necessitates larger studies. c-reactive protein testing alone, although imperfect, reduce prescribing compared routine care. targeted crp testing clinical scoring may cost-effective approach ruling gas infection.',\n",
       " 'activation somatic mutation conferring sensitivity epidermal growth factor receptor (egfr) tyrosine kinase inhibitor widely used development advanced metastatic primary lung cancer therapy. therefore, identification egfr mutation essential. present study, loop-mediated isothermal amplification (lamp) used identify egfr mutations, efficiency compared therascreen quantitative pcr assay. lamp therascreen analyze surgically resected tissue sample pulmonary adenocarcinoma, egfr mutation observed 32/59 tumor sample (lamp) 33/59 tumor sample (therascreen). notably, lamp assay identified tumor wild-type, identified deletion mutation exon 19 via therascreen assay (case x). however, direct sequencing confirm egfr status x adhered result lamp assay. experiment x dna identified exon 19 deletion mutation methods. addition, novel deletion mutation exon 19 egfr identified. overall, present show lamp may serve valuable alternative identification oncogene mutations.',\n",
       " 'gene transcription profile across tissue largely defined activity regulatory elements, correspond region accessible chromatin. regulatory element activity turn modulated genetic variation, resulting variable transcription rate across individuals. interplay factors, however, poorly understood. characterize expression chromatin state dynamic across three tissuesâ\\x80\\x94liver, lung, kidneyâ\\x80\\x94in 47 strain collaborative cross (cc) mouse population, examining regulation dynamic expression quantitative trait locus (eqtl) chromatin qtl (cqtl). qtl whose allelic effect consistent across tissue detected 1,101 gene 133 chromatin regions. detected eqtl cqtl whose allelic effect differed across tissues, local-eqtl pik3c2g detected three tissue distinct allelic effects. leveraging overlapping measurement gene expression chromatin accessibility mouse multiple tissues, used mediation analysis identify chromatin gene expression intermediate eqtl effects. based qtl mediation analysis multiple tissues, propose causal model distal genetic regulation akr1e1, gene involved glycogen metabolism, zinc finger transcription factor zfp985 chromatin intermediates. analysis demonstrates complexity transcriptional chromatin dynamic regulation multiple tissues, well value cc related genetic resource population identifying specific regulatory mechanism within cell tissues.',\n",
       " 'temperate phage considered natural vector gene transmission among bacteria due ability integrate genome host chromosome, therefore, affect fitness phenotype host bacteria. many virulence gene pathogenic bacteria identified temperate phage genomes, supporting concept temperate phage play important role increasing bacterial pathogenicity delivery virulence genes. however, little known role temperate phage attenuation bacterial virulence. here, report novel bordetella bronchiseptica temperate phage, vb_bbrs_phb09 (phb09), 42,129-bp dsdna genome g+c content 62.8%. phylogenetic analysis based terminase subunit indicated phage phb09 represented member family siphoviridae. genome phb09 contains gene encoding lysogen-associated proteins, integrase ci protein. integration site phb09 specifically located within pilin gene b. bronchiseptica. importantly, found integration phage phb09 significantly decreased virulence parental strain b. bronchiseptica bb01 mice, likely disruption expression pilin gene. moreover, single shot prophage bearing b. bronchiseptica strain completely protected mouse lethal challenge wild-type virulent b. bronchiseptica, indicating vaccine potential lysogenized strain. finding indicate complicated role temperate phage bacterial virulence simple delivery virulent gene provide potential strategy developing bacterial vaccines.',\n",
       " 'syndrome (ds) frequently comorbid congenital heart reduce sedative effect benzodiazepine (bdz)-class anesthesia effect clinical setting studied. therefore, compared midazolam sedation heart surgery d normal children. retrospectively reviewed record pediatric intensive care unit (picu) pediatric cardiovascular operation march 2015 march 2018. selected five day continuous post-operative termination muscle relaxants. midazolam sedation estimated bayesian inference generalized linear mixed models. enrolled 104 (average age 26 weeks) 16 (15%) ds. d high probability receiving higher midazolam dosage dexmedetomidine dosage period (probability = 0.99, probability = 0.97) depth sedation different d (probability = 0.35). multi regression modeling included severity score demographic showed d decrease midazolam sedation compared control (posterior = 1.32, 95% cri = 1.01â\\x80\\x931.75). conclusion, midazolam dosage carefully adjusted d significantly decrease midazolam sedative effect pediatric heart surgery patients.',\n",
       " 'background: protective mechanical ventilation recommended acute respiratory distress syndrome (ards), usually requires controlled ventilation sedation. neurally adjusted ventilatory assist (nava) pressure support ventilation (psv) could additional benefits, use lower sedative doses, improved patientâ\\x80\\x93ventilator interaction shortened duration mechanical ventilation. designed pilot ass feasibility keeping tidal volume (v(t)) protective level nava psv ards. methods: conducted prospective randomized crossover trial five icu university hospital brazil included ards transitioning controlled ventilation partial ventilatory support. nava psv applied random order, 15 min each, followed 3 h nava. flow, peak airway pressure (paw) electrical activity diaphragm (eadi) captured ventilator, software (matlab, mathworks, usa), automatically detected inspiratory effort calculated respiratory rate (rr) v(t). asynchrony event detection based waveform analysis. results: randomized 20 patients, protocol interrupted five (25%) unable maintain v(t) 6.5 ml/kg psv due strong inspiratory effort could detect eadi signal. 14 completed protocol, v(t) 5.8 â± 1.1 ml/kg nava 5.6 â± 1.0 ml/kg psv (p = 0.455) difference rr (24 â± 7 nava 23 â± 7 psv, p = 0.661). paw greater nava (21 â± 3 cmh(2)o) psv (19 â± 3 cmh(2)o, p = 0.001). continuous sedation study. nava reduced triggering delay compared psv (p = 0.020) median asynchrony index 0.7% (0â\\x80\\x932.7) psv 0% (0â\\x80\\x932.2) nava (p = 0.6835). conclusions: feasible keep v(t) protective level nava psv 75% patients. nava resulted similar v(t), rr paw compared psv. finding suggest partial ventilatory assistance nava psv feasible protective ventilation strategy selected ards continuous sedation. trial registration clinicaltrials.gov (nct01519258). registered 26 january 2012, https://clinicaltrials.gov/ct2/show/nct01519258',\n",
       " 'positive-sense single-stranded rna virus form largest diverse group eukaryote-infecting viruses. genome comprise segment coding-sense rna function directly messenger rna upon release cytoplasm infected cells. positive-sense rna virus generally accepted encode protein solely positive strand. however, identified surprisingly long (â\\x88¼1,000-codon) open reading frame (orf) negative strand member family narnaviridae which, together rna bacteriophage family leviviridae, form sister group positive-sense rna viruses. here, completed genome three mosquito-associated narnaviruses, long reverse-frame orf. systematically identified narnaviral sequence public set wide range sources, arthropod, fungal, plant transcriptomic sets. long reverse-frame orfs widespread clade narnaviruses, frequently occupy >95 per cent genome. reverse-frame orfs correspond specific avoidance cua, uua, uca codon (i.e. stop codon reverse complements) forward-frame rna-dependent rna polymerase orf. however, absence codon cannot explained factor inability decode codon gc3 bias. together analyses, provide strongest evidence yet coding capacity negative strand positive-sense rna virus. orfs comprise longest known overlapping genes, may broad relevance understanding overlapping gene evolution de novo origin genes.',\n",
       " 'background: current option palmoplantar pustulosis (ppp), debilitating chronic skin affect hand feet, limited. anakinra pustular psoriasis: response controlled trial (apricot) aim determine efficacy anakinra ppp. article describes statistical analysis plan final analysis two-staged trial, determined prior unblinding database lock. update published protocol stage analysis plan. methods: apricot randomised, double-blind, placebo-controlled trial anakinra versus placebo, two stage adaptive element. stage compared arm ensure proof-of-concept determined primary outcome stage two trial. primary outcome selected change palmoplantar pustulosis psoriasis area severity index (pppasi) 8 weeks. secondary outcome include investigator-assessed efficacy measure severity, participant-reported measure efficacy safety measures. manuscript describes detail outcomes, sample size, general analysis principles, pre-specified statistical analysis plan outcomes, handling missing outcome planned sensitivity supplementary analysis second stage apricot trial. discussion: statistical analysis plan developed compliance international trial guideline published increase transparency trial analysis. result trial analysis indicate whether anakinra role ppp. trial registration: iscrtn, iscrtn13127147. registered 1 august 2016. eudract number 2015-003600-23. registered 1 april 2016.',\n",
       " 'background: number long-term chronic disease increasing. place strain care system care professional (hcps). presently, aimed systematically review literature hcpsâ\\x80\\x99 experience working long-term chronic disease type 2 diabetes, chronic obstructive pulmonary (copd), chronic kidney (ckd). method: systematic search paper published 2002 july 2019 conducted embase, amed, psycinfo, medline, cinahl, cochrane database identify study reporting qualitative interview addressing hcpsâ\\x80\\x99 experience working adult copd, ckd type 2 diabetes. interdisciplinary research group involved phase study. help nvivo, extract paper coded, code compared across paper refined translational analysis. code clustered category turn formed overarching themes. results: comprehensive search identified 4170 citations. these, 20 paper met inclusion criteria. regarding hcpsâ\\x80\\x99 experience working copd, ckd, type 2 diabetes, developed 10 sub-categories formed three overarching main theme work experiences: 1) individualizing oneâ\\x80\\x99s professional approach within clinical encounter; 2) managing oneâ\\x80\\x99s emotion time; 3) working maintain professionalism. overall three theme suggest hcpsâ\\x80\\x99 work complex balancing act depending interaction professional, reality professional ideals, contextual support managing oneâ\\x80\\x99s emotions. conclusion: qualitative study highlighted hcpsâ\\x80\\x99 general working experiences, mainly focused patientsâ\\x80\\x99 experience hcpsâ\\x80\\x99 experience particular clinical procedures. brings insight complexity embedded hcpsâ\\x80\\x99 work term weighing different, often contrasting aspects, order deliver appropriate practice. acknowledging, discussing supporting complexity empower hcps avoid burning out. leaders, organizations, educational institution particular responsibility provide hcps thorough professional knowledge systematic support. trial registration: prospero number: crd42019119052.',\n",
       " 'background: older adult reside long-term care facility (ltcfs) particularly high risk infection, morbidity mortality pneumonia influenza (p&i) compared individual younger age living outside institutional settings. risk factor p&i hospitalization specific ltcfs remain poorly understood. objective evaluate incidence p&i hospitalization associated person- facility-level factor among post-acute (short-stay) long-term (long-stay) care resident residing ltcfs 2013 2015. methods: retrospective cohort study, used medicare administrative claim linked minimum set ltcf-level identify short-stay (< 100 days, index = admission date) long-stay (100+ days, index = 100) resident followed index date first hospitalization, ltcf discharge, medicare disenrollment, death. measured incidence rate (irs) p&i hospitalization per 100,000 person-days, estimated association baseline demographics, geriatric syndromes, clinical characteristics, medication use cox regression models. results: analyzed 1,118,054 short-stay 593,443 long-stay residents. crude 30-day irs (95% ci) hospitalization p&i principal position 26.0 (25.4, 26.6) 34.5 (33.6, 35.4) among short- long-stay residents, respectively. variable associated p&i varied short long-stay residents, common risk factor included: advanced age (85+ years), admission acute hospital, select cardiovascular respiratory conditions, impaired functional status, receipt antibiotic beer criterion medications. facility staffing care quality measure important risk factor among long-stay resident short-stay residents. conclusions: short-stay resident lower crude 30- 90-day incidence rate p&i hospitalization long-stay ltcf residents. difference risk factor p&i short- long-stay population suggest importance considering distinct profile post-acute long-term care resident prevention control strategy ltcfs. finding help clinician target intervention subgroup ltcf resident highest p&i risk.',\n",
       " 'background: analyzed result 3-year surveillance epidemiological clinical characteristic healthcare associated-infections (hais) elderly inpatient tertiary hospital china. methods: real-time surveillance performed january 1, 2015 december 31, 2017. hais identified control practitioner doctors. inpatient collected automatic surveillance system. results: total 134,637 inpatient 60,332 (44.8%) elderly â\\x89¥60 year included. overall incidence hai 2.0%. incidence hai elderly significantly higher non-elderly (2.6% vs. 1.5%, ï\\x87(2) = 202.421, p < 0.01) increased age. top five site hais elderly lower respiratory tract, urinary tract, blood stream, antibiotic-associated diarrhea, surgical site. five common pathogen detected elderly hai candida albicans, klebsiella pneumonia, acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa. incidence ventilator-associated pneumonia elderly lower non-elderly, catheter-associated urinary tract infection common elderly patients, rate central line-associated bloodstream similar groups. number male comorbidities special medical procedure (e.g., intensive care unit admission, cerebrovascular disease, brain neoplasms, hypertension, hyperlipidemia, diabetes mellitus, coronary artery disease, chronic obstructive pulmonary disease, malignant tumor, malignant hematonosis, osteoarthropathy) significantly higher elderly group, number underwent surgery lower. conclusion: observed significantly higher overall incidence hai elderly inpatient â\\x89¥60 compared non-elderly inpatient < 60 years, trend different device-associated hais, attributed higher rate comorbidities special medical procedure elderly group. main hai site elderly inpatient lower respiratory tract, urinary tract, bloodstream, main pathogen gram-negative bacillus candida albicans.',\n",
       " 'primary function respiratory system gas exchange render vulnerable environmental pathogen circulate air. physical cellular barrier respiratory tract mucosal surface utilize variety strategy obstruct microbe entry. physical barrier defense surface fluid replete antimicrobials, neutralizing immunoglobulins, mucus, epithelial cell layer rapidly beating cilium form near impenetrable wall separate external environment internal soft tissue host. resident leukocytes, primarily innate immune branch, maintain airway integrity constant surveillance maintenance homeostasis release cytokine growth factors. unfortunately, pathogen influenza streptococcus pneumoniae require host replication dissemination, prey respiratory tract ideal environment causing severe damage host invasion. review, outline host-pathogen interaction influenza post-influenza bacterial pneumonia focus inter- intra-cellular crosstalk important pulmonary immune responses.',\n",
       " 'background: influenza highly contagious acute respiratory tract infection. emergence influenza a(h1n1)pdm09 2009 caused pandemic. since become seasonal influenza virus. cause symptom ranging mild severe illness, might fatal, particularly people underlying chronic medical conditions, immunocompromised people, elderly, pregnant women. objective: describe generated influenza a(h1n1) pdm09 surveillance saudi arabia 2010 2016. design: retrospective, descriptive. setting: hospital reporting ministry health. material methods: studied aggregate hospitalized case influenza a(h1n1)pdm09 saudi arabia 2010 2016. surveillance system used definition proposed who. case confirmed performing real-time pcr (polymerase chain reaction) upper respiratory samples. main outcome measures: suspected confirmed influenza a(h1n1)pdm09 cases. sample size: 113 502 suspected h1n1 case 17 094 (15.1%) confirmed cases. results: reported case registered riyadh region. period study, highest number confirmed cases, 9262 (54.2 %), 2015. fatality rate confirmed case 3.6%. conclusion: influenza a(h1n1)pdm09 showed seasonal trends. number suspected influenza case year proportionate number confirmed case year. riyadh, jeddah eastern area (regions highest population) reported cases. limitation: strain h1n1 tested. conflict interest: none.',\n",
       " 'humoral immune response initiate lymph node draining site (dln). virus subvert ln b cell activation; however, knowledge hindrance b cell response important human pathogen lacking. here, define mechanism whereby chikungunya (chikv), mosquito-transmitted rna cause outbreak acute chronic arthritis humans, hinders dln antiviral b cell responses. wt mouse pathogenic, acutely cleared chikv, induced myd88-dependent recruitment monocyte neutrophil dln. blocking influx improved lymphocyte accumulation, dln organization, chikv-specific b cell responses. inducible nitric oxide synthase (inos) phagocyte nadph oxidase (nox2) contributed impaired dln organization function. infiltrating monocyte expressed inos local irf5- ifnar1-dependent pathway partially tlr7-dependent. together, suggest pathogenic chikv trigger influx activation monocyte neutrophil dln impairs virus-specific b cell responses.',\n",
       " 'actinobacillus pleuropneumoniae important veterinary pathogen cause porcine pleuropneumonia. lipoprotein bacterial pathogen play pleiotropic role process. addition, many bacterial lipoprotein antigenic immunoprotective. therefore, characterization lipoprotein strategy identification novel vaccine candidate diagnostic markers. cloned 58 lipoprotein a. pleuropneumoniae jl03 (serovar 3) expressed escherichia coli. five protein strong positive signal western blotting analysis used immunize mice. protein elicited significant antibody responses, three (apjl_0922, apjl_1380 apjl_1976) generated efficient immunoprotection mouse lethal heterologous challenge a. pleuropneumoniae 4074 (serovar 1), active passive immunization assays. immunogenicity three lipoprotein (apjl_0922, apjl_1380 apjl_1976) tested pigs. result showed protein elicited considerable humoral immune response effective protective immunity virulent a. pleuropneumoniae challenge. finding suggest three novel lipoprotein could potential subunit vaccine candidates.',\n",
       " 'background: necrotizing enterocolitis (nec) leading cause death among preterm infant born < 30 weeksâ\\x80\\x99 gestation. incidence nec reduced infant fed human milk. however, many neonatal intensive care unit (nicus), standard practice freeze and/or pasteurize human milk, deactivates bioactive component may offer additional protective benefits. indeed, pilot showed feed fresh motherâ\\x80\\x99s milk per safe, feasible, reduce morbidity preterm infants. evaluate benefit fresh human milk nicu, randomized controlled trial needed. methods: prospective multicenter, double-blinded, randomized, controlled trial include infant born < 30 weeksâ\\x80\\x99 gestation admitted 29 tertiary nicu china. infant intervention (fresh human milk) group (n = 1549) receive least two feed fresh human milk (i.e., within 4 h expression) per time enrollment 32 weeksâ\\x80\\x99 corrected age discharge home. infant control group (n = 1549) receive frozen human milk following current standard protocols. following informed consent, enrolled infant randomly allocated control fresh human milk groups. primary outcome composite outcome mortality nec â\\x89¥ stage 2 32 weeksâ\\x80\\x99 corrected age, secondary outcome mortality, nec â\\x89¥ stage 2, nec needing surgery, late-onset sepsis, retinopathy prematurity (rop), bronchopulmonary dysplasia (bpd), weight gain, change weight, increase length, increase head circumference, time full enteral feeds, finally, number type critical incident reports, feeding errors. discussion: double-blinded, randomized, controlled trial aim examine whether fresh human milk improve infant outcomes. result impact chinese international medical practice feeding policy preterm infants. addition, inform change policy nicu across china, mother encouraged enter nicu express fresh milk infants. trial registration: chinese clinical trial registry; #chictr1900020577; registered january 1, 2019; http://www.chictr.org.cn/showprojen.aspx?proj=34276',\n",
       " 'background: decision-making public policy complex requires careful deliberation many sometimes conflicting normative technical criteria. several approach tools, multi-criteria decision analysis, technology assessment evidence-to-decision (etd) frameworks, proposed guide decision-makers selecting criterion relevant appropriate transparent decision-making process. form part development who-integrate etd framework, framework rooted global norm value reflected key document world organization united nation system. objective provide comprehensive overview criterion used proposed real-world decision-making processes, guideline development, technology assessment, resource allocation others. methods: conducted overview systematic review combination systematic literature search extensive reference searches. systematic review reporting criterion used real-world decision-making governmental non-governmental organization supranational, national, programme level included quality assessed bespoke critical appraisal tool. criterion reported review extracted, de-duplicated sorted first-level (i.e. criteria), second-level (i.e. sub-criteria) third-level (i.e. decision aspects) categories. first-level category developed priori normative approach; second- third-level category developed inductively. results: included 36 systematic review providing criteria, met another eleven met least five item critical appraisal tool. criterion subsumed 8 criteria, 45 sub-criteria 200 decision aspects. first-level category system comprised following seven substantive criteria: â\\x80\\x9chealth-related balance benefit harmsâ\\x80\\x9d; â\\x80\\x9chuman individual rightsâ\\x80\\x9d; â\\x80\\x9cacceptability considerationsâ\\x80\\x9d; â\\x80\\x9csocietal considerationsâ\\x80\\x9d; â\\x80\\x9cconsiderations equity, equality fairnessâ\\x80\\x9d; â\\x80\\x9ccost financial considerationsâ\\x80\\x9d; â\\x80\\x9cfeasibility system considerationsâ\\x80\\x9d. addition, identified eight criterion â\\x80\\x9cevidenceâ\\x80\\x9d. conclusion: overview systematic review provides comprehensive overview criterion used suggested real-world decision-making. discus key challenge selection appropriate criterion seeking implement fair decision-making process.',\n",
       " 'background: traumatic brain injury (tbi) major socioeconomic problem world. immune-enhancing enteral formula proven significantly reduce rate tbi patients. ingredient used immunonutrition formula reduce inflammation oxidative stress pycnogenol. objective: objective work survey effect pycnogenol clinical, nutritional, inflammatory status tbi patients. methods: double-blind, randomized controlled trial. block randomization used. intervention group receive pycnogenol supplementation 150 mg 10 day control group receive placebo duration. inflammatory status (il-6, il- 1î², c-reactive protein) oxidative stress status (malondialdehyde, total antioxidant capacity), baseline, 5th day, end (10th day) measured. clinical nutritional status assessed three time intervention. sequential organ failure assessment (sofa) questionnaire assessment organ failure filled every day. mortality rate calculated within 28 day start intervention. weight, body mass index, body composition measured. analysis conducted initially assigned arm intention-to-treat analysis. discussion: expect supplementation 150 mg pycnogenol 10 day improve clinical nutritional status reduce inflammation oxidative stress tbi patients. trial registration: trial registered clinicaltrials.gov (ref: nct03777683) 12/13/2018.',\n",
       " 'infection multidrug-resistant (mdr) gram-negative organism (gn) associated high mortality rate present increasing challenge healthcare system worldwide. recent years, increasing evidence support association healthcare environment transmission mdrgn healthcare workers. better understand role environment transmission acquisition mdrgn, conducted utilitarian review based literature published 2014 2019.',\n",
       " 'background: prolonged difficult weaning associated higher rate complication mortality. therefore, important identify associated factors. presentation: describe experience 37-year-old man diagnosed severe pneumonia (influenza a). presented acute respiratory failure type admission. intubation, blood pressure heart rate decreased, epinephrine norepinephrine administered. although clinical condition improved 8 day intensive care unit (icu) admission, experienced difficulty weaning. remained conscious poor spontaneous cough sputum production weak limb muscle strength. cough reflex absent bronchoscopic sputum suction, used abdominal breathing t-tube test. magnetic resonance imaging revealed arnoldâ\\x80\\x93chiari malformation type i, posterior dislocation odontoid process, syringomyelia, compression deformation medulla high cervical cord. successfully weaned ventilator 20 day icu admission. conclusions: arnoldâ\\x80\\x93chiari malformation type posterior dislocation odontoid process, aggravate medullary compression increase risk cervical nerve injury, might rare factor affecting prolonged weaning critical illness.',\n",
       " 'ebola (ebov) cause severe outbreak hemorrhagic fever humans. virus-host interaction target antivirals, limited knowledge regarding interaction ebov cellular host factors. recently, performed genome-wide sirna screen identified nuclear rna export factor 1 (nxf1) important host factor ebov life cycle. nxf1 major component nuclear mrna export pathway usurped many virus whose life cycle include nuclear stages. however, role nxf1 life cycle ebov, replicating cytoplasmic inclusion bodies, remains unknown. order better understand role nxf1 ebov life cycle, performed combination co-immunoprecipitation double immunofluorescence assay characterize interaction nxf1 protein rnas. additionally, sirna-mediated knockdown nxf1 together functional assays, analyzed role nxf1 individual aspect life cycle. approach identified ebov nucleoprotein (np) interaction partner nxf1. study revealed np interacts rna-binding domain nxf1 competes rna interaction. co-localization study showed rna binding-deficient, wildtype nxf1, accumulates np-derived inclusion bodies, knockdown experiment demonstrated nxf1 necessary protein expression, rna synthesis. finally, result showed nxf1 interacts mrnas, genomic rnas. based result suggest model whereby nxf1 recruited inclusion body promote export mrna:nxf1 complex sites. would represent novel function nxf1 life cycle cytoplasmically replicating viruses, may provide basis therapeutic approach ebov, possibly emerging viruses.',\n",
       " 'background: severe blunt chest injury sometimes induces acute respiratory failure (arf), requiring ventilator use. aimed evaluate effect performing rib fixation addition video-assisted thoracoscopic surgery (vats) arf caused blunt thoracic injury ventilator dependence. methods: observational prospectively enrolled multiple bicortical rib fracture hemothorax caused severe blunt chest trauma. received positive pressure mechanical ventilation within 24 h trauma arf. received rib fixation vat enrolled group 1, others received vat designated group 2. length ventilator use primary clinical outcome. rate pneumonia length hospital stay constituted secondary outcomes. results: total 61 included study. basic demographic characteristic two group exhibited statistical differences. received operation within 6 day trauma. length ventilator use shorter group 1 (3.19 â± 3.37 day vs. 8.05 â± 8.23, p = 0.002). rate pneumonia higher group 2 (38.1% vs. 75.0%, p = 0.005). length hospital stay much shorter group 1 (17.76 â± 8.38 day vs. 24.13 â± 9.80, p = 0.011). conclusion: rib fixation combined vat could shorten length ventilator use reduce pneumonia rate severe chest blunt injury arf. therefore, operation could shorten overall length hospital stay.',\n",
       " 'zika (zikv) caused significant disease, widespread case neurological pathology congenital neurologic defects. rapid vaccine development led number candidate capable eliciting potent zikv-neutralizing antibody (reviewed refs. (1â\\x80\\x933)). despite advance vaccine development, remains unclear zikv vaccination affect immune response human prior flavivirus immunity. single-dose immunization zikv purified inactivated vaccine (zpiv)(4â\\x80\\x937) dengue (denv)-experienced human elicited potent cross-neutralizing antibody zikv denv. unique zikv virion-based sorting strategy, isolated characterized multiple antibodies, termed mz4, target novel site vulnerability centered envelope (e) domain i/iii linker region protects mouse viremia dissemination following zikv denv-2 challenge. demonstrate zika vaccination denv-experienced individual boost pre-existing flavivirus immunity elicit protective response zikv denv. zpiv vaccination puerto rican individual prior flavivirus experience yielded similar cross-neutralizing potency single vaccination, highlighting potential benefit zikv vaccination flavivirus-endemic areas.',\n",
       " 'combination antiretroviral therapy (art) highly effective controlling human immunodeficiency (hiv)-1 requires lifelong medication due existence latent reservoir(1,2). potent broadly neutralizing antibody (bnabs) represent potential alternative adjuvant art. addition suppressing viremia, bnabs may cell immunomodulatory effect seen form immunotherapy(3). however, established individual infected hiv-1. here, document increased hiv-1 gag-specific cd8(+) cell response peripheral blood nine participant infected hiv-1 suppressed blood viremia, receiving bnab therapy art interruption(4). increased cd4(+) cell response detected eight individuals. increased cell response due newly detectable reactivity hiv-1 gag epitope expansion pre-existing measurable responses. demonstrate bnab therapy art interruption associated enhanced hiv-1-specific cell responses. whether augmented cell response contribute bnab-mediated control remains determined.',\n",
       " 'background: right ventricular (rv) function evaluation echocardiography key management icu acute respiratory distress syndrome (ards), however, remains challenging. quantification rv deformation speckle-tracking echocardiography (ste) available reproducible technique provides integrated analysis rv. however, scarce regarding use critically ill patients. aim ass feasibility clinical usefulness moderateâ\\x80\\x93severe ards patients. results: forty-eight ards invasive mechanical ventilation (mv) consecutively enrolled prospective observational study. full transthoracic echocardiography performed within 36 h mv initiation. ste-derived conventional parameter recorded. strain imaging rv lateral, inferior septal wall highly feasible (47/48 (98%) patients). interobserver reproducibility rv strain value displayed good reliability (intraclass correlation coefficient (icc) > 0.75 ste-derived parameters) ards patients. roc curve analysis showed lateral, inferior, global (average 3 rv walls) longitudinal systolic strain (lss) global strain rate demonstrated significant diagnostic value compared several conventional index (tapse, sâ\\x80², rv fac). rv global l value > â\\x88\\x92 13.7% differentiated tapse < v > 12 mm sensitivity 88% specificity 83%. regarding clinical outcomes, mortality cumulative incidence weaning mv 28 different normal versus abnormal ste-derived parameters. conclusions: global ste assessment rv highly achievable reproducible moderateâ\\x80\\x93severe ards mv additionally correlated several conventional parameter rv function. cohort, ste-derived parameter provide incremental value term survival weaning mv prediction. investigation needed evaluate theranostic usefulness. trial registration nct02638844: nct',\n",
       " \"lassa fever (lf) increasingly recognised important rodent-borne haemorrhagic fever presenting severe public threat sub-saharan west africa. 2017â\\x80\\x9318, lf caused unprecedented epidemic nigeria situation worsening 2018â\\x80\\x9319. work aim epidemiological feature epidemic different nigerian region quantify association reproduction number (r) state rainfall. quantify infectivity lf reproduction number estimated four different growth models: richards, three-parameter logistic, gompertz weibull growth models. lf surveillance used fit growth model estimate r epidemic turning point (ï\\x84) different region different time periods. cochran's q test applied test spatial heterogeneity lf epidemics. linear random-effect regression model adopted quantify association r state rainfall various lag terms. estimated r 2017â\\x80\\x9318 (1.33 95% ci 1.29â\\x80\\x931.37) significantly higher 2016â\\x80\\x9317 (1.23 95% ci: (1.22, 1.24)) 2018â\\x80\\x9319 (ranged 1.08 1.36). report spatial heterogeneity r epidemic different nigerian regions. find one-unit (mm) increase average monthly rainfall past 7 month could cause 0.62% (95% ci 0.20%â\\x80\\x931.05%)) rise r. significant spatial heterogeneity lf epidemic different nigerian regions. report clear evidence rainfall impact lf epidemic nigeria quantify impact.\",\n",
       " 'lassa (lasv) mopeia (mopv) two closely related, rodent-born mammarenaviruses. lasv causative agent lassa fever, deadly hemorrhagic fever endemic west africa, whereas mopv non-pathogenic humans. z matrix protein arenavirus essential assembly budding recruiting host factors, mechanism remains partially defined. better characterize interaction involved, yeast two-hybrid screen conducted z protein lasv mopv bait. cellular protein itch wwp1, two member nedd4 family hect e3 ubiquitin ligases, found bind z protein lasv, mopv arenaviruses. ppxy late-domain motif z protein required interaction itch, although e3 ubiquitin-ligase activity itch involved z ubiquitination. silencing itch affect replication old-world mammarenaviruses lasv, mopv, lymphocytic choriomeningitis (lcmv) lesser extent lujo (lujv). precisely, itch involved egress virus-like particle release infectious progeny viruses. thus, itch constitutes novel interactor lasv mopv z protein involved assembly release.',\n",
       " 'nipah (niv) emerging zoonotic transmitted bat human pigs, causing severe respiratory often fatal encephalitis. antibody directed niv-glycoprotein (g) protein known play major role clearing niv providing vaccine-induced protective immunity. recently, cell involved recovery niv infection. far, relatively little known role cell response antigenic target niv-g recognized cd8 cells. study, niv-g protein served target immunogen activate niv-specific cellular immune responses. modified vaccinia ankara (mva), safety-tested strain vaccinia preclinical clinical vaccine research, used generation mvaâ\\x80\\x93niv-g candidate vaccine expressing different version recombinant niv-g. overlapping peptide covering entire niv-g protein used identify major histocompatibility complex class i/ii-restricted cell response type interferon receptor-deficient (ifnarâ\\x88\\x92/â\\x88\\x92) mouse vaccination mvaâ\\x80\\x93niv-g candidate vaccines. identified h2-b-restricted nonamer peptide epitope cd8 cell antigenicity h2-b 15mer cd4 cell antigenicity niv-g protein. identification epitope availability mvaâ\\x80\\x93niv-g candidate vaccine help evaluate niv-g-specific immune response potential immune correlate vaccine-mediated protection appropriate murine model niv-g infection. note, soluble version niv-g advantageous activating niv-g-specific cellular immune response peptides.',\n",
       " 'dendritic cell (dcs) among first cell recognize incoming virus mucosal portal entry. initial interaction dc virus facilitates cell activation migration secondary lymphoid tissues, antigen presenting cell (apcs) prime specific adaptive immune responses. viruses, however, evolved strategy subvert migratory capacity dc way disseminate systemically. focus role siglec-1, sialic acid-binding type lectin receptor potently upregulated type interferon dcs, act double edge sword, containing replication induction antiviral immunity, favoring spread within tissues. distant enveloped virus like human immunodeficiency (hiv)-1 ebola (ebov), incorporate sialic acid-containing gangliosides membrane effectively recognized siglec-1. review siglec-1 highly induced surface human dc upon infection, way impact different antigen presentation pathways, enveloped virus evolved exploit apc function potent dissemination strategy different anatomical compartments.',\n",
       " 'recent outbreak zika (zikv) america devastating developmental neurological manifestation prompted development field-based diagnostics rapid, reliable, handheld, specific, sensitive, inexpensive. gold standard molecular lab-based diagnosis zikv, either sample insect vectors, reverse transcription-quantitative polymerase chain reaction (rt-qpcr). method, however, costly requires lab-based equipment expertise, severely limit use point-of-care (poc) tool resource-poor settings. moreover, given lack antiviral approved vaccine zikv infection, poc diagnostic test urgently needed early detection outbreak adequately manage patients. loop-mediated isothermal amplification (lamp) compelling alternative rt-qpcr zikv arboviruses. low-cost molecular system freeze-dried distribution exhibit high specificity, sensitivity, efficiency. growing body evidence suggests lamp assay provide greater accessibility much-needed diagnostics zikv infections, especially developing country zikv endemic. review summarizes different lamp method developed summarizes features, advantages, limitations.',\n",
       " 'porcine epidemic diarrhea (pedv) continuously caused severe economic loss global swine industries; however, successful vaccine pedv developed. study, generated four autologous recombinant viruses, highly virulent ipedvpt-p5, attenuated ipedvpt-p96, two chimeric virus (ipedvpt-p5-96s ipedvpt-p96-5s) reciprocally exchanged spike (s) gene, role gene pedv pathogenesis. deeper understanding pedv attenuation aid rational design live attenuated vaccine (lav) reverse genetics system. result showed replacing gene highly virulent ipedvpt-p5 led complete restoration virulence attenuated ipedvpt-p96, nearly identical shedding, diarrhea pattern, mortality rate parental ipedvpt-p5. contrast, substitution gene attenuated ipedvpt-p96 resulted partial attenuation ipedvpt-p5, exhibiting similar shedding diarrhea pattern parental ipedvpt-p96 slightly severe histological lesion higher mortality rate. collectively, confirmed attenuation pedvpt-p96 primarily attributed mutation gene. however, mutation gene alone could fully attenuate virulence ipedvpt-p5. gene (s) gene might play role determining virulence.',\n",
       " 'ebola infection lead severe hemorrhagic fever human nonhuman primates; human fatality rate high 67%â\\x80\\x9390%. since ebola discovered 1976, available treatment medical support emergency administration experimental drugs. absence licensed vaccine drug ebola impedes prevention infection. study, generated recombinant baculoviruses (rbv) expressing sudan (sudv) matrix structural protein (vp40) (rbv-vp40-vp40) sudv glycoprotein (gp) (rbv-gp-gp), sudv virus-like particle (vlps) produced co-infection sf9 cell rbv-sudv-vp40 rbv-sudv-gp. expression sudv vp40 gp sudv vlps demonstrated ifa western blot analysis. electron microscopy result demonstrated sudv vlps filamentous morphology. immunogenicity sudv vlps produced insect cell evaluated immunization mice. analysis antibody response showed mouse vaccinated sudv vlps adjuvant montanide isa 201 produced sudv gp-specific igg antibodies. serum sudv vlp-immunized mouse able block sudv gp pseudotyped hiv, indicating neutralizing antibody sudv gp protein produced. furthermore, activation b cell group immunized vlps mixed montanide isa 201 significant week primary immunization. vaccination sudv vlps markedly increased frequency antigen-specific cell secreting type 1 type 2 cytokines. therapeutic effect sudv antibodies, horse immunized sudv vlps emulsified freundâ\\x80\\x99s complete adjuvant freundâ\\x80\\x99s incomplete adjuvant. result showed horse could produce sudv gp-specific antibody neutralizing antibodies. result showed sudv vlps demonstrate excellent immunogenicity represent approach vaccine development sudv infection. further, horse anti-sudv purified immunoglobulin lay foundation sudv therapeutic drug research.',\n",
       " 'response infection, host cell activate various antiviral response inhibit replication. feline herpesvirus 1 (fhv-1) manipulates host early innate immune response many different ways, host could activate antiviral response counteract mechanisms. micrornas (mirnas) serve class regulatory factor host, participate regulation host innate immune response infection. study, found expression level mir-26a significantly upregulated upon fhv-1 infection. furthermore, fhv-1 induced expression mir-26a via cgas-dependent pathway, knockdown cellular cgas significantly blocked expression mir-26a induced poly (da:dt) fhv-1 infection. next, investigated biological function mir-26a infection. mir-26a able increase phosphorylation stat1 promote type ifn signaling, thus inhibiting replication. mechanism showed mir-26a directly targeted host socs5. knockdown socs5 increased phosphorylation stat1 enhanced type ifn-mediated antiviral response, overexpression suppressor cytokine signalling 5 (socs5) decreased phosphorylation stat1 inhibited type ifn-mediated antiviral response. meanwhile, knockdown socs5, upregulated expression phosphorylated stat1 anti-virus effect induced mir-26a significantly inhibited. taken together, demonstrated strategy host mirnas fhv-1 enhancing ifn antiviral signaling.',\n",
       " 'background: septoplasty (surgery straighten deviation nasal septum) frequently performed operation worldwide, approximately 250,000 performed annually u 22,000 uk. septoplasties aim improve diurnal nocturnal nasal obstruction. evidence base septoplasty clinical effectiveness hitherto limited. aims: establish, inform guidance for, best management strategy individual nasal obstruction associated deviated septum. methods/design: multicentre, mixed-methods, open label, randomised controlled trial septoplasty versus medical management adult deviated septum reduced nasal airway. eligible septal deflection visible nasendoscopy nasal symptom score â\\x89¥ 30 nose questionnaire. surgical comprises septoplasty without reduction inferior nasal turbinate anatomically wider side nose. medical management comprises nasal saline spray followed fluorinated steroid spray daily six months. recruitment target 378 patients, recruited 17 site across scotland, england wales. randomisation 1:1 basis, stratified gender severity (nose score). participant followed 12 month post randomisation. primary outcome measure total snot-22 score 6 months. clinical economic outcome modelled baseline severity (nose scale) inform clinical decision-making. includes recruitment enhancement process, economic evaluation. discussion: nairos trial evaluate clinical effectiveness cost-effectiveness septoplasty versus medical management adult deviated septum symptom nasal blockage. identifying individual likely benefit surgery enable efficient effective clinical decision-making, avoid unnecessary operation low likelihood benefit. trial registration: eudract: 2017â\\x80\\x93000893-12, isrctn: 16168569. registered 24 march 2017.',\n",
       " 'background: sought develop test objective scorecard-based system assessing categorizing available research site lassa fever-affected country based preparedness capability host lassa fever vaccine clinical trials. methods: mapped available clinical research site interrogation online clinical trial registry relevant disease-based consortia. structured online questionnaire used ass capability clinical trial site conduct lassa fever vaccine clinical trials. developed scoring template allocating score questionnaire parameter based perceived importance conduct clinical trial described who/tdr global competency framework clinical research. cutoff point 75% 50% used categorize site category a, b, c. results: identified 44 clinical trial site 8 lassa fever-affected countries. these, 35 site characterized based capacity hold lassa fever vaccine clinical trials. total 14 site 4 country identified ready host lassa fever vaccine trial immediately little support. conclusion: feasible hold lassa fever vaccine trial affected country based outcome survey. however, finding validated sitesâ\\x80\\x99 visits. experience standardized objective site assessment encouraging, site selection used serve orientation sponsor researcher planning clinical trial region.',\n",
       " 'mycobacterium avium subsp. paratuberculosis (m. paratuberculosis) cause johneâ\\x80\\x99s ruminant characterized chronic gastroenteritis leading heavy economic loss dairy industry worldwide. currently available vaccine (inactivated bacterin oil base) effective preventing pathogen shedding rarely used control johneâ\\x80\\x99s dairy herds. develop better vaccine prevent spread johneâ\\x80\\x99s disease, utilized polyanhydride nanoparticles (pan) encapsulate mycobacterial antigen composed whole cell lysate (pan-lysate) culture filtrate (pan-cf) m. paratuberculosis. nanoparticle-based vaccine (i.e., nanovaccines) well tolerated mouse causing inflammatory lesion site injection. immunological assay demonstrated substantial increase level antigen-specific cell response post-vaccination pan-cf vaccinated group indicated high percentage triple cytokine (ifn-î³, il-2, tnf-î±) producing cd8(+) cells. following challenge, animal vaccinated pan-cf continued produce significant level double (ifn-î³, tnf-î±) single cytokine (ifn-î³) secreting cd8(+) cell compared animal vaccinated inactivated vaccine. significant reduction bacterial load observed multiple organ animal vaccinated pan-cf, clear indication protection. overall, use polyanhydride nanovaccines resulted development protective sustained immunity johneâ\\x80\\x99s disease, approach could applied counter intracellular pathogens.',\n",
       " 'retrospective aimed clarify short- mid-term outcome elderly underwent surgery treat left-sided native valve infective endocarditis (lsnie). july 2005 september 2015, 179 underwent surgical active lsnie single institution. classified two groups: â\\x89¥65 year (elderly group) <65 year (non-elderly group). clinical features, surgical information, postoperative complications, three-year survival rate compared. average age 74.2 â± 6.4 45.2 â± 12.6 year elderly non-elderly groups, respectively. elderly group higher predicted mortality rate lower incidence preoperative septic emboli-related complications. echocardiographic assessment infected valve generally homogenous groups. elderly higher in-hospital mortality rate non-elderly (26.3% vs. 5.7%, p = 0.001). survived discharge, three-year cumulative survival rate 75.0% â± 8.2% 81.2% â± 3.4% elderly non-elderly groups, respectively (p = 0.484). conclusion, elderly higher risk in-hospital mortality surgery lsnie. however, elderly stabilized surgical survive discharge, mid-term outcome promising.',\n",
       " 'numerous epidemic model developed capture aspect human contact patterns, making model selection challenging fit (often-scarce) early epidemic equally well differ predictions. consider invasion novel directly transmissible perform extensive, systematic transparent comparison model explicit age and/or household structure, determine accuracy loss prediction absence intervention ignoring either social components. conclude that, heterogeneous assortative contact pattern relevant respiratory infections, modelâ\\x80\\x99s age stratification crucial accurate predictions. conversely, household structure needed transmission highly concentrated households, suggested empirical robust rule thumb based household secondary attack rate. work serf template guide simplicity/accuracy trade-off designing model aimed initial, rapid assessment potential epidemic severity.',\n",
       " 'situation drug resistance become complicated due scarcity plant resistance genes, overcoming challenge imperative. isatis indigotica used wounds, infections, inflammation centuries. antimicrobial peptide (amps) found class life ranging prokaryote eukaryotes. identify amps, i. indigotica explored novel, sensitive, high-throughput bacillus subtilis screening system. found iir515 iir915 exhibited significant antimicrobial activity variety bacterial (xanthomonas oryzae, ralstonia solanacearum, clavibacter michiganensis, c. fangii) fungal (phytophthora capsici botrytis cinerea) pathogens. scanning electron microscope cytometric analysis revealed possible mechanism peptides, target disrupt bacterial cell membrane. model supported membrane fluidity electrical potential analyses. hemolytic activity assay revealed peptide may act potential source clinical medicine development. conclusion, plant-derived novel amp iir515 iir915 effective biocontrol agent used raw material drug discovery field.',\n",
       " 'htlv-1 first described human retrovirus soon found associated severe clinical diseases, devastating lymphoma/leukemia inflammatory diseases. although htlv-2 usually pathogenic, widely distributed among native indian population brazil, particularly amazon region country. presently, htlv spread mainly sexual route mother child, persistence active biological factor aiding transmission. recently, use illicit drug additional risk factor, showing influence habit epidemiology htlv region. despite detection several different population amazon region brazil almost 30 years, exact prevalence htlv-1/2 well defined. original bias sampling selection epidemiologically unsuitable population commonly repeated prevalence studies, generating unreliable conflicting figure represent actual prevalence htlv. improvement clinical laboratory facility resulted description several clinical manifestation region. extent spread must defined region, largest geographical area country. prophylaxis advance toward use vaccine htlv-1, important determine risk infected developing successfully implement preventive measures, particularly proposal made eradicate among humans.',\n",
       " 'background: number child requiring long-term home ventilation consistently increased last 25 years. given growing population child complex care need (ccns), important area focus within model child appraised (mocha) project, funded european union (eu) horizon 2020 programme. examined structure process care place child ccns identified key constituent effective integration care child community acute care interface across 30 eu/ european economic area (eea) countries. methods: non-experimental descriptive embedded qualitative element. collected country agent 30 countries, local expert child services. analysed descriptive statistic thematic analysis undertaken free text provided. results: total 27 survey returned possible 30 country (90.0%) countries. respondent indicated country child long-term ventilation (ltv) home, therefore, response 26 country (86.7%) analysed. none responding country reported core component place country. three theme emerged free text provided: â\\x80\\x98family preparedness transitioning homeâ\\x80\\x99, â\\x80\\x98coordinated pathway specialist careâ\\x80\\x99 â\\x80\\x98legal governance structuresâ\\x80\\x99. conclusions: clinical care child ltv acute sector received considerable attention, result identify need enhanced focus care required following discharge community setting. result highlight need commitment supporting care delivery acknowledges complexity contemporary child issue context family become primary care givers.',\n",
       " 'background: optimal timing start vasopressor (vp) septic shock widely studied since assumed fluid must administered advance. sought evaluate whether early start vp, even without completing initial fluid loading, might impact clinical outcome septic shock. methods: total 337 sepsis requiring vp support least 6 h initially selected prospectively collected database 90-bed mixed-icu 24-month period. classified very-early (ve-vps) delayed vasopressor start (d-vps) category according whether norepinephrine initiated within/before next hour first resuscitative fluid load. then, ve-vps (n = 93) 1:1 propensity matched d-vps (n = 93) based age; source admission (emergency room, general wards, intensive care unit); chronic acute comorbidities; lactate, heart rate, systolic, diastolic pressure vasopressor start. risk-adjusted cox proportional hazard model fitted ass association ve-vps 28 mortality. finally, sensitivity analysis performed requiring vp support le 6 h. results: subjected ve-vps received significantly le resuscitation fluid vasopressor starting (0[0â\\x80\\x93510] vs. 1500[650â\\x80\\x932300] ml, p < 0.001) first 8 h resuscitation (1100[500â\\x80\\x931900] vs. 2600[1600â\\x80\\x933800] ml, p < 0.001), significant increase acute renal failure and/or renal replacement therapy requirements. ve-vps related significant lower net fluid balance 8 24 h vps. ve-vps associated significant reduction risk death compared d-vps (hr 0.31, ci95% 0.17â\\x80\\x930.57, p < 0.001) 28. association maintained receiving vasopressor < 6 h. conclusion: early start vasopressor support seems safe, might limit amount fluid resuscitate septic shock, could lead better clinical outcomes.',\n",
       " 'vaccination effective measure preventing influenza infections. however, current seasonal influenza vaccine protective closely matched circulating strains. even extensive monitoring annual reformulation effort remain step behind rapidly evolving virus, often resulting mismatch low vaccine effectiveness. fortunately, many next-generation influenza vaccine currently development, utilizing array innovative technique shorten production time increase breadth protection. review summarizes production method current vaccines, recent advance made influenza vaccine research, highlight potential challenge yet overcome. special emphasis put potential role glycoengineering influenza vaccine development, advantage removing glycan shield influenza surface antigen increase vaccine immunogenicity. potential future development novel influenza vaccine candidate discussed industry perspective.',\n",
       " 'background: micrornas (mirnas) play essential role gene regulator many biological molecular phenomena. unraveling involvement mirna key cellular factor vitro canine parvovirus (cpv) may facilitate discovery potential intervention candidates. however, examination mirna expression profile cpv tissue culture system fully elucidated. method: present study, utilized high-throughput small rna-seq (srna-seq) technology investigate altered mirna profiling mirna library uninfected (control) cpv-2c infected crandell reese feline kidney cells. results: identified five known mirnas (mir-222-5p, mir-365-2-5p, mir-1247-3p, mir-322-5p mir-361-3p) three novel mirnas (novel 137, novel 141 novel 102) srna-seq differentially expressed gene mirna repertoire cpv-infected cell control. predicted potential target gene aforementioned mirnas sequence homology algorithms. notably, target mir-1247-3p exhibited potential function associated cellular defense humoral response cpv. extend probing scheme gene target mir-1247-3p, explored performed gene ontology (go) enrichment analysis target genes. discovered 229 putative target total 38 enriched go terms. top over-represented go enrichment biological process lymphocyte activation differentiation, marginal zone b cell differentiation, negative regulation cytokine production, negative regulation programed cell death, negative regulation signaling. next constructed go biological process network composed 28 target gene mir-1247-3p, which, genes, namely bcl6, dll1, gata3, il6, lef1, lfng wnt1 among gene obviously intersected multiple go terms. conclusion: mirna-1247-3p cognate target gene suggested great potential novel therapeutic target diagnostic biomarkers cpv related viruses.',\n",
       " '',\n",
       " 'lactic acid bacteria (lab) major microorganism used probiotic purpose prime part human mammalian gut microbiota, exert important health-promoting effect host. present aimed evaluate compare probiotic potential safety lab strain isolated gastrointestinal tract wild boar greater khingan mountains, china. amongst isolated lab strains, five isolates identified lactobacillus mucosae, lactobacillus salivarius, enterococcus hirae, enterococcus durans, enterococcus faecium, remarkably resistant acid bile salt. probiotic characteristic (including adhesion capability, antimicrobial activities, autoaggregation, coaggregation abilities), safety property (including hemolytic activity, antibiotic resistance, absence/presence virulence factors, vivo safety) evaluated. result showed five isolates exhibited high adhesive potential, remarkable aggregation capacity, antibacterial activities. upon assessment safety, strain negative hemolytic activity tested virulence genes. vivo safety assessment showed adverse effect isolated strain supplementation body weight gain organ index treated mice. revealed lab isolates, especially l. salivarius m2-71, posse desirable probiotic property great potential development feed additive animal promote health.',\n",
       " 'background: usage chloroquine discontinued plasmodium falciparum almost endemic region global spread resistant parasites. since first report malawi, numerous epidemiological study demonstrated discontinuance led re-emergence chloroquine-susceptible p. falciparum, suggesting possible role future malaria control. however, study cross-sectional, study looking persistence chloroquine recovery long term. fill gap providing, period least 6 years, proof persistent re-emergence/stable recovery susceptible parasite population molecular phenotypic methods. methods: ex vivo drug-susceptibility assay chloroquine (n = 319) lumefantrine (n = 335) performed 2013 2018 gulu, northern uganda, chloroquine removed official malaria regimen since 2006. genotyping pfcrt pfmdr1 performed. results: chloroquine resistance (â\\x89¥ 100 nm) observed 3 (1.3%) samples. average ic(50) value chloroquine persistently low throughout period (17.4â\\x80\\x9324.9 nm). parasite harbouring pfcrt k76 allele showed significantly lower ic(50)s chloroquine parasite harbouring k76t allele (21.4 nm vs. 43.1 nm, p-value = 3.9 ã\\x97 10(â\\x88\\x928)). prevalence k76 allele gradually increased 71% 2013 100% 2018. conclusion: found evidence stable persistence chloroquine susceptibility fixation pfcrt k76 northern uganda discontinuation chloroquine region. accumulation similar evidence endemic area uganda could open channel possible future re-use chloroquine option malaria prevention.',\n",
       " 'background: optimal antimicrobial drug exposure lung required successful outcome nosocomial pneumonia. little known intrapulmonary pharmacokinetics (pk) meropenem administered continuous infusion (ci). aim evaluate pk two dosage meropenem (3 g v 6 g/day ci) plasma epithelial lining fluid (elf) critically ill nosocomial pneumonia. methods: thirty-one (81% male, median (iqr) age 72 (22) years) enrolled prospective, randomized, clinical trial. sixteen received 1 g/8 h 15 2 g/8 h ci (8 h infusion). plasma elf meropenem concentration modeled population methodology, monte carlo simulation performed estimate probability attaining (pta) free elf concentration 50% time mic (50% ft>mic), result logarithmic killing suppression resistance experimental model pneumonia. results: median (iqr) meropenem auc(0â\\x80\\x9324 h) plasma elf 287.6 (190.2) 84.1 (78.8) mg h/l 1 g/8 h group v 448.1 (231.8) 163.0 (201.8) mg h/l 2 g/8 h group, respectively. penetration ratio approximately 30% comparable dosage groups. monte carlo simulations, highest approved dose meropenem 2 g/8 h ci allowed achieve optimal pta isolates mic < 4 mg/l. conclusions: increase dose meropenem administered ci achieved higher exposure plasma elf. use highest licensed dose 6 g/day may necessary achieve optimal coverage elf susceptible isolates (mic â\\x89¤ 2 mg/l) conserved renal function. alternative therapy considered presence microorganism mic greater 2 mg/l suspected. trial registration: trial registered european union drug regulating authority clinical trial database (eudract-no. 2016-002796-10). registered 27 december 2016.',\n",
       " 'background: aimed synthesize up-to-date trial validate effect neuromuscular blocking agent (nmba) use moderate-to-severe acute respiratory distress syndrome (ards). methods: several database pubmed, embase, web science, cochrane central register searched november 14, 2019. randomized trial investigating use nmbas moderate-to-severe ards reporting mortality included meta-analysis. primary outcome mortality, secondary outcome clinical outcomes, respiratory physiological parameters, incidence barotrauma, icu-free days, ventilation-free days. results: total 7 trial enrolling 1598 finally included meta-analysis. result revealed use nmbas moderate-to-severe ards could significantly decrease mortality truncated 28 (rr 0.74, 95% ci 0.56 0.98, p = 0.03) 90 (rr 0.77, 95% ci 0.60 0.99, p = 0.04). nmba use could significantly decrease incidence barotrauma (rr 0.56, 95% ci 0.36 0.87, p = 0.009). significant difference observed icu-free day ventilation-free day nmba control groups. conclusion: use nmbas could significantly decrease mortality moderate-to-severe ards decrease incidence barotrauma mechanical ventilation. however, large-scale randomized trial needed validate effect nmba use ards.',\n",
       " 'background: whether borna (bdv-1) human pathogen remained controversial recent encephalitis case showed bdv-1 could even deadly. called mind previous evidence infectious contribution bdv-1 mental disorders. pilot open trial suggested bdv-1 infected depressed benefitted antiviral therapy licensed drug (amantadine) tested sensitive vitro. here, designed double-blind placebo-controlled randomized clinical trial (rct) cross-linked depression bdv-1 infection, addressing antidepressant antiviral efficacy amantadine. methods: interventional phase ii rct (two 7-weeks-treatment period 12-months follow-up) hannover medical school (mhh), germany, assigned currently depressed bdv-1 infected either major depression (md; n = 23) bipolar disorder (bd; n = 13) amantadine sulphate (pk-merzâ®; twice 100 mg orally daily) placebo treatment, contrariwise, respectively. clinical change assessed every 2â\\x80\\x933 week 21-item hamilton rating scale depression (hamd) (total, single, combined scores). bdv-1 activity determined accordingly blood plasma enzyme immune assay antigen (pag), antibody (ab) circulating immune complex (cic). results: primary outcome (â\\x89¥25% hamd reduction, week 7) 81.3% amantadine vs. 35.3% placebo responder (p = 0.003), clinical effect size (es; cohenâ\\x80\\x99s d) 1.046, excellent drug tolerance. amantadine safe reducing suicidal behaviour first 2 weeks. pre-treatment maximum level predictive clinical improvement (ab, p = 0.001; pag, p = 0.026; hamd week 7). respective pag cic level correlated ab reduction (p = 0,001 p = 0.034, respectively). follow-up benefit (12 months) correlated dropped cumulative measure time (p < 0.001). vitro, amantadine concentration low 2.4â\\x80\\x9310 ng/ml (50% infection-inhibitory dose) prevented human bdv hu-h1, closely related memantine failed 100,000-fold higher concentration (200 î¼g/ml). conclusions: finding indicate profound antidepressant efficacy safe oral amantadine treatment, paralleling antiviral effect various levels. support paradigm link bdv-1 depression. provides novel possibly practice-changing low cost mental care perspective depressed bdv-1-infected addressing global needs. trial registration: trial retrospectively registered german clinical trial registry 04th march 2015. trial id drks00007649; https://www.drks.de/drks_web/setlocale_en.do',\n",
       " 'present study, hepatic tissueâ\\x80\\x90origin cell line european eel anguilla anguilla developed characterized. cell line designated el maintained leibovitz lâ\\x80\\x9015 supplemented 10% fetal bovine serum 72 months, subcultured 90 times. el cell line consisted predominantly fibroblastâ\\x80\\x90like cells, could survive 100 day vitro, could grow 15â\\x80\\x9332â°c. optimum temperature growth 27â°c. chromosome analysis revealed modal diploid karyotype 2n = 38. origin cell line confirmed 18 recombinant (r)rna sequencing. susceptibility test indicated significant cytopathic effect el cell regard rana grylio herpesvirus anguillae. replication confirmed transmission electron microscopy polymerase chain reaction analysis. following poly (i:c) exposure, expression level immuneâ\\x80\\x90related molecule interferon regulatory factorâ\\x80\\x907 (irf7) transforming growth factorâ\\x80\\x90î² (tgfâ\\x80\\x90î²) downregulated el cells, whereas expression level rf3 cytochrome p450 (cyp450) upregulated. four gene significantly upregulated following inflammation lipopolysaccharide (lps). suggested application el cell line identification, well immunodiagnosis pharmacological targeting.',\n",
       " 'human metapneumovirus (hmpv) important pathogen cause upper lower respiratory tract infection child worldwide. hmpv two major genotypes, hmpv-a hmpv-b. epidemiological study two hmpv genotype alternate predominance worldwide recent years. co-circulation two genotype hmpv usually observed interaction them, competitive replication, maybe possible mechanism alternating prevalence subtypes. present used two different genotype hmpv (genotype a: nl/1/00; b: nl/1/99) different proportion animal model (balb/c mice) cell model (vero-e6) separately. showed competitive growth exist balb/c mice, genotype b strong competitive advantage. however, genotype b cause severe non-predominant (genotype a) mixed strain study, evaluated body weight, airway hyperresponsiveness lung pathology mouse. cell model, competitive growth two genotype alternately prevalence observed. summary, confirmed competitive replication hmpv genotype b, difference severity caused two subtypes. show insight understand alternation hmpv genotype prevalence genotype competition provide experimental evidence control vaccine design.',\n",
       " '',\n",
       " 'background: miller fisher syndrome variant acute inflammatory demyelinating polyneuropathy classically characterized ataxia, ophthalmoplegia, areflexia. miller fisher syndrome present uncommon symptom bulbar, facial, somatic muscle palsy micturition disturbance. presentation: describe 76-year-old white man new-onset ataxia, stridor, areflexia, upper lower extremity weakness required intubation presentation. initial work-up imaging study serum test inconclusive. eventually, neurophysiological testing cerebrospinal fluid analysis suggested diagnosis miller fisher syndrome. responded intravenous immunoglobulin supportive therapy. conclusion: occurrence acute subacute descending paralysis involvement bulbar muscle respiratory failure often divert clinician diagnosis neuromuscular junction disorder (such botulism myasthenia gravis), vascular cause like stroke, electrolyte metabolic abnormalities. early identification miller fisher syndrome appropriate testing essential prompt prevention further, potentially fatal, deterioration.',\n",
       " 'background: novel method necessary reduce morbidity mortality suffering infection pseudomonas aeruginosa. common infectious specie pseudomonas genus, p. aeruginosa primary gram-negative etiology responsible nosocomial infections. due ubiquity high adaptability species, effective universal p. aeruginosa still eludes investigators, despite extensive research area. results: report bacterial inhibition iron-oxide (nominally magnetite) nanoparticles (nps) alone, mean hydrodynamic diameter ~ 16 nm, well alginate-capped iron-oxide nps. alginate capping increased average hydrodynamic diameter ~ 230 nm. investigated alginate-capped iron-oxide np-drug conjugates, practically unchanged hydrodynamic diameter ~ 232 nm. susceptibility minimum inhibitory concentration (mic) nps, np-tobramycin conjugates, tobramycin alone determined pao1 bacterial colonies. investigation susceptibility disk diffusion done 3 day biofilm growth 60 day growth. mic compound interest determined 60-days growth, ensure thorough establishment biofilm colonies. conclusions: positive inhibition reported uncapped alginate-capped iron-oxide nps, corresponding mics presented. report zero susceptibility iron-oxide np capped polyethylene glycol, suggesting capping agent play major role enabling bactericidal ability nanocomposite. finding suggest alginate-coated nanocomposites investigated potential overcome bacterial biofilm barrier. magnetic field application increase action, likely via enhanced diffusion iron-oxide np np-drug conjugate mucin alginate barriers, characteristic cystic-fibrosis respiratory infections. demonstrate iron-oxide np coated alginate, well alginate-coated magnetiteâ\\x80\\x93tobramycin conjugate inhibit p. aeruginosa growth biofilm formation established colonies. determined susceptibility tobramycin decrease longer culture times. however, susceptibility iron-oxide np compound demonstrate comparable decrease increasing culture time. finding imply iron-oxide np lower-cost alternative silver np antibacterial coatings, solutions, drugs, well application microbial abolition infestation prevention sought.',\n",
       " 'background: according world organization reports, billion people around world risk malaria important consider preventive strategy protecting people living high risk areas. main reason survival diversity vector parasite different malaria region specific features, behaviour biology. therefore, specific regional strategy necessary successful control malaria. tool need developed elimination prevention reintroduction malaria vaccine interrupt malaria transmission (vimts). vimt broad concept adjusted biological characteristic region. type vimt vector-based vaccine affect sexual stage plasmodium life cycle. according recent studies, aminopeptidase n-1 anopheles gambiae (agapn-1) potent vector-based vimt considerable inhibition activity sexual stage plasmodium parasite. methods: system rapid amplification cdna end (3ê¹-race) genome walking method used sequence determination apn-1 gene anopheles stephensi distinct bioinformatics software used structural analysis. asapn-1 expressed spodoptera frugiperda (sf9) insect cell line baculovirus expression system. recombinant asapn-1 purified hybrid condition biological activity assayed. results: asapn-1 gene coded protein an. stephensi characterized first time study. subsequently, structural feature immunological property coded protein evaluated silico approaches. enzymatic activity recombinant asapn-1, expressed sf9 insect cell line, equal 6 unit/î¼l. conclusions: result revealed asapn-1 similar counterpart an. gambiae. silico evaluation fundamental necessary evaluation vimt-based vaccine next step acquired could useful research group malaria vaccine country an. stephensi main malaria vector there.',\n",
       " 'background: intraoperative driving pressure (î\\x94p) associated development postoperative pulmonary complication (ppc). tidal volume (v(t)) kept constant, î\\x94p may change according positive end-expiratory pressure (peep)-induced change lung aeration. î\\x94p may decrease peep lead recruitment collapsed lung tissue increase peep mainly cause pulmonary overdistension. test hypothesis individualized high peep, compared fixed low peep, protects ppc undergoing open abdominal surgery. methods: â\\x80\\x9cdriving pressure general anesthesia open abdominal surgery trialâ\\x80\\x9d (designation) international, multicenter, two-group, double-blind randomized clinical superiority trial. total 1468 randomly assigned two intraoperative ventilation strategies. investigator screen aged â\\x89¥ 18 year body mass index â\\x89¤ 40 kg/m(2), scheduled open abdominal surgery risk ppc. either receive intraoperative ventilation strategy individualized high peep recruitment maneuver (rm) (â\\x80\\x9cindividualized high peepâ\\x80\\x9d) peep 5 cm h(2)o without rm used (â\\x80\\x9clow peepâ\\x80\\x9d). â\\x80\\x9cindividualized high peepâ\\x80\\x9d group, peep set level î\\x94p lowest. group trial, v(t) kept 8 ml/kg predicted body weight. primary endpoint occurrence ppc, recorded collapsed composite adverse pulmonary events. discussion: designation first randomized clinical trial adequately powered compare effect individualized high peep rm versus fixed low peep without rm occurrence ppc open abdominal surgery. result designation support anesthesiologist decision regarding peep setting open abdominal surgery. trial registration: clinicaltrials.gov, nct03884543. registered 21 march 2019.',\n",
       " 'despite evidence supporting effectiveness best practice prevention management, many healthcare worker fail implement evidence-based practice tend underused routine practice. prevention management infection across surgical pathway always focus collaboration among healthcare worker sharing knowledge best practices. clarify key issue prevention management infection across surgical pathway, multidisciplinary task force expert convened ancona, italy, may 31, 2019, national meeting. document represents executive summary final statement approved expert panel.',\n",
       " 'background: influenza spread rapidly around world seasonal epidemics, resulting significant morbidity mortality. influenza-related incidence limited many country africa despite established sentinel surveillance. aimed address information gap estimating burden seasonality medically attended influenza like illness ethiopia. method: influenza sentinel surveillance collected 3 influenza like illness (ili) 5 severe acute respiratory illness (sari) site 2012 2017 used analysis. descriptive statistic applied simple analysis. proportion medically attended influenza positive case incidence rate ili determined total admitted catchment area population. seasonality estimated based weekly trend ili predicted threshold done applying â\\x80\\x9cmoving epidemic (mem)â\\x80\\x9d. result: total 5715 medically attended influenza suspected fulfills ili sari definition (77% ili 23% sari) enrolled. laboratory confirmed influenza (influenza positive case) among ili sari suspected 25% (1130/4426) 3% (36/1289). which, 65% influenza type a. predominantly circulating influenza subtype seasonal influenza a(h3n2) (n = 455, 60%) influenza a(h1n1)pdm09 (n = 293, 38.81%). estimated mean annual influenza positive proportion ili incidence rate 160.04 52.48 per 100,000 population. incidence rate ili higher age group 15â\\x80\\x9344 year age [â\\x80\\x98incidence rate (r) = 254.6 per 100,000 populationâ\\x80\\x99, 95% ci; 173.65, 335.55] 5â\\x80\\x9314 year age [r = 49.5, ci 95%; 31.47, 130.43]. seasonality influenza two peak seasons; period octoberâ\\x80\\x93december aprilâ\\x80\\x93june. conclusion: significant morbidity influenza like illness observed two peak season year seasonal influenza (h3n2) remains predominantly circulating influenza subtype. need considered identify potential risk improving surveillance system continue early detection monitoring circulating influenza country paramount importance.',\n",
       " 'novel (2019-ncov) originating wuhan, china present potential respiratory pandemic world population. current effort focused containment quarantine infected individuals. ultimately, outbreak could controlled protective vaccine prevent 2019-ncov infection. vaccine research pursued intensely, exists today therapy treat 2019-ncov upon infection, despite urgent need find option help preclude potential death. herein, review potential option treat 2019-ncov patients, emphasis necessity speed timeliness developing effective therapy outbreak. consider option drug repurposing, developing neutralizing monoclonal antibody therapy, oligonucleotide strategy targeting rna genome, emphasizing promise pitfall approaches. finally, advocate fastest strategy develop now, could resistant mutation may future. proposal biologic block 2019-ncov entry soluble version receptor, angiotensin-converting enzyme 2 (ace2), fused immunoglobulin fc domain (ace2-fc), providing neutralizing antibody maximal breath avoid escape, helping recruit immune system build lasting immunity. ace2-fc therapy would supplement decreased ace2 level lung infection, thereby directly treating acute respiratory distress pathophysiology third mechanism action. sequence ace2-fc protein provided investigators, allowing possible use recombinant protein expression system start producing drug today treat compassionate use, formal clinical trial later undertaken. could help infected protective vaccine developed widely available coming month year(s).',\n",
       " 'simple susceptibleâ\\x80\\x93infectiousâ\\x80\\x93removed epidemic model smallpox, birth death rate based historical data, produce oscillatory dynamic remarkably accurate periodicity. stochastic population cause oscillation sustained rather damped, analysis regarding oscillation provides insight set population data. notably, oscillation arise naturally model, instead periodic forcing term exogenous mechanism guarantee oscillation: model mechanism. emergent natural oscillation display appropriate periodicity smallpox, even model applied different location populations. model datasets, turn, offer observation dynamic solution trajectories. result call renewed attention relatively simple models, combination datasets real outbreaks.',\n",
       " 'ecological systems, heterogeneous interaction pathogen take place simultaneously. occurs, instance, two pathogen cooperate, time, multiple strain pathogen co-circulate compete. notable example include cooperation human immunodeficiency antibiotic-resistant susceptible strain tuberculosis respiratory infection streptococcus pneumoniae strains. model focusing competition cooperation separately fail describe concurrent interaction shape epidemiology diseases. studied problem considering two cooperating pathogens, pathogen structured two strains. spreading follows susceptible-infected-susceptible process strain differ transmissibility extent cooperation pathogen. combined mean-field stability analysis stochastic simulation network considering well-mixed structured populations. observed emergence complex phase diagram, condition le transmissible, cooperative strain dominate non-trivial, e.g. non-monotonic boundary bistability. coupled community structure, presence cooperative pathogen enables coexistence strain breaking spatial symmetry dynamically creating different ecological niches. result shed light ecological mechanism may impact epidemiology disease public concern.',\n",
       " 'eliciting protective titer hiv-1 broadly neutralizing antibody (bnabs) goal hiv-1 vaccine development, current vaccine strategy yet induce bnabs humans. many bnabs isolated hiv-1-infected individual encoded immunoglobulin gene rearrangments infrequent naive b cell precursor unusual genetic feature may subject host regulatory control. here, administer antibody targeting immune cell regulatory receptor ctla-4, pd-1 ox40 along hiv envelope (env) vaccine rhesus macaque bnab immunoglobulin knock-in (ki) mouse expressing diverse precursor cd4 binding site hiv-1 bnabs. ctla-4 blockade augments hiv-1 env antibody response macaques, bnab-precursor mouse model, ctla-4 blocking ox40 agonist antibody increase germinal center b follicular helper cell plasma neutralizing antibodies. thus, modulation ctla-4 ox40 immune checkpoint vaccination promote germinal center activity enhance hiv-1 env antibody responses.',\n",
       " 'oral rabies vaccination (orv) highly effective fox raccoon dogs, whereas reason efficacy orv reservoir specie le pronounced. investigate possible variation species-specific cell tropism local replication vaccine virus, different reservoir specie foxes, raccoon dogs, raccoons, mongooses, dog skunk orally immunised highly attenuated, high-titred gfp-expressing rabies (rabv). immunofluorescence rt-qpcr screening revealed clear difference among specie suggesting host specific limitation orv. responsive specie palatine tonsil (tonsilla palatina) identified main site replication, le dissemination observed tonsil rather refractory species. comparison vaccine tropism emphasizes important role tonsilla palatina play eliciting immune response orv, indicate lymphoid tissue may important role originally anticipated. overall, support model susceptibility oral live rabv vaccine lymphatic tissue major determinant vaccination efficacy. present result may help direct future research improving vaccine uptake efficacy oral rabies vaccine field conditions.',\n",
       " 'clinical implication bacteremia among septic remain unclear, although vast amount accumulated sepsis. aimed compare clinical characteristic outcome severe sepsis without bacteremia. secondary analysis multicenter, prospective cohort included 59 intensive care unit (icus) japan january 2016 march 2017. cohort comprised 1,184 adult (aged â\\x89¥ 16 years) admitted icu severe sepsis diagnosed according sepsis-2 criteria. 1,167 included analysis, 636 (54.5%) bacteremia. bacteremia significantly higher rate septic shock (66.4% vs. 58.9%, p = 0.01) higher sepsis severity scores, acute physiology chronic evaluation (apache) ii sequential organ failure assessment (sofa). significant difference in-hospital mortality seen without bacteremia (25.6% vs. 21.0%, p = 0.08). conclusion, half severe sepsis icu bacteremia. although bacteremia severe state, between-group difference patient-centered outcomes, in-hospital mortality, fully elucidated.',\n",
       " 'adiponectin prime determinant status insulin resistance. association study adiponectin (adipoq) gene single nucleotide polymorphism (snps) metabolic disease reported earlier. however, result ambiguous due apparent contradictions. hence, investigated (1) association adipoq snps: â\\x88\\x9211377c/g, +10211t/g, +45t/g +276g/t risk towards type 2 diabetes (t2d) and, (2) genotype-phenotype association snp various biochemical parameter two cohorts. genomic dna diabetic control gujarat and, jammu kashmir (j&k) genotyped pcr-rflp, taqman assay massarray. transcript level adipoq assessed visceral adipose tissue samples, plasma adiponectin level estimated qpcr elisa respectively. result suggest: (i) reduced hmw adiponectin/total adiponectin ratio gujarat association +10211t/g +276g/t, reduced adipoq transcript level t2d, (ii) association snp increased fbg, bmi, tg, tc gujarat (iii) increased ggtg haplotype obese gujarat population and, (iv) association â\\x88\\x9211377c/g t2d j&k population. reduced hmw adiponectin, backdrop obesity adipoq genetic variant might alter metabolic profile posing risk towards t2d.',\n",
       " \"cooperation fundamental behaviour observed form life. evolution cooperation widely studied, almost theory focused cooperating individual genes. suggest different approach, taking account microbe carried interacting individuals. accumulating evidence reveals microbe affect host's well-being behaviour, yet host evolve mechanism resist manipulation microbes. thus propose coevolution microbe host may favour microbe induce host cooperate. computational modelling, microbe-induced cooperation evolve maintained wide range conditions, facing hosts' resistance microbial effect. find hostâ\\x80\\x93microbe coevolution lead population rockâ\\x80\\x93paperâ\\x80\\x93scissors dynamic enables maintenance cooperation polymorphic state. result suggest mechanism evolution maintenance cooperation may relevant wide variety organisms, case difficult explain current theories. provides perspective coevolution host microbiome, emphasizing potential role microbe shaping host's behaviour.\",\n",
       " 'background: key focus system strengthening low- middle-income country increasing reach access task-shifting. model become common, critical understand experience lay provider forefront delivering care services. greater understanding would improve lay provider support help provide high-quality care. especially providing mental services, providing psychological care may pose unique stressors. sought understand experience lay counselors, focusing identity, motivation, self-efficacy, stress, burnout. goal understand taking provider role influence life beyond simply assuming task, would turn help identify actionable step improve intervention task-shifting components. methods: semi-structured interview (n = 20) focus group discussion (n = 3) conducted three lay counselor group varying level experience delivering community-based family therapy intervention eldoret, kenya. thematic analysis conducted, intercoder reliability checks. stress map created visualize stress profile free-listing pile-sorting collected interview focus group discussions. results: counselor described high intrinsic motivation become counselor high self-efficacy training. reported positive experience counselor role, skill improving counseling personal lives. challenge arose, client engagement difficulty balancing many responsibilities, stress burnout increased, dampening motivation self-efficacy. response, counselor described coping strategies, seeking peer supervisor support, restored motivation persevere. completion, experienced high self-efficacy desire continue. conclusions: finding informed suggestion way incorporate support lay provider task-shifting intervention initiation, training, throughout implementation. include acknowledging preparing counselor challenge training, increasing explicit attention counselor stress supervision, fostering peer support among lay providers, ensuring fair balance workload compensation. improving building evidence base around practice supporting lay provider improve effectiveness sustainability lay provider-delivered interventions.',\n",
       " 'background: mechanism pathway impact public research uk widely studied. lens funder (nihr), aim map diversity public research, term funding mechanisms, disciplinary contributions, public impacts, identify example impacts, pathway impact existing reporting mechanism may otherwise captured, provide illustration public researcher perceive generation non-academic impact work. methods: total 1386 project identified â\\x80\\x98public researchâ\\x80\\x99 nihr listed nihr public overview database (2000â\\x80\\x932016). these, subset 857 project matched potentially begun reporting impact via external data-gathering platform (researchfish). 857 project analyzed quantitatively, nine project selected investigate semi-structured interview principal investigators. two workshop took place validate emerging final finding facilitate analysis. results: addition nihr school public research nihr public research programme, 89% project contained nihr public overview portfolio â\\x80\\x98public researchâ\\x80\\x99 funded via nihr research programmes, suggesting significant diversity discipline contributing public research outcomes. pathway impact observed in-depth study include contributing debate constitutes appropriate evidence national policy change, acknowledging local â\\x80\\x98unintendedâ\\x80\\x99 impacts, building trusted relationship stakeholder across non-health sector actors, collaborating local authorities, non-academic dissemination channels. conclusions: public discipline contributes substantially impact beyond academia. support diversity impacts, need recognise localized smaller-scale impacts, difference type evidence required community local authority-based impacts. require building capacity resource enable impact take place public research. finally, support required engagement local authority working non-health sector contribute outcomes.',\n",
       " 'background: emergence human avian influenza a(h7n9) reported wenshan city, southwestern china 2017. describes epidemiological virological feature outbreak discus origin infection. methods: poultry exposure timeline key event collected. sample derived patients, close contacts, environment tested influenza a(h7n9) real-time reverse transcription polymerase chain reaction. genetic sequencing phylogenetic analysis conducted. results: five reported outbreak. epidemiological investigation showed exposed live poultry markets. a(h7n9) isolates low pathogenicity avian species. epidemiological investigation chicken source phylogenetic analysis gene sequence indicated source guangxi province, lie 100 km east wenshan city. conclusions: study, sudden emergence human case h7n9 documented urban area wenshan city. chicken important carrier h7n9 spreading guangxi wenshan. hygienic management live poultry market virological screening chicken transported across region reinforced limit spread h7n9 virus.',\n",
       " 'paper present performance two eukaryotic genomic ribosomal regions, its1 its2, describing fungal diversity aerosol sample amplicon-based high-throughput sequencing (hts). composting sites, biomethanization facilities, dairy farms, affected presence fungi, visited collect air samples. amplicon-based hts approach target enrichment relies amplification specific target particular primer sequencing. thus, result highly dependent quality amplification. reason, author paper used shotgun metagenomic approach compare outcome amplicon-based method. indeed, shotgun metagenomic rely amplification prior sequencing, gene sequenced without specific target. addition, culture method added analysis biomethanization dairy farm sample validate contribution fungal diversity aerosols. result obtained unequivocal towards its1 outperformance its2 term richness, taxonomic coverage. differential abundance analysis demonstrate taxon exclusively detected its2, vice-versa its1. however, shotgun metagenomic approach showed taxonomic profile resembling its1 its2. based results, neither barcodes evaluated perfect term distinguishing species. barcodes offer broader view fungal aerosol population. however, actual knowledge, author strongly recommend its1 universal fungal barcode quick general analysis diversity limited financial resource available, primarily due ability capture taxonomic profile similar obtained shotgun metagenomic. culture comparison amplicon-based sequencing showed complementarity approach describing abundant taxa.',\n",
       " 'acute aortic syndrome (aass) difficult diagnose emergencies. plasma soluble st2 (sst2), prognostic biomarker heart failure, proposed diagnostic biomarker aas outperforming d-dimer, current diagnostic standard. performed prospective diagnostic accuracy sst2 aas emergency department (ed). 2017â\\x80\\x932018, enrolled â\\x89¥1 red-flag symptom (chest/abdominal/back pain, syncope, perfusion deficit) clinical suspicion aas. sst2 detected presageâ® assay. adjudication based computed tomography angiography (cta) diagnostic outcome inclusive 30-day follow-up. 297 enrolled, 88 aass. median age 67 years. 162 cta, median sst2 level 41.7 ng/ml (iqr 29.4â\\x80\\x93103.2) aas 34.6 ng/ml (iqr 21.4â\\x80\\x9351.5) alternative diagnosis (p = 0.005). roc analysis, auc sst2 0.63, compared 0.82 d-dimer (p < 0.001). sensitivity specificity value sst2 associated different cutoff were: 95.5% 10.8% (â\\x89¥12 ng/ml), 84.1% 29.7% (â\\x89¥23.7 ng/ml), 35.2% 85.1% (â\\x89¥66.5 ng/ml). result similar full cohort. conclusion, european ed, plasma sst2 provided modest accuracy diagnosis aass.',\n",
       " 'uv light widely-employed, environmentally-sensitive bactericide mechanism action fully defined. protein major chromophore target damage due abundance, role protein inducing damage bound dna, effect dna-protein interaction le well characterized. e. coli (and gram-negative bacteria) cyclic amp receptor protein (crp/cap) regulates 500 genes. exposure isolated dimeric crp-camp uv modifies specific met, trp, tyr, pro side-chains, induces inter-protein tyr63-tyr41 cross-links, decrease dna binding via oxidation met114/pro110 residue close proximity crp dimer interface. uv exposure modifies dna-bound camp-crp, resulting dna cleavage specific g/c residue within sequence bound crp, g/c sites. oxidation increase crp dissociation dna. modification crp dimer interface, site-specific dna strand cleavage proposed occur via oxidation two specie met residue (met114 met189, respectively) reactive persulfoxides damage neighbouring amino acid dna bases. suggest modification crp, bound dna, contributes uv sensitivity.',\n",
       " 'recommended antiviral drug available prevention influenza neuraminidase inhibitor (nais). aim evaluate age-related clinical manifestation adverse event (aes) related nais. faers webmd downloaded. available nais selected analysis oseltamivir, peramivir, zanamivir, laninamivir. disproportionality analyzed proportional reporting ratio (prr), reporting odds ratio (ror), information component (ic) methods. total, 16729 aes 4598 575 aes 440 faers webmd, respectively, included analysis. faers, aes common among younger (<19 years) zanamivir, older (>65 years) peramivir. disproportionality analysis showed signal vomiting hallucination detected younger given oseltamivir, abnormal hepatic function, cardiac failure, shock, cardio-respiratory arrest detected older given peramivir. psychiatric disorder common younger older patients, gastrointestinal disorder common adult given oseltamivir webmd. adverse symptom related nais varied depended drug used age patient.',\n",
       " 'emergence spread antibiotic resistance call development non-chemical option bacterial infections. plasma medicine applies low-temperature plasma (ltp) physic address biomedical problem wound healing tumor suppression. ltp used surface disinfection. however, still much learned regarding effectiveness ltp bacteria suspension liquids, especially porous surfaces. investigated efficacy ltp treatment bacteria atmospheric-pressure plasma jet ltp treatment ability inhibit gram-positive (s. aureus) gram-negative (e. coli) bacteria solid porous surfaces. additionally, direct ltp plasma-activated medium effective bacteria suspended liquid culture. indicate reactive oxygen specie key mediator bactericidal effect ltp hydrogen peroxide necessary sufficient antibacterial effects. addition, suggests bacteria exposed ltp develop resistance ltp. finding suggest novel atmospheric-pressure plasma jet could used potential alternative antibiotic treatment vivo.',\n",
       " 'hookworm intestinal parasite cause major public problems, especially developing countries. differentiate egg different hookworm species, necessary use molecular methodologies, since egg morphologically similar. here, performed molecular identification single hookworm egg six brazilian states. 634 egg individually analyzed, 98.1% (622/634) represented necator americanus, surprisingly, 1.9% (12/634 egg patient) represented ancylostoma caninum. dna analysis a. caninum-positive stool sample revealed contamination animal feces. first report presence a. caninum egg human feces, may direct implication epidemiology hookworm caused species. suggests need special attention regarding prophylaxis, different reservoirs, described, may great relevance spread a. caninum.',\n",
       " 'vaccine elicitation broadly neutralizing antibody hiv-1 long-sought goal. reported amino-terminal eight residue hiv-1-fusion peptide (fp8) â\\x80\\x93 conjugated carrier protein, keyhole limpet hemocyanin (klh) â\\x80\\x93 capable inducing broadly neutralizing response hiv-1 animal models. however, klh multi-subunit particle derived natural source, manufacture clinical product remains challenge. report preclinical development recombinant tetanus toxoid heavy chain fragment (rtthc) linked fp8 (fp8-rtthc) suitable fp-conjugate vaccine immunogen. assessed 16 conjugates, made coupling 4 prevalent fp8 sequence 4 carrier proteins: aforementioned klh rtthc; h. influenzae protein (hid); cross-reactive material diphtheria toxin (crm197). 16 fp8-carrier conjugate could elicit hiv-1-neutralizing responses, rtthc conjugate induced higher fp-directed response overall. sulfo-siab linker yielded superior result sm(peg)2 linker combination carriers, conjugation ratio peptide carrier, choice adjuvant (adjuplex alum) significantly impact elicited fp-directed neutralizing response mice. overall, siab-linked fp8-rtthc appears vaccine candidate advancing clinical assessment.',\n",
       " 'repeating unit c. difficile toxin (raru, known crop [combined repetitive oligopeptides]) c-terminal region, elicit protective immunity c. difficile consideration possible vaccine pathogen. however, expression recombinant raru e. coli standard vaccine production process low. transcriptome proteome analysis showed restricted dissolved oxygen (do) number differentially expressed gene (degs) 2.5-times lower expressed unrestricted oxygen. additionally, 7.4-times smaller number ribosome formation gene (needed translation) down-regulated compared unrestricted do. higher raru expression restricted associated up-regulation 24 heat shock chaperone involved protein folding up-regulation global regulator rna chaperone hfq. cellular stress response leading down-regulation transcription, translation, energy generating pathway unrestricted associated lower raru expression. investigation c. difficile dna sequence revealed presence cell wall binding profiles, based structural similarity prediction blastp, possibly interact cellular protein e. coli transcriptional repressor ular, ankyrins repeat proteins. restricted do, raru mrna 5-fold higher protein expression 27-fold higher compared unrestricted do. report show strategy improved production c. difficile vaccine candidate e. coli restricted growth. strategy could improve expression recombinant protein anaerobic origin cell wall binding profiles.',\n",
       " 'porphyromonas gulae major periodontal pathogen dogs, transmitted owners. major virulence factor p. gulae consists 41-kda filamentous appendage (fima) cell surface, classified three genotypes: a, b, c. thus far, inhibition periodontal dog remains difficult. present assessed inhibitory effect combination clindamycin interferon alpha (ifn-î±) formulation p. gulae periodontal disease. growth p. gulae significantly inhibited clindamycin; inhibition greater effect type c p. gulae type b isolates. contrast, ifn-î± formulation inhibited expression il-1î² cox-2 elicited type b isolates, elicited type c isolates. furthermore, periodontal recovery promoted administration clindamycin ifn-î± formulation dog undergoing periodontal treatment; moreover, combined reduced number fima genotype oral specimen treated dogs. result suggest combination clindamycin ifn-î± formulation inhibit p. gulae virulence thus may effective prevention periodontal induced p. gulae.',\n",
       " 'influenza-related severe pneumonia acute respiratory distress syndrome (ards) severe threat human health. objective ass effect systematic corticosteroid therapy pneumonia ards. pubmed, embase, web science scopus database searched july, 2019. nineteen study 6637 individual identified, fifteen study (6427 patients) included meta-analysis mortality. eighteen observational study randomized controlled trial (rct). meta-analysis result showed corticosteroid therapy associated significantly higher mortality (or 1.53, 95% ci [1.16, 2.01]) incidence nosocomial (or 3.15, 95% ci [1.54, 6.45]). subgroup analysis showed among unadjusted estimates, odds mortality higher receiving corticosteroid (or 1.98, 95% ci [1.23, 3.17]), however, among adjusted estimates, showed statistically significant difference corticosteroid group control group (or 1.31, 95% ci [0.95, 1.80]). current support routine use corticosteroid influenza severe pneumonia ards. rcts needed provide robust evidence.',\n",
       " 'background: malaria-endemic areas, human population frequently exposed immunomodulatory salivary component injected mosquito blood feeding. consequence pathogen-specific immune response well known. evaluated compared humoral response specific merozoite stage vaccine candidate plasmodium falciparum, child differentially exposed anopheles bite natural setting. methods: cross-sectional carried bouakã© (cã´te dâ\\x80\\x99ivoire) entomological blood sample child (0â\\x80\\x9314 years) collected two site similar malaria prevalence. antibody (igg, igg1, igg3) response pfama1 pfmsp1 evaluated elisa. univariate multivariate analysis performed ass relationship immune response p. falciparum antigen exposure anopheles bite total cohort site, separately. individual level exposure anopheles bite evaluated quantifying specific igg response anopheles gsg6-p1 salivary peptide, represents proxy anopheles exposure. results: anti-plasmodium humoral response different according level exposure children, highly exposed anopheles presenting significantly lower antibody response pfmsp1 total population (igg igg3) petessou village (igg, igg1, igg3). significant difference seen pfama1 antigen child differently exposed anopheles. dar-es-salam, neighbourhood high culex density reported, child presented low antibody level specific antigens, difference according exposure anopheles bite found. conclusion: finding may suggest immunomodulatory component anopheles saliva, addition factors, may participate modulation humoral response specific plasmodium merozoite stage antigens. epidemiological observation may form starting point additional work decipher role mosquito saliva modulation anti-plasmodium acquired immunity clinical protection combining field ex vivo immunological studies.',\n",
       " 'objectives: requirement prolonged mechanical ventilation (pmv) associated increased medical care demand expenses, high early long-term mortality, worse life quality. however, assessed prognostic factor associated 1-year mortality among pmv patients, le 21 day surgery. analyzed predictor 1-year mortality requiring pmv intensive care unit (icus) surgery. methods: multicenter, respective cohort study, 124 required pmv surgery icu five tertiary hospital beijing january 2007 june 2016 enrolled. primary outcome duration survival within 1 year. predictor 1-year mortality identified multivariable cox proportional hazard model. predictive effect provent score validated. results: 124 enrolled, cumulative 1-year mortality 74.2% (92/124). multivariable cox proportional hazard analysis, cancer diagnosis (hazard ratio [hr] 2.14, 95% confidence interval [ci] 1.37â\\x80\\x933.35; p < 0.01), tracheostomy (hr 2.01, 95% ci 1.22â\\x80\\x933.30; p < 0.01), enteral nutrition intolerance (hr 1.88, 95% ci 1.19â\\x80\\x932.97; p = 0.01), blood platelet count â\\x89¤150 ã\\x97 10(9)/l (hr 1.77, 95% ci 1.14â\\x80\\x932.75; p = 0.01), requirement vasopressor (hr 1.78, 95% ci 1.13â\\x80\\x932.80; p = 0.02), renal replacement therapy (hr 1.71, 95% ci 1.01â\\x80\\x932.91; p = 0.047) 21st mechanical ventilation (mv) associated shortened 1-year survival. conclusions: required pmv surgery, cancer diagnosis, tracheostomy, enteral nutrition intolerance, blood platelet count â\\x89¤150 ã\\x97 10(9)/l, vasopressor requirement, renal replacement therapy 21st mv associated shortened 1-year survival. prognosis pmv icu facilitate decision-making process physician patientsâ\\x80\\x99 family member schedule.',\n",
       " 'background: real-time bedside information regional ventilation perfusion mechanical ventilation (mv) may help elucidate physiological pathophysiological effect mv setting healthy injured lungs. aimed effect positive end-expiratory pressure (peep) tidal volume (v(t)) distribution regional ventilation perfusion electrical impedance tomography (eit) healthy injured lungs. methods: one-hit acute lung injury model established 6 piglet repeated lung lavage (injured group). four ventilated piglet served control group. randomized sequence possible combination three v(t) (7, 10, 15 ml/kg) four level peep (5, 8, 10, 12 cmh(2)o) performed animals. ventilation perfusion distribution computed eit within three regions-of-interest (rois): nondependent, middle, dependent. mixed design between-subjects factor (group: intervention control), two within-subjects factor (peep v(t)) used, three-way mixed analysis variance (anova). results: two-way interaction peep group, v(t) group, observed dependent roi (p = 0.035 0.012, respectively), indicating increase dependent roi ventilation greater higher peep v(t) injured group control group. two-way interaction peep v(t) observed perfusion distribution roi: nondependent (p = 0.030), middle (p = 0.006), dependent (p = 0.001); interaction observed injured control groups. conclusions: peep v(t) level associated greater pulmonary ventilation dependent lung region experimental lung injury, whereas affected pulmonary perfusion lung region control experimental lung injury groups.',\n",
       " 'background: several study assessed predictor weaning extubation outcome short-term mechanically ventilated patients, study predictor weaning prolonged mechanical ventilation. methods: retrospective, single-center, observational specialized national weaning center germany. patientsâ\\x80\\x99 medical record reviewed obtain demographics, comorbidities, respiratory indices, prospectively documented, standardized spontaneous breathing trial (sbt) upon admission weaning center. respiratory index assessed ventilatory ratio (vr) parameter derived calculated mechanical power (mp). predictor associated failure prolonged weaning failure sbt assessed binary logistic regression model. results: total 263 prolonged mechanically ventilated, tracheotomized patients, treated 5-year period analyzed. 3 week mechanical ventilation, unsuccessful weaning failed sbt frequently showed significantly increased value inspiratory positive airway pressure, driving pressure, vr, absolute mp, mp normalized predicted body weight dynamic lung-thorax compliance (ltc-mp). logistic regression analyses, variable independently correlated weaning failure female gender (adjusted odds ratio 0.532 [95% ci 0.291â\\x80\\x930.973]; p = 0.040), obesity (body mass index â\\x89¥ 30 kg/m(2)) (2.595 [1.210â\\x80\\x935.562]; p = 0.014), copd (3.209 [1.563â\\x80\\x936.589]; p = 0.002), ltc-mp (3.470 [1.067â\\x80\\x9311.284]; p = 0.039), p(a)co(2) mechanical ventilation (1.101 [95% ci 1.034â\\x80\\x931.173]; p = 0.003), failure sbt (4.702 [2.250â\\x80\\x939.825]; p < 0.001). addition, female gender (0.401 [0.216â\\x80\\x930.745]; p = 0.004), ltc-mp (3.017 [1.027â\\x80\\x938.862]; p = 0.046), p(a)co(2) mechanical ventilation (1.157 [1.083â\\x80\\x931.235]; p < 0.001) independent risk factor unsuccessful sbt. conclusions: present study, derived predictor weaning point crucial role workload imposed respiratory muscle spontaneous breathing. mechanical power normalized lung-thorax compliance independently correlated weaning outcome may identify high risk weaning failure.',\n",
       " 'objective: septic patients, multiple retrospective study association volume fluid administered first 24 h mortality, suggesting benefit fluid restrictive strategies. however, study directly estimate causal effect fluid-restrictive strategies, analysis properly adjust time-varying confounding indication. study, used causal inference technique estimate mortality outcome would imposing range arbitrary limit (â\\x80\\x9ccapsâ\\x80\\x9d) fluid volume administration first 24 h intensive care unit (icu) care. design: retrospective cohort setting: icu beth israel deaconess medical center, 2008â\\x80\\x932012 patients: thousand six hundred thirty-nine septic (defined sepsis-3 criteria) 18 year older, admitted icu emergency department (ed), received le 4 l fluid administered prior icu admission measurement main results: obtained medical information mart intensive care iii (mimic-iii). employed dynamic marginal structural model fit inverse probability weighting obtain confounding adjusted estimate mortality rate would observed fluid resuscitation volume cap 4 lâ\\x80\\x9312 l imposed population. 30-day mortality cohort 17%. estimated cap 6 10 l 24 h fluid volume would reduced 30-day mortality â\\x88\\x92 0.6 â\\x88\\x92 1.0%, greatest reduction 8 l (â\\x88\\x92 1.0% mortality, 95% ci [â\\x88\\x92 1.6%, â\\x88\\x92 0.3%]). conclusions: found 30-day mortality would likely decreased relative observed mortality current practice subject â\\x80\\x9ccapsâ\\x80\\x9d total volume fluid administered 6 10 l, greatest reduction mortality rate 8 l.',\n",
       " 'background: even though enterococci cause serious infection multiple sites, rare cause pneumonia. reported uremic vancomycin-resistant e. faecium (vre-fm) pneumonia, possibly related epileptic seizures. presentation: 57-year old man uremia hemodialysis admitted hospital complaint recurrent epileptic seizures, followed two-week history recurrent fever cough purulent sputum. chest ct demonstrated multiple exudation lungs. diagnosed community acquired pneumonia. despite antibiotic combination therapy, abnormal chest shadow aggravated. sputum blood culture initially negative, later blood culture grew vre-fm. suspected aspiration gastrointestinal content induced epilepsy likely mechanism. successfully treated four-week course linezolid according antibiotic susceptibility testing. conclusions: physician consider multi-drug resistant organism vre uremic pneumonia fails resolve broad-spectrum antibiotics, especially case aspiration induced epilepsy, immunocompromised conditions, repeated prolonged hospitalizations.',\n",
       " 'background: identifying immunogen induce hiv-1-specific immune response lengthy process benefit computational methods, predict t-cell epitope various hla types. methods: tested performance netmhcpan4.0 computational neural network re-identifying 93 t-cell epitope independently mapped whole proteome ifn-î³ elispot assay 6 hla class typed ugandan individual infected hiv-1 subtypes a1 d. provide benchmark compared prediction netmhcpan4.0 mhcflurry1.2.0 netctl1.2. results: netmhcpan4.0 performed best correctly predicting 88 93 experimentally mapped epitope set length 9-mer matched hla class alleles. receiver operator characteristic (roc) analysis gave area curve (auc) 0.928. setting netmhcpan4.0 predict 11-14mer length improve prediction (37â\\x80\\x9379 93 peptides) inverse correlation number prediction length set. late time point peptide significantly stronger binder early peptide (wilcoxon signed rank test: p = 0.0000005). mhcflurry1.2.0 similarly predicted 2 peptide netmhcpan4.0 predicted netctl1.2 predicted 14 93 experimental peptides. conclusion: netmhcpan4.0 class epitope prediction covered 95% epitope response identified six hiv-1 infected individuals, would reduced number experimental confirmatory test > 80%. algorithmic epitope prediction conjunction hla allele frequency information cost-effectively assist immunogen design minimizing experimental effort.',\n",
       " 'background: available antibiotic resistance sub-saharan africa limited despite increasing threat global public health. previous antibiotic resistance clinical feature healthcare-associated infection (hais) sierra leone, research needed inform public policies. aimed ass antibiotic resistance rate isolates urine sputum sample clinical feature hais. methodology: conducted cross-sectional adult inpatient aged â\\x89¥18 year connaught hospital, urban tertiary care hospital freetown february june 2018. results: course study, enrolled 164 patients. risk factor hais previous antibiotic use (93.3%), comorbidities (58.5%) age (â\\x89¥65 years) (23.9%). 164 samples, 89.6% urine. bacterial growth recorded 58.8% cultured specimens; type specimen independent predictor bacterial growth (p < 0.021). common isolates escherichia coli klebsiella pneumoniae; 29.2% 19.0% urine sample 18.8% 31.3% sputum samples, respectively. overall resistance rate 58% extended-spectrum beta-lactamase (esbl)-producing organisms, 13.4% carbapenem-resistant non-lactose fermenting gram-negative bacilli, 8.7% carbapenem-resistant acinetobacter baumannii (crab) 1.3% carbapenem-resistant enterobacteriaceae (cre). carbapenem-resistant p. aeruginosa (crpa) isolates staphylococcus aureus isolates methicillin-resistant s. aureus. conclusion: demonstrated high prevalence rate esbl-producing organism significant burden main tertiary hospital sierra leone. urgent action needed strengthen microbiological diagnostic infrastructure, initiate surveillance antibiotic resistance develop implement policy framework antibiotic stewardship.',\n",
       " 'background: respiratory tract (rti) young child leading cause morbidity hospitalization worldwide. study assessing performance bronchoalveolar lavage fluid (balf) versus oropharyngeal swab (ops) specimen microbiological finding child rti. primary purpose compare detection rate ops paired balf detecting key respiratory pathogen suspension microarray. methods: collected paired ops balf specimen 76 hospitalized child respiratory illness. sample tested simultaneously 8 respiratory virus 5 bacteria suspension microarray. results: 76 paired specimens, 62 (81.6%) least pathogen. balf ops identified respiratory pathogen infection 57 (75%) 49 (64.5%) patients, respectively (p > 0.05). etiology analysis revealed virus responsible 53.7% patients, whereas bacteria accounted 32.9% mycoplasma pneumoniae 13.4%. leading 5 pathogen identified respiratory syncytial virus, streptococcus pneumoniaee, haemophilus influenzae, mycoplasma pneumoniae adenovirus, accounted 74.2% etiological fraction. detection pathogen, overall detection rate balf (81%) marginally higher (69%) ops (p = 0.046). difference frequency distribution sensitivity pathogen detected two sampling method statistically significant. conclusions: study, balf ops similar microbiological yields. result indicated clinical value ops testing pediatric respiratory illness.',\n",
       " 'background: low cardiac output syndrome (lcos) important complication cardiac surgery. associated increased morbidity mortality. incidence lcos surgery high congenital heart (chd). therefore, determining risk factor lcos clinical significance management chd. aimed analyze risk factor lcos. methods: conducted retrospective analysis child chd underwent cardiac surgery shanghai childrenâ\\x80\\x99s medical center january 1, 2014, december 31, 2017. demographic characteristic baseline extracted resource center hospital, integrates clinical routine medical records, diagnoses, orders, surgeries, laboratory tests, imaging, nursing, subsystems. logistic regression performed analyze risk factor lcos. results: overall, 8660 infant chd included, 864 (9.98%) lcos surgery. multivariate regression analysis identified age (or 0.992, 95% ci: 0.988â\\x80\\x930.997, p = 0.001), tricuspid regurgitation (1.192, 1.072â\\x80\\x931.326, p = 0.001), risk adjustment congenital heart surgery-1 risk grade (1.166, 1.011â\\x80\\x931.345, p = 0.035), aortic shunt (left-to-right: 1.37, 1.005â\\x80\\x931.867, p = 0.046; bi-directional: 1.716, 1.138â\\x80\\x932.587, p = 0.01), atrial shunt (left-to-right: 1.407, 1.097â\\x80\\x931.805, p = 0.007; right-to-left: 3.168, 1.944â\\x80\\x935.163, p < 0.001; bi-directional: 1.87, 1.389â\\x80\\x932.519, p < 0.001), ventricular level shunt (left-to-right: 0.676, 0.486â\\x80\\x930.94, p = 0.02; bi-directional: 2.09, 1.611â\\x80\\x932.712, p < 0.001), residual shunt (3.489, 1.502â\\x80\\x938.105, p = 0.004), left ventricular outflow tract obstruction (3.934, 1.673â\\x80\\x939.254, p = 0.002), right ventricular outflow tract obstruction (3.638, 1.225â\\x80\\x9310.798, p = 0.02), circulating temperature (mild hypothermia: 1.526, 95% ci: 1.205â\\x80\\x931.934, p < 0.001; middle low temperature: 1.738, 1.236â\\x80\\x932.443, p = 0.001), duration cardiopulmonary bypass (1.009, 1.006â\\x80\\x931.012, p < 0.001), myocardial preservation histidine-tryptophan-ketoglutarate (1.677, 1.298â\\x80\\x932.167, p < 0.001), mitral insufficiency (1.714, 1.239â\\x80\\x932.37, p < 0.001) independent risk predictor lcos. conclusions: incidence postoperative lcos chd child remains high. circulation temperature, myocardial preservation histidine-tryptophan-ketoglutarate, usage residual shunt surgery independent risk predictor lcos.',\n",
       " 'non-structural protein 1 (ns1) influenza multifunctional protein play important role replication virulence. study, acetylation modification identified k108 residue ns1 protein h1n1 influenza virus. explore function k108 acetylation modification ns1 protein, deacetylation-mimic mutation (k108r) constant acetylation-mimic mutation (k108q) introduced ns1 protein background a/wsn/1933 h1n1 (wsn), resulting two mutant virus (wsn-ns1-108r wsn-ns1-108q). vitro mouse study showed deacetylation-mimic mutation k108r ns1 protein attenuated replication virulence wsn-ns1-108r, constant acetylation-mimic mutant wsn-ns1-108q showed similar replication pathogenicity wild-type wsn (wsn-wt). result indicated acetylation k108 ns1 protein important role replication virulence influenza virus. explore potential mechanism, type interferon (ifn-i) antagonistic activity three ns1 protein (ns1-108q, ns1-108r, ns1-wt) compared cells, showed k108r mutation significantly attenuated ifn-î² antagonistic activity ns1 protein compared ns1-wt ns1-108q. ns1-wt ns1-108q inhibited ifn-î² response activated rig-i card domain, mavs, tbk1, irf3 efficiently ns1-108r protein cells. taken together, result indicated acetylation ns1 k108 important ifn antagonistic activity ns1 protein virulence influenza virus.',\n",
       " 'million exposed human immunodeficiency type 1 (hiv-1) every year, acquire virus, suggesting potential role host genetics moderation hiv-1 acquisition. here, analyzed summary statistic largest genome-wide association hiv-1 acquisition to-date, consisting 6,334 infected 7,247 population controls, advance understanding genetic mechanism implicated trait. found hiv-1 acquisition polygenic heritable, snp heritability estimate explaining 28â\\x80\\x9342% variance trait population level. genetic correlation alongside uk biobank revealed association smoking, prospective memory socioeconomic traits. gene-level enrichment analysis identified ef-hand calcium binding domain 14 novel susceptibility gene hivâ\\x80\\x931 acquisition. observed susceptibility variant hiv-1 acquisition significantly enriched gene expressed t-cells, striatal hippocampal neurons. finally, tested polygenic risk score hiv-1 acquisition influence blood level 35 inflammatory marker 406 hiv-1-negative individuals. found higher genetic risk hiv-1 acquisition associated lower level c-c motif chemokine ligand 17. finding corroborate complex model hiv-1 acquisition, whereby susceptibility partly heritable moderated specific behavioral, cellular immunological parameters.',\n",
       " 'absence correlate(s) protection human tuberculosis validated animal model disease, tool facilitate vaccine development must identified. present optimised ex vivo mycobacterial growth inhibition assay (mgia) ass ability host cell within lung inhibit mycobacterial growth, bacille calmetteâ\\x80\\x93guã©rin (bcg) mycobacterium tuberculosis (mtb) erdman. growth bcg reduced 0.39, 0.96 0.73 log(10) cfu following subcutaneous (s.c.) bcg, intranasal (i.n.) bcg, bcg s.c. + mucosal boost, respectively, versus naã¯ve mice. comparatively, 0.49 (s.c.), 0.60 (i.n.) 0.81 (s.c. + mucosal boost) log(10) reduction mtb cfu found. bcg growth inhibitor, 2-thiophenecarboxylic acid hydrazide (tch), used prevent quantification residual bcg i.n. immunisation allow accurate mtb quantification. tch, 0.58 log(10) reduction mtb cfu revealed i.n. group. combination existing methods, ex vivo lung mgia may represent important tool analysis vaccine efficacy immune mechanism associated vaccination organ primarily affected mtb disease.',\n",
       " 'background: topical 0.12% chlorhexidine used widely prevent ventilator-associated pneumonia undergoing mechanical ventilation. however, approved mucosal application japan. aim investigate topical povidone iodine (i) inhibits bacterial growth (ii) disrupts balance oral microbiota. methods: randomized controlled clinical trial included 23 underwent mechanical ventilation intensive care unit. divided randomly two groups: intervention group (n = 16) control group (n = 7). received oral cleaning 3% hydrogen peroxide, followed irrigation tap water. intervention group received 10% povidone iodine applied topically oral cavity. concentration total bacteria oropharyngeal fluid determined before, immediately after, 1 h, 2 h, 3 h oral care rapid oral bacteria quantification system, based dielectrophoresis impedance measurements. number streptococci, methicillin-resistant staphylococcus aureus, streptococcus pneumoniae, pseudomonas aeruginosa, porphyromonas gingivalis, candida albicans before, immediately after, 1 h, 3 h oral care estimated based real-time polymerase chain reaction data. results: irrigation oral cavity, number bacteria decreased, increased 1 h oral care control group; however, intervention group, concentration bacteria significantly lower control group 1 hour (p = 0.009), 2 h (p = 0.001), 3 h (p = 0.001) oral care. growth bacterial specie tested inhibited intervention group 3 h oral care, suggesting povidone iodine disturb balance oral microbiota. conclusions: topical application povidone iodine cleaning irrigation oral cavity inhibited bacterial growth oropharyngeal fluid mechanical ventilation disrupting balance oral microbiota. trial registration: university hospital medical information network clinical trial registry (umin-ctr), umin000028307. registered 1 september 2017.',\n",
       " 'background: extreme persistent dysbiosis occurs among critically ill patients, regardless heterogeneity disease. dysbiosis critically ill may make prone hospital-acquired infections, sepsis, multi-organ failure (mof), energy homeostasis disturbance, muscle wasting, cachexia. modulation gut microbiota synbiotics considered potential muscle wasting macronutrient homeostasis disturbances. methods: prospective, single-center, double-blind, parallel randomized controlled trial aim evaluate effect synbiotic supplementation energy macronutrient homeostasis muscle wasting critically ill patients. total 40 hemodynamically stable, adult, critically ill receive enteral nutrition via nasogasteric tube (ngt) 24â\\x80\\x9348 h admission critical care included study. eligible randomly assigned receive lactocare (zisttakhmir) capsule 500 mg every 12 h placebo capsule, contains sterile maize starch similar synbiotic capsule 14 days. synbiotic placebo capsule given nasogastric tube, separately gavage, feeding. discussion: gut microbiota modulation synbiotics proposed improve clinical prognosis reduce infectious complications, ventilator dependency, length icu stay improving energy macronutrient homeostasis reducing muscle protein catabolism. trial registration: iranian registry clinical trials, irct20190227042857n1. registered 17 march 2019.',\n",
       " 'plo medicine editor discus prospect development coming decade.',\n",
       " 'selective decontamination digestive tract (sdd) prevention measure intensive care unit (icu) proposed 30 year ago, currently considered standard care netherlands, used sporadically icu countries. narrative review, first describe rationale individual component sdd review evidence base patient-centered outcomes, distinguish icu low prevalence antibiotic resistance icu moderateâ\\x80\\x93high prevalence resistance. setting low prevalence antibiotic resistance, sdd associated improved outcome three cluster-randomized studies. benefit confirmed international cluster-randomized setting moderate-to-high prevalence antibiotic resistance. evidence sdd increase antibiotic resistance. end future direction research. electronic supplementary material: online version article (10.1007/s00134-019-05883-9) contains supplementary material, available authorized users.',\n",
       " 'concerted evolution often observed multigene family cea gene family. result, sequence similarity paralogous gene significantly higher expected evolutionary distance. gene conversion, â\\x80\\x9ccopy pasteâ\\x80\\x9d dna repair mechanism transfer sequence gene another homologous recombination driver concerted evolution. nevertheless, gene family member escape concerted evolution acquire sufficient sequence difference orthologous gene assigned descendant species. reason gene family member escape others captured concerted evolution poorly understood. analyzing entire cea gene family cattle (bos taurus) identified member (ceacam32) created gene duplication cooption unique transmembrane domain exon recent ancestor ruminants. ceacam32 show unique, testis-specific expression pattern. phylogenetic analysis indicated ceacam32 involved concerted evolution ceacam1 paralogs ruminants. however, analysis gene conversion event revealed ceacam32 subject gene conversion remarkably, event found leader exon intron sequence exon coding ig-like domains. finding suggest natural selection hinders gene conversion affecting protein sequence mature protein thereby support escape ceacam32 concerted evolution.',\n",
       " 'renin angiotensin system (ras) endocrine system widely known physiological role electrolyte homeostasis, body fluid volume regulation cardiovascular control peripheral circulation. however, brain ra independent form ra expressed locally brain, known involved brain function disorders. strong evidence major involvement excessive brain angiotensin converting enzyme (ace)/angiotensin ii (ang ii)/angiotensin type-1 receptor (at-1r) axis increased activation oxidative stress, apoptosis neuroinflammation causing neurodegeneration several brain disorders. numerous study demonstrated strong neuroprotective effect blocking at1r brain disorders. additionally, angiotensin converting enzyme 2 (ace2)/angiotensin (1â\\x80\\x937)/mas receptor (masr), another axis brain ra counteracts damaging effect ace/ang ii/at1r axis neuron brain. thus, angiotensin ii receptor blocker (arbs) activation ace2/angiotensin (1â\\x80\\x937)/masr axis may serve exciting novel neuroprotection several neurodegenerative diseases. review article, discus expression ra brain highlight altered ra level may cause neurodegeneration. understanding pathophysiology ra link neurodegeneration enormous potential identify potentially effective pharmacological tool treat neurodegenerative disease brain.',\n",
       " 'background: hospice worker required regularly use emotional regulation strategy attempt encourage sustain terminally ill families. daily emotional regulation reaction constantly watching suffering may intensified among hospice professional high level compassion fatigue. main object examine relationship daily exposition seeing suffering daily emotional work, ass whether compassion fatigue (secondary traumatic stress burnout) buffer relationship. methods: used diary research design collecting daily fluctuation seeing suffering emotional work display. participant filled general survey daily survey period eight consecutive workdays. total 39 hospice professional two italian hospice participated study. results: multilevel analysis demonstrated daily fluctuation seeing suffering positively related daily emotional work display controlling daily death patients. moreover, considering previous level compassion fatigue, buffering effect high burnout seeing suffering - daily emotional work display relationship found. conclusions: central finding fluctuation daily witness suffering positively related daily use positive emotional regulations. further, result burnout buffer relationship hospice professional high burnout use emotional display day recurrently witness suffering.',\n",
       " 'background: salmonella enterica serovar typhi (s. typhi) highly invasive bacterium infects human intestinal mucosa cause ~ 11.9â\\x80\\x9320.6 million infection ~ 130,000â\\x80\\x93223,000 death annually worldwide. oral typhoid vaccine ty21a confers moderate level long-lived protection (5â\\x80\\x937 years) field. improved vaccine enteric pathogen needed development hindered lack immunological correlate protection especially site infection. tissue resident memory (t(rm)) cell provide immediate adaptive effector immune responsiveness site. however, mechanism(s) s. typhi induces t(rm) intestinal mucosa unknown. here, focus induction s. typhi-specific cd4+t(rm) subset ty21a human terminal ileum lamina propria epithelial compartments. methods: terminal ileum biopsy obtained consenting volunteer undergoing routine colonoscopy either immunized orally 4 dos ty21a not. isolated lamina propria mononuclear cell (lpmc) intraepithelial lymphocyte (iel) cd4+t(rm) immune response determined either s. typhi-infected non-infected autologous ebv-b cell line stimulator cells. t-cmi assessed production 4 cytokine [interferon (ifn)î³, interleukin (il)-2, il-17a tumor necrosis factor (tnf)î±] 36 volunteer (18 vaccinee 18 control volunteers). results: although frequency lpmc cd103+ cd4+t(rm) significant decreased, cd103+ cd103â\\x88\\x92 cd4+t(rm) subset spontaneously produced significantly higher level cytokine (ifnî³ il-17a) following ty21a-immunization. importantly, observed significant increase s. typhi-specific lpmc cd103+ cd4+t(rm) (ifnî³ il-17a) cd103â\\x88\\x92 cd4+t(rm) (il-2 il-17a) response following ty21a-immunization. further, difference s. typhi-specific response two cd4+t(rm) subset observed following multifunctional analysis. addition, determined effect ty21a-immunization iel observed significant change frequency iel cd103+ (decrease) cd103â\\x88\\x92 cd4+t(rm) (increase) following immunization. finally, observed iel cd103â\\x88\\x92 cd4+t(rm), cd103+ cd4+t(rm), produced increased cytokine (ifnî³, tnfî± il-17a) s. typhi-specific stimulation following ty21a-immunization. conclusions: oral ty21a-immunization elicits distinct compartment specific immune response cd4+t(rm) (cd103+ cd103â\\x88\\x92) subsets. provides novel insight generation local vaccine-specific responses. trial registration approved institutional review board registered clinicaltrials.gov (identifier nct03970304, registered 29 may 2019â\\x80\\x94retrospectively registered, http://www.clinicaltrials.gov/nct03970304)',\n",
       " '',\n",
       " 'tissue-resident memory cell (t(rm) cells) critical cellular immunity respiratory pathogen reside airway interstitium. present study, found airway environment drove transcriptional epigenetic change specifically regulated cytolytic function airway t(rm) cell promoted apoptosis due amino acid starvation activation integrated stress response. comparison airway t(rm) cell splenic effector-memory cell transferred airway indicated environment necessary activate pathways, induce t(rm) cell lineage reprogramming. importantly, activation integrated stress response reversed airway t(rm) cell placed nutrient-rich environment. defined genetic program distinct lung t(rm) cell population local environmental cue altered airway t(rm) cell limit cytolytic function promote cell death, ultimately lead fewer t(rm) cell lung.',\n",
       " 'angiotensin-converting enzyme 2 (ace2) critically involved cardiovascular physiology pathology, currently clinically evaluated treat acute lung failure. b38-cap, carboxypeptidase derived paenibacillus sp. b38, ace2-like enzyme decrease angiotensin ii level mice. protein 3d structure analysis, b38-cap homolog share structural similarity mammalian ace2 low sequence identity. vitro, recombinant b38-cap protein catalyzed conversion angiotensin ii angiotensin 1â\\x80\\x937, well known ace2 target peptides. b38-cap suppressed angiotensin ii-induced hypertension, cardiac hypertrophy, fibrosis mice. moreover, b38-cap inhibited pressure overload-induced pathological hypertrophy, myocardial fibrosis, cardiac dysfunction mice. identify bacterial b38-cap ace2-like carboxypeptidase, indicating evolution shaped bacterial carboxypeptidase human ace2-like enzyme. bacterial engineering could utilized design improved protein drug hypertension heart failure.',\n",
       " 'peripheral arterial (pad) develops due narrowing blockage artery supplying blood lower limbs. surgical endovascular intervention main treatment advanced pad alternative adjunctive medical therapy needed. currently main preclinical experimental model employed pad research based induction acute hind limb ischemia (hli) 1-stage procedure. since concern regarding ability translate finding animal model patients, aimed develop novel clinically relevant animal model pad. hli induced male apolipoprotein e (apoe(â\\x88\\x92/â\\x88\\x92)) deficient mouse 2-stage procedure initial gradual femoral artery occlusion ameroid constrictor 14 day subsequent excision femoral artery. 2-stage hli model compared classical 1-stage hli model sham controls. ischemia severity assessed laser doppler perfusion imaging (ldpi). ambulatory ability assessed open field test, treadmill test established scoring scales. molecular marker angiogenesis shear stress assessed within gastrocnemius muscle tissue sample quantitative polymerase chain reaction. hli severe mouse receiving 2-stage compared 1-stage ischemia induction procedure assessed ldpi (p = 0.014), reflected higher ischemic score (p = 0.004) lower average distance travelled treadmill test (p = 0.045). mouse undergoing 2-stage hli lower expression angiogenesis marker (vascular endothelial growth factor, p = 0.004; vascular endothelial growth factor- receptor 2, p = 0.008) shear stress response mechano-transducer transient receptor potential vanilloid 4 (p = 0.041) within gastrocnemius muscle samples, compared animal 1-stage hli procedure. mouse subjected 2-stage hli receiving exercise program showed significantly greater improvement ambulatory ability treadmill test sedentary control group. describes novel model hli lead severe sustained ischemia conventionally used model. exercise therapy, established efficacy pad patients, effective model. model maybe useful evaluation potential novel pad therapies.',\n",
       " 'nigeria highest number aids-related death world. study, characterised hiv-1 molecular epidemiology analysing 1442 hiv-1 pol sequence collected 1999â\\x80\\x932014 four geopolitical zone nigeria state-of-the-art maximum-likelihood bayesian phylogenetic analyses. main circulating form circulating recombinant form (crf) 02_ag (44% analysed sequences), crf43_02g (16%), subtype g (8%). twenty-three percent sequence represented unique recombinant form (urfs), whereof 37 (11%) could grouped seven potentially novel crfs. bayesian phylodynamic analysis suggested five major nigerian hiv-1 sub-epidemics introduced 1960s 1970s, close nigerian civil war. analysis indicated number effective infection decreased nigeria introduction free antiretroviral 2006. finally, bayesian phylogeographic analysis suggested gravity-like dynamic lineage first emerge expand within urban center abuja lagos, migrating towards smaller rural areas. provides novel insight nigerian hiv-1 epidemic may implication future hiv-1 prevention strategy nigeria severely affected countries.',\n",
       " 'critical global need exists zika vaccine capable mitigating effect future zika epidemics. evaluated antibody response efficacy aluminum hydroxide adjuvanted purified inactivated zika vaccine (pizv) challenge zika (zikv) strain prvabc59. indian rhesus macaque received two dos pizv varying concentration ranging 0.016 âµg â\\x88\\x92 10 âµg subsequently challenged zikv six week year following second immunization. pizv induced dose-dependent immune response boosted second immunization. complete protection zikv achieved higher pizv dos 0.4 âµg, 2 âµg, 10 âµg 6 week 10 ug pizv 1 year following vaccination. partial protection achieved lower pizv dos 0.016 âµg 0.08 âµg. based data, neutralizing antibody response 3.02 log(10) ec50 determined correlate protection macaques. pizv elicited dose-dependent neutralizing antibody response protective least 1 year following vaccination.',\n",
       " 'respiratory distress syndrome (rds) commonest diagnosis premature birth. aimed audit clinical practice introduction national guideline wale rds management. anonymised, prospective infant born <34 week gestation cared participating neonatal unit wale collected two six-month time period 2015 2018. national guideline introduced 2016 wale neonatal network. collection included area antenatal management, delivery room stabilisation, invasive non-invasive respiratory support, surfactant element supportive care. univariate multivariate method used compare two epochs. comparing care introduction national guideline, area significant improvement include use targeted tidal volume ventilation, use caffeine therapy, oxygen therapy post-surfactant increasing early use parenteral nutrition. area poorer management included level positive end expiratory pressure timing introduction enteral feeds. little variation seen level two three units, although gestational age significant independent variable several practices, delayed cord clamping, stabilisation intubation, early enteral feeding caffeine administration. national guideline management rds wale significantly improved practice several areas. however, despite volume high-quality evidence robust guidance, remains significant variation element best practice rds management. work focus education training, especially element requiring cross-departmental work.',\n",
       " 'conducted systematic review meta-analysis ass clinical efficacy high-flow nasal cannula (hfnc) therapy apneic oxygenation critically ill require endotracheal intubation intensive care unit (icu). systematic review meta-analysis included six randomized controlled trial prospective identified pubmed, embase, cochrane library, web science august 18, 2019. meta-analysis 956 participants, hfnc noninferior standard care endotracheal intubation regarding incidence severe hypoxemia, mean lowest oxygen saturation, in-hospital mortality. hfnc significantly shortened icu stay mean 1.8 days. linear meta-regression interaction analysis, risk ratio severe hypoxemia decreased increasing baseline partial oxygen pressure (pao(2)) fraction inspired oxygen (fio(2)) ratio. subgroup analysis, hfnc significantly reduced incidence severe hypoxemia endotracheal intubation mild hypoxemia (pao(2)/fio(2)> 200 mmhg; risk difference, â\\x88\\x920.06; 95% confidence interval, â\\x88\\x920.12 â\\x88\\x920.01; number needed treat = 16.7). conclusion, hfnc noninferior standard care oxygen delivery endotracheal intubation associated significantly shorter icu stay. beneficial effect hfnc reducing incidence severe hypoxemia observed mild hypoxemia.',\n",
       " 'background: mosquito-borne infection recent years, become public threat globally. review aimed provide overview ecological epidemiological profile mosquito-borne infection democratic republic congo (drc). methods: search literature conducted google scholar, pubmed website following keywords: â\\x80\\x9cdemocratic republic congoâ\\x80\\x9d, â\\x80\\x9czaireâ\\x80\\x9d, â\\x80\\x9cbelgian congoâ\\x80\\x9d either following: â\\x80\\x9cmosquito-borne virusâ\\x80\\x9d, â\\x80\\x9carbovirusâ\\x80\\x9d, â\\x80\\x9cyellow feverâ\\x80\\x9d, â\\x80\\x9cdengueâ\\x80\\x9d, â\\x80\\x9cchikungunyaâ\\x80\\x9d, â\\x80\\x9cwest nileâ\\x80\\x9d, â\\x80\\x9crift valley feverâ\\x80\\x9d, â\\x80\\x9coâ\\x80\\x99nyongâ\\x80\\x99nyongâ\\x80\\x9d, â\\x80\\x9czikaâ\\x80\\x9d, â\\x80\\x9cepidemiologyâ\\x80\\x9d, â\\x80\\x9cecologyâ\\x80\\x9d, â\\x80\\x9cmorbidityâ\\x80\\x9d, â\\x80\\x9cmortalityâ\\x80\\x9d. published article english french covering period 1912 october 2018 reviewed. results: total 37 article included review. finding indicate burden mosquito-borne infection drc increasing time space. north-western, north-eastern, western central region highest burden mosquito-borne infection compared south eastern highland regions. yellow fever, chikungunya, dengue, zika, rift valley fever, west nile oâ\\x80\\x99nyongâ\\x80\\x99nyong reported country. mosquito-borne virus found circulating human, wildlife domestic animals. yellow fever chikungunya outbreak frequently reported. aedes aegypti ae. simpsoni documented main vector mosquito-borne infections. heavy rains, human movements, forest encroachment deforestation identified driver mosquito-borne virus occurrence drc. conclusions: mosquito-borne infection becoming common serious public problem drc. current context climate change, urgent need improve understanding ecological epidemiology disease strengthen surveillance system prompt response epidemic drc.',\n",
       " 'background: effect alternative spontaneous breathing trial (sbt) technique extubation success clinically important outcome uncertain. systematic review meta-analysis performed clarify preferable sbt (t-piece pressure support ventilation [psv]). methods: searched pubmed, cochrane, embase database randomized controlled trial (rcts) inception 31st july 2019. included rcts involving adult (> 18 years) underwent least two different sbt methods. author reported primary outcome successful extubation rate clearly compared p versus t-piece clinically relevant secondary outcome (rate reintubation, icu hospital length stay, icu hospital mortality). result expressed odds ratio (or) mean difference (md) accompanying 95% confidence interval (ci). results: ten rcts 3165 included. result meta-analysis showed significant difference successful extubation rate t-piece group p group (odds ratio [or] = 0.91; 95% ci, 0.78â\\x80\\x931.07; p = 0.27; i(2) = 79%). addition, compared p group, t-piece group showed significant difference rate reintubation (odds ratio [or] = 0.99; 95% ci, 0.78â\\x80\\x931.26; p = 0.95; i(2) = 5%), icu mortality (odds ratio [or] = 1.22; 95% ci, 0.83â\\x80\\x931.80; p = 0.30; i(2) = 0%), hospital mortality (odds ratio [or] = 1.36; 95% ci, 0.99â\\x80\\x931.87; p = 0.06; i(2) = 19%), icu length stay (mean difference = â\\x88\\x92 0.10; 95% ci, â\\x88\\x92 0.59 0.39; p = 0.69; i(2) = 13%), hospital length stay (mean difference = â\\x88\\x92 0.82;95% ci, â\\x88\\x92 2.2 0.55; p = 0.24; i(2) = 0%). conclusions: t-piece psv sbts considered comparable predictive power successful extubation critically ill patients. analysis secondary outcome show significant difference rate reintubation, icu hospital length stay, icu hospital mortality two groups. randomized controlled study sbts still required.',\n",
       " 'belief that, individual patient, benefit prompt continued use antimicrobial outweighs potential harm significant barrier improved stewardship vital agents. antimicrobial stewardship may perceived utilitarian rationing, seeking preserve availability effective antimicrobial limiting development resistance manner could conflict immediate need. view account growing evidence antimicrobial-associated harm individual patients. review set evidence antimicrobial-associated harm balanced need prompt appropriate therapy infection. describes mechanism antimicrobial may harm including: mitochondrial toxicity; immune cell toxicity; adverse drug reactions; selection resistant organism within given patient; disruption microbiome. finally, article indicates harm antimicrobial may mitigated identifies area research development field.',\n",
       " 'background: corticosteroid widely used septic shock, influenza, ards, although previous study discourage use severe influenza patients. multicenter retrospective cohort conducted intensive care unit (icus) eight medical center across taiwan aim determine real-world status corticosteroid influenza-associated acute respiratory distress syndrome (ards) impact clinical outcomes. october 2015 march 2016, consecutive icu virology-proven influenza infection fulfilled ards received invasive mechanical ventilation enrolled. impact early corticosteroid (â\\x89¥ 200 mg hydrocortisone equivalent dose within 3 day icu admission, determined sensitivity analysis) hospital mortality (the primary outcome) assessed multivariable logistic regression analysis, confirmed propensity score-matched cohort. results: among 241 influenza-associated ards, 85 (35.3%) receiving early corticosteroid similar baseline characteristics, significantly higher hospital mortality rate without early corticosteroid [43.5% (37/85) vs. 19.2% (30/156), p < 0.001]. early corticosteroid independently associated increased hospital mortality overall [adjusted odds ratio (95% ci) = 5.02 (2.39â\\x80\\x9310.54), p < 0.001] subgroups. earlier higher dosing associated higher hospital mortality. early corticosteroid associated significantly increased odds subsequent bacteremia [adjusted odds ratio (95% ci) = 2.37 (1.01â\\x80\\x935.56)]. analysis propensity score-matched cohort showed consistent results. conclusions: early corticosteroid associated significantly increased hospital mortality adult influenza-associated ards. earlier higher dosing associated higher hospital mortality. clinician cautious corticosteroid group.',\n",
       " 'porcine circovirus type 2 (pcv2) considered primary pathogen porcine circovirus-associated (pcvad), result significant economic loss worldwide. clinically, pcv2 often cause coinfection bacterial pathogens, streptococcus suis (s. suis), especially highly prevalent s. suis serotype 2 (ss2). present determined continuous pcv2 piglet down-regulates tight junction protein (tj) zo-1 occludin lungs. swine tracheal epithelial cell (stec) used explore mechanism consequence disruption tj, vitro tracheal epithelial barrier model established. result pcv2 stec decrease expression level zo-1 occludin increase permeability tracheal epithelial barrier, resulting easier translocation ss2. moreover, western blot analysis indicates pcv2 activates jnk/mapk pathway. disruption tj setc increased permeability epithelial barrier induced pcv2 could alleviated inhibition jnk phosphorylation, indicates jnk/mapk pathway regulates expression zo-1 occludin pcv2 infection. allows u better understand mechanism pcv2 coinfection bacterial pathogen provides insight controlling occurrence pcvad.',\n",
       " 'objective: administration diuretic assist fluid management improve clinical outcome critically ill post-shock resolution. current guideline yet included standardization guidance diuretic-based de-resuscitation critically ill patients. aimed evaluate impact multi-disciplinary protocol diuresis-guided de-resuscitation critically ill. methods: pre-post single-center pilot within medical intensive care unit (icu) academic medical center. adult admitted medical icu receiving mechanical ventilation either (1) clinical sign volume overload via chest radiography physical exam (2) cumulative fluid balance â\\x89¥ 0 ml since hospital admission eligible inclusion. received diuresis per clinician discretion 2-year period (historical control) followed diuresis protocol 1 year (intervention). within intervention group matched 1:3 ratio historical cohort met inclusion exclusion criteria. results: total 364 included, 91 protocol group 273 receiving standard care. protocolized diuresis associated significant decrease 72-h post-shock cumulative fluid balance [median, iqr â\\x88\\x92 2257 (â\\x88\\x92 5676â\\x80\\x93920) ml v 265 (â\\x88\\x92 2283â\\x80\\x933025) ml; p < 0.0001]. in-hospital mortality intervention group lower compared historical group (5.5% v 16.1%; p = 0.008) higher icu-free day (p = 0.03). however, statistically significant difference found ventilator-free days, increased rate hypernatremia hypokalemia demonstrated. conclusions: showed protocol diuresis de-resuscitation significantly improve 72-h post-shock fluid balance potential benefit clinical outcomes.',\n",
       " 'staphylococcus aureus common cause infection humans. emergence virulent, antibiotic-resistant strain s. aureus significant public concern. virulence resistance factor s. aureus encoded mobile genetic elements, transduction bacteriophage represents main mechanism horizontal gene transfer. baseplate specialized structure tip bacteriophage tail play key role host recognition, cell wall penetration, dna ejection. used high-resolution cryo-electron microscopy determine structure s. aureus bacteriophage 80î± baseplate 3.75 ã resolution, allowing atomic model built major tail baseplate proteins, two tail fibers, receptor binding protein, part tape measure protein. structure provides structural basis understanding host recognition, cell wall penetration dna ejection virus infecting gram-positive bacteria. comparison phage demonstrates modular design baseplate proteins, adaptation host take place evolution staphylococci pathogens.',\n",
       " 'background: almost preventable neonatal death take place low- middle-income country affect poorest least access high quality services. cost care factor preventing access quality service universal coverage. nepal, majority expense related newborn care borne caregiver, regardless socioeconomic status. conducted ass pocket expenditure (oope) sick newborn care hospital nepal. methods: cross-sectional hospital care newborn conducted 11 hospital nepal explored oope incurred caregiver sick newborn care. collected caregiver sick newborn topic cost travel, accommodation, (drugs, diagnosis) documented sick newborn record form. results: collected 814 caregivers. cost caregiversâ\\x80\\x99 stay accounted 40% oope sick newborn care, followed cost travel, babyâ\\x80\\x99s stay treatment. overall oope ranged 13.6 226.1 u dollar (usd). median oope highest preterm complication ($33.2 usd; ci 14.0â\\x80\\x93226.1), followed hyperbilirubinemia ($31.9 usd; ci 14.0â\\x80\\x9360.7), respiratory distress syndrome ($26.9 usd; 15.3â\\x80\\x93121.5), neonatal sepsis ($ 25.8 usd; ci 13.6â\\x80\\x93139.8) hypoxic ischemic encephalopathy ($23.4 usd; ci 13.6â\\x80\\x9397.7). discussion practice: nepal, oope sick newborn care hospital varied neonatal morbidity duration stay. largest proportion oope accommodation travel. affordable accessible care substantially reduce oope sick newborn care hospitals.',\n",
       " 'sarcocystis neurona recognised important cause mortality southern sea otter (enhydra lutris nereis) outbreak april 2004 since detected many marine mammal specie northeast pacific ocean. risk s. neurona exposure sea otter associated consumption clam soft-sediment prey temporally associated runoff events. examined spatial distribution s. neurona exposure risk based serum antibody testing assessed risk factor exposure animal california, washington, british columbia alaska. significant spatial clustering seropositive animal observed california washington, compared british columbia alaska. adult male greatest risk exposure s. neurona, strong association terrestrial feature (wetlands, cropland, high human housing-unit density). california, habitat containing soft sediment exhibited greater risk hard substrate kelp beds. consuming diet rich clam associated increased exposure risk. finding suggest transmission pathway analogous described toxoplasma gondii, infectious stage traveling freshwater runoff concentrated particular location marine habitat features, ocean physical processes, invertebrate bioconcentration.',\n",
       " 'fungal disease seriously affect agricultural production food industry. crop protection usually achieved synthetic fungicides, therefore sustainable innovative technology increasingly required. atmospheric pressure low-temperature plasma novel suitable measure. report effect plasma phytopathogenic fungi causing quantitative qualitative loss product field postharvest. focus attention vitro direct inhibitory effect non-contact surface dielectric barrier discharge conidium germination botrytis cinerea, monilinia fructicola, aspergillus carbonarius alternaria alternata. minute required completely inactivate fungi artificial medium. morphological analysis spore scanning electron microscopy suggests main mechanism plasma etching due reactive oxygen specie uv radiation. spectroscopic analysis plasma generated humid air give hint rotational temperature gas play relevant role close room temperature. vivo experiment artificially inoculated cherry fruit demonstrated inactivation fungal spore direct inhibitory effect plasma extend shelf life. pre-treatment fruit inoculation improve resistance infection maybe activating defense response plant tissues.',\n",
       " 'background: hip osteoarthritis (hoa) common hip disorder major cause disability adult population, estimated prevalence end-stage total hip replacement. thus, diagnosis, prevention, early stage young adult crucial reduce incidence end-stage hoa. purpose determine whether (1) relationship among inflammatory status labrum synovium collected femoroacetabular impingement (fai) would exist; (2) investigate association among histopathological feature joint tissues, pre-operative symptom post-operative outcome arthroscopic surgery. methods: joint tissue 21 undergoing hip arthroscopy fai collected histological immunohistochemical feature correlated clinical parameters. results: synovial mononuclear cell infiltration observed 25% fai patients, inversely correlated hip disability osteoarthritis outcome score (hoos) pain function subscales absolute relative change total hoos. labral sample showed pattern degeneration 67% sample showed calcium deposits. total labral score associated increased cd68 positive cell synovium. presence labral calcifications, along chondral damage worsened hoos post-op symptom (adjusted r-square = 0.76 p = 0.0001). conclusions: reveals relationship histologic labral features, synovial inflammation, cartilage condition time fai. presence labral calcifications, along cartilage damage synovitis negatively affect post-operative outcome fai.',\n",
       " 'background: dysphagia serious complication treated halo-vest brace. however, cause dysphagia development halo-vest fixation yet clear. therefore investigated incidence dysphagia cervical alignment well clinical medical chart treated halo-vest brace. methods: retrospectively reviewed clinical medical chart 49 undergone halo-vest fixation. occipito (o)-c2 angle, c2-c6 angle, pharyngeal inlet angle assessed lateral plain x-ray cervical spine. impact parameter incidence severity dysphagia analyzed. results: thirteen (32%) suffered dysphagia halo-vest fixation, age length intensive care unit (icu) stay greater dysphagia group (p = 0.044 0.013, respectively) develop dysphagia. o-c2 angle smaller dysphagia group (p = 0.016). multivariate logistic analysis, body mass index, icu stay, o-c2 angle remained independent risk factor related incidence dysphagia. spearman rank correlation showed negative correlation icu stay food intake level scale (fils) (p = 0.026), positive correlation o-c2 angle fils (p = 0.008). conclusion: suggested o-c2 angle related incidence severity dysphagia due halo-vest fixation.',\n",
       " 'background: among case nosocomial pneumonia, staphylococcus aureus second prevalent pathogen (17.8%). europe, 29.9% isolates oxacillin-resistant. changing epidemiology methicillin-resistant staphylococcus aureus (mrsa) nosocomial infection decreasing susceptibility first-line antibiotic leave clinician therapeutic options. objective determine antimicrobial susceptibility, associated molecular mechanism resistance epidemiological relatedness mrsa strain isolated endotracheal tube (ett) intubated critically ill intensive care unit (icu) nosocomial pneumonia caused staphylococcus aureus. methods: antimicrobial susceptibility vancomycin, linezolid, ciprofloxacin, clindamycin, erythromycin, chloramphenicol, fusidic acid, gentamicin, quinupristin-dalfopristin, rifampicin, sulfamethoxazole/trimethoprim, tetracycline measured. resistance mechanism analyzed polymerase chain reaction sequencing. molecular epidemiology carried multi-locus sequence typing. results: s. aureus isolates resistant ciprofloxacin, erythromycin, gentamicin, tetracycline, clindamycin, fusidic acid. frequent mutation quinolone-resistant s. aureus strain s84l gyra gene, v511a gyrb gene, s144p grla gene, k401r/e grlb gene. strain resistant erythromycin carried ermc, erma, msra genes; ermc erma gene detected strain resistant clindamycin. aac(6â\\x80²)-aph(2â\\x80³) gene related gentamicin resistance, resistance tetracycline related tetk (efflux pump). fusb gene detected strain resistant fusidic acid. frequent sequence type st22, st8, st217, distributed four clonal complex (cc5, cc22, cc45, cc59). conclusions: high level resistance second-line antimicrobial threatens nosocomial respiratory infection due methicillin-resistant s. aureus decreased susceptibility linezolid vancomycin. wide genotypic diversity found reinforces central role icu control preventing nosocomial transmission.',\n",
       " \"use vaccine resulted remarkable improvement global health. saved several lives, reduced cost raised quality animal human lives. current traditional vaccine came empirically either vague completely knowledge modulate immune system. even face potential vaccine design advance, immune-related concern (as seen specific vulnerable populations, case emerging/re-emerging infectious disease, pathogen complex lifecycle antigenic variability, need personalized vaccinations, concern vaccines' immunological safety -specifically vaccine likelihood trigger non-antigen-specific response may cause autoimmunity vaccine allergy) raised. concern driven immunologist toward research better approach vaccine design consider challenges. currently, immunoinformatics paved way better understanding infectious pathogenesis, diagnosis, immune system response computational vaccinology. importance immunoinformatics infectious disease diverse term computational approach used, united common quality related hostâ\\x80\\x93pathogen relationship. bioinformatics method used assign function uncharacterized gene targeted candidate vaccine design better approach toward inclusion woman pregnant vaccine trial programs. essence review give insight need focus novel computational, experimental computation-driven experimental approach studying hostâ\\x80\\x93pathogen interaction thus making use vaccine development.\",\n",
       " 'objectives: review fill paucity information k. pneumoniae nosocomial pathogen providing pooled epidemiological risk factors, resistant trend profile resistant virulent gene organism asia. methods: exhaustive search conducted pubmed, web science, google scholar study addressing prevalence, risk factors, drug resistant-mediated gene and/or virulent factor k. pneumoniae asia. extracted meta-analysis analyzed comprehensive meta-analysis version 3. trend isolation rate resistance rate entered excel spread sheet result presented graphs. results: prevalence rate drug resistance k. pneumoniae were; amikacin (40.8%) [95% ci 31.9â\\x80\\x9350.4], aztreonam (73.3%) [95% ci 59.9â\\x80\\x9383.4], ceftazidime (75.7%) [95% ci 65.4â\\x80\\x9383.6], ciprofloxacin (59.8%) [95% ci 48.6â\\x80\\x9370.1], colistin (2.9%) [95% ci 1.8â\\x80\\x934.4], cefotaxime (79.2%) [95% ci 68.0â\\x80\\x9387.2], cefepime (72.6) [95% ci 57.7â\\x80\\x9383.8] imipenem (65.6%) [95% ci 30.8â\\x80\\x9389.0]. tem (39.5%) [95% ci 15.4â\\x80\\x9370.1], shv-11 (41.8%) [95% ci 16.2â\\x80\\x9372.6] kpc-2 (14.6%) [95% ci 6.0â\\x80\\x9331.4] resistance mediated gene observed study. virulent factor utilized k. pneumoniae are; hypermucoviscous phenotype mucoviscosity-related genes, gene biosynthesis lipopolysaccharide, iron uptake transport gene finally, adhesive genes. conclusion: concluded that, antimicrobial resistant k. pneumoniae clear present danger asia need strong surveillance curb menace. important public healthcare department monitor report change antimicrobial-resistant isolates.',\n",
       " 'purpose review: men sex men (msm) china experience elevated risk mental issue comparison general population china, contribute vulnerability hiv/sti risk comprise effectiveness hiv prevention efforts. conceptual framework understanding mental disparity minority stress theory, posit experience external prejudice event (i.e., distal stressors) internal stress process internalized homophobia concealment (i.e., proximal stressors) contribute sexual minoritiesâ\\x80\\x99 elevated risk psychological distress. deepen understanding mental among chinese msm explore potential utility minority stress theory population, paper synthesizes research evidence regarding prevalent mental issue well minority stress may linked psychological chinese msm. recent findings: result indicate chinese msm experience high prevalence several mental issue depression, anxiety, suicidal behaviors, alcohol dependence. summary: review reveals minority stress important determinant psychological distress among chinese msm, though evidence mixed regarding relationship proximal minority stress psychological health. nonetheless, lack mental service intervention focusing msm china. culturally relevant, competent, lgbt-affirmative mental intervention needed chinese msm. guide future intervention research, provide consideration reducing minority stress promoting psychological among chinese msm.',\n",
       " 'purpose: suggested that, recruiting lung region enlarging distribution volume cold indicator, increasing positive end-expiratory pressure (peep) may lead artefactual overestimation extravascular lung water (evlw) transpulmonary thermodilution (tptd). methods: 60 ards patients, measured evlw (picco2 device) peep level set reach plateau pressure 30 cmh(2)o (highpeep(start)) 15 45 min decreasing peep 5 cmh(2)o (lowpeep(15â\\x80²) lowpeep(45â\\x80²), respectively). then, increased peep back baseline level (highpeep(end)). highpeep(start) lowpeep(15â\\x80²), estimated degree lung derecruitment either measuring change compliance respiratory system (crs) whole population, measuring lung derecruited volume 30 patients. defined derecruitment one cr change measured derecruited volume larger median variable observed whole population. results: reducing peep highpeep(start) (14 â± 2 cmh(2)o) lowpeep(15â\\x80²) significantly decreased evlw 20 â± 4 18 â± 4 ml/kg, central venous pressure (cvp) 15 â± 4 12 â± 4 mmhg, arterial oxygen tension inspired oxygen fraction (pao(2)/fio(2)) ratio 184 â± 76 150 â± 69 mmhg lung volume 144 [68â\\x80\\x93420] ml. evlw decrease similar â\\x80\\x9clarge derecruitersâ\\x80\\x9d patients. peep re-increased highpeep(end), cvp, pao(2)/fio(2) evlw significantly re-increased. linear mixed effect model, evlw change significantly determined change peep cvp (p < 0.001 p = 0.03, respectively, n = 60). analysis performed estimating recruitment according lung volume change (n = 30), cvp remained significantly associated change evlw (p < 0.001). conclusions: ards patients, changing peep level induced parallel, small reversible change evlw. change due artefact tptd technique likely due peep-induced change cvp, backward pressure lung lymphatic drainage. trial registration id rcb: 2015-a01654-45. registered 23 october 2015',\n",
       " 'background: existing method preparing influenza vaccine pose greatest challenge highly pandemic avian influenza h7n9 outbreak poultry humans. exploring strategy manufacturing delivering safe effective h7n9 vaccine needed urgently. results: alternative approach develop influenza h7n9 oral vaccine based yeast display technology timely manner. hemagglutinin (ha) a/anhui/1/2013 (ah-h7n9) used model antigen characterized expression surface saccharomyces cerevisiae (s.cerevisiae) eby 100. mouse administrated orally s.cerevisiae eby100/pyd5-ha produced significant titer igg antibody well significant amount cytokine ifn-î³ il-4. importantly, s.cerevisiae eby100/pyd5-ha could provide effective immune protection homologous a/anhui/1/2013 (ah-h7n9) challenge. conclusions: finding suggest platform based yeast surface technology provides alternative approach prepare influenza h7n9 oral vaccine candidate significantly shorten preparedness period effective protection influenza pandemic.',\n",
       " 'vaccine based plasmodium falciparum apical membrane antigen 1 (ama1) failed due extensive polymorphism ama1. ass strain-specificity antibody response malaria ama1 vaccination, designed protein peptide microarrays representing hundred unique ama1 variants. following clinical malaria episodes, child short-lived, sequence-independent increase average whole-protein seroreactivity, well strain-specific response peptide representing diverse epitopes. vaccination resulted dramatically increased seroreactivity 263 ama1 whole-protein variants. high-density peptide analysis revealed vaccinated child increase seroreactivity four distinct epitope exceeded response natural infection. single amino acid change critical seroreactivity peptide region ama1 associated strain-specific vaccine efficacy. antibody measurement whole antigen may biased towards conserved, immunodominant epitopes. peptide microarrays may help identify immunogenic epitopes, define correlate vaccine protection, measure strain-specific vaccine-induced antibodies.',\n",
       " 'background: optimal timing renal replacement therapy (rrt) initiation debatable. many article field enrolled trial based acute kidney injury. safety watchful waiting strategy fully discussed, late rrt initiation criterion vary across studies. effect early rrt initiation aki population high plasma neutrophil gelatinase-associated lipocalin (ngal) examined yet. methods: accordance prisma guidelines, pubmed, embase, cochrane database systemically searched randomized controlled trial (rcts). trial conducted aki population excluded. characteristics, primary outcome (all-cause mortality), related secondary outcome [mechanical ventilation (mv) days, length hospital stay, rrt days, length icu stay] extracted. outcome compared early late rrt group estimating pooled odds ratio (or) binary outcome weighted mean difference continuous outcomes. prospective trial examined analyzed method. results: nine rcts 1938 included. early rrt provide survival benefit (pooled or, 0.88; 95% confidence interval [ci] 0.62â\\x80\\x931.27). however, early rrt group significantly fewer mv day (pooled mean difference, â\\x88\\x92 3.98 days; 95% ci â\\x88\\x92 7.81 â\\x88\\x92 0.15 days). subgroup analysis showed rcts enrolling surgical population (p = .001) aki population high plasma ngal (p = .031) favorable outcome regarding rrt day early initiation group. moreover, 6 9 rcts selected examining safety watchful waiting strategy, significant difference found primary secondary outcome early late rrt groups. conclusions: overall, early rrt initiation provide survival benefit, possible benefit fewer mv day detected. early rrt might provide benefit shorter mv rrt support surgical population aki high plasma ngal. depending conventional indication rrt initiation, watchful waiting strategy safe basis primary secondary outcomes.',\n",
       " 'release bilateral ureteral obstruction (buo), postobstructive diuresis impaired urine concentration mechanism associated reduced aquaporin 2 (aqp2) abundance inner medullary collecting duct (imcd). however, underlying molecular mechanism aqp2 reduction incompletely understood. elucidate mechanism responsible phenomenon, studied molecular change imcds isolated rat 4-h buo sham operation early onset aqp2 downregulation mass spectrometry-based proteomic analysis. two-hundred fifteen protein significant change abundances, 65% downregulated imcd 4-h buo rat compared sham rats. bioinformatic analysis revealed significantly changed protein associated functional gene ontology terms, â\\x80\\x9ccell-cell adhesion,â\\x80\\x9d â\\x80\\x9ccell-cell adherens junction,â\\x80\\x9d â\\x80\\x9cmitochondrial inner membrane,â\\x80\\x9d â\\x80\\x9cendoplasmic reticulum chaperone complex,â\\x80\\x9d kegg pathway glycolysis/gluconeogenesis. targeted liquid chromatography-tandem mass spectrometry immunoblot analysis confirmed change 19 protein representative predominant cluster, aqp2. electron microscopy demonstrated disrupted tight junctions, disorganized adherens junctions, swollen mitochondria, enlargement endoplasmic reticulum lumen, numerous autophagosomes/lysosomes imcd rat 4-h buo. aqp2 seven protein chosen representative significantly altered cluster significant increase immunofluorescence-based colocalization autophagosomes/lysosomes. immunogold electron microscopy confirmed colocalization aqp2 autophagosome marker microtubule-associated protein 1a/1b-light chain 3 lysosomal marker cathepsin imcd cell rat 4-h buo. conclude enhanced autophagic degradation aqp2 critical proteins, well endoplasmic reticulum stress imcd, initiated shortly buo.',\n",
       " 'background: hymenoptera venom allergy (hva) underestimated condition representing important cause morbidity mortality worldwide. preventing future allergic reaction already developed systemic reaction based correct management acute phase reaction followed correct diagnosis and, indicated, prescription adrenaline autoinjector vit. possible strategy optimize care process improve outcome implementation diagnostic therapeutic care pathways, known integrated care pathway clinical pathway (cpws). aim care pathway enhance quality care improving riskâ\\x80\\x90adjusted outcomes, promoting safety, increasing satisfaction, optimizing use resources. knowledge, currently italy well europe, cpws codified management hva patients. paper describes development clinical content care pathway management hva. methods: methodology applied based eight step build clinical content evidence-based care pathway suggested lodewijckx et al. results: three hundred seventeen different clinical activity extracted selected literature. expert panel involved evaluation, expressing judgment relevance delphi study. result, 126 clinical activity appraised valid feasible. final recommendation (126) translated 123 key interventions. six indicator produced clinical activities. conclusion: set 123 key intervention six process indicator found appropriate development standardization clinical content hymenoptera venom allergy care pathway.',\n",
       " '',\n",
       " 'background: intractable, mechanical hemolytic anemia (imha) rare catastrophic complication following mitral valve surgery. analyzed characteristic imha management reoperations mitral valve surgery. methods: collected medical record mitral valve requiring reoperation due imha. inclusion criteria: hemoglobin < 100 g/l; positive hemolysis test echocardiography results; exclusion hemolysis causes. results: 25 imha case included 10 (40%) early onset (1.3 (0.3,3.0) months) 15 (60%) late onset (120 (24,204) months) cases. early imha etiology included surgical defect (6, 60%), uncontrolled (3, 30%) bechetâ\\x80\\x99s (1, 10%). late imha etiology included degeneration (13, 87%), (1, 7%) trauma (1, 7%). mechanical valve (15, 88%) bio-valves (2, 12%); main valvular dysfunction paravalvular leak (16, 64%). imha manifestation included jaundice (18, 72%), dark urine (21, 84%), heart failure (16, 64%), acute kidney injury (11, 44%), hepatomegaly (15, 60%), splenomegaly (15, 60%) pancreatitis (1, 4%). laboratory result showed decreased hemoglobin (70 â± 14 g/l) increased bilirubin (72 â± 57 î¼mol/l), lactate dehydrogenase (2607 â± 2142 iu/l) creatinine (136 â± 101 î¼mol/l) levels. creatinine level negatively correlated hemoglobin level (b = -3.33, s.e. b = 1.31, exp(b) = 368.15, p = 0.018). preoperative medication included iron supplement (20, 80%), erythropoietin (16, 64%) beta-blocker (22, 88%). two died cardiac cause reoperation. 23 underwent reoperation long surgical time (aortic cross clamp 124 â± 50 min, cardiopulmonary bypass 182 â± 69 min) blood transfusion (red blood cell 6 (6, 8) units, plasma 600 (400,800) ml, platelet 1(0,2) units). postoperative complication included cardiac dysfunction (5, 22%), arrhythmia (10, 43%), sepsis (6, 26%), pulmonary (5, 22%), gastrointestinal bleeding (3, 13%), cerebral hemorrhage (2, 9%), chronic renal dysfunction (1, 4%) surgical hemorrhage (1, 4%). five (33%) died reoperation cardiac dysfunction (3, 60%), septic shock (1, 20%) self-discharge (1, 20%). conclusions: imha induces severe multi-organ dysfunction, contributing high mortality. perioperative management focus etiological treatment, organ protection, blood management.',\n",
       " 'porcine epidemic diarrhea (pedv) caused enormous economic loss swine industry worldwide recent years. puerarin (pr), major isoflavonoid isolated chinese herb gegen, posse many pharmacological activities, anti-inflammatory, anti-viral activities. conducted pedv-infected african green monkey kidney cell (vero) neonatal pig determine effect pr pedv elucidate underlying mechanism proteomic analyses. twenty-four piglet fed milk replacer randomly allocated three group (control, pedv, pedv + pr). 5-day period adaption, piglet (n = 8/group) pedv + pr orally administered pr (0.5 mg/kg body weight) day 5 9, whereas piglet two group received volume liquid milk replacer. 9, piglet orally administered either sterile saline pedv (yunnan province strain) 10(4.5) tcid(50) (50% tissue culture infectious dose) per pig. 12 trial, jugular vein blood intestinal sample collected. addition, vero cell assigned randomly three group (control, pedv, pedv + pr). cell pedv pedv + pr group infected pedv multiplicity 0.01, cell control group treated volume sterile saline. hour later, cell control pedv group cultured serum-free dmem, cell pedv + pr group supplemented pr. 36 h culture, cell harvested. pr attenuated reduction cell proliferation vitro growth performance pedv-infected piglets, inhibited pedv replication expression several cytokine (including il-8) vitro vivo. proteomic analysis identified abundance 29 protein ileum altered pedv restored control level pr. pathway analysis revealed pr restored expression several interferon-stimulated gene selectively upregulated expression guanylate-binding proteins. western blot analysis showed pr supplementation inhibited pedv-induced nf-îºb activation. collectively, result indicate pr could exert antiviral anti-inflammatory effect piglet infected pedv potential effective antiviral feed additive.',\n",
       " 'base j, î²-d-glucosyl-hydroxymethyluracil, modification thymine dna base involved rna polymerase (pol) ii transcription termination kinetoplastid protozoa. little understood regarding specific thymine residue targeted j-modification mechanism j regulated transcription termination. identify protein involved j-synthesis, expressed tagged version j-glucosyltransferase (jgt) leishmania tarentolae, identified four co-purified protein mass spectrometry: protein phosphatase (pp1), homolog wdr82, potential pp1 regulatory protein (pnuts) protein containing j-dna binding domain (named jbp3). gel shift study indicate jbp3 j-dna binding protein. reciprocal tagging, co-ip sucrose gradient analysis indicate pp1, jgt, jbp3, wdr82 pnuts form multimeric complex kinetoplastids, similar mammalian ptw/pp1 complex involved transcription termination via pp1 mediated dephosphorylation pol ii. rnai analysis pol ii termination rna-seq rt-pcr, demonstrate ablation pnuts, jbp3 wdr82 lead defect pol ii termination 3â\\x80\\x99-end polycistronic gene array trypanosoma brucei. mutant contain increased antisense rna level upstream transcription start sites, suggesting additional role complex regulating termination bi-directional transcription. addition, pnuts loss cause derepression silent variant surface glycoprotein gene involved host immune evasion. result suggest novel mechanistic link base j pol ii polycistronic transcription termination kinetoplastids.',\n",
       " '',\n",
       " 'introduction: safety critical care quality remain challenging issue icu. however, effect national quality improvement (qi) program remain china. methods: national icu qi program implemented controlled cohort 586 hospital 2016 2018. effect qi program critical care quality comprehensively investigated. main results: total 81,461,554 enrolled 586 hospitals, 1,587,724 admitted icu 3 years. 2018, significantly higher number icu bed (2016 vs. 2018: 10668 vs. 13,661, p = 0.0132) lower doctor-to-bed ratio (2016 vs. 2018: 0.64 (0.50, 0.83) vs. 0.60 (0.45, 0.75), p = 0.0016) nurse-to-bed ratio (2016 vs. 2018: 2.00 (1.64, 2.50) vs. 2.00 (1.50, 2.40), p = 0.031) 2016. continuous significant improvement ventilator-associated pneumonia (vap) incidence rate, microbiology detection rate antibiotic use deep vein thrombosis (dvt) prophylaxis rate associated implementation qi program (vap incidence rate (per 1000 ventilator-days), 2016 vs. 2017 vs. 2018: 11.06 (4.23, 22.70) vs. 10.20 (4.25, 23.94) vs. 8.05 (3.13, 17.37), p = 0.0002; microbiology detection rate antibiotic use (%), 2016 vs. 2017 vs. 2018: 83.91 (49.75, 97.87) vs. 84.14 (60.46, 97.24) vs. 90.00 (69.62, 100), p < 0.0001; dvt prophylaxis rate, 2016 vs. 2017 vs. 2018: 74.19 (33.47, 96.16) vs. 71.70 (38.05, 96.28) vs. 83.27 (47.36, 97.77), p = 0.0093). moreover, 6-h ssc bundle compliance rate 2018 significantly higher 2016 (6-h ssc bundle compliance rate, 2016 vs. 2018: 64.93 (33.55, 93.06) vs. 76.19 (46.88, 96.67)). significant change trend found icu mortality rate 2016 2018 (icu mortality rate (%), 2016 vs. 2017 vs. 2018: 8.49 (4.42, 14.82) vs. 8.95 (4.89, 15.70) vs. 9.05 (5.12, 15.80), p = 0.1075). conclusions: relationship medical human resource icu overexpansion mismatched past 3 years. implementation national qi program improved icu performance reduce icu mortality.',\n",
       " 'background: acute respiratory distress syndrome (ards) caused rapid-onset (within hours) acute inflammatory process lung tissue, life-threatening condition high mortality. ards date focused prevention iatrogenic damage lung rather initial inflammatory process. several preclinical study revealed beneficial effect iloprost control pulmonary inflammation, small number ards, iloprost resulted improved oxygenation. therefore, plan conduct multicenter trial evaluate effect iloprost ards. methods: therapeutic iloprost ards trial (thilo trial) multicenter, randomized, single blinded, clinical phase ii trial assessing efficacy inhaled iloprost prevention development progression ards critically ill patients. hundred fifty critically ill suffering acute ards treated either nebulized iloprost nacl 0.9% 5 days. blood sample drawn defined time point elucidate serum level iloprost inflammatory marker treatment. mechanical ventilation standardized. follow-up visit day 28 90 well 6 month enrollment, functional status according barthel index care-related questionnaire, frailty (vulnerable elder survey) evaluated. primary endpoint improvement oxygenation, defined ratio pao(2)/fio(2). secondary endpoint include 90-day all-cause mortality, sequential organ failure assessment score period 90, duration mechanical ventilation, length intensive care unit (icu) stay, ventilator-associated pneumonia, delirium, icu-acquired weakness, discharge localization. conducted three university ards center germany. discussion: result thilo trial highlight anti-inflammatory effect iloprost early inflammatory process ards, resulting improvement outcome parameter ards. trial registration: eudra-ct: 2016-003168-37. registered 12 april 2017. clinicaltrials.gov: nct03111212. registered 4 june 2017.',\n",
       " 'background: human psittacosis, caused chlamydia (c.) psittaci, likely underdiagnosed underreported, since test c. psittaci often included routine microbiological diagnostics. source tracing traditionally focus psittacine pet birds, animal specie gaining attention possible source human psittacosis. review aim provide overview suspected animal source human psittacosis case reported international literature. addition, animal specie strength evidence zoonotic transmission estimated. methods: systematic literature search conducted four database (pubmed, embase, scopus proquest). article included mention least human psittacosis possible animal source. investigator independently extracted included article estimated strength evidence zoonotic transmission, based self-developed scoring system taking account number human cases, epidemiological evidence laboratory test result human, animals, environment. results: eighty article included, provided information 136 different situation possible zoonotic transmission. maximum score zoonotic transmission highest turkeys, followed ducks, owls, category â\\x80\\x98other poultryâ\\x80\\x99. article reporting zoonotic transmission unspecified birds, psittaciformes columbiformes provided relatively low strength evidence. genotypical match human animal sample reported twenty-eight times, transmission chickens, turkeys, guinea fowl, peafowl, pigeons, ducks, geese, songbirds, parrot-like bird owls. conclusions: strong evidence exists zoonotic transmission turkeys, chicken ducks, addition traditionally reported parrot-like animal sources. based scoring system, evidence generally stronger poultry parrot-like birds. psittaciformes disregarded important source human psittacosis, still clinician public official include poultry bird specie parrot medical history source tracing.',\n",
       " 'background: pseudomonas aeruginosa infection serious threat intensive care unit (icus). aim confirmatory, randomized, multicenter, placebo-controlled, double-blind, phase 2/3 ass efficacy, immunogenicity, safety ic43 recombinant pseudomonas aeruginosa vaccine non-surgical icu patients. methods: eight hundred aged 18 80 year admitted icu expected need mechanical ventilation â\\x89¥ 48 h randomized 1:1 either ic43 100 î¼g saline placebo, given two vaccination 7 day apart. primary efficacy endpoint all-cause mortality 28 day first vaccination. immunogenicity safety evaluated. findings: all-cause mortality rate 28 29.2% v 27.7% ic43 placebo groups, respectively (p = .67). overall survival (kaplan-meier survival estimates, p = .46) proportion â\\x89¥ confirmed p. aeruginosa invasive respiratory tract differ significantly groups. geometric mean fold increase oprf/i titer 1.5 first vaccination, 20 28, second vaccination, 2.9 180. significantly placebo group (96.5%) â\\x89¥ adverse event (ae) versus ic43 100 î¼g group (93.1%) (p = .04). frequently reported severe aes ic43 placebo group respiratory failure (6.9% v 5.7%, respectively), septic shock (4.1% v 6.5%), cardiac arrest (4.3% v 5.7%), multiorgan failure (4.6% v 5.5%), sepsis (4.6% v 4.2%). related serious aes reported ic43 group. interpretation: ic43 100 î¼g vaccine well tolerated population medically ill, mechanically ventilated patients. vaccine achieved high immunogenicity provided clinical benefit placebo term overall mortality. trial registration: https://clinicaltrials.gov (nct01563263). registration sent clinicaltrials.gov march 14, 2012, posted clinicaltrials.gov march 26, 2012. first subject included trial march 22, 2012.',\n",
       " '',\n",
       " 'background: aim validate published consensus-based quality indicator set management traumatic brain injury (tbi) intensive care unit (icus) europe potential quality measurement improvement. methods: analysis based 2006 adult admitted 54 icu 2014 2018, enrolled center-tbi study. indicator score calculated percentage adherence structure process indicator event rate median score outcome indicators. feasibility quantified completeness variables. discriminability determined between-centre variation, estimated random effect regression model adjusted case-mix severity quantified median odds ratio (mor). statistical uncertainty outcome indicator determined median number event per centre, cut-off 10. results: total 26/42 indicator could calculated center-tbi database. quality indicator proved feasible obtain 70% completeness. sub-optimal adherence found quality indicators, ranging 26 93% 20 99% structure process indicators. significant (p < 0.001) between-centre variation found seven process five outcome indicator mors ranging 1.51 4.14. statistical uncertainty outcome indicator generally high; five seven le 10 event per centre. conclusions: overall, nine structures, five processes, none outcome indicator showed potential quality improvement purpose tbi icu. future research focus implementation effort continuous reevaluation quality indicators. trial registration: core registered clinicaltrials.gov, number nct02210221, registered august 06, 2014, resource identification portal (rrid: scr_015582).',\n",
       " 'background: microbial main cause increased morbidity mortality burn patients, especially infection caused multiple drug-resistant organism (mdro). purpose explore major microbial trend burn patients. methods: retrospective conducted burn ward intensive care units, burn admitted following event dust explosion. collected number variable severity burns, demographic clinical characteristics, laboratory data, therapeutic devices. results: total 1132 specimen collected 37 hospitalized burn mean tbsa 46.1%.the commonly isolated specie staphylococcus spp. (22.4%). highest rate antibiotic resistance observed carbapenemâ\\x80\\x93resistant a. baumannii (14.6%), followed methicillin-resistant s. aureus (11.3%). additional 10% tbsa, isolation mdro increased 2.58â\\x80\\x9317.57 time (p < 0.05); additional 10% third-degree burn severity, risk mdro significantly decreased 47% (95% ci, 0.38â\\x80\\x930.73, p < 0.001) cox model. conclusions: proportion overall microbial isolates increased increase tbsa duration time burns. extent tbsa important factor affecting mdro.',\n",
       " 'canine distemper (cdv) belongs morbillivirus genus paramyxoviridae family, cause threat domestic dog fur-animal industry. hemagglutinin protein major membrane protein vital molecular factor cdv tropism, known induce host produce neutralizing antibodies. current study, prepared two monoclonal antibodies, 1a5 2b8, h protein cdv-ps strain. series partially overlapping synthetic peptide covering hemagglutinin protein (amino acid 50â\\x80\\x93204) screened define linear epitope identified 1a5 2b8 mabs. (120)qktnffnpnrefdfr(134) (f8) (178)argdifppy(186) (f14-1) minimal linear epitope recognized 1a5 2b8 mabs, respectively. investigation revealed f8 conserved different cdv strains; however, f14-1 contains mutant residue 178, 179, 180. epitope f8 f14-1 localized surface hemagglutinin protein three-dimensional (3d) structure. cdv-infected dog serum recognize identified b-cell epitopes.',\n",
       " 'background: weaning mechanical ventilation remains critical decision intensive care unit. aimed evaluate accuracy thoracic fluid content (tfc) predictor weaning outcome. methods: observational cohort included 64 critically ill surgical eligible extubation. initiating spontaneous breathing trial, tfc measured electrical cardiometry technology. followed extubation divided successful weaning group failed weaning group. group compared according respiratory cardiovascular parameters. receiver operating characteristic (roc) curve constructed evaluate ability tfc predict weaning outcome. results: number successfully weaned 41/64 (64%). twenty (31%) impaired cardiac contractility, them, 13/20 (64%) successfully extubated. groups, successful weaning group failed weaning group, comparable baseline characteristics; however, tfc significantly higher failed weaning group compared successful weaning group. area roc curve (aucs) showed moderate predictive ability tfc predicting weaning failure (auc [95% confidence interval] 0.69 [0.57â\\x80\\x930.8], cutoff value > 50 kî©(â\\x88\\x921)), predictive ability tfc excellent subgroup ejection fraction < 40% (auc [95% confidence interval 0.93 [0.72â\\x80\\x931], cutoff value > 50 kî©(â\\x88\\x921)). conclusions: thoracic fluid content showed moderate ability predicting weaning outcome surgical critically ill patients. however, subgroup ejection fraction le 40%, tfc 50 kî©(â\\x88\\x921) excellent ability predict weaning failure.',\n",
       " 'background: little known prescription, frequency nature airway clearance therapy (act) child hospitalised lower respiratory tract infection (lrtis). objectives: describe characteristic outcome child hospitalised lrtis tertiary paediatric hospital south africa investigate role impact act children. method: retrospective folder review child hospitalised lrti january june 2015 conducted, extracting demographic characteristics, condition, act intervention outcomes. results: total 1208 individual case (median [iqr] age 7.6 (2.8â\\x80\\x9319.0) months), 1440 hospitalisations, included. majority child hospitalised primarily management bronchiolitis. comorbidities present 52.6% least hospitalisations. airway clearance therapy administered 5.9% (n = 85) admissions, commonly conventional (manual) act. transient oxyhaemoglobin desaturation reported six children, child developed lobar collapse hour post-treatment. adverse event reported. median (iqr) duration hospitalisation 2.3 (1.5â\\x80\\x935.0) days, overall mortality rate 0.7%. child hospitalised presumed nosocomial infection pneumonia longest length stay, likely receive act highest mortality rate. conclusion: airway clearance therapy infrequently used population commonly applied nosocomial lrti pneumonia. clinical implications: although act generally well tolerated, safety ascertained, oxygen saturation carefully monitored therapy.',\n",
       " 'background: public research organization interaction industry partner play crucial role public access medicines. development commercialization human papillomavirus (hpv) vaccine illustrate licensing practice public research organization contribute high price resulting product affect accessibility vulnerable populations. effort international community improve access medicine recognised issue promote public health-sensitive management research conducted public research organizations. paper explores: medical knowledge exchanged public private actors; role inventor scientist play process; view implementation public health-sensitive knowledge exchange strategies. methods: conducted systematic qualitative literature review medical knowledge exchange qualitative interview purposive sample public sector scientist working hpv vaccines. explored strategy knowledge exchanged across institutional boundaries, strategy negotiated, view scientist regarding public health-sensitive knowledge exchange. results: included 13 study systematic review conducted seven semi-structured interview high-ranking scientists. main avenue public-private medical knowledge exchange publications, formal transfer patented knowledge, problem-specific exchange service agreements, informal exchange collaborative research. scientist played crucial role process appeared sceptical public health-sensitive knowledge exchange strategies, believed deter corporate interest development medicine thus risk translation scientistsâ\\x80\\x99 research. conclusion: medical scientist public research institution play key role exchange knowledge generate concerned accessibility medicine resulting research. scepticism towards implementing public health-sensitive knowledge management strategy appears based biased understanding cost risk involved drug development perceived lack alternative private engagement. scientist could encouraged exchange knowledge public health-sensitive manner not-for-profit drug development mechanisms, education industry engagement, stronger institutional legal backing.',\n",
       " 'background: aimed explore feasibility applying respiratory â\\x80\\x9ccritical care-sub-critical care-rehabilitation integrated management modelâ\\x80\\x9d severe stroke-associated pneumonia evaluate effect. methods: january september 2018, 24 severe stroke-associated pneumonia, admitted respiratory intensive care unit respiratory critical care medicine department henan provincial peopleâ\\x80\\x99s hospital, randomly divided two groups: integrated management group control group. according admission criterion respiratory â\\x80\\x9ccritical care-sub-critical care-rehabilitation integrated modelâ\\x80\\x9d prescribed above-mentioned hospital, grouped. professional respiratory therapy team participated whole treatment. acute physiology chronic evaluation ii (apache ii) score, clinical pulmonary score (cpis) oxygenation index two group dynamically observed, average hospital stay, 28-day mortality satisfaction investigated. results: integrated management group control group similar (p > 0.05). treatment, main indicators, apache ii score, cpi score oxygenation index, significantly different integration group control group (p < 0.05). secondary indicators, average hospitalization day patient/family member satisfaction scores, significantly different integration group control group (p < 0.05). however, 28-day mortality wasnâ\\x80\\x99t significantly different (p > 0.05). conclusions: severe stroke-associated pneumonia, feasible implement respiratory â\\x80\\x9ccritical care-sub-critical care-rehabilitation integrated management modelâ\\x80\\x9d, could significantly improve effect, shorten average hospitalization day improve patient/family satisfaction.',\n",
       " 'collaborative cross (cc) panel mouse-inbred line derived eight founder strain (nod/shiltj, nzo/hiltj, a/j, c57bl/6j, 129s1/svimj, cast/eij, pwk/phj, wsb/eij). here, performed comprehensive comparative phenotyping screening identify phenotypic difference similarity eight founder strains. total, 300 parameter allergy, behavior, cardiovascular, clinical blood chemistry, dysmorphology, bone cartilage, energy metabolism, eye vision, immunology, lung function, neurology, nociception, pathology analyzed; trait sixteen female sixteen males. identified 270 parameter significantly different strains. highlight value founder cc strain phenotype-genotype association many genetic trait highly relevant human diseases. described publicly available mouse phenome database analysis downloads. electronic supplementary material: online version article (10.1007/s00335-020-09827-3) contains supplementary material, available authorized users.',\n",
       " 'background: high-frequency oscillatory ventilation (hfov) may theoretically provide lung protective ventilation. negative clinical result may due inadequate mean airway pressure (mpaw) setting hfov. objective evaluate air distribution, ventilatory hemodynamic effect individual mpaw titration hfov ards animal based oxygenation electrical impedance tomography (eit). methods: ards introduced repeated bronchoalveolar lavage followed injurious mechanical ventilation ten healthy male pig (51.2 â± 1.9 kg). setting hfov 9 hz (respiratory frequency), 33% (inspiratory time) 70 cmh(2)o (â\\x88\\x86pressure). lung recruitment, mpaw reduced step 3 cmh(2)o every 6 min. hemodynamics blood gas obtained step. regional ventilation distribution determined eit. results: pao(2)/fio(2) decreased significantly mpaw decremental phase (p < 0.001). lung overdistended region decreased, recruitable region increased mpaw decreased. optimal mpaw respect pao(2)/fio(2) 21 (18.0â\\x80\\x9321.0) cmh(2)o, comparable eit-based center ventilation (eit-cov) eit-collapse/over, 19.5 (15.0â\\x80\\x9321.0) 19.5 (18.0â\\x80\\x9321.8), respectively (p = 0.07). eit-cov decreasing along mpaw decrease revealed redistribution toward non-dependent regions. individual mpaw titrated eit-based index improved regional ventilation distribution respect overdistension collapse (p = 0.035). conclusion: suggested personalized optimal mpaw titration eit-based index improves regional ventilation distribution lung homogeneity high-frequency oscillatory ventilation.',\n",
       " 'background: flow cytometry powerful tool multiparameter analysis leukocyte subset single cell level. recent advance greatly increased number fluorochrome-labeled antibody flow cytometry. particular, increase available fluorochrome distinct excitation emission spectrum combined novel multicolor flow cytometers several laser enhanced generation multidimensional expression leukocyte cell types. however, advance mainly benefited analysis human mouse cell sample given lack reagent animal species. flow cytometric analysis important veterinary, agricultural, wildlife, animal specie still hampered several technical limitations, even though animal specie mouse serve accurate model specific human physiology diseases. results: present time-tested approach laboratory regularly us multiparameter flow cytometric analysis ovine leukocytes. discussed approach applicable analysis cell animal specie include direct modification antibody covalent conjugation fc-directed labeling (zenonâ\\x84¢ technology), labeled secondary antibody second step reagents, labeled receptor ligands, antibody specie cross-reactivity. conclusions: refined technical approaches, number parameter analyzed flow cytometry per cell sample greatly increased, enabling multidimensional analysis rare sample giving critical insight veterinary le commonly analyzed species. maximizing information cell sample, multicolor flow cytometry reduce required number animal used study.',\n",
       " 'background: community-acquired pneumonia (cap) requires urgent specific antimicrobial therapy. however, causal pathogen typically point anti-infective therapeutic must initiated. physician synthesize information diverse stream make appropriate decisions. artificial intelligence (ai) excels finding complex relationship volume data. aimed evaluate ability experienced physician ai answer question admission: bacterial pneumonia? methods: included hospitalized cap recorded available first 3-h period care (clinical, biological radiological information). proof-of-concept investigation, decided cap caused singular identified pathogen. built machine learning model prediction collected data. finally, independent validation set sample used test pathogen prediction performance of: (i) panel three expert (ii) ai algorithm. blinded regarding final microbial diagnosis. positive likelihood ratio (lr) value > 10 negative lr value < 0.1 considered clinically relevant. results: included 153 cap (70.6% men; 62 [51â\\x80\\x9373] year old; mean sapsii, 37 [27â\\x80\\x9347]), 37% pneumonia, 24% bacterial pneumonia, 20% co-infection 19% identified respiratory pathogen. performed analysis 93 co-pathogen no-pathogen case excluded. discriminant ability ai approach low moderate (lr+ = 2.12 6.29 bacterial pneumonia), discriminant ability expert low low (lr+ = 3.81 1.89 bacterial pneumonia). conclusion: neither expert ai algorithm predict microbial etiology cap within first hour hospitalization urgent need define anti-infective therapeutic strategy.',\n",
       " 'chronic kidney (ckd) become global healthcare issue. ckd progress irreversible end-stage renal disease (esrd) renal failure. major risk factor ckd include obesity, diabetes, cardiovascular diseases. understanding key process involved development may lead novel interventive strategies, currently lagging behind. peroxisome proliferator-activated receptor î³ (pparî³) ligand-activated transcription factor superfamily member globally expressed human tissues. agonist thiazolidinediones (tzds) applied effective antidiabetic drug control insulin sensitivity multiple metabolic tissues. besides, tzds exert protective effect multiple ckd risk contexts. pparî³ abundantly expressed major kidney cells, physiological role cell studied cell animal models. function pparî³ kidney range energy metabolism, cell proliferation inflammatory suppression, although major renal side effect existing agonist (including tzds) reported, limited application treating ckd. current review, systemically ass function pparî³ ckds benefit current limitation agonist clinical applications.',\n",
       " 'esophageal malignancy poor prognosis. curative therapy incorporates surgery burdensome high rate morbidity mortality. role yeast causative organism post-esophagectomy infection poorly defined. consequently, benefit specific antifungal prophylactic therapy improving outcome unclear. therefore, aimed investigating incidence yeast infection university medical center groningen among 565 post-esophagectomy 1991 2017. result 7.3% developed yeast esophageal resection significantly increased incidence among suffering diabetes mellitus. yeast infections, higher acute physiology chronic evaluation (apache) ii scores, frequent intensive care unit readmissions, prolonged hospital stay higher mortality rate observed. one-year survival significantly lower yeast infection, well diabetes mellitus yeast-positive pleural effusion. conclude incidence yeast infection following esophagectomy considerable, diabetes mellitus increased risk. furthermore, yeast infection associated higher complication rate mortality. observation encourage prospective investigation possible benefit antifungal prophylactic therapy esophagectomy patients.',\n",
       " 'vaccine protective diverse hcv variant needed control hcv epidemic. structure e2 complex front layer-specific broadly neutralizing antibody (bnabs) isolated hcv-infected individuals, revealed disulfide bond-containing cdrh3 adopts straight (individuals clear infection) bent (individuals chronic infection) conformation. investigate whether straight versus bent disulfide bond-containing cdrh3 specific particular hcv-infected individuals, solved crystal structure hcv e2 ectodomain complex ar3x, bnab unusually long cdrh2 isolated chronically-infected individual bent cdrh3 bnabs derived. structure revealed ar3x utilizes ultralong cdrh2 disulfide motif-containing straight cdrh3 recognize e2 front layer. result demonstrate straight bent cdrh3 class hcv bnab elicited single individual, revealing structural plasticity vh1-69-derived bnabs.',\n",
       " 'recent global advocacy effort highlighted importance development vaccine group streptococcus (gas). combo5 non-m protein-based vaccine provides protection gas skin mouse reduces severity pharyngitis nonhuman primates. however, combo5 addition aluminum hydroxide (alum) adjuvant failed protect invasive gas mice. here, formulation combo5 adjuvant containing saponin qs21 significantly improves protective efficacy, even though 7 adjuvant tested generated high antigen-specific igg antibody titers, alum. detailed characterization combo5 formulated smq adjuvant, squalene-in-water emulsion containing tlr4 agonist qs21, showed significant difference result obtained alum igg subclass generated following immunization, absence gas opsonizing antibodies. smq, alum, generated strong interleukin-6 (il-6), gamma interferon (ifn-î³), tumor necrosis alpha (tnf-î±) responses. work highlight importance adjuvant selection non-m protein-based gas vaccine optimize immune response protective efficacy.',\n",
       " 'nonsense-mediated decay (nmd) pathway present challenge rna virus termination codon precede extended 3â\\x80² untranslated region (utrs). umbravirus pea enation mosaic 2 (pemv2) nonsegmented, positive-sense rna unusually long 3â\\x80² utr susceptible nmd. establish systemic infection, pemv2 long-distance movement protein p26 stabilize rna bind transport plantâ\\x80\\x99s vascular system. current demonstrated p26 protects nonviral messenger rna nmd. although p26 localizes cytoplasm nucleolus, p26 exerts anti-nmd effect exclusively cytoplasm independently long-distance movement. transcriptome-wide approach model plant nicotiana benthamiana, p26 protected subset cellular nmd target transcripts, particularly containing long, structured, gc-rich 3â\\x80² utrs. furthermore, transcriptome sequencing (rna-seq) revealed nmd pathway highly dysfunctional pemv2 infection, 1,820 (48%) nmd target increasing abundance. widespread change host transcriptome common plant rna infections, result suggest that, least instances, virus-mediated nmd inhibition may major contributing factor.',\n",
       " 'background: tick-borne lymphadenopathy (tibola) infectious disease, mainly caused specie spotted fever group rickettsia characterized enlarged lymph node following tick bite. among case tibola, scalp eschar neck lymphadenopathy tick bite (senlat) diagnosed eschar present scalp, accompanied peripheral lymphadenopathy (lap). case senlat caused bartonella henselae reported. presentation: 58-year-old male sought medical advice suffering high fever diarrhea. three week visit, hunting water deer, upon bringing deer home discovered tick scalp area. symptom occurred week hunting, lump palpated right neck area 6 day onset symptoms. physical examination upon presentation confirmed eschar-like lesion right scalp area, cervical palpation revealed lymph node right side non-painful enlarged 2.5 ã\\x97 1.5 cm. fine needle aspiration enlarged lymph node performed, result nested pcr bartonella internal transcribed spacer (its) confirmed b. henselae causative agent. conclusion: isolated senlat confirmation b. henselae korea, pertinent raise awareness physician asian country b. henselae could causative agent senlat.',\n",
       " 'last two decades, pig population africa grown rapidly, reflecting increased adoption pig production important economic activity. species, pig likely constitute greater share growth livestock subsector. however, constraint respiratory infectious disease cause significant economic loss pig industry worldwide. compared industrialized countries, occurrence impact respiratory disease pig production africa under-documented. hence, knowledge prevalence incidence economically important swine respiratory pathogen pig africa necessary guide intervention prevention control. purpose review document current status research five important respiratory pathogen swine africa inform future research interventions. pathogen included porcine reproductive respiratory syndrome (pprsv), porcine circovirus 2 (pcv2), mycoplasma hyopneumoniae (m. hyopneumoniae), actinobacillus pleuropneumoniae (app) swine influenza virus (iav). review, published article obtained harzingâ\\x80\\x99s publish perish software tool googlescholar. article sourced pubmed, sciencedirect, fao oie websites. term used search africa, swine porcine, respiratory pathogens, m. hyopneumoniae, app, pcv2, pprsv, iav, prevention control. all, 146 article found considered relevant, upon screening, 85 article retained review. search limited study published 2000 2019. study documented occurrence five respiratory pathogens, iav (48.4%, n = 15), followed pcv2 (25.8%, n = 8), pprsv (19.4%, n = 6), (3.2%, n = 1) reported app m. hyopneumoniae. review highlight knowledge information gap epidemiologic aspect well economic impact various pathogen reported swine africa, call studies.',\n",
       " 'background: bovine orthopneumovirus, formerly known bovine respiratory syncytial (brsv), frequently associated bovine respiratory (brd). aim: perform molecular characterization g f protein brazilian wild-type brsv strain derived bovine respiratory infection beef dairy cattle. material methods: ten brsv strain derived dairy heifer rearing unit (n = 3) 2011 steer three feedlot (n = 7) 2014 2015 analyzed. brsv g f partial gene amplifications, rt-nested-pcr assay performed sequencing direction forward reverse primer used. results: g gene-based analysis revealed two strain highly similar brsv sequence representative subgroup iii, bayovac vaccine strain. however, remaining seven brazilian brsv strain diverse compared strain representative brsv viii subgroups. central hydrophobic region brazilian brsv g gene showed replacement conserved cysteine residue importance antibody reactivity. deduced f gene amino acid sequence brazilian brsv strain showed change absent representative sequence known subgroups. isolation nasopharyngeal swab suspension failed isolate brsv. conclusion: result suggest strain represent putative subgroup brsv mutation observed immunodominant region g protein. however, study brazilian brsv strain performed establish pathogenic potential.',\n",
       " 'recent years, many study drawn attention important role collective awareness human behaviour epidemic outbreaks. number modelling effort investigated interaction transmission dynamic human behaviour change mediated news coverage information spreading population. yet, given scarcity public awareness epidemic, study relied empirical data. here, use fine-grained, geo-referenced three online sourcesâ\\x80\\x94wikipedia, gdelt project internet archiveâ\\x80\\x94to quantify population-scale information seeking 2016 zika epidemic u.s., explicitly linking behavioural signal epidemiological data. geo-localized wikipedia pageview reveal visiting pattern zika-related page wikipedia highly synchronized across united state largely explained exposure national television broadcast. contrary assumption theoretical epidemic models, news volume wikipedia visiting pattern significantly correlated magnitude extent epidemic. attention zika, term zika-related wikipedia pageviews, high beginning outbreak, public agency raised international alert triggered medium coverage, subsequently exhibited activity profile suggests nonlinear dependency memory effect relation information seeking, medium pressure, dynamics. call general modelling framework describe interaction medium exposure, public awareness dynamic epidemic outbreaks.',\n",
       " 'purpose: examine time drug administration witnessed cardiac arrest enrolled pre-hospital assessment role adrenaline: measuring effectiveness drug administration cardiac arrest (paramedic2) randomised controlled trial. methods: paramedic2 trial undertaken across 5 nh ambulance service england wale randomisation december 2014 october 2017. out-of-hospital cardiac arrest unresponsive initial resuscitation attempt randomly assigned 1 mg intravenous adrenaline matching placebo according pack identical apart number. participant staff masked allocation. results: 8016 enrolled, 4902 sustained witnessed cardiac arrest 2437 received placebo 2465 received adrenaline. odds return spontaneous circulation decreased group time greater rate placebo arm odds ratio (or) 0.93 (95% ci 0.92â\\x80\\x930.95) compared adrenaline arm 0.96 (95% ci 0.95â\\x80\\x930.97); interaction or: 1.03, 95% ci 1.01â\\x80\\x931.05, p = 0.005. contrast, although rate survival favourable neurological outcome decreased time increased, rate differ adrenaline placebo groups. conclusion: rate return spontaneous circulation, survival favourable neurological outcome decrease time. time drug increases, adrenaline increase chance return spontaneous circulation. longer term outcome affected time adrenaline administration. (isrctn73485024). electronic supplementary material: online version article (10.1007/s00134-019-05836-2) contains supplementary material, available authorized users.',\n",
       " 'macrophage important protective function herpes simplex type 1 (hsv-1). however, molecular mechanism restrict propagation protect severe unclear. macrophage take hsv-1 via endocytosis transport virion multivesicular body (mvbs). mvbs, acid ceramidase (acdase) convert ceramide sphingosine increase formation sphingosine-rich intraluminal vesicle (ilvs). hsv-1 particle reach mvbs, sphingosine-rich ilvs bind hsv-1 particles, restricts fusion limiting endosomal membrane prevents cellular infection. lack acdase macrophage culture asah1(â\\x88\\x92/â\\x88\\x92) mouse result replication hsv-1 asah1(â\\x88\\x92/â\\x88\\x92) mouse die soon systemic intravaginal inoculation. macrophage sphingosine enhancing compound block hsv-1 propagation, suggesting therapeutic potential pathway. conclusion, acdase load ilvs sphingosine, prevents hsv-1 capsid penetrating cytosol.',\n",
       " '',\n",
       " 'although mechanical ventilation may patientâ\\x80\\x99s vital ally acute illness, quickly transform enemy chronic conditions. weaning process fundamental phase enables resumption physiological respiratory function; however, associated number life-threatening complications, percentage critically ill never achieve airway device removal require resumption mechanical ventilation day post-weaning. indeed, weaning process is, present, art science. such, urgent need novel contribution scientific literature abate growing rate morbidity mortality associated weaning failure. physician attempting wean must integrate clinical parameter common-sense criteria. numerous study striven identify single predictive factor weaning failure sought standardize weaning process, result characterized remarkable heterogeneity. despite lack benchmarks, clear analysis respiratory function must include detailed overview five situation described rather single aspect. purpose two-part review provide comprehensive description situation clarify â\\x80\\x9carenaâ\\x80\\x9d physician entering weaning critically ill mechanical ventilation.',\n",
       " 'assessing heart diaphragm function constitutes step consider along weaning path. second part review, deal systematic evaluation pulmonary parenchymaâ\\x80\\x94often implicated genesis respiratory failure. consider possible cause weaning failure lie beyond cardio-pulmonary-diaphragmatic system. finally, take moment consider remaining unsolved problem arising mechanical ventilation describe so-called protective approach parenchyma diaphragm ventilation.',\n",
       " '',\n",
       " 'knowledge human behavior important improving indoor-environment design, building-energy efficiency, productivity, study spread. however, lacking. study, designed device detecting recording, second second, 3d indoor positioning head body motion graduate student office. 400 person hour data. student spent 92.2%, 4.1%, 2.9%, 0.8% time office cubicles, office cubicles, aisles, area near public facilities, respectively. spent 9.7% time close contact, student averagely 4.0 close contacts/h. student spent long time close contact office may lead high risk. average interpersonal distance close contact 0.81 m. sitting, student preferred small relative face orientation angle. pair standing student preferred face-to-face orientation close contact mean pattern lower risk via close contact. probability close contact decreased exponentially increasing distance two studentsâ\\x80\\x99 cubicles. human behaviour close contact helpful risk analysis control prevention.',\n",
       " 'leptospirosis reported endemic tropical countries. among high risk occupations, leptospirosis includes worker agriculture domestic animal industries. environmental hygiene wet market established link presence rodent probability leptospirosis infection. aimed compare level knowledge, attitude preventive practice leptospirosis healthy malaysian non-malaysian wet market worker selected wet market urban area selangor. cross-sectional determined area conducted participation 147 respondents. respondent randomly chosen list provided state agency regulates markets. self-administered bilingual validated questionnaire (english bahasa melayu) distributed selected respondents. 68 (48.3%) malaysian respondent 79 (53.7%) non-malaysian respondents. majority males, attained formal education le 40 year old. meanwhile, respondent earned le rm3000. among malaysian respondents, 80.9% aware leptospirosis compared 17.7% non-malaysian colleague (p < 0.05). item knowledge showed malaysian respondent scored higher compared non-malaysian respondents. attitude towards prevention, malaysian respondent positive attitude, non-malaysian respondent undecided perception majority crucial attitude items. practicing preventive measures, marked significant difference proportion malaysian non-malaysian respondent item â\\x80\\x9cspecific protection isolation source.â\\x80\\x9d significant gap knowledge, attitude preventive practice among malaysian worker compared non-malaysian workers. therefore, highly recommended promotion implementation provide specific focus non-malaysian workers.',\n",
       " 'background: poorly known mycobacterial specie mycobacterium monacense rapidly growing non-tuberculous mycobacterium first described 2006 (reischl et al., int j syst evol microbiol 56:2575-8, 2006); reported isolation usually associated skin lung infections, especially immunosuppressed (hogardt et al., jpn j infect dis 61:77-8, 2008; taieb et al., j hand surg 33:94-6, 2008; therese et al., lung india 28:124-6, 2011; shojaei et al., ann lab med 32:87-90, 2012; romero et al., microbe infect 10:112-5, 2016 ). clinical significance mycobacterium monacense yet fully understood. here, report first isolation mycobacterium monacense blood culture china severe pneumonia. presentation: june 26, 2018, 38-year-old man admitted intensive care unit breathing difficulty. prior, discovered face immersed small pond (non-chlorinated water) limb convulsions. undergone craniocerebral surgery trauma 5 year earlier, left epilepsy sequela. bilateral diffuse ground-glass opacity found lung chest x ray chest ct image admission. hiv serology test negative. diagnosed severe pneumonia. drug-susceptible klebsiella pneumoniae candida glabrata isolated balf, yellow-pigmented colony isolated blood culture patient. strain isolated blood identified 16 rdna sequencing mycobacteria monacense, rapidly growing mycobacterium (rgm). treated combination cefoperazone sulbactam, linezolid voriconazole 10 days, symptom improved. one-year follow-up time, relapse. conclusions: report first m. monacense isolated blood culture severe pneumonia, provided evidence environmental microorganism possessed pathogenic characteristics.',\n",
       " 'background: child syndrome (ds) high susceptibility recurrent infection (ri), caused immune defect abnormality airways. goal investigate effect pidotimod ri prevention child ds, comparing immune clinical parameter (t0) (t1) pidotimod. methods: conducted syndrome outpatient center bambino gesã¹ childrenâ\\x80\\x99s hospital, rome. reviewed medical record child positive history ri received oral prophylaxis pidotimod september 2016 february 2017. results: thirty-three child met inclusion criterion (males: 51.5%; average age: 6 year â±sd: 3). found significant decrease number child upper respiratory infection (82% t0 v 24% t1; p = 0,0001) lower respiratory infection (36% t0 v 9% t1; p = 0.003) pidotimod. demonstrated significant decrease number child hospitalized respiratory infection (18% t0 v 3% t1; p = 0.03). measured b cell peripheral blood b cell function vitro t0 t1. found response cpg improved t1. significant increase b cell frequency (p = 0.0009), b cell proliferation (p = 0.0278) igm secretion (p = 0.0478) observed child d treatment. conclusions: result provided evidence pidotimod may able prevent ri child syndrome.',\n",
       " 'background: international standard safe practice anesthesia (isspa) developed behalf world federation society anaesthesiologists world organization. recommend assessment tool allows anesthetic provider developing country ass compliance needs. performed describe anesthesia service main public hospital 8-month medical mission cambodia evaluate anesthetic safety issue according isspa. methods: conduct retrospective involving 1953 preah ket mealea hospital. demographics, anesthetic techniques, complication reviewed according register anesthetic service questionnaires. inadequacy personnel, facilities, equipment, medications, conduct anesthesia drug recorded checklist based isspa. results: total 1792 received general regional anesthesia operating room, 161 receiving sedation gastroscopy. patientsâ\\x80\\x99 mean age 45.0 â± 16.6 year (range, 17â\\x80\\x9387 years). three common surgical procedure abdominal (52.0%; confidence interval [ci], 49.3â\\x80\\x9354.7), orthopedic (27.6%; ci, 25.2â\\x80\\x9329.9), urological surgery (14.7%; ci, 12.8â\\x80\\x9316.6). general anesthesia, spinal anesthesia, brachial plexus block performed 54.3% (ci, 51.7â\\x80\\x9356.8), 28.2% (ci, 25.9â\\x80\\x9330.5), 9.4% (ci, 7.9â\\x80\\x9310.9) patients, respectively. death occurred. twenty-six item related professional aspects, monitoring, conduct anesthesia meet isspa-recommended standards. lack commonly used drug monitoring equipment noted, posing major threat safety anesthesia practice, especially emergency situations. conclusions: add scarce literature anesthesia practice low- middle-income country cambodia. future medical assistance help strengthen countriesâ\\x80\\x99 inadequacies, allowing adoption international standard safe practice anesthesia.',\n",
       " 'background: diaphragm atrophy dysfunction consequence mechanical ventilation determinant clinical outcomes. hypothesize partial preservation diaphragm function, assisted mode ventilation, restore diaphragm thickness. aim correlate change diaphragm thickness function outcome clinical factors. methods: prospective, multicentre, observational study. mechanically ventilated 48 h controlled mode eventually switched assisted ventilation enrolled. diaphragm ultrasound clinical collection performed every 48 h discharge death. threshold 10% used define thinning controlled recovery thickness assisted ventilation. classified based level diaphragm activity assisted ventilation. evaluated association change diaphragm thickness activity clinical outcome data, ventilation parameters. results: sixty-two ventilated controlled mode switched assisted mode ventilation enrolled. diaphragm thickness significantly decreased controlled ventilation (1.84 â± 0.44 1.49 â± 0.37 mm, p < 0.001) partially restored assisted ventilation (1.49 â± 0.37 1.75 â± 0.43 mm, p < 0.001). diaphragm thinning 10% associated longer duration controlled ventilation (10 [5, 15] versus 5 [4, 8.5] days, p = 0.004) higher peep level (12.6 â± 4 versus 10.4 â± 4 cmh(2)o, p = 0.034). increase diaphragm thickness 10% assisted ventilation associated clinical outcome lower respiratory rate (16.7 â± 3.2 versus 19.2 â± 4 bpm, p = 0.019) rapid shallow breathing index (37 â± 11 versus 44 â± 13, p = 0.029) higher pressure muscle index (2 [0.5, 3] versus 0.4 [0, 1.9], p = 0.024). change diaphragm thickness related diaphragm function expressed diaphragm thickening fraction. conclusion: mode ventilation affect diaphragm thickness, preservation diaphragmatic contraction, assisted modes, partially reverse muscle atrophy process. avoiding strenuous inspiratory work, measured rapid shallow breathing index pressure muscle index, may help diaphragm thickness restoration.',\n",
       " 'background: â\\x80\\x9cend-of-life scoring-systemâ\\x80\\x9d (ending-s) developed identify high-risk dying icu facilitate practical integration palliative intensive care. aim prospectively validate ending-s cohort long-term critical care patients. material methods: adult long-term icu (with length-of-stay> 4 days) considered prospective multicenter observational study. ending-s sofa score calculated daily evaluated patientâ\\x80\\x99s icu outcome. predictive property evaluated receiver operating characteristic (roc) analysis. results: two hundred twenty enrolled study. among these, 21.46% died icu stay. ending-s correctly predicted icu outcome 71.4% patients. sensitivity, specificity, positive negative predictive value associated identified ending-s cut-off 11.5 68.1, 72.3, 60 89.3%, respectively. roc-auc outcome prediction 0.79 ending-s 0.88 sofa cohort. conclusions: ending-s, accurately pilot study, demonstrated acceptable discrimination property identifying long-term icu high-risk dying. ending-s may useful tool aimed facilitating practical integration palliative, end-of-life intensive care. trial registration: clinicaltrials.gov identifier: nct02875912; first registration august 4, 2016.',\n",
       " 'background: dengue emerging infectious infects 390 million people yearly. growing demand dengue diagnostics especially low-resource setting gave rise many rapid diagnostic test (rdt). evaluated accuracy utility virotrack dengue acute - biosensors-based dengue ns1 rdt, sd bioline dengue duo ns1/igm/igg combo - commercially available rdt, sd dengue ns1 ag enzyme-linked immunosorbent assay (elisa), diagnosis acute dengue infection. methods: prospective cross-sectional consecutively recruited 494 suspected dengue clinic malaysia. rdts performed onsite. evaluated elisa reference test performed virology laboratory. reference test comprised reverse transcription-polymerase chain reaction three elisa detection dengue ns1 antigen, igm igg antibodies, respectively. diagnostic performance evaluated test computed stata version 12. results: sensitivity specificity virotrack 62.3% (95%ci 55.6â\\x80\\x9368.7) 95.0% (95%ci 91.7â\\x80\\x9397.3), versus 66.5% (95%ci 60.0â\\x80\\x9372.6) 95.4% (95%ci 92.1â\\x80\\x9397.6) sd ns1 elisa, 52.4% (95%ci 45.7â\\x80\\x9359.1) 97.7% (95%ci 95.1â\\x80\\x9399.2) ns1 component sd bioline, respectively. combination latter igm igg component able increase test sensitivity 82.4% (95%ci 76.8â\\x80\\x9387.1) corresponding decrease specificity 87.4% (95%ci 82.8â\\x80\\x9391.2). although positive test ns1 assay would increase probability dengue 90% patient, negative would reduce probability 23.0â\\x80\\x9329.3%. contrast, probability false negative diagnosis would reduced 14.7% (95%ci 11.4â\\x80\\x9318.6) sd bioline ns1/igm/igg combo negative. conclusions: performance virotrack dengue acute comparable sd dengue ns1 ag elisa. addition serology component sd bioline dengue duo significantly improved sensitivity reduced false negative rate missed fewest dengue patients, making better point-of-care diagnostic tool. rdt like virotrack dengue acute may potential alternative existing rdt combination serology component proven better future studies.',\n",
       " 'background: traumatic brain injury (tbi) associated high rate long-term disability mortality. aim investigate effect thoracic trauma in-hospital course outcome tbi. methods: performed matched pair analysis multicenter trauma database traumaregisterdguâ® (tr-dgu) 5-year period 2012 2016. included adult (â\\x89¥18 year age) moderate severe tbi (abbreviated injury scale (ais)= 3â\\x80\\x935). isolated tbi (group 1) compared tbi varying degree additional blunt thoracic trauma (ais(thorax)= 2â\\x80\\x935) (group 2). matching criterion gender, age, severity tbi, initial gc presence/absence shock. ï\\x87(2)-test used comparing categorical variable mann-whitney-u-test chosen continuous parameters. statistical significance defined p-value < 0.05. results: total 5414 matched pair (10,828 patients) included. presence additional thoracic injury tbi associated longer duration mechanical ventilation prolonged icu hospital length stay. additional thoracic trauma associated higher mortality rates. effect pronounced thoracic ai subgroup 4 5. additional thoracic trauma, regardless severity (ais(thorax) â\\x89¥2) associated significantly decreased rate good neurologic recovery (gos = 5) tbi. conclusions: chest trauma general, regardless initial severity (ais(thorax)= 2â\\x80\\x935), associated decreased chance good neurologic recovery tbi. affected considered â\\x80\\x9cat riskâ\\x80\\x9d vigilance maintenance optimal neuro-protective measure high.',\n",
       " 'background: china emerged powerful platform global pharmaceutical research development (r&d) amid 2014 ebola outbreak. research development impact developing country prevention control infectious outbreak long underestimated, particularly emerging economy like china. here, studied research development progress government support response ebola outbreak timeline, input, output research development stage. contribute deeper understanding research development gap challenge faced china, well providing evidence-based suggestion accelerate drug development process meet urgent need future outbreaks. methods: obtained national nature science foundation china database, pubmed database, patent search system state intellectual property office china, national medical product administration, national policy report literature jan 1st, 2006 dec 31st, 2017. overview research funding, research output, pharmaceutical product patent, product licensed described analyzed microsoft excel. descriptive analysis visualization plotting chart graph conducted reporting mean â± standard deviation. results: china successfully completed research development ebola ad5-ebov vaccine within 26 months, preparation implementation clinical trial took relative long time. national nature science foundation china funded cny 44.05 million (usd 6.27 million) ebola-related research committed strongly phase basic research (87.8%). proliferation literature arose 2014 2015, 1.7-fold increase drug research 2.5-fold increase diagnostic research within 1 year. three year ebola outbreak, six ebola-related product china approved national medical product administration. conclusions: china started emphasize importance medical product innovation solution tackling emerging infectious diseases. continuing research development regulatory market incentives, well multilateral collaboration mechanism unifies cross-channel supports, would advance process china enter global r&d market effectively.',\n",
       " 'critical comment review okada et al. effect early versus delayed mobilization definition early mobilization mobilization within week icu admission contrast current evidence.',\n",
       " 'adjuvant central efficacy subunit vaccines. aluminum hydroxide (alum) commonly used vaccine adjuvant, yet adjuvanticity often weak mechanism triggering antibody response remain poorly understood. demonstrate site-specific modification immunogen short peptide composed repeating phosphoserine (pser) residue enhances binding alum prolongs immunogen bioavailability. pser-modified immunogen formulated alum elicited greatly increased germinal center, antibody, neutralizing antibody, memory long-lived plasma cell response compared conventional alum-adsorbed immunogens. mechanistically, pser-immunogen:alum complex form nanoparticles traffic lymph node trigger b cell activation multivalent oriented antigen display. direct uptake antigen-decorated alum particle b cell upregulated antigen processing presentation pathways, enhancing b cell activation. provide insight mechanism action alum introduce readily translatable approach significantly improve humoral immunity subunit vaccine clinical adjuvant.',\n",
       " 'term â\\x80\\x9camyloidâ\\x80\\x9d refers proteinaceous deposit peptide might generated larger precursor protein e.g., proteolysis. common peptide stable cross-î² dominated secondary structure allows self-assembly, leading insoluble oligomers lastly fibrils. highly ordered protein aggregate been, long time, mainly associated human neurodegenerative disease alzheimerâ\\x80\\x99s (amyloid-î² peptides). however, exert physiological function release deposited hormone human beings. light rediscovery microbial commensal important companion disease, fact microbe posse amyloidogenic peptide intriguing. transmission amyloid iatrogenic mean consumption contaminated meat diseased animal well-known fact. microbial commensal might drive human amyloidosis suffer aggregated amyloids? moreover, microbial amyloid evolutionarily older, might learn organism cope sword damocles forged endogenous, potentially toxic peptides. review summarizes knowledge interplay human amyloid involved neurodegenerative disease microbial amyloids.',\n",
       " 'hookworm major public problem threatens 500 million people throughout tropical area world. adult hookworm survive many year host intestine, suck blood, causing iron deficiency anemia malnutrition. numerous molecules, named excretory/secretory (es) products, secreted hookworm adult and/or larva aid parasite survival pathobiology. although molecular cloning characterization hookworm e product began 25 year ago, biological role molecular nature many still unclear. hookworm e products, distinct structure functions, linked many essential event pathogenesis. event include host invasion tissue migration, parasite nourishment reproduction, immune modulation. several product represent vaccine target controlling hookworm therapeutic target many inflammatory diseases. review aim summarize present knowledge hookworm e products, role parasite biology, host-parasite interactions, vaccine pharmaceutical target identify research gap future research direction field. [image: see text]',\n",
       " 'background: majority worldâ\\x80\\x99s perinatal death occur low- middle-income countries. substantial proportion occurs intrapartum avoidable better care. low-resource tertiary hospital, assessed quality intrapartum care adherence locally-tailored clinical guidelines. methods: non-participatory, structured, direct observation held mnazi mmoja hospital, zanzibar, tanzania, october november 2016. woman active labour followed structure, process labour care outcome care systematically recorded. descriptive analysis performed labour observation compared local guideline supplemented qualitative findings. poisson regression analysis assessed factor affecting foetal heart rate monitoring (fhrm) guideline adherence. results: 161 labouring woman observed. nurse/midwife-to-labouring-women ratio 1:4, resulted doctor providing significant part intrapartum monitoring. care labour two-thirds delivery provided one-room labour ward shared beds. screening privacy communication examination finding done 50 34%, respectively. majority, delayed recognition labour progress insufficient support second stage labour. fhrm generally performed suboptimally median interval 105 (interquartile range 57â\\x80\\x93160) minutes, occurrence intrapartum risk event (non-reassuring fhr, oxytocin use poor progress) increased assessment frequency significantly (rate ratio 1.32 (ci 1.09â\\x80\\x931.58)). conclusions: neither international locally-adapted standard intrapartum routine care optimally achieved. likely due grossly inadequate capacity birth attendants; without innovative intervention birth unlikely succeed. call international local stakeholder address root cause unsafe intrafacility care low-resource settings, number skilled birth attendant required safe respectful births.',\n",
       " 'background: halyomorpha halys (stã¥l), brown marmorated stink bug, highly invasive insect specie due part exceptionally high level polyphagy. specie nuisance due overwintering human-made structures. caused significant agricultural loss recent year along atlantic seaboard north america continental europe. genomic resource assist determining molecular basis speciesâ\\x80\\x99 feeding habitat traits, defining potential target pest management strategies. results: analysis 1.15-gb draft genome assembly identified wide variety genetic element underpinning biological characteristic formidable pest species, encompassing role sensory functions, digestion, immunity, detoxification development, likely support h. halysâ\\x80\\x99 capacity invasiveness. many gene identified herein potential biomolecular pesticide applications. conclusions: availability h. halys genome sequence useful development environmentally friendly biomolecular pesticide applied concert traditional, synthetic chemical-based controls.',\n",
       " '[image: see text] uncovering mechanism assembly crucial preventing spread virus treating disease. technique single-virus tracking (svt), known single-virus tracing, allows follow individual virus different part life cycle thereby provides dynamic insight fundamental process virus occurring live cells. svt typically based fluorescence imaging reveals insight unreported mechanisms. review article, provide reader broad overview svt technique. first summarize recent advance svt, choice fluorescent label labeling strategy imaging implementation analytical methodologies. describe representative application detail elucidate svt serf valuable tool virological research. finally, present perspective regarding future possibility challenge svt.',\n",
       " 'investigated antibiotic resistance level among bla(ndm)-positive (n = 9) -negative (n = 65) a. baumannii clinical isolates collected 2010 2015 alexandria main university hospital, egypt disc diffusion minimum inhibitory concentration (mic) determination. plasmid bla(ndm)-positive isolates transformed carbapenem-susceptible a. baumannii (cs-ab) isolate ass role plasmid transfer mediating carbapenem resistance. imipenem, meropenem, ertapenem mic90 value bla(ndm)-positive isolates 128, > 256, 256 âµg/ml, respectively. plasmid isolation polymerase chain reaction revealed bla(ndm) plasmid mediated. plasmid electroporated cell cs-ab isolate efficiency 1.3 ã\\x97 10(â\\x80\\x938) 2.6 ã\\x97 10(â\\x80\\x937), transforming bla(ndm)-positive carbapenem-resistant cell imipenem mic increase 256-fold. addition carbapenem resistance, bla(ndm)-positive isolates exhibited higher level cephalosporins, tetracycline, aminoglycosides, fluoroquinolones, colistin resistance bla(ndm)-negative isolates. acquisition bla(ndm)-carrying plasmid dramatically increased imipenem resistance among a. baumannii isolates. intriguingly, bla(ndm)-positive isolates showed high degree resistance antibiotic different classes. potential co-existence different resistance determinant a. baumannii plasmid possible transfer owing natural competence pathogen especially alarming. effective control antibiotic stewardship program needed curb spread treat infection hospital community settings. electronic supplementary material: online version article (10.1007/s13205-020-2157-y) contains supplementary material, available authorized users.',\n",
       " 'infection major global problem, representing significant cause mortality unfavorable continuously amplified socio-economic impact. increased drug resistance constant replication trigger important study regarding use nanotechnology antiviral therapies. nanomaterials offer unique physico-chemical property linked benefit drug delivery ideal tool treatment. currently, different type nanomaterials namely nanoparticles, liposomes, nanospheres, nanogels, nanosuspensions nanoemulsions studied either vitro vivo drug delivery antiviral agent prospect translated clinical practice. review highlight drug delivery nanosystems incorporating major antiviral class transport across specific barrier cellular intracellular level. important reflection nanomedicines currently approved undergoing investigation infection discussed. finally, author present overview requirement design antiviral nanotherapeutics.',\n",
       " 'background: obesity occurs bodyâ\\x80\\x99s energy intake constantly greater energy consumption pharmacological enhancing activity brown adipose tissue (bat) (or) browning white adipose tissue (wat) considered strategy treat obesity. methods: study, took multi-pronged approach screen ucp1 activators, silico predictions, vitro assays, well vivo experiments. results: base connectivity map (cmap) screening, obtained multiple drug posse remarkably correlating gene expression pattern enhancing activity bat (or) swat signature. particularly, focused unreported drug-indirubin, compound obtained indigo plant, mainly used chronic myelogenous leukemia (cml). current study, result indirubin could enhance bat activity, evidenced up-regulated ucp1 expression enhanced mitochondrial respiratory function vitro cellular model. furthermore, indirubin restrained high-fat diet (hfd)-induced body weight gain, improved glucose homeostasis ameliorated hepatic steatosis associated increase energy expenditure mouse model. moreover, revealed indirubin increased bat activity promoting thermogenesis mitochondrial biogenesis bat induced browning subcutaneous inguinal white adipose tissue (swat) mouse hfd. besides, result indicated indirubin induced ucp1 expression brown adipocytes, least part, via activation pka p38mapk signaling pathways. conclusions: result clearly effective bat (as well beige cells) activator, indirubin may protective effect prevention obesity complications.',\n",
       " 'background: explore effect respiratory rate (rr) venous-to-arterial co(2) tension difference (gapco(2)) septic shock undergoing volume mechanical ventilation. methods: adult septic shock underwent volume mechanical ventilation october 2015 october 2016. rr started 10 breaths/min, 2 breaths/min added every 60 min 16 breaths/min reached. every point, central venous arterial blood gas measurement obtained simultaneously. results: study, gapco(2) induced hyperventilation significantly increased, central venous carbon dioxide pressure (pvco(2)) partial pressure co(2) (paco(2)) artery decreased. decreasing trend paco(2) obvious pvco(2). hco(3)(â\\x88\\x92) ctco(2) markedly decreased, rr increased (p < 0.05). central venous oxygen saturation (s(cv)o(2)) decreasing trend 14 (77.1 â± 8.3%) 16 (75.2 â± 8.7%) breaths/min; however, difference significant. conclusions: septic undergoing ventilation, respiratory alkalosis induced hyperventilation caused increase gapco(2). clinician cautiously interpret gapco(2) hemodynamically stable ventilated septic shock relationship low cardiac output inadequate perfusion.',\n",
       " 'dna virus replicate nucleus encompass range ubiquitous clinically important viruses, acute pathogen persistent tumor viruses. virus must co-opt nuclear process benefit virus, whilst evading host process would otherwise attenuate replication. accordingly, dna virus induce formation membraneless assembly termed replication compartment (vrcs). compartment facilitate spatial organization process regulate virusâ\\x80\\x93host interactions. here, review advance understanding vrcs. cover initiation formation, function site processes, aspect composition organization. so, highlight ongoing emerging area research highly pertinent understanding nuclear-replicating dna viruses.',\n",
       " 'infection responsible numerous death worldwide. flaviviruses, contain rna genetic material, pathogenic family viruses. increasing amount evidence suggesting 5â\\x80\\x99 3â\\x80\\x99 non-coding terminal region critical survival. information structural feature essential gain detailed insight function interaction host proteins. study, 5â\\x80\\x99 3â\\x80\\x99 terminal region murray valley encephalitis powassan examined biophysical computational modeling methods. first, used size exclusion chromatography analytical ultracentrifuge method investigate purity in-vitro transcribed rnas. next, employed small-angle x-ray scattering technique solution conformation low-resolution structure rnas, suggest 3â\\x80\\x99 terminal region highly extended compared 5â\\x80\\x99 terminal region viruses. computational modeling tools, reconstructed 3-dimensional structure rna fragment compared derived small-angle x-ray scattering low-resolution structures. approach allowed u reinforce 5â\\x80\\x99 terminal region adopt dynamic structure compared mainly double-stranded structure 3â\\x80\\x99 terminal regions.',\n",
       " 'vesicular stomatitis (vsv) zoonotic, negative-stranded rna family rhabdoviridae. nucleoprotein (n) vsv protects genomic rna play essential role transcription replication, make nucleoprotein ideal target host defense. however, whether host innate/intrinsic immunity limit vsv targeting n protein unknown. study, found n protein vsv (vsv-n) interacted ubiquitin e3 ligase, tripartite motif protein 41 (trim41). overexpression trim41 inhibited vsv infection. conversely, depletion trim41 increased host susceptibility vsv. furthermore, e3 ligase defective mutant trim41 failed limit vsv infection, suggesting requirement e3 ligase activity trim41 restriction. indeed, trim41 ubiquitinated vsv-n cell vitro. trim41-mediated ubiquitination lead degradation vsv-n proteasome, thereby limiting vsv infection. taken together, identifies trim41 intrinsic immune factor vsv targeting nucleoprotein ubiquitination subsequent protein degradation.',\n",
       " 'discovery characterization novel arthropod-borne virus provide valuable information genetic diversity, ecology, evolution potential threaten animal public health. arbovirus surveillance conducted regularly romania, particularly scarce remote diverse area like danube delta. describe detection genetic characterization novel orbivirus (reoviridae: orbivirus) designated letea virus, found grass snake (natrix natrix) metagenomic metatranscriptomic survey conducted 2014 2017. first orbivirus discovered reptiles. phylogenetic analysis placed letea highly divergent specie culicoides-/sand fly-borne orbivirus clade. gene reassortment intragenic recombination detected majority nine letea strain obtained, implying mechanism play important role evolution diversification virus. however, screening arthropods, culicoides biting midge collected within surveillance program, tested negative letea could confirm arthropod vector virus. provided complete genome sequence nine letea strain information orbivirus diversity, host range, ecology evolution. phylogenetic association warrant screening arthropods, well sustained surveillance effort elucidation letea natural cycle possible implication animal human health.',\n",
       " 'histiocytic sarcoma represent malignant tumor require strategies. canine distemper (cdv) candidate due oncolytic feature reported canine histiocytic sarcoma cell line (dh82 cells). interestingly, underlying mechanism might include dysregulation angiogenesis. based findings, aim present investigate impact persistent cdv-infection oxidative stress mediated change expression hypoxia-inducible factor (hif)-1î± angiogenic downstream pathway dh82 cell vitro. microarray analysis, immunofluorescence 8-hydroxyguanosine, superoxide dismutase 2 catalase, flow cytometry oxidative burst displayed increased oxidative stress persistently cdv-infected dh82 cell (dh82ond pi) compared controls. hif-1î± expression dh82ond pi increased, demonstrated western blot, showed unexpected, often sub-membranous distribution, immunofluorescence immunoelectron microscopy. furthermore, microarray analysis immunofluorescence confirmed reduced expression vegf-b dh82ond pi compared controls. summary, result suggest reduced activation hif-1î± angiogenic downstream pathway dh82ond pi cell vitro, likely due excessive, unusually localized, non-functional expression hif-1î± triggered cdv-induced increased oxidative stress.',\n",
       " 'real-time molecular technique become reference method direct diagnosis pathogens. reduction step key factor order decrease risk human error resulting invalid series delayed results. describe process preparation oligonucleotide primer hydrolysis probe single tube predefined optimized concentration stabilized via lyophilization (lyoph-p&p). lyoph-p&p compared versus classic protocol extemporaneously prepared liquid reagent (i) sensitivity study, (ii) long-term stability 4 â°c, (iii) long-term stability 37 â°c mimicking transportation without cold chain. two published molecular assay selected study. target two emerging virus listed blueprint considered preparedness response actions: chikungunya (chikv) rift valley fever phlebovirus (rvfv). result demonstrate (i) lyoph-p&p stable least 4 day 37 â°c supporting shipping without need cold chain, (ii) lyoph-p&p rehydrated solution stable +4 â°c least two weeks, (iii) sensitivity observed lyoph-p&p least equal to, often better than, observed liquid formulation, (iv) validation result observed low-copy specimen rendered easier higher fluorescence level. conclusion, lyoph-p&p hold several advantage extemporaneously preparer liquid formulation merit considered novel real-time molecular assay implemented laboratory charge routine diagnostic activity.',\n",
       " 'rabies (rabv) lyssavirus known present within caribbean. island trinidad, richly diverse chiropteran fauna endemic bat-transmitted rabies low rabv isolation rate observed population. aimed determine seroprevalence rabies neutralizing antibody (rvna) light spatio-temporal bat demographic factor infer extent natural exposure rabv trinidadian bat population. rvna titer determined rabv micro-neutralization test 383 bat sample representing 21 species, comprising 30.9% local bat diversity, 31 location across island 5 years. rvna positively detected 33 sample (8.6%) representing 6 bat specie (mainly frugivorous) titer ranging 0.1 19 iu/ml (mean 1.66 iu/ml). analysis based multivariable binomial generalised linear mixed-effects model showed bat age year capture significant predictor seropositivity. thus, juvenile bat likely seropositive compared adult (estimate 1.13; p = 0.04) may suggest early exposure rabv possible implication amplification population. temporal variation rabies seropositivity, 2012â\\x80\\x932014 versus 2015â\\x80\\x932017 (estimate 1.07; p = 0.03) may related prevailing rabies epizootic situation. regarding factor investigated, rvna found bat rural non-rural areas, well hematophagous non-hematophagous bat species. common seropositive species, artibeus jamaicensis planirostris ubiquitous throughout island may potentially facilitate human exposure. finding factored public assessment potential rabies transmission non-hematophagous bat trinidad.',\n",
       " 'background: anxiety depression common symptom coronary heart (chd) percutaneous coronary intervention (pci). 24-form tai chi may exert protective function chd pci improving anxiety depression. methods: received pci 1â\\x80\\x934 day randomly assigned 24-form tai chi group (tg) control group (cg). difference anxiety depression, medical outcome 36â\\x88\\x92item shortâ\\x88\\x92form survey (sf-36), average 10 month tai chi intervention compared group analyze effect tai chi emotion life quality chd patients. meanwhile, relative level mir-17-92 measured real-time qpcr. association relative level mir-17-92 anxiety depression chd pci analyzed. adjusted cox model used explore effect tai chi exercise chd patients. results: 10 month intervention, change anxiety subscale (p = 0.002), depression subscale (p = 0.008), stress (p = 0.015) score higher tg group compared cg group. proportion anxious (p = 0.045) depressed subject (p = 0.042) tg group lower cg group. hand, increase sf-36 score relative level mir-17-92 significantly higher tg group compared cg group (p < 0.05). serum level mir-17-92 negative correlation anxiety, depression, stress score (p < 0.01). conclusion: 24-form tai chi improved anxiety depression symptom upregulated mir-17-92 level chd pci.',\n",
       " '',\n",
       " '',\n",
       " 'hivâ\\x80\\x901 tat essential hivâ\\x80\\x901 replication appears play important role pathogenesis hivâ\\x80\\x90associated neurological complications. secreted infected transfected cells, tat extraordinary ability cross plasma membrane. brain, tat taken cns cell via receptorâ\\x80\\x90mediated endocytosis. following endocytosis internalization endolysosomes, tat must released order activate hivâ\\x80\\x901 ltr promoter facilitate hivâ\\x80\\x901 replication nucleus. however, underlying mechanism whereby tat escape endolysosomes remain unclear. tat disrupts intracellular calcium homeostasis, investigated involvement calcium tat endolysosome escape subsequent ltr transactivation. demonstrated chelating endolysosome calcium highâ\\x80\\x90affinity rhodamineâ\\x80\\x90dextran chelating cytosolic calcium baptaâ\\x80\\x90am attenuated tat endolysosome escape ltr transactivation. significantly, demonstrated pharmacologically blocking knocking endolysosomeâ\\x80\\x90resident twoâ\\x80\\x90pore channel (tpcs) attenuated tat endolysosome escape ltr transactivation. calciumâ\\x80\\x90mediated effect appears selective tpcs knocking trpml1 calcium channel without effect. finding suggest calcium released tpcs involved tat endolysosome escape subsequent ltr transactivation. tpcs might represent novel therapeutic target hivâ\\x80\\x901 hivâ\\x80\\x90associated neurological complications.',\n",
       " 'background: acute respiratory distress syndrome continues drive significant morbidity mortality severe trauma. incidence trauma-induced, moderate-to-severe hypoxaemia, according berlin definition, could high 45%. pathophysiology includes release damage-associated molecular pattern (damps), propagate tissue injury triggering neutrophil extracellular trap (nets). net include dna backbone coated cytoplasmic proteins, drive pulmonary cytotoxic effects. structure net many damp includes double-stranded dna, prevents neutralization plasma. dornase alfa u food drug administration-approved recombinant dnase, cleaves extracellular dna may therefore break backbone net damps. aerosolized dornase alfa reduce trauma-induced lung injury experimental model improve arterial oxygenation ventilated patients. methods: traumadornase institution-led, multicentre, double-blinded, placebo-controlled randomized trial ventilated trauma patients. primary trial objective demonstrate reduction incidence moderate-to-severe hypoxaemia severe trauma first 7 day 45% 30% providing aerosolized dornase alfa compared placebo. secondary objective demonstrate improvement lung function reduction morbidity mortality. randomization 250 per arm carried secure, web-based system. statistical analysis include descriptive step inferential step fully bayesian techniques. approved agence nationale de la sã©curitã© du mã©dicament et de produits de santã© (ansm, 5 october 2018) national institutional review board (cpp, 6 november 2018). participant recruitment began march 2019. result published international peer-reviewed medical journals. discussion: early administration inhaled dornase alfa actually reduces incidence moderate-to-severe hypoxaemia severe trauma, therapeutic strategy may easily implemented many clinical trauma care settings. may facilitate ventilator weaning, reduce burden trauma-induced lung inflammation facilitate recovery rehabilitation severe trauma patients. trial registration: clinicaltrials.gov, nct03368092. registered 11 december 2017.',\n",
       " 'background: healthcare-associated infection (hais) occur frequently intensive care unit (nicus). aim analyze result surveillance hais iii level nicu naples, italy 2013â\\x80\\x932017 compare obtained 2006â\\x80\\x932010. methods: surveillance included 1265 neonate birth weight (bw) class > 2 day nicu stay. infection defined standard center control prevention definition adapted neonatal pathology. results: total 125 hais registered 2013â\\x80\\x932017 frequency 9.9% incidence density 3.2 per 1000 days. hais occurred bw class decreasing trend lowest highest bw class (p = < 0.001). central line-associated blood stream (clabsi) frequent (69.6%), followed ventilator associated pneumonia (vap) (20%), urinary tract (uti) (8.8%) necrotizing enterocolitis (nec) (1.6%). also, clabsi vap incidence density decreased lower highest bw class showing significant trend (p = 0.007). frequent pathogen responsible clabsi were: coagulase-negative staphylococci (cons) (25.3%), candida parapsilosis (21.8%), pseudomonas aeruginosa (5.7), escherichia coli klebsiella pneumoniae (6.8%). microbiological diagnosis achieved 20.7% clabsi. pseudomonas aeruginosa (28%), stenotrophomonas maltophilia (20%), con (20%) frequent pathogen responsible vap. clabsi incidence density showed difference 2006 2010 2013â\\x80\\x932017, vap incidence density 751â\\x80\\x93100 g bw class higher 2006â\\x80\\x932010 2013â\\x80\\x932017 (p = 0.006). higher incidence clabsi caused gram positive bacteria (p = 0.002) undetermined etiology (p = 0.01) observed 2013â\\x80\\x932017 2006â\\x80\\x932010, significant lower incidence vap caused gram-negative bacteria found 2013â\\x80\\x932017 2006â\\x80\\x932010 (p = 0.007). conclusion: hais nicu developed bw class decreasing trend lowest highest bw class periods. difference aetiology clabsi vap found two periods. reinforces importance hais surveillance protocol nicu, monitor microbiological isolates use medical device bw class neonates.',\n",
       " 'increasing number critically ill immunocompromised. acute hypoxemic respiratory failure (arf), chiefly due pulmonary infection, leading reason icu admission. identifying cause arf increase chance survival, may extremely challenging, underlying disease, treatments, combine create complex clinical pictures. addition, may infectious agent, pulmonary manifestation may related infectious non-infectious insults. clinically microbiologically documented bacterial pneumonia account one-third case arf immunocompromised patients. early antibiotic therapy recommended decrease chance identifying causative organism(s) 50%. virus second common cause severe respiratory infections. positive test respiratory sample necessarily indicate role current acute illness. invasive fungal infection (aspergillus, mucorales, pneumocystis jirovecii) account 15% severe respiratory infections, whereas parasite rarely cause severe acute infection immunocompromised patients. review focus diagnosis severe respiratory infection immunocompromised patients. special attention given newly validated diagnostic test designed used non-invasive sample bronchoalveolar lavage fluid capable increasing likelihood early etiological diagnosis. electronic supplementary material: online version article (10.1007/s00134-019-05906-5) contains supplementary material, available authorized users.',\n",
       " '',\n",
       " '',\n",
       " 'abnormal level end-tidal carbon dioxide (etco(2)) resuscitation delivery suite associated intraventricular haemorrhage (ivh) development. aim determine whether carbon dioxide (co(2)) level first 3 day birth reflected abnormal etco(2) level delivery suite, hence, prolonged rather early insult resulted ivh. addition, determined greater etco(2)level fluctuation resuscitation occurred infant developed ivh. etco(2) level delivery suite resuscitation co(2) level neonatal unit evaluated 58 infant (median gestational age 27.3 weeks). delta etco(2) difference highest lowest level etco(2). thirteen infant developed grade 3â\\x80\\x934 ivh (severe group). significant difference co(2) level develop ivh (or severe ivh) nicu. delta etco(2) resuscitation differed infant ivh (6.2 (5.4â\\x80\\x937.5) kpa) ivh (3.8 (2.7â\\x80\\x934.3) kpa) (p < 0.001) adjusting difference gestational age. delta etco(2) level gave area roc curve 0.940 prediction ivh. conclusion: result emphasize importance monitoring etco(2) level delivery suite.',\n",
       " '',\n",
       " 'cell suspension escherichia coli lactobacillus acidophilus exposed 600-ns pulsed electric field (nspefs) varying amplitude (low-13.5, mid-18.5 high-23.5 kv cm(â\\x88\\x921)) pulse number (0 (sham), 1, 5, 10, 100 1000) 1 hertz (hz) repetition rate. induced temperature rise generated exposure parameters, hereafter termed thermal gradient, measured applied independently cell suspension order differentiate inactivation triggered electric field (e-field) heating. treated cell suspension plated cellular inactivation quantified colony count 24-hour (h) incubation period. additionally, cell exposure condition incubated various antibiotic-soaked disc determine nspef exposure would induce change antibiotic susceptibility. result indicate that, species, total delivered energy (amplitude, pulse number pulse duration) determined magnitude cell inactivation. specifically, 18.5 23.5 kv cm(â\\x88\\x921) exposures, l. acidophilus sensitive inactivation effect nspef e. coli, however, 13.5 kv cm(â\\x88\\x921) exposure e. coli sensitive, suggesting l. acidophilus may need meet e-field threshold significant inactivation occur. result indicate antibiotic susceptibility enhanced multiple nspef exposures, observed increased zone growth inhibition. moreover, species, temperature increase â\\x89¤ 20 â°c (89% exposures) sufficient significantly alter cell inactivation, whereas none thermal equivalent exposure sufficient change antibiotic susceptibility categories.',\n",
       " 'background: adult chronic condition heart disease, diabetes, lung likely develop complication number vaccine-preventable diseases, influenza pneumonia. study, use chronic management information system shanghai estimate vaccination coverage characterize predictor seasonal influenza 23-valent pneumococcal polysaccharide vaccine (ppsv23) vaccination among people chronic shanghai. methods: shanghai center control prevention information system related chronic management, hospital records, immunizations. individual hypertension, diabetes chronic obstructive pulmonary (copd) abstracted july 2017. main outcome coverage pneumococcal influenza vaccination. vaccination coverage calculated across demographic groups. significance bivariate association assessed pearsonâ\\x80\\x99s chi-square tests, multivariable model logistic regression model forward stepwise select variables. results: sample 2,531,227 individual â\\x89¥15 years, 22.8% vaccinated pneumonia january 2013 july 2017, vaccination coverage influenza 2016/17 influenza season 0.4%. vaccination coverage highest 70â\\x80\\x9379 lowest younger 60. compared urban areas, uptake rural area higher pneumonia vaccination (or: 2.43, 95% ci: 2.41, 2.45), lower influenza vaccination (or: 0.55, 95% ci: 0.51, 0.59). greater number chronic disease associated higher likelihood pneumonia vaccination (3 v 1: or: 1.68, 95% ci: 1.64, 1.71), relationship statistically significant influenza vaccination. conclusions: found low level pneumococcal vaccination, extremely low uptake influenza vaccination among individual high risk condition shanghai priority group targeted vaccination. intervention could designed target group low uptake â\\x80\\x93 like younger adults, individual yet retired.',\n",
       " 'background: since declaration 10th ebola (evd) outbreak drc 1st aug 2018, several neighboring country developing implementing preparedness effort prevent evd cross-border transmission enable timely detection, investigation, response event confirmed evd outbreak country. describe ugandaâ\\x80\\x99s experience evd preparedness. results: 4 august 2018, uganda ministry (moh) activated public emergency operation centre (pheoc) national task force (ntf) public emergency plan, guide, coordinate evd preparedness country. ntf selected incident management team (imt), constituting national rapid response team (nrrt) supported activation district task force (dtfs) district rapid response team (drrts) jointly assessed level preparedness 30 designated high-risk district representing category 1 (20 districts) category 2 (10 districts). moh, technical guidance world organisation (who), led evd preparedness activity worked together ministry partner organisation enhance community-based surveillance systems, develop disseminate risk communication messages, engage communities, reinforce evd screening prevention measure point entry (poes) high-risk facilities, construct equip evd isolation units, establish coordination procurement mechanisms. conclusion: 31 may 2019, confirmed evd uganda continued make significant verifiable progress evd preparedness. need sustain efforts, evd preparedness across entire spectrum multi-hazard framework. effort strengthen country capacity compel country avail resource preparedness management incident source effectively cutting cost â\\x80\\x9cfire-fightingâ\\x80\\x9d approach public emergencies.',\n",
       " 'background: birth asphyxia account one-quarter newborn deaths. providing quality care service neonatal resuscitation reduces neonatal mortality. however, challenge providing quality neonatal resuscitation well investigated ethiopia. hence, conducted ass quality provision neonatal resuscitation ethiopia. method: used ethiopian 2016 emergency obstetric newborn care survey, conducted 3804 facility providing maternal newborn services. described quality neonatal resuscitation service according structure, process outcome triad quality dimension. register birth record last 12 month prior survey extracted. facility, three last eligible chart resuscitated neonate reviewed highest frequency chart resuscitated baby considered analysis. thus, total 555 chart assessed. logistic regression model used ass relationship neonatal resuscitation processes, provider, facility newborn characteristic neonatal outcome time discharge. results: finding suggested that, around two-third, 364(65.6%) asphyxiated baby resuscitated bag mask type neonatal resuscitation. baby got neonatal resuscitation 463 (83.4%) survived. resuscitated neonate gestational age greater 37 week (adjusted odds ratio (aor) =1.82; 95% confidence interval (ci) (1.09â\\x80\\x933.04)), availability priority equipment facility neonatal resuscitation (aor = 1.24, 95% ci (1.09, 1.54)) woman 12 h le duration labor (aor = 1.76; 95% ci (1.23, 3.13)) independent factor survival neonate. conclusion: half facility ready neonatal resuscitation (nr) term priority equipmentâ\\x80\\x99s. however, eight ten baby survived nr ethiopia. gestational age, priority equipment nr duration labor determinant survival resuscitated neonate ethiopia. therefore, availability priority equipment attentive care follow-up premature neonate face prolonged labor need improved ethiopia.',\n",
       " 'background: detection mycobacterium tuberculosis (mtb) intensive care unit (icu) present several challenges, mainly associated clinical state patient. presence hiv aggravates scenario, requiring reliable collection method, better performance microbiological/molecular technique used. evaluated performance two method sample collection, mini bronchoalveolar lavage (mini-bal) endotracheal aspirate (eta), diagnosis pulmonary tuberculosis (ptb) critically ill patients. methods: prospective involved 26 hiv positive icu internalized patients, presumptive ptb required mechanical ventilation. two sample obtained prospectively 26 hiv icu presumptive ptb mini-bal eta. sample processed smear microscopy, lã¶wenstein-jensen medium bactec mycobacteria growth indicator tube 960 systemâ®. define confirmed ptb positive mtb culture. furthermore, sample obtained mini-bal analyzed xpertâ® mtb/rif. results: result demonstrated respiratory sample obtained mini-bal able increase mtb detection critically ill presumptive ptb. mini-bal allowed 30% increased recovery guaranteed enough sample volume processing methods. addition, larger volume sample obtained technique enabled xpertâ® mtb/rif molecular test diagnosis tb. conclusions: mini-bal showed acceptable alternative eta population, since critically ill often-immunocompromised likely develop complication related invasive procedures.',\n",
       " 'background: infection multidrug-resistant organism (mdro) pose serious threat dysregulated immunity hemophagocytic lymphohistiocytosis (hlh), infection rarely comprehensively characterized. here, present fatal hlh secondary cytomegalovirus (cmv) complicated anti-viral drug resistance sepsis multiple mdros pandrug-resistant superbug bacteria. presentation: healthy, six-year-old boy presented 45-day history fever prior diagnosis hemophagocytic lymphohistiocytosis hemorrhagic colitis, associated cmv. hospital admission, found colonized multiple, multidrug-resistant (mdr) bacteria vancomycin-resistant enterococci (vre) carbapenamase-producing organism (cpo). eventually developed respiratory, urine bloodstream infection highly drug-resistant, pandrug-resistant bacteria, could controlled antibiotic treatment. antiviral therapy failed contain cmv succumbed overwhelming bacterial infection. whole genome sequencing (wgs) mdr bacteria metagenomic analysis blood sample revealed unusual accumulation wide range antimicrobial resistance mechanism single patient, antiviral resistance ganciclovir, resistance mechanism currently available antibiotics. conclusions: highlight risk acquiring mdr superbug severity infection hlh patients.',\n",
       " 'human cytomegalovirus (hcmv) infection wide-spread among general population manifestation ranging asymptomatic severe developmental disability newborn life-threatening illness individual compromised immune system. nearly current drug suffer limitations, emphasizes critical need develop approach molecules. reasoned â\\x80\\x98poly-pharmacyâ\\x80\\x99 approach relying simultaneous binding multiple receptor involved hcmv entry host cell could pave way effective therapeutic outcome. work present synthetic, small molecule displaying pleiotropicity interaction competitive antagonist cell surface receptor heparan sulfate proteoglycans heparan sulfate-binding proteins, play important role hcmv entry spread. sulfated pentagalloylglucoside (spgg), functional mimetic heparan sulfate, inhibits hcmv entry human foreskin fibroblast neuroepithelioma cell high potency. time, spgg exhibit toxicity level high 50-fold inhibition potency. interestingly, cell-elisa assay showed downregulation hcmv immediate-early gene 1 2 (ie 1&2) expression presence spgg supporting inhibition entry. finally, hcmv focus observed decrease significantly presence spgg suggesting impact spread too. overall, work offer first evidence pleiotropicity, demonstrated spgg, may offer poly-therapeutic approach toward effective inhibition hcmv.',\n",
       " 'background: current national influenza vaccination schedule mexico recommend vaccination school-aged population (5â\\x80\\x9311 years). currently, limited middle-income country analysing cost-effectiveness influenza vaccination population. explored clinical effect economic benefit expanding current national influenza vaccination schedule mexico include school-aged population. methods: static 1-year model incorporating herd effect used ass cost-effectiveness expanding current national influenza vaccination schedule mexico include school-aged population. performed cross-sectional epidemiological influenza record (2009â\\x80\\x932018), death record (2010â\\x80\\x932015), discharge hospitalisation record (2010â\\x80\\x932016), database mexicoâ\\x80\\x99s influenza surveillance system (sisveflu), national mortality epidemiological statistical system (seed), automated hospital discharge system (saeh), respectively. cost estimate influenza case based 7 scenario analysed sisveflu; assumption clinical management case defined according mexicoâ\\x80\\x99s national clinical guidelines. primary outcome number influenza case avoided. sensitivity analysis performed conservative optimistic parameter (vaccination coverage: 30% / 70%, vaccine effectiveness: 19% / 68%). results: estimated expanding influenza immunisation programme cover school-aged population mexico 2018â\\x80\\x932019 influenza season would 671,461 case influenza avoided (50% coverage 50% effectiveness assumed). associated 262,800 fewer outpatient consultations; 154,100 fewer emergency room consultations; 97,600 fewer hospitalisations, 15 fewer deaths. analysis case avoided age-group showed 55.4% school-aged population, decrease outpatient consultation largest population. overall decrease economic burden mexican care system 111.9 million u dollars; immunization programme determined cost-saving base, conservative optimistic scenarios. conclusions: vaccinating school-aged population mexico would cost-effective; expansion current national vaccination schedule age group supported.',\n",
       " 'background: noticeable interest ketamine infusion sedation management developed among critical care physician critically ill patients. 2018 pain, agitation/sedation, delirium, immobility, sleep disruption guideline suggested low-dose ketamine infusion adjunct opioid therapy reduce opioid requirement post-surgical intensive care unit (icu). was, however, rated conditional due low quality evidence. ketamine favorable characteristics, making especially viable alternative respiratory hemodynamic instability. analgo-sedative adjunct ketamine infusion mechanically ventilated icu (attainment) trial aim ass effect safety adjunct low-dose continuous infusion ketamine analgo-sedative compared standard care critically ill mechanical ventilation (mv) â\\x89¥ 24 h. methods/design: trial prospective, randomized, active controlled, open-label, pilot, feasibility adult icu (> 14 year old) mv. take place adult icu king faisal specialist hospital research center (kfsh&rc), riyadh, saudi arabia, enroll 80 patients. randomized post-intubation two groups: intervention group receive adjunct low-dose continuous infusion ketamine plus standard care. ketamine administered period 48 h fixed infusion rate 2 î¼g/kg/min (0.12 mg/kg/h) first 24 h followed 1 î¼g/kg/min (0.06 mg/kg/h) second 24 h. control group receive standard care icu (propofol and/or fentanyl and/or midazolam) according kfsh&rc sedation analgesia protocol clinically appropriate. primary outcome mv duration icu discharge, death, extubation, 28 day post-randomization, whichever come first. discussion: first enrolled 1 september 2019. 10 october 2019, total 16 enrolled. expect complete recruitment 31 december 2020. finding pilot trial likely justify investigation role adjunct low-dose ketamine infusion analgo-sedative agent larger, multicenter, randomized controlled trial. trial registration: clinicaltrials.gov: nct04075006. registered 30 august 2019. current controlled trials: isrctn14730035. registered 3 february 2020.',\n",
       " 'background: drug safety assessment clinical trial present unique analytical challenges. include adjusting individual follow-up time, repeated measurement multiple outcome missing among others. furthermore, pre-specifying appropriate analysis becomes difficult safety endpoint unexpected. although existing guideline consort encourage thorough reporting adverse event (aes) clinical trials, provide limited detail safety analysis. limited guideline may influence suboptimal analysis failing account analysis challenge above. typical example challenge exist trial anti-malarial drug malaria prevention pregnancy. lack proper standardized evaluation safety antimalarial drug limited ability draw conclusion safety. therefore, systematic review conducted establish current practice statistical analysis preventive antimalarial drug safety pregnancy. methods: search included five database (pubmed, embase, scopus, malaria pregnancy library cochrane central register controlled trials) identify original english article reporting phase iii randomized controlled trial (rcts) anti-malarial drug malaria prevention pregnancy published january 2010 july 2019. results: eighteen trial included review collected multiple longitudinal safety outcome aes. statistical analysis reporting safety outcome trial used descriptive statistics; proportions/counts (n = 18, 100%) mean/median (n = 2, 11.1%). result presentation included tabular (n = 16, 88.9%) text description (n = 2, 11.1%). univariate inferential method reported trial (n = 16, 88.9%); chi square/fisherâ\\x80\\x99s exact test (n = 12, 66.7%), test (n = 2, 11.1%) mannâ\\x80\\x93whitney/wilcoxon test (n = 1, 5.6%). multivariable methods, poisson negative binomial reported trial (n = 3, 16.7%). assessment potential link missing efficacy safety outcome reported trial reported efficacy missing (n = 7, 38.9%). conclusion: review demonstrated statistical analysis safety anti-malarial drug malarial chemoprevention pregnancy rcts inadequate. analysis insufficiently account multiple safety outcome potential dependence, follow-up time informative missing compromise anti-malarial drug safety evidence development, based available data.',\n",
       " 'a. acute hypercapnic respiratory failure a1. acute exacerbation copd: recommendations: niv used management acute exacerbation copd acute acute-on-chronic respiratory acidosis (ph = 7.25-7.35). (1a) niv attempted acute exacerbation copd (ph <7.25 & paco2 â\\x89¥ 45) initiating invasive mechanical ventilation (imv) except requiring immediate intubation. (2a). lower ph higher chance failure niv. (2b) niv used routinely normo- mildly hyper-capneic acute exacerbation copd, without acidosis (ph > 7.35). (2b) a2. niv arf due chest wall deformities/neuromuscular diseases: recommendations: niv may used arf due chest wall deformity/neuromuscular diseases. (paco2 â\\x89¥ 45) (upp) a3. niv arf due obesity hypoventilation syndrome (ohs): recommendations: niv may used ahrf oh present acute hypercapnic acute chronic respiratory failure (ph 45). (3b) niv/cpap may used obese, hypercapnic oh and/or right heart failure absence acidosis. (upp) b. niv acute hypoxemic respiratory failure: b1. niv acute cardiogenic pulmonary oedema: recommendations: niv recommended hospital arf, due cardiogenic pulmonary edema. (1a). niv used acute heart failure/ cardiogenic pulmonary edema, right emergency department itself. (1b) cpap bipap mode safe effective cardiogenic pulmonary edema. (1a). however, bpap (niv-ps) preferred cardiogenic pulmonary edema hypercapnia. (3a) b2. niv acute hypoxemic respiratory failure: recommendations: niv may used conventional oxygen therapy mild early acute hypoxemic respiratory failure (p/f ratio <300 >200 mmhg), close supervision. (2b) strongly recommend trial niv acute hypoxemic failure p/f ratio <150. (2a) b3. niv arf due chest trauma: recommendations: niv may used traumatic flail chest along adequate pain relief. (3b) b4. niv immunocompromised host: recommendations: immunocompromised early arf, may consider niv conventional oxygen. (2b). b5. niv palliative care: recommendations: strongly recommend use niv reducing dyspnea palliative care setting. (2a) b6. niv post-operative cases: recommendations: niv used post-operative acute respiratory failure. (2a) b6a. niv abdominal surgery: recommendations: niv may used arf following abdominal surgeries. (2a) b6b. niv bariatric surgery: recommendations: niv may used post-bariatric surgery pre-existent osa ohs. (3a) b6c. niv thoracic surgery: recommendations: cardiothoracic surgeries, use niv recommended post operatively acute respiratory failure improve oxygenation reduce chance reintubation. (2a) niv used undergoing esophageal surgery. (upp) b6d. niv post lung transplant: recommendations: niv may used shortening weaning time avoid re-intubation following lung transplantation. (2b) b7. niv procedure (eti/bronchoscopy/tee/endoscopy): recommendations: niv may used pre-oxygenation intubation. (2b) niv appropriate interface may used arf bronchoscopy/endoscopy improve oxygenation. (3b) b8. niv pneumonitis ards: recommendations: niv cannot considered choice acute respiratory failure h1n1 pneumonia. however, may reasonable use niv selected single organ involvement, strictly controlled environment close monitoring. (2b) b9. niv acute exacerbation pulmonary tuberculosis: recommendations: careful use niv acute tuberculosis may considered, effective control precaution prevent air-borne transmission. (3b) b10. niv planned extubation high risk patients: recommendation: recommend niv may used wean high risk invasive mechanical ventilation reduces re-intubation rate. (2b) b11. niv respiratory distress post extubation: recommendations: recommend niv therapy used manage respiratory distress post-extubation high risk patients. (2b) c. application niv: recommendation: choice mode mainly decided factor like etiology severity, breathing effort operator familiarity experience. (upp) suggest flow trigger pressure triggering assisted modes, provides better ventilator synchrony. especially copd patients, flow triggering found benefit auto peep. (3b) d. management niv: d1. sedation: recommendations: non-pharmacological approach calm (reassuring patient, proper environment) always tried administrating sedatives. (upp) niv, sedation may used extremely close monitoring icu setting lookout sign niv failure. (upp) e. equipment: recommendations: recommend portable bilevel ventilator specifically designed icu ventilator non-invasive mode used delivering nonâ\\x80\\x93invasive ventilation critically ill patients. (upp) critical care ventilator leak compensation bi-level ventilator equally effective decreasing wob, rr, paco2. (3b) currently, oronasal mask preferred interface non-invasive ventilation acute respiratory failure. (3b) f. weaning: recommendations: recommend weaning niv may done standardized protocol driven approach unit. (2b) cite article: chawla r, dixit sb, zirpe kg, chaudhry d, khilnani gc, mehta y, et al. isccm guideline use non-invasive ventilation acute respiratory failure adult icus. indian j crit care med 2020;24(suppl 1):s61â\\x80\\x93s81.',\n",
       " 'background: porcine circovirus type 2 (pcv2) causative agent porcine circovirus-associated (pcvad). prevalence swine herd first reported china 2000. pcv2 cause immunosuppression lead multiple diseases, causing serious economic problem swine industry china. since information genetic variation pcv2 yunnan province limited, aim investigate molecular epidemiological evolutionary characteristic pcv2 2016 2019. methods: total 279 clinical sample collected different region yunnan 2016 2019, pcv2 detected pcr. amplified full genome positive samples, sequence analysed homology genetic evolution. results: overall, 60.93% (170/279) screened swine herd sample positive pcv2. sequenced 15 yunnan province pcv2 strain positive samples. analysis complete genome cap gene led classification 15 yunnan pcv2 strain pcv2a (2 15), pcv2b (1of 15) pcv2d (12 15). strain shared 94.3â\\x80\\x9399.9% identity nucleotide sequence complete genome shared 94.2â\\x80\\x9399.9% identity reference sequences. strain share 89.4â\\x80\\x93100% 86.8â\\x80\\x93100% identity nucleotide amino acid (aa) sequence cap, respectively. conclusions: result provide evidence pcv2a, pcv2b pcv2d genotype coexisted yunnan province 2016 2019, priority prevalence genotype pcv2d. provide evidence increased genetic diversity insight molecular epidemiology pcv2. provides basic yunnan province pcv2 molecular epidemiological survey accumulates effective material development pcv2 vaccines.',\n",
       " '',\n",
       " '',\n",
       " 'complication idiopathic pulmonary fibrosis (ipf) responsible relevant proportion mortality. importantly, acute exacerbation lead in-hospital mortality 50% mean survival time months. therefore, consideration complication ipf great importance understanding planning. furthermore, evidence pneumological rehabilitation ipf greatly increased. resulted specific recommendation american thoracic society (ats) european respiratory society (ers) improvement physical capacity, quality life symptom control.',\n",
       " '',\n",
       " '',\n",
       " 'research dedicated reactive oxygen specie (ros) performed decades, yet outcome remain controversial. relentless effort studies, researcher explored role ro biosystem various diseases. ro beneficial biosystem presenting signalling molecule enhancing immunologic defence. however, harmful effect causing tissue organ damages. result controversial study focusing ro ros-related disease regulating ro inhibitor promotors. competing result hindered process investigation specific mechanism lying behind. opinion presented review interpret research ro different dimension might explain competing result ro introduced far broader perspective. review brings different thinking researchers, neglected feature potential ros, relate work ro explore mechanism subject ros.',\n",
       " 'identification cause poor oral vaccine immunogenicity low-income country might lead effective vaccines. measured mucosal systemic immune parameter time vaccination oral poliovirus vaccine (opv) 292 indian infant aged 6â\\x80\\x9311 months, plasma cytokines, leukocyte counts, fecal biomarkers environmental enteropathy peripheral blood t-cell phenotype, focused gut-homing regulatory cd4+ populations. find distinct immune phenotype associated opv immunogenicity, although pathogen prevalent stool time immunization among infant failed seroconvert (63.9% vs. 45.6%, p = 0.002). machine-learning approach, could predict seroconversion priori immune parameter status median 58% accuracy (cross-validation iqr: 50â\\x80\\x9369%) compared 50% expected chance. better identification immune predictor opv immunogenicity likely require sampling mucosal tissue improved oral poliovirus models.',\n",
       " '',\n",
       " 'influenza continues baffle human constantly changing nature. twenty-first century witnessed considerable advance understanding influenza pathogenesis, synergy bacterial infection diagnostic methods. however, challenge continue: find le expensive reliable point-of-care test use developing countries, produce efficacious antiviral drugs, explore way combat emerging antiviral resistance develop vaccine either produced shorter production time overcome need annual matching circulating influenza strains. importantly india, nation suffered highest mortality influenza pandemic 1918, urgent need gear existing preparedness next pandemic capable hit moment time.',\n",
       " 'toen dit nummer voor u samenstelden de coronacrisis nog ver van ons. inmiddels zitten er middenin en bloeddrukbehandeling lijkt nu geen prioriteit. toch vinden huisartsen het altijd al lastig om met oudere patiã«nten hun bloeddrukbehandeling te praten. uit het artikel van emma van bussel blijkt dat patiã«nten er zelf ook niet graag beginnen. hoewel dit kwalitatieve onderzoek van van bussel gedaan bij een beperkt aantal ouderen, geeft het een duidelijk signaal af. ouderen willen juist wã¨l graag met hun huisarts praten afbouwen van bloeddrukmedicatie, de invloed van leeftijd en bijwerkingen. ondanks hun controles bij de praktijkondersteuner. dat de huisarts erkent dat er onzekerheid bestaat de gevolgen van mogelijke keuzes, stellen ze daarbij op prijs.',\n",
       " 'elane neutropenia associated myelodysplasia acute leukemia (mdsâ\\x80\\x93al), severe infections. mdsâ\\x80\\x93al risk associated exposure gcsf, since 2005, france, receiving high daily gcsf dos (>15 î¼g/kg/day) eligible hsct, addition classic indication (mdsâ\\x80\\x93al gcsf refractoriness). analyzed effect policy. among 144 prospectively followed elane-neutropenia enrolled french severe congenital neutropenia registry, defined two group according period: â\\x80\\x9cbefore 2005â\\x80\\x9d born 2005 followed 31/12/2004 (1588 person-years); â\\x80\\x9cafter 2005â\\x80\\x9d comprised born 2005 born 2005 followed 2005 31/03/2019 (1327 person-years). sixteen cohort underwent hsct (14 long-term survivors) six developed mdsâ\\x80\\x93als. six leukemic transformation occurred before-2005 group none 2005 (respective frequency 3.8 ã\\x97 10(â\\x80\\x933) vs. 0; p < 0.01), four hscts done 2005 12 since 2005 (respective hsct rate increased 2.5 ã\\x97 10(â\\x80\\x933) vs. 9 ã\\x97 10(â\\x80\\x933); p < 0.01). result support early hsct elane mutation received high gcsf doses, might lower risk leukemic transformation.',\n",
       " 'vitamin testing use vitamin supplement increased substantially recent years. currently, role vitamin supplementation, optimal vitamin dose status, subject debate, interventional study unable clear benefit (in mostly vitamin replete populations). may attributed limitation trial design, study meet basic requirement nutrient intervention study, vitamin d-replete populations, small sample sizes, inconsistent intervention method regarding dose metabolites. vitamin deficiency (serum 25-hydroxyvitamin [25(oh)d] < 50 nmol/l 20 ng/ml) associated unfavorable skeletal outcomes, fracture bone loss. 25(oh)d level >50 nmol/l 20 ng/ml is, therefore, primary goal, although suggest benefit higher threshold. severe vitamin deficiency 25(oh)d concentration <30 nmol/l (or 12 ng/ml) dramatically increase risk excess mortality, infections, many diseases, avoided whenever possible. benefit mortality prevention infections, least severely deficient individuals, appear convincing. vitamin clearly panacea, likely efficient deficiency. given rare side effect relatively wide safety margin, may important, inexpensive, safe adjuvant therapy many diseases, future well-designed study evaluate further. worldwide public intervention includes vitamin supplementation certain risk groups, systematic vitamin food fortification avoid severe vitamin deficiency, would appear important. narrative review, current international literature vitamin deficiency, relevance, therapeutic option discussed.',\n",
       " '',\n",
       " '',\n",
       " 'article ten review selected annual update intensive care emergency medicine 2020. selected article found online https://www.biomedcentral.com/collections/annualupdate2020. information annual update intensive care emergency medicine available http://www.springer.com/series/8901.',\n",
       " 'background: effect renal replacement therapy (rrt) outcome severe acute kidney injury (aki) out-of-hospital cardiac arrest (ohca) uncertain. aimed evaluate association rrt 6-month mortality severe aki treated targeted temperature management (ttm) ohca. methods: retrospective analysis prospectively collected multicentre observational cohort included adult ohca treated ttm across 22 hospital south korea october 2015 december 2018. aki diagnosed kidney disease: improving global outcome criteria. primary outcome 6-month mortality secondary outcome cerebral performance category (cpc) 6 months. multivariate cox regression analysis performed define role rrt stage 3 aki. results: among 10,426 ohca, 1373 treated ttm. excluding died within 48 h return spontaneous circulation (rosc) pre-arrest chronic kidney disease, cohort comprised 1063 patients. aki developed 590 (55.5%) 223 (21.0%) stage 3 aki. among them, 115 (51.6%) treated rrt. common modality among rrt continuous renal replacement therapy (111 [96.5%]), followed intermittent haemodialysis (4 [3.5%]). distribution cpc (1â\\x80\\x935) 6 month non-rrt vs. rrt group 3/108 (2.8%) vs. 12/115 (10.4%) cpc 1, 0/108 (0.0%) vs. 1/115 (0.9%) cpc 2, 1/108 (0.9%) vs. 3/115 (2.6%) cpc 3, 6/108 (5.6%) vs. 6/115 (5.2%) cpc 4, 98/108 (90.7%) vs. 93/115 (80.9%) cpc 5, respectively (p = 0.01). rrt group significantly lower 6-month mortality non-rrt group (93/115 [81%] vs. 98/108 [91%], p = 0.04). multivariate cox regression analysis showed rrt independently associated lower risk death stage 3 aki (hazard ratio, 0.569 [95% confidence interval, 0.377â\\x80\\x930.857, p = 0.01]). conclusion: dialysis intervention independently associated lower risk death stage 3 aki treated ttm ohca.',\n",
       " 'article ten review selected annual update intensive care emergency medicine 2020. selected article found online https://www.biomedcentral.com/collections/annualupdate2020. information annual update intensive care emergency medicine available http://www.springer.com/series/8901.',\n",
       " 'background: tuberculous pleurisy (tbp) common form extrapulmonary tuberculosis (tb). however, rapid diagnostic method high accuracy tuberculous pleurisy urgently needed. present study, evaluated diagnostic accuracy xpert mtb/rif, lamp sat-tb assay pleural fluid culture-positive tbp patients. methods: prospectively enrolled 300 exudative pleural effusion used sample xpert mtb/rif, lamp sat-tb assay. these, 265 223 diagnosed tbp 42 non-tbp used control analyzed. results: sensitivity xpert mtb/rif (27.4%), lamp (26.5%) sat-tb assay (32.3%) significantly higher pleural effusion smear (14.3%, x(2) = 20.65, p < 0.001), whereas much lower expected analysis pleural effusion samples. sat-tb assay xpert mtb/rif demonstrated high specificity (100%) ppvs (100%), npvs test < 22%. area roc curve pleural effusion smear, lamp, xpert mtb/rif sat-tb assay 0.524 (95% ci 0.431â\\x80\\x930.617), 0.632 (95% ci 0.553â\\x80\\x930.71), 0.637 (95% ci 0.56â\\x80\\x930.714) 0.673 (95% ci 0.6â\\x80\\x930.745). sat-tb assay highest auc. conclusion: nucleic acid amplification test first choice diagnosis tuberculous pleurisy. type test, sat-tb recommended low cost, relatively accurate compared two tests. prospective approved ethic committee shanghai pulmonary hospital (approval number: k19â\\x80\\x93148). trial registration: clinicaltrials.gov identifier: chictr1900026234 (retrospectively registered). registration date september 28, 2019.',\n",
       " 'article ten review selected annual update intensive care emergency medicine 2020. selected article found online https://www.biomedcentral.com/collections/annualupdate2020. information annual update intensive care emergency medicine available http://www.springer.com/series/8901.',\n",
       " 'article ten review selected annual update intensive care emergency medicine 2020. selected article found online https://www.biomedcentral.com/collections/annualupdate2020. information annual update intensive care emergency medicine available http://www.springer.com/series/8901.',\n",
       " '',\n",
       " 'article ten review selected annual update intensive care emergency medicine 2020. selected article found online https://www.biomedcentral.com/collections/annualupdate2020. information annual update intensive care emergency medicine available http://www.springer.com/series/8901.',\n",
       " 'article ten review selected annual update intensive care emergency medicine 2020. selected article found online https://www.biomedcentral.com/collections/annualupdate2020. information annual update intensive care emergency medicine available http://www.springer.com/series/8901.',\n",
       " 'background: v. parahaemolyticus autochthonous marine environment cause seafood-borne gastroenteritis humans. generally, v. parahaemolyticus recovered environment and/or seafood thought non-pathogenic relationship environmental isolates acute diarrhoeal poorly understood. study, explored virulence potential environmental v. parahaemolyticus isolated water, plankton assorted seafood sample collected indian coast. results: twenty-two v. parahaemolyticus isolates seafood harboured virulence associated gene encoding thermostable-direct haemolysin (tdh), tdh-related haemolysin (trh), type 3 secretion system (t3ss) 95.5% toxigenic isolates pandemic strain attribute (toxrs/new(+)). nine serovars, pandemic strain trait newly identified o4:k36 tdh(â\\x88\\x92)trh(+)v. parahaemolyticus bearing pandemic marker gene recognised first time. result obtained reverse transcription pcr showed trh, t3ss1 t3ss2î² functional seafood isolates. moreover, environmental strain cytotoxic could invade caco-2 cell upon well induce change tight junction protein, zo-1 actin cytoskeleton. conclusion: provides evidence environmental isolates v. parahaemolyticus potentially invasive capable eliciting pathogenic characteristic typical clinical strain present potential risk. demonstrate virulence pathogen highly complex hence draw attention need investigate reliable virulence marker order distinguish environmental clinical isolates, crucial pathogenomics control pathogen.',\n",
       " 'background: several study found weak moderate correlation oxygenation lung aeration response change peep. aimed investigate association change shunt, low high ventilation/perfusion (v/q) mismatch, computed tomography-measured lung aeration following increase peep ards. methods: preliminary study, 12 ards subjected recruitment maneuver followed setting peep 5 either 15 20 cmh(2)o. lung aeration measured computed tomography. value pulmonary shunt low high v/q mismatch calculated model-based measurement oxygenation, ventilation, metabolism taken different inspired oxygen level arterial blood gas sample. results: increasing peep resulted reduced value pulmonary shunt percentage non-aerated tissue, increased percentage normally aerated tissue (p < 0.05). change shunt normally aerated tissue significantly correlated (r = â\\x88\\x92 0.665, p = 0.018). three distinct response increase peep observed value shunt v/q mismatch: beneficial response seven patients, shunt decreased without increasing high v/q; detrimental response four shunt high v/q increased; detrimental response reduced shunt increased high v/q mismatch. non-aerated tissue decreased increased peep patients, hyperinflated tissue increased detrimental response shunt v/q mismatch. conclusions: result improved lung aeration following increase peep always consistent reduced shunt v/q mismatch. poorly matched redistribution ventilation perfusion, dependent non-dependent region lung, may explain showed detrimental change shunt v/q mismatch increase peep, despite improved aeration. trial registration: clinicaltrails.gov, nct04067154. retrospectively registered august 26, 2019.',\n",
       " 'article ten review selected annual update intensive care emergency medicine 2020. selected article found online https://www.biomedcentral.com/collections/annualupdate2020. information annual update intensive care emergency medicine available http://www.springer.com/series/8901.',\n",
       " 'article ten review selected annual update intensive care emergency medicine 2020. selected article found online https://www.biomedcentral.com/collections/annualupdate2020. information annual update intensive care emergency medicine available http://www.springer.com/series/8901.',\n",
       " 'article ten review selected annual update intensive care emergency medicine 2020. selected article found online https://www.biomedcentral.com/collections/annualupdate2020. information annual update intensive care emergency medicine available http://www.springer.com/series/8901.',\n",
       " 'national policy global (npgh) arena multisectoral governing arrangement cooperation health, development, foreign affair sector government policy global governance. explore relationship national global process governing global health, paper asks: form interaction npgh arena global governance learning networking process present? multiple norwegian swiss npgh arenas, collected intersectoral policy process semi-structured interview 33 informant 2014-2015. adapting real-datoâ\\x80\\x99s framework, analyzed separately, producing monograph comparing npgh arenas. analyzing npgh arena relational structure linking external resource internal policy arena processes, found five zone interaction - institutions, transgovernmental clubs, connective forms. interaction circulate idea soften arenasâ\\x80\\x99 boundaries. argue npgh characteristic transnational governance global health. electronic supplementary material: online version article (10.1007/s11077-020-09375-2) contains supplementary material, available authorized users.',\n",
       " 'detection pathogen-specific antibody remains cornerstone clinical diagnostics. yet, many test exhibit undesirable performance completely lacking. given this, developed serum epitope repertoire analysis (sera), rapidly discover conserved, pathogen-specific antigen epitopes, applied develop assay chaga caused protozoan parasite trypanosoma cruzi. antibody binding peptide motif identified 28 chaga repertoire bacterial display random 12-mer peptide library next-generation sequencing (ngs). thirty-three motif selected mapped candidate chaga antigens. blinded validation set (n = 72), 30/30 chaga positive, 30/30 non-chagas negative, 1/12 leishmania sp. positive. unblinding, leishmania cross-reactive epitope identified removed panel. chaga assay exhibited 100% sensitivity (30/30) specificity (90/90) second blinded validation set individual parasitic infections. amongst additional epitope repertoire chaga serostatus, assay specificity 99.8% (998/1000). thus, chaga assay achieved combined sensitivity specificity equivalent superior diagnostic algorithm rely three separate test achieve high specificity. ngs-based serology via serum provides effective approach discover antigenic epitope develop high performance multiplex serological assays.',\n",
       " 'design: descriptive study. objectives: aim manuscript describe development process set national spinal cord injury registry iran (nscir-ir). setting: sci community iran. methods: nscir-ir set developed 8 months, march 2015 october 2015. expert panel 14 member formed. review set similar registry developed countries, selection modification basic framework performed 16 meetings, based objective feasibility registry. results: final version set composed 376 element sociodemographic, hospital admission, injury incidence, prehospital procedures, emergency department visit, medical history, vertebral injury, spinal cord injury details, interventions, complications, discharge data. includes 163 component international standard neurologic classification spinal cord injury (isncsci) 65 element related quality life, pressure ulcers, pain, spasticity. conclusion: nscir-ir set developed order meet quality improvement objective registry. process centered around choosing element assessing care provided individual acute chronic phase sci hospital settings. international spinal cord injury set selected basic framework, helped comparison countries. expert panel modification facilitated implementation registry process current clinical workflow hospitals.',\n",
       " 'mayaro (mayv) endemic south american country responsible sporadic outbreak acute febrile illness. hallmark mayv highly debilitating chronic arthralgia. although mayv emergence potential threat, specific therapy licensed vaccine. study, developed murine model mayv emulates many relevant clinical feature human tested live-attenuated mayv vaccine candidate (mayv/ires). intraplantar inoculation wt strain mayv immunocompetent mouse induced persistent hypernociception, transient replication target organs, systemic production inflammatory cytokines, chemokines specific humoral igm igg responses. inoculation mayv/ires balb/c mouse induced strong specific cellular humoral responses. moreover, mayv/ires vaccination immunocompetent interferon receptor-defective mouse resulted protection induced virulent wt mayv strain. thus, describes novel model mayv immunocompetent mouse highlight potential role live-attenuated mayv vaccine candidate hostâ\\x80\\x99s protection induced virulent mayv strain.',\n",
       " 'background: ventilation/perfusion inequality impair gas exchange acute respiratory distress syndrome (ards). although increased dead-space ventilation (v(d)/v(t)) described ards, mechanism clearly understood. sought evaluate relationship dynamic variation v(d)/v(t) extra-pulmonary microcirculatory blood flow detected sublingual mucosa hypothesizing altered microcirculation, generalized phenomenon severe inflammatory conditions, could influence ventilation/perfusion mismatching manifested increase v(d)/v(t) fraction early stage ards. methods: forty-two consecutive early moderate severe ards included. peep set targeting best respiratory-system compliance peep-decremental recruitment maneuver. 60 min stabilization, hemodynamics respiratory mechanic recorded blood gas collected. v(d)/v(t) calculated co(2) production ([formula: see text] ) co(2) exhaled fraction ([formula: see text] ) measurement volumetric capnography. sublingual microcirculatory image simultaneously acquired sidestream dark-field device ulterior blinded semi-quantitative analysis. measurement repeated 24 h after. results: percentage small vessel perfused (ppv) microcirculatory flow index (mfi) inverse significantly related v(d)/v(t) baseline (spearmanâ\\x80\\x99s rho = â\\x88\\x92 0.76 â\\x88\\x92 0.63, p < 0.001; r(2) = 0.63, 0.48, p < 0.001, respectively) 24 h (spearmanâ\\x80\\x99s rho = â\\x88\\x92 0.71, â\\x88\\x92 0.65; p < 0.001; r(2) = 0.66 0.60, p < 0.001, respectively). respiratory, macro-hemodynamic oxygenation parameter correlate v(d)/v(t). variation ppv baseline 24 h inverse significantly related simultaneous change v(d)/v(t) (spearmanâ\\x80\\x99s rho = â\\x88\\x92 0.66, p < 0.001; r(2) = 0.67, p < 0.001). conclusion: increased heterogeneity microcirculatory blood flow evaluated sublingual mucosa seems related increase v(d)/v(t), respiratory mechanic oxygenation parameter not. whether causeâ\\x80\\x93effect relationship microcirculatory dysfunction dead-space ventilation ards addressed future research.',\n",
       " 'global transport communication network enable information, ideas, infectious disease spread speed far beyond historically possible. effectively monitor, design, intervene epidemic-like processes, need predict speed particular contagion particular network, distinguish node likely become infected sooner later outbreak. here, quantity message-passing approach derive simple effective prediction validated epidemic simulation variety real-world network good agreement. addition individualized prediction different nodes, find overall sudden transition low density almost full network saturation contagion progress time. theory developed explained setting simple contagion treelike networks, able extends remarkably well complex contagion highly clustered networks.',\n",
       " '',\n",
       " '',\n",
       " '[image: see text] vaccine profound impact management prevention infectious disease. addition, development vaccine chronic disease attracted considerable interest approach prevent, rather treat, condition cancer, alzheimerâ\\x80\\x99s disease, others. subunit vaccine consist nongenetic component infectious agent disease-related epitope. review, discus peptide-based vaccine potential three therapeutic areas: infectious disease, alzheimerâ\\x80\\x99s disease, cancer. discus factor contribute vaccine efficacy parameter may potentially modulated design. examine clinically tested vaccine well nascent approach explore current challenge potential remedies. peptide vaccine hold substantial promise prevention human disease, many obstacle remain hampered clinical use; thus, continued research effort address challenge warranted.',\n",
       " 'influenza virus infect million people around globe annually, usually causing self-limited upper respiratory tract infections. however, small non-negligible proportion suffer life-threatening pulmonary disease. affected include otherwise healthy individuals, child primary infection particular. much effort devoted virological study influenza vaccine development. contrast, enormous interindividual variability susceptibility influenza received little attention. interesting hypothesis interindividual variability driven largely genetic makeup infected patients. unbiased genomic approach used search genetic lesion child life-threatening pulmonary influenza. four monogenic cause severe influenza pneumonitisâ\\x80\\x94deficiencies gata2, irf7, irf9, tlr3â\\x80\\x94have provided evidence severe influenza pneumonitis genetic often severe infections. deficiency highlight importance human type iii ifn-mediated immunity host defense influenza. clinical penetrance incomplete, underlying mechanism yet understood. however, human genetic study clearly revealed seemingly sporadic isolated life-threatening influenza pneumonitis otherwise healthy individual genetic.',\n",
       " 'background: severe pneumonia caused influenza secondary invasive pulmonary fungal (ipf) infection. objectives: aimed summarize incidence ipf secondary influenza explore etiologic mechanism high-risk factors. methods: adult confirmed influenza (h1n1) admitted intensive care unit (icus) nanjing drum hospital november 2017 march 2018 retrospectively selected. difference baseline factors, risk factors, immune function outcome parameter studied without ipf. results: 19 critically ill h1n1 infection, 11 (57.9%) developed ipf 7 day icu admission. two proven nine probable ipf infection. difference human leukocyte antigenâ\\x80\\x93dr isotype (â\\x96³hla-dr; 7â\\x80\\x93day 1) found two groups. â\\x96³hla-dr (day 7â\\x80\\x93day 1) higher ipf ipf [(14.52 â± 14.21)% v ( â\\x88\\x92 11.74 â± 20.22)%, p = 0.019]. decline hla-dr indicated impaired immune function secondary fungal h1n1 infection. conclusions: ipf diagnosed 57.9% critically ill h1n1 median 7 day following icu admission. continuous decline immune function could lead development ipf infections. dynamic monitoring immune function may help early detection ipf infection.',\n",
       " 'objectives: develop evidence-based recommendation clinician caring child (including infants, school-aged children, adolescents) septic shock sepsis-associated organ dysfunction. design: panel 49 international experts, representing 12 international organizations, well three methodologists three public member convened. panel member assembled key international meeting (for panel member attending conference), stand-alone meeting held panel member november 2018. formal conflict-of-interest policy developed onset process enforced throughout. teleconference electronic-based discussion among chairs, co-chairs, methodologists, group heads, well within subgroups, served integral part guideline development process. methods: panel consisted six subgroups: recognition management infection, hemodynamics resuscitation, ventilation, endocrine metabolic therapies, adjunctive therapies, research priorities. conducted systematic review population, intervention, control, outcome question identify best available evidence, statistically summarized evidence, assessed quality evidence grading recommendation assessment, development, evaluation approach. used evidence-to-decision framework formulate recommendation strong weak, best practice statement. addition, â\\x80\\x9cin practiceâ\\x80\\x9d statement included evidence inconclusive issue recommendation, panel felt guidance based practice pattern may appropriate. results: panel provided 77 statement management resuscitation child septic shock sepsis-associated organ dysfunction. overall, six strong recommendations, 49 weak recommendations, nine best-practice statements. 13 questions, recommendation could made; but, 10 these, â\\x80\\x9cin practiceâ\\x80\\x9d statement provided. addition, 52 research priority identified. conclusions: cohort international expert able achieve consensus regarding many recommendation best care child sepsis, acknowledging aspect care relatively low quality evidence resulting frequent issuance weak recommendations. despite challenge, recommendation regarding management child septic shock sepsis-associated organ dysfunction provide foundation consistent care improve outcome inform future research.',\n",
       " 'objective: influenza infection cause high economic burden seasonal epidemics. however, still need reliable burden estimate provide detailed picture impact influenza. therefore, objective estimate incidence hospitalisation influenza associated hospitalisation cost adult netherlands two consecutive influenza seasons. methods: conducted retrospective adult laboratory confirmed influenza three dutch hospital respiratory season 2014â\\x80\\x932015 2015â\\x80\\x932016. incidence calculated weekly number hospitalised influenza divided total population catchment population three hospitals. arithmetic mean hospitalisation cost per estimated included cost emergency department consultation, diagnostics, general ward and/or intensive care unit admission, isolation, antibiotic and/or antiviral treatment. hospitalisation cost extrapolated national level expressed 2017 euros. results: population consisted 380 hospitalised adult influenza patients. seasonal cumulative incidence 3.5 case per 10,000 person respiratory season 2014â\\x80\\x932015, compared 1.8 case per 10,000 person 2015â\\x80\\x932016. arithmetic mean hospitalisation cost per influenza â\\x82¬6128 (95% ci â\\x82¬4934â\\x80\\x93â\\x82¬7737) per 2014â\\x80\\x932015 â\\x82¬8280 (95% ci â\\x82¬6254â\\x80\\x93â\\x82¬10,665) 2015â\\x80\\x932016, potentially reaching total hospitalisation cost â\\x82¬28 million 2014â\\x80\\x932015 â\\x82¬20 million 2015â\\x80\\x932016. conclusions: influenza infection lead 1.8â\\x80\\x933.5 hospitalised per 10,000 persons, mean hospitalisation cost â\\x82¬6100â\\x80\\x93â\\x82¬8300 per adult patient, resulting 20â\\x80\\x9328 million euro annually netherlands. highest arithmetic mean hospitalisation cost per found 45â\\x80\\x9364 year age group. influenza burden estimate could used future influenza cost-effectiveness impact studies. electronic supplementary material: online version article (10.1007/s10198-020-01172-1) contains supplementary material, available authorized users.',\n",
       " 'widespread use combination antiretroviral therapy (cart) converted prognosis hiv rapidly progressive ultimately fatal chronic condition limited impact life expectancy. yet, hiv-infected remain high risk critical illness due occurrence severe opportunistic infection advanced immunosuppression (i.e., inaugural admission limited access cart), pronounced susceptibility bacterial sepsis tuberculosis every stage hiv infection, rising prevalence underlying comorbidities chronic obstructive pulmonary diseases, atherosclerosis non-aids-defining neoplasm cart-treated aging controlled replication. several pattern intensive care markedly evolved population late cart era, steady decline aids-related admissions, opposite trend admission exacerbated comorbidities, emergence additional driver immunosuppression (e.g., anti-neoplastic chemotherapy solid organ transplantation), management cart acute phase critical illness, dramatic progress short-term survival mainly result general advance intensive care practices. besides, lack regarding feature icu post-icu care patients, especially impact sociological factor clinical presentation prognosis, optimal timing cart introduction aids-related admissions, determinant end-of-life decisions, long-term survival, functional outcomes. narrative review, sought depict current evidence regarding management hiv-infected admitted intensive care unit.',\n",
       " 'background: malaria dengue cause major morbidity developing nation severe pregnancy. maternal, fetal, neonatal outcome pregnant infected dengue malaria studied. methods: medical record pregnant woman admitted either dengue malaria infection 2011â\\x80\\x932015 hospital reviewed. clinical outcome laboratory test examined. results: 85 women, 56%, 21%, 22% contracted dengue, malaria, multiple infections, respectively. pregnant woman contracted dengue fever alone likely present hospital earlier gestational age (24 weeks, p = 0.03). woman multiple infections, likely deliver earlier (30 weeks, p < 0.01). woman malaria likely low birth weight delivery (mean birth weight 2394 g, p = 0.03). incidence in-hospital death among cohort 7%. conclusion: imperative develop guideline screen diagnose dengue malaria pregnancy. electronic supplementary material: online version article (10.1007/s00508-019-01606-8) contains supplementary material, available authorized users.',\n",
       " '',\n",
       " 'ventilator-associated pneumonia (vap) frequent icu-acquired infections. reported incidence vary widely 5 40% depending setting diagnostic criteria. vap associated prolonged duration mechanical ventilation icu stay. estimated attributable mortality vap around 10%, higher mortality rate surgical icu mid-range severity score admission. microbiological confirmation strongly encouraged. sampling use still matter controversy. emerging microbiological tool likely modify routine approach diagnosing treating vap next future. prevention vap based minimizing exposure mechanical ventilation encouraging early liberation. bundle combine multiple prevention strategy may improve outcomes, randomized trial needed confirm this. limited 7 day vast majority cases. reassessed daily confirm ongoing suspicion disease, antibiotic narrowed soon antibiotic susceptibility result available, clinician consider stopping antibiotic culture negative.',\n",
       " '',\n",
       " 'influenza significant morbidity mortality. expert consider influenza b milder influenza a. objective evaluate outcome hospitalized laboratory-confirmed influenza b 2017â\\x80\\x932018 influenza season. hospitalized october 2017 april 2018 laboratory-confirmed influenza b included. primary composite outcome pneumonia/myocarditis/encephalitis, mechanical ventilation, icu admission, 30-day mortality. secondary outcome 30-/90-day mortality, length hospital stay, readmission rates. included 201 influenza 325 influenza b. primary composite outcome, significant difference demonstrated influenza b. rate mortality similar 30 90 days. influenza higher pneumonia rate mechanical ventilation. multivariate analysis, higher charlsonâ\\x80\\x99s score, hypoalbuminemia, vasopressor use associated 30-day mortality, either influenza b not. influenza associated higher pneumonia mechanical ventilation rates. however, influenza b resulted similar 30-day mortality rate influenza a.',\n",
       " 'damage integrity heparin sulfate (hs) endothelial glycocalyx important factor glomerular filtration barrier dysfunction, basic pathological feature acute kidney injury (aki). aki common clinical critical illness drug option offering effective treatment. phillyrin (phil), main pharmacological component forsythia suspensa, posse wide range pharmacological activities. however, effect phil lipopolysaccharide (lps)-induced aki yet reported. aim present analyze effect phil h damage inflammatory signaling pathway lps-induced aki. result revealed phil reduces pathological change improves renal function lps-induced aki. analysis indicated phil effectively protects glycocalyx h degradation lps-stimulated ea.hy926 cell vitro lps-induced aki mouse vivo. protective effect phil h damage may associated isolateâ\\x80\\x99s ability suppress production reactive oxygen species, decrease expression level cathepsin l heparanase vitro vivo. addition, elisa western blot result revealed phil inhibits activation nf-îºb mapk signaling pathway decrease level inflammatory cytokine (il-1î², il-6, tnf-î±) lps-induced ards mice. general, protection endothelial glycocalyx h damage inhibition inflammatory response phil may used target lps-induced aki.',\n",
       " 'acute lung injury (ali)-triggered pulmonary injury associated high mortality, despite advance drug supportive therapy. remarkable progress made attenuating inflammatory injury associated ali mesenchymal stem cell (mscs)-based cell gene therapy. however, date, benefit interleukin-35 (il-35)-modified msc ali intervention investigated. present study, adult male c57bl/6 mouse randomly received intravenous infusion adipose-derived mesenchymal stem cell (adscs) constitutively expressing il-35 (il-35-gfp-adscs) gfp (gfp-adscs) via retrovirus-mediated transduction (8 ã\\x97 10(5) cell per mice) isotonic saline 7 day ali modeling investigate effect related mechanism. ali performed lipopolysaccharide (lps) inhalation 24 h. normal mouse served sham group. result indicated compared gfp-adscs, il-35-modified adscs significantly increased cellular pulmonary il-10 il-35 production. pretreatment il-35-adscs markedly reduced body weight loss, pulmonary wet/dry weight ratio pathological injury. po(2) rescued normal level mouse received il-35-adscs. il-35-adscs infusion apparently inhibited il-6 release, protein leakage mpo activity greatly elevated il-35 level bronchoalveolar lavage fluid (balf). splenic regulatory cell il-35-adscs-pretreated mouse got effective increase. moreover, il-35-adscs pretreatment remarkably inhibited neutrophil macrophage infiltration greatly decreased il-6, tumor necrosis factor î± (tnf-î±) toll-like receptor 4 (tlr4) expression. conclusion, pretreatment il-35-engineered adscs provided effective protection lps-induced ali suppression pulmonary inflammation and, thus, might strategy improve outcome ali. enhanced paracrine immunosuppressive capacity il-35-adscs might contribute beneficial effects. however, study needed illuminate detailed mechanism.',\n",
       " 'annual flu season typically characterized change type subtypes influenza, variation term severity. despite remarkable improvement prevention management suspected laboratory-confirmed diagnosis influenza, annual seasonal influenza continues associated high morbidity mortality. admission intensive care unit required severe form seasonal influenza infection, primary pneumonia present cases. review summarizes recent knowledge diagnosis strategy critically ill influenza, focused diagnostic testing methods, antiviral therapy, use corticosteroids, antibacterial antifungal therapy, supportive measures. review focus diagnostic testing methods, antiviral therapy, use corticosteroids, antibacterial antifungal therapy, supportive measure relevant existing evidence, order provide non-expert clinician useful overview. enhanced understanding current diagnostic aspect influenza contribute improve outcome reduce mortality among icu influenza.',\n",
       " 'effectively responding global emergency requires substantial financial commitment many stakeholders, governments, multilateral agencies, nongovernmental organizations. major current policy challenge need attention: better coordinate investment among actor aiming address common problem, outbreaks. donor commit colossal sum money outbreak response, current model neither efficient transparent. innovative approach coordinate financing tested part broader development agenda humanitarian response. adopting system enables donor invest outbreak rather actor represents opportunity deliver cost-effective, transparent, unified global response infectious outbreaks. achieving challenging, world organization (who) must play vital role. thinking required improve emergency response increasingly crowded financially convoluted global arena.',\n",
       " 'objective: explore mechanism crocin glycocalyx damage inflammatory injury lipopolysaccharide (lps)-induced acute respiratory distress syndrome (ards) mouse lps-stimulated human umbilical vein endothelial cell (huvecs). methods: mouse randomly divided control, lps, crocin + lp (15, 30, 60 mg/kg) groups. huvecs separated eight groups: control, crocin, matrix metalloproteinase 9 inhibitor (mmp-9 inhib), cathepsin l inhibitor (ctl inhib), lps, mmp-9 inhib + lps, ctl inhib + lps, crocin + lps. potential cytotoxic effect crocin huvecs mainly evaluated methylthiazolyldiphenyl-tetrazolium bromide assay. histological change assessed via hemotoxylin eosin staining. lung capillary permeability detected basis wetâ\\x80\\x93dry ratio fluorescein isothiocyanate-albumin assay. then, protein level detected western blot analysis, immunohistochemical staining, immunofluorescence. results: showed crocin improve pulmonary vascular permeability mouse lps-induced ards inhibit inflammatory signaling pathway high mobility group box, nuclear factor îºb, mitogen-activated protein kinase vivo vitro. crocin protected degradation endothelial glycocalyx heparan sulfate syndecan-4 inhibiting expression ctl, heparanase, mmp-9 vivo vitro. overall, revealed protective effect crocin lps-induced ards elaborated underlying mechanism. conclusion: crocin alleviated lps-induced ards protecting glycocalyx damage suppressing inflammatory signaling pathways.',\n",
       " 'celebrate end 25th anniversary year, asked thought leader expert field answer question: shape next 25 year medical research?',\n",
       " 'introduction: acetabular cup placement important modifiable factor determining complication rate like aseptic loosening hip dislocation related faulty cup placement, standard largely dependent upon eyeballing surgeonâ\\x80\\x99s judgment. evaluated self-designed, low-cost, patient-specific acetabular jig guide cup placement total hip arthroplasty comparison conventional technique. methods: prospective randomized control study. thirty-six categorized group-a & group-b. group-a, virtually designed acetabular jig 3 dimensional (3d) printed used intra-operatively guide cup placement. group-b, standard cup placement used. acetabular cup placement evaluated post-operative x-ray compared two groups. results: group-a, angle anteversion significantly centre range safe zone compared group b hip maximally stable precision creating hip centre compared group-b without significant(p = 0.325) increase surgical time blood loss. conclusion: computed tomography (ct) scan based virtual pre-operative templating cup placement guided virtually designed, patient-specific acetabular jig low-cost tool short learning curve designed made available easily. useful tool decreasing chance malpositioning cup recreates hip centre close anatomical especially case anatomy distorted bony ankylosis developmental dysplasia hip.',\n",
       " 'purpose investigate incidence symptomatic venous thromboembolism (vte) chemoprophylaxis pelvic lower-extremity fractures, identify risk factor vtes subgroup patients. detect vte, multi-detector computed tomography (ct) angiography performed. 363 assessed, incidence symptomatic vte 12.4% (45 patients), incidence symptomatic pe 5.2% (19 patients). risk-factor analysis, higher charlson comorbidity index (p = 0.037), history external fixator application (p = 0.007) associated increased vte risk. among vte, male sex (p = 0.017), above-the-knee fracture (p = 0.035) associated increased pulmonary embolism (pe) risk. conclusions, incidence vte post-traumatic low chemoprophylaxis. risk factor vte pe different among pelvic lower-extremity fractures.',\n",
       " 'background: strong ion model (sim) alternative paradigm characterization acidâ\\x80\\x90base disturbance particularly complex disorders. hypothesis/objectives: compare acidâ\\x80\\x90base change dog parvoviral enteritis (pe) hendersonâ\\x80\\x90hasselbalch (hh) approach, 2 strong ion approaches. animals: fortyâ\\x80\\x90four dog pe, 16 ageâ\\x80\\x90matched control dogs. methods: prospective controlled observational study. acidâ\\x80\\x90base status evaluated hh model, fenclâ\\x80\\x90stewart (fs) approach validated strong ion model (vdm). acidâ\\x80\\x90base change according model classified compared. statistical correlation ph, co(2), various sim variable performed, well sum effect (soe) sim individual variable comprising soe. results: hh model identified acidâ\\x80\\x90base disorder 31/44 case 16/31 mixed metabolic acidosis concurrent respiratory alkalosis common (10/31). f approach, metabolic change present 36/42 cases, change free water (fw), chloride, unmeasured anion (ua) prevalent. fw ua correlated well ph; however, ua consistently abnormal severe acidemia. similarly hh, vdm detected acidâ\\x80\\x90base disturbance 28/44 cases. major contributor acidâ\\x80\\x90base change hyponatremia, hypochloremia, a(tot) acidosis elevated globulin increased ua. conclusion clinical importance: acidâ\\x80\\x90base change common complex dog pe, easier understand sim paradigm. increase ua documented pe dogs.',\n",
       " 'rift valley fever (rvf) mosquito-borne zoonosis showing complex epidemiological pattern poorly understood south africa. outbreak occur central interior long, irregular intervals, 2010â\\x80\\x932011; however, level herd immunity ruminant livestock, key determinant outbreaks, unknown. 2015â\\x80\\x932016 cross-sectional 234 randomly-selected farm investigated prevalence, pattern of, factor associated with, antibody rvf (rvfv) livestock area heavily affected outbreak. rvfv inhibition elisa used screen 977 cattle, 1,549 sheep 523 goat information potential risk factor collected comprehensive questionnaire. estimated rvfv seroprevalence, adjusted survey design, 42.9% cattle, 28.0% sheep 9.3% goats, showing high degree farm-level clustering. seroprevalence increased age higher private vs. communal land, farm seasonal pan (temporary, shallow wetlands) perennial river vaccinated animals. seropositivity amongst unvaccinated animal born last outbreak indicates likely circulation post-epidemic period. current level herd immunity livestock may insufficient prevent another outbreak, suitable condition recur.',\n",
       " 'aim present investigate whether tipe2 participates protective action dexmedetomidine (dex) mouse model sepsis-induced acute lung injury (ali). administered tipe2 adeno-associated (aav-tipe2) intratracheally lung mice. control mouse infected adeno-associated expressing transgene. three week later, animal model caecal ligation-perforation (clp)-induced sepsis established. dex administered intravenously 30 min clp. twenty-four hour sepsis, lung injury assayed lung histology, ratio polymorphonuclear leukocyte (pmns) total cell bronchoalveolar lavage fluid (balf), myeloperoxidase (mpo) activity, balf protein content lung wet-to-dry (w/d) weight ratio. proinflammatory factor level balf mouse measured. protein expression level lung tissue analysed western blotting. result showed dex markedly mitigated sepsis-induced lung injury, characterized deterioration histopathology, histologic scores, w/d weight ratio total protein level balf. moreover, dex markedly attenuated sepsis-induced lung inflammation, evidenced decrease number pmns balf, lung mpo activity proinflammatory cytokine balf. addition, dex dramatically prevented sepsis-induced pulmonary cell apoptosis mice, reflected decrease number tunel-positive cells, protein expression cleaved caspase-9 cleaved caspase 3 bax/bcl-2 ratio. addition, evaluation protein expression showed dex blocked sepsis-activated jnk phosphorylation nf-îºb p65 nuclear translocation. similar result observed tipe2 overexpression group. demonstrated dex inhibits acute inflammation apoptosis murine model sepsis-stimulated ali via upregulation tipe2 suppression activation nf-îºb jnk signalling pathways.',\n",
       " '',\n",
       " '',\n",
       " 'aim: malaria report 2017 estimated 216 million case malaria 445,000 death worldwide, 91% death affecting african region. results/methodology: microwave promoted synthesis cycloalkyl amine substituted isoindoline-1,3-dione-4-aminoquinolines urbanized evaluating antiplasmodial activities. compound optimum combination propyl chain length hydroxyethyl piperazine proved potent among synthesized scaffold chloroquine-resistant w2 strain plasmodium falciparum ic(50) value 0.006 î¼m. heme-binding along density functional theory study carried order delineate mechanism action active compound. conclusion: synthesized scaffold act therapeutic template synthetic modification toward search antimalarial agent.',\n",
       " 'background: understanding factor driving virological failure, contribution hiv drug resistance mutation (drm), critical ensuring hiv remains effective. examine contribution drug resistance mutation low suppression hiv-positive participant population-based sero-prevalence survey rural south africa. methods: conducted hiv drug resistance genotyping art analyte testing dried blood spot (dbs) hiv-positive adult participating 2014 survey north west province. among virologic failure (> 5000 copies/ml), describe frequency drm protease inhibitor (pi), nucleoside reverse transcriptase inhibitor (nrti), non-nucleoside reverse transcriptase inhibitor (nnrti), report association resistance antiretroviral therapy (art) status, ass resistance first second line therapy. analysis weighted account sampling design. results: overall 170 db sample assayed load art analytes; 78.4% men 50.0% woman evidence virologic failure assessed drug resistance, successful sequencing 76/107 samples. found â\\x89¥1 drm 22% participants; 47% sample detectable analyte (efavirenz, nevirapine lopinavir). drm detectable analyte, 60% showed highâ\\x80\\x93level resistance reduced predicted virologic response â\\x89¥1 nrti/nnrti typically used first second-line regimens. conclusions: drm predicted reduced susceptibility first second-line regimen common among adult art exposure rural south african population-based sample. result underscore importance ongoing virologic monitoring, regimen optimization adherence counseling optimize durable virologic suppression.',\n",
       " 'background: resistant pseudomonas aeruginosa continues challenge latin american country (latam). synthesize literature use appropriate initial antibiotic therapy (aiat) inappropriate initial antibiotic therapy (iiat) p. aeruginosa infections, literature risk factor acquisition resistant p. aeruginosa among hospitalized adult latam. methods: medline, embase, cochrane, lilac searched 2000 august 2019. abstract full-text article screened duplicate. random effect meta-analysis conducted study sufficiently similar. results: screening 165 citation identified literature search yielded 98 full-text article retrieved assessed eligibility, 19 article conducted brazil (14 articles), colombia (4 articles), cuba (1 article) met inclusion criteria. 19 eligible articles, six article (840 subjects) examined aiat compared iiat p. aeruginosa infections; 17 article (3203 total subjects) examined risk factor acquisition resistant p. aeruginosa; four article evaluated both. four 19 article rated low risk bias remaining deemed unclear high risk bias. meta-analysis, aiat associated lower mortality p. aeruginosa infection (unadjusted summary 0.48, 95% ci 0.28â\\x80\\x930.81; i(2) = 59%), compared iiat association mortality persisted subgroup meta-analysis low risk bias (3 articles; unadjusted summary 0.46, 95% ci 0.28â\\x80\\x930.81; i(2) = 0%). meta-analysis performed study evaluating risk factor acquisition resistant p. aeruginosa sufficiently similar. significant risk factor acquisition resistant p. aeruginosa included: prior use antibiotic (11 articles), stay intensive care unit (icu) (3 articles), comorbidity score (3 articles). outcome graded low strength evidence owing unclear high risk bias imprecise estimates. conclusion: highlight association aiat lower mortality prior use antibiotic significantly predicts acquiring resistant p. aeruginosa infections. review reinforces need rigorous structured antimicrobial stewardship program latam region.',\n",
       " 'background: malignant tumor risk factor pulmonary embolism (pe), pe caused tumor uncommon. primary pleural squamous cell carcinoma (ppscc) rare malignancy; thus, related pe extremely rare. presentation: healthy 49-year-old female admitted northern jiangsu peopleâ\\x80\\x99s hospital owing chest tightness, cough, breathing difficulty persisted 3 days. following admission, computed tomography (ct) pulmonary angiography revealed embolism main pulmonary artery, upper lower pulmonary artery branch. treated alteplase, warfarin, antibiotics. following year, experienced recurrent chest pain tightness breathing difficulty, multiple ct pulmonary angiography revealing thrombosis right left main pulmonary artery. abnormality observed surrogate marker autoimmune diseases, tumor antigen testing, ultrasonography; thus, cause recurrent pe identified. subsequently, positron emission tomography-computed tomography (pet-ct) examination revealed diffuse heterogeneous thickening right pleura substantially increased glucose metabolism. ct-guided pleural biopsy performed, histopathological examination pleura eventually revealed diagnosis ppscc. conclusions: ppscc rare tumor lack specific clinical manifestation difficult detect imaging techniques. occurrence pe primary manifesting symptom ppscc extremely rare. thus, malignant tumor considered risk factor pe and/or recurrent pe. immediate diagnosis adequate intervention achieved increased awareness diagnosis subsequent related examinations.',\n",
       " 'paper, delayed model two different transmission method treatment investigated. model time-delayed version model (zhang et al. comput. math. method med. 2015:758362, 2015). virus-free equilibrium locally asymptotically stable basic reproduction number smaller one, regarding time delay bifurcation parameter, existence local hopf bifurcation investigated. result time delay change stability endemic equilibrium. finally, give numerical simulation illustrate theoretical findings.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'forced convection (air supply jet) natural convection (thermal plume passenger) co-exist aircraft cabin simultaneously. due notable difference reynolds number two convection processes, traditional rans hardly simulate forced/natural convection flow accurately time. addition, geometric ratio main air supply inlet whole cabin lead difficulty grid generation cabin space. efficient computational model based standard k-e model established solve problems. coefficient dissipative equation modified compensate enlarged numerical dissipation caused coarse grid; meanwhile, piecewise-defined turbulent viscosity introduced combine forced natural convection. modified model validated available experimental result boeing 737-200 mock-up. furthermore, unsteady characteristic aircraft cabin environment obtained analyzed. according frequency analysis, turn thermal plume main factor unsteady fluctuation cabin. electronic supplementary material: electronic supplementary material (esm): supplementary material available online version article 10.1007/s12273-020-0609-2.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'vaccine study shigella flexneri enterotoxigenic escherichia coli impaired lack optimal animal models. used two murine model s. flexneri 2a bivalent vaccine (cvd 1208s-122) expressing enterotoxigenic escherichia coli colonization factor antigen-i (cfa/i) binding subunit a2 b heat labile-enterotoxin (ltb) immunogenic protects weight loss diarrhea. finding document immunogenicity pre-clinical efficacy effect cvd 1208s-122 vaccine suggest work help elucidate relevant immune response ultimately clinical efficacy humans.',\n",
       " 'background: public surveillance based continuous systematic collection, analysis, interpretation data. informs development early warning system monitor epidemic document impact intervention measures. introduction digital sources, specifically source available internet, impacted field public surveillance. opportunity enabled underlying availability scale internet-based source (ibss) paved way novel approach surveillance, exploration communities, epidemic dynamics. field approach known infodemiology infoveillance. objective: review aimed ass research finding regarding application ibss public surveillance (infodemiology infoveillance). achieve this, presented comprehensive systematic literature review focus source limitations, disease targeted, commonly applied methods. methods: systematic literature review conducted targeting publication 2012 2018 leveraged ibss public surveillance, outbreak forecasting, characterization, diagnosis prediction, content analysis, health-topic identification. search result filtered according defined inclusion exclusion criteria. results: spanning total 162 publications, determined infectious disease preferred (108/162, 66.7%). eight category ibss (search queries, social media, news, discussion forums, websites, web encyclopedia, online obituaries), search query social medium applied 95.1% (154/162) reviewed publications. identified limitation representativeness biased user age groups, well high susceptibility medium event search queries, social media, web encyclopedias. conclusions: ibss valuable proxy illness affecting general population; however, important characterize disease best suited available sources; literature show level engagement among online platform potential indicator. necessity understand populationâ\\x80\\x99s online behavior; addition, exploration information dissemination content significantly unexplored. information, understand population communicates illness online and, process, benefit public health.',\n",
       " 'oncolytic virotherapy (ovt) novel form immunotherapy natural genetically modified virus selectively replicate kill malignant cells. many genetically modified oncolytic virus (ovs) enhanced tumor targeting, antitumor efficacy, safety generated, assessed clinical trials. combining ovt immunotherapy remarkably enhance antitumor efficacy. work, review use wild-type virus ovt strategy ov genetic modification. review discus combination ovt immunotherapies.',\n",
       " 'past decades, interdisciplinary research great interest scholars. thiazolidine motif behave bridge organic synthesis medicinal chemistry compel researcher explore drug candidates. thiazolidine motif intriguing heterocyclic five-membered moiety present diverse natural bioactive compound sulfur first position nitrogen third position. presence sulfur enhances pharmacological properties, and, therefore, used vehicle synthesis valuable organic combinations. varied biological property viz. anticancer, anticonvulsant, antimicrobial, anti-inflammatory, neuroprotective, antioxidant activity on. diversity biological response make highly prized moiety. based literature studies, various synthetic approach like multicomponent reaction, click reaction, nano-catalysis green chemistry employed improve selectivity, purity, product yield pharmacokinetic activity. review article, summarized systematic approach synthesis thiazolidine derivatives, along pharmacological activity, advantage green synthesis, atom economy, cleaner reaction profile catalyst recovery help scientist probe stimulate scaffolds.',\n",
       " 'purpose: investigate technical feasibility, safety clinical outcome coil-assisted retrograde transvenous obliteration ii (carto-ii) gastric varix (gv). material methods: thirty-six consecutive undergone carto-ii june 2016 april 2018 included study. carto procedure, coil embolization drainage vein performed â\\x80\\x9cbeforeâ\\x80\\x9d injection sclerosant replace use balloon catheter. carto-ii procedure, coil embolization drainage vein performed â\\x80\\x9cafterâ\\x80\\x9d injection sclerosant prevent migration sclerosant. carto-ii performed ethanolamine oleate iopamidol, balloon catheter immediately removed coil placement. technical clinical success rates, number coil used, presence absence severe complications, timing procedure, rate gv recurrence procedure analyzed retrospectively. results: patients, gv sclerosis, coil placement removal balloon catheter successfully completed. technical success rate 100%. experienced severe complication coil migration pulmonary embolization. mean number metallic coil used per procedure 3.36. mean length procedure 132.8 min. contrast-enhanced computed tomography carto-ii confirmed complete variceal thrombosis cases. recurrence rate gv follow-up 2.8% (mean follow-up, 207 days). conclusion: carto-ii feasible safe could performed relatively quickly. number coil used rate gv recurrence low. carto-ii may important role play management gv.',\n",
       " 'since first novel h7n9 reported, china experienced five epidemic h7n9. fifth wave, highly pathogenic h7n9 strain emerged. meanwhile, h7n9 continues accumulate mutations, affinity human respiratory epithelial sialic acid 2â\\x80\\x936 receptor increased. therefore, pandemic still possible. past 6 years, accumulated rich experience dealing h7n9, especially term tracing, epidemiological research, key site mutation monitoring, critical mechanisms, clinical treatment, vaccine development. research field above, significant progress made effectively control spread epidemic reduce fatality rate. fully document research progress concerning h7n9, reviewed clinical epidemiological characteristic h7n9, key gene mutation virus, h7n9 vaccine, thus providing scientific basis monitoring prevention h7n9 influenza epidemics. electronic supplementary material: supplementary material available online version article 10.1007/s11684-020-0739-z accessible authorized users.',\n",
       " 'purpose review: main goal article discus development state-of-the-art technology made possible address fundamental question related renin-angiotensin system (ras) operates within brain neurophysiological molecular perspective. recent findings: existence brain ra remains surprisingly controversial. sensitive situ hybridization technique novel transgenic animal expressing reporter gene provided pivotal information expression ra gene within brain. discus study genetically engineered animal combined targeted microinjections molecular mechanism implicated regulation brain ras. discus novel drug targeting brain ra result clinical study trials. summary: last 50 years, several physiological role brain ra identified. coming years, effort incorporate cutting-edge technology optogenetics, chemogenetics, single-cell rna sequencing lead dramatic advance full understanding brain ra operates molecular neurophysiological levels.',\n",
       " 'increased use medical imaging, incidental detection benign solid liver tumor become frequent. facing benign disease, indication surgery still object discussion light stable natural course lesion obvious drawback surgical intervention; therefore, situations, conservative approach recommended, surgery mainly reserved case persistent worsening symptoms, risk complication malignant transformation. advent ablative technique widened range option available patients, presenting valid alternative resection term safety efficacy selected cases, particularly considered poor surgical candidate smaller lesions. review outline role percutaneous ablative method benign solid liver tumor encountered adults, providing per histology analysis existing evidence. up-to-date strategy management common benign solid tumor recapitulated.',\n",
       " 'design: retrospective review kid inpatient database (kid) 2003, 2006, 2009, 2012. objectives: aim evaluate impact advance spinal surgery outcome scheuermann kyphosis (sk). summary background data: sk common cause back pain adolescents. trend diagnosis surgical approach sk well described. methods: sk aged 0â\\x80\\x9320 year kid identified icd-9 code 732.0. kid-supplied year- hospital-trend weight used establish prevalence. demographics, surgical details, outcome analyzed analysis variance. results: total 1,070 sk identified (33.2% female), increasing incidence sk diagnosed 2003 2012 (3.6â\\x80\\x937.5 per 100,000, p < .001). average age operative 16.1â±2.0 year change (16.27â\\x80\\x9316.06 years, p = .905). surgical rate changed time (72.8%â\\x80\\x9372.8%, p = .909). overall, 96.3% operative underwent fusion, 82.2% case spanning â©¾4 levels; addition, 8.6% underwent anterior-only surgery, 74.6% posterior-only, 13.6% combined approach. 2003 2012, rate posterior-only surgery increased (62.4%â\\x80\\x9384.4%, p < .001) whereas rate combined-approach surgery decreased (37.6%â\\x80\\x938.8%, p < .001). overall complication rate sk surgery decreased (2003: 20.9%; 2012: 11.9%, p = .029). concurrently, rate â©¾4-level fusion increased (43.5%â\\x80\\x9389.6%, p < .001), well use smith-peterson (7.8%â\\x80\\x9323.6%, p < .001) three-column osteotomy (0.0%â\\x80\\x932.7%, p = .011). subanalysis comparing posterior combined approaches, complication rate significantly different (posterior: 9.88%, combined: 19.46%, p = .005). undergoing combined approach longer length stay (los) undergoing posterior-only approach (7.8 vs. 5.6 days, p < .001). conclusions: despite unchanged demographic operative rate sk, shift combined isolated posterior approaches, concurrent increase level treated. combined approach associated increased complication rates, los, total charge compared isolated approaches. awareness inherent difference important surgical decision making education. level evidence: level iii.',\n",
       " 'mesenchymal stromal cell may reverse acute inflammatory disorders. placenta important feto-maternal tolerance. used placenta-derived decidua stromal cell (dscs) treat graft-versus-host found immunomodulatory anti-inflammatory effect. report use dscs two radiculomyelopathy. first 73-year old man treated parotidectomy irradiation lymphoma neck. following yersinia infection, developed radiculomyelopathy c3/c4 could elevate arms. second 34-year old woman admitted 8 month allogeneic hematopoietic stem cell transplantation due hemolysis, impaired sensorium arcus, difficulty ambulation. following intravenous infusion dscs (1 ã\\x97 10(6)/kg/infusion), first could elevate arm facial level. experienced recurrent paralysis 6 months, efficacy four additional dsc infusions, subsequent occasions, limited transient. second treated two dos dscs (1 ã\\x97 10(6)/kg/infusion). cell infusion, able stand leg, sensation belly normalized, discharged. two case suggest dscs may useful neuroinflammatory disorders.',\n",
       " 'purpose ass value metagenomic next-generation sequencing (mngs) bronchoalveolar lavage fluid (balf) diagnosis severe respiratory disease based interpretation sequencing results. balf sample harvested used mngs well microbiological detection. infectious bacteria fungi defined according relative abundance number unique reads. performed mngs 35 balf sample 32 patients. positive rate reached 100% mngs analysis nine immunocompromised patients. compared culture method, mngs diagnostic sensitivity 88.89% specificity 74.07% agreement rate 77.78% two methods. compared smear pcr, mngs diagnostic sensitivity 77.78% specificity 70.00%. 13 cases, detection result positive mngs negative culture/smear pcr. mngs finding 11/32 (34.4%) case led change strategies. linear regression analysis showed diversity significantly correlated interval onset sampling. dynamic change read could indirectly reflect therapeutic effectiveness. balf mngs improves sensitivity pathogen detection provides guidance clinical practice. potential pathogen identified based relative abundance number unique reads. electronic supplementary material: online version article (10.1007/s10096-019-03734-5) contains supplementary material, available authorized users.',\n",
       " 'background: oncologic diseases, particularly hematologic malignancies, increased risk common infection unique treatment-related complication high mortality morbidity. annual incidence prevalence cancer germany rising. although modern treatment generally led improved survival, increasing age, comorbidities, frailty require multidisciplinary strategy handling complex therapeutic concept associated complications. methods: selective literature search guideline european society medical oncology (esmo), german society hematology medical oncology (deutsche gesellschaft fã¼r hã¤matologie und medizinische onkologie, dgho), infectious disease working group dgho (arbeitsgemeinschaft infektionen der hã¤matologie und onkologie, agiho), american society clinical oncology (asco) formed basis study. conclusion: recognition severe infection cancer discrimination treatment-associated complication challenge. neutropenic fever frequent infectious emergency oncology. early empiric broad-spectrum antibiotic escalated diagnostic strategy needed successfully treat vulnerable group. article, range potentially life-threatening infection immunocompromised discussed.',\n",
       " \"election tsai ing-wen president republic china (taiwan) 2016 reignited beijing's quest poach taiwan's diplomatic allies. election january 2016 reelection january 2020, taiwan lost seven country china. eight year â\\x80\\x9cdiplomatic truceâ\\x80\\x9d president ying-jeou, china re-started multi-pronged strategy pressure taiwan eventual unification, key tactic poach taiwan's now-15 remaining diplomatic ally eliminate international legitimacy. article seek explain what, any, benefit formal diplomatic relation provide taiwan way beijing induces country switch ties. concludes providing recommendation action united state undertake slow impending completion â\\x80\\x9crace zero.â\\x80\\x9d\",\n",
       " '',\n",
       " 'respiratory muscle ultrasound used evaluate anatomy function respiratory muscle pump. safe, repeatable, accurate, non-invasive bedside technique successfully applied different settings, general intensive care emergency department. mastery technique allows intensivist rapidly diagnose ass respiratory muscle dysfunction critically ill unexplained dyspnea. furthermore, used ass patientâ\\x80\\x93ventilator interaction weaning failure critically ill patients. paper provides overview basic advanced principle underlying respiratory muscle ultrasound emphasis diaphragm. review different ultrasound technique useful monitoring respiratory muscle pump possible therapeutic consequences. ideally, respiratory muscle ultrasound used conjunction component critical care ultrasound obtain comprehensive evaluation critically ill patient. propose abcde-ultrasound approach, systematic ultrasound evaluation heart, lung respiratory muscle pump, weaning failure. electronic supplementary material: online version article (10.1007/s00134-019-05892-8) contains supplementary material, available authorized users.',\n",
       " 'background: multi-organ dysfunction critical illness common frequently involves lung kidneys, often requiring organ support invasive mechanical ventilation (imv), renal replacement therapy (rrt) and/or extracorporeal membrane oxygenation (ecmo). methods: consensus conference spectrum lungâ\\x80\\x93kidney interaction critical illness held auspex acute quality initiative (adqi) innsbruck, austria, june 2018. review critical appraisal available evidence, current state research, clinical research recommendation described following topics: epidemiology, pathophysiology strategy mitigate pulmonary dysfunction among acute kidney injury and/or kidney dysfunction among acute respiratory failure/acute respiratory distress syndrome. furthermore, emphasis put receiving organ support (rrt, imv and/or ecmo) impact lung kidney function. conclusion: adqi 21 conference found significant knowledge gap organ crosstalk lung kidney relevance critically ill patients. lung protective ventilation, conservative fluid management early recognition pulmonary infection clinical recommendation higher quality evidence. recommendation research formulated, targeting lungâ\\x80\\x93kidney interaction improve care process outcome critical illness. electronic supplementary material: online version article (10.1007/s00134-019-05869-7) contains supplementary material, available authorized users.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'level automation mechanical ventilation steadily increasing last decades. renewed interest physiological closed-loop control ventilation. development system followed similar path manual clinical ventilation, starting ensuring optimal gas exchange shifting prevention ventilator-induced lung injury. system currently aim encompass aspects, early commercial system appearing. development remain many clinician and, hence, limit adoption clinical environment. review show evolution physiological closed-loop control mechanical ventilation.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'biomedical application increasingly require fully characterized nanomaterials. strong evidence showing nanomaterials interact cell passively actively, mediating essential molecular process regulation cellular functions, starting understand mechanism interactions. systematic study cell behavior response specific nanoparticle property scarce literature even necessary rational design medical nanodevices. information literature show physicochemical property determine bioactivity, biocompatibility, safety nanomaterials. information available regarding interaction response cell nanomaterials analyzed discussed single document. hence, review, present latest advance cellular response nanomaterials integrate available information concrete consideration development innovative, efficient, specific and, importantly, safe biomedical nanodevices. focus physicochemical nanoparticle property (size, chemical surface, shape, charge, topography) influence cell behavior first attempt provide practical guide designing medical nanodevices, avoiding common experimental omission may lead misinterpretation. finally, emphasize importance systematic nanoâ\\x80\\x93bio interaction acquire sufficient reproducible information allows accurate control cell behavior based tuning nanomaterial properties. information useful guide design specific nanodevices nanomaterials elicit desired cell responses, like targeting, drug delivery, cell attachment, differentiation, etc, avoid undesired side effects.',\n",
       " 'herpes simplex 1 (hsv-1) initiated ocular, nasal, oral cavity, sensory neuron within trigeminal ganglion (tg) become infected. following burst transcription tg neurons, lytic cycle gene suppressed latency established. latency-associated transcript (lat) gene abundantly expressed latency, lat expression important latency-reactivation cycle. reactivation latency required transmission recurrent disease, encephalitis. wnt/î²-catenin signaling pathway differentially expressed tg bovine herpesvirus 1 latency-reactivation cycle. hence, hypothesized hsv-1 regulates wnt/î²-catenin pathway promotes maintenance latency pathway enhances neuronal survival axonal repair. study revealed î²-catenin expressed significantly tg neuron latency compared tg uninfected mouse mouse latently infected lat(-/-) mutant virus. tg explants incubated medium containing dexamethasone stimulate reactivation, significantly fewer î²-catenin+ tg neuron detected. conversely, tg explants uninfected mouse mouse latently infected lat(-/-) mutant increased number î²-catenin+ tg neuron presence dex relative sample treated dex. impairing wnt signaling small molecule antagonist reduced shedding explant-induced reactivation. study suggested î²-catenin differentially expressed latency-reactivation cycle, part due lat expression.',\n",
       " '',\n",
       " 'infectious disease commonly occur contaminated water, food, bodily fluid spread rapidly, resulting death human animal worldwide. among infectious agents, virus pose serious threat public global economy often difficult detect infection hard treat. since crucial develop rapid, accurate, cost-effective, in-situ method early detection viruses, variety sensor reported far. review provides overview recent development electrochemical sensor biosensors detecting virus use sensor environmental, clinical food monitoring. electrochemical biosensors determining virus divided four main group nucleic acid-based, antibody-based, aptamer-based antigen-based electrochemical biosensors. finally, drawback advantage type sensor identified discussed.',\n",
       " 'purpose: purpose investigate effectiveness safety operation type iii esophageal atresia thoracoscope. methods: clinical 92 type iii esophageal atresia hospital january 2015 december 2018 analyzed retrospectively. 49 group underwent thoracoscopic surgery 43 group b underwent conventional surgery. results: mechanical ventilation time (55.7 â± 11.4 h v 75.6 â± 19.2 h), intensive care time (3.6 â± 1.8d v 4.7 â± 2.0d), postoperative hospitalization time (13.1 â± 2.2d v 16.8 â± 4.3d), thoracic drainage volume (62.7 â± 25.5 ml v 125.4 â± 46.1 ml), blood transfusion volume (30.5 â± 10.4 ml v 55.3 â± 22.7 ml) surgical incision length (2.0 â± 0.5 cm v 8.0 â± 1.8 cm) group lower group b, difference statistically significant (p < 0.05). among postoperative complications, incidence postoperative severe pneumonia (8.2% v 23.3%), poor wound healing (2.0% v 14.0%) chest wall deformity (0% v 11.6%) group significantly lower group b (p < 0.05). significant difference incidence anastomotic stricture, tracheomalacia gastroesophageal reflux two group surgery early follow-up (p > 0.05), complication achalasia sign esophageal diverticulum either group. conclusion: surgery type iii esophageal atresia via thoracoscopy safety clinical effectiveness traditional surgery advantage smaller incision chest wall deformity.',\n",
       " 'background: inflammatory response activated cardiopulmonary bypass (cpb), may lead acute respiratory distress syndrome (ards) procalcitonin (pct) increase inflammatory response. objective validate whether higher serum pct concentration higher incidence ards. methods: prospective, single-center, observational cohort study. received cardiac surgery cpb screened eligibility. assigned pct-elevated cohort control cohort according serum pct concentration first postoperative cut-off value 7.0 ng/ml. followed 7th postoperative day. primary endpoint incidence ards, diagnosed according berlin definition. results: total 296 enrolled, 64 assigned pct-elevated cohort 232 assigned control cohort. pct concentration 16.23 â± 5.9 ng/ml pct-elevated cohort, 2.70 â± 1.43 ng/ml control cohort (p < 0.001). incidence ards significantly higher pct-elevated cohort control cohort (21.9% versus 5.6%, p < 0.001). incidence moderate-to-severe ards significantly higher pct-elevated cohort control cohort (10.9% versus 0.4%, p < 0.001). hazard ratio ards 7 day pct-elevated cohort, compared control cohort, 6.8 (95% confidence interval 2.7 17.4). hazard ratio moderate-to-severe ards pct-elevated cohort 57.3 (95% confidence interval 10.4 316.3). positive predictive value pct ards moderate-to-severe ards 0.242 0.121, respectively; negative predictive value pct ards moderate-to-severe ards 0.952 1.0, respectively. conclusion: cardiac surgical elevated pct concentration higher incidence ards. elevated pct may serve warning signal postoperative ards undergoing cardiac surgery cpb. registration chinese clinical trial registry (chictr-och-14005076)',\n",
       " 'background: owing amount host dna clinical samples, generation high-quality plasmodium falciparum whole genome sequencing (wgs) requires enrichment parasite dna. enrichment often achieved leukocyte depletion infected blood prior storage. however, leukocyte depletion difficult low-resource setting limit analysis prospectively-collected samples. result, approach selective whole genome amplification (swga) used enrich parasite dna. however, swga limited success generating reliable sequencing low parasitaemia samples. study, enzymatic digestion mspji prior swga whole genome sequencing evaluated determine whether approach improved genome coverage compared swga alone. potential swga cause amplification bias polyclonal infection examined. methods: dna extracted laboratory-created dried blood spot treated modification-dependent restriction endonuclease, mspji, filtered via vacuum filtration. sample selectively amplified reported swga protocol subjected wgs. genome coverage statistic compared optimized swga approach reported swga approach performed parallel. differential amplification swga assessed comparing wgs generated lab-created mixture parasite isolates, geographical region, generated without swga. results: mspji digestion enrich parasite dna. sample underwent vacuum filtration (without mspji digestion) prior swga highest parasite dna concentration displayed greater genome coverage compared mspji + swga swga alone, particularly low parasitaemia samples. optimized swga (filtration + swga) approach successfully used generate wgs 218 non-leukocyte depleted field sample malawi. sequence lab-created mixture parasite evidence differential amplification parasite strain compared directly sequenced samples. conclusion: optimized swga approach reliable obtain wgs non-leukocyte depleted, low parasitaemia samples. absence amplification bias generated mixture isolates geographic region suggests approach appropriately used molecular epidemiological studies.',\n",
       " 'background: probability weaning long-term survival chronically mechanically ventilated cancer unknown, incomplete information available guide therapeutic decisions. sought determine probability weaning overall survival cancer requiring long-term mechanical ventilation specialized weaning unit. methods: single-institution retrospective review requiring mechanical ventilation outside critical care setting 2008 2012 january 1 december 31, 2018, performed. demographic clinical recorded, cancer specifics, comorbidities, treatments, outcomes. overall survival determined kaplan-meier approach. time weaning analyzed cumulative incidence function, death considered competing risk. prognostic factor evaluated use prospective evaluation weaning protocols. results: 2008 2012, 122 required mechanical ventilation outside critical care setting weaning goal care. cumulative incidence weaning discharge intensive care unit 42% 21 days, 49% 30 days, 58% 60 days, 61% 90 days, 61% 120 days. median survival 0.16 year (95% ci, 0.12 0.33) weaned 1.05 year (95% ci, 0.60 1.34) weaned. overall survival 1 year 2 year 52 32% among weaned 16 9% among weaned. 2018, 36 institution required mechanical ventilation outside critical care setting, weaning goal care. overall, median follow-up 140 day (range, 0â\\x80\\x93425 days; average, 141 days), 25% requiring long-term mechanical ventilation (9 36) alive. conclusions: cancer weaned long-term mechanical ventilation, even prolonged period support. implementation resource-intensive weaning program improve rate successful weaning. clear time mechanical ventilation could identified beyond weaning unprecedented. short-term overall survival poor.',\n",
       " 'background: erythrocytic cycle, plasmodium falciparum malaria parasite express p. falciparum erythrocyte membrane protein 1 (pfemp1) anchor infected erythrocyte (ie) vascular lining host. cidrî±1 domain pfemp1 responsible binding host endothelial protein c receptor (epcr), increasing evidence support interaction trigger severe malaria, accounting majority malaria-related deaths. high transmission regions, child develop immunity severe malaria first infections. immunity believed mediated antibody targeting inhibiting pfemp1, causing infected erythrocyte circulate cleared spleen. development immunity malaria coincides acquisition broad antibody reactivity across cidrî±1 protein family. altogether, identifies cidrî±1 important vaccine target. however, antigenic diversity cidrî±1 domain family challenge vaccine development. methods: immune response mouse vaccinated virus-like particle (vlp) presenting cidrî±1 antigen investigated. antibody reactivity tested panel recombinant cidrî±1 domains, antibody ability inhibit epcr binding recombinant cidrî±1 domain tested luminex-based multiplex assays. results: vlp-presented cidrî±1.4 antigen induced rapid strong igg response capable inhibiting epcr-binding multiple cidrî±1 domain mainly within group cidrî±1.4â\\x80\\x937 subgroups. conclusions: observation mirror previous cidrî±1 vaccine study vaccine construct platforms. suggests broad cidrî±1 antibody reactivity may achieved vaccination limited number cidrî±1 variants. addition, suggest may achieved vaccination human compatible vlp vaccine platform.',\n",
       " 'background: calcium-selective channel trpv6 (transient receptor potential cation channel subfamily v member 6) crucial maternal-fetal calcium transport across placenta. trpv6 mutation associated antenatally severe under-mineralising skeletal dysplasia accompanied postnatal biochemical abnormalities. first post-mortem report trpv6 skeletal dysplasia. presentation: female infant severe antenatal postnatal skeletal abnormality 20 week gestation ventilator-dependent birth. skeletal abnormality apparent earlier gestational age previous reported case severe clinical course ensued. biochemical skeletal abnormalities, bone density, improved postnatally cardiac arrest 4 month age led withdrawal intensive care. compound heterozygous trpv6 variant (c.1978g > c p.(gly660arg) c.1528c > p.(arg510ter)) identified exome sequencing. post-mortem identified skeletal abnormality specific abnormality organ systems. placental pathology found, multi-organ histological feature reflected prolonged intensive care only. post-mortem macroscopic examination indicated reduced thoracic size short, pale pliable ribs. histological examination identified reduced number trabecula diaphysis (away growth plates), whereas metaphyses showed adequate mineralisation normal number trabeculae, slightly enlarged reactive chondrocytes, indicating post-natal skeletal growth recovery. post-mortem radiological finding demonstrated improved bone density, improved rib width, healed fractures, although rib still shorter normal. long bone (especially humerus femur) improved initial poorly defined metaphyses reduced bone density sharply defined metaphyses, prominent growth restart line distal diaphysis bone-in-bone appearance along diaphyses. conclusions: provide bone histological confirmation human skeletal development compromised presence trpv6 pathogenic variants. post-mortem finding consistent abnormal utero skeletal mineralisation due severe calcium deficit compromised placental calcium transfer, followed subsequent phenotypic improvement adequate postnatal calcium availability. significant skeletal recovery occurs early week postnatal life trpv6 skeletal dysplasia.',\n",
       " 'background: urgent need effective vaccine control eradicate malaria, serious global infectious diseases. plasmodium merozoite surface protein 4 (msp4) listed blood-stage subunit vaccine candidate malaria. plasmodium ovale specie p. ovale wallikeri p. ovale curtisi, source malaria burden tropical region sometimes mixed plasmodium species. however, little known p. ovale msp4. methods: msp4 gene amplified polymerase chain reaction genomic dna extracted blood sample 46 infected p. ovale spp. amplified product sequenced. open reading frame predicted immunogenic peptide consisting 119 97 amino acid p. ovale curtisi msp4 (pocmsp4) p. ovale wallikeri msp4 (powmsp4), respectively, selected protein expression. recombinant protein (rpomsp4) expressed escherichia coli, purified, analysed, immunized balb/c mice. specificity anti-msp4-immunoglobulin (ig) g antibody evaluated western blot enzyme-linked immunosorbent assays, cellular immune response analysed via lymphocyte proliferation assays. results: full peptide sequence pocmsp4 powmsp4 completely conserved clinical isolates, except epidermal growth factor-like domain carboxyl terminus mutation observed p. o. wallikeri isolate. further, truncated pomsp4 segment successfully expressed purified ~ 32 kda proteins. importantly, high antibody response end-point titre ranging 1:10,000 1:2,560,000 immunized mouse group observed, high igg avidity pocmsp4 (80.5%) powmsp4 (92.3%). furthermore, rpocmsp4 rpowmsp4 cross-reacted anti-powmsp4-specific anti-pocmsp4-specific antibodies. additionally, anti-pomsp4 igg antibody showed broad immuno-specificity reacting rpomsp1 rpoama1. lastly, pocmsp4- powmsp4-immunized mouse induced cellular immune response pocmsp4 (36%) powmsp4 cell (15.8%) splenocyte proliferation assays. conclusion: finding suggest conservation pomsp4 protein sequence high immunogenicity observed rpomsp4. furthermore, induction immune response pocmsp4- powmsp4-immunized mouse informed humoral cellular immune response play crucial role pomsp4 protection.',\n",
       " '',\n",
       " 'examine potential role melatonin cd uptake, accumulation detoxification malus plants, exposed two different apple rootstock varying greatly cd uptake accumulation either 0 30 î¼m cd together 0 100 î¼m melatonin. cd stress stimulated endogenous melatonin production greater extent cd-tolerant m. baccata cd-susceptible m. micromalus â\\x80\\x98qingzhoulinqinâ\\x80\\x99. melatonin application attenuated cd-induced reduction growth, photosynthesis, enzyme activity, well ro mda accumulation. melatonin effectively restored photosynthesis, photosynthetic pigments, biomass cd-challenged m. micromalus â\\x80\\x98qingzhoulinqinâ\\x80\\x99 cd-stressed m. baccata. exogenous melatonin lowered root cd(2+) uptake, reduced leaf cd accumulation, decreased cd translocation factor (t(f)s), increased root, stem, leaf melatonin content cd-exposed rootstocks. melatonin application increased antioxidant concentration enzyme activity scavenge cd-induced ros. exogenous melatonin altered mrna level several gene regulating cd uptake, transport, detoxification ha7, nramp1, nramp3, hma4, pcr2, nas1, mt2, abcc1, mhx. taken together, result suggest exogenous melatonin reduced aerial part cd accumulation mitigated cd toxicity malus plants, probably due melatonin-mediated cd allocation tissues, induction antioxidant defense system transcriptionally regulated key gene involved detoxification.',\n",
       " 'background: number serious human adenovirus (hadv) outbreak reported: hadv-b7 (israel, singapore, usa), hadv-b7d (usa china), hadv-d8, -d54, -c2 (japan), hadv-b14p1 (usa, europe, china), hadv-b55 (china, singapore, france). methods: understand epidemiology hadv infection singapore, studied 533 hadv-positive clinical sample collected 396 pediatric 137 adult singapore 2012 2018. genome sequencing phylogenetic analysis performed identify hadv genotypes, clonal clusters, recombinant novel hadvs. results: prevalent genotype identified hadv-b3 (35.6%), hadv-b7 (15.4%), hadv-e4 (15.2%). detected 4 hadv-c strain detected incursion hadv-b7 (odds ratio [or], 14.6; 95% confidence interval [ci], 4.1â\\x80\\x9352.0) hadv-e4 (or, 13.6; 95% ci, 3.9â\\x80\\x9346.7) among pediatric time. addition, immunocompromised (adjusted [aor], 11.4; 95% ci, 3.8â\\x80\\x9334.8) infected hadv-c2 (aor, 8.5; 95% ci, 1.5â\\x80\\x9348.0), hadv-b7 (aor, 3.7; 95% ci, 1.2â\\x80\\x9310.9), hadv-e4 (aor, 3.2; 95% ci, 1.1â\\x80\\x938.9) increased risk severe disease. conclusions: singapore would benefit frequent study clinical hadv genotype identify risk severe help guide use antiviral therapies, brincidofovir, potential administration hadv 4 7 vaccine.',\n",
       " 'key challenge field genetics inference haplotype next generation sequencing data. minion oxford nanopore sequencer allows sequencing long reads, potential sequencing complete genes, even complete genome viruses, individual reads. however, minion suffers high error rates, rendering detection true variant difficult. here, propose statistical approach named associvar, differentiates true mutation sequencing error direct rna/dna sequencing minion. strategy relies assumption sequencing error dispersed randomly along sequencing reads, hence associated other, whereas real mutation display non-random pattern association mutations. demonstrate approach direct rna sequencing evolved population ms2 bacteriophage, whose small genome make ideal minion sequencing. associvar inferred several mutation phage genome, corroborated parallel illumina sequencing. allowed u reconstruct full genome haplotype constituting different strain present sample. approach applicable long read sequencing organism accurate detection bona fide mutation inter-strain polymorphisms.',\n",
       " 'background: hematopoietic-cell transplant (hct) recipient risk severe respiratory syncytial (rsv) infection. evaluated rsv fusion inhibitor presatovir randomized, double-blind, phase ii trial hct recipient rsv upper respiratory tract infections. methods: stratified lymphopenia (<200/âµl) ribavirin use; randomized, stratified lymphopenia (<200/î¼l) ribavirin use, receive oral presatovir 200 mg placebo day 1, 5, 9, 13, 17, followed 28. coprimary efficacy endpoint time-weighted average change nasal rsv load day 1 9 proportion developing lower respiratory tract complication (lrtcs) 28. results: 23 january 2015 16 june 2017, 189 randomly assigned (96 presatovir 93 placebo). presatovir treatment, compared placebo treatment, significantly affect (prespecified î± = 0.01) time-weighted average decline rsv load 1 9 (treatment difference, â\\x88\\x920.33 log(10) copies/ml; 95% confidence interval [ci] â\\x88\\x92.64 â\\x88\\x92.02 log(10) copies/ml; p = .040) progression lrtc (11.2% v 19.5%, respectively; odds ratio, 0.50; 95% ci, .22â\\x80\\x931.18; p = .11). post hoc analysis among lymphopenia, presatovir decreased lrtc development 28 (2/15 [13.3%] v 9/14 [64.3%], respectively; p = .008), compared placebo. adverse event similar receiving presatovir placebo. conclusions: presatovir favorable safety profile adult hct recipient rsv achieve coprimary endpoints. exploratory analysis suggest antiviral effect among lymphopenia. clinical trial registration: nct02254408; eudra-ct#2014-002474-36.',\n",
       " 'background: recent report described contribution adult respiratory syncytial (rsv) infection use advanced healthcare resource death. methods: regarding aged â\\x89¥18 year admitted marylandâ\\x80\\x99s 50 acute-care hospital evaluated 12 consecutive year (2001â\\x80\\x932013). examined rsv influenza (flu) surveillance u national respiratory enteric surveillance system center control prevention used information define rsv flu outbreak period maryland area. outbreak period consisted consecutive individual week least 10% rsv and/or flu diagnostic test positive. examined relationship rsv flu outbreak occurrence 4 advanced medical outcome (hospitalization, intensive care unit admission, intubated mechanical ventilation, death) due medically attended acute respiratory illness (maari). results: occurrence 4 maari-related hospital advanced medical outcome consistently greater adult age rsv, flu, combined rsvâ\\x80\\x93flu outbreak period compared nonoutbreak period tended greatest adult aged â\\x89¥65 year combined rsvâ\\x80\\x93flu outbreak periods. rate ratio 4 maari-related advanced medical outcome ranged 1.04 1.38 rsv, flu, combined rsvâ\\x80\\x93flu outbreak compared nonoutbreak periods, 95% lower confidence limit >1. conclusions: rsv flu outbreak associated surge maari-related advanced medical outcome (hospitalization, intensive care unit admission, intubated mechanical ventilation, death) adult ages.',\n",
       " '',\n",
       " 'background: presatovir significantly reduced nasal load, signs, symptom respiratory syncytial (rsv) human challenge study. evaluated presatovir hematopoietic-cell transplant (hct) recipient rsv lower respiratory tract (lrti). methods: confirmed rsv upper lower respiratory tract chest x-ray abnormality randomized (1:1), stratified supplemental oxygen ribavirin use, receive oral presatovir 200 mg placebo every 4 day 5 doses. primary endpoint time-weighted average change nasal rsv load 9. secondary endpoint included supplemental oxygen-free days, incident respiratory failure requiring mechanical ventilation, all-cause mortality. results: january 31, 2015, march 20, 2017, 60 17 center randomized (31 presatovir, 29 placebo); 59 received (50 allogeneic, 9 autologous hct). efficacy population (29 presatovir, 28 placebo), presatovir significantly reduce time-weighted average change load (â\\x88\\x921.12 v â\\x88\\x921.09 log(10) copies/ml; difference â\\x88\\x920.02 log(10) copies/ml, 95% confidence interval: â\\x88\\x92.62, .57; p = .94), median supplemental oxygen-free day (26 v 28 days, p = .84), incident respiratory failure (10.3 v 10.7%, p = .98), all-cause mortality (0 v 7.1%, p = .19) versus placebo. adverse event similar arm (presatovir 80%, placebo 79%). resistance-associated substitution rsv fusion protein emerged 6/29 presatovir-treated patients. conclusions: presatovir well tolerated hct rsv lrti improve virologic clinical outcome versus placebo. clinical trial registration: www.clinicaltrials.gov, nct02254421; eudract, #2014-002475-29',\n",
       " 'renal angina index proposed identify high risk persistent aki, based slight change serum creatinine conditions. however, concise scoring proposed pediatric patients, adult yet. here, developed validated concise scoring admitted icu 21 japanese hospital 2012 2014. randomly assigned either discovery validation cohorts, identified factor significantly associated persistent aki multivariable logistic regression model discovery cohort establish scoring system, assessed validity scoring validation cohort receiver operating characteristic analysis calibration slope. among 8,320 admitted icus, persistent aki present 1,064 (12.8%) patients. discovery cohort (n = 4,151), â\\x80\\x98hyperbilirubinemiaâ\\x80\\x99, â\\x80\\x98sepsisâ\\x80\\x99 â\\x80\\x98ventilator and/or vasoactiveâ\\x80\\x99 small change serum creatinine selected establish scoring. validation cohort (n = 4,169), predicting model based scoring c-statistic 0.79 (95%ci, 0.77â\\x80\\x930.81) well calibrated. conclusion, established concise scoring identify potential persistent aki, performed well validation cohort.',\n",
       " 'background: tg01 first cancer immunotherapy targeting kras oncogenic mutations. assessed safety efficacy tg01/gm-csf resected pancreatic adenocarcinoma. methods: stage ii pancreatic adenocarcinoma undergone surgical resection (r0 r1) received adjuvant gemcitabine tg01/gm-csf two schedule vaccination. immune response defined positive delayed-type hypersensitivity (dth) response and/or positive t-cell proliferation assay. results: thirty-two enrolled february 2013 may 2016. nineteen treated high antigen burden, four serious adverse reaction considered possibly related tg01 treatment, three allergic reactions. basis, 13 received modified vaccination schedule reduced antigen burden, serious adverse event related tg01. ninety-five percent main cohort 92% modified cohort positive immune response. median overall survival (os) 33.1 months, median disease-free survival (dfs) 13.9 month main cohort. modified cohort, median o 34.3 month median dfs 19.5 months. conclusions: tg01/gm-csf gemcitabine well tolerated, high level immune activation. o dfs compare favourably published adjuvant gemcitabine. clinical trial registration: clinical trial registered clinicaltrials.gov (nct02261714).',\n",
       " 'innate immune system play crucial role host defense microbial infection. exosomes constitute subset extracellular vesicle (evs) released almost cell types. owing capacity shield payload degradation evade recognition subsequent removal immune system, exosomes efficiently transport functional component recipient cells. accumulating evidence exosomes derived tumor cells, host cell even bacteria parasite mediate communication invader innate immune cell thus play irreplaceable function dissemination pathogen donor cell-derived molecules, modulating innate immune response host. review, describe current understanding ev (mainly focusing exosomes) summarize discus crucial role determining innate immune responses. additionally, discus potential exosomes biomarkers cancer vaccine diagnostic therapeutic applications.',\n",
       " 'gangliosides structurally functionally polymorphic sialic acid containing glycosphingolipids widely distributed human body. play important role protecting u immune attacks, yet become target autoimmunity act receptor microbes, like influenza viruses, toxins, cholera toxin. expression pattern gangliosides vary different tissues, different life periods, well different animals. antibody gangliosides (aga) target immune attack e.g., neuronal cell neutralize complement inhibitory activity. aga important especially acquired demyelinating immune-mediated neuropathies, like guillainâ\\x80\\x93barrã© syndrome (gbs) variant, millerâ\\x80\\x93fisher syndrome (mfs). emerge response different microbial agent immunological insults. thereby, involved variety diseases. addition, antibody gm3 found serum vaccinated pandemrixâ®, developed secondary narcolepsy, strongly supporting autoimmune etiology disease.',\n",
       " 'newcastle (ndv) cause severe economic loss severe morbidity mortality pose significant threat global poultry industry. significant effort made develop novel vaccine therapeutics; however, interaction ndv host yet fully understood. interferon (ifns), integral component innate immune signaling, act first line defense invading viruses. compared mammalian repertoire ifns, limited information available antiviral potential ifns chickens. here, expressed chicken ifn-î³ (chifn-î³) baculovirus expression vector system, characterized antiviral potential ndv, determined antiviral potential. priming chicken embryo fibroblast chifn-î³ elicited antiviral environment primary cells, mainly due interferon-stimulated gene (isgs). genome-wide transcriptomics approach used elucidate possible signaling pathway associated ifn-î³-induced immune responses. rna-sequencing (rna-seq) revealed significant induction isg-associated pathways, activated temporal expression isgs, antiviral mediators, transcriptional regulator cascade antiviral responses. collectively, found ifn-î³ significantly elicited antiviral response ndv infection. provide foundation chifn-î³-mediated antiviral response underpin functional annotation important chifn-î³-induced antiviral influencers.',\n",
       " 'interaction protein membrane play critical role signal transduction, cell motility, transport, involved many type diseases. molecular dynamic (md) simulation greatly contributed understanding proteinâ\\x80\\x93membrane interactions, promoted dramatic development md-related software, increasingly accurate force fields, available computer power. chapter, present available method studying proteinâ\\x80\\x93membrane system md simulations, overview various all-atom coarse-grained force field lipids, useful software membrane simulation setup analysis. set study discussed.',\n",
       " '',\n",
       " 'specific feature finnish pension system rule-based preparation mortality change. earned pension capital adjusted life expectancy lowest age limit flexible retirement age adapted ratio expected year employment retirement fixed year 2030.',\n",
       " '',\n",
       " '',\n",
       " 'background: oncology nurses, compassion fatigue, burn compassion satisfaction frequently experienced psychosocial consequence oncology work environment. surveying phenomenon help understand nurse feel behave cancer care provided. besides, tracking evolving nature three concept lend hand early detection personal professional suffering nurse offering healing remedy struggling body souls. purpose: purpose explore level compassion fatigue, burn compassion satisfaction among group specialized oncology nurses. besides, aimed detect probable interesting inference compassion satisfaction concept rest leisure. correlation compassion fatigue, burn compassion satisfaction investigated. correlation oncology nursesâ\\x80\\x99 score three subscales group demographic, organizational leisure-related variable examined. methods: adopted descriptive correlation design survey compassion fatigue, burn compassion satisfaction among convenient sample 100 oncology nurse work specialized cancer care centre. participant completed compassion fatigue self-test developed figely (compassion fatigue, york: brunner/mazel. b. hudnallstamm, traumatic stress research group; 1995â\\x80\\x931998. http://www.dartmouth.edu/~bhstamm/index.htm, 1995) literature-based demographic survey. analysis included descriptive statistic pearson correlation co-efficient. results: nurse reported low level compassion satisfaction, moderate risk burn extremely high risk compassion fatigue. result revealed significant negative relationship among compassion satisfaction number dependent per nurse. additionally correlation compassion satisfaction nursesâ\\x80\\x99 number hour slept positive. two component concept rest leisure yielded statistical significance correlated concept compassion satisfaction. significant negative relationship observed compassion satisfaction compassion fatigue strong positive relationship observed compassion fatigue burn out. conclusions: studied oncology nurse sample evidently low level compassion satisfaction contrasted significantly increased risk burn compassion fatigue. thus, authority management advised care, holistic approach, nurse work oncology departments. staff-oriented service offer comfort, reward, leisure, screening, consultation support urgently recommended.',\n",
       " 'background: concern exist regarding prevalence impact unnecessary oxygen use acute respiratory distress syndrome (ards). examined issue ards enrolled observational understand global impact severe acute respiratory failure (lung safe) study. methods: secondary analysis lung safe study, wished determine prevalence outcome associated hyperoxemia 1, sustained hyperoxemia, excessive oxygen use early ards. fulfilled criterion ards 1 2 acute hypoxemic respiratory failure categorized based presence hyperoxemia (pao(2) > 100 mmhg) 1, sustained (i.e., present 1 2) hyperoxemia, excessive oxygen use (fio(2) â\\x89¥ 0.60 hyperoxemia). results: 2005 met inclusion criteria, 131 (6.5%) hypoxemic (pao(2) < 55 mmhg), 607 (30%) hyperoxemia 1, 250 (12%) sustained hyperoxemia. excess fio(2) use occurred 400 (66%) 607 hyperoxemia. excess fio(2) use decreased 1 2 ards, hyperoxemic 2 receiving relatively low fio(2). multivariate analysis found independent relationship 1 hyperoxemia, sustained hyperoxemia, excess fio(2) use adverse clinical outcomes. mortality 42% excess fio(2) use, compared 39% propensity-matched sample normoxemic (pao(2) 55â\\x80\\x93100 mmhg) (p = 0.47). conclusions: hyperoxemia excess oxygen use prevalent early ards often non-sustained. relationship found hyperoxemia excessive oxygen use outcome cohort. trial registration: lung-safe registered clinicaltrials.gov, nct02010073',\n",
       " '',\n",
       " 'severe fever thrombocytopenia syndrome (sfts) emerging tick-borne caused sfts (sftsv) infection. despite gradual increase sfts case high mortality endemic regions, specific therapy vaccine available. here, developed single recombinant plasmid dna encoding sftsv genes, gn gc together np-ns fusion antigen, vaccine candidate. antigen fused fms-like tyrosine kinase-3 ligand (flt3l) il-12 gene incorporated plasmid enhance cell-mediated immunity. vaccination dna provides complete protection ifnar ko mouse upon lethal sftsv challenge, whereas immunization plasmid without il-12 gene resulted partial protection. since failed detect antibody surface glycoproteins, gn gc, immunized mice, antigen-specific cellular immunity, confirmed enhanced antigen-specific cell responses, might play major role protection. finally, evaluated degree protective immunity provided protein immunization individual glycoprotein, gn gc. although protein antigen induced significant level neutralizing activity sftsv, gn vaccination resulted relatively higher neutralizing activity better protection gc vaccination. however, antigen failed provide complete protection. given dna vaccine failed induce sufficient immunogenicity human trial compared protein vaccines, optimal combination dna protein elements, proper selection target antigens, incorporation efficient adjuvant, need investigated sftsv vaccine development.',\n",
       " '',\n",
       " 'cancer leading cause death worldwide. cervical cancer caused human papillomavirus (hpv) major problem women. dna vaccine perfect approach immunization, potency clinical trial insufficient generating effective immunity, may related degradation dna via nucleases, poor delivery antigen-presenting cell (apcs), insufficient uptake dna plasmid cell upon injection. archaeosome nano-delivery system based liposome immunological role developed gene delivery. study, human papillomavirus type 16 genes, containing truncated l1, e6, e7, simultaneously used combination therapy archaeosome assessed vivo. finding supported archaeosomes promotes immune response dna vaccine long-term ctl response generated low antigen dose. combination therapy archaeosome/l1/e6/e7 vaccine exhibited strong cytolytic activity tumor cell induced prophylactic therapeutic effect development tumor animal model.',\n",
       " '27,000 people sickened ebola 11,000 people died march 2014 june 2016. u center control prevention (cdc; atlanta, georgia usa) many public organization sought stop outbreak. agency deployed almost 2,000 individual west africa timeframe. deployment country exposed individual wide variety dangers, stressors, risks. concerned at-risk population africa, well-being professional willingly deployed, cdc several thing help safeguard health, safety, resilience team member before, during, deployment. accompanying special report highlight innovative pre-deployment training initiatives, customized screening processes, post-deployment outreach effort intended protect support public professional fighting ebola. deploying, cdc team member expected participate internally-created externally-provided trainings. ranged pre-deployment briefings, preparing work overseas (pfwo) public readiness certificate program (phrcp) courses, incident command system (ics) 100, 200, 400 courses. small subset non-clinical deployers participated three-day training designed collaboration center traumatic stress (csts; bethesda, maryland usa) train individual ass address well-being resilience teammate field deployment. participant unique training immersed virtual reality environment (vre) simulated deployment seven different type emergencies. cdc leadership requested pre-deployment screening process helped professional cdcâ\\x80\\x99s occupational clinic (ohc) determine whether individual increased risk negative outcome participating rigorous deployment time. deployers returned field, received personalized invitation participate voluntary, confidential, post-deployment operational debriefing one-on-one group. implementing approach provided information clinical decision maker readiness deployers. provided deployers greater awareness kind challenge likely face field. post-deployment outreach effort reminded staff contribution appreciated resource available needed help processing potentially-traumatizing thing may experienced.',\n",
       " '',\n",
       " 'present detail eaere award best paper published environmental resource economics 2019 together highly commended paper published period.',\n",
       " 'background: limited information available regarding intraoperative ventilator setting incidence postoperative pulmonary complication (ppcs) undergoing neurosurgical procedures. aim post-hoc analysis â\\x80\\x98multicentre local assessment ventilatory management general anaesthesia surgeryâ\\x80\\x99 (las vegas) examine ventilator setting undergoing neurosurgical procedures, explore association perioperative variable development ppcs neurosurgical patients. methods: post-hoc analysis la vega study, restricted undergoing neurosurgery. stratified group based type surgery (brain spine), occurrence ppcs ass respiratory risk surgical catalonia (ariscat) score risk ppcs. results: seven hundred eighty-four included analysis; 408 (52%) underwent spine surgery 376 (48%) brain surgery. median tidal volume (v(t)) 8 ml [interquartile range, iqr = 7.3â\\x80\\x939] per predicted body weight; median positive endâ\\x80\\x93expiratory pressure (peep) 5 [3 5] cmh(2)0. planned recruitment manoeuvre used 6.9% patients. difference ventilator setting found among sub-groups. ppcs occurred 81 (10.3%). duration anaesthesia (odds ratio, 1.295 [95% confidence interval 1.067 1.572]; p = 0.009) higher age brain group (odds ratio, 0.000 [0.000 0.189]; p = 0.031), intraoperative ventilator setting independently associated development ppcs. conclusions: neurosurgical ventilated low v(t) low peep, recruitment manoeuvre seldom applied. intraoperative ventilator setting associated ppcs.',\n",
       " 'background: lung recruitment birth advocated effective improving respiratory transition birth. sustained inflation (si) dynamic positive end-expiratory pressure (peep) assessed clinical animal study define optimal level. working hypothesis low gestational age infant (vlgai) < 32 weeksâ\\x80\\x99 gestation require individualized lung recruitment based combining manoeuvers. methods: 2014 2016, 91 72 inborn vlgai, requiring respiratory support beyond continuous positive airway pressure (cpap) = 5 cmh2o, enrolled introducing manoeuvers based progressive increase si 15 s, simultaneous gradual increase peep 15 cmh2o, according cardiorespiratory response. retrospective comparison incidence mechanical ventilation (mv) < 72 h life, short-term discharge morbidity performed. results: among extremely low gestational age infant (elgai) < 29 weeksâ\\x80\\x99 gestation, following outcome decreased significantly: intubation (90 55%) surfactant administration (54 12%) delivery room, mv (92 71%) mean duration < 72 h life (45 h 13 h), administration 2nd dose surfactant (35 12%) postnatal corticosteroid (52 19%), rate bronchopulmonary dysplasia (23 5%). among vlgai, result significant. neonatal mortality morbidity different. conclusions: setting, combining two individualized lung recruitment maneuver birth feasible may beneficial short-term discharge pulmonary outcomes. randomized controlled trial needed confirm results.',\n",
       " 'background: influenza vaccine manufacturer traditionally use egg-derived candidate vaccine virus (cvvs) produce high-yield influenza virus seasonal pandemic vaccines; however, egg-derived cvvs need adaptation process grow mammalian cells. low yield cell-based manufacturing system egg-derived cvvs remain unsolved issue. aimed develop high-growth cell-derived cvvs mdck cell-based vaccine manufacturing platforms. methods: four h7n9 cvvs generated characterized vero adherent mdck (amdck) cells. furthermore, reassortant virus amplified adherent mdck (amdck) cell certification, growth characteristic detected amdck cell suspension mdck (smdck) cells. finally, plaque-forming ability, biosafety, immunogenicity h7n9 reassortant virus evaluated. results: ha titer cvvs produced proprietary suspension mdck (smdck) cell chicken embryo 2- 8-fold higher amdck cells. h7n9 cvvs showed attenuated characteristic trypsin-dependent plaque assay chicken embryo lethality test. alum-adjuvanted nhri-rg5 (derived fifth wave h7n9 a/guangdong/sp440/2017) vaccine highest immunogenicity cross-reactivity among four h7n9 cvvs. finally, found addavax adjuvant improved cross-reactivity low pathogenic h7n9 highly pathogenic h7n9 viruses. conclusions: indicates cell-derived h7n9 cvvs possessed high growth rate smdck cell low pathogenicity chicken embryo, cvvs generated platform suitable cell- egg-based prepandemic vaccine production.',\n",
       " 'campaign eliminate infectious disease could greatly aided method providing early warning signal resurgence. theory predicts transmission system undergoes transition stability disease-free equilibrium sustained transmission, exhibit characteristic behaviour known critical slowing down, referring speed fluctuation number case dampened, instance extinction local transmission chain imported case. phenomenon include increase several summary statistics, lag-1 autocorrelation, variance first difference variance. here, report first empirical test prediction resurgence malaria kericho, kenya. 10 summary statistics, measured approach criticality rolling window quantify size effect directions. nine statistic increased predicted variance, first difference variance, autocovariance, lag-1 autocorrelation decay time returned early warning signal critical slowing based permutation tests. result time series incidence collected ordinary surveillance activity may exhibit characteristic signature prior outbreak, phenomenon may quite general among infectious systems.',\n",
       " 'existing method infer relative role age group epidemic transmission normally accommodate age classes, and/or require highly specific studied. here, symbolic transfer entropy (ste), measure developed identify asymmetric transfer information stochastic processes, presented way reveal asymmetric transmission pattern age group epidemic. ste provides ranking age group may dominate transmission, rather reconstruction explicit between-age-group transmission matrix. simulations, establish ste identify age group dominate transmission even difference reporting rate age group even noisy. then, pairwise ste calculated time series influenza-like illness 12 age group 884 u city autumn 2009. elevated ste 5 19 year-olds indicates school-aged child likely important transmitter autumn wave 2009 pandemic usa. result may partially confounded higher rate physician-seeking behaviour child compared adults, unlikely difference reporting rate explain observed difference ste.',\n",
       " 'increasing interest development new, â\\x80\\x98universalâ\\x80\\x99 influenza vaccine (uivs) thatâ\\x80\\x93â\\x80\\x93unlike current vaccinesâ\\x80\\x93â\\x80\\x93are effective broad range seasonal influenza strains, well novel pandemic viruses. existing literature discus potential epidemiological benefit uivs, important anticipate potential unintended population consequences. mathematical modelling, illustrate two type adverse consequences. first, reducing amount infection-induced immunity population without fully replacing it, seasonal uiv programme may permit larger pandemic absence vaccination. second, successful future uiv programme reducing transmission seasonal influenza, vulnerable population could become emergence vaccine escape variant. risk could mitigated optimal deployment future uiv vaccine: namely, use combined vaccine formulation (incorporating conventional well multiple universal antigenic targets) achieving sufficient population coverage compensate reduction infection-induced immunity. absence large-scale trial uivs, disease-dynamic model provide helpful, early insight potential impact. future, continuing vaccine development invaluable developing robustly predictive modelling approaches.',\n",
       " 'order monitor progress towards malaria elimination, crucial able measure change spatio-temporal transmission. however, common metric malaria transmission parasite prevalence powered elimination contexts. china achieved major reduction malaria incidence track eliminate, reporting zero locally-acquired malaria case 2017 2018. understanding spatio-temporal pattern underlying decline, especially relationship locally-acquired imported cases, inform effort maintain elimination prevent re-emergence. particularly pertinent yunnan province, potential local transmission highest. geo-located individual-level dataset case recorded yunnan province 2011 2016, introduce novel bayesian framework model latent diffusion process estimate joint likelihood transmission case number case unobserved source infection. used estimate reproduction number, rc. use estimate within spatio-temporal geostatistical model map transmission varied time space, estimate timeline elimination risk resurgence. estimate mean rc 2011 2016 0.171 (95% ci = 0.165, 0.178) p. vivax case 0.089 (95% ci = 0.076, 0.103) p. falciparum cases. 2014 onwards, case estimated rc value one. unobserved source estimated moderately likely (p>0.5) 19/ 611 case high (p>0.8) 2 cases, suggesting high level ascertainment. estimate suggest that, maintaining current intervention efforts, yunnan unlikely experience sustained local transmission 2020. however, even mean 0.005 projected 2020, locally-acquired case possible due high level importation.',\n",
       " 'objective: identify difference feeding skill performance among preterm infant term equivalent age compared full-term infants. design: ninety-two infant (44 preterm infant born â\\x89¤32 week gestation term equivalent age 48 full-term infant within 4 day birth) standardized oral feeding assessment. result: preterm infant term equivalent age lower neonatal eating outcome assessment score (67.8 â± 13.6 compared 82.2 â± 8.1; p < 0.001) likely poor arousal (p = 0.04), poor tongue positioning (p = 0.04), suckâ\\x80\\x93swallowâ\\x80\\x93breathe discoordination (p < 0.001), inadequate sucking burst (p = 0.01), tonal abnormality (p < 0.001), discoordination jaw tongue sucking (p < 0.001), lack positive engagement feeder and/or discomfort (p < 0.001), sign aspiration (p < 0.001), difficulty regulating breathing (p < 0.001), inability maintain appropriate state (p < 0.001), complete feeding (<0.001). conclusion: broad range feeding-related difficulty appear remain evident preterm infant term equivalent age.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'hematopoietic cell transplant (hct) cure child adult sickle cell disease. outcome historically poor vast majority lack matched sibling donor. however, development haploidentical hct (haplo-hct) high dos posttransplant cyclophosphamide (ptcy) allowed curative long-term potential favorable transplant-related outcomes, though obviated potential graft rejection human leukocyte antigen mismatch repeated red blood cell transfusions. accordingly, multiple strategy developed improve outcomes, majority based john hopkins platform 2012. presently, aim discus result pertinent study compare outcome two recent approach involving either thiotepa plus 200-cgy total body irradiation 400-cgy total body irradiation. direct comparison required determine optimized curative potential. transplant-eligible must referred tertiary medical center consideration haplo-hct.',\n",
       " '',\n",
       " 'paper, proposed two-phase procedure (combining discrete graph wavelets) constructing true epidemic growth. first phase, graph-theory-based approach developed update partial available second phase, used partial generate plausible complete wavelets. provided two numerical examples. procedure novel implementable adaptable machine learning modeling framework.',\n",
       " '',\n",
       " '',\n",
       " 'background: public response zika outbreak mostly focused epidemiological surveillance, vector control, individual level preventative measures. qualitative employ social-ecological framework examine macro (historical, legislative, political, socio-economic factors), meso (sources information, social support, social mobilization) micro level factor (individual actions, behavioral changes) interacted influence response behavior woman respect zika different contexts. methods: qualitative carried out. woman recruited snowball sampling technique various location brazil, puerto rico, united states. different nationality ethnicities. collected semi-structured interviews. transcript analyzed thematic analysis. results: woman deemed information provided insufficient, led actively reach access variety medium sources. social network played vital role sharing information resulted spread hoax rumors. participant research perceived socio-economic inequity focused remedy microenvironments. engage major social activities. lack trust government placed woman vulnerable situation preventing follow guidance authorities. impact response tactic government administration failed attempt ensure well-being countriesâ\\x80\\x99 populations. conclusions: finding call public intervention go beyond individual level behavioral change campaigns, comprehensively address broader meso macro level factor influence womenâ\\x80\\x99 willingness possibility protect themselves.',\n",
       " '',\n",
       " 'background: physician-staffed emergency medical service (p-ems) resource demanding, research needed evaluate potential effect p-ems. templates, designed expert agreement, valuable feasible, need updated regular basis due development available equipment options. 2011, consensus-based template documenting reporting p-ems published. aimed revise update template documenting reporting p-ems. methods: delphi applied achieve consensus panel selected european experts. expert blinded consensus reached, response anonymized. expert asked propose variable within five predefined sections. optional sixth section variable fit pre-defined sections. expert asked review rate variable 1 (totally disagree) 5 (totally agree) based relevance, consensus defined variable rated â\\x89¥4 70% experts. results: eleven expert participated. expert generated 194 unique variable first round. five rounds, consensus reached. updated dataset expanded version original dataset template expanded 45 73 main variables. expert approved final version template. conclusions: delphi method, updated template documenting reporting p-ems. recommend implementing dataset standard reporting p-ems.',\n",
       " '',\n",
       " '',\n",
       " 'chromatin dynamic regulated epigenetic modification crucial genome stability gene expression. various epigenetic mechanism identified pathogenesis human diseases. here, examined effect ten epigenetic agent pseudorabies (prv) gfp-reporter assays. inhibitor bromodomain protein 4 (brd4), receives much attention cancer infection, found exhibit substantial anti-viral activity prv well range dna rna viruses. demonstrated brd4 inhibition boosted robust innate immune response. brd4 inhibition de-compacted chromatin structure induced dna damage response, thereby triggering activation cgas-mediated innate immunity increasing host resistance vitro vivo. mechanistically, inhibitory effect brd4 inhibition mainly attributed attenuation attachment. finding reveal unique mechanism brd4 inhibition restrains point potent therapeutic value infectious diseases.',\n",
       " '',\n",
       " 'identification tumor antigen induce cytotoxic lymphocyte (ctls) crucial cancer-vaccine development. despite predictive ability, current algorithmic approach human leukocyte antigen (hla)-peptidomic analysis allow limited selectivity. here, optimized rapidly screen identify highly immunogenic epitope trigger ctl responses. used combined application involving immune-specific signature analysis hla-associated peptidomics sample six triple-negative breast cancer (tnbc) order select immunogenic hla epitope vitro testing. additionally, applied high-throughput imaging single-cell level order confirm immunoreactivity selected peptides. result indicated enabled identification ctl peptide capable inducing antitumor immunity. platform combining high-resolution computational analysis, hla-peptidomics, high-throughput immunogenicity testing allowed rapid robust identification highly immunogenic epitope represents powerful technique cancer-vaccine development.',\n",
       " 'epidemic evolution many pathogen occur similar timescales dynamic often entangled. here, first step problem theoretically, analyze mutating pathogen spreading simple sir network grid-like connectivity. mind spatial aspect epidemics, often advance transport link host group host city countries. focus mutation enhance agentâ\\x80\\x99s rate. uncover small-world property, i.e., presence long-range connections, make network vulnerable, supporting frequent supercritical mutation bringing network extinction full blown epidemic. number long-range links, however, effect revers find reduced chance outbreaks. two cases, discrete number mutational step continuous genetic variable, analyze various scaling regimes. continuous derive fokker-planck-like equation probability density solve small number shortcut wkb approximation. analysis support claim potentiating mutation transmissibility might occur epidemic wave necessarily initiation.',\n",
       " 'curcumin derivative inhibit replication human influenza virus (iavs). however, clear whether curcumin derivative inhibit neuraminidase (na) influenza virus. study, meaningful 3d quantitative structureâ\\x80\\x93activity relationship model (comparative molecular field analysis r(2) = 0.997, q(2) = 0.527, = 0.064, f = 282.663) built understand chemicalâ\\x80\\x93biological interaction activity neuraminidase. molecular docking used predict binding model curcumin derivative neuraminidase. real-time polymerase chain reaction showed five active curcumin derivative might direct effect particle infectivity h1n1-infected lung epithelial (mdck) cells. neuraminidase activation assay showed five active curcumin derivative decreased h1n1-induced neuraminidase activation mdck cells. indirect immunofluorescence assay indicated two active curcumin derivative (tetramethylcurcumin curcumin) down-regulated nucleoprotein expression. curcumin inhibited iav vivo. therapeutic mechanism curcumin influenza pneumonia related improving immune function infected mouse regulating secretion tumor necrosis-î±, interleukin-6, interferon-î³. result indicate curcumin derivative inhibit iav blocking neuraminidase cellular model curcumin anti-iav activity animal model.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'dieser zum nun abgesagten internistenkongress 2020 geplanten mmw-ausgabe legen wir den schwerpunkt â\\x80\\x94 wie kã¶nnte e anders sein â\\x80\\x94 auf die infektiologie.',\n",
       " 'sie sind ein dorn im fleische der vertragsã¤rzte: die wirtschaftlichkeitsprã¼fungen. kã¼rzlich hat der gesetzgeber verfã¼gt, das nicht mehr jedes quartal 2% der ã\\x84rzte per zufall geprã¼ft werden. stattdessen hat die kbv nun viele neue regeln vorgestellt.',\n",
       " '',\n",
       " '',\n",
       " 'cellular function rely series organized regulated multienzyme cascade reactions. catalytic efficiency cascade depend precise spatial organization constituent enzymes, optimized facilitate substrate transport regulate activities. mimicry organization non-living, artificial system would useful broad range applicationsâ\\x80\\x94with impact scientific community society large. self-assembled dna nanostructures application organize biomolecular component prescribed, multidimensional patterns. review, focus recent progress field dna-scaffolded assembly confinement multienzyme reactions. dna self-assembly exploited build spatially organized multienzyme cascade control relative distance, substrate diffusion paths, compartmentalization activity actuation. combination addressable dna assembly multienzyme cascade deliver breakthrough toward engineering novel synthetic biomimetic reactors.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'â\\x80¢ several study suggested baricitinib potential drug management 19 drug repurposing strategy ability act at2 cell aak1 mediated endocytosis. â\\x80¢ baricitinib, januase kinase inhibitor, known cause lymphocytopenia, neutropenia reactivation. â\\x80¢ reported epidemiological study 19 lesser absolute lymphocyte count closer threshold value. â\\x80¢ moreover, incidence co-infection 19 leading cause mortality. baricitinib may enhance incidence co-infection. â\\x80¢ hence, baricitinib may ideal option management 19.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'transmissible gastroenteritis (tge) piglets, closely resembling human rotavirus enteritis, studied timing extent epithelial invasion along small intestine single oral inoculum virus; related finding measured alteration mucosal structure, kinetics, differentiation, documented abnormality ion transport occurred height diarrhea. six twelve hour inoculation, diarrhea, extensive specific immunofluorescence particle electron microscopy seen villus crypt enterocytes jejunum, mid-intestine, ileum. 24 40 hr, diarrhea severe, immunofluorescence patchy; villus blunting (p < 0.001) increased crypt depth (p < 0.001) observed light microscopy segments; radioautographically labeled enterocytes showed accelerated migration shortened life span; cell villus deficient sucrose activity (p < 0.001) rich thymidine kinase activity (p < 0.005), suggesting relative immaturity. villus structure recovered 72 144 hr, although deeper crypt (p < 0.001) accelerated migration still persisted. conclude extensive, almost simultaneous direct invasion villus enterocytes occur along entire length small intestine single exposure virus, thus cause shedding mature villus cell proliferation accelerated migration cell crypts. height diarrhea, enterocyte turnover maximal, epithelium consists predominantly immature virus-free cell migrated villus relatively undifferentiated state.',\n",
       " 'understand mechanism diarrhea further, studied ileal ion transport vitro relation mucosal change epithelial differentiation transmissible gastroenteritis piglets, invasive enteritis thought involve mainly proximal intestine. infected pigs, height diarrhea, short-circuited ileal epithelium failed actively transport na(+) cl(â\\x88\\x92), defect glucose-mediated na(+) transport. cl(â\\x88\\x92) secretory response theophylline remained intact. conductance measurement indicate paracellular permeability may reduced transcellular transport may altered. mucosal lesion observed time transport changes, characterized villus blunting, crypt hyperplasia, immature crypt-type enterocytes villus epithelium, deficient disaccharidase (na(+), k(+))atpase activity rich thymidine kinase. consideration major determinant diarrhea invasive enteritis must take account altered mucosal function differentiation extent intestinal involvement, ileum, major site fluid absorption intestine.',\n",
       " 'absorption water electrolyte small intestine examined nonabsorbable marker technique 3-day-old 3-wkold pigs. one-half pig group orally infected transmissible gastroenteritis virus; remaining pig served controls. threeday-old control pig concentrated nonabsorbable fluid marker twelve f old along small intestine, indicating efficiency 95% absorption exogenous daily fluid load presented intestine. contrast, marker concentration infected pig showed change whatsoever along either small intestine, indicating complete absence net fluid absorption secretion animals. three-week-old control pig concentrated marker similarly 3-day-old group, bulk fluid absorption occurring small intestine. infected pig 3-wk-old group marked net fluid secretion proximal small intestine, twice fluid load presented intestine 3-wk-old infected pig compared 3-day-old infected group. however, contrast 3-day-old infected group, intestine 3-wk-old infected pig increased fluid absorption six time control, compensatory response prevented diarrhea older animals. analysis luminal content indicated older pigs, unabsorbed carbohydrate almost completely fermented short-chain fatty acid colon, whereas younger pig carbohydrate passed colon unchanged. result demonstrate development microbial digestion, together rapid short-chain fatty acid absorption, primary feature responsible colonic compensation older pig transmissible gastroenteritis.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'serine repeat antigen (sera) conserved among specie genus plasmodium. serum gene form multigene family generally tandemly clustered single chromosome. although plasmodium specie encode multiple serum genes, number varies species. among species, member share similar sequence gene organization. serum posse central papain-like cysteine protease domain, however, members, active site cysteine residue substituted serine. recent study implicate gene family number aspect parasite biology induction protective immune response. review summarizes current understanding important gene family several plasmodium species. plasmodium falciparum (pf)-sera family, example, consists nine gene members. unlike multigene family plasmodium species, pf-sera gene exhibit antigenic variation. pf-sera5 nucleotide diversity low. moreover, although pf-sera5 highly transcribed blood stage malaria infection, amount released host blood following schizont rupture, malaria endemic country sero-positive rate pf-sera5 low, likely due pf-sera5 binding host protein avoid immune recognition. antigen, n-terminal 47 kda domain pf-sera5 vaccine candidate currently undergoing clinical trials. pf-sera5 pf-sera6, well p. berghei (pb)-sera3, pb-sera5, investigated role parasite egress. two p. yoelii sera, serine residue protease active center, implicated parasite virulence. overall, study provide insight evolution plasmodium parasite, serum gene family member increased gene duplication, acquired various function enable parasite survive successfully maintain host. [image: see text]',\n",
       " 'background: predicting detail epidemic evolves highly valuable institution need better plan towards limiting propagation effect optimizing prediction response capabilities. simulation cost- time-effective way predicting evolution joint influence many different factors: interaction patterns, personal characteristics, travel patterns, meteorological conditions, previous vaccination, etc. work presented paper extends epigraph, influenza epidemic simulator, introducing meteorological model modular component interacts rest epigraphâ\\x80\\x99s module refine previous simulation results. goal estimate effect change temperature relative humidity pattern epidemic influenza based provided spanish influenza sentinel surveillance system (sisss) spanish meteorological agency (aemet). methods: meteorological model based regression model developed ab js, tuned influenza surveillance obtained sisss. pre-processing clean reconstruct missing samples, obtain value reproduction number urban region spain, every 10 minute 2011. simulate propagation influenza setting date epidemic onset initial influenza-illness rate urban region. results: simulation result propagation shape weekly influenza rate recorded sisss. perform experiment realistic scenario based actual meteorological 2010-2011, synthetic value assumed simplified predicted climate change conditions. result diminishing relative humidity 10% produce increment 1.6% final rate. effect temperature change spread noticeable, decrease 1.1% per extra degree.conclusions: tool like could help predict shape developing epidemic peaks, would permit quickly run scenario determine evolution epidemic different conditions. make epigraph source code epidemic publicly available.',\n",
       " '',\n",
       " '',\n",
       " 'professional partnership premise practice, practice furnishing nonmedical personnel jointly utilized two physicians, medical personnel jointly employed. rule, income expenditure run jointly practice. outwardly, professional partnership form legal unit reflected mutual liability partners. protection unit, professional partnership allowed participate replacement licensing retiring partner successor, licensing replaced within professional partnership. within framework partnership contract, overall great care many aspect caution warranted. additionally, individual situation partnership individual partner must always essentially taken consideration. even local situation important influence respect requirement planning, particularly regulation retirement partner. view complexity material, partial aspect structure contract article appropriate regulatory option represent small excerpt. view legal overlap corporate law, law concerning medical profession necessary licensing laws, lawyer appropriate experience expertise commissioned construct medical partnership contract.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'role individual characteristics, symptom demographics, norovirus transmissibility poorly understood. six nursing home norovirus outbreak occurring south carolina, u.s. 2014 2016 examined. aimed quantify contribution symptom characteristic norovirus transmission reproduction number (r(ei)) estimate individual infectivity examine transmission change course outbreak. individual estimate r(ei) calculated maximum likelihood procedure infer average number secondary case generated case. association characteristic r(ei) estimated weighted multivariate mixed linear model. outbreak began three index case(s) estimated r(ei)â\\x80\\x99s (range: 1.48 8.70) relative subsequent cases. 209 cases, 155 (75%) vomited, 164 (79%) diarrhea, 158 (76%) nursing home resident (vs. staff). case vomited infected 2.12 (95% ci: 1.68, 2.68) time number individual non-vomiters, case diarrhea infected 1.39 (95% ci: 1.03, 1.87) time number individual case without diarrhea, resident-cases infected 1.53 (95% ci: 1.15, 2.02) time number individual staff-cases. index case tended resident (vs. staff) vomited infected considerably secondary case compared non-index cases. result suggest individuals, particularly residents, vomit infectious tend drive norovirus transmission u.s. nursing home norovirus outbreaks. diarrhea play role norovirus transmission, lesser degree vomiting settings. result lend support prevention control measure focus case vomit, particularly case residents.',\n",
       " '',\n",
       " 'background: important anti-hbv drug, pegylated interferon î± (pegifnî±) offer clinical efficacy, biomarkers accurately forecast response yet elucidated. here, evaluated whether hbv rna could act early monitor pegylated interferon responses. methods: analyzed phase 3, multicenter, randomized cohort 727 hbeag-positive non-cirrhotic receiving 48-week pegifnî±-2a pegifnî±-2b 24-week treatment-free follow-up. serum level hbv rna, hbv dna, hbeag, hbsag measured week 0, 12, 24, 48, 72. results: hbeag seroconversion hbsag loss week 72 observed 217 (29.8%) 21 (2.9%) patients, respectively. 48-week treatment, hbv rna decreased rapidly hbv dna hbsag, hbv rna hbeag shared similar dynamic positive correlations. multivariate regression analysis consistently revealed significance hbv rna week 0, 12, 24, 48 monitor hbeag seroconversion hbsag loss. although baseline hbv rna showed modest auc performance, hbv rna significant increase auc week 12 outperformed hbv biomarkers forecast hbeag seroconversion (p value < 0.05). hbv rna â\\x89¤ 1000 copies/ml optimized cutoff week 12 offered better prediction hbv biomarkers. optimized cutoff plus age, hbv genotype b, hbeag offered strong estimation hbeag seroconversion (accuracy 95.2%, true negative rate 99.8%). conclusion: hbv rna week 12 effective monitor hbeag seroconversion hbeag-positive treated pegylated interferons. electronic supplementary material: online version article (10.1007/s12072-020-10015-3) contains supplementary material, available authorized users.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'background: derive list opportunistic infection (oi) analysis juvenile idiopathic arthritis (jia) pharmachild registry independent safety adjudication committee (sac). methods: sac (3 pediatric rheumatologist 2 pediatric infectious specialists) elaborated approved consensus provisional list oi use jia. 5 step-procedure, severe serious infections, classified per meddra dictionary retrieved pharmachild registry, evaluated sac answering six question adjudicated agreement 3/5 specialists. final evidence-based list oi resulted matching adjudicated infection provisional list oi. results: total 772 infectious event 572 eligible patients, 335 serious/severe/very severe non-oi 437 oi (any intensity/severity), according provisional list, retrieved. six hundred eighty-two 772 (88.3%) adjudicated infections, 603/682 (88.4%) common 119/682 (17.4%) oi sac. matching 119 opportunistic event provisional list, 106 confirmed sac oi, among infection herpes virus frequent (68%), followed tuberculosis (27.4%). remaining event divided group non-oi possible/patient and/or pathogen-related oi. conclusions: found significant number oi jia immunosuppressive therapy. proposed list oi, created consensus validated pharmachild cohort, could facilitate comparison among future pharmacovigilance studies. trial registration: clinicaltrials.gov nct 01399281; encepp seal: awarded 25 november 2011.',\n",
       " 'background: sphingosine-1-phosphate (s1p) signaling phospholipid involved pathophysiologic progression acute respiratory distress syndrome (ards) role endothelial barrier function immune modulation. hypothesized decreased serum s1p level associated clinical outcome ards polymorphism s1p gene associated serum s1p levels. methods: multicenter prospective includes ards healthy blood donor controls. serum s1p level quantified enzyme-linked immunosorbent assays. eight tag single nucleotide polymorphism (snps) s1p gene detected, association s1p level evaluated. results: total 121 ards 100 healthy individual enrolled. serum s1p level lower ards control (p < 0.001). decreased s1p level correlated organ dysfunction higher acute physiology chronic evaluation ii scores. change s1p level ards associated clinical outcomes. recessive model snp rs3743631 suggests gg homozygote associate higher risk ards. dominant model snp rs907045 suggests aa ta genotype might increase risk ards. ards patients, rs3743631 gg genotype showed lower s1p level harboring ag aa genotypes. serum s1p level rs907045 aa ta genotype lower tt genotype. conclusions: serum s1p level dramatically decreased ards patients. reduced s1p level associated worse clinical outcomes. significant association s1p rs3743631, rs907045 polymorphism susceptibility ards.',\n",
       " 'background: antigen expressed sexual stage malaria parasite target transmission-blocking vaccine (tbvs). hap2/gcs1, tbv candidate, critical fertilization plasmodium. here, genetic diversity pvhap2 studied plasmodium vivax parasite population greater mekong subregion (gms). methods: plasmodium vivax clinical isolates collected clinic china-myanmar border region (135 samples), western thailand (41 samples) western myanmar (51 samples). near full-length pvhap2 (nucleotides 13â\\x80\\x932574) amplified sequenced isolates. molecular evolution study conducted evaluate genetic diversity, selection population differentiation. results: sequencing pvhap2 gene total 227 sample three p. vivax population revealed limited genetic diversity gene gm (ï\\x80 = 0.00036 â± 0.00003), highest ï\\x80 value observed myanmar (0.00053 â± 0.00009). y133s dominant mutation china-myanmar border (99.26%), myanmar (100%) thailand (95.12%). result neutrality test negative three populations, suggesting possible action purifying selection. codon-based test identified specific codon purifying positive selections. wrightâ\\x80\\x99s fixation index showed low moderate genetic differentiation p. vivax population gms, f(st) ranging 0.04077 0.24833, whereas high level genetic differentiation detected china-myanmar border iran population (f(st) = 0.60266), thailand iran population (f(st) = 0.44161). total 20 haplotype identified, h2 abundant haplotype china-myanmar border, myanmar thailand populations. epitope mapping prediction pvhap2 antigen showed high-score b-cell epitope located s307-g324, l429-p453 v623-d637 regions. e317k d637n mutation located within s307-g324 v623-d637 epitope slightly reduced predicted score potential epitopes. conclusions: present showed low level genetic diversity pvhap2 gene among p. vivax population greater mekong subregion. relative conservation pvhap2 support evaluation pvhap2-based tbv. [image: see text]',\n",
       " 'background: leptospirosis neglected zoonotic major challenge clinician public professional tropical countries. cytokine storm second (immune) phase thought major contributory factor leptospirosis severity. aim summarize evidence cytokine response leptospirosis different clinical outcomes. methods: systematic review carried examine cytokine response leptospirosis relevant scientific databases. reference list selected article screened. quality selected study assessed national institute quality assessment tool observational cohort cross-sectional studies. results: 239 article retrieved initial search, 18 study fulfilled selection criteria. india thailand produced highest number study (17% each, n = 3). majority comparative cross-sectional study (72%, n = 13). overall quality selected study fair regardless drawback reporting sample size lack adjustment confounders. microscopic agglutination test (67% - 12/18) enzyme-linked immunosorbent assay (50% - 9/18) commonly used confirmation leptospirosis measurement cytokine respectively. il-1b, il-2, il-4, il-6, il-8, il-10 tnf-î± level found significantly higher severe mild leptospirosis. equivocal finding association il-1î², tnf-î± il-10/tnf-î± ratio severity. conclusions: leptospirosis wide-range elevated cytokines. however, prospective study in-relation onset symptom required better understand pathophysiology cytokine response leptospirosis.',\n",
       " 'background: subphenotypes reported within clinical acute respiratory distress syndrome (ards), distinct outcome therapeutic responses. experimental model long used mimic feature ards pathophysiology, presence distinct subphenotypes among preclinical ards remains unknown. review investigate whether: 1) subphenotypes identified among preclinical ards models; 2) subphenotypes identify responsive traits. methods: include comparative preclinical (in vivo ex vivo) ards study published 2009 2019 pre-specified therapy assessed (interleukin (il)-10, il-2, stem cells, beta-agonists, corticosteroids, fibroblast growth factors, modulators receptor advanced glycation end-products pathway, anticoagulants, halogenated agents) outcome compared control condition. primary outcome composite four key feature preclinical ards per american thoracic society consensus conference (histologic evidence lung injury, altered alveolar-capillary barrier, lung inflammatory response, physiological dysfunction). secondary outcome include single component primary composite outcome, net alveolar fluid clearance, death. medline, embase, cochrane database searched electronically eligible study extracted, pooled, analyzed random-effects models. individual reporting assessed according animal research: reporting vivo experiment guidelines. meta-regressions performed identify subphenotypes prior comparing outcome across subphenotypes effects. discussion: inform presence underlying pathophysiological feature subphenotypes among preclinical model ards help determine whether sufficient evidence exists perform preclinical trial subphenotype-targeted therapies, prior potential clinical translation. systematic review registration: prospero (id: crd42019157236).',\n",
       " 'background: scrub typhus acute febrile illness, caused orientia tsutsugamushi transmitted bite chiggers. diagnosis scrub typhus could missed diagnosis due absence pathognomonic eschar. presentation: 76-year-old man hospitalized fever kidney injury diagnosed hemorrhagic fever renal syndrome first. however, situation illness deteriorated refractory septic shock multiple organ dysfunction rapidly,although anti-sepsis used 3rd-5th day. orientia tsutsugamushi determined causative pathogen next-generation sequencing plasma sample 6th day. then, treated doxycycline azithromycin recovered quickly. conclusions: next-generation sequencing diagnostic technology could identify scrub typhus accurately fast without pathognomonic eschar.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'identification host cell factor entry useful molecular explanation tropism often lead profound understanding virus-induced diseases. severe fever thrombocytopenia syndrome (sfts) emerging infectious caused sfts virus. countermeasure exist. report, efficient virus-like particle functional screening cellular cdna library identify sfts entry factors. two variant encoding dendritic cell-specific icam-3 grabbing non-integrin related (dc-signr), calcium-dependent lectin known enhance sfts infection, successfully identified human liver cdna library. discus application yet unidentified factor(s) sfts entry entry factor(s) virus related sfts virus.',\n",
       " 'background: pendelluft, movement gas within different lung regions, present animal model assisted mechanical ventilation associated lung overstretching. due rebreathing co(2) compared fresh gas, pendelluft might reduce ventilatory efficiency possibly exacerbating patientâ\\x80\\x99s respiratory workload weaning. aim measure pendelluft electrical impedance tomography (eit) failed spontaneous breathing trial (sbt). methods: observational conducted general intensive care unit tertiary-level teaching hospital. eit signal recorded 20 pressure support (ps) ventilation progressively reduced clinical level (baseline) 2 cmh(2)o, sbt; four ventral-to-dorsal lung region interest identified pendelluft measurement. regional gas movement (> 6 ml) occurring direction opposite global eit signal considered diagnostic high pendelluft. results: eight 20 (40%) classified high-pendelluft; baseline clinical characteristic differ high- low-pendelluft patients. p reduction, pendelluft etco(2) increased high-pendelluft group (p < .001 .011, respectively). volume gas subject pendelluft moved almost completely ventral towards dorsal lung regions, opposite movement minimal (16.3 [10:32.8] vs. 0 [0:1.8] ml, p = .001). subgroup patients, increased pendelluft volume positively correlated marker respiratory distress increased respiratory rate, p0.1, etco(2). conclusions: occult pendelluft measured eit, frequently present failing sbt. present, pendelluft increase reduction ventilator support associated increased etco(2), suggesting reduction ability eliminate co(2).',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'dna glycosylases emerging relevant pharmacological target inflammation, cancer neurodegenerative diseases. consequently, search inhibitor enzyme become active research field. continuation previous work showed 2-thioxanthine (2tx) irreversible inhibitor zinc finger (znf)-containing fpg/nei dna glycosylases, designed synthesized mini-library 2tx-derivatives (txn) evaluated ability inhibit fpg/nei enzymes. among forty compounds, four txn better inhibitor 2tx fpg. unexpectedly, interestingly, two dithiolated derivative selectively efficiently inhibit zincless finger (znlf)-containing enzyme (human mimivirus neil1 dna glycosylases hneil1 mvnei1, respectively). combining chemistry, biochemistry, mass spectrometry, blind flexible docking x-ray structure analysis, localized txn binding site fpg/nei enzymes. endeavor allowed u decipher atomic level mode action best txn inhibitor znf-containing enzymes. discovered original inhibition mechanism znlf-containing fpg/nei dna glycosylases disulfide cyclic trimeric form dithiopurines. work pave way design synthesis structural class inhibitor selective pharmacological targeting hneil1 cancer neurodegenerative diseases.',\n",
       " 'post-translational modification (ptm) protein crucial fine-tuning cellâ\\x80\\x99s response intracellular extracellular cues. adp-ribosylation ptm, occurs two flavours: modification target multiple adp-ribose moiety (poly(adp-ribosyl)ation parylation) unit (marylation), added different enzyme parp family (also known artd family). parylation relatively well-studied, particularly dna damage response. resulted development parp inhibitor olaparib, increasingly employed cancer chemotherapeutic approaches. despite fact majority parp enzyme catalyse marylation, marylation well understood parylation. marylation dynamic process: enzyme reversing intracellular marylation acidic amino acid (macrod1, macrod2, targ1) discovered 2013. since then, however, little information published physiological function. macrod1, macrod2, targ1 â\\x80\\x98macrodomainâ\\x80\\x99 harbouring catalytic site, domain identified. despite lack information regarding cellular roles, number study linking cancer. however, publication oppose other, rely poorly-characterised antibodies, aberrant localisation overexpressed rather native protein. review, critically ass available literature role hydrolases cancer find that, currently, limited evidence role macrod1, macrod2, targ1 tumorigenesis.',\n",
       " 'hepatitis c (hcv) major cause chronic hepatitis liver worldwide. tissue specie tropism largely defined entry process required subsequent productive establishment chronic infection. review provides overview host factor involved hcv entry hepatocytes, summarizes understanding molecular mechanism governing process highlight therapeutic potential host-targeting entry inhibitors.',\n",
       " 'background: fluid resuscitation become cornerstone early septic shock management, optimal fluid rate still well studied. goal investigation examine relationship fluid resuscitation rate septic shock resolution. method: retrospectively studied adult (â\\x89¥ 18 years) septic shock, defined based sepsis iii definition, january 1, 2006, may 31, 2018, medical intensive care unit (micu) mayo clinic rochester. fluid resuscitation time defined time required infuse initial fluid bolus 30 ml/kg, based recommendation 2016 surviving sepsis campaign. cohort divided four group based average fluid rate (group 1 â\\x89¥ 0.5, group 2 0.25â\\x80\\x930.49, group 3 0.17â\\x80\\x930.24, group 4 < 0.17 ml/kg/min). primary outcome time shock reversal. multivariable regression analysis conducted account potential confounders. result: total 1052 met eligibility criterion included analysis. time-to-shock reversal significantly different among group (p < .001). group 1 received fluid resuscitation faster rate shorter time shock reversal (hr = 0.78; 95% ci 0.66â\\x80\\x930.91; p = .01) compared group 4 median (iqr) time-to-shock reversal 1.7 (1.5, 2.0) vs. 2.8 (2.6, 3.3) days, respectively. 0.25 ml/kg/min cutoff, higher fluid infusion rate associated shorter time shock reversal (hr = 1.22; 95% ci 1.06â\\x80\\x931.41; p = .004) decreased odds 28-day mortality (hr = 0.71; 95% ci 0.60â\\x80\\x930.85; p < .001). conclusion: septic shock patients, initial fluid resuscitation rate 0.25â\\x80\\x930.50 ml/kg/min (i.e., completion initial 30 ml/kg fluid resuscitation within first 2 h), may associated early shock reversal lower 28-day mortality compared slower rate infusion.',\n",
       " 'dynamic interaction cancer cell microenvironment consisting stromal cell (cellular part) extracellular matrix (ecm) component (non-cellular) essential stimulate heterogeneity cancer cell, clonal evolution increase multidrug resistance ending cancer cell progression metastasis. reciprocal cell-cell/ecm interaction tumor cell hijacking non-malignant cell force stromal cell lose function acquire phenotype promote development invasion tumor cells. understanding underlying cellular molecular mechanism governing interaction used novel strategy indirectly disrupt cancer cell interplay contribute development efficient safe therapeutic strategy fight cancer. furthermore, tumor-derived circulating material used cancer diagnostic tool precisely predict monitor outcome therapy. review evaluates potential various advanced cancer models, focus 3d system well lab-on-chip devices.',\n",
       " '',\n",
       " 'influenza increase methylation lysine 79 histone 3 catalyzed dot1l enzyme. role dot1l infection highlighted increase influenza vesicular stomatitis replication dot1l-inhibited cell mediated decreased antiviral response. interferon-beta (ifn-î²) reporter assay indicate dot1l involved control retinoic acid-inducible gene-i protein (rig-i) signaling. accordingly, dot1l inhibition decrease ifn-î² promoter stimulation rig-i- mitochondria-associated sensor (rig-i-mavs) association upon infection. replication influenza lacking ns1 (delns1), incapable counteracting antiviral response, affected dot1l inhibition. consequently, rig-i-mavs association nuclear factorâ\\x80\\x93îºb (nf-îºb) nuclear translocation, affected dot1l inhibition delns1 infected cells. restoration ns1 expression trans reinstated dot1l regulator rig-i-dependent signaling delns1 infections. interferon-inducible e3 ligase tripartite motif-containing protein 25 (trim25) expression increase influenza infected cells, dot1l inhibition reduces trim25 expression trim25 protein levels. trim25 overexpression revers defective innate response mediated dot1l inhibition elicited upon overexpression rig-i signaling intermediates. thus, trim25 control point rig-i recognition pathway controlled dot1l may general role rna virus recognized rig-i sensor.',\n",
       " 'community-acquired pneumonia (cap) leading cause death among infectious disease important problem, considerable implication healthcare system worldwide. despite important advance prevention vaccines, rapid diagnostic test antibiotics, cap management still significant drawbacks. mortality remains high severely ill presenting respiratory failure shock high elderly. even cap episode, higher risk death remains long period, risk mainly driven inflammation patient-related co-morbidities. cap microbiology altered molecular diagnostic test turned virus identified pathogens, notwithstanding uncertainty specific role cap pathogenesis. pneumococcal vaccine impacted cap etiology thus changed streptococcus pneumoniae circulating serotypes. pathogen specific region kept mind treating cap. antibiotic cap tested severely ill focused multidrug-resistant pathogen unrelated cap, limiting general use indication intensive care unit (icu) patients. similarly, cap management could personalized use adjunctive therapy showed outcome improvement particular groups. although pneumococcal vaccination convincingly reduce invasive pneumococcal disease, le significant effect pneumococcal cap, remains best therapeutic intervention prevent bacterial cap. research cap needed reduce population impact improve individual outcomes.',\n",
       " 'introduction: liver transplantation recognised option propionic acidemia (pa) methylmalonic acidemia (mma) without renal impairment. mma moderate-to-severe renal impairment, combined liverâ\\x80\\x93kidney transplantation indicated. however, clinical experience transplantation option pa mma remains limited fragmented. undertook overview post-transplantation outcome pa mma current available evidence. methods: literature search identified publication use transplantation pa mma. publication considered presented adequate demographic outcome pa mma. publication report specific outcome provided insufficient excluded. results: seventy publication identified 38 full papers. total 373 underwent liver/kidney/combined liverâ\\x80\\x93kidney transplantation pa mma. typical reason transplantation recurrent metabolic decompensation. total 27 post-transplant death reported pa [14.0% (27/194)]. mma, 18 post-transplant death reported [11% (18/167)]. total 62 complication reported 115 pa (54%) cardiomyopathy (n = 12), hepatic arterial thrombosis (hat; n = 14) infection (n = 12) commonly reported. total 52 complication reported 106 mma (49%) infection (n = 14) renal failure/impairment (n = 10) commonly reported. conclusions: liver transplantation combined liverâ\\x80\\x93kidney transplantation appears benefit pa mma, respectively, approach provide complete correction metabolic defect remain risk disease-related transplantation-related complications, death. thus, avenue exhausted consideration organ transplantation benefit approach must weighed risk perioperative complication individual basis.',\n",
       " '',\n",
       " '',\n",
       " 'dengue (denv) transmitted infectious mosquito blood-feeding via saliva containing biologically-active proteins. here, examined effect varying denv modality rhesus macaque order improve denv nonhuman primate (nhp) challenge model. nhps exposed denv-1 via subcutaneous intradermal inoculation only, intradermal inoculation salivary gland extract, infectious mosquito feeding. infectious mosquito feeding group exhibited delayed onset viremia, greater loads, altered clinical immune response compared groups. 15 months, nhps subcutaneous infectious mosquito feeding group re-exposed either denv-1 denv-2. replication neutralizing antibody following homologous challenge suggestive sterilizing immunity, whereas heterologous challenge resulted productive, yet reduced, denv-2 replication boosted neutralizing antibody. result transmission-relevant exposure modality resulted replication closer observed humans.',\n",
       " '',\n",
       " '',\n",
       " 'acquisition resistance mutation hiv-1 isolates cause failure among infected receiving antiretroviral therapy (art). determined pattern drug-resistance mutation (drms) among hiv-1 isolates receiving first-line art south-eastern nigeria. blood sample collected hiv-1 infected accessing antiretroviral center general hospital awo-omamma, imo state, state hospital asaba, delta state st josephâ\\x80\\x99s catholic hospital adazi, anambra state used hiv-1 dna sequencing phylogenetic analysis. drms scored combination stanford algorithm 2015 international antiviral society-usa list drug susceptibility predicted stanford algorithm. twenty eight hiv-1 isolates sequenced identified subtypes g (35.7%), crf02_ag (57.1%) unclassifiable, u(g) (7.1%). major pi resistance-associated mutation identified two site m46l (16.7% subtype g/u(g)) v82l (6.3% crf02_ag). minor pi resistance-associated mutation identified among subtype g/u(g) l10v/i (8.3%) k20i (100%) l10v/i (50%), k20i (100%), l33f (6.3%) n88d (6.3%) identified among crf02_ag. polymorphism found include; i13v/a, e35q, m36i/l, n37d/s/e/h, r57k/g, l63t/p/s/q, c67e/s, h69k/r, k70r, v82i l89m range 28.6% 100% among different subtypes. interpretation based stanford algorithm showed darunavir/ritonavir regimen whose potency compromised circulating mutations. identification major minor pi resistance mutation underscore need drug resistance testing prior initiation second line antiretroviral therapy nigeria.',\n",
       " 'effort develop effective safe drug tuberculosis require preclinical evaluation animal models. alongside efficacy testing novel therapies, effect pulmonary pathology progression monitored histopathology image infected animals. compare severity across cohorts, pathologist historically assigned semi-quantitative histopathology score may subjective term training, experience, personal bias. manual histopathology therefore limitation regarding reproducibility study pathologists, potentially masking successful treatments. report describes pathologist-assistive software tool reduces user limitations, providing rapid, quantitative scoring system digital histopathology image analysis. software, called â\\x80\\x98lesion image recognition analysisâ\\x80\\x99 (lira), employ convolutional neural network classify seven different pathology features, three different lesion type pulmonary tissue c3heb/fej tuberculosis mouse model. lira developed improve efficiency histopathology analysis mouse tuberculosis models, approach broader application model tissues. full source code documentation available https://github.com/tb-imaging/lira.',\n",
       " 'vaccine-enhanced (ved) occurs vaccination followed virulent mycoplasma pneumoniae. date ved prevented development efficacious vaccine significant human respiratory pathogen. herein report vaccination balb/c mouse m. pneumoniae lipid-associated membrane protein (lamps) induces lung lesion consistent exacerbated following challenge, without reducing bacterial loads. removal lipid moiety lamp prior vaccination eliminates ved reduces bacterial load infection. collectively, indicate lipid moiety lipoprotein causative factor m. pneumoniae ved.',\n",
       " '',\n",
       " '',\n",
       " 'chapter review early recent seminal contribution discovery characterization heparanase non-anticoagulant heparin inhibiting peculiar enzymatic activity. indeed, heparanase display unique versatility degrading heparan sulfate chain several proteoglycans expressed mammalian cells. endo-î²-d-glucuronidase overexpressed cancer, inflammation, diabetes, atherosclerosis, nephropathy pathologies. starting known low- non-anticoagulant heparins, search heparanase inhibitor evolved focusing structure-activity relationship study taking advantage chemical-physical analytical method allowed characterization sequencing polysaccharide chains. method screen heparanase inhibitor evaluate mechanism action vivo activity experimental model prompted development. non-anticoagulant heparin derivative endowed anti-heparanase activity reported. lead clinical evaluation oncology field (e.g., acute myeloid leukemia, multiple myeloma, pancreatic carcinoma) pathological condition (e.g., sickle cell disease, malaria, labor arrest).',\n",
       " '',\n",
       " '2 week attending one never forget, worry next 2 week bring.',\n",
       " 'antibody neutralization cytomegalovirus (cmv) entry diverse cell type key consideration development vaccine immunotherapeutics. cmv entry fibroblast differs significantly entry epithelial endothelial cells: fibroblast entry mediated gb gh/gl/go, whereas epithelial endothelial cell entry require additional pentameric complex (pc) comprised gh/gl/ul128/ul130/ul131a. pc-specific antibody cmv-seropositive human serum affect fibroblast entry potently block entry epithelial endothelial cells, substantially higher neutralizing potency cmv-positive serum observed assayed epithelial cell target fibroblasts. certain serum exhibit similar discordance neutralizing potency measured epithelial vs. endothelial cell (gerna g. et al.j gen virol, 89:853â\\x80\\x93865, 2008) suggested additional mechanistic difference may exist epithelial endothelial cell entry. explore issue, neutralizing potency epithelial endothelial cell simultaneously determined eight cmv-positive human sera, cmv-hyperimmune globulin, panel monoclonal anti-peptide antibody targeting specific epitope gb, gh, gh/gl, pc. significant difference observed epithelial endothelial neutralizing potency epitope-specific antibodies, cmv-hyperimmune globulin, seven eight human sera. however, human serum exhibited six-fold higher potency neutralizing entry epithelial cell vs. endothelial cells. result suggest epitope exist important epithelial entry le critical, perhaps dispensable, endothelial cell entry. existence considered developing monoclonal antibody therapy subunit vaccine representing limited epitopes.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'isothermal amplification assays, loop-mediated isothermal amplification (lamp), great utility development rapid diagnostics infectious disease high sensitivity, pathogen-specificity potential implementation point care. however, elimination non-specific amplification remains key challenge optimization lamp assays. here, chlamydia dna clinically relevant target high-throughput sequencing analytical tool, investigate potential mechanism non-specific amplification. develop real-time digital lamp (dlamp) high-resolution melting temperature (hrm) analysis use single-molecule approach analyze approximately 1.2 million amplification events. single-molecule hrm provides insight specific non-specific amplification lamp difficult deduce bulk measurements. use real-time dlamp hrm evaluate difference polymerase enzymes, impact assay parameter (e.g. time, rate florescence intensity), effect background human dna. differentiating true false positives, hrm enables determination optimal assay analysis parameter lead lowest limit detection (lod) digital isothermal amplification assay.',\n",
       " 'electrophilic (het)arenes undergo reaction nucleophiles yielding ï\\x80- meisenheimer (ï\\x83-) complex product s(n)ar addition/elimination reactions. building block rarely employed design enzyme inhibitors. herein, demonstrate combination peptidic recognition sequence electrophilic (het)arenes generate highly active inhibitor disease-relevant proteases. elucidate unexpected mode action trypanosomal protease rhodesain nmr spectroscopy mass spectrometry, enzyme kinetics various type simulations. hydrolysis ester function recognition sequence weakly active prodrug inhibitor, liberated carboxylic acid represents highly potent inhibitor rhodesain (k(i) = 4.0 nm). simulation indicate that, cleavage ester, carboxylic acid leaf active site re-binds enzyme orientation allows formation stable ï\\x80-complex catalytic dyad (cys-25/his-162) rhodesain electrophilic aromatic moiety. reversible inhibition mode result s(n)ar reaction, found alkaline solvent containing low molecular weight thiol, hindered within enzyme due presence positively charged imidazolium ring his-162. comparison measured calculated nmr shift support interpretation.',\n",
       " 'newcastle (ndv) replication depends translation machinery host cell; therefore, eukaryotic translation initiation factor 2 (eif2) gene family likely candidate control replication. hypothesized differential expression host gene related translation innate immune response could contribute differential resistance ndv inbred fayoumi leghorn lines. expression twenty-one gene related interferon signaling pathway eif2 family evaluated two- six-days post (dpi) spleen lines, either challenged ndv nonchallenged. higher expression oasl ndv challenged versus nonchallenged spleen observed leghorn 2 dpi. lower expression eif2b5 found ndv challenged nonchallenged fayoumis leghorn 2 dpi. 2 dpi, ndv challenged fayoumis lower expression eif2b5 eif2s3 ndv challenged leghorns. 6 dpi, ndv challenged fayoumis lower expression eif2s3 eif2b4 ndv challenged leghorns. genetic line difference expression eif2-related gene may contribute differential resistance ndv understanding interaction protein synthesis shut-off control chickens.',\n",
       " 'genomics-based neoantigen discovery enhanced proteomic evidence, remains lack consensus performance different quality control method variant peptide identification proteogenomics. propose use difference accurately predicted observed retention time peptide metric evaluate different quality control methods. end, develop autort, deep learning algorithm high accuracy retention time prediction. analysis three cancer set total 287 tumor sample different quality control strategy result substantially different number identified variant peptide putative neoantigens. systematic evaluation, proposed retention time metric, provides insight practical guidance selection quality control strategies. implement recommended strategy computational workflow named neoflow support proteogenomics-based neoantigen prioritization, enabling sensitive discovery putative neoantigens.',\n",
       " '',\n",
       " 'chronic low-grade inflammation adipose tissue play causal role obesity-induced insulin resistance associated pathophysiological consequences. study, investigated effect extract broussonetia papyrifera root bark (pre) bioactive component inflammation insulin sensitivity. pre inhibited tnf-î±-induced nf-îºb transcriptional activity nf-îºb luciferase assay pro-inflammatory genesâ\\x80\\x99 expression blocking phosphorylation iîºb nf-îºb 3t3-l1 adipocytes, mediated activating ampk. ten-week-high fat diet (hfd)-fed c57bl6 male mouse treated pre improved glucose intolerance decreased inflammation adipose tissue, indicated reduction nf-îºb phosphorylation pro-inflammatory genesâ\\x80\\x99 expression. furthermore, pre activated amp-activated protein kinase (ampk) reduced lipogenic genesâ\\x80\\x99 expression adipose tissue liver. finally, identified broussoflavonol b (bf) kazinol j (kj) bioactive constituent suppress pro-inflammatory response via activating ampk 3t3-l1 adipocytes. taken together, result indicate therapeutic potential pre, especially bf kj, metabolic disease obesity type 2 diabetes.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'background: cystic echinococcosis, caused cestode echinococcus granulosus, neglected tropical remarkable morbidity human problem worldwide economic importance livestock industry. understanding molecular basis parasite growth development essential diagnosis, management control. tetraspanin (tsp) family protein transmembrane protein role many physiological process eukaryotic organisms. tsps present tegumental surface platyhelminth play pivotal role host-parasite interaction. however, little known role tsps growth development platyhelminthes. understand role tsp1 growth development e. granulosus investigated effect egtsp1-specific long dsrna different vitro stage parasite. methods: different stage e. granulosus, protoscoleces strobilated worms, cultivated vitro di-phasic media. long dsrna two delivery methods, i.e. electroporation electro-soaking, egtsp1 silencing performed egtsp1-specific dsrna. tsp1 expression profile assessed well biological ultrastructural property parasites. results: three day dsrna treatment, egtsp1 expression significantly reduced stage e. granulosus compared irrelevant/unrelated dsrna untreated controls. silencing expression egtsp1 different stage e. granulosus resulted reduced viability body contractions, inhibition protoscoleces evagination distinctive tegumental changes. ultrastructural morphology strobilated worm treated egtsp1-specific dsrna indicative microtriches impairment vacuolated tegument compared control helminths. conclusions: result present suggest egtsp1 play important structural role tegument configuration e. granulosus. egtsp1 proved potential target development vaccine rnai-based drugs. [image: see text]',\n",
       " '',\n",
       " '',\n",
       " 'aim: population screening â\\x80\\x98healthyâ\\x80\\x99 individual widely adopted, important consider harm benefit receiving positive result harm benefit may differ age. subject & methods: participant preventive genomic screening screened 17 gene associated 11 conditions. interviewed 11 participant received positive results. results: interviewee expressed little concern positive result light older age, risk condition tested positive, pressing concerns. conclusion: researcher clinician recognize returning positive result may impact presume given diversity condition screened choose undergo screening.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'background: understanding genetic structure natural population provides insight demographic adaptive process affected populations. information, particularly integrated geospatial data, translational application variety fields, public health. estimated effective migration surface (eems) approach allows visualization spatial pattern genomic understand population structure migration. study, developed workflow optimize resolution spatial grid used generate eems migration map applied optimized workflow estimate migration plasmodium falciparum cambodia bordering region thailand vietnam. methods: optimal density eems grid determined based workflow created density clustering define genomic cluster spatial distance genomic clusters. topological skeleton used capture spatial distribution genomic cluster determine eems grid density; i.e., genomic spatial clustering used guide optimization eems grids. model accuracy migration estimate optimized workflow tested compared grid resolution selected without optimized workflow. test case, optimized workflow applied genomic generated p. falciparum sampled cambodia bordering regions, migration map compared estimate malaria endemicity, well geographic property area, mean validating observed migration patterns. results: optimized grid displayed high model accuracy reduced computing time compared grid density selected unguided manner. addition, eems migration map generated p. falciparum optimized grid corresponded estimate malaria endemicity geographic property region might expected impact malaria parasite migration, supporting validity observed migration patterns. conclusions: optimized grid reduce spatial uncertainty eems contour user-defined parameters, resolution spatial grid used model. workflow useful broad range eems user applied analysis involving organism interest geographic areas.',\n",
       " 'background: neutrophil extracellular trap (nets) fibrous structure released activated neutrophils. net formation reported associated acute respiratory distress syndrome (ards). however, report dealing serial change net formation tracheal aspirate ards patients. presentation: report three case ards. 1 69-year-old man necrotizing fasciitis buttocks, 2 49-year-old woman extensive burn (80% total body surface), 3 73-year-old woman severe bacterial pneumonia. found abundant expression citrullinated histone h3 (cit-h3) formation net onset ards cases. amount cit-h3 net decreased amelioration respiratory failure case 1 2. 2, amount cit-h3 net increased aggravation respiratory status. 3, abundant expression cit-h3 net persisted; recover ards eventually died. cit-h3 net found tracheal aspirate even direct injury lung case 1 2. conclusions: three cases, formation net observed tracheal aspirate ards either direct indirect insult lung. amount net formation changed dynamically clinical course patient.',\n",
       " 'development safe effective combination antiretroviral therapy human immunodeficiency (hiv) past several decade significantly reduced hiv-associated morbidity mortality. additionally, antiretroviral drug provided effective mean protection hiv transmission. despite advances, significant limitation exist; namely, inability eliminate hiv reservoirs, inability reverse lymphoid tissue damage, lack effective vaccine preventing hiv transmission. evaluation safety efficacy therapeutic vaccine eliminating hiv reservoir preventing hiv transmission requires robust vivo models. since hiv human-specific pathogen, target hematopoietic lineage cell lymphoid tissues, vivo animal model hiv-host interaction require incorporation human hematopoietic lineage cell lymphoid tissues. review, discus construction mouse model human lymphoid tissue and/or hematopoietic lineage cells, termed, human immune system (his)-humanized mice. his-humanized mouse model support development functional human innate adaptive immune cells, along primary (thymus) secondary (spleen) lymphoid tissues. discus application his-humanized mouse model evaluating safety efficacy therapeutic hiv reservoir associated immunopathology, delineate human immune response elicited candidate hiv vaccines. addition focusing his-humanized mouse model already furthered understanding hiv contributed hiv therapeutic development, discus emerging his-humanized rat model could address limitation his-mouse models.',\n",
       " 'modified mrna (modrna) gene-delivery platform transiently introducing single gene several gene interest different cell type tissues. modrna considered safe vector gene transfer, negligibly activates innate immune system compromise genome integrity. use modrna basic translational science rising, due clinical potential modrna. currently modrna induce cardiac regeneration post-ischemic injury. major obstacle modrna cardiac ischemic include need direct single administration modrna heart inefficient translation modrna due short half-life. modulation 5â\\x80² untranslated region (5â\\x80² utr) enhance translation efficiency ischemic cardiac great value, reduce amount modrna needed per delivery achieve higher longer protein production post-single delivery. here, identified 5â\\x80² utr, fatty acid metabolism gene carboxylesterase 1d (ces1d), enhanced translation firefly luciferase (luc) modrna 2-fold heart post-myocardial infarction (mi). moreover, identified, ces1d, specific rna element (element d) responsible improvement modrna translation lead 2.5-fold translation increment luc modrna carrying artificial 5â\\x80² utr, post-mi. importantly, able 5â\\x80² utr ces1d enhances modrna translation liver, kidney, post-ischemic injury, indicating ces1d 5â\\x80² utr element may play wider role translation protein ischemic condition.',\n",
       " 'paramyxovirus pneumoviruses infect cell fusion (f) protein-mediated merger envelope target membranes. member family include range major human animal pathogens, respiratory syncytial (rsv), measles (mev), human parainfluenza virus (hpivs), highly pathogenic nipah (niv). high-resolution f protein structure metastable pre- postfusion conformation solved several member family number f-targeting entry inhibitor progressed advanced development clinical testing. however, small-molecule rsv entry inhibitor overall disappointed clinical trial resistance developed rapidly experimental setting patients, raising question whether available structural information may provide path counteract escape proactive inhibitor engineering. article summarize current mechanistic insight f-mediated membrane fusion examine contribution structural information development small-molecule f inhibitors. implication outlined future drug target selection rational drug engineering strategies.',\n",
       " 'flavivirus arthropod-borne viruses, transmitted either tick mosquitoes, cause morbidity mortality worldwide. endemic many country emerged regions, zika (zikv) south-and central america, west nile (wnv) north america, yellow fever (yfv) brazil many african countries, highlighting need preparedness. currently, antiviral drug available treat flavivirus infections. discovered broad-spectrum antiviral compound, benzavir-2, potent antiviral activity dna- rna-viruses. purpose investigate inhibitory activity benzavir-2 flaviviruses. used zikv zsgreen-expressing vector, two lineage wild-type zikv, medically important flaviviruses. benzavir-2 inhibited zikv derived reporter gene expression ec(50) value 0.8 â± 0.1 âµm. furthermore, zikv plaque formation, progeny production, rna expression strongly inhibited. addition, 2.5 âµm benzavir-2 reduced vitro three five order magnitude five flaviviruses: wnv, yfv, tick-borne encephalitis virus, japanese encephalitis virus, dengue virus. conclusion, benzavir-2 potent inhibitor flavivirus infection, supported broad-spectrum antiviral activity benzavir-2.',\n",
       " 'interferon-inducible transmembrane protein (ifitm1/2/3) reported suppress entry wide range viruses. however, antiviral functional residue specific mechanism still unclear. here, firstly resolved topology ifitm1 plasma membrane n-terminus point cytoplasm c-terminus resides extracellularly. further, krrk basic residue ifitm1 locating 62â\\x80\\x9367 conserved intracellular loop (cil) found play key role restriction zika (zikv) dengue (denv). similarly, krrk basic residue ifitm2/3 contributed suppressing zikv replication. finally, ifitm1 revealed capable restricting release zikv particle endosome cytosol impede entry zikv host cells, tightly related inhibition ifitm1 acidification organelles. overall, provided topology, antiviral functional residue mechanism interferon-inducible transmembrane proteins.',\n",
       " 'background: berberine (bbr) isoquinoline alkaloid exhibit variety biological therapeutic properties, reported block replication influenza virus. however, contradictory result presented, mechanistic explanation lacking. methods: panel cell line (madinâ\\x80\\x93darby canine kidney (mdck), adenocarcinoma human alveolar basal epithelial cell (a549), lung epithelial type (let1)) primary human airway epithelial cell (hae) susceptible influenza infected seasonal influenza presence absence bbr. cytotoxicity towards cell line measured xtt assay. yield analyzed rt-qpcr. molecular mechanism bbr, confocal microscopy western blot analysis cellular fraction applied. result conclusions: result cell-type-dependent anti-influenza property bbr vitro suggests compound act cell virus. importantly, bbr hamper influenza replication primary human airway epithelium 3d culture mimic natural replication site virus. study influenza upregulates mitogen-activated protein kinase/extracellular signal-related kinase (mapk/erk) pathway hijack pathway nucleolar export ribonucleoprotein. result suggest bbr interferes process hamper influenza replication.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'ex vivo cell/tissue-based model essential step workflow pathophysiology studies, assay development, modeling, drug discovery, development personalized therapeutic strategies. purposes, scientific pharmaceutical research adopted ex vivo stem cell model better predictive power. matter fact, advancing isolation vitro expansion protocol culturing autologous human stem cells, standardization method generating patient-derived induced pluripotent stem cell made feasible generate investigate human cellular model even greater speed efficiency. furthermore, potential stem cell generating complex systems, scaffold-cell models, organoids, organ-on-a-chip, allowed overcome limitation two-dimensional culture system well better mimic tissue structure functions. finally, advent genome-editing/gene therapy technology great impact generation proficient stem cell-disease model establishing effective therapeutic treatment. review, discus important breakthrough stem cell-based model highlighting current directions, advantages, limitation point need combine experimental biology computational tool able describe complex biological system deliver result prediction context personalized medicine.',\n",
       " 'congenital heart disease-associated pulmonary arterial hypertension (chd-pah) major complication chd. timely closure left-to-right shunt generally normalization pulmonary hemodynamics, severe prognosis early childhood. hypothesized wide-ranging pathological mechanism pah could elucidate clinical state severe chd-pah. electronic medical records, retrospectively analyzed six infant severe chd-pah treatment-resistant ph. born congenital malformation syndrome. starting pulmonary vasodilator, five six developed complication pulmonary edema interstitial lung (ild), four alveolar hemorrhage. steroid therapy, clinical condition improved four patients, two died. autopsy finding deceased indicated presence recurrent alveolar hemorrhage, pulmonary venous hypertension, ild, pah. based clinical course chd-pah literature, chd-pah occur pulmonary vascular obstructive (pvod)/pulmonary capillary hemangiomatosis (pch), ild, and/or alveolar hemorrhage. severity chd-pah may depend genetic disorder, respiratory infection, upper airway stenosis. additionally, pulmonary vasodilator may involved development pvod/pch ild. chd-pah unexpected deterioration, clinician consider complication associated pvod/pch and/or pulmonary disease. addition, choice upfront combination therapy pediatric chd-pah selected carefully.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'well known, multimedia widely used voip mobile communications. research establish covert communication channel popular public application flourishing recent years. paper try present novel effective construct covert channel common compressed speech stream embedding sense information it. method, analysing characteristic feature excitation pulse position itu-t g.723.1 g.729a speech codec, design novel effective covert communication channel finely modulating code excitation pulse position two codecs line secret information hidden. improve embedding capacity proposed method, use odd/even characteristic pulse code position conduct information hiding. test verify proposed approach, experiment conducted several different scenarios. experimental result method algorithm perform higher degree secrecy sound information embedding efficacy compared exiting similar methods.',\n",
       " '',\n",
       " '',\n",
       " 'paper, consider problem accelerating numerical simulation time dependent problem time domain decomposition. available algorithm enabling decomposition present severe efficiency limitation obstacle solution scale high dimensional problems. main contribution improvement parallel efficiency parareal time method. parareal based combining prediction made numerically inexpensive solver (with coarse physic and/or coarse resolution) correction coming expensive solver (with high-fidelity physic high resolution). convergence, algorithm provides solution fine solverâ\\x80\\x99s high-fidelity physic high resolution. classical version, fine solver fixed high accuracy major obstacle achieve competitive parallel efficiency. paper, develop adaptive variant overcomes obstacle dynamically increasing accuracy fine solver across parareal iterations. theoretically parallel efficiency becomes competitive ideal cost coarse solver small, thus proving remaining factor impeding full scalability become cost coarse solver communication time. developed theory merit setting general framework understand success several extension parareal based iteratively improving quality fine solver re-using information previous parareal steps. illustrate actual performance stiff odes, challenging family problem since mechanism adaptivity time efficiency affected cost coarse solver.',\n",
       " 'background: first month crucial period child survival. neonatal mortality continues remain high little improvement year sub-saharan africa, ethiopia. region show least progress reducing neonatal mortality continues significant public issue. setting, cause predictor neonatal death neonatal intensive care unit well documented. hence, aimed determine cause predictor neonatal mortality among infant admitted neonatal intensive care unit eastern ethiopia. methods: facility-based prospective follow-up conducted among neonate admitted neonatal intensive care unit public hospital eastern ethiopia november 1 december 30, 2018. collected pre-tested structured questionnaire follow-up checklist. main outcome cause death set pediatrician medical residents. epidata 3.1 statistical package social science version 25 software used entry analysis, respectively. multivariable logistic regression used identify predictor facility-based neonatal mortality. results: proportion facility-based neonatal mortality 20% (95% ci:16.7â\\x80\\x9323.8%). cause death complication preterm birth (28.58%), birth asphyxia (22.45%), neonatal (18.36%), meconium aspiration syndrome (9.18%), respiratory distress syndrome (7.14%), congenital malformation (4.08%). low birth weight, preterm births, length stay neonatal intensive care unit, low 5 min apgar score, hyperthermia, initiation feeding predictor neonatal death among infant admitted neonatal intensive care unit public hospital eastern ethiopia. conclusions: proportion facility-based neonatal death unacceptably high. main cause death preventable treatable. hence, improving timing quality antenatal care essential early detection, anticipating high-risk newborns, timely interventions. furthermore, early initiation feeding better referral linkage tertiary facility could lead reduction neonatal death setting.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'methamphetamine use emerged risk factor intracerebral hemorrhage (ich). aim investigate clinical characteristic outcome methamphetamine-associated ich (meth-ich) versus non-meth-ich. ich january 2011 december 2017 studied. meth-ich non-meth-ich defined history abuse urine drug screen (uds). clinical feature 2 group explored. among 677 consecutive patients, 61 (9.0%) identified meth-ich 350 non-meth ich. meth-ich common hispanic (14.6%) white (10.1%) compared asian (1.2%). meth-ich often younger (51.2 vs. 62.2 years, p < 0.001), male (77.0% vs. 61.4.0%, p < 0.05), smoker (44.3% vs. 13.4%, p < 0.001). non-meth-ich likely history hypertension (72.61% v. 59%, p < 0.05) antithrombotic use (10.9% vs. 1.6%, p < 0.05). significant difference clinical severity, hospital length stay (los), rate functional independence (29.5% vs. 25.7%, p = 0.534), mortality (18.0% vs. 24.6%, p = 0.267) 2 groups. methamphetamine use independent predictor poor outcome. despite difference demographics, meth-ich similar non-meth ich hospital course outcome.',\n",
       " 'dengue (denv) infection may cause life-threatening dengue hemorrhagic fever (dhf). suppressed protective immunity patients. although several hypothesis formulated, mechanism denv-induced immunosuppression remains unclear. previously, found cross-reactive antibody tumor necrosis factor-related apoptosis-inducing ligand (trail) receptor 1 (death receptor 4 [dr4]) elicited dhf patients, anti-dr4 autoantibody fraction elicited nonstructural protein 1 (ns1) immunization experimental mice. study, found anti-dr4 antibody could suppress b lymphocyte function vitro vivo. anti-dr4 immunoglobulin (ig) induced caspase-dependent cell death immortalized b lymphocyte raji cell vitro. anti-dr4 ig elicited ns1 dr4 immunization markedly suppressed mouse spleen transitional t2 b (igm(+)igd(+)), bone marrow pre-pro-b (b220(+)cd43(+)), pre-b (b220(+)cd43(â\\x88\\x92)), mature b cell (b220(+)igd(+)) subset mice. furthermore, functional analysis revealed pre-elicitation anti-ns1 anti-dr4 ig titer suppressed subsequently neutralizing antibody production immunization denv envelop protein. suggest elicitation anti-dr4 titer denv ns1 immunization play suppressive role humoral immunity mice.',\n",
       " 'dengue (denv) co-circulation brazil represents challenge vaccine development. despite public impact, occurrence coinfections virus common event. increased cell activation altered inflammatory response found denv coinfection human immunodeficiency (hiv) impacting hiv-pathogenesis. even antiretroviral therapy (art), hiv- treated chronic immune activation lymphocyte apoptosis. however, apoptotic mechanism investigated coinfection denv. attention attracted apoptotic cell marker expression pbmcs denv denv/hiv coinfected patients. found cd4/cd8 ratio inversion coinfected patients. cd4 cd8 t-cell subset denv denv/hiv group expressed low level anti-apoptotic protein bcl-2. furthermore, cd8 cd95 double positive cell frequency expressing low level bcl-2 significantly higher patients. additionally, density bcl-2 classical monocyte (cd14(++)cd16(â\\x88\\x92)) significantly lower denv infection. upregulation pro-apoptotic protein anti-apoptotic protein found denv denv/hiv, catalase, antioxidant protein, upregulated mainly denv/hiv coinfection. finding provide evidence apoptosis triggering denv/hiv coinfection, may contribute knowledge immunological response denv acute hiv-patients treated art.',\n",
       " '',\n",
       " 'acute diarrhea wide-spread disease. prescription enterosorbents appropriate primary measure acute diarrhea effective prevention fluid electrolyte loss, well symptom relief attack disease. aim - antidiarrheal efficacy safety high-dispersion silicon dioxide enterosorbent tablet dosage form acute diarrhea. randomized, double-blind, placebo-controlled, 4-center study. acute diarrhea defined three episode watery stool per either 48 hour le entry normal stool recently. postulated symptom sign acute diarrhea caused direct gastrointestinal tract associated moderate-to-severe systemic states. 144 established acute diarrhea randomized group (enterosorbent â\\x80\\x9ccarbowhiteâ\\x80\\x9d, n = 120) placebo group. date collection severity diarrhea, systemic symptom performed baseline daily 7 days. stool examination serological assay performed baseline. primary end point declared time complete recovery acute diarrhea. found use siliceous enterosorbent (â\\x80\\x9ccarbowhiteâ\\x80\\x9d) allowed reduce (p < 0.001) period averagely 0.9 day (95% confidence interval 0.5â\\x80\\x931.2 days) comparison placebo. safety monitoring revealed group negative stool culture, initiation antibiotic run frequently placebo group (8.3%) compared investigational product group (4.1%, p = 0.044). siliceous enterosorbent â\\x80\\x9ccarbowhiteâ\\x80\\x9d well tolerated reduced recovery time acute episode diarrhea clinically significant form.',\n",
       " 'skeletal muscle major organ glucose disposal thermogenesis. hepatic fructose-1,6-bisphosphatase well known key enzyme gluconeogenesis, role muscle fructose-1,6-bisphosphatase 2 (fbp2) glucose disposal thermogenesis unknown. here, fbp2 knockout (ko) mice, assessed physiological role fbp2 energy glucose metabolism thermogenesis. vivo assessment energy metabolism, glucose metabolism, thermogenesis performed indirect calorimetry, hyperinsulinemic-euglycemic clamp, cold challenge studies, respectively. feeding fasting conditions, fbp2 ko mouse showed similar phenotype regarding energy glucose metabolism compared wild-type (wt) mice. however, fbp2 ko mouse severely intolerant cold challenge fasting conditions. mechanistically, cold-induced intramuscular conversion lactate glycogen (glyconeogenesis) completely abolished ko muscle, lead lack glycogen source thermogenesis fbp2 ko mice. cold-intolerant phenotype ko mouse disappeared feeding, ko mouse equally cold tolerant wt mouse survived cold challenge three weeks. taken together, demonstrate fbp2 essential muscle thermogenesis replenishing intramuscular glycogen pool glyconeogenesis exogenous glucose source limited. imply physiological importance fbp2 thermal homeostasis suggest potential novel therapy targeted increase glycogen replenishment upon cold stress.',\n",
       " 'outcome cardiac surgery influenced systemic inflammation. high mobility group box 1 (hmgb1), pivotal inflammatory mediator, play potential role prognostic biomarker cardiovascular disease. aim prospective, observational investigate relationship serum hmgb1 concentration composite morbidity endpoint cardiac surgery. arterial blood sample hmgb1 measurement collected 250 anaesthetic induction (baseline) 1 h weaning cardiopulmonary bypass (post-cpb). incidence composite morbidity endpoint (death, myocardial infarction, stroke, renal failure prolonged ventilator care) compared relation tertile distribution serum hmgb1 concentrations. incidence composite morbidity endpoint significantly different respect tertile distribution post-cpb hmgb1 concentration (p = 0.005) only, baseline. multivariable analysis revealed post-cpb hmgb1 concentration (or, 1.072; p = 0.044), pre-operative creatinine duration cpb independent risk factor adverse outcome. accounting prominent role mediating sterile inflammation relation detrimental outcome, hmgb1 measured 1 h weaning cpb would serve useful biomarker accurate risk stratification cardiac surgical may guide tailored anti-inflammatory therapy.',\n",
       " '',\n",
       " '',\n",
       " 'background: porcine reproductive respiratory syndrome (prrs) virus major cause economic loss pig worldwide. high genetic diversity among prrsv strain problematic successful control vaccination. mosaic dna vaccinia (vacv) vaccine developed order improve protection heterologous prrsv strains. methods: piglet primed boosted gp5-mosaic dna vaccine recombinant gp5-mosaic vacv (rgp5-mosaic vacv), respectively. pig vaccinated rgp5-wt (vr2332) dna rgp5-wt vacv, empty vector dna empty vacv respectively, served controls. challenge given separate group vaccinated pig vr2332 mn184c. necropsy performed 14 day challenge. results: vaccination gp5-mosaic-based vaccine resulted cellular reactivity higher level neutralizing antibody vr2332 mn184c prrsv strains. contrast, vaccination animal gp5-wt vaccine induced response vr2332. furthermore, vaccination gp5-mosaic based vaccine resulted protection challenge two heterologous strains, demonstrated significantly lower load serum, tissues, porcine alveolar macrophage (pams), bronchoalveolar lavage (bal) fluids, le severe lung lesion challenge either mn184c vr2332, 85% identity. contrast, significant protection gp5-wt based vaccine achieved vr2332 strain. conclusions: gp5-mosaic vaccines, dna-prime/vacv boost regimen, conferred protection pig heterologous viruses.',\n",
       " 'intramuscular (im) immunization generally considered incapable generating protective mucosal immune response. swine industry, attempt develop safe protective vaccine controlling porcine epidemic diarrhea (ped) via im route administration unsuccessful. present study, porcine chemokine ligand protein ccl25, 27, 28 constructed stably expressed mammalian expression system. im co-administration inactivated pedv (ipedv) particle different cc chemokines freundâ\\x80\\x99s adjuvant resulted recruiting ccr9+ and/or ccr10+ inflammatory cell injection site, thereby inducing superior systemic pedv specific igg, fecal iga, neutralizing antibody pigs. moreover, pig immunized ipedv combination ccl25 ccl28 elicited substantial protection virulent pedv challenge. porcine cc chemokines could novel adjuvant developing im vaccine modulating mucosal immune response mucosal transmissible pathogen pigs.',\n",
       " 'vitro neutralizing antibody often correlated protection rift valley fever (rvfv) infection. reported single inoculation sucrose-purified modified vaccinia ankara (mva) encoding rvfv glycoprotein (rmvagngc) sufficient induce protective immune response mouse lethal rvfv challenge. protection related presence glycoprotein specific cd8+ cells, low-level detection vitro neutralizing antibodies. work extended observation aimed explore role humoral response mva vaccination contribution glycoprotein antigen protective efficacy. thus, tested efficacy immune response balb/c mouse recombinant mva virus expressing either glycoprotein gn (rmvagn) gc (rmvagc). absence serum neutralizing antibodies, strongly suggest protection vaccinated mouse upon rvfv challenge achieved activation cellular response mainly directed gc epitopes. involvement cellular immunity stressed fact protection mouse strain dependent. furthermore, suggest rmva based single dose vaccination elicits suboptimal humoral immune response gn antigen since mouse exacerbated upon challenge presence rmvagngc rmvagn immune serum. thus, gc-specific cellular immunity could important component protection challenge observed balb/c mice, contributing elimination infected cell reducing morbidity mortality counteracting deleterious effect subneutralizing antibody immune response.',\n",
       " 'wild migratory bird often implicated introduction, maintenance, global dissemination different pathogens, influenza virus (iav) antimicrobial-resistant (amr) bacteria. trapping migratory bird resting period northern coast egypt common ancient practice performed mainly selling live bird market (lbm). present study, sample collected 148 wild birds, representing 14 species, offered sale lbm. bird tested presence aiv enterobacteriaceae. ten sample collected northern shoveler bird (spatula clypeata) positive iav pcr sub-typing pan ha/na sequencing assay detected h5n8, h9n2, h6n2 virus four, four, birds, respectively. sequencing full haemagglutinin (ha) gene revealed high similarity currently circulating iav egypt. birds, e. coli recovered 37.2% salmonella 20.2%, 66â\\x80\\x9396% 23â\\x80\\x9343% isolates resistant least seven selected critically important antimicrobial (cia), respectively. presence enzootic iav wide prevalence amr enterobacteriaceae wild bird highlight potential role lbm spread different pathogen wild birds. continued surveillance aiv antimicrobial-resistant enterobacteriaceae wild birdsâ\\x80\\x99 habitat urgently needed.',\n",
       " 'human antibody repertoire generated recombination different gene segment well process somatic mutation. together mechanism tremendous diversity antibody able combat various pathogen virus bacteria, malignant cells. review, summarize opportunity challenge associated analysis b cell receptor repertoire antigen-specific b cell response. discus recent advance increased understanding antibody response repertoire analysis exploited inform vaccine strategies, particularly hiv-1.',\n",
       " 'live-attenuated vaccine (lav) represent important medical innovation human history. past three centuries, lav saved hundred million lives, continue many decade come. interestingly, successful lavs, smallpox vaccine, measles vaccine, yellow fever vaccine, isolated and/or developed purely empirical manner without understanding immunological mechanism trigger. today, mechanism governing potent lav immunogenicity long-term induced protective immunity continue elusive, therefore hamper rational design innovative vaccine strategies. serious roadblock understanding lav-induced immunity lack suitable cost-effective animal model accurately mimic human immune responses. last two decades, human-immune system mouse (his mice), i.e., mouse engrafted component human immune system, instrumental investigating life-cycle immune response multiple human-tropic pathogens. however, use lav research remained limited. here, discus strong potential lav tool enhance understanding human immunity review past, current future contribution mouse endeavor.',\n",
       " 'need malaria vaccine indisputable. single vaccine plasmodium pre-erythrocytic stage targeting major sporozoite antigen circumsporozoite protein (csp) partial success. additionally, cd8+ cell targeting liver-stage (ls) antigen induced live attenuated sporozoite vaccine associated protection human challenge experiments. evaluate protection mediated l antigens, focused exported pre-erythrocytic protein (exported protein 1 (exp1), profilin (pfn), exported protein 2 (exp2), inhibitor cysteine protease (icp), transmembrane protein 21 (tmp21), upregulated infective sporozoites-3 (uis3)) expressed plasmodium specie designed optimized, synthetic dna (syndna) immunogens. syndna antigen cocktail tested without molecular adjuvant plasmid il-33. immunized animal developed robust cell response induction antigen-specific liver-localized cd8+ cells, enhanced co-delivery plasmid il-33. total, 100% mouse adjuvanted group 71%â\\x80\\x9388% non-adjuvanted group protected blood-stage following plasmodium yoelii sporozoite challenge. support potential syndna l antigen vaccine component malaria parasite infection.',\n",
       " 'basic mechanism flavivirus entry fusion understood, little known postfusion event precede rna replication, nucleocapsid disassembly. describe sensitive, conditionally replication-defective yellow fever (yfv) entry reporter, yfvî\\x94sk/nluc, quantitively monitor translation incoming, particle-delivered genomes. validated yfvî\\x94sk/nluc gene expression neutralized yfv-specific antiserum requires known flavivirus entry pathway cellular factors, clathrin- dynamin-mediated endocytosis, endosomal acidification, yfv e glycoprotein-mediated fusion, cellular ly6e rplp1 expression. initial round yfv translation require cellular ubiquitylation, consistent recent finding dengue capsid protein must ubiquitylated order nucleocapsid uncoating occur. importantly, translation incoming yfv genome required valosin-containing protein (vcp)/p97, cellular atpase unfolds extract ubiquitylated client protein complexes. rna transfection washout experiment showed vcp/p97 function postfusion, pretranslation step yfv entry. finally, vcp/p97 activity required flavivirus mammalian cell yfv mosquito cells. together, support critical role vcp/p97 disassembly incoming flavivirus nucleocapsids postfusion step entry.',\n",
       " 'multiple pharmacological intervention tested last decade failed reduce ards mortality. short note recount past indicating (i) neutrophil home along il-8 gradient, (ii) ards, massive neutrophil accumulation degranulation along bronchoalveolar space contributes damage hypoxia, (iii) increase il-8 chemotaxic signal drawing neutrophil ards lung, (iv) old dermatology glioblastoma research showed old drug hansenâ\\x80\\x99s disease, dapsone, inhibits neutrophilsâ\\x80\\x99 chemotaxis il-8. therefore dapsone might lower neutrophilsâ\\x80\\x99 contribution ards lung pathology. dapsone create methemoglobinemia although rarely problematic would particularly undesirable ards. common antacid drug cimetidine lower risk dapsone related methemoglobinemia given concomitantly.',\n",
       " 'background: visceral leishmaniasis ethiopia re-emerging threat public health, increased geographical distribution number cases. fatal without early diagnosis treatment; thus, availability affordable diagnostic tool crucial. however, due delay caused import regulations, procurement late delivery imported test kits, accessibility remains problem control program. therefore, aimed produce evaluate performance in-house liquid (aq) direct agglutination test (dat) antigen. result: aq-dat produced armauer hansen research institute, leishmania donovani strain (mhom/et/67/l82). serum 272 participants; 110 microscopically confirmed case vl, 76 apparently healthy 86 infectious vl tested aq-dat, standard kits: freeze-dried dat (fd-dat) rk39. taking microscopy gold standard; sensitivity specificity aq-dat 97.3 98.8%, respectively. high degree agreement (k > 0.8), significant (p < 0.05) correlation compared microscopy, fd-dat, rk39. conclusion: although standardization required, in-house aq-dat could improve diagnostic accessibility, minimize intermittent stock out strengthen national vl control program.',\n",
       " 'background: appropriate antimicrobial dosing challenging change pharmacokinetics (pk) parameter increase multidrug-resistant (mdr) organism critically ill patients. aimed evaluate effect empirical therapy high-dose versus standard-dose meropenem sepsis septic shock patients. methods: performed prospective randomized open-label compare change modified sequential organ failure assessment (msofa) score clinical outcome high-dose meropenem (2-g infusion 3 h every 8 h) versus standard-dose meropenem (1-g infusion 3 h every 8 h) sepsis septic shock patients. patientsâ\\x80\\x99 characteristics, clinical microbiological outcomes, 14 28-day mortality, vasopressor- ventilator-free days, intensive care unit (icu) hospital-free days, percent time antibiotic concentration minimum inhibitory concentration (%t>mic), safety assessed. results: seventy-eight enrolled. median delta msofa comparable two group (â\\x80\\x93 1 high-dose group vs. â\\x80\\x93 1 standard-dose group; p value = 0.75). difference two group regarding clinical microbiological cure, 14- 28-day mortality, vasopressor- ventilator-free days, icu- hospital-free days. admitted emergency department (ed) msofa score â\\x89¥ 7, high-dose group demonstrated significantly better microbiological cure compared standard-dose group (75% (9/12 patients) vs. 20% (2/10 patients); p value = 0.03). likewise, high-dose group presented higher microbiological cure rate admitted ed either apache ii score > 20 (83.3% (10/12) vs. 28.6% (2/7); p value = 0.045) mechanical ventilator (87.5% (7/8) vs. 23.1% (3/13); p value = 0.008) standard-dose group. adverse event comparable two groups. conclusions: empirical therapy high-dose meropenem presented comparable clinical outcome standard-dose meropenem sepsis septic shock patients. besides, subgroup analysis manifested superior microbiological cure rate sepsis septic shock admitted ed. trial registration: clinicaltrials.gov, nct03344627, registered november 17, 2017',\n",
       " 'background: study investigated spinal cord autoregulation near-infrared spectroscopy (nirs). here, assessed spinal cord autoregulation normal, hypovolemic, post-fluid resuscitation condition compared cerebral autoregulation. methods: ten pig (36.1 â± 1.1 kg) anesthetized 2.5% isoflurane, phenylephrine administration 0.5, 1, 2, 5 î¼g kg(â\\x88\\x921) min(â\\x88\\x921) stepwise fashion 10-min interval (baseline), followed similar administration sodium nitroprusside (snp). hypovolemia induced 600-ml bleed (25% estimated total blood volume). phenylephrine readministered (same protocol). hypovolemia reversed infusing 600 ml hydroxyethyl starch, readministering phenylephrine snp. relationship mean arterial pressure (map) cerebral, thoracic, lumbar spinal cord tissue oxygenation index (tois) evaluated. results: thoracic lumbar spinal cord tois approximately 15% 10% lower, respectively, cerebral toi similar maps. average relationship map toi showed autoregulatory pattern, negative correlation observed cerebral toi phenylephrine infusion. 600-ml bleed lowered relationship < 5% subsequent fluid resuscitation change relationship. individual oxygenation response blood pressure indicated spinal cord pressure-passive cerebrum. paradoxical response (an inverse relationship tissue oxygenation map) observed particularly cerebrum phenylephrine infusion rare spinal cord. conclusions: spinal cord autoregulation le robust cerebral autoregulation pressure-dependent. similar cerebral oxygenation, spinal cord oxygenation volume-tolerant sensitive hypotension.',\n",
       " 'background: emergence zika (zv) tropical subtropical area world created urgent need vaccine zv. however, approved vaccine prevent zv available. develop effective vaccine zv infection, lipidated form zv envelope protein domain iii posse intrinsic adjuvant property rationally designed. goal examine immunogenicity recombinant lipidated zv envelope protein domain iii (rlze3) evaluate potential vaccine candidate zv. methods: recombinant zv envelope protein domain iii (rze3) rlze3 prepared escherichia coli-based system. dendritic cell surface marker expression cytokine production upon stimulation analyzed evaluate function rlze3. neutralizing antibody capacity evaluated focus reduction neutralization test immunization. investigate protective immunity immunized mice, serum sample collected immunized mouse adoptively transferred ag129 mice, viremia level survival time examined zv challenge. results: rlze3 alone rze3 alone efficiently activated dendritic cell vitro taken dendritic cell vivo. immunization c57bl/6 mouse rlze3 alone (without exogenous adjuvant) could induce zv-specific neutralizing antibody responses. furthermore, serum sample obtained rlze3-immunized mouse provided protection indicated reduction viremia level prolongation survival time zv challenge. conclusion: result indicate rlze3 excellent vaccine candidate great potential evaluated preclinical studies.',\n",
       " 'background: since 2009 a/h1n1 pandemic, public england developed suite real-time statistical model utilising enhanced pandemic surveillance nowcast forecast future pandemic. ability track seasonal influenza predict heightened winter healthcare burden light high activity australia 2017 untested. methods: four transmission model used forecasting 2017/2018 seasonal influenza epidemic england: stratified primary care model daily, region-specific, count virological swab positivity influenza-like illness consultation general practice (gp); strain-specific (ss) model weekly, national gp ili virological data; intensive care model (icu) report icu influenza admissions; synthesis model included sources. first 12 week 2018, model applied latest provide estimate epidemic parameter short-term influenza forecasts. added value pre-season population susceptibility explored. results: combined result provided valuable nowcasts state epidemic. short-term prediction burden primary secondary service initially highly variable reaching consensus beyond observed peak activity week 3â\\x80\\x934 2018. estimate r(0) consistent time three four model week 12 2018, consistency estimation r(0) across spc s models, icu attack rate estimated icu synthesis model. estimation prediction varied according assumed level pre-season immunity. conclusions: exercise successfully applied range pandemic model seasonal influenza. forecasting early season remains challenging represents crucially important activity inform planning. improved knowledge pre-existing level immunity would valuable.',\n",
       " '',\n",
       " '1 march 2020, amendment german protection act introduced act protect measles strengthen vaccination prevention (measles protection act) entered force. reason change number individual measles significantly increased recent years. protect public health, measles protection act implemented regulation requiring person certain institution must either adequate protection measles immunity measles. article current legal situation regard care facility presented.',\n",
       " 'cpg dinucleotides suppressed genome many vertebrate rna viruses, hiv-1. cellular antiviral protein zap (zinc finger antiviral protein) bind cpgs inhibits hiv-1 replication cpgs introduced genome. however, known zap-mediated restriction mechanism driving cpg suppression. determine cpg dinucleotides affect hiv-1 replication, increased abundance multiple region genome analyzed effect rna expression, protein abundance, infectious-virus production. found antiviral effect cpgs correlated abundance. interestingly, cpgs inserted region genome sensitize zap antiviral activity efficiently insertion regions, sensitivity modulated interferon zap overexpression. furthermore, sensitivity endogenous zap correlated sensitivity zap cofactor khnyn. finally, cpgs context inhibit hiv-1 replication zap-independent mechanisms, activation cryptic splice site expense canonical splice site. overall, location sequence context cpg genome determines antiviral activity. importance rna genome suppressed nucleotide combination cytosine followed guanosine (cpg), indicating detrimental virus. antiviral protein zap bind rna containing cpgs prevents multiplying. however, remains number position cpgs genome affect restriction zap whether cpgs antiviral mechanisms. importantly, manipulating cpg content genome could help create vaccines. hiv-1 show marked cpg suppression, introducing cpgs genome, zap efficiently target specific region genome, number cpgs predict magnitude antiviral activity, cpgs inhibit hiv-1 gene expression zap-independent mechanism. overall, position cpgs hiv-1 genome determines magnitude mechanism inhibit virus.',\n",
       " '',\n",
       " 'dna vaccine expressing codon-optimized venezuelan equine encephalitis (veev) ebola (ebov) glycoprotein gene provide protective immunity mouse nonhuman primate delivered intramuscular (im) electroporation (ep). achieve equivalent protective efficacy absence ep, evaluated veev ebov dna vaccine constructed minimalized nanoplasmid expression vector smaller conventional plasmid used dna vaccination. vector may designed co-express type interferon inducing innate immune agonist gene adjuvant effect. nanoplasmid vaccinated mouse increased antibody response compared receiving conventional pwrg7077-based vaccine delivered im injection, response enhanced inclusion innate immune agonist genes. nanoplasmid veev dna vaccine significantly increased protection aerosol veev challenge compared pwrg7077 veev dna vaccine. although mouse receiving pwrg7077 nanoplasmid ebov dna vaccine dose tested survived ebov challenge, mouse receiving nanoplasmid ebov dna vaccine co-expresses innate immune agonist gene failed lose weight challenge. result suggest nanoplasmid vector improve immunogenicity protective efficacy alphavirus filovirus dna vaccines.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'previous study surveyed potential impact loss-of-function (lof) variant identified lof-tolerant protein-coding genes. however, tolerance human genome losing enhancer yet evaluated. present catalog lof-tolerant enhancer structural variant whole-genome sequences. conservative approach, estimate individual human genome posse least 28 lof-tolerant enhancer average. assessed property lof-tolerant enhancer unified regulatory network constructed integrating tissue-specific enhancer gene-gene interactions. find lof-tolerant enhancer tend tissue-specific regulate fewer dispensable gene relative enhancers. enriched immune-related cell enhancer low lof-tolerance enriched kidney brain/neuronal stem cells. developed supervised learning approach predict lof-tolerance enhancers, achieved area receiver operating characteristic curve (auroc) 98%. predict 3,519 enhancer would likely tolerant lof 129 enhancer would low lof-tolerance. prediction supported known set enhancer novel deletion pacbio sequencing. lof-tolerance score provided serve important reference studies.',\n",
       " 'sevenâ\\x80\\x90membered n,nâ\\x80²â\\x80\\x90heterocyclic potassium alumanyl nucleophile introduced utilised metathetical synthesis mgâ\\x88\\x92al caâ\\x88\\x92al bonded derivatives. specie characterised experimental theoretical means, allowing rationalisation greater reactivity heavier group 2 specie implied initial assay reactivity.',\n",
       " 'sevenâ\\x80\\x90membered n,nâ\\x80²â\\x80\\x90heterocyclic potassium alumanyl nucleophile introduced utilised metathetical synthesis mgâ\\x88\\x92al caâ\\x88\\x92al bonded derivatives. specie characterised experimental theoretical means, allowing rationalisation greater reactivity heavier group 2 specie implied initial assay reactivity.',\n",
       " '',\n",
       " 'background: loss vascular tone key pathophysiological feature septic shock. combination gradual diastolic hypotension tachycardia could reflect serious vasodilatory conditions. sought evaluate relationship heart rate (hr) diastolic arterial pressure (dap) ratio clinical outcome early phase septic shock. methods: diastolic shock index (dsi) defined ratio hr dap. dsi calculated starting vasopressor (pre-vps/dsi) preliminary cohort 337 septic shock (january 2015 february 2017) vasopressor start (vps/dsi) 424 septic shock included recent randomized controlled trial (andromeda-shock; march 2017 april 2018) partitioned five quantiles estimate relative risk (rr) death respect mean risk population (assumed 1). matched hr dap subsamples created evaluate effect individual component dsi rrs. addition, time-course dsi interaction dsi vasopressor dose (dsi*ne.dose) compared survivor non-survivors populations, roc curve used identify variable predicting mortality. finally, exploratory observation, effect early start vasopressor evaluated pre-vps/dsi quintile preliminary cohort. results: risk death progressively increased gradual increment pre-vps/dsi vps/dsi (one-way anova, p < 0.001). progressive dap decrease hr increase associated higher mortality risk dsi concomitantly increased. area roc curve pre-vps/dsi, sofa initial lactate similar, mean arterial pressure systolic shock index showed poor performance predict mortality. time-course dsi dsi*ne.dose significantly higher non-survivors population (repeated-measures anova, p < 0.001). early start vasopressor exhibited apparent benefit higher pre-vps/dsi quintile. conclusions: dsi pre-vasopressor vasopressor start point might represent early identifier high risk death. isolated dap hr value clearly identify risk. usefulness dsi trigger direct therapeutic intervention early resuscitation septic shock need addressed future studies.',\n",
       " '',\n",
       " 'background & aims: inflammation play important role pathogenesis cholestatic liver injury, unclear whether inflammasome involved objective study. methods: gene expression analyzed liver primary biliary cholangitis (n = 15) primary sclerosing cholangitis (n = 15). bile duct ligation (bdl) sham operation performed wild-type (wt) caspase-1(â\\x80\\x93/â\\x80\\x93) (casp1(â\\x80\\x93/â\\x80\\x93)) mouse 7 days. mouse hepatocytes macrophage treated bile acids. results: caspase-1, nlrp1, nlrp3 il-1î² significantly increased liver cholestatic compared healthy control subject (n = 9). significantly higher level plasma il-1î² (826 v 345 pg/ml), alt (674 v 482 u/l) alp (900 v 622 u/l) seen wt bdl mouse compared casp1(â\\x80\\x93/â\\x80\\x93) bdl mice. caspase-1 cleavage found wt bdl livers. assessment liver histology indicated fibrosis casp1(â\\x80\\x93/â\\x80\\x93) bdl mouse wt bdl mice, confirmed analysis liver hydroxyproline content expression fibrotic genes. profiling immune cell revealed macrophage casp1(â\\x80\\x93/â\\x80\\x93) bdl liver wt bdl livers. macrophage phenotype characterization indicated casp1(â\\x80\\x93/â\\x80\\x93) bdl liver m2 anti-inflammatory macrophage evidenced cd206 positive cell higher expression il-4, cd163, fizz1 il-33. mouse hepatocytes peritoneal macrophage exposed cholestatic level major endogenous bile acid (300î¼m tca), neither il-1î² induction procaspase-1 cleavage detected. conclusions: inflammasome exacerbates cholestatic liver injury, bile acid directly activate inflammasome.',\n",
       " 'background: visceral leishmaniasis (vl) caused dimorphic leishmania specie parasitic high socioeconomic burden endemic area worldwide. sustaining control vl term proper prevailing immunity development global necessity amid unavailability prophylactic vaccine. screening experimental proteome human propagating form leishmania donovani (amastigote) pragmatic silico mining novel vaccine candidates. methods: immunoinformatic approach, cd4+ cd8+ cell-specific epitope experimentally reported l. donovani protein secretory potential increased abundance amastigotes screened. chimera linked toll-like receptor 4 (tlr4) peptide adjuvant constructed evaluated physicochemical characteristics, binding interaction tlr4 simulated physiological condition trend immune response following hypothetical immunization. results: selected epitope physiologically important l. donovani protein found mostly conserved l. infantum, covering theoretically 98% global population. multi-epitope chimeric vaccine predicted stable, antigenic non-allergenic. structural analysis vaccine-tlr4 receptor docked complex molecular dynamic simulation suggest sufficiently stable binding interface along prospect non-canonical receptor activation. simulation dynamic immune response following hypothetical immunization indicate active memory b well cd4+ cell generation potential, likely chance th1 polarized response. conclusions: methodological approach result could facilitate informed screening selection candidate antigenic protein entry vaccine production pipeline future control human vl. [image: see text]',\n",
       " 'background: aboriginal torres strait islander child experience highest rate otitis medium world. key risk factor otitis medium aboriginal child australia largely social environmental factor overcrowded housing, poverty limited access services. despite this, little known address risk factors. scoping content review performed determine relationship social determinant otitis medium aboriginal torres strait islander child described peer-reviewed grey literature. method: search term established location, population condition. search term used conduct literature search six research databases. following exclusion process, article scoped, analysed categorised scoping parameter social determinant framework. results: housing-related issue frequently reported determinant otitis medium (56%). two article (4%) directly investigated impact social determinant rate otitis medium within aboriginal torres strait islander children. majority literature (68%) highlight social determinant playing key role high rate otitis medium seen aboriginal population australia. intervention study targeting social determinant mean reduce otitis medium rate among aboriginal torres strait islander children. conclusions: review identifies disconnect otitis medium driver focus public intervention within aboriginal torres strait islander populations. despite consensus social determinant play key role high rate otitis medium aboriginal torres strait islander children, majority intervention study within literature focussed biomedical approach research vaccine antibiotics. review highlight need otitis medium intervention study shift away purely biomedical model toward investigating underlying social determinant health. shifting intervention upstream, otitis medium rate may decrease within aboriginal torres strait islander children, focus shifted away treatment-focussed model toward preventative model.',\n",
       " 'background: malaria parasite plasmodium falciparum protozoan develops red blood cell (rbcs) requires various host factors. development rbcs, nutrient rbc cytosol extracellular milieu must acquired. although utilization host nutrient p. falciparum extensively analysed, study reported utilization host serum proteins. hence, aim current comprehensively identify host serum protein taken p. falciparum parasite elucidate role pathogenesis. methods: plasmodium falciparum cultured human serum vitro. uptake serum protein parasite comprehensively determined via shotgun liquid chromatographyâ\\x80\\x93mass spectrometry/mass spectrometry western blotting. calcium ion concentration serum evaluated, coagulation activity parasite lysate assessed. results: three proteins, vitamin k-dependent protein s, prothrombin, vitronectin, selectively internalized sufficient ca(2+) level culture medium. uptake protein initiated dna replication, increased trophozoite schizont stages, irrespective assembly/disassembly actin filaments. coagulation assay revealed prothrombin activated thereby induced blood coagulation. conclusions: serum protein taken parasite culture condition sufficient ca(2+) levels. uptake phenomenon associated pathogenicity.',\n",
       " 'background: 13-valent pneumococcal conjugate vaccine (pcv-13) introduced national immunization programme (nip) schedule russia march 2014. previously, 7-valent pneumococcal conjugate vaccine (pcv-7) marketed russia 2009 never offered mass vaccination. carriage performed among child arkhangelsk 2006. objective determine prevalence carriage, serotype distribution, antimicrobial susceptibility molecular structure streptococcus pneumoniae strain marketing introduction pcv-13. methods: cross-sectional conducted cluster-randomized sample child self-administrated questionnaire parents/guardians. nasopharyngeal sample collected 438 child younger 7 year attending nursery kindergarten arkhangelsk region, russia. detailed demographic data, well information childâ\\x80\\x99s health, traveling, exposure antimicrobial within last 3 month anthropometric measurement collected subjects. variable extracted questionnaire analysed statistic regression model estimate risk carriage. pneumococcal isolates examined susceptibility testing, serotyping multilocus sequence typing. results: overall prevalence asymptomatic carriage high peaking 36 month rate 57%. pcv-13 covered 67.3% detected strains. high rate non-susceptibility penicillin, macrolides multidrug resistance associated specific vaccine serotypes, pandemic clones, local sequence types. nine percent isolates represented three globally disseminated disease-associated pandemic clones; penicillin- macrolide-resistant clone norway(nt)-42 poland(6b)-20, well penicillin- macrolide-susceptible clone netherlands(3)-31. high level antimicrobial consumption noted study. according parentâ\\x80\\x99s reports, 89.5% child used least antimicrobial regime since birth. none hypothesised predictor s. pneumoniae carriage statistically significant univariable multivariable logistic models. conclusions: identified high coverage pcv-13-vaccine, serotype replacement expansion globally disseminated disease-associated clone non-vaccine serotypes may expected. surveillance antimicrobial resistance serotype distribution therefore required.',\n",
       " 'enterovirus a71 (ev-a71) causative pathogen hand, foot, mouth (hfmd), may cause severe neurological cardiopulmonary complication children. review, discus pathogenesis, clinical manifestations, management strategy, clinical outcome cardiopulmonary failure (cpf) ev-a71 infection. pathogenesis cpf involves catecholamine-related cardiotoxicity following brainstem encephalitis vasodilatory shock due cytokine storm. sympathetic hyperactivity, tachycardia hypertension, early clinical manifestation cardiopulmonary involvement, may progress pulmonary edema/hemorrhage and/or cpf. management strategy comprises multidisciplinary supportive treatment, fluid management, positive pressure ventilation support, use milrinone, vasopressors, inotropes. may require extracorporeal membrane oxygenation. major neurological sequela almost inevitable child develops life-threatening illness. long-term care child important medico-social issue.',\n",
       " 'background: development assistance (dah) important mean japan promote diplomacy developing country contribute international community. study, first time, estimated gross disbursement japanâ\\x80\\x99s dah 2012 2016 clarified flows, source, aid type, channel, target region, target focus area. methods: japan tracker, first platform japanâ\\x80\\x99s dah, used. dah definition based organisation economic co-operation developmentâ\\x80\\x99s (oecd) sector classification. regarding core funding non-health-specific multilateral agencies, estimated dah flow based oecd methodology calculating imputed multilateral official development assistance (oda). results: japanâ\\x80\\x99s dah estimated 1472.94 (2012), 823.15 (2013), 832.06 (2014), 701.98 (2015), 894.57 million usd (2016) constant price 2016. multilateral agency received largest dah share 44.96â\\x80\\x9357.01% periods, followed bilateral grant (34.59â\\x80\\x9353.08%) bilateral loan (1.96â\\x80\\x9315.04%). ministry foreign affair (mofa) largest contributor dah (76.26â\\x80\\x9382.68%), followed ministry finance (mof) (10.86â\\x80\\x9316.25%). japanâ\\x80\\x99s dah heavily distributed african region 41.64â\\x80\\x9353.48% share. channel dah went global fund fight aids, tuberculosis, malaria (20.04â\\x80\\x9334.89%). 2012 2016, approximately 70% allocated primary care rest system strengthening. conclusions: many major high-level related meeting ahead, coming year play powerful opportunity reevaluate dah shape future dah japan. hope result enhance social debate contribute implementation japanâ\\x80\\x99s dah efficient effective strategy.',\n",
       " '',\n",
       " '',\n",
       " 'checkpoint inhibitor part family immunotherapy increasingly used wide variety cancers. immune-related adverse event pose major challenge cancer patients. pneumonitis rare immune-related adverse event present distinct patterns. goal chapter instruct reader incidence clinical manifestation pneumonitis offer guidance evaluation pneumonitis.',\n",
       " 'achieving accurate, real-time estimate activity challenged delay reporting. â\\x80\\x9cnowcastâ\\x80\\x9d approach attempt estimate complete count given reporting date, time series report known incomplete due reporting delays. modeling reporting delay distribution common feature nowcast approaches. however, many nowcast approach ignore crucial feature infectious transmissionâ\\x80\\x94that future case intrinsically linked past reported casesâ\\x80\\x94and optimized two applications, may limit generalizability. here, present bayesian approach, nobbs (nowcasting bayesian smoothing) capable producing smooth accurate nowcasts multiple settings. test nobbs dengue puerto rico influenza-like illness (ili) united state examine performance robustness across setting exhibiting range common reporting delay characteristic (from stable time-varying), compare approach published nowcasting software package investigating feature approach contribute good poor performance. introducing temporal relationship case considerably improves performance reporting delay distribution time-varying, identify trade-off role moving window accurately capture change delay. present software implementing approach (r package â\\x80\\x9cnobbsâ\\x80\\x9d) widespread application provide practical guidance implementation.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'background: developing country exhibit high burden shigellosis. owing different incidence male females, aim analyze feature involved transmission shigellosis among male (subscript m) female (subscript f) individual newly developed sex-based model. methods: reported shigellosis case collected china information system control prevention hubei province 2005 2017. sex-based susceptibleâ\\x80\\x93exposedâ\\x80\\x93infectious/asymptomaticâ\\x80\\x93recovered (seiar) model applied explore dataset, sex-age-based seiar model applied 2010 explore sex- age-specific transmissions. results: 2005 2017, 130 770 shigellosis case (including 73 981 male 56 789 female cases) reported hubei province. seiar model exhibited significant fitting effect shigellosis (p < 0.001). median value shigellosis transmission 2.3225 ã\\x97 10(8) sar(mm) (secondary attack rate male male), 2.5729 ã\\x97 10(8) sar(mf), 2.7630 ã\\x97 10(-8) sar(fm), 2.1061 ã\\x97 10(-8) sar(ff). top five mean value transmission relative rate 2010 (where subscript 1 defined male age â\\x89¤ 5 years, 2 male age 6 59 years, 3 male age â\\x89¥ 60 years, 4 female age â\\x89¤ 5 years, 5 female age 6 59 years, 6 male age â\\x89¥ 60 years) 5.76 ã\\x97 10(-8) î²(61), 5.32 ã\\x97 10(-8) î²(31), 4.01 ã\\x97 10(-8) î²(34), 7.52 ã\\x97 10(-9) î²(62), 6.04 ã\\x97 10(-9) î²(64). conclusions: transmissibility shigellosis differed among male female individuals. transmissibility gender higher within genders, particularly female-to-male transmission. important route child (age â\\x89¤ 5 years) transmission elderly (age â\\x89¥ 60 years). therefore, greatest intervention applied female elderly.',\n",
       " '',\n",
       " 'effective analysis pathogen causing human veterinary disease demand rapid, specific sensitive detection method applied research laboratory setup field routine diagnosis. paper lateral flow biosensors (lfbs) established attractive tool analytical applications. present prototype lfb designed whole particle (virions) detection nodavirus fish nervous necrosis virus. nodavirus important threat aquaculture industry, causing severe economic loss environmental problems. lfb based polyclonal antibody conjugated gold nanoparticles signal visualization. brain retina fish sample homogenized, centrifuged supernatant directly applied lfb. formation red test line indicative nodavirus virion presence. nodavirus visual detection completed short time (30 min). key factor lfb development influencing assaysâ\\x80\\x99 detection limit characterized optimum parameter determined, enabling increased efficiency, excluding non-specific interactions. therefore, proposed lfb assay consists robust, simple, low cost accurate detection nodavirus virion fish samples. proposed biosensor ideal development commercial kit used aquaculture facility fish farmers. anticipated monitoring environmental safety benefit simplification time consuming costly procedures.',\n",
       " 'helicobacter pylorus (hp) colonizes human stomach induces acute gastritis, peptic ulcer disease, atrophic gastritis, gastric adenocarcinoma. increased virulence hp isolates derives harboring cag (cytotoxin-associated genes) pathogenicity island (cagpai). analyzed microvariants cagpai gene hypothesis may play important role determining hp virulence. tested dna caga positive hp isolates; total 74 chronic gastritis (cg, n = 37), intestinal metaplasia (im, n = 21) gastric cancer (gc, n = 16) mexico colombia. selected 520 non-synonymous variant least 7.5% frequency original sequence output minimum 5 isolates minor allele. adjustment multiple comparisons, variant statistically significantly associated im gc. however, 19 non-synonymous showed conventional p-values < 0.05 comparing frequency allele isolates subject gastritis isolates subject im gc; 12 showed significant correlation severity disease. present revealed several cagpai gene latin american western hp strain contains number non-synonymous variant relatively high frequency could influence clinical outcome. however, none association remained statistically significant adjustment multiple comparison.',\n",
       " '',\n",
       " 'coastal zone characterized interaction continent ocean and, therefore, fresh salt surface groundwater. wetland coastal zone represent transitional ecosystem affected conditions, although little known hydrogeochemistry wetlands, especially coastal wetlands. present study, hydrogeochemical characterization coastal freshwater herbaceous wetland ciã©naga del fuerte protected natural area veracruz, mexico, american tropic carried per plant community. four herbaceous wetland (alligator flag, saw grass, cattail, floodplain pasture) monitored understand origin water feeding ecosystems, hydrogeochemical composition groundwater, relationship groundwater ecology ecosystem dry rainy seasons. result indicate ciã©naga del fuerte located regional discharge area receives local recharge, fed regional local flows. chemical composition varied temporally spatially, creating unique condition determined habitat occupied hydrophytic vegetation. spatiotemporal behaviour groundwater factor that, along hydroperiod, determines wetland dynamic affect wetland biota (ecohydrogeochemistry). generalist plant community established zone local recharge, whereas specialized and/or plastic community inhabited zone receiving regional flow greater ion concentrations. information form basis establishing appropriate scale (municipal, state, larger regions) sustainable management good service provided wetlands.',\n",
       " '',\n",
       " '',\n",
       " 'background: larval index house index (hi), breteau index (bi) container index (ci) widely used interpret arbovirus vector density surveillance programmes. however, use alarm signal rarely considered consciously planning programmes. present aim investigate spatial distribution pattern infestation aedes aegypti, considering available ae. aegypti infestation index rapid survey (liraa) city campina grande, paraã\\xadba state brazil. methods: global local moranê¼s index used spatial analysis measure effect spatial dependency neighbourhoods, secondary related hi bi gathered surveillance service. results: analysis show predominance high rate mosquito infestation, placing campina grande near-constant risk arbovirus outbreak epidemics. highly significant moranê¼s index value (p < 0.001) observed, indicating positive spatial dependency neighbourhood campina grande. moran mapping lisa mapping, autocorrelation pattern ae. aegypti infestation rate among neighbourhood revealed hotpot considered priority preventive action entomological surveillance services. predominance high infestation rate clearer relationship neighbourhood observed month may july, period highest rainfall city. conclusions: analysis innovative strategy capable providing detailed information infestation location relevant public authorities, enable efficient allocation resources, particularly arbovirus prevention. [image: see text]',\n",
       " '',\n",
       " 'three-dimensional (3d) printing may solution shortage equipment spare part healthcare sector low- middle-income country (lmics). polylactic acid (pla) 3d printing widely available biocompatible, gap knowledge concerning compatibility chemical disinfectants. study, 3d-printed pla tensile sample created six different printer settings. six batch consisted five set five six samples. first set remained untreated, others soaked cidex opa chlorine solution. applied seven consecutive day 25 short cycles. sample weighed subjected tensile test. result showed third treatment led increase median weight maximum 8.3%, however, sample best surface quality change. median strength increase 12.5% largest decrease 8.8%. median stiffness decreased 3.6% set increased three others 13.6%. 3d printing pla medical tools, surface porosity must minimized prevent transfer disinfectant people. wide variability mechanical property due 3d printing consequence disinfection must considered designing medical tool selecting appropriate printer settings. condition met, reusing 3d-printed pla medical tool seems safe mechanical point view.',\n",
       " 'wireless controller found application supervision hospitals. valid issue developing country developed countries. reason, scientist working advancement medical device capable decreasing workload caregivers. study, development iontophoretic drug delivery device could controlled mobile described. purpose, hardware software module developed. hardware module consisted two-channel voltage-controlled constant current source used driving iontophoretic device. mobile app developed control two-channel iontophoretic device monitor loose lead active passive patches. detection loose lead, specific iontophoretic channel stopped. further, audio-visual indicator developed detection detachment patch (loose lead). device tested vitro performing drug release drug-loaded emulsion gel formulated.',\n",
       " 'development diagnostics medical device historically concentrated high-income countries, despite significant need expand healthcare service low- middle-income country (lmic). poor quality healthcare extends beyond lmic underserved community developed countries. paper review disease condition received much attention past despite imposing significant burden healthcare system circumstances. review underlying mechanism action condition current technology use diagnosis surgical intervention. aim identify area technological development review policy consideration enable real-world adoption. specifically, review focus disease prevalent sub-saharan africa south asia: melioidosis, infant maternal mortality, schistosomiasis, heavy metal pesticide poisoning. aim review identify problem facing world require attention medical device community provide recommendation research direction group interested field.',\n",
       " 'paper proposes structure development ai diagnostic system highly leveraged step toward improvement delivery healthcare underserved regions. first, paper provides high-level, general review current effort provide healthcare service underserved area many effort made impact outcome various international, governmental, ngo entities. briefly review university program research institution specific technical institutional asset significant potential carry research partially implement plan. review us weighted value decision-system take variety asset consider fundamental successful engagement delivery new, innovative, technology-enabled healthcare system under-resourced settings. review nine factor hinder advancement healthcare under-resourced settings, well described current literature may bring perspectives. paper attempt review proposed system manage operate successfully within context nine named hindrance factors. primary focus paper description system increase availability diagnostics technology-enabled systems. system would impact outcome person underserved regions. paper describes making diagnostics available critical priority among effort improvement global health.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'background: severe traumatic brain injury (tbi) often develop acute respiratory failure. optimal ventilator strategy setting well established. performed international survey investigate practice ventilatory management tbi without respiratory failure. methods: electronic questionnaire, 38 item 3 different clinical scenario [arterial partial pressure oxygen (pao(2))/inspired fraction oxygen (fio(2)) > 300 (scenario 1), 150â\\x80\\x93300 (scenario 2), < 150 (scenario 3)], available european society intensive care medicine (esicm) website november 2018 march 2019. survey endorsed esicm. results: 687 respondent [472 (69%) europe], mainly intensivists [328 (48%)] anesthesiologist [206 (30%)]. standard protocol mechanical ventilation tbi utilized 277 (40%) respondent specific weaning protocol 198 (30%). common tidal volume (tv) applied 6â\\x80\\x938 ml/kg predicted body weight (pbw) scenario 1â\\x80\\x932 (72% pao(2)/fio(2) > 300 61% pao(2)/fio(2) 150â\\x80\\x93300) 4â\\x80\\x936 ml/kg/pbw scenario 3 (53% pao(2)/fio(2) < 150). common level highest positive end-expiratory pressure (peep) used 15 cmh(2)o pao(2)/fio(2) â\\x89¤ 300 without intracranial hypertension (41% pao(2)/fio(2) 150â\\x80\\x93300 50% pao(2)/fio(2) < 150) 10 cmh(2)o intracranial hypertension (32% pao(2)/fio(2) 150â\\x80\\x93300 33% pao(2)/fio(2) < 150). regardless presence intracranial hypertension, common carbon dioxide target remained 36â\\x80\\x9340 mmhg whereas common pao(2) target 81â\\x80\\x93100 mmhg 3 scenarios. frequent rescue strategy utilized refractory respiratory failure despite conventional ventilator setting neuromuscular blocking agent [406 (88%)], recruitment manoeuvre [319 (69%)] prone position [292 (63%)]. conclusions: ventilatory management, target practice adult severe tbi without respiratory failure widely different among centres. finding may helpful define future investigation topic.',\n",
       " 'background: profiling immune response induced either vaccination provide insight identification correlate protection. furthermore, profiling serological response used identify biomarkers indicative exposure pathogens. conducting immune surveillance requires readout method high-throughput, robust, require small sample volumes. enzyme-linked immunosorbent assay (elisa) classical readout assessing serological responses, advent multiplex assay significantly increased throughput capacity immunoprofiling. report describes development assay performance (sensitivity, linearity detection, requirement multiple dilution sample, intra- inter-assay variability) electro-chemiluminescence (eclia)-based multiplex assay. methods: current describes development multiplex eclia-based assay characterizes sensitivity, linear range, inter- intra-assay variability eclia platform agreement traditional elisa. special emphasis placed potential antigenic competition testing closely related antigen multiplex format. results: multiplexing antigen eclia provides significant practical benefit term reducing sample volume requirement experimental time. beyond practical advantage multiplexing, eclia provides superior assay performance compared elisa. eclia good agreement elisa assay, linear range eclia sufficiently wide permit single-dilution measurement concentration without need serial dilutions. lack antigenic competition allows simultaneous testing closely related antigens, plate antigen representing different allele protein, inform cross-reactivitiesâ\\x80\\x94or lack thereofâ\\x80\\x94of serological responses. conclusion: advantage newly developed tool assessing antigen profile serological response may ultimately lead identification biomarkers associated various stage protection disease.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'background: available diagnostics often fail distinguish bacterial cause pediatric communityâ\\x80\\x90acquired pneumonia (pcap). metabolomics, aim characterizing disease based metabolic signatures, applied expand pathophysiological understanding many diseases. exploratory study, used untargeted metabolomic analysis shed light etiology pcap. methods: liquid chromatography coupled mass spectrometry used quantify metabolite content urine sample collected child hospitalized cap pneumococcal etiology, ascertained conservative algorithm combining microbiological biochemical data. results: fiftyâ\\x80\\x90nine child cap enrolled 16 months. pneumococcal case distinguished mean multivariate model based 93 metabolites, 20 identified considered putative biomarkers. among these, six metabolite belonged adrenal steroid synthesis degradation pathway. conclusions: preliminary suggests pneumococcal pneumonia differently affect systemic metabolome, stronger disruption adrenal steroid pathway pneumococcal pneumonia. finding may lead discovery novel diagnostic biomarkers bring u closer personalized therapy pcap.',\n",
       " '',\n",
       " '',\n",
       " 'background: approximately 30% child worldwide infected gastrointestinal parasites. depending species, parasite disrupt intestinal bacterial microbiota affecting essential vitamin biosynthesis. methods: stool sample collected 37 asymptomatic child previous cross-sectional argentinian study. multi-parallel real-time quantitative pcr implemented ascaris lumbricoides, ancylostoma duodenale, necator americanus, strongyloides stercoralis, trichuris trichiura, cryptosporidium spp., entamoeba histolytica giardia duodenalis. addition, whole-genome sequencing analysis conducted bacterial microbiota sample analyzed livermore metagenomic analysis toolkit diamond software. separate analysis carried uninfected, giardia-only, giardia + helminth co-infections, helminth-only groups. results: giardia-only infected child compared uninfected children, dna sequencing showed decrease microbiota biodiversity correlated increasing giardia burden statistically significant shannonê¼s alpha diversity (giardia-only > 1 fg/âµl 2.346; non-infected group 3.253, p = 0.0317). increase diversity observed helminth-only infection decrease diversity giardia + helminth co-infections (p = 0.00178). giardia-only infections, microbiome taxonomy changed firmicutes towards increasing proportion prevotella, degree change related intensity compared uninfected (p = 0.0317). abundance prevotella bacteria decreased helminths-only group increased giardia + helminth co-infections (p = 0.0262). metagenomic analysis determined cobalamin synthesis decreased giardia > 1 fg/âµl group compared giardia < 1 fg/âµl uninfected group (p = 0.0369). giardia + helminth group decrease cobalamin cbim gene helminth-only infection (p = 0.000754). conclusion: result may provide evidence effect parasitic infection enabling permissive growth anaerobic bacteria prevotella, suggesting altered capacity vitamin b12 (cobalamin) biosynthesis potential impact growth development child [image: see text].',\n",
       " 'background: present aimed investigate relationship arterial lactate level outcome severe acute pancreatitis. methods: retrospectively analyzed medical 329 severe acute pancreatitis january 2014 february 2019. compared baseline characteristics, laboratory data, severity scores, type persistent organ failure, primary secondary outcome without elevated arterial lactate level admission. multivariate logistic regression analysis model receiver operating characteristic curve adopted evaluate value arterial lactate â\\x89¥4 mmol/l identifying high-risk patients. trend arterial lactate level compared survivor nonsurvivor group period 7 days. results: compared normal arterial lactate levels, elevated arterial lactate level significantly higher incidence multiple persistent organ failure (3% v 30%, p < 0.01), death (2% v 11%, p < 0.01), septic shock (4% v 24%, p < 0.01), pancreatic (12% v 37%, p < 0.01), abdominal compartment syndrome (3% v 20%, p < 0.01), pancreatic necrosis (41% v 63%, p < 0.01), need ventilator support (26% v 54%, p < 0.01). predicting mortality, arterial lactate level â\\x89¥4 mmol/l high hazard ratio (10, 95% ci; 3.7â\\x80\\x9327; p < 0.01) highest area curve (0.78). conclusions: result indicate initially elevated arterial lactate independently associated poor outcome death severe acute pancreatitis may serve early high-risk stratification indicator.',\n",
       " \"estimation epidemic onset timing important component controlling spread seasonal infectious disease within community healthcare sites. local elevated respiratory illness threshold (alert) algorithm us thresholdâ\\x80\\x90based approach suggest incidence level historically indicated transition endemic epidemic activity. paper, present first detailed overview computational approach underlying algorithm. motivating example section, evaluate performance alert determining onset increased respiratory incidence laboratory testing children's hospital colorado. threshold 10 case per week, alertâ\\x80\\x90selected intervention period performed better observed hospital site period (2004/2005â\\x80\\x932012/2013) cusum method. additional simulation study property may effect alert performance novel data. found condition alert showed ideal performance generally included high seasonality low offâ\\x80\\x90season incidence.\",\n",
       " 'bovine respiratory (brd) remains leading cause morbidity, mortality, economic loss cattle industry. continued high prevalence underline gap understanding host immune response respiratory infection. host immune response beneficial detrimental, required clearing often leading tissue damage long-term defect lung function. article highlight advancement made understanding innate adaptive immunity brd, factor predispose animal brd, novel intervention strategy may lead change approach treating controlling brd.',\n",
       " '',\n",
       " 'high-frequency oscillatory ventilation (hfov) rescue neonate refractory respiratory failure early elective therapy preterm infant severe respiratory distress syndrome (rds). however, little known current evolution therapeutic limitation hfov. therefore aimed describe use clinical practice predict risk mortality neonate receiving hfov. retrospective observational neonate treated hfov quaternary referral nicu january 2007 december 2016 conducted. classified five subgroup based primary respiratory diagnoses. performed logistic regression decision tree regression analysis identify independent factor 30-day mortality following hfov. total 1125 ever supported hfov enrolled, 64.1% received hfov rescue therapy, 27.2% received elective therapy, 8.7% received air leak. average oxygenation index (oi) greater 25 first 24 hour initiation hfov secondary pulmonary hypertension found greatest risk in-hospital mortality (p < 0.0001). overall in-hospital mortality rate 25.8% (290/1125). decision tree regression analysis revealed neonate refractory respiratory failure pre-hfov oi value higher 20.5 oi value higher 21.5, 23.5 34 2 hours, 6 hours, 12 hour use hfov, respectively, significantly increased risk 30-day mortality. identified predictor cutoff point oi initiation hfov neonate respiratory failure, clinically used reference 30-day mortality. effort still needed optimize outcomes.',\n",
       " 'plasmodium falciparum merozoite invasion erythrocyte essential step blood-stage cycle, survival parasites, malaria pathogenesis. p. falciparum merozoite rh5 interacting protein (pfripr) form complex rh5 cyrpa sequential molecular event leading erythrocyte invasion. described pfripr conserved protein induces strain-transcending growth inhibitory antibody vitro assays. however, complex protein 1086 amino acid (aa) 87 cysteine residues, pfripr difficult express conventional expression system towards vaccine development. sought identify potent region pfripr could developed overcome difficulty related protein expression, well elucidate invasion inhibitory mechanism anti-pfripr antibodies. wheat germ cell-free system, ecto- pfripr truncates approximately 200 aa expressed soluble proteins. demonstrate antibody pfripr truncate 5 (pfripr_5: c(720)-d(934)), region within pfripr c-terminal egf-like domains, potently inhibit merozoite invasion. furthermore, antibody strongly block pfripr/rh5 interaction, well pfripr erythrocyte-surface receptor, sema7a. taken together, pfripr_5 potential candidate development blood-stage malaria vaccine.',\n",
       " 'background: copepod key component aquatic ecosystem help regulate global carbon cycle. much attention paid specie diversity copepod worldwide, phylogeography genetic diversity copepod nigeria unexplored. results: mitochondrial cytochrome c oxidase subunit marker, preformed phylogenetic phylogeographic analysis cyclopidae copepod southeast nigeria. high specie diversity cyclopidae nigeria: 5 specie tropocyclops, 5 specie mesocyclops 2 specie thermocyclops cyclopidae identified 15 populations. moreover, detected 18 unique haplotypes, fell two distinct clades. pairwise genetic distance (uncorrected p-distances) among specie cyclopidae ranged 0.05 0.257. several specie co-existed lake, haplotype shared among different geographic populations, suggesting dispersal cyclopidae sampling region. finally, found population genetic diversity specie cyclopidae low nigeria. conclusions: finding explored specie diversity distribution copepod within family cyclopidae 15 nigerian freshwater ecosystems: high specie diversity cyclopidae copepod detected small geographic sampling range. result contribute better understanding copepod diversity nigerian freshwater ecosystems.',\n",
       " 'background: endemic area zoonotic leishmaniosis caused l. infantum, early detection leishmania dog essential control dissemination parasite humans. aim evaluate serological and/or molecular diagnostic performance minimally non-invasive sample (conjunctiva cell (cs) peripheral blood (pb)) monitoring leishmania infection/exposure phlebotomus perniciosus salivary antigen dog beginning end sand fly seasonal activity (may october, respectively) ass associated risk factors. methods: total 208 sheltered dog endemic area leishmaniosis screened. leishmania dna detection pb filter paper c performed nested-pcr (npcr), detection anti-leishmania antibody performed ifat elisa. exposure p. perniciosus salivary antigen (sgh, rsp01 rsp03b + rsp01) measured elisa. results: ninety-seven (46.6%) 116 (55.8%) 208 dog positive leishmania antibody dna least test beginning end sand fly season, respectively. ifat elisa presented substantial agreement serodiagnosis leishmaniosis. discrepant pb npcr result obtained sampling points. leishmania dna detected c 72 dog end phlebotomine season. presence antibody parasite measured elisa significantly higher dog presenting clinical sign compatible leishmaniosis sampling points. phlebotomus perniciosus salivary antibody detected 179 (86.1%) 198 (95.2%) screened dog beginning end phlebotomine season, respectively. conclusions: association elisa positivity clinical sign suggests usefulness confirm clinical suspicion. c npcr seems effective non-invasive assessing early exposure parasite. pb npcr used sole diagnostic tool monitor leishmania infection. correlation level antibody p. perniciosus saliva leishmania antibody suggests use humoral response sand fly salivary antigen biomarkers l. infantum infection. [image: see text]',\n",
       " '',\n",
       " 'ste24, integral membrane protein zinc metalloprotease, found every kingdom eukaryotes. discovered approximately 20 year ago yeast genetic screen identifying factor responsible processing yeast mating a-factor pheromone. animals, ste24 process prelamin a, component nuclear lamina; mutation human ortholog ste24 diminish activity, giving rise genetic disease accelerated aging (progerias). additionally, lipodystrophy, acquired standard highly active antiretroviral therapy used treat aid patients, likely result off-target interaction hiv (aspartyl) protease inhibitor drug ste24. ste24 posse novel â\\x80\\x9cî±-barrelâ\\x80\\x9d structure, consisting ring seven transmembrane î±-helices enclosing (> 12,000 ã (3)) interior volume contains active-site substrate-binding region; â\\x80\\x9cmembrane-interior reaction chamberâ\\x80\\x9d unprecedented integral membrane protein structures. additionally, surface membrane-interior reaction chamber posse strikingly negative electrostatic surface potential, adding additional â\\x80\\x9cfunctional mystery.â\\x80\\x9d recent publication implicate ste24 key factor several endoplasmic reticulum processes, unfolded protein response, cellular stress response endoplasmic reticulum, removal misfolded protein translocon. ste24, provocative structure, enigmatic mechanism, emergent biological role â\\x80\\x9ctranslocon uncloggerâ\\x80\\x9d (non-enyzmatic) broad-spectrum restriction factor, present far differently 2016, viewed â\\x80\\x9ccaax proteaseâ\\x80\\x9d responsible cleavage prenylated (farnesylated geranylgeranylated) substrates. emphasis review ste24 â\\x80\\x9cpost-caax-protease era.â\\x80\\x9d',\n",
       " '',\n",
       " '',\n",
       " 'introduction: multimonth dispensing (mmd) antiretroviral (art) aim reduce patient-related barrier access long-term improve system efficiency. however, randomized evidence clinical effectiveness lacking. compared mmd within community art refill group (cargs) vs. standard-of-care facility-based art delivery zimbabwe. methods: three-arm, cluster-randomized, pragmatic noninferiority trial performed. thirty care facility associated cargs allocated either art collected three-monthly facility (3mf, control); art delivered three-monthly cargs (3mc); art delivered six-monthly cargs (6mc). stable adult receiving art â\\x89¥six month baseline load (vl) <1000 copies/ml eligible. retention art care (primary outcome) suppression (vs) 12 month enrollment compared, regression model specified clustering (clinicaltrials.gov: nct03238846). results: 4800 participant recruited, 1919, 1335, 1546 arm 3mf, 3mc, 6mc, respectively. retention, prespecified noninferiority limit (-3.25%, risk difference [rd]) met comparison arms, 3mc (94.8%) vs. 3mf (93.0%), adjusted rd = 1.1% (95% ci: -0.5% 2.8%); 6mc (95.5%) vs. 3mf: ard = 1.2% (95% ci: -1.0% 3.6%); 6mc vs. 3mc: ard = 0.1% (95% ci: -2.4% 2.6%). vl completion 12 month 49%, 45%, 8% 3mf, 3mc, 6mc, respectively. v 3mc (99.7%) high different 3mf (99.1%), relative risk = 1.0 (95% ci: 1.0-1.0). v marginally reduced 6mc (92.9%) vs. 3mf, relative risk = 0.9 (95% ci: 0.9-1.0). conclusion: retention cargs receiving three- six-monthly mmd noninferior versus standard-of-care facility-based art delivery. v 3mc high. v six-monthly cargs requires evaluation.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'sepsis commonly known affect neonatal outcomes. assessed much center-to-center variability sepsis rate affect outcome very-low-birth-weight infant (vlbwis). 7,493 vlbwis registered korean neonatal network 2013 2016 classified three group according sepsis rate: low sepsis group (ls) < 25(th) percentile versus intermediate sepsis group (is) 25(th)â\\x80\\x9375(th) versus high sepsis group (hs) â\\x89¥ 75(th). incidence density sepsis ls, is, h group 1.17, 3.17, 8.88 cases/1,000 person-days. propensity score matching done multiple antenatal perinatal factors, odds ratio death, moderate severe bronchopulmonary dysplasia and/or death, periventricular leukomalacia, survival without major morbidity h group 2.0 (95% confidence interval 1.4â\\x80\\x932.8), 1.9 (1.5â\\x80\\x932.4), 1.5 (1.1â\\x80\\x932.3) 0.7 (0.5â\\x80\\x930.8) compared group, 2.2 (1.6â\\x80\\x933.2), 2.3 (1.8â\\x80\\x932.9), 2.0 (1.3â\\x80\\x932.9), 0.7 (0.6â\\x80\\x930.9) compared l group. significant difference outcome l groups. hence, nationwide quality improvement control sepsis rate especially unit high sepsis rate helpful improve outcome vlbwis.',\n",
       " '',\n",
       " 'according leading german economic research institutes, german economy experiencing drastic slump corona pandemic. order slow wave infection, state severely restricted economic activity germany. result, gdp expected shrink 4.2% year. recession leaving clear trace labour market national budget. peak, unemployment rate soar 5.9% number short-time worker 2.4 million. year, fiscal policy stabilisation measure lead record deficit general government budget 159 billion euro. shutdown, economy gradually recover. accordingly, increase gdp next year strong 5.8%. forecast associated considerable downside risks, e.g. pandemic slowed faster recovery economic activity le successful expected may wave infection.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'nanotechnology considered growing importance vaccine field. decoration immunogen multivalent nanoparticles, designed nanovaccines elicit improved humoral immunity. however, significant practical monetary challenge largeâ\\x80\\x90scale production nanovaccines impeded widespread clinical translation. here, alternative approach illustrated integrating computational protein modeling adaptive electroporationâ\\x80\\x90mediated synthetic dna delivery, thus enabling direct vivo production nanovaccines. dnaâ\\x80\\x90launched nanoparticles demonstrated displaying hiv immunogen spontaneously selfâ\\x80\\x90assembled vivo. dnaâ\\x80\\x90launched nanovaccines induce stronger humoral response monomeric counterpart mouse guinea pigs, uniquely elicit cd8+ effector tâ\\x80\\x90cell immunity compared recombinant protein nanovaccines. improvement vaccine response recapitulate dnaâ\\x80\\x90launched nanovaccines alternative scaffold decorated antigen designed evaluated. finally, evaluation functional immune response induced dlnanovaccines demonstrates that, comparison control mouse mouse immunized dnaâ\\x80\\x90encoded hemagglutinin monomer, mouse immunized dnaâ\\x80\\x90launched hemagglutinin nanoparticle vaccine fully survive lethal influenza challenge, substantially lower load, weight loss, influenzaâ\\x80\\x90induced lung pathology. additional nextâ\\x80\\x90generation vivoâ\\x80\\x90produced nanovaccines may offer advantage immunization multiple targets.',\n",
       " 'nonstructural (ns) protein ns3/4a protease critical factor hepatitis c (hcv) maturation requires activation ns4a. synthetic peptide mutant ns4a found inhibit ns3 function. bridging peptide inhibitor heterocyclic peptidomimetics ns4a considered literature and, therefore, decided explore strategy developing class ns3 inhibitors. report, structure-based design approach used convert bound form ns4a 1h-imidazole-2,5-dicarboxamide derivative first generation peptidomimetics. scaffold mimic buried amino acid sequence ile-25` arg-28` core ns4a(21`â\\x80\\x9333`) needed activate ns3 protease. synthesized compound (coded moc) able compete displace ns4a(21`â\\x80\\x9333`) binding ns3. instance, n(5)-(4-guanidinobutyl)-n(2)-(n-hexyl)-1h-imidazole-2,5-dicarboxamide (moc-24) inhibited binding ns4a(21`â\\x80\\x9333`) competition half maximal inhibitory concentration (ic(50)) 1.9 â± 0.12 âµm fluorescence anisotropy assay stabilized denaturation ns3 increasing aggregation temperature (40% compared ns4a(21`â\\x80\\x9333`)). moc-24 inhibited ns3 protease activity fluorometric assay. molecular dynamic simulation conducted rationalize difference structureâ\\x80\\x93activity relationship (sar) active moc-24 inactive moc-26. moc compound possibly first example ns4a peptidomimetics demonstrated activity ns3 proteins.',\n",
       " 'background: severe accidental hypothermia associated high morbidity mortality. veno-arterial extracorporeal membrane oxygenation (va-ecmo) provides efficient rewarming complete cardiopulmonary support. use va-ecmo indication greatly improved vital functional prognosis patients. presentation: report 46-year-old treated severe hypothermia temperature 22.4 â°c along initial cardiac arrest, whose progression favorable implementation va-ecmo support. two month initial cardiac arrest, reassessed showed sign complete recovery regard mental physical capacities. conclusions: recent international publication group expert recommend use va ecmo gold standard therapy treat severe hypothermia. therefore, seems suitable update current knowledge topic analysing latest international publications. performance technique call question ethical economic factors. two distinct medical team tried identify regroup prognosis factor predictive survival scores. raise question utility score clinical practice. indeed, according survival rate proceed prolonged resuscitation implement va-ecmo? additional study needed external approval survival scores, additional reflection expert required.',\n",
       " 'background: prevalence infection due carbapenem-resistant acinetobacter baumannii (crab) rise worldwide. polymyxin considered last-resort drug crab infections, still controversy regarding efficacy safety polymyxin based therapy crab infections. present systematic review designed compare efficacy safety polymyxin based therapy versus non-polymyxins based therapy crab infections. methods: performed systematic literature search pubmed, embase, cinahl, cochrane library, clinicaltrials.gov identify eligible study reporting clinical outcome crab infections. meta-analysis employed random-effects model estimate odds ratio (or) standardized mean difference (smd) 95% confidence interval (ci). primary outcome 1-month mortality cause. examined clinical response, microbiological response, length stay hospital, adverse events. results: eleven eligible study analyzed (1052 total), 2 randomized clinical trials. serious risk bias found 8 11 studies. statistically significant difference polymyxin based therapy non-polymyxins based therapy 1-month mortality cause (or, 0.95; 95% ci, 0.59 1.53), microbiological response (or, 3.83; 95% ci, 0.90 16.29) length stay hospital (smd, 0.24; 95% ci, â\\x88\\x92 0.08 0.56). pooled clinical response indicated significant difference favor polymyxin based therapy (or, 1.99; 95% ci, 1.31 3.03). pooled adverse event showed non-polymyxins based therapy associated fewer adverse event (or, 4.32; 95% ci, 1.39 13.48). conclusion: performance polymyxin based therapy better non-polymyxin based therapy clinical response rate similar non-polymyxin based therapy term 1-month mortality microbiological response treating crab infections. due limitation study, cannot draw firm optimal crab infections, polymyxin would relatively effective crab infections. adequate well-designed scale randomized controlled trial required clarify relative efficacy polymyxin based non-polymyxins based therapies.',\n",
       " 'background: inconsistency exist regarding severity illness caused different influenza strains. aim compare clinical outcome hospitalized adult adolescent influenza-related pneumonia (flu-p) type type b strain china. methods: retrospectively reviewed flu-p five hospital china january 2013 may 2019. multivariate logistic cox regression model used ass effect influenza subtypes clinical outcomes, explore risk factor 30-day mortality flu-p patients. results: total, 963 laboratory-confirmed influenza a-related pneumonia (flua-p) 386 influenza b-related pneumonia (flub-p) included. upon adjustment confounders, multivariate logistic regression model showed flua-p associated increased risk invasive ventilation (adjusted odds ratio [aor]: 3.824, 95% confidence interval [ci]: 2.279â\\x80\\x936.414; p < 0.001), admittance intensive care unit (aor: 1.630, 95% ci: 1.074â\\x80\\x932.473, p = 0.022) 30-day mortality (aor: 2.427, 95% ci: 1.568â\\x80\\x933.756, p < 0.001) compared flub-p. multivariate cox regression model confirmed influenza (hazard ratio: 2.637, 95% ci: 1.134â\\x80\\x936.131, p = 0.024) independent predictor 30-day mortality flu-p patients. conclusions: severity illness clinical outcome flua-p severe flub-p. highlight importance identifying strain management severe influenza.',\n",
       " 'background: canine leishmaniosis (canl) parasitic zoonotic disease, endemic mediterranean basin spain. knowledge canl, management, treatment, prevention control mounts, remains unclear whether clinical veterinarian follow international recommendations, leishvet group. thus designed ass recent trend clinical management canl veterinary clinic across spain questionnaire-based survey. result compared prior national multicenter questionnaire administered research team 2005. methods: questionnaire consisting 28 question canl developed google form distributed email 1428 veterinary clinic spain. question designed obtain common clinical signs, technique complementary exam used diagnose disease, monitoring, control measures. collected database statistical analysis. results: completed questionnaire returned 295 clinics. compared situation 2005, response indicate clinical sign canl changed significantly, cutaneous lesion still prevalent sign observed practitioners. quantitative serological technique considered adequate approach diagnosis, provided result supported finding thorough physical exam, well complementary test (complete blood count, biochemical profile, plasma protein electrophoretogram complete urinalysis). protocol check-ups follow international recommendations. finally, multimodal approach endorsed adequately control canl preventive measure annual serological check-ups combination repellent vaccines. additionally, owner better informed canl veterinarians, translates improved control zoonosis. conclusions: clinical management canl undergone significant change owing improvement clinical knowledge disease, unified international criteria, improved diagnostic technique adequate interpretation, well greater awareness transmitted owners. [image: see text]',\n",
       " 'background: oncologic diseases, particularly hematologic malignancies, increased risk common infection unique treatment-related complication high mortality morbidity. annual incidence prevalence cancer germany rising. although modern treatment generally led improved survival, increasing age, comorbidities, frailty require multidisciplinary strategy handling complex therapeutic concept associated complications. methods: selective literature search guideline european society medical oncology (esmo), german society hematology medical oncology (deutsche gesellschaft fã¼r hã¤matologie und medizinische onkologie, dgho), infectious disease working group dgho (arbeitsgemeinschaft infektionen der hã¤matologie und onkologie, agiho), american society clinical oncology (asco) formed basis study. conclusion: recognition severe infection cancer discrimination treatment-associated complication challenge. neutropenic fever frequent infectious emergency oncology. early empiric broad-spectrum antibiotic escalated diagnostic strategy needed successfully treat vulnerable group. article, range potentially life-threatening infection immunocompromised discussed.',\n",
       " '20 november 2019, lassa fever diagnosed physician repatriated sierra leone netherlands. second physician suspected lassa fever, repatriated day later healthcare facility, confirmed infected lassa 21 november. comprehensive contact monitoring involving high- low-risk contact proved feasible follow-up contact reveal secondary transmission netherlands.',\n",
       " '',\n",
       " '',\n",
       " 'acquired immune deficiency syndrome (aids) still life-threatening disease world. moreover, infection still potentially increasing. difficult problem must solved. early warning effective way solve problem. here, aim determine best performing model track epidemic aids, provide methodological basis testing time characteristic disease. january 2004 january 2018, built four computing method based aid dataset: bpnn model, rnn model, lstm model mhpso-gru model. compare final estimated performance determine preferred method. result. considering root mean square error (rmse), mean absolute error (mae), mean error rate (mer) mean absolute percentage error (mape) simulation prediction subsets, mhpso-gru model determined best performance technology. estimate period may 2018 december 2020 suggest event appears continue increase remain high.',\n",
       " 'tuberculosis (tb) infectious lead towards death left untreated. tb detection involves extraction complex tb manifestation feature lung cavity, air space consolidation, endobronchial spread, pleural effusion chest x-ray (cxrs). deep learning based approach named convolutional neural network (cnn) ability learn complex feature cxr images. main problem cnn consider uncertainty classify cxrs softmax layer. lack presenting true probability cxrs differentiating confusing case tb detection. paper present solution tb identification bayesian-based convolutional neural network (b-cnn). deal uncertain case low discernibility among tb non-tb manifested cxrs. proposed tb identification methodology based b-cnn evaluated two tb benchmark datasets, i.e., montgomery shenzhen. training testing proposed scheme utilized google colab platform provides nvidia tesla k80 12 gb vram, single core 2.3 ghz xeon processor, 12 gb ram 320 gb disk. b-cnn achieves 96.42% 86.46% accuracy dataset, respectively compared state-of-the-art machine learning cnn approaches. moreover, b-cnn validates result filtering cxrs confusion case variance b-cnn predicted output certain threshold. result prove supremacy b-cnn identification tb non-tb sample cxrs compared counterpart term accuracy, variance predicted probability model uncertainty.',\n",
       " 'canine distemper (cdv) multi-host pathogen cause significant mortality domestic, wild terrestrial marine mammals. major conservation threat endangered species. severe respiratory fatal encephalitis. diagnosis monitoring wildlife, differentiation cdv rabies (a life-threatening zoonotic produce similar neurologic signs), would benefit availability portable, point-of-care (poc) diagnostic test. therefore developed quantitative rt-pcr assay cdv shelf-stable, lyophilized reagent target-specific primer probe use handheld biomeme two3(â\\x84¢) qpcr thermocycler. biomemeâ\\x80\\x99s extraction methodology, lyophilized reagents, thermocycler compared standard laboratory-based method ass sensitivity, efficiency overall test performance. result positive control plasmid cdv showed comparable sensitivity (detection 50 copies) pcr efficiency two platforms, cdv detection similar platform tested modified live cdv vaccine. significantly higher ct value (average ct = 5.1 cycles) observed biomeme platform known cdv positive animal samples. cdv detection biomeme platform similar 25 26 sample suspect cdv case compared standard virology laboratory testing. false positive observed negative upon retest. biomeme methodology adapted detection specific targets, portable technology save time eliminating need local international sample transport laboratory-based diagnostics. however, result testing suggest decreased diagnostic sensitivity (higher ct values) relative laboratory-based method observed animal samples, careful validation optimization essential. portable qpcr platform empower biologist wildlife professional remote low-resource settings, greatly improve understanding cdv ecology associated conservation threat wildlife.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'human-plasma-derived immune globulin (ig) used augmentation therapy provide protective level antibody primary immune deficiency disease (pidd) prophylaxis infectious diseases. maintain breadth antibody necessary clinical protection, important understand regional pattern antibody seroprevalence source plasma ig product manufactured. study, source plasma donation center various location southwestern quarter united state surveyed antibody titer hepatitis (hav), measles (mev), cytomegalovirus (cmv). broad range anti-hav ig plasma titer observed among centers, center exhibiting 3â\\x80\\x935 time titer others. minor difference observed level anti-mev anti-cmv, respectively. importantly, elevated anti-hav ig titer broadly observed across plasma unit obtained center exhibiting high titers, indicative potential regional phenomenon among donor opposed donor singularly high titers. plasma high-titer center conferred significantly greater neutralization hav vitro. outcome give glimpse antibody diversity inherent human plasma used manufacture ig products..',\n",
       " 'construct model revolution transition democracy individualistic collectivist cultures. main that, despite facing potentially challenging collective action problems, country individualistic culture likely end adopting democracy earlier country collectivist cultures. empirical analysis suggests strong robust association individualistic culture average polity score duration democracy, even controlling determinant democracy emphasized literature. provide evidence country collectivist culture likely experience autocratic breakdown transition autocracy autocracy.',\n",
       " '',\n",
       " '',\n",
       " 'emergency nurse frequently encounter uncertainty change management emerging infectious diseases, challenge capability perform duty well-planned systematic manner. date, little known coping strategy adopted emergency nurse addressing uncertainty change epidemic event. present explored emergency nursesâ\\x80\\x99 behaviour strategy handling uncertainty practice change epidemic event. qualitative based straussian grounded theory approach established. semi-structured, face-to-face, individual interview conducted 26 emergency nurse collection. adapting protocol evolving context practice revealed core category. four interplaying subcategories identified: (1) completing comprehensive assessment, (2) continuing education emerging infectious management, (3) incorporating guideline update (4) navigating duty competencies. nurse demonstrated prudence orientate ambiguous work situation displayed ability adapt embrace change practice duties. finding offer insight need education training scheme allow emergency nurse acquire develop necessary decision-making problem-solving skill handle public emergency.',\n",
       " 'rapid population migration viewed critical factor impacting urban network construction regional sustainable development. supervision analysis population migration necessary guiding optimal allocation urban resource attaining high efficiency development region. currently, exploration population migration often restricted limitation data. information era, search engine widely collect public attention, implying potential individual actions, freely provide open, timelier, large-scope search query helping explore regional phenomenon problems. paper, endeavor explore possibility adopting depict population migration. based search query baidu search engine, three migration attention index (mais) constructed capture public migration attention cyber space. taking three major urban agglomeration china study, conduct correlation analysis among cyber mais population migration geographical space. result external-mai local-mai positively reflect population migration inner region across region holistic lens intercity-mai helpful supplement delineation specific population flow. along accumulation cyber search query data, potential exploring population migration reinforced.',\n",
       " 'background: predictive scoring system acute respiratory distress syndrome (ards) patients, incorporates age, pao(2)/flo(2), plateau pressure, apps, developed recently. validated externally caucasian population studied asian populations. aim validate apps korean ards patients. methods: retrospectively reviewed medical record diagnosed ards berlin criterion admitted medical icu seoul national university hospital january 2015 december 2016. validation apps performed evaluating calibration predictive accuracy. calibration plotted quantified hosmerâ\\x80\\x93lemeshow test. predictive accuracy assessed calculating area receiver operating characteristic (aucâ\\x80\\x93roc) curve. results: total 116 analyzed, 32 survived. 116 patients, 11 (9.5%) classified apps grade 1 (score 3â\\x80\\x934), 88 (75.9%) grade 2 (score 5â\\x80\\x937) 17 (14.6%) grade 3 (score 8â\\x80\\x939). in-hospital mortality 27.3% grade 1, 73.9% grade 2 94.1% grade 3 (p trend < 0.001). apps well calibrated (hosmerâ\\x80\\x93lemeshow test, p = 0.578) predictive accuracy acceptable (aucâ\\x80\\x93roc 0.704, 95% confidence interval 0.599â\\x80\\x930.809). conclusions: apps predicted in-hospital mortality korean ards similar power application western population acceptable predictive accuracy. trial registration: retrospectively registered.',\n",
       " 'host cell protease tmprss2 cleaves influenza (iav) hemagglutinin (ha). several report described resistance tmprss2(â\\x88\\x92/â\\x88\\x92) knock-out (ko) mouse iav iav h2 subtype examined yet. here, demonstrate tmprss2 able cleave h2-ha cell culture tmprss2(â\\x88\\x92/â\\x88\\x92) mouse resistant re-assorted pr8_ha(h2) virus. ko mouse cause major body weight loss death. furthermore, significant increase lung weight replication observed tmprss2(â\\x88\\x92/â\\x88\\x92) mice. finally, minor tissue damage infiltration immune cell detected virus-positive cell found histological section tmprss2(â\\x88\\x92/â\\x88\\x92) mice. summary, study indicate tmprss2 required h2 iav spread pathogenesis mice. finding extend previous result pointing towards central role tmprss2 iav validate host protease potential target antiviral therapy.',\n",
       " 'background: prophylactic vaccine critical preventing hand, foot, mouth (hfmd) primarily caused human enterovirus 71 (ev71) infection. child aged le 5 year especially susceptible ev71 infections. addition development vaccine containing inactivated virus, containing virus-like particle (vlps) repeated antigen constitute effective preventive strategy ev71 infections, safety productivity advantages. developed fusion protein composed truncated peptide ev71 capsid protein, assembled spherical particles. aimed ass immunoprotective effect fusion protein vaccine candidate mouse model ev71 infection. methods: evaluate protective effect fusion protein vaccine candidate, neonatal mouse born immunized female mice, well normal neonatal mouse immunized twice infected ev71 virus. whereafter, survival rates, clinical score load measured. results: high dosage booster immunization helped induce specific serum antibody high neutralization titers, transferred neonatal mice, thereby facilitating effective resistance towards ev71 infection. active immune response observed neonatal mouse generated following immunization. conclusions: present result suggest fusion protein suitable vaccine candidate treating ev71 infections.',\n",
       " 'present work aim design synthesize novel series spiro pyrazole-3,3â\\x80\\x99-oxindoles analogue investigate bioactivity antioxidant antimicrobial agents, well antiproliferative potency selected human cancerous cell line (i.e., breast, mcf-7; colon, hct-116 liver, hepg-2) relative healthy noncancerous control skin fibroblast cell (bj-1). mechanism cytotoxic activity examined immunoassaying level key anti- proapoptotic protein markers. analytical spectral synthesized target congener compatible structures. synthesized compound showed diverse moderate powerful antimicrobial antioxidant activities. result mtt assay revealed seven synthesized compound (i.e., 11a, 11b, 12a, 12b, 13b, 13c 13h) particularly exhibited significant cytotoxicity three cancerous cell line investigation. range ic(50) value obtained 5.7â\\x80\\x9321.3 5.8â\\x80\\x9337.4 âµg/ml hct-116 mcf-7, respectively; 3.8 6.5-fold (based least ic(50) values) significant relative reference chemotherapeutic drug doxorubicin. hepg-2 cells, analogue 13h exhibited highest cytotoxicity ic(50) value 19.2âµg/ml relative doxorubicin (ic(50) = 21.6âµg/ml). observed cytotoxicity specific cancerous cells, evidenced minimal toxicity noncancerous control skin-fibroblast cells. elisa result indicated observed antiproliferative effect examined cancer cell line mediated via engaging activation apoptosis illustrated significant increase proapoptotic protein marker (p53, bax caspase-3) reduction antiapoptotic marker bcl-2. taken together, result present emphasize potential spiro pyrazole-oxindole analogue valuable candidate anticancer agent human cancer cells.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'background: risk factor affecting prognosis acute respiratory distress syndrome (ards) adult investigated. aim identify predictor ards prognosis, clinical, pathophysiological, atypical immunodeficiency. methods: ards retrospectively included. grouped analysed according different oxygenation index grade prognosis, factor influencing prognosis survival examined. adolescent patients, typical immunodeficiency died within 24 h diagnosed ards excluded. predictive value mortality determined cox proportional hazard analysis. results: total, 201 fulfilled berlin definition ards included. severity critical illness enrolment, measured acute physiology chronic evaluation (apache) ii score (p = 0.016), sequential organ failure assessment (sofa) score (p = 0.027), pao(2)/fio(2) (p = 0.000), worsened mild severe ards cases. compared survivors, non-survivors significantly older higher apache ii sofa scores. moreover, significantly lower lymphocyte/neutrophil ratio leukocyte count found among non-survivors survivor (p = 0.008, p = 0.012). moderate positive correlation lymphocyte/neutrophil pao(2)/fio(2) ratio (p = 0.023) observed. predicting 100-day survival ards, area curve (auc) lymphocyte/neutrophil ratio significantly higher pao(2)/fio(2) ratio alone, body mass index (bmi) alone, lymphocyte count alone (p = 0.0062, 0.0001, 0.0154). age (per log(10) years), bmi < 24, sofa score, leukocyte count, lymphocyte/neutrophil ratio independent predictor 28-day mortality ards patients. additionally, ards lymphocyte/neutrophil ratio < 0.0537 increased 28-day mortality rate (p = 0.0283). old age affected 28-day 100-day mortality rate (p = 0.0064,0.0057). conclusions: age (per log(10) years), bmi < 24, sofa score, lymphocytes, lymphocyte/neutrophil ratio independent predictor 100-day mortality ards. lymphocyte/neutrophil ratio may represent potential molecular marker evaluate atypical immunosuppression impairment ards.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'despite leading cause severe respiratory disease, remains licensed respiratory syncytial (rsv) vaccine. neutralizing antibody reduce severity rsv-associated disease, sufficient preventing reinfection. contrast, role memory cd8 cell protecting secondary rsv le established. demonstrated high-magnitude memory cd8 cell efficiently reduced lung titer following rsv infection, induced fatal immunopathology mediated ifn-î³. evaluate ability rsv-specific neutralizing antibody prevent memory cd8 cell-mediated immunopathology, mouse high-magnitude memory cd8 cell response treated neutralizing antibody prior rsv challenge. neutralizing antibody significantly reduced morbidity prevented mortality following rsv challenge compared igg-treated controls. neutralizing antibody restricted early replication, caused substantial reduction memory cd8 cell activation ifn-î³ production, directly resulting survival. contrast, therapeutic neutralizing antibody administration impact morbidity, mortality, ifn-î³ levels, despite significantly reducing lung titers. therefore, pre-existing neutralizing antibody prevent memory cd8 cell-mediated immunopathology following rsv infection. overall, result important implication development future rsv vaccines.',\n",
       " '',\n",
       " 'background: evaluating cirrhotic severity essential individualizing surgical modality hepatocellular carcinoma (hcc). previous proposed non-invasive named cirrhotic severity scoring (css) stage liver cirrhosis. indocyanine green retention rate 15 min (icg-r15) widely used preoperative evaluation hepatic functional reserve; however, whether icg-r15 well correlated cirrhotic severity, especially whether comparable cs predicting cirrhotic severity hcc child-pugh grade liver function remains unknown. methods: overall, 510 hcc child-pugh grade liver function undergoing hepatectomy january 2011 december 2014 retrospectively studied. cirrhotic severity pathologically assessed laennec staging system. correlation icg-r15, css, cirrhotic severity analyzed. furthermore, performance icg-r15 cs predicting posthepatectomy liver failure (phlf) 90-day mortality compared. results: no, mild, moderate, severe cirrhosis accounted 15.9%, 29.2%, 35.9%, 19.0%, respectively, entire cohort. icg-r15 found le 10% 100%, 93.3%, 86.3%, 70.1% no, mild, moderate, severe cirrhosis, respectively. weak correlation icg-r15 pathological severity liver cirrhosis (r = 0.325; p < 0.001). however, cs showed strong correlation pathological severity liver cirrhosis (r = 0.788; p < 0.001). icg-r15 normal range, accuracy cs diagnosing no/mild, moderate, severe cirrhosis 89.1%, 72.8%, 72.1%, respectively. addition, cs superior icg-r15 predicting phlf 90-day mortality. conclusions: cs useful icg-r15 preoperative assessment cirrhotic severity hcc child-pugh grade liver function. study needed validate cs different child-pugh grades.',\n",
       " 'background: safeboosc-iii international randomised clinical trial evaluate effect extremely preterm infant first 3 day life based cerebral near-infrared spectroscopy (nirs) monitoring versus monitoring usual. ensure high quality trial intervention well care, developed multilingual web-based training program train relevant staff test competence. enter under-explored area e-learning, conducted pilot first five module comprising web-based training program test feasibility developing program international trial limited resources. methods: module focus principle practice nirs monitoring. pedagogical idea integrate training certification. one-hundred doctor nurse five neonatal intensive care unit across china, spain denmark invited participate pilot study. upon completion nirs module, participant invited evaluate experience completing online survey. closed-ended question analysed descriptive statistic open-ended question underwent thematic analysis. results: total, 81 100 invited staff member entered training module completed online survey. median time number question pas module 15 minute seven questions, respectively. staff found academic level learning material quiz appropriate (85% 93% staff members, respectively), well agreeing module relevant prepare â\\x80\\x98use nirs deviceâ\\x80\\x99 (90%). thematic analysis revealed issue discrepancy learning material quiz questions, lack clarity, technical issues. conclusion: provide evidence feasibility developing multilingual web-based training program international trial, despite challenge low budget, language barrier possibly difference clinical training staff. exploring integration training certification international trials, positive result motivate developments. trial registration: clinicaltrial.gov, nct03770741. registered 10 december 2018.',\n",
       " 'surveyed 56 ebola center (etcs) united state identified cost incurred since 2014 ($1.76 million/etc) sustainability strategies. etcs reported heavy reliance federal funding. uncertain if, long, etcs maintain capability federal funding expire 2020.',\n",
       " '',\n",
       " '',\n",
       " 'introduction: existing evidence relationship childhood lower respiratory tract infection (lrti) subsequent atopy development controversial. aimed investigate association lrti <5 year development atopy > 2 years. methods: conducted search embase, pubmed, web science, global index medicus. collected included articles. estimated odds ratio 95% confidence interval random effect model. determined factor associated atopy development childhood lrti univariate multivariate meta-regression analyses. recorded systematic review prospero number crd42018116955. results: included 24 studies. relationship lrti <5 year skin prick test-diagnosed-atopy (or = 1.2, [95% ci = 0.7â\\x80\\x932.0]), diagnosed-atopy (or = 0.7, [95% ci = 0.4â\\x80\\x931.3]), atopic dermatitis (or = 1.2, [95% ci = 0.9â\\x80\\x931.6]), hyperreactivity pollen (or = 0.8, [95% ci = 0.3â\\x80\\x932.7]), food (or = 0.8, [95% ci = 0.3â\\x80\\x932.5]), house dust mite (or = 1.1, [95% ci = 0.6â\\x80\\x932.2]). although confirmed study symmetric distribution 23 confounding factor investigated, overall analysis showed relationship childhood lrti < 5 year serum test diagnosed-atopy (or = 2.0, [95% ci = 1.0â\\x80\\x934.1]), allergic rhinoconjunctivitis (or = 1.7, [95% ci = 1.1â\\x80\\x932.9]), hyperreactivity diagnosed serum test food (or = 5.3, [1.7â\\x80\\x9316.7]) inhaled allergen (or = 4.2, [95% ci = 2.1â\\x80\\x938.5]), furred animal (or = 0.6, [95% ci = 0.5â\\x80\\x930.9]). conclusion: result suggest association lrti < 5 year majority category atopy studied work. results, however, confirmed remaining category atopy particularly diagnosed serum tests. real need develop accurate atopy diagnostic tools.',\n",
       " 'flaviviridae family enveloped virus positive-sense single-stranded rna genome. contains many virus threaten human health, japanese encephalitis (jev) yellow fever (yfv) genus flavivirus well hepatitis c genus hepacivirus. cell culture system highly permissive flaviviridae virus useful isolation, propagation, diagnosis, understanding biology, development vaccine antiviral agents. previously, isolated human hepatoma huh-7-derived cell clone, huh7.5.1â\\x80\\x938, highly permissive hepatitis c infection. here, characterized flavivirus huh7.5.1â\\x80\\x938 cell line comparing african green monkey kidney-derived vero cell line, permissive wide spectrum viruses. upon jev, huh7.5.1â\\x80\\x938 cell produced higher amount particle early susceptible virus-induced cell death vero cells. similar outcome obtained cell infected another flavivirus, yfv (17d-204 strain). quantification cellular extracellular rna revealed high jev production huh7.5.1â\\x80\\x938 cell attributed rapid replication kinetics efficient release early infection. plaque assay, huh7.5.1â\\x80\\x938 cell developed jev plaque rapidly vero cells. although yfv plaques, huh7.5.1â\\x80\\x938 cell developed higher number yfv plaque vero cells. sequence analysis cdna encoding antiviral rna helicase, rig-i, showed huh7.5.1â\\x80\\x938 cell expressed full-length rig-i mrna known dominant-negative missense mutation variant without mutation. however, latter mrna lacked exon 5/6â\\x88\\x9212, indicating functional loss rig-i cells. characteristic huh7.5.1â\\x80\\x938 cell line helpful flavivirus detection, titration, propagation.',\n",
       " '',\n",
       " 'background: intellivent-asvâ® (i-asv) closed-loop ventilation mode automatically control ventilation settings. although number study reported usefulness i-asv, clinical situation may useful yet clarified. aimed report initial 3 year experience i-asv, particularly clinical condition technical organizational factor associated use. furthermore, evaluated usefulness i-asv determined predictive factor successful management i-asv. methods: single-center, retrospective observational included ventilated hamilton g5â® ventilator (hamilton medical ag, rhã¤zã¼ns, switzerland) january 2016 december 2018. categorized â\\x80\\x9ci-asv successâ\\x80\\x9d group â\\x80\\x9ci-asv failureâ\\x80\\x9d group (those receiving mechanical ventilation i-asv along mode). multivariate analysis performed identify factor associated successful i-asv management. results: 189 patients, 135 (71.4%) categorized i-asv success group. i-asv success group, reason icu admission included post-elective surgery (94.1%), post-emergent surgery (81.5%), medical reason (55.6%). i-asv failure associated low p/f ratio (278 vs. 167, p = 0.0003) high acute physiology chronic evaluation (apache) ii score (21 vs. 26, p < 0.0001). main reason i-asv included strong inspiratory effort asynchrony. apache ii score independent predictive factor successful management i-asv, odds ratio 0.92 (95% confidential interval 0.87â\\x80\\x930.96, p = 0.0006). area receiver operating curve apache ii score 0.722 (cut-off: 24). conclusions: study, found 71.4% fully mechanically ventilated could managed successfully i-asv. apache ii score independent factor could help predict successful management i-asv. improve i-asv management, necessary focus patient-ventilator interactions.',\n",
       " 'background: mechanical ventilation (mv), compared spontaneous breathing (sb), found increase abdominal edema inflammation experimental sepsis. hypothesis primary acute respiratory distress syndrome (ards) mv would enhance inflammation edema abdomen. methods: thirteen piglet randomized two group (sb mv) induction ards lung lavage 1 h injurious ventilation. 1. sb: continuous positive airway pressure 15 cmh(2)o, fraction inspired oxygen (fio(2)) 0.5 respiratory rate (rr) maintained 40 cycle min(â\\x88\\x92 1) titrating remifentanil infusion. 2. mv: volume control, tidal volume 6 ml kg(â\\x88\\x92 1), positive end-expiratory pressure 15 cmh(2)o, rr 40 cycle min(â\\x88\\x92 1), fio(2) 0.5. main outcomes: abdominal edema, assessed tissue histopathology wet-dry weight; abdominal inflammation, assessed cytokine concentration tissues, blood ascites, tissue histopathology. results: group significant difference hemodynamic respiratory parameters. moreover, edema inflammation abdominal organ similar. however, blood il6 increased mv group vascular bed (p < 0.001). addition, tnfî± ratio blood increased lung mv group (+ 26% â± 3) decreased sb group (â\\x88\\x92 17% â± 3). conclusions: difference mv sb group abdominal edema inflammation. however, systemic increase il6 tnfî± increase lung suggest mv, model, harmful lungs.',\n",
       " 'background: leptospirosis potentially fatal zoonosis. cause wide range symptoms, diffuse alveolar haemorrhage occurs minority case carry mortality 70%. may present severe acute respiratory failure. differential diagnosis diffuse alveolar haemorrhage broad whereas prompt diagnosis lifesaving. presentation: 20-year-old fit well trout farm worker presented 3-day history malaise, fevers, diarrhoea, vomiting jaundice. developed haemoptysis, severe headaches, neck stiffness photophobia emergency admission. anaemic thrombocytopenic. anuric acute kidney injury (urea 32, creat 507) required immediate haemofiltration. view progressive respiratory failure four-quadrant lung infiltrates imaging, given broad spectrum antibiotic pulsed methylprednisolone empirically, vasculitic pulmonary-renal presentation. intubated within 48 h admission. despite attempted protective ventilatory management, remained hypoxaemic developed pneumomediastinum. retrieved specialist cardiorespiratory intensive care unit femoro-femoral mobile vv-ecmo. three day admission, result showed positive leptospira igm real-time pcr. serial bronchoscopies showed old fresh clots, classical progressive late red tinge returned lavage fluid. eight days, vv-ecmo weaned, extubated three day later, made full recovery. 9 month follow-up, clinically better, resolution ct scan finding near normal lung function, albeit low normal gas transfer. conclusions: leptospirosis rare important differential considered diffuse alveolar haemorrhage presenting icu, especially young males. thorough history occupational recreational risk factor may offer diagnostic clue. recover fully antibiotics. however, resulting acute severe respiratory failure ensue. situation, early consideration respiratory ecmo support offer time clearance endobronchial clot, parenchymal recovery, prevention ventilator-induced lung injury. steroid clear evidence may used avoid delay treating suspected vasculitic autoimmune cause diffuse alveolar haemorrhage.',\n",
       " 'sweden long tradition monitoring occurrence antibiotic resistant bacteria animal humans, currently organised harmonized monitoring carriage enterobacteriaceae producing extended-spectrum beta-lactamase (esbl), plasmid-mediated ampc beta-lactamase (pampc), methicillin-resistant coagulase positive staphylococci e.g. methicillin-resistant staphylococcus aureus (mrsa) methicillin-resistant staphylococcus pseudintermedius (mrsp) dogs. aim current therefore determine prevalence esbl/pampc producing enterobacteriaceae methicillin-resistant coagulase positive staphylococci healthy dog sweden, phenotypically genotypically characterize identified isolates. 0.9% (95% confident interval 0.3â\\x80\\x932.7%) dog (n = 325) carried multi-resistant esbl-producing escherichia coli, methicillin-resistant coagulase positive staphylococci could detected. conclusion, occurrence multi-drug resistant bacteria remains rare among healthy dog sweden. addition, esbl-producing e. coli identified showed genetic characteristic related reported humans.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '1 march 2020, amendment german protection act introduced act protect measles strengthen vaccination prevention (measles protection act) entered force. reason change number individual measles significantly increased recent years. protect public health, measles protection act implemented regulation requiring person certain institution must either adequate protection measles immunity measles. article current legal situation regard care facility presented.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'background: hydrops fetalis well abdominal compartment syndrome (acs) condition associated high mortality rates. rare immature gastric teratoma causing fetal hydrops subsequent ac presented. related pathophysiologic mechanism discussed, importance timely recognition appropriate intervention highlighted. presentation: male born preterm, weighing 3.9 kg., cesarean section. prior prenatal ultrasound normal, scan done delivery finding indicating polyhydramnios, fetal ascites, meconium peritonitis. upon delivery, respiratory distress, anasarca massively distended abdomen. resuscitation measures, ventilatory support, instituted. imaging study showed ascites well large, complex intra-abdominal lesion calcifications. succeeding hours, anuria persisted, anasarca worsened, abdomen became distended, inotrope requirement increased. occurrence acs, presumed retroperitoneal teratoma, therefore considered. laparotomy done 28th hour life, en bloc excision massive tumor attached section greater curvature stomach. passage urine occurred intra-operatively, soon weaned inotropes ventilator support. histopathologic immature gastric teratoma. chemotherapy given, patientâ\\x80\\x99s serum afp normal level 15 month following surgery. conclusion: presence massive intra-abdominal lesion pathophysiologic continuum hydrops fetalis neonatal acs. early recognition association enable appropriate expectant management similarly affected neonates, emergent decompression laparotomy.',\n",
       " 'background: acute hypoxemic respiratory failure leading cause intensive care unit admission associated high mortality. noninvasive oxygenation strategy high-flow nasal cannula, standard oxygen therapy, noninvasive ventilation (delivered either face mask helmet interface) widely available intervention applied patients. remains unclear intervention effective decreasing rate invasive mechanical ventilation mortality. primary objective network meta-analysis summarize evidence compare effect noninvasive oxygenation strategy mortality need invasive mechanical ventilation acute hypoxemic respiratory failure. methods: search key database randomized controlled trial assessing effect noninvasive oxygenation strategy adult acute hypoxemic respiratory failure. exclude study primary focus either acute exacerbation chronic obstructive pulmonary cardiogenic pulmonary edema. primary outcome all-cause mortality (longest available 90 days). secondary outcome receipt invasive mechanical ventilation (longest available 30 days). ass risk bias outcome cochrane risk bias tool. bayesian network meta-analyses conducted obtain pooled estimate head-to-head comparisons. report pairwise network meta-analysis effect estimate risk ratio 95% credible intervals. subgroup analysis conducted examining key population immunocompromised hosts. sensitivity analysis conducted excluding study high risk bias different etiology acute respiratory failure. ass certainty effect estimate grade methodology. discussion: help guide clinical decision-making caring adult acute hypoxemic respiratory failure improve understanding limitation available literature assessing noninvasive oxygenation strategy acute hypoxemic respiratory failure. systematic review registration: prospero crd42019121755',\n",
       " 'aim: frequent cause lower respiratory tract infant bronchiolitis. agreement upper limit age bronchiolitis. aim identify clinical difference infant hospitalized bronchiolitis 0â\\x80\\x936 month 6â\\x80\\x9312 month age. secondary aim establish whether difference term recurrent wheezing 12, 24, 36 month follow-up. methods: retrospectively analyzed clinical virological record 824 infant hospitalized bronchiolitis 11 consecutive epidemic seasons. infant admission hospital nasopharyngeal washing collected, clinical severity assessed clinical extracted structured questionnaire. 12â\\x80\\x9324â\\x80\\x9336 month discharge, parent interviewed seeking information recurrent wheezing. results: total 773 infant (group1) â\\x89¤6 month age, 51 >6 month (group 2). difference family history atopy passive smoking exposure observed two groups. respiratory syncyzial detected frequently group 1 human bocavirus group 2. clinical severity score (p = 0.011) use intravenous fluid (p = 0.0001) higher group 1 respect group 2 infants. 36 month follow-up 163/106 (39.4%) group 1 9/9 group 2 infant experienced recurrent wheezing (p = 0.149). conclusion: demonstrated 0-6 month old infant bronchiolitis differs > 6 month bronchiolitis.',\n",
       " 'german university pathology affected corona pandemic respective measures. survey among 36 university pathology conducted (return rate 83%) evaluated; allows ass current situation show significant restriction diagnostic research performance high willingness perform coviid autopsy',\n",
       " '',\n",
       " 'rural amenity migration, relocation quality life purpose opposed monetary enhancement, occurring decade particularly pronounced american west phenomenon peaked 1990s. researcher illustrated place attractive migrant others certain regional amenity hold considerable influence migrant relocate. increased migration level typically increased economic growth indicators, making amenity migration attractive rural development strategy. comprehensive econometric analysis focused amenity migration american west lacking. address this, conducted econometric analysis attribute influenced migration rural western county 1980 2010. 20 potential amenity supply category collated 356 rural county 11 western states, focus public lands. descriptive statistic ols regression estimated interpreted. traditional amenity climate, water area, regional access highly associated migration levels, designated natural amenity wilderness national monument influential public land migration rural western counties. farming oil gas dependency negatively associated migration levels. increasing amount protected areas, branding campaign based natural amenities, critical development strategy rural communities.',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " '',\n",
       " 'despite significant progress research prevention psychological, behavioral, problems, translation knowledge population-wide benefit remains limited. paper review state americaâ\\x80\\x99s child families, highlighting influence stressful contextual social condition child family well-being concentration disadvantage numerous neighborhood community throughout nation. briefly review progress made pinpointing policy reduce stressful contextual condition poverty, discrimination, marketing unhealthful food substances. describes numerous family school intervention proven benefit preventing psychological behavioral problem diverse tobacco, alcohol, drug use; depression; antisocial behavior; academic failure; obesity prevention; early childbearing. argue progress translating existing knowledge widespread benefit require nationwide effort intervene comprehensively neighborhood community concentrated disadvantage. present strategic plan effort could organized. first step organizing would creation broad diverse coalition organization concerned advancing public well-being. coalition could increase public support policy needed focus disadvantaged area research needed incrementally improve ability help areas.',\n",
       " '',\n",
       " 'immune memory defining feature acquired immune system, activation innate immune system enhanced responsiveness subsequent triggers. process termed â\\x80\\x98trained immunityâ\\x80\\x99, de facto innate immune memory. research past decade pointed broad benefit trained immunity host defence suggested potentially detrimental outcome immune-mediated chronic inflammatory diseases. define â\\x80\\x98trained immunityâ\\x80\\x99 biological process discus innate stimulus epigenetic metabolic reprogramming event shape induction trained immunity.',\n",
       " 'background: reduced response hepatitis b vaccine associated aging, confounding comorbid conditions, well inadvertent subcutaneous (sc) inoculation. hypothesized antibody cell-mediated immune response (t-cmi) elderly adult vaccine intended intramuscular (im) administration would attenuated deposited sc fat, independent confounding conditions. results: fifty-two healthy, community dwelling elderly adult (65â\\x80\\x9382 years), seronegative hbv, enrolled senieur protocol strictly healthy population. senior randomized receive licensed alum-adjuvanted recombinant hbv vaccine either sc im, inoculum site verified imaging. response rates, defined hepatitis b surface antibody (hbsab) â\\x89¥10 iu/l, significantly lower elderly young adults, group 12, healthy, 21â\\x80\\x9334-year-old volunteers. moreover, elderly participant received vaccine im significantly likely responder immunized sc (54% versus 16%, p = 0.008). low seroconversion rate im group progressively declined increasing age, responder significantly lower hbsab titer limited isotype responses. moreover, t-cmi (proliferation cytokine production) significantly reduced percentage responder intensity response th1 th2 subset elderly. conclusions: demonstrate blunted immunogenicity sc inoculation measured peak titer response rates. further, qualitative quantitative deficit b- t-cmi response primary alum adjuvanted protein antigen persisted even strictly healthy elderly population verified im placement compared younger populations. clinical trial registration: clinicaltrials.gov, nct04162223. registered 14 november 2019. retrospectively registered.',\n",
       " 'introduction: influenza hospitalized intensive care unit (icu) respiratory failure associated 25% mortality, despite timely oseltamivir treatment. systematic review randomized controlled trial (rcts) conducted evaluate efficacy safety alternative neuraminidase inhibitor (nai) regimen compared standard care hospitalized h1n1, h3n2, b influenza. methods: cochrane collaboration searching method followed cochrane library, pubmed, web science database (2009â\\x80\\x932019). eligibility criterion rcts comparing different regimen nais hospitalized (at least 1 year old) clinically diagnosed influenza (h1n1, h3n2, b). pre-defined endpoint time clinical resolution (ttcr), overall mortality, hospital discharge, clearance, drug-related adverse event (aes), serious adverse events. results: seven trial (1579 patients) included. two trial compared two regimen oral oseltamivir therapy, trial compared two regimen intravenous zanamivir therapy v oral oseltamivir therapy. four trial focused intravenous peramivir therapy: two trial compared two different regimen two trial compared two different regimen v oral oseltamivir therapy. overall, different regimen well tolerated, significant difference aes; nonetheless non-significant difference reported among different regimen regarding ttcr, mortality, clearance. conclusion: higher compared standard dos nais systemic peramivir therapy compared oral oseltamivir therapy demonstrate benefit. electronic supplementary material: online version article (10.1007/s12325-020-01347-5) contains supplementary material, available authorized users.',\n",
       " '',\n",
       " '',\n",
       " 'lesson florence nightingale relevant today 150 year ago. learn nurse leader follow lead embrace importance nurturing highly motivated nurse critical thinkers.',\n",
       " 'objective: ass efficacy safety ultra-low dose 0.005% estriol vaginal gel woman breast cancer receiving nonsteroidal aromatase inhibitor (nsais) experiencing treatment-related vulvovaginal symptom signs. methods: woman hormone receptor-positive early breast cancer receiving nsais randomized either estriol vaginal gel placebo 12 weeks. vaginal maturation, vaginal ph, total individual score symptom sign vulvovaginal atrophy assessed baseline week 3 12; sexual functioning evaluated female sexual functioning index (fsfi) questionnaire, well circulating estrogens, follicle-stimulating hormone (fsh) luteinizing hormone (lh). results: sixty-one woman mean age 59 year included: 50 received 0.005% estriol vaginal gel 11 received placebo. active significantly improved maturation value ph, vaginal dryness global score symptom signs. active increased total fsfi score fsfi domains, exception pain. small oscillation observed fsh lh, remained within postmenopausal range. estriol level increased initially normalized week 12, estradiol estrone remained mostly undetectable throughout study. conclusions: ultra-low dose 0.005% estriol vaginal gel showed efficacy improving symptom sign vulvovaginal atrophy. results, together minimal oscillation hormonal level throughout treatment, support use ultra-low dose 0.005% estriol vaginal gel option vulvovaginal atrophy woman breast cancer receiving nsais indication vaginal estrogens.',\n",
       " 'series report, review 2 among first participate henry ford telemedicine home-based cardiac rehabilitation (tm-hbcr) program. barrier full participation facility-based cardiac rehabilitation (cr) program due return work access transportation. however, willing able participate tm-hbcr program. discussion: two case discussed herein example individual likely would fully participated cr option available facility-based program. hbcr option patients, address several barrier known limit participation facility-based cr individuals. summary: technology made possible provide key component facility-based cr program tm-hbcr model secure connection via personal mobile device.',\n",
       " 'objectives: evaluate safety, pharmacokinetics, preliminary efficacy nt-814, dual neurokinin 1,3 antagonist, postmenopausal woman vasomotor symptom (hot flashes). methods: completed double-blind, randomized, placebo-controlled trial three u clinical research unit 76 postmenopausal woman moderate/severe hot flashes. participant randomized 14 day once-daily nt-814 placebo within four sequential dose cohorts; 50, 100, 150, 300 mg. participant completed diary hot flash frequency severity waking due night sweat (baseline) treatment. results: prespecified efficacy parameter (24-h hot flash frequency severity, frequency waking due night sweats) decreased group (including placebo). mean reduction baseline week 2 moderate/severe hot flash frequency 37% placebo group and, respectively, 24% (p = 0.048 v placebo), 59% (p = 0.155), 84% (p < 0.001) 66% (p = 0.022) 50 mg, 100 mg, 150 mg, 300 mg nt-814 groups; waking due night sweat reduction 20% (p = 0.059), 55% (p = 0.135), 81% (p < 0.001), 63% (p = 0.031) nt-814 group 32% placebo group. improvement nt-814 â\\x89¥150 mg evident first week treatment. common treatment-related adverse event mild somnolence headache, frequently 300 mg group. safety monitoring identified concerns. conclusions: once-daily nt-814 (â\\x89¥150 mg/d) resulted rapid, marked improvement hot flash waking due night sweats. safety concern identified. dos 300 mg well tolerated.',\n",
       " '',\n",
       " 'objective: menopausal transition contributes sarcopenia, effect hormone therapy (ht) sarcopenia postmenopausal woman determined. assessed effect ht sarcopenia postmenopausal women. methods: present included 4,254 postmenopausal woman participated korea national nutritional examination survey 2008 2011. appendicular skeletal muscle mass divided weight (asm/wt) prevalence sarcopenia analyzed group woman stratified duration ht use. results: asm/wt higher prevalence sarcopenia lower participant history prolonged (â\\x89¥13 mo) ht use participant shorter duration ht use ht use. adjusting multiple confounding factors, prolonged use ht remained significantly associated estimated mean asm/wt prevalence sarcopenia (odds ratio: 0.60; 95% confidence interval: 0.41-0.88; p = 0.01). addition, prevalence sarcopenia linearly associated history hypertension, duration hypertension, physical activity, duration ht use. subgroup analysis showed association duration ht use prevalence sarcopenia maintained younger (<65 old) leaner (body mass index <25 kg/m(2)) postmenopausal women. conclusions: present showed prolonged use ht associated high muscle mass low prevalence sarcopenia postmenopausal women.',\n",
       " '',\n",
       " '',\n",
       " 'purpose: ae37 gp2 her2 derived peptide vaccines. ae37 primarily elicits cd4+ response gp2 elicits cd8+ response her2 antigen. peptide tested randomized trial ass ability prevent recurrence her2 expressing breast cancer patients. primary analysis found difference 5-year overall disease-free survival (dfs) possible benefit subgroups. here, present final landmark analysis. methods: 4-arm, prospective, randomized, single-blinded, multi-center phase ii trial, disease-free node positive high-risk node negative breast cancer enrolled standard care therapy. six monthly inoculation vaccine (vg) vs. control (cg) given primary vaccine series 4 booster 6-month intervals. demographic, safety, immunologic, dfs evaluated. results: 456 enrolled; 154 vg 147 cg ae37, 89 vg 91 cg gp2. ae37 arm difference dfs compared cg, pre-specified exploratory subgroup analysis showed trend towards benefit advanced stage (p = 0.132, hr 0.573 ci 0.275â\\x80\\x931.193), her2 under-expression (p = 0.181, hr 0.756 ci 0.499â\\x80\\x931.145), triple-negative breast cancer (p = 0.266, hr 0.443 ci 0.114â\\x80\\x931.717). her2 under-expression advanced stage, significant benefit vg (p = 0.039, hr 0.375 ci 0.142â\\x80\\x930.988) compared cg. gp2 arm significant difference dfs compared cg, subgroup analysis, her2 positive recurrence trend toward improved dfs (p = 0.052) vg compared cg. conclusions: phase ii trial reveals ae37 gp2 safe possibly associated improved clinical outcome dfs certain subgroup breast cancer patients. findings, evaluation warranted ae37 gp2 vaccine given combination and/or separately specific subset breast cancer based biology.',\n",
       " 'vitamin essential nutrient key cofactor enzyme regulate cellular metabolism, activate immune system. recent study vitamin b1 (v(b)(1)) vitamin c (vc) inhibit mycobacterium tuberculosis growth, precise mechanism still well understood. present study, used rna-sequencing (rna-seq), liquid chromatography coupled mass spectrometry (lc-ms) single-molecule real-time (smrt) sequencing analyze transcriptional, metabolic methylation profile mycobacterium bovis bcg treated v(b)(1) vc. result that, vitamin treatment, variant metabolite mainly clustered pathway related amino acid metabolism. vitamin significantly up-regulated gene encoding cysteine synthase a. additionally, bcg treated v(c) showed m4c modifications. gene harboring methylation up-regulated, suggesting m4c methylation promote gene transcription extent. overall, contributes understanding effect v(b)(1) v(c), suggests vitamin constitute potential anti-tuberculosis drugs.',\n",
       " 'autophagy dependent upon lysosomes, fuse autophagosome complete autophagic process whose acidic interior permit activity intraluminal degradative enzymes. chloroquine (cq) bafilomycin a1 (bafa) cause alkalinisation lumen thus impair lysosomal function, although distinct mechanisms. cq diffuses lysosome undergoes protonation, bafa inhibits ability vacuolar type h(+)-atpase (v-atpase) transfer proton lysosome. present study, examine impact cq bafa activity mammalian target rapamycin complex 1 (mtorc1), inhibition early step promoting autophagy. find compound inhibits mtorc1 signalling, without affecting level protein component mtorc1 signalling pathway. furthermore, effect related agentsâ\\x80\\x99 capacity inhibit autophagy reduction amino acid supply lysosomal proteolysis. instead, indicate reduction mtorc1 signalling appears due accumulation lysosomal storage material. however, difference response agents, instance, ability up-regulate direct target transcription factor eb (tfeb), substrate mtorc1 drive transcription many lysosomal autophagy-related genes. nonetheless, imply widely used agent alkalinise intralysosomal ph mimetics acute lysosomal storage disorder (lsds) emphasise importance considering cq bafa mtorc1 signalling interpreting effect agent cellular physiology.',\n",
       " 'background: intensive care unit (icus) daunting environment physiotherapy (pt) student performing clinical rotations. prepare student environment, newly developed, evidence-based e-learning module designed implemented undergraduate curriculum. aim investigate whether e-learning feasible preparing pt student clinical work complex icu environments, perceived student experts. methods: mixed method proof concept undertaken. participant final-year student international curriculum, expert didactic clinical fields. e-learning module consisting 7 separate chapter based latest scientific evidence clinical expertise developed, piloted incorporated undergraduate curriculum compulsory course completed prior clinical icu rotations. collected 3 focus group meeting 5 semi-structured interviews; meeting interview audio recorded, transcribed verbatim analyzed. results: sample comprised 14 student 5 experts. thematic analysis revealed three themes: expected competency pt student icu, feeling prepared icu clinical work dealing local variety. e-learning module enabled student anticipate clinical situation pt task icu. higher level clinical reasoning skills, handling line wire dealing out-of-textbook situation could achieved e-learning module alone. conclusions: e-learning module sufficiently prepare pt student clinical task icu, long integrated with, closely connected to, studentsâ\\x80\\x99 clinical placement.',\n",
       " \"critical illness, homeostatic correction representing culmination hundred million year evolution, modulated activated glucocorticoid receptor alpha (grî±) associated enormous bioenergetic metabolic cost. appreciation homeostatic correction work evolved provides conceptual framework understand complex pathobiology critical illness. emerging literature place activated grî± center phase development resolution, activation re-enforcement innate immunity, downregulation pro-inflammatory transcription factors, restoration anatomy function. time critically ill necessitate vital organ support survival, reached near exhaustion exhaustion neuroendocrine homeostatic compensation, cell bio-energetic adaptation functions, reserve vital micronutrients. review critical illness-related corticosteroid insufficiency, mitochondrial dysfunction/damage, hypovitaminosis collectively interact accelerate anti-homeostatic active process natural selection. importantly, allostatic overload imposed homeostatic correction impact negatively acute long-term morbidity mortality. since bioenergetic metabolic reserve support homeostatic correction time-limited, early intervention directed increasing grî± mitochondrion number function. present understanding activated gc-grî±'s role immunomodulation resolution taken account re-evaluating administer glucocorticoid co-interventions improve cellular responsiveness. activated grî± interdependence functional mitochondrion three vitamin reserve (b1, c, d) provides rationale co-interventions include prolonged glucocorticoid association rapid correction hypovitaminosis.\",\n",
       " '',\n",
       " '',\n",
       " 'systemic immune checkpoint inhibitor (ici) revolutionized hematological oncological disease recent years. mechanism action hinge enhancing natural ability immune system eliminate malignant cells. important substance arena include inhibitor pdâ\\x80\\x911, pd-l1 ctlaâ\\x80\\x914. consequence, spectrum treatment-associated adverse reaction shifting away classical cytotoxic effect (e.g. pancytopenia polyneuropathy) towards novel entity immune-mediated complex diseases. so-called immune-related adverse event (iraes) involve organ system mimic known classical autoimmune conditions. timely recognition iraes key rapid initiation suitable especially challenging clinical routine requires intensive interdisciplinary management. nephrologists particularly confronted kind problem due highly interdisciplinary nature work. article summarizes broad spectrum currently known renal frequently occuring non-renal form iraes aim prime reader diagnostic therapeutic options.',\n",
       " 'despite similar structure, functioning, size, pathogen enjoy different, usually well-defined way life. occupy host day (influenza), week (measles), even lifelong (hcv), manifest acute chronic infections. various transmission route (airborne, via direct physical contact, etc.), degree infectiousness (referring load required transmission), antigenic variation/immune escape virulence define aspect pathogenic lifestyles. survive, pathogen must infect hosts; success determines fitness. happens certain likelihood contact hosts, contact mediated vectors. besides structural aspect host-contact network, three parameter appear key: contact rate infectiousness contact, encode mode transmission, third immunity susceptible hosts. grounds, said reproductive success pathogens? biological question addressed paper. answer extends earlier result author make explicit connection another basic work evolution pathogens. mathematical framework presented model intra- inter-host dynamic minimalistic unified fashion covering broad spectrum pathogens, cause flu-like infections, childhood diseases, sexually transmitted infections. pathogen turn local maximum numerically simulated fitness landscapes. model involve differential integral equations, agent-based simulation, networks, probability.',\n",
       " '',\n",
       " 'introduction: emergency airway management critically ill child emergency department (ed) associated risk intubation-related desaturation, minimized apneic oxygenation. evaluated use apneic oxygenation pediatric ed reported quality improvement initiative incorporate apneic oxygenation routine standard care rapid sequence intubation (rsis). methods: baseline period june 2016 april 2017 highlighted practice gaps. quality improvement intervention subsequently developed implemented care bundle consisting pre-intubation checklist, placing reminder additional oxygen source resuscitation bays, incorporating responsibility airway doctor airway nurse (copiloting), education airway workshop simulation training doctor nurses, well enhancing documentation intubation process. monitored post-intervention observation period may 2017 april 2018 effectiveness care bundle. results: apneic oxygenation performed 22 rsis baseline period. among 25 rsis post-intervention observation period, provider performed apneic oxygenation 17 (68%) cases. significant difference utilization apneic oxygenation among emergency physician pediatric anesthetist performing rsis pediatric ed. conclusions: successfully implemented care bundle targeted incorporating apneic oxygenation routine standard care emergency intubation performed ed. could adopted pediatric ed improve airway management critically ill children.',\n",
       " 'introduction: bedside nurse (rn) presence family-centered round (fcr) enhances communication collaboration safer, higher-quality care.1â\\x80\\x933 institution, rn participation fcr variable lower desired. content discussed bedside round inconsistent, contributing irregular achievement established fcr checklist items. methods: scheduling tool prioritization algorithm set time allotment/patient, implemented schedule-based family-centered round (sbfcr) pediatric acute care unit. primary outcome metric included rn attendance participation. tracked rounding checklist compliance, parent presence rounds, adherence schedule. survey provided information provider family satisfaction. perceived impact teaching balancing measure structure discouraged spending extra time cost team tardiness next patient. results: created schedule 95% workweek days, rounding order kept 93%. mean rn attendance increased 69% 87% participation increased 48% 80% sbfcr (p < 0.001 each). fcr checklist compliance increased 60% 94% (p < 0.001). family felt informed able attend; presence round rose 66% 85% (p < 0.001). faculty trainee felt sbfcr efficient observed increased teaching sbfcr. conclusions: sbfcr provides organizational framework increased rn attendance participation well greater family presence rounds. system elevated provider satisfaction rounding without degrading perceived educational experience.',\n",
       " 'introduction: despite participating solution safety (sps) childrenâ\\x80\\x99s hospital attempted implementation sps hospital-acquired pressure injury (hapis) prevention bundle, hospital remained hapi rate 3 time mean sps participating childrenâ\\x80\\x99s hospitals. performance led launch enterprise-wide hapi reduction initiative organization. purpose article describe improvement initiative, key drivers, resulting decrease sps-reportable hapi rate. methods: designed hospital-wide hapi reduction initiative action grouped 3 key driver areas: standardization, transparency, accountability. paused individual hospital unit-based hapi reduction initiatives. calculated rate sps-reportable hapis per 1,000 day pre- postimplementation phase compared mean rate 2-sided test assuming unequal variances. results: mean sps-reportable hapi rate preimplementation phase 0.3489, postimplementation phase 0.0609. difference rate statistically significant (p < 0.00032). equates 82.5% reduction hapi rate. conclusions: institutional pause retooled initiative reduce hapi key driver area standardization, transparency, accountability statistically significant reduction organizationâ\\x80\\x99s sps-reportable hapi rate.',\n",
       " 'introduction: virtual reality (vr) emerging tool anxiety fear reduction pediatric patients. vr use facilitated certified child life specialist (ccls) pediatric hospitals. primary aim retrospectively review safety vr analyzing adverse event utilization vr ccls supervision. secondary objective characterize efficacy vr enhancing cooperation, describe integration vr child life services, identify intervention accompanied vr. methods: stanford chariot program developed vr applications, customized vr interfaces, head straps, distributed ccls. chart review analyzed vr utilization ccls notes. inclusion criterion age 6 18-years-old received child life intervention. results: june 2017 july 2018, 31 ccls saw 8,098 patients, 3,696 met age criterion pre- post-intervention cooperation data. two hundred thirteen received vr accompanying intervention, 34 received vr. adverse event rare, included increased anxiety (3.8%, n=8), dizziness (0.5%, n=1), nausea (0.5%, n=1). likely cooperative receiving vr (99.5%, n=212) compared pre-intervention (96.7%, n=206, p=0.041). vr use common perioperative setting (60%, n=128), followed outpatient clinic (15%, n=32). conclusion: vr safe pediatric appropriate hardware, software, selection. side effect rare self-limited. vr appears associated improvement cooperation.',\n",
       " 'introduction: pediplace, busy pediatric not-for-profit clinic lewisville, tex., struggle prolonged wait times. quality improvement (qi) project aimed reduce appointment length improve experience. methods: pediplace introduced 3 interventions: improved tracking measure timing electronic record interface, elimination script repetition medical assistant providers, art kits. results: 2,000 survey indicated satisfied; percentage negative survey comment decreased 20% 2017 2018 10% 2019. overall rating clinic rose 3.8 4.75 (on scale 1â\\x80\\x935) qi intervention well. number checked declined 49 error octoberâ\\x80\\x93december 2018 25 error januaryâ\\x80\\x93march 2019, indicating part initiative initially successful. however, subsequent month experienced higher error rates. analysis 20,000 appointment june 2018 july 2019 showed appointment length change interventions. conclusions: difference appointment length hispanic/latino patients, encouraging finding suggests pediplace provider effective bilingual communicators. furthermore, anecdotal evidence indicated art kit positively received. intervention appeared improve experience impact appointment length. pediplace plan continue qi initiative future.',\n",
       " 'introduction: anaphylaxis potentially life-threatening allergic reaction. common allergy clinic procedures, oral food challenge subcutaneous immunotherapy, carry risk anaphylaxis, epinephrine. goal develop standardized process management documentation allergic reaction occur tertiary care pediatric allergy clinic. methods: single institution quality improvement pilot study. multidisciplinary team allergy department designed, implemented, studied use standardized form documentation allergic reaction within clinic. results: standardized form developed based evidence-based guideline management allergic reaction included space documentation. clinic provider staff approved form. year introduction, reached 100% adherence use form visit experienced severe allergic reaction requiring epinephrine. two required transfer emergency room; quality improvement form utilized case document assist hand-off emergency room personnel transfer. conclusions: successfully implemented standardized form documentation anaphylaxis within allergy clinic. next step focus integrating form electronic medical record, determining compliance evidence-based management anaphylaxis, formally assessing use form handoff tool event transfer.',\n",
       " 'introduction: meaningful conversation diagnostic error require safety culture clinician comfortable discussing error openly. however, clinician comfort discussing diagnostic error publicly barrier discussion remain unexplored. compared cliniciansâ\\x80\\x99 comfort discussing diagnostic error medical error identified barrier open discussion. methods: pediatric clinician 4 hospital surveyed may june 2018. survey assessed respondentsâ\\x80\\x99 comfort discussing medical error (with varying degree system versus individual clinician responsibility) morbidity mortality conference privately peers. respondent reported significant barrier discussing diagnostic error publicly. poststratification weighting accounted nonresponse bias; benjaminiâ\\x80\\x93hochberg adjustment applied control false discovery (significance set p < 0.018). results: clinician (n = 838; response rate 22.6%) significantly le comfortable discussing error type morbidity mortality conference privately (p < 0.004) significantly le comfortable discussing diagnostic error compared medical error (p < 0.018). comfort differ clinician type year practice; clinician institution significantly le comfortable discussing diagnostic error compared peer institutions. frequently cited barrier discussing diagnostic error publicly included feeling like bad clinician, loss reputation, peer judgment knowledge base decision-making. conclusions: clinician uncomfortable discussing diagnostic error type medical errors. frequent barrier involve public perception clinical performance. addressing aspect safety culture may improve clinician participation effort reduce harm diagnostic errors.',\n",
       " 'introduction: risk light siren use emergency medical service well documented. critical care transport team performs 1,800 interfacility nonemergency medical service transport annually dense urban environment. historically, utilized light siren navigate traffic patterns. use exceeded industry standards. quality improvement project undertaken decrease use light sirens. methods/results: baseline use light siren 2011 76% en route 73% return facility. revised internal policy guiding appropriate usage light sirens. 2012, without improvement usage, use justification process implemented. 2013, use light siren still high en route, decreased 53% return trip. 2014, added accountability measure requiring justification, subsequent drop 2015 14% en route 13% return. following 3 years, transport team sustained light siren use 20% below. conclusions: quality improvement initiative impacted team behavior decreased use light siren 5 years, sustained improvement 20%. improvement accomplished ongoing evaluation, education, gathering, open communication. negative impact outcome time. light siren continue used indicated.',\n",
       " 'introduction: direct hospital admission child without evaluation emergency department (ed) common, guideline exist maximize safety assessing stability. report describes novel approach support safety. methods: interdisciplinary childrenâ\\x80\\x99s hospital team developed brief ed-based evaluation process called ed rapid assessment intended inpatient disposition (ed rapid). entail brief evaluation vital sign clinical stability ed attending physician nurse. child deemed stable admitted inpatient wards, whereas requiring immediate intervention undergo full ed evaluation disposition. assessed outcome child evaluated process march 2013 february 2015. results: period, identified 715 undergoing ed rapid evaluation. these, directly admitted 691 (96.4%) hospital ward ed rapid evaluation; median ed time 4.0 minutes. transitioned 24 (3.4%) full ed evaluation, 14 (2.0%) ward bed unavailable, 10 (1.4%) clinical reason identified evaluation. admitted four 10 stopped (40% stops, 0.6% total) intensive care unit, 6 (60% stops, 0.8% total) hospital ward ed care. eight child (1.1%) admitted hospital ward ed rapid evaluation required transfer intensive care unit within 12 hours. conclusion: ed rapid evaluation process child directly admitted hospital feasible effective setting.',\n",
       " 'introduction: pediatric early warning score (pews) identify hospitalized child risk deterioration. manual calculation prone human error. electronic record (ehrs) enable automated calculation, removing human error. studyâ\\x80\\x99s objective compare accuracy automated ehr-based pew calculation (autopews) manual calculation evaluate non-inferiority autopews predicting deterioration. methods: performed retrospective cohort inclusive non-intensive care unit inpatient freestanding childrenâ\\x80\\x99s hospital 4.5 month fall 2018. autopews mapped historical manual pew scoring rubric frequently used ehr documentation. determined accuracy comparing expected respiratory subset score based current respiratory rate actual respiratory score autopews manual pews. agreement determined kappa statistics. used predicted probability generalized linear mixed model calculate area curve combination score (autopews, manual) deterioration outcome (rapid response team activation, unplanned intensive care unit transfer, critical deterioration event). compared adjusted difference area curve scores. non-inferiority defined difference <0.05. results: 23,514 total pew representative 5,384 patients. autopews respiratory score 99.97% accurate, manual pew respiratory score 86% accurate. autopews higher overall manual pew (mean 0.65 versus 0.34). showed fair-to-good agreement (weighted kappa 0.42). non-inferiority autopews compared manual pew demonstrated deterioration outcomes. conclusions: automation pew calculation improved accuracy without sacrificing predictive ability.',\n",
       " 'objective: herpes simplex (hsv) encephalitis overall mortality rate 11%â\\x80\\x9329% treatment. although rare, hsv encephalitis frequently tested empirically treated, especially neonatal population. hsv diagnosed polymerase chain reaction (pcr) testing, although frequently requires sending sample reference laboratories. inherent delay result may lead prolonging empiric hospital stay, resulting increased costs. investigates whether onsite hsv pcr testing decrease hospitalization duration, acyclovir duration, financial cost institution. project design: single-center project utilized ihi model improvement evaluate third-party hsv pcr processing versus implemented onsite pcr-based meningitisâ\\x80\\x93encephalitis panel hsv central nervous system evaluation. primary outcome hospital cost differential secondary outcomes, duration acyclovir administration time result. results: identified 96 child age 0â\\x80\\x9318 2010 2016, 74 utilizing offsite third-party testing, 22 utilizing onsite. observed per-patient cost saving $428 ($618.43â\\x80\\x93$190.43, p = 0.029) upon implementation onsite testing. mean duration acyclovir therapy decreased 3.7 0.26 day per (p < 0.001). time decreased 4.6 0.13 day (p < 0.001). conclusions: acquisition real-time local hsv pcr capability significantly decreased time empiric medication use significantly reducing hospital cost military facility.',\n",
       " 'introduction: bubble continuous positive airway pressure (bcpap) associated decreased risk chronic lung (cld) preterm neonates. report examined effectiveness adopting bcpap reduce respiratory complication medication usage community hospital nicu. methods: efficacy bcpap assessed retrospective examination comparison 45 neonate received bcpap 87 neonate received conventional ventilation only. medication usage collected analyzed. results: introduction bcpap protocol, median number day oxygen decreased bcpap group compared conventional ventilation group (median = 33 days, iqr = 7.5â\\x80\\x9366 v median = 0, iqr = 0â\\x80\\x930; p < 0.001). exposure conventional ventilation decreased bcpap group compared conventional ventilation group (median = 18 days, iqr = 5â\\x80\\x9342.5 v median = 0, iqr = 0â\\x80\\x937; p < 0.001). postimplementation bcpap revealed decrease cld 26 (30%) conventional ventilation group 2 (4%) bcpap group (p = 0.002); significant decrease use sedative medication bcpap group compared conventional ventilation group (mean = 5.20 doses, sd = 31.97 v mean = 1.43, sd = 9.98; p < 0.001). conclusion: use bcpap result significant decrease use conventional ventilation, risk cld, need sedative medication.',\n",
       " 'introduction: pediatric hospital readmission represent gap care quality discharge follow-up, social factor typically addressed hospitals. aimed reduce 30-day pediatric readmission rate 2 general pediatric service intervention enhance care spanning hospital stay, discharge, follow-up process. methods: multidisciplinary team developed intervention bundle based need assessment evidence-based model transitional care. intervention included pre-discharge planning transition coordinator, screening intervention adverse social determinant (sdh), medication reconciliation discharge, communication primary care provider, access hospital-based transition clinic, access 24-hour direct telephone line staffed hospital attending pediatricians. implemented sequentially october 2013 february 2017. primary outcome readmission rate within 30 day index discharge. length stay balancing measure. results: intervention, included service discharged 4,853 children. pre-implementation readmission rate 10.3% declined 7.4% remained stable 4-month post-intervention observation period. among 1,394 family screened adverse sdh, 48% reported received assistance â\\x89¥ 1 concern. length stay increased 4.10 day 2013 4.30 day 2017. conclusions: intervention bundle, sdh, associated sustained reduction readmission rate 2 general pediatric services. transitional care address multiple domain family need childâ\\x80\\x99s crisis help reduce pediatric readmissions.',\n",
       " 'introduction: dissemination quality improvement (qi) intervention broader range healthcare setting requires proactive assessment local work system processes. objective examine feasibility survey-based work system assessment (wsa) tool facilitate dissemination program optimizing blood culture (bc) use. methods: informed finding onsite, interview-based wsa 2 hospitals, 50-item wsa survey devised administrated 15 hospital participating qi collaborative. wsa survey summarized, shared, discussed individual hospital inform adaptation implementation bc program. physician champion leading local qi team assessed use wsa survey completing 8-item survey. results: total 347 clinician completed wsa survey, physician champion 12 hospital evaluated use wsa survey. wsa survey evaluation wsa survey showed survey-based wsa tool could help participating hospital understand current bc ordering practice identify potential barrier implementing program perspective different clinicians. conclusions: demonstrated survey-based tool could used facilitate wsa dissemination program improving bc use multisite collaborative. survey-based wsa tool used facilitate future large-scale intervention dissemination efforts.',\n",
       " 'introduction: healthcare cost rising, clinical pathway (cpw) mean promote high-value care standardizing care improving outcome without compromising cost quality. however, provider always follow cpw, understanding perception limited. objective examine pediatric hospital medicine (phm) pediatric emergency medicine (pem) physician perspective cpw. methods: conducted semistructured, in-depth, one-on-one qualitative interview phm pem physician february 2017 august 2017. interview audio-recorded, professionally transcribed, accuracy verified. inductive analytic strategy, systematically coded identify themes. results: interviewed 15 phm 15 pem physicians. provider identified many benefit limitation cpw, positively negatively impact resource utilization, communication, education personnel, patients, families, well practice behavior attitudes. perceived benefit included (1) reduction unnecessary utilization, (2) standardization care, (3) improved communication, (4) education oneself others, (5) confidence validation action align cpw. limitation cpw (1) resource utilization revisions, updates, dissemination; (2) â\\x80\\x9ctunnel visionâ\\x80\\x9d cognitive biases; (3) loss autonomy; (4) prescriptive medicine; (5) information overload; (6) pressure adhere; (7) guilt action align cpw. conclusions: cpw tool advantage disadvantage used viewed differently providers. insight physician perceive cpw may help optimize hospital improvement work enhance high-value care.',\n",
       " 'introduction: handoff transition care common weak point healthcare provider communication move sites. consistent pattern communication st. jude childrenâ\\x80\\x99s research hospital (st. jude) affiliated clinics, affiliate program office st. jude developed implemented standardized communication tool facilitate transition different healthcare sites. methods: team provider created flow diagram define current state communication transitioning remote sites. fishbone diagram identified common barrier effective communication lack consistent communication ownership. developed communication tool address barriers, disseminated secure email. measured percent usage completed hand-off tool transitioned, staff experience, number errors. results: time send receive communication bundle <10 minutes. within 3 month implementing smart bundle 3 pilot sites, bundle used completely 6 8 transition associated somewhat improved staff satisfaction. identified adverse event related communication bundle. conclusions: small pilot study, accomplished closed-loop communication geographically remote healthcare site electronically transmitted standardized communication bundle.',\n",
       " 'introduction: pediatric in-hospital cardiac arrest emergent transfer pediatric intensive care unit (icu) represent serious safety concern associated increased morbidity mortality. institution turned electronic record predictive analytics search earlier accurate detection risk decompensation. methods: objective electronic record 2011 2017 utilized develop automated early warning system score aimed identifying hospitalized child risk clinical deterioration. five vital sign measurement supplemental oxygen requirement used build vitals risk index (vri) model, multivariate logistic regression. compared vri hospitalâ\\x80\\x99s existing early warning system, adaptation monaghanâ\\x80\\x99s pediatric early warning score system (pews). population included hospitalized child 18 year age younger cared outside icu. dataset included 158 hospitalization (102 emergent transfer icu 56 â\\x80\\x9ccode blueâ\\x80\\x9d events) 135,597 control hospitalizations. results: identifying deteriorating 2 hour event, significant difference pediatric early warning score vriâ\\x80\\x99s area receiver operating characteristic curve false-positive rate â\\x89¤ 10% (pauc(10) 0.065 0.064, respectively; p = 0.74), threshold chosen compare 2 approach clinically tolerable false-positive rates. conclusions: vri represents objective, simple, automated predictive analytics tool identifying hospitalized pediatric risk deteriorating outside icu setting.',\n",
       " 'introduction: accurate timely documentation pediatric early warning score (pews) bedside nurse electronic record (ehr) important promote early identification stage deterioration. implementation pew calculator embedded ehr, hope improve accuracy recorded score reduce time vital sign collection final documentation ehr. methods: identification highest pew value 24 hour unplanned transfer rapid response activation without transfer occurred period november 1, 2013, december 31, 2016. accuracy calculated cardiac respiratory subscore based heart rate respiratory rate time pew calculation determined. tracked calculation time chart via difference nursing documentation pew compared vital sign collection. september 3, 2015, pew calculated mentally bedside nurse; afterward, nurse entered unique pew feature ehr, ehr automatically calculated pews. results: evaluated 2,409 pew scores, 1,411 998 initiation pew calculator. accuracy ehr calculator 71%, median time document 55 minutes. following implementation calculator, score incorrectly calculated low, median time document 20 minutes. conclusions: transition ehr-based pew calculator eliminated inaccurately low pew value reduced time document.',\n",
       " ...]"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text1=text.tolist()\n",
    "text1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#working\n",
    "def get_genes_entries(en):#funtion to create a of names from caption\n",
    "    \n",
    "    \n",
    "    spans = []\n",
    "    \n",
    "    \n",
    "    doc=nlp(en)\n",
    "    for token in doc:\n",
    "        #print(token.ent_type_)\n",
    "        if token.ent_type_ =='GENE': \n",
    "            i=token.i\n",
    "            span = doc[i-8:i+8]\n",
    "            spans.append(span)\n",
    "         \n",
    "    return spans\n",
    "    \n",
    "\n",
    "\n",
    "def get_all_genesesntries(lst_lst):\n",
    "    list_genes=[]\n",
    "    for lst in lst_lst:\n",
    "        a=get_genes_entries(lst)\n",
    "        list_genes.append(a)  \n",
    "    return list_genes\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'text1' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[1;32m<ipython-input-39-aecf5455a8ad>\u001b[0m in \u001b[0;36m<module>\u001b[1;34m\u001b[0m\n\u001b[1;32m----> 1\u001b[1;33m \u001b[0mtext1\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[1;31mNameError\u001b[0m: name 'text1' is not defined"
     ]
    }
   ],
   "source": [
    "text1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "gene_listsof_ls=get_all_genes(text1)\n",
    "gene_listsof_ls"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_genes(en):#funtion to create a of names from caption\n",
    "    \n",
    "    \n",
    "    genes = []\n",
    "    \n",
    "    \n",
    "    doc=nlp(en)\n",
    "    for token in doc:\n",
    "        #print(token.ent_type_)\n",
    "        if token.ent_type_ =='GENE': \n",
    "            \n",
    "            genes.append(token) \n",
    "         \n",
    "    return genes\n",
    "    \n",
    "\n",
    "\n",
    "def get_all_genes(lst_lst):\n",
    "    list_genes=[]\n",
    "    for lst in lst_lst:\n",
    "        a=get_genes(lst)\n",
    "        list_genes.append(a)  \n",
    "    return list_genes\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "entrie=(\"Epigenetic Silencing of the mutL homolog 1 (MLH1) Promoter in Relation to the Development of Gastric Cancer (GC) and its use as a Biomarker for Patients with Microsatellite, CD8 and HIF-1α, HIF1 for the Covid19 gene N, TRPM7 mmp8 MMP1 MMP2  and GAID2a, HNF4α, hnf4 ACE2  ORF1b  a nrf2 , Nucleoprotein1 , Nrf2 and brca2 Instability.\")\n",
    "a=get_genes(entrie)\n",
    "a\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def gene_checker(lst_lst):\n",
    "    gene_found=[]\n",
    "    for lst in lst_lst:\n",
    "        lstgene_found=[]\n",
    "        for g in lst:\n",
    "            a=(''+g.text+'')\n",
    "            a=a.lower()\n",
    "            #print(a)\n",
    "            if a in gene_check_lower:\n",
    "                lstgene_found.append(a)\n",
    "        gene_found.append(lstgene_found)\n",
    "    return gene_found\n",
    "\n",
    "genes_found=gene_checker(gene_listsof_ls)\n",
    "genes_found[:100]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "len(genes_found)\n",
    "dataset['genes_found']=genes_found\n",
    "\n",
    "\n",
    "#dataset.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "dataset.head(20)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "genes_found=gene_checker(gene_listsof_ls)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "len(genes_found)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "def gene_unique(lst_lst):\n",
    "    \n",
    "    list_clean = list(filter(None, lst_lst))\n",
    "    for lst in list_clean:\n",
    "        list_unique= list(dict.fromkeys(lst))\n",
    "        print(lst)\n",
    "        #for gene in list_unique:\n",
    "            #list_cmb.append(gene)\n",
    "\n",
    "    return list_cmb\n",
    "\n",
    "a=gene_unique(genes_found)\n",
    "a"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "from spacy import displacy\n",
    "from scispacy.abbreviation import AbbreviationDetector\n",
    "from scispacy.umls_linking import UmlsEntityLinker\n",
    "import scispacy\n",
    "#import en_core_sci_sm   #The model we are going to use\n",
    "from spacy import displacy\n",
    "from scispacy.abbreviation import AbbreviationDetector\n",
    "from scispacy.umls_linking import UmlsEntityLinker\n",
    "import en_ner_bionlp13cg_md"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#scispacy\n",
    "from scispacy.umls_linking import UmlsEntityLinker\n",
    "\n",
    "nlp = spacy.load('en_core_web_sm')\n",
    "#linker = UmlsEntityLinker(resolve_abbreviations=True)\n",
    "\n",
    "#nlp.add_pipe(linker)\n",
    "#abbreviation_pipe = AbbreviationDetector(nlp)\n",
    "#nlp.add_pipe(abbreviation_pipe)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_scispacy(en):#funtion to create a of names from caption\n",
    "    \n",
    "    \n",
    "    genes = []\n",
    "    \n",
    "    \n",
    "    doc=nlp(en)\n",
    "    print(list(doc.ents))\n",
    "    #for abrv in doc._.abbreviations:\n",
    "     #   print(f\"{abrv} \\t ({abrv.start}, {abrv.end}) {abrv._.long_form}\")\n",
    "    #display_entities(en_ner_bionlp13cg_md,doc)\n",
    "    #displacy.render(next(doc.sents), style='dep', jupyter=True)\n",
    "    #for token in doc:\n",
    "     #   #print(token.ent_type_)\n",
    "      #  if token.ent_type_ =='GENE': \n",
    "            \n",
    "       #     genes.append(token) \n",
    "         \n",
    "    return genes\n",
    "    \n",
    "\n",
    "\n",
    "def get_all_scispacy(lst_lst):\n",
    "    list_genes=[]\n",
    "    for lst in lst_lst:\n",
    "        a=get_genes(lst)\n",
    "        list_genes.append(a)  \n",
    "    return list_genes\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "get_scispacy(text1[9])\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#linker = UmlsEntityLinker(resolve_abbreviations=True)\n",
    "nlp = spacy.blank('en')          # create a spacy model\n",
    "nlp.meta['name'] = 'gene'        # name the model 'gene'\n",
    "\n",
    "ner = nlp.create_pipe('ner')     # create an NER stage\n",
    "ner.add_label('GENE')            # add the label 'GENE' to the stage\n",
    "\n",
    "nlp.add_pipe(ner)                # put the pipe together\n",
    "optimizer = nlp.begin_training() # get an optimizer for training the model\n",
    "genenlp=nlp.from_disk(r\"C:\\Users\\mese4\\Documents\\The Data incubator\\project\\Spacy model\\gene_id_model\")\n",
    "\n",
    "#nlp.add_pipe(genenlp)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "nlp.add_pipe(genenlp)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
